Trimethadione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.735 -1.5357 0 0
M  V30 2 N 1.8298 -0.2898 0 0
M  V30 3 C 0.2898 -0.2898 0 0
M  V30 4 O -0.6154 -1.5357 0 0
M  V30 5 O -0.1861 1.1748 0 0
M  V30 6 C 1.0598 2.08 0 0
M  V30 7 C 0.0294 3.2244 0 0
M  V30 8 C 2.0903 3.2244 0 0
M  V30 9 C 2.3057 1.1748 0 0
M  V30 10 O 3.7703 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 2 9
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201618106

>  <MW>
143.058

>  <MW (desalted)>
143.141

>  <ClogP>
-0.117

>  <logS>
-1.113

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
46.61

>  <RotBonds>
0

>  <Action on targets>
- | - | - | - | -

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.67 ?M | Km (Michaelis constant)  0.67 ?M | Km (Michaelis constant)  0.81 ?M | Km (Michaelis constant)  0.81 ?M | Km (Michaelis constant)  4.8 ?M

>  <CAS>
127-48-0

>  <Description>
Trimethadione is an anticonvulsant effective in absence seizures. It is used in the control of absence (petit mal) seizures that are refractory to treatment with other medications. Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels.

>  <EBC_ID>
EBC-12262

>  <IUPAC Name>
trimethyl-1,3-oxazolidine-2,4-dione

>  <Main Tar all refs>
BIOCHEM. PHARMACOL., 1994, vol. 47, # 2, p. 247 - 251 | BIOCHEM. PHARMACOL., 1994, vol. 47, # 2, p. 247 - 251 | BIOCHEM. PHARMACOL., 1994, vol. 47, # 2, p. 247 - 251 | BIOCHEM. PHARMACOL., 1994, vol. 47, # 2, p. 247 - 251 | J. Clin. Pharm. Ther., 2003, vol. 28, # 6, p. 493 - 496

>  <Main tar all>
CYP2B1 pX=6.17 | CYP2C11 pX=6.17 | CYP2C pX=6.09 | Cytochrome P450 3A4 pX=6.09 | CYP2E1 pX=5.32

$$$$
Bemegride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8402 3.2223 0 0
M  V30 2 C 2.3236 3.4897 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 0.3438 3.4897 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 O 4.001 -0.77 0 0
M  V30 8 N 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 3 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z99599698

>  <MW>
155.095

>  <MW (desalted)>
155.194

>  <ClogP>
0.954

>  <logS>
-1.01

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.17

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  5  | pKi  5  | pKi  5  | Ki (inhibition constant) = 11.9 ?M

>  <CAS>
64-65-3

>  <Description>
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.

>  <EBC_ID>
EBC-03219

>  <IUPAC Name>
4-ethyl-4-methylpiperidine-2,6-dione

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146 | EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146 | EUR. J. PHARMACOL., 1995, vol. 286, # 2, p. 137 - 146 | ChemMedChem, 2012, vol. 7, # 8, p. 1369 - 1374

>  <Main tar all>
GABAA receptor ?1 subunit pX=5.0 | GABAA receptor ?2 subunit pX=5.0 | GABAA receptor ? subunit pX=5.0 | synaptic vesicle glycoprotein 2A pX=4.92

$$$$
Carbocisteine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.621 4.9774 0 0
M  V30 2 C 8.621 3.4374 0 0 CFG=1
M  V30 3 C 7.2874 2.6674 0 0
M  V30 4 S 5.9537 3.4374 0 0
M  V30 5 C 4.62 2.6674 0 0
M  V30 6 C 3.2863 3.4374 0 0
M  V30 7 O 1.9526 2.6674 0 0
M  V30 8 O 3.2863 4.9774 0 0
M  V30 9 C 9.9547 2.6674 0 0
M  V30 10 O 11.2884 3.4374 0 0
M  V30 11 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 2 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1222399234

>  <MW>
179.025

>  <MW (desalted)>
179.194

>  <ClogP>
-2.608

>  <logS>
-0.487

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
100.62

>  <RotBonds>
5

>  <CAS>
638-23-3

>  <Description>
Carbocisteine is a expectorant mucolytic. It significantly reduces sputum viscosity, cough, dyspnea and fatigue. Additionally, it prevents pulmonary infections by decreasing accumulated mucus in the respiratory tract. Carbocisteine is used in the relief of respiratory of COPD and other conditions associated with increased mucus viscosity.

>  <EBC_ID>
EBC-26139

>  <IUPAC Name>
(2R)-2-amino-3-[(carboxymethyl)sulfanyl]propanoic acid

$$$$
Bethanidine iodide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0
M  V30 2 C 7.0674 4.62 0 0
M  V30 3 N 7.0674 3.08 0 0
M  V30 4 C 5.7337 2.31 0 0
M  V30 5 N 4.4 3.08 0 0
M  V30 6 C 4.4 4.62 0 0
M  V30 7 N 5.7337 0.77 0 0
M  V30 8 C 7.0674 0 0 0
M  V30 9 C 7.0674 -1.54 0 0
M  V30 10 C 8.401 -2.31 0 0
M  V30 11 C 8.401 -3.85 0 0
M  V30 12 C 7.0674 -4.62 0 0
M  V30 13 C 5.7337 -3.85 0 0
M  V30 14 C 5.7337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6 CFG=2
M  V30 5 1 4 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1089994842

>  <MW>
305.039

>  <MW (desalted)>
177.246

>  <ClogP>
1.496

>  <logS>
-2.56

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
36.42

>  <RotBonds>
2

>  <CAS>
2863-34-5

>  <Description>
Bethanidine is a  guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

>  <EBC_ID>
EBC-15023

>  <IUPAC Name>
N'-benzyl-N,N''-dimethylguanidine hydroiodide

$$$$
Aminacrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.001 3.85 0 0
M  V30 2 C 4.001 2.31 0 0
M  V30 3 C 5.3347 1.54 0 0
M  V30 4 C 6.6684 2.31 0 0
M  V30 5 C 8.0021 1.54 0 0
M  V30 6 C 8.0021 -0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 5.3347 0 0 0
M  V30 9 N 4.001 -0.77 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C -0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 2 15
M  V30 17 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56871821

>  <MW>
194.084

>  <MW (desalted)>
194.232

>  <ClogP>
3.086

>  <logS>
-3.65

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.91

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | concentration (parameter) = 9.6 nM | inhibition percentage Active

>  <CAS>
90-45-9

>  <Description>
Aminacrine is a slow-acting germicide effective against bacteria and fungi which is included in drug formulations for its anti-septic properties. It is a highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA.

>  <EBC_ID>
EBC-44123

>  <IUPAC Name>
acridin-9-amine

>  <Main Tar all refs>
INCURON - US9108916, 2015, B2 | J. MED. CHEM., 1985, vol. 28, # 11, p. 1568 - 1574 | Mol. Pharmacol., 2018, vol. 94, # 1, p. 722 - 730

>  <Main tar all>
NF-kappa-B/Dorsal pX=9.0 | DNA pX=8.02 | Ryanodine receptor 1 (R2163C) pX=8.0

$$$$
Hydrochlorothiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -3.85 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -1.8974 -4.4137 0 0
M  V30 4 O -3.4374 -1.7463 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 N 4.001 -2.31 0 0
M  V30 12 S 2.6674 -3.08 0 0
M  V30 13 O 3.3903 -4.4397 0 0
M  V30 14 O 1.9444 -4.4397 0 0
M  V30 15 C 0 -0 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 17 Cl -2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 2 8 15
M  V30 16 1 15 16
M  V30 17 2 5 16
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56347248

>  <MW>
296.964

>  <MW (desalted)>
297.739

>  <ClogP>
-0.365

>  <logS>
-1.8

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
118.36

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 7.2 nM | Ki (inhibition constant)  50.2 nM | Ki (inhibition constant)  50.2 nM | Ki (inhibition constant) = 50.2 nM | Ki (inhibition constant)  79.5 nM | Ki (inhibition constant)  87 nM | Ki (inhibition constant)  134 nM | Ki (inhibition constant) = 153 nM | Kd (dissociation constant)  200 nM

>  <CAS>
58-93-5

>  <Description>
Hydrochlorothiazide is a thiazide diuretic used to treat edema associated with a number of conditions, and hypertension. Hydrochlorothiazide acts on the proximal region of the distal convoluted tubule, inhibiting reabsorption by the sodium-chloride symporter.

>  <EBC_ID>
EBC-13865

>  <IUPAC Name>
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
Bioorg. Med. Chem., 2013, vol. 21, # 15, p. 4521 - 4525 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | Bioorg. Med. Chem. Lett., 2014, vol. 24, # 1, p. 275 - 279 | J. Med. Chem., 2013, vol. 56, # 18, p. 7372 - 7381 | Bioorg. Med. Chem., 2016, vol. 24, # 5, p. 1115 - 1120 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 7, p. 1821 - 1826 | Bioorg. Med. Chem. Lett., 2014, vol. 24, # 13, p. 2797 - 2801 | Bioorg. Med. Chem., 2015, vol. 23, # 3, p. 526 - 531 | PLoS ONE, 2021, vol. 16, # 6 June

>  <Main tar all>
carbonic anhydrase pX=8.14 | ?-carbonic anhydrase pX=7.3 | ?-carbonic anhydrase pX=7.3 | ?-carbonic anhydrase 1 pX=7.3 | ?-carbonic anhydrases pX=7.1 | ?-carbonic anhydrase 1 pX=7.06 | ?-carbonic anhydrases pX=6.87 | ?-carbonic anhydrase pX=6.82 | Carbonic anhydrase 5B, mitochondrial pX=6.7

$$$$
Naproxen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 O 0 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 2.6674 0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 8.0021 -0 0 0 CFG=2
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 9.3358 -0.77 0 0
M  V30 16 O 10.6694 -0 0 0
M  V30 17 O 9.3358 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 2 3 12
M  V30 14 1 13 8
M  V30 15 1 13 14 CFG=3
M  V30 16 1 13 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1695772815

>  <MW>
230.094

>  <MW (desalted)>
230.259

>  <ClogP>
2.816

>  <logS>
-3.447

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.6 pM

>  <CAS>
22204-53-1

>  <Description>
Naproxen is an NSAID used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and mild to moderate pain. Naproxen is a non-selective COX inhibitor.

>  <EBC_ID>
EBC-03706

>  <IUPAC Name>
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1

>  <Main tar all>
COX-1  pX=12.2

$$$$
Sulfamerazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -3.85 0 0
M  V30 3 C 5.3347 -4.62 0 0
M  V30 4 C 5.3347 -6.16 0 0
M  V30 5 N 4.001 -6.93 0 0
M  V30 6 C 2.6674 -6.16 0 0
M  V30 7 N 1.3337 -6.93 0 0
M  V30 8 S 0 -6.16 0 0
M  V30 9 O 0.77 -4.8263 0 0
M  V30 10 O -0.77 -7.4937 0 0
M  V30 11 C -1.3337 -5.39 0 0
M  V30 12 C -2.6674 -6.16 0 0
M  V30 13 C -4.001 -5.39 0 0
M  V30 14 C -4.001 -3.85 0 0
M  V30 15 N -5.3347 -3.08 0 0
M  V30 16 C -2.6674 -3.08 0 0
M  V30 17 C -1.3337 -3.85 0 0
M  V30 18 N 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 6 18
M  V30 19 2 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954804578

>  <MW>
264.068

>  <MW (desalted)>
264.304

>  <ClogP>
0.599

>  <logS>
-2.66

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
97.97

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKa (association)  6.98 | Ki (inhibition constant)  696 nM | Ki (inhibition constant)  696 nM

>  <CAS>
127-79-7

>  <Description>
Sulfamerazine is an antibacterial agent. It is  used in the treatment of various bacterial infections, such as bronchitis, prostatitis, and urinary tract infections.

>  <EBC_ID>
EBC-03812

>  <IUPAC Name>
4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Hazard. Mater., 2018, vol. 341, p. 438 - 447 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951

>  <Main tar all>
dihydrofolate synthase pX=6.98 | ?2B-adrenoceptor pX=6.16 | ?2B-adrenoceptor pX=6.16

$$$$
Ensulizole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.925 5.1528 0 0
M  V30 2 S 7.5913 4.3828 0 0
M  V30 3 O 6.8213 5.7165 0 0
M  V30 4 O 8.3613 3.0491 0 0
M  V30 5 C 6.2576 3.6128 0 0
M  V30 6 C 6.2576 2.0728 0 0
M  V30 7 C 4.9239 1.3028 0 0
M  V30 8 C 3.5902 2.0728 0 0
M  V30 9 N 2.1256 1.5969 0 0
M  V30 10 C 1.2204 2.8428 0 0
M  V30 11 N 2.1256 4.0887 0 0
M  V30 12 C 3.5902 3.6128 0 0
M  V30 13 C 4.9239 4.3828 0 0
M  V30 14 C -0.3196 2.8428 0 0
M  V30 15 C -1.0896 1.5091 0 0
M  V30 16 C -2.6296 1.5091 0 0
M  V30 17 C -3.3996 2.8428 0 0
M  V30 18 C -2.6296 4.1765 0 0
M  V30 19 C -1.0896 4.1765 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 8 12
M  V30 13 1 12 13
M  V30 14 2 5 13
M  V30 15 1 10 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z203045352

>  <MW>
274.041

>  <MW (desalted)>
274.295

>  <ClogP>
0.876

>  <logS>
-3.91

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
83.05

>  <RotBonds>
2

>  <CAS>
27503-81-7

>  <Description>
Ensulizole is a water-soluble sunscreen agent that absorbs strongly at UV-B wavelengths. It is indicated to be used as an UV-B-absorbing molecule in sunscreen formulations.

>  <EBC_ID>
EBC-12605

>  <IUPAC Name>
2-phenyl-1H-1,3-benzodiazole-6-sulfonic acid

$$$$
Vorinostat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -11.55 0 0
M  V30 2 N 5.3347 -12.32 0 0
M  V30 3 C 6.6684 -11.55 0 0
M  V30 4 O 6.6684 -10.01 0 0
M  V30 5 C 8.0021 -12.32 0 0
M  V30 6 C 9.3358 -11.55 0 0
M  V30 7 C 10.6694 -12.32 0 0
M  V30 8 C 12.0031 -11.55 0 0
M  V30 9 C 13.3368 -12.32 0 0
M  V30 10 C 14.6705 -11.55 0 0
M  V30 11 C 16.0041 -12.32 0 0
M  V30 12 O 16.0041 -13.86 0 0
M  V30 13 N 17.3378 -11.55 0 0
M  V30 14 C 18.6715 -12.32 0 0
M  V30 15 C 20.0052 -11.55 0 0
M  V30 16 C 21.3389 -12.32 0 0
M  V30 17 C 21.3389 -13.86 0 0
M  V30 18 C 20.0052 -14.63 0 0
M  V30 19 C 18.6715 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532755

>  <MW>
264.147

>  <MW (desalted)>
264.32

>  <ClogP>
0.989

>  <logS>
-2.82

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
78.43

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.001 nM | IC50  1.22E-06 ?M | IC50  0.004 nM | IC50  0.005 nM | IC50  0.035 nM

>  <CAS>
149647-78-9

>  <Description>
Vorinostat is a histone deacetylase inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma following prior systemic therapies.

>  <EBC_ID>
EBC-11271

>  <IUPAC Name>
N-hydroxy-N'-phenyloctanediamide

>  <Main Tar all refs>
ACS Chem. Neurosci., 2014, vol. 5, # 7, p. 588 - 596 | REACTION BIOLOGY CORP - US2017/360761, 2017, A1 | ACS Chem. Neurosci., 2014, vol. 5, # 7, p. 588 - 596 | ACS Chem. Neurosci., 2014, vol. 5, # 7, p. 588 - 596 | Proc. Natl. Acad. Sci. U. S. A., 2016, vol. 113, # 46, p. 13162 - 13167

>  <Main tar all>
histone deacetylase 1 pX=12.0 | histone deacetylase 5 pX=11.9 | histone deacetylase 2 pX=11.4 | histone deacetylase 3 pX=11.3 | histone deacetylase 6 pX=10.5

$$$$
Stearic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 17.1463 11.4394 0 0
M  V30 2 C 18.48 10.6694 0 0
M  V30 3 C 19.8137 11.4394 0 0
M  V30 4 C 21.1474 10.6694 0 0
M  V30 5 C 22.481 11.4394 0 0
M  V30 6 C 23.8147 10.6694 0 0
M  V30 7 C 25.1484 11.4394 0 0
M  V30 8 C 26.4821 10.6694 0 0
M  V30 9 C 27.8158 11.4394 0 0
M  V30 10 C 29.1494 10.6694 0 0
M  V30 11 C 30.4831 11.4394 0 0
M  V30 12 C 31.8168 10.6694 0 0
M  V30 13 C 33.1505 11.4394 0 0
M  V30 14 C 34.4841 10.6694 0 0
M  V30 15 C 35.8178 11.4394 0 0
M  V30 16 C 37.1515 10.6694 0 0
M  V30 17 C 38.4852 11.4394 0 0
M  V30 18 C 39.8189 10.6694 0 0
M  V30 19 O 41.1525 11.4394 0 0
M  V30 20 O 39.8189 9.1294 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474964

>  <MW>
284.272

>  <MW (desalted)>
284.477

>  <ClogP>
8.27

>  <logS>
-7.67

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
16

>  <Action on targets>
Inhibitor | Inhibitor | - | -

>  <Activity coefficients and valu>
Kd (dissociation constant) = 14 nM | Kd (dissociation constant) = 14 nM | Kd (dissociation constant) = 2.72E-08 M | Kd (dissociation constant) = 290 nM

>  <CAS>
57-11-4

>  <Description>
Stearic acid is one of the useful types of saturated fatty acids that comes from many animal and vegetable fats and oils. It is used as an ingredient found in topical products as a skin protectant.

>  <EBC_ID>
EBC-26446

>  <IUPAC Name>
octadecanoic acid

>  <Main Tar all refs>
Biochem. J., 2002, vol. 363, # 3, p. 809 - 815 | Biochem. J., 2002, vol. 363, # 3, p. 809 - 815 | Arch. Biochem. Biophys., 2013, vol. 529, # 1, p. 1 - 10 | Curr. Pharm. Des., 2011, vol. 17, # 2, p. 168 - 175

>  <Main tar all>
Albumin pX=7.85 | Serum albumin pX=7.85 | Peptidoglycan recognition protein 1 pX=7.57 | fatty acid binding protein 5 pX=6.54

$$$$
Fenoldopam mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -1.54 0 0
M  V30 2 S 0 0 0 0
M  V30 3 O 0 1.54 0 0
M  V30 4 O 1.54 -0 0 0
M  V30 5 O -1.54 0 0 0
M  V30 6 O 8.8943 6.1618 0 0
M  V30 7 C 9.237 4.6604 0 0
M  V30 8 C 10.7086 4.2064 0 0
M  V30 9 C 11.0513 2.7051 0 0
M  V30 10 C 9.9224 1.6576 0 0
M  V30 11 C 8.4508 2.1115 0 0
M  V30 12 C 8.1081 3.6129 0 0
M  V30 13 C 10.2651 0.1562 0 0
M  V30 14 C 11.7664 -0.1865 0 0
M  V30 15 N 12.4346 -1.574 0 0
M  V30 16 C 11.7664 -2.9615 0 0
M  V30 17 C 10.2651 -3.3041 0 0
M  V30 18 C 9.061 -2.344 0 0
M  V30 19 C 7.7274 -3.114 0 0
M  V30 20 Cl 7.7274 -4.654 0 0
M  V30 21 C 6.3937 -2.344 0 0
M  V30 22 O 5.06 -3.114 0 0
M  V30 23 C 6.3937 -0.804 0 0
M  V30 24 O 5.06 -0.034 0 0
M  V30 25 C 7.7274 -0.034 0 0
M  V30 26 C 9.061 -0.804 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 7 12
M  V30 12 1 10 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 23 24
M  V30 24 2 23 25
M  V30 25 1 25 26
M  V30 26 1 13 26
M  V30 27 2 18 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2210694608

>  <MW>
401.862

>  <MW (desalted)>
305.756

>  <ClogP>
2.4

>  <logS>
-1.32

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
1

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
inhibition percentage  46 %

>  <CAS>
67227-57-0

>  <Description>
Fenoldopam mesylate is an agonist of dopamine D1 receptors.  It lowers blood pressure through arteriolar vasodilation.

>  <EBC_ID>
EBC-07658

>  <IUPAC Name>
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; methanesulfonic acid

>  <Main Tar all refs>
MIA LEVITE - WO2007/19266, 2007, A2

>  <Main tar all>
D1 receptor pX=11.9

$$$$
Nitazoxanide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.4682 1.425 0 0
M  V30 2 C 3.8019 2.195 0 0
M  V30 3 O 3.8019 3.735 0 0
M  V30 4 O 5.1355 1.425 0 0
M  V30 5 C 6.4692 2.195 0 0
M  V30 6 C 6.4692 3.735 0 0
M  V30 7 C 7.8029 4.505 0 0
M  V30 8 C 9.1366 3.735 0 0
M  V30 9 C 9.1366 2.195 0 0
M  V30 10 C 7.8029 1.425 0 0
M  V30 11 C 7.8029 -0.115 0 0
M  V30 12 O 9.1366 -0.885 0 0
M  V30 13 N 6.4692 -0.885 0 0
M  V30 14 C 6.4692 -2.425 0 0
M  V30 15 N 7.7151 -3.3302 0 0
M  V30 16 C 7.2392 -4.7948 0 0
M  V30 17 C 5.6992 -4.7948 0 0
M  V30 18 S 5.2233 -3.3302 0 0
M  V30 19 N 4.794 -6.0407 0 0 CHG=1
M  V30 20 O 5.4204 -7.4476 0 0
M  V30 21 O 3.2625 -5.8797 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1514087129

>  <MW>
307.026

>  <MW (desalted)>
307.282

>  <ClogP>
1.243

>  <logS>
-4.68

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
111.43

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC90  0.86 ?M | Cyst volume decrease Active   | IC50 = 100 nM | IC50 ~ 100 nM | EC90  1.49 ?M | EC50  0.3 ?M | Ki (inhibition constant) = 0.3 ?M | EC50  0.3 ?M | EC90  3.23 ?M | IC50  0.424 ?M | EC50  590 nM | EC50  0.8 ?M | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage < 90 % | inhibition percentage  50 % | IC50  1.63 ?M | IC50  2.12 ?M | Ki (inhibition constant) = 2.2 ?M

>  <CAS>
55981-09-4

>  <Description>
Nitazoxanide is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. Nitazoxanide disrupts the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle.

>  <EBC_ID>
EBC-06082

>  <IUPAC Name>
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2014, vol. 58, # 4, p. 2045 - 2051 | FRIEDRICH-ALEXANDER-UNIVERSIT?T ERLANGEN-N?RNBERG - WO2021/122239, 2021, A1 | J. Antibiot., 2009, vol. 62, # 12, p. 655 - 667 | Mol. Cancer Ther., 2013, vol. 12, # 9, p. 1896 - 1905 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | HEALTH RESEARCH, INC - US2022/24884, 2022, A1 | Antimicrob. Agents Chemother., 2007, vol. 51, # 6, p. 1979 - 1986 | HEALTH RESEARCH, INC - US2022/24884, 2022, A1 | Antimicrob. Agents Chemother., 2018, vol. 62, # 12 | Eur. J. Med. Chem., 2022, vol. 237 | ACS Infect. Dis., 2020, vol. 6, # 8, p. 2057 - 2072 | Virus Res., 2018, vol. 247, p. 26 - 33 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Antimicrob. Agents Chemother., 2014, vol. 58, # 8, p. 4703 - 4712 | Viruses, 2018, vol. 10, # 8 | Antimicrob. Agents Chemother., 2013, vol. 57, # 8, p. 3829 - 3835 | Int. J. Parasitol Drugs Drug Resist., 2016, vol. 6, # 3, p. 148 - 153 | Arch. Pharm., 2022, vol. 355, # 9 | Antimicrob. Agents Chemother., 2007, vol. 51, # 3, p. 868 - 876

>  <Main tar all>
Neuraminidase?(S245N,S247P) pX=7.02 | CaCC pX=7.0 | IkappaB kinase pX=7.0 | Luciferin 4-monooxygenase pX=7.0 | methionine-tRNA ligase pX=6.78 | Flavivirus non-structural protein NS2B pX=6.52 | Nitroreductase pX=6.52 | Nonstructural protein 3 pX=6.52 | pyruvate synthase (PFOR) pX=6.45 | calcium-activated chloride channel anoctamin-1 pX=6.37 | tubulin alpha 1a pX=6.23 | Protein disulfide-isomerase pX=6.1 | CYP1A2 pX=6.0 | Cytochrome P450 2B6 pX=6.0 | Cytochrome P450 2C19 pX=6.0 | Cytochrome P450 2C9 pX=6.0 | Cytochrome P450 2D6 pX=6.0 | Cytochrome P450 3A4 pX=6.0 | Pro-Pol polyprotein pX=5.95 | Glucose-6-phosphate isomerase pX=5.85 | Putative thioredoxin reductase pX=5.79 | Replicase polyprotein 1ab pX=5.67 | Pyruvate synthase (gene POR) pX=5.66

$$$$
Tetrabenazine Racemate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4847 -2.8737 0 0
M  V30 2 O 2.2547 -1.54 0 0
M  V30 3 C 3.7947 -1.54 0 0
M  V30 4 C 4.5647 -0.2063 0 0
M  V30 5 C 6.1047 -0.2063 0 0
M  V30 6 C 6.8747 1.1274 0 0
M  V30 7 C 8.4147 1.1274 0 0
M  V30 8 N 9.1847 -0.2063 0 0
M  V30 9 C 10.7247 -0.2063 0 0
M  V30 10 C 11.4947 -1.54 0 0
M  V30 11 C 13.0347 -1.54 0 0
M  V30 12 C 13.8047 -2.8737 0 0
M  V30 13 C 15.3447 -2.8737 0 0
M  V30 14 C 13.0347 -4.2074 0 0
M  V30 15 C 10.7247 -2.8737 0 0
M  V30 16 O 11.4947 -4.2074 0 0
M  V30 17 C 9.1847 -2.8737 0 0
M  V30 18 C 8.4147 -1.54 0 0
M  V30 19 C 6.8747 -1.54 0 0
M  V30 20 C 6.1047 -2.8737 0 0
M  V30 21 C 4.5647 -2.8737 0 0
M  V30 22 O 3.7947 -4.2074 0 0
M  V30 23 C 2.2547 -4.2074 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 10 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 8 18
M  V30 19 1 18 19
M  V30 20 1 5 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 3 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404943

>  <MW>
317.199

>  <MW (desalted)>
317.423

>  <ClogP>
3.465

>  <logS>
-3.44

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
38.77

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.49 nM | Ki (inhibition constant) = 7.51 nM

>  <CAS>
718635-93-9

>  <Description>
Tetrabenazine is an inhibitor of vesicular monoamine transporter 2. It is used in the treatment of chorea associated with Huntington's disease.

>  <EBC_ID>
EBC-07022

>  <IUPAC Name>
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one

>  <Main Tar all refs>
FIVE ONE ONE PHARMACEUTICAL SHARE LTD; FIVE ELEVEN PHARMA INC - WO2018/222549, 2018, A1 | Eur. J. Med. Chem., 1997, vol. 32, p. 53 - 57

>  <Main tar all>
Vesicular monoamine transporter 2 pX=8.83 | DAT pX=8.12

$$$$
Clofazimine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 2.6674 0 0 0
M  V30 4 N 1.3337 -2.31 0 0
M  V30 5 C 2.6674 -3.08 0 0
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 C 5.3347 -3.08 0 0
M  V30 8 N 6.6684 -2.31 0 0
M  V30 9 C 6.6684 -0.77 0 0
M  V30 10 C 5.3347 0 0 0
M  V30 11 C 5.3347 1.54 0 0
M  V30 12 C 6.6684 2.31 0 0
M  V30 13 Cl 6.6684 3.85 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 8.0021 0 0 0
M  V30 16 C 8.0021 -3.08 0 0
M  V30 17 C 9.3358 -2.31 0 0
M  V30 18 C 10.6694 -3.08 0 0
M  V30 19 C 10.6694 -4.62 0 0
M  V30 20 C 9.3358 -5.39 0 0
M  V30 21 C 8.0021 -4.62 0 0
M  V30 22 N 6.6684 -5.39 0 0
M  V30 23 C 5.3347 -4.62 0 0
M  V30 24 C 4.001 -5.39 0 0
M  V30 25 C 2.6674 -4.62 0 0
M  V30 26 N 1.3337 -5.39 0 0
M  V30 27 C 0 -4.62 0 0
M  V30 28 C -1.3337 -5.39 0 0
M  V30 29 C -2.6674 -4.62 0 0
M  V30 30 C -2.6674 -3.08 0 0
M  V30 31 Cl -4.001 -2.31 0 0
M  V30 32 C -1.3337 -2.31 0 0
M  V30 33 C 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=2
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 14 15
M  V30 15 2 9 15
M  V30 16 1 8 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 7 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 5 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 2 28 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 2 30 32
M  V30 36 1 32 33
M  V30 37 2 27 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037279473

>  <MW>
473.396

>  <MW (desalted)>
473.396

>  <ClogP>
7.699

>  <logS>
-7.448

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
39.99

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Substrate | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | - | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  0.275 ?M | IC50 = 300 nM | Km (Michaelis constant)  0.35 ?M | Km (Michaelis constant)  0.35 ?M | IC50  0.47 ?M | Kd (dissociation constant)  0.73 ?M | IC50  0.731 ?M | IC50  2.01 ?M | MIC  1 ?g/ml | MIC  1 ?g/ml | MIC  1 ?g/ml | inhibition percentage  79.1 %

>  <CAS>
2030-63-9

>  <Description>
Clofazimine is a riminophenazine antimycobacterial used to treat leprosy.

>  <EBC_ID>
EBC-13571

>  <IUPAC Name>
N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine

>  <Main Tar all refs>
CLEVELAND CLINIC - WO2019/60409, 2019, A1 | Biol. Pharm. Bull., 2015, vol. 38, # 9, p. 1425 - 1429 | THE JOHNS HOPKINS UNIVERSITY - WO2009/42114, 2009, A2 | Antimicrob. Agents Chemother., 2014, vol. 58, # 6, p. 3168 - 3176 | Antimicrob. Agents Chemother., 2014, vol. 58, # 6, p. 3168 - 3176 | Virus Res., 2021, vol. 299 | Eur. J. Med. Chem., 2022, vol. 234 | ACS Chem. Neurosci., 2020, vol. 11, # 15, p. 2277 - 2285 | J. Asian Nat. Prod. Res., 2019, vol. 21, # 9, p. 887 - 894 | Antimicrob. Agents Chemother., 2019, vol. 63, # 7 | Antimicrob. Agents Chemother., 2019, vol. 63, # 7 | Antimicrob. Agents Chemother., 2019, vol. 63, # 7 | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - WO2016/24015, 2016, A1

>  <Main tar all>
Cx46 pX=7.0 | Cytochrome P450 3A4 pX=6.56 | Kv9.1 pX=6.52 | ABCB1 pX=6.46 | ATP-dependent translocase ABCB1 pX=6.46 | NS5 RNA-directed RNA polymerase pX=6.33 | Major spike protein pX=6.14 | Zinc finger CCCH domain-containing protein 14 pX=6.14 | Kv1.3 pX=5.7 | External NADH-ubiquinone oxidoreductase 2, mitochondrial pX=5.68 | F-type ATPase ? subunit pX=5.68 | ubiquinol-cytochrome-c reductase pX=5.68 | Cytochrome P450 2J2 pX=5.58

$$$$
Buspirone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 9.8498 -4.001 0 0
M  V30 3 C 9.0798 -2.6674 0 0
M  V30 4 C 7.5398 -2.6674 0 0
M  V30 5 C 6.7698 -1.3337 0 0
M  V30 6 C 5.8646 -2.5796 0 0
M  V30 7 C 4.4 -2.1037 0 0
M  V30 8 C 4.4 -0.5637 0 0
M  V30 9 C 5.8646 -0.0878 0 0
M  V30 10 C 7.5398 -0 0 0
M  V30 11 C 9.0798 -0 0 0
M  V30 12 O 9.8498 1.3337 0 0
M  V30 13 N 9.8498 -1.3337 0 0
M  V30 14 C 11.3898 -1.3337 0 0
M  V30 15 C 12.1598 -0 0 0
M  V30 16 C 13.6998 -0 0 0
M  V30 17 C 14.4698 1.3337 0 0
M  V30 18 N 16.0098 1.3337 0 0
M  V30 19 C 16.7798 2.6674 0 0
M  V30 20 C 18.3198 2.6674 0 0
M  V30 21 N 19.0898 1.3337 0 0
M  V30 22 C 18.3198 0 0 0
M  V30 23 C 16.7798 0 0 0
M  V30 24 C 20.6298 1.3337 0 0
M  V30 25 N 21.3998 2.6674 0 0
M  V30 26 C 22.9398 2.6674 0 0
M  V30 27 C 23.7098 1.3337 0 0
M  V30 28 C 22.9398 0 0 0
M  V30 29 N 21.3998 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 5 9
M  V30 9 1 5 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 3 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 18 23
M  V30 25 1 21 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 24 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759502

>  <MW>
421.964

>  <MW (desalted)>
385.503

>  <ClogP>
2.185

>  <logS>
-3.59

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
69.64

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1 nM | Ki (inhibition constant) = 2.1 nM | Ki (inhibition constant) = 13 nM | Ki (inhibition constant) = 17 nM

>  <CAS>
33386-08-2

>  <Description>
Buspirone is an anxiolytic agent used for short-term treatment of generalized anxiety and second-line treatment of depression.

>  <EBC_ID>
EBC-14142

>  <IUPAC Name>
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione hydrochloride

>  <Main Tar all refs>
Curr. Med. Chem., 2001, vol. 8, # 9, p. 999 - 1034 | J. Med. Chem., 2001, vol. 44, # 25, p. 4431 - 4442 | J. MED. CHEM., 1993, vol. 36, # 15, p. 2066 - 2074 | J. MED. CHEM., 1994, vol. 37, # 1, p. 105 - 112

>  <Main tar all>
5-HT1A receptor pX=9.0 | 5-HT1A receptor pX=8.68 | D2 receptor pX=7.89 | 5-HT1B receptor pX=7.77

$$$$
Maraviroc
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.204 5.0428 0 0
M  V30 2 C 7.1736 3.8984 0 0
M  V30 3 C 5.6672 4.2185 0 0
M  V30 4 C 7.6494 2.4337 0 0
M  V30 5 N 9.1141 1.9578 0 0
M  V30 6 N 9.1141 0.4178 0 0
M  V30 7 C 7.6494 -0.058 0 0
M  V30 8 C 7.1736 -1.5227 0 0
M  V30 9 N 6.7443 1.1878 0 0
M  V30 10 C 5.2043 1.1878 0 0
M  V30 11 C 4.5361 2.5753 0 0
M  V30 12 C 3.0347 2.918 0 0 CFG=2
M  V30 13 C 1.8307 1.9578 0 0
M  V30 14 C 1.8307 0.4178 0 0
M  V30 15 C 3.0347 -0.5423 0 0 CFG=2
M  V30 16 C 4.5361 -0.1997 0 0
M  V30 17 N 2.6021 1.1878 0 0
M  V30 18 C 1.0621 1.1878 0 0
M  V30 19 C 0.2921 2.5215 0 0
M  V30 20 C -1.2479 2.5215 0 0 CFG=2
M  V30 21 N -2.0179 3.8552 0 0
M  V30 22 C -3.5579 3.8552 0 0
M  V30 23 O -4.3279 2.5215 0 0
M  V30 24 C -4.3279 5.1889 0 0
M  V30 25 C -5.8679 5.1889 0 0
M  V30 26 C -6.6379 6.5226 0 0
M  V30 27 C -5.8679 7.8562 0 0
M  V30 28 F -7.315 8.3829 0 0
M  V30 29 F -5.6004 9.3728 0 0
M  V30 30 C -4.3279 7.8562 0 0
M  V30 31 C -3.5579 6.5226 0 0
M  V30 32 C -2.0179 1.1878 0 0
M  V30 33 C -1.2479 -0.1458 0 0
M  V30 34 C -2.0179 -1.4795 0 0
M  V30 35 C -3.5579 -1.4795 0 0
M  V30 36 C -4.3279 -0.1458 0 0
M  V30 37 C -3.5579 1.1878 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 12 11
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 15 14
M  V30 16 1 15 16
M  V30 17 1 10 16
M  V30 18 1 15 17 CFG=3
M  V30 19 1 12 17 CFG=3
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 20 19
M  V30 23 1 20 21 CFG=1
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 1 27 30
M  V30 33 1 30 31
M  V30 34 1 24 31
M  V30 35 1 20 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 2 32 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1614451557

>  <MW>
513.666

>  <MW (desalted)>
513.666

>  <ClogP>
3.262

>  <logS>
-5.04

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
63.05

>  <RotBonds>
8

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50  0.0024 nM

>  <CAS>
376348-65-1

>  <Description>
Maraviroc is a CCR5 co-receptor antagonist used with other antiretroviral medications to treat CCR5-tropic HIV-1 infection.

>  <EBC_ID>
EBC-11333

>  <IUPAC Name>
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 23, p. 10405 - 10413

>  <Main tar all>
CCR5 pX=11.6

$$$$
Etofenamate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -11.55 0 0
M  V30 2 C 5.3347 -12.32 0 0
M  V30 3 C 6.6684 -11.55 0 0
M  V30 4 O 8.0021 -12.32 0 0
M  V30 5 C 9.3358 -11.55 0 0
M  V30 6 C 10.6694 -12.32 0 0
M  V30 7 O 12.0031 -11.55 0 0
M  V30 8 C 13.3368 -12.32 0 0
M  V30 9 O 13.3368 -13.86 0 0
M  V30 10 C 14.6705 -11.55 0 0
M  V30 11 C 14.6705 -10.01 0 0
M  V30 12 C 16.0041 -9.24 0 0
M  V30 13 C 17.3378 -10.01 0 0
M  V30 14 C 17.3378 -11.55 0 0
M  V30 15 C 16.0041 -12.32 0 0
M  V30 16 N 16.0041 -13.86 0 0
M  V30 17 C 17.3378 -14.63 0 0
M  V30 18 C 18.6715 -13.86 0 0
M  V30 19 C 20.0052 -14.63 0 0
M  V30 20 C 20.0052 -16.17 0 0
M  V30 21 C 18.6715 -16.94 0 0
M  V30 22 C 17.3378 -16.17 0 0
M  V30 23 C 18.6715 -18.48 0 0
M  V30 24 F 18.6715 -20.02 0 0
M  V30 25 F 17.1315 -18.48 0 0
M  V30 26 F 20.2115 -18.48 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 23 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1248763315

>  <MW>
369.335

>  <MW (desalted)>
369.335

>  <ClogP>
4.886

>  <logS>
-4.332

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
67.79

>  <RotBonds>
10

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  51.8 % | IC50  0.014 mM | IC50 = 53000 nM | Ki (inhibition constant)  62.07 ?M

>  <CAS>
30544-47-9

>  <Description>
Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug.

>  <EBC_ID>
EBC-07699

>  <IUPAC Name>
2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate

>  <Main Tar all refs>
Pharm. Res., 2019, vol. 36, # 9 | Appl. Biochem. Biotechnol., 2020, vol. 190, # 2, p. 437 - 447 | Nippon. Yakurigaku Zasshi., 1987, vol. 89, # 1, p. 15 - 24 | Appl. Biochem. Biotechnol., 2020, vol. 190, # 2, p. 437 - 447

>  <Main tar all>
Kv7.1 pX=5.03 | Sorbitol dehydrogenase pX=4.85 | Lipoxygenase 1 pX=4.28 | Alpha-glucosidase pX=4.21

$$$$
Thiamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 4.4 0 0 0 CHG=-1
M  V30 3 C -1.7683 -3.0929 0 0
M  V30 4 C -1.7683 -4.6329 0 0
M  V30 5 C -3.0142 -5.5381 0 0
M  V30 6 C -4.4788 -5.0622 0 0
M  V30 7 C -4.799 -3.5559 0 0
M  V30 8 O -6.2636 -3.08 0 0
M  V30 9 S -2.5383 -7.0027 0 0
M  V30 10 C -0.9983 -7.0027 0 0
M  V30 11 N -0.5224 -5.5381 0 0 CHG=1
M  V30 12 C 0.9422 -5.0622 0 0
M  V30 13 C 2.0867 -6.0927 0 0
M  V30 14 C 3.5513 -5.6168 0 0
M  V30 15 N 4.6958 -6.6473 0 0
M  V30 16 C 4.3756 -8.1536 0 0
M  V30 17 C 5.52 -9.1841 0 0
M  V30 18 N 2.9109 -8.6295 0 0
M  V30 19 C 1.7665 -7.599 0 0
M  V30 20 N 0.3019 -8.0749 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 2 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 5 9
M  V30 7 1 9 10
M  V30 8 2 10 11
M  V30 9 1 4 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 2 16 18
M  V30 17 1 18 19
M  V30 18 2 13 19
M  V30 19 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954805523

>  <MW>
337.269

>  <MW (desalted)>
265.355

>  <ClogP>
-5.967

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
75.91

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  99.9 % | Ki (inhibition constant) = 333000 nM

>  <CAS>
67-03-8

>  <Description>
Thiamine is a vitamin used to correct vitamin B1 deficiency. It plays a key role in intracellular glucose metabolism and it is thought that thiamine inhibits the effect of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine plays an important role in helping the body convert carbohydrates and fat into energy.

>  <EBC_ID>
EBC-12622

>  <IUPAC Name>
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium hydrochloride chloride

>  <Main Tar all refs>
Lett. Drug Des. Discov., 2015, vol. 12, # 10, p. 819 - 827 | J. MED. CHEM., 1977, vol. 20, # 1, p. 161 - 164

>  <Main tar all>
Urease (peptide) pX=4.88 | acetylcholinesterase (Cartwright blood group) pX=3.48

$$$$
Plerixafor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0 -1.54 0 0
M  V30 2 N -1.3337 -0.77 0 0
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 C -2.6674 -3.08 0 0
M  V30 5 C -4.001 -2.31 0 0
M  V30 6 N -4.001 -0.77 0 0
M  V30 7 C -5.3347 -0 0 0
M  V30 8 C -5.3347 1.54 0 0
M  V30 9 N -4.001 2.31 0 0
M  V30 10 C -4.001 3.85 0 0
M  V30 11 C -2.6674 4.62 0 0
M  V30 12 C -1.3337 3.85 0 0
M  V30 13 N -1.3337 2.31 0 0
M  V30 14 C -0 1.54 0 0
M  V30 15 C -0 0 0 0
M  V30 16 C -0 -3.08 0 0
M  V30 17 C 1.3337 -3.85 0 0
M  V30 18 C 1.3337 -5.39 0 0
M  V30 19 C -0 -6.16 0 0
M  V30 20 C -0 -7.7 0 0
M  V30 21 N -1.3337 -8.47 0 0
M  V30 22 C -0 -9.24 0 0
M  V30 23 C -0 -10.78 0 0
M  V30 24 C -1.3337 -11.55 0 0
M  V30 25 N -2.6674 -10.78 0 0
M  V30 26 C -4.001 -11.55 0 0
M  V30 27 C -5.3347 -10.78 0 0
M  V30 28 N -5.3347 -9.24 0 0
M  V30 29 C -6.6684 -8.47 0 0
M  V30 30 C -6.6684 -6.93 0 0
M  V30 31 C -5.3347 -6.16 0 0
M  V30 32 N -4.001 -6.93 0 0
M  V30 33 C -2.6674 -6.16 0 0
M  V30 34 C -1.3337 -6.93 0 0
M  V30 35 C -1.3337 -5.39 0 0
M  V30 36 C -1.3337 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 2 15
M  V30 16 1 1 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 1 21 34
M  V30 36 2 19 35
M  V30 37 1 35 36
M  V30 38 2 16 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1889837352

>  <MW>
502.782

>  <MW (desalted)>
502.782

>  <ClogP>
-0.249

>  <logS>
1.37

>  <HBD>
6

>  <HBA>
8

>  <TPSA>
78.66

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | Inhibitor | Antagonist | - | Agonist | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
IC90 = 0.007 ?M | IC50 = 0.004 ?M | IC50 = 0.004 ?M | IC50  0.006134 ?M | concentration (parameter) = 10 nM | EC50  12 nM | EC50  12 nM | EC50  12 nM | IC50  12 nM

>  <CAS>
110078-46-1

>  <Description>
Plerixafor is a selective chemokine receptor (CXCR4) antagonist used with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin?s lymphoma and multiple myeloma.

>  <EBC_ID>
EBC-13587

>  <IUPAC Name>
1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane

>  <Main Tar all refs>
EMORY UNIVERSITY - WO2012/75362, 2012, A2 | Curr. Pharm. Des., 2004, vol. 10, # 32, p. 4005 - 4037 | Curr. Pharm. Des., 2004, vol. 10, # 32, p. 4005 - 4037 | Eur. J. Med. Chem., 2020, vol. 205 | Curr. Top. Med. Chem., 2004, vol. 4, # 9, p. 883 - 893 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4172 - 4180 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4172 - 4180 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4172 - 4180 | PLoS ONE, 2017, vol. 12, # 4

>  <Main tar all>
CXCR4 pX=9.11 | Glycoprotein 41 pX=8.4 | Surface protein gp120 pX=8.4 | CXCR4B pX=8.21 | Protease pX=8.0 | CCR5 pX=7.92 | CCR5 pX=7.92 | CD4 pX=7.92 | Stromal cell-derived factor 1 pX=7.92

$$$$
Cisatracurium besilate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 87 92 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -12.4783 -8.3485 0 0
M  V30 2 O -13.2013 -6.9887 0 0
M  V30 3 C -12.3852 -5.6827 0 0
M  V30 4 C -13.1082 -4.323 0 0
M  V30 5 C -12.2921 -3.017 0 0
M  V30 6 C -10.7531 -3.0707 0 0
M  V30 7 C -9.937 -1.7647 0 0
M  V30 8 C -10.66 -0.405 0 0 CFG=2
M  V30 9 C -12.1991 -0.3513 0 0
M  V30 10 C -13.0151 -1.6573 0 0
M  V30 11 C -14.5542 -1.6035 0 0
M  V30 12 O -15.3703 -2.9095 0 0
M  V30 13 C -16.9093 -2.8558 0 0
M  V30 14 C -15.2772 -0.2438 0 0
M  V30 15 O -16.8162 -0.19 0 0
M  V30 16 C -17.5392 1.1697 0 0
M  V30 17 C -14.4611 1.0622 0 0
M  V30 18 C -12.922 1.0085 0 0
M  V30 19 C -12.106 2.3145 0 0
M  V30 20 C -10.5669 2.2607 0 0
M  V30 21 N -9.8439 0.901 0 0 CHG=1 CFG=1
M  V30 22 C -8.4598 1.5761 0 0
M  V30 23 C -8.5102 0.131 0 0
M  V30 24 C -7.1766 0.901 0 0
M  V30 25 C -5.8429 0.131 0 0
M  V30 26 O -5.8429 -1.409 0 0
M  V30 27 O -4.5092 0.901 0 0
M  V30 28 C -3.1755 0.131 0 0
M  V30 29 C -1.8418 0.901 0 0
M  V30 30 C -0.5082 0.131 0 0
M  V30 31 C 0.8255 0.901 0 0
M  V30 32 C 2.1592 0.131 0 0
M  V30 33 O 3.4929 0.901 0 0
M  V30 34 C 4.8265 0.131 0 0
M  V30 35 O 4.8265 -1.409 0 0
M  V30 36 C 6.1602 0.901 0 0
M  V30 37 C 7.4939 0.131 0 0
M  V30 38 N 8.8276 0.901 0 0 CHG=1 CFG=1
M  V30 39 C 9.3543 -0.5461 0 0
M  V30 40 C 7.8377 2.0807 0 0
M  V30 41 C 8.3644 3.5278 0 0
M  V30 42 C 9.881 3.7952 0 0
M  V30 43 C 10.4077 5.2424 0 0
M  V30 44 C 11.9243 5.5098 0 0
M  V30 45 O 12.451 6.9569 0 0
M  V30 46 C 13.9676 7.2243 0 0
M  V30 47 C 12.9142 4.3301 0 0
M  V30 48 O 14.4308 4.5975 0 0
M  V30 49 C 15.4207 3.4178 0 0
M  V30 50 C 12.3875 2.883 0 0
M  V30 51 C 10.8709 2.6155 0 0
M  V30 52 C 10.3442 1.1684 0 0 CFG=1
M  V30 53 C 11.3341 -0.0113 0 0
M  V30 54 C 12.8507 0.2561 0 0
M  V30 55 C 13.3774 1.7032 0 0
M  V30 56 C 14.894 1.9707 0 0
M  V30 57 C 15.8839 0.791 0 0
M  V30 58 O 17.4005 1.0584 0 0
M  V30 59 C 17.9272 2.5055 0 0
M  V30 60 C 15.3572 -0.6562 0 0
M  V30 61 O 16.3471 -1.8359 0 0
M  V30 62 C 15.8204 -3.283 0 0
M  V30 63 C 13.8406 -0.9236 0 0
M  V30 64 C -10.0301 -4.4305 0 0
M  V30 65 C -10.8462 -5.7365 0 0
M  V30 66 O -10.1232 -7.0962 0 0
M  V30 67 C -10.9393 -8.4022 0 0
M  V30 68 O 22.7809 3.234 0 0 CHG=-1
M  V30 69 S 22.7809 1.694 0 0
M  V30 70 O 21.2409 1.694 0 0
M  V30 71 O 24.3209 1.694 0 0
M  V30 72 C 22.7809 0.154 0 0
M  V30 73 C 24.1146 -0.616 0 0
M  V30 74 C 24.1146 -2.156 0 0
M  V30 75 C 22.7809 -2.926 0 0
M  V30 76 C 21.4472 -2.156 0 0
M  V30 77 C 21.4472 -0.616 0 0
M  V30 78 O 0 -11.4822 0 0 CHG=-1
M  V30 79 S 0 -13.0222 0 0
M  V30 80 O -1.54 -13.0222 0 0
M  V30 81 O 1.54 -13.0222 0 0
M  V30 82 C -0 -14.5622 0 0
M  V30 83 C 1.3337 -15.3322 0 0
M  V30 84 C 1.3337 -16.8722 0 0
M  V30 85 C -0 -17.6422 0 0
M  V30 86 C -1.3337 -16.8722 0 0
M  V30 87 C -1.3337 -15.3322 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 11 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 14 17
M  V30 17 1 17 18
M  V30 18 2 9 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 21 20
M  V30 22 1 8 21
M  V30 23 1 21 22 CFG=1
M  V30 24 1 21 23 CFG=3
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 34 36
M  V30 38 1 36 37
M  V30 39 1 38 37 CFG=1
M  V30 40 1 38 39 CFG=3
M  V30 41 1 38 40
M  V30 42 1 40 41
M  V30 43 1 41 42
M  V30 44 1 42 43
M  V30 45 2 43 44
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 1 44 47
M  V30 49 1 47 48
M  V30 50 1 48 49
M  V30 51 2 47 50
M  V30 52 1 50 51
M  V30 53 2 42 51
M  V30 54 1 52 51
M  V30 55 1 38 52
M  V30 56 1 52 53 CFG=1
M  V30 57 1 53 54
M  V30 58 1 54 55
M  V30 59 2 55 56
M  V30 60 1 56 57
M  V30 61 1 57 58
M  V30 62 1 58 59
M  V30 63 2 57 60
M  V30 64 1 60 61
M  V30 65 1 61 62
M  V30 66 1 60 63
M  V30 67 2 54 63
M  V30 68 2 6 64
M  V30 69 1 64 65
M  V30 70 2 3 65
M  V30 71 1 65 66
M  V30 72 1 66 67
M  V30 73 1 68 69
M  V30 74 2 69 70
M  V30 75 2 69 71
M  V30 76 1 69 72
M  V30 77 1 72 73
M  V30 78 2 73 74
M  V30 79 1 74 75
M  V30 80 2 75 76
M  V30 81 1 76 77
M  V30 82 2 72 77
M  V30 83 1 78 79
M  V30 84 2 79 80
M  V30 85 2 79 81
M  V30 86 1 79 82
M  V30 87 1 82 83
M  V30 88 2 83 84
M  V30 89 1 84 85
M  V30 90 2 85 86
M  V30 91 1 86 87
M  V30 92 2 82 87
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2185279095

>  <MW>
1243.479

>  <MW (desalted)>
929.145

>  <ClogP>
3.497

>  <logS>
-5.54

>  <HBD>
0

>  <HBA>
10

>  <TPSA>
126.44

>  <RotBonds>
28

>  <CAS>
96946-42-8

>  <Description>
Cisatracurium is a skeletal muscle relaxant used to facilitate tracheal intubation, muscle relaxation in surgery, or mechanical ventilation. It acts on cholinergic receptors, blocking neuromuscular transmission.

>  <EBC_ID>
EBC-12894

>  <IUPAC Name>
(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium dibenzenesulfonate

$$$$
SN-38
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4124 4.8437 0 0
M  V30 2 C 2.9187 4.5235 0 0
M  V30 3 C 3.3946 3.0589 0 0
M  V30 4 C 4.9009 2.7387 0 0
M  V30 5 C 6.1468 3.6439 0 0
M  V30 6 N 7.3927 2.7387 0 0
M  V30 7 C 6.9168 1.2741 0 0
M  V30 8 C 7.9473 0.1296 0 0
M  V30 9 C 9.4536 0.4498 0 0
M  V30 10 C 9.9295 1.9144 0 0
M  V30 11 C 11.4359 2.2346 0 0
M  V30 12 O 12.4663 1.0902 0 0
M  V30 13 C 11.9905 -0.3744 0 0
M  V30 14 O 13.0209 -1.5189 0 0
M  V30 15 C 10.4841 -0.6946 0 0 CFG=1
M  V30 16 O 10.7515 -2.2112 0 0
M  V30 17 C 9.3763 -1.7644 0 0
M  V30 18 C 7.896 -1.3399 0 0
M  V30 19 C 8.8991 3.0589 0 0
M  V30 20 O 9.375 4.5235 0 0
M  V30 21 C 5.3768 1.2741 0 0
M  V30 22 N 4.3464 0.1296 0 0
M  V30 23 C 2.84 0.4498 0 0
M  V30 24 C 1.8096 -0.6946 0 0
M  V30 25 C 0.3032 -0.3744 0 0
M  V30 26 C -0.1727 1.0902 0 0
M  V30 27 O -1.679 1.4104 0 0
M  V30 28 C 0.8578 2.2346 0 0
M  V30 29 C 2.3641 1.9144 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 15 13
M  V30 15 1 15 9
M  V30 16 1 15 16 CFG=1
M  V30 17 1 15 17 CFG=3
M  V30 18 1 17 18
M  V30 19 1 10 19
M  V30 20 1 6 19
M  V30 21 2 19 20
M  V30 22 1 7 21
M  V30 23 2 4 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 31 1 28 29
M  V30 32 2 3 29
M  V30 33 1 23 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759909

>  <MW>
392.405

>  <MW (desalted)>
392.405

>  <ClogP>
1.974

>  <logS>
-4.61

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
99.96

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | inhibition percentage Active   | dead cell percentage increase Active   | EC50  0.75 nM | EC50  0.89 nM | IC50 = 1.6 nM

>  <CAS>
86639-52-3

>  <Description>
SN-38 is the active metabolite of Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others.

>  <EBC_ID>
EBC-11025

>  <IUPAC Name>
(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione

>  <Main Tar all refs>
Cells, 2019, vol. 8, # 7 | Cells, 2019, vol. 8, # 7 | Nat. Commun., 2021, vol. 12, # 1 | OREGON HEALTH & SCIENCE UNIVERSITY - WO2023/288002, 2023, A1 | Cell Chem. Biol., 2022, vol. 29, # 12, p. 1694 - 10,1708 | NOVARTIS AG; Novartis (w/o Sandoz) - WO2004/32925, 2004, A1

>  <Main tar all>
ABCG2 pX=10.0 | ABCG2 (Q141K) pX=10.0 | topoisomerase (DNA) I mitochondrial pX=9.28 | Reverse gyrase pX=9.12 | poly(ADP-ribose) polymerase 1 pX=9.05 | ABCG2 pX=8.8

$$$$
Tenoxicam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 C 4.9239 1.3028 0 0
M  V30 5 O 4.9239 -0.2372 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 S 2.1256 1.5969 0 0
M  V30 8 C 1.2204 2.8428 0 0
M  V30 9 C 2.1256 4.0887 0 0
M  V30 10 C 3.5902 3.6128 0 0
M  V30 11 S 4.9239 4.3828 0 0
M  V30 12 O 4.2009 5.7426 0 0
M  V30 13 O 5.6469 5.7426 0 0
M  V30 14 C 7.5913 1.3028 0 0
M  V30 15 O 7.5913 -0.2372 0 0
M  V30 16 N 8.925 2.0728 0 0
M  V30 17 C 10.2586 1.3028 0 0
M  V30 18 C 11.5923 2.0728 0 0
M  V30 19 C 12.926 1.3028 0 0
M  V30 20 C 12.926 -0.2372 0 0
M  V30 21 C 11.5923 -1.0072 0 0
M  V30 22 N 10.2586 -0.2372 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 1 2 11
M  V30 13 2 11 12
M  V30 14 2 11 13
M  V30 15 1 3 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038907

>  <MW>
337.019

>  <MW (desalted)>
337.374

>  <ClogP>
1.609

>  <logS>
-3.172

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
99.6

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.032 ?M | IC50 = 0.13 ?M | IC50 = 0.201 ?M | inhibition percentage Active

>  <CAS>
59804-37-4

>  <Description>
Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) that acts as a COX inhibitor.  It demonstrates analgesic and antipyretic properties and has been used to clinically treat osteoarthritis or to control acute pain.

>  <EBC_ID>
EBC-04427

>  <IUPAC Name>
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1lambda6-thieno[2,3-e][1,2]thiazine-3-carboxamide

>  <Main Tar all refs>
Chem. Phys. Lipids, 2011, vol. 164, # 4, p. 292 - 299 | EVA BINDER - US2007/275958, 2007, A1 | LAURAS - US2004/82640, 2004, A1 | Nat. Commun., 2019, vol. 10, # 1

>  <Main tar all>
Phospholipase A2 pX=7.49 | COX-2  pX=6.89 | COX-1  pX=6.7 | Nucleoprotein pX=6.0

$$$$
Scopolamine hydrobromide trihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 O 8.8 0 0 0
M  V30 4 Br 0 -6.1439 0 0
M  V30 5 C 4.4 -4.8102 0 0
M  V30 6 N 5.94 -4.8102 0 0
M  V30 7 C 6.3725 -6.5403 0 0 CFG=1
M  V30 8 C 7.8739 -6.1977 0 0
M  V30 9 C 8.5421 -4.8102 0 0 CFG=1
M  V30 10 C 7.8739 -3.4227 0 0
M  V30 11 C 6.3725 -3.08 0 0 CFG=2
M  V30 12 C 5.1685 -4.0402 0 0 CFG=1
M  V30 13 O 3.8348 -4.8102 0 0
M  V30 14 C 5.1685 -5.5802 0 0 CFG=1
M  V30 15 O 10.0821 -4.8102 0 0
M  V30 16 C 10.8521 -6.1439 0 0
M  V30 17 O 10.0821 -7.4775 0 0
M  V30 18 C 12.3921 -6.1439 0 0 CFG=2
M  V30 19 C 13.1621 -4.8102 0 0
M  V30 20 O 14.7021 -4.8102 0 0
M  V30 21 C 13.1621 -7.4775 0 0
M  V30 22 C 14.7021 -7.4775 0 0
M  V30 23 C 15.4721 -8.8112 0 0
M  V30 24 C 14.7021 -10.1449 0 0
M  V30 25 C 13.1621 -10.1449 0 0
M  V30 26 C 12.3921 -8.8112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 6
M  V30 2 1 7 6 CFG=3
M  V30 3 1 7 8
M  V30 4 1 9 8
M  V30 5 1 9 10
M  V30 6 1 11 10
M  V30 7 1 11 6 CFG=3
M  V30 8 1 12 11
M  V30 9 1 12 13 CFG=3
M  V30 10 1 14 13 CFG=3
M  V30 11 1 12 14
M  V30 12 1 14 7
M  V30 13 1 9 15 CFG=1
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 18 16 CFG=3
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 18 21
M  V30 20 1 21 22
M  V30 21 2 22 23
M  V30 22 1 23 24
M  V30 23 2 24 25
M  V30 24 1 25 26
M  V30 25 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3207130668

>  <MW>
437.105

>  <MW (desalted)>
303.353

>  <ClogP>
0.29

>  <logS>
-2.295

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
62.3

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  10.96  | pKi  10.6  | Ki (inhibition constant)  0.085 nM | Ki (inhibition constant)  0.25 nM

>  <CAS>
6533-68-2

>  <Description>
Scopolamine is a belladonna alkaloid with anticholinergic effects indicated for the treatment of nausea and vomiting associated with motion sickness and postoperative nausea and vomiting. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.

>  <EBC_ID>
EBC-15037

>  <IUPAC Name>
(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0,2,4]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate trihydrate hydrobromide

>  <Main Tar all refs>
BIOORG. MED. CHEM., 1995, vol. 3, # 11, p. 1465 - 1477 | LIFE SCI., 1987, vol. 40, # 20, p. 1981 - 1987 | Br. J. Pharmacol., 1999, vol. 126, # 3, p. 735 - 745 | Psychopharmacology, 1995, vol. 117, # 2, p. 208 - 215

>  <Main tar all>
M3 receptor pX=11.0 | mAChR pX=10.6 | M1 receptor pX=10.1 | M2 receptor pX=9.6

$$$$
Clarithromycin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 52 54 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.001 8.47 0 0
M  V30 2 C -5.3347 7.7 0 0
M  V30 3 C -5.3347 6.16 0 0 CFG=1
M  V30 4 O -4.001 6.93 0 0
M  V30 5 C -2.6674 6.16 0 0
M  V30 6 O -1.3337 6.93 0 0
M  V30 7 C -2.6674 4.62 0 0 CFG=2
M  V30 8 C -1.1358 4.781 0 0
M  V30 9 C -4.001 3.85 0 0 CFG=1
M  V30 10 O -2.6674 3.08 0 0
M  V30 11 C -1.3337 3.85 0 0 CFG=1
M  V30 12 C -1.3337 5.39 0 0
M  V30 13 C -0 6.16 0 0 CFG=1
M  V30 14 C -0.9899 7.3397 0 0
M  V30 15 O 0.9899 7.3397 0 0
M  V30 16 C 0.4632 8.7868 0 0
M  V30 17 C 1.3337 5.39 0 0 CFG=1
M  V30 18 O 2.6674 6.16 0 0
M  V30 19 C 1.3337 3.85 0 0 CFG=2
M  V30 20 C 2.6674 3.08 0 0
M  V30 21 O -0 3.08 0 0
M  V30 22 C -4.001 2.31 0 0 CFG=2
M  V30 23 C -2.6674 1.54 0 0
M  V30 24 C -5.3347 1.54 0 0 CFG=1
M  V30 25 O -5.3347 0 0 0
M  V30 26 C -4.001 -0.77 0 0 CFG=2
M  V30 27 O -2.6674 0 0 0
M  V30 28 C -1.3337 -0.77 0 0 CFG=2
M  V30 29 C -0 0 0 0
M  V30 30 C -1.3337 -2.31 0 0
M  V30 31 C -2.6674 -3.08 0 0 CFG=1
M  V30 32 C -4.001 -2.31 0 0 CFG=1
M  V30 33 O -5.3347 -3.08 0 0
M  V30 34 N -2.6674 -4.62 0 0
M  V30 35 C -1.3337 -5.39 0 0
M  V30 36 C -4.001 -5.39 0 0
M  V30 37 C -6.6684 2.31 0 0 CFG=1
M  V30 38 C -6.1417 0.8629 0 0
M  V30 39 C -8.0021 1.54 0 0
M  V30 40 C -9.3358 2.31 0 0 CFG=1
M  V30 41 C -10.6694 1.54 0 0
M  V30 42 C -9.3358 3.85 0 0
M  V30 43 O -10.6694 4.62 0 0
M  V30 44 C -8.0021 4.62 0 0 CFG=2
M  V30 45 C -6.6684 3.85 0 0
M  V30 46 C -8.0021 6.16 0 0 CFG=1
M  V30 47 O -9.3358 6.93 0 0
M  V30 48 C -6.6684 6.93 0 0 CFG=1
M  V30 49 C -7.3914 8.2897 0 0
M  V30 50 O -5.9454 8.2897 0 0
M  V30 51 O -7.1951 0.8629 0 0
M  V30 52 C -8.7117 0.5955 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7 CFG=1
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 17 13
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 19 21
M  V30 21 1 11 21
M  V30 22 1 9 22
M  V30 23 1 22 23 CFG=3
M  V30 24 1 22 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 32 31
M  V30 33 1 32 26
M  V30 34 1 32 33 CFG=1
M  V30 35 1 31 34 CFG=3
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 24 37
M  V30 39 1 37 38 CFG=1
M  V30 40 1 37 39
M  V30 41 1 40 39
M  V30 42 1 40 41 CFG=1
M  V30 43 1 40 42
M  V30 44 2 42 43
M  V30 45 1 44 42
M  V30 46 1 44 45 CFG=1
M  V30 47 1 46 44
M  V30 48 1 46 47 CFG=1
M  V30 49 1 46 48
M  V30 50 1 48 3
M  V30 51 1 48 49 CFG=1
M  V30 52 1 48 50 CFG=3
M  V30 53 1 37 51 CFG=3
M  V30 54 1 51 52
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385076

>  <MW>
747.477

>  <MW (desalted)>
747.953

>  <ClogP>
2.374

>  <logS>
-2.422

>  <HBD>
4

>  <HBA>
13

>  <TPSA>
182.91

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.002 ?g/ml | MIC  0.01 mg/l | MIC  0.02 ?g/ml | MIC90  0.27 ?M | MIC90  0.4 ?M | MIC  0.07 ?M

>  <CAS>
81103-11-9

>  <Description>
Clarithromycin is a macrolide antibiotic used for the treatment of a wide variety of bacterial infections such as acute otitis, pharyngitis, tonsillitis, respiratory tract infections, uncomplicated skin infections, and helicobacter pylori infection.

>  <EBC_ID>
EBC-11206

>  <IUPAC Name>
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

>  <Main Tar all refs>
, 2021, vol. 12, # 11, p. 1894 - 1909 | J. Enzyme Inhib. Med. Chem., 2023, vol. 38, # 1 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 1362 - 1375 | J. Med. Chem., 2023, vol. 66, # 7, p. 5079 - 5098 | Antimicrob. Agents Chemother., 2022, vol. 66, # 1 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5

>  <Main tar all>
N-acetyltransferase Eis pX=8.57 | Urease pX=7.87 | Urease (urea amidohydrolase) pX=7.57 | RNA polymerase pX=7.52 | Beta sliding clamp pX=7.35 | Leucine-tRNA ligase (activity) pX=7.15

$$$$
Isosorbide dinitrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.0883 -4.9712 0 0 CHG=-1
M  V30 2 N 0.3876 -3.5066 0 0 CHG=1
M  V30 3 O -0.6429 -2.3621 0 0
M  V30 4 O 1.8939 -3.1864 0 0
M  V30 5 C 2.3698 -1.7218 0 0 CFG=2
M  V30 6 C 1.4646 -0.4759 0 0
M  V30 7 O 2.3698 0.77 0 0
M  V30 8 C 3.8344 0.2941 0 0 CFG=2
M  V30 9 C 5.2991 0.77 0 0 CFG=2
M  V30 10 C 6.2043 -0.4759 0 0
M  V30 11 O 5.2991 -1.7218 0 0
M  V30 12 C 3.8344 -1.2459 0 0 CFG=2
M  V30 13 O 5.775 2.2346 0 0
M  V30 14 N 7.2813 2.5548 0 0 CHG=1
M  V30 15 O 7.7572 4.0194 0 0
M  V30 16 O 8.3118 1.4104 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 5
M  V30 13 1 8 12
M  V30 14 1 9 13 CFG=1
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2044782386

>  <MW>
236.028

>  <MW (desalted)>
236.136

>  <ClogP>
-3.497

>  <logS>
-2.758

>  <HBD>
0

>  <HBA>
8

>  <TPSA>
123.2

>  <RotBonds>
4

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
87-33-2

>  <Description>
Isosorbide dinitrate is a vasodilator used to treat angina in coronary artery disease. Isosorbide dinitrate is converted to the active nitric oxide to activate guanylate cyclase.

>  <EBC_ID>
EBC-07863

>  <IUPAC Name>
(3R,3aS,6S,6aS)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate

$$$$
Edoxaban
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -5.7096 -5.3039 0 0
M  V30 2 N -4.9396 -3.9702 0 0
M  V30 3 C -3.3996 -3.9702 0 0
M  V30 4 C -5.7096 -2.6365 0 0
M  V30 5 O -7.2496 -2.6365 0 0
M  V30 6 C -4.9396 -1.3028 0 0 CFG=1
M  V30 7 C -5.7096 0.0309 0 0
M  V30 8 C -4.9396 1.3645 0 0
M  V30 9 C -3.3996 1.3645 0 0 CFG=2
M  V30 10 N -2.6296 2.6982 0 0
M  V30 11 C -3.3996 4.0319 0 0
M  V30 12 O -4.9396 4.0319 0 0
M  V30 13 C -2.6296 5.3656 0 0
M  V30 14 O -1.0896 5.3656 0 0
M  V30 15 N -3.3996 6.6992 0 0
M  V30 16 C -2.6296 8.0329 0 0
M  V30 17 C -3.3996 9.3666 0 0
M  V30 18 C -2.6296 10.7003 0 0
M  V30 19 C -1.0896 10.7003 0 0
M  V30 20 Cl -0.3196 12.034 0 0
M  V30 21 C -0.3196 9.3666 0 0
M  V30 22 N -1.0896 8.0329 0 0
M  V30 23 C -2.6296 0.0309 0 0 CFG=1
M  V30 24 C -3.3996 -1.3028 0 0
M  V30 25 N -1.0896 0.0309 0 0
M  V30 26 C -0.3196 -1.3028 0 0
M  V30 27 O -1.0896 -2.6365 0 0
M  V30 28 C 1.2204 -1.3028 0 0
M  V30 29 N 2.1256 -0.0569 0 0
M  V30 30 C 3.5902 -0.5328 0 0
M  V30 31 C 4.9239 0.2372 0 0
M  V30 32 C 6.2576 -0.5328 0 0
M  V30 33 N 6.2576 -2.0728 0 0
M  V30 34 C 7.5913 -2.8428 0 0
M  V30 35 C 4.9239 -2.8428 0 0
M  V30 36 C 3.5902 -2.0728 0 0
M  V30 37 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 6 4 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 21 22
M  V30 22 2 16 22
M  V30 23 1 9 23
M  V30 24 1 23 24
M  V30 25 1 6 24
M  V30 26 1 23 25 CFG=3
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 33 35
M  V30 37 1 35 36
M  V30 38 2 30 36
M  V30 39 1 36 37
M  V30 40 1 28 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301684749

>  <MW>
548.058

>  <MW (desalted)>
548.058

>  <ClogP>
0.152

>  <logS>
-3.101

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
136.63

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.457 nM | concentration (parameter)  823.73 ng/l

>  <CAS>
480449-70-5

>  <Description>
Edoxaban is an anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). It is a rapidly acting, oral, selective factor Xa inhibitor.

>  <EBC_ID>
EBC-27305

>  <IUPAC Name>
N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide

>  <Main Tar all refs>
J. Thromb. Haemost., 2008, vol. 6, # 9, p. 1542 - 1549 | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. - EP3213749, 2017, A1

>  <Main tar all>
coagulation factor X pX=9.34 | PAF receptor pX=8.82

$$$$
Triprolidine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 12.8558 3.4652 0 0
M  V30 3 C 11.5221 2.6952 0 0
M  V30 4 C 11.5221 1.1552 0 0
M  V30 5 C 10.1884 0.3852 0 0
M  V30 6 C 8.8547 1.1552 0 0
M  V30 7 C 8.8547 2.6952 0 0
M  V30 8 C 10.1884 3.4652 0 0
M  V30 9 C 7.521 0.3852 0 0
M  V30 10 C 7.521 -1.1548 0 0
M  V30 11 C 8.8547 -1.9248 0 0
M  V30 12 N 8.8547 -3.4648 0 0
M  V30 13 C 10.1006 -4.37 0 0
M  V30 14 C 9.6247 -5.8346 0 0
M  V30 15 C 8.0847 -5.8346 0 0
M  V30 16 C 7.6088 -4.37 0 0
M  V30 17 C 6.1874 1.1552 0 0
M  V30 18 C 4.8537 0.3852 0 0
M  V30 19 C 3.52 1.1552 0 0
M  V30 20 C 3.52 2.6952 0 0
M  V30 21 C 4.8537 3.4652 0 0
M  V30 22 N 6.1874 2.6952 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 6 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 12 16
M  V30 17 1 9 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2312950560

>  <MW>
314.155

>  <MW (desalted)>
278.391

>  <ClogP>
3.634

>  <logS>
-3.992

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
16.13

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
pA2  9.94  | Ki (inhibition constant)  0.12 nM | Ki (inhibition constant)  1 nM | Ki (inhibition constant)  3.3 nM

>  <CAS>
550-70-9

>  <Description>
Triprolidine binds to the histamine H1 receptor. It is a first generation antihistamine, used for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis.

>  <EBC_ID>
EBC-67029

>  <IUPAC Name>
2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2006, vol. 14, # 11, p. 3625 - 3634 | Brain Res., 1999, vol. 837, # 1-2, p. 95 - 105 | MOL. PHARMACOL., 1978, vol. 14, # 6, p. 971 - 982 | ELI LILLY & CO - US2005/80265, 2005, A1

>  <Main tar all>
H1 receptor pX=9.94 | Sigma 3 receptor pX=9.92 | H2 receptor pX=9.0 | M1 receptor pX=8.48

$$$$
Benzyl alcohol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104476418

>  <MW>
108.058

>  <MW (desalted)>
108.138

>  <ClogP>
1.104

>  <logS>
-0.9

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  15.29 ?M | Km (Michaelis constant) = 17.3 ?M | Km (Michaelis constant) = 50000 nM | percentage increase  51.18 % | concentration (parameter) = 0.1 mM | Ki (inhibition constant)  153.5 ?M | activation percentage  79.64 %

>  <CAS>
100-51-6

>  <Description>
Benzyl alcohol is an antiparasitic agent used for the topical treatment of head lice infestation in patients 6 months of age and older. It inhibits lice from closing their respiratory spiracles, allowing the vehicle to obstruct the spiracles and causing the lice to asphyxiate.

>  <EBC_ID>
EBC-26043

>  <IUPAC Name>
phenylmethanol

>  <Main Tar all refs>
Biochem. J., 2005, vol. 389, # 2, p. 569 - 576 | EUR. J. BIOCHEM., 1990, vol. 191, # 3, p. 705 - 714 | J. Med. Chem., 2002, vol. 45, # 25, p. 5514 - 5522 | PROCTER & GAMBLE CO; Gillette (in: P&G) - US2017/713, 2017, A1 | Arch. Pharmacal Res., 2006, vol. 29, # 10, p. 849 - 858 | Biochem. Biophys. Res. Commun., 2021, vol. 548, p. 217 - 221 | PROCTER & GAMBLE CO - WO2015/153184, 2015, A1

>  <Main tar all>
TRH-specific aminopeptidase pX=4.82 | Aryl-alcohol dehydrogenase pX=4.76 | Sulfotransferase 1A1 pX=4.3 | TRPV1 pX=4.02 | COX-1  pX=4.0 | carbonic anhydrase 2 pX=3.81 | TRPA1 pX=3.59

$$$$
Chlorzoxazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 7.5913 4.3828 0 0
M  V30 2 C 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 C 4.9239 1.3028 0 0
M  V30 5 C 3.5902 2.0728 0 0
M  V30 6 O 2.1256 1.5969 0 0
M  V30 7 C 1.2204 2.8428 0 0
M  V30 8 O -0.3196 2.8428 0 0
M  V30 9 N 2.1256 4.0887 0 0
M  V30 10 C 3.5902 3.6128 0 0
M  V30 11 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 2 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57183224

>  <MW>
168.993

>  <MW (desalted)>
169.565

>  <ClogP>
1.871

>  <logS>
-2.87

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.33

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Activator | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 8.7 ?M | IC50 = 9.2 ?M | Ki (inhibition constant)  10.2 ?M | IC50 = 14.1 ?M | EC50 = 18 ?M | EC50 = 18 ?M | threshold increase Active   | IC50 = 50 ?M | Ki (inhibition constant)  52.3 ?M | EC50 = 100 ?M | IC50  165.9 ?M | IC50  165.9 ?M | inhibition percentage  42 %

>  <CAS>
95-25-0

>  <Description>
Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. Chlorzoxazone act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation.

>  <EBC_ID>
EBC-12579

>  <IUPAC Name>
5-chloro-2,3-dihydro-1,3-benzoxazol-2-one

>  <Main Tar all refs>
Curr. Pharm. Des., 2002, vol. 8, # 3, p. 177 - 200 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 996 - 1005 | J. Pharm. Sci., 2021, vol. 110, # 1, p. 347 - 353 | Curr. Pharm. Des., 2002, vol. 8, # 3, p. 177 - 200 | Curr. Med. Chem., 2008, vol. 15, # 11, p. 1126 - 1146 | Curr. Med. Chem., 2008, vol. 15, # 11, p. 1126 - 1146 | UNIVERSITY OF MICHIGAN - US2019/134007, 2019, A1 | Curr. Pharm. Des., 2002, vol. 8, # 3, p. 177 - 200 | J. Pharm. Sci., 2021, vol. 110, # 1, p. 347 - 353 | Curr. Med. Chem., 2007, vol. 14, # 13, p. 1437 - 1457 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Drug Metab. Dispos., 2015, vol. 43, # 6, p. 812 - 818

>  <Main tar all>
Endothelial NOS pX=5.06 | CYP2E1 pX=5.04 | Organic anion transporter 3 pX=4.99 | Inducible NOS pX=4.85 | KCa?1 pX=4.74 | KCa1.1 pX=4.74 | KNa1.1 pX=4.3 | Neuronal NOS pX=4.3 | Organic anion transporter 1 pX=4.28 | KCa3.1 pX=4.0 | Organic cation/carnitine transporter 2 pX=3.78 | Organic cation/carnitine transporter 2 pX=3.78 |  UDP glucuronosyltransferase family 1 member A8 pX=3.56

$$$$
Carbamoylcholine chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 5.17 3.7343 0 0
M  V30 3 N 5.94 2.4006 0 0 CHG=1
M  V30 4 C 4.6063 1.6306 0 0
M  V30 5 C 7.2737 3.1706 0 0
M  V30 6 C 6.71 1.0669 0 0
M  V30 7 C 5.94 -0.2667 0 0
M  V30 8 O 6.71 -1.6004 0 0
M  V30 9 C 5.94 -2.9341 0 0
M  V30 10 O 6.71 -4.2678 0 0
M  V30 11 N 4.4 -2.9341 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255415481

>  <MW>
182.082

>  <MW (desalted)>
147.196

>  <ClogP>
-4.319

>  <logS>
-0.02

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
52.32

>  <RotBonds>
4

>  <Action on targets>
- | Agonist | Agonist | - | - | - | -

>  <Activity coefficients and valu>
left ventricular pressure decrease Active   | percentage of viable cells decrease Active   | percentage of viable cells decrease Active   | Kd (dissociation constant) = 27 pM | Kd (dissociation constant) = 27 pM | Kd (dissociation constant) = 27 pM | Kd (dissociation constant) = 27 pM

>  <CAS>
51-83-2

>  <Description>
Carbamoylcholine is an analog of acetylcholine that activates acetylcholine receptors (AChR). Carbachol is a direct acting miotic agent administered ophthalmically to decrease intraocular pressure after cataract surgery, and to induce miosis during surgery.

>  <EBC_ID>
EBC-03255

>  <IUPAC Name>
2-(trimethylazaniumyl)ethyl carbamate chloride

>  <Main Tar all refs>
Steroids, 2020, vol. 158 | Int. Immunopharmacol., 2020, vol. 84 | Int. Immunopharmacol., 2020, vol. 84 | J. Biol. Chem., 2011, vol. 286, # 46, p. 39726 - 39737 | J. Biol. Chem., 2011, vol. 286, # 46, p. 39726 - 39737 | J. Biol. Chem., 2011, vol. 286, # 46, p. 39726 - 39737 | J. Biol. Chem., 2011, vol. 286, # 46, p. 39726 - 39737

>  <Main tar all>
M2 receptor pX=12.0 | M3 receptor pX=12.0 | M4 receptor pX=12.0 | nicotinic acetylcholine receptor ?-like 1 pX=10.6 | nicotinic acetylcholine receptor ?-like 1 pX=10.6 | nicotinic acetylcholine receptor ?1 subunit pX=10.6 | nicotinic acetylcholine receptor ?1 subunit pX=10.6

$$$$
Metaraminol bitartrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.778 3.9142 0 0
M  V30 2 C -0.778 2.3742 0 0 CFG=2
M  V30 3 N -2.1117 1.6042 0 0
M  V30 4 C 0.5557 1.6042 0 0 CFG=2
M  V30 5 O 1.8894 2.3742 0 0
M  V30 6 C 0.5557 0.0642 0 0
M  V30 7 C 1.8894 -0.7058 0 0
M  V30 8 C 1.8894 -2.2458 0 0
M  V30 9 C 0.5557 -3.0158 0 0
M  V30 10 C -0.778 -2.2458 0 0
M  V30 11 O -2.1117 -3.0158 0 0
M  V30 12 C -0.778 -0.7058 0 0
M  V30 13 O 9.1904 1.925 0 0
M  V30 14 C 9.1904 0.385 0 0 CFG=2
M  V30 15 C 7.8567 -0.385 0 0 CFG=1
M  V30 16 O 7.8567 -1.925 0 0
M  V30 17 C 6.5231 0.385 0 0
M  V30 18 O 5.1894 -0.385 0 0
M  V30 19 O 6.5231 1.925 0 0
M  V30 20 C 10.5241 -0.385 0 0
M  V30 21 O 11.8578 0.385 0 0
M  V30 22 O 10.5241 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 6 12
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16 CFG=1
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 14 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2050038784

>  <MW>
317.111

>  <MW (desalted)>
167.205

>  <ClogP>
-0.083

>  <logS>
-0.674

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
66.48

>  <RotBonds>
5

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
pEC50  5.11

>  <CAS>
33402-03-8

>  <Description>
Metaraminol An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension.

>  <EBC_ID>
EBC-04139

>  <IUPAC Name>
(2R,3R)-2,3-dihydroxybutanedioic acid; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol

>  <Main Tar all refs>
Br. J. Pharmacol., 1972, vol. 45, # 3, p. 510 - 518

>  <Main tar all>
?-adrenoceptor pX=5.11

$$$$
Nicotine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 2.5796 -3.2152 0 0
M  V30 4 C 2.1037 -4.6798 0 0
M  V30 5 C 0.5637 -4.6798 0 0
M  V30 6 C 0.0878 -3.2152 0 0 CFG=1
M  V30 7 C -1.3768 -2.7393 0 0
M  V30 8 C -2.5213 -3.7698 0 0
M  V30 9 C -3.9859 -3.2939 0 0
M  V30 10 C -4.3061 -1.7875 0 0
M  V30 11 N -3.1616 -0.7571 0 0
M  V30 12 C -1.697 -1.233 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 2
M  V30 7 1 6 7 CFG=1
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198150037

>  <MW>
162.116

>  <MW (desalted)>
162.232

>  <ClogP>
0.883

>  <logS>
-0.14

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
16.13

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.2E-11 M | Ki (inhibition constant) = 1.5E-10 M | Ki (inhibition constant) = 1.5E-10 M | Ki (inhibition constant) = 1.5E-10 M | Ki (inhibition constant) = 1.5E-10 M | Ki (inhibition constant) = 1.5E-10 M | Ki (inhibition constant)  0.0002 ?M | Ki (inhibition constant)  0.0002 ?M

>  <CAS>
54-11-5

>  <Description>
Nicotine is a stimulatory alkaloid found in tobacco products. It is often used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation. Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission.

>  <EBC_ID>
EBC-12757

>  <IUPAC Name>
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

>  <Main Tar all refs>
J. MED. CHEM., 1985, vol. 28, # 9, p. 1245 - 1251 | J. Med. Chem., 2012, vol. 55, # 20, p. 8603 - 8614 | J. Med. Chem., 2012, vol. 55, # 20, p. 8603 - 8614 | J. Med. Chem., 2012, vol. 55, # 20, p. 8603 - 8614 | J. Med. Chem., 2012, vol. 55, # 20, p. 8603 - 8614 | J. Med. Chem., 2012, vol. 55, # 20, p. 8603 - 8614 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 23, p. 5827 - 5830 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 23, p. 5827 - 5830

>  <Main tar all>
nicotinic acetylcholine receptor pX=10.7 | Acetylcholine receptor subunit gamma (isoform 1) pX=9.82 | nicotinic acetylcholine receptor ?-like 1 pX=9.82 | nicotinic acetylcholine receptor ?-like 1 pX=9.82 | nicotinic acetylcholine receptor ?1 subunit pX=9.82 | nicotinic acetylcholine receptor ?1 subunit pX=9.82 | nicotinic acetylcholine receptor ?4 subunit pX=9.7 | nicotinic acetylcholine receptor ?2 subunit pX=9.7

$$$$
Zonisamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -1.363 -4.6537 0 0
M  V30 2 S 0.1434 -4.3335 0 0
M  V30 3 O 0.4636 -5.8399 0 0
M  V30 4 O -0.1768 -2.8272 0 0
M  V30 5 C 1.6497 -4.0133 0 0
M  V30 6 C 2.1256 -2.5487 0 0
M  V30 7 N 1.2204 -1.3028 0 0
M  V30 8 O 2.1256 -0.0569 0 0
M  V30 9 C 3.5902 -0.5328 0 0
M  V30 10 C 4.9239 0.2372 0 0
M  V30 11 C 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 C 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 6 14
M  V30 15 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z223042524

>  <MW>
212.026

>  <MW (desalted)>
212.226

>  <ClogP>
-0.363

>  <logS>
-1.503

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
86.19

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 2.791 nM | Ki (inhibition constant) = 5 nM | Ki (inhibition constant) = 5.1 nM | Ki (inhibition constant) = 10.3 nM | Ki (inhibition constant) = 13 nM | Ki (inhibition constant) = 20 nM | Ki (inhibition constant) = 35 nM | Ki (inhibition constant)  35 nM | Ki (inhibition constant)  35 nM | Ki (inhibition constant)  35 nM | Ki (inhibition constant) = 35 nM | Ki (inhibition constant) = 56 nM | Ki (inhibition constant)  56 nM | Ki (inhibition constant)  85.6 nM | Ki (inhibition constant) = 89 nM | Ki (inhibition constant) = 89 nM

>  <CAS>
68291-97-4

>  <Description>
Zonisamide is a sulfonamide anticonvulsant. It is a carbonic anhydrase inhibitor. It act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. It is used as adjunctive treatment of partial seizures in adults with epilepsy.

>  <EBC_ID>
EBC-11182

>  <IUPAC Name>
(1,2-benzoxazol-3-yl)methanesulfonamide

>  <Main Tar all refs>
Bioorg. Med. Chem., 2013, vol. 21, # 6, p. 1495 - 1502 | J. Med. Chem., 2006, vol. 49, # 18, p. 5544 - 5551 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 1, p. 152 - 158 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 9, p. 2315 - 2320 | Bioorg. Med. Chem., 2010, vol. 18, # 15, p. 5498 - 5503 | Bioorg. Med. Chem. Lett., 2011, vol. 21, # 5, p. 1334 - 1337 | Bioorg. Med. Chem. Lett., 2016, vol. 26, p. 1821 - 1826 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 4, p. 1253 - 1259 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | Int. J. Mol. Sci., 2020, vol. 21, # 11, p. 1 - 14 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 1, p. 152 - 158 | Bioorg. Med. Chem. Lett., 2016, vol. 26, p. 1821 - 1826 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 4, p. 1253 - 1259 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 1, p. 152 - 158 | J. Med. Chem., 2009, vol. 52, # 3, p. 646 - 654

>  <Main tar all>
carbonic anhydrase pX=8.55 | carbonic anhydrase 9 pX=8.3 | carbonic anhydrase 7 pX=8.29 | carbonic anhydrase 2 pX=7.99 | carbonic anhydrase 1 pX=7.89 | carbonic anhydrase 5 pX=7.7 | ?-carbonic anhydrase 2 pX=7.46 | Alpha carbonic anhydrase 2 pX=7.46 | carbonic anhydrase 2 pX=7.46 | carbonic anhydrase 2 pX=7.46 | carbonic anhydrase 3 pX=7.46 | ?-carbonic anhydrase 1 pX=7.25 | carbonic anhydrase 1 pX=7.25 | ?-carbonic anhydrase pX=7.07 | carbonic anhydrase 12 pX=7.05 | carbonic anhydrase 6 pX=7.05

$$$$
Abametapir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 N 0 -4.62 0 0
M  V30 7 C 0 -3.08 0 0
M  V30 8 C 1.3337 -6.93 0 0
M  V30 9 C 2.6674 -7.7 0 0
M  V30 10 C 2.6674 -9.24 0 0
M  V30 11 C 1.3337 -10.01 0 0
M  V30 12 C 1.3337 -11.55 0 0
M  V30 13 C 0 -9.24 0 0
M  V30 14 N 0 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 13 14
M  V30 15 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255488813

>  <MW>
184.1

>  <MW (desalted)>
184.237

>  <ClogP>
2.562

>  <logS>
-1.833

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
25.78

>  <RotBonds>
1

>  <CAS>
1762-34-1

>  <Description>
Abametapir is a novel pediculicidal metalloproteinase inhibitor. Abametapir is indicated, in the context of an overall lice management program, for the topical treatment of head lice infestation in patients 6 months of age and older.

>  <EBC_ID>
EBC-03993

>  <IUPAC Name>
5-methyl-2-(5-methylpyridin-2-yl)pyridine

$$$$
S-Medetomidine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.1553 0 0
M  V30 3 C 5.7337 0.3853 0 0 CFG=2
M  V30 4 C 5.7337 -1.1547 0 0
M  V30 5 C 6.9796 -2.0599 0 0
M  V30 6 N 6.5037 -3.5245 0 0
M  V30 7 C 4.9637 -3.5245 0 0
M  V30 8 N 4.4878 -2.0599 0 0
M  V30 9 C 7.0674 1.1553 0 0
M  V30 10 C 7.0674 2.6953 0 0
M  V30 11 C 8.401 3.4653 0 0
M  V30 12 C 9.7347 2.6953 0 0
M  V30 13 C 9.7347 1.1553 0 0
M  V30 14 C 11.0684 0.3853 0 0
M  V30 15 C 8.401 0.3853 0 0
M  V30 16 C 8.401 -1.1547 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=1
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 4 8
M  V30 8 1 3 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 9 15
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1617901127

>  <MW>
236.108

>  <MW (desalted)>
200.28

>  <ClogP>
3.105

>  <logS>
-3.75

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
28.68

>  <RotBonds>
2

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
EC50  0.13 nM | IC50  0.24 nM | EC50  1.1 nM | EC50  1.5 nM | EC50  1.6 nM

>  <CAS>
145108-58-3

>  <Description>
S- Medetomidine hydrochloride is an agonist of adrenergic alpha-2 receptor. It is used in veterinary medicine for its analgesic and sedative properties.

>  <EBC_ID>
EBC-08198

>  <IUPAC Name>
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2010, vol. 159, # 1, p. 129 - 141 | Br. J. Pharmacol., 2010, vol. 159, # 1, p. 129 - 141 | Eur. J. Pharmacol., 2008, vol. 599, # 1-3, p. 65 - 71 | Eur. J. Pharmacol., 2008, vol. 599, # 1-3, p. 65 - 71 | Eur. J. Pharmacol., 2008, vol. 599, # 1-3, p. 65 - 71

>  <Main tar all>
?1-adrenoceptor pX=9.89 | ?2-adrenoceptor pX=9.62 | ?2B-adrenoceptor pX=8.96 | ?2A-adrenoceptor pX=8.82 | ?2C-adrenoceptor pX=8.8

$$$$
Propranolol hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.3647 0 0
M  V30 3 C 5.7337 0.4053 0 0
M  V30 4 C 5.7337 1.9453 0 0
M  V30 5 N 7.0674 -0.3647 0 0
M  V30 6 C 8.401 0.4053 0 0
M  V30 7 C 9.7347 -0.3647 0 0
M  V30 8 O 9.7347 -1.9047 0 0
M  V30 9 C 11.0684 0.4053 0 0
M  V30 10 O 12.4021 -0.3647 0 0
M  V30 11 C 13.7358 0.4053 0 0
M  V30 12 C 13.7358 1.9453 0 0
M  V30 13 C 15.0694 2.7153 0 0
M  V30 14 C 16.4031 1.9453 0 0
M  V30 15 C 16.4031 0.4053 0 0
M  V30 16 C 17.7368 -0.3647 0 0
M  V30 17 C 17.7368 -1.9047 0 0
M  V30 18 C 16.4031 -2.6747 0 0
M  V30 19 C 15.0694 -1.9047 0 0
M  V30 20 C 15.0694 -0.3647 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 19 20
M  V30 19 2 11 20
M  V30 20 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z90121066

>  <MW>
295.134

>  <MW (desalted)>
259.343

>  <ClogP>
2.753

>  <logS>
-4.24

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
41.49

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.2 nM | pA2  9.48  | Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant)  1.6E-09 M | pA2  8.62

>  <CAS>
318-98-9

>  <Description>
Propranolol is a non-selective beta adrenergic antagonist used to treat hypertension, angina, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, and pheochromocytoma.

>  <EBC_ID>
EBC-13532

>  <IUPAC Name>
1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2001, vol. 9, # 7, p. 1739 - 1746 | J. MED. CHEM., 1974, vol. 17, # 5, p. 507 - 513 | Bioorg. Med. Chem., 2001, vol. 9, # 7, p. 1739 - 1746 | Farmaco, 2003, vol. 58, # 8, p. 557 - 562 | J. MED. CHEM., 1980, vol. 23, # 6, p. 620 - 624

>  <Main tar all>
?1-adrenoceptor pX=9.7 | ?-adrenoceptor pX=9.48 | ?2-adrenoceptor pX=9.22 | ?1-adrenoceptor pX=8.8 | ?1-adrenoceptor pX=8.62

$$$$
Tenofovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.8871 -3.1891 0 0
M  V30 2 C 0.1434 -4.3335 0 0 CFG=2
M  V30 3 C 1.6497 -4.0133 0 0
M  V30 4 N 2.1256 -2.5487 0 0
M  V30 5 C 1.2204 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 3.5902 -0.5328 0 0
M  V30 8 C 4.9239 0.2372 0 0
M  V30 9 N 4.9239 1.7772 0 0
M  V30 10 N 6.2576 -0.5328 0 0
M  V30 11 C 6.2576 -2.0728 0 0
M  V30 12 N 4.9239 -2.8428 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 14 O -0.3325 -5.7982 0 0
M  V30 15 C -1.8389 -6.1183 0 0
M  V30 16 P -2.3147 -7.583 0 0
M  V30 17 O -2.7906 -9.0476 0 0
M  V30 18 O -3.7794 -7.1071 0 0
M  V30 19 O -0.8501 -8.0588 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 4 13
M  V30 14 2 7 13
M  V30 15 1 2 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616194

>  <MW>
287.078

>  <MW (desalted)>
287.212

>  <ClogP>
-1.564

>  <logS>
0.015

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
136.38

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.18E-10 M | IC50  0.0011 ?M

>  <CAS>
147127-20-6

>  <Description>
Tenofovir acts as an antiviral acyclic nucleoside phosphonate. It acts with different mechanisms including the inhibition of viral polymerase causing chain termination and the inhibition of viral synthesis. Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.

>  <EBC_ID>
EBC-02044

>  <IUPAC Name>
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid

>  <Main Tar all refs>
SCRIPPS RESEARCH - WO2014/153164, 2014, A1 | Antimicrob. Agents Chemother., 2013, vol. 57, # 11, p. 5500 - 5508

>  <Main tar all>
Folate hydrolase (prostate-specific membrane antigen) 1 pX=9.93 | RNA-directed DNA polymerase pX=8.96

$$$$
Anastrozole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.541 12.63 0 0
M  V30 2 C -4.001 12.63 0 0
M  V30 3 C -2.461 12.63 0 0
M  V30 4 C -4.001 14.17 0 0
M  V30 5 N -4.001 15.71 0 0
M  V30 6 C -4.001 11.09 0 0
M  V30 7 C -2.6674 10.32 0 0
M  V30 8 C -2.6674 8.78 0 0
M  V30 9 C -1.3337 8.01 0 0
M  V30 10 N -1.3337 6.47 0 0
M  V30 11 C -0.0878 5.5648 0 0
M  V30 12 N -0.5637 4.1002 0 0
M  V30 13 C -2.1037 4.1002 0 0
M  V30 14 N -2.5796 5.5648 0 0
M  V30 15 C -4.001 8.01 0 0
M  V30 16 C -5.3347 8.78 0 0
M  V30 17 C -5.3347 10.32 0 0
M  V30 18 C -6.6684 8.01 0 0
M  V30 19 C -7.4384 9.3437 0 0
M  V30 20 C -5.8984 6.6763 0 0
M  V30 21 C -8.0021 7.24 0 0
M  V30 22 N -9.3358 6.47 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 3 4 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 10 14
M  V30 15 1 8 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 6 17
M  V30 19 1 16 18
M  V30 20 1 18 19
M  V30 21 1 18 20
M  V30 22 1 18 21
M  V30 23 3 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385077

>  <MW>
293.164

>  <MW (desalted)>
293.366

>  <ClogP>
1.475

>  <logS>
-2.8

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
78.29

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.13 nM | Ki (inhibition constant) = 0.13 nM | concentration (parameter)  0.9 pmol/ml | IC50 = 1.5 nM | IC50 = 1.5 nM

>  <CAS>
120511-73-1

>  <Description>
Anastrozole is a competitive, selective, non-steroidal aromatase inhibitor. Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive locally advanced or metastatic breast cancer in postmenopausal women.

>  <EBC_ID>
EBC-06099

>  <IUPAC Name>
2-[3-(1-cyano-1-methylethyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]phenyl]-2-methylpropanenitrile

>  <Main Tar all refs>
Bioorg. Med. Chem., 2012, vol. 20, # 7, p. 2427 - 2434 | Bioorg. Med. Chem., 2012, vol. 20, # 7, p. 2427 - 2434 | Mol. Pharmacol., 2015, vol. 88, # 3, p. 428 - 436 | J. Med. Chem., 2010, vol. 53, # 5, p. 2155 - 2170 | ChemMedChem, 2008, vol. 3, # 11, p. 1708 - 1730

>  <Main tar all>
CYP19A1 pX=9.89 | CYP19A1 pX=9.89 | CYP27A1 pX=9.05 | Aromatase (gene CYP19A1) pX=8.82 | Aromatase (peptide) pX=8.82

$$$$
Propafenone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 2.0328 0 0
M  V30 3 C 5.7337 1.2628 0 0
M  V30 4 C 7.0674 2.0328 0 0
M  V30 5 N 8.401 1.2628 0 0
M  V30 6 C 9.7347 2.0328 0 0
M  V30 7 C 11.0684 1.2628 0 0
M  V30 8 O 11.0684 -0.2772 0 0
M  V30 9 C 12.4021 2.0328 0 0
M  V30 10 O 13.7358 1.2628 0 0
M  V30 11 C 15.0694 2.0328 0 0
M  V30 12 C 15.0694 3.5728 0 0
M  V30 13 C 16.4031 4.3428 0 0
M  V30 14 C 17.7368 3.5728 0 0
M  V30 15 C 17.7368 2.0328 0 0
M  V30 16 C 16.4031 1.2628 0 0
M  V30 17 C 16.4031 -0.2772 0 0
M  V30 18 O 17.7368 -1.0472 0 0
M  V30 19 C 15.0694 -1.0472 0 0
M  V30 20 C 15.0694 -2.5872 0 0
M  V30 21 C 16.4031 -3.3572 0 0
M  V30 22 C 17.7368 -2.5872 0 0
M  V30 23 C 19.0705 -3.3572 0 0
M  V30 24 C 19.0705 -4.8972 0 0
M  V30 25 C 17.7368 -5.6672 0 0
M  V30 26 C 16.4031 -4.8972 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 2 11 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z608353988

>  <MW>
377.905

>  <MW (desalted)>
341.444

>  <ClogP>
3.636

>  <logS>
-4.52

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
58.56

>  <RotBonds>
11

>  <Action on targets>
-

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.01 ?M

>  <CAS>
34183-22-7

>  <Description>
Propafenone HCl is an inhibitor of voltage-dependent sodium channels and potassium voltage-gated channel. It is a Class I antiarrhythmic drug. Propafenone HCl is used to treat cardiac arrhythmia.

>  <EBC_ID>
EBC-03874

>  <IUPAC Name>
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one hydrochloride

>  <Main Tar all refs>
Drug Metab. Dispos., 2008, vol. 36, # 9, p. 1938 - 1943

>  <Main tar all>
Cytochrome P450 2D6 pX=8.0

$$$$
Piketoprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.0031 2.31 0 0
M  V30 2 C 10.6694 1.54 0 0
M  V30 3 C 10.6694 0 0 0
M  V30 4 O 9.3358 -0.77 0 0
M  V30 5 N 12.0031 -0.77 0 0
M  V30 6 C 12.0031 -2.31 0 0
M  V30 7 C 13.3368 -3.08 0 0
M  V30 8 C 13.3368 -4.62 0 0
M  V30 9 C 14.6705 -5.39 0 0
M  V30 10 C 12.0031 -5.39 0 0
M  V30 11 C 10.6694 -4.62 0 0
M  V30 12 N 10.6694 -3.08 0 0
M  V30 13 C 9.3358 2.31 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 6.6684 2.31 0 0
M  V30 16 C 6.6684 3.85 0 0
M  V30 17 C 8.0021 4.62 0 0
M  V30 18 C 9.3358 3.85 0 0
M  V30 19 C 8.0021 6.16 0 0
M  V30 20 O 6.6684 6.93 0 0
M  V30 21 C 9.3358 6.93 0 0
M  V30 22 C 9.3358 8.47 0 0
M  V30 23 C 10.6694 9.24 0 0
M  V30 24 C 12.0031 8.47 0 0
M  V30 25 C 12.0031 6.93 0 0
M  V30 26 C 10.6694 6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1537384907

>  <MW>
344.406

>  <MW (desalted)>
344.406

>  <ClogP>
3.876

>  <logS>
-5.752

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
59.06

>  <RotBonds>
5

>  <CAS>
60576-13-8

>  <Description>
A nonsteroidal anti-inflammatory drug (NSAID) for topical use in form of a cream.

>  <EBC_ID>
EBC-12818

>  <IUPAC Name>
2-(3-benzoylphenyl)-N-(4-methylpyridin-2-yl)propanamide

$$$$
Phenol red
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6311 -8.1762 0 0
M  V30 2 C 4.0047 -6.7693 0 0
M  V30 3 C 2.4732 -6.6083 0 0
M  V30 4 C 1.8468 -5.2015 0 0
M  V30 5 C 2.752 -3.9556 0 0
M  V30 6 C 4.2836 -4.1165 0 0
M  V30 7 C 4.9099 -5.5234 0 0
M  V30 8 C 2.1256 -2.5487 0 0
M  V30 9 O 1.2204 -1.3028 0 0
M  V30 10 S 2.1256 -0.0569 0 0
M  V30 11 O 0.7919 0.7131 0 0
M  V30 12 O 2.752 1.3499 0 0
M  V30 13 C 3.5902 -0.5328 0 0
M  V30 14 C 4.9239 0.2372 0 0
M  V30 15 C 6.2576 -0.5328 0 0
M  V30 16 C 6.2576 -2.0728 0 0
M  V30 17 C 4.9239 -2.8428 0 0
M  V30 18 C 3.5902 -2.0728 0 0
M  V30 19 C 0.7919 -3.3187 0 0
M  V30 20 C 0.7919 -4.8587 0 0
M  V30 21 C -0.5417 -5.6287 0 0
M  V30 22 C -1.8754 -4.8587 0 0
M  V30 23 O -3.2091 -5.6287 0 0
M  V30 24 C -1.8754 -3.3187 0 0
M  V30 25 C -0.5417 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 8 18
M  V30 21 1 8 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 2 22 24
M  V30 27 1 24 25
M  V30 28 2 19 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56768517

>  <MW>
354.376

>  <MW (desalted)>
354.376

>  <ClogP>
2.379

>  <logS>
-4.41

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
83.83

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1 ?M | IC50 = 1.5 ?M | Ki (inhibition constant)  2.9 ?M | inhibition percentage  98.4 % | inhibition percentage  98.4 % | IC50 = 17 ?M | inhibition percentage  84 % | inhibition percentage  84 %

>  <CAS>
143-74-8

>  <Description>
Phenol red shows inhibitory activity against amyloid proteins.

>  <EBC_ID>
EBC-03857

>  <IUPAC Name>
3,3-bis(4-hydroxyphenyl)-3H-2,1lambda6-benzoxathiole-1,1-dione

>  <Main Tar all refs>
Chem. Biol. Drug Des., 2006, vol. 67, # 1, p. 27 - 37 | Chem. Biol. Drug Des., 2006, vol. 67, # 1, p. 27 - 37 | Biol. Pharm. Bull., 1999, vol. 22, # 7, p. 741 - 744 | Bioorg. Chem., 2018, vol. 79, p. 235 - 249 | Med. Chem., 2019, vol. 15, # 1, p. 59 - 76 | Chem. Biol. Drug Des., 2006, vol. 67, # 1, p. 27 - 37 | Lett. Drug Des. Discov., 2018, vol. 15, # 11, p. 1131 - 1140 | Lett. Drug Des. Discov., 2018, vol. 15, # 11, p. 1131 - 1140

>  <Main tar all>
Islet amyloid polypeptide pX=6.0 | Insulin pX=5.82 | Aldo-keto reductase family 1 member B1 pX=5.54 | Amyloid beta 1-42 ; Abeta 1-42 pX=5.28 | Amyloid beta A4 protein (1-42) pX=5.28 | Amyloid-beta precursor protein pX=4.77 | acetylcholinesterase (acetyl.beta-methylcholinesterase) pX=4.72 | amyloid-beta a4 protein pX=4.72

$$$$
Gliquidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -0.77 0 0
M  V30 2 O -2.6674 0 0 0
M  V30 3 C -1.3337 -0.77 0 0
M  V30 4 C -1.3337 -2.31 0 0
M  V30 5 C 0 -3.08 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 -0 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 O 2.6674 1.54 0 0
M  V30 11 N 4.001 -0.77 0 0
M  V30 12 C 5.3347 -0 0 0
M  V30 13 C 5.3347 1.54 0 0
M  V30 14 C 6.6684 2.31 0 0
M  V30 15 C 6.6684 3.85 0 0
M  V30 16 C 8.0021 4.62 0 0
M  V30 17 C 9.3358 3.85 0 0
M  V30 18 C 9.3358 2.31 0 0
M  V30 19 C 8.0021 1.54 0 0
M  V30 20 S 10.6694 4.62 0 0
M  V30 21 O 11.4394 3.2863 0 0
M  V30 22 O 9.8994 5.9537 0 0
M  V30 23 N 12.0031 5.39 0 0
M  V30 24 C 13.3368 4.62 0 0
M  V30 25 O 13.3368 3.08 0 0
M  V30 26 N 14.6705 5.39 0 0
M  V30 27 C 16.0041 4.62 0 0
M  V30 28 C 17.3378 5.39 0 0
M  V30 29 C 18.6715 4.62 0 0
M  V30 30 C 18.6715 3.08 0 0
M  V30 31 C 17.3378 2.31 0 0
M  V30 32 C 16.0041 3.08 0 0
M  V30 33 C 4.001 -2.31 0 0
M  V30 34 O 5.3347 -3.08 0 0
M  V30 35 C 2.6674 -3.08 0 0
M  V30 36 C 3.3903 -4.4397 0 0
M  V30 37 C 1.9444 -4.4397 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 21 1 17 20
M  V30 22 2 20 21
M  V30 23 2 20 22
M  V30 24 1 20 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 27 32
M  V30 35 1 11 33
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 6 35
M  V30 39 1 35 36
M  V30 40 1 35 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56785257

>  <MW>
527.632

>  <MW (desalted)>
527.632

>  <ClogP>
5.058

>  <logS>
-6.09

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
121.88

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  2.8 nM

>  <CAS>
33342-05-1

>  <Description>
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

>  <EBC_ID>
EBC-06092

>  <IUPAC Name>
1-cyclohexyl-3-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea

>  <Main Tar all refs>
Bioorg. Med. Chem., 2003, vol. 11, # 9, p. 2099 - 2113

>  <Main tar all>
Potassium channel ATP dependent pX=8.55

$$$$
Cefoperazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 48 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -10.9751 -0.894 0 0
M  V30 2 C -10.5765 0.5935 0 0
M  V30 3 N -9.0889 0.9921 0 0
M  V30 4 C -8.6904 2.4796 0 0
M  V30 5 C -7.2028 2.8782 0 0
M  V30 6 N -6.1139 1.7892 0 0
M  V30 7 C -4.6264 2.1878 0 0
M  V30 8 O -4.2278 3.6754 0 0
M  V30 9 N -3.5374 1.0989 0 0
M  V30 10 C -2.0499 1.4975 0 0 CFG=1
M  V30 11 C -0.961 0.4085 0 0
M  V30 12 O -1.3595 -1.079 0 0
M  V30 13 N 0.5266 0.8071 0 0
M  V30 14 C 1.6155 -0.2818 0 0 CFG=1
M  V30 15 C 3.1555 -0.2818 0 0 CFG=1
M  V30 16 S 4.4892 0.4882 0 0
M  V30 17 C 5.8229 -0.2818 0 0
M  V30 18 C 5.8229 -1.8218 0 0
M  V30 19 C 4.4892 -2.5918 0 0
M  V30 20 N 3.1555 -1.8218 0 0
M  V30 21 C 1.6155 -1.8218 0 0
M  V30 22 O 0.5266 -2.9108 0 0
M  V30 23 C 4.4892 -4.1318 0 0
M  V30 24 O 3.1555 -4.9018 0 0
M  V30 25 O 5.8229 -4.9018 0 0
M  V30 26 C 7.1566 -2.5918 0 0
M  V30 27 S 8.4902 -1.8218 0 0
M  V30 28 C 9.8239 -2.5918 0 0
M  V30 29 N 11.2308 -1.9655 0 0
M  V30 30 N 12.2612 -3.1099 0 0
M  V30 31 N 11.4912 -4.4436 0 0
M  V30 32 N 9.9849 -4.1234 0 0
M  V30 33 C 8.8404 -5.1539 0 0
M  V30 34 C -1.6513 2.985 0 0
M  V30 35 C -2.7403 4.0739 0 0
M  V30 36 C -2.3417 5.5615 0 0
M  V30 37 C -0.8542 5.96 0 0
M  V30 38 O -0.4556 7.4476 0 0
M  V30 39 C 0.2348 4.8711 0 0
M  V30 40 C -0.1638 3.3836 0 0
M  V30 41 C -6.5125 0.3017 0 0
M  V30 42 O -5.4235 -0.7872 0 0
M  V30 43 C -8 -0.0969 0 0
M  V30 44 O -8.3986 -1.5844 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 15 20 CFG=1
M  V30 21 1 20 21
M  V30 22 1 14 21
M  V30 23 2 21 22
M  V30 24 1 19 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 18 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 1 28 32
M  V30 35 1 32 33
M  V30 36 1 10 34
M  V30 37 1 34 35
M  V30 38 2 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 2 37 39
M  V30 42 1 39 40
M  V30 43 2 34 40
M  V30 44 1 6 41
M  V30 45 2 41 42
M  V30 46 1 41 43
M  V30 47 1 3 43
M  V30 48 2 43 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242164637

>  <MW>
645.142

>  <MW (desalted)>
645.667

>  <ClogP>
-0.216

>  <logS>
-5.213

>  <HBD>
4

>  <HBA>
11

>  <TPSA>
220.26

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  2.36E-08 M | Kd (dissociation constant)  1.51E-07 M | Ki (inhibition constant)  0.21 ?M | IC50  0.421 ?M

>  <CAS>
62893-19-0

>  <Description>
Cefoperazone is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections in various locations, including the respiratory tract, abdomen, skin, and female genital tracts.

>  <EBC_ID>
EBC-13165

>  <IUPAC Name>
(6R,7R)-7-[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Mol. Neurobiol., 2018, p. 1 - 11 | TOTTORI UNIVERSITY - US2018/338899, 2018, A1 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | FEBS J., 2021, vol. 288, # 3, p. 945 - 960

>  <Main tar all>
Alternative prion protein pX=7.63 | Homeobox-leucine zipper protein HAT1 pX=6.82 | Organic anion transporter 1 pX=6.68 | endoplasmic reticulum to nucleus signaling 1 pX=6.38

$$$$
spectinomycin dihydrochloride pentahydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 O 8.8 0 0 0
M  V30 4 O 0 -3.08 0 0
M  V30 5 O 4.4 -3.08 0 0
M  V30 6 Cl 8.14 -3.08 0 0
M  V30 7 Cl 0 -9.5413 0 0
M  V30 8 C 4.4 -8.47 0 0
M  V30 9 N 5.7337 -7.7 0 0
M  V30 10 C 7.0674 -8.47 0 0 CFG=2
M  V30 11 C 7.0674 -10.01 0 0 CFG=2
M  V30 12 O 5.7337 -10.78 0 0
M  V30 13 C 8.401 -10.78 0 0 CFG=2
M  V30 14 N 8.401 -12.32 0 0
M  V30 15 C 9.7347 -13.09 0 0
M  V30 16 C 9.7347 -10.01 0 0 CFG=1
M  V30 17 O 11.0684 -10.78 0 0
M  V30 18 C 12.4021 -10.01 0 0 CFG=2
M  V30 19 O 12.4021 -11.55 0 0
M  V30 20 C 12.4021 -8.47 0 0 CFG=1
M  V30 21 O 13.7358 -7.7 0 0
M  V30 22 C 15.0694 -8.47 0 0 CFG=2
M  V30 23 C 16.4031 -7.7 0 0
M  V30 24 C 15.0694 -10.01 0 0
M  V30 25 C 13.7358 -10.78 0 0
M  V30 26 O 13.7358 -12.32 0 0
M  V30 27 O 11.0684 -7.7 0 0
M  V30 28 C 9.7347 -8.47 0 0 CFG=2
M  V30 29 C 8.401 -7.7 0 0 CFG=1
M  V30 30 O 8.401 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 8 9
M  V30 2 1 10 9 CFG=1
M  V30 3 1 10 11
M  V30 4 1 11 12 CFG=1
M  V30 5 1 11 13
M  V30 6 1 13 14 CFG=1
M  V30 7 1 14 15
M  V30 8 1 13 16
M  V30 9 1 16 17 CFG=3
M  V30 10 1 18 17
M  V30 11 1 18 19 CFG=1
M  V30 12 1 18 20
M  V30 13 1 20 21 CFG=3
M  V30 14 1 22 21
M  V30 15 1 22 23 CFG=3
M  V30 16 1 22 24
M  V30 17 1 24 25
M  V30 18 1 18 25
M  V30 19 2 25 26
M  V30 20 1 20 27
M  V30 21 1 28 27 CFG=1
M  V30 22 1 28 16
M  V30 23 1 29 28
M  V30 24 1 10 29
M  V30 25 1 29 30 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z608353996

>  <MW>
495.348

>  <MW (desalted)>
332.35

>  <ClogP>
-2.878

>  <logS>
-1.73

>  <HBD>
5

>  <HBA>
9

>  <TPSA>
129.51

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Allosteric Modulator

>  <Activity coefficients and valu>
MIC  0.005 ?g/ml | stimulation rate  100 %

>  <CAS>
22189-32-8

>  <Description>
Spectinomycin is an aminocyclitol antibiotic.

>  <EBC_ID>
EBC-15031

>  <IUPAC Name>
(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0,3,8]tetradecan-7-one pentahydrate dihydrochloride

>  <Main Tar all refs>
, 2021, vol. 12, # 11, p. 1894 - 1909 | GOVERNMENT OF THE UNITED STATES - WO1998/10757, 1998, A3

>  <Main tar all>
N-acetyltransferase Eis pX=7.82 | NMDA receptor pX=7.28

$$$$
Apixaban
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2525 -9.5517 0 0
M  V30 2 O 0.2221 -8.4072 0 0
M  V30 3 C 0.698 -6.9426 0 0
M  V30 4 C -0.3325 -5.7982 0 0
M  V30 5 C 0.1434 -4.3335 0 0
M  V30 6 C 1.6497 -4.0133 0 0
M  V30 7 C 2.6802 -5.1578 0 0
M  V30 8 C 2.2043 -6.6224 0 0
M  V30 9 N 2.1256 -2.5487 0 0
M  V30 10 N 1.2204 -1.3028 0 0
M  V30 11 C 2.1256 -0.0569 0 0
M  V30 12 C 1.6497 1.4077 0 0
M  V30 13 O 2.6802 2.5521 0 0
M  V30 14 N 0.1434 1.7279 0 0
M  V30 15 C 3.5902 -0.5328 0 0
M  V30 16 C 4.9239 0.2372 0 0
M  V30 17 C 6.2576 -0.5328 0 0
M  V30 18 N 6.2576 -2.0728 0 0
M  V30 19 C 4.9239 -2.8428 0 0
M  V30 20 O 4.9239 -4.3828 0 0
M  V30 21 C 3.5902 -2.0728 0 0
M  V30 22 C 7.5913 -2.8428 0 0
M  V30 23 C 8.925 -2.0728 0 0
M  V30 24 C 10.2586 -2.8428 0 0
M  V30 25 C 10.2586 -4.3828 0 0
M  V30 26 C 8.925 -5.1528 0 0
M  V30 27 C 7.5913 -4.3828 0 0
M  V30 28 N 11.5923 -5.1528 0 0
M  V30 29 C 12.926 -4.3828 0 0
M  V30 30 C 14.2597 -5.1528 0 0
M  V30 31 C 14.2597 -6.6928 0 0
M  V30 32 C 12.926 -7.4628 0 0
M  V30 33 C 11.5923 -6.6928 0 0
M  V30 34 O 10.2586 -7.4628 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 11 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 2 15 21
M  V30 23 1 9 21
M  V30 24 1 18 22
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 22 27
M  V30 31 1 25 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 28 33
M  V30 38 2 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z195110238

>  <MW>
459.497

>  <MW (desalted)>
459.497

>  <ClogP>
1.892

>  <logS>
-5.14

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
110.76

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.08 nM | Ki (inhibition constant) = 8E-05 ?M | Ki (inhibition constant) = 1.7 nM | concentration (parameter)  876.64 ng/l | IC50  2.26 nM

>  <CAS>
503612-47-3

>  <Description>
Apixaban is an anticoagulant used for the prophylaxis of stroke and systemic embolism in nonvalvular atrial fibrillation, and deep vein thrombosis(DVT) leading to pulmonary embolism(PE), including in patients after a hip or knee replacement surgery. It selectively inhibits factor Xa in its free and bound forms, independant of antithrombin III. Apixaban also inhibits prothrominase.

>  <EBC_ID>
EBC-11355

>  <IUPAC Name>
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2008, vol. 18, # 9, p. 2845 - 2849 | ACS Meeting, 2005, 2005 | J. Enzyme Inhib. Med. Chem., 2011, vol. 26, # 4, p. 514 - 526 | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. - EP3213749, 2017, A1 | Bioorg. Med. Chem. Lett., 2023, vol. 80

>  <Main tar all>
Activated factor Xa heavy chain pX=10.1 | coagulation factor X pX=10.1 | prothrombinase complex pX=8.77 | PAF receptor pX=8.72 | Antistasin pX=8.65

$$$$
Glutathione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 23.5531 8.9784 0 0
M  V30 2 C 23.5531 7.4384 0 0 CFG=1
M  V30 3 C 22.2194 6.6684 0 0
M  V30 4 C 20.8858 7.4384 0 0
M  V30 5 C 19.5521 6.6684 0 0
M  V30 6 O 19.5521 5.1284 0 0
M  V30 7 N 18.2184 7.4384 0 0
M  V30 8 C 16.8847 6.6684 0 0 CFG=1
M  V30 9 C 16.8847 5.1284 0 0
M  V30 10 S 15.551 4.3584 0 0
M  V30 11 C 15.551 7.4384 0 0
M  V30 12 O 15.551 8.9784 0 0
M  V30 13 N 14.2174 6.6684 0 0
M  V30 14 C 12.8837 7.4384 0 0
M  V30 15 C 11.55 6.6684 0 0
M  V30 16 O 10.2163 7.4384 0 0
M  V30 17 O 11.55 5.1284 0 0
M  V30 18 C 24.8868 6.6684 0 0
M  V30 19 O 26.2205 7.4384 0 0
M  V30 20 O 24.8868 5.1284 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 2 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2183947556

>  <MW>
307.323

>  <MW (desalted)>
307.323

>  <ClogP>
-3.051

>  <logS>
-0.972

>  <HBD>
6

>  <HBA>
7

>  <TPSA>
158.82

>  <RotBonds>
9

>  <Action on targets>
Substrate | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKa (association)  8.6 | IC50  0.02 ?M | inhibition percentage > 60 %

>  <CAS>
70-18-8

>  <Description>
Glutathione is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals. Glutathione participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It is used as a nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-02054

>  <IUPAC Name>
(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid

>  <Main Tar all refs>
J. Mol. Catal. B Enzym., 2014, vol. 106, p. 71 - 75 | J. Med. Chem., 1998, vol. 41, # 13, p. 2278 - 2288 | J. BIOL. CHEM., 1996, vol. 271, # 16, p. 9675 - 9682

>  <Main tar all>
glutathione S-transferase phi 5 pX=8.6 | H-PGDS pX=7.7 | Multi drug resistance-associated protein pX=7.18

$$$$
Aztreonam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.3554 -2.0895 0 0
M  V30 2 C -2.3554 -3.6295 0 0 CFG=1
M  V30 3 C -1.2665 -4.7185 0 0 CFG=2
M  V30 4 N 0.2735 -4.7185 0 0
M  V30 5 C 1.0435 -6.0521 0 0
M  V30 6 O 0.2735 -7.3858 0 0
M  V30 7 C 2.5835 -6.0521 0 0
M  V30 8 N 3.3535 -7.3858 0 0
M  V30 9 O 4.8935 -7.3858 0 0
M  V30 10 C 5.6635 -8.7195 0 0
M  V30 11 C 6.9972 -7.9495 0 0
M  V30 12 C 4.3299 -9.4895 0 0
M  V30 13 C 6.4335 -10.0532 0 0
M  V30 14 O 7.9735 -10.0532 0 0
M  V30 15 O 5.6635 -11.3869 0 0
M  V30 16 C 3.3535 -4.7185 0 0
M  V30 17 C 2.7272 -3.3116 0 0
M  V30 18 S 3.8716 -2.2811 0 0
M  V30 19 C 5.2053 -3.0511 0 0
M  V30 20 N 6.6121 -2.4248 0 0
M  V30 21 N 4.8851 -4.5575 0 0
M  V30 22 C -2.3554 -5.8074 0 0
M  V30 23 O -2.3554 -7.3474 0 0
M  V30 24 N -3.4443 -4.7185 0 0
M  V30 25 S -4.9843 -4.7185 0 0
M  V30 26 O -6.5243 -4.7185 0 0
M  V30 27 O -4.9843 -3.1785 0 0
M  V30 28 O -4.9843 -6.2585 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=3
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9 CFG=2
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 7 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 16 21
M  V30 22 1 3 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 2 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 2 25 27
M  V30 29 1 25 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1511483977

>  <MW>
435.052

>  <MW (desalted)>
435.433

>  <ClogP>
0.337

>  <logS>
-3.302

>  <HBD>
4

>  <HBA>
11

>  <TPSA>
201.58

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.0002 ?M | IC50 = 0.0015 ?M | IC50  0.003 ?M

>  <CAS>
78110-38-0

>  <Description>
Aztreonam is a synthetic monocyclic beta-lactam antibiotic, which has a very high affinity for penicillin-binding protein 3. It is  used to treat Gram-negative aerobic bacteria infection.

>  <EBC_ID>
EBC-07849

>  <IUPAC Name>
2-({[(2-amino-1,3-thiazol-4-yl)({[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]carbamoyl})methylidene]amino}oxy)-2-methylpropanoic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2001, vol. 45, # 11, p. 3189 - 3194 | Antimicrob. Agents Chemother., 2002, vol. 46, # 1, p. 1 - 11 | Antimicrob. Agents Chemother., 2020, vol. 64, # 10

>  <Main tar all>
Beta-lactamase pX=9.7 | Beta-Lactamase AmpC pX=8.82 | Beta-lactamase pX=8.52

$$$$
Clomipramine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.3737 0 0
M  V30 3 N 5.7337 0.6037 0 0
M  V30 4 C 5.7337 -0.9363 0 0
M  V30 5 C 7.0674 1.3737 0 0
M  V30 6 C 8.401 0.6037 0 0
M  V30 7 C 9.7347 1.3737 0 0
M  V30 8 N 11.0684 0.6037 0 0
M  V30 9 C 12.3408 1.4712 0 0
M  V30 10 C 11.9981 2.9726 0 0
M  V30 11 C 13.127 4.0201 0 0
M  V30 12 C 14.5986 3.5661 0 0
M  V30 13 C 14.9413 2.0647 0 0
M  V30 14 C 13.8124 1.0173 0 0
M  V30 15 C 14.375 -0.4163 0 0
M  V30 16 C 13.605 -1.7499 0 0
M  V30 17 C 12.0822 -1.9795 0 0
M  V30 18 C 11.7395 -3.4809 0 0
M  V30 19 C 10.2679 -3.9348 0 0
M  V30 20 C 9.139 -2.8873 0 0
M  V30 21 Cl 7.6675 -3.3412 0 0
M  V30 22 C 9.4817 -1.3859 0 0
M  V30 23 C 10.9533 -0.932 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 1 8 23
M  V30 24 2 17 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516761

>  <MW>
350.132

>  <MW (desalted)>
314.852

>  <ClogP>
5.921

>  <logS>
-5.11

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2 nM | EC50 = 8 nM | IC50  0.035 ?M | Ki (inhibition constant)  40 nM

>  <CAS>
17321-77-6

>  <Description>
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant. It is a potent inhibitor of serotonin and norepinephrine reuptake.

>  <EBC_ID>
EBC-13156

>  <IUPAC Name>
(3-{5-chloro-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine hydrochloride

>  <Main Tar all refs>
Eur. J. Pharmacol., 1985, vol. 118, # 1-2, p. 107 - 114 | Chem. Biol., 2009, vol. 16, # 6, p. 644 - 656 | EUR. J. PHARMACOL., 1981, vol. 70, # 3, p. 393 - 407 | NEUROPHARMACOLOGY, 1996, vol. 35, # 1, p. 63 - 70

>  <Main tar all>
SERT pX=8.7 | neurotrophic receptor tyrosine kinase 1 pX=8.1 | ?-adrenoceptor pX=7.46 | NET pX=7.4

$$$$
Doxycycline hyclate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 70 72 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 Cl 7.48 0 0 0
M  V30 4 C -1.3337 -6.7215 0 0
M  V30 5 C 0 -7.4915 0 0
M  V30 6 O 1.3337 -6.7215 0 0
M  V30 7 C 8.8547 -3.85 0 0
M  V30 8 C 8.8547 -5.39 0 0 CFG=2
M  V30 9 C 10.1884 -6.16 0 0 CFG=1
M  V30 10 C 11.5221 -5.39 0 0 CFG=2
M  V30 11 O 11.5221 -3.85 0 0
M  V30 12 C 12.8558 -6.16 0 0 CFG=1
M  V30 13 C 14.1894 -5.39 0 0 CFG=2
M  V30 14 N 14.1894 -3.85 0 0
M  V30 15 C 15.5231 -3.08 0 0
M  V30 16 C 12.8558 -3.08 0 0
M  V30 17 C 15.5231 -6.16 0 0
M  V30 18 C 15.5231 -7.7 0 0
M  V30 19 C 16.8568 -8.47 0 0
M  V30 20 O 16.8568 -10.01 0 0
M  V30 21 N 18.1905 -7.7 0 0
M  V30 22 C 14.1894 -8.47 0 0
M  V30 23 O 14.1894 -10.01 0 0
M  V30 24 C 12.8558 -7.7 0 0 CFG=2
M  V30 25 O 12.8558 -9.24 0 0
M  V30 26 C 11.5221 -8.47 0 0
M  V30 27 C 10.1884 -7.7 0 0
M  V30 28 C 8.8547 -8.47 0 0
M  V30 29 O 8.8547 -10.01 0 0
M  V30 30 C 7.521 -7.7 0 0
M  V30 31 C 6.1874 -8.47 0 0
M  V30 32 O 6.1874 -10.01 0 0
M  V30 33 C 4.8537 -7.7 0 0
M  V30 34 C 4.8537 -6.16 0 0
M  V30 35 C 6.1874 -5.39 0 0
M  V30 36 C 7.521 -6.16 0 0
M  V30 37 O 11.5221 -10.01 0 0
M  V30 38 O 16.8568 -5.39 0 0
M  V30 39 C 25.7115 -3.85 0 0
M  V30 40 C 25.7115 -5.39 0 0 CFG=2
M  V30 41 C 27.0452 -6.16 0 0 CFG=1
M  V30 42 C 28.3789 -5.39 0 0 CFG=2
M  V30 43 O 28.3789 -3.85 0 0
M  V30 44 C 29.7125 -6.16 0 0 CFG=1
M  V30 45 C 31.0462 -5.39 0 0 CFG=2
M  V30 46 N 31.0462 -3.85 0 0
M  V30 47 C 32.3799 -3.08 0 0
M  V30 48 C 29.7125 -3.08 0 0
M  V30 49 C 32.3799 -6.16 0 0
M  V30 50 C 32.3799 -7.7 0 0
M  V30 51 C 33.7136 -8.47 0 0
M  V30 52 O 33.7136 -10.01 0 0
M  V30 53 N 35.0473 -7.7 0 0
M  V30 54 C 31.0462 -8.47 0 0
M  V30 55 O 31.0462 -10.01 0 0
M  V30 56 C 29.7125 -7.7 0 0 CFG=2
M  V30 57 O 29.7125 -9.24 0 0
M  V30 58 C 28.3789 -8.47 0 0
M  V30 59 C 27.0452 -7.7 0 0
M  V30 60 C 25.7115 -8.47 0 0
M  V30 61 O 25.7115 -10.01 0 0
M  V30 62 C 24.3778 -7.7 0 0
M  V30 63 C 23.0441 -8.47 0 0
M  V30 64 O 23.0441 -10.01 0 0
M  V30 65 C 21.7105 -7.7 0 0
M  V30 66 C 21.7105 -6.16 0 0
M  V30 67 C 23.0441 -5.39 0 0
M  V30 68 C 24.3778 -6.16 0 0
M  V30 69 O 28.3789 -10.01 0 0
M  V30 70 O 33.7136 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 1 8 7 CFG=3
M  V30 4 1 9 8
M  V30 5 1 10 9
M  V30 6 1 10 11 CFG=3
M  V30 7 1 12 10 CFG=1
M  V30 8 1 12 13
M  V30 9 1 13 14 CFG=3
M  V30 10 1 14 15
M  V30 11 1 14 16
M  V30 12 1 13 17
M  V30 13 2 17 18
M  V30 14 1 18 19
M  V30 15 2 19 20
M  V30 16 1 19 21
M  V30 17 1 18 22
M  V30 18 2 22 23
M  V30 19 1 24 22
M  V30 20 1 12 24
M  V30 21 1 24 25 CFG=3
M  V30 22 1 24 26
M  V30 23 2 26 27
M  V30 24 1 9 27 CFG=1
M  V30 25 1 27 28
M  V30 26 2 28 29
M  V30 27 1 28 30
M  V30 28 1 30 31
M  V30 29 1 31 32
M  V30 30 2 31 33
M  V30 31 1 33 34
M  V30 32 2 34 35
M  V30 33 1 35 36
M  V30 34 1 8 36
M  V30 35 2 30 36
M  V30 36 1 26 37
M  V30 37 1 17 38
M  V30 38 1 40 39 CFG=3
M  V30 39 1 41 40
M  V30 40 1 42 41
M  V30 41 1 42 43 CFG=3
M  V30 42 1 44 42 CFG=1
M  V30 43 1 44 45
M  V30 44 1 45 46 CFG=3
M  V30 45 1 46 47
M  V30 46 1 46 48
M  V30 47 1 45 49
M  V30 48 2 49 50
M  V30 49 1 50 51
M  V30 50 2 51 52
M  V30 51 1 51 53
M  V30 52 1 50 54
M  V30 53 2 54 55
M  V30 54 1 56 54
M  V30 55 1 44 56
M  V30 56 1 56 57 CFG=3
M  V30 57 1 56 58
M  V30 58 2 58 59
M  V30 59 1 41 59 CFG=1
M  V30 60 1 59 60
M  V30 61 2 60 61
M  V30 62 1 60 62
M  V30 63 1 62 63
M  V30 64 1 63 64
M  V30 65 2 63 65
M  V30 66 1 65 66
M  V30 67 2 66 67
M  V30 68 1 67 68
M  V30 69 1 40 68
M  V30 70 2 62 68
M  V30 71 1 58 69
M  V30 72 1 49 70
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2791720087

>  <MW>
1024.312

>  <MW (desalted)>
444.435

>  <ClogP>
-0.499

>  <logS>
-3.175

>  <HBD>
6

>  <HBA>
9

>  <TPSA>
181.62

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.1 ?M | phosphorylation level decrease Active   | Ki (inhibition constant)  3 ?M | EC50 (unbound)  6.1 ?M | inhibition percentage  26 % | IC50  16.4 ?M | IC50  24 ?M | IC50  25 ?M | IC50  28 ?M | IC50  30 ?M | IC50  31 ?M

>  <CAS>
24390-14-5

>  <Description>
Doxycycline is a tetracycline antibiotic used to treat a wide variety of bacterial infections.

>  <EBC_ID>
EBC-15046

>  <IUPAC Name>
bis((4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide) ethanol hydrate dihydrochloride

>  <Main Tar all refs>
Eur. J. Drug Metab. Pharmacokinet., 1999, vol. 24, # 3, p. 272 - 278 | J. Med. Chem., 2022, vol. 65, # 23, p. 15627 - 15641 | MONDELEZ INTERNATIONAL, INC. - US2011/104179, 2011, A1 | Drug Metab. Dispos., 2008, vol. 36, # 8, p. 1689 - 1697 | DRUG METAB. DISPOS., 1990, vol. 18, # 5, p. 595 - 606 | J. Pharmacol. Exp. Ther., 1997, vol. 283, # 3, p. 1168 - 1176 | Bioorg. Med. Chem., 2007, vol. 15, # 6, p. 2368 - 2374 | Bioorg. Med. Chem., 2007, vol. 15, # 6, p. 2368 - 2374 | Mol. Pharmacol., 2005, vol. 67, # 4, p. 1128 - 1136 | Antimicrob. Agents Chemother., 2001, vol. 45, # 10, p. 2871 - 2876 | Bioorg. Med. Chem., 2007, vol. 15, # 6, p. 2368 - 2374

>  <Main tar all>
Cytochrome P450 3A4 pX=5.96 | p21 (RAC1) activated kinase 1 pX=5.67 | Gingipain R1 pX=5.52 | Pregnane X receptor pX=5.21 | CYP3A pX=4.85 | CYP1A1 pX=4.79 | MMP2 pX=4.62 | MMP3 pX=4.6 | MMP7 pX=4.55 | Papain pX=4.52 | MMP8 pX=4.51

$$$$
Tocopherol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.3929 0.8043 0 0
M  V30 2 C 15.7266 1.5743 0 0
M  V30 3 C 15.7266 3.1143 0 0
M  V30 4 C 17.0602 0.8043 0 0
M  V30 5 C 18.3939 1.5743 0 0
M  V30 6 C 19.7276 0.8043 0 0
M  V30 7 C 21.0613 1.5743 0 0 CFG=1
M  V30 8 C 21.0613 3.1143 0 0
M  V30 9 C 22.3949 0.8043 0 0
M  V30 10 C 23.7286 1.5743 0 0
M  V30 11 C 25.0623 0.8043 0 0
M  V30 12 C 26.396 1.5743 0 0 CFG=1
M  V30 13 C 26.396 3.1143 0 0
M  V30 14 C 27.7297 0.8043 0 0
M  V30 15 C 29.0633 1.5743 0 0
M  V30 16 C 30.397 0.8043 0 0
M  V30 17 C 30.397 -0.7357 0 0 CFG=2
M  V30 18 C 28.8804 -0.4683 0 0
M  V30 19 C 31.9136 -0.4683 0 0
M  V30 20 C 32.9035 -1.648 0 0
M  V30 21 C 32.3768 -3.0951 0 0
M  V30 22 C 33.3667 -4.2748 0 0
M  V30 23 C 34.8833 -4.0074 0 0
M  V30 24 C 32.84 -5.7219 0 0
M  V30 25 O 33.8299 -6.9016 0 0
M  V30 26 C 31.3234 -5.9893 0 0
M  V30 27 C 30.7967 -7.4365 0 0
M  V30 28 C 30.3335 -4.8096 0 0
M  V30 29 C 28.8169 -5.0771 0 0
M  V30 30 C 30.8602 -3.3625 0 0
M  V30 31 O 29.8703 -2.1828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16 CFG=3
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 22 24
M  V30 24 1 24 25
M  V30 25 1 24 26
M  V30 26 1 26 27
M  V30 27 2 26 28
M  V30 28 1 28 29
M  V30 29 1 28 30
M  V30 30 2 21 30
M  V30 31 1 30 31
M  V30 32 1 17 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811339

>  <MW>
430.381

>  <MW (desalted)>
430.706

>  <ClogP>
12.048

>  <logS>
-10.081

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
12

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  14.98 pg/ml

>  <CAS>
59-02-9

>  <Description>
Tocopherol is a lipid-soluble form of vitamin E. It is used in many skin creams and multivitamin preparations as an antioxidant.

>  <EBC_ID>
EBC-27078

>  <IUPAC Name>
(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-ol

>  <Main Tar all refs>
Life Sci., 2020, vol. 248

>  <Main tar all>
NAD-dependent protein deacetylase sirtuin-1 pX=10.5

$$$$
Cloxacillin sodium salt monohydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Na 14.8927 -5.9154 0 0 CHG=1
M  V30 3 C 4.4 0.2578 0 0
M  V30 4 C 5.0991 1.63 0 0
M  V30 5 O 4.4 3.0021 0 0
M  V30 6 N 5.4889 4.0911 0 0
M  V30 7 C 6.8611 3.3919 0 0
M  V30 8 C 6.6202 1.8709 0 0
M  V30 9 C 7.7091 0.7819 0 0
M  V30 10 O 9.1967 1.1805 0 0
M  V30 11 N 7.3105 -0.7056 0 0
M  V30 12 C 8.3995 -1.7945 0 0 CFG=1
M  V30 13 C 9.9395 -1.7945 0 0 CFG=1
M  V30 14 S 11.4041 -1.3187 0 0
M  V30 15 C 12.3093 -2.5645 0 0
M  V30 16 C 13.4538 -1.5341 0 0
M  V30 17 C 13.4538 -3.595 0 0
M  V30 18 C 11.4041 -3.8104 0 0 CFG=1
M  V30 19 N 9.9395 -3.3345 0 0
M  V30 20 C 8.3995 -3.3345 0 0
M  V30 21 O 7.3105 -4.4235 0 0
M  V30 22 C 11.88 -5.2751 0 0
M  V30 23 O 10.8495 -6.4195 0 0
M  V30 24 O 13.3864 -5.5952 0 0 CHG=-1
M  V30 25 C 8.2332 4.0911 0 0
M  V30 26 C 9.5248 3.2523 0 0
M  V30 27 C 10.8969 3.9515 0 0
M  V30 28 C 10.9775 5.4894 0 0
M  V30 29 C 9.686 6.3281 0 0
M  V30 30 C 8.3138 5.629 0 0
M  V30 31 Cl 7.0223 6.4677 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 2 6 7
M  V30 5 1 7 8
M  V30 6 2 4 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 12 11 CFG=1
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 15 17
M  V30 16 1 18 15
M  V30 17 1 18 19
M  V30 18 1 13 19 CFG=1
M  V30 19 1 19 20
M  V30 20 1 12 20
M  V30 21 2 20 21
M  V30 22 1 18 22 CFG=3
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 7 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 25 30
M  V30 32 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404032

>  <MW>
475.058

>  <MW (desalted)>
435.881

>  <ClogP>
-0.3

>  <logS>
-6.762

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
115.57

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 0.0005 ?M

>  <CAS>
7081-44-9

>  <Description>
Cloxacillin is an antibiotic agent used for the treatment of beta-hemolytic streptococcal and pneumococcal infections as well as staphylococcal infections.

>  <EBC_ID>
EBC-12270

>  <IUPAC Name>
sodium (2S,5R,6R)-6-[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2000, vol. 44, # 5, p. 1387 - 1390

>  <Main tar all>
Beta-Lactamase AmpC pX=9.3

$$$$
Cilostazol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -8.0021 7.7 0 0
M  V30 2 C -6.6684 6.93 0 0
M  V30 3 C -5.3347 7.7 0 0
M  V30 4 C -4.001 6.93 0 0
M  V30 5 C -4.001 5.39 0 0
M  V30 6 C -2.6674 4.62 0 0
M  V30 7 C -2.6674 3.08 0 0
M  V30 8 O -1.3337 2.31 0 0
M  V30 9 C -0 3.08 0 0
M  V30 10 C 1.3337 2.31 0 0
M  V30 11 C 2.6674 3.08 0 0
M  V30 12 C 4.001 2.31 0 0
M  V30 13 C 5.3347 3.08 0 0
M  V30 14 N 5.4957 4.6116 0 0
M  V30 15 N 7.002 4.9317 0 0
M  V30 16 N 7.772 3.5981 0 0
M  V30 17 N 6.7416 2.4536 0 0
M  V30 18 C 7.0618 0.9473 0 0
M  V30 19 C 8.5264 0.4714 0 0
M  V30 20 C 8.8466 -1.035 0 0
M  V30 21 C 7.7021 -2.0654 0 0
M  V30 22 C 6.2375 -1.5895 0 0
M  V30 23 C 5.9173 -0.0832 0 0
M  V30 24 C -4.001 2.31 0 0
M  V30 25 C -5.3347 3.08 0 0
M  V30 26 C -5.3347 4.62 0 0
M  V30 27 N -6.6684 5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 13 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 18 23
M  V30 25 1 7 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 5 26
M  V30 29 1 26 27
M  V30 30 1 2 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485368

>  <MW>
369.216

>  <MW (desalted)>
369.461

>  <ClogP>
3.528

>  <logS>
-2.869

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
81.93

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
cell viability increase rate Active

>  <CAS>
73963-72-1

>  <Description>
Cilostazol and several of its metabolites are cyclic AMP phosphodiesterase III inhibitors, inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. Cilostazol is indicated for the alleviation of symptoms of intermittent claudication.

>  <EBC_ID>
EBC-11191

>  <IUPAC Name>
6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one

>  <Main Tar all refs>
Clin. Cancer Res., 2019, vol. 25, # 5, p. 1676 - 1687

>  <Main tar all>
cGMP-specific 3',5'-cGMP phosphodiesterase 3 pX=10.0

$$$$
Guaiacol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474028

>  <MW>
124.052

>  <MW (desalted)>
124.137

>  <ClogP>
1.324

>  <logS>
-0.99

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.62 ?M | Ki (inhibition constant)  2.6 ?mol/l | Ki (inhibition constant) = 3.56 ?M | IC50 ~ 20 ?M | IC50 = 24.5 ?M

>  <CAS>
90-05-1

>  <Description>
Guaiacol is an agent thought to have disinfectant properties and used as an expectorant.

>  <EBC_ID>
EBC-13356

>  <IUPAC Name>
2-methoxyphenol

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2013, vol. 13, # 3, p. 408 - 430 | Chem. Pharm. Bull., 2020, vol. 68, # 12, p. 1193 - 1200 | J. Enzyme Inhib. Med. Chem., 2012, vol. 27, # 6, p. 880 - 885 | UNIVERSITY OF KENTUCKY - US2020/215031, 2020, A1 | Mini-Rev. Med. Chem., 2013, vol. 13, # 3, p. 408 - 430

>  <Main tar all>
carbonic anhydrase 2 pX=5.79 | acetylcholinesterase (Cartwright blood group) pX=5.59 | carbonic anhydrase 4 pX=5.45 | Glycogen synthase (family) pX=4.7 | carbonic anhydrase 1 pX=4.61

$$$$
Methionine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 S 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0
M  V30 4 C 7.2874 2.6674 0 0
M  V30 5 C 8.621 3.4374 0 0 CFG=2
M  V30 6 N 8.621 4.9774 0 0
M  V30 7 C 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 9 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440050

>  <MW>
149.051

>  <MW (desalted)>
149.211

>  <ClogP>
-1.731

>  <logS>
-0.59

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  17.8 nM | Ki (inhibition constant) = 30 nM

>  <CAS>
63-68-3

>  <Description>
Methionine is an amino acid commonly found as a component in total parenteral nutrition. It is used for protein synthesis including the formation of SAMe, L-homocysteine, L-cysteine, taurine, and sulfate.

>  <EBC_ID>
EBC-04026

>  <IUPAC Name>
(2S)-2-amino-4-(methylsulfanyl)butanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2022, vol. 65, # 14, p. 9735 - 9749 | JOHNSON & JOHNSON INC - US6838249, 2005, B2

>  <Main tar all>
kallikrein related peptidase 7 pX=7.75 | voltage-gated calcium channel (alpha 2 delta) pX=7.52

$$$$
Pargyline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -6.93 0 0
M  V30 2 N 4.001 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 1.3337 -5.39 0 0
M  V30 5 C 0 -6.16 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 C 8.0021 -7.7 0 0
M  V30 12 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 3 4 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z103710848

>  <MW>
159.105

>  <MW (desalted)>
159.228

>  <ClogP>
2.576

>  <logS>
-2.18

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.15 nM | IC50  0.0014 ?M

>  <CAS>
555-57-7

>  <Description>
Pargyline is an irreversible non-selective monoamine oxidase inhibitor drug. Pargyline has been used to treat moderate hypertension.

>  <EBC_ID>
EBC-00006

>  <IUPAC Name>
benzyl(methyl)(prop-2-yn-1-yl)amine

>  <Main Tar all refs>
ACS Chem. Neurosci., 2019, vol. 10, # 1, p. 252 - 265 | Biol. Pharm. Bull., 2010, vol. 33, # 4, p. 725 - 728

>  <Main tar all>
Monoamine oxidase B pX=9.82 | Monoamine oxidase A pX=8.85

$$$$
Levetiracetam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.2739 5.93 0 0
M  V30 2 C -0.2739 4.39 0 0
M  V30 3 C 1.0598 3.62 0 0 CFG=2
M  V30 4 N 1.0598 2.08 0 0
M  V30 5 C 2.3057 1.1748 0 0
M  V30 6 C 1.8298 -0.2898 0 0
M  V30 7 C 0.2898 -0.2898 0 0
M  V30 8 C -0.1861 1.1748 0 0
M  V30 9 O -1.6507 1.6507 0 0
M  V30 10 C 2.3935 4.39 0 0
M  V30 11 O 3.7272 3.62 0 0
M  V30 12 N 2.3935 5.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 2 8 9
M  V30 10 1 3 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255435426

>  <MW>
170.106

>  <MW (desalted)>
170.209

>  <ClogP>
-0.344

>  <logS>
-0.981

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
63.4

>  <RotBonds>
3

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
EC50 = 0.04 ?M | IC50 = 75.7 nM | IC50 = 75.7 nM | pIC50  7.1 | concentration (parameter)  0.09 nmol/mL | IC50 = 0.2 ?M

>  <CAS>
102767-28-2

>  <Description>
Levetiracetam is an antiepileptic agent that binds to the synaptic vesicle protein SV2A. It is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older.

>  <EBC_ID>
EBC-06279

>  <IUPAC Name>
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide

>  <Main Tar all refs>
Curr. Med. Chem., 2013, vol. 20, # 13, p. 1623 - 1634 | J. Med. Chem., 2015, vol. 58, # 15, p. 6018 - 6032 | J. Med. Chem., 2015, vol. 58, # 15, p. 6018 - 6032 | PLoS ONE, 2015, vol. 10, # 2 | Epilepsia, 2003, vol. 44, # 2, p. 171 - 178 | Curr. Med. Chem., 2013, vol. 20, # 13, p. 1623 - 1634

>  <Main tar all>
glycine receptor ?1 subunit pX=7.4 | acetylcholinesterase (Cartwright blood group) pX=7.12 | acetylcholinesterase (Cartwright blood group) pX=7.12 | synaptic vesicle glycoprotein 2A pX=7.1 | Carboxylesterase pX=7.05 | Cav1.1 pX=6.7

$$$$
Clofibric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.4374 3.2863 0 0
M  V30 2 C 2.6674 4.62 0 0
M  V30 3 C 1.8974 5.9537 0 0
M  V30 4 O 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 Cl 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 C 4.001 5.39 0 0
M  V30 13 O 4.001 6.93 0 0
M  V30 14 O 5.3347 4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 12 1 2 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57727844

>  <MW>
214.04

>  <MW (desalted)>
214.646

>  <ClogP>
2.821

>  <logS>
-2.95

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
pKb  8.95  | pKb  8.95

>  <CAS>
882-09-7

>  <Description>
Clofibric acid is a fibric acid derivative used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. It is an agonist of the PPAR-? receptor in muscle, liver, and other tissues.

>  <EBC_ID>
EBC-03507

>  <IUPAC Name>
2-(4-chlorophenoxy)-2-methylpropanoic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663

>  <Main tar all>
Aldo-keto reductase family 1 member B1 pX=8.95 | Aldose reductase pX=8.95

$$$$
Temozolomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 N 6.2576 2.0728 0 0
M  V30 4 N 4.9239 1.3028 0 0
M  V30 5 C 3.5902 2.0728 0 0
M  V30 6 C 2.1256 1.5969 0 0
M  V30 7 N 1.2204 2.8428 0 0
M  V30 8 C 2.1256 4.0887 0 0
M  V30 9 N 3.5902 3.6128 0 0
M  V30 10 C 4.9239 4.3828 0 0
M  V30 11 O 4.9239 5.9228 0 0
M  V30 12 C 1.6497 0.1323 0 0
M  V30 13 O 2.6802 -1.0121 0 0
M  V30 14 N 0.1434 -0.1879 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 12 2 10 11
M  V30 13 1 6 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201620684

>  <MW>
194.055

>  <MW (desalted)>
194.151

>  <ClogP>
-0.811

>  <logS>
-1.3

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
105.94

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 > 100 nM | IC50 = 366 nM | IC50  1 ?M | inhibition rate Active

>  <CAS>
85622-93-1

>  <Description>
Temozolomide is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent.  It is effective in a variety of types of cancer, including aggressive brain cancers.

>  <EBC_ID>
EBC-00562

>  <IUPAC Name>
3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide

>  <Main Tar all refs>
QIU; JEAN CLAUDE - WO2002/68396, 2002, A1 | QIU; JEAN CLAUDE - WO2002/68396, 2002, A1 | Toxicol. Vitro, 2019, vol. 61 | OncoTargets Ther., 2020, vol. 13, p. 2215 - 2224

>  <Main tar all>
epidermal growth factor receptor pX=7.0 | Methylated-DNA-protein-cysteine methyltransferase pX=6.44 | ABCG2 pX=6.0 | signal transducer and activator of transcription 3 pX=6.0

$$$$
Guaifenesin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 3.08 0 0
M  V30 2 O 1.3337 2.31 0 0
M  V30 3 C 2.6674 3.08 0 0
M  V30 4 C 2.6674 4.62 0 0
M  V30 5 C 4.001 5.39 0 0
M  V30 6 C 5.3347 4.62 0 0
M  V30 7 C 5.3347 3.08 0 0
M  V30 8 C 4.001 2.31 0 0
M  V30 9 O 4.001 0.77 0 0
M  V30 10 C 5.3347 0 0 0
M  V30 11 C 6.6684 0.77 0 0
M  V30 12 O 6.6684 2.31 0 0
M  V30 13 C 8.0021 0 0 0
M  V30 14 O 9.3358 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255415511

>  <MW>
198.089

>  <MW (desalted)>
198.216

>  <ClogP>
0.102

>  <logS>
-1.261

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
58.92

>  <RotBonds>
5

>  <CAS>
93-14-1

>  <Description>
Guaifenesin is an expectorant commonly found in OTC products for the symptomatic relief from congested chests and coughs associated with cold, bronchitis, and/or other breathing illnesses.

>  <EBC_ID>
EBC-11064

>  <IUPAC Name>
3-(2-methoxyphenoxy)propane-1,2-diol

$$$$
Xylazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -0.77 0 0
M  V30 2 C 4.001 -2.31 0 0
M  V30 3 C 5.3347 -3.08 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 1.3337 -5.39 0 0
M  V30 8 C 2.6674 -3.08 0 0
M  V30 9 N 1.3337 -2.31 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 N 0 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 13 C 1.3337 2.31 0 0
M  V30 14 C 2.6674 1.54 0 0
M  V30 15 S 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56828371

>  <MW>
220.103

>  <MW (desalted)>
220.334

>  <ClogP>
0.52

>  <logS>
-3.44

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.39

>  <RotBonds>
1

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
pD2  8.49

>  <CAS>
7361-61-7

>  <Description>
Xylazine is an agonist of  alpha2-adrenergic receptors. It is an analog of clonidine, an alpha2-adrenergic receptor agonist used to reduce blood pressure. Veterinarians also use xylazine as an emetic, especially in cats.

>  <EBC_ID>
EBC-03663

>  <IUPAC Name>
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1979, vol. 59, # 1-2, p. 1 - 9

>  <Main tar all>
?-adrenoceptor pX=8.49

$$$$
Pantothenic acid sodium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 11.2884 1.8974 0 0 CHG=1
M  V30 2 C 1.389 4.771 0 0
M  V30 3 C 0.619 3.4374 0 0
M  V30 4 C -0.151 2.1037 0 0
M  V30 5 C -0.7147 4.2074 0 0
M  V30 6 O -2.0484 3.4374 0 0
M  V30 7 C 1.9526 2.6674 0 0 CFG=1
M  V30 8 O 1.9526 1.1274 0 0
M  V30 9 C 3.2863 3.4374 0 0
M  V30 10 O 3.2863 4.9774 0 0
M  V30 11 N 4.62 2.6674 0 0
M  V30 12 C 5.9537 3.4374 0 0
M  V30 13 C 7.2874 2.6674 0 0
M  V30 14 C 8.621 3.4374 0 0
M  V30 15 O 8.621 4.9774 0 0
M  V30 16 O 9.9547 2.6674 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 7 3
M  V30 6 1 7 8 CFG=3
M  V30 7 1 7 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741981540

>  <MW>
241.093

>  <MW (desalted)>
219.235

>  <ClogP>
-4.454

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
109.69

>  <RotBonds>
6

>  <CAS>
867-81-2

>  <Description>
Pantothenic acid is a vitamin B5 found in various nutritional supplements. Pantothenic acid is used in the synthesis of coenzyme A (CoA) and protects cells against peroxidative damage by increasing the level of gluatathione. It is studied for the treatment of many uses such as treatment of testicular torsion, diabetic ulceration, wound healing, acne, obesity, diabetic peripheral polyneuropathy. It has also been investigated for its hypolipidemic effects and as cholesterol lowering agent.

>  <EBC_ID>
EBC-13974

>  <IUPAC Name>
sodium 3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanoate

$$$$
Isoprenaline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.2833 0 0
M  V30 3 C 5.7337 0.5133 0 0
M  V30 4 C 5.7337 -1.0267 0 0
M  V30 5 N 7.0674 1.2833 0 0
M  V30 6 C 8.401 0.5133 0 0
M  V30 7 C 9.7347 1.2833 0 0
M  V30 8 O 9.7347 2.8233 0 0
M  V30 9 C 11.0684 0.5133 0 0
M  V30 10 C 12.4021 1.2833 0 0
M  V30 11 C 13.7358 0.5133 0 0
M  V30 12 C 13.7358 -1.0267 0 0
M  V30 13 O 15.0694 -1.7967 0 0
M  V30 14 C 12.4021 -1.7967 0 0
M  V30 15 O 12.4021 -3.3367 0 0
M  V30 16 C 11.0684 -1.0267 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 12 14
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 2 9 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1416254508

>  <MW>
247.098

>  <MW (desalted)>
211.258

>  <ClogP>
0.153

>  <logS>
-1.25

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
4

>  <Action on targets>
Agonist | Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
pEC50  10.26 | IC50 = 0.2 nM | pD2  9.01  | pEC50  8.81

>  <CAS>
51-30-9

>  <Description>
Isoprenaline is a non-selective beta adrenergic receptor agonist. It is indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.

>  <EBC_ID>
EBC-12590

>  <IUPAC Name>
4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2020, vol. 28, # 1 | Eur. J. Med. Chem., 1988, vol. 23, p. 511 - 515 | BR. J. PHARMACOL., 1992, vol. 106, # 2, p. 335 - 341 | Bioorg. Med. Chem., 2020, vol. 28, # 1

>  <Main tar all>
?2-adrenoceptor pX=10.3 | ?1-adrenoceptor pX=9.7 | ?-adrenoceptor pX=9.01 | ?1-adrenoceptor pX=8.81

$$$$
Orciprenaline sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.7793 1.078 0 0
M  V30 2 C -4.4456 0.308 0 0
M  V30 3 C -4.4456 -1.232 0 0
M  V30 4 N -3.1119 1.078 0 0
M  V30 5 C -1.7782 0.308 0 0
M  V30 6 C -0.4446 1.078 0 0
M  V30 7 O -0.4446 2.618 0 0
M  V30 8 C 0.8891 0.308 0 0
M  V30 9 C 2.2228 1.078 0 0
M  V30 10 C 3.5565 0.308 0 0
M  V30 11 O 4.8902 1.078 0 0
M  V30 12 C 3.5565 -1.232 0 0
M  V30 13 C 2.2228 -2.002 0 0
M  V30 14 O 2.2228 -3.542 0 0
M  V30 15 C 0.8891 -1.232 0 0
M  V30 16 C 9.2902 1.078 0 0
M  V30 17 C 10.6238 0.308 0 0
M  V30 18 C 10.6238 -1.232 0 0
M  V30 19 N 11.9575 1.078 0 0
M  V30 20 C 13.2912 0.308 0 0
M  V30 21 C 14.6249 1.078 0 0
M  V30 22 O 14.6249 2.618 0 0
M  V30 23 C 15.9586 0.308 0 0
M  V30 24 C 17.2922 1.078 0 0
M  V30 25 C 18.6259 0.308 0 0
M  V30 26 O 19.9596 1.078 0 0
M  V30 27 C 18.6259 -1.232 0 0
M  V30 28 C 17.2922 -2.002 0 0
M  V30 29 O 17.2922 -3.542 0 0
M  V30 30 C 15.9586 -1.232 0 0
M  V30 31 O 0 -9.702 0 0
M  V30 32 S 0 -8.162 0 0
M  V30 33 O 0 -6.622 0 0
M  V30 34 O 1.54 -8.162 0 0
M  V30 35 O -1.54 -8.162 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 8 15
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 1 25 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 1 28 30
M  V30 30 2 23 30
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 2 32 34
M  V30 34 1 32 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z955123630

>  <MW>
520.209

>  <MW (desalted)>
211.258

>  <ClogP>
0.083

>  <logS>
-0.22

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 14 ?M | Ki (inhibition constant) = 14 ?M

>  <CAS>
5874-97-5

>  <Description>
Orciprenaline stimulates the ?2-adrenergic receptor expressed in the lungs, uterus, and vasculature supplying skeletal muscles by acting as a moderately selective agonist. It is indicated for the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.

>  <EBC_ID>
EBC-15025

>  <IUPAC Name>
bis(5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol); sulfuric acid

>  <Main Tar all refs>
J. Biomol. Screen., 2009, vol. 14, # 8, p. 936 - 943 | J. Biomol. Screen., 2009, vol. 14, # 8, p. 936 - 943

>  <Main tar all>
?2-adrenoceptor pX=4.85 | ?2-adrenoceptor pX=4.85

$$$$
Amiloride hydrochloride hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 Cl 0 -7.546 0 0
M  V30 4 N 4.4 -3.08 0 0
M  V30 5 C 5.7337 -3.85 0 0
M  V30 6 N 7.0674 -3.08 0 0
M  V30 7 N 5.7337 -5.39 0 0
M  V30 8 C 7.0674 -6.16 0 0
M  V30 9 O 8.401 -5.39 0 0
M  V30 10 C 7.0674 -7.7 0 0
M  V30 11 N 8.401 -8.47 0 0
M  V30 12 C 8.401 -10.01 0 0
M  V30 13 Cl 9.7347 -10.78 0 0
M  V30 14 C 7.0674 -10.78 0 0
M  V30 15 N 7.0674 -12.32 0 0
M  V30 16 N 5.7337 -10.01 0 0
M  V30 17 C 5.7337 -8.47 0 0
M  V30 18 N 4.4 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 2 5 6
M  V30 3 1 5 7
M  V30 4 1 7 8
M  V30 5 2 8 9
M  V30 6 1 8 10
M  V30 7 1 10 11
M  V30 8 2 11 12
M  V30 9 1 12 13
M  V30 10 1 12 14
M  V30 11 1 14 15
M  V30 12 2 14 16
M  V30 13 1 16 17
M  V30 14 2 10 17
M  V30 15 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541632803

>  <MW>
301.046

>  <MW (desalted)>
229.627

>  <ClogP>
0.108

>  <logS>
-2.65

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
156.79

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1.59 nM | IC50  1.59 nM | IC50  1.59 nM | inhibition percentage Active   | inhibition percentage Active   | Ki (inhibition constant)  48 nM

>  <CAS>
17440-83-4

>  <Description>
Amiloride is a pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. It is indicated for use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

>  <EBC_ID>
EBC-11033

>  <IUPAC Name>
3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide dihydrate hydrochloride

>  <Main Tar all refs>
Cancers, 2020, vol. 12, # 8, p. 1 - 9 | Cancers, 2020, vol. 12, # 8, p. 1 - 9 | Cancers, 2020, vol. 12, # 8, p. 1 - 9 | J. Med. Chem., 2018, vol. 61, # 18, p. 8299 - 8320 | J. Med. Chem., 2018, vol. 61, # 18, p. 8299 - 8320 | Eur. J. Pharmacol., 1989, vol. 159, # 2, p. 199 - 203

>  <Main tar all>
ENaC ? pX=8.8 | ENaC ? pX=8.8 | ENaC ? pX=8.8 | Dipeptidyl-peptidase 7 pX=8.0 | Prolylcarboxypeptidase pX=8.0 | ?2-adrenoceptor pX=7.32

$$$$
Zileuton
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.0896 0.0309 0 0
M  V30 2 C -0.3196 -1.3028 0 0
M  V30 3 N -1.0896 -2.6365 0 0
M  V30 4 O -0.3196 -3.9702 0 0
M  V30 5 C -2.6296 -2.6365 0 0
M  V30 6 O -3.3996 -3.9702 0 0
M  V30 7 N -3.3996 -1.3028 0 0
M  V30 8 C 1.2204 -1.3028 0 0
M  V30 9 C 2.1256 -0.0569 0 0
M  V30 10 C 3.5902 -0.5328 0 0
M  V30 11 C 4.9239 0.2372 0 0
M  V30 12 C 6.2576 -0.5328 0 0
M  V30 13 C 6.2576 -2.0728 0 0
M  V30 14 C 4.9239 -2.8428 0 0
M  V30 15 C 3.5902 -2.0728 0 0
M  V30 16 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 17 1 8 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610483

>  <MW>
236.062

>  <MW (desalted)>
236.29

>  <ClogP>
2.483

>  <logS>
-3.26

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
66.56

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.77 nM | IC50  0.86 nM

>  <CAS>
111406-87-2

>  <Description>
Zileuton is used in the prophylaxis and treatment of chronic asthma. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.

>  <EBC_ID>
EBC-08204

>  <IUPAC Name>
1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea

>  <Main Tar all refs>
Arch. Pharm., 2020 | Arch. Biochem. Biophys., 2020, vol. 689

>  <Main tar all>
Polyunsaturated fatty acid 5-lipoxygenase pX=9.11 | 5-LOX pX=9.07

$$$$
Dapsone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 -2.31 0 0
M  V30 2 C 1.3337 -3.85 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 2.6674 -6.16 0 0
M  V30 5 C 1.3337 -6.93 0 0
M  V30 6 C 0 -6.16 0 0
M  V30 7 C 0 -4.62 0 0
M  V30 8 S 1.3337 -8.47 0 0
M  V30 9 O -0.2063 -8.47 0 0
M  V30 10 O 2.8737 -8.47 0 0
M  V30 11 C 1.3337 -10.01 0 0
M  V30 12 C 2.6674 -10.78 0 0
M  V30 13 C 2.6674 -12.32 0 0
M  V30 14 C 1.3337 -13.09 0 0
M  V30 15 N 1.3337 -14.63 0 0
M  V30 16 C -0 -12.32 0 0
M  V30 17 C -0 -10.78 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104472374

>  <MW>
248.062

>  <MW (desalted)>
248.301

>  <ClogP>
0.886

>  <logS>
-2.85

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
86.18

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 2.98 nM | Ki (inhibition constant)  0.09 ?M

>  <CAS>
80-08-0

>  <Description>
Dapsone is a sulfone drug. It has anti-inflammatory, antimalarial, and antibacterial activity. It inhibits Dihydrofolate reductase (gene DHFR) and Dihydropteroate synthase. Dapsone is used for the treatment and management of leprosy and dermatitis herpetiformis.

>  <EBC_ID>
EBC-03730

>  <IUPAC Name>
4-(4-aminobenzenesulfonyl)aniline

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 1998, vol. 42, # 1, p. 164 - 169 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1966 - 1975

>  <Main tar all>
dihydrofolate reductase pX=8.53 | Cytochrome P450 2C9 pX=7.05

$$$$
Felbamate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -2.31 0 0
M  V30 2 C -2.6674 -3.08 0 0
M  V30 3 O -2.6674 -4.62 0 0
M  V30 4 O -1.3337 -2.31 0 0
M  V30 5 C 0 -3.08 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 O 4.001 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 O 6.6684 -2.31 0 0
M  V30 11 N 5.3347 -4.62 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 C 0 -0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 15 C 1.3337 2.31 0 0
M  V30 16 C 2.6674 1.54 0 0
M  V30 17 C 2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521554005

>  <MW>
238.095

>  <MW (desalted)>
238.24

>  <ClogP>
0.497

>  <logS>
-1.99

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
104.64

>  <RotBonds>
7

>  <Action on targets>
Allosteric Modulator | Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Blocker

>  <Activity coefficients and valu>
IC50  95 nM | IC50  95 nM | IC50 = 95 nM | IC50 = 95 nM | IC50 = 95 nM | Ki (inhibition constant)  289 nM | inhibition percentage  78.6 % | inhibition percentage  78.6 %

>  <CAS>
25451-15-4

>  <Description>
Felbamate is an inhibitor of NMDA receptors and a modulator of GABAA receptors that also has broad-spectrum inhibitory activity against excitatory amino acid receptors. Felbamate is an anticonvulsant used to treat severe epilepsy.

>  <EBC_ID>
EBC-06581

>  <IUPAC Name>
3-(carbamoyloxy)-2-phenylpropyl carbamate

>  <Main Tar all refs>
J. Med. Chem., 2009, vol. 52, # 7, p. 2119 - 2125 | J. Med. Chem., 2009, vol. 52, # 7, p. 2119 - 2125 | J. Med. Chem., 2009, vol. 52, # 7, p. 2119 - 2125 | J. Med. Chem., 2009, vol. 52, # 7, p. 2119 - 2125 | J. Med. Chem., 2009, vol. 52, # 7, p. 2119 - 2125 | VIATRIS INC - US5256690, 1993, A | Pharm. Res., 2019, vol. 36, # 9 | Pharm. Res., 2019, vol. 36, # 9

>  <Main tar all>
GABAA receptor pX=7.02 | GABAA receptor pX=7.02 | GABAA receptor ?1 subunit pX=7.02 | GABAA receptor ?2 subunit pX=7.02 | GABAA receptor ? subunit pX=7.02 | NMDA receptor pX=6.54 | Nav1.8 pX=5.57 | Nav1.8 pX=5.57

$$$$
Melperone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -2.31 0 0
M  V30 2 C -2.6674 -3.08 0 0
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 N 0 -4.62 0 0
M  V30 6 C 1.3337 -5.39 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 C 5.3347 -4.62 0 0
M  V30 10 O 5.3347 -3.08 0 0
M  V30 11 C 6.6684 -5.39 0 0
M  V30 12 C 8.0021 -4.62 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 9.3358 -6.93 0 0
M  V30 15 F 10.6694 -7.7 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 C 6.6684 -6.93 0 0
M  V30 18 C -1.3337 -5.39 0 0
M  V30 19 C -2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 5 18
M  V30 19 1 18 19
M  V30 20 1 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z138288808

>  <MW>
263.169

>  <MW (desalted)>
263.35

>  <ClogP>
3.884

>  <logS>
-2.855

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
20.31

>  <RotBonds>
5

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Agonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  4.9 nM | pKi  7.5  | pEC50  7.28  | Ki (inhibition constant)  82 nM | Ki (inhibition constant) = 102 nM

>  <CAS>
3575-80-2

>  <Description>
Melperone demonstrates antagonist activity at D2 dopaminergic and 5HT2A serotonergic receptors. Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It is used for the treatment of schizophrenia, sleep, disorders, agitation and mentally confused states.

>  <EBC_ID>
EBC-06851

>  <IUPAC Name>
1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. PHARMACOL. EXP. THER., 1989, vol. 251, # 1, p. 238- 246 | Psychopharmacology, 2005, vol. 178, # 4, p. 451 - 460 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | Bull. Korean Chem. Soc., 2012, vol. 33, # 9, p. 2930 - 2936

>  <Main tar all>
D2S receptor pX=8.44 | D3 receptor pX=8.31 | 5-HT2A receptor pX=7.5 | M1 receptor pX=7.28 | D2 receptor pX=7.09 | 5-HT2A receptor pX=6.99

$$$$
Fenspiride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.2459 -0.9052 0 0
M  V30 2 C -0 0 0 0
M  V30 3 N 0 1.54 0 0
M  V30 4 C 1.4646 2.0159 0 0
M  V30 5 C 2.3698 0.77 0 0
M  V30 6 C 3.1398 2.1037 0 0
M  V30 7 C 4.6798 2.1037 0 0
M  V30 8 N 5.4498 0.77 0 0
M  V30 9 C 6.9898 0.77 0 0
M  V30 10 C 7.7598 2.1037 0 0
M  V30 11 C 9.2998 2.1037 0 0
M  V30 12 C 10.0698 3.4374 0 0
M  V30 13 C 11.6098 3.4374 0 0
M  V30 14 C 12.3798 2.1037 0 0
M  V30 15 C 11.6098 0.77 0 0
M  V30 16 C 10.0698 0.77 0 0
M  V30 17 C 4.6798 -0.5637 0 0
M  V30 18 C 3.1398 -0.5637 0 0
M  V30 19 O 1.4646 -0.4759 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 8 17
M  V30 18 1 17 18
M  V30 19 1 5 18
M  V30 20 1 5 19
M  V30 21 1 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1266873958

>  <MW>
260.152

>  <MW (desalted)>
260.332

>  <ClogP>
1.183

>  <logS>
-2.033

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
41.57

>  <RotBonds>
3

>  <CAS>
5053-06-5

>  <Description>
Fenspiride is an oxazolidinone spiro compound with antispasmodic and bronchodilator effects used in the treatment of ENT and respiratory diseases.

>  <EBC_ID>
EBC-12700

>  <IUPAC Name>
8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one

$$$$
Ramelteon
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0581 -1.5888 0 0
M  V30 2 C 10.3918 -2.3588 0 0
M  V30 3 C 11.7254 -1.5888 0 0
M  V30 4 O 11.7254 -0.0488 0 0
M  V30 5 N 13.0591 -2.3588 0 0
M  V30 6 C 14.3928 -1.5888 0 0
M  V30 7 C 15.7265 -2.3588 0 0
M  V30 8 C 17.0602 -1.5888 0 0 CFG=2
M  V30 9 C 17.2211 -0.0572 0 0
M  V30 10 C 18.7275 0.263 0 0
M  V30 11 C 19.4975 -1.0707 0 0
M  V30 12 C 21.0038 -1.3909 0 0
M  V30 13 C 21.4797 -2.8555 0 0
M  V30 14 C 20.4493 -4 0 0
M  V30 15 O 20.6102 -5.5315 0 0
M  V30 16 C 19.2034 -6.1579 0 0
M  V30 17 C 18.1729 -5.0135 0 0
M  V30 18 C 18.9429 -3.6798 0 0
M  V30 19 C 18.467 -2.2152 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 14 18
M  V30 19 1 18 19
M  V30 20 1 8 19
M  V30 21 2 11 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037281108

>  <MW>
259.157

>  <MW (desalted)>
259.343

>  <ClogP>
2.485

>  <logS>
-3.25

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.33

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  11.82  | pKi  11.52  | Ki (inhibition constant) = 14 pM | Ki (inhibition constant) = 14 pM | IC50  20.8 pM | Ki (inhibition constant)  23.1 pM | Ki (inhibition constant) = 0.045 nM

>  <CAS>
196597-26-9

>  <Description>
Ramelteon is a melatonin receptor agonist. It is used for insomnia, particularly delayed sleep onset.

>  <EBC_ID>
EBC-08367

>  <IUPAC Name>
N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide

>  <Main Tar all refs>
Br. J. Pharmacol., 2014, vol. 171, # 1, p. 186 - 201 | Br. J. Pharmacol., 2014, vol. 171, # 1, p. 186 - 201 | Annu. Rep. Med. Chem., 2004, vol. 39, p. 25 - 37 | Annu. Rep. Med. Chem., 2004, vol. 39, p. 25 - 37 | J. Med. Chem., 2002, vol. 45, # 19, p. 4222 - 4239 | Neuropharmacology, 2005, vol. 48, # 2, p. 301 - 310 | FERRER INTERNACIONAL SA - US2011/144178, 2011, A1

>  <Main tar all>
MT1 receptor pX=11.8 | MT2 receptor pX=11.5 | MT1 receptor pX=10.9 | MT1 receptor pX=10.9 | MT receptor pX=10.7 | MT1C receptor  pX=10.6 | MT2 receptor pX=10.3

$$$$
Venlafaxine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 6.0618 0 0
M  V30 3 O 7.0674 5.2918 0 0
M  V30 4 C 7.0674 3.7518 0 0
M  V30 5 C 8.401 2.9818 0 0
M  V30 6 C 8.401 1.4418 0 0
M  V30 7 C 7.0674 0.6718 0 0
M  V30 8 C 5.7337 1.4418 0 0
M  V30 9 C 5.7337 2.9818 0 0
M  V30 10 C 7.0674 -0.8682 0 0
M  V30 11 C 5.7337 -1.6382 0 0
M  V30 12 N 5.7337 -3.1782 0 0
M  V30 13 C 7.0674 -3.9482 0 0
M  V30 14 C 4.4 -3.9482 0 0
M  V30 15 C 8.401 -1.6382 0 0
M  V30 16 O 7.4111 -2.8179 0 0
M  V30 17 C 8.9277 -0.1911 0 0
M  V30 18 C 10.4444 0.0763 0 0
M  V30 19 C 11.4342 -1.1034 0 0
M  V30 20 C 10.9075 -2.5505 0 0
M  V30 21 C 9.3909 -2.8179 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 4 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 10 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557494602

>  <MW>
313.181

>  <MW (desalted)>
277.402

>  <ClogP>
3.269

>  <logS>
-3.115

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
32.7

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 8.9 nM | IC50 = 90 nM | Ki (inhibition constant) = 138 nM | IC50  0.2 ?M | IC50 = 280 nM

>  <CAS>
99300-78-4

>  <Description>
Venlafaxine hydrochloride is an orally active, potent serotonin (5-HT)/norepinephrine reuptake dual inhibitor. It is used for the treatment of major depression.

>  <EBC_ID>
EBC-00592

>  <IUPAC Name>
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 1998, vol. 8, # 5, p. 487 - 492 | J. MED. CHEM., 1990, vol. 33, # 10, p. 2899 - 2905 | MAYO FOUNDATION - US6069177, 2000, A | Bioorg. Med. Chem., 2017, vol. 25, # 20, p. 5278 - 5289 | Drug Dev. Res., 1991, vol. 23, # 3, p. 191 - 199

>  <Main tar all>
SERT pX=8.05 | Imipramine Receptor pX=7.05 | NET pX=6.86 | SERT pX=6.7 | DAT pX=6.55

$$$$
Nitisinone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 0 0 0 CHG=-1
M  V30 2 N 4.001 -0.77 0 0 CHG=1
M  V30 3 O 5.3347 0 0 0
M  V30 4 C 4.001 -2.31 0 0
M  V30 5 C 2.6674 -3.08 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 4.001 -5.39 0 0
M  V30 8 C 5.3347 -4.62 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 C 6.6684 -2.31 0 0
M  V30 11 O 6.6684 -0.77 0 0
M  V30 12 C 8.0021 -3.08 0 0
M  V30 13 C 9.3358 -2.31 0 0
M  V30 14 O 9.3358 -0.77 0 0
M  V30 15 C 10.6694 -3.08 0 0
M  V30 16 C 10.6694 -4.62 0 0
M  V30 17 C 9.3358 -5.39 0 0
M  V30 18 C 8.0021 -4.62 0 0
M  V30 19 O 6.6684 -5.39 0 0
M  V30 20 C 1.3337 -5.39 0 0
M  V30 21 F 0 -6.16 0 0
M  V30 22 F 0.5637 -4.0563 0 0
M  V30 23 F 2.1037 -6.7237 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 12 18
M  V30 20 2 18 19
M  V30 21 1 6 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 20 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1172207721

>  <MW>
329.051

>  <MW (desalted)>
329.228

>  <ClogP>
1.384

>  <logS>
-4.3

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
94.35

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 37 nM | IC50  173 nM | IC50  173 nM

>  <CAS>
104206-65-7

>  <Description>
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1.

>  <EBC_ID>
EBC-07016

>  <IUPAC Name>
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione

>  <Main Tar all refs>
Bioorg. Med. Chem., 2014, vol. 22, # 19, p. 5194 - 5211 | UNIVERSITY OF SIENA - WO2017/144583, 2017, A1 | ChemMedChem, 2016, vol. 11, # 7, p. 674 - 678

>  <Main tar all>
4-hydroxyphenylpyruvate dioxygenase pX=7.43 | 4-hydroxyphenylacetate decarboxylase pX=6.76 | p-hydroxyphenylpyruvate dioxygenase (4-HPPD) pX=6.76

$$$$
Pentamidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 -13.86 0 0
M  V30 2 C 0 -12.32 0 0
M  V30 3 N -1.3337 -11.55 0 0
M  V30 4 C 1.3337 -11.55 0 0
M  V30 5 C 1.3337 -10.01 0 0
M  V30 6 C 2.6674 -9.24 0 0
M  V30 7 C 4.001 -10.01 0 0
M  V30 8 O 5.3347 -9.24 0 0
M  V30 9 C 6.6684 -10.01 0 0
M  V30 10 C 8.0021 -9.24 0 0
M  V30 11 C 9.3358 -10.01 0 0
M  V30 12 C 10.6694 -9.24 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 O 13.3368 -9.24 0 0
M  V30 15 C 14.6705 -10.01 0 0
M  V30 16 C 16.0041 -9.24 0 0
M  V30 17 C 17.3378 -10.01 0 0
M  V30 18 C 17.3378 -11.55 0 0
M  V30 19 C 16.0041 -12.32 0 0
M  V30 20 C 14.6705 -11.55 0 0
M  V30 21 C 18.6715 -12.32 0 0
M  V30 22 N 20.0052 -11.55 0 0
M  V30 23 N 18.6715 -13.86 0 0
M  V30 24 C 4.001 -11.55 0 0
M  V30 25 C 2.6674 -12.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 21 1 18 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 2 7 24
M  V30 25 1 24 25
M  V30 26 2 4 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977993

>  <MW>
340.19

>  <MW (desalted)>
340.419

>  <ClogP>
2.308

>  <logS>
-4.642

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
118.2

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Substrate | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1 nM | Ki (inhibition constant)  1.4 nM | EC50  1.7 - 2.4 nM | EC50  0.0019 ?M | EC50  0.0019 ?M | EC50  0.0033 ?M | EC50  0.011 ?M | EC50  0.011 ?M | IC50  0.026 ?M | EC50  0.026 ?M

>  <CAS>
100-33-4

>  <Description>
Pentamidine is an antiprotozoal agent.Pentamidine is a potent and selective protein tyrosine phosphatases and phosphatase of regenerating liver inhibitor. Pentamidine has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment.

>  <EBC_ID>
EBC-02046

>  <IUPAC Name>
4-{[5-(4-carbamimidoylphenoxy)pentyl]oxy}benzene-1-carboximidamide

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2014, vol. 58, # 5, p. 2925 - 2928 | Eur. J. Pharmacol., 1998, vol. 353, # 1, p. 97 - 103 | RSC. Med. Chem., 2020, vol. 11, # 8, p. 885 - 895 | J. Med. Chem., 2022, vol. 65, # 13, p. 9011 - 9033 | J. Med. Chem., 2022, vol. 65, # 13, p. 9011 - 9033 | Eur. J. Med. Chem., 2018, vol. 150, p. 385 - 402 | Eur. J. Med. Chem., 2019, vol. 164, p. 689 - 705 | Eur. J. Med. Chem., 2019, vol. 164, p. 689 - 705 | Eur. J. Med. Chem., 2020, vol. 185 | J. Med. Chem., 2021, vol. 64, # 17, p. 13054 - 13071

>  <Main tar all>
Mitochondrial ATPase pX=9.0 | Imidazoline 2 binding site pX=8.85 | Methionyl-tRNA synthetase pX=8.77 | Pteridine reductase 1 pX=8.72 | dihydrofolate reductase pX=8.72 | Alternative oxidase pX=8.48 | TbAT1/P1 transporter pX=7.96 | TbAT1/P2 transporter pX=7.96 | Leucine-tRNA ligase (L-leucine:tRNALeu ligase (AMP-forming)) pX=7.59 | Rhodesain pX=7.59

$$$$
Alogliptin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 N -1.3337 -2.31 0 0
M  V30 3 C -2.6674 -3.08 0 0
M  V30 4 O -4.001 -2.31 0 0
M  V30 5 C -2.6674 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0
M  V30 7 N -1.3337 -6.93 0 0
M  V30 8 C 0 -7.7 0 0
M  V30 9 C 0 -9.24 0 0
M  V30 10 C -1.3337 -10.01 0 0
M  V30 11 C -2.6674 -9.24 0 0 CFG=1
M  V30 12 N -4.001 -10.01 0 0
M  V30 13 C -2.6674 -7.7 0 0
M  V30 14 N 0 -4.62 0 0
M  V30 15 C 1.3337 -5.39 0 0
M  V30 16 C 2.6674 -4.62 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 18 C 4.001 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 5.3347 -4.62 0 0
M  V30 21 C 4.001 -5.39 0 0
M  V30 22 C 4.001 -6.93 0 0
M  V30 23 N 4.001 -8.47 0 0
M  V30 24 C 0 -3.08 0 0
M  V30 25 O 1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 7 13
M  V30 14 1 6 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 23 1 21 22
M  V30 24 3 22 23
M  V30 25 1 14 24
M  V30 26 1 2 24
M  V30 27 2 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1718280150

>  <MW>
339.17

>  <MW (desalted)>
339.392

>  <ClogP>
0.989

>  <logS>
-3.032

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
93.67

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.9 nM

>  <CAS>
850649-61-5

>  <Description>
Alogliptin is a dipeptidyl peptidase-4 inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus.

>  <EBC_ID>
EBC-26650

>  <IUPAC Name>
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile

>  <Main Tar all refs>
SCRIPPS RESEARCH - WO2022/155674, 2022, A1

>  <Main tar all>
dipeptidyl peptidase 4 pX=9.05

$$$$
Topiramate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.1104 -1.6376 0 0
M  V30 2 C 1.3959 -1.9578 0 0
M  V30 3 C 0.92 -3.4225 0 0
M  V30 4 O 1.5569 -0.4263 0 0
M  V30 5 C 3.0633 -0.1061 0 0 CFG=2
M  V30 6 C 3.8333 1.2276 0 0
M  V30 7 O 5.3733 1.2276 0 0
M  V30 8 C 6.1433 -0.1061 0 0 CFG=1
M  V30 9 C 7.0484 1.1398 0 0
M  V30 10 O 8.58 0.9788 0 0
M  V30 11 S 9.4852 2.2247 0 0
M  V30 12 O 10.3904 3.4706 0 0
M  V30 13 O 10.7311 1.3195 0 0
M  V30 14 N 8.2393 3.1299 0 0
M  V30 15 O 7.6496 -0.4263 0 0
M  V30 16 C 7.8106 -1.9578 0 0
M  V30 17 C 9.3169 -1.6376 0 0
M  V30 18 C 8.2865 -3.4225 0 0
M  V30 19 O 6.4037 -2.5842 0 0
M  V30 20 C 5.3733 -1.4398 0 0 CFG=1
M  V30 21 C 3.8333 -1.4398 0 0 CFG=2
M  V30 22 O 2.8028 -2.5842 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 2 11 13
M  V30 13 1 11 14
M  V30 14 1 8 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 19 1 20 19 CFG=1
M  V30 20 1 20 8
M  V30 21 1 20 21
M  V30 22 1 21 5
M  V30 23 1 21 22 CFG=3
M  V30 24 1 2 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1511495258

>  <MW>
339.362

>  <MW (desalted)>
339.362

>  <ClogP>
0.041

>  <logS>
-2.56

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
115.54

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.87 nM | Ki (inhibition constant) = 3.5 nM | Ki (inhibition constant) = 0.0038 ?M | Ki (inhibition constant)  5 nM | Ki (inhibition constant)  5 nM | Ki (inhibition constant) = 5 nM | Ki (inhibition constant)  5 nM | Ki (inhibition constant) = 0.005 ?M | Ki (inhibition constant) = 6.6 nM | Ki (inhibition constant) = 10 nM | Ki (inhibition constant)  10 nM | Ki (inhibition constant)  10 nM | Ki (inhibition constant) = 25.4 nM

>  <CAS>
97240-79-4

>  <Description>
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It inhibits carbonic anhydrase, also blocks sodium and calcium channels.

>  <EBC_ID>
EBC-07086

>  <IUPAC Name>
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0,2,6]dodecan-6-yl]methyl sulfamate

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 971 - 976 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 963 - 969 | J. Med. Chem., 2009, vol. 52, # 20, p. 6421 - 6432 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 1149 - 1154 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 1149 - 1154 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 1, p. 217 - 223 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 1149 - 1154 | J. Med. Chem., 2009, vol. 52, # 20, p. 6421 - 6432 | Bioorg. Med. Chem., 2013, vol. 21, # 15, p. 4521 - 4525 | Bioorg. Med. Chem. Lett., 2016, vol. 26, p. 1821 - 1826 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | Int. J. Mol. Sci., 2020, vol. 21, # 11, p. 1 - 14 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 9, p. 2315 - 2320

>  <Main tar all>
carbonic anhydrase 7 pX=9.06 | carbonic anhydrase 12 pX=8.46 | carbonic anhydrase 2 pX=8.42 | ?-carbonic anhydrase pX=8.3 | Extracellular calcium-sensing receptor (isoform 2) pX=8.3 | carbonic anhydrase 1 pX=8.3 | carbonic anhydrase 4 pX=8.3 | carbonic anhydrase 9 pX=8.3 | carbonic anhydrase pX=8.18 | ?-carbonic anhydrase 2 pX=8.0 | carbonic anhydrase 2 pX=8.0 | carbonic anhydrase 2 pX=8.0 | carbonic anhydrase 5 pX=7.6

$$$$
Aripiprazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 4.001 -10.01 0 0
M  V30 2 C 4.001 -8.47 0 0
M  V30 3 C 2.6674 -7.7 0 0
M  V30 4 C 2.6674 -6.16 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -6.16 0 0
M  V30 7 N 6.6684 -5.39 0 0
M  V30 8 C 6.6684 -3.85 0 0
M  V30 9 C 8.0021 -3.08 0 0
M  V30 10 N 9.3358 -3.85 0 0
M  V30 11 C 10.6694 -3.08 0 0
M  V30 12 C 12.0031 -3.85 0 0
M  V30 13 C 13.3368 -3.08 0 0
M  V30 14 C 14.6705 -3.85 0 0
M  V30 15 O 16.0041 -3.08 0 0
M  V30 16 C 17.3378 -3.85 0 0
M  V30 17 C 18.6715 -3.08 0 0
M  V30 18 C 20.0052 -3.85 0 0
M  V30 19 C 20.0052 -5.39 0 0
M  V30 20 C 21.3389 -6.16 0 0
M  V30 21 C 21.3389 -7.7 0 0
M  V30 22 C 20.0052 -8.47 0 0
M  V30 23 O 20.0052 -10.01 0 0
M  V30 24 N 18.6715 -7.7 0 0
M  V30 25 C 18.6715 -6.16 0 0
M  V30 26 C 17.3378 -5.39 0 0
M  V30 27 C 9.3358 -5.39 0 0
M  V30 28 C 8.0021 -6.16 0 0
M  V30 29 C 5.3347 -7.7 0 0
M  V30 30 Cl 6.6684 -8.47 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 2 19 25
M  V30 26 1 25 26
M  V30 27 2 16 26
M  V30 28 1 10 27
M  V30 29 1 27 28
M  V30 30 1 7 28
M  V30 31 1 6 29
M  V30 32 2 2 29
M  V30 33 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553846

>  <MW>
448.385

>  <MW (desalted)>
448.385

>  <ClogP>
5.312

>  <logS>
-4.82

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
44.81

>  <RotBonds>
7

>  <Action on targets>
Agonist | Inhibitor | Inhibitor | Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  62 % | pKi  10.49 | pKi  10.49 | EC50  0.1 nM | pKi  9.11 - 9.92 | Ki (inhibition constant)  0.2 nM

>  <CAS>
129722-12-9

>  <Description>
Aripiprazole is an atypical antipsychotic used in the treatment of a wide variety of mood and psychotic disorders, such as schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's syndrome. It is an agonist of dopaminic and 5-HT1A receptors and antagonist of alpha adrenergic and 5-HT2A receptors

>  <EBC_ID>
EBC-12081

>  <IUPAC Name>
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one

>  <Main Tar all refs>
ACS Chem. Neurosci., 2011, vol. 2, # 6, p. 308 - 316 | Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | ACS Chem. Biol., 2019, vol. 14, # 8, p. 1780 - 1792 | Bioorg. Med. Chem. Lett., 2013, vol. 23, # 2, p. 543 - 547

>  <Main tar all>
D2L receptor pX=11.2 | D2 receptor pX=10.5 | D2 receptor pX=10.5 | D2S receptor pX=10.0 | D2S receptor pX=9.92 | D2 receptor pX=9.7

$$$$
Ethinylestradiol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 C 10.2985 -4.155 0 0 CFG=1
M  V30 6 C 9.3058 -2.9776 0 0 CFG=1
M  V30 7 C 9.829 -1.5293 0 0
M  V30 8 C 11.345 -1.2582 0 0
M  V30 9 C 12.3377 -2.4355 0 0
M  V30 10 C 13.8537 -2.1644 0 0
M  V30 11 C 14.8464 -3.3418 0 0
M  V30 12 O 16.3624 -3.0707 0 0
M  V30 13 C 14.3232 -4.7901 0 0
M  V30 14 C 12.8072 -5.0612 0 0
M  V30 15 C 11.8145 -3.8839 0 0
M  V30 16 C 7.7898 -3.2487 0 0 CFG=2
M  V30 17 C 6.574 -2.3035 0 0
M  V30 18 C 5.2994 -3.1677 0 0
M  V30 19 C 5.7274 -4.6471 0 0 CFG=2
M  V30 20 O 4.3071 -5.2423 0 0
M  V30 21 C 5.5008 -6.1703 0 0
M  V30 22 C 5.2742 -7.6935 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 5 15
M  V30 16 2 9 15
M  V30 17 1 16 6
M  V30 18 1 2 16
M  V30 19 1 16 17 CFG=1
M  V30 20 1 17 18
M  V30 21 1 19 18
M  V30 22 1 2 19
M  V30 23 1 19 20 CFG=1
M  V30 24 1 19 21 CFG=3
M  V30 25 3 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553721

>  <MW>
296.403

>  <MW (desalted)>
296.403

>  <ClogP>
3.864

>  <logS>
-4.81

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
0

>  <Action on targets>
Agonist | Activator | Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  0.002 nM | EC50  6.63E-12 M | EC50  0.008 nM | Ki (inhibition constant)  0.025 nM

>  <CAS>
57-63-6

>  <Description>
Ethinylestradiol is a synthetic estrogen that decreases luteinizing hormone to decrease endometrial vascularization, and decreases gonadotrophic hormone to prevent ovulation. Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.

>  <EBC_ID>
EBC-11049

>  <IUPAC Name>
(1R,3aS,3bR,9bS,11aS)-1-ethynyl-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol

>  <Main Tar all refs>
Steroids, 2002, vol. 67, # 8, p. 681 - 686 | Toxicol. Appl. Pharmacol., 2016, vol. 307, p. 108 - 114 | Biochem. Pharmacol., 2006, vol. 71, # 10, p. 1459 - 1469 | ESTETRA SRL - WO2004/37269, 2004, A1

>  <Main tar all>
Estrogen receptor pX=11.7 | Estrogen receptor-?2 pX=11.2 | nuclear estrogen receptor pX=11.1 | Estrogen receptor-? pX=10.6

$$$$
Ibutilide hemifumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 60 59 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -12.8238 0 0 0
M  V30 2 C -11.4902 0.77 0 0
M  V30 3 C -10.1565 0 0 0
M  V30 4 C -8.8228 0.77 0 0
M  V30 5 C -7.4891 0 0 0
M  V30 6 C -6.1554 0.77 0 0
M  V30 7 C -4.8218 0 0 0
M  V30 8 N -3.4881 0.77 0 0
M  V30 9 C -3.4881 2.31 0 0
M  V30 10 C -2.1544 3.08 0 0
M  V30 11 C -2.1544 0 0 0
M  V30 12 C -0.8207 0.77 0 0
M  V30 13 C 0.513 0 0 0
M  V30 14 C 1.8466 0.77 0 0
M  V30 15 O 1.8466 2.31 0 0
M  V30 16 C 3.1803 0 0 0
M  V30 17 C 4.514 0.77 0 0
M  V30 18 C 5.8477 0 0 0
M  V30 19 C 5.8477 -1.54 0 0
M  V30 20 N 7.1813 -2.31 0 0
M  V30 21 S 8.515 -1.54 0 0
M  V30 22 O 9.8487 -0.77 0 0
M  V30 23 O 9.285 -2.8737 0 0
M  V30 24 C 7.745 -0.2063 0 0
M  V30 25 C 4.514 -2.31 0 0
M  V30 26 C 3.1803 -1.54 0 0
M  V30 27 C 14.2487 0 0 0
M  V30 28 C 15.5824 0.77 0 0
M  V30 29 C 16.9161 0 0 0
M  V30 30 C 18.2497 0.77 0 0
M  V30 31 C 19.5834 0 0 0
M  V30 32 C 20.9171 0.77 0 0
M  V30 33 C 22.2508 0 0 0
M  V30 34 N 23.5845 0.77 0 0
M  V30 35 C 23.5845 2.31 0 0
M  V30 36 C 24.9181 3.08 0 0
M  V30 37 C 24.9181 0 0 0
M  V30 38 C 26.2518 0.77 0 0
M  V30 39 C 27.5855 0 0 0
M  V30 40 C 28.9192 0.77 0 0
M  V30 41 O 28.9192 2.31 0 0
M  V30 42 C 30.2529 0 0 0
M  V30 43 C 31.5865 0.77 0 0
M  V30 44 C 32.9202 0 0 0
M  V30 45 C 32.9202 -1.54 0 0
M  V30 46 N 34.2539 -2.31 0 0
M  V30 47 S 35.5876 -1.54 0 0
M  V30 48 O 36.9213 -0.77 0 0
M  V30 49 O 36.3576 -2.8737 0 0
M  V30 50 C 34.8176 -0.2063 0 0
M  V30 51 C 31.5865 -2.31 0 0
M  V30 52 C 30.2529 -1.54 0 0
M  V30 53 O 3.08 -7.2874 0 0
M  V30 54 C 1.54 -7.2874 0 0
M  V30 55 O 0.77 -5.9537 0 0
M  V30 56 C 0.77 -8.621 0 0
M  V30 57 C -0.77 -8.621 0 0
M  V30 58 C -1.54 -9.9547 0 0
M  V30 59 O -0.77 -11.2884 0 0
M  V30 60 O -3.08 -9.9547 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 2 21 23
M  V30 23 1 21 24
M  V30 24 2 19 25
M  V30 25 1 25 26
M  V30 26 2 16 26
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 1 34 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 1 40 42
M  V30 42 1 42 43
M  V30 43 2 43 44
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 2 47 48
M  V30 48 2 47 49
M  V30 49 1 47 50
M  V30 50 2 45 51
M  V30 51 1 51 52
M  V30 52 2 42 52
M  V30 53 1 53 54
M  V30 54 2 54 55
M  V30 55 1 54 56
M  V30 56 2 56 57
M  V30 57 1 57 58
M  V30 58 2 58 59
M  V30 59 1 58 60
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2583205878

>  <MW>
884.5

>  <MW (desalted)>
384.576

>  <ClogP>
3.778

>  <logS>
-6.861

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
69.64

>  <RotBonds>
28

>  <Action on targets>
- | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 2.3 nM | Kd (dissociation constant)  4.6 nM | IC50  0.016 ?M

>  <CAS>
122647-32-9

>  <Description>
Ibutilide is a class III antiarrhythmic agent used to correct atrial fibrillation and atrial flutter, which can be considered as an alternative to cardioversion.

>  <EBC_ID>
EBC-15052

>  <IUPAC Name>
(2E)-but-2-enedioic acid; bis(N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide)

>  <Main Tar all refs>
Curr. Med. Chem.: Cardiovasc. Hematol. Agents, 2003, vol. 1, # 3, p. 203 - 223 | Br. J. Pharmacol., 2015, vol. 172, # 3, p. 940 - 955 | THERAVANCE BIOPHARMA, INC. - US6362371, 2002, B1

>  <Main tar all>
Kir pX=8.64 | Kv11.1 pX=8.34 | KNa1.1 pX=7.8

$$$$
Ivacaftor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -8.47 0 0
M  V30 2 C -5.3347 -7.7 0 0
M  V30 3 C -4.5647 -9.0337 0 0
M  V30 4 C -6.1047 -6.3663 0 0
M  V30 5 C -4.001 -6.93 0 0
M  V30 6 C -2.6674 -7.7 0 0
M  V30 7 C -1.3337 -6.93 0 0
M  V30 8 C -1.3337 -5.39 0 0
M  V30 9 N 0 -4.62 0 0
M  V30 10 C 0 -3.08 0 0
M  V30 11 O -1.3337 -2.31 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 N 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 21 C 2.6674 -3.08 0 0
M  V30 22 O 2.6674 -4.62 0 0
M  V30 23 C -2.6674 -4.62 0 0
M  V30 24 C -4.001 -5.39 0 0
M  V30 25 O -5.3347 -4.62 0 0
M  V30 26 C -0 -7.7 0 0
M  V30 27 C 1.3337 -8.47 0 0
M  V30 28 C -0.77 -9.0337 0 0
M  V30 29 C 0.77 -6.3663 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 21 1 20 21
M  V30 22 1 12 21
M  V30 23 2 21 22
M  V30 24 2 8 23
M  V30 25 1 23 24
M  V30 26 2 5 24
M  V30 27 1 24 25
M  V30 28 1 7 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 1 26 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2146566713

>  <MW>
392.491

>  <MW (desalted)>
392.491

>  <ClogP>
3.823

>  <logS>
-6.574

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
78.43

>  <RotBonds>
4

>  <Action on targets>
- | Activator | Activator

>  <Activity coefficients and valu>
EC50 = 0.003 ?M | activation rate Active   | EC50  11.7 nM

>  <CAS>
873054-44-5

>  <Description>
Ivacaftor is a cystic fibrosis transmembrane conductance regulator potentiator used alone or in combination products to treat cystic fibrosis in patients who have specific genetic mutations that are responsive to the medication.

>  <EBC_ID>
EBC-11412

>  <IUPAC Name>
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

>  <Main Tar all refs>
J. Med. Chem., 2014, vol. 57, # 23, p. 9774 - 9775 | J. Med. Chem., 2021, vol. 64, # 1, p. 343 - 353 | Eur. J. Med. Chem., 2020, vol. 190

>  <Main tar all>
CFTR pX=8.52 | CFTR (G551D) pX=8.0 | CFTR (delF508) pX=7.93

$$$$
Hydroxyzine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 O -10.2078 -3.85 0 0
M  V30 4 C -8.8741 -3.08 0 0
M  V30 5 C -7.5404 -3.85 0 0
M  V30 6 O -6.2067 -3.08 0 0
M  V30 7 C -4.8731 -3.85 0 0
M  V30 8 C -3.5394 -3.08 0 0
M  V30 9 N -2.2057 -3.85 0 0
M  V30 10 C -0.872 -3.08 0 0
M  V30 11 C 0.4617 -3.85 0 0
M  V30 12 N 0.4617 -5.39 0 0
M  V30 13 C -0.872 -6.16 0 0
M  V30 14 C -2.2057 -5.39 0 0
M  V30 15 C 1.7953 -6.16 0 0
M  V30 16 C 1.7953 -7.7 0 0
M  V30 17 C 3.129 -8.47 0 0
M  V30 18 C 3.129 -10.01 0 0
M  V30 19 C 1.7953 -10.78 0 0
M  V30 20 C 0.4617 -10.01 0 0
M  V30 21 C 0.4617 -8.47 0 0
M  V30 22 C 3.129 -5.39 0 0
M  V30 23 C 3.129 -3.85 0 0
M  V30 24 C 4.4627 -3.08 0 0
M  V30 25 C 5.7964 -3.85 0 0
M  V30 26 Cl 7.1301 -3.08 0 0
M  V30 27 C 5.7964 -5.39 0 0
M  V30 28 C 4.4627 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 9 14
M  V30 13 1 12 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 2 17 18
M  V30 17 1 18 19
M  V30 18 2 19 20
M  V30 19 1 20 21
M  V30 20 2 16 21
M  V30 21 1 15 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 25 27
M  V30 27 1 27 28
M  V30 28 2 22 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2680630178

>  <MW>
446.129

>  <MW (desalted)>
374.904

>  <ClogP>
3.995

>  <logS>
-3.702

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
35.94

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKi  8.7

>  <CAS>
2192-20-3

>  <Description>
Hydroxyzine is an antihistamine used to treat anxiety and tension associated with psychoneuroses, as well as allergic conditions such as pruritus and chronic urticaria.

>  <EBC_ID>
EBC-13167

>  <IUPAC Name>
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethan-1-ol dihydrochloride

>  <Main Tar all refs>
Mol. Pharmacol., 2002, vol. 61, # 2, p. 391 - 399

>  <Main tar all>
H1 receptor pX=8.7

$$$$
Pemetrexed disodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 0.9463 16.4119 0 0 CHG=1
M  V30 2 Na 11.6158 16.4119 0 0 CHG=1
M  V30 3 N 14.6194 2.0634 0 0
M  V30 4 C 13.5889 3.2078 0 0
M  V30 5 N 12.0826 2.8876 0 0
M  V30 6 C 11.0521 4.0321 0 0
M  V30 7 N 9.5121 4.0321 0 0
M  V30 8 C 9.0362 5.4967 0 0
M  V30 9 C 10.2821 6.4019 0 0
M  V30 10 C 10.2821 7.9419 0 0
M  V30 11 C 8.9484 8.7119 0 0
M  V30 12 C 8.9484 10.2519 0 0
M  V30 13 C 7.6147 11.0219 0 0
M  V30 14 C 7.6147 12.5619 0 0
M  V30 15 C 8.9484 13.3319 0 0
M  V30 16 C 10.2821 12.5619 0 0
M  V30 17 C 10.2821 11.0219 0 0
M  V30 18 C 8.9484 14.8719 0 0
M  V30 19 O 10.2821 15.6419 0 0
M  V30 20 N 7.6147 15.6419 0 0
M  V30 21 C 7.6147 17.1819 0 0 CFG=2
M  V30 22 C 6.2811 17.9519 0 0
M  V30 23 C 4.9474 17.1819 0 0
M  V30 24 C 3.6137 17.9519 0 0
M  V30 25 O 3.6137 19.4919 0 0
M  V30 26 O 2.28 17.1819 0 0 CHG=-1
M  V30 27 C 8.9484 17.9519 0 0
M  V30 28 O 8.9484 19.4919 0 0
M  V30 29 O 10.2821 17.1819 0 0 CHG=-1
M  V30 30 C 11.528 5.4967 0 0
M  V30 31 C 13.0343 5.8169 0 0
M  V30 32 O 13.5102 7.2815 0 0
M  V30 33 N 14.0648 4.6724 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 2 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 2 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 2 13 14
M  V30 12 1 14 15
M  V30 13 2 15 16
M  V30 14 1 16 17
M  V30 15 2 12 17
M  V30 16 1 15 18
M  V30 17 2 18 19
M  V30 18 1 18 20
M  V30 19 1 21 20 CFG=3
M  V30 20 1 21 22
M  V30 21 1 22 23
M  V30 22 1 23 24
M  V30 23 2 24 25
M  V30 24 1 24 26
M  V30 25 1 21 27
M  V30 26 2 27 28
M  V30 27 1 27 29
M  V30 28 1 9 30
M  V30 29 2 6 30
M  V30 30 1 30 31
M  V30 31 2 31 32
M  V30 32 1 31 33
M  V30 33 1 4 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2953646389

>  <MW>
471.113

>  <MW (desalted)>
427.411

>  <ClogP>
-7.225

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
192.63

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  24 nmol/l | IC50  24 nmol/l | IC50  0.0499 ?M | Ki (inhibition constant)  0.056 ?M | IC50  70 nM | cleaved caspase-3 level decrease Active   | percentage decrease Active   | percentage decrease Active   | IC50  165 nmol/l | inhibition percentage  85 % | Km (Michaelis constant) = 0.3 ?M | IC50 = 0.43 ?M | Ki (inhibition constant)  0.583 ?M

>  <CAS>
150399-23-8

>  <Description>
Pemetrexed is a folate analog used to treat mesothelioma and non-small cell lung cancer. Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication.

>  <EBC_ID>
EBC-15041

>  <IUPAC Name>
disodium (2R)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate

>  <Main Tar all refs>
Mol. Cancer Ther., 2019, vol. 18, # 10, p. 1787 - 1799 | Mol. Cancer Ther., 2019, vol. 18, # 10, p. 1787 - 1799 | Front. Oncol., 2022, vol. 12 | Mol. Pharmacol., 2020, vol. 97, # 1, p. 9 - 22 | Mol. Pharmacol., 2014, vol. 85, # 2, p. 310 - 321 | Cancer Cell Int., 2021, vol. 21, # 1 | UNIVERSITY OF BRITISH COLUMBIA - US9717792, 2017, B2 | UNIVERSITY OF BRITISH COLUMBIA - US9717792, 2017, B2 | Mol. Cancer Ther., 2019, vol. 18, # 10, p. 1787 - 1799 | J. Med. Chem., 2018, vol. 61, # 5, p. 2027 - 2040 | Eur. J. Pharm. Sci., 2006, vol. 27, # 5, p. 524 - 532 | J. Med. Chem., 2009, vol. 52, # 15, p. 4892 - 4902 | Mol. Pharmacol., 2020, vol. 97, # 1, p. 9 - 22

>  <Main tar all>
Bifunctional purine biosynthesis protein ADE16 pX=7.62 | beta-glycinamide ribonucleotide formyltransferase pX=7.62 | Thymidylate synthase pX=7.3 | Proton-coupled folate transporter-4 (PCFT4) pX=7.25 | Folate receptor alpha pX=7.15 | ABCC5 pX=7.0 | epidermal growth factor receptor pX=7.0 | heat shock protein 27 pX=7.0 | Serine hydroxymethyltransferase 1 pX=6.78 | Proton-coupled folate transporter pX=6.75 | ABCC5 pX=6.52 | dihydrofolate reductase pX=6.37 | Replication factor C subunit 2 pX=6.23

$$$$
Methylene blue
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 4.4 -0.231 0 0
M  V30 3 N 5.7337 -1.001 0 0
M  V30 4 C 5.7337 -2.541 0 0
M  V30 5 C 7.0674 -0.231 0 0
M  V30 6 C 7.0674 1.309 0 0
M  V30 7 C 8.401 2.079 0 0
M  V30 8 C 9.7347 1.309 0 0
M  V30 9 N 11.0684 2.079 0 0
M  V30 10 C 12.4021 1.309 0 0
M  V30 11 C 13.7358 2.079 0 0
M  V30 12 C 15.0694 1.309 0 0
M  V30 13 C 15.0694 -0.231 0 0
M  V30 14 C 13.7358 -1.001 0 0
M  V30 15 C 12.4021 -0.231 0 0
M  V30 16 S 11.0684 -1.001 0 0 CHG=1
M  V30 17 C 9.7347 -0.231 0 0
M  V30 18 C 8.401 -1.001 0 0
M  V30 19 N 16.4031 -1.001 0 0
M  V30 20 C 17.7368 -0.231 0 0
M  V30 21 C 16.4031 -2.541 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 10 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 8 17
M  V30 18 1 17 18
M  V30 19 2 5 18
M  V30 20 1 13 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954806063

>  <MW>
319.852

>  <MW (desalted)>
284.399

>  <ClogP>
0.95

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
19.37

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 5.5 nM | IC50  9.6 nM | Ki (inhibition constant) = 0.017 ?M | protection percentage Active   | Ki (inhibition constant) = 27 nM | IC50  27 - 180 nM | IC50  0.03 ?M | percentage increase Active   | IC50  60.3 nM | Ki (inhibition constant) = 69 nM | EC50  0.087 ?M | EC50  0.087 ?M | Ki (inhibition constant)  0.09 ?M | EC50  0.1 ?M | inhibition percentage Active   | Ki (inhibition constant)  110 nM

>  <CAS>
61-73-4

>  <Description>
Methylene blue is an oxidation-reduction agent. Main mechanism of action involves inhibition of nitric oxide synthase and guanylate cyclase. It is used for the treatment of pediatric and adult patients with acquired methemoglobinemia.

>  <EBC_ID>
EBC-26786

>  <IUPAC Name>
3,7-bis(dimethylamino)-5lambda4-phenothiazin-5-ylium chloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2007, vol. 152, # 6, p. 946 - 951 | Int. J. Mol. Sci., 2022, vol. 23, # 22 | Chem.-Biol. Interact., 2008, vol. 175, # 1-3, p. 309 - 311 | Mol. Neurobiol., 2017, vol. 54, # 3, p. 2209 - 2222 | Br. J. Pharmacol., 2007, vol. 152, # 6, p. 946 - 951 | Med. Res. Rev., 2011, vol. 31, # 1, p. 93 - 117 | Antimicrob. Agents Chemother., 2022, vol. 66, # 1 | Mol. Neurobiol., 2017, vol. 54, # 3, p. 2209 - 2222 | GOVERNMENT OF ITALY; THE UNIVERSITY OF MILAN - WO2019/122981, 2019, A1 | J. Med. Chem., 2013, vol. 56, # 8, p. 3121 - 3147 | Emerg. Microbes Infect., 2020, vol. 9, # 1, p. 2404 - 2416 | Emerg. Microbes Infect., 2020, vol. 9, # 1, p. 2404 - 2416 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | GOVERNMENT OF THE UNITED STATES; HEALTH RESEARCH, INC - WO2017/223491, 2017, A1 | DOSHISHA UNIVERSITY; NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY - EP2962687, 2016, A1 | Biochemistry, 2013, vol. 52, # 42, p. 7486 - 7499

>  <Main tar all>
Monoamine oxidase B pX=8.26 | GluN2C pX=8.02 | acetylcholinesterase (Cartwright blood group) pX=7.77 | Myocyte-specific enhancer factor 2D pX=7.6 | Monoamine oxidase A pX=7.57 | amine oxidase copper containing 3 pX=7.57 | Rac-like GTP-binding protein RAC1 pX=7.52 | Myocyte-specific enhancer factor 2C pX=7.3 | Ras-related protein Rac1 pX=7.22 | Neuronal NOS pX=7.16 | Flavivirus NS3, petidase S7 pX=7.06 | Flavivirus non-structural protein NS2B pX=7.06 | acetylcholinesterase (Cartwright blood group) pX=7.05 | Nonstructural protein 3 pX=7.0 | Tau-383 pX=7.0 | acetylcholinesterase (Cartwright blood group) pX=6.96

$$$$
Estradiol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 C 10.2985 -4.155 0 0 CFG=1
M  V30 6 C 9.3058 -2.9776 0 0 CFG=1
M  V30 7 C 9.829 -1.5293 0 0
M  V30 8 C 11.345 -1.2582 0 0
M  V30 9 C 12.3377 -2.4355 0 0
M  V30 10 C 13.8537 -2.1644 0 0
M  V30 11 C 14.8464 -3.3418 0 0
M  V30 12 O 16.3624 -3.0707 0 0
M  V30 13 C 14.3232 -4.7901 0 0
M  V30 14 C 12.8072 -5.0612 0 0
M  V30 15 C 11.8145 -3.8839 0 0
M  V30 16 C 7.7898 -3.2487 0 0 CFG=2
M  V30 17 C 6.574 -2.3035 0 0
M  V30 18 C 5.2994 -3.1677 0 0
M  V30 19 C 5.7274 -4.6471 0 0 CFG=2
M  V30 20 O 4.7822 -5.8629 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 5 15
M  V30 16 2 9 15
M  V30 17 1 16 6
M  V30 18 1 2 16
M  V30 19 1 16 17 CFG=1
M  V30 20 1 17 18
M  V30 21 1 19 18
M  V30 22 1 2 19
M  V30 23 1 19 20 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553843

>  <MW>
272.382

>  <MW (desalted)>
272.382

>  <ClogP>
3.784

>  <logS>
-3.93

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
0

>  <Action on targets>
Agonist | Agonist | Agonist | Inhibitor | Agonist | - | -

>  <Activity coefficients and valu>
EC50  1.2E-13 M | qualitative Active   | EC50  1.6E-12 M | EC50  2.3 pM | EC50  0.0042 nM | estrogen receptor-related transcription increase Active   | estrogen receptor-related transcription increase Active

>  <CAS>
50-28-2

>  <Description>
Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol workings by binding to subtypes of the estrogen receptor: estrogen receptor alpha (ER?) and estrogen receptor beta (ER?). It also exerts potent agonism of G Protein-coupled estrogen receptor (GPER), which is recognized an important regulator of this drug's rapid effects.

>  <EBC_ID>
EBC-06093

>  <IUPAC Name>
(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol

>  <Main Tar all refs>
J. Hazard. Mater., 2017, vol. 338, p. 57 - 65 | Eur. J. Med. Chem., 2014, vol. 85, p. 391 - 398 | Food Chem. Toxicol., 2017, vol. 108, p. 257 - 266 | Front. Endocrinol., 2022, vol. 13 | Steroids, 2008, vol. 73, # 1, p. 59 - 68 | Chemosphere, 2022, vol. 286 | Chemosphere, 2022, vol. 286

>  <Main tar all>
Estrogen receptor pX=12.9 | nuclear estrogen receptor pX=12.0 | estrogen response element binding protein pX=11.8 | Progesterone receptor pX=11.6 | Estrogen receptor-? pX=11.4 | Tegument protein VP16 pX=11.4 | Transcription regulator LexA pX=11.4

$$$$
Dexrazoxane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0 CFG=1
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 O 5.3347 -7.7 0 0
M  V30 8 N 2.6674 -7.7 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 O 0 -7.7 0 0
M  V30 11 C 1.3337 -5.39 0 0
M  V30 12 N 1.3337 -0.77 0 0
M  V30 13 C 0 0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 15 O -1.3337 2.31 0 0
M  V30 16 N 1.3337 2.31 0 0
M  V30 17 C 2.6674 1.54 0 0
M  V30 18 O 4.001 2.31 0 0
M  V30 19 C 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 4 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 12 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741978506

>  <MW>
268.269

>  <MW (desalted)>
268.269

>  <ClogP>
-1.333

>  <logS>
0.425

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
98.82

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
cell protection rate Active   | inhibition percentage Active

>  <CAS>
24584-09-6

>  <Description>
Dexrazoxane is a cytoprotective drug. It is used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer.

>  <EBC_ID>
EBC-26383

>  <IUPAC Name>
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

>  <Main Tar all refs>
Toxicol. Appl. Pharmacol., 2020, vol. 399 | Bioorg. Med. Chem., 2014, vol. 22, # 21, p. 5935 - 5949

>  <Main tar all>
DNA topoisomerase II pX=6.3 | DNA topoisomerase II alpha pX=6.0

$$$$
Ulipristal
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 15.2622 -10.0416 0 0
M  V30 2 N 13.7462 -10.3126 0 0
M  V30 3 C 13.223 -11.761 0 0
M  V30 4 C 12.7535 -9.1353 0 0
M  V30 5 C 11.2375 -9.4064 0 0
M  V30 6 C 10.2448 -8.2291 0 0
M  V30 7 C 10.768 -6.7807 0 0
M  V30 8 C 12.284 -6.5096 0 0
M  V30 9 C 13.2767 -7.6869 0 0
M  V30 10 C 9.7753 -5.6034 0 0 CFG=1
M  V30 11 C 8.2593 -5.8744 0 0
M  V30 12 C 7.2666 -4.6971 0 0 CFG=1
M  V30 13 C 6.5949 -6.0829 0 0
M  V30 14 C 7.7898 -3.2487 0 0 CFG=1
M  V30 15 C 6.574 -2.3035 0 0
M  V30 16 C 5.2994 -3.1677 0 0
M  V30 17 C 5.7274 -4.6471 0 0 CFG=1
M  V30 18 O 4.3071 -5.2423 0 0
M  V30 19 C 3.0815 -4.3099 0 0
M  V30 20 O 1.6612 -4.9051 0 0
M  V30 21 C 3.2761 -2.7822 0 0
M  V30 22 C 5.5008 -6.1703 0 0
M  V30 23 O 6.7067 -7.1282 0 0
M  V30 24 C 4.0683 -6.7357 0 0
M  V30 25 C 9.3058 -2.9776 0 0 CFG=2
M  V30 26 C 9.829 -1.5293 0 0
M  V30 27 C 11.345 -1.2582 0 0
M  V30 28 C 12.3377 -2.4355 0 0
M  V30 29 C 13.8537 -2.1644 0 0
M  V30 30 C 14.8464 -3.3418 0 0
M  V30 31 O 16.3624 -3.0707 0 0
M  V30 32 C 14.3232 -4.7901 0 0
M  V30 33 C 12.8072 -5.0612 0 0
M  V30 34 C 11.8145 -3.8839 0 0
M  V30 35 C 10.2985 -4.155 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 10 7 CFG=1
M  V30 11 1 10 11
M  V30 12 1 12 11
M  V30 13 1 12 13 CFG=1
M  V30 14 1 12 14
M  V30 15 1 14 15 CFG=1
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 12 17
M  V30 19 1 17 18 CFG=3
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 17 22 CFG=1
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 14 25
M  V30 27 1 25 26 CFG=3
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 28 34
M  V30 37 2 34 35
M  V30 38 1 10 35
M  V30 39 1 25 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2185283535

>  <MW>
475.619

>  <MW (desalted)>
475.619

>  <ClogP>
4.507

>  <logS>
-4.91

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
63.68

>  <RotBonds>
5

>  <Action on targets>
Antagonist | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50  0.2 nM | IC50  0.57 nM | IC50  2 nM

>  <CAS>
126784-99-4

>  <Description>
Ulipristal acetate is an orally active, selective progesterone receptor modulator (SPRM). It is used for emergency contraception after an unprotected intercourse or contraceptive failure.

>  <EBC_ID>
EBC-07665

>  <IUPAC Name>
(1R,3aS,3bS,10R,11aS)-1-acetyl-10-[4-(dimethylamino)phenyl]-11a-methyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate

>  <Main Tar all refs>
Bioorg. Med. Chem., 2008, vol. 16, # 6, p. 2753 - 2763 | J. Steroid Biochem. Mol. Biol., 2010, vol. 118, # 3, p. 151 - 161 | J. Steroid Biochem. Mol. Biol., 2004, vol. 88, # 3, p. 277 - 288

>  <Main tar all>
Progesterone receptor (isoform B) pX=9.7 | Progesterone receptor pX=9.24 | Progesterone receptor (isoform A) pX=8.7

$$$$
Pramocaine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 2.1267 0 0
M  V30 3 C 5.7337 1.3567 0 0
M  V30 4 C 7.0674 2.1267 0 0
M  V30 5 C 8.401 1.3567 0 0
M  V30 6 O 9.7347 2.1267 0 0
M  V30 7 C 11.0684 1.3567 0 0
M  V30 8 C 12.4021 2.1267 0 0
M  V30 9 C 13.7358 1.3567 0 0
M  V30 10 C 13.7358 -0.1833 0 0
M  V30 11 O 15.0694 -0.9533 0 0
M  V30 12 C 16.4031 -0.1833 0 0
M  V30 13 C 17.7368 -0.9533 0 0
M  V30 14 C 19.0705 -0.1833 0 0
M  V30 15 N 20.4041 -0.9533 0 0
M  V30 16 C 21.7378 -0.1833 0 0
M  V30 17 C 23.0715 -0.9533 0 0
M  V30 18 O 23.0715 -2.4933 0 0
M  V30 19 C 21.7378 -3.2633 0 0
M  V30 20 C 20.4041 -2.4933 0 0
M  V30 21 C 12.4021 -0.9533 0 0
M  V30 22 C 11.0684 -0.1833 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 15 20
M  V30 20 2 10 21
M  V30 21 1 21 22
M  V30 22 2 7 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516943

>  <MW>
329.176

>  <MW (desalted)>
293.401

>  <ClogP>
4.16

>  <logS>
-3.441

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
30.93

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Activator | Activator

>  <Activity coefficients and valu>
change rate Active   | IC50 = 21200 nM | IC50 = 21200 nM | increase rate Active   | increase rate Active

>  <CAS>
637-58-1

>  <Description>
Pramocaine is a topical anesthetic and antipruritic. It reversibly binds and inhibits voltage gated sodium channels on neurons decreasing sodium permeability into the cell. It is indicated for temporary relief of pain and pruritus from minor lip and skin irritations as well as for temporary relief from pain, burning, itching and discomfort associated with hemorrhoids and other anorectal/anogenital disorders.

>  <EBC_ID>
EBC-28050

>  <IUPAC Name>
4-[3-(4-butoxyphenoxy)propyl]morpholine hydrochloride

>  <Main Tar all refs>
CASE WESTERN RESERVE UNIVERSITY - WO2018/22904, 2018, A2 | J. Med. Chem., 1985, vol. 28, # 3, p. 381 - 388 | J. Med. Chem., 1985, vol. 28, # 3, p. 381 - 388 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1

>  <Main tar all>
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase pX=5.7 | Nav?1 pX=4.67 | Nav1.7 pX=4.67 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3

$$$$
Salicylamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z68590124

>  <MW>
137.048

>  <MW (desalted)>
137.136

>  <ClogP>
1.277

>  <logS>
-1.17

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
63.32

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 >> 1000 nM | IC50  1000 nM

>  <CAS>
65-45-2

>  <Description>
Salicylamide is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin.

>  <EBC_ID>
EBC-03127

>  <IUPAC Name>
2-hydroxybenzamide

>  <Main Tar all refs>
J. Med. Chem., 2003, vol. 46, # 24, p. 5258 - 5270 | UNIVERSITY OF COLORADO (SYSTEM) - WO2005/34856, 2005, A2

>  <Main tar all>
Androgen receptor pX=6.0 | Androgen receptor (W741L) pX=6.0

$$$$
Curcumin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 -6.93 0 0
M  V30 2 O 8.0021 -7.7 0 0
M  V30 3 C 8.0021 -9.24 0 0
M  V30 4 C 9.3358 -10.01 0 0
M  V30 5 C 9.3358 -11.55 0 0
M  V30 6 C 10.6694 -12.32 0 0
M  V30 7 C 10.6694 -13.86 0 0
M  V30 8 C 12.0031 -14.63 0 0
M  V30 9 O 13.3368 -13.86 0 0
M  V30 10 C 12.0031 -16.17 0 0
M  V30 11 C 13.3368 -16.94 0 0
M  V30 12 O 14.6705 -16.17 0 0
M  V30 13 C 13.3368 -18.48 0 0
M  V30 14 C 14.6705 -19.25 0 0
M  V30 15 C 14.6705 -20.79 0 0
M  V30 16 C 16.0041 -21.56 0 0
M  V30 17 C 16.0041 -23.1 0 0
M  V30 18 C 14.6705 -23.87 0 0
M  V30 19 O 14.6705 -25.41 0 0
M  V30 20 C 13.3368 -23.1 0 0
M  V30 21 O 12.0031 -23.87 0 0
M  V30 22 C 10.6694 -23.1 0 0
M  V30 23 C 13.3368 -21.56 0 0
M  V30 24 C 8.0021 -12.32 0 0
M  V30 25 C 6.6684 -11.55 0 0
M  V30 26 C 6.6684 -10.01 0 0
M  V30 27 O 5.3347 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 5 CFG=2
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 13 11 CFG=2
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 20 23
M  V30 23 2 15 23
M  V30 24 1 5 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 3 26
M  V30 28 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104500108

>  <MW>
368.38

>  <MW (desalted)>
368.38

>  <ClogP>
2.251

>  <logS>
-3.9

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
93.06

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
activity percentage  128 - 134 % | inhibition percentage  83.17 % | inhibition percentage  100 % | inhibition percentage  100 % | inhibition percentage  83.06 % | inhibition percentage  81.57 % | inhibition percentage  40 % | IC50  1.93 ?M | IC50  1.93 ?M | IC50  1.93 ?M | stimulation rate Active   | stimulation rate Active   | MIC  1 ?g/ml | IC50  1.04 ?g/ml | IC50  1.04 ?g/ml | IC50  2.9 ?M | IC50  2.9 ?M | inhibition percentage  51.53 % | IC50  3.3 ?M | inhibition percentage  66.29 % | inhibition percentage  68.9 % | EC50 < 5 ?M | IC50  2.03 ?g/ml | IC75  20 ?M | IC50  8.3 ?M | IC50  8.3 ?M

>  <CAS>
458-37-7

>  <Description>
Curcumin is an active component in the golden spice turmeric. It acts as a scavenger of oxygen species, such as hydroxyl radical, superoxide anion, and singlet oxygen and inhibit lipid peroxidation as well as peroxide-induced DNA damage 3. Curcumin mediates potent anti-inflammatory agent and anti-carcinogenic actions via modulating various signalling molecules. Curcumin is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment.

>  <EBC_ID>
EBC-00665

>  <IUPAC Name>
1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione

>  <Main Tar all refs>
Neurochem. Int., 2019, vol. 125, p. 175 - 186 | Chem. Biol. Drug Des., 2014, vol. 83, # 6, p. 670 - 681 | Eur. J. Med. Chem., 2018, vol. 158, p. 353 - 370 | Eur. J. Med. Chem., 2018, vol. 158, p. 353 - 370 | Chem. Biol. Drug Des., 2014, vol. 83, # 6, p. 670 - 681 | Chem. Biol. Drug Des., 2014, vol. 83, # 6, p. 670 - 681 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 16, p. 2157 - 2161 | NEW YORK BLOOD CENTER INC. - WO2021/35068, 2021, A2 | NEW YORK BLOOD CENTER INC. - WO2021/35068, 2021, A2 | NEW YORK BLOOD CENTER INC. - WO2021/35068, 2021, A2 | J. Biol. Chem., 2014, vol. 289, # 45, p. 31397 - 31410 | J. Biol. Chem., 2014, vol. 289, # 45, p. 31397 - 31410 | MedChemComm, 2014, vol. 5, # 10, p. 1540 - 1547 | Mol. Pharm., 2018, vol. 15, # 4, p. 1653 - 1663 | Mol. Pharm., 2018, vol. 15, # 4, p. 1653 - 1663 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | Chem. Biol. Drug Des., 2014, vol. 83, # 6, p. 670 - 681 | Chem.-Biol. Interact., 2019, vol. 297, p. 34 - 43 | Chem. Biol. Drug Des., 2014, vol. 83, # 6, p. 670 - 681 | Eur. J. Med. Chem., 2016, vol. 114, p. 365 - 379 | Neurochem. Int., 2019, vol. 125, p. 175 - 186 | Med. Chem. Res., 2019, vol. 28, # 10, p. 1773 - 1782 | J. Biomol. Struct. Dyn., 2017, p. 1 - 15 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112

>  <Main tar all>
Amyloid-beta precursor protein pX=6.58 | mPGES1 pX=6.46 | acetylcholinesterase (Cartwright blood group) pX=6.28 | sigma non-opioid intracellular receptor 1 pX=6.28 | COX-1  pX=6.16 | PLA2-G5 pX=6.12 | Amyloid-beta protein 1-42 (A?42) pX=5.82 | CoV Envelope protein pX=5.71 | Flavivirus non-structural protein NS2B pX=5.71 | Nonstructural protein 3 pX=5.71 | ABCG2 pX=5.7 | P-type sodium:potassium-exchanging transporter pX=5.7 | NorA multidrug efflux pump pX=5.57 | integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide) pX=5.55 | integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) pX=5.55 | 10 kDa chaperonin 1 pX=5.54 | 60 kDa chaperonin pX=5.54 | COX-2  pX=5.5 | myeloperoxidase pX=5.48 | Lipoxygenase pX=5.46 | Amyloid beta 1-42 pX=5.35 | Amyloid beta 42 peptide pX=5.3 | Histone?deacetylase pX=5.26 | Serine/threonine-protein kinase mTOR pX=5.18 | 10 kDa heat shock protein, mitochondrial pX=5.08 | Heat shock protein 60, mitochondrial pX=5.08

$$$$
Raloxifene hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 3.52 4.0322 0 0
M  V30 3 C 5.06 4.0322 0 0
M  V30 4 C 5.83 5.3659 0 0
M  V30 5 C 7.37 5.3659 0 0
M  V30 6 C 8.14 4.0322 0 0
M  V30 7 C 7.37 2.6986 0 0
M  V30 8 C 5.83 2.6986 0 0
M  V30 9 C 9.68 4.0322 0 0
M  V30 10 S 10.5852 5.2781 0 0
M  V30 11 C 12.0498 4.8022 0 0
M  V30 12 C 13.3835 5.5722 0 0
M  V30 13 C 14.7172 4.8022 0 0
M  V30 14 O 16.0509 5.5722 0 0
M  V30 15 C 14.7172 3.2622 0 0
M  V30 16 C 13.3835 2.4922 0 0
M  V30 17 C 12.0498 3.2622 0 0
M  V30 18 C 10.5852 2.7863 0 0
M  V30 19 C 10.1093 1.3217 0 0
M  V30 20 O 8.603 1.0015 0 0
M  V30 21 C 11.1398 0.1773 0 0
M  V30 22 C 12.6461 0.4975 0 0
M  V30 23 C 13.6766 -0.647 0 0
M  V30 24 C 13.2007 -2.1116 0 0
M  V30 25 O 14.2311 -3.2561 0 0
M  V30 26 C 13.7553 -4.7207 0 0
M  V30 27 C 14.7857 -5.8651 0 0
M  V30 28 N 14.3098 -7.3298 0 0
M  V30 29 C 15.3403 -8.4742 0 0
M  V30 30 C 14.8644 -9.9388 0 0
M  V30 31 C 13.3581 -10.259 0 0
M  V30 32 C 12.3276 -9.1146 0 0
M  V30 33 C 12.8035 -7.6499 0 0
M  V30 34 C 11.6943 -2.4318 0 0
M  V30 35 C 10.6639 -1.2874 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 19 2 9 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 28 33
M  V30 36 2 24 34
M  V30 37 1 34 35
M  V30 38 2 21 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754931262

>  <MW>
510.044

>  <MW (desalted)>
473.583

>  <ClogP>
6.861

>  <logS>
-7.29

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
70

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.017 nM | Kd (dissociation constant) = 171 pM | activity percentage  82.5 % | Ki (inhibition constant)  0.37 nM

>  <CAS>
82640-04-8

>  <Description>
Raloxifene is a selective estrogen receptor modulator that is used to prevent and treat osteoporosis and reduce the risk of invasive breast cancer in high-risk postmenopausal women.

>  <EBC_ID>
EBC-13033

>  <IUPAC Name>
2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol hydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2002, vol. 303, # 1, p. 196 - 203 | ELI LILLY & CO - US5532254, 1996, A | Drug Metab. Dispos., 2014, vol. 42, # 8, p. 1326 - 1333 | J. Med. Chem., 2005, vol. 48, # 22, p. 6772 - 6775

>  <Main tar all>
Estrogen receptor pX=10.8 | voltage-gated calcium channel pX=9.77 | Aldehyde oxidase pX=9.67 | nuclear estrogen receptor pX=9.43

$$$$
Ursodeoxycholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3626 -7.2893 0 0
M  V30 2 C 4.7822 -5.8629 0 0 CFG=2
M  V30 3 C 3.2567 -5.6522 0 0
M  V30 4 C 2.3115 -6.868 0 0
M  V30 5 C 0.786 -6.6574 0 0
M  V30 6 O -0.1592 -7.8732 0 0
M  V30 7 O 0.2057 -5.2309 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 C 5.2994 -3.1677 0 0
M  V30 10 C 6.574 -2.3035 0 0
M  V30 11 C 7.7898 -3.2487 0 0 CFG=1
M  V30 12 C 9.3058 -2.9776 0 0 CFG=2
M  V30 13 C 9.829 -1.5293 0 0 CFG=1
M  V30 14 O 8.8363 -0.3519 0 0
M  V30 15 C 11.345 -1.2582 0 0
M  V30 16 C 12.3377 -2.4355 0 0 CFG=2
M  V30 17 C 13.8537 -2.1644 0 0
M  V30 18 C 14.8464 -3.3418 0 0 CFG=2
M  V30 19 O 16.3624 -3.0707 0 0
M  V30 20 C 14.3232 -4.7901 0 0
M  V30 21 C 12.8072 -5.0612 0 0
M  V30 22 C 11.8145 -3.8839 0 0 CFG=1
M  V30 23 C 11.2913 -5.3323 0 0
M  V30 24 C 10.2985 -4.155 0 0 CFG=1
M  V30 25 C 9.7753 -5.6034 0 0
M  V30 26 C 8.2593 -5.8744 0 0
M  V30 27 C 7.2666 -4.6971 0 0 CFG=2
M  V30 28 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 2 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 16 17
M  V30 17 1 18 17
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 12 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 8
M  V30 30 1 11 27
M  V30 31 1 27 28 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588039022

>  <MW>
392.293

>  <MW (desalted)>
392.572

>  <ClogP>
4.514

>  <logS>
-5.066

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
77.76

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Modulator | Substrate | Substrate | Substrate | Substrate | Substrate | Substrate | Substrate | Substrate | Substrate | Inhibitor

>  <Activity coefficients and valu>
IC50  0.14 ?M | IC50  0.14 ?M | MMP increase Active   | Ki (inhibition constant)  0.819 ?M | EC50 = 0.9 ?M | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | observed parameter Active   | IC50  3.6 ?M

>  <CAS>
128-13-2

>  <Description>
Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis, dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients. Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells.

>  <EBC_ID>
EBC-11069

>  <IUPAC Name>
(4R)-4-[(1R,3aS,3bR,4S,5aS,7R,9aS,9bS,11aR)-4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
J. Am. Chem. Soc., 2008, vol. 130, # 43, p. 14123 - 14128 | J. Am. Chem. Soc., 2008, vol. 130, # 43, p. 14123 - 14128 | Pharm. Res., 2021, vol. 38, # 5, p. 803 - 817 | Pharm. Res., 2006, vol. 23, # 7, p. 1451 - 1459 | INTERCEPT PHARMACEUTICALS, INC. - WO2010/59853, 2010, A1 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | Chem.-Biol. Interact., 2019, vol. 310 | J. Pharmacol. Exp. Ther., 1999, vol. 291, # 3, p. 1204 - 1209

>  <Main tar all>
Aldo-keto reductase family 1 member C1 pX=6.85 | Aldo-keto reductase family 1 member C2 pX=6.85 | CDGSH iron-sulfur domain-containing protein 1 pX=6.3 | Sodium/bile acid and sulphated solute cotransporter 2 pX=6.09 | GPBA receptor pX=6.05 |  UDP glucuronosyltransferase family 1 member A3 pX=6.0 |  UDP glucuronosyltransferase family 1 member A3 pX=6.0 |  UDP glucuronosyltransferase family 1 member A4 pX=6.0 |  UDP glucuronosyltransferase family 1 member A8 pX=6.0 |  UDP glucuronosyltransferase family 1 member A8 pX=6.0 |  UDP glucuronosyltransferase family 1 member A9 pX=6.0 |  UDP glucuronosyltransferase family 1 member A9 pX=6.0 |  UDP glucuronosyltransferase family 2 member B7 pX=6.0 | UDP-glucuronosyltransferase 1A4 pX=6.0 | Sodium/bile acid cotransporter pX=5.44

$$$$
Erythromycin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 51 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 C -0 -1.54 0 0
M  V30 3 C 1.3337 -0.77 0 0 CFG=1
M  V30 4 O 0 0 0 0
M  V30 5 C 0 1.54 0 0
M  V30 6 O -1.3337 2.31 0 0
M  V30 7 C 1.3337 2.31 0 0 CFG=2
M  V30 8 C 0.4285 3.5559 0 0
M  V30 9 C 2.6674 1.54 0 0 CFG=1
M  V30 10 O 2.6674 3.08 0 0
M  V30 11 C 1.3337 3.85 0 0 CFG=1
M  V30 12 C 1.3337 5.39 0 0
M  V30 13 C -0 6.16 0 0 CFG=1
M  V30 14 C 0.9899 7.3397 0 0
M  V30 15 O -0.9899 7.3397 0 0
M  V30 16 C -0.4632 8.7868 0 0
M  V30 17 C -1.3337 5.39 0 0 CFG=1
M  V30 18 O -2.6674 6.16 0 0
M  V30 19 C -1.3337 3.85 0 0 CFG=2
M  V30 20 C -2.6674 3.08 0 0
M  V30 21 O -0 3.08 0 0
M  V30 22 C 4.001 2.31 0 0 CFG=2
M  V30 23 C 4.001 3.85 0 0
M  V30 24 C 5.3347 1.54 0 0 CFG=1
M  V30 25 O 6.6684 2.31 0 0
M  V30 26 C 6.6684 3.85 0 0 CFG=2
M  V30 27 O 5.3347 4.62 0 0
M  V30 28 C 5.3347 6.16 0 0 CFG=2
M  V30 29 C 4.001 6.93 0 0
M  V30 30 C 6.6684 6.93 0 0
M  V30 31 C 8.0021 6.16 0 0 CFG=1
M  V30 32 C 8.0021 4.62 0 0 CFG=1
M  V30 33 O 9.3358 3.85 0 0
M  V30 34 N 9.3358 6.93 0 0
M  V30 35 C 9.3358 8.47 0 0
M  V30 36 C 10.6694 6.16 0 0
M  V30 37 C 5.3347 0 0 0 CFG=2
M  V30 38 C 6.3246 1.1797 0 0
M  V30 39 O 6.8513 0.2674 0 0
M  V30 40 C 6.6684 -0.77 0 0
M  V30 41 C 6.6684 -2.31 0 0 CFG=1
M  V30 42 C 8.0021 -3.08 0 0
M  V30 43 C 5.3347 -3.08 0 0
M  V30 44 O 5.3347 -4.62 0 0
M  V30 45 C 4.001 -2.31 0 0 CFG=2
M  V30 46 C 4.001 -0.77 0 0
M  V30 47 C 2.6674 -3.08 0 0 CFG=1
M  V30 48 O 2.6674 -4.62 0 0
M  V30 49 C 1.3337 -2.31 0 0 CFG=1
M  V30 50 C 0.5176 -3.616 0 0
M  V30 51 O -0.2054 -2.3637 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7 CFG=1
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 10 CFG=3
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15 CFG=3
M  V30 15 1 15 16
M  V30 16 1 17 13
M  V30 17 1 17 18 CFG=3
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=1
M  V30 20 1 19 21
M  V30 21 1 11 21
M  V30 22 1 9 22
M  V30 23 1 22 23 CFG=3
M  V30 24 1 22 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 32 31
M  V30 33 1 32 26
M  V30 34 1 32 33 CFG=1
M  V30 35 1 31 34 CFG=3
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 24 37
M  V30 39 1 37 38 CFG=1
M  V30 40 1 37 39 CFG=3
M  V30 41 1 37 40
M  V30 42 1 41 40
M  V30 43 1 41 42 CFG=1
M  V30 44 1 41 43
M  V30 45 2 43 44
M  V30 46 1 45 43
M  V30 47 1 45 46 CFG=1
M  V30 48 1 47 45
M  V30 49 1 47 48 CFG=1
M  V30 50 1 47 49
M  V30 51 1 49 3
M  V30 52 1 49 50 CFG=1
M  V30 53 1 49 51 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996953

>  <MW>
733.461

>  <MW (desalted)>
733.927

>  <ClogP>
1.611

>  <logS>
-2.273

>  <HBD>
5

>  <HBA>
13

>  <TPSA>
193.91

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  7.36  | inhibition percentage Active   | inhibition percentage Active   | MIC <= 0.125 ?g/ml | IC50  0.19 ?M | MIC95  4 ?g/ml | MIC  0.25 ?g/ml | Ki u  0.34 ?M | MIC  0.42 ?g/ml | IC50  0.45 ?g/ml | MIC  0.5 ?g/ml | IC50  0.72 ?M | MIC  1 ?g/ml

>  <CAS>
114-07-8

>  <Description>
Erythromycin is a macrolide antibiotic used to treat and prevent a variety of bacterial infections.

>  <EBC_ID>
EBC-13806

>  <IUPAC Name>
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

>  <Main Tar all refs>
BIOORG. MED. CHEM. LETT., 1995, vol. 5, # 8, p. 835 - 838 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2009, vol. 379, # 1, p. 11 - 26 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2009, vol. 379, # 1, p. 11 - 26 | Bioorg. Med. Chem., 2020, vol. 28, # 21 | J. Med. Chem., 2009, vol. 52, # 4, p. 1180 - 1189 | Nat. Commun., 2022, vol. 13, # 1 | REDX PHARMA PLC - WO2017/93747, 2017, A1 | Drug Metab. Dispos., 2012, vol. 40, # 9, p. 1658 | Bioorg. Med. Chem., 2022, vol. 54 | Chem. Biodivers., 2018, vol. 15, # 9 | ACS Infect. Dis., 2020, vol. 6, # 12, p. 3163 - 3173 | Drug Metab. Dispos., 2007, vol. 35, # 2, p. 246 - 255 | Eur. J. Med. Chem., 2019, vol. 175, p. 49 - 62

>  <Main tar all>
motilin receptor pX=7.36 | ABCB1 pX=7.1 | ATP-dependent translocase ABCB1 pX=7.1 | Cell division protein FtsZ pX=6.77 | Cytochrome P450 3A4 pX=6.72 | Multidrug?efflux?pump?subunit?AcrB pX=6.54 | DNA topoisomerase II pX=6.47 | NADPH-cytochrome P450 reductase pX=6.47 | Efflux pump NorA pX=6.24 | Dihydromonapterin reductase (gene folM) pX=6.21 | Elongation factor Tu pX=6.17 | CYP3A pX=6.14 | Undecaprenyl-diphosphatase (gene uppP) pX=5.87

$$$$
Dorzolamide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 11.4172 5.1089 0 0
M  V30 3 C 11.4172 3.5689 0 0
M  V30 4 N 10.0835 2.7989 0 0
M  V30 5 C 10.0835 1.2589 0 0 CFG=1
M  V30 6 C 11.4172 0.4889 0 0
M  V30 7 C 11.4172 -1.0511 0 0 CFG=2
M  V30 8 C 12.7509 -1.8211 0 0
M  V30 9 S 10.0835 -1.8211 0 0
M  V30 10 O 11.0734 -3.0008 0 0
M  V30 11 O 9.0936 -3.0008 0 0
M  V30 12 C 8.7498 -1.0511 0 0
M  V30 13 S 7.2852 -1.527 0 0
M  V30 14 C 6.38 -0.2811 0 0
M  V30 15 C 7.2852 0.9648 0 0
M  V30 16 C 8.7498 0.4889 0 0
M  V30 17 S 4.84 -0.2811 0 0
M  V30 18 O 3.3 -0.2811 0 0
M  V30 19 O 4.84 1.2589 0 0
M  V30 20 N 4.84 -1.8211 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 5 4 CFG=1
M  V30 4 1 5 6
M  V30 5 1 7 6
M  V30 6 1 7 8 CFG=3
M  V30 7 1 7 9
M  V30 8 2 9 10
M  V30 9 2 9 11
M  V30 10 1 9 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 1 5 16
M  V30 16 2 12 16
M  V30 17 1 14 17
M  V30 18 2 17 18
M  V30 19 2 17 19
M  V30 20 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516872

>  <MW>
360.004

>  <MW (desalted)>
324.44

>  <ClogP>
-0.425

>  <logS>
-3.435

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
106.33

>  <RotBonds>
3

>  <Action on targets>
Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pEC50  8.2  | Ki (inhibition constant) = 8 nM | IC50  0.024 ?M | IC50  0.036 ?M | Ki (inhibition constant) = 43 nM | Ki (inhibition constant) = 59 nM

>  <CAS>
130693-82-2

>  <Description>
Dorzolamide is a carbonic anhydrase inhibitor. It is used to treat high intraocular pressure in ocular hypertension and open angle glaucoma.

>  <EBC_ID>
EBC-79037

>  <IUPAC Name>
(2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1lambda6-thieno[2,3-b]thiopyran-6-sulfonamide hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2013, vol. 23, # 4, p. 939 - 943 | Eur. J. Med. Chem., 2000, vol. 35, # 9, p. 859 - 865 | Pharmaceuticals, 2022, vol. 15, # 9 | Pharmaceuticals, 2022, vol. 15, # 9 | J. Med. Chem., 2000, vol. 43, # 23, p. 4542 - 4551 | Eur. J. Med. Chem., 1998, vol. 33, # 7 - 8, p. 577 - 594

>  <Main tar all>
FP receptor pX=8.2 | carbonic anhydrase 2 pX=8.1 | carbonic anhydrase 12 pX=7.62 | carbonic anhydrase 9 pX=7.44 | carbonic anhydrase 4 pX=7.37 | carbonic anhydrase 1 pX=7.23

$$$$
Indinavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 50 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -8.5575 2.2356 0 0
M  V30 2 C -7.2238 3.0056 0 0
M  V30 3 C -7.9938 4.3393 0 0
M  V30 4 C -6.4538 1.672 0 0
M  V30 5 N -5.8901 3.7756 0 0
M  V30 6 C -4.5564 3.0056 0 0
M  V30 7 O -3.2227 3.7756 0 0
M  V30 8 C -4.5564 1.4656 0 0 CFG=2
M  V30 9 C -5.8901 0.6956 0 0
M  V30 10 N -5.8901 -0.8444 0 0
M  V30 11 C -7.2238 -1.6144 0 0
M  V30 12 C -7.2238 -3.1544 0 0
M  V30 13 C -5.8901 -3.9244 0 0
M  V30 14 C -5.8901 -5.4644 0 0
M  V30 15 C -7.2238 -6.2344 0 0
M  V30 16 N -8.5575 -5.4644 0 0
M  V30 17 C -8.5575 -3.9244 0 0
M  V30 18 C -4.5564 -1.6144 0 0
M  V30 19 C -3.2227 -0.8444 0 0
M  V30 20 N -3.2227 0.6956 0 0
M  V30 21 C -1.8891 1.4656 0 0
M  V30 22 C -0.5554 0.6956 0 0 CFG=1
M  V30 23 O -0.5554 -0.8444 0 0
M  V30 24 C 0.7783 1.4656 0 0
M  V30 25 C 2.112 0.6956 0 0 CFG=1
M  V30 26 C 2.112 -0.8444 0 0
M  V30 27 C 3.4456 -1.6144 0 0
M  V30 28 C 4.7793 -0.8444 0 0
M  V30 29 C 6.113 -1.6144 0 0
M  V30 30 C 6.113 -3.1544 0 0
M  V30 31 C 4.7793 -3.9244 0 0
M  V30 32 C 3.4456 -3.1544 0 0
M  V30 33 C 3.4456 1.4656 0 0
M  V30 34 O 3.4456 3.0056 0 0
M  V30 35 N 4.7793 0.6956 0 0
M  V30 36 C 6.113 1.4656 0 0 CFG=2
M  V30 37 C 6.274 2.9972 0 0 CFG=2
M  V30 38 O 5.1295 4.0277 0 0
M  V30 39 C 7.7803 3.3174 0 0
M  V30 40 C 8.5503 1.9837 0 0
M  V30 41 C 10.0567 1.6635 0 0
M  V30 42 C 10.5326 0.1989 0 0
M  V30 43 C 9.5021 -0.9455 0 0
M  V30 44 C 7.9958 -0.6254 0 0
M  V30 45 C 7.5199 0.8393 0 0
M  V30 46 O 15.5926 -1.54 0 0
M  V30 47 S 15.5926 0 0 0
M  V30 48 O 15.5926 1.54 0 0
M  V30 49 O 17.1326 -0 0 0
M  V30 50 O 14.0526 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 10 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 8 20
M  V30 22 1 20 21
M  V30 23 1 22 21
M  V30 24 1 22 23 CFG=3
M  V30 25 1 22 24
M  V30 26 1 25 24 CFG=3
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 27 32
M  V30 35 1 25 33
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 36 35 CFG=3
M  V30 39 1 36 37
M  V30 40 1 37 38 CFG=3
M  V30 41 1 37 39
M  V30 42 1 39 40
M  V30 43 1 40 41
M  V30 44 2 41 42
M  V30 45 1 42 43
M  V30 46 2 43 44
M  V30 47 1 44 45
M  V30 48 1 36 45
M  V30 49 2 40 45
M  V30 50 1 46 47
M  V30 51 2 47 48
M  V30 52 2 47 49
M  V30 53 1 47 50
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616207

>  <MW>
711.33

>  <MW (desalted)>
613.789

>  <ClogP>
3.681

>  <logS>
-1.852

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
118.03

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.03 nM | Ki (inhibition constant) = 0.07 nM | IC50  0.6 nM

>  <CAS>
157810-81-6

>  <Description>
Indinavir is an HIV-1 protease inhibitor. It is used in combination with antiretroviral agents in the treatment of HIV infection.

>  <EBC_ID>
EBC-08495

>  <IUPAC Name>
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide; sulfuric acid

>  <Main Tar all refs>
Viruses, 2015, vol. 7, # 12, p. 6152 - 6162 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 4, p. 959 - 963 | HUENING TRACY T; MERCK & CO INC - WO2002/96359, 2002, A2

>  <Main tar all>
HIV-2?protease pX=10.5 | Protease pX=10.2 | HIV-1 protease pX=9.22

$$$$
Trovafloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -4.541 2.6217 0 0
M  V30 2 C -3.2073 1.8517 0 0 CFG=1
M  V30 3 C -1.6673 1.8517 0 0 CFG=2
M  V30 4 C -0.161 1.5316 0 0
M  V30 5 N 0 -0 0 0
M  V30 6 C -1.4069 -0.6264 0 0
M  V30 7 C -2.4373 0.5181 0 0 CFG=2
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 N 5.3347 0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 C 8.0021 -3.08 0 0
M  V30 15 O 8.0021 -4.62 0 0
M  V30 16 O 9.3358 -2.31 0 0
M  V30 17 C 5.3347 -3.08 0 0
M  V30 18 O 5.3347 -4.62 0 0
M  V30 19 C 4.001 -2.31 0 0
M  V30 20 C 2.6674 -3.08 0 0
M  V30 21 C 1.3337 -2.31 0 0
M  V30 22 F 0 -3.08 0 0
M  V30 23 C 5.3347 1.54 0 0
M  V30 24 C 4.001 2.31 0 0
M  V30 25 C 4.001 3.85 0 0
M  V30 26 C 5.3347 4.62 0 0
M  V30 27 F 5.3347 6.16 0 0
M  V30 28 C 6.6684 3.85 0 0
M  V30 29 C 6.6684 2.31 0 0
M  V30 30 F 8.0021 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=3
M  V30 7 1 2 7
M  V30 8 1 3 7
M  V30 9 1 5 8
M  V30 10 1 8 9
M  V30 11 2 9 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 2 12 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 13 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 10 19
M  V30 22 2 19 20
M  V30 23 1 20 21
M  V30 24 2 8 21
M  V30 25 1 21 22
M  V30 26 1 11 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 2 26 28
M  V30 32 1 28 29
M  V30 33 2 23 29
M  V30 34 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996506

>  <MW>
416.11

>  <MW (desalted)>
416.353

>  <ClogP>
-0.178

>  <logS>
-5.505

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
99.76

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | pKi  7.5  | pKi  7.5

>  <CAS>
147059-72-1

>  <Description>
Trovafloxacin is a broad spectrum antibiotic. It is used to treat gonorrhea and chlamydia.

>  <EBC_ID>
EBC-27022

>  <IUPAC Name>
7-[(1R,5S,6R)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2017, vol. 27, # 5, p. 1162 - 1168 | Nat. Chem. Biol., 2011, vol. 7, # 4, p. 200 - 202 | Nat. Chem. Biol., 2011, vol. 7, # 4, p. 200 - 202

>  <Main tar all>
DNA topoisomerase II pX=8.33 | fms related receptor tyrosine kinase 4 pX=7.5 | glycogen synthase kinase 3 beta pX=7.5

$$$$
Besifloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.5599 -7.1347 0 0
M  V30 2 C -1.0138 -5.6632 0 0 CFG=2
M  V30 3 C -2.5366 -5.4336 0 0
M  V30 4 C -3.3066 -4.1 0 0
M  V30 5 C -2.744 -2.6664 0 0
M  V30 6 C -1.2724 -2.2125 0 0
M  V30 7 N 0 -3.08 0 0
M  V30 8 C 0.1151 -4.6157 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 F 0 0 0 0
M  V30 12 C 2.6674 0 0 0
M  V30 13 C 4.001 -0.77 0 0
M  V30 14 C 5.3347 0 0 0
M  V30 15 O 5.3347 1.54 0 0
M  V30 16 C 6.6684 -0.77 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 N 5.3347 -3.08 0 0
M  V30 19 C 5.3347 -4.62 0 0
M  V30 20 C 6.1047 -5.9537 0 0
M  V30 21 C 4.5647 -5.9537 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 23 C 2.6674 -3.08 0 0
M  V30 24 Cl 2.6674 -4.62 0 0
M  V30 25 C 8.0021 -0 0 0
M  V30 26 O 8.0021 1.54 0 0
M  V30 27 O 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 19 21
M  V30 23 1 18 22
M  V30 24 2 13 22
M  V30 25 1 22 23
M  V30 26 2 9 23
M  V30 27 1 23 24
M  V30 28 1 16 25
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811595

>  <MW>
393.126

>  <MW (desalted)>
393.84

>  <ClogP>
0.694

>  <logS>
-3.795

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
86.87

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 2.5 ?M

>  <CAS>
141388-76-3

>  <Description>
Besifloxacin is a fluoroquinolone antibiotic agent used for the treatment of bacterial conjunctivitis.

>  <EBC_ID>
EBC-26926

>  <IUPAC Name>
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
J. Antimicrob. Chemother., 2009, vol. 63, # 3, p. 443 - 450

>  <Main tar all>
DNA?gyrase pX=5.6

$$$$
Posaconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 51 57 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 23.1524 -3.6549 0 0
M  V30 2 C 23.1524 -5.1949 0 0
M  V30 3 C 21.8187 -5.9649 0 0 CFG=1
M  V30 4 C 20.485 -5.1949 0 0 CFG=2
M  V30 5 C 19.1513 -5.9649 0 0
M  V30 6 O 20.485 -3.6549 0 0
M  V30 7 N 21.8187 -7.5049 0 0
M  V30 8 N 23.0646 -8.4101 0 0
M  V30 9 C 22.5887 -9.8747 0 0
M  V30 10 N 21.0487 -9.8747 0 0
M  V30 11 C 20.1435 -11.1206 0 0
M  V30 12 C 20.7699 -12.5275 0 0
M  V30 13 C 19.8647 -13.7733 0 0
M  V30 14 C 18.3331 -13.6124 0 0
M  V30 15 C 17.7068 -12.2055 0 0
M  V30 16 C 18.6119 -10.9596 0 0
M  V30 17 N 17.4279 -14.8583 0 0
M  V30 18 C 18.0543 -16.2651 0 0
M  V30 19 C 17.1491 -17.511 0 0
M  V30 20 N 15.6176 -17.35 0 0
M  V30 21 C 14.9912 -15.9432 0 0
M  V30 22 C 15.8964 -14.6973 0 0
M  V30 23 C 14.7124 -18.5959 0 0
M  V30 24 C 15.3387 -20.0028 0 0
M  V30 25 C 14.4336 -21.2487 0 0
M  V30 26 C 12.902 -21.0877 0 0
M  V30 27 O 11.9968 -22.3336 0 0
M  V30 28 C 10.4652 -22.1726 0 0
M  V30 29 C 9.5601 -23.4185 0 0 CFG=2
M  V30 30 C 10.0359 -24.8831 0 0
M  V30 31 O 8.7901 -25.7883 0 0
M  V30 32 C 7.5442 -24.8831 0 0 CFG=2
M  V30 33 C 6.7742 -26.2168 0 0
M  V30 34 N 7.5442 -27.5505 0 0
M  V30 35 C 6.9178 -28.9573 0 0
M  V30 36 N 8.0622 -29.9878 0 0
M  V30 37 C 9.3959 -29.2178 0 0
M  V30 38 N 9.0757 -27.7114 0 0
M  V30 39 C 8.0201 -23.4185 0 0
M  V30 40 C 6.1373 -24.2567 0 0
M  V30 41 C 4.8914 -25.1619 0 0
M  V30 42 C 3.4846 -24.5356 0 0
M  V30 43 C 3.3236 -23.004 0 0
M  V30 44 F 1.9167 -22.3776 0 0
M  V30 45 C 4.5695 -22.0988 0 0
M  V30 46 C 5.9763 -22.7252 0 0
M  V30 47 F 7.2222 -21.82 0 0
M  V30 48 C 12.2756 -19.6808 0 0
M  V30 49 C 13.1808 -18.4349 0 0
M  V30 50 C 20.5728 -8.4101 0 0
M  V30 51 O 19.1082 -7.9342 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6 CFG=3
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 14 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 24 1 20 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 29 28 CFG=3
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 32 31
M  V30 34 1 32 33 CFG=3
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 34 38
M  V30 41 1 32 39
M  V30 42 1 29 39
M  V30 43 1 32 40 CFG=1
M  V30 44 1 40 41
M  V30 45 2 41 42
M  V30 46 1 42 43
M  V30 47 1 43 44
M  V30 48 2 43 45
M  V30 49 1 45 46
M  V30 50 2 40 46
M  V30 51 1 46 47
M  V30 52 2 26 48
M  V30 53 1 48 49
M  V30 54 2 23 49
M  V30 55 1 10 50
M  V30 56 1 7 50
M  V30 57 2 50 51
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802256

>  <MW>
700.33

>  <MW (desalted)>
700.777

>  <ClogP>
4.113

>  <logS>
-6.783

>  <HBD>
1

>  <HBA>
9

>  <TPSA>
111.79

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pEC50  8.9 | IC50  9 nM | MIC  0.0078 ?g/ml

>  <CAS>
171228-49-2

>  <Description>
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

>  <EBC_ID>
EBC-11286

>  <IUPAC Name>
4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one

>  <Main Tar all refs>
PLoS. Negl. Trop. Dis., 2018, vol. 12, # 7 | J. Steroid Biochem. Mol. Biol., 2020, vol. 199 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 15, p. 3243 - 3248

>  <Main tar all>
Eburicol 14-alpha-demethylase pX=8.9 | CYP11B2 pX=8.05 | CYP51A1 pX=7.95

$$$$
Bepotastine besilate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -9.7309 1.5685 0 0
M  V30 2 C -8.3972 0.7985 0 0
M  V30 3 O -8.3972 -0.7415 0 0
M  V30 4 C -7.0636 1.5685 0 0
M  V30 5 C -5.7299 0.7985 0 0
M  V30 6 C -4.3962 1.5685 0 0
M  V30 7 N -3.0625 0.7985 0 0
M  V30 8 C -1.7288 1.5685 0 0
M  V30 9 C -0.3952 0.7985 0 0
M  V30 10 C -0.3952 -0.7415 0 0
M  V30 11 C -1.7288 -1.5115 0 0
M  V30 12 C -3.0625 -0.7415 0 0
M  V30 13 O 0.9385 -1.5115 0 0
M  V30 14 C 2.2722 -0.7415 0 0 CFG=1
M  V30 15 C 3.6059 -1.5115 0 0
M  V30 16 C 4.9396 -0.7415 0 0
M  V30 17 C 6.2732 -1.5115 0 0
M  V30 18 C 6.2732 -3.0515 0 0
M  V30 19 Cl 7.6069 -3.8215 0 0
M  V30 20 C 4.9396 -3.8215 0 0
M  V30 21 C 3.6059 -3.0515 0 0
M  V30 22 C 2.2722 0.7985 0 0
M  V30 23 C 0.9385 1.5685 0 0
M  V30 24 C 0.9385 3.1085 0 0
M  V30 25 C 2.2722 3.8785 0 0
M  V30 26 C 3.6059 3.1085 0 0
M  V30 27 N 3.6059 1.5685 0 0
M  V30 28 O 12.4606 3.234 0 0
M  V30 29 S 12.4606 1.694 0 0
M  V30 30 O 10.9206 1.694 0 0
M  V30 31 O 14.0006 1.694 0 0
M  V30 32 C 12.4606 0.154 0 0
M  V30 33 C 13.7943 -0.616 0 0
M  V30 34 C 13.7943 -2.156 0 0
M  V30 35 C 12.4606 -2.926 0 0
M  V30 36 C 11.1269 -2.156 0 0
M  V30 37 C 11.1269 -0.616 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13
M  V30 14 1 14 13 CFG=3
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 20 21
M  V30 22 2 15 21
M  V30 23 1 14 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 22 27
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 2 29 31
M  V30 33 1 29 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 36 37
M  V30 39 2 32 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802230

>  <MW>
546.159

>  <MW (desalted)>
388.888

>  <ClogP>
0.283

>  <logS>
-3.534

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
62.66

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  101 nM

>  <CAS>
190786-44-8

>  <Description>
Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.

>  <EBC_ID>
EBC-07869

>  <IUPAC Name>
4-{4-[(S)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid; benzenesulfonic acid

>  <Main Tar all refs>
Arzneimittelforschung, 1997, vol. 47, # 10, p. 1116 - 1124

>  <Main tar all>
H1 receptor pX=7.0

$$$$
Daclatasvir dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 56 59 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C 9.2638 -13.8129 0 0
M  V30 4 O 7.9301 -14.5829 0 0
M  V30 5 C 7.9301 -16.1229 0 0
M  V30 6 O 9.2638 -16.8929 0 0
M  V30 7 N 6.5964 -16.8929 0 0
M  V30 8 C 6.5964 -18.4329 0 0 CFG=1
M  V30 9 C 7.9301 -19.2029 0 0
M  V30 10 C 7.9301 -20.7429 0 0
M  V30 11 C 9.2638 -18.4329 0 0
M  V30 12 C 5.2627 -19.2029 0 0
M  V30 13 O 3.9291 -18.4329 0 0
M  V30 14 N 5.2627 -20.7429 0 0
M  V30 15 C 6.5086 -21.6481 0 0
M  V30 16 C 6.0327 -23.1127 0 0
M  V30 17 C 4.4927 -23.1127 0 0
M  V30 18 C 4.0169 -21.6481 0 0 CFG=1
M  V30 19 C 2.5522 -21.1722 0 0
M  V30 20 N 1.3063 -22.0774 0 0
M  V30 21 C 0.0605 -21.1722 0 0
M  V30 22 C 0.5363 -19.7076 0 0
M  V30 23 N 2.0763 -19.7076 0 0
M  V30 24 C -0.3688 -18.4617 0 0
M  V30 25 C -1.9004 -18.6227 0 0
M  V30 26 C -2.8056 -17.3768 0 0
M  V30 27 C -2.1792 -15.9699 0 0
M  V30 28 C -0.6477 -15.809 0 0
M  V30 29 C 0.2575 -17.0548 0 0
M  V30 30 C -3.0844 -14.724 0 0
M  V30 31 C -4.616 -14.885 0 0
M  V30 32 C -5.5212 -13.6391 0 0
M  V30 33 C -4.8948 -12.2323 0 0
M  V30 34 C -3.3632 -12.0713 0 0
M  V30 35 C -2.458 -13.3172 0 0
M  V30 36 C -5.8 -10.9864 0 0
M  V30 37 C -7.34 -10.9864 0 0
M  V30 38 N -7.8159 -9.5218 0 0
M  V30 39 C -6.57 -8.6166 0 0
M  V30 40 N -5.3241 -9.5218 0 0
M  V30 41 C -6.57 -7.0766 0 0 CFG=2
M  V30 42 C -7.8159 -6.1714 0 0
M  V30 43 C -7.34 -4.7068 0 0
M  V30 44 C -5.8 -4.7068 0 0
M  V30 45 N -5.3241 -6.1714 0 0
M  V30 46 C -3.8595 -6.6473 0 0
M  V30 47 O -3.5393 -8.1536 0 0
M  V30 48 C -2.715 -5.6168 0 0 CFG=1
M  V30 49 N -1.2504 -6.0927 0 0
M  V30 50 C -0.106 -5.0622 0 0
M  V30 51 O -0.4261 -3.5559 0 0
M  V30 52 O 1.3587 -5.5381 0 0
M  V30 53 C 2.5031 -4.5077 0 0
M  V30 54 C -3.0352 -4.1105 0 0
M  V30 55 C -4.4998 -3.6346 0 0
M  V30 56 C -1.8908 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 2 5 6
M  V30 4 1 5 7
M  V30 5 1 8 7 CFG=1
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 9 11
M  V30 9 1 8 12
M  V30 10 2 12 13
M  V30 11 1 12 14
M  V30 12 1 14 15
M  V30 13 1 15 16
M  V30 14 1 16 17
M  V30 15 1 18 17
M  V30 16 1 18 14
M  V30 17 1 18 19 CFG=1
M  V30 18 2 19 20
M  V30 19 1 20 21
M  V30 20 2 21 22
M  V30 21 1 22 23
M  V30 22 1 19 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 2 24 29
M  V30 30 1 27 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 34 35
M  V30 36 2 30 35
M  V30 37 1 33 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 39 40
M  V30 42 1 36 40
M  V30 43 1 41 39 CFG=3
M  V30 44 1 41 42
M  V30 45 1 42 43
M  V30 46 1 43 44
M  V30 47 1 44 45
M  V30 48 1 41 45
M  V30 49 1 45 46
M  V30 50 2 46 47
M  V30 51 1 48 46
M  V30 52 1 48 49 CFG=3
M  V30 53 1 49 50
M  V30 54 2 50 51
M  V30 55 1 50 52
M  V30 56 1 52 53
M  V30 57 1 48 54
M  V30 58 1 54 55
M  V30 59 1 54 56
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3247611631

>  <MW>
810.339

>  <MW (desalted)>
738.875

>  <ClogP>
4.722

>  <logS>
-8.56

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
174.64

>  <RotBonds>
13

>  <Action on targets>
-

>  <Activity coefficients and valu>
EC50  1 - 999 pM

>  <CAS>
1009119-65-6

>  <Description>
Daclatasvir is a direct-acting antiviral agent used to treat specific hepatitis C virus infections in combination with other antiviral agents.

>  <EBC_ID>
EBC-28060

>  <IUPAC Name>
methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride

>  <Main Tar all refs>
BRISTOL-MYERS SQUIBB CO - US2010/158862, 2010, A1

>  <Main tar all>
Nonstructural?protein?5A pX=12.0

$$$$
Sacubitril calcium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 61 62 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Ca 7.907 5.6773 0 0 CHG=2
M  V30 2 C -0.1584 6.8414 0 0
M  V30 3 C -0.6625 5.3862 0 0
M  V30 4 O 0.3457 4.2221 0 0
M  V30 5 C -0.1584 2.7669 0 0
M  V30 6 O -1.6706 2.4759 0 0
M  V30 7 C 0.8498 1.6028 0 0 CFG=1
M  V30 8 C 2.362 1.8939 0 0
M  V30 9 C 0.3457 0.1477 0 0
M  V30 10 C 1.3539 -1.0165 0 0 CFG=2
M  V30 11 C 0.8498 -2.4716 0 0
M  V30 12 C -0.6625 -2.7627 0 0
M  V30 13 C -1.1665 -4.2178 0 0
M  V30 14 C -2.6788 -4.5089 0 0
M  V30 15 C -3.687 -3.3447 0 0
M  V30 16 C -3.1829 -1.8896 0 0
M  V30 17 C -1.6706 -1.5985 0 0
M  V30 18 C -5.1992 -3.6358 0 0
M  V30 19 C -5.7033 -5.0909 0 0
M  V30 20 C -7.2155 -5.382 0 0
M  V30 21 C -8.2237 -4.2178 0 0
M  V30 22 C -7.7196 -2.7627 0 0
M  V30 23 C -6.2074 -2.4716 0 0
M  V30 24 N 2.8661 -0.7254 0 0
M  V30 25 C 3.3702 0.7297 0 0
M  V30 26 O 3.2388 2.2641 0 0
M  V30 27 C 4.8825 1.0208 0 0
M  V30 28 C 5.3865 2.4759 0 0
M  V30 29 C 6.8988 2.7669 0 0
M  V30 30 O 7.907 1.6028 0 0
M  V30 31 O 7.4029 4.2221 0 0 CHG=-1
M  V30 32 C 15.428 -6.6778 0 0
M  V30 33 C 15.428 -5.1378 0 0
M  V30 34 O 16.7617 -4.3678 0 0
M  V30 35 C 16.7617 -2.8278 0 0
M  V30 36 O 15.428 -2.0578 0 0
M  V30 37 C 18.0954 -2.0578 0 0 CFG=1
M  V30 38 C 19.429 -2.8278 0 0
M  V30 39 C 18.0954 -0.5178 0 0
M  V30 40 C 19.429 0.2522 0 0 CFG=2
M  V30 41 C 19.429 1.7922 0 0
M  V30 42 C 18.0954 2.5622 0 0
M  V30 43 C 16.7617 1.7922 0 0
M  V30 44 C 15.428 2.5622 0 0
M  V30 45 C 15.428 4.1022 0 0
M  V30 46 C 16.7617 4.8722 0 0
M  V30 47 C 18.0954 4.1022 0 0
M  V30 48 C 14.0943 4.8722 0 0
M  V30 49 C 12.7606 4.1022 0 0
M  V30 50 C 11.427 4.8722 0 0
M  V30 51 C 11.427 6.4122 0 0
M  V30 52 C 12.7606 7.1822 0 0
M  V30 53 C 14.0943 6.4122 0 0
M  V30 54 N 20.7627 -0.5178 0 0
M  V30 55 C 20.7627 -2.0578 0 0
M  V30 56 O 20.1363 -3.4646 0 0
M  V30 57 C 22.0964 -2.8278 0 0
M  V30 58 C 22.0964 -4.3678 0 0
M  V30 59 C 23.4301 -5.1378 0 0
M  V30 60 O 24.7638 -4.3678 0 0
M  V30 61 O 23.4301 -6.6778 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 7 5
M  V30 6 1 7 8 CFG=1
M  V30 7 1 7 9
M  V30 8 1 10 9
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 2 12 17
M  V30 17 1 15 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 18 23
M  V30 24 1 10 24 CFG=1
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 29 31
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 2 35 36
M  V30 36 1 37 35
M  V30 37 1 37 38 CFG=3
M  V30 38 1 37 39
M  V30 39 1 40 39
M  V30 40 1 40 41
M  V30 41 1 41 42
M  V30 42 1 42 43
M  V30 43 2 43 44
M  V30 44 1 44 45
M  V30 45 2 45 46
M  V30 46 1 46 47
M  V30 47 2 42 47
M  V30 48 1 45 48
M  V30 49 1 48 49
M  V30 50 2 49 50
M  V30 51 1 50 51
M  V30 52 2 51 52
M  V30 53 1 52 53
M  V30 54 2 48 53
M  V30 55 1 40 54 CFG=3
M  V30 56 1 54 55
M  V30 57 2 55 56
M  V30 58 1 55 57
M  V30 59 1 57 58
M  V30 60 1 58 59
M  V30 61 2 59 60
M  V30 62 1 59 61
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3313642143

>  <MW>
860.356

>  <MW (desalted)>
411.491

>  <ClogP>
1.509

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
95.53

>  <RotBonds>
24

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.0023 ?M

>  <CAS>
1369773-39-6

>  <Description>
Sacubitril is a neprilysin inhibitor used in combination with valsartan as an adjunct to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

>  <EBC_ID>
EBC-15054

>  <IUPAC Name>
calcium bis(3-{[(2R,4S)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoate)

>  <Main Tar all refs>
Toxicol. Appl. Pharmacol., 2017, vol. 323, p. 53 - 65

>  <Main tar all>
Neutral endopeptidase pX=8.64

$$$$
Aminobenzoic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 O 2.6674 -3.08 0 0
M  V30 10 O -0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127446

>  <MW>
137.048

>  <MW (desalted)>
137.136

>  <ClogP>
0.978

>  <logS>
-1.34

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 35.2 nM | IC50 = 35.2 nM | Ki (inhibition constant) = 200 nM

>  <CAS>
150-13-0

>  <Description>
Aminobenzoic acid is a member of the vitamin B complex. It is used to reduce the progression of penile deviation in Peyronie's Disease in adults.

>  <EBC_ID>
EBC-26078

>  <IUPAC Name>
4-aminobenzoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem., 2012, vol. 20, # 1, p. 521 - 530 | Bioorg. Med. Chem., 2012, vol. 20, # 1, p. 521 - 530 | Antimicrob. Agents Chemother., 1998, vol. 42, # 5, p. 1062 - 1067

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=7.45 | acetylcholinesterase (Cartwright blood group) pX=7.45 | Dihydropteroate synthase pX=6.7

$$$$
Acetylcholine bromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0 CHG=-1
M  V30 2 C 4.6337 -4.081 0 0
M  V30 3 C 4.6337 -2.541 0 0
M  V30 4 O 3.3 -1.771 0 0
M  V30 5 O 5.9674 -1.771 0 0
M  V30 6 C 5.9674 -0.231 0 0
M  V30 7 C 7.301 0.539 0 0
M  V30 8 N 7.301 2.079 0 0 CHG=1
M  V30 9 C 7.301 3.619 0 0
M  V30 10 C 8.841 2.079 0 0
M  V30 11 C 5.761 2.079 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 8 10
M  V30 9 1 8 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z600425176

>  <MW>
225.036

>  <MW (desalted)>
146.207

>  <ClogP>
-3.467

>  <logS>
-0.12

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
26.3

>  <RotBonds>
4

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
pD2  6.88

>  <CAS>
66-23-9

>  <Description>
Acetylcholine is a parasympathomimetic neurotransmitter used to induce miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required. It exhibits an agonistic effect on muscarinic acetylcholine receptor family.

>  <EBC_ID>
EBC-03392

>  <IUPAC Name>
[2-(acetyloxy)ethyl]trimethylazanium bromide

>  <Main Tar all refs>
Farmaco Ed. Sci., 1981, vol. 36, # 9, p. 749 - 764

>  <Main tar all>
mAChR pX=6.88

$$$$
Eugenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 4.001 -2.31 0 0
M  V30 8 C 5.3347 -3.08 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 3 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56347226

>  <MW>
164.084

>  <MW (desalted)>
164.201

>  <ClogP>
2.397

>  <logS>
-2.26

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
3

>  <Action on targets>
Blocker | Blocker | Agonist | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition Active   | inhibition Active   | EC50  0.08 ?M | EC50  0.08 ?M | stimulation rate Active   | EC50  1.02E-07 M | inhibition percentage  30.8 % | IC50  0.04 ?g/ml | IC50  0.04 ?g/ml

>  <CAS>
97-53-0

>  <Description>
Eugenol is a phenol used for the temporary relief of toothaches. It has been found to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties. It inhibits Phosphoethanolamine transferase Mcr-1 (Escherichia coli), Acetylcholinesterase (Psoroptes cuniculi).

>  <EBC_ID>
EBC-12073

>  <IUPAC Name>
2-methoxy-4-(prop-2-en-1-yl)phenol

>  <Main Tar all refs>
Life Sci., 2021, vol. 282 | Life Sci., 2021, vol. 282 | F1000 Res., 2014, vol. 3 | F1000 Res., 2014, vol. 3 | J. Biol. Chem., 2009, vol. 284, # 44, p. 30547 - 30555 | PeerJ, 2018, vol. 2018, # 6 | Vet. Parasitol., 2019, vol. 267, p. 54 - 59 | World J. Pediatr., 2023, vol. 19, # 1, p. 68 - 75 | World J. Pediatr., 2023, vol. 19, # 1, p. 68 - 75

>  <Main tar all>
Nav1.5 pX=8.0 | Nav1.5 pX=8.0 | Odorant receptor (Or65) pX=7.1 | Odorant receptor (Orco) pX=7.1 | Olfactory receptor 73 pX=7.0 | Olfactory receptor 1 (Apis cerana) pX=6.99 | acetylcholinesterase (Cartwright blood group) pX=6.98 | Albumin pX=6.61 | Serum albumin pX=6.61

$$$$
Tolazoline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.17 0.4175 0 0
M  V30 3 C 5.17 -1.1225 0 0
M  V30 4 N 6.4159 -2.0277 0 0
M  V30 5 C 5.94 -3.4923 0 0
M  V30 6 C 4.4 -3.4923 0 0
M  V30 7 N 3.9241 -2.0277 0 0
M  V30 8 C 6.5037 1.1875 0 0
M  V30 9 C 6.5037 2.7275 0 0
M  V30 10 C 7.8374 3.4975 0 0
M  V30 11 C 9.171 2.7275 0 0
M  V30 12 C 9.171 1.1875 0 0
M  V30 13 C 7.8374 0.4175 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 3 7
M  V30 7 1 2 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255415487

>  <MW>
196.077

>  <MW (desalted)>
160.216

>  <ClogP>
2.652

>  <logS>
-1.66

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.39

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  6.9  | Kb (antagonist dissociation constant)  0.162 ?M | pKi  6.74  | pKi  6.7  | pKi  6.64  | pKi  5.96  | IC50  2.1E-06 M | pKi  5.54  | pA2  5.41

>  <CAS>
59-97-2

>  <Description>
Tolazoline HCl is a competitive alpha1- and alpha2-adrenergic receptor antagonist. It is used in veterinary medicine as reversal agent for the sedative effects of alpha2-adrenergic receptor.

>  <EBC_ID>
EBC-03430

>  <IUPAC Name>
2-benzyl-4,5-dihydro-1H-imidazole hydrochloride

>  <Main Tar all refs>
BR. J. PHARMACOL., 1997, vol. 121, # 8, p. 1721 - 1729 | J. PHARMACOL. EXP. THER., 1979, vol. 211, # 1, p. 74 - 79 | Bioorg. Med. Chem., 2001, vol. 9, # 3, p. 585 - 592 | BIOORG. MED. CHEM., 1997, vol. 5, # 5, p. 833 - 841 | Bioorg. Med. Chem., 2001, vol. 9, # 3, p. 585 - 592 | BR. J. PHARMACOL., 1997, vol. 121, # 8, p. 1721 - 1729 | MOL. PHARMACOL., 1981, vol. 20, # 2, p. 295 - 301 | BR. J. PHARMACOL., 1997, vol. 121, # 8, p. 1721 - 1729 | J. MED. CHEM., 1984, vol. 27, # 4, p. 495 - 503

>  <Main tar all>
?2A-adrenoceptor pX=6.9 | ?-adrenoceptor pX=6.79 | ?2-adrenoceptor pX=6.74 | Imidazoline 2 receptor pX=6.7 | Nischarin pX=6.64 | ?2B-adrenoceptor pX=5.96 | ?1-adrenoceptor pX=5.68 | ?2C-adrenoceptor pX=5.54 | ?1-adrenoceptor pX=5.41

$$$$
Lithium citrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Li -7.6447 -0.2063 0 0 CHG=1
M  V30 2 Li 1.691 5.1837 0 0 CHG=1
M  V30 3 Li 1.54 0 0 0 CHG=1
M  V30 4 O -3.08 2.6674 0 0
M  V30 5 C -2.31 1.3337 0 0
M  V30 6 C -3.6437 0.5637 0 0
M  V30 7 C -4.9774 1.3337 0 0
M  V30 8 O -4.9774 2.8737 0 0
M  V30 9 O -6.311 0.5637 0 0 CHG=-1
M  V30 10 C -0.9763 2.1037 0 0
M  V30 11 C -0.9763 3.6437 0 0
M  V30 12 O -2.31 4.4137 0 0
M  V30 13 O 0.3574 4.4137 0 0 CHG=-1
M  V30 14 C -1.54 -0 0 0
M  V30 15 O -2.31 -1.3337 0 0
M  V30 16 O 0 0 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 1 6 7
M  V30 4 2 7 8
M  V30 5 1 7 9
M  V30 6 1 5 10
M  V30 7 1 10 11
M  V30 8 2 11 12
M  V30 9 1 11 13
M  V30 10 1 5 14
M  V30 11 2 14 15
M  V30 12 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289798095

>  <MW>
210.052

>  <MW (desalted)>
192.124

>  <ClogP>
-9.716

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
140.62

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 9.9E-05 mM | Ka (association constant) = 1 ?M

>  <CAS>
919-16-4

>  <Description>
Lithium citrate is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.

>  <EBC_ID>
EBC-14506

>  <IUPAC Name>
trilithium(1+) ion 2-hydroxypropane-1,2,3-tricarboxylate

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 573 - 578 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 573 - 578

>  <Main tar all>
carbonic anhydrase 4 pX=7.0 | carbonic anhydrase 1 pX=6.0

$$$$
Aminohippuric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 2.31 0 0
M  V30 2 C -2.6674 3.08 0 0
M  V30 3 C -2.6674 4.62 0 0
M  V30 4 C -1.3337 5.39 0 0
M  V30 5 C 0 4.62 0 0
M  V30 6 C 0 3.08 0 0
M  V30 7 C -1.3337 2.31 0 0
M  V30 8 C 1.3337 5.39 0 0
M  V30 9 O 1.3337 6.93 0 0
M  V30 10 N 2.6674 4.62 0 0
M  V30 11 C 4.001 5.39 0 0
M  V30 12 C 5.3347 4.62 0 0
M  V30 13 O 6.6684 5.39 0 0
M  V30 14 O 5.3347 3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104484866

>  <MW>
194.069

>  <MW (desalted)>
194.187

>  <ClogP>
-0.253

>  <logS>
-1.67

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
92.42

>  <RotBonds>
3

>  <Action on targets>
Substrate

>  <Activity coefficients and valu>
inhibition percentage  90 %

>  <CAS>
61-78-9

>  <Description>
Aminohippuric acid is a hippuric acid derivative injection utilized in the measurement of effective renal plasma flow and functional capacity of the renal excretory system.

>  <EBC_ID>
EBC-03450

>  <IUPAC Name>
2-[(4-aminophenyl)formamido]acetic acid

>  <Main Tar all refs>
Drug Metab. Dispos., 2015, vol. 43, # 12, p. 1847 - 1854

>  <Main tar all>
Organic anion transporter 1 pX=8.95

$$$$
Pyridostigmine bromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0 CHG=-1
M  V30 2 C 4.4 4.1462 0 0
M  V30 3 N 5.7337 3.3762 0 0
M  V30 4 C 7.0674 4.1462 0 0
M  V30 5 C 5.7337 1.8362 0 0
M  V30 6 O 4.4 1.0662 0 0
M  V30 7 O 7.0674 1.0662 0 0
M  V30 8 C 7.0674 -0.4738 0 0
M  V30 9 C 8.401 -1.2438 0 0
M  V30 10 C 8.401 -2.7838 0 0
M  V30 11 C 7.0674 -3.5538 0 0
M  V30 12 N 5.7337 -2.7838 0 0 CHG=1
M  V30 13 C 4.4 -3.5538 0 0
M  V30 14 C 5.7337 -1.2438 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 1 12 14
M  V30 13 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269171738

>  <MW>
260.016

>  <MW (desalted)>
181.212

>  <ClogP>
-4.264

>  <logS>
-1.03

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
33.42

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
percentage increase Active   | Ki (inhibition constant)  276 nM | IC50  350 nM | IC50 = 360 nM

>  <CAS>
101-26-8

>  <Description>
Pyridostigmine bromide is a cholinesterase inhibitor. It has been used as neuroprotective agents against organophosphate poisoning.

>  <EBC_ID>
EBC-03590

>  <IUPAC Name>
3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium bromide

>  <Main Tar all refs>
Biol. Pharm. Bull., 2017, vol. 40, # 7, p. 1092 - 1100 | J. PHARMACOKINET. BIOPHARM., 1996, vol. 24, # 4, p. 327 - 348 | MedChemComm, 2014, vol. 5, # 11, p. 1729 - 1735 | Bioorg. Med. Chem., 2010, vol. 18, # 13, p. 4687 - 4693

>  <Main tar all>
butyrylcholinesterase pX=7.0 | acetylcholinesterase (Cartwright blood group) pX=6.56 | acetylcholinesterase (Cartwright blood group) pX=6.46 | acetylcholinesterase (Cartwright blood group) pX=6.44

$$$$
Altretamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 4.62 0 0
M  V30 2 N 1.3337 3.85 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 N 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 N 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 N 0 1.54 0 0
M  V30 10 N -1.3337 -0.77 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C -2.6674 0 0 0
M  V30 13 N 4.001 -0.77 0 0
M  V30 14 C 4.001 -2.31 0 0
M  V30 15 C 5.3347 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57931197

>  <MW>
210.159

>  <MW (desalted)>
210.279

>  <ClogP>
1.665

>  <logS>
-2.05

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
48.39

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 > 1 ?M

>  <CAS>
645-05-6

>  <Description>
Altretamine is an antineoplastic agent with antiproliferative activity. It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

>  <EBC_ID>
EBC-03618

>  <IUPAC Name>
N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine

>  <Main Tar all refs>
THE ROCKEFELLER UNIVERSITY - WO2012/83190, 2012, A1

>  <Main tar all>
Odorant receptor 47a pX=6.0

$$$$
Furazolidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.6612 -1.3512 0 0 CHG=-1
M  V30 2 N 4.3276 -2.1212 0 0 CHG=1
M  V30 3 O 2.9939 -1.3512 0 0
M  V30 4 C 4.3276 -3.6612 0 0
M  V30 5 C 5.5734 -4.5664 0 0
M  V30 6 C 5.0976 -6.031 0 0
M  V30 7 C 3.5576 -6.031 0 0
M  V30 8 C 2.6524 -7.2769 0 0
M  V30 9 N 3.2787 -8.6838 0 0
M  V30 10 N 2.3736 -9.9297 0 0
M  V30 11 C 2.8494 -11.3943 0 0
M  V30 12 C 1.6036 -12.2995 0 0
M  V30 13 O 0.3577 -11.3943 0 0
M  V30 14 C 0.8336 -9.9297 0 0
M  V30 15 O -0.0716 -8.6838 0 0
M  V30 16 O 3.0817 -4.5664 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 7 CFG=2
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 10 14
M  V30 15 2 14 15
M  V30 16 1 7 16
M  V30 17 1 4 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57152562

>  <MW>
225.039

>  <MW (desalted)>
225.158

>  <ClogP>
-0.038

>  <logS>
-3.54

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
98.18

>  <RotBonds>
3

>  <CAS>
67-45-8

>  <Description>
Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone and its related free radical products are believed to bind DNA and induce cross-links.

>  <EBC_ID>
EBC-06471

>  <IUPAC Name>
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one

$$$$
Procainamide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -1.4947 0 0
M  V30 3 C 5.7337 -2.2647 0 0
M  V30 4 N 7.0674 -1.4947 0 0
M  V30 5 C 7.0674 0.0453 0 0
M  V30 6 C 8.401 0.8153 0 0
M  V30 7 C 8.401 -2.2647 0 0
M  V30 8 C 9.7347 -1.4947 0 0
M  V30 9 N 11.0684 -2.2647 0 0
M  V30 10 C 12.4021 -1.4947 0 0
M  V30 11 O 13.7358 -2.2647 0 0
M  V30 12 C 12.4021 0.0453 0 0
M  V30 13 C 11.0684 0.8153 0 0
M  V30 14 C 11.0684 2.3553 0 0
M  V30 15 C 12.4021 3.1253 0 0
M  V30 16 N 12.4021 4.6653 0 0
M  V30 17 C 13.7358 2.3553 0 0
M  V30 18 C 13.7358 0.8153 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 4 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 10 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 15 17
M  V30 16 1 17 18
M  V30 17 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104477706

>  <MW>
271.145

>  <MW (desalted)>
235.325

>  <ClogP>
1.423

>  <logS>
-2.74

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
58.36

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3.56 ?M | Ki (inhibition constant)  29.3 ?M | IC50  44.4 ?M | inhibition percentage = 60 %

>  <CAS>
614-39-1

>  <Description>
Procainamide hydrochloride is an anti-arrhythmic agent and is used to treat cardiac arrhythmia; induces rapid block of the batrachotoxin(BTX)-activated sodium channels of the heart muscle and acts as antagonist to long gating closures.

>  <EBC_ID>
EBC-06617

>  <IUPAC Name>
4-amino-N-[2-(diethylamino)ethyl]benzamide hydrochloride

>  <Main Tar all refs>
Xenobiotica, 2008, vol. 38, # 9, p. 1203 - 1218 | Drug Metab. Dispos., 2009, vol. 37, # 5, p. 956 - 961 | Biochim. Biophys. Acta, 1999, vol. 1417, p. 224 | J. Med. Pharm. Chem., 1960, vol. 2, p. 591 - 607

>  <Main tar all>
Organic cation transporter 1 pX=5.45 | carboxylesterase 1 pX=4.53 | Organic cation transporter 2 pX=4.35 | Amine oxidase [flavin-containing] pX=4.18

$$$$
Brimonidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 N 0 -3.08 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 N -2.7405 -2.9364 0 0
M  V30 7 C -3.771 -1.7919 0 0
M  V30 8 C -3.001 -0.4583 0 0
M  V30 9 N -1.4947 -0.7784 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 C 2.6674 0 0 0
M  V30 12 C 4.001 -0.77 0 0
M  V30 13 N 5.3347 0 0 0
M  V30 14 C 6.6684 -0.77 0 0
M  V30 15 C 6.6684 -2.31 0 0
M  V30 16 N 5.3347 -3.08 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 2 17
M  V30 19 1 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z608061562

>  <MW>
291.012

>  <MW (desalted)>
292.135

>  <ClogP>
1.486

>  <logS>
-1.95

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
62.2

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
IC50 = 2.4E-06 ?M | IC50 = 2.4E-06 ?M | EC50  6E-05 ?M | EC50  6E-05 ?M | EC50 > 6E-05 ?M

>  <CAS>
59803-98-4

>  <Description>
Brimonidine is an alpha adrenergic receptor agonist. It is used for the treatment of open-angle glaucoma or ocular hypertension to lower intraocular pressure.

>  <EBC_ID>
EBC-06648

>  <IUPAC Name>
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

>  <Main Tar all refs>
J. MED. CHEM., 1984, vol. 27, # 4, p. 495 - 503 | J. MED. CHEM., 1984, vol. 27, # 4, p. 495 - 503 | TACTOGEN - WO2022/10937, 2022, A1 | TECOGEN; TACTOGEN - WO2022/10937, 2022, A1 | TACTOGEN - WO2022/61242, 2022, A1

>  <Main tar all>
?1-adrenoceptor pX=11.6 | ?1-adrenoceptor pX=11.6 | ?2A-adrenoceptor pX=10.2 | ?2A-adrenoceptor pX=10.2 | ?2A-adrenoceptor pX=10.2

$$$$
Methocarbamol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -6.16 0 0
M  V30 2 O 2.6674 -4.62 0 0
M  V30 3 C 1.3337 -3.85 0 0
M  V30 4 C 0 -4.62 0 0
M  V30 5 C -1.3337 -3.85 0 0
M  V30 6 C -1.3337 -2.31 0 0
M  V30 7 C 0 -1.54 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 O 2.6674 -1.54 0 0
M  V30 10 C 4.001 -2.31 0 0
M  V30 11 C 5.3347 -1.54 0 0
M  V30 12 O 5.3347 0 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 O 8.0021 -1.54 0 0
M  V30 15 C 9.3358 -2.31 0 0
M  V30 16 O 10.6694 -1.54 0 0
M  V30 17 N 9.3358 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553984

>  <MW>
241.095

>  <MW (desalted)>
241.241

>  <ClogP>
0.146

>  <logS>
-1.797

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
91.01

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  179 ?M | IC50  179 ?M | pIC50  2.58

>  <CAS>
532-03-6

>  <Description>
Methocarbamol is a CNS depressant. It is an orally bioavailable skeletal muscle relaxant. Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells.

>  <EBC_ID>
EBC-03743

>  <IUPAC Name>
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | J. Med. Chem., 2005, vol. 48, # 16, p. 5154 - 5161

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=3.75 | Organic cation/carnitine transporter 2 pX=3.75 | CYP1A2 pX=2.58

$$$$
Leflunomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -3.08 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 O 3.9132 -5.5252 0 0
M  V30 4 N 3.4374 -6.9898 0 0
M  V30 5 C 1.8974 -6.9898 0 0
M  V30 6 C 1.4215 -5.5252 0 0
M  V30 7 C -0.0432 -5.0493 0 0
M  V30 8 O -0.3633 -3.543 0 0
M  V30 9 N -1.1876 -6.0798 0 0
M  V30 10 C -2.6522 -5.6039 0 0
M  V30 11 C -3.7967 -6.6343 0 0
M  V30 12 C -5.2613 -6.1585 0 0
M  V30 13 C -5.5815 -4.6521 0 0
M  V30 14 C -4.437 -3.6216 0 0
M  V30 15 C -2.9724 -4.0975 0 0
M  V30 16 C -7.0461 -4.1762 0 0
M  V30 17 F -8.5107 -3.7003 0 0
M  V30 18 F -6.5702 -2.7116 0 0
M  V30 19 F -7.522 -5.6408 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 1 13 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z228668542

>  <MW>
270.062

>  <MW (desalted)>
270.207

>  <ClogP>
2.324

>  <logS>
-3.1

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
55.13

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 9 nM | IC50  0.2 ?M

>  <CAS>
75706-12-6

>  <Description>
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase. It is used as an immunosuppressant agent.

>  <EBC_ID>
EBC-08359

>  <IUPAC Name>
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide

>  <Main Tar all refs>
J. MED. CHEM., 1996, vol. 39, # 23, p. 4608 - 4621 | Clin. Cancer Res., 1997, vol. 3, # 7, p. 1167 - 1177

>  <Main tar all>
Dihydroorotate dehydrogenase (quinone), mitochondrial pX=8.05 | platelet derived growth factor receptor beta pX=6.7

$$$$
Desipramine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.1598 0 0
M  V30 3 N 5.7337 0.3898 0 0
M  V30 4 C 7.0674 1.1598 0 0
M  V30 5 C 8.401 0.3898 0 0
M  V30 6 C 9.7347 1.1598 0 0
M  V30 7 N 11.0684 0.3898 0 0
M  V30 8 C 12.3408 1.2573 0 0
M  V30 9 C 11.9981 2.7587 0 0
M  V30 10 C 13.127 3.8062 0 0
M  V30 11 C 14.5986 3.3523 0 0
M  V30 12 C 14.9413 1.8509 0 0
M  V30 13 C 13.8124 0.8034 0 0
M  V30 14 C 14.375 -0.6301 0 0
M  V30 15 C 13.605 -1.9638 0 0
M  V30 16 C 12.0822 -2.1933 0 0
M  V30 17 C 11.7395 -3.6947 0 0
M  V30 18 C 10.2679 -4.1487 0 0
M  V30 19 C 9.139 -3.1012 0 0
M  V30 20 C 9.4817 -1.5998 0 0
M  V30 21 C 10.9533 -1.1459 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 7 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2106607416

>  <MW>
302.155

>  <MW (desalted)>
266.381

>  <ClogP>
4.468

>  <logS>
-4.154

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
15.27

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.65 nM | pKi  8.93 | IC50  2.5 nM

>  <CAS>
58-28-6

>  <Description>
Desipramine is a tricyclic antidepressant that selectively blocks reuptake of norepinephrine from the neuronal synapse. It also inhibits serotonin reuptake, but to a lesser extent compared to tertiary amine TCAs such as imipramine.

>  <EBC_ID>
EBC-28045

>  <IUPAC Name>
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine hydrochloride

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1987, vol. 242, # 1, p. 74 - 84 | Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | BIOORG. MED. CHEM. LETT., 1997, vol. 7, # 20, p. 2559 - 2564

>  <Main tar all>
NET pX=9.19 | NET pX=8.93 | SERT pX=8.6

$$$$
Flumazenil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 15.0701 -1.2918 0 0
M  V30 2 C 13.7207 -2.0339 0 0
M  V30 3 O 12.4033 -1.2363 0 0
M  V30 4 C 11.0539 -1.9784 0 0
M  V30 5 O 11.0219 -3.5181 0 0
M  V30 6 C 9.7365 -1.1809 0 0
M  V30 7 N 9.6075 0.3537 0 0
M  V30 8 C 8.1081 0.7052 0 0
M  V30 9 N 7.3105 -0.6122 0 0
M  V30 10 C 8.317 -1.7778 0 0
M  V30 11 C 8.0331 -3.2915 0 0
M  V30 12 N 6.6728 -4.0133 0 0
M  V30 13 C 6.7329 -5.5521 0 0
M  V30 14 C 5.2603 -3.3998 0 0
M  V30 15 O 4.0946 -4.4062 0 0
M  V30 16 C 4.8593 -1.9129 0 0
M  V30 17 C 3.3287 -1.743 0 0
M  V30 18 C 2.7105 -0.3325 0 0
M  V30 19 F 1.1799 -0.1626 0 0
M  V30 20 C 3.623 0.9081 0 0
M  V30 21 C 5.1536 0.7382 0 0
M  V30 22 C 5.7717 -0.6723 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 16 22
M  V30 24 1 9 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610479

>  <MW>
303.102

>  <MW (desalted)>
303.288

>  <ClogP>
1.291

>  <logS>
-3.34

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
64.43

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Allosteric Modulator

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.14 nM | Kd (dissociation constant)  0.14 nM | Ki (inhibition constant)  0.14 nM | Kd (dissociation constant)  0.36 nM | Kd (dissociation constant)  0.36 nM | Ki (inhibition constant)  0.00038 ?M | Kd (dissociation constant)  0.42 nM | Kd (dissociation constant)  0.42 nM | Kd (dissociation constant) = 0.45 nM | Kd (dissociation constant) = 0.45 nM | Ki (inhibition constant)  0.5 - 0.9 nM | Ki (inhibition constant)  0.5 nM | concentration (parameter) = 0.5 nM | Ki (inhibition constant)  0.6 nM | Kd (dissociation constant)  0.74 nM | Ki (inhibition constant)  0.9 nM | Ki (inhibition constant)  0.9 nM | IC50  1.232 nM | stimulation rate  105 %

>  <CAS>
78755-81-4

>  <Description>
Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. It is  is used for the complete or partial reversal of the sedative effects caused by benzodiazepines in various clinical settings, such as induced general anesthesia for diagnostic and therapeutic procedures.

>  <EBC_ID>
EBC-06995

>  <IUPAC Name>
ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate

>  <Main Tar all refs>
Eur. J. Pharmacol., 1998, vol. 354, # 2-3, p. 283 - 287 | Eur. J. Pharmacol., 1998, vol. 354, # 2-3, p. 283 - 287 | Mol. Pharmacol., 1998, vol. 54, # 6, p. 1097 - 1105 | ANIONA APS - WO2014/1280, 2014, A1 | ANIONA APS - WO2014/1280, 2014, A1 | Curr. Top. Med. Chem., 2012, vol. 12, # 4, p. 286 - 311 | PROC. NATL. ACAD. SCI. U. S. A., 1992, vol. 89, # 14, p. 6378 - 6382 | J. Neurochem., 2001, vol. 77, # 2, p. 445 - 451 | J. Med. Chem., 2013, vol. 56, # 3, p. 593 - 624 | J. Med. Chem., 2013, vol. 56, # 3, p. 593 - 624 | UWM RESEARCH FOUNDATION INC - WO2019/70910, 2019, A1 | J. MED. CHEM., 1994, vol. 37, # 26, p. 4576 - 4580 | Br. J. Pharmacol., 2005, vol. 146, # 6, p. 817 - 825 | J. MED. CHEM., 1994, vol. 37, # 26, p. 4576 - 4580 | Eur. J. Pharmacol., 2002, vol. 437, # 1-2, p. 31 - 39 | J. Med. Chem., 2007, vol. 50, # 7, p. 1627 - 1634 | J. Med. Chem., 2000, vol. 43, # 1, p. 96 - 102 | J. Med. Chem., 2020, vol. 63, # 13, p. 7033 - 7051 | Mol. Pharmacol., 1998, vol. 54, # 6, p. 1097 - 1105

>  <Main tar all>
GABAA receptor ?1 subunit pX=9.85 | GABAA receptor ?2 subunit pX=9.85 | GABAA receptor ?2 subunit pX=9.85 | GABAA receptor pX=9.44 | GABAA receptor pX=9.44 | Peripheral-type benzodiazepine receptor-associated protein 1 pX=9.42 | GABAA receptor ?2L subunit pX=9.38 | GABAA receptor ?1 subunit pX=9.38 | GABAA receptor ?3 subunit pX=9.35 | GABAA receptor ?3 subunit pX=9.35 | GABAA receptor ?2 subunit pX=9.3 | GABAA receptor ?5 subunit pX=9.3 | GABAA receptor ? subunit pX=9.3 | GABAA receptor ?4 subunit pX=9.22 | GABAA receptor ?2s subunit pX=9.13 | GABA receptor pX=9.05 | GABAA receptor pX=9.05 | GABAA receptor pX=8.91 | GABAA receptor ? subunit pX=8.49

$$$$
Piroxicam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 0 0 0 0
M  V30 5 O -1.3337 -0.77 0 0
M  V30 6 N 0 1.54 0 0
M  V30 7 C -1.3337 2.31 0 0
M  V30 8 C -2.6674 1.54 0 0
M  V30 9 C -4.001 2.31 0 0
M  V30 10 C -4.001 3.85 0 0
M  V30 11 C -2.6674 4.62 0 0
M  V30 12 N -1.3337 3.85 0 0
M  V30 13 C 2.6674 0 0 0
M  V30 14 O 2.6674 1.54 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 21 S 2.6674 -3.08 0 0
M  V30 22 O 3.3903 -4.4397 0 0
M  V30 23 O 1.9444 -4.4397 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5 CFG=2
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 3 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 1 2 21
M  V30 24 2 21 22
M  V30 25 2 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1137167677

>  <MW>
331.063

>  <MW (desalted)>
331.346

>  <ClogP>
2.438

>  <logS>
-3.23

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
99.6

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 < 30 ?M | IC50 = 0.414 mM

>  <CAS>
36322-90-4

>  <Description>
Piroxicam is an NSAID used to treat the symptoms of osteoarthritis and rheumatoid arthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis.

>  <EBC_ID>
EBC-11158

>  <IUPAC Name>
3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione

>  <Main Tar all refs>
Br. J. Pharmacol., 2007, vol. 152, # 6, p. 838 - 854 | J. Enzyme Inhib. Med. Chem., 2006, vol. 21, # 2, p. 231 - 234

>  <Main tar all>
myeloperoxidase pX=4.52 | catalase pX=3.38

$$$$
Indapamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.3196 -1.3028 0 0
M  V30 2 C 1.2204 -1.3028 0 0
M  V30 3 C 2.1256 -0.0569 0 0
M  V30 4 C 3.5902 -0.5328 0 0
M  V30 5 C 4.9239 0.2372 0 0
M  V30 6 C 6.2576 -0.5328 0 0
M  V30 7 C 6.2576 -2.0728 0 0
M  V30 8 C 4.9239 -2.8428 0 0
M  V30 9 C 3.5902 -2.0728 0 0
M  V30 10 N 2.1256 -2.5487 0 0
M  V30 11 N 1.6497 -4.0133 0 0
M  V30 12 C 2.6802 -5.1578 0 0
M  V30 13 O 4.1865 -4.8376 0 0
M  V30 14 C 2.2043 -6.6224 0 0
M  V30 15 C 3.2348 -7.7669 0 0
M  V30 16 C 2.7589 -9.2315 0 0
M  V30 17 C 1.2525 -9.5517 0 0
M  V30 18 Cl 0.7766 -11.0163 0 0
M  V30 19 C 0.2221 -8.4072 0 0
M  V30 20 C 0.698 -6.9426 0 0
M  V30 21 S -1.2843 -8.7274 0 0
M  V30 22 O -2.7906 -9.0476 0 0
M  V30 23 O -1.6045 -7.2211 0 0
M  V30 24 N -0.9641 -10.2338 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 17 19
M  V30 21 1 19 20
M  V30 22 2 14 20
M  V30 23 1 19 21
M  V30 24 2 21 22
M  V30 25 2 21 23
M  V30 26 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485351

>  <MW>
365.06

>  <MW (desalted)>
365.835

>  <ClogP>
2.957

>  <logS>
-4.767

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
92.5

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.23 nM | Ki (inhibition constant)  0.23 nM

>  <CAS>
26807-65-8

>  <Description>
Indapamide is a non-thiazide sulphonamide diuretic compound that blocks delayed-rectifier potassium currents, generally used in the treatment of hypertension, as well as decompensated cardiac failure. Carbonic anhydrase inhibitor

>  <EBC_ID>
EBC-06876

>  <IUPAC Name>
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide

>  <Main Tar all refs>
Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328

>  <Main tar all>
carbonic anhydrase 3 pX=9.64 | carbonic anhydrase 7 pX=9.64

$$$$
Diphenpyramide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.0021 -3.08 0 0
M  V30 2 C 6.6684 -2.31 0 0
M  V30 3 C 5.3347 -3.08 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 6.6684 -5.39 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 C 5.3347 -7.7 0 0
M  V30 8 C 4.001 -6.93 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 C 5.3347 -9.24 0 0
M  V30 11 C 6.6684 -10.01 0 0
M  V30 12 C 6.6684 -11.55 0 0
M  V30 13 C 5.3347 -12.32 0 0
M  V30 14 C 4.001 -11.55 0 0
M  V30 15 C 4.001 -10.01 0 0
M  V30 16 N 6.6684 -0.77 0 0
M  V30 17 C 8.0021 0 0 0
M  V30 18 C 8.0021 1.54 0 0
M  V30 19 C 9.3358 2.31 0 0
M  V30 20 C 10.6694 1.54 0 0
M  V30 21 C 10.6694 -0 0 0
M  V30 22 N 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 1 2 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z60744762

>  <MW>
288.343

>  <MW (desalted)>
288.343

>  <ClogP>
3.918

>  <logS>
-4.874

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
41.99

>  <RotBonds>
4

>  <CAS>
51484-40-3

>  <Description>
Diphenpyramide  is a non-steroidal anti-inflammatory compound, that has been studied in degenerative and inflammatory arthropathies treatment. Diphenpyramide inhibits the synthesis of inflammatory prostaglandins and antagonizes the mediators of inflammation, but does not affect platelet aggregation or blood clotting.

>  <EBC_ID>
EBC-13421

>  <IUPAC Name>
2-{[1,1'-biphenyl]-4-yl}-N-(pyridin-2-yl)acetamide

$$$$
Fostamatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 -9.24 0 0
M  V30 2 O -8.0021 -7.7 0 0
M  V30 3 C -6.6684 -6.93 0 0
M  V30 4 C -6.6684 -5.39 0 0
M  V30 5 C -5.3347 -4.62 0 0
M  V30 6 N -5.3347 -3.08 0 0
M  V30 7 C -4.001 -2.31 0 0
M  V30 8 N -4.001 -0.77 0 0
M  V30 9 C -2.6674 0 0 0
M  V30 10 C -1.3337 -0.77 0 0
M  V30 11 F 0 -0 0 0
M  V30 12 C -1.3337 -2.31 0 0
M  V30 13 N 0 -3.08 0 0
M  V30 14 C 1.3337 -2.31 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 O 5.3347 0 0 0
M  V30 19 C 6.6684 -0.77 0 0
M  V30 20 C 7.1951 0.6771 0 0
M  V30 21 C 8.185 -1.0374 0 0
M  V30 22 C 6.6684 -2.31 0 0
M  V30 23 O 8.0021 -3.08 0 0
M  V30 24 N 5.3347 -3.08 0 0
M  V30 25 C 5.3347 -4.62 0 0
M  V30 26 O 6.6684 -5.39 0 0
M  V30 27 P 6.6684 -6.93 0 0
M  V30 28 O 6.6684 -8.47 0 0
M  V30 29 O 8.2084 -6.93 0 0
M  V30 30 O 5.1284 -6.93 0 0
M  V30 31 C 4.001 -2.31 0 0
M  V30 32 N 2.6674 -3.08 0 0
M  V30 33 N -2.6674 -3.08 0 0
M  V30 34 C -4.001 -5.39 0 0
M  V30 35 C -4.001 -6.93 0 0
M  V30 36 O -2.6674 -7.7 0 0
M  V30 37 C -2.6674 -9.24 0 0
M  V30 38 C -5.3347 -7.7 0 0
M  V30 39 O -5.3347 -9.24 0 0
M  V30 40 C -6.6684 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 1 19 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 27 29
M  V30 29 1 27 30
M  V30 30 1 24 31
M  V30 31 2 17 31
M  V30 32 1 31 32
M  V30 33 2 14 32
M  V30 34 1 12 33
M  V30 35 2 7 33
M  V30 36 1 5 34
M  V30 37 2 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 35 38
M  V30 41 2 3 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801948

>  <MW>
580.148

>  <MW (desalted)>
580.46

>  <ClogP>
2.524

>  <logS>
-4.561

>  <HBD>
4

>  <HBA>
13

>  <TPSA>
186.72

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.005 ?M | IC50  8 nM | IC50 = 37 nM | IC50  0.05 ?M | IC50 = 63 nM | IC50 = 63 nM | decrease rate Active

>  <CAS>
901119-35-5

>  <Description>
Fostamatinib is a spleen tyrosine kinase inhibitor. It is used to treat chronic immune thrombocytopenia after attempting one other treatment.

>  <EBC_ID>
EBC-27347

>  <IUPAC Name>
{[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-4-yl]methoxy}phosphonic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2011, vol. 18, # 2, p. 162 - 175 | Mol. Cells, 2018, vol. 41, # 6, p. 545 - 552 | Drugs Future, 2011, vol. 36, # 4, p. 273 - 280 | Drug Metab. Dispos., 2016, vol. 44, # 3, p. 398 - 408 | Drugs Future, 2011, vol. 36, # 4, p. 273 - 280 | Drugs Future, 2011, vol. 36, # 4, p. 273 - 280 | GENERATION BIO CO - US2022/288231, 2022, A1

>  <Main tar all>
ret proto-oncogene pX=8.3 | spleen associated tyrosine kinase pX=8.1 | LCK proto-oncogene, Src family tyrosine kinase pX=7.43 | ABCG2 pX=7.3 | LYN proto-oncogene, Src family tyrosine kinase pX=7.2 | fms related receptor tyrosine kinase 3 pX=7.2 | protein tyrosine kinase 2 pX=7.0

$$$$
Oxyphenisatin acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.789 -9.744 0 0
M  V30 2 C 6.1627 -8.3371 0 0
M  V30 3 O 7.0679 -7.0912 0 0
M  V30 4 O 4.6311 -8.1762 0 0
M  V30 5 C 4.0047 -6.7693 0 0
M  V30 6 C 2.4732 -6.6083 0 0
M  V30 7 C 1.8468 -5.2015 0 0
M  V30 8 C 2.752 -3.9556 0 0
M  V30 9 C 4.2836 -4.1165 0 0
M  V30 10 C 4.9099 -5.5234 0 0
M  V30 11 C 2.1256 -2.5487 0 0
M  V30 12 C 1.2204 -1.3028 0 0
M  V30 13 O -0.3196 -1.3028 0 0
M  V30 14 N 2.1256 -0.0569 0 0
M  V30 15 C 3.5902 -0.5328 0 0
M  V30 16 C 4.9239 0.2372 0 0
M  V30 17 C 6.2576 -0.5328 0 0
M  V30 18 C 6.2576 -2.0728 0 0
M  V30 19 C 4.9239 -2.8428 0 0
M  V30 20 C 3.5902 -2.0728 0 0
M  V30 21 C 0.7919 -3.3187 0 0
M  V30 22 C 0.7919 -4.8587 0 0
M  V30 23 C -0.5417 -5.6287 0 0
M  V30 24 C -1.8754 -4.8587 0 0
M  V30 25 O -3.2091 -5.6287 0 0
M  V30 26 C -4.5428 -4.8587 0 0
M  V30 27 O -5.8765 -5.6287 0 0
M  V30 28 C -4.5428 -3.3187 0 0
M  V30 29 C -1.8754 -3.3187 0 0
M  V30 30 C -0.5417 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 11 20
M  V30 23 1 11 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 26 28
M  V30 31 2 24 29
M  V30 32 1 29 30
M  V30 33 2 21 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56791187

>  <MW>
401.411

>  <MW (desalted)>
401.411

>  <ClogP>
2.521

>  <logS>
-4.54

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
81.7

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) <= 1 ?M

>  <CAS>
115-33-3

>  <Description>
Oxyphenisatin acetate inhibits the growth of the breast cancer cell lines MCF7, T47D, HS578T, and MDA-MB-468.

>  <EBC_ID>
EBC-26955

>  <IUPAC Name>
4-{3-[4-(acetyloxy)phenyl]-2-oxo-2,3-dihydro-1H-indol-3-yl}phenyl acetate

>  <Main Tar all refs>
UNIVERSITY OF PENNSYLVANIA - WO2006/83869, 2006, A2

>  <Main tar all>
tumor necrosis factor receptor 1 pX=6.0

$$$$
Sucrose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.4536 -8.0384 0 0
M  V30 2 C -2.08 -6.6316 0 0
M  V30 3 C -1.1748 -5.3857 0 0 CFG=1
M  V30 4 O -1.6507 -3.9211 0 0
M  V30 5 C -0.4048 -3.0159 0 0 CFG=1
M  V30 6 C -1.4353 -1.8714 0 0
M  V30 7 O -2.9416 -2.1916 0 0
M  V30 8 O 0.6256 -1.8714 0 0
M  V30 9 C 0.1498 -0.4068 0 0 CFG=1
M  V30 10 O -1.3566 -0.0866 0 0
M  V30 11 C -1.8325 1.378 0 0 CFG=2
M  V30 12 C -3.3388 1.6982 0 0
M  V30 13 O -4.3693 0.5537 0 0
M  V30 14 C -0.802 2.5224 0 0 CFG=1
M  V30 15 O -1.2779 3.9871 0 0
M  V30 16 C 0.7043 2.2023 0 0 CFG=2
M  V30 17 O 1.7348 3.3467 0 0
M  V30 18 C 1.1802 0.7376 0 0 CFG=1
M  V30 19 O 2.6866 0.4174 0 0
M  V30 20 C 0.8411 -3.9211 0 0 CFG=1
M  V30 21 O 2.3057 -3.4452 0 0
M  V30 22 C 0.3652 -5.3857 0 0 CFG=2
M  V30 23 O 1.2704 -6.6316 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 5 8 CFG=1
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 12 13
M  V30 13 1 14 11
M  V30 14 1 14 15 CFG=1
M  V30 15 1 14 16
M  V30 16 1 16 17 CFG=3
M  V30 17 1 16 18
M  V30 18 1 18 9
M  V30 19 1 18 19 CFG=1
M  V30 20 1 20 5
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 22 3
M  V30 24 1 22 23 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1589255958

>  <MW>
342.296

>  <MW (desalted)>
342.296

>  <ClogP>
-3.087

>  <logS>
0.42

>  <HBD>
8

>  <HBA>
11

>  <TPSA>
189.53

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
inhibition percentage  48 % | activation percentage  84.13 % | activation percentage  80.86 %

>  <CAS>
57-50-1

>  <Description>
Sucrose is a disaccharide which is composed of  glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.

>  <EBC_ID>
EBC-03884

>  <IUPAC Name>
(2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

>  <Main Tar all refs>
SAINT LOUIS UNIVERSITY - US10329542, 2019, B2 | PROCTER & GAMBLE CO - WO2015/153184, 2015, A1 | PROCTER & GAMBLE CO - WO2015/153184, 2015, A1

>  <Main tar all>
Ribonuclease H1 pX=4.97 | TRPA1 pX=3.72 | TRPV1 pX=3.63

$$$$
Glibenclamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -14.6705 -11.55 0 0
M  V30 2 O -13.3368 -10.78 0 0
M  V30 3 C -13.3368 -9.24 0 0
M  V30 4 C -14.6705 -8.47 0 0
M  V30 5 C -14.6705 -6.93 0 0
M  V30 6 C -13.3368 -6.16 0 0
M  V30 7 Cl -13.3368 -4.62 0 0
M  V30 8 C -12.0031 -6.93 0 0
M  V30 9 C -12.0031 -8.47 0 0
M  V30 10 C -10.6694 -9.24 0 0
M  V30 11 O -10.6694 -10.78 0 0
M  V30 12 N -9.3358 -8.47 0 0
M  V30 13 C -8.0021 -9.24 0 0
M  V30 14 C -6.6684 -8.47 0 0
M  V30 15 C -5.3347 -9.24 0 0
M  V30 16 C -4.001 -8.47 0 0
M  V30 17 C -2.6674 -9.24 0 0
M  V30 18 C -2.6674 -10.78 0 0
M  V30 19 C -4.001 -11.55 0 0
M  V30 20 C -5.3347 -10.78 0 0
M  V30 21 S -1.3337 -11.55 0 0
M  V30 22 O -2.1037 -12.8837 0 0
M  V30 23 O -0.5637 -10.2163 0 0
M  V30 24 N 0 -12.32 0 0
M  V30 25 C 0 -13.86 0 0
M  V30 26 O -1.3337 -14.63 0 0
M  V30 27 N 1.3337 -14.63 0 0
M  V30 28 C 2.6674 -13.86 0 0
M  V30 29 C 2.6674 -12.32 0 0
M  V30 30 C 4.001 -11.55 0 0
M  V30 31 C 5.3347 -12.32 0 0
M  V30 32 C 5.3347 -13.86 0 0
M  V30 33 C 4.001 -14.63 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 3 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 18 21
M  V30 23 2 21 22
M  V30 24 2 21 23
M  V30 25 1 21 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 28 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z277540138

>  <MW>
494.004

>  <MW (desalted)>
494.004

>  <ClogP>
4.239

>  <logS>
-5.927

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
113.6

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  10.19  | IC50 = 0.12 nM | Ki (inhibition constant)  0.25 nM | IC50  0.25 nM | Ki (inhibition constant)  0.25 nM | Kd (dissociation constant) = 0.37 nM | Ki (inhibition constant) = 4.71E-10 M | Ki (inhibition constant) = 0.65 nM | Ki (inhibition constant) = 0.8 nM | IC50  0.00087 ?M | IC50  1.11 nM | IC50 = 1.3 nM

>  <CAS>
10238-21-8

>  <Description>
Glibenclamide is a selective inhibitor of ATP-sensitive K+ channel. It is used in the treatment of type 2 diabetes.

>  <EBC_ID>
EBC-08611

>  <IUPAC Name>
5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamide

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1995, vol. 273, # 2, p. 778 - 786 | Biochem. Pharmacol., 2004, vol. 68, # 5, p. 901 - 910 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332 | Pharmacol. Res., 2019, vol. 141, p. 319 - 330 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332 | Br. J. Pharmacol., 2005, vol. 145, # 7, p. 907 - 915 | J. Pharmacol. Exp. Ther., 2011, vol. 338, # 2, p. 622 - 632 | Bioorg. Med. Chem. Lett., 2013, vol. 23, # 6, p. 1834 - 1838 | Br. J. Pharmacol., 2005, vol. 144, # 4, p. 551 - 557 | Pharmaceuticals, 2023, vol. 16, # 2 | J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540 | VASOPHARM GMBH - WO2004/84906, 2004, A1

>  <Main tar all>
Potassium channel ATP dependent pX=10.2 | ABCC9 pX=9.92 | KATP?channel?SUR1 pX=9.6 | Kir6.1 pX=9.6 | Kir6.2 pX=9.6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=9.43 | KATP?channel pX=9.33 | Kir6.2 pX=9.19 | Beta-Cell Katp Channel pX=9.1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=9.06 | sepiapterin reductase pX=8.95 | Kir6.2 pX=8.89

$$$$
Palbociclib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 C 0 -0 0 0
M  V30 3 O 0 1.54 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 2.6674 0 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 4.001 -0.77 0 0
M  V30 8 C 5.3347 0 0 0
M  V30 9 N 6.6684 -0.77 0 0
M  V30 10 C 6.6684 -2.31 0 0
M  V30 11 N 8.0021 -3.08 0 0
M  V30 12 C 8.0021 -4.62 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 9.3358 -6.93 0 0
M  V30 15 C 8.0021 -7.7 0 0
M  V30 16 C 6.6684 -6.93 0 0
M  V30 17 N 6.6684 -5.39 0 0
M  V30 18 N 8.0021 -9.24 0 0
M  V30 19 C 9.3358 -10.01 0 0
M  V30 20 C 9.3358 -11.55 0 0
M  V30 21 N 8.0021 -12.32 0 0
M  V30 22 C 6.6684 -11.55 0 0
M  V30 23 C 6.6684 -10.01 0 0
M  V30 24 N 5.3347 -3.08 0 0
M  V30 25 C 4.001 -2.31 0 0
M  V30 26 N 2.6674 -3.08 0 0
M  V30 27 C 2.6674 -4.62 0 0
M  V30 28 C 3.9132 -5.5252 0 0
M  V30 29 C 3.4374 -6.9898 0 0
M  V30 30 C 1.8974 -6.9898 0 0
M  V30 31 C 1.4215 -5.5252 0 0
M  V30 32 C 1.3337 -2.31 0 0
M  V30 33 O 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 18 23
M  V30 25 2 10 24
M  V30 26 1 24 25
M  V30 27 2 7 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 27 31
M  V30 35 1 26 32
M  V30 36 1 4 32
M  V30 37 2 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216894329

>  <MW>
447.533

>  <MW (desalted)>
447.533

>  <ClogP>
2.345

>  <logS>
-4.853

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
103.35

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
percentage decrease Active   | percentage decrease Active   | IC50  0.14 nM | Ki (inhibition constant)  0.2 nM | inhibition rate Active   | IC50  2.2 nM | IC50  2.43 nM | decrease rate of viability Active   | IC50  2.43 nM | decrease rate of viability Active   | IC50  3 nM

>  <CAS>
571190-30-2

>  <Description>
Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer.

>  <EBC_ID>
EBC-17116

>  <IUPAC Name>
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one

>  <Main Tar all refs>
MERRIMACK PHARMACEUTICALS INC - WO2017/160990, 2017, A1 | MERRIMACK PHARMACEUTICALS INC - WO2017/160990, 2017, A1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - WO2021/150945, 2021, A1 | J. Med. Chem., 2021, vol. 64, # 13, p. 9056 - 9077 | Cell Death Dis., 2022, vol. 13, # 2 | CHENGDU CYNOGEN BIO PHARMACEUTICAL TECHNOLOGY - EP3992196, 2022, A1 | SINO BIOPHARMACEUTICAL LIMITED - US2019/194168, 2019, A1 | SYROS PHARMACEUTICALS INC - WO2018/231859, 2018, A1 | SINO BIOPHARMACEUTICAL LIMITED - US2019/194168, 2019, A1 | SYROS PHARMACEUTICALS INC - WO2018/231859, 2018, A1 | VIROSTATICS - WO2020/202232, 2020, A1

>  <Main tar all>
cyclin dependent kinase 4 pX=10.0 | cyclin dependent kinase 6 pX=10.0 | Cyclin-D1-1 pX=9.85 | G1/S-specific cyclin-D1 pX=9.7 | proteasome 20S subunit alpha 1 pX=9.0 | Cyclin-D3-1 pX=8.66 | Cyclin-A2 pX=8.61 | Cyclin-dependent kinase 4 homolog pX=8.61 | cyclin dependent kinase 2 pX=8.61 | cyclin dependent kinase 7 pX=8.61 | Cyclin D/Cdk6 complex pX=8.52

$$$$
Aminosalicylic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 O 2.6674 -3.08 0 0
M  V30 8 O -0 -3.08 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 5 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 2 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z90121065

>  <MW>
153.043

>  <MW (desalted)>
153.135

>  <ClogP>
1.056

>  <logS>
-0.95

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50  0.02 ?M

>  <CAS>
65-49-6

>  <Description>
Aminosalicylic acid is an aminosalicylate drug used to induce remission in ulcerative colitis. Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli.

>  <EBC_ID>
EBC-03237

>  <IUPAC Name>
4-amino-2-hydroxybenzoic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2019, vol. 63, # 10

>  <Main tar all>
Trehalose?monomycolate?exporter?MmpL3 pX=7.7

$$$$
Palmitoylethanolamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 15.8126 10.6694 0 0
M  V30 2 C 17.1463 11.4394 0 0
M  V30 3 C 18.48 10.6694 0 0
M  V30 4 C 19.8137 11.4394 0 0
M  V30 5 C 21.1474 10.6694 0 0
M  V30 6 C 22.481 11.4394 0 0
M  V30 7 C 23.8147 10.6694 0 0
M  V30 8 C 25.1484 11.4394 0 0
M  V30 9 C 26.4821 10.6694 0 0
M  V30 10 C 27.8158 11.4394 0 0
M  V30 11 C 29.1494 10.6694 0 0
M  V30 12 C 30.4831 11.4394 0 0
M  V30 13 C 31.8168 10.6694 0 0
M  V30 14 C 33.1505 11.4394 0 0
M  V30 15 C 34.4841 10.6694 0 0
M  V30 16 C 35.8178 11.4394 0 0
M  V30 17 O 35.8178 12.9794 0 0
M  V30 18 N 37.1515 10.6694 0 0
M  V30 19 C 38.4852 11.4394 0 0
M  V30 20 C 39.8189 10.6694 0 0
M  V30 21 O 41.1525 11.4394 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242151306

>  <MW>
299.282

>  <MW (desalted)>
299.492

>  <ClogP>
6.001

>  <logS>
-6.58

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
16

>  <Action on targets>
Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
stimulation rate Active   | IC50 = 1 nM | Ki (inhibition constant)  0.001 ?M

>  <CAS>
544-31-0

>  <Description>
Palmitoylethanolamide is an endogenous CB2 cannabinoid receptor agonist and selective GPR55 agonist.

>  <EBC_ID>
EBC-47502

>  <IUPAC Name>
N-(2-hydroxyethyl)hexadecanamide

>  <Main Tar all refs>
Br. J. Pharmacol., 2013, vol. 170, # 5, p. 978 - 990 | Curr. Med. Chem., 2002, vol. 9, # 6, p. 663 - 674 | INNOVET ITALIA; CONSIGLIO NAZIONALE DELLE RICHERCHE - EP1115392, 2002, B1

>  <Main tar all>
GPR55 pX=10.0 | CB1 receptor pX=9.0 | CB2 receptor pX=9.0

$$$$
Nilutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3641 -1.1656 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 0.3032 -1.1656 0 0
M  V30 4 N 2.5796 -3.2152 0 0
M  V30 5 C 2.1037 -4.6798 0 0
M  V30 6 O 3.0089 -5.9257 0 0
M  V30 7 N 0.5637 -4.6798 0 0
M  V30 8 C 0.0878 -3.2152 0 0
M  V30 9 O -1.3768 -2.7393 0 0
M  V30 10 C -0.3415 -5.9257 0 0
M  V30 11 C 0.2849 -7.3326 0 0
M  V30 12 C -0.6203 -8.5784 0 0
M  V30 13 C -2.1519 -8.4175 0 0
M  V30 14 N -3.0571 -9.6634 0 0 CHG=1
M  V30 15 O -2.4307 -11.0702 0 0
M  V30 16 O -4.5886 -9.5024 0 0 CHG=-1
M  V30 17 C -2.7783 -7.0106 0 0
M  V30 18 C -1.8731 -5.7647 0 0
M  V30 19 C -4.3098 -6.8496 0 0
M  V30 20 F -5.8414 -6.6887 0 0
M  V30 21 F -4.1489 -5.3181 0 0
M  V30 22 F -4.4708 -8.3812 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 2 8 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 2 13 17
M  V30 18 1 17 18
M  V30 19 2 10 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 19 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242164525

>  <MW>
317.062

>  <MW (desalted)>
317.221

>  <ClogP>
1.708

>  <logS>
-3.757

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
92.55

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  9 nM

>  <CAS>
63612-50-0

>  <Description>
Nilutamide is a non-steroidal antiandrogen that is an antagonist of the androgen receptor. It is indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs.

>  <EBC_ID>
EBC-07883

>  <IUPAC Name>
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione

>  <Main Tar all refs>
J. Med. Chem., 2003, vol. 46, # 24, p. 5258 - 5270

>  <Main tar all>
Androgen receptor pX=8.05

$$$$
Gluconolactone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0 CFG=1
M  V30 4 O 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 O 4.001 -0.77 0 0
M  V30 7 C 1.3337 -0.77 0 0 CFG=2
M  V30 8 O 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0 CFG=1
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0 CFG=2
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 3
M  V30 12 1 11 12 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255427181

>  <MW>
178.048

>  <MW (desalted)>
178.14

>  <ClogP>
-2.229

>  <logS>
0.089

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
107.22

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 8.3 nM

>  <CAS>
90-80-2

>  <Description>
Gluconolactone?is a polyhydroxy acid used in the dissolution of calculi and used as an additive in various drug products to maintain consistency and other characteristics.

>  <EBC_ID>
EBC-03911

>  <IUPAC Name>
(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-one

>  <Main Tar all refs>
Biochem. J., 2001, vol. 353, # 1, p. 117 - 127

>  <Main tar all>
Beta-glucosidase?(gene?abg) pX=8.08

$$$$
Dexamethasone acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.851 -2.6445 0 0
M  V30 2 C 5.2994 -3.1677 0 0 CFG=2
M  V30 3 C 6.574 -2.3035 0 0
M  V30 4 C 7.7898 -3.2487 0 0 CFG=1
M  V30 5 C 9.3058 -2.9776 0 0 CFG=2
M  V30 6 C 9.829 -1.5293 0 0
M  V30 7 C 11.345 -1.2582 0 0
M  V30 8 C 12.3377 -2.4355 0 0
M  V30 9 C 13.8537 -2.1644 0 0
M  V30 10 C 14.8464 -3.3418 0 0
M  V30 11 O 16.3624 -3.0707 0 0
M  V30 12 C 14.3232 -4.7901 0 0
M  V30 13 C 12.8072 -5.0612 0 0
M  V30 14 C 11.8145 -3.8839 0 0 CFG=1
M  V30 15 C 11.2913 -5.3323 0 0
M  V30 16 C 10.2985 -4.155 0 0 CFG=2
M  V30 17 F 10.4097 -5.6909 0 0
M  V30 18 C 9.7753 -5.6034 0 0 CFG=1
M  V30 19 O 10.768 -6.7807 0 0
M  V30 20 C 8.2593 -5.8744 0 0
M  V30 21 C 7.2666 -4.6971 0 0 CFG=1
M  V30 22 C 6.5949 -6.0829 0 0
M  V30 23 C 5.7274 -4.6471 0 0 CFG=2
M  V30 24 O 5.5008 -6.1703 0 0
M  V30 25 C 4.3071 -5.2423 0 0
M  V30 26 O 4.1124 -6.7699 0 0
M  V30 27 C 3.0815 -4.3099 0 0
M  V30 28 O 1.6612 -4.9051 0 0
M  V30 29 C 0.4355 -3.9727 0 0
M  V30 30 O -0.9848 -4.5679 0 0
M  V30 31 C 0.6302 -2.4451 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 16 5
M  V30 18 1 16 17 CFG=3
M  V30 19 1 16 18
M  V30 20 1 18 19 CFG=1
M  V30 21 1 18 20
M  V30 22 1 21 20
M  V30 23 1 4 21
M  V30 24 1 21 22 CFG=1
M  V30 25 1 21 23
M  V30 26 1 23 2
M  V30 27 1 23 24 CFG=3
M  V30 28 1 23 25 CFG=1
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 29 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417819627

>  <MW>
434.21

>  <MW (desalted)>
434.498

>  <ClogP>
2.322

>  <logS>
-4.254

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
100.9

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  12.5 nM

>  <CAS>
1177-87-3

>  <Description>
Dexamethasone acetate is a glucocorticosteroid used for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions.

>  <EBC_ID>
EBC-17107

>  <IUPAC Name>
2-[(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

>  <Main Tar all refs>
STEROIDS, 1997, vol. 62, # 6, p. 491 - 499

>  <Main tar all>
Glucocorticoid receptor pX=7.9

$$$$
(1R,2S)-Tranylcypromine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 8.291 3.3769 0 0
M  V30 3 C 8.291 1.8369 0 0 CFG=2
M  V30 4 C 9.061 0.5033 0 0
M  V30 5 C 7.521 0.5033 0 0 CFG=1
M  V30 6 C 6.1874 -0.2667 0 0
M  V30 7 C 6.1874 -1.8067 0 0
M  V30 8 C 4.8537 -2.5767 0 0
M  V30 9 C 3.52 -1.8067 0 0
M  V30 10 C 3.52 -0.2667 0 0
M  V30 11 C 4.8537 0.5033 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=3
M  V30 2 1 3 4
M  V30 3 1 5 4
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242067488

>  <MW>
169.066

>  <MW (desalted)>
133.19

>  <ClogP>
1.478

>  <logS>
-2.155

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
26.02

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.04 ?M | Km (Michaelis constant) <= 50 nM | Km (Michaelis constant) <= 50 nM | Ki (inhibition constant)  140 nM | pIC50  6.7  | Ki (inhibition constant)  269 nM | inhibition percentage  97.4 % | IC50  0.69 ?M | IC50  0.72 ?M | IC50 = 1.1 ?M

>  <CAS>
37388-05-9

>  <Description>
Tranylcypromine is a monoamine oxidase inhibitor used to treat major depressive disorder.

>  <EBC_ID>
EBC-07853

>  <IUPAC Name>
(1R,2S)-2-phenylcyclopropan-1-amine hydrochloride

>  <Main Tar all refs>
ARCH. BIOCHEM. BIOPHYS., 1997, vol. 341, # 1, p. 47 - 61 | Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | MOL. PHARMACOL., 1977, vol. 13, # 3, p. 454 - 473 | J. Med. Chem., 1968, vol. 11, # 1, p. 95 - 97 | Life Sci., 2002, vol. 71, # 23, p. 2691 - 2700 | J. Med. Chem., 2012, vol. 55, # 2, p. 812 - 823 | Chem. Biol. Drug Des., 2008, vol. 71, # 2, p. 131 - 139 | Arch. Pharm., 2022, vol. 355, # 2 | SYNDROME X - WO2008/104975, 2008, A2

>  <Main tar all>
Cytochrome P450 2A6 pX=7.4 | ?2 pX=7.3 | sigma non-opioid intracellular receptor 1 pX=7.3 | ?-adrenoceptor pX=6.85 | Amine oxidase [flavin-containing] pX=6.7 | D2- like receptor pX=6.57 | Cytochrome P450 3A4 pX=6.28 | Cytochrome P450 2C19 pX=6.16 | Probable flavin-containing monoamine oxidase B pX=6.14 | CYP1A2 pX=5.96

$$$$
Benperidol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -0.0964 -18.0192 0 0
M  V30 2 C 0.3794 -16.5546 0 0
M  V30 3 C -0.651 -15.4102 0 0
M  V30 4 C -0.1751 -13.9455 0 0
M  V30 5 C 1.3312 -13.6254 0 0
M  V30 6 C 2.3617 -14.7698 0 0
M  V30 7 C 1.8858 -16.2344 0 0
M  V30 8 C 1.8071 -12.1607 0 0
M  V30 9 O 3.3135 -11.8405 0 0
M  V30 10 C 0.7766 -11.0163 0 0
M  V30 11 C 1.2525 -9.5517 0 0
M  V30 12 C 0.2221 -8.4072 0 0
M  V30 13 N 0.698 -6.9426 0 0
M  V30 14 C -0.3325 -5.7982 0 0
M  V30 15 C 0.1434 -4.3335 0 0
M  V30 16 C 1.6497 -4.0133 0 0
M  V30 17 C 2.6802 -5.1578 0 0
M  V30 18 C 2.2043 -6.6224 0 0
M  V30 19 N 2.1256 -2.5487 0 0
M  V30 20 C 1.2204 -1.3028 0 0
M  V30 21 O -0.3196 -1.3028 0 0
M  V30 22 N 2.1256 -0.0569 0 0
M  V30 23 C 3.5902 -0.5328 0 0
M  V30 24 C 4.9239 0.2372 0 0
M  V30 25 C 6.2576 -0.5328 0 0
M  V30 26 C 6.2576 -2.0728 0 0
M  V30 27 C 4.9239 -2.8428 0 0
M  V30 28 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 19 28
M  V30 31 2 23 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2271075295

>  <MW>
381.185

>  <MW (desalted)>
381.443

>  <ClogP>
3.8

>  <logS>
-4.413

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
52.65

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.18 nM | pKi  9.7  | Ki (inhibition constant)  0.24 nM | Ki (inhibition constant)  1.2 nM | Ki (inhibition constant) = 1.2 nM | pIC50  8.47

>  <CAS>
2062-84-2

>  <Description>
Benperidol is a neuroleptic butyrophenone derivative. It is indicated in the treatment of psychoses, manic episodes, and psychomotor agitation. It binds to dopamine receptor, 5-hydroxytryptamine receptor.

>  <EBC_ID>
EBC-13168

>  <IUPAC Name>
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

>  <Main Tar all refs>
J. Neurochem., 1981, vol. 36, # 1, p. 201 - 219 | J. PHARMACOL. EXP. THER., 1989, vol. 251, # 1, p. 238- 246 | Mol. Pharmacol., 1985, vol. 28, # 5, p. 391 - 399 | Mol. Pharmacol., 1982, vol. 21, # 2, p. 301 - 314 | Annu. Rep. Med. Chem., 1986, vol. 21, p. 41 - 50 | Chem. Biol. Drug Des., 2009, vol. 73, # 1, p. 17 - 25

>  <Main tar all>
Dopamine receptor pX=9.74 | D2S receptor pX=9.7 | D2L receptor pX=9.62 | 5-HT2A receptor pX=8.92 | 5-HT2A receptor pX=8.92 | Kv11.1 pX=8.47

$$$$
Delavirdine mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.1545 -5.7743 0 0
M  V30 2 C -1.3855 -5.7743 0 0
M  V30 3 C -2.1555 -7.108 0 0
M  V30 4 N -2.1555 -4.4406 0 0
M  V30 5 C -3.6955 -4.4406 0 0
M  V30 6 C -4.4655 -5.7743 0 0
M  V30 7 C -6.0055 -5.7743 0 0
M  V30 8 C -6.7755 -4.4406 0 0
M  V30 9 N -6.0055 -3.1069 0 0
M  V30 10 C -4.4655 -3.1069 0 0
M  V30 11 N -3.6955 -1.7733 0 0
M  V30 12 C -4.4655 -0.4396 0 0
M  V30 13 C -3.6955 0.8941 0 0
M  V30 14 N -2.1555 0.8941 0 0
M  V30 15 C -1.3855 -0.4396 0 0
M  V30 16 C -2.1555 -1.7733 0 0
M  V30 17 C -1.3855 2.2278 0 0
M  V30 18 O -2.1555 3.5615 0 0
M  V30 19 C 0.1545 2.2278 0 0
M  V30 20 C 1.0597 3.4737 0 0
M  V30 21 C 2.5243 2.9978 0 0
M  V30 22 C 3.858 3.7678 0 0
M  V30 23 C 5.1917 2.9978 0 0
M  V30 24 N 6.5254 3.7678 0 0
M  V30 25 S 6.5254 5.3078 0 0
M  V30 26 O 6.5254 6.8478 0 0
M  V30 27 O 8.0654 5.3078 0 0
M  V30 28 C 4.9854 5.3078 0 0
M  V30 29 C 5.1917 1.4578 0 0
M  V30 30 C 3.858 0.6878 0 0
M  V30 31 C 2.5243 1.4578 0 0
M  V30 32 N 1.0597 0.9819 0 0
M  V30 33 C 13.1254 -1.54 0 0
M  V30 34 S 13.1254 0 0 0
M  V30 35 O 13.1254 1.54 0 0
M  V30 36 O 14.6654 -0 0 0
M  V30 37 O 11.5854 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 11 16
M  V30 18 1 14 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 2 25 27
M  V30 29 1 25 28
M  V30 30 1 23 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 21 31
M  V30 34 1 31 32
M  V30 35 1 19 32
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 2 34 36
M  V30 39 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3243811539

>  <MW>
552.182

>  <MW (desalted)>
456.561

>  <ClogP>
2.412

>  <logS>
-3.349

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
110.43

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.001 - 0.027 ?M | IC50 = 1.3 nM

>  <CAS>
147221-93-0

>  <Description>
Delavirdine is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.

>  <EBC_ID>
EBC-28058

>  <IUPAC Name>
N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide; methanesulfonic acid

>  <Main Tar all refs>
NEKTAR THERAPEUTICS - US9226970, 2016, B2 | J. Med. Chem., 1999, vol. 42, # 20, p. 4150 - 4160

>  <Main tar all>
Reverse transcriptase pX=9.0 | RNA-directed DNA polymerase pX=8.89

$$$$
Terconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.1269 -15.5563 0 0
M  V30 2 C 9.5954 -15.7173 0 0
M  V30 3 C 8.969 -17.1241 0 0
M  V30 4 N 8.6902 -14.4714 0 0
M  V30 5 C 7.1586 -14.6324 0 0
M  V30 6 C 6.2534 -13.3865 0 0
M  V30 7 N 6.8798 -11.9796 0 0
M  V30 8 C 8.4114 -11.8187 0 0
M  V30 9 C 9.3166 -13.0645 0 0
M  V30 10 C 5.9746 -10.7337 0 0
M  V30 11 C 4.4431 -10.8947 0 0
M  V30 12 C 3.5379 -9.6488 0 0
M  V30 13 C 4.1642 -8.242 0 0
M  V30 14 O 3.2591 -6.9961 0 0
M  V30 15 C 3.8854 -5.5892 0 0
M  V30 16 C 2.9802 -4.3433 0 0 CFG=1
M  V30 17 C 1.4402 -4.3433 0 0
M  V30 18 O 0.9644 -2.8787 0 0
M  V30 19 C 2.2102 -1.9735 0 0 CFG=1
M  V30 20 C 1.1798 -0.8291 0 0
M  V30 21 N -0.3266 -1.1493 0 0
M  V30 22 C -1.471 -0.1188 0 0
M  V30 23 N -2.8047 -0.8888 0 0
M  V30 24 C -2.4845 -2.3951 0 0
M  V30 25 N -0.9529 -2.5561 0 0
M  V30 26 O 3.4561 -2.8787 0 0
M  V30 27 C 3.2407 -0.8291 0 0
M  V30 28 C 2.7648 0.6356 0 0
M  V30 29 C 3.7953 1.78 0 0
M  V30 30 C 5.3016 1.4598 0 0
M  V30 31 Cl 6.3321 2.6043 0 0
M  V30 32 C 5.7775 -0.0048 0 0
M  V30 33 C 4.7471 -1.1493 0 0
M  V30 34 Cl 5.2229 -2.6139 0 0
M  V30 35 C 5.6958 -8.081 0 0
M  V30 36 C 6.601 -9.3269 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 16 15 CFG=1
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=1
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 21 25
M  V30 27 1 19 26
M  V30 28 1 16 26
M  V30 29 1 19 27 CFG=3
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 2 30 32
M  V30 35 1 32 33
M  V30 36 2 27 33
M  V30 37 1 33 34
M  V30 38 2 13 35
M  V30 39 1 35 36
M  V30 40 2 10 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996962

>  <MW>
532.462

>  <MW (desalted)>
532.462

>  <ClogP>
4.814

>  <logS>
-5.656

>  <HBD>
0

>  <HBA>
7

>  <TPSA>
64.88

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.045 ?M | IC50 = 410 nM

>  <CAS>
67915-31-5

>  <Description>
Terconazole is an antifungal drug used in the treatment of vulvovaginal candidiasis.

>  <EBC_ID>
EBC-27286

>  <IUPAC Name>
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine

>  <Main Tar all refs>
J. ANTIMICROB. CHEMOTHER., 1988, vol. 21, # 3, p. 333 - 343 | J. Pharmacol. Exp. Ther., 2006, vol. 319, # 1, p. 277 - 284

>  <Main tar all>
CYP1A1 pX=7.35 | Haem oxygenase 1 pX=6.39

$$$$
Geraniol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.93 4.001 0 0
M  V30 2 C 6.16 2.6674 0 0
M  V30 3 C 4.62 2.6674 0 0
M  V30 4 C 3.85 1.3337 0 0
M  V30 5 C 2.31 1.3337 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C -0.77 -1.3337 0 0
M  V30 9 O 0 -2.6674 0 0
M  V30 10 C 2.31 -1.3337 0 0
M  V30 11 C 6.93 1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 6 10
M  V30 10 1 2 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315575190

>  <MW>
154.136

>  <MW (desalted)>
154.249

>  <ClogP>
2.969

>  <logS>
-2.474

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Agonist | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.2 ?M | qualitative Active   | qualitative Active   | EC50 > 2.5 ?M | Km (Michaelis constant) = 4.2 ?M

>  <CAS>
106-24-1

>  <Description>
Geraniol is a monoterpene that is found within many essential oils of fruits, vegetables, and herbs. It has demonstrated a wide spectrum of pharmacological activities including antimicrobial, anti-inflammatory, antioxidant, anti-cancer, and neuroprotective. Geraniol is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.

>  <EBC_ID>
EBC-02060

>  <IUPAC Name>
(2E)-3,7-dimethylocta-2,6-dien-1-ol

>  <Main Tar all refs>
Eur. J. Med. Chem., 2010, vol. 45, # 9, p. 4354 - 4357 | Comp. Biochem. Physiol., Part A Mol. Integr. Physiol., 2017, vol. 213, p. 20 - 27 | Comp. Biochem. Physiol., Part A Mol. Integr. Physiol., 2017, vol. 213, p. 20 - 27 | TAKEDA PHARMACEUTICAL COMPANY LIMITED - US2004/248208, 2004, A1 | Arch. Biochem. Biophys., 2013, vol. 529, # 2, p. 131 - 139

>  <Main tar all>
Aldo-keto reductase family 1 member B10 pX=6.7 | Odorant-binding protein 1 pX=5.7 | Odorant-binding protein 7 pX=5.7 | Hydroxycarboxylic acid receptor 2 pX=5.6 | Aldo-Keto Reductase Family 1, Member C28 pX=5.38

$$$$
Methylchloroisothiazolinone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 N 1.0598 2.08 0 0
M  V30 3 S 2.3057 1.1748 0 0
M  V30 4 C 1.8298 -0.2898 0 0
M  V30 5 Cl 2.735 -1.5357 0 0
M  V30 6 C 0.2898 -0.2898 0 0
M  V30 7 C -0.1861 1.1748 0 0
M  V30 8 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417817741

>  <MW>
148.97

>  <MW (desalted)>
149.599

>  <ClogP>
0.603

>  <logS>
-1.629

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
20.31

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 3 ?M

>  <CAS>
26172-55-4

>  <Description>
Methylchloroisothiazolinone is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties. Methylchloroisothiazolinone is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older.

>  <EBC_ID>
EBC-26096

>  <IUPAC Name>
5-chloro-2-methyl-2,3-dihydro-1,2-thiazol-3-one

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 2, p. 460 - 466

>  <Main tar all>
Histone acetyltransferase KAT2B pX=5.52

$$$$
Aminocaproic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 C 4.62 2.6674 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 7.2874 2.6674 0 0
M  V30 6 C 8.621 3.4374 0 0
M  V30 7 C 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 9 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127439

>  <MW>
131.095

>  <MW (desalted)>
131.173

>  <ClogP>
-2.235

>  <logS>
0.16

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
Kd (dissociation constant) = 6.8 nM

>  <CAS>
60-32-2

>  <Description>
Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. It acts by inhibiting plasminogen activators which have fibrinolytic properties.

>  <EBC_ID>
EBC-04018

>  <IUPAC Name>
6-aminohexanoic acid

>  <Main Tar all refs>
J. Biol. Chem., 2011, vol. 286, # 46, p. 40219 - 40231

>  <Main tar all>
Aldolase B, Fructose-Bisphosphate pX=8.17

$$$$
Methenamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.2171 -3.7934 0 0
M  V30 2 N 1.5898 -3.0959 0 0
M  V30 3 C 2.963 -3.7934 0 0
M  V30 4 N 3.802 -2.3182 0 0
M  V30 5 C 2.4289 -3.0158 0 0
M  V30 6 N 1.056 -2.3182 0 0
M  V30 7 C 1.056 -0.9231 0 0
M  V30 8 N 2.4289 -0.2255 0 0
M  V30 9 C 1.5898 -1.7007 0 0
M  V30 10 C 3.802 -0.9231 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 1 6
M  V30 7 1 8 10
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 2 9
M  V30 11 1 6 7
M  V30 12 1 4 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z362014242

>  <MW>
140.106

>  <MW (desalted)>
140.186

>  <ClogP>
2.435

>  <logS>
0.94

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
12.96

>  <RotBonds>
0

>  <CAS>
100-97-0

>  <Description>
Methenamine is a urinary tract antiseptic and antibacterial drug used for the prophylaxis and treatment of frequently recurring urinary tract infections requiring a long-term therapy. Methenamine does not have antibacterial properties in an alkaline environment (pH?6); however, in a more acidic environment (pH<6), methenamine is hydrolyzed to formaldehyde. Formaldehyde is considered to be highly bactericidal.

>  <EBC_ID>
EBC-03957

>  <IUPAC Name>
1,3,5,7-tetraazatricyclo[3.3.1.1,3,7]decane

$$$$
Acetylcysteine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.9763 0.9763 0 0
M  V30 2 C 2.31 0.2063 0 0
M  V30 3 O 3.6437 0.9763 0 0
M  V30 4 N 2.31 -1.3337 0 0
M  V30 5 C 3.6437 -2.1037 0 0 CFG=1
M  V30 6 C 3.6437 -3.6437 0 0
M  V30 7 S 4.9774 -4.4137 0 0
M  V30 8 C 4.9774 -1.3337 0 0
M  V30 9 O 4.9774 0.2063 0 0
M  V30 10 O 6.311 -2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1143441555

>  <MW>
163.03

>  <MW (desalted)>
163.195

>  <ClogP>
-0.624

>  <logS>
-0.66

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
percentage decrease Active   | IC50 = 0.27 ?M

>  <CAS>
616-91-1

>  <Description>
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.

>  <EBC_ID>
EBC-11098

>  <IUPAC Name>
(2R)-2-acetamido-3-sulfanylpropanoic acid

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2017, vol. 360, # 1, p. 239 - 248 | PHILERA NEW ZEALAND - US6348465, 2002, B1

>  <Main tar all>
RyR2 pX=8.0 | Fructosamine Oxidase pX=6.57

$$$$
Succimer
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.3574 1.3337 0 0
M  V30 2 C 0.9763 2.1037 0 0
M  V30 3 O 0.9763 3.6437 0 0
M  V30 4 C 2.31 1.3337 0 0 CFG=1
M  V30 5 S 2.31 -0.2063 0 0
M  V30 6 C 3.6437 2.1037 0 0 CFG=1
M  V30 7 S 3.6437 3.6437 0 0
M  V30 8 C 4.9774 1.3337 0 0
M  V30 9 O 6.311 2.1037 0 0
M  V30 10 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255431202

>  <MW>
181.971

>  <MW (desalted)>
182.218

>  <ClogP>
-1.476

>  <logS>
-1.178

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
74.6

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.33 ?M | IC50  1.72 ?M

>  <CAS>
304-55-2

>  <Description>
Succimer is a mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.

>  <EBC_ID>
EBC-03170

>  <IUPAC Name>
(2R,3S)-2,3-disulfanylbutanedioic acid

>  <Main Tar all refs>
THE UNIVERSITY OF IOWA - US2013/225517, 2013, A1 | DOMPE' FARMACEUTICI - S.P.A.; FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - EP4011367, 2022, A1

>  <Main tar all>
DNA methyltransferase 1 pX=6.48 | main protease pX=5.76

$$$$
Metronidazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 C 1.0598 2.08 0 0
M  V30 3 N 2.3057 1.1748 0 0
M  V30 4 C 1.8298 -0.2898 0 0
M  V30 5 C 0.2898 -0.2898 0 0
M  V30 6 N -0.6154 -1.5357 0 0 CHG=1
M  V30 7 O 0.011 -2.9426 0 0
M  V30 8 O -2.1469 -1.3747 0 0 CHG=-1
M  V30 9 N -0.1861 1.1748 0 0
M  V30 10 C -1.6507 1.6507 0 0
M  V30 11 C -1.9709 3.157 0 0
M  V30 12 O -3.4355 3.6329 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z87001124

>  <MW>
171.064

>  <MW (desalted)>
171.154

>  <ClogP>
-0.457

>  <logS>
-0.41

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
81.19

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  96 % | inhibition percentage  97.5 % | inhibition percentage  89.5 % | inhibition percentage  87.5 % | inhibition percentage  72.5 % | inhibition percentage  70 %

>  <CAS>
443-48-1

>  <Description>
Metronidazole is an antibiotic that has activity against anaerobic bacteria and protozoa including T. vaginalis, E. histolytica, G. lamblia, C. difficile, and H. pylori. Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections.

>  <EBC_ID>
EBC-03271

>  <IUPAC Name>
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol

>  <Main Tar all refs>
Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004

>  <Main tar all>
CYP1A2 pX=8.8 | Cytochrome P450 2B6 pX=8.8 | Cytochrome P450 2D6 pX=8.45 | Cytochrome P450 2C9 pX=8.37 | Cytochrome P450 3A4 pX=7.94 | CYP2E1 pX=7.89

$$$$
4-Phenylbutyric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 O 1.3337 -6.93 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 C 8.0021 -7.7 0 0
M  V30 12 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z234895119

>  <MW>
164.084

>  <MW (desalted)>
164.201

>  <ClogP>
2.282

>  <logS>
-1.87

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 2.8 ?M | oxygen consumption rate decrease Active   | Kd (dissociation constant)  12.25 ?M | Ki (inhibition constant) = 56 ?M | IC50 = 64 ?M | IC50 = 65 ?M | IC50 = 86 ?M

>  <CAS>
1821-12-1

>  <Description>
4-Phenylbutyric acid is an agent indicated for the adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in specific enzymes, including the neonatal-onset deficiency and late-onset disease with a history of hyperammonemic encephalopathy.

>  <EBC_ID>
EBC-03322

>  <IUPAC Name>
4-phenylbutanoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 14, p. 5219 - 5228 | J. Med. Chem., 2022, vol. 65, # 14, p. 9955 - 9973 | Clin. Transl. Med., 2021, vol. 11, # 4 | J. Biochem., 1984, vol. 96, # 2, p. 421 - 427 | Curr. Med. Chem., 2011, vol. 18, # 36, p. 5545 - 5553 | Curr. Med. Chem., 2011, vol. 18, # 36, p. 5545 - 5553 | Proc. Natl. Acad. Sci. U. S. A., 2010, vol. 107, # 28, p. 12617 - 12622

>  <Main tar all>
Histone?deacetylase pX=5.55 | [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial pX=5.3 | Peroxisome proliferator-activated receptor-? pX=4.91 | phenylalanine 2-monooxygenase pX=4.25 | histone deacetylase 1 pX=4.19 | histone deacetylase 2 pX=4.19 | histone deacetylase 8 pX=4.07

$$$$
Caffeine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.6497 -4.0133 0 0
M  V30 2 N 2.1256 -2.5487 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 N 2.1256 -0.0569 0 0
M  V30 5 C 3.5902 -0.5328 0 0
M  V30 6 N 4.9239 0.2372 0 0
M  V30 7 C 4.9239 1.7772 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 O 7.5913 0.2372 0 0
M  V30 10 N 6.2576 -2.0728 0 0
M  V30 11 C 7.5913 -2.8428 0 0
M  V30 12 C 4.9239 -2.8428 0 0
M  V30 13 O 4.9239 -4.3828 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 2 14
M  V30 15 2 5 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104507896

>  <MW>
194.08

>  <MW (desalted)>
194.191

>  <ClogP>
-0.04

>  <logS>
-0.65

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
58.44

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | - | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.06 nM | Ki (inhibition constant) = 0.27 nM | Kd (dissociation constant)  0.53 nM | Km (Michaelis constant)  0.0012 ?M

>  <CAS>
58-08-2

>  <Description>
Caffeine is a methylxanthine alkaloid naturally found in various plant parts that acts as an antagonist at central adenosine receptors at relevant physiological concentrations.  It is used to increase alertness. It is also used in to prevent and treat pulmonary complications of premature birth.

>  <EBC_ID>
EBC-03517

>  <IUPAC Name>
1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2013, vol. 13, # 10, p. 1462 - 1474 | Mini-Rev. Med. Chem., 2013, vol. 13, # 10, p. 1462 - 1474 | J. Neurochem., 2016, p. 557 - 570 | Drug Metab. Dispos., 2000, vol. 28, # 10, p. 1222 - 1230

>  <Main tar all>
MT1 receptor pX=10.2 | MT2 receptor pX=9.57 | Plasma membrane monoamine transporter pX=9.28 | CYP1A2 pX=8.92

$$$$
Busulfan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.461 -10.01 0 0
M  V30 2 S -2.461 -8.47 0 0
M  V30 3 O -0.921 -8.47 0 0
M  V30 4 O -4.001 -8.47 0 0
M  V30 5 O -2.461 -6.93 0 0
M  V30 6 C -1.1274 -6.16 0 0
M  V30 7 C -1.1274 -4.62 0 0
M  V30 8 C 0.2063 -3.85 0 0
M  V30 9 C 0.2063 -2.31 0 0
M  V30 10 O 1.54 -1.54 0 0
M  V30 11 S 1.54 0 0 0
M  V30 12 O 1.54 1.54 0 0
M  V30 13 O 3.08 -0 0 0
M  V30 14 C 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 2 11 13
M  V30 13 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z276508890

>  <MW>
246.023

>  <MW (desalted)>
246.302

>  <ClogP>
-0.592

>  <logS>
-0.02

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
86.74

>  <RotBonds>
7

>  <Action on targets>
Antagonist | Inhibitor

>  <Activity coefficients and valu>
IC25  1 - 3 ?M | increase rate Active

>  <CAS>
55-98-1

>  <Description>
Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent. It forms both intra- and interstrand crosslinks on DNA. It is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.

>  <EBC_ID>
EBC-03587

>  <IUPAC Name>
4-(methanesulfonyloxy)butyl methanesulfonate

>  <Main Tar all refs>
Chem. Res. Toxicol., 2008, vol. 21, # 4, p. 813 - 823 | Biomaterials, 2019, vol. 209, p. 25 - 40

>  <Main tar all>
Androgen receptor pX=5.52 | scavenger receptor pX=4.91

$$$$
Monobenzone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -3.08 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 C 4.001 -6.93 0 0
M  V30 5 C 2.6674 -7.7 0 0
M  V30 6 O 2.6674 -9.24 0 0
M  V30 7 C 4.001 -10.01 0 0
M  V30 8 C 4.001 -11.55 0 0
M  V30 9 C 5.3347 -12.32 0 0
M  V30 10 C 5.3347 -13.86 0 0
M  V30 11 C 4.001 -14.63 0 0
M  V30 12 C 2.6674 -13.86 0 0
M  V30 13 C 2.6674 -12.32 0 0
M  V30 14 C 1.3337 -6.93 0 0
M  V30 15 C 1.3337 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 2 5 14
M  V30 15 1 14 15
M  V30 16 2 2 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104478412

>  <MW>
200.084

>  <MW (desalted)>
200.233

>  <ClogP>
3.342

>  <logS>
-2.89

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
IC50  0.25 ?M | IC50  0.25 ?M | IC50  0.4507 ?M | EC50  5.43E-07 M | EC50  5.43E-07 M

>  <CAS>
103-16-2

>  <Description>
Monobenzone is the monobenzyl ether of hydroquinone used medically for depigmentation. It exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.

>  <EBC_ID>
EBC-04128

>  <IUPAC Name>
4-(benzyloxy)phenol

>  <Main Tar all refs>
Int. J. Environ. Res. Public Health, 2022, vol. 19, # 19 | Cancers, 2022, vol. 14, # 19 | Front. Pharmacol., 2021, vol. 12 | J. Chem. Inf. Comput. Sci., 2003, vol. 43, # 4, p. 1166 - 1176 | J. Chem. Inf. Comput. Sci., 2003, vol. 43, # 4, p. 1166 - 1176

>  <Main tar all>
Ribonucleoside-diphosphate reductase large subunit (peptide) pX=6.6 | Ribonucleoside-diphosphate reductase subunit M2 pX=6.6 | Lysine-specific histone demethylase 1A pX=6.35 | Estrogen receptor pX=6.27 | Estrogen receptor pX=6.27

$$$$
L-Tryptophan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.1865 -4.8376 0 0
M  V30 2 C 2.6802 -5.1578 0 0 CFG=1
M  V30 3 C 1.6497 -4.0133 0 0
M  V30 4 C 2.1256 -2.5487 0 0
M  V30 5 C 1.2204 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 3.5902 -0.5328 0 0
M  V30 8 C 4.9239 0.2372 0 0
M  V30 9 C 6.2576 -0.5328 0 0
M  V30 10 C 6.2576 -2.0728 0 0
M  V30 11 C 4.9239 -2.8428 0 0
M  V30 12 C 3.5902 -2.0728 0 0
M  V30 13 C 2.2043 -6.6224 0 0
M  V30 14 O 3.2348 -7.7669 0 0
M  V30 15 O 0.698 -6.9426 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 4 12
M  V30 13 2 7 12
M  V30 14 1 2 13
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440056

>  <MW>
204.09

>  <MW (desalted)>
204.225

>  <ClogP>
-1.566

>  <logS>
-2.16

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
79.11

>  <RotBonds>
3

>  <Action on targets>
Activator | -

>  <Activity coefficients and valu>
Ka (association constant)  0.002 ?M | Ka (association constant) = 0.007 ?M

>  <CAS>
73-22-3

>  <Description>
L-Tryptophan is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3. It acts like a natural mood regulator that is necessary for normal growth in infants and for nitrogen balance in adults. L-Tryptophan may be useful in increasing serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight.

>  <EBC_ID>
EBC-01051

>  <IUPAC Name>
(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid

>  <Main Tar all refs>
J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 25 - 30 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327

>  <Main tar all>
?-carbonic anhydrase pX=8.7 | carbonic anhydrase pX=8.15

$$$$
Felbinac
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 1.54 0 0
M  V30 2 C 0 0 0 0
M  V30 3 O -1.3337 -0.77 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 C 1.3337 -5.39 0 0
M  V30 9 C 0 -4.62 0 0
M  V30 10 C 0 -3.08 0 0
M  V30 11 C 1.3337 -6.93 0 0
M  V30 12 C 2.6674 -7.7 0 0
M  V30 13 C 2.6674 -9.24 0 0
M  V30 14 C 1.3337 -10.01 0 0
M  V30 15 C 0 -9.24 0 0
M  V30 16 C 0 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104476858

>  <MW>
212.084

>  <MW (desalted)>
212.244

>  <ClogP>
3.302

>  <logS>
-3.49

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50 = 25000 nM | IC50  58 ?M | IC50 = 100000 nM | IC50 = 100000 nM | IC50 = 100000 nM

>  <CAS>
5728-52-9

>  <Description>
Felbinac is a potent non-steroidal anti-inflammatory agent. It is used to treat muscle inflammation and arthritis.

>  <EBC_ID>
EBC-04197

>  <IUPAC Name>
2-(4-phenylphenyl)acetic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2001, vol. 62, # 3, p. 363 - 367 | ACS Chem. Neurosci., 2022, vol. 13, # 13, p. 2060 - 2077 | BR. J. PHARMACOL., 1997, vol. 122, # 3, p. 584 - 590 | BR. J. PHARMACOL., 1997, vol. 122, # 3, p. 584 - 590 | BR. J. PHARMACOL., 1997, vol. 122, # 3, p. 584 - 590

>  <Main tar all>
fatty acid ligase pX=4.6 | Palmitoleoyl-protein carboxylesterase NOTUM (C330S) pX=4.24 | GABAA receptor ?1 subunit pX=4.0 | GABAA receptor ?2 subunit pX=4.0 | GABAA receptor ? subunit pX=4.0

$$$$
Myristic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.5263 8.7721 0 0
M  V30 2 C 13.86 8.0021 0 0
M  V30 3 C 15.1937 8.7721 0 0
M  V30 4 C 16.5274 8.0021 0 0
M  V30 5 C 17.861 8.7721 0 0
M  V30 6 C 19.1947 8.0021 0 0
M  V30 7 C 20.5284 8.7721 0 0
M  V30 8 C 21.8621 8.0021 0 0
M  V30 9 C 23.1958 8.7721 0 0
M  V30 10 C 24.5294 8.0021 0 0
M  V30 11 C 25.8631 8.7721 0 0
M  V30 12 C 27.1968 8.0021 0 0
M  V30 13 C 28.5305 8.7721 0 0
M  V30 14 C 29.8641 8.0021 0 0
M  V30 15 O 31.1978 8.7721 0 0
M  V30 16 O 29.8641 6.4621 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954802504

>  <MW>
228.209

>  <MW (desalted)>
228.371

>  <ClogP>
6.154

>  <logS>
-5.632

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | - | - | Inhibitor | - | Activator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.041 ?M | Kd (dissociation constant)  0.21 ?M | Kd (dissociation constant)  0.28 ?M | Kd (dissociation constant)  0.3 ?M | Kd (dissociation constant) = 459 nM | amount increase Active   | Ki (inhibition constant)  1.1 ?M | Ki (inhibition constant)  1.3 ?M

>  <CAS>
544-63-8

>  <Description>
Myristic acid is a saturated 14-carbon fatty acid occurring in most animal and vegetable fats. It has antibiotic activity.

>  <EBC_ID>
EBC-46129

>  <IUPAC Name>
tetradecanoic acid

>  <Main Tar all refs>
Chem. Biol., 2007, vol. 14, # 4, p. 453 - 465 | Chem. Biol., 2010, vol. 17, # 12, p. 1295 - 1305 | Arch. Biochem. Biophys., 2013, vol. 539, # 1, p. 63 - 69 | Int. J. Mol. Sci., 2023, vol. 24, # 6 | Biochem. J., 2002, vol. 363, # 3, p. 809 - 815 | EIDGEN?SSISCHE TECHNISCHE HOCHSCHULE Z?RICH - US2015/368666, 2015, A1 | Arch. Biochem. Biophys., 2016, vol. 609, p. 69 - 76 | J. Biochem., 2017, vol. 162, # 5, p. 371 - 379

>  <Main tar all>
fatty acid binding protein 2 pX=7.39 | CYP109D1 pX=6.68 | CYP147F1 pX=6.55 | Fatty acid-binding protein, heart pX=6.52 | Serum albumin pX=6.34 | Lipid sensing receptor pX=6.0 | Aldo-keto reductase family 1 member B10 pX=5.96 | Aldo-keto reductase family 1 member C1 pX=5.89

$$$$
Clofibrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 9.24 0 0
M  V30 2 C -2.6674 7.7 0 0
M  V30 3 O -1.3337 6.93 0 0
M  V30 4 C -1.3337 5.39 0 0
M  V30 5 O -2.6674 4.62 0 0
M  V30 6 C 0 4.62 0 0
M  V30 7 C -0.77 3.2863 0 0
M  V30 8 C 0.77 5.9537 0 0
M  V30 9 O 1.3337 3.85 0 0
M  V30 10 C 1.3337 2.31 0 0
M  V30 11 C 2.6674 1.54 0 0
M  V30 12 C 2.6674 -0 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 Cl 1.3337 -2.31 0 0
M  V30 15 C 0 0 0 0
M  V30 16 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53835984

>  <MW>
242.071

>  <MW (desalted)>
242.699

>  <ClogP>
3.679

>  <logS>
-3.462

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
35.53

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Agonist | - | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 6.9 ?M | IC50  9 ?M | EC50  50 ?M | EC50 ~ 55 ?M | EC50 = 55 ?M | inhibition percentage < 50 % | stimulation rate  30 - 70 % | stimulation rate  30 - 70 % | stimulation rate  30 - 70 %

>  <CAS>
637-07-0

>  <Description>
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

>  <EBC_ID>
EBC-12356

>  <IUPAC Name>
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate

>  <Main Tar all refs>
J. Med. Chem., 2009, vol. 52, # 17, p. 5344 - 5355 | Drug Metab. Dispos., 1999, vol. 27, # 3, p. 410 - 416 | J. Med. Chem., 2000, vol. 43, # 4, p. 527 - 550 | Cardiovasc. Hematol. Agents Med. Chem., 2007, vol. 5, # 1, p. 55 - 66 | J. Med. Chem., 2004, vol. 47, # 17, p. 4118 - 4127 | Aquat. Toxicol., 2019, vol. 208, p. 196 - 207 | Biochem. J., 2003, vol. 376, # 2, p. 465 - 472 | Biochem. J., 2003, vol. 376, # 2, p. 465 - 472 | Biochem. J., 2003, vol. 376, # 2, p. 465 - 472

>  <Main tar all>
Fatty acid-binding protein pX=5.16 | Cytochrome P450 2C9 pX=5.05 | Peroxisome proliferator-activated receptor-? pX=4.3 | Peroxisome proliferator-activated receptor-? pX=4.26 | Peroxisome proliferator-activated receptor-? pX=4.26 | Teleost-specific glutathione S-transferase Gstr1 pX=4.0 | Constitutive androstane receptor pX=3.7 | NCoR pX=3.7 | nuclear receptor coactivator 1 pX=3.7

$$$$
Phenoxybenzamine HCl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.14 2.3498 0 0
M  V30 3 C 8.91 1.0161 0 0
M  V30 4 C 8.14 -0.3175 0 0
M  V30 5 O 6.6 -0.3175 0 0
M  V30 6 C 5.83 -1.6512 0 0
M  V30 7 C 6.6 -2.9849 0 0
M  V30 8 C 5.83 -4.3186 0 0
M  V30 9 C 4.29 -4.3186 0 0
M  V30 10 C 3.52 -2.9849 0 0
M  V30 11 C 4.29 -1.6512 0 0
M  V30 12 N 10.45 1.0161 0 0
M  V30 13 C 11.22 -0.3175 0 0
M  V30 14 C 12.76 -0.3175 0 0
M  V30 15 Cl 13.53 -1.6512 0 0
M  V30 16 C 11.22 2.3498 0 0
M  V30 17 C 12.76 2.3498 0 0
M  V30 18 C 13.53 3.6835 0 0
M  V30 19 C 15.07 3.6835 0 0
M  V30 20 C 15.84 2.3498 0 0
M  V30 21 C 15.07 1.0161 0 0
M  V30 22 C 13.53 1.0161 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 3 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 12 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754931256

>  <MW>
339.116

>  <MW (desalted)>
303.826

>  <ClogP>
4.917

>  <logS>
-5.11

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.9 nM | Ki (inhibition constant) = 1.8 nM

>  <CAS>
63-92-3

>  <Description>
Phenoxybenzamine HCl is a selective antagonist of alpha-adrenoceptor and calmodulin.It is used for the treatment of hypertension.

>  <EBC_ID>
EBC-06086

>  <IUPAC Name>
benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine hydrochloride

>  <Main Tar all refs>
Eur. J. Pharmacol., 1979, vol. 55, # 3, p. 323 - 326 | J. MED. CHEM., 1986, vol. 29, # 8, p. 1394 - 1398

>  <Main tar all>
?-adrenoceptor pX=9.05 | ?1-adrenoceptor pX=8.74

$$$$
Amizon
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0 CHG=-1
M  V30 2 C 8.8547 6.2959 0 0
M  V30 3 N 8.8547 4.7559 0 0 CHG=1
M  V30 4 C 10.1884 3.9859 0 0
M  V30 5 C 10.1884 2.4459 0 0
M  V30 6 C 8.8547 1.6759 0 0
M  V30 7 C 7.521 2.4459 0 0
M  V30 8 C 7.521 3.9859 0 0
M  V30 9 C 8.8547 0.1359 0 0
M  V30 10 O 10.1884 -0.6341 0 0
M  V30 11 N 7.521 -0.6341 0 0
M  V30 12 C 7.521 -2.1741 0 0
M  V30 13 C 6.1874 -2.9441 0 0
M  V30 14 C 6.1874 -4.4841 0 0
M  V30 15 C 4.8537 -5.2541 0 0
M  V30 16 C 3.52 -4.4841 0 0
M  V30 17 C 3.52 -2.9441 0 0
M  V30 18 C 4.8537 -2.1741 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 6 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56761710

>  <MW>
354.023

>  <MW (desalted)>
227.282

>  <ClogP>
-2.576

>  <logS>
-3.23

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
32.98

>  <RotBonds>
3

>  <CAS>
201349-37-3

>  <Description>
An anti-influenza compound.

>  <EBC_ID>
EBC-12839

>  <IUPAC Name>
4-(benzylcarbamoyl)-1-methylpyridin-1-ium iodide

$$$$
Atenolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -6.93 0 0
M  V30 2 C 2.6674 -7.7 0 0
M  V30 3 C 2.6674 -9.24 0 0
M  V30 4 N 4.001 -6.93 0 0
M  V30 5 C 5.3347 -7.7 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 O 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -7.7 0 0
M  V30 9 O 9.3358 -6.93 0 0
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 12.0031 -6.93 0 0
M  V30 12 C 13.3368 -7.7 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 C 14.6705 -10.01 0 0
M  V30 15 C 14.6705 -11.55 0 0
M  V30 16 O 16.0041 -12.32 0 0
M  V30 17 N 13.3368 -12.32 0 0
M  V30 18 C 12.0031 -10.01 0 0
M  V30 19 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 2 13 18
M  V30 18 1 18 19
M  V30 19 2 10 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553991

>  <MW>
266.163

>  <MW (desalted)>
266.336

>  <ClogP>
-0.109

>  <logS>
-1.47

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
84.58

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.33 nM | Ki (inhibition constant)  0.33 nM | IC50 = 1.77 nM | IC50 = 1.77 nM | Kd (dissociation constant) = 8.14 nM

>  <CAS>
29122-68-7

>  <Description>
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Selective activity at the beta 1 adrenergic receptor produces cardioselectivity due to the higher population of this receptor in cardiac tissue. Atenolol is used in the management of hypertension and chronic angina, and to reduce mortality in known or suspected myocardial infarction in hemodynamically stable patients.

>  <EBC_ID>
EBC-03835

>  <IUPAC Name>
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide

>  <Main Tar all refs>
NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | J. Med. Chem., 2005, vol. 48, # 22, p. 6887 - 6896 | J. Med. Chem., 2005, vol. 48, # 22, p. 6887 - 6896 | Curr. Med. Chem., 2005, vol. 12, # 18, p. 2057 - 2074

>  <Main tar all>
?1-adrenoceptor pX=9.48 | ?1-adrenoceptor pX=9.48 | A3 receptor pX=8.75 | A3 receptor pX=8.75 | ?2-adrenoceptor pX=8.09

$$$$
Ketorolac
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.3876 -3.5066 0 0
M  V30 2 C 1.8939 -3.1864 0 0
M  V30 3 O 2.9244 -4.3308 0 0
M  V30 4 C 2.3698 -1.7218 0 0
M  V30 5 C 1.4646 -0.4759 0 0
M  V30 6 C 2.3698 0.77 0 0
M  V30 7 N 3.8344 0.2941 0 0
M  V30 8 C 5.2991 0.77 0 0
M  V30 9 C 6.2043 -0.4759 0 0
M  V30 10 C 5.2991 -1.7218 0 0
M  V30 11 C 3.8344 -1.2459 0 0
M  V30 12 C 5.775 2.2346 0 0
M  V30 13 O 4.7445 3.3791 0 0
M  V30 14 C 7.2813 2.5548 0 0
M  V30 15 C 7.7572 4.0194 0 0
M  V30 16 C 9.2635 4.3396 0 0
M  V30 17 C 10.294 3.1952 0 0
M  V30 18 C 9.8181 1.7306 0 0
M  V30 19 C 8.3118 1.4104 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 4 11
M  V30 12 1 7 11
M  V30 13 1 8 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2429420872

>  <MW>
255.09

>  <MW (desalted)>
255.269

>  <ClogP>
1.622

>  <logS>
-2.735

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
59.3

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  21.3 nM | IC50 = 0.039 ?M | IC50  0.23 ?M

>  <CAS>
74103-06-3

>  <Description>
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) and a non-selective prostaglandin synthase (COX) inhibitor. Ketorolac has been used to manage postoperative pain and as ophthalmic solutions to treat ocular pain and inflammation.

>  <EBC_ID>
EBC-03780

>  <IUPAC Name>
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1997, vol. 75, # 9, p. 1088 - 1095 | EVA BINDER - US2007/275958, 2007, A1 | J. MED. CHEM., 1991, vol. 34, # 3, p. 1099 - 1110

>  <Main tar all>
COX-1  pX=7.67 | COX-2  pX=7.41 | Cyclooxygenase pX=6.64

$$$$
Edetic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.4504 1.8677 0 0
M  V30 2 C 10.9627 2.1587 0 0
M  V30 3 O 11.4667 3.6139 0 0
M  V30 4 C 11.9708 0.9946 0 0
M  V30 5 N 11.4667 -0.4606 0 0
M  V30 6 C 9.9545 -0.7516 0 0
M  V30 7 C 9.4504 -2.2068 0 0
M  V30 8 N 7.9382 -2.4978 0 0
M  V30 9 C 7.4341 -3.953 0 0
M  V30 10 C 8.4422 -5.1171 0 0
M  V30 11 O 9.9545 -4.8261 0 0
M  V30 12 O 7.9382 -6.5723 0 0
M  V30 13 C 6.93 -1.3337 0 0
M  V30 14 C 5.4178 -1.6247 0 0
M  V30 15 O 4.4096 -0.4606 0 0
M  V30 16 O 4.9137 -3.0799 0 0
M  V30 17 C 12.4749 -1.6247 0 0
M  V30 18 C 13.9872 -1.3337 0 0
M  V30 19 O 14.4912 0.1215 0 0
M  V30 20 O 14.9953 -2.4978 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 8 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 5 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038976

>  <MW>
292.091

>  <MW (desalted)>
292.243

>  <ClogP>
-1.925

>  <logS>
0.465

>  <HBD>
4

>  <HBA>
10

>  <TPSA>
155.68

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.01 - 0.1 ?M | Kd (dissociation constant)  0.047 ?M | Kd (dissociation constant)  0.078 ?M | percentage decrease > 84 % | activity percentage  101 % | IC50  0.3 ?M

>  <CAS>
60-00-4

>  <Description>
Edetic acid is a chelating agent  that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive. It is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.

>  <EBC_ID>
EBC-13902

>  <IUPAC Name>
2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid

>  <Main Tar all refs>
Novartis (w/o Sandoz); NOVARTIS AG - US2014/194381, 2014, A1 | Biomolecules, 2019, vol. 9, # 10 | Biomolecules, 2019, vol. 9, # 10 | Eur. J. Med. Chem., 2016, vol. 123, p. 282 - 297 | J. Inorg. Biochem., 2018, vol. 186, p. 104 - 115 | J. MED. CHEM., 1993, vol. 36, # 1, p. 173 - 176

>  <Main tar all>
Beta-lactamase NDM-1 pX=8.0 | DNA polymerase I, thermostable pX=7.33 | Deoxyuridine triphosphate nucleotidohydrolase pX=7.11 | beta-amyloid 1-42 pX=6.82 | penicillinase pX=6.58 | Endothelin-converting enzyme 1 pX=6.52

$$$$
Famotidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -10.1579 2.5347 0 0
M  V30 2 C -8.6263 2.3738 0 0
M  V30 3 N -7.7212 3.6197 0 0
M  V30 4 C -6.1896 3.4587 0 0
M  V30 5 N -5.1591 4.6031 0 0
M  V30 6 C -3.7523 3.9768 0 0
M  V30 7 C -2.4186 4.7468 0 0
M  V30 8 S -1.0849 3.9768 0 0
M  V30 9 C 0.2488 4.7468 0 0
M  V30 10 C 1.5824 3.9768 0 0
M  V30 11 C 2.9161 4.7468 0 0
M  V30 12 N 2.9161 6.2868 0 0
M  V30 13 N 4.2498 3.9768 0 0
M  V30 14 S 5.5835 4.7468 0 0
M  V30 15 O 6.9172 5.5168 0 0
M  V30 16 O 6.3535 3.4131 0 0
M  V30 17 N 4.8135 6.0804 0 0
M  V30 18 C -3.9132 2.4452 0 0
M  V30 19 S -5.4196 2.125 0 0
M  V30 20 N -8 0.9669 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 2 14 16
M  V30 16 1 14 17
M  V30 17 2 6 18
M  V30 18 1 18 19
M  V30 19 1 4 19
M  V30 20 1 2 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553705

>  <MW>
337.045

>  <MW (desalted)>
337.445

>  <ClogP>
-0.371

>  <logS>
-2.11

>  <HBD>
5

>  <HBA>
8

>  <TPSA>
173.33

>  <RotBonds>
6

>  <CAS>
76824-35-6

>  <Description>
Famotidine is a competitive histamine H2-receptor antagonist. Famotidine has been used in the treatment of ulcers, gastroesophageal reflux disease, heartburn, also to decrease the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs.

>  <EBC_ID>
EBC-06823

>  <IUPAC Name>
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide

$$$$
Trimethobenzamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -9.3358 10.01 0 0
M  V30 2 O -8.0021 9.24 0 0
M  V30 3 C -8.0021 7.7 0 0
M  V30 4 C -6.6684 6.93 0 0
M  V30 5 C -6.6684 5.39 0 0
M  V30 6 C -8.0021 4.62 0 0
M  V30 7 C -9.3358 5.39 0 0
M  V30 8 O -10.6694 4.62 0 0
M  V30 9 C -12.0031 5.39 0 0
M  V30 10 C -9.3358 6.93 0 0
M  V30 11 O -10.6694 7.7 0 0
M  V30 12 C -10.6694 9.24 0 0
M  V30 13 C -5.3347 4.62 0 0
M  V30 14 O -4.001 5.39 0 0
M  V30 15 N -5.3347 3.08 0 0
M  V30 16 C -4.001 2.31 0 0
M  V30 17 C -2.6674 3.08 0 0
M  V30 18 C -2.6674 4.62 0 0
M  V30 19 C -1.3337 5.39 0 0
M  V30 20 C 0 4.62 0 0
M  V30 21 O 1.3337 5.39 0 0
M  V30 22 C 2.6674 4.62 0 0
M  V30 23 C 4.001 5.39 0 0
M  V30 24 N 5.3347 4.62 0 0
M  V30 25 C 6.6684 5.39 0 0
M  V30 26 C 5.3347 3.08 0 0
M  V30 27 C 0 3.08 0 0
M  V30 28 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 2 20 27
M  V30 28 1 27 28
M  V30 29 2 17 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z667611948

>  <MW>
388.457

>  <MW (desalted)>
388.457

>  <ClogP>
2.332

>  <logS>
-3.318

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
69.26

>  <RotBonds>
10

>  <CAS>
138-56-7

>  <Description>
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. It is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

>  <EBC_ID>
EBC-13568

>  <IUPAC Name>
N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4,5-trimethoxybenzamide

$$$$
Cholesterol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.0591 -3.8988 0 0
M  V30 2 C 14.3928 -4.6688 0 0
M  V30 3 C 14.3928 -6.2088 0 0
M  V30 4 C 15.7265 -3.8988 0 0
M  V30 5 C 17.0602 -4.6688 0 0
M  V30 6 C 18.3938 -3.8988 0 0
M  V30 7 C 19.7275 -4.6688 0 0 CFG=1
M  V30 8 C 19.7275 -6.2088 0 0
M  V30 9 C 21.0612 -3.8988 0 0 CFG=1
M  V30 10 C 21.2222 -2.3672 0 0
M  V30 11 C 22.7285 -2.047 0 0
M  V30 12 C 23.4985 -3.3807 0 0 CFG=1
M  V30 13 C 25.0049 -3.7009 0 0 CFG=2
M  V30 14 C 26.0353 -2.5565 0 0
M  V30 15 C 27.5417 -2.8767 0 0
M  V30 16 C 28.0176 -4.3413 0 0
M  V30 17 C 29.5239 -4.6615 0 0
M  V30 18 C 29.9998 -6.1261 0 0 CFG=1
M  V30 19 O 31.5061 -6.4463 0 0
M  V30 20 C 28.9693 -7.2705 0 0
M  V30 21 C 27.463 -6.9503 0 0
M  V30 22 C 26.9871 -5.4857 0 0 CFG=1
M  V30 23 C 25.9566 -6.6302 0 0
M  V30 24 C 25.4808 -5.1655 0 0 CFG=1
M  V30 25 C 24.4503 -6.31 0 0
M  V30 26 C 22.9439 -5.9898 0 0
M  V30 27 C 22.4681 -4.5252 0 0 CFG=2
M  V30 28 C 21.3236 -5.5556 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 18 17
M  V30 18 1 18 19 CFG=1
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 13 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 9 27
M  V30 30 1 27 12
M  V30 31 1 27 28 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2033589790

>  <MW>
386.654

>  <MW (desalted)>
386.654

>  <ClogP>
9.52

>  <logS>
-9.502

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
5

>  <Action on targets>
Stimulator | Inhibitor | Inhibitor | Inhibitor | Allosteric Modulator | Antagonist | - | Substrate | Substrate

>  <Activity coefficients and valu>
EC50 ~ 70 nM | Kd (dissociation constant)  213.4 nM | Kd (dissociation constant) = 0.3 ?M | Kd (dissociation constant)  332.9 nM | EC50  0.7 ?M | percentage decrease Active   | Km (Michaelis constant) = 1.6 ?M | Km (Michaelis constant)  1.87 ?M | Km (Michaelis constant)  1.9 ?M

>  <CAS>
57-88-5

>  <Description>
Cholesterol is a major sterol produced in mammalian cells that is required for cell viability and proliferation.  Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol is also an endogenous estrogen-related receptor 1 (ERR1) agonist.

>  <EBC_ID>
EBC-03865

>  <IUPAC Name>
(1R,3aS,3bS,7S,9aR,9bS,11aR)-9a,11a-dimethyl-1-[(2R)-6-methylheptan-2-yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol

>  <Main Tar all refs>
Cells, 2020, vol. 9, # 8, p. 1 - 20 | Cells, 2020, vol. 9, # 8, p. 1 - 20 | Curr. Drug Metab., 2007, vol. 8, # 6, p. 594 - 611 | Front. Genet., 2022, vol. 13 | J. Lipid Res., 2021, vol. 62 | J. Cell. Biochem., 2018, vol. 119, # 3, p. 2929 - 2938 | Biochem. J., 2007, vol. 401, # 2, p. 597 - 605 | J. Am. Chem. Soc., 2018, vol. 140, # 3, p. 916 - 918 | Chem. Commun., 2019, vol. 55, # 12, p. 1829 - 1832

>  <Main tar all>
Estrogen-related receptor-? pX=7.15 | H-PGDS pX=6.67 | CYP11A1 pX=6.52 | Oxysterol-binding protein homolog 3 pX=6.48 | ATP-dependent translocase ABCB1 pX=6.15 | nuclear estrogen receptor pX=6.0 | ABCB1 pX=5.8 | Hedgehog protein pX=5.73 | protein hedgehog pX=5.72

$$$$
Mabuprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 6.93 0 0
M  V30 2 C -5.3347 6.16 0 0
M  V30 3 C -5.3347 4.62 0 0
M  V30 4 C -4.001 6.93 0 0
M  V30 5 C -2.6674 6.16 0 0
M  V30 6 C -1.3337 6.93 0 0
M  V30 7 C 0 6.16 0 0
M  V30 8 C 0 4.62 0 0
M  V30 9 C -1.3337 3.85 0 0
M  V30 10 C -2.6674 4.62 0 0
M  V30 11 C 1.3337 3.85 0 0
M  V30 12 C 1.3337 2.31 0 0
M  V30 13 C 2.6674 4.62 0 0
M  V30 14 O 2.6674 6.16 0 0
M  V30 15 N 4.001 3.85 0 0
M  V30 16 C 5.3347 4.62 0 0
M  V30 17 C 6.6684 3.85 0 0
M  V30 18 O 8.0021 4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1537048897

>  <MW>
249.349

>  <MW (desalted)>
249.349

>  <ClogP>
2.576

>  <logS>
-3.487

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  39 %

>  <CAS>
82821-47-4

>  <Description>
Mabuprofen is an amide prodrug of ibuprofen, a non-steroidal anti-inflammatory drug with analgesic, antipyretic and anti-inflammatory properties.

>  <EBC_ID>
EBC-50108

>  <IUPAC Name>
N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propanamide

>  <Main Tar all refs>
J. Med. Chem., 2005, vol. 48, # 13, p. 4312 - 4331

>  <Main tar all>
Cyclooxygenase pX=4.81

$$$$
Sorafenib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 -3.08 0 0
M  V30 2 N -8.0021 -4.62 0 0
M  V30 3 C -6.6684 -5.39 0 0
M  V30 4 O -5.3347 -4.62 0 0
M  V30 5 C -6.6684 -6.93 0 0
M  V30 6 C -5.3347 -7.7 0 0
M  V30 7 C -5.3347 -9.24 0 0
M  V30 8 O -4.001 -10.01 0 0
M  V30 9 C -4.001 -11.55 0 0
M  V30 10 C -2.6674 -12.32 0 0
M  V30 11 C -2.6674 -13.86 0 0
M  V30 12 C -4.001 -14.63 0 0
M  V30 13 N -4.001 -16.17 0 0
M  V30 14 C -5.3347 -16.94 0 0
M  V30 15 O -6.6684 -16.17 0 0
M  V30 16 N -5.3347 -18.48 0 0
M  V30 17 C -4.001 -19.25 0 0
M  V30 18 C -2.6674 -18.48 0 0
M  V30 19 C -1.3337 -19.25 0 0
M  V30 20 C -1.3337 -20.79 0 0
M  V30 21 Cl -0 -21.56 0 0
M  V30 22 C -2.6674 -21.56 0 0
M  V30 23 C -4.001 -20.79 0 0
M  V30 24 C -2.6674 -23.1 0 0
M  V30 25 F -2.6674 -24.64 0 0
M  V30 26 F -4.2074 -23.1 0 0
M  V30 27 F -1.1274 -23.1 0 0
M  V30 28 C -5.3347 -13.86 0 0
M  V30 29 C -5.3347 -12.32 0 0
M  V30 30 C -6.6684 -10.01 0 0
M  V30 31 C -8.0021 -9.24 0 0
M  V30 32 N -8.0021 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 17 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 2 12 28
M  V30 29 1 28 29
M  V30 30 2 9 29
M  V30 31 1 7 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 5 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z89277543

>  <MW>
464.825

>  <MW (desalted)>
464.825

>  <ClogP>
5.455

>  <logS>
-6.37

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
92.35

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2 pM | IC (inhibitory concentration) = 0.006 nM | IC (inhibitory concentration) = 0.012 nM | Ki (inhibition constant)  22 pM | IC50  4E-05 ?M

>  <CAS>
284461-73-0

>  <Description>
Sorafenib is a kinase inhibitor used in the treatment of unresectable liver carcinoma and advanced renal carcinoma.

>  <EBC_ID>
EBC-00643

>  <IUPAC Name>
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide

>  <Main Tar all refs>
BRISTOL-MYERS SQUIBB CO - WO2007/53452, 2007, A1 | Eur. J. Med. Chem., 2014, vol. 87, p. 782 - 793 | Eur. J. Med. Chem., 2014, vol. 87, p. 782 - 793 | Bioorg. Med. Chem., 2011, vol. 19, # 18, p. 5342 - 5351 | J. Enzyme Inhib. Med. Chem., 2021, vol. 36, # 1, p. 1454 - 1471

>  <Main tar all>
FIP1L1-PDGFR-alpha pX=11.7 | Raf-1 proto-oncogene, serine/threonine kinase pX=11.2 | B-Raf proto-oncogene, serine/threonine kinase pX=10.9 | kinase insert domain receptor pX=10.7 | epidermal growth factor receptor pX=10.4

$$$$
Zalcitabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 C 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=1
M  V30 7 C 2.5796 5.5648 0 0
M  V30 8 C 2.1037 4.1002 0 0
M  V30 9 C 0.5637 4.1002 0 0 CFG=1
M  V30 10 C -0.3415 2.8543 0 0
M  V30 11 O 0.2849 1.4474 0 0
M  V30 12 O 0.0878 5.5648 0 0
M  V30 13 C 0 8.78 0 0
M  V30 14 O -1.3337 8.01 0 0
M  V30 15 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=1
M  V30 10 1 10 11
M  V30 11 1 9 12
M  V30 12 1 6 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 2 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1550648753

>  <MW>
211.218

>  <MW (desalted)>
211.218

>  <ClogP>
-1.247

>  <logS>
-0.63

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
88.15

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | - | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.02 ?M | IC50  33 nM | Ki (inhibition constant) = 0.051 ?M | Km (Michaelis constant)  0.13 ?M | Km (Michaelis constant)  0.13 ?M | IC50 = 0.6 ?M | IC50 = 0.6 ?M

>  <CAS>
7481-89-2

>  <Description>
Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor. In cells, it is phosphorylated to the active triphosphate form, ddCTP, which acts as a substrate for HIV reverse transcriptase. It incorporates into viral DNA where it terminates chain elongation when the missing hydroxyl group is encountered.

>  <EBC_ID>
EBC-07537

>  <IUPAC Name>
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
Annu. Rep. Med. Chem., 1995, vol. 30, p. 139 - 149 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 6, p. 923 - 928 | J. Med. Chem., 2005, vol. 48, # 7, p. 2695 - 2700 | Mol. Pharmacol., 1998, vol. 53, # 5, p. 801 - 807 | Mol. Pharmacol., 1998, vol. 53, # 5, p. 801 - 807 | MOL. PHARMACOL., 1997, vol. 51, # 1, p. 132 - 138 | MOL. PHARMACOL., 1997, vol. 51, # 1, p. 132 - 138

>  <Main tar all>
DNA pX=7.7 | CXCR4 pX=7.48 | RNA-directed DNA polymerase pX=7.29 | DNA?polymerase?beta pX=6.89 | DNA?polymerase?subunit?gamma-1 pX=6.89 | Deoxycytidine kinase pX=6.22 | deoxycytidine kinase pX=6.22

$$$$
Sertraline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.0674 -5.5825 0 0
M  V30 3 N 5.7337 -4.8125 0 0
M  V30 4 C 5.7337 -3.2725 0 0 CFG=1
M  V30 5 C 4.4 -2.5025 0 0
M  V30 6 C 4.4 -0.9625 0 0
M  V30 7 C 5.7337 -0.1925 0 0 CFG=1
M  V30 8 C 5.7337 1.3475 0 0
M  V30 9 C 4.4 2.1175 0 0
M  V30 10 C 4.4 3.6575 0 0
M  V30 11 C 5.7337 4.4275 0 0
M  V30 12 Cl 5.7337 5.9675 0 0
M  V30 13 C 7.0674 3.6575 0 0
M  V30 14 Cl 8.401 4.4275 0 0
M  V30 15 C 7.0674 2.1175 0 0
M  V30 16 C 7.0674 -0.9625 0 0
M  V30 17 C 8.401 -0.1925 0 0
M  V30 18 C 9.7347 -0.9625 0 0
M  V30 19 C 9.7347 -2.5025 0 0
M  V30 20 C 8.401 -3.2725 0 0
M  V30 21 C 7.0674 -2.5025 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3 CFG=1
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 7 6
M  V30 6 1 7 8 CFG=1
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 11 13
M  V30 12 1 13 14
M  V30 13 1 13 15
M  V30 14 2 8 15
M  V30 15 1 7 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 4 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404500

>  <MW>
342.691

>  <MW (desalted)>
306.23

>  <ClogP>
5.347

>  <logS>
-5.46

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.29 nM

>  <CAS>
79559-97-0

>  <Description>
Sertraline hydrochloride a selective serotonin reuptake inhibitor. Formulations containing sertraline are applicable to depression and related disorders.

>  <EBC_ID>
EBC-03877

>  <IUPAC Name>
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 1998, vol. 8, # 5, p. 487 - 492

>  <Main tar all>
SERT pX=9.54

$$$$
Raltegravir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 -11.55 0 0
M  V30 2 C 6.6684 -13.09 0 0
M  V30 3 N 7.9143 -13.9952 0 0
M  V30 4 N 7.4384 -15.4598 0 0
M  V30 5 C 5.8984 -15.4598 0 0
M  V30 6 O 5.4225 -13.9952 0 0
M  V30 7 C 4.9932 -16.7057 0 0
M  V30 8 O 3.4616 -16.5447 0 0
M  V30 9 N 5.6196 -18.1126 0 0
M  V30 10 C 4.7144 -19.3584 0 0
M  V30 11 C 3.4685 -18.4533 0 0
M  V30 12 C 5.9603 -20.2636 0 0
M  V30 13 C 3.8092 -20.6043 0 0
M  V30 14 N 4.4356 -22.0112 0 0
M  V30 15 C 3.5304 -23.2571 0 0
M  V30 16 C 4.1568 -24.6639 0 0
M  V30 17 O 5.6883 -24.8249 0 0
M  V30 18 N 3.2516 -25.9098 0 0
M  V30 19 C 3.8779 -27.3167 0 0
M  V30 20 C 2.9728 -28.5626 0 0
M  V30 21 C 3.5991 -29.9694 0 0
M  V30 22 C 2.6939 -31.2153 0 0
M  V30 23 C 1.1624 -31.0543 0 0
M  V30 24 F 0.2572 -32.3002 0 0
M  V30 25 C 0.536 -29.6475 0 0
M  V30 26 C 1.4412 -28.4016 0 0
M  V30 27 C 1.9988 -23.0961 0 0
M  V30 28 O 1.0936 -24.342 0 0
M  V30 29 C 1.3724 -21.6892 0 0
M  V30 30 O -0.1591 -21.5283 0 0
M  V30 31 N 2.2776 -20.4434 0 0
M  V30 32 C 1.6513 -19.0365 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 23 25
M  V30 26 1 25 26
M  V30 27 2 20 26
M  V30 28 2 15 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 13 31
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1532717445

>  <MW>
444.416

>  <MW (desalted)>
444.416

>  <ClogP>
1.16

>  <logS>
-2.36

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
150.02

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.11 nM | EC50  0.58 nM | IC50  0.97 nM | EC50  1.6 nM | IC50  2 nM

>  <CAS>
518048-05-0

>  <Description>
Raltegravir is a potent integrase (IN) inhibitor. Raltegravir is an antiretroviral drug used for the treatment of HIV-1 infection in conjunction with other antiretrovirals.

>  <EBC_ID>
EBC-07544

>  <IUPAC Name>
N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide

>  <Main Tar all refs>
Curr. Med. Chem., 2013, vol. 20, # 5, p. 724 - 733 | Virol. J., 2021, vol. 18, # 1 | Biochem. Biophys. Res. Commun., 2016, vol. 475, # 1, p. 113 - 118 | Science, 2020, vol. 367, # 6479, p. 806 - 810 | Eur. J. Med. Chem., 2016, vol. 117, p. 99 - 112

>  <Main tar all>
Integrase pX=9.96 | Integrase pX=9.24 | Envelope glycoprotein pX=9.01 | Integrase pX=8.8 | Integrase pX=8.7

$$$$
Cetirizine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 O -9.8791 -5.39 0 0
M  V30 4 C -8.5454 -4.62 0 0
M  V30 5 O -8.5454 -3.08 0 0
M  V30 6 C -7.2117 -5.39 0 0
M  V30 7 O -5.8781 -4.62 0 0
M  V30 8 C -4.5444 -5.39 0 0
M  V30 9 C -3.2107 -4.62 0 0
M  V30 10 N -1.877 -5.39 0 0
M  V30 11 C -0.5434 -4.62 0 0
M  V30 12 C 0.7903 -5.39 0 0
M  V30 13 N 0.7903 -6.93 0 0
M  V30 14 C -0.5434 -7.7 0 0
M  V30 15 C -1.877 -6.93 0 0
M  V30 16 C 2.124 -7.7 0 0
M  V30 17 C 2.124 -9.24 0 0
M  V30 18 C 3.4577 -10.01 0 0
M  V30 19 C 3.4577 -11.55 0 0
M  V30 20 C 2.124 -12.32 0 0
M  V30 21 C 0.7903 -11.55 0 0
M  V30 22 C 0.7903 -10.01 0 0
M  V30 23 C 3.4577 -6.93 0 0
M  V30 24 C 3.4577 -5.39 0 0
M  V30 25 C 4.7914 -4.62 0 0
M  V30 26 C 6.125 -5.39 0 0
M  V30 27 Cl 7.4587 -4.62 0 0
M  V30 28 C 6.125 -6.93 0 0
M  V30 29 C 4.7914 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 2 4 5
M  V30 3 1 4 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 1 10 15
M  V30 14 1 13 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 19 20
M  V30 19 2 20 21
M  V30 20 1 21 22
M  V30 21 2 17 22
M  V30 22 1 16 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 2 26 28
M  V30 28 1 28 29
M  V30 29 2 23 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242062189

>  <MW>
460.109

>  <MW (desalted)>
388.888

>  <ClogP>
2.08

>  <logS>
-3.877

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
53.01

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active

>  <CAS>
83881-52-1

>  <Description>
Cetirizine is a selective histamine-1 antagonist drug used in allergic rhinitis and chronic urticaria.

>  <EBC_ID>
EBC-11214

>  <IUPAC Name>
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid dihydrochloride

>  <Main Tar all refs>
J. Clin. Pharmacol., 2020, vol. 60, # 8, p. 1076 - 1086

>  <Main tar all>
Organic cation/carnitine transporter 1 pX=11.0

$$$$
Didanosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.0952 -9.1142 0 0
M  V30 2 C 2.1256 -7.9697 0 0
M  V30 3 C 1.6497 -6.5051 0 0 CFG=2
M  V30 4 C 0.1851 -6.0292 0 0
M  V30 5 C 0.1851 -4.4892 0 0
M  V30 6 C 1.6497 -4.0133 0 0 CFG=1
M  V30 7 O 2.5549 -5.2592 0 0
M  V30 8 N 2.1256 -2.5487 0 0
M  V30 9 C 1.2204 -1.3028 0 0
M  V30 10 N 2.1256 -0.0569 0 0
M  V30 11 C 3.5902 -0.5328 0 0
M  V30 12 C 4.9239 0.2372 0 0
M  V30 13 O 4.9239 1.7772 0 0
M  V30 14 N 6.2576 -0.5328 0 0
M  V30 15 C 6.2576 -2.0728 0 0
M  V30 16 N 4.9239 -2.8428 0 0
M  V30 17 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 3 7
M  V30 8 1 6 8 CFG=3
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 8 17
M  V30 19 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616193

>  <MW>
236.227

>  <MW (desalted)>
236.227

>  <ClogP>
-1.924

>  <logS>
-0.99

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
88.74

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
EC50 = 0.0056 ?M

>  <CAS>
69655-05-6

>  <Description>
Didanosine is a reverse transcriptase inhibitor. It is used in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.

>  <EBC_ID>
EBC-13588

>  <IUPAC Name>
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

>  <Main Tar all refs>
J. Nat. Prod., 2001, vol. 64, # 2, p. 265 - 277

>  <Main tar all>
RNA-directed DNA polymerase pX=8.25

$$$$
Camphor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.3892 0.6833 0 0
M  V30 2 C 1.8644 0.2413 0 0
M  V30 3 C 0.3892 -0.2007 0 0
M  V30 4 C 2.2494 1.7813 0 0 CFG=2
M  V30 5 C 0.9157 1.0113 0 0
M  V30 6 C 0.9157 -0.5287 0 0
M  V30 7 C 2.2494 -1.2987 0 0 CFG=2
M  V30 8 C 2.2494 -2.8387 0 0
M  V30 9 C 3.5831 -0.5287 0 0
M  V30 10 O 4.9167 -1.2987 0 0
M  V30 11 C 3.5831 1.0113 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5 CFG=3
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 2
M  V30 8 1 7 8 CFG=1
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 4 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255434759

>  <MW>
152.233

>  <MW (desalted)>
152.233

>  <ClogP>
2.177

>  <logS>
-1.887

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.07

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Allosteric Modulator | Allosteric Modulator | Allosteric Modulator | -

>  <Activity coefficients and valu>
inhibition percentage  6.9 - 89.7 % | IC50  119.01 ?M | stimulation rate  40 - 50 % | stimulation rate  40 - 50 % | stimulation rate  40 - 50 % | EC50 = 469.1 ?M

>  <CAS>
464-49-3

>  <Description>
Camphor is a compound used topically to help relieve pain and also as a topical antiseptic.

>  <EBC_ID>
EBC-12039

>  <IUPAC Name>
(1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

>  <Main Tar all refs>
KAO CORPORATION - WO2013/103155, 2013, A1 | Biomolecules, 2020, vol. 10, # 2 | Eur. J. Pharmacol., 2004, vol. 506, # 1, p. 9 - 16 | Eur. J. Pharmacol., 2004, vol. 506, # 1, p. 9 - 16 | Eur. J. Pharmacol., 2004, vol. 506, # 1, p. 9 - 16 | Biochem. Pharmacol., 2005, vol. 69, # 7, p. 1101 - 1111

>  <Main tar all>
TRPA1 pX=4.49 | Cytochrome P450 2B6 pX=3.92 | GABAA receptor ?2s subunit pX=3.44 | GABAA receptor ?1 subunit pX=3.44 | GABAA receptor ?2 subunit pX=3.44 | GABAA receptor ? subunit pX=3.33

$$$$
Riboflavin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -2.31 0 0
M  V30 2 C 0 -1.54 0 0
M  V30 3 C 0 0 0 0
M  V30 4 C 1.3337 0.77 0 0
M  V30 5 N 1.3337 2.31 0 0
M  V30 6 C 2.6674 3.08 0 0
M  V30 7 C 2.6674 4.62 0 0
M  V30 8 O 1.3337 5.39 0 0
M  V30 9 N 4.001 5.39 0 0
M  V30 10 C 5.3347 4.62 0 0
M  V30 11 O 6.6684 5.39 0 0
M  V30 12 N 5.3347 3.08 0 0
M  V30 13 C 4.001 2.31 0 0
M  V30 14 N 4.001 0.77 0 0
M  V30 15 C 5.3347 0 0 0
M  V30 16 C 6.6684 0.77 0 0 CFG=2
M  V30 17 O 6.6684 2.31 0 0
M  V30 18 C 8.0021 0 0 0 CFG=2
M  V30 19 O 8.0021 -1.54 0 0
M  V30 20 C 9.3358 0.77 0 0 CFG=2
M  V30 21 O 9.3358 2.31 0 0
M  V30 22 C 10.6694 0 0 0
M  V30 23 O 12.0031 0.77 0 0
M  V30 24 C 2.6674 0 0 0
M  V30 25 C 2.6674 -1.54 0 0
M  V30 26 C 1.3337 -2.31 0 0
M  V30 27 C 1.3337 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=3
M  V30 18 1 18 16
M  V30 19 1 18 19 CFG=1
M  V30 20 1 18 20
M  V30 21 1 20 21 CFG=3
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 14 24
M  V30 25 1 4 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 2 26
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216887959

>  <MW>
376.364

>  <MW (desalted)>
376.364

>  <ClogP>
-0.725

>  <logS>
-2.793

>  <HBD>
5

>  <HBA>
9

>  <TPSA>
155.05

>  <RotBonds>
5

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1.3 nM | Kd (dissociation constant) = 5 nM

>  <CAS>
83-88-5

>  <Description>
Riboflavin is a vitamin used to correct vitamin B2 deficiency. It binds to riboflavin hydrogenase, riboflavin kinase, and riboflavin synthase. Riboflavin is the precursor of flavin mononucleotide (FMN, riboflavin monophosphate) and flavin adenine dinucleotide.

>  <EBC_ID>
EBC-26847

>  <IUPAC Name>
7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-2H,3H,4H,10H-benzo[g]pteridine-2,4-dione

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2011, vol. 2, # 5, p. 363 - 367 | ACS Med. Chem. Lett., 2011, vol. 2, # 5, p. 363 - 367

>  <Main tar all>
riboflavin binding protein pX=8.89 | riboflavin-binding protein pX=8.3

$$$$
Levofloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -0.77 0 0 CFG=1
M  V30 3 C 2.6674 0 0 0
M  V30 4 O 2.6674 1.54 0 0
M  V30 5 C 4.001 2.31 0 0
M  V30 6 C 4.001 3.85 0 0
M  V30 7 N 2.6674 4.62 0 0
M  V30 8 C 1.3337 3.85 0 0
M  V30 9 C -0 4.62 0 0
M  V30 10 N -0 6.16 0 0
M  V30 11 C -1.3337 6.93 0 0
M  V30 12 C 1.3337 6.93 0 0
M  V30 13 C 2.6674 6.16 0 0
M  V30 14 C 5.3347 4.62 0 0
M  V30 15 F 5.3347 6.16 0 0
M  V30 16 C 6.6684 3.85 0 0
M  V30 17 C 6.6684 2.31 0 0
M  V30 18 C 8.0021 1.54 0 0
M  V30 19 O 9.3358 2.31 0 0
M  V30 20 C 8.0021 0 0 0
M  V30 21 C 6.6684 -0.77 0 0
M  V30 22 N 5.3347 0 0 0
M  V30 23 C 5.3347 1.54 0 0
M  V30 24 C 9.3358 -0.77 0 0
M  V30 25 O 10.6694 -0 0 0
M  V30 26 O 9.3358 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 2 22
M  V30 24 1 22 23
M  V30 25 2 5 23
M  V30 26 1 17 23
M  V30 27 1 20 24
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1590790198

>  <MW>
361.368

>  <MW (desalted)>
361.368

>  <ClogP>
-0.508

>  <logS>
-2.41

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
73.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | - | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | -

>  <Activity coefficients and valu>
MIC  0.0019 ?g/ml | MIC  7.8 nM | MIC  0.008 ?g/ml | MIC <= 0.008 ?g/ml | MIC  0.015 - 0.5 ?g/ml | MIC  0.015 ?g/ml | MIC  0.015 - 0.5 ?g/ml | MIC  0.016 ?g/ml | MIC90  0.49 ?M | MIC  0.02 ?g/ml | MIC  0.03 ?g/ml | MIC = 0.03 ?g/mL | MIC  0.0313 ?g/ml | MIC  0.032 ?g/ml | IC90  0.91 ?M | IC50 > 0.1 ?M | MIC <= 0.06 ?g/ml | MIC  0.06 - 8 mg/l | MIC = 0.06 ?g/mL | MIC = 0.06 ?g/mL

>  <CAS>
100986-85-4

>  <Description>
Levofloxacin is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria of the upper respiratory tract, skin and skin structures, urinary tract, and prostate, as well as for post-exposure treatment of inhaled anthrax and the plague. Levofloxacin, like other fluoroquinolone antibiotics, exerts its antimicrobial activity via the inhibition of two key bacterial enzymes: DNA gyrase and topoisomerase IV.

>  <EBC_ID>
EBC-11226

>  <IUPAC Name>
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2019, vol. 29, # 7, p. 882 - 889 | Lett. Drug Des. Discov., 2018, vol. 15, # 8, p. 895 - 904 | Antimicrob. Agents Chemother., 2021, vol. 65, # 4 | UNIVERSITY OF CALIFORNIA - WO2020/251953, 2020, A1 | J. Med. Chem., 2021, vol. 64, # 20, p. 15214 - 15249 | Bioconjugate Chem., 2019, vol. 30, # 3, p. 751 - 759 | J. Med. Chem., 2021, vol. 64, # 20, p. 15214 - 15249 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - WO2018/165612, 2018, A1 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | Antimicrob. Agents Chemother., 2018, vol. 62, # 6 | J. Med. Chem., 1999, vol. 42, # 24, p. 4928 - 4931 | ACS Infect. Dis., 2022, vol. 8, # 2, p. 255 - 270 | J. Antibiot., 2022, vol. 75, # 7, p. 385 - 395 | Bioorg. Chem., 2021, vol. 115 | Antimicrob. Agents Chemother., 1999, vol. 43, # 7, p. 1693 - 1699 | SUTTON LARRY D; KEENAN RICHARD M - WO2020/206381, 2020, A1 | Antimicrob. Agents Chemother., 2019, vol. 63, # 8 | J. Med. Chem., 1999, vol. 42, # 24, p. 4928 - 4931 | J. Med. Chem., 1999, vol. 42, # 24, p. 4928 - 4931

>  <Main tar all>
Multidrug?efflux?pump?subunit?AcrB pX=8.28 | DNA supercoiling protein pX=8.11 | DNA topoisomerase II pX=7.66 | ribosome 50S-subunit pX=7.66 | DNA?gyrase pX=7.38 | Nitroreductase pX=7.38 | Topoisomerase IV pX=7.38 | efflux transmembrane transporter pX=7.35 | DNA?gyrase pX=7.26 | DNA?gyrase subunit A pX=7.26 | ATP synthase subunit c pX=7.08 | Mexef-Oprn Efflux Pump pX=7.08 | Multidrug?efflux?pump?subunit?AcrA pX=7.06 | Cell division protein FtsZ pX=7.05 | DNA?gyrase subunit B pX=7.0 | Sporulation kinase A pX=7.0 | Beta-Lactamase AmpC pX=6.78 | Carbapenem-hydrolyzing beta-lactamase KPC pX=6.78 | Mexab-Oprm Efflux Pump pX=6.78 | Mexcd-Oprj Efflux Pump pX=6.78

$$$$
Bezafibrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.2321 -4.8263 0 0
M  V30 2 C -8.0021 -6.16 0 0
M  V30 3 C -8.7721 -7.4937 0 0
M  V30 4 O -6.6684 -6.93 0 0
M  V30 5 C -5.3347 -6.16 0 0
M  V30 6 C -5.3347 -4.62 0 0
M  V30 7 C -4.001 -3.85 0 0
M  V30 8 C -2.6674 -4.62 0 0
M  V30 9 C -1.3337 -3.85 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 N 1.3337 -3.85 0 0
M  V30 12 C 2.6674 -4.62 0 0
M  V30 13 O 2.6674 -6.16 0 0
M  V30 14 C 4.001 -3.85 0 0
M  V30 15 C 4.001 -2.31 0 0
M  V30 16 C 5.3347 -1.54 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 Cl 8.0021 -1.54 0 0
M  V30 19 C 6.6684 -3.85 0 0
M  V30 20 C 5.3347 -4.62 0 0
M  V30 21 C -2.6674 -6.16 0 0
M  V30 22 C -4.001 -6.93 0 0
M  V30 23 C -9.3358 -5.39 0 0
M  V30 24 O -10.6694 -6.16 0 0
M  V30 25 O -9.3358 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 19 20
M  V30 20 2 14 20
M  V30 21 2 8 21
M  V30 22 1 21 22
M  V30 23 2 5 22
M  V30 24 1 2 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588039015

>  <MW>
361.108

>  <MW (desalted)>
361.819

>  <ClogP>
3.698

>  <logS>
-4.862

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
75.63

>  <RotBonds>
7

>  <Action on targets>
- | Allosteric Modulator

>  <Activity coefficients and valu>
pKb  9.1  | EC50  13.5 nM

>  <CAS>
41859-67-0

>  <Description>
Bezafibrate is an antilipemic agent that lowers cholesterol and triglycerides. It is an agonist of PPAR-alpha. Bezafibrate is a lipid-lowering fibrate used in the management of primary and secondary hyperlipidaemia, when there is a lack of clinical improvement following lifestyle modifications or correction of the underlying disorder.

>  <EBC_ID>
EBC-26794

>  <IUPAC Name>
2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | J. Enzyme Inhib. Med. Chem., 2021, vol. 36, # 1, p. 377 - 383

>  <Main tar all>
Aldose reductase pX=9.1 | FFA1 receptor pX=7.87

$$$$
Taurolidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.9909 -1.1303 0 0
M  V30 2 S 4.001 -2.31 0 0
M  V30 3 O 3.0111 -1.1303 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 N 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 N 2.6674 -7.7 0 0
M  V30 9 C 2.6674 -9.24 0 0
M  V30 10 C 1.3337 -10.01 0 0
M  V30 11 S -0 -9.24 0 0
M  V30 12 O -0.5267 -10.6871 0 0
M  V30 13 O -1.5166 -8.9726 0 0
M  V30 14 N 0 -7.7 0 0
M  V30 15 C 1.3337 -6.93 0 0
M  V30 16 C 2.6674 -4.62 0 0
M  V30 17 N 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 2 11 13
M  V30 13 1 11 14
M  V30 14 1 14 15
M  V30 15 1 8 15
M  V30 16 1 6 16
M  V30 17 1 16 17
M  V30 18 1 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681892608

>  <MW>
284.061

>  <MW (desalted)>
284.356

>  <ClogP>
-0.087

>  <logS>
1.007

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
98.82

>  <RotBonds>
2

>  <CAS>
19388-87-5

>  <Description>
Taurolidine is an antimicrobial derivative of taurine. It is used for prophylaxis of catheter-related infections.

>  <EBC_ID>
EBC-26441

>  <IUPAC Name>
4-[(1,1-dioxo-1lambda6,2,4-thiadiazinan-4-yl)methyl]-1lambda6,2,4-thiadiazinane-1,1-dione

$$$$
Bendamustine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.732 -3.193 0 0
M  V30 3 N 6.7016 -2.0486 0 0
M  V30 4 C 5.17 -2.2095 0 0
M  V30 5 C 4.4 -3.5432 0 0
M  V30 6 C 5.17 -4.8769 0 0
M  V30 7 C 4.4 -6.2106 0 0
M  V30 8 C 5.17 -7.5443 0 0
M  V30 9 O 4.4 -8.8779 0 0
M  V30 10 O 6.71 -7.5443 0 0
M  V30 11 N 4.5436 -0.8027 0 0
M  V30 12 C 5.6881 0.2278 0 0
M  V30 13 C 5.6881 1.7678 0 0
M  V30 14 C 7.0217 2.5378 0 0
M  V30 15 C 8.3554 1.7678 0 0
M  V30 16 C 8.3554 0.2278 0 0
M  V30 17 C 7.0217 -0.5422 0 0
M  V30 18 N 7.0217 4.0778 0 0
M  V30 19 C 5.6881 4.8478 0 0
M  V30 20 C 5.6881 6.3878 0 0
M  V30 21 Cl 4.3544 7.1578 0 0
M  V30 22 C 8.3554 4.8478 0 0
M  V30 23 C 8.3554 6.3878 0 0
M  V30 24 Cl 9.6891 7.1578 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 9 2 4 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 1 3 17
M  V30 17 2 12 17
M  V30 18 1 14 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 18 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802251

>  <MW>
393.078

>  <MW (desalted)>
358.263

>  <ClogP>
3.237

>  <logS>
-3.19

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
58.36

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  16.88 ?M | IC50  91.6 ?M

>  <CAS>
3543-75-7

>  <Description>
Bendamustine is an antineoplastic agent used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed following rituximab therapy. Bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death.

>  <EBC_ID>
EBC-17087

>  <IUPAC Name>
4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}butanoic acid hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2022, vol. 65, # 21, p. 14578 - 14588 | Chem. Biodivers., 2023, vol. 20, # 1

>  <Main tar all>
Organic anion transporter 2 pX=4.77 | Transforming growth factor beta-1 proprotein pX=4.04

$$$$
Prednisone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 O 10.768 -6.7807 0 0
M  V30 6 C 10.2985 -4.155 0 0 CFG=1
M  V30 7 C 9.3058 -2.9776 0 0 CFG=1
M  V30 8 C 9.829 -1.5293 0 0
M  V30 9 C 11.345 -1.2582 0 0
M  V30 10 C 12.3377 -2.4355 0 0
M  V30 11 C 13.8537 -2.1644 0 0
M  V30 12 C 14.8464 -3.3418 0 0
M  V30 13 O 16.3624 -3.0707 0 0
M  V30 14 C 14.3232 -4.7901 0 0
M  V30 15 C 12.8072 -5.0612 0 0
M  V30 16 C 11.8145 -3.8839 0 0 CFG=2
M  V30 17 C 11.2913 -5.3323 0 0
M  V30 18 C 7.7898 -3.2487 0 0 CFG=2
M  V30 19 C 6.574 -2.3035 0 0
M  V30 20 C 5.2994 -3.1677 0 0
M  V30 21 C 5.7274 -4.6471 0 0 CFG=1
M  V30 22 O 4.3071 -5.2423 0 0
M  V30 23 C 5.5008 -6.1703 0 0
M  V30 24 O 6.7067 -7.1282 0 0
M  V30 25 C 4.0683 -6.7357 0 0
M  V30 26 O 3.8417 -8.2589 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4 CFG=1
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 16 15
M  V30 16 1 6 16
M  V30 17 1 16 10
M  V30 18 1 16 17 CFG=1
M  V30 19 1 18 7
M  V30 20 1 2 18
M  V30 21 1 18 19 CFG=1
M  V30 22 1 19 20
M  V30 23 1 21 20
M  V30 24 1 2 21
M  V30 25 1 21 22 CFG=3
M  V30 26 1 21 23 CFG=1
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756390288

>  <MW>
358.428

>  <MW (desalted)>
358.428

>  <ClogP>
1.661

>  <logS>
-3.379

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
91.67

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  5 nM | Ki (inhibition constant)  5.3 nM | Ki (inhibition constant)  5.3 nM | decrease rate Active

>  <CAS>
53-03-2

>  <Description>
Prednisone is a corticosteroid used to treat inflammation or immune-mediated reactions.

>  <EBC_ID>
EBC-26720

>  <IUPAC Name>
(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione

>  <Main Tar all refs>
LIGAND PHARMACEUTICALS INC - WO2009/103007, 2009, A2 | LIGAND PHARMACEUTICALS INC - WO2006/19716, 2006, A1 | LIGAND PHARMACEUTICALS INC - WO2006/19716, 2006, A1 | Int. J. Mol. Sci., 2019, vol. 20, # 8

>  <Main tar all>
Glucocorticoid receptor pX=8.3 | Peroxisome proliferator-activated receptor-? pX=8.28 | Peroxisome proliferator-activated receptor-? pX=8.28 | SMO pX=7.0

$$$$
Lisinopril
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 -12.32 0 0
M  V30 2 C 6.6684 -11.55 0 0
M  V30 3 C 8.0021 -12.32 0 0
M  V30 4 C 9.3358 -11.55 0 0
M  V30 5 C 10.6694 -12.32 0 0
M  V30 6 C 12.0031 -11.55 0 0 CFG=2
M  V30 7 N 13.3368 -12.32 0 0
M  V30 8 C 14.6705 -11.55 0 0 CFG=1
M  V30 9 C 16.0041 -12.32 0 0
M  V30 10 C 17.3378 -11.55 0 0
M  V30 11 C 18.6715 -12.32 0 0
M  V30 12 C 20.0052 -11.55 0 0
M  V30 13 C 21.3389 -12.32 0 0
M  V30 14 C 21.3389 -13.86 0 0
M  V30 15 C 20.0052 -14.63 0 0
M  V30 16 C 18.6715 -13.86 0 0
M  V30 17 C 14.6705 -10.01 0 0
M  V30 18 O 16.0041 -9.24 0 0
M  V30 19 O 13.3368 -9.24 0 0
M  V30 20 C 12.0031 -10.01 0 0
M  V30 21 O 12.6295 -8.6031 0 0
M  V30 22 N 10.6694 -9.24 0 0
M  V30 23 C 9.2626 -9.8664 0 0
M  V30 24 C 8.2321 -8.7219 0 0
M  V30 25 C 9.0021 -7.3883 0 0
M  V30 26 C 10.5085 -7.7084 0 0 CFG=1
M  V30 27 C 11.6529 -6.678 0 0
M  V30 28 O 13.1175 -7.1539 0 0
M  V30 29 O 11.3327 -5.1716 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 8 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 6 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 26 25
M  V30 27 1 26 22
M  V30 28 1 26 27 CFG=1
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515376765

>  <MW>
405.226

>  <MW (desalted)>
405.488

>  <ClogP>
-1.822

>  <logS>
-3.047

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
132.96

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1E-10 M | Ki (inhibition constant)  0.1 nM

>  <CAS>
76547-98-3

>  <Description>
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II. Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients <6 years, and as an adjunct therapy for heart failure.

>  <EBC_ID>
EBC-02057

>  <IUPAC Name>
(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

>  <Main Tar all refs>
J. Med. Chem., 2003, vol. 46, # 15, p. 3326 - 3332 | J. Med. Chem., 2013, vol. 56, # 24, p. 9826 - 9836

>  <Main tar all>
Angiotensin-converting enzyme pX=10.0 | sACE-1 pX=10.0

$$$$
Cefixime
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 0.9026 6.0439 0 0
M  V30 2 C -0.2942 5.0748 0 0
M  V30 3 N -0.2136 3.5369 0 0
M  V30 4 C -1.6513 2.985 0 0
M  V30 5 C -2.6205 4.1818 0 0
M  V30 6 S -1.7817 5.4734 0 0
M  V30 7 C -2.0499 1.4975 0 0
M  V30 8 N -3.5374 1.0989 0 0
M  V30 9 O -3.936 -0.3886 0 0
M  V30 10 C -5.4235 -0.7872 0 0
M  V30 11 C -6.5125 0.3017 0 0
M  V30 12 O -6.1139 1.7892 0 0
M  V30 13 O -8 -0.0969 0 0
M  V30 14 C -0.961 0.4085 0 0
M  V30 15 O -1.3595 -1.079 0 0
M  V30 16 N 0.5266 0.8071 0 0
M  V30 17 C 1.6155 -0.2818 0 0 CFG=1
M  V30 18 C 3.1555 -0.2818 0 0 CFG=1
M  V30 19 S 4.4892 0.4882 0 0
M  V30 20 C 5.8229 -0.2818 0 0
M  V30 21 C 5.8229 -1.8218 0 0
M  V30 22 C 4.4892 -2.5918 0 0
M  V30 23 N 3.1555 -1.8218 0 0
M  V30 24 C 1.6155 -1.8218 0 0
M  V30 25 O 0.5266 -2.9108 0 0
M  V30 26 C 4.4892 -4.1318 0 0
M  V30 27 O 3.1555 -4.9018 0 0
M  V30 28 O 5.8229 -4.9018 0 0
M  V30 29 C 7.1566 -2.5918 0 0
M  V30 30 C 8.4902 -1.8218 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 7 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 17 16 CFG=1
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 18 23 CFG=1
M  V30 25 1 23 24
M  V30 26 1 17 24
M  V30 27 2 24 25
M  V30 28 1 22 26
M  V30 29 2 26 27
M  V30 30 1 26 28
M  V30 31 1 21 29
M  V30 32 2 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568664267

>  <MW>
453.041

>  <MW (desalted)>
453.45

>  <ClogP>
0.252

>  <logS>
-4.594

>  <HBD>
4

>  <HBA>
10

>  <TPSA>
184.51

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.0039 - 0.5 ?g/ml | Kd (dissociation constant)  2.39E-08 M | IC50  0.026 ?M | Kd (dissociation constant)  3.34E-08 M | MIC < 0.031 ?g/ml | percentage decrease Active   | MIC  0.1 ?g/ml | MIC  0.1 ?g/ml

>  <CAS>
79350-37-1

>  <Description>
Cefixime is a third generation cephalosporin used to treat susceptible Gram negative and Gram positive bacterial infections. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

>  <EBC_ID>
EBC-27134

>  <IUPAC Name>
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2018, vol. 62, # 4 | Mol. Neurobiol., 2018, p. 1 - 11 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | TOTTORI UNIVERSITY - US2018/338899, 2018, A1 | ACS Infect. Dis., 2020, vol. 6, # 11, p. 3034 - 3047 | FOX CHASE CANCER CENTER; INSTITUT CURIE; INSTITUT DE GENETIQUE ET DE BIOLOGIE MOLECULAIRE E; INSTITUT DE GENETIQUE ET DE BIOLOGIE MOLECULAIRE AT CELLULAIRE; INSTITUT DE GENETIQUE ET DE BIOLOGIE MOLECULAIRE ET CELLULAIRE; INST DE GENETIQUE ET DE BIOLOGIE MOLECULAIRE ET CE - WO2015/48718, 2015, A2 | Eur. J. Med. Chem., 2019, vol. 166, p. 224 - 231 | Eur. J. Med. Chem., 2019, vol. 166, p. 224 - 231

>  <Main tar all>
Isoleucine-tRNA ligase, cytoplasmic pX=8.07 | Alternative prion protein pX=7.62 | Penicillin-binding?protein B pX=7.59 | Homeobox-leucine zipper protein HAT1 pX=7.48 | Beta-Lactamase AmpC pX=7.16 | G/T mismatch-specific thymine DNA glycosylase pX=7.0 | DNA supercoiling protein pX=6.66 | DNA?gyrase pX=6.66

$$$$
Ketoconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.1269 -15.5563 0 0
M  V30 2 C 9.5954 -15.7173 0 0
M  V30 3 O 8.969 -17.1241 0 0
M  V30 4 N 8.6902 -14.4714 0 0
M  V30 5 C 7.1586 -14.6324 0 0
M  V30 6 C 6.2534 -13.3865 0 0
M  V30 7 N 6.8798 -11.9796 0 0
M  V30 8 C 8.4114 -11.8187 0 0
M  V30 9 C 9.3166 -13.0645 0 0
M  V30 10 C 5.9746 -10.7337 0 0
M  V30 11 C 4.4431 -10.8947 0 0
M  V30 12 C 3.5379 -9.6488 0 0
M  V30 13 C 4.1642 -8.242 0 0
M  V30 14 O 3.2591 -6.9961 0 0
M  V30 15 C 3.8854 -5.5892 0 0
M  V30 16 C 2.9802 -4.3433 0 0 CFG=2
M  V30 17 C 1.4402 -4.3433 0 0
M  V30 18 O 0.9644 -2.8787 0 0
M  V30 19 C 2.2102 -1.9735 0 0 CFG=2
M  V30 20 C 1.1798 -0.8291 0 0
M  V30 21 N -0.3266 -1.1493 0 0
M  V30 22 C -1.471 -0.1188 0 0
M  V30 23 C -2.8047 -0.8888 0 0
M  V30 24 N -2.4845 -2.3951 0 0
M  V30 25 C -0.9529 -2.5561 0 0
M  V30 26 O 3.4561 -2.8787 0 0
M  V30 27 C 3.2407 -0.8291 0 0
M  V30 28 C 2.7648 0.6356 0 0
M  V30 29 C 3.7953 1.78 0 0
M  V30 30 C 5.3016 1.4598 0 0
M  V30 31 Cl 6.3321 2.6043 0 0
M  V30 32 C 5.7775 -0.0048 0 0
M  V30 33 C 4.7471 -1.1493 0 0
M  V30 34 Cl 5.2229 -2.6139 0 0
M  V30 35 C 5.6958 -8.081 0 0
M  V30 36 C 6.601 -9.3269 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 16 15 CFG=3
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=3
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 21 25
M  V30 27 1 19 26
M  V30 28 1 16 26
M  V30 29 1 19 27 CFG=1
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 2 30 32
M  V30 35 1 32 33
M  V30 36 2 27 33
M  V30 37 1 33 34
M  V30 38 2 13 35
M  V30 39 1 35 36
M  V30 40 2 10 36
M  V30 END BOND
M  V30 BEGIN COLLECTION
M  V30 MDLV30/STERAC1 ATOMS=(2 16 19)
M  V30 END COLLECTION
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3219503092

>  <MW>
530.149

>  <MW (desalted)>
531.431

>  <ClogP>
3.635

>  <logS>
-5.925

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
69.06

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  4.31 nM | IC50  16.5 nM | IC50  0.02 ?M | IC50  0.03 ?M | IC50  0.038 ?M | Ki (inhibition constant)  0.039 ?M | inhibition percentage  100 % | inhibition percentage  100 % | IC50  0.0537 ?M | IC50  0.06 ?M | IC50  93 nM

>  <CAS>
65277-42-1

>  <Description>
Ketoconazole is an broad-spectrum imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.

>  <EBC_ID>
EBC-06116

>  <IUPAC Name>
rac-1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2016, vol. 60, # 12, p. 7364 - 7371 | J. Med. Chem., 2016, vol. 59, # 12, p. 5766 - 5779 | J. Med. Chem., 2016, vol. 59, # 12, p. 5766 - 5779 | Planta Med., 2017, vol. 83, # 8, p. 727 - 736 | Anal. Chem., 2007, vol. 79, # 12, p. 4657 - 4665 | Drug Metab. Dispos., 2015, vol. 43, # 7, p. 1137 - 1146 | Xenobiotica, 2018, vol. 48, # 8, p. 793 - 803 | Toxicol. Vitro, 2017, vol. 41, p. 83 - 91 | Toxicol. Vitro, 2017, vol. 41, p. 83 - 91 | Biopharm. Drug Dispos., 2015, vol. 36, # 5, p. 265 - 274 | Eur. J. Med. Chem., 2014, vol. 85, p. 268 - 288 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 23, p. 5825 - 5829

>  <Main tar all>
Cytochrome P450 3A4 pX=8.47 | Cytochrome P450 2C19 pX=8.37 | Cytochrome P450 2C9 pX=7.78 | Cytochrome P450 3A5 pX=7.7 | Cytochrome P450 2C9-Cys358, Asp417 pX=7.52 | CYP3A pX=7.42 | CYP1A1 pX=7.41 | CYP3A94 pX=7.28 | CYP3A97 pX=7.28 | Cytochrome P450, E-class, CYP3A pX=7.27 | CYP1A2 pX=7.22 | CYP17A1 pX=7.03

$$$$
Urea
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.31 1.3337 0 0
M  V30 2 C 1.54 0 0 0
M  V30 3 O 2.31 -1.3337 0 0
M  V30 4 N 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473900

>  <MW>
60.032

>  <MW (desalted)>
60.055

>  <ClogP>
-1.66

>  <logS>
0.49

>  <HBD>
2

>  <HBA>
1

>  <TPSA>
69.11

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1 nM

>  <CAS>
57-13-6

>  <Description>
Urea is a compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. It is a keratolytic emollient used to treat hyperkeratotic lesions and moisturize the skin.

>  <EBC_ID>
EBC-03021

>  <IUPAC Name>
urea

>  <Main Tar all refs>
Biochem. J., 2001, vol. 354, # 2, p. 337 - 344

>  <Main tar all>
?2A-adrenoceptor pX=9.0

$$$$
Taurine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.2063 -3.85 0 0
M  V30 2 C 0.2063 -2.31 0 0
M  V30 3 C 1.54 -1.54 0 0
M  V30 4 S 1.54 0 0 0
M  V30 5 O 1.54 1.54 0 0
M  V30 6 O 3.08 -0 0 0
M  V30 7 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z248489432

>  <MW>
125.015

>  <MW (desalted)>
125.147

>  <ClogP>
-4.794

>  <logS>
0.96

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
80.39

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.1 nM

>  <CAS>
107-35-7

>  <Description>
Taurine is a competitive inhibitor of the human taurine transporter.

>  <EBC_ID>
EBC-03933

>  <IUPAC Name>
2-aminoethane-1-sulfonic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2004, vol. 67, # 6, p. 1089 - 1096

>  <Main tar all>
KATP?channel pX=10.0

$$$$
5-Fluorouracil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 N 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 O 1.3337 -2.31 0 0
M  V30 7 N 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275128052

>  <MW>
130.018

>  <MW (desalted)>
130.077

>  <ClogP>
-0.577

>  <logS>
-1.18

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
0

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  13.95 pg/ml

>  <CAS>
51-21-8

>  <Description>
Fluorouracil is a pyrimidine analog  that is an antineoplastic antimetabolite. It is used to treat basal cell carcinomas, and as an injection in palliative cancer treatment. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

>  <EBC_ID>
EBC-00529

>  <IUPAC Name>
5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
Pharmacol. Res., 2018, vol. 132, p. 188 - 203

>  <Main tar all>
COX-2  pX=9.97

$$$$
Thymol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127464

>  <MW>
150.104

>  <MW (desalted)>
150.218

>  <ClogP>
3.201

>  <logS>
-2.73

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Opener | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.2 ?M | IC50 = 0.2 ?M | IC50  0.22 ?M | EC50 ~ 2 ?M | Ki (inhibition constant)  3.4 ?M | inhibition percentage  93.97 % | inhibition percentage  93.97 %

>  <CAS>
89-83-8

>  <Description>
Thymol is the main monoterpene phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge.

>  <EBC_ID>
EBC-12254

>  <IUPAC Name>
5-methyl-2-(propan-2-yl)phenol

>  <Main Tar all refs>
Planta Med., 2005, vol. 71, # 8, p. 739 - 742 | Med. Res. Rev., 2009, vol. 29, # 5, p. 767 - 820 | Xenobiotica, 2020, vol. 50, # 4, p. 408 - 414 | REDPOINT BIO CORP - WO2008/13861, 2008, A2 | Int. J. Mol. Sci., 2021, vol. 22, # 21 | Int. J. Biol. Macromol., 2018, vol. 119, p. 1298 - 1310 | Int. J. Biol. Macromol., 2018, vol. 119, p. 1298 - 1310

>  <Main tar all>
COX-1  pX=6.7 | COX-2  pX=6.7 | CYP1A1 pX=6.66 | TRPA1 pX=5.7 | ?-carbonic anhydrase pX=5.47 | xanthine dehydrogenase pX=5.21 | xanthine dehydrogenase pX=5.21

$$$$
Gabapentin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.8402 3.2223 0 0
M  V30 2 C 2.3236 3.4897 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 0.3438 3.4897 0 0
M  V30 5 C 0.8705 4.9368 0 0
M  V30 6 O -0.1194 6.1165 0 0
M  V30 7 O 2.3871 5.2043 0 0
M  V30 8 C 2.6674 1.54 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 C 0 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 3 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 3 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z336079954

>  <MW>
171.126

>  <MW (desalted)>
171.237

>  <ClogP>
-0.66

>  <logS>
-1.08

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | inhibition rate Active   | inhibition rate Active

>  <CAS>
60142-96-3

>  <Description>
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid. It is  used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures.

>  <EBC_ID>
EBC-03348

>  <IUPAC Name>
2-[1-(aminomethyl)cyclohexyl]acetic acid

>  <Main Tar all refs>
J. Clin. Pharmacol., 2020, vol. 60, # 8, p. 1076 - 1086 | J. Clin. Pharmacol., 2020, vol. 60, # 8, p. 1076 - 1086 | J. Clin. Pharmacol., 2020, vol. 60, # 8, p. 1076 - 1086

>  <Main tar all>
Organic cation transporter 1 pX=11.0 | Organic cation transporter 1 pX=11.0 | Organic cation transporter 3 pX=11.0

$$$$
Mecamylamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 6.4022 -3.1288 0 0
M  V30 3 N 5.4124 -1.9491 0 0
M  V30 4 C 5.9391 -0.5019 0 0
M  V30 5 C 4.4225 -0.2345 0 0
M  V30 6 C 7.2727 -1.2719 0 0
M  V30 7 C 8.6064 -0.5019 0 0
M  V30 8 C 8.6064 1.0381 0 0
M  V30 9 C 7.2727 1.8081 0 0
M  V30 10 C 6.8877 0.2681 0 0
M  V30 11 C 5.9391 1.0381 0 0
M  V30 12 C 5.123 2.3441 0 0
M  V30 13 C 4.4 1.0918 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 6 10
M  V30 10 1 9 11
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2685925293

>  <MW>
203.144

>  <MW (desalted)>
167.291

>  <ClogP>
2.825

>  <logS>
-2.331

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50 = 100 nM | IC50 = 100 nM | IC50 = 100 nM | IC50 = 100 nM | EC50 = 200 nM | inhibition percentage  91.5 % | inhibition percentage  91.5 %

>  <CAS>
826-39-1

>  <Description>
Mecamylamine HCl is a noncompetitive nicotinic acetylcholine receptor antagonist. Mecamylamine is widely used as a broad-spectrum antagonist of neuronal nicotinic acetylcholine receptors in basic nicotine research. It has been reported to be effective as an aid to smoking cessation and may also be of use in various nicotine-responsive, neuropsychiatric disorders.

>  <EBC_ID>
EBC-08094

>  <IUPAC Name>
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2004, vol. 14, # 14, p. 3739 - 3742 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 14, p. 3739 - 3742 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 14, p. 3739 - 3742 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 14, p. 3739 - 3742 | J. Med. Chem., 1997, vol. 40, # 26, p. 4169 - 4194 | Biol. Pharm. Bull., 2018, vol. 41, # 1, p. 65 - 72 | Biol. Pharm. Bull., 2018, vol. 41, # 1, p. 65 - 72

>  <Main tar all>
nicotinic acetylcholine receptor ?-like 1 pX=7.0 | nicotinic acetylcholine receptor ?-like 1 pX=7.0 | nicotinic acetylcholine receptor ?1 subunit pX=7.0 | nicotinic acetylcholine receptor ?1 subunit pX=7.0 | nicotinic acetylcholine receptor ?1 subunit pX=6.7 | nicotinic acetylcholine receptor ?3 subunit pX=6.03 | nicotinic acetylcholine receptor ?4 subunit pX=6.03

$$$$
Clioquinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 I 0 -3.08 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 2.6674 0 0 0
M  V30 7 Cl 2.6674 1.54 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 N 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 2 13
M  V30 14 1 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104483432

>  <MW>
304.91

>  <MW (desalted)>
305.5

>  <ClogP>
3.729

>  <logS>
-3.352

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <Action on targets>
Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
decrease rate Active   | Ki (inhibition constant)  11.3 nM | Ki (inhibition constant)  15.6 nM

>  <CAS>
130-26-7

>  <Description>
Clioquinol is a metal-chelating antimicrobial agent with neuroprotective properties and antifungal properties.  It is used as an antifungal and antiprotozoal topical drug OTC product for treatment of human infections. It shows effectivity for Alzheimer's disease treatment and induce cancer cell death.

>  <EBC_ID>
EBC-03520

>  <IUPAC Name>
5-chloro-7-iodoquinolin-8-ol

>  <Main Tar all refs>
ACS Synth. Biol., 2022, vol. 11, # 8, p. 2820 - 2828 | Biosci. Rep., 2021, vol. 41, # 5 | Biosci. Rep., 2021, vol. 41, # 5

>  <Main tar all>
H2 receptor pX=9.0 | carbonic anhydrase 12 pX=7.95 | carbonic anhydrase 2 pX=7.81

$$$$
Levodopa
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -1.3337 3.85 0 0
M  V30 2 C 0 4.62 0 0 CFG=1
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 O 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 C 0 6.16 0 0
M  V30 13 O -1.3337 6.93 0 0
M  V30 14 O 1.3337 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 4 11
M  V30 12 1 2 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440064

>  <MW>
197.069

>  <MW (desalted)>
197.188

>  <ClogP>
-2.82

>  <logS>
-0.56

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
103.78

>  <RotBonds>
3

>  <Action on targets>
- | Activator | Activator | Agonist | Agonist

>  <Activity coefficients and valu>
Ka (association constant) = 0.004 ?M | Ka (association constant)  0.009 ?M | Ka (association constant)  0.072 ?M | uptake rate increase Active   | uptake rate increase Active

>  <CAS>
59-92-7

>  <Description>
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier.

>  <EBC_ID>
EBC-12565

>  <IUPAC Name>
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2013, vol. 23, # 4, p. 1087 - 1090 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 25 - 30 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 1, p. 77 - 80 | Brain Res., 2021, vol. 1768 | Brain Res., 2021, vol. 1768

>  <Main tar all>
carbonic anhydrase pX=8.4 | ?-carbonic anhydrase pX=8.05 | ?-carbonic anhydrase pX=7.14 | D1 receptor pX=7.0 | D2 receptor pX=7.0

$$$$
Amrinone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 N 0 -4.62 0 0
M  V30 7 C 0 -3.08 0 0
M  V30 8 O -1.3337 -2.31 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 C 5.3347 -4.62 0 0
M  V30 11 C 6.6684 -5.39 0 0
M  V30 12 N 6.6684 -6.93 0 0
M  V30 13 C 5.3347 -7.7 0 0
M  V30 14 C 4.001 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 7 8
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198150288

>  <MW>
187.075

>  <MW (desalted)>
187.198

>  <ClogP>
-0.689

>  <logS>
-1.949

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
68.01

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.45 ?M | IC50 = 4.8 ?M

>  <CAS>
60719-84-8

>  <Description>
Amrinone is a positive inotropic agent and phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

>  <EBC_ID>
EBC-12099

>  <IUPAC Name>
3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one

>  <Main Tar all refs>
Front. Physiol., 2022, vol. 13 | J. MED. CHEM., 1987, vol. 30, # 5, p. 824 - 829

>  <Main tar all>
cGMP-specific 3',5'-cGMP phosphodiesterase 3 pX=6.35 | 3',5'-cyclic adenosine monophosphate phosphodiesterase CpdA pX=5.32

$$$$
Hexylresorcinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 C 5.3347 -7.7 0 0
M  V30 4 C 6.6684 -6.93 0 0
M  V30 5 C 8.0021 -7.7 0 0
M  V30 6 C 9.3358 -6.93 0 0
M  V30 7 C 10.6694 -7.7 0 0
M  V30 8 C 12.0031 -6.93 0 0
M  V30 9 C 13.3368 -7.7 0 0
M  V30 10 C 13.3368 -9.24 0 0
M  V30 11 O 14.6705 -10.01 0 0
M  V30 12 C 12.0031 -10.01 0 0
M  V30 13 C 10.6694 -9.24 0 0
M  V30 14 O 9.3358 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1197943321

>  <MW>
194.131

>  <MW (desalted)>
194.27

>  <ClogP>
3.902

>  <logS>
-3.48

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
5

>  <Action on targets>
Agonist | Agonist | Blocker

>  <Activity coefficients and valu>
EC50  7 nM | EC50  7 nM | IC50  0.05 ?M

>  <CAS>
136-77-6

>  <Description>
Hexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. Hexylresorcinol is predominantly employed as the active ingredient in lotions, sprays, or lozenges indicated as a topical antiseptic to help prevent skin infection in minor cuts, scrapes, or burns, or as an antiseptic and local anesthetic for the relief of a sore throat and its associated pain.

>  <EBC_ID>
EBC-03468

>  <IUPAC Name>
4-hexylbenzene-1,3-diol

>  <Main Tar all refs>
Chem. Res. Toxicol., 2009, vol. 22, # 1, p. 52 - 63 | Chem. Res. Toxicol., 2009, vol. 22, # 1, p. 52 - 63 | RECKITT BENCKISER GROUP PLC - WO2009/63223, 2009, A1

>  <Main tar all>
Estrogen receptor pX=8.15 | Estrogen receptor pX=8.15 | Nav1.2 pX=7.3

$$$$
Cystine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 13.5984 6.311 0 0
M  V30 2 C 13.5984 4.771 0 0 CFG=1
M  V30 3 C 12.2647 4.001 0 0
M  V30 4 S 10.931 4.771 0 0
M  V30 5 S 9.5974 4.001 0 0
M  V30 6 C 8.2637 4.771 0 0
M  V30 7 C 6.93 4.001 0 0 CFG=2
M  V30 8 N 6.93 2.461 0 0
M  V30 9 C 5.5963 4.771 0 0
M  V30 10 O 4.2626 4.001 0 0
M  V30 11 O 5.5963 6.311 0 0
M  V30 12 C 14.9321 4.001 0 0
M  V30 13 O 16.2658 4.771 0 0
M  V30 14 O 14.9321 2.461 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 2 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269145231

>  <MW>
240.024

>  <MW (desalted)>
240.3

>  <ClogP>
-4.462

>  <logS>
-1.693

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
126.64

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | - | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.43 ?M | Km (Michaelis constant)  0.8 ?M | Ki (inhibition constant)  3240 nM | Km (Michaelis constant)  4.3 ?M | Kd (dissociation constant)  9.3 ?M

>  <CAS>
56-89-3

>  <Description>
Cystine is an oxidated derivative of the amino acid cysteine found in various nutritional products, acne treatments, and creams to treat cervical injury or inflammation. Cystine serves as a major precursor for synthesis of glutathione.

>  <EBC_ID>
EBC-26280

>  <IUPAC Name>
(2R)-2-amino-3-{[(2R)-2-amino-2-carboxyethyl]disulfanyl}propanoic acid

>  <Main Tar all refs>
J. NEUROCHEM., 1987, vol. 49, # 4, p. 1301 - 1307 | Proc. Natl. Acad. Sci. U. S. A., 2014, vol. 111, # 19, p. 6964 - 6969 | J. Pharmacol. Exp. Ther., 2003, vol. 305, # 1, p. 131 - 142 | Proc. Natl. Acad. Sci. U. S. A., 2014, vol. 111, # 19, p. 6964 - 6969 | J. Biol. Chem., 2020, vol. 295, # 16, p. 5245 - 5256

>  <Main tar all>
mGlu receptor pX=6.37 | TRP14 S-denitrosylate and L-cystein reductase pX=6.1 | NMDA receptor pX=5.49 | Thioredoxin pX=5.37 | L-cystine-binding protein FliY pX=5.03

$$$$
Ethambutol dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C -5.797 -3.371 0 0
M  V30 4 C -4.2847 -3.08 0 0
M  V30 5 C -3.2765 -4.2441 0 0 CFG=1
M  V30 6 C -3.7806 -5.6993 0 0
M  V30 7 O -5.2929 -5.9903 0 0
M  V30 8 N -1.7643 -3.9531 0 0
M  V30 9 C -0.7561 -5.1172 0 0
M  V30 10 C 0.7561 -4.8262 0 0
M  V30 11 N 1.7643 -5.9903 0 0
M  V30 12 C 3.2765 -5.6993 0 0 CFG=1
M  V30 13 C 4.2847 -6.8634 0 0
M  V30 14 C 5.797 -6.5724 0 0
M  V30 15 C 3.7806 -4.2441 0 0
M  V30 16 O 5.2929 -3.9531 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 5 4
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 5 8 CFG=3
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 12 11 CFG=3
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 12 15
M  V30 13 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1486001934

>  <MW>
276.137

>  <MW (desalted)>
204.31

>  <ClogP>
0.119

>  <logS>
-1.41

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
64.52

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.05 ?g/ml | IC50  61.73 ng/ml | MIC  0.78 ?M | MIC  0.2 ?g/ml | Kd (dissociation constant)  1.06 ?M | MIC  0.39 ?g/ml | MIC = 0.5 ?g/mL | MIC  0.5 ?g/ml | MIC  0.976 ?g/ml | MIC  1 ?g/ml | MIC  7.63 ?M | MIC  7.63 ?M

>  <CAS>
1070-11-7

>  <Description>
Ethambutol is an antituberculosis agent used in the prophylaxis and treatment of tuberculosis. Ethambutol diffuses into Mycobacterium cells. Once inside the cell, ethambutol inhibits the arabinosyltransferases, preventing formation of the cell wall components arabinogalactan and lipoarabinomannan, and preventing cell division.

>  <EBC_ID>
EBC-12936

>  <IUPAC Name>
(2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol dihydrochloride

>  <Main Tar all refs>
J. Biol. Chem., 2019, vol. 293, # 43, p. 16741 - 16750 | Bioorg. Chem., 2023, vol. 131 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - WO2019/46467, 2019, A1 | PloS Biol., 2022, vol. 20, # 5 | J. Biol. Chem., 2019, vol. 293, # 43, p. 16741 - 16750 | Biomolecules, 2022, vol. 12, # 11 | ASTRAZENECA PLC - US2007/275982, 2007, A1 | , 2021, vol. 12, # 11, p. 1894 - 1909 | Eur. J. Pharm. Sci., 2018, vol. 121, p. 155 - 165 | Mol. Diversity, 2022 | Eur. J. Med. Chem., 2020, vol. 193 | Bioorg. Med. Chem. Lett., 2020, vol. 30, # 22

>  <Main tar all>
Enoyl-[acyl-carrier-protein] reductase pX=6.61 | Thymidylate kinase pX=6.52 | 3-oxoacyl-[acyl-carrier-protein] synthase 1 pX=6.11 | triglyceride lipase pX=6.01 | Transcription factor EtbR pX=5.97 | Probable proline-tRNA ligase, mitochondrial pX=5.72 | Acetolactate synthase, chloroplastic pX=5.61 | N-acetyltransferase Eis pX=5.61 | Enoyl-[acyl-carrier-protein] reductase pX=5.32 | Probable trehalose monomycolate exporter MmpL3 pX=5.31 | Ketol-acid reductoisomerase, chloroplastic pX=5.12 | UDP-N-acetylenolpyruvoylglucosamine reductase (gene murB) pX=5.12

$$$$
Trapidil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.787 6.16 0 0
M  V30 2 C 4.787 4.62 0 0
M  V30 3 N 6.1207 3.85 0 0
M  V30 4 C 7.4543 4.62 0 0
M  V30 5 C 8.788 3.85 0 0
M  V30 6 C 6.1207 2.31 0 0
M  V30 7 C 7.4543 1.54 0 0
M  V30 8 C 7.4543 0 0 0
M  V30 9 C 8.788 -0.77 0 0
M  V30 10 N 6.1207 -0.77 0 0
M  V30 11 C 4.787 0 0 0
M  V30 12 N 3.3224 -0.4759 0 0
M  V30 13 C 2.4172 0.77 0 0
M  V30 14 N 3.3224 2.0159 0 0
M  V30 15 N 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 6 15
M  V30 16 1 11 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56791867

>  <MW>
205.133

>  <MW (desalted)>
205.26

>  <ClogP>
1.752

>  <logS>
-2.546

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
46.32

>  <RotBonds>
3

>  <CAS>
15421-84-8

>  <Description>
Trapidil is a platelet-derived growth factor antagonist It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

>  <EBC_ID>
EBC-13445

>  <IUPAC Name>
N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

$$$$
Terbutaline hemisulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.1675 4.5237 0 0
M  V30 2 C -1.8338 3.7538 0 0
M  V30 3 C -2.6038 2.4201 0 0
M  V30 4 C -1.0638 5.0874 0 0
M  V30 5 N -0.5001 2.9838 0 0
M  V30 6 C -0.5001 1.4438 0 0
M  V30 7 C 0.8335 0.6738 0 0
M  V30 8 O 2.1672 1.4438 0 0
M  V30 9 C 0.8335 -0.8662 0 0
M  V30 10 C 2.1672 -1.6363 0 0
M  V30 11 C 2.1672 -3.1763 0 0
M  V30 12 O 3.5009 -3.9463 0 0
M  V30 13 C 0.8335 -3.9463 0 0
M  V30 14 C -0.5001 -3.1762 0 0
M  V30 15 O -1.8338 -3.9462 0 0
M  V30 16 C -0.5001 -1.6362 0 0
M  V30 17 C 7.9009 4.5237 0 0
M  V30 18 C 9.2346 3.7538 0 0
M  V30 19 C 8.4646 2.4201 0 0
M  V30 20 C 10.0046 5.0874 0 0
M  V30 21 N 10.5683 2.9838 0 0
M  V30 22 C 10.5683 1.4438 0 0
M  V30 23 C 11.9019 0.6738 0 0
M  V30 24 O 13.2356 1.4438 0 0
M  V30 25 C 11.9019 -0.8662 0 0
M  V30 26 C 13.2356 -1.6363 0 0
M  V30 27 C 13.2356 -3.1763 0 0
M  V30 28 O 14.5693 -3.9463 0 0
M  V30 29 C 11.9019 -3.9463 0 0
M  V30 30 C 10.5683 -3.1762 0 0
M  V30 31 O 9.2346 -3.9462 0 0
M  V30 32 C 10.5683 -1.6362 0 0
M  V30 33 O 0 -10.1063 0 0
M  V30 34 S 0 -8.5663 0 0
M  V30 35 O 0 -7.0263 0 0
M  V30 36 O 1.54 -8.5663 0 0
M  V30 37 O -1.54 -8.5663 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 9 16
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 1 18 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 1 27 29
M  V30 29 2 29 30
M  V30 30 1 30 31
M  V30 31 1 30 32
M  V30 32 2 25 32
M  V30 33 1 33 34
M  V30 34 2 34 35
M  V30 35 2 34 36
M  V30 36 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1556051334

>  <MW>
548.24

>  <MW (desalted)>
225.284

>  <ClogP>
0.482

>  <logS>
-0.165

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  1633.6 ?M

>  <CAS>
23031-32-5

>  <Description>
Terbutaline is a selective beta-2 adrenergic receptor agonist. It  is indicated for preventio and reversal of bronchospasm in patients at least 12 years old, with asthma and reversible bronchospasm associated with bronchitis and emphysema.

>  <EBC_ID>
EBC-12610

>  <IUPAC Name>
bis(5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol); sulfuric acid

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=2.79

$$$$
Viloxazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -0.77 0 0
M  V30 2 C 4.001 -2.31 0 0
M  V30 3 O 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 C 2.6674 -7.7 0 0
M  V30 8 C 1.3337 -6.93 0 0
M  V30 9 C 1.3337 -5.39 0 0
M  V30 10 O 0 -4.62 0 0
M  V30 11 C -1.3337 -5.39 0 0
M  V30 12 C -2.6674 -4.62 0 0
M  V30 13 C -4.001 -5.39 0 0
M  V30 14 N -5.3347 -4.62 0 0
M  V30 15 C -5.3347 -3.08 0 0
M  V30 16 C -4.001 -2.31 0 0
M  V30 17 O -2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1235945951

>  <MW>
237.136

>  <MW (desalted)>
237.295

>  <ClogP>
1.76

>  <logS>
-1.96

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
39.72

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0435 ?M | Kd (dissociation constant) = 155 nM | Kd (dissociation constant) = 155 nM | IC50 = 0.22 ?M

>  <CAS>
46817-91-8

>  <Description>
Viloxazine is a selective norepinephrine reuptake inhibitor with minimal inhibitory effect on the reuptake of 5-HT. It is indicated for the treatment of clinical depression.

>  <EBC_ID>
EBC-06656

>  <IUPAC Name>
2-[(2-ethoxyphenoxy)methyl]morpholine

>  <Main Tar all refs>
Xenobiotica, 2020, vol. 50, # 11, p. 1285 - 1300 | Bioorg. Med. Chem. Lett., 1998, vol. 8, # 5, p. 487 - 492 | Bioorg. Med. Chem. Lett., 1998, vol. 8, # 5, p. 487 - 492 | J. MED. CHEM., 1987, vol. 30, # 1, p. 222 - 235

>  <Main tar all>
CYP1A2 pX=7.36 | DAT pX=6.81 | NET pX=6.81 | ?1A-adrenoceptor pX=6.66

$$$$
Practolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -6.93 0 0
M  V30 2 C 2.6674 -7.7 0 0
M  V30 3 C 2.6674 -9.24 0 0
M  V30 4 N 4.001 -6.93 0 0
M  V30 5 C 5.3347 -7.7 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 O 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -7.7 0 0
M  V30 9 O 9.3358 -6.93 0 0
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 12.0031 -6.93 0 0
M  V30 12 C 13.3368 -7.7 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 N 14.6705 -10.01 0 0
M  V30 15 C 14.6705 -11.55 0 0
M  V30 16 O 16.0041 -12.32 0 0
M  V30 17 C 13.3368 -12.32 0 0
M  V30 18 C 12.0031 -10.01 0 0
M  V30 19 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 2 13 18
M  V30 18 1 18 19
M  V30 19 2 10 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z274728816

>  <MW>
266.163

>  <MW (desalted)>
266.336

>  <ClogP>
0.755

>  <logS>
-1.89

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
70.59

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 8E-07 mM | Ki (inhibition constant)  1.03 nM | Kd (dissociation constant) = 11 nM

>  <CAS>
6673-35-4

>  <Description>
Practolol is a beta-adrenergic receptor antagonist that has been used in the emergency treatment of cardiac arrhythmias. Like other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites.

>  <EBC_ID>
EBC-06844

>  <IUPAC Name>
N-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide

>  <Main Tar all refs>
BRISTOL-MYERS SQUIBB CO - US4994476, 1991, A | NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | Curr. Med. Chem., 2005, vol. 12, # 18, p. 2057 - 2074

>  <Main tar all>
?-adrenoceptor pX=9.1 | ?1-adrenoceptor pX=8.99 | ?1-adrenoceptor pX=7.96

$$$$
Nortriptyline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.1833 6.2466 0 0
M  V30 3 N 5.1833 4.7066 0 0
M  V30 4 C 6.517 3.9366 0 0
M  V30 5 C 6.517 2.3966 0 0
M  V30 6 C 7.8507 1.6266 0 0
M  V30 7 C 7.8507 0.0866 0 0
M  V30 8 C 9.2381 -0.5816 0 0
M  V30 9 C 10.367 0.4659 0 0
M  V30 10 C 11.8386 0.012 0 0
M  V30 11 C 12.1813 -1.4894 0 0
M  V30 12 C 11.0524 -2.5369 0 0
M  V30 13 C 9.5808 -2.0829 0 0
M  V30 14 C 8.6207 -3.287 0 0
M  V30 15 C 7.0807 -3.287 0 0
M  V30 16 C 6.1205 -2.0829 0 0
M  V30 17 C 4.6489 -2.5369 0 0
M  V30 18 C 3.52 -1.4894 0 0
M  V30 19 C 3.8627 0.012 0 0
M  V30 20 C 5.3343 0.4659 0 0
M  V30 21 C 6.4632 -0.5816 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 7 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z227834786

>  <MW>
299.144

>  <MW (desalted)>
263.377

>  <ClogP>
4.315

>  <logS>
-4.9

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.04 nM | IC50 = 0.05 nM

>  <CAS>
894-71-3

>  <Description>
Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant. It is indicated for the relief of the symptoms of major depressive disorder.

>  <EBC_ID>
EBC-12661

>  <IUPAC Name>
methyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 1999, vol. 42, # 16, p. 3154 - 3162 | J. Med. Chem., 1999, vol. 42, # 16, p. 3154 - 3162

>  <Main tar all>
?1-adrenoceptor pX=10.4 | H1 receptor pX=10.3

$$$$
Pizotifen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.0186 6.8112 0 0
M  V30 2 N 7.0358 5.2713 0 0
M  V30 3 C 8.378 4.5163 0 0
M  V30 4 C 8.3952 2.9764 0 0
M  V30 5 C 7.0702 2.1915 0 0
M  V30 6 C 7.0875 0.6516 0 0
M  V30 7 C 8.4823 -0.001 0 0
M  V30 8 C 9.7954 0.8036 0 0
M  V30 9 C 10.9664 -0.1966 0 0
M  V30 10 S 10.377 -1.6194 0 0
M  V30 11 C 8.8418 -1.4985 0 0
M  V30 12 C 7.8951 -2.7132 0 0
M  V30 13 C 6.3552 -2.7304 0 0
M  V30 14 C 5.3816 -1.5372 0 0
M  V30 15 C 3.9152 -2.0075 0 0
M  V30 16 C 2.7747 -0.9728 0 0
M  V30 17 C 3.1006 0.5324 0 0
M  V30 18 C 4.567 1.0027 0 0
M  V30 19 C 5.7075 -0.0321 0 0
M  V30 20 C 5.728 2.9465 0 0
M  V30 21 C 5.7108 4.4864 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 7 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 6 19
M  V30 21 2 14 19
M  V30 22 1 5 20
M  V30 23 1 20 21
M  V30 24 1 2 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z995240796

>  <MW>
295.139

>  <MW (desalted)>
295.442

>  <ClogP>
4.702

>  <logS>
-3.552

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.21 nM | Ki (inhibition constant) = 0.28 nM | Ki (inhibition constant)  2.5 nM | pA2  8.5  | pKi  8.3

>  <CAS>
15574-96-6

>  <Description>
Pizotifen is a serotonin and tryptamine antagonist. It is indicated for the prophylactic management of migraines.

>  <EBC_ID>
EBC-26504

>  <IUPAC Name>
1-methyl-4-{6-thiatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),4,11,13-pentaen-2-ylidene}piperidine

>  <Main Tar all refs>
J. Neurochem., 1987, vol. 49, # 6, p. 1833 - 1838 | Annu. Rep. Med. Chem., 1986, vol. 21, p. 41 - 50 | Bioorg. Med. Chem., 2013, vol. 21, # 24, p. 7841 - 7852 | PFIZER INC - WO2010/72774, 2010, A2 | Eur. J. Pharmacol., 1988, vol. 150, # 1-2, p. 181 - 184

>  <Main tar all>
5-HT2A receptor pX=9.68 | 5-HT2A receptor pX=9.55 | 5-HT2B receptor pX=8.6 | 5-HT2B receptor pX=8.5 | 5-HT2C receptor pX=8.3

$$$$
Amoxapine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -0.6917 -2.9969 0 0
M  V30 2 C 0.7799 -2.543 0 0
M  V30 3 C 1.1226 -1.0416 0 0
M  V30 4 C 2.5942 -0.5877 0 0
M  V30 5 C 3.7231 -1.6352 0 0
M  V30 6 O 5.1106 -0.967 0 0
M  V30 7 C 6.4981 -1.6352 0 0
M  V30 8 C 7.627 -0.5877 0 0
M  V30 9 C 9.0985 -1.0416 0 0
M  V30 10 C 9.4412 -2.543 0 0
M  V30 11 C 8.3123 -3.5905 0 0
M  V30 12 C 6.8407 -3.1365 0 0
M  V30 13 N 5.8806 -4.3406 0 0
M  V30 14 C 4.3406 -4.3406 0 0
M  V30 15 N 3.6724 -5.7281 0 0
M  V30 16 C 4.5399 -7.0005 0 0
M  V30 17 C 3.8717 -8.388 0 0
M  V30 18 N 2.336 -8.503 0 0
M  V30 19 C 1.4685 -7.2306 0 0
M  V30 20 C 2.1367 -5.8431 0 0
M  V30 21 C 3.3804 -3.1365 0 0
M  V30 22 C 1.9088 -3.5905 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 15 20
M  V30 22 1 14 21
M  V30 23 2 5 21
M  V30 24 1 21 22
M  V30 25 2 2 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610475

>  <MW>
313.098

>  <MW (desalted)>
313.781

>  <ClogP>
3.406

>  <logS>
-4.55

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
36.86

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor | Antagonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
pIC50  9.72 | pIC50  9.72 | pKi  8.7  | pKi  8.7  | pEC50  8.64  | pIC50  8.57 | Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  6 nM

>  <CAS>
14028-44-5

>  <Description>
Amoxapine is a tetracyclic antidepressant of the dibenzoxazepine family with a wide range of pharmalogical effects. It is an agonist of 5-Hydroxytryptamine 2A, 2B, 2C receptors. It is used in the treatment of neurotic or reactive depressive disorders and endogenous or psychotic depression.

>  <EBC_ID>
EBC-06994

>  <IUPAC Name>
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene

>  <Main Tar all refs>
Neuropharmacology, 2014, vol. 77, p. 475 - 480 | Neuropharmacology, 2014, vol. 77, p. 475 - 480 | J. PHARMACOL. EXP. THER., 1994, vol. 268, # 3, p. 1403 - 1410 | J. PHARMACOL. EXP. THER., 1994, vol. 268, # 3, p. 1403 - 1410 | ACADIA PHARMACEUTICALS INC - WO2000/20636, 2000, A1 | Neuropharmacology, 2014, vol. 77, p. 475 - 480 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. PHARMACOL. EXP. THER., 1994, vol. 268, # 3, p. 1403 - 1410

>  <Main tar all>
5-HT2A receptor pX=9.72 | 5-HT2A receptor pX=9.72 | 5-HT2C receptor pX=8.7 | 5-HT2C receptor pX=8.7 | 5-HT2A receptor pX=8.64 | H1 receptor pX=8.57 | D2 receptor (isoform 2) pX=8.44 | D2S receptor pX=8.44 | 5-HT6 receptor pX=8.22

$$$$
Hydroxychloroquine sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.4069 2.5443 0 0
M  V30 2 C -5.7406 1.7743 0 0
M  V30 3 N -5.7406 0.2343 0 0
M  V30 4 C -7.0743 -0.5357 0 0
M  V30 5 C -8.408 0.2343 0 0
M  V30 6 O -9.7417 -0.5357 0 0
M  V30 7 C -4.4069 -0.5357 0 0
M  V30 8 C -3.0733 0.2343 0 0
M  V30 9 C -1.7396 -0.5357 0 0
M  V30 10 C -0.4059 0.2343 0 0
M  V30 11 C -0.4059 1.7743 0 0
M  V30 12 N 0.9278 -0.5357 0 0
M  V30 13 C 2.2615 0.2343 0 0
M  V30 14 C 2.2615 1.7743 0 0
M  V30 15 C 3.5951 2.5443 0 0
M  V30 16 N 4.9288 1.7743 0 0
M  V30 17 C 4.9288 0.2343 0 0
M  V30 18 C 6.2625 -0.5357 0 0
M  V30 19 C 6.2625 -2.0757 0 0
M  V30 20 Cl 7.5962 -2.8457 0 0
M  V30 21 C 4.9288 -2.8457 0 0
M  V30 22 C 3.5951 -2.0757 0 0
M  V30 23 C 3.5951 -0.5357 0 0
M  V30 24 O 12.6562 -1.54 0 0
M  V30 25 S 12.6562 0 0 0
M  V30 26 O 12.6562 1.54 0 0
M  V30 27 O 14.1962 -0 0 0
M  V30 28 O 11.1162 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 13 23
M  V30 24 1 17 23
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 2 25 27
M  V30 28 1 25 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551900864

>  <MW>
433.95

>  <MW (desalted)>
335.872

>  <ClogP>
4.116

>  <logS>
-2.38

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
48.39

>  <RotBonds>
9

>  <Action on targets>
Antagonist | Antagonist

>  <Activity coefficients and valu>
decrease rate Active   | decrease rate Active

>  <CAS>
747-36-4

>  <Description>
Hydroxychloroquine is an antimalarial medication used to treat uncomplicated cases of malaria and for chemoprophylaxis in specific regions. Also a disease modifying anti-rheumatic drug indicated for treatment of rheumatoid arthritis and lupus erythematosus.

>  <EBC_ID>
EBC-13031

>  <IUPAC Name>
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol; sulfuric acid

>  <Main Tar all refs>
MERCK KGAA - WO2021/231941, 2021, A1 | MERCK KGAA - WO2021/231941, 2021, A1

>  <Main tar all>
TLR7 pX=10.0 | TLR8 pX=10.0

$$$$
Tiagabine HCl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 13.6094 0.1208 0 0
M  V30 3 C 13.6094 -1.4192 0 0
M  V30 4 C 14.8553 -2.3244 0 0
M  V30 5 C 14.3794 -3.789 0 0
M  V30 6 S 12.8394 -3.789 0 0
M  V30 7 C 12.3635 -2.3244 0 0
M  V30 8 C 10.8989 -1.8485 0 0
M  V30 9 C 10.5787 -0.3421 0 0
M  V30 10 C 9.1141 0.1338 0 0
M  V30 11 C 8.7939 1.6401 0 0
M  V30 12 N 7.3293 2.116 0 0
M  V30 13 C 6.1848 1.0855 0 0
M  V30 14 C 4.7202 1.5614 0 0
M  V30 15 C 4.4 3.0678 0 0
M  V30 16 C 5.5444 4.0982 0 0 CFG=2
M  V30 17 C 7.0091 3.6223 0 0
M  V30 18 C 5.2243 5.6046 0 0
M  V30 19 O 3.7596 6.0805 0 0
M  V30 20 O 6.3687 6.635 0 0
M  V30 21 C 9.7544 -2.8789 0 0
M  V30 22 S 9.9154 -4.4105 0 0
M  V30 23 C 8.5085 -5.0369 0 0
M  V30 24 C 7.4781 -3.8924 0 0
M  V30 25 C 8.2481 -2.5588 0 0
M  V30 26 C 7.6217 -1.1519 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 3 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 1 16 18 CFG=1
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 8 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 21 25
M  V30 27 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2196311163

>  <MW>
412.009

>  <MW (desalted)>
375.548

>  <ClogP>
2.775

>  <logS>
-4.76

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
40.54

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  67 nM | Ki (inhibition constant) = 67 nM

>  <CAS>
145821-59-6

>  <Description>
Tiagabine HCl is an inhibitor of GABA transporter 1. Tiagabine HCl is used as adjunctive therapies in the treatment of partial seizures.

>  <EBC_ID>
EBC-08666

>  <IUPAC Name>
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1993, vol. 36, # 12, p. 1716 - 1725 | J. Med. Chem., 1999, vol. 42, # 18, p. 3447 - 3462

>  <Main tar all>
GAT pX=7.17 | GAT1 pX=7.17

$$$$
Moclobemide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -4.001 -2.31 0 0
M  V30 2 C -2.6674 -3.08 0 0
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 C 0 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0
M  V30 7 C -2.6674 -4.62 0 0
M  V30 8 C 1.3337 -5.39 0 0
M  V30 9 O 1.3337 -6.93 0 0
M  V30 10 N 2.6674 -4.62 0 0
M  V30 11 C 4.001 -5.39 0 0
M  V30 12 C 5.3347 -4.62 0 0
M  V30 13 N 6.6684 -5.39 0 0
M  V30 14 C 8.0021 -4.62 0 0
M  V30 15 C 9.3358 -5.39 0 0
M  V30 16 O 9.3358 -6.93 0 0
M  V30 17 C 8.0021 -7.7 0 0
M  V30 18 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z32409934

>  <MW>
268.739

>  <MW (desalted)>
268.739

>  <ClogP>
2.171

>  <logS>
-2.362

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
41.57

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 5E-07 ?M

>  <CAS>
71320-77-9

>  <Description>
Moclobemide is a reversible monoamine oxidase inhibitor selective for isoform A used to treat major depressive disorder. It is used in the treatment of major depressive disorder and bipolar disorder. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants.

>  <EBC_ID>
EBC-06887

>  <IUPAC Name>
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 2013, vol. 69, p. 762 - 767

>  <Main tar all>
Monoamine oxidase A pX=12.3

$$$$
Cyclizine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.521 5.852 0 0
M  V30 3 N 7.521 4.312 0 0
M  V30 4 C 8.8547 3.542 0 0
M  V30 5 C 8.8547 2.002 0 0
M  V30 6 N 7.521 1.232 0 0
M  V30 7 C 6.1874 2.002 0 0
M  V30 8 C 6.1874 3.542 0 0
M  V30 9 C 7.521 -0.308 0 0
M  V30 10 C 6.1874 -1.078 0 0
M  V30 11 C 6.1874 -2.618 0 0
M  V30 12 C 4.8537 -3.388 0 0
M  V30 13 C 3.52 -2.618 0 0
M  V30 14 C 3.52 -1.078 0 0
M  V30 15 C 4.8537 -0.308 0 0
M  V30 16 C 8.8547 -1.078 0 0
M  V30 17 C 10.1884 -0.308 0 0
M  V30 18 C 11.5221 -1.078 0 0
M  V30 19 C 11.5221 -2.618 0 0
M  V30 20 C 10.1884 -3.388 0 0
M  V30 21 C 8.8547 -2.618 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 3 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 9 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3245419176

>  <MW>
302.155

>  <MW (desalted)>
266.381

>  <ClogP>
3.798

>  <logS>
-2.817

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
3

>  <Action on targets>
Antagonist | Antagonist

>  <Activity coefficients and valu>
Kd (dissociation constant) = 5 nM | Ki (inhibition constant)  12 nM

>  <CAS>
303-25-3

>  <Description>
Cyclizine is an antihistamine and antiemetic drug used for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo.

>  <EBC_ID>
EBC-28049

>  <IUPAC Name>
1-(diphenylmethyl)-4-methylpiperazine hydrochloride

>  <Main Tar all refs>
PHARMACOL. REV., 1990, vol. 42, # 1, p. 45 - 83 | MOL. PHARMACOL., 1978, vol. 14, # 6, p. 971 - 982

>  <Main tar all>
H1 receptor pX=8.3 | H2 receptor pX=7.92

$$$$
Aprepitant
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0 CFG=1
M  V30 3 O 0 -3.08 0 0
M  V30 4 C 0 -4.62 0 0 CFG=1
M  V30 5 O 1.3337 -5.39 0 0
M  V30 6 C 1.3337 -6.93 0 0
M  V30 7 C 0 -7.7 0 0
M  V30 8 N -1.3337 -6.93 0 0
M  V30 9 C -2.6674 -7.7 0 0
M  V30 10 C -2.6674 -9.24 0 0
M  V30 11 N -1.4215 -10.1452 0 0
M  V30 12 C -1.8974 -11.6098 0 0
M  V30 13 O -0.9922 -12.8557 0 0
M  V30 14 N -3.4374 -11.6098 0 0
M  V30 15 N -3.9132 -10.1452 0 0
M  V30 16 C -1.3337 -5.39 0 0 CFG=1
M  V30 17 C -2.6674 -4.62 0 0
M  V30 18 C -4.001 -5.39 0 0
M  V30 19 C -5.3347 -4.62 0 0
M  V30 20 C -5.3347 -3.08 0 0
M  V30 21 F -6.6684 -2.31 0 0
M  V30 22 C -4.001 -2.31 0 0
M  V30 23 C -2.6674 -3.08 0 0
M  V30 24 C 1.3337 -0.77 0 0
M  V30 25 C 0 -0 0 0
M  V30 26 C 0 1.54 0 0
M  V30 27 C 1.3337 2.31 0 0
M  V30 28 C 2.6674 1.54 0 0
M  V30 29 C 2.6674 -0 0 0
M  V30 30 C 4.001 2.31 0 0
M  V30 31 F 5.3347 3.08 0 0
M  V30 32 F 4.771 0.9763 0 0
M  V30 33 F 3.231 3.6437 0 0
M  V30 34 C -1.3337 2.31 0 0
M  V30 35 F -2.6674 3.08 0 0
M  V30 36 F -0.5637 3.6437 0 0
M  V30 37 F -2.1037 0.9763 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 16 8
M  V30 17 1 4 16
M  V30 18 1 16 17 CFG=1
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 22 23
M  V30 25 2 17 23
M  V30 26 1 2 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 24 29
M  V30 33 1 28 30
M  V30 34 1 30 31
M  V30 35 1 30 32
M  V30 36 1 30 33
M  V30 37 1 26 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2937147473

>  <MW>
534.427

>  <MW (desalted)>
534.427

>  <ClogP>
4.827

>  <logS>
-5.501

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
75.19

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.14 nM | Ki (inhibition constant)  0.14 nM

>  <CAS>
170729-80-3

>  <Description>
Aprepitant is a substance P/neurokinin 1 receptor antagonist used to treat nausea and vomiting caused by chemotherapy and surgery.

>  <EBC_ID>
EBC-11285

>  <IUPAC Name>
5-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,3-dihydro-1H-1,2,4-triazol-3-one

>  <Main Tar all refs>
VANDA PHARMACEUTICALS INC - WO2019/99883, 2019, A1 | VANDA PHARMACEUTICALS INC - WO2020/117811, 2020, A1

>  <Main tar all>
NK1 receptor pX=9.85 | Neurokinin NK1 receptor pX=9.85

$$$$
Filgotinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.3196 -3.9702 0 0
M  V30 2 C -1.0896 -2.6365 0 0
M  V30 3 N -0.3196 -1.3028 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 N 2.1256 -0.0569 0 0
M  V30 6 C 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 4.9239 -4.3828 0 0
M  V30 12 C 6.2576 -5.1528 0 0
M  V30 13 C 6.2576 -6.6928 0 0
M  V30 14 C 4.9239 -7.4628 0 0
M  V30 15 C 4.9239 -9.0028 0 0
M  V30 16 N 3.5902 -9.7728 0 0
M  V30 17 C 3.5902 -11.3128 0 0
M  V30 18 C 2.2566 -12.0828 0 0
M  V30 19 S 0.9229 -11.3128 0 0
M  V30 20 O 0.3962 -12.76 0 0
M  V30 21 O -0.5937 -11.0454 0 0
M  V30 22 C 0.9229 -9.7728 0 0
M  V30 23 C 2.2566 -9.0028 0 0
M  V30 24 C 3.5902 -6.6928 0 0
M  V30 25 C 3.5902 -5.1528 0 0
M  V30 26 N 3.5902 -2.0728 0 0
M  V30 27 N 2.1256 -2.5487 0 0
M  V30 28 C -2.6296 -2.6365 0 0
M  V30 29 C -3.9633 -3.4065 0 0
M  V30 30 C -3.9633 -1.8665 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 2 19 21
M  V30 21 1 19 22
M  V30 22 1 22 23
M  V30 23 1 16 23
M  V30 24 2 14 24
M  V30 25 1 24 25
M  V30 26 2 11 25
M  V30 27 1 10 26
M  V30 28 1 6 26
M  V30 29 1 26 27
M  V30 30 2 4 27
M  V30 31 1 2 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280227

>  <MW>
425.504

>  <MW (desalted)>
425.504

>  <ClogP>
1.831

>  <logS>
-4.457

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
96.67

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
cell proliferation decrease Active   | IC50 = 25 nM

>  <CAS>
1206161-97-8

>  <Description>
Filgotinib is a Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. It inhibits JAK1  with IC50 =10 nM.

>  <EBC_ID>
EBC-13676

>  <IUPAC Name>
N-(5-{4-[(1,1-dioxo-1lambda6-thiomorpholin-4-yl)methyl]phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide

>  <Main Tar all refs>
J. Clin. Med., 2021, vol. 10, # 7 | J. Med. Chem., 2015, vol. 58, # 18, p. 7596 - 7602

>  <Main tar all>
Janus kinase 1 pX=9.0 | Janus kinase 2 pX=7.6

$$$$
Ranolazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -13.3368 -10.78 0 0
M  V30 2 O -12.0031 -10.01 0 0
M  V30 3 C -12.0031 -8.47 0 0
M  V30 4 C -13.3368 -7.7 0 0
M  V30 5 C -13.3368 -6.16 0 0
M  V30 6 C -12.0031 -5.39 0 0
M  V30 7 C -10.6694 -6.16 0 0
M  V30 8 C -10.6694 -7.7 0 0
M  V30 9 O -9.3358 -8.47 0 0
M  V30 10 C -8.0021 -7.7 0 0
M  V30 11 C -6.6684 -8.47 0 0
M  V30 12 O -6.6684 -10.01 0 0
M  V30 13 C -5.3347 -7.7 0 0
M  V30 14 N -4.001 -8.47 0 0
M  V30 15 C -2.6674 -7.7 0 0
M  V30 16 C -1.3337 -8.47 0 0
M  V30 17 N -1.3337 -10.01 0 0
M  V30 18 C 0 -10.78 0 0
M  V30 19 C 0 -12.32 0 0
M  V30 20 O -1.3337 -13.09 0 0
M  V30 21 N 1.3337 -13.09 0 0
M  V30 22 C 2.6674 -12.32 0 0
M  V30 23 C 2.6674 -10.78 0 0
M  V30 24 C 1.3337 -10.01 0 0
M  V30 25 C 4.001 -10.01 0 0
M  V30 26 C 5.3347 -10.78 0 0
M  V30 27 C 5.3347 -12.32 0 0
M  V30 28 C 4.001 -13.09 0 0
M  V30 29 C 4.001 -14.63 0 0
M  V30 30 C -2.6674 -10.78 0 0
M  V30 31 C -4.001 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 23 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 22 28
M  V30 30 1 28 29
M  V30 31 1 17 30
M  V30 32 1 30 31
M  V30 33 1 14 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z68563450

>  <MW>
427.537

>  <MW (desalted)>
427.537

>  <ClogP>
1.012

>  <logS>
-3.2

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
74.27

>  <RotBonds>
9

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.32 ?M | IC50  1 - 10 ?M | IC50  1 - 10 ?M | concentration (parameter)  4.4 ?M | Ki (inhibition constant)  4.73 ?M | Ki (inhibition constant)  4.73 ?M | EC50  5 - 21 ?M | IC50  5.9 - 15 ?M | IC50  6.5 ?M | IC50  6.7 ?M | pKi  5.1  | pKi  5.1

>  <CAS>
95635-55-5

>  <Description>
Ranolazine is an anti-anginal drug used for the treatment of chronic angina.

>  <EBC_ID>
EBC-11221

>  <IUPAC Name>
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2011, vol. 339, # 3, p. 952 - 958 | Br. J. Pharmacol., 2008, vol. 153, # 6, p. 1128 - 1132 | Br. J. Pharmacol., 2008, vol. 153, # 6, p. 1128 - 1132 | GILEAD SCIENCES INC - US2015/38489, 2015, A1 | Br. J. Pharmacol., 2018, vol. 175, # 13, p. 2635 - 2652 | Br. J. Pharmacol., 2018, vol. 175, # 13, p. 2635 - 2652 | Br. J. Pharmacol., 2008, vol. 153, # 6, p. 1133 - 1142 | Br. J. Pharmacol., 2008, vol. 153, # 6, p. 1128 - 1132 | Mol. Pharmacol., 2020, vol. 98, # 5, p. 540 - 547 | GILEAD SCIENCES INC - US2013/5706, 2013, A1 | J. CARDIOVASC. PHARMACOL., 1993, vol. 21, # 6, p. 869 - 873 | J. CARDIOVASC. PHARMACOL., 1993, vol. 21, # 6, p. 869 - 873

>  <Main tar all>
Kv4.3 pX=6.49 | Nav?1 pX=6.0 | Nav1.7 pX=6.0 | Nav1.5 pX=5.36 | ?2-adrenoceptor pX=5.33 | ?2-adrenoceptor pX=5.33 | Kv9.1 pX=5.3 | Nav1.7 pX=5.23 | Voltage-gated?sodium?channel pX=5.19 | Nav1.5 pX=5.17 | ?1-adrenoceptor pX=5.1 | ?1-adrenoceptor pX=5.1

$$$$
Amprenavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.8737 -12.9794 0 0
M  V30 2 C 2.1037 -14.3131 0 0
M  V30 3 C 2.8737 -15.6468 0 0
M  V30 4 C 0.5637 -14.3131 0 0
M  V30 5 N -0.2063 -12.9794 0 0
M  V30 6 C 0.5637 -11.6458 0 0
M  V30 7 C -0.2063 -10.3121 0 0 CFG=1
M  V30 8 O -1.7463 -10.3121 0 0
M  V30 9 C 0.5637 -8.9784 0 0 CFG=2
M  V30 10 C -0.2063 -7.6447 0 0
M  V30 11 C -1.7463 -7.6447 0 0
M  V30 12 C -2.5163 -8.9784 0 0
M  V30 13 C -4.0563 -8.9784 0 0
M  V30 14 C -4.8263 -7.6447 0 0
M  V30 15 C -4.0563 -6.311 0 0
M  V30 16 C -2.5163 -6.311 0 0
M  V30 17 N 2.1037 -8.9784 0 0
M  V30 18 C 2.8737 -7.6447 0 0
M  V30 19 O 2.1037 -6.311 0 0
M  V30 20 O 4.4137 -7.6447 0 0
M  V30 21 C 5.1837 -6.311 0 0 CFG=1
M  V30 22 C 4.5573 -4.9042 0 0
M  V30 23 C 5.7017 -3.8737 0 0
M  V30 24 O 7.0354 -4.6437 0 0
M  V30 25 C 6.7152 -6.1501 0 0
M  V30 26 S -1.7463 -12.9794 0 0
M  V30 27 O -3.2863 -12.9794 0 0
M  V30 28 O -1.7463 -11.4394 0 0
M  V30 29 C -1.7463 -14.5194 0 0
M  V30 30 C -0.4126 -15.2894 0 0
M  V30 31 C -0.4126 -16.8294 0 0
M  V30 32 C -1.7463 -17.5994 0 0
M  V30 33 N -1.7463 -19.1394 0 0
M  V30 34 C -3.08 -16.8294 0 0
M  V30 35 C -3.08 -15.2894 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 9 17 CFG=3
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 21 20 CFG=1
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 21 25
M  V30 27 1 5 26
M  V30 28 2 26 27
M  V30 29 2 26 28
M  V30 30 1 26 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 2 32 34
M  V30 36 1 34 35
M  V30 37 2 29 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551900491

>  <MW>
505.627

>  <MW (desalted)>
505.627

>  <ClogP>
3.293

>  <logS>
-4.89

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
131.19

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.007 nM | Ki (inhibition constant)  0.03 nM | Ki (inhibition constant) = 36 pM | Ki (inhibition constant)  0.04 nM | Ki (inhibition constant)  0.04 nM | Ki (inhibition constant)  0.04 nM | Ki (inhibition constant)  0.041 nM | Ki (inhibition constant)  0.13 nM | Ki (inhibition constant)  0.15 nM | Ki (inhibition constant)  0.15 nM | Ki (inhibition constant)  0.195 nM

>  <CAS>
161814-49-9

>  <Description>
Amprenavir is a protease inhibitor used to treat HIV infection.

>  <EBC_ID>
EBC-13715

>  <IUPAC Name>
(3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | Antimicrob. Agents Chemother., 2007, vol. 51, # 9, p. 3147 - 3154 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 1, p. 81 - 84 | Bioorg. Med. Chem. Lett., 2000, vol. 10, # 11, p. 1159 - 1162 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 19, p. 5226 - 5230 | J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | J. Am. Chem. Soc., 2008, vol. 130, # 19, p. 6099 - 6113 | J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341

>  <Main tar all>
HIV-1?protease?(Q7K) pX=11.2 | HIV-1?protease?(I50V,?A71V) pX=10.5 | Protease pX=10.4 | Gag-Pol polyprotein pX=10.4 | HIV protease pX=10.4 | HIV-1 protease pX=10.4 | HIV-1 protease (L10I, G48V, I54V, L63P, V82A) pX=10.4 | HIV-1?protease?(L10F,?L19I,?K20R,?L33F,?E35D,?M36I,?R41K,?F53L,?I54V,?L63P,?H69K,?A71V,?T74P,?I84V,?L89M,?L90M,?I93L) pX=9.89 | HIV-1 protease (L10I, I15V, E35D, N37S, R41K, I62V, L63P, A71V, G73S, L90M) pX=9.82 | HIV-1?protease?(L10I,?G48V,?V82A) pX=9.82 | HIV-1 protease (L10I, L63P, A71V, G73S, I84V, L90M) pX=9.71

$$$$
Lincomycin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.118 4.0564 0 0
M  V30 2 C -2.4916 2.6496 0 0
M  V30 3 C -0.96 2.4886 0 0
M  V30 4 C -0.3336 1.0817 0 0 CFG=2
M  V30 5 C 1.1727 0.7616 0 0
M  V30 6 C 1.3337 -0.77 0 0 CFG=2
M  V30 7 N -0.0732 -1.3964 0 0
M  V30 8 C -0.3934 -2.9027 0 0
M  V30 9 C -1.1036 -0.2519 0 0
M  V30 10 C 2.6674 -1.54 0 0
M  V30 11 O 4.001 -0.77 0 0
M  V30 12 N 2.6674 -3.08 0 0
M  V30 13 C 4.001 -3.85 0 0 CFG=2
M  V30 14 C 5.3347 -3.08 0 0 CFG=1
M  V30 15 C 5.3347 -1.54 0 0
M  V30 16 O 6.6684 -3.85 0 0
M  V30 17 C 4.001 -5.39 0 0 CFG=1
M  V30 18 O 5.3347 -6.16 0 0
M  V30 19 C 5.3347 -7.7 0 0 CFG=2
M  V30 20 S 6.6684 -8.47 0 0
M  V30 21 C 8.0021 -7.7 0 0
M  V30 22 C 4.001 -8.47 0 0 CFG=2
M  V30 23 O 4.001 -10.01 0 0
M  V30 24 C 2.6674 -7.7 0 0 CFG=1
M  V30 25 O 1.3337 -8.47 0 0
M  V30 26 C 2.6674 -6.16 0 0 CFG=1
M  V30 27 O 1.3337 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 4 9
M  V30 10 1 6 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 13 12 CFG=3
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16 CFG=1
M  V30 17 1 13 17
M  V30 18 1 17 18 CFG=1
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=3
M  V30 21 1 20 21
M  V30 22 1 22 19
M  V30 23 1 22 23 CFG=3
M  V30 24 1 24 22
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 24
M  V30 27 1 17 26
M  V30 28 1 26 27 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385088

>  <MW>
406.537

>  <MW (desalted)>
406.537

>  <ClogP>
1.28

>  <logS>
-2.44

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
122.49

>  <RotBonds>
7

>  <Action on targets>
-

>  <Activity coefficients and valu>
MIC < 0.48 ?g/ml

>  <CAS>
154-21-2

>  <Description>
Lincomycin is an antibiotic indicated only for the treatment of serious infections and is typically reserved for use in cases of penicillin allergy or where penicillin is inappropriate.

>  <EBC_ID>
EBC-13871

>  <IUPAC Name>
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide

>  <Main Tar all refs>
Arch. Microbiol., 2017, vol. 199, # 8, p. 1103 - 1112

>  <Main tar all>
Multidrug?efflux?pump?EmrD3 pX=5.93

$$$$
Fexofenadine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 9.677 0 0
M  V30 3 C 5.94 9.677 0 0
M  V30 4 C 7.48 9.677 0 0
M  V30 5 C 5.94 11.217 0 0
M  V30 6 O 4.6063 11.987 0 0
M  V30 7 O 7.2737 11.987 0 0
M  V30 8 C 5.94 8.137 0 0
M  V30 9 C 7.2737 7.367 0 0
M  V30 10 C 7.2737 5.827 0 0
M  V30 11 C 5.94 5.057 0 0
M  V30 12 C 4.6063 5.827 0 0
M  V30 13 C 4.6063 7.367 0 0
M  V30 14 C 5.94 3.517 0 0
M  V30 15 O 4.6063 2.747 0 0
M  V30 16 C 7.2737 2.747 0 0
M  V30 17 C 7.2737 1.207 0 0
M  V30 18 C 8.6074 0.437 0 0
M  V30 19 N 8.6074 -1.103 0 0
M  V30 20 C 9.941 -1.873 0 0
M  V30 21 C 9.941 -3.413 0 0
M  V30 22 C 8.6074 -4.183 0 0
M  V30 23 C 7.2737 -3.413 0 0
M  V30 24 C 7.2737 -1.873 0 0
M  V30 25 C 8.6074 -5.723 0 0
M  V30 26 O 7.0674 -5.723 0 0
M  V30 27 C 8.6074 -7.263 0 0
M  V30 28 C 9.941 -8.033 0 0
M  V30 29 C 9.941 -9.573 0 0
M  V30 30 C 8.6074 -10.343 0 0
M  V30 31 C 7.2737 -9.573 0 0
M  V30 32 C 7.2737 -8.033 0 0
M  V30 33 C 10.1474 -5.723 0 0
M  V30 34 C 10.9174 -4.3893 0 0
M  V30 35 C 12.4574 -4.3893 0 0
M  V30 36 C 13.2274 -5.723 0 0
M  V30 37 C 12.4574 -7.0567 0 0
M  V30 38 C 10.9174 -7.0567 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 3 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 11 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 19 24
M  V30 25 1 22 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 27 32
M  V30 34 1 25 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 2 33 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754918912

>  <MW>
538.117

>  <MW (desalted)>
501.656

>  <ClogP>
1.957

>  <logS>
-5.1

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
81

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKi  7.5

>  <CAS>
153439-40-8

>  <Description>
Fexofenadine is a histamine H1 receptor antagonist. It  is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial.

>  <EBC_ID>
EBC-08661

>  <IUPAC Name>
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid hydrochloride

>  <Main Tar all refs>
Eur. J. Pharmacol., 2018, vol. 838, p. 107 - 111

>  <Main tar all>
H1 receptor pX=7.5

$$$$
Idebenone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 0.77 0 0
M  V30 2 O -4.001 2.31 0 0
M  V30 3 C -2.6674 3.08 0 0
M  V30 4 C -2.6674 4.62 0 0
M  V30 5 O -4.001 5.39 0 0
M  V30 6 C -4.001 6.93 0 0
M  V30 7 C -1.3337 5.39 0 0
M  V30 8 O -1.3337 6.93 0 0
M  V30 9 C 0 4.62 0 0
M  V30 10 C 0 3.08 0 0
M  V30 11 C 1.3337 2.31 0 0
M  V30 12 C -1.3337 2.31 0 0
M  V30 13 O -1.3337 0.77 0 0
M  V30 14 C 1.3337 5.39 0 0
M  V30 15 C 2.6674 4.62 0 0
M  V30 16 C 4.001 5.39 0 0
M  V30 17 C 5.3347 4.62 0 0
M  V30 18 C 6.6684 5.39 0 0
M  V30 19 C 8.0021 4.62 0 0
M  V30 20 C 9.3358 5.39 0 0
M  V30 21 C 10.6694 4.62 0 0
M  V30 22 C 12.0031 5.39 0 0
M  V30 23 C 13.3368 4.62 0 0
M  V30 24 O 14.6705 5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 4 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 3 12
M  V30 13 2 12 13
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216898922

>  <MW>
338.439

>  <MW (desalted)>
338.439

>  <ClogP>
3.424

>  <logS>
-4.628

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
72.83

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1E-07 M | IC50  1E-07 M | Kd (dissociation constant)  410 nM | inhibition percentage  29.62 %

>  <CAS>
58186-27-9

>  <Description>
Idebenone is a synthetic analogue of ubiquinone, a vital cell antioxidant and essential component of the Electron Transport Chain. Idebenone is indicated for use by the European Medicines Agency for the treatment of visual impairment in adolescent and adult patients with Leber?s Hereditary Optic Neuropathy.

>  <EBC_ID>
EBC-15034

>  <IUPAC Name>
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione

>  <Main Tar all refs>
Pharmacol. Res., 2018, vol. 137, p. 89 - 103 | Pharmacol. Res., 2018, vol. 137, p. 89 - 103 | Pharmacol. Res., 2018, vol. 137, p. 89 - 103 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 23, p. 6793 - 6796

>  <Main tar all>
Insulin receptor pX=7.0 | SHC-transforming protein 1 (isoform p52Shc?) pX=7.0 | Tyrosine-protein phosphatase non-receptor type 1 pX=6.39 | Fatty acid amide hydrolase pX=5.62

$$$$
Entacapone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 9.24 0 0
M  V30 2 C -1.3337 8.47 0 0
M  V30 3 N -1.3337 6.93 0 0
M  V30 4 C -2.6674 6.16 0 0
M  V30 5 C -2.6674 4.62 0 0
M  V30 6 C 0 6.16 0 0
M  V30 7 O 1.3337 6.93 0 0
M  V30 8 C 0 4.62 0 0
M  V30 9 C 1.3337 3.85 0 0
M  V30 10 C 1.3337 2.31 0 0
M  V30 11 C 2.6674 1.54 0 0
M  V30 12 C 2.6674 -0 0 0
M  V30 13 O 4.001 -0.77 0 0
M  V30 14 C 1.3337 -0.77 0 0
M  V30 15 O 1.3337 -2.31 0 0
M  V30 16 C 0 0 0 0
M  V30 17 C 0 1.54 0 0
M  V30 18 N -1.3337 -0.77 0 0 CHG=1
M  V30 19 O -2.6674 0 0 0
M  V30 20 O -1.3337 -2.31 0 0 CHG=-1
M  V30 21 C -1.3337 3.85 0 0
M  V30 22 N -2.6674 3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 10 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 8 21
M  V30 22 3 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315574782

>  <MW>
305.101

>  <MW (desalted)>
305.286

>  <ClogP>
1.761

>  <logS>
-2.952

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
127.7

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.3 nM | Kiu  0.00036 - 0.0022 ?M | IC50  0.00047 ?M | IC50  0.00047 ?M | Ki (inhibition constant) = 1.9 nM

>  <CAS>
130929-57-6

>  <Description>
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor. It is used  for the treatment of Parkinson's disease.

>  <EBC_ID>
EBC-07837

>  <IUPAC Name>
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide

>  <Main Tar all refs>
CNS Neurol. Disord. Drug Targets, 2012, vol. 11, # 3, p. 324 - 332 | Xenobiotica, 2021, vol. 51, # 3, p. 268 - 278 | Mol. Diversity, 2021, vol. 25, # 2, p. 753 - 762 | Mol. Diversity, 2021, vol. 25, # 2, p. 753 - 762 | ORION OYJ - WO2007/10085, 2007, A2

>  <Main tar all>
Catechol-O-methyltransferase pX=9.52 | Catechol O-methyltransferase B pX=9.44 | Catechol-O-methyltransferase pX=9.33 | Catechol-O-methyltransferase pX=9.33 | Catechol-O-methyltransferase pX=8.72

$$$$
Anthralin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -6.93 0 0
M  V30 2 C 4.001 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 2.6674 -3.08 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 C 5.3347 -3.08 0 0
M  V30 7 C 6.6684 -2.31 0 0
M  V30 8 C 8.0021 -3.08 0 0
M  V30 9 C 9.3358 -2.31 0 0
M  V30 10 C 10.6694 -3.08 0 0
M  V30 11 C 10.6694 -4.62 0 0
M  V30 12 C 9.3358 -5.39 0 0
M  V30 13 O 9.3358 -6.93 0 0
M  V30 14 C 8.0021 -4.62 0 0
M  V30 15 C 6.6684 -5.39 0 0
M  V30 16 O 6.6684 -6.93 0 0
M  V30 17 C 5.3347 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 8 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 2 17
M  V30 19 1 6 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891492

>  <MW>
226.063

>  <MW (desalted)>
226.227

>  <ClogP>
4.064

>  <logS>
-3.274

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.23 ?M | Ki (inhibition constant) = 0.6 ?M | Ki (inhibition constant) = 0.6 ?M | inhibition rate Active   | IC50  1.26 ?M | Ki (inhibition constant) = 2 ?M | IC50  2.5 ?M | IC50  4.5 ?M | IC50 = 7000 nM | IC50 = 7 ?M

>  <CAS>
1143-38-0

>  <Description>
Anthralin is a natural anthraquinone derivative, anti-psoriatic and anti-inflammatory agent. It inhibits the proliferation of keratinocytes (epidermal skin cells), prevents the action of T-cells, and promotes cell differentiation, likely through mitochondrial dysfunction. It is used to treat stable plaque psoriasis.

>  <EBC_ID>
EBC-26240

>  <IUPAC Name>
1,8-dihydroxy-9,10-dihydroanthracen-9-one

>  <Main Tar all refs>
FRED HUTCHINSON CANCER RESEARCH CENTER - US9182402, 2015, B2 | THE UNIVERSITY OF TEXAS SYSTEM - US2013/35284, 2013, A1 | THE UNIVERSITY OF TEXAS SYSTEM - US2013/35284, 2013, A1 | Front. Microbiol., 2020, vol. 11 | FRED HUTCHINSON CANCER RESEARCH CENTER - US9182402, 2015, B2 | THE UNIVERSITY OF TEXAS SYSTEM - US2013/35284, 2013, A1 | J. Med. Chem., 2021, vol. 64, # 23, p. 17530 - 17539 | Biosci. Biotechnol. Biochem., 2000, vol. 64, # 7, p. 1373 - 1378 | J. Med. Chem., 2011, vol. 54, # 6, p. 1943 - 1947 | J. MED. CHEM., 1994, vol. 37, # 11, p. 1660 - 1669

>  <Main tar all>
Hepsin pX=6.64 | serine protease 1 pX=6.22 | serine protease 1 pX=6.22 | RNA-dependent RNA polymerase pX=6.11 | Trypsin pX=5.9 | Ns2B/3 Protease pX=5.7 | malate?dehydrogenase pX=5.6 | CYP1A1 pX=5.35 | 5-LOX pX=5.15 | Polyunsaturated fatty acid 5-lipoxygenase pX=5.15

$$$$
Benziodarone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.0896 0.0309 0 0
M  V30 2 C -0.3196 -1.3028 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 O 2.1256 -0.0569 0 0
M  V30 5 C 3.5902 -0.5328 0 0
M  V30 6 C 4.9239 0.2372 0 0
M  V30 7 C 6.2576 -0.5328 0 0
M  V30 8 C 6.2576 -2.0728 0 0
M  V30 9 C 4.9239 -2.8428 0 0
M  V30 10 C 3.5902 -2.0728 0 0
M  V30 11 C 2.1256 -2.5487 0 0
M  V30 12 C 1.6497 -4.0133 0 0
M  V30 13 O 2.6802 -5.1578 0 0
M  V30 14 C 0.1434 -4.3335 0 0
M  V30 15 C -0.3325 -5.7982 0 0
M  V30 16 C -1.8389 -6.1183 0 0
M  V30 17 I -2.3147 -7.583 0 0
M  V30 18 C -2.8693 -4.9739 0 0
M  V30 19 O -4.3757 -5.2941 0 0
M  V30 20 C -2.3934 -3.5093 0 0
M  V30 21 I -3.4239 -2.3648 0 0
M  V30 22 C -0.8871 -3.1891 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 3 11
M  V30 13 1 11 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 14 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681892428

>  <MW>
517.888

>  <MW (desalted)>
518.084

>  <ClogP>
6.358

>  <logS>
-6.132

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
50.44

>  <RotBonds>
3

>  <CAS>
68-90-6

>  <Description>
Benziodarone is a uricostatic and a uricosuric agent. It is used in the treatment of gout.

>  <EBC_ID>
EBC-27265

>  <IUPAC Name>
4-(2-ethyl-1-benzofuran-3-carbonyl)-2,6-diiodophenol

$$$$
Repaglinide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -10.3674 0.7147 0 0
M  V30 2 C -9.5974 -0.619 0 0
M  V30 3 O -8.0574 -0.619 0 0
M  V30 4 C -7.2874 -1.9526 0 0
M  V30 5 C -5.7474 -1.9526 0 0
M  V30 6 C -4.9774 -3.2863 0 0
M  V30 7 C -3.4374 -3.2863 0 0
M  V30 8 C -2.6674 -4.62 0 0
M  V30 9 O -3.4374 -5.9537 0 0
M  V30 10 N -1.1274 -4.62 0 0
M  V30 11 C -0.3574 -5.9537 0 0 CFG=1
M  V30 12 C 1.1826 -5.9537 0 0
M  V30 13 C 1.9526 -4.62 0 0
M  V30 14 C 1.1826 -3.2863 0 0
M  V30 15 C 3.4926 -4.62 0 0
M  V30 16 C -1.1274 -7.2874 0 0
M  V30 17 C -2.6674 -7.2874 0 0
M  V30 18 C -3.4374 -8.621 0 0
M  V30 19 C -2.6674 -9.9547 0 0
M  V30 20 C -1.1274 -9.9547 0 0
M  V30 21 C -0.3574 -8.621 0 0
M  V30 22 N 1.1826 -8.621 0 0
M  V30 23 C 1.9526 -7.2874 0 0
M  V30 24 C 3.4926 -7.2874 0 0
M  V30 25 C 4.2626 -8.621 0 0
M  V30 26 C 3.4926 -9.9547 0 0
M  V30 27 C 1.9526 -9.9547 0 0
M  V30 28 C -5.7474 -4.62 0 0
M  V30 29 C -7.2874 -4.62 0 0
M  V30 30 C -8.0574 -3.2863 0 0
M  V30 31 C -9.5974 -3.2863 0 0
M  V30 32 O -10.3674 -1.9526 0 0
M  V30 33 O -10.3674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 11 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 16 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 22 27
M  V30 29 1 6 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 4 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485370

>  <MW>
452.586

>  <MW (desalted)>
452.586

>  <ClogP>
5.303

>  <logS>
-5.69

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
78.87

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Blocker | Blocker | Blocker | Blocker | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.06 nM | IC50  0.00094 ?M | IC50  0.00094 ?M | IC50  0.0011 ?M | IC50  0.0011 ?M | Ki (inhibition constant) = 1.8 nM

>  <CAS>
135062-02-1

>  <Description>
Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium channels in pancreatic ?-cells. It is used to control blood sugar levels in patients with type 2 diabetes.

>  <EBC_ID>
EBC-06064

>  <IUPAC Name>
2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid

>  <Main Tar all refs>
Br. J. Pharmacol., 2005, vol. 144, # 4, p. 551 - 557 | Pharmaceuticals, 2023, vol. 16, # 2 | Pharmaceuticals, 2023, vol. 16, # 2 | Pharmaceuticals, 2023, vol. 16, # 2 | Pharmaceuticals, 2023, vol. 16, # 2 | J. Pharmacol. Exp. Ther., 2000, vol. 293, # 2, p. 444 - 452

>  <Main tar all>
Beta-Cell Katp Channel pX=10.2 | ABCC9 (isoform SUR2A) pX=9.03 | Kir6.2 pX=9.03 | ABCC9 (isoform SUR2B) pX=8.96 | Kir6.1 pX=8.96 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=8.74

$$$$
Ticarcillin dinatrium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 4.8204 4.4738 0 0 CHG=1
M  V30 2 Na -6.0462 -2.2716 0 0 CHG=1
M  V30 3 C -7.9963 4.4935 0 0
M  V30 4 C -7.1576 3.2019 0 0
M  V30 5 C -8.5297 2.5028 0 0
M  V30 6 S -5.9608 4.1711 0 0
M  V30 7 C -4.6692 3.3324 0 0 CFG=2
M  V30 8 C -3.1817 2.9338 0 0 CFG=2
M  V30 9 N -1.848 3.7038 0 0
M  V30 10 C -0.5144 2.9338 0 0
M  V30 11 O -0.5144 1.3938 0 0
M  V30 12 C 0.8193 3.7038 0 0 CFG=2
M  V30 13 C 2.153 2.9338 0 0
M  V30 14 O 2.153 1.3938 0 0
M  V30 15 O 3.4867 3.7038 0 0 CHG=-1
M  V30 16 C 0.8193 5.2438 0 0
M  V30 17 C -0.4266 6.149 0 0
M  V30 18 C 0.0493 7.6136 0 0
M  V30 19 S 1.5893 7.6136 0 0
M  V30 20 C 2.0652 6.149 0 0
M  V30 21 C -3.5803 1.4462 0 0
M  V30 22 O -2.8103 0.1126 0 0
M  V30 23 N -5.0678 1.8448 0 0
M  V30 24 C -6.6057 1.7642 0 0 CFG=1
M  V30 25 C -7.4445 0.4727 0 0
M  V30 26 O -8.9823 0.5533 0 0
M  V30 27 O -6.7453 -0.8995 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 4 6
M  V30 4 1 7 6
M  V30 5 1 7 8
M  V30 6 1 8 9 CFG=3
M  V30 7 1 9 10
M  V30 8 2 10 11
M  V30 9 1 12 10 CFG=1
M  V30 10 1 12 13
M  V30 11 2 13 14
M  V30 12 1 13 15
M  V30 13 1 12 16
M  V30 14 1 16 17
M  V30 15 2 17 18
M  V30 16 1 18 19
M  V30 17 1 19 20
M  V30 18 2 16 20
M  V30 19 1 8 21
M  V30 20 2 21 22
M  V30 21 1 21 23
M  V30 22 1 7 23 CFG=3
M  V30 23 1 24 23
M  V30 24 1 24 4
M  V30 25 1 24 25 CFG=1
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041519356

>  <MW>
428.009

>  <MW (desalted)>
384.427

>  <ClogP>
-4.56

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
129.67

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.146 ?M | IC50  0.251 ?M | Km (Michaelis constant) = 0.35 ?M | Km (Michaelis constant) = 0.5 ?M | IC50  0.827 ?M | IC50  1.008 ?M | Km (Michaelis constant) = 1.11 ?M | MIC = 0.5 ?g/mL | Ki (inhibition constant)  2.5 ?M | IC50  3.338 ?M

>  <CAS>
29457-07-6

>  <Description>
Ticarcillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria.

>  <EBC_ID>
EBC-80158

>  <IUPAC Name>
disodium (2S,5R,6R)-6-[(2R)-2-carboxylato-2-(thiophen-3-yl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

>  <Main Tar all refs>
Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | Curr. Pharm. Des., 2013, vol. 19, # 2, p. 164 - 208 | Antimicrob. Agents Chemother., 2002, vol. 46, # 10, p. 3316 - 3319 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | Curr. Pharm. Des., 2013, vol. 19, # 2, p. 164 - 208 | Antimicrob. Agents Chemother., 2002, vol. 46, # 6, p. 2004 - 2006 | Antimicrob. Agents Chemother., 2014, vol. 58, # 10, p. 6294 - 6296 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443

>  <Main tar all>
Penicillin-binding?protein B pX=6.84 | Penicillin-binding?protein 2X pX=6.6 | Beta-lactamase SPM-1 pX=6.46 | Beta-Lactamase AmpC pX=6.3 | Penicillin-binding?protein 1A pX=6.08 | Penicillin-binding?protein 1B pX=6.0 | Beta-lactamase VIM-1 pX=5.95 | Beta-lactamase OXA-23 pX=5.89 | Beta-lactamase TEM-149 pX=5.6 | Penicillin-binding?protein 2B pX=5.48

$$$$
Sodium novobiocin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 16.0041 3.08 0 0 CHG=1
M  V30 2 C 1.3337 -10.01 0 0
M  V30 3 O 0 -9.24 0 0
M  V30 4 C 0 -7.7 0 0 CFG=2
M  V30 5 C -1.3337 -6.93 0 0 CFG=1
M  V30 6 O -2.6674 -7.7 0 0
M  V30 7 C -2.6674 -9.24 0 0
M  V30 8 O -1.3337 -10.01 0 0
M  V30 9 N -4.001 -10.01 0 0
M  V30 10 C -1.3337 -5.39 0 0 CFG=1
M  V30 11 O -2.6674 -4.62 0 0
M  V30 12 C 0 -4.62 0 0 CFG=2
M  V30 13 O 0 -3.08 0 0
M  V30 14 C 1.3337 -2.31 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 C 5.3347 0 0 0
M  V30 19 O 5.3347 1.54 0 0
M  V30 20 C 6.6684 -0.77 0 0
M  V30 21 N 8.0021 -0 0 0
M  V30 22 C 9.3358 -0.77 0 0
M  V30 23 O 9.3358 -2.31 0 0
M  V30 24 C 10.6694 -0 0 0
M  V30 25 C 10.6694 1.54 0 0
M  V30 26 C 12.0031 2.31 0 0
M  V30 27 C 13.3368 1.54 0 0
M  V30 28 O 14.6705 2.31 0 0 CHG=-1
M  V30 29 C 13.3368 -0 0 0
M  V30 30 C 14.6705 -0.77 0 0
M  V30 31 C 16.0041 -0 0 0
M  V30 32 C 17.3378 -0.77 0 0
M  V30 33 C 18.6715 -0 0 0
M  V30 34 C 17.3378 -2.31 0 0
M  V30 35 C 12.0031 -0.77 0 0
M  V30 36 C 6.6684 -2.31 0 0
M  V30 37 O 8.0021 -3.08 0 0
M  V30 38 O 5.3347 -3.08 0 0
M  V30 39 C 4.001 -2.31 0 0
M  V30 40 C 2.6674 -3.08 0 0
M  V30 41 C 2.6674 -4.62 0 0
M  V30 42 O 1.3337 -5.39 0 0
M  V30 43 C 1.3337 -6.93 0 0
M  V30 44 C 2.8727 -6.9837 0 0
M  V30 45 C 2.1498 -8.236 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3 CFG=3
M  V30 3 1 5 4
M  V30 4 1 5 6 CFG=1
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 8 1 5 10
M  V30 9 1 10 11 CFG=1
M  V30 10 1 10 12
M  V30 11 1 12 13 CFG=3
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 2 18 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 2 22 23
M  V30 22 1 22 24
M  V30 23 1 24 25
M  V30 24 2 25 26
M  V30 25 1 26 27
M  V30 26 1 27 28
M  V30 27 2 27 29
M  V30 28 1 29 30
M  V30 29 1 30 31
M  V30 30 2 31 32
M  V30 31 1 32 33
M  V30 32 1 32 34
M  V30 33 1 29 35
M  V30 34 2 24 35
M  V30 35 1 20 36
M  V30 36 2 36 37
M  V30 37 1 36 38
M  V30 38 1 38 39
M  V30 39 2 17 39
M  V30 40 1 39 40
M  V30 41 2 14 40
M  V30 42 1 40 41
M  V30 43 1 12 42
M  V30 44 1 42 43
M  V30 45 1 4 43
M  V30 46 1 43 44
M  V30 47 1 43 45
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516923

>  <MW>
634.606

>  <MW (desalted)>
612.624

>  <ClogP>
0.777

>  <logS>
-7.11

>  <HBD>
4

>  <HBA>
9

>  <TPSA>
198.93

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  4 ?M | IC50  4.6 ?M | Kd (dissociation constant)  7.1 ?M | IC50  21.7 ?M | Ki (inhibition constant)  39.28 ?M

>  <CAS>
1476-53-5

>  <Description>
Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. It is indicated for the treatment of infections due to staphylococci and other susceptible organisms.

>  <EBC_ID>
EBC-12058

>  <IUPAC Name>
sodium 4-[(7-{[(2R,3R,4S,5R)-4-(carbamoyloxy)-3-hydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy}-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl)carbamoyl]-2-(3-methylbut-2-en-1-yl)benzen-1-olate

>  <Main Tar all refs>
Med. Chem. Res., 2022, vol. 31, # 7, p. 1176 - 1191 | Med. Chem. Res., 2022, vol. 31, # 7, p. 1176 - 1191 | Helmholtz Association; GOETHE UNIVERSITY FRANKFURT - EP3184514, 2017, A1 | Helmholtz Association; GOETHE UNIVERSITY FRANKFURT - EP3184514, 2017, A1 | J. Recept. Signal Transduction, 2020

>  <Main tar all>
DNA topoisomerase type II (double strand cut ATP-hydrolyzing) activator pX=5.4 | DNA topoisomerase II pX=5.34 | Microtubule-associated proteins 1A/1B light chain 3A pX=5.15 | Microtubule-associated proteins 1A/1B light chain 3B pX=4.66 | Adenosine deaminase pX=4.41

$$$$
Asenapine maleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.2901 5.0361 0 0
M  V30 2 N -0.2901 3.4961 0 0
M  V30 3 C -1.536 2.5909 0 0
M  V30 4 C -1.0601 1.1263 0 0 CFG=1
M  V30 5 C 0.4799 1.1263 0 0 CFG=2
M  V30 6 C 0.9558 2.5909 0 0
M  V30 7 C 1.4401 -0.0777 0 0
M  V30 8 C 2.9116 0.3762 0 0
M  V30 9 C 4.0405 -0.6713 0 0
M  V30 10 Cl 5.5121 -0.2173 0 0
M  V30 11 C 3.6979 -2.1726 0 0
M  V30 12 C 2.2263 -2.6266 0 0
M  V30 13 C 1.0974 -1.5791 0 0
M  V30 14 O -0.2901 -2.2473 0 0
M  V30 15 C -1.6776 -1.5791 0 0
M  V30 16 C -2.8065 -2.6266 0 0
M  V30 17 C -4.2781 -2.1726 0 0
M  V30 18 C -4.6208 -0.6713 0 0
M  V30 19 C -3.4919 0.3762 0 0
M  V30 20 C -2.0203 -0.0777 0 0
M  V30 21 O 15.1921 -0 0 0
M  V30 22 C 13.6521 -0 0 0
M  V30 23 O 12.8821 -1.3337 0 0
M  V30 24 C 12.8821 1.3337 0 0
M  V30 25 C 11.3421 1.3337 0 0
M  V30 26 C 10.5721 -0 0 0
M  V30 27 O 11.3421 -1.3337 0 0
M  V30 28 O 9.0321 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 7 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 4 20
M  V30 23 2 15 20
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2312380776

>  <MW>
401.103

>  <MW (desalted)>
285.768

>  <ClogP>
4.577

>  <logS>
-4.135

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
12.47

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.03 nM | pKi  10.5  | Ki (inhibition constant) = 0.06 nM | pKi  10.2  | IC50  0.0611 nM | pKi  9.94  | pKi  9.9  | Ki (inhibition constant) = 0.16 nM | pKi  9.8  | IC50  0.173 nM | Ki (inhibition constant) = 0.25 nM | pKi  9.6  | IC50  0.3 nM | IC50  0.3 nM | pKi  9.5  | pKi  9.5  | pKi  9.4  | Ki (inhibition constant)  0.61 nM | pKi  9.2  | pKi  9.15 | Kb (antagonist dissociation constant)  0.78 nM | pKb  9.1  | Ki (inhibition constant) = 0.001 ?M | pKi > 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | Ki (inhibition constant) = 0.001 ?M | pKi  9  | pKi  9

>  <CAS>
85650-56-2

>  <Description>
Asenapine is an atypical antipsychotic used to treat patients with bipolar I disorder and patients with schizophrenia. It is a serotonin, dopamine, noradrenaline, and histamine antagonist.

>  <EBC_ID>
EBC-13597

>  <IUPAC Name>
(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.0^{2,6}.0^{7,12}]octadeca-1(18),7,9,11,14,16-hexaene; (2Z)-but-2-enedioic acid

>  <Main Tar all refs>
Schering Corporation, Asenapine (saphris) sublingual tablets, Product leaflet | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Schering Corporation, Asenapine (saphris) sublingual tablets, Product leaflet | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Curr. Top. Med. Chem., 2010, vol. 10, # 5, p. 554 - 578 | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Schering Corporation, Asenapine (saphris) sublingual tablets, Product leaflet | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Schering Corporation, Asenapine (saphris) sublingual tablets, Product leaflet | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3 | J. Pharmacol. Exp. Ther., 2015, vol. 352, # 1, p. 53 - 60 | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Curr. Top. Med. Chem., 2010, vol. 10, # 5, p. 554 - 578 | Curr. Top. Med. Chem., 2010, vol. 10, # 5, p. 554 - 578 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Drugs Future, 1993, vol. 18, # 12, p. 1117 - 1123 | J. Med. Chem., 2018, vol. 61, # 1, p. 174 - 188 | J. Pharmacol. Exp. Ther., 1997, vol. 282, # 1, p. 181 - 191 | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | Drug Data Rep., 1991, vol. 13, # 8, p. 641 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | Drug Data Rep., 1991, vol. 13, # 8, p. 641 | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73 | J. Psychopharmacol., 2009, vol. 23, # 1, p. 65 - 73

>  <Main tar all>
5-HT2C receptor pX=10.5 | 5-HT2C receptor pX=10.5 | 5-HT2A receptor pX=10.2 | 5-HT2A receptor pX=10.2 | D2S receptor pX=10.2 | 5-HT7 receptor pX=9.94 | 5-HT7 receptor pX=9.9 | 5-HT2B receptor pX=9.8 | 5-HT2B receptor pX=9.8 | D3 receptor pX=9.76 | 5-HT6 receptor pX=9.6 | 5-HT6 receptor pX=9.6 | D2 receptor pX=9.52 | D2- like receptor pX=9.52 | ?2B-adrenoceptor pX=9.5 | ?2B-adrenoceptor pX=9.5 | D3 receptor pX=9.4 | D2L receptor pX=9.21 | ?1-adrenoceptor pX=9.2 | D4 receptor pX=9.15 | D4.4 receptor pX=9.11 | D2 receptor pX=9.1 | ?1-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | ?2A-adrenoceptor pX=9.0 | 5-HT1A receptor pX=9.0 | 5-HT1B receptor pX=9.0 | 5-HT1D receptor pX=9.0 | D1 receptor pX=9.0 | D4 receptor pX=9.0 | H1 receptor pX=9.0

$$$$
Acarbose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 C -1.3337 -2.31 0 0 CFG=1
M  V30 3 O -2.6674 -3.08 0 0
M  V30 4 C -2.6674 -4.62 0 0 CFG=2
M  V30 5 O -4.001 -5.39 0 0
M  V30 6 C -5.3347 -4.62 0 0 CFG=1
M  V30 7 C -6.6684 -5.39 0 0 CFG=2
M  V30 8 O -6.6684 -6.93 0 0
M  V30 9 C -8.0021 -4.62 0 0 CFG=1
M  V30 10 O -9.3358 -5.39 0 0
M  V30 11 C -8.0021 -3.08 0 0 CFG=1
M  V30 12 O -9.3358 -2.31 0 0
M  V30 13 C -9.3358 -0.77 0 0 CFG=1
M  V30 14 C -10.6694 -0 0 0 CFG=2
M  V30 15 O -12.0031 -0.77 0 0
M  V30 16 C -10.6694 1.54 0 0 CFG=1
M  V30 17 O -12.0031 2.31 0 0
M  V30 18 C -9.3358 2.31 0 0 CFG=2
M  V30 19 O -9.3358 3.85 0 0
M  V30 20 O -8.0021 1.54 0 0
M  V30 21 C -8.0021 -0 0 0 CFG=2
M  V30 22 C -6.6684 -0.77 0 0
M  V30 23 O -5.3347 -0 0 0
M  V30 24 O -6.6684 -2.31 0 0
M  V30 25 C -5.3347 -3.08 0 0 CFG=2
M  V30 26 C -4.001 -2.31 0 0
M  V30 27 O -4.001 -0.77 0 0
M  V30 28 C -1.3337 -5.39 0 0 CFG=2
M  V30 29 O -1.3337 -6.93 0 0
M  V30 30 C 0 -4.62 0 0 CFG=1
M  V30 31 O 1.3337 -5.39 0 0
M  V30 32 C 0 -3.08 0 0 CFG=2
M  V30 33 N 1.3337 -2.31 0 0
M  V30 34 C 1.3337 -0.77 0 0 CFG=1
M  V30 35 C 0 -0 0 0
M  V30 36 C 0 1.54 0 0
M  V30 37 C -1.3337 2.31 0 0
M  V30 38 O -2.6674 1.54 0 0
M  V30 39 C 1.3337 2.31 0 0 CFG=1
M  V30 40 O 1.3337 3.85 0 0
M  V30 41 C 2.6674 1.54 0 0 CFG=2
M  V30 42 O 4.001 2.31 0 0
M  V30 43 C 2.6674 -0 0 0 CFG=1
M  V30 44 O 4.001 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 12 CFG=1
M  V30 12 1 13 12 CFG=1
M  V30 13 1 13 14
M  V30 14 1 14 15 CFG=3
M  V30 15 1 14 16
M  V30 16 1 16 17 CFG=1
M  V30 17 1 16 18
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 21 20
M  V30 21 1 13 21
M  V30 22 1 21 22 CFG=3
M  V30 23 1 22 23
M  V30 24 1 11 24
M  V30 25 1 25 24
M  V30 26 1 6 25
M  V30 27 1 25 26 CFG=3
M  V30 28 1 26 27
M  V30 29 1 28 4
M  V30 30 1 28 29 CFG=1
M  V30 31 1 28 30
M  V30 32 1 30 31 CFG=3
M  V30 33 1 30 32
M  V30 34 1 32 2
M  V30 35 1 32 33 CFG=1
M  V30 36 1 34 33 CFG=1
M  V30 37 1 34 35
M  V30 38 2 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 39 36
M  V30 42 1 39 40 CFG=1
M  V30 43 1 41 39
M  V30 44 1 41 42 CFG=3
M  V30 45 1 41 43
M  V30 46 1 43 34
M  V30 47 1 43 44 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2238899645

>  <MW>
645.605

>  <MW (desalted)>
645.605

>  <ClogP>
-6.657

>  <logS>
0.523

>  <HBD>
14

>  <HBA>
19

>  <TPSA>
321.17

>  <RotBonds>
9

>  <Action on targets>
nhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  12.6 nM | IC50  0.018 ?M | Ki (inhibition constant) = 0.024 ?M | IC50 = 0.046 ?M | IC50  0.05 ?M | IC50 = 39.3 ng/mL | IC50 = 87.1 ng/mL

>  <CAS>
56180-94-0

>  <Description>
Acarbose is an alpha-glucosidase inhibitor used in adjunctly with diet and exercise for the management of glycemic control in patients with type 2 diabetes mellitus.

>  <EBC_ID>
EBC-46065

>  <IUPAC Name>
(2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol

>  <Main Tar all refs>
Arch. Pharm., 2018, vol. 351, # 2 | Med. Chem. Res., 2022, vol. 31, # 2, p. 350 - 367 | J. Nat. Prod., 2013, vol. 76, # 3, p. 468 - 483 | Nat. Prod. Rep., 2012, vol. 29, # 5, p. 580 - 606 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 416 - 423 | CHINESE ACADEMY OF MEDICAL SCIENCES - EP2255822, 2010, A1 | CHINESE ACADEMY OF MEDICAL SCIENCES - EP2255822, 2010, A1

>  <Main tar all>
maltase pX=7.9 | Alpha-glucosidase pX=7.74 | Alpha-glucosidase?(gene?aglA) pX=7.62 | Alpha-glucosidase IV pX=7.34 | Alpha-glucosidase pX=7.3 | Lysosomal?alpha-glucosidase pX=7.22 | Oligo-1,6-glucosidase (peptide) pX=6.87

$$$$
Apremilast
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -7.2496 -5.3039 0 0
M  V30 2 C -5.7096 -5.3039 0 0
M  V30 3 O -4.9396 -3.9702 0 0
M  V30 4 C -3.3996 -3.9702 0 0
M  V30 5 C -2.6296 -2.6365 0 0
M  V30 6 C -1.0896 -2.6365 0 0
M  V30 7 C -0.3196 -3.9702 0 0
M  V30 8 C -1.0896 -5.3039 0 0
M  V30 9 C -2.6296 -5.3039 0 0
M  V30 10 O -3.3996 -6.6375 0 0
M  V30 11 C -4.9396 -6.6375 0 0
M  V30 12 C -0.3196 -1.3028 0 0 CFG=1
M  V30 13 C -1.0896 0.0309 0 0
M  V30 14 S -0.3196 1.3645 0 0
M  V30 15 O 1.0141 0.5945 0 0
M  V30 16 O -1.6533 2.1345 0 0
M  V30 17 C 0.4504 2.6982 0 0
M  V30 18 N 1.2204 -1.3028 0 0
M  V30 19 C 2.1256 -0.0569 0 0
M  V30 20 O 1.6497 1.4077 0 0
M  V30 21 C 3.5902 -0.5328 0 0
M  V30 22 C 4.9239 0.2372 0 0
M  V30 23 C 6.2576 -0.5328 0 0
M  V30 24 C 6.2576 -2.0728 0 0
M  V30 25 C 4.9239 -2.8428 0 0
M  V30 26 N 4.9239 -4.3828 0 0
M  V30 27 C 6.2576 -5.1528 0 0
M  V30 28 O 7.5913 -4.3828 0 0
M  V30 29 C 6.2576 -6.6928 0 0
M  V30 30 C 3.5902 -2.0728 0 0
M  V30 31 C 2.1256 -2.5487 0 0
M  V30 32 O 1.6497 -4.0133 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 12 6
M  V30 13 1 12 13 CFG=1
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 2 14 16
M  V30 17 1 14 17
M  V30 18 1 12 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 27 29
M  V30 30 1 25 30
M  V30 31 2 21 30
M  V30 32 1 30 31
M  V30 33 1 18 31
M  V30 34 2 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1837762189

>  <MW>
460.13

>  <MW (desalted)>
460.5

>  <ClogP>
1.461

>  <logS>
-4.128

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
119.08

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4.5 nM | IC50  6.4 nM | IC50  9.85 nM | IC50  10 - 50 nM | IC50  12 nM | IC50  14.5 nM | IC50  16.5 nM | IC50  24 nM | IC50  26 nM | IC50  30 nM | IC50  41 nM | IC50  44 nM | IC50  49 nM | IC50  50 nM | IC50  61 nM | IC50  74 nM | IC50  0.077 ?M | IC50  100 - 200 nM | IC50  117 nM

>  <CAS>
608141-41-9

>  <Description>
Apremilast is a non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. It is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.

>  <EBC_ID>
EBC-27155

>  <IUPAC Name>
N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

>  <Main Tar all refs>
ACS Chem. Neurosci., 2020, vol. 11, # 15, p. 2231 - 2242 | KANGPU BIOPHARMACEUTICALS - EP3590924, 2020, A1 | KANGPU BIOPHARMACEUTICALS - EP3590924, 2020, A1 | SUZHOU INTRAGRAND PHARMA CO LTD; SUZHOU PUZHENG PHARMACEUTICAL - CN114790164, 2022, B | ACS Chem. Neurosci., 2020, vol. 11, # 15, p. 2231 - 2242 | KANGPU BIOPHARMACEUTICALS - EP3590924, 2020, A1 | WUXI APPTEC CO., LTD. - US2021/198253, 2021, A1 | J. Med. Chem., 2019, vol. 62, # 10, p. 4884 - 4901 | J. Med. Chem., 2019, vol. 62, # 10, p. 4884 - 4901 | Br. J. Pharmacol., 2010, vol. 159, # 4, p. 842 - 855 | UNION THERAPEUTICS AS - WO2022/200339, 2022, A1 | UNION THERAPEUTICS AS - WO2022/200339, 2022, A1 | Br. J. Pharmacol., 2010, vol. 159, # 4, p. 842 - 855 | Br. J. Pharmacol., 2010, vol. 159, # 4, p. 842 - 855 | UNION THERAPEUTICS AS - WO2022/200339, 2022, A1 | ABBVIE INC - WO2018/17713, 2018, A1 | Xenobiotica, 2011, vol. 41, # 12, p. 1063 - 1075 | SUZHOU INTRAGRAND PHARMA CO LTD; SUZHOU PUZHENG PHARMACEUTICAL - CN114790164, 2022, B | UNION THERAPEUTICS AS - WO2022/200339, 2022, A1

>  <Main tar all>
phosphodiesterase 4D pX=8.35 | phosphodiesterase 4D3 pX=8.19 | phosphodiesterase 4A1 pX=8.01 | phosphodiesterase 4D33 pX=8.0 | phosphodiesterase 4B pX=7.92 | phosphodiesterase 4B1 pX=7.84 | phosphodiesterase 4 pX=7.78 | phosphodiesterase 4B1 pX=7.62 | phosphodiesterase 4D7 pX=7.59 | phosphodiesterase 4D2 pX=7.52 | cAMP-specific 3',5'-cyclic phosphodiesterase 4D (isoform 4) pX=7.39 | cAMP-specific 3',5'-cyclic phosphodiesterase 4D (isoform 1) pX=7.36 | phosphodiesterase 4B2 pX=7.31 | phosphodiesterase 4C2 pX=7.3 | cAMP-specific 3',5'-cyclic phosphodiesterase 4D (isoform 5) pX=7.21 | phosphodiesterase 4B2 pX=7.13 | ADAM17 pX=7.11 | phosphodiesterase 4A4 pX=7.0 | cAMP-specific 3',5'-cyclic phosphodiesterase 4B (isoform PDE4B3) pX=6.93

$$$$
Mycophenolate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 O 1.3337 5.39 0 0
M  V30 3 C 2.6674 6.16 0 0
M  V30 4 C 2.6674 7.7 0 0
M  V30 5 C 1.3337 8.47 0 0
M  V30 6 C 4.001 8.47 0 0
M  V30 7 C 4.3212 9.9763 0 0
M  V30 8 O 5.8528 10.1373 0 0
M  V30 9 C 6.4792 8.7305 0 0
M  V30 10 O 7.9855 8.4103 0 0
M  V30 11 C 5.3347 7.7 0 0
M  V30 12 C 5.3347 6.16 0 0
M  V30 13 O 6.6684 5.39 0 0
M  V30 14 C 4.001 5.39 0 0
M  V30 15 C 4.001 3.85 0 0
M  V30 16 C 5.3347 3.08 0 0
M  V30 17 C 5.3347 1.54 0 0
M  V30 18 C 4.001 0.77 0 0
M  V30 19 C 6.6684 0.77 0 0
M  V30 20 C 8.0021 1.54 0 0
M  V30 21 C 9.3358 0.77 0 0
M  V30 22 O 9.3358 -0.77 0 0
M  V30 23 O 10.6694 1.54 0 0
M  V30 24 C 12.0031 0.77 0 0
M  V30 25 C 13.3368 1.54 0 0
M  V30 26 N 14.6705 0.77 0 0
M  V30 27 C 16.0041 1.54 0 0
M  V30 28 C 17.3378 0.77 0 0
M  V30 29 O 17.3378 -0.77 0 0
M  V30 30 C 16.0041 -1.54 0 0
M  V30 31 C 14.6705 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 3 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 26 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568665233

>  <MW>
433.21

>  <MW (desalted)>
433.495

>  <ClogP>
2.98

>  <logS>
-2.931

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
94.53

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.19 ?M | EC50  0.19 ?M | IC50  5.29E-07 M | IC50  4.47 ?M | IC50  5.53 ?M

>  <CAS>
128794-94-5

>  <Description>
Mycophenolate mofetil is an inosine monophosphate dehydrogenase inhibitor used to prevent the rejection of kidney, heart, or liver transplants.

>  <EBC_ID>
EBC-11251

>  <IUPAC Name>
2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate

>  <Main Tar all refs>
PeerJ, 2021, vol. 9 | Viruses, 2022, vol. 14, # 5 | STATE UNIVERSITY SYSTEM OF FLORIDA; THE JOHNS HOPKINS UNIVERSITY; GOVERNMENT OF THE UNITED STATES - US2018/15153, 2018, A1 | PeerJ, 2021, vol. 9 | PeerJ, 2021, vol. 9

>  <Main tar all>
COX-2  pX=6.72 | IMP dehydrogenase pX=6.72 | Nonstructural protein 1 pX=6.28 | Polyunsaturated fatty acid lipoxygenase ALOX12 pX=5.35 | COX-1  pX=5.26

$$$$
Nicotinamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 N 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z33546463

>  <MW>
122.048

>  <MW (desalted)>
122.125

>  <ClogP>
-0.206

>  <logS>
-0.42

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
55.98

>  <RotBonds>
1

>  <Action on targets>
- | - | -

>  <Activity coefficients and valu>
Km (Michaelis constant) = 5 nM | Km (Michaelis constant) = 5 nM | Km (Michaelis constant) ~ 100 nM

>  <CAS>
98-92-0

>  <Description>
Nicotinamide is an amide form of vitamin B3. It is an important compound functioning as a component of the coenzyme NAD, which is involved in energy metabolism.

>  <EBC_ID>
EBC-11065

>  <IUPAC Name>
pyridine-3-carboxamide

>  <Main Tar all refs>
Curr. Med. Chem., 2011, vol. 18, # 13, p. 1947 - 1961 | Curr. Med. Chem., 2011, vol. 18, # 13, p. 1947 - 1961 | Curr. Pharm. Des., 2009, vol. 15, # 1, p. 20 - 28

>  <Main tar all>
Nicotinamide phosphoribosyltransferase pX=8.3 | nicotinamide phosphoribosyltransferase pX=8.3 | Nicotinamide phosphoribosyltransferase (peptide) pX=7.0

$$$$
Aminolevulinic acid hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 0.3422 0 0
M  V30 3 C 5.7337 -0.4278 0 0
M  V30 4 C 7.0674 0.3422 0 0
M  V30 5 O 7.0674 1.8822 0 0
M  V30 6 C 8.401 -0.4278 0 0
M  V30 7 C 9.7347 0.3422 0 0
M  V30 8 C 11.0684 -0.4278 0 0
M  V30 9 O 12.4021 0.3422 0 0
M  V30 10 O 11.0684 -1.9678 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 4 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741972992

>  <MW>
167.035

>  <MW (desalted)>
131.13

>  <ClogP>
-3.415

>  <logS>
-0.063

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
80.39

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
inhibition percentage  32 % | Km (Michaelis constant) = 172000 nM

>  <CAS>
5451-09-2

>  <Description>
Aminolevulinic acid is a porphyrin precursor used to treat actinic keratosis of the face, scalp, and upper extremities, as well as to visualize a glioma.

>  <EBC_ID>
EBC-17028

>  <IUPAC Name>
5-amino-4-oxopentanoic acid hydrochloride

>  <Main Tar all refs>
PLoS ONE, 2019, vol. 14, # 3 | Bioorg. Med. Chem. Lett., 1996, vol. 6, # 11, p. 1191 - 1194

>  <Main tar all>
glutathione S-transferase alpha 3 pX=4.67 | Delta-aminolevulinic acid dehydratase pX=3.76

$$$$
Tiopronin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 C 4.62 2.6674 0 0
M  V30 3 S 4.62 1.1274 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 O 5.9537 4.9774 0 0
M  V30 6 N 7.2874 2.6674 0 0
M  V30 7 C 8.621 3.4374 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 O 11.2884 3.4374 0 0
M  V30 10 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891170

>  <MW>
163.03

>  <MW (desalted)>
163.195

>  <ClogP>
-0.235

>  <logS>
-1.194

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKa (association)  8.4

>  <CAS>
1953-02-2

>  <Description>
Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation.

>  <EBC_ID>
EBC-26113

>  <IUPAC Name>
2-(2-sulfanylpropanamido)acetic acid

>  <Main Tar all refs>
J. Biol. Inorg. Chem., 2020

>  <Main tar all>
Beta-lactamase NDM-1 pX=8.4

$$$$
Tranexamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0 CFG=1
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0 CFG=1
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 O 2.6674 -3.08 0 0
M  V30 11 O -0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 1 6 9 CFG=3
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741970429

>  <MW>
157.11

>  <MW (desalted)>
157.21

>  <ClogP>
-1.801

>  <logS>
-0.646

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 45 ?M | inhibition rate Active   | inhibition rate Active

>  <CAS>
1197-18-8

>  <Description>
Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin.

>  <EBC_ID>
EBC-04330

>  <IUPAC Name>
(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2004, vol. 67, # 4, p. 643 - 654 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1

>  <Main tar all>
plasminogen pX=4.35 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3

$$$$
Favipiravir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 N 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 F 4.001 -0.77 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255381648

>  <MW>
157.029

>  <MW (desalted)>
157.103

>  <ClogP>
0.719

>  <logS>
-0.624

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
89.1

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | IC90  290 nM

>  <CAS>
259793-96-9

>  <Description>
Favipiravir is an antiviral used to manage influenza, and that has the potential to target other viral infections.

>  <EBC_ID>
EBC-06186

>  <IUPAC Name>
6-fluoro-3-hydroxypyrazine-2-carboxamide

>  <Main Tar all refs>
J. Med. Chem., 2022, vol. 65, # 1, p. 369 - 385 | Front. Microbiol., 2022, vol. 13

>  <Main tar all>
RNA-dependent RNA polymerase pX=8.0 | Neuraminidase pX=7.49

$$$$
Lipoic Acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.5713 -6.2801 0 0
M  V30 2 C 5.905 -5.5101 0 0
M  V30 3 O 5.905 -3.9701 0 0
M  V30 4 C 7.2387 -6.2801 0 0
M  V30 5 C 8.5723 -5.5101 0 0
M  V30 6 C 9.906 -6.2801 0 0
M  V30 7 C 11.2397 -5.5101 0 0
M  V30 8 C 12.5734 -6.2801 0 0 CFG=2
M  V30 9 C 13.9802 -5.6538 0 0
M  V30 10 C 15.0107 -6.7982 0 0
M  V30 11 S 14.2407 -8.1319 0 0
M  V30 12 S 12.7343 -7.8117 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 8 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269228108

>  <MW>
206.044

>  <MW (desalted)>
206.326

>  <ClogP>
2.386

>  <logS>
-2.931

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  71 pg/ml

>  <CAS>
1200-22-2

>  <Description>
Lipoic acid is generally involved in oxidative decarboxylations of keto acids and is presented as a growth factor for some organisms. It is able to pass the blood-brain barrier and is putatively used for detoxification of mercury attached to the brain cells. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26201

>  <IUPAC Name>
5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid

>  <Main Tar all refs>
Pharmacol. Rep., 2019, vol. 71, # 4, p. 614 - 623

>  <Main tar all>
TLR2 pX=9.46

$$$$
Azelaic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 7.9063 6.1047 0 0
M  V30 2 C 9.24 5.3347 0 0
M  V30 3 O 9.24 3.7947 0 0
M  V30 4 C 10.5737 6.1047 0 0
M  V30 5 C 11.9074 5.3347 0 0
M  V30 6 C 13.241 6.1047 0 0
M  V30 7 C 14.5747 5.3347 0 0
M  V30 8 C 15.9084 6.1047 0 0
M  V30 9 C 17.2421 5.3347 0 0
M  V30 10 C 18.5758 6.1047 0 0
M  V30 11 C 19.9094 5.3347 0 0
M  V30 12 O 21.2431 6.1047 0 0
M  V30 13 O 19.9094 3.7947 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127532

>  <MW>
188.105

>  <MW (desalted)>
188.221

>  <ClogP>
1.563

>  <logS>
-1.43

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
74.6

>  <RotBonds>
8

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  0.6 ?M

>  <CAS>
123-99-9

>  <Description>
Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is used for the topical treatment of mild-to-moderate inflammatory acne vulgaris. It is thought that azelaic acid manifests its antibacterial effects by inhibiting the synthesis of cellular protein in anaerobic and aerobic bacteria.

>  <EBC_ID>
EBC-13419

>  <IUPAC Name>
nonanedioic acid

>  <Main Tar all refs>
J. Biol. Chem., 2005, vol. 280, # 12, p. 11807 - 11815

>  <Main tar all>
Olfactory receptor 544 pX=6.22

$$$$
Diphenylguanidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.0021 -3.08 0 0
M  V30 2 C 6.6684 -2.31 0 0
M  V30 3 N 5.3347 -3.08 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 6.6684 -5.39 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 C 5.3347 -7.7 0 0
M  V30 8 C 4.001 -6.93 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 N 6.6684 -0.77 0 0
M  V30 11 C 8.0021 0 0 0
M  V30 12 C 8.0021 1.54 0 0
M  V30 13 C 9.3358 2.31 0 0
M  V30 14 C 10.6694 1.54 0 0
M  V30 15 C 10.6694 -0 0 0
M  V30 16 C 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 2 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z203045076

>  <MW>
211.111

>  <MW (desalted)>
211.262

>  <ClogP>
2.01

>  <logS>
-3.57

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
47.91

>  <RotBonds>
2

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
IC50  6.9 nM

>  <CAS>
102-06-7

>  <Description>
Diphenylguanidine is a complexing agent used in the detection of metals and organic bases and used as an accelerator in the vulcanization of rubber. It is a dermatological sensitizer and allergen. It is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older.

>  <EBC_ID>
EBC-04196

>  <IUPAC Name>
N,N'-diphenylguanidine

>  <Main Tar all refs>
Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258

>  <Main tar all>
Kv11.1 pX=8.16

$$$$
Kinetin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.787 4.62 0 0
M  V30 2 N 6.1207 3.85 0 0
M  V30 3 C 6.1207 2.31 0 0
M  V30 4 N 7.4543 1.54 0 0
M  V30 5 C 7.4543 0 0 0
M  V30 6 N 6.1207 -0.77 0 0
M  V30 7 C 4.787 0 0 0
M  V30 8 N 3.3224 -0.4759 0 0
M  V30 9 C 2.4172 0.77 0 0
M  V30 10 N 3.3224 2.0159 0 0
M  V30 11 C 4.787 1.54 0 0
M  V30 12 C 4.787 6.16 0 0
M  V30 13 C 3.5411 7.0652 0 0
M  V30 14 C 4.017 8.5298 0 0
M  V30 15 C 5.557 8.5298 0 0
M  V30 16 O 6.0329 7.0652 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 3 11
M  V30 12 1 7 11
M  V30 13 1 1 12
M  V30 14 2 12 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 1 12 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z372953774

>  <MW>
215.081

>  <MW (desalted)>
215.211

>  <ClogP>
1.306

>  <logS>
-3.265

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
79.63

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Stimulator

>  <Activity coefficients and valu>
Ki (inhibition constant) = 3.2 ?M | inhibition percentage Active

>  <CAS>
525-79-1

>  <Description>
Kinetin is a cytokinin which are plant hormones promotes cell division and plant growth. It was shown to naturally exist in DNA of organisms including humans and various plants. While kinetin is used in tissue cultures to produce new plants, it is also found in cosmetic products as an anti-aging agents.

>  <EBC_ID>
EBC-04338

>  <IUPAC Name>
N-[(furan-2-yl)methyl]-7H-purin-6-amine

>  <Main Tar all refs>
Chem. Biol., 2007, vol. 14, # 5, p. 589 - 599 | UNIVERSITY OF CALIFORNIA; MITOKININ - WO2014/124458, 2014, A1

>  <Main tar all>
Chitinase (gene chiA2) pX=5.49 | PTEN induced kinase 1 pX=4.3

$$$$
Methoxsalen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 4.62 0 0
M  V30 2 O 4.001 3.85 0 0
M  V30 3 C 4.001 2.31 0 0
M  V30 4 C 5.3347 1.54 0 0
M  V30 5 O 6.7993 2.0159 0 0
M  V30 6 C 7.7045 0.77 0 0
M  V30 7 C 6.7993 -0.4759 0 0
M  V30 8 C 5.3347 -0 0 0
M  V30 9 C 4.001 -0.77 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C -0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 O -1.3337 2.31 0 0
M  V30 15 O 1.3337 2.31 0 0
M  V30 16 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 4 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 3 16
M  V30 18 1 10 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754918916

>  <MW>
216.042

>  <MW (desalted)>
216.19

>  <ClogP>
2.305

>  <logS>
-3.42

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
48.67

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1.1 nM | IC50 < 0.01 ?M | Ki (inhibition constant)  0.01 - 0.2 ?M | IC50  21.22 nM

>  <CAS>
298-81-7

>  <Description>
Methoxsalen is a naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is used for the treatment of psoriasis and vitiligo.

>  <EBC_ID>
EBC-11074

>  <IUPAC Name>
9-methoxy-7H-furo[3,2-g]chromen-7-one

>  <Main Tar all refs>
Toxicol. Appl. Pharmacol., 2017, vol. 337, p. 22 - 29 | Drug Metab. Dispos., 2022, vol. 50, # 9, p. 1259 - 1271 | Curr. Top. Med. Chem., 2011, vol. 11, # 4, p. 382 - 403 | Toxicol. Appl. Pharmacol., 2017, vol. 337, p. 22 - 29

>  <Main tar all>
ABCG2 pX=8.96 | CYP1A2 pX=8.0 | Cytochrome P450 2A6 pX=8.0 | ABCB1 pX=7.67

$$$$
Morpholinylmercaptobenzothiazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.3996 -3.9702 0 0
M  V30 2 C -2.6296 -2.6365 0 0
M  V30 3 N -1.0896 -2.6365 0 0
M  V30 4 C -0.3196 -3.9702 0 0
M  V30 5 C -1.0896 -5.3039 0 0
M  V30 6 O -2.6296 -5.3039 0 0
M  V30 7 S -0.3196 -1.3028 0 0
M  V30 8 C 1.2204 -1.3028 0 0
M  V30 9 N 2.1256 -0.0569 0 0
M  V30 10 C 3.5902 -0.5328 0 0
M  V30 11 C 4.9239 0.2372 0 0
M  V30 12 C 6.2576 -0.5328 0 0
M  V30 13 C 6.2576 -2.0728 0 0
M  V30 14 C 4.9239 -2.8428 0 0
M  V30 15 C 3.5902 -2.0728 0 0
M  V30 16 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 1 6
M  V30 7 1 3 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 1 15 16
M  V30 18 1 8 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56821717

>  <MW>
252.039

>  <MW (desalted)>
252.356

>  <ClogP>
2.968

>  <logS>
-4.16

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
25.36

>  <RotBonds>
2

>  <CAS>
102-77-2

>  <Description>
Morpholinylmercaptobenzothiazole is a chemical allergen, it is used in the vulcanization of rubber. It is used for diagnosis of contact allergy.

>  <EBC_ID>
EBC-12355

>  <IUPAC Name>
2-(morpholin-4-ylsulfanyl)-1,3-benzothiazole

$$$$
isocarboxazid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.2937 -1.3614 0 0
M  V30 2 C -1.6673 -2.7683 0 0
M  V30 3 C -0.161 -3.0884 0 0
M  V30 4 C 0 -4.62 0 0
M  V30 5 N -1.4069 -5.2464 0 0
M  V30 6 O -2.4373 -4.1019 0 0
M  V30 7 C 1.3337 -5.39 0 0
M  V30 8 O 1.3337 -6.93 0 0
M  V30 9 N 2.6674 -4.62 0 0
M  V30 10 N 4.001 -5.39 0 0
M  V30 11 C 5.3347 -4.62 0 0
M  V30 12 C 6.6684 -5.39 0 0
M  V30 13 C 8.0021 -4.62 0 0
M  V30 14 C 9.3358 -5.39 0 0
M  V30 15 C 9.3358 -6.93 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2044793215

>  <MW>
231.101

>  <MW (desalted)>
231.251

>  <ClogP>
0.994

>  <logS>
-2.219

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
67.16

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
shift in thermal unfolding curve Active

>  <CAS>
59-63-2

>  <Description>
Isocarboxazid is a monoamine oxidase inhibitor used to treat enduring and debilitating symptoms of depression following inadequate clinical response to other antidepressant drugs.

>  <EBC_ID>
EBC-10021

>  <IUPAC Name>
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide

>  <Main Tar all refs>
BETH ISRAEL LAHEY HEALTH - WO2021/133777, 2021, A1

>  <Main tar all>
Renalase pX=7.0

$$$$
Bretylium tosylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.744 4.0869 0 0
M  V30 2 C -1.744 2.5469 0 0
M  V30 3 N -0.4104 1.7769 0 0 CHG=1
M  V30 4 C -1.1804 0.4432 0 0
M  V30 5 C 0.3596 3.1106 0 0
M  V30 6 C 0.9233 1.0069 0 0
M  V30 7 C 0.9233 -0.5331 0 0
M  V30 8 C 2.257 -1.3031 0 0
M  V30 9 C 2.257 -2.8431 0 0
M  V30 10 C 0.9233 -3.6131 0 0
M  V30 11 C -0.4104 -2.8431 0 0
M  V30 12 C -0.4104 -1.3031 0 0
M  V30 13 Br -1.744 -0.5331 0 0
M  V30 14 C 7.1107 4.06 0 0
M  V30 15 C 7.1107 2.52 0 0
M  V30 16 C 8.4444 1.75 0 0
M  V30 17 C 8.4444 0.21 0 0
M  V30 18 C 7.1107 -0.56 0 0
M  V30 19 C 5.777 0.21 0 0
M  V30 20 C 5.777 1.75 0 0
M  V30 21 S 7.1107 -2.1 0 0
M  V30 22 O 7.1107 -3.64 0 0
M  V30 23 O 5.5707 -2.1 0 0
M  V30 24 O 8.6507 -2.1 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 12 13
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 21 1 18 21
M  V30 22 2 21 22
M  V30 23 2 21 23
M  V30 24 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2050011174

>  <MW>
413.066

>  <MW (desalted)>
243.163

>  <ClogP>
-1.246

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
4

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pA2  5.66  | Ki (inhibition constant)  2.8 ?M | Ki (inhibition constant)  15.8 ?M | Ki (inhibition constant)  28.6 ?M | Ki (inhibition constant)  31.8 ?M

>  <CAS>
61-75-6

>  <Description>
Bretylium tosylate is an agonist of muscarinic acetylcholine receptor family.

>  <EBC_ID>
EBC-08151

>  <IUPAC Name>
[(2-bromophenyl)methyl](ethyl)dimethylazanium 4-methylbenzene-1-sulfonate

>  <Main Tar all refs>
BR. J. PHARMACOL., 1990, vol. 99, # 4, p. 753 - 761 | Biochem. Pharmacol., 2001, vol. 62, # 7, p. 883 - 892 | Biochem. Pharmacol., 2001, vol. 62, # 7, p. 883 - 892 | Biochem. Pharmacol., 2001, vol. 62, # 7, p. 883 - 892 | Biochem. Pharmacol., 2001, vol. 62, # 7, p. 883 - 892

>  <Main tar all>
mAChR pX=5.66 | ?2-adrenoceptor pX=5.55 | ?-adrenoceptor pX=4.8 | ?-adrenoceptor pX=4.54 | ?1-adrenoceptor pX=4.5

$$$$
Sulfadiazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 -1.54 0 0
M  V30 2 C 5.3347 -3.08 0 0
M  V30 3 C 6.6684 -3.85 0 0
M  V30 4 C 6.6684 -5.39 0 0
M  V30 5 C 5.3347 -6.16 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -3.85 0 0
M  V30 8 S 5.3347 -7.7 0 0
M  V30 9 O 3.7947 -7.7 0 0
M  V30 10 O 6.8747 -7.7 0 0
M  V30 11 N 5.3347 -9.24 0 0
M  V30 12 C 4.001 -10.01 0 0
M  V30 13 N 4.001 -11.55 0 0
M  V30 14 C 2.6674 -12.32 0 0
M  V30 15 C 1.3337 -11.55 0 0
M  V30 16 C 1.3337 -10.01 0 0
M  V30 17 N 2.6674 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104472626

>  <MW>
250.052

>  <MW (desalted)>
250.277

>  <ClogP>
0.1

>  <logS>
-2.43

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
97.97

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
IC50  0.135 ?M | IC50  0.135 ?M | Ki (inhibition constant) = 0.341 ?M | pKa (association)  6.36 | IC50  0.62 ?M | IC50 > 1000 nM | IC50 > 1000 nM | IC50 > 1000 nM | IC50 > 1000 nM | IC50 = 1.5 ?M | Km (Michaelis constant)  2.98 ?M

>  <CAS>
68-35-9

>  <Description>
Sulfadiazine is a sulfonamide antibiotic. It inhibits dihydropteroate synthase (DHPS). It is used for the treatment of a variety of infections, such as urinary tract infections, trachoma, and chancroid.

>  <EBC_ID>
EBC-03731

>  <IUPAC Name>
4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
Bioorg. Chem., 2020, vol. 99 | Bioorg. Chem., 2020, vol. 99 | J. Enzyme Inhib. Med. Chem., 2013, vol. 28, # 2, p. 294 - 298 | J. Hazard. Mater., 2018, vol. 341, p. 438 - 447 | ANTIMICROB. AGENTS CHEMOTHER., 1996, vol. 40, # 3, p. 727 - 733 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | J. Enzyme Inhib. Med. Chem., 2011, vol. 26, # 5, p. 603 - 609 | Drug Metab. Dispos., 2005, vol. 33, # 7, p. 969 - 976

>  <Main tar all>
dihydrofolate reductase pX=6.87 | dihydrofolate reductase pX=6.87 | carbonic anhydrase 2 pX=6.47 | dihydrofolate synthase pX=6.36 | Dihydropteroate synthase pX=6.21 | ?2B-adrenoceptor pX=6.0 | ?2B-adrenoceptor pX=6.0 | ?2C-adrenoceptor pX=6.0 | ?2C-adrenoceptor pX=6.0 | heat shock protein 90 beta family member 1 pX=5.82 | Arylamine N-acetyltransferase 2 pX=5.53

$$$$
Albendazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5923 3.6128 0 0
M  V30 2 C 10.2586 4.3828 0 0
M  V30 3 C 8.925 3.6128 0 0
M  V30 4 S 7.5913 4.3828 0 0
M  V30 5 C 6.2576 3.6128 0 0
M  V30 6 C 6.2576 2.0728 0 0
M  V30 7 C 4.9239 1.3028 0 0
M  V30 8 C 3.5902 2.0728 0 0
M  V30 9 N 2.1256 1.5969 0 0
M  V30 10 C 1.2204 2.8428 0 0
M  V30 11 N -0.3196 2.8428 0 0
M  V30 12 C -1.0896 1.5091 0 0
M  V30 13 O -0.3196 0.1755 0 0
M  V30 14 O -2.6296 1.5091 0 0
M  V30 15 C -3.3996 0.1755 0 0
M  V30 16 N 2.1256 4.0887 0 0
M  V30 17 C 3.5902 3.6128 0 0
M  V30 18 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 10 16
M  V30 16 1 16 17
M  V30 17 2 8 17
M  V30 18 1 17 18
M  V30 19 2 5 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z594284186

>  <MW>
265.088

>  <MW (desalted)>
265.331

>  <ClogP>
3.461

>  <logS>
-4.46

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
67.01

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  60.8 nM

>  <CAS>
54965-21-8

>  <Description>
Albendazole is?an anthelmintic.

>  <EBC_ID>
EBC-06035

>  <IUPAC Name>
methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate

>  <Main Tar all refs>
Int. J. Parasitol Drugs Drug Resist., 2016, vol. 6, # 3, p. 148 - 153

>  <Main tar all>
Putative thioredoxin reductase pX=7.22

$$$$
Cloranolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 10.01 0 0
M  V30 2 C -2.6674 9.24 0 0
M  V30 3 C -3.4374 7.9063 0 0
M  V30 4 C -1.8974 10.5737 0 0
M  V30 5 N -1.3337 8.47 0 0
M  V30 6 C -1.3337 6.93 0 0
M  V30 7 C 0 6.16 0 0
M  V30 8 O 1.3337 6.93 0 0
M  V30 9 C 0 4.62 0 0
M  V30 10 O 1.3337 3.85 0 0
M  V30 11 C 1.3337 2.31 0 0
M  V30 12 C 2.6674 1.54 0 0
M  V30 13 C 2.6674 -0 0 0
M  V30 14 Cl 4.001 -0.77 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C 0 0 0 0
M  V30 17 C 0 1.54 0 0
M  V30 18 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z55682028

>  <MW>
291.079

>  <MW (desalted)>
292.201

>  <ClogP>
3.363

>  <logS>
-3.49

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
41.49

>  <RotBonds>
6

>  <CAS>
39563-28-5

>  <Description>
Cloranolol is a specific beta-adrenergic antagonist. It is used as an antiarrhythmic agent. Cloranolol has mainly cardiorespiratory side effects.

>  <EBC_ID>
EBC-12114

>  <IUPAC Name>
1-(tert-butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol

$$$$
Cridanimod
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 6.16 0 0
M  V30 2 C 2.6674 4.62 0 0
M  V30 3 O 1.3337 3.85 0 0
M  V30 4 C 4.001 3.85 0 0
M  V30 5 N 4.001 2.31 0 0
M  V30 6 C 5.3347 1.54 0 0
M  V30 7 C 6.6684 2.31 0 0
M  V30 8 C 8.0021 1.54 0 0
M  V30 9 C 8.0021 -0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 5.3347 0 0 0
M  V30 12 C 4.001 -0.77 0 0
M  V30 13 O 4.001 -2.31 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C -0 0 0 0
M  V30 17 C 0 1.54 0 0
M  V30 18 C 1.3337 2.31 0 0
M  V30 19 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 5 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57473348

>  <MW>
253.074

>  <MW (desalted)>
253.253

>  <ClogP>
1.314

>  <logS>
-3.35

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
57.61

>  <RotBonds>
2

>  <CAS>
38609-97-1

>  <Description>
Cridanimod is a potent anti-Hepatitis B virus agent.

>  <EBC_ID>
EBC-13622

>  <IUPAC Name>
2-(9-Oxo-9,10-dihydroacridin-10-yl)acetic acid

$$$$
Oxaprozin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 O 1.3337 2.31 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 N 2.5796 -3.2152 0 0
M  V30 8 C 2.1037 -4.6798 0 0
M  V30 9 C 0.5637 -4.6798 0 0
M  V30 10 O 0.0878 -3.2152 0 0
M  V30 11 C -0.3415 -5.9257 0 0
M  V30 12 C 0.2849 -7.3326 0 0
M  V30 13 C -0.6203 -8.5784 0 0
M  V30 14 C -2.1519 -8.4175 0 0
M  V30 15 C -2.7783 -7.0106 0 0
M  V30 16 C -1.8731 -5.7647 0 0
M  V30 17 C 3.0089 -5.9257 0 0
M  V30 18 C 4.5404 -5.7647 0 0
M  V30 19 C 5.4456 -7.0106 0 0
M  V30 20 C 4.8192 -8.4175 0 0
M  V30 21 C 3.2877 -8.5784 0 0
M  V30 22 C 2.3825 -7.3326 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 6 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 8 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z212055564

>  <MW>
293.105

>  <MW (desalted)>
293.317

>  <ClogP>
2.948

>  <logS>
-3.97

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.33

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.05 ?M | IC50  0.11 ?M | IC50  0.74 ?M | IC50  1 ?M | IC50  1 ?M

>  <CAS>
21256-18-8

>  <Description>
Oxaprozin is a non-narcotic, NSAID, used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. It inhibits COX-1 and COX-2.

>  <EBC_ID>
EBC-04209

>  <IUPAC Name>
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2019, vol. 62, # 18, p. 8443 - 8460 | J. Med. Chem., 2019, vol. 62, # 18, p. 8443 - 8460 | J. Med. Chem., 2019, vol. 62, # 18, p. 8443 - 8460 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 241 - 254 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 241 - 254

>  <Main tar all>
epoxide hydrolase 2 pX=7.3 | Cytochrome c oxidase subunit 2 pX=6.96 | Cytochrome c oxidase subunit 1 pX=6.13 | Bifunctional riboflavin kinase/FMN adenylyltransferase pX=6.0 | FAD synthase pX=6.0

$$$$
Difenidol hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 7.631 3.4446 0 0
M  V30 3 C 8.401 2.1109 0 0
M  V30 4 C 7.0674 1.3409 0 0
M  V30 5 C 7.0674 -0.1991 0 0
M  V30 6 C 5.7337 -0.9691 0 0
M  V30 7 N 5.7337 -2.5091 0 0
M  V30 8 C 7.0674 -3.2791 0 0
M  V30 9 C 7.0674 -4.8191 0 0
M  V30 10 C 5.7337 -5.5891 0 0
M  V30 11 C 4.4 -4.8191 0 0
M  V30 12 C 4.4 -3.2791 0 0
M  V30 13 C 9.7347 2.8809 0 0
M  V30 14 C 9.7347 4.4209 0 0
M  V30 15 C 11.0684 5.1909 0 0
M  V30 16 C 12.4021 4.4209 0 0
M  V30 17 C 12.4021 2.8809 0 0
M  V30 18 C 11.0684 2.1109 0 0
M  V30 19 C 9.171 0.7772 0 0
M  V30 20 C 10.711 0.7772 0 0
M  V30 21 C 11.481 -0.5565 0 0
M  V30 22 C 10.711 -1.8901 0 0
M  V30 23 C 9.171 -1.8901 0 0
M  V30 24 C 8.401 -0.5565 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 7 12
M  V30 12 1 3 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 3 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57257314

>  <MW>
345.186

>  <MW (desalted)>
309.445

>  <ClogP>
4.067

>  <logS>
-3.88

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
23.47

>  <RotBonds>
6

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKb  7.02  | pKb  6.72  | pKi  6.37  | pKi  6.04  | pKi  5.89

>  <CAS>
3254-89-5

>  <Description>
Diphenidol HCl is a non-selective muscarinic acetylcholine receptor antagonist. It is employed as an antiemetic and as an antivertigo agent.

>  <EBC_ID>
EBC-03840

>  <IUPAC Name>
1,1-diphenyl-4-(piperidin-1-yl)butan-1-ol hydrochloride

>  <Main Tar all refs>
Med. Chem. Res., 1996, vol. 6, # 9, p. 571 - 580 | Med. Chem. Res., 1996, vol. 6, # 9, p. 571 - 580 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 9, p. 2972 - 2976 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 9, p. 2972 - 2976 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 9, p. 2972 - 2976

>  <Main tar all>
M3 receptor pX=7.02 | M2 receptor pX=6.72 | M1 receptor pX=6.37 | M4 receptor pX=6.04 | M5 receptor pX=5.89

$$$$
Enoxacine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -5.39 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O 0 1.54 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 O 2.6674 1.54 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 F 8.0021 -0 0 0
M  V30 15 C 6.6684 -2.31 0 0
M  V30 16 N 5.3347 -3.08 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 18 N 8.0021 -3.08 0 0
M  V30 19 C 9.3358 -2.31 0 0
M  V30 20 C 10.6694 -3.08 0 0
M  V30 21 N 10.6694 -4.62 0 0
M  V30 22 C 9.3358 -5.39 0 0
M  V30 23 C 8.0021 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 3 17
M  V30 18 2 11 17
M  V30 19 1 15 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404495

>  <MW>
320.128

>  <MW (desalted)>
320.319

>  <ClogP>
-1.596

>  <logS>
-2.56

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
85.77

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.000631 ?M | Ki (inhibition constant) = 0.000631 ?M | Ki (inhibition constant) = 0.000631 ?M | Ki (inhibition constant) = 4 nM | concentration (parameter) = 18 nM

>  <CAS>
74011-58-8

>  <Description>
Enoxacine a broad-spectrum 6-fluoronaphthyridinone antibacterial agent structurally related to nalidixic acid. Enoxacin exerts its bactericidal action via the inhibition of the essential bacterial enzyme DNA gyrase.

>  <EBC_ID>
EBC-00603

>  <IUPAC Name>
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

>  <Main Tar all refs>
Drug Metab. Pharmacokinet., 2009, vol. 24, # 2, p. 167 - 174 | Drug Metab. Pharmacokinet., 2009, vol. 24, # 2, p. 167 - 174 | Drug Metab. Pharmacokinet., 2009, vol. 24, # 2, p. 167 - 174 | Chem. Biol., 2005, vol. 12, # 6, p. 621 - 637 | Chem. Biol., 2005, vol. 12, # 6, p. 621 - 637

>  <Main tar all>
GABAA receptor ?1 subunit pX=9.2 | GABAA receptor ?2 subunit pX=9.2 | GABAA receptor ? subunit pX=9.2 | transforming growth factor beta receptor 1 pX=8.4 | Transforming growth factor ? receptor pX=7.74

$$$$
Itopride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -6.93 0 0
M  V30 2 O -5.3347 -6.16 0 0
M  V30 3 C -5.3347 -4.62 0 0
M  V30 4 C -6.6684 -3.85 0 0
M  V30 5 C -6.6684 -2.31 0 0
M  V30 6 C -5.3347 -1.54 0 0
M  V30 7 C -4.001 -2.31 0 0
M  V30 8 C -4.001 -3.85 0 0
M  V30 9 O -2.6674 -4.62 0 0
M  V30 10 C -2.6674 -6.16 0 0
M  V30 11 C -5.3347 -0 0 0
M  V30 12 O -6.6684 0.77 0 0
M  V30 13 N -4.001 0.77 0 0
M  V30 14 C -4.001 2.31 0 0
M  V30 15 C -2.6674 3.08 0 0
M  V30 16 C -2.6674 4.62 0 0
M  V30 17 C -1.3337 5.39 0 0
M  V30 18 C 0 4.62 0 0
M  V30 19 O 1.3337 5.39 0 0
M  V30 20 C 2.6674 4.62 0 0
M  V30 21 C 4.001 5.39 0 0
M  V30 22 N 5.3347 4.62 0 0
M  V30 23 C 6.6684 5.39 0 0
M  V30 24 C 5.3347 3.08 0 0
M  V30 25 C 0 3.08 0 0
M  V30 26 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 18 25
M  V30 26 1 25 26
M  V30 27 2 15 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z667612124

>  <MW>
358.431

>  <MW (desalted)>
358.431

>  <ClogP>
2.726

>  <logS>
-3.341

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
60.03

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.16 nM

>  <CAS>
122898-67-3

>  <Description>
Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions. It is used for the treatment in gastrointestinal diseases and disorders (miscellaneous).

>  <EBC_ID>
EBC-07163

>  <IUPAC Name>
N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide

>  <Main Tar all refs>
J. NUCL. MED., 1991, vol. 32, # 8, p. 1593 - 1600

>  <Main tar all>
D2 receptor pX=9.8

$$$$
Pazopanib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.925 3.6128 0 0
M  V30 2 N 7.5913 4.3828 0 0
M  V30 3 C 6.2576 3.6128 0 0
M  V30 4 C 6.2576 2.0728 0 0
M  V30 5 C 4.9239 1.3028 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 C 2.1256 1.5969 0 0
M  V30 8 C 1.6497 0.1323 0 0
M  V30 9 N 1.2204 2.8428 0 0
M  V30 10 C -0.3196 2.8428 0 0
M  V30 11 N 2.1256 4.0887 0 0
M  V30 12 C 3.5902 3.6128 0 0
M  V30 13 C 4.9239 4.3828 0 0
M  V30 14 C 7.5913 5.9228 0 0
M  V30 15 C 6.2576 6.6928 0 0
M  V30 16 C 6.2576 8.2328 0 0
M  V30 17 N 7.5913 9.0028 0 0
M  V30 18 C 8.925 8.2328 0 0
M  V30 19 N 10.2586 9.0028 0 0
M  V30 20 C 11.5923 8.2328 0 0
M  V30 21 C 12.926 9.0028 0 0
M  V30 22 C 14.2597 8.2328 0 0
M  V30 23 C 14.2597 6.6928 0 0
M  V30 24 C 15.5934 5.9228 0 0
M  V30 25 C 12.926 5.9228 0 0
M  V30 26 C 11.5923 6.6928 0 0
M  V30 27 S 12.926 4.3828 0 0
M  V30 28 O 12.926 2.8428 0 0
M  V30 29 O 11.386 4.3828 0 0
M  V30 30 N 14.466 4.3828 0 0
M  V30 31 N 8.925 6.6928 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 6 12
M  V30 13 1 12 13
M  V30 14 2 3 13
M  V30 15 1 2 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 25 26
M  V30 28 2 20 26
M  V30 29 1 25 27
M  V30 30 2 27 28
M  V30 31 2 27 29
M  V30 32 1 27 30
M  V30 33 1 18 31
M  V30 34 2 14 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541638525

>  <MW>
437.518

>  <MW (desalted)>
437.518

>  <ClogP>
3.654

>  <logS>
-4.88

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
119.03

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | - | - | - | - | Inhibitor | - | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  300 pM | IC50  1 - 200 nM | Kd (dissociation constant)  1.8 nM | Kd (dissociation constant)  2 nM | Kd (dissociation constant)  2.3 nM | Kd (dissociation constant)  2.8 nM | IC50 = 4.2 nM | Kd (dissociation constant)  4.9 nM | Kd (dissociation constant)  6.5 nM

>  <CAS>
444731-52-6

>  <Description>
Pazopanib is an antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy.

>  <EBC_ID>
EBC-12617

>  <IUPAC Name>
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide

>  <Main Tar all refs>
ACS Chem. Biol., 2013, vol. 8, # 5, p. 978 - 986 | NOVARTIS AG; Novartis (w/o Sandoz) - WO2002/59110, 2002, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | J. Biochem., 2012, vol. 151, # 1, p. 47 - 55 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132

>  <Main tar all>
kinase insert domain receptor pX=9.52 | vascular endothelial growth factor-activated receptor pX=9.0 | KIT (L576P) pX=8.74 | platelet derived growth factor receptor beta pX=8.7 | KIT (V559D) pX=8.64 | Mast/stem cell growth factor receptor Kit pX=8.55 | colony stimulating factor 1 receptor pX=8.38 | platelet derived growth factor receptor alpha pX=8.31 | KIT (V559D, T670I) pX=8.19

$$$$
Galantamine hydrobromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0
M  V30 2 C 5.1132 -4.4989 0 0
M  V30 3 O 4.0803 -3.3567 0 0
M  V30 4 C 4.553 -1.891 0 0
M  V30 5 C 3.52 -0.7488 0 0
M  V30 6 C 3.9927 0.7168 0 0
M  V30 7 C 5.5685 1.1001 0 0
M  V30 8 C 5.6983 2.5926 0 0
M  V30 9 N 6.6705 3.8126 0 0
M  V30 10 C 6.3369 5.3161 0 0
M  V30 11 C 8.0811 3.1116 0 0
M  V30 12 C 7.8527 1.5265 0 0
M  V30 13 C 8.0713 -0.0985 0 0 CFG=1
M  V30 14 C 9.0992 1.0482 0 0
M  V30 15 C 10.6063 0.7313 0 0
M  V30 16 C 11.0854 -0.7323 0 0 CFG=2
M  V30 17 O 12.5924 -1.0492 0 0
M  V30 18 C 10.0574 -1.879 0 0
M  V30 19 C 8.5504 -1.5621 0 0 CFG=2
M  V30 20 O 7.3065 -2.47 0 0
M  V30 21 C 6.0586 -1.5675 0 0
M  V30 22 C 6.5313 -0.1019 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 13 12
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 16 15
M  V30 15 1 16 17 CFG=3
M  V30 16 1 16 18
M  V30 17 1 19 18
M  V30 18 1 13 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 20 21
M  V30 21 2 4 21
M  V30 22 1 21 22
M  V30 23 2 7 22
M  V30 24 1 13 22 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557400300

>  <MW>
368.265

>  <MW (desalted)>
287.354

>  <ClogP>
1.025

>  <logS>
-2.29

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
41.93

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.037 ?M | IC50  0.1 ?M | pEC50  6.99  | IC50  0.12 ?M | pEC50  6.77  | Ki (inhibition constant) = 190 nM | Ki (inhibition constant)  0.54 ?M | Ki (inhibition constant)  0.54 ?M | pEC50  6.06  | pEC50  6  | IC50  1.18 ?M

>  <CAS>
1953-04-4

>  <Description>
Galantamine is a cholinesterase inhibitor used to manage mild to moderate dementia associated with Alzheimer's Disease.

>  <EBC_ID>
EBC-13578

>  <IUPAC Name>
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol hydrobromide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2018, vol. 28, # 20, p. 3315 - 3319 | Front. Pharmacol., 2020, vol. 11 | J. Pharmacol. Exp. Ther., 2003, vol. 305, # 3, p. 1024 - 1036 | Med. Chem. Res., 2018, vol. 27, # 2, p. 538 - 545 | J. Pharmacol. Exp. Ther., 2003, vol. 305, # 3, p. 1024 - 1036 | Bioorg. Med. Chem., 2004, vol. 12, # 9, p. 1995 - 2003 | Bioorg. Chem., 2019, vol. 85, p. 23 - 32 | Bioorg. Chem., 2019, vol. 90 | J. Pharmacol. Exp. Ther., 2003, vol. 305, # 3, p. 1024 - 1036 | J. Pharmacol. Exp. Ther., 2003, vol. 305, # 3, p. 1024 - 1036 | J. Nat. Prod., 2022, vol. 85, # 9, p. 2207 - 2216

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=7.43 | acetylcholinesterase (Cartwright blood group) pX=7.0 | M3 receptor pX=6.99 | butyrylcholinesterase pX=6.92 | M2 receptor pX=6.77 | acetylcholinesterase (Cartwright blood group) pX=6.72 | Acetylcholinesterase 1 pX=6.27 | acetylcholinesterase (acetyl.beta-methylcholinesterase) pX=6.27 | M1 receptor pX=6.06 | M4 receptor pX=6.0 | acetylcholinesterase (Cartwright blood group) pX=5.93

$$$$
Hydrocortisone acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1331 -8.357 0 0
M  V30 2 C 1.6491 -8.086 0 0
M  V30 3 O 2.6418 -9.2633 0 0
M  V30 4 O 2.1723 -6.6376 0 0
M  V30 5 C 3.6883 -6.3665 0 0
M  V30 6 C 4.2115 -4.9181 0 0
M  V30 7 O 3.2187 -3.7408 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 O 5.8386 -6.183 0 0
M  V30 10 C 5.2994 -3.1677 0 0
M  V30 11 C 6.574 -2.3035 0 0
M  V30 12 C 7.7898 -3.2487 0 0 CFG=1
M  V30 13 C 9.3058 -2.9776 0 0 CFG=2
M  V30 14 C 9.829 -1.5293 0 0
M  V30 15 C 11.345 -1.2582 0 0
M  V30 16 C 12.3377 -2.4355 0 0
M  V30 17 C 13.8537 -2.1644 0 0
M  V30 18 C 14.8464 -3.3418 0 0
M  V30 19 O 16.3624 -3.0707 0 0
M  V30 20 C 14.3232 -4.7901 0 0
M  V30 21 C 12.8072 -5.0612 0 0
M  V30 22 C 11.8145 -3.8839 0 0 CFG=1
M  V30 23 C 11.2913 -5.3323 0 0
M  V30 24 C 10.2985 -4.155 0 0 CFG=1
M  V30 25 C 9.7753 -5.6034 0 0 CFG=1
M  V30 26 O 10.768 -6.7807 0 0
M  V30 27 C 8.2593 -5.8744 0 0
M  V30 28 C 7.2666 -4.6971 0 0 CFG=2
M  V30 29 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22 CFG=1
M  V30 25 1 24 13
M  V30 26 1 24 25
M  V30 27 1 25 26 CFG=1
M  V30 28 1 25 27
M  V30 29 1 28 27
M  V30 30 1 12 28
M  V30 31 1 28 8
M  V30 32 1 28 29 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z600425184

>  <MW>
404.497

>  <MW (desalted)>
404.497

>  <ClogP>
2.424

>  <logS>
-3.39

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
100.9

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  7.55  | IC50  234.2 nM

>  <CAS>
50-03-3

>  <Description>
Hydrocortisone acetate is a corticosteroid used to treat inflammatory and pruritic corticosteroid-responsive dermatoses and ulcerative colitis.

>  <EBC_ID>
EBC-13580

>  <IUPAC Name>
2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

>  <Main Tar all refs>
J. Med. Chem., 2004, vol. 47, # 11, p. 2732 - 2742 | STEROIDS, 1997, vol. 62, # 6, p. 491 - 499

>  <Main tar all>
Corticosteroid-binding globulin pX=7.55 | Glucocorticoid receptor pX=6.63

$$$$
Celecoxib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 -0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 2.5796 -3.2152 0 0
M  V30 10 C 2.1037 -4.6798 0 0
M  V30 11 N 0.5637 -4.6798 0 0
M  V30 12 N 0.0878 -3.2152 0 0
M  V30 13 C -1.3768 -2.7393 0 0
M  V30 14 C -2.5213 -3.7698 0 0
M  V30 15 C -3.9859 -3.2939 0 0
M  V30 16 C -4.3061 -1.7875 0 0
M  V30 17 C -3.1616 -0.7571 0 0
M  V30 18 C -1.697 -1.233 0 0
M  V30 19 S -5.7707 -1.3116 0 0
M  V30 20 O -7.2353 -0.8358 0 0
M  V30 21 O -5.2948 0.153 0 0
M  V30 22 N -6.2466 -2.7763 0 0
M  V30 23 C 3.0089 -5.9257 0 0
M  V30 24 F 3.9141 -7.1716 0 0
M  V30 25 F 1.763 -6.8309 0 0
M  V30 26 F 4.2548 -5.0205 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 8 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 13 18
M  V30 21 1 16 19
M  V30 22 2 19 20
M  V30 23 2 19 21
M  V30 24 1 19 22
M  V30 25 1 10 23
M  V30 26 1 23 24
M  V30 27 1 23 25
M  V30 28 1 23 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1258938406

>  <MW>
381.372

>  <MW (desalted)>
381.372

>  <ClogP>
4.372

>  <logS>
-5.43

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
77.98

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 15 pM | IC50 = 0.015 nM | IC50 <= 0.1 nM | IC50  0.49 nM

>  <CAS>
169590-42-5

>  <Description>
Celecoxib is a selective COX-2 inhibitor. Celecoxib demonstrates potent, oral anti-inflammatory activity.

>  <EBC_ID>
EBC-06063

>  <IUPAC Name>
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1 | J. Pharmacol. Exp. Ther., 2004, vol. 311, # 3, p. 904 - 912 | MERCK & CO INC - WO2003/86314, 2003, A2 | Arch. Pharm., 2020

>  <Main tar all>
COX-1  pX=10.8 | COX-2  pX=10.8 | Insulin receptor pX=10.0 | Polyunsaturated fatty acid 5-lipoxygenase pX=9.31

$$$$
Methylparaben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 O 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z19674820

>  <MW>
152.047

>  <MW (desalted)>
152.147

>  <ClogP>
1.985

>  <logS>
-1.3

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
2

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
percentage increase Active

>  <CAS>
99-76-3

>  <Description>
Methylparaben is preservative in the food, cosmetic, and pharmaceutical industries. It is used in allergenic testing.

>  <EBC_ID>
EBC-26102

>  <IUPAC Name>
methyl 4-hydroxybenzoate

>  <Main Tar all refs>
Environ. Sci. Technol., 2017, vol. 51, # 11, p. 6452 - 6460

>  <Main tar all>
Androgen receptor pX=11.3

$$$$
Vinblastine sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 64 71 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.5689 -2.5947 0 0
M  V30 2 C 9.2612 -3.408 0 0
M  V30 3 C 7.9029 -2.6822 0 0 CFG=2
M  V30 4 O 8.8122 -1.4392 0 0
M  V30 5 C 6.7592 -1.5679 0 0
M  V30 6 C 5.1525 -1.865 0 0 CFG=2
M  V30 7 C 5.3306 -3.2688 0 0
M  V30 8 N 5.7788 -4.6111 0 0
M  V30 9 C 7.3554 -4.1822 0 0
M  V30 10 C 4.5243 -5.6589 0 0
M  V30 11 C 2.9257 -5.8175 0 0
M  V30 12 C 1.6506 -4.9002 0 0
M  V30 13 C 1.3082 -3.3987 0 0
M  V30 14 N -0.2256 -3.2604 0 0
M  V30 15 C -0.8311 -4.6764 0 0
M  V30 16 C -2.2886 -5.1739 0 0
M  V30 17 C -2.5864 -6.6848 0 0
M  V30 18 C -1.4269 -7.6982 0 0
M  V30 19 C 0.0306 -7.2007 0 0
M  V30 20 C 0.3284 -5.6898 0 0
M  V30 21 C 2.0585 -2.0149 0 0 CFG=1
M  V30 22 C 3.5678 -1.4646 0 0
M  V30 23 C 0.6449 -1.4038 0 0
M  V30 24 O -0.3979 -0.2707 0 0
M  V30 25 O -0.591 -2.3225 0 0
M  V30 26 C -2.0046 -1.7115 0 0
M  V30 27 C 1.6615 -0.5269 0 0
M  V30 28 C 0.1744 -0.1268 0 0
M  V30 29 C -0.2226 1.3612 0 0
M  V30 30 C 0.8675 2.449 0 0
M  V30 31 C 2.3546 2.0488 0 0
M  V30 32 C 2.7516 0.5609 0 0
M  V30 33 O 4.2387 0.1607 0 0
M  V30 34 C 5.3288 1.2485 0 0
M  V30 35 N 0.1698 3.8219 0 0
M  V30 36 C 0.8704 5.1933 0 0
M  V30 37 C -1.3515 3.5826 0 0 CFG=2
M  V30 38 C -1.594 2.0618 0 0 CFG=2
M  V30 39 C -0.6261 0.8639 0 0
M  V30 40 C -1.4662 -0.4267 0 0
M  V30 41 N -3.2748 -0.0094 0 0
M  V30 42 C -4.7131 -0.5598 0 0
M  V30 43 C -5.9089 0.4107 0 0
M  V30 44 C -5.6664 1.9314 0 0
M  V30 45 C -4.2281 2.4818 0 0 CFG=2
M  V30 46 C -5.4239 3.4522 0 0
M  V30 47 C -6.8622 2.9019 0 0
M  V30 48 C -3.0323 1.5114 0 0 CFG=1
M  V30 49 C -3.9856 4.0026 0 0 CFG=1
M  V30 50 O -5.1814 4.973 0 0
M  V30 51 C -6.6197 4.4226 0 0
M  V30 52 O -7.8155 5.3931 0 0
M  V30 53 C -7.7098 3.3349 0 0
M  V30 54 C -2.5473 4.553 0 0 CFG=1
M  V30 55 O -1.6192 5.7819 0 0
M  V30 56 C -3.0471 6.0096 0 0
M  V30 57 O -4.5585 6.305 0 0
M  V30 58 O -2.0356 7.1708 0 0
M  V30 59 C -2.5354 8.6274 0 0
M  V30 60 O 15.6289 -1.54 0 0
M  V30 61 S 15.6289 0 0 0
M  V30 62 O 15.6289 1.54 0 0
M  V30 63 O 17.1689 -0 0 0
M  V30 64 O 14.0889 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 12 20
M  V30 22 2 15 20
M  V30 23 1 21 13
M  V30 24 1 21 22
M  V30 25 1 6 22
M  V30 26 1 21 23 CFG=3
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 25 26
M  V30 30 1 21 27 CFG=1
M  V30 31 1 27 28
M  V30 32 2 28 29
M  V30 33 1 29 30
M  V30 34 2 30 31
M  V30 35 1 31 32
M  V30 36 2 27 32
M  V30 37 1 32 33
M  V30 38 1 33 34
M  V30 39 1 30 35
M  V30 40 1 35 36
M  V30 41 1 37 35 CFG=3
M  V30 42 1 37 38
M  V30 43 1 38 29 CFG=3
M  V30 44 1 38 39
M  V30 45 1 39 40
M  V30 46 1 40 41
M  V30 47 1 41 42
M  V30 48 1 42 43
M  V30 49 2 43 44
M  V30 50 1 45 44
M  V30 51 1 45 46 CFG=3
M  V30 52 1 46 47
M  V30 53 1 48 45
M  V30 54 1 48 41 CFG=1
M  V30 55 1 38 48
M  V30 56 1 49 45
M  V30 57 1 49 50 CFG=1
M  V30 58 1 50 51
M  V30 59 2 51 52
M  V30 60 1 51 53
M  V30 61 1 54 49
M  V30 62 1 37 54
M  V30 63 1 54 55 CFG=1
M  V30 64 1 54 56 CFG=3
M  V30 65 2 56 57
M  V30 66 1 56 58
M  V30 67 1 58 59
M  V30 68 1 60 61
M  V30 69 2 61 62
M  V30 70 2 61 63
M  V30 71 1 61 64
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3014322079

>  <MW>
908.388

>  <MW (desalted)>
810.974

>  <ClogP>
5.227

>  <logS>
-3.639

>  <HBD>
3

>  <HBA>
9

>  <TPSA>
154.1

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.00019 ?M | IC50  0.000264 ?M | IC50  0.5 nM | IC50  0.66 nM | IC50  0.0011 ?M | IC50 = 1.6 nM | IC50  2.2 nM

>  <CAS>
143-67-9

>  <Description>
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR.

>  <EBC_ID>
EBC-09046

>  <IUPAC Name>
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate; sulfuric acid

>  <Main Tar all refs>
Bioorg. Chem., 2020, vol. 105 | Bioorg. Med. Chem., 2006, vol. 14, # 21, p. 7138 - 7145 | Eur. J. Med. Chem., 2019, vol. 162, p. 290 - 320 | J. Pharmacol. Exp. Ther., 2004, vol. 310, # 3, p. 1199 - 1207 | Mol. Pharm., 2018, vol. 15, # 9, p. 4021 - 4030 | J. Pharmacol. Exp. Ther., 2011, vol. 337, # 2, p. 423 - 432 | CUREGENICS - WO2004/110337, 2004, A2

>  <Main tar all>
tubulin alpha 1a pX=9.72 | ABCB1 pX=9.58 | Tubulin beta chain pX=9.3 | MDR1 (S400N) pX=9.18 | Multidrug resistance protein 1B pX=8.96 | ABCG2 pX=8.8 | AKT serine/threonine kinase 1 pX=8.66

$$$$
Gallamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0 CHG=-1
M  V30 2 I 1.87 0 0 0 CHG=-1
M  V30 3 I 0 -9.0898 0 0 CHG=-1
M  V30 4 C 17.7368 -3.4374 0 0
M  V30 5 C 17.7368 -4.9774 0 0
M  V30 6 N 16.4031 -5.7474 0 0 CHG=1
M  V30 7 C 15.6331 -4.4137 0 0
M  V30 8 C 16.4031 -3.08 0 0
M  V30 9 C 17.1731 -7.081 0 0
M  V30 10 C 16.4031 -8.4147 0 0
M  V30 11 C 15.0694 -6.5174 0 0
M  V30 12 C 15.0694 -8.0574 0 0
M  V30 13 O 13.7358 -8.8274 0 0
M  V30 14 C 13.7358 -10.3674 0 0
M  V30 15 C 15.0694 -11.1374 0 0
M  V30 16 C 15.0694 -12.6774 0 0
M  V30 17 C 13.7358 -13.4474 0 0
M  V30 18 C 12.4021 -12.6774 0 0
M  V30 19 O 11.0684 -13.4474 0 0
M  V30 20 C 9.7347 -12.6774 0 0
M  V30 21 C 8.401 -13.4474 0 0
M  V30 22 N 7.0674 -12.6774 0 0 CHG=1
M  V30 23 C 5.7337 -11.9074 0 0
M  V30 24 C 4.4 -12.6774 0 0
M  V30 25 C 7.8374 -11.3437 0 0
M  V30 26 C 7.0674 -10.01 0 0
M  V30 27 C 6.2974 -14.011 0 0
M  V30 28 C 4.7574 -14.011 0 0
M  V30 29 C 12.4021 -11.1374 0 0
M  V30 30 O 11.0684 -10.3674 0 0
M  V30 31 C 11.0684 -8.8274 0 0
M  V30 32 C 12.4021 -8.0574 0 0
M  V30 33 N 12.4021 -6.5174 0 0 CHG=1
M  V30 34 C 12.4021 -4.9774 0 0
M  V30 35 C 13.7358 -4.2074 0 0
M  V30 36 C 13.9421 -6.5174 0 0
M  V30 37 C 14.7121 -5.1837 0 0
M  V30 38 C 10.8621 -6.5174 0 0
M  V30 39 C 10.0921 -7.851 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 1 6 7
M  V30 4 1 7 8
M  V30 5 1 6 9
M  V30 6 1 9 10
M  V30 7 1 6 11
M  V30 8 1 11 12
M  V30 9 1 12 13
M  V30 10 1 13 14
M  V30 11 1 14 15
M  V30 12 2 15 16
M  V30 13 1 16 17
M  V30 14 2 17 18
M  V30 15 1 18 19
M  V30 16 1 19 20
M  V30 17 1 20 21
M  V30 18 1 21 22
M  V30 19 1 22 23
M  V30 20 1 23 24
M  V30 21 1 22 25
M  V30 22 1 25 26
M  V30 23 1 22 27
M  V30 24 1 27 28
M  V30 25 1 18 29
M  V30 26 2 14 29
M  V30 27 1 29 30
M  V30 28 1 30 31
M  V30 29 1 31 32
M  V30 30 1 32 33
M  V30 31 1 33 34
M  V30 32 1 34 35
M  V30 33 1 33 36
M  V30 34 1 36 37
M  V30 35 1 33 38
M  V30 36 1 38 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616201

>  <MW>
891.177

>  <MW (desalted)>
510.816

>  <ClogP>
-5.399

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
27.69

>  <RotBonds>
21

>  <Action on targets>
Allosteric Modulator

>  <Activity coefficients and valu>
inhibition percentage  64 %

>  <CAS>
65-29-2

>  <Description>
Gallamine is an allosteric modulator of muscarinic acetylcholine receptors. Formulations containing gallamine have previously been used as neuromuscular blockers during surgery.

>  <EBC_ID>
EBC-08484

>  <IUPAC Name>
(2-{2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy}ethyl)triethylazanium triiodide

>  <Main Tar all refs>
Eur. J. Pharmacol., 2007, vol. 569, # 1-2, p. 37 - 40

>  <Main tar all>
M2 receptor pX=7.93

$$$$
Buclizine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3358 0.77 0 0
M  V30 2 C 9.3358 -0.77 0 0
M  V30 3 C 7.7958 -0.77 0 0
M  V30 4 C 10.8758 -0.77 0 0
M  V30 5 C 9.3358 -2.31 0 0
M  V30 6 C 10.6694 -3.08 0 0
M  V30 7 C 10.6694 -4.62 0 0
M  V30 8 C 9.3358 -5.39 0 0
M  V30 9 C 9.3358 -6.93 0 0
M  V30 10 N 8.0021 -7.7 0 0
M  V30 11 C 8.0021 -9.24 0 0
M  V30 12 C 6.6684 -10.01 0 0
M  V30 13 N 5.3347 -9.24 0 0
M  V30 14 C 5.3347 -7.7 0 0
M  V30 15 C 6.6684 -6.93 0 0
M  V30 16 C 4.001 -10.01 0 0
M  V30 17 C 4.001 -11.55 0 0
M  V30 18 C 5.3347 -12.32 0 0
M  V30 19 C 5.3347 -13.86 0 0
M  V30 20 C 4.001 -14.63 0 0
M  V30 21 C 2.6674 -13.86 0 0
M  V30 22 C 2.6674 -12.32 0 0
M  V30 23 C 2.6674 -9.24 0 0
M  V30 24 C 1.3337 -10.01 0 0
M  V30 25 C -0 -9.24 0 0
M  V30 26 C 0 -7.7 0 0
M  V30 27 Cl -1.3337 -6.93 0 0
M  V30 28 C 1.3337 -6.93 0 0
M  V30 29 C 2.6674 -7.7 0 0
M  V30 30 C 8.0021 -4.62 0 0
M  V30 31 C 8.0021 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 16 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 2 26 28
M  V30 30 1 28 29
M  V30 31 2 23 29
M  V30 32 2 8 30
M  V30 33 1 30 31
M  V30 34 2 5 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1734282227

>  <MW>
432.233

>  <MW (desalted)>
433.028

>  <ClogP>
8.059

>  <logS>
-6.184

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
6

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
82-95-1

>  <Description>
Buclizine is an antihistamine and antiemetic drug for the treatment of allergy symptoms and prevention of nausea and vomiting.

>  <EBC_ID>
EBC-27083

>  <IUPAC Name>
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)(phenyl)methyl]piperazine

$$$$
Balsalazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -14.63 0 0
M  V30 2 C 5.3347 -13.86 0 0
M  V30 3 O 5.3347 -12.32 0 0
M  V30 4 C 6.6684 -14.63 0 0
M  V30 5 C 8.0021 -13.86 0 0
M  V30 6 N 9.3358 -14.63 0 0
M  V30 7 C 10.6694 -13.86 0 0
M  V30 8 O 10.6694 -12.32 0 0
M  V30 9 C 12.0031 -14.63 0 0
M  V30 10 C 13.3368 -13.86 0 0
M  V30 11 C 14.6705 -14.63 0 0
M  V30 12 C 14.6705 -16.17 0 0
M  V30 13 N 16.0041 -16.94 0 0
M  V30 14 N 17.3378 -16.17 0 0
M  V30 15 C 18.6715 -16.94 0 0
M  V30 16 C 20.0052 -16.17 0 0
M  V30 17 C 21.3389 -16.94 0 0
M  V30 18 C 21.3389 -18.48 0 0
M  V30 19 O 22.6725 -19.25 0 0
M  V30 20 C 20.0052 -19.25 0 0
M  V30 21 C 18.6715 -18.48 0 0
M  V30 22 C 20.0052 -20.79 0 0
M  V30 23 O 18.6715 -21.56 0 0
M  V30 24 O 21.3389 -21.56 0 0
M  V30 25 C 13.3368 -16.94 0 0
M  V30 26 C 12.0031 -16.17 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 20 21
M  V30 21 2 15 21
M  V30 22 1 20 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 2 12 25
M  V30 26 1 25 26
M  V30 27 2 9 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038982

>  <MW>
357.318

>  <MW (desalted)>
357.318

>  <ClogP>
3.209

>  <logS>
-3.429

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
148.65

>  <RotBonds>
7

>  <CAS>
80573-04-2

>  <Description>
Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. Balsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis.

>  <EBC_ID>
EBC-12048

>  <IUPAC Name>
5-[(1E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid

$$$$
Brexpiprazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 C 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 6.6684 -2.31 0 0
M  V30 9 O 8.0021 -3.08 0 0
M  V30 10 C 8.0021 -4.62 0 0
M  V30 11 C 9.3358 -5.39 0 0
M  V30 12 C 9.3358 -6.93 0 0
M  V30 13 C 10.6694 -7.7 0 0
M  V30 14 N 10.6694 -9.24 0 0
M  V30 15 C 12.0031 -10.01 0 0
M  V30 16 C 12.0031 -11.55 0 0
M  V30 17 N 10.6694 -12.32 0 0
M  V30 18 C 9.3358 -11.55 0 0
M  V30 19 C 9.3358 -10.01 0 0
M  V30 20 C 10.6694 -13.86 0 0
M  V30 21 C 12.0031 -14.63 0 0
M  V30 22 C 12.0031 -16.17 0 0
M  V30 23 C 10.6694 -16.94 0 0
M  V30 24 C 9.3358 -16.17 0 0
M  V30 25 S 7.8711 -16.6459 0 0
M  V30 26 C 6.9659 -15.4 0 0
M  V30 27 C 7.8711 -14.1541 0 0
M  V30 28 C 9.3358 -14.63 0 0
M  V30 29 C 5.3347 -3.08 0 0
M  V30 30 C 4.001 -2.31 0 0
M  V30 31 N 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 19
M  V30 20 1 17 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 20 28
M  V30 30 1 24 28
M  V30 31 2 8 29
M  V30 32 1 29 30
M  V30 33 2 5 30
M  V30 34 1 30 31
M  V30 35 1 2 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2373117814

>  <MW>
433.182

>  <MW (desalted)>
433.566

>  <ClogP>
4.652

>  <logS>
-5.926

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
44.81

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ka (association constant)  0.09 nM | Ka (association constant)  0.09 nM | Kd (dissociation constant)  0.17 nM | Kd (dissociation constant)  0.17 nM | Ki (inhibition constant) = 0.2 nM | Ki (inhibition constant) = 0.2 nM | Ka (association constant)  0.3 nM | Ka (association constant)  0.3 nM | Ka (association constant)  0.35 nM | Ka (association constant)  0.47 nM | Ka (association constant)  0.47 nM | pKi  9.29 | Kd (dissociation constant)  0.59 nM | Kd (dissociation constant)  0.59 nM | Ka (association constant)  1.1 nM | Ka (association constant)  1.1 nM | Kd (dissociation constant)  1.9 nM | Kd (dissociation constant)  1.9 nM | Ka (association constant)  2.6 nM | Ka (association constant)  2.6 nM

>  <CAS>
913611-97-9

>  <Description>
Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is used as an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.

>  <EBC_ID>
EBC-08678

>  <IUPAC Name>
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-1,2-dihydroquinolin-2-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | OTSUKA HOLDINGS CO LTD - US2010/179322, 2010, A1 | OTSUKA HOLDINGS CO LTD - US2010/179322, 2010, A1 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Med. Chem., 2021, vol. 64, # 23, p. 17239 - 17258 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604

>  <Main tar all>
5-HT1A receptor pX=10.0 | 5-HT1A receptor pX=10.0 | ?1B-adrenoceptor pX=9.77 | ?1B-adrenoceptor pX=9.77 | D2 receptor pX=9.7 | D2 receptor pX=9.7 | D2 receptor (isoform?1) pX=9.52 | D2L receptor pX=9.52 | D2 receptor pX=9.46 | 5-HT2A receptor pX=9.33 | 5-HT2A receptor pX=9.33 | D2 receptor pX=9.29 | ?2C-adrenoceptor pX=9.23 | ?2C-adrenoceptor pX=9.23 | D3 receptor pX=8.96 | D3 receptor pX=8.96 | 5-HT2B receptor pX=8.72 | 5-HT2B receptor pX=8.72 | ?1D-adrenoceptor pX=8.59 | ?1D-adrenoceptor pX=8.59

$$$$
Dabigatran etexilate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 46 49 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -10.4728 25.7288 0 0
M  V30 2 C -11.2428 24.3951 0 0
M  V30 3 C -10.4728 23.0615 0 0
M  V30 4 C -11.2428 21.7278 0 0
M  V30 5 C -10.4728 20.3941 0 0
M  V30 6 C -11.2428 19.0604 0 0
M  V30 7 O -10.4728 17.7268 0 0
M  V30 8 C -11.2428 16.3931 0 0
M  V30 9 O -12.7828 16.3931 0 0
M  V30 10 N -10.4728 15.0594 0 0
M  V30 11 C -11.2428 13.7257 0 0
M  V30 12 N -12.7828 13.7257 0 0
M  V30 13 C -10.4728 12.392 0 0
M  V30 14 C -8.9328 12.392 0 0
M  V30 15 C -8.1628 11.0584 0 0
M  V30 16 C -8.9328 9.7247 0 0
M  V30 17 N -8.1628 8.391 0 0
M  V30 18 C -6.6228 8.391 0 0
M  V30 19 C -5.8528 7.0573 0 0
M  V30 20 N -4.3212 6.8963 0 0
M  V30 21 C -4.001 5.39 0 0
M  V30 22 C -2.6674 4.62 0 0
M  V30 23 C -2.6674 3.08 0 0
M  V30 24 C -4.001 2.31 0 0
M  V30 25 C -5.3347 3.08 0 0
M  V30 26 C -5.3347 4.62 0 0
M  V30 27 N -6.4792 5.6505 0 0
M  V30 28 C -7.9855 5.3303 0 0
M  V30 29 C -1.3337 2.31 0 0
M  V30 30 O -1.3337 0.77 0 0
M  V30 31 N -0 3.08 0 0
M  V30 32 C 1.3337 2.31 0 0
M  V30 33 C 2.6674 3.08 0 0
M  V30 34 C 4.001 2.31 0 0
M  V30 35 O 4.001 0.77 0 0
M  V30 36 O 5.3347 3.08 0 0
M  V30 37 C 6.6684 2.31 0 0
M  V30 38 C 8.0021 3.08 0 0
M  V30 39 C -0 4.62 0 0
M  V30 40 C -1.3337 5.39 0 0
M  V30 41 C -1.3337 6.93 0 0
M  V30 42 C -0 7.7 0 0
M  V30 43 C 1.3337 6.93 0 0
M  V30 44 N 1.3337 5.39 0 0
M  V30 45 C -10.4728 9.7247 0 0
M  V30 46 C -11.2428 11.0584 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 10 8 CFG=2
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 21 26
M  V30 27 1 26 27
M  V30 28 1 19 27
M  V30 29 1 27 28
M  V30 30 1 23 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 34 36
M  V30 38 1 36 37
M  V30 39 1 37 38
M  V30 40 1 31 39
M  V30 41 1 39 40
M  V30 42 2 40 41
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 43 44
M  V30 46 2 39 44
M  V30 47 2 16 45
M  V30 48 1 45 46
M  V30 49 2 13 46
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811583

>  <MW>
627.733

>  <MW (desalted)>
627.733

>  <ClogP>
4.129

>  <logS>
-6.802

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
154.03

>  <RotBonds>
17

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
percentage increase Active

>  <CAS>
211915-06-9

>  <Description>
Dabigatran etexilate is an anticoagulant used for the prevention of venous thromboembolic events or stroke in patients with recent elective hip or knee replacement surgery and atrial fibrillation. It is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.

>  <EBC_ID>
EBC-11306

>  <IUPAC Name>
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate

>  <Main Tar all refs>
Thromb. Res., 2016, vol. 142, p. 44 - 51

>  <Main tar all>
coagulation factor II, thrombin pX=8.52

$$$$
Pantethine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.0653 -10.6694 0 0
M  V30 2 C 10.8353 -9.3358 0 0
M  V30 3 C 11.6053 -8.0021 0 0
M  V30 4 C 9.5016 -8.5658 0 0
M  V30 5 O 8.1679 -9.3358 0 0
M  V30 6 C 12.169 -10.1058 0 0 CFG=1
M  V30 7 O 12.169 -11.6458 0 0
M  V30 8 C 13.5026 -9.3358 0 0
M  V30 9 O 13.5026 -7.7958 0 0
M  V30 10 N 14.8363 -10.1058 0 0
M  V30 11 C 16.17 -9.3358 0 0
M  V30 12 C 17.5037 -10.1058 0 0
M  V30 13 C 18.8374 -9.3358 0 0
M  V30 14 O 18.8374 -7.7958 0 0
M  V30 15 N 20.171 -10.1058 0 0
M  V30 16 C 21.5047 -9.3358 0 0
M  V30 17 C 22.8384 -10.1058 0 0
M  V30 18 S 24.1721 -9.3358 0 0
M  V30 19 S 25.5058 -10.1058 0 0
M  V30 20 C 26.8394 -9.3358 0 0
M  V30 21 C 28.1731 -10.1058 0 0
M  V30 22 N 29.5068 -9.3358 0 0
M  V30 23 C 30.8405 -10.1058 0 0
M  V30 24 O 30.8405 -11.6458 0 0
M  V30 25 C 32.1741 -9.3358 0 0
M  V30 26 C 33.5078 -10.1058 0 0
M  V30 27 N 34.8415 -9.3358 0 0
M  V30 28 C 36.1752 -10.1058 0 0
M  V30 29 O 36.1752 -11.6458 0 0
M  V30 30 C 37.5089 -9.3358 0 0 CFG=2
M  V30 31 O 37.5089 -7.7958 0 0
M  V30 32 C 38.8425 -10.1058 0 0
M  V30 33 C 38.0725 -11.4394 0 0
M  V30 34 C 39.6125 -8.7721 0 0
M  V30 35 C 40.1762 -10.8758 0 0
M  V30 36 O 41.5099 -10.1058 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 2
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 30 28
M  V30 30 1 30 31 CFG=3
M  V30 31 1 30 32
M  V30 32 1 32 33
M  V30 33 1 32 34
M  V30 34 1 32 35
M  V30 35 1 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681892334

>  <MW>
554.721

>  <MW (desalted)>
554.721

>  <ClogP>
-2.198

>  <logS>
-1.986

>  <HBD>
8

>  <HBA>
8

>  <TPSA>
197.32

>  <RotBonds>
19

>  <CAS>
16816-67-4

>  <Description>
Pantethine is a naturally occurring compound derived from panthothenic acid. It acts as an intermediate in endogenous coenzyme A synthesis and is used as a dietary supplement to treat hypertriglyceridemia.

>  <EBC_ID>
EBC-27309

>  <IUPAC Name>
(2R)-N-[2-({2-[(2-{3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanamido}ethyl)disulfanyl]ethyl}carbamoyl)ethyl]-2,4-dihydroxy-3,3-dimethylbutanamide

$$$$
Difelikefalin trifluoroacetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 70 69 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.7108 3.4244 0 0
M  V30 2 C 0.2159 3.7943 0 0
M  V30 3 C -0.2113 5.2738 0 0
M  V30 4 C -0.8519 2.6846 0 0
M  V30 5 C -0.4248 1.205 0 0 CFG=1
M  V30 6 N -1.4926 0.0953 0 0
M  V30 7 C -2.9875 0.4652 0 0
M  V30 8 O -3.4146 1.9448 0 0
M  V30 9 C -4.0553 -0.6445 0 0 CFG=1
M  V30 10 C -3.6282 -2.1241 0 0
M  V30 11 C -2.1333 -2.494 0 0
M  V30 12 C -1.0655 -1.3843 0 0
M  V30 13 C 0.4294 -1.7542 0 0
M  V30 14 C 0.8565 -3.2338 0 0
M  V30 15 C -0.2113 -4.3435 0 0
M  V30 16 C -1.7062 -3.9736 0 0
M  V30 17 N -5.5502 -0.2746 0 0
M  V30 18 C -6.618 -1.3843 0 0
M  V30 19 O -6.1909 -2.8639 0 0
M  V30 20 C -8.113 -1.0144 0 0 CFG=2
M  V30 21 N -8.5401 0.4652 0 0
M  V30 22 C -9.1808 -2.1241 0 0
M  V30 23 C -10.6757 -1.7542 0 0
M  V30 24 C -11.7435 -2.8639 0 0
M  V30 25 C -13.2384 -2.494 0 0
M  V30 26 C -13.6655 -1.0144 0 0
M  V30 27 C -12.5977 0.0953 0 0
M  V30 28 C -11.1028 -0.2746 0 0
M  V30 29 C 1.0701 0.8351 0 0
M  V30 30 O 1.4972 -0.6445 0 0
M  V30 31 N 2.1379 1.9448 0 0
M  V30 32 C 3.6328 1.5749 0 0 CFG=2
M  V30 33 C 4.0599 0.0953 0 0
M  V30 34 C 5.5549 -0.2746 0 0
M  V30 35 C 5.982 -1.7542 0 0
M  V30 36 C 7.4769 -2.1241 0 0
M  V30 37 N 7.904 -3.6037 0 0
M  V30 38 C 4.7006 2.6846 0 0
M  V30 39 O 4.2735 4.1642 0 0
M  V30 40 N 6.1955 2.3147 0 0
M  V30 41 C 7.2633 3.4244 0 0
M  V30 42 C 8.7582 3.0545 0 0
M  V30 43 C 9.1854 1.5749 0 0
M  V30 44 N 10.5683 2.2524 0 0
M  V30 45 C 8.1176 0.4652 0 0
M  V30 46 C 6.6227 0.8351 0 0
M  V30 47 C 10.0928 0.3306 0 0
M  V30 48 O 11.624 0.4943 0 0
M  V30 49 O 9.4689 -1.0774 0 0
M  V30 50 O 15.144 -1.65 0 0
M  V30 51 C 16.4777 -0.88 0 0
M  V30 52 O 17.8114 -1.65 0 0
M  V30 53 C 16.4777 0.66 0 0
M  V30 54 F 16.4777 2.2 0 0
M  V30 55 F 18.0177 0.66 0 0
M  V30 56 F 14.9377 0.66 0 0
M  V30 57 O -1.3337 -11.2735 0 0
M  V30 58 C 0 -10.5035 0 0
M  V30 59 O 1.3337 -11.2735 0 0
M  V30 60 C 0 -8.9635 0 0
M  V30 61 F 0 -7.4235 0 0
M  V30 62 F 1.54 -8.9635 0 0
M  V30 63 F -1.54 -8.9635 0 0
M  V30 64 O 5.06 -11.2735 0 0
M  V30 65 C 6.3937 -10.5035 0 0
M  V30 66 O 7.7274 -11.2735 0 0
M  V30 67 C 6.3937 -8.9635 0 0
M  V30 68 F 6.3937 -7.4235 0 0
M  V30 69 F 7.9337 -8.9635 0 0
M  V30 70 F 4.8537 -8.9635 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 9 17 CFG=1
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 20 18
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 23 28
M  V30 30 1 5 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 32 31 CFG=1
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 1 32 38
M  V30 40 2 38 39
M  V30 41 1 38 40
M  V30 42 1 40 41
M  V30 43 1 41 42
M  V30 44 1 42 43
M  V30 45 1 43 44
M  V30 46 1 43 45
M  V30 47 1 45 46
M  V30 48 1 40 46
M  V30 49 1 43 47
M  V30 50 2 47 48
M  V30 51 1 47 49
M  V30 52 1 50 51
M  V30 53 2 51 52
M  V30 54 1 51 53
M  V30 55 1 53 54
M  V30 56 1 53 55
M  V30 57 1 53 56
M  V30 58 1 57 58
M  V30 59 2 58 59
M  V30 60 1 58 60
M  V30 61 1 60 61
M  V30 62 1 60 62
M  V30 63 1 60 63
M  V30 64 1 64 65
M  V30 65 2 65 66
M  V30 66 1 65 67
M  V30 67 1 67 68
M  V30 68 1 67 69
M  V30 69 1 67 70
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3905817531

>  <MW>
1021.919

>  <MW (desalted)>
679.849

>  <ClogP>
0.619

>  <logS>
-5.818

>  <HBD>
7

>  <HBA>
9

>  <TPSA>
222.97

>  <RotBonds>
21

>  <Action on targets>
Agonist | -

>  <Activity coefficients and valu>
EC50  2.62 pM | EC50 = 0.048 nM

>  <CAS>
1024828-77-0

>  <Description>
Difelikefalin is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.

>  <EBC_ID>
EBC-58081

>  <IUPAC Name>
4-amino-1-[(2R)-6-amino-2-[(2R)-2-[(2R)-2-[(2R)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-4-methylpentanamido]hexanoyl]piperidine-4-carboxylic acid; tris(trifluoroacetic acid)

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2020, vol. 11, # 11, p. 2151 - 2155 | CARA THERAPEUTICS, INC. - WO2008/57608, 2008, A2

>  <Main tar all>
? receptor pX=11.6 | ? receptor pX=10.3

$$$$
Lumefantrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.8172 2.294 0 0
M  V30 2 C 11.8172 3.834 0 0
M  V30 3 C 13.1509 4.604 0 0
M  V30 4 C 13.1509 6.144 0 0
M  V30 5 N 14.4845 6.914 0 0
M  V30 6 C 15.8182 6.144 0 0
M  V30 7 C 15.8182 4.604 0 0
M  V30 8 C 17.1519 3.834 0 0
M  V30 9 C 17.1519 2.294 0 0
M  V30 10 C 14.4845 8.454 0 0
M  V30 11 C 15.8182 9.224 0 0
M  V30 12 O 17.1519 8.454 0 0
M  V30 13 C 15.8182 10.764 0 0
M  V30 14 C 14.4845 11.534 0 0
M  V30 15 C 14.4845 13.074 0 0
M  V30 16 Cl 13.1509 13.844 0 0
M  V30 17 C 15.8182 13.844 0 0
M  V30 18 C 17.1519 13.074 0 0
M  V30 19 C 18.6165 13.5499 0 0
M  V30 20 C 19.0924 15.0145 0 0
M  V30 21 C 18.0619 16.159 0 0
M  V30 22 C 16.5556 15.8388 0 0
M  V30 23 C 15.5251 16.9832 0 0
M  V30 24 C 16.001 18.4479 0 0
M  V30 25 Cl 14.9706 19.5923 0 0
M  V30 26 C 17.5074 18.768 0 0
M  V30 27 C 18.5378 17.6236 0 0
M  V30 28 C 19.5217 12.304 0 0
M  V30 29 C 21.0533 12.143 0 0
M  V30 30 C 21.6797 10.7362 0 0
M  V30 31 Cl 23.2112 10.5752 0 0
M  V30 32 C 20.7745 9.4903 0 0
M  V30 33 C 19.2429 9.6513 0 0
M  V30 34 C 18.6165 11.0581 0 0
M  V30 35 C 17.1519 11.534 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 2 24 26
M  V30 26 1 26 27
M  V30 27 2 21 27
M  V30 28 1 19 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 1 30 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 2 28 34
M  V30 36 1 34 35
M  V30 37 1 18 35
M  V30 38 2 13 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568712703

>  <MW>
527.155

>  <MW (desalted)>
528.94

>  <ClogP>
10.202

>  <logS>
-10.23

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
23.47

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.011 ?M

>  <CAS>
82186-77-4

>  <Description>
Lumefantrine is an antimalarial agent used in combination with artemether for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum.

>  <EBC_ID>
EBC-12232

>  <IUPAC Name>
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol

>  <Main Tar all refs>
GLAXOSMITHKLINE PLC - WO2022/263557, 2022, A1

>  <Main tar all>
Cytochrome bc1 complex, cytochrome c subunit pX=7.96

$$$$
Neratinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 2.31 0 0
M  V30 2 C 0 1.54 0 0
M  V30 3 O 0 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 2.6674 0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 N 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 C 8.0021 -3.08 0 0
M  V30 11 N 9.3358 -3.85 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 N 5.3347 -4.62 0 0
M  V30 14 C 6.6684 -5.39 0 0
M  V30 15 C 8.0021 -4.62 0 0
M  V30 16 C 9.3358 -5.39 0 0
M  V30 17 C 9.3358 -6.93 0 0
M  V30 18 O 10.6694 -7.7 0 0
M  V30 19 C 12.0031 -6.93 0 0
M  V30 20 C 12.0031 -5.39 0 0
M  V30 21 C 10.6694 -4.62 0 0
M  V30 22 C 10.6694 -3.08 0 0
M  V30 23 C 12.0031 -2.31 0 0
M  V30 24 C 13.3368 -3.08 0 0
M  V30 25 N 13.3368 -4.62 0 0
M  V30 26 C 8.0021 -7.7 0 0
M  V30 27 Cl 8.0021 -9.24 0 0
M  V30 28 C 6.6684 -6.93 0 0
M  V30 29 C 4.001 -2.31 0 0
M  V30 30 C 2.6674 -3.08 0 0
M  V30 31 C 1.3337 -2.31 0 0
M  V30 32 N 0 -3.08 0 0
M  V30 33 C -1.3337 -2.31 0 0
M  V30 34 O -2.6674 -3.08 0 0
M  V30 35 C -1.3337 -0.77 0 0
M  V30 36 C -2.6674 -0 0 0
M  V30 37 C -2.6674 1.54 0 0
M  V30 38 N -4.001 2.31 0 0
M  V30 39 C -5.3347 1.54 0 0
M  V30 40 C -4.001 3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 3 10 11
M  V30 11 2 9 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 20 25
M  V30 26 2 17 26
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 2 14 28
M  V30 30 1 12 29
M  V30 31 1 6 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 4 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 33 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 38 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568723556

>  <MW>
556.199

>  <MW (desalted)>
557.043

>  <ClogP>
5.147

>  <logS>
-5.842

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
112.4

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | - | - | Inhibitor | - | -

>  <Activity coefficients and valu>
IC50  0.02 nM | IC50  0.02 nM | IC50 = 0.059 nM | IC50  0.08 nM | Kd (dissociation constant)  0.37 nM | Kd (dissociation constant)  0.37 nM | Kd (dissociation constant)  0.37 nM | Kd (dissociation constant)  0.37 nM | IC50  0.51 nM | Kd (dissociation constant)  0.61 nM | Kd (dissociation constant)  0.63 nM

>  <CAS>
698387-09-6

>  <Description>
Neratinib is a tyrosine kinase inhibitor which exhibits antitumor action against Epidermal Growth Factor Receptor, HER2, and Human Epidermal Growth Factor Receptor 4 (HER4) postive carcinomas. It is used to treat breast cancer that over expresses the HER2 receptor.

>  <EBC_ID>
EBC-27314

>  <IUPAC Name>
(2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 20, p. 11725 - 11755 | J. Med. Chem., 2020, vol. 63, # 20, p. 11725 - 11755 | Anti-Cancer Agents Med. Chem., 2007, vol. 7, # 6, p. 685 - 709 | Bioorg. Med. Chem., 2007, vol. 15, # 11, p. 3635 - 3648 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | THE UNIVERSITY OF TEXAS SYSTEM - WO2019/191279, 2019, A2 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051

>  <Main tar all>
Epidermal growth factor receptor (L858R) pX=10.7 | epidermal growth factor receptor pX=10.7 | erb-b2 receptor tyrosine kinase 2 pX=10.2 | epidermal growth factor receptor pX=10.1 | Epidermal growth factor receptor (G719C) pX=9.43 | Epidermal growth factor receptor (G719C) pX=9.43 | Epidermal growth factor receptor (L861Q) pX=9.43 | Epidermal growth factor receptor (L861Q) pX=9.43 | erb-b2 receptor tyrosine kinase 2 (D769N) pX=9.29 | Epidermal growth factor receptor (L747-A750del, insP) pX=9.21 | Epidermal growth factor receptor (Del S752-I759) pX=9.2

$$$$
Pyrvinium methyl sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.1114 -1.925 0 0
M  V30 2 O 0.2223 -1.155 0 0
M  V30 3 S 0.2223 0.385 0 0
M  V30 4 O 0.2223 1.925 0 0
M  V30 5 O 1.7623 0.385 0 0
M  V30 6 O -1.3177 0.385 0 0 CHG=-1
M  V30 7 C 7.496 -3.9627 0 0
M  V30 8 N 7.496 -2.4227 0 0
M  V30 9 C 6.1623 -1.6527 0 0
M  V30 10 C 8.8296 -1.6527 0 0
M  V30 11 C 8.8296 -0.1127 0 0
M  V30 12 C 10.1633 0.6573 0 0
M  V30 13 C 11.497 -0.1127 0 0
M  V30 14 N 12.8307 0.6573 0 0 CHG=1
M  V30 15 C 12.8307 2.1973 0 0
M  V30 16 C 14.1644 -0.1127 0 0
M  V30 17 C 15.498 0.6573 0 0
M  V30 18 C 16.8317 -0.1127 0 0
M  V30 19 C 18.1654 0.6573 0 0
M  V30 20 C 18.3264 2.1889 0 0
M  V30 21 C 19.8327 2.5091 0 0
M  V30 22 C 20.4591 3.9159 0 0
M  V30 23 N 20.6027 1.1754 0 0
M  V30 24 C 19.5723 0.0309 0 0
M  V30 25 C 19.8924 -1.4754 0 0
M  V30 26 C 22.1343 1.0144 0 0
M  V30 27 C 23.0395 2.2603 0 0
M  V30 28 C 24.571 2.0993 0 0
M  V30 29 C 25.1974 0.6925 0 0
M  V30 30 C 24.2922 -0.5534 0 0
M  V30 31 C 22.7607 -0.3924 0 0
M  V30 32 C 14.1644 -1.6527 0 0
M  V30 33 C 12.8307 -2.4227 0 0
M  V30 34 C 11.497 -1.6527 0 0
M  V30 35 C 10.1633 -2.4227 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 8 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 14 16
M  V30 15 1 16 17
M  V30 16 2 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 2 20 21
M  V30 20 1 21 22
M  V30 21 1 21 23
M  V30 22 1 23 24
M  V30 23 2 19 24
M  V30 24 1 24 25
M  V30 25 1 23 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 2 29 30
M  V30 30 1 30 31
M  V30 31 2 26 31
M  V30 32 1 16 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 2 13 34
M  V30 36 1 34 35
M  V30 37 2 10 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3400110582

>  <MW>
493.618

>  <MW (desalted)>
382.521

>  <ClogP>
2.786

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
12.05

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | - | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
inhibition percentage Active   | EC50 = 10 nM | EC50 ~ 20 nM | EC50 ~ 20 nM | amount increase Active   | enzyme activity decrease Active   | enzyme activity decrease Active   | enzyme activity decrease Active   | IC50  0.194 ?M | protein expression level increase Active

>  <CAS>
2136666-28-7

>  <Description>
Pyrvinium is an anthelmintic agent used for the treatment of pinworm infestations.

>  <EBC_ID>
EBC-50059

>  <IUPAC Name>
2-[(1E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-6-(dimethylamino)-1-methylquinolin-1-ium methyl sulfate

>  <Main Tar all refs>
UMASS MEMORIAL HEALTH CARE INC - WO2018/222831, 2018, A1 | Annual Reports in Medicinal Chemistry, 2012, vol. 47, p. 393 - 409 | J. Biol. Chem., 2022, vol. 298, # 8 | J. Biol. Chem., 2022, vol. 298, # 8 | UNIVERSITY SYSTEM OF MARYLAND - WO2017/151786, 2017, A1 | Cancer Res., 2020, vol. 80, # 19 | Cancer Res., 2020, vol. 80, # 19 | Cancer Res., 2020, vol. 80, # 19 | UNIVERSITY OF BRITISH COLUMBIA - WO2015/120543, 2015, A1 | J. Biol. Chem., 2022, vol. 298, # 8

>  <Main tar all>
Histone lysine demethylase (KDM) pX=8.0 | Proto-oncogene Wnt-1 pX=8.0 | Protein cereblon pX=7.7 | casein kinase 1 alpha pX=7.7 | Wnt pX=7.6 | NADH dehydrogenase (ubiquinone) pX=7.0 | cytochrome-c oxidase pX=7.0 | succinate dehydrogenase (ubiquinone) pX=7.0 | Androgen receptor pX=6.71 | Casein kinase 1 alpha (G40N) pX=6.7

$$$$
Methoxyfluran
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.31 4.001 0 0
M  V30 2 O 3.08 2.6674 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 F 0.9763 2.1037 0 0
M  V30 5 F 3.6437 0.5637 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 Cl 2.31 -1.3337 0 0
M  V30 8 Cl 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201617823

>  <MW>
163.961

>  <MW (desalted)>
164.966

>  <ClogP>
2.493

>  <logS>
-1.99

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
9.23

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
EC50  0.21 mM

>  <CAS>
76-38-0

>  <Description>
Methoxyfluran is an inhalation anesthetic. Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times.

>  <EBC_ID>
EBC-03096

>  <IUPAC Name>
2,2-dichloro-1,1-difluoro-1-methoxyethane

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1995, vol. 274, # 3, p. 1355 - 1361

>  <Main tar all>
ion channel pX=3.68

$$$$
Amyl Nitrite
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 C 4.62 2.6674 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 7.2874 2.6674 0 0
M  V30 6 O 8.621 3.4374 0 0
M  V30 7 N 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255461260

>  <MW>
117.079

>  <MW (desalted)>
117.146

>  <ClogP>
2.792

>  <logS>
-1.96

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
38.66

>  <RotBonds>
5

>  <CAS>
463-04-7

>  <Description>
Amyl Nitrite is a fast acting vasodilator used for rapid relief of angina pectoris.

>  <EBC_ID>
EBC-26048

>  <IUPAC Name>
pentyl nitrite

$$$$
Adenine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 C 2.4172 0.77 0 0
M  V30 9 N 3.3224 2.0159 0 0
M  V30 10 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 2 10
M  V30 11 1 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104498572

>  <MW>
135.054

>  <MW (desalted)>
135.127

>  <ClogP>
-0.148

>  <logS>
-1.66

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
80.48

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1.96 nM | EC50 = 2.24 nM | Ki (inhibition constant) ~ 18 nM

>  <CAS>
73-24-5

>  <Description>
Adenine is a purine base which forms a component of DNA among other functions and is present in many multivitamins. Adenine combines with the sugar ribose to form adenosine, which in turn can be bonded with from one to three phosphoric acid units, yielding AMP, ADP and ATP .

>  <EBC_ID>
EBC-03112

>  <IUPAC Name>
9H-purin-6-amine

>  <Main Tar all refs>
Bioorg. Med. Chem., 2003, vol. 11, # 13, p. 3029 - 3037 | UCB - EP2141166, 2010, A1 | ChemBioChem, 2007, vol. 8, # 13, p. 1527 - 1539

>  <Main tar all>
Ryanodine receptor pX=8.71 | Adenine 1 receptor pX=8.65 | Mas-Related Gpr, Member A pX=7.74

$$$$
Methyl nicotinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 O 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57036282

>  <MW>
137.048

>  <MW (desalted)>
137.136

>  <ClogP>
0.767

>  <logS>
-0.55

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
39.19

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.677 mM

>  <CAS>
93-60-7

>  <Description>
Methyl nicotinate is the methyl ester of Niacin that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation.

>  <EBC_ID>
EBC-26077

>  <IUPAC Name>
methyl pyridine-3-carboxylate

>  <Main Tar all refs>
XENOBIOTICA, 1992, vol. 22, # 3, p. 273 - 282

>  <Main tar all>
Carboxylesterase pX=3.17

$$$$
Carmustine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 5.5963 4.771 0 0
M  V30 2 C 6.93 4.001 0 0
M  V30 3 C 8.2637 4.771 0 0
M  V30 4 N 9.5974 4.001 0 0
M  V30 5 C 10.931 4.771 0 0
M  V30 6 O 10.931 6.311 0 0
M  V30 7 N 12.2647 4.001 0 0
M  V30 8 C 13.5984 4.771 0 0
M  V30 9 C 14.9321 4.001 0 0
M  V30 10 Cl 16.2658 4.771 0 0
M  V30 11 N 12.2647 2.461 0 0
M  V30 12 O 13.5984 1.691 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 7 11
M  V30 11 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269141329

>  <MW>
213.007

>  <MW (desalted)>
214.05

>  <ClogP>
1.316

>  <logS>
-2.43

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
61.77

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  8.1 ?M | IC50  8.1 ?M | IC50 = 21.2 ?M

>  <CAS>
154-93-8

>  <Description>
Carmustine is an alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others. Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA. It is used for the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

>  <EBC_ID>
EBC-08119

>  <IUPAC Name>
1,3-bis(2-chloroethyl)-3-nitrosourea

>  <Main Tar all refs>
Eur. J. Med. Chem., 2014, vol. 71, p. 282 - 289 | Eur. J. Med. Chem., 2014, vol. 71, p. 282 - 289 | J. Pharmacol. Exp. Ther., 1999, vol. 290, # 3, p. 1467 - 1474

>  <Main tar all>
glutathione-disulfide reductase pX=5.09 | glutathione-disulfide reductase pX=5.09 | Methylated-DNA-protein-cysteine methyltransferase pX=4.67

$$$$
Actarit
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 O -1.3337 3.85 0 0
M  V30 4 N 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C -0 -3.08 0 0
M  V30 11 O -0 -4.62 0 0
M  V30 12 O -1.3337 -2.31 0 0
M  V30 13 C 0 0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 2 5 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z90122510

>  <MW>
193.074

>  <MW (desalted)>
193.199

>  <ClogP>
0.433

>  <logS>
-1.22

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  422 nM

>  <CAS>
18699-02-0

>  <Description>
Actarit is an orally active immunomodulator. It is used in the treatment of rheumatoid arthritis.

>  <EBC_ID>
EBC-04008

>  <IUPAC Name>
2-(4-acetamidophenyl)acetic acid

>  <Main Tar all refs>
Biomolecules, 2020, vol. 10, # 11, p. 1 - 11

>  <Main tar all>
carbonic anhydrase 2 pX=6.37

$$$$
Cyclophosphamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -3.7027 -2.862 0 0
M  V30 2 C -2.1627 -2.862 0 0
M  V30 3 C -1.3927 -1.5283 0 0
M  V30 4 N 0.1473 -1.5283 0 0
M  V30 5 C 0.9173 -2.862 0 0
M  V30 6 C 2.4573 -2.862 0 0
M  V30 7 Cl 3.2273 -4.1957 0 0
M  V30 8 P 0.9173 -0.1946 0 0
M  V30 9 O 2.097 -1.1845 0 0
M  V30 10 N -0.5298 0.3321 0 0
M  V30 11 C -0.7973 1.8487 0 0
M  V30 12 C 0.3825 2.8386 0 0
M  V30 13 C 1.8296 2.3119 0 0
M  V30 14 O 2.097 0.7953 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z276509078

>  <MW>
260.025

>  <MW (desalted)>
261.086

>  <ClogP>
0.803

>  <logS>
-1.05

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
41.57

>  <RotBonds>
5

>  <Action on targets>
- | - | - | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 0.4 ?M | Km (Michaelis constant) = 0.49 ?M | Km (Michaelis constant) = 1.6 ?M | Km (Michaelis constant) = 2.3 ?M | pKi  5.22  | IC50 < 10 ?M

>  <CAS>
50-18-0

>  <Description>
Cyclophosphamide is an antineoplastic in the class of alkylating agents. It is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast.

>  <EBC_ID>
EBC-26356

>  <IUPAC Name>
2-[bis(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one

>  <Main Tar all refs>
Curr. Drug Metab., 2010, vol. 11, # 2, p. 153 - 161 | Curr. Drug Metab., 2010, vol. 11, # 2, p. 153 - 161 | Curr. Drug Metab., 2006, vol. 7, # 7, p. 705 - 714 | Curr. Drug Metab., 2010, vol. 11, # 2, p. 153 - 161 | ChemMedChem, 2006, vol. 1, # 1, p. 73 - 81 | UNIVERSITY OF DUNDEE - US2010/305070, 2010, A1

>  <Main tar all>
Cytochrome P450 2C19 pX=6.4 | Cytochrome P450 2C9 pX=6.31 | Cytochrome P450 2B6 pX=5.8 | Cytochrome P450 2C8 pX=5.64 | Cytochrome P450 3A4 pX=5.22 | CYP1B1 pX=5.0

$$$$
Zoledronate monohydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.29 1.9013 0 0
M  V30 3 C 5.6237 1.1313 0 0
M  V30 4 C 6.9574 0.3613 0 0
M  V30 5 N 6.9574 -1.1787 0 0
M  V30 6 C 8.2032 -2.0839 0 0
M  V30 7 C 7.7274 -3.5486 0 0
M  V30 8 N 6.1874 -3.5486 0 0
M  V30 9 C 5.7115 -2.0839 0 0
M  V30 10 P 6.3937 2.4649 0 0
M  V30 11 O 7.1637 3.7986 0 0
M  V30 12 O 7.7274 1.6949 0 0
M  V30 13 O 5.06 3.2349 0 0
M  V30 14 P 4.8537 -0.2024 0 0
M  V30 15 O 6.1874 -0.9724 0 0
M  V30 16 O 4.0837 -1.5361 0 0
M  V30 17 O 3.52 0.5676 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 5 9
M  V30 9 1 3 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 13 1 3 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2660640472

>  <MW>
290.007

>  <MW (desalted)>
272.09

>  <ClogP>
-3.066

>  <logS>
3.375

>  <HBD>
5

>  <HBA>
8

>  <TPSA>
153.11

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | Ki (inhibition constant) = 0.07 nM | IC50  0.11 nM | IC50  1.6E-10 M | IC50  2.1E-10 M

>  <CAS>
165800-06-6

>  <Description>
Zoledronic acid is a third generation, nitrogen containing bisphosphonate. It is used to treat malignancy associated hypercalcemia, multiple myeloma, and bone metastasis from solid tumors.

>  <EBC_ID>
EBC-15027

>  <IUPAC Name>
[1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid hydrate

>  <Main Tar all refs>
MONE ZAIDI CONSULTING - US2016/38516, 2016, A1 | J. Med. Chem., 2008, vol. 51, # 7, p. 2187 - 2195 | Cells, 2023, vol. 12, # 6 | Pharmaceutics, 2021, vol. 13, # 9 | Pharmaceutics, 2021, vol. 13, # 9

>  <Main tar all>
erb-b2 receptor tyrosine kinase 2 pX=11.0 | farnesyl diphosphate synthase pX=10.2 | Kir6.1 pX=9.96 | atp-binding cassette sub-family c member 9 pX=9.8 | Kir6.2 pX=9.68

$$$$
Dichlorophenamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 5.39 0 0
M  V30 2 S 1.3337 3.85 0 0
M  V30 3 O -0.2063 3.85 0 0
M  V30 4 O 2.8737 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 Cl 4.001 -0.77 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 Cl 1.3337 -2.31 0 0
M  V30 11 C 0 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 13 S -1.3337 -0.77 0 0
M  V30 14 O -2.6674 -1.54 0 0
M  V30 15 O -2.1037 0.5637 0 0
M  V30 16 N -0.5637 -2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 5 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 2 13 15
M  V30 16 1 13 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037279821

>  <MW>
303.915

>  <MW (desalted)>
305.159

>  <ClogP>
0.241

>  <logS>
-2.759

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
120.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.03 nM | IC50 = 0.03 nM | Kd (dissociation constant)  0.25 nM | Kd (dissociation constant)  0.46 nM | Kd (dissociation constant)  0.92 nM

>  <CAS>
120-97-8

>  <Description>
Dichlorphenamide is a sulfonamide and an orally bioavailable carbonic anhydrase inhibitor. It is used for the management of open-angle and secondary glaucoma, as well as acute angle-closure glaucoma in delayed pre-operative setting requiring a reduction in intraocular pressure.

>  <EBC_ID>
EBC-06667

>  <IUPAC Name>
4,5-dichlorobenzene-1,3-disulfonamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 1996, vol. 31, # 11, p. 843 - 846 | Eur. J. Med. Chem., 1996, vol. 31, # 11, p. 843 - 846 | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June

>  <Main tar all>
carbonic anhydrase pX=10.5 | carbonic anhydrase 2 pX=10.5 | Carbonic anhydrase 5B, mitochondrial pX=9.6 | carbonic anhydrase 7 pX=9.34 | carbonic anhydrase 14 pX=9.04

$$$$
4-(Isopropylamino)diphenylamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 1.54 0 0
M  V30 2 C 2.6674 0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 N 4.001 -0.77 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 C 5.3347 -3.08 0 0
M  V30 7 C 5.3347 -4.62 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 N 4.001 -6.93 0 0
M  V30 10 C 2.6674 -7.7 0 0
M  V30 11 C 2.6674 -9.24 0 0
M  V30 12 C 1.3337 -10.01 0 0
M  V30 13 C -0 -9.24 0 0
M  V30 14 C 0 -7.7 0 0
M  V30 15 C 1.3337 -6.93 0 0
M  V30 16 C 2.6674 -4.62 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 2 8 16
M  V30 17 1 16 17
M  V30 18 2 5 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56821893

>  <MW>
226.147

>  <MW (desalted)>
226.317

>  <ClogP>
3.957

>  <logS>
-3.6

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
24.06

>  <RotBonds>
4

>  <CAS>
101-72-4

>  <Description>
4-(Isopropylamino)diphenylamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older.

>  <EBC_ID>
EBC-26245

>  <IUPAC Name>
N1-phenyl-N4-(propan-2-yl)benzene-1,4-diamine

$$$$
Phentolamine acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.77 1.3337 0 0
M  V30 2 C 0 -0 0 0
M  V30 3 O 0.77 -1.3337 0 0
M  V30 4 O -1.54 -0 0 0
M  V30 5 C 9.6247 6.3252 0 0
M  V30 6 C 9.6247 4.7852 0 0
M  V30 7 C 10.9584 4.0152 0 0
M  V30 8 C 10.9584 2.4752 0 0
M  V30 9 C 9.6247 1.7052 0 0
M  V30 10 C 8.291 2.4752 0 0
M  V30 11 C 8.291 4.0152 0 0
M  V30 12 N 9.6247 0.1652 0 0
M  V30 13 C 10.9584 -0.6048 0 0
M  V30 14 C 10.9584 -2.1448 0 0
M  V30 15 N 12.2043 -3.05 0 0
M  V30 16 C 11.7284 -4.5146 0 0
M  V30 17 C 10.1884 -4.5146 0 0
M  V30 18 N 9.7125 -3.05 0 0
M  V30 19 C 8.291 -0.6048 0 0
M  V30 20 C 8.291 -2.1448 0 0
M  V30 21 C 6.9574 -2.9148 0 0
M  V30 22 C 5.6237 -2.1448 0 0
M  V30 23 C 5.6237 -0.6048 0 0
M  V30 24 O 4.29 0.1652 0 0
M  V30 25 C 6.9574 0.1652 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 14 18
M  V30 19 1 12 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 2 19 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1318255133

>  <MW>
341.174

>  <MW (desalted)>
281.352

>  <ClogP>
3.809

>  <logS>
-3.05

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
47.86

>  <RotBonds>
4

>  <Action on targets>
Antagonist | Antagonist | Antagonist | Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.03 nM | IC50  0.03 nM | IC50  0.03 nM | pKi  9.61  | Ki (inhibition constant)  0.71 nM | pA2  9.04  | Ki (inhibition constant) = 0.93 nM

>  <CAS>
249607-96-3

>  <Description>
Phentolamine is an alpha adrenergic antagonist used to reverse soft tissue anesthesia.

>  <EBC_ID>
EBC-15029

>  <IUPAC Name>
3-{[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino}phenol; acetic acid

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2022, vol. 119, # 20 | Proc. Natl. Acad. Sci. U. S. A., 2022, vol. 119, # 20 | Proc. Natl. Acad. Sci. U. S. A., 2022, vol. 119, # 20 | NEUROCHEM. RES., 1993, vol. 18, # 8, p. 921 - 925 | MOL. PHARMACOL., 1982, vol. 21, # 1, p. 27 - 35 | BR. J. PHARMACOL., 1981, vol. 73, # 2, p. 355 - 362 | J. MED. CHEM., 1983, vol. 26, # 12, p. 1769 - 1772

>  <Main tar all>
?1A-adrenoceptor pX=10.5 | ?1B-adrenoceptor pX=10.5 | ?1D-adrenoceptor pX=10.5 | Octopamine 3 receptor pX=9.61 | ?1-adrenoceptor pX=9.15 | ?-adrenoceptor pX=9.04 | ?2-adrenoceptor pX=9.03

$$$$
Meclizine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C 5.811 -7.7 0 0
M  V30 4 C 5.811 -9.24 0 0
M  V30 5 C 7.1447 -10.01 0 0
M  V30 6 C 7.1447 -11.55 0 0
M  V30 7 C 5.811 -12.32 0 0
M  V30 8 C 4.4774 -11.55 0 0
M  V30 9 C 3.1437 -12.32 0 0
M  V30 10 N 1.81 -11.55 0 0
M  V30 11 C 0.4763 -12.32 0 0
M  V30 12 C -0.8574 -11.55 0 0
M  V30 13 N -0.8574 -10.01 0 0
M  V30 14 C 0.4763 -9.24 0 0
M  V30 15 C 1.81 -10.01 0 0
M  V30 16 C -2.191 -9.24 0 0
M  V30 17 C -3.5247 -10.01 0 0
M  V30 18 C -3.5247 -11.55 0 0
M  V30 19 C -4.8584 -12.32 0 0
M  V30 20 C -6.1921 -11.55 0 0
M  V30 21 C -6.1921 -10.01 0 0
M  V30 22 C -4.8584 -9.24 0 0
M  V30 23 C -2.191 -7.7 0 0
M  V30 24 C -3.5247 -6.93 0 0
M  V30 25 C -3.5247 -5.39 0 0
M  V30 26 C -2.191 -4.62 0 0
M  V30 27 Cl -2.191 -3.08 0 0
M  V30 28 C -0.8574 -5.39 0 0
M  V30 29 C -0.8574 -6.93 0 0
M  V30 30 C 4.4774 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 2 5 6
M  V30 4 1 6 7
M  V30 5 2 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 1 10 15
M  V30 14 1 13 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 19 20
M  V30 19 2 20 21
M  V30 20 1 21 22
M  V30 21 2 17 22
M  V30 22 1 16 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 2 26 28
M  V30 28 1 28 29
M  V30 29 2 23 29
M  V30 30 1 8 30
M  V30 31 2 4 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1182332248

>  <MW>
463.87

>  <MW (desalted)>
390.948

>  <ClogP>
6.732

>  <logS>
-6.36

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
5

>  <Action on targets>
Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 ~ 25 nM | fold decrease Active   | Ki (inhibition constant) = 108 nM

>  <CAS>
1104-22-9

>  <Description>
Meclizine is a histamine H1 antagonist used to treat nausea, vomiting, and dizziness associated with motion sickness.

>  <EBC_ID>
EBC-13153

>  <IUPAC Name>
1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine dihydrochloride

>  <Main Tar all refs>
Mol. Endocrinol., 2004, vol. 18, # 10, p. 2402 - 2408 | Pharmaceuticals, 2020, vol. 13, # 12, p. 1 - 18 | J. Biol. Chem., 1999, vol. 274, # 42, p. 29994 - 30000

>  <Main tar all>
Constitutive androstane receptor pX=7.6 | CREB-regulated transcription coactivator 1 pX=7.0 | H1 receptor pX=6.97

$$$$
Butenafine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 N 1.3337 -5.39 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 C 0 -7.7 0 0
M  V30 5 C 0 -9.24 0 0
M  V30 6 C -1.3337 -10.01 0 0
M  V30 7 C -2.6674 -9.24 0 0
M  V30 8 C -2.6674 -7.7 0 0
M  V30 9 C -1.3337 -6.93 0 0
M  V30 10 C -4.001 -10.01 0 0
M  V30 11 C -5.3347 -10.78 0 0
M  V30 12 C -3.231 -11.3437 0 0
M  V30 13 C -4.771 -8.6763 0 0
M  V30 14 C 2.6674 -4.62 0 0
M  V30 15 C 2.6674 -3.08 0 0
M  V30 16 C 1.3337 -2.31 0 0
M  V30 17 C 1.3337 -0.77 0 0
M  V30 18 C 2.6674 0 0 0
M  V30 19 C 4.001 -0.77 0 0
M  V30 20 C 5.3347 0 0 0
M  V30 21 C 6.6684 -0.77 0 0
M  V30 22 C 6.6684 -2.31 0 0
M  V30 23 C 5.3347 -3.08 0 0
M  V30 24 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 2 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 15 24
M  V30 26 1 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z54757159

>  <MW>
317.467

>  <MW (desalted)>
317.467

>  <ClogP>
6.744

>  <logS>
-6.427

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 76 ?M

>  <CAS>
101828-21-1

>  <Description>
Butenafine is a topical antifungal used to treat tinea versicolor, tinea pedis, tinea cruris, and tinea corporis.

>  <EBC_ID>
EBC-26773

>  <IUPAC Name>
[(4-tert-butylphenyl)methyl](methyl)[(naphthalen-1-yl)methyl]amine

>  <Main Tar all refs>
J. Med. Chem., 2013, vol. 56, # 13, p. 5275 - 5287

>  <Main tar all>
Enoyl-[acyl-carrier-protein] reductase pX=4.12

$$$$
Amodiaquine dihydrochloride dihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 Cl 8.14 0 0 0
M  V30 4 Cl 0 -7.0532 0 0
M  V30 5 C 4.4 -8.47 0 0
M  V30 6 C 5.7337 -7.7 0 0
M  V30 7 N 7.0674 -8.47 0 0
M  V30 8 C 7.0674 -10.01 0 0
M  V30 9 C 5.7337 -10.78 0 0
M  V30 10 C 8.401 -7.7 0 0
M  V30 11 C 9.7347 -8.47 0 0
M  V30 12 C 11.0684 -7.7 0 0
M  V30 13 C 12.4021 -8.47 0 0
M  V30 14 N 13.7358 -7.7 0 0
M  V30 15 C 13.7358 -6.16 0 0
M  V30 16 C 12.4021 -5.39 0 0
M  V30 17 C 12.4021 -3.85 0 0
M  V30 18 N 13.7358 -3.08 0 0
M  V30 19 C 15.0694 -3.85 0 0
M  V30 20 C 16.4031 -3.08 0 0
M  V30 21 C 17.7368 -3.85 0 0
M  V30 22 Cl 19.0705 -3.08 0 0
M  V30 23 C 17.7368 -5.39 0 0
M  V30 24 C 16.4031 -6.16 0 0
M  V30 25 C 15.0694 -5.39 0 0
M  V30 26 C 12.4021 -10.01 0 0
M  V30 27 C 11.0684 -10.78 0 0
M  V30 28 C 9.7347 -10.01 0 0
M  V30 29 O 8.401 -10.78 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 6
M  V30 2 1 6 7
M  V30 3 1 7 8
M  V30 4 1 8 9
M  V30 5 1 7 10
M  V30 6 1 10 11
M  V30 7 1 11 12
M  V30 8 2 12 13
M  V30 9 1 13 14
M  V30 10 1 14 15
M  V30 11 1 15 16
M  V30 12 2 16 17
M  V30 13 1 17 18
M  V30 14 2 18 19
M  V30 15 1 19 20
M  V30 16 2 20 21
M  V30 17 1 21 22
M  V30 18 1 21 23
M  V30 19 2 23 24
M  V30 20 1 24 25
M  V30 21 2 15 25
M  V30 22 1 19 25
M  V30 23 1 13 26
M  V30 24 2 26 27
M  V30 25 1 27 28
M  V30 26 2 11 28
M  V30 27 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552192759

>  <MW>
464.814

>  <MW (desalted)>
355.861

>  <ClogP>
5.465

>  <logS>
-5.52

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
48.39

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Activator | Activator | Stimulator | Stimulator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3 - 1 nM | IC50  5 nM | IC50  7.4 nM | stimulation rate Active   | stimulation rate Active   | stimulation rate Active   | stimulation rate Active   | Ki (inhibition constant) = 0.01 ?M | IC50  0.018 ?M

>  <CAS>
6398-98-7

>  <Description>
Amodiaquine, a 4-aminoquinoline similar to chloroquine in structure and activity, has been used as both an antimalarial and an anti-inflammatory agent.

>  <EBC_ID>
EBC-12791

>  <IUPAC Name>
4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol dihydrate dihydrochloride

>  <Main Tar all refs>
IDOGEN AB - WO2008/147283, 2008, A1 | J. Chem. Inf. Model., 2010, vol. 50, # 9, p. 1706 - 1723 | Cell Chem. Biol., 2022, vol. 29, # 2, p. 191 - 8,201 | NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3498279, 2019, A1 | NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3498279, 2019, A1 | NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3260121, 2017, A1 | NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3260121, 2017, A1 | Bioorg. Med. Chem., 2003, vol. 11, # 10, p. 2163 - 2174 | Pharmaceutics, 2022, vol. 14, # 6

>  <Main tar all>
Aldehyde oxidase pX=8.52 | Heat shock protein HSP 90-alpha pX=8.3 | acetate-CoA ligase pX=8.13 | Peroxisome proliferator-activated receptor-? pX=8.0 | Peroxisome proliferator-activated receptor-? pX=8.0 | Peroxisome proliferator-activated receptor-? pX=8.0 | Regulatory protein GAL4 pX=8.0 | histamine N-methyltransferase pX=8.0 | Thioredoxin reductase pX=7.74

$$$$
Pimozide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -0.0964 -18.0192 0 0
M  V30 2 C 0.3794 -16.5546 0 0
M  V30 3 C -0.651 -15.4102 0 0
M  V30 4 C -0.1751 -13.9455 0 0
M  V30 5 C 1.3312 -13.6254 0 0
M  V30 6 C 2.3617 -14.7698 0 0
M  V30 7 C 1.8858 -16.2344 0 0
M  V30 8 C 1.8071 -12.1607 0 0
M  V30 9 C 0.7766 -11.0163 0 0
M  V30 10 C 1.2525 -9.5517 0 0
M  V30 11 C 0.2221 -8.4072 0 0
M  V30 12 N 0.698 -6.9426 0 0
M  V30 13 C -0.3325 -5.7982 0 0
M  V30 14 C 0.1434 -4.3335 0 0
M  V30 15 C 1.6497 -4.0133 0 0
M  V30 16 C 2.6802 -5.1578 0 0
M  V30 17 C 2.2043 -6.6224 0 0
M  V30 18 N 2.1256 -2.5487 0 0
M  V30 19 C 1.2204 -1.3028 0 0
M  V30 20 O -0.3196 -1.3028 0 0
M  V30 21 N 2.1256 -0.0569 0 0
M  V30 22 C 3.5902 -0.5328 0 0
M  V30 23 C 4.9239 0.2372 0 0
M  V30 24 C 6.2576 -0.5328 0 0
M  V30 25 C 6.2576 -2.0728 0 0
M  V30 26 C 4.9239 -2.8428 0 0
M  V30 27 C 3.5902 -2.0728 0 0
M  V30 28 C 3.3135 -11.8405 0 0
M  V30 29 C 3.7893 -10.3759 0 0
M  V30 30 C 5.2957 -10.0557 0 0
M  V30 31 C 6.3261 -11.2002 0 0
M  V30 32 F 7.8325 -10.88 0 0
M  V30 33 C 5.8503 -12.6648 0 0
M  V30 34 C 4.3439 -12.985 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 12 17
M  V30 19 1 15 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 18 27
M  V30 30 2 22 27
M  V30 31 1 8 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 2 31 33
M  V30 37 1 33 34
M  V30 38 2 28 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z241910386

>  <MW>
461.546

>  <MW (desalted)>
461.546

>  <ClogP>
6.401

>  <logS>
-6.262

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
35.58

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.00051 nM | Ki (inhibition constant) = 0.00051 nM

>  <CAS>
2062-78-4

>  <Description>
Pimozide is an antipsychotic used to manage debilitating motor and phonic tics in patients with Tourette's Disorder. It has an ability to blockade dopaminergic receptors on neurons in the central nervous system.

>  <EBC_ID>
EBC-12825

>  <IUPAC Name>
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

>  <Main Tar all refs>
Eur. J. Med. Chem., 1996, vol. 31, # 12, p. 957 - 964 | Eur. J. Med. Chem., 1996, vol. 31, # 12, p. 957 - 964

>  <Main tar all>
D2 receptor pX=12.3 | D2 receptor pX=12.3

$$$$
Benzethonium cloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 5.94 -5.2103 0 0
M  V30 3 C 5.94 -3.6703 0 0
M  V30 4 C 7.48 -3.6703 0 0
M  V30 5 C 4.4 -3.6703 0 0
M  V30 6 C 5.94 -2.1303 0 0
M  V30 7 C 7.2737 -1.3603 0 0
M  V30 8 C 8.0437 -2.694 0 0
M  V30 9 C 6.5037 -0.0267 0 0
M  V30 10 C 8.6074 -0.5903 0 0
M  V30 11 C 8.6074 0.9497 0 0
M  V30 12 C 9.941 1.7197 0 0
M  V30 13 C 11.2747 0.9497 0 0
M  V30 14 O 12.6084 1.7197 0 0
M  V30 15 C 13.9421 0.9497 0 0
M  V30 16 C 15.2758 1.7197 0 0
M  V30 17 O 16.6094 0.9497 0 0
M  V30 18 C 17.9431 1.7197 0 0
M  V30 19 C 19.2768 0.9497 0 0
M  V30 20 N 20.6105 1.7197 0 0 CHG=1
M  V30 21 C 21.3805 0.386 0 0
M  V30 22 C 19.8405 3.0533 0 0
M  V30 23 C 21.9441 2.4897 0 0
M  V30 24 C 23.2778 1.7197 0 0
M  V30 25 C 24.6115 2.4897 0 0
M  V30 26 C 25.9452 1.7197 0 0
M  V30 27 C 25.9452 0.1797 0 0
M  V30 28 C 24.6115 -0.5903 0 0
M  V30 29 C 23.2778 0.1797 0 0
M  V30 30 C 11.2747 -0.5903 0 0
M  V30 31 C 9.941 -1.3603 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 7 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 1 20 22
M  V30 21 1 20 23
M  V30 22 1 23 24
M  V30 23 1 24 25
M  V30 24 2 25 26
M  V30 25 1 26 27
M  V30 26 2 27 28
M  V30 27 1 28 29
M  V30 28 2 24 29
M  V30 29 2 13 30
M  V30 30 1 30 31
M  V30 31 2 10 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z324590202

>  <MW>
448.081

>  <MW (desalted)>
412.628

>  <ClogP>
4.285

>  <logS>
-6.62

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
18.46

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Blocker

>  <Activity coefficients and valu>
Kd (dissociation constant)  2 nM | Kd (dissociation constant)  2 nM | Kd (dissociation constant)  3 nM | IC50  3.6 nM | Kd (dissociation constant)  10 - 200 nM | IC50  18 nM

>  <CAS>
121-54-0

>  <Description>
Benzethonium chloride has surfactant, antiseptic, and anti-infective properties. It is used as a topical antimicrobial agent in first aid antiseptics. It also shows inhibitory effect at potassium voltage-gated channel.

>  <EBC_ID>
EBC-03895

>  <IUPAC Name>
benzyldimethyl(2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl)azanium chloride

>  <Main Tar all refs>
Biochem. Biophys. Res. Commun., 2021, vol. 583, p. 162 - 168 | Biochem. Biophys. Res. Commun., 2021, vol. 583, p. 162 - 168 | Biochem. Biophys. Res. Commun., 2021, vol. 583, p. 162 - 168 | Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258 | Biochem. Biophys. Res. Commun., 2021, vol. 583, p. 162 - 168 | Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258

>  <Main tar all>
Exendin-4 pX=8.7 | GLP-1 receptor pX=8.7 | Guanine nucleotide-binding protein G(s) subunit alpha pX=8.52 | Kv11.1 pX=8.44 | G protein alpha i subunit pX=8.0 | Kv3.1 pX=7.74

$$$$
Cytidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 C 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=2
M  V30 7 O 2.5796 5.5648 0 0
M  V30 8 C 2.1037 4.1002 0 0 CFG=2
M  V30 9 C 3.0089 2.8543 0 0
M  V30 10 O 4.5404 3.0153 0 0
M  V30 11 C 0.5637 4.1002 0 0 CFG=1
M  V30 12 O -0.3415 2.8543 0 0
M  V30 13 C 0.0878 5.5648 0 0 CFG=1
M  V30 14 O -1.3768 6.0407 0 0
M  V30 15 C 0 8.78 0 0
M  V30 16 O -1.3337 8.01 0 0
M  V30 17 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 8
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 6
M  V30 14 1 13 14 CFG=1
M  V30 15 1 5 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1879263740

>  <MW>
243.217

>  <MW (desalted)>
243.217

>  <ClogP>
-2.195

>  <logS>
-0.535

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
128.61

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Substrate | Substrate | Substrate | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1.2 ?M | Km (Michaelis constant)  2.2 ?M | Km (Michaelis constant)  2.8 ?M | Km (Michaelis constant)  3.4 ?M | Km (Michaelis constant)  3.5 ?M | Km (Michaelis constant) = 3.9 ?M | inhibition percentage Active   | Km (Michaelis constant) = 7.84 ?M | IC50  9.44 ?M | Km (Michaelis constant) = 10.8 ?M | IC50  15.55 ?M | Km (Michaelis constant) = 21.2 ?M

>  <CAS>
65-46-3

>  <Description>
Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine.

>  <EBC_ID>
EBC-14152

>  <IUPAC Name>
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
Eur. J. Med. Chem., 1999, vol. 34, # 5, p. 423 - 431 | Pharmacogenet. Genomics, 2005, vol. 15, # 3, p. 173 - 182 | Pharmacogenet. Genomics, 2005, vol. 15, # 3, p. 173 - 182 | Pflug. Arch. Eur. J. Physiol., 2003, vol. 447, # 2, p. 195 - 204 | Pharmacogenet. Genomics, 2005, vol. 15, # 3, p. 173 - 182 | ChemMedChem, 2011, vol. 6, # 8, p. 1452 - 1458 | Life Sci., 2009, vol. 84, # 1-2, p. 45 - 51 | Biol. Pharm. Bull., 2007, vol. 30, # 5, p. 979 - 981 | Drug Metab. Dispos., 2020, vol. 48, # 7, p. 603 - 612 | Biochem. J., 2004, vol. 383, # 1, p. 19 - 26 | Xenobiotica, 2019, vol. 49, # 7, p. 840 - 851 | Biochem. J., 2004, vol. 383, # 1, p. 19 - 26

>  <Main tar all>
deoxycytidine kinase pX=5.92 | CNT3 (Y513F) pX=5.66 | CNT3 (L131F) pX=5.55 | Solute carrier family 28 member 3 pX=5.47 | CNT3 (S5N) pX=5.46 | cytidine deaminase pX=5.41 | Nucleoside transporter pX=5.3 | Equilibrative nucleoside transporter 2 pX=5.11 | Equilibrative nucleoside transporter 1 pX=5.03 | Equilibrative nucleoside transporter 3 pX=4.97 | Sodium/nucleoside cotransporter 1 pX=4.81 | Equilibrative nucleotide transporter 6 pX=4.67

$$$$
Nilotinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.3358 -14.63 0 0
M  V30 2 C 9.3358 -16.17 0 0
M  V30 3 C 10.5816 -17.0752 0 0
M  V30 4 N 10.1058 -18.5398 0 0
M  V30 5 C 8.5658 -18.5398 0 0
M  V30 6 N 8.0899 -17.0752 0 0
M  V30 7 C 11.0109 -19.7857 0 0
M  V30 8 C 12.5425 -19.6247 0 0
M  V30 9 C 13.4477 -20.8706 0 0
M  V30 10 N 14.9793 -20.7096 0 0
M  V30 11 C 15.8844 -21.9555 0 0
M  V30 12 O 15.2581 -23.3624 0 0
M  V30 13 C 17.416 -21.7946 0 0
M  V30 14 C 18.0424 -20.3877 0 0
M  V30 15 C 19.574 -20.2267 0 0
M  V30 16 C 20.4791 -21.4726 0 0
M  V30 17 C 22.0107 -21.3116 0 0
M  V30 18 C 19.8528 -22.8795 0 0
M  V30 19 N 20.758 -24.1254 0 0
M  V30 20 C 22.2895 -23.9644 0 0
M  V30 21 N 22.9159 -22.5575 0 0
M  V30 22 C 24.4475 -22.3965 0 0
M  V30 23 C 25.3526 -23.6424 0 0
M  V30 24 C 24.7263 -25.0493 0 0
M  V30 25 N 23.1947 -25.2103 0 0
M  V30 26 C 25.6315 -26.2952 0 0
M  V30 27 C 27.163 -26.1342 0 0
M  V30 28 C 28.0682 -27.3801 0 0
M  V30 29 C 27.4418 -28.7869 0 0
M  V30 30 N 25.9103 -28.9479 0 0
M  V30 31 C 25.0051 -27.702 0 0
M  V30 32 C 18.3212 -23.0404 0 0
M  V30 33 C 12.8213 -22.2775 0 0
M  V30 34 C 11.2898 -22.4384 0 0
M  V30 35 C 10.3846 -21.1926 0 0
M  V30 36 C 10.6634 -23.8453 0 0
M  V30 37 F 10.037 -25.2522 0 0
M  V30 38 F 9.2565 -23.2189 0 0
M  V30 39 F 12.0702 -24.4717 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 20 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 26 31
M  V30 34 1 18 32
M  V30 35 2 13 32
M  V30 36 1 9 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 7 35
M  V30 40 1 34 36
M  V30 41 1 36 37
M  V30 42 1 36 38
M  V30 43 1 36 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741976994

>  <MW>
529.516

>  <MW (desalted)>
529.516

>  <ClogP>
5.844

>  <logS>
-6.929

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
97.62

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.29 - 0.6 nM | IC50  0.33 nM | GI50  0.86 nM | IC50 = 0.001 ?M | Kd (dissociation constant)  1 nM | IC50 = 0.001 ?M | IC50  1.5 nM | IC50  1.54 nM | IC50  1.89 nM | IC50 = 0.002 ?M | inhibition percentage  66.9 % | GI50  2.52 nM | IC50  2.5 - 11 nM | IC50  3 - 10 nM | IC50  3 - 10 nM | IC50  2.99 nM | GI50  3.52 nM | GI50  3.71 nM | Ki (inhibition constant)  4 - 32 nM | Ki (inhibition constant)  4 - 32 nM | Kd (dissociation constant)  4.5 nmol/l | IC50  4.66 nM | GI50  4.82 nM | IC50  5.07 - 6.05 nM | IC50  5.13 nM | IC50  5.2 nM | IC50  6.34 nM | IC50  6.5 nM | IC50  8.38 nM | IC50  8.8 nM | Kd (dissociation constant)  9 nM | Kd (dissociation constant)  9 nM | GI50  9.21 nM

>  <CAS>
641571-10-0

>  <Description>
Nilotinib is a kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib.

>  <EBC_ID>
EBC-11364

>  <IUPAC Name>
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2020, vol. 11, # 4, p. 491 - 496 | Bioorg. Med. Chem., 2013, vol. 21, # 9, p. 2527 - 2534 | Eur. J. Pharmacol., 2021, vol. 897 | STANFORD UNIVERSITY - US2008/32989, 2008, A1 | Biochim. Biophys. Acta Gen. Subj., 2010, vol. 1804, p. 445 | STANFORD UNIVERSITY - US2008/32989, 2008, A1 | J. Biol. Chem., 2022, vol. 298, # 8 | J. Med. Chem., 2012, vol. 55, # 22, p. 10033 - 10046 | HARBIN GLORIA PHARMACEUTICALS COMPANY LINITED - EP2385035, 2011, A1 | J. Med. Chem., 2014, vol. 57, # 10, p. 4252 - 4262 | QUEST DIAGNOSTICS INC - US2010/113470, 2010, A1 | Eur. J. Pharmacol., 2021, vol. 897 | Biochim. Biophys. Acta Gen. Subj., 2010, vol. 1804, p. 445 | Novartis (w/o Sandoz); NOVARTIS AG - WO2007/147613, 2007, A2 | NOVARTIS AG; Novartis (w/o Sandoz) - WO2007/10014, 2007, A3 | HARBIN GLORIA PHARMACEUTICALS COMPANY LINITED - EP2385035, 2011, A1 | J. Med. Chem., 2018, vol. 61, # 18, p. 8120 - 8135 | J. Med. Chem., 2018, vol. 61, # 18, p. 8120 - 8135 | Curr. Pharm. Des., 2010, vol. 16, # 29, p. 3233 - 3245 | Curr. Pharm. Des., 2010, vol. 16, # 29, p. 3233 - 3245 | Cancer Res., 2022, vol. 82, # 15, p. 2777 - 2791 | HARBIN GLORIA PHARMACEUTICALS COMPANY LINITED - EP2385035, 2011, A1 | J. Med. Chem., 2018, vol. 61, # 18, p. 8120 - 8135 | ACS Med. Chem. Lett., 2020, vol. 11, # 4, p. 491 - 496 | HARBIN GLORIA PHARMACEUTICALS COMPANY LINITED - EP2385035, 2011, A1 | Bioorg. Med. Chem., 2010, vol. 18, # 19, p. 6977 - 6986 | J. Med. Chem., 2012, vol. 55, # 22, p. 10033 - 10046 | J. Enzyme Inhib. Med. Chem., 2017, vol. 32, # 1, p. 331 - 336 | J. Med. Chem., 2012, vol. 55, # 22, p. 10033 - 10046 | GUANGZHOU HEALTHQUEST PHARMA CO LTD; ASCENTAGE PHARMACEUTICAL GROUP CO LTD - WO2021/223664, 2021, A1 | Biochim. Biophys. Acta Gen. Subj., 2010, vol. 1804, p. 445 | Biochim. Biophys. Acta Gen. Subj., 2010, vol. 1804, p. 445 | J. Med. Chem., 2018, vol. 61, # 18, p. 8120 - 8135

>  <Main tar all>
Kv11.1 pX=9.54 | BCR-ABL tyrosine kinase pX=9.48 | BCR-ABL tyrosine kinase pX=9.07 | Tyrosine-protein kinase ABL pX=9.0 | discoidin domain receptor tyrosine kinase 1 pX=9.0 | platelet derived growth factor receptor alpha pX=9.0 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=8.82 | BCR-ABL p210/M244V pX=8.81 | Tyrosine-protein?kinase?ABL1?(M351T) pX=8.72 | discoidin domain receptor tyrosine kinase 2 pX=8.7 | BCR-ABL p210 isoform pX=8.61 | BCR-ABL p210 isoform pX=8.6 | platelet derived growth factor receptor alpha pX=8.6 | KIT (V560G) pX=8.52 | Mast/stem cell growth factor receptor Kit pX=8.52 | Tyrosine-protein?kinase?ABL1?(H396P) phosphorylated pX=8.52 | BCR-ABL tyrosine kinase pX=8.45 | BCR-ABL (G250H) pX=8.43 | carbonic anhydrase 1 pX=8.4 | carbonic anhydrase 2 pX=8.4 | BCR-ABL tyrosine kinase pX=8.35 | Tyrosine-protein?kinase?ABL1?(Q252H) phosphorylated pX=8.33 | BCR-ABL (E355G) pX=8.32 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=8.29 | Tyrosine-protein?kinase?ABL1?(Y253F) phosphorylated pX=8.29 | Discoidin domain-containing receptor 1/2 pX=8.28 | BCR-ABL p210/H369P pX=8.2 | Breakpoint cluster region protein pX=8.19 | BCR-ABL p210/E355G pX=8.08 | BCR-ABL tyrosine kinase pX=8.06 | Mitogen-activated protein kinase kinase kinase 20 pX=8.05 | ZAK sterile alpha motif and leucine zipper containing kinase AZK pX=8.05 | BCR-ABL (E459K) pX=8.04

$$$$
Mepivacaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -3.08 0 0
M  V30 2 N 2.6674 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 C 4.001 -6.93 0 0
M  V30 5 C 2.6674 -7.7 0 0
M  V30 6 C 1.3337 -6.93 0 0
M  V30 7 C 1.3337 -5.39 0 0
M  V30 8 C 0 -4.62 0 0
M  V30 9 O 0 -3.08 0 0
M  V30 10 N -1.3337 -5.39 0 0
M  V30 11 C -2.6674 -4.62 0 0
M  V30 12 C -4.001 -5.39 0 0
M  V30 13 C -4.001 -6.93 0 0
M  V30 14 C -5.3347 -4.62 0 0
M  V30 15 C -5.3347 -3.08 0 0
M  V30 16 C -4.001 -2.31 0 0
M  V30 17 C -2.6674 -3.08 0 0
M  V30 18 C -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 11 17
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741980843

>  <MW>
246.348

>  <MW (desalted)>
246.348

>  <ClogP>
2.104

>  <logS>
-2.589

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Blocker

>  <Activity coefficients and valu>
IC50 < 10 ?M | Ki (inhibition constant)  10.3 ?M | inhibition percentage  29.3 % | IC50  285.2 ?M

>  <CAS>
96-88-8

>  <Description>
Mepivacaine is an amide-type local anesthetic agent. It binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization. It is indicated for production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.

>  <EBC_ID>
EBC-04411

>  <IUPAC Name>
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 2013, vol. 65, p. 304 - 314 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 1, p. 71 - 80 | J. Med. Chem., 1985, vol. 28, # 3, p. 381 - 388 | Eur. J. Pharmacol., 2010, vol. 630, # 1-3, p. 19 - 28

>  <Main tar all>
Kv11.1 pX=5.0 | Alpha-1-acid glycoprotein pX=4.99 | Voltage-gated?sodium?channel pX=3.62 | Nav1.8 pX=3.55

$$$$
Amiodarone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.0199 -3.8815 0 0
M  V30 3 C 6.0504 -2.737 0 0
M  V30 4 C 5.5745 -1.2724 0 0
M  V30 5 C 6.605 -0.128 0 0
M  V30 6 C 6.1291 1.3367 0 0
M  V30 7 O 4.6644 1.8126 0 0
M  V30 8 C 4.6644 3.3526 0 0
M  V30 9 C 3.52 4.383 0 0
M  V30 10 C 3.8402 5.8894 0 0
M  V30 11 C 5.3048 6.3653 0 0
M  V30 12 C 6.4493 5.3348 0 0
M  V30 13 C 6.1291 3.8284 0 0
M  V30 14 C 7.0343 2.5826 0 0
M  V30 15 C 8.5743 2.5826 0 0
M  V30 16 O 9.3443 3.9162 0 0
M  V30 17 C 9.3443 1.2489 0 0
M  V30 18 C 10.8843 1.2489 0 0
M  V30 19 C 11.6543 -0.0848 0 0
M  V30 20 I 13.1943 -0.0848 0 0
M  V30 21 C 10.8843 -1.4185 0 0
M  V30 22 O 11.6543 -2.7522 0 0
M  V30 23 C 13.1943 -2.7522 0 0
M  V30 24 C 13.9643 -4.0858 0 0
M  V30 25 N 15.5043 -4.0858 0 0
M  V30 26 C 16.2743 -5.4195 0 0
M  V30 27 C 17.8143 -5.4195 0 0
M  V30 28 C 16.2743 -2.7522 0 0
M  V30 29 C 17.8143 -2.7522 0 0
M  V30 30 C 9.3443 -1.4185 0 0
M  V30 31 I 8.5743 -2.7522 0 0
M  V30 32 C 8.5743 -0.0848 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 25 28
M  V30 29 1 28 29
M  V30 30 2 21 30
M  V30 31 1 30 31
M  V30 32 1 30 32
M  V30 33 2 17 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1554104509

>  <MW>
681.773

>  <MW (desalted)>
645.312

>  <ClogP>
8.945

>  <logS>
-8.41

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
42.68

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1 nM | pEC50  8.5  | pKi  8.1  | IC50  10.7 nM | IC50  0.015 ?M | pKi  7.8  | inhibition percentage  82 % | Ki (inhibition constant)  0.024 ?M | Ki (inhibition constant) = 25 nM

>  <CAS>
19774-82-4

>  <Description>
Amiodarone hydrochloride is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel.

>  <EBC_ID>
EBC-07659

>  <IUPAC Name>
{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2005, vol. 48, # 15, p. 4754 - 4764 | J. Pharmacol. Exp. Ther., 2014, vol. 348, # 1, p. 116 - 124 | J. Pharmacol. Exp. Ther., 2014, vol. 348, # 1, p. 116 - 124 | Cell, 2022, vol. 185, # 25, p. 4801 - 13,4810 | THE ROCKEFELLER UNIVERSITY - WO2017/173257, 2017, A1 | J. Pharmacol. Exp. Ther., 2014, vol. 348, # 1, p. 116 - 124 | J. Pharmacol. Exp. Ther., 2010, vol. 334, # 1, p. 214 - 222 | Drug Metab. Dispos., 2017, vol. 45, # 9, p. 1008 - 1018 | J. Med. Chem., 2005, vol. 48, # 15, p. 4754 - 4764

>  <Main tar all>
sigma non-opioid intracellular receptor 1 pX=9.0 | H3 receptor (isoform 2) pX=8.5 | H3 receptor (isoform 1) pX=8.1 | Cav1.2 pX=7.97 | Kv11.1 pX=7.82 | H3 receptor pX=7.8 | M1 receptor pX=7.66 | Cytochrome P450 2C9 pX=7.62 | 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase pX=7.6

$$$$
Isoxicam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 O 2.6674 1.54 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 S 2.6674 -3.08 0 0
M  V30 13 O 3.3903 -4.4397 0 0
M  V30 14 O 1.9444 -4.4397 0 0
M  V30 15 C 0 0 0 0
M  V30 16 O 0 1.54 0 0
M  V30 17 N -1.3337 -0.77 0 0
M  V30 18 C -2.6674 0 0 0
M  V30 19 C -4.0742 -0.6264 0 0
M  V30 20 C -5.1047 0.5181 0 0
M  V30 21 C -6.6362 0.3571 0 0
M  V30 22 O -4.3347 1.8517 0 0
M  V30 23 N -2.8283 1.5316 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 1 2 12
M  V30 14 2 12 13
M  V30 15 2 12 14
M  V30 16 1 3 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 22 23
M  V30 25 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2511727314

>  <MW>
335.058

>  <MW (desalted)>
335.335

>  <ClogP>
1.61

>  <logS>
-2.993

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
112.74

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  1320 nM

>  <CAS>
34552-84-6

>  <Description>
Isoxicam is a non-steroidal anti-inflammatory agent. It is an inhibitor of prostaglandin G/H synthase 1.

>  <EBC_ID>
EBC-07777

>  <IUPAC Name>
4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1997, vol. 75, # 9, p. 1088 - 1095

>  <Main tar all>
COX-1  pX=5.88

$$$$
Suprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.5329 12.745 0 0
M  V30 2 C -1.5329 11.205 0 0
M  V30 3 C -2.8665 10.435 0 0
M  V30 4 O -4.2002 11.205 0 0
M  V30 5 O -2.8665 8.895 0 0
M  V30 6 C -0.1992 10.435 0 0
M  V30 7 C 1.1345 11.205 0 0
M  V30 8 C 2.4682 10.435 0 0
M  V30 9 C 2.4682 8.895 0 0
M  V30 10 C 1.1345 8.125 0 0
M  V30 11 C -0.1992 8.895 0 0
M  V30 12 C 3.8019 8.125 0 0
M  V30 13 O 5.1355 8.895 0 0
M  V30 14 C 3.8019 6.585 0 0
M  V30 15 C 5.0477 5.6798 0 0
M  V30 16 C 4.5719 4.2152 0 0
M  V30 17 C 3.0319 4.2152 0 0
M  V30 18 S 2.556 5.6798 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 9 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996507

>  <MW>
260.051

>  <MW (desalted)>
260.308

>  <ClogP>
2.538

>  <logS>
-3.854

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
4

>  <Action on targets>
Allosteric Modulator

>  <Activity coefficients and valu>
pEC50  8.94

>  <CAS>
40828-46-4

>  <Description>
Suprofen is an ibuprofen-type anti-inflammatory analgesic and antipyretic. Suprofen is a dual COX-1/COX-2 inhibitor, it binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response.

>  <EBC_ID>
EBC-07778

>  <IUPAC Name>
2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid

>  <Main Tar all refs>
Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345

>  <Main tar all>
MC3 receptor pX=8.94

$$$$
Rose bengale (base)
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 0.4285 2.6041 0 0
M  V30 4 C 2.6674 4.62 0 0
M  V30 5 C 2.6674 6.16 0 0
M  V30 6 Cl 1.3337 6.93 0 0
M  V30 7 C 4.001 6.93 0 0
M  V30 8 Cl 4.001 8.47 0 0
M  V30 9 C 5.3347 6.16 0 0
M  V30 10 Cl 6.6684 6.93 0 0
M  V30 11 C 5.3347 4.62 0 0
M  V30 12 Cl 6.6684 3.85 0 0
M  V30 13 C 4.001 3.85 0 0
M  V30 14 C 4.001 2.31 0 0
M  V30 15 C 5.3347 1.54 0 0
M  V30 16 C 6.6684 2.31 0 0
M  V30 17 C 8.0021 1.54 0 0
M  V30 18 I 9.3358 2.31 0 0
M  V30 19 C 8.0021 -0 0 0
M  V30 20 O 9.3358 -0.77 0 0
M  V30 21 C 6.6684 -0.77 0 0
M  V30 22 I 6.6684 -2.31 0 0
M  V30 23 C 5.3347 0 0 0
M  V30 24 O 4.001 -0.77 0 0
M  V30 25 C 2.6674 0 0 0
M  V30 26 C 1.3337 -0.77 0 0
M  V30 27 I 1.3337 -2.31 0 0
M  V30 28 C -0 0 0 0
M  V30 29 O -1.3337 -0.77 0 0
M  V30 30 C 0 1.54 0 0
M  V30 31 I -1.3337 2.31 0 0
M  V30 32 C 1.3337 2.31 0 0
M  V30 33 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 4 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 2 15 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 30 31
M  V30 33 2 30 32
M  V30 34 1 32 33
M  V30 35 2 14 33
M  V30 36 1 25 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417819564

>  <MW>
973.673

>  <MW (desalted)>
973.673

>  <ClogP>
9.694

>  <logS>
-8.956

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
83.83

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 19 nM | IC50 = 2.4E-08 M | Ki (inhibition constant) = 64 nM | IC50 = 0.25 ?M

>  <CAS>
152-74-9

>  <Description>
Rose bengal is a pink stain derived as an analogue of fluorescein. Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells. It is also used in laboratory settings, including the preparation of Foraminifera for microscopic analysis and suppression of bacterial growth in several microbiological media.

>  <EBC_ID>
EBC-27510

>  <IUPAC Name>
2,3,4,5-tetrachloro-6-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-yl)benzoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem., 2010, vol. 18, # 18, p. 6922 - 6933 | Biol. Pharm. Bull., 2008, vol. 31, # 3, p. 357 - 362 | Bioorg. Med. Chem., 2010, vol. 18, # 18, p. 6922 - 6933 | ChemMedChem, 2012, vol. 7, # 4, p. 571 - 577

>  <Main tar all>
Vesicular glutamate transporter 1 pX=7.72 | CYP19A1 pX=7.62 | VMAT pX=7.19 | Seca ATPase pX=6.6

$$$$
Etoposide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 48 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.5902 -11.3128 0 0
M  V30 2 O 3.5902 -9.7728 0 0
M  V30 3 C 4.9239 -9.0028 0 0
M  V30 4 C 4.9239 -7.4628 0 0
M  V30 5 C 6.2576 -6.6928 0 0
M  V30 6 C 7.5913 -7.4628 0 0
M  V30 7 C 7.5913 -9.0028 0 0
M  V30 8 O 8.925 -9.7728 0 0
M  V30 9 C 8.925 -11.3128 0 0
M  V30 10 C 6.2576 -9.7728 0 0
M  V30 11 O 6.2576 -11.3128 0 0
M  V30 12 C 6.2576 -5.1528 0 0 CFG=1
M  V30 13 C 4.9239 -4.3828 0 0 CFG=2
M  V30 14 C 4.9239 -2.8428 0 0 CFG=2
M  V30 15 C 3.4593 -2.3669 0 0
M  V30 16 O 2.5541 -3.6128 0 0
M  V30 17 C 3.4593 -4.8587 0 0
M  V30 18 O 2.9834 -6.3233 0 0
M  V30 19 C 6.2576 -2.0728 0 0 CFG=2
M  V30 20 O 6.2576 -0.5328 0 0
M  V30 21 C 7.5913 0.2372 0 0 CFG=2
M  V30 22 O 8.925 -0.5328 0 0
M  V30 23 C 10.2586 0.2372 0 0 CFG=2
M  V30 24 C 11.5923 -0.5328 0 0
M  V30 25 O 12.926 0.2372 0 0
M  V30 26 C 12.926 1.7772 0 0 CFG=1
M  V30 27 C 14.2597 2.5472 0 0
M  V30 28 O 11.5923 2.5472 0 0
M  V30 29 C 10.2586 1.7772 0 0 CFG=1
M  V30 30 C 8.925 2.5472 0 0 CFG=2
M  V30 31 O 8.925 4.0872 0 0
M  V30 32 C 7.5913 1.7772 0 0 CFG=1
M  V30 33 O 6.2576 2.5472 0 0
M  V30 34 C 7.5913 -2.8428 0 0
M  V30 35 C 8.925 -2.0728 0 0
M  V30 36 C 10.2586 -2.8428 0 0
M  V30 37 O 11.7233 -2.3669 0 0
M  V30 38 C 12.6285 -3.6128 0 0
M  V30 39 O 11.7233 -4.8587 0 0
M  V30 40 C 10.2586 -4.3828 0 0
M  V30 41 C 8.925 -5.1528 0 0
M  V30 42 C 7.5913 -4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 12 5 CFG=1
M  V30 13 1 13 12
M  V30 14 1 13 14
M  V30 15 1 14 15 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 13 17 CFG=1
M  V30 19 2 17 18
M  V30 20 1 14 19
M  V30 21 1 19 20 CFG=3
M  V30 22 1 21 20 CFG=1
M  V30 23 1 21 22
M  V30 24 1 23 22 CFG=1
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 26 27 CFG=3
M  V30 29 1 26 28
M  V30 30 1 29 28 CFG=3
M  V30 31 1 29 23
M  V30 32 1 29 30
M  V30 33 1 30 31 CFG=1
M  V30 34 1 30 32
M  V30 35 1 32 21
M  V30 36 1 32 33 CFG=3
M  V30 37 1 19 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 36 40
M  V30 45 2 40 41
M  V30 46 1 41 42
M  V30 47 1 12 42
M  V30 48 2 34 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1304065033

>  <MW>
588.184

>  <MW (desalted)>
588.557

>  <ClogP>
0.03

>  <logS>
-3.401

>  <HBD>
3

>  <HBA>
12

>  <TPSA>
160.83

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  90.64 pg/ml | IC50 = 3.5 nM

>  <CAS>
33419-42-0

>  <Description>
Etoposide is a podophyllotoxin derivative used to treat testicular and small cell lung tumors.

>  <EBC_ID>
EBC-11154

>  <IUPAC Name>
(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one

>  <Main Tar all refs>
Bioorg. Chem., 2021, vol. 110 | J. Med. Chem., 2013, vol. 56, # 20, p. 8008 - 8018

>  <Main tar all>
DNA topoisomerase II pX=9.81 | ABCB1 pX=8.46

$$$$
Benazepril hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 5.9533 0 0
M  V30 3 C 4.4 4.4133 0 0
M  V30 4 O 5.7337 3.6433 0 0
M  V30 5 C 5.7337 2.1033 0 0
M  V30 6 O 4.4 1.3333 0 0
M  V30 7 C 7.0674 1.3333 0 0 CFG=2
M  V30 8 C 8.401 2.1033 0 0
M  V30 9 C 8.401 3.6433 0 0
M  V30 10 C 9.7347 4.4133 0 0
M  V30 11 C 9.7347 5.9533 0 0
M  V30 12 C 11.0684 6.7233 0 0
M  V30 13 C 12.4021 5.9533 0 0
M  V30 14 C 12.4021 4.4133 0 0
M  V30 15 C 11.0684 3.6433 0 0
M  V30 16 N 7.0674 -0.2067 0 0
M  V30 17 C 8.401 -0.9767 0 0 CFG=1
M  V30 18 C 9.6734 -0.1092 0 0
M  V30 19 C 11.145 -0.5631 0 0
M  V30 20 C 11.7077 -1.9967 0 0
M  V30 21 C 13.2477 -1.9967 0 0
M  V30 22 C 14.0177 -3.3303 0 0
M  V30 23 C 13.2477 -4.664 0 0
M  V30 24 C 11.7077 -4.664 0 0
M  V30 25 C 10.9377 -3.3303 0 0
M  V30 26 N 9.4149 -3.5599 0 0
M  V30 27 C 8.9609 -5.0314 0 0
M  V30 28 C 10.0084 -6.1603 0 0
M  V30 29 O 9.5545 -7.6319 0 0
M  V30 30 O 11.5098 -5.8177 0 0
M  V30 31 C 8.286 -2.5124 0 0
M  V30 32 O 6.8524 -3.075 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 7 5
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 10 15
M  V30 15 1 7 16 CFG=3
M  V30 16 1 17 16 CFG=1
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 20 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 26 31
M  V30 32 1 17 31
M  V30 33 2 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801846

>  <MW>
460.176

>  <MW (desalted)>
424.49

>  <ClogP>
1.824

>  <logS>
-5.182

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
95.94

>  <RotBonds>
10

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
inhibition percentage  44.8 %

>  <CAS>
86541-74-4

>  <Description>
Benazepril is an ACE inhibitor prodrug used to treat hypertension.

>  <EBC_ID>
EBC-11216

>  <IUPAC Name>
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid hydrochloride

>  <Main Tar all refs>
Pharm. Res., 2019, vol. 36, # 9

>  <Main tar all>
Kv7.1 pX=4.91

$$$$
Argatroban hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 C 7.301 7.678 0 0
M  V30 3 C 7.301 6.138 0 0 CFG=2
M  V30 4 C 8.6347 5.368 0 0
M  V30 5 C 8.6347 3.828 0 0
M  V30 6 N 7.301 3.058 0 0
M  V30 7 C 5.9674 3.828 0 0 CFG=2
M  V30 8 C 5.9674 5.368 0 0
M  V30 9 C 4.6337 3.058 0 0
M  V30 10 O 3.3 3.828 0 0
M  V30 11 O 4.6337 1.518 0 0
M  V30 12 C 7.301 1.518 0 0
M  V30 13 O 5.9674 0.748 0 0
M  V30 14 C 8.6347 0.748 0 0 CFG=2
M  V30 15 C 9.9684 1.518 0 0
M  V30 16 C 11.3021 0.748 0 0
M  V30 17 C 12.6358 1.518 0 0
M  V30 18 N 13.9694 0.748 0 0
M  V30 19 C 15.3031 1.518 0 0
M  V30 20 N 15.3031 3.058 0 0
M  V30 21 N 16.6368 0.748 0 0
M  V30 22 N 8.6347 -0.792 0 0
M  V30 23 S 9.9684 -1.562 0 0
M  V30 24 O 9.1984 -2.8957 0 0
M  V30 25 O 10.7384 -0.2283 0 0
M  V30 26 C 11.3021 -2.332 0 0
M  V30 27 C 12.6358 -1.562 0 0
M  V30 28 C 13.9694 -2.332 0 0
M  V30 29 C 13.9694 -3.872 0 0
M  V30 30 C 12.6358 -4.642 0 0
M  V30 31 C 12.6358 -6.182 0 0
M  V30 32 C 11.3021 -6.952 0 0
M  V30 33 C 11.3021 -8.492 0 0
M  V30 34 C 9.9684 -6.182 0 0
M  V30 35 N 9.9684 -4.642 0 0
M  V30 36 C 11.3021 -3.872 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 7 6
M  V30 6 1 7 8
M  V30 7 1 3 8
M  V30 8 1 7 9 CFG=1
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 12
M  V30 12 2 12 13
M  V30 13 1 14 12
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 14 22 CFG=3
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 2 23 25
M  V30 25 1 23 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 2 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 32 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 2 26 36
M  V30 37 1 30 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3014475009

>  <MW>
526.257

>  <MW (desalted)>
508.634

>  <ClogP>
-0.569

>  <logS>
-3.788

>  <HBD>
6

>  <HBA>
9

>  <TPSA>
177.71

>  <RotBonds>
8

>  <CAS>
141396-28-3

>  <Description>
Argatroban is a synthetic direct thrombin inhibitor.

>  <EBC_ID>
EBC-28059

>  <IUPAC Name>
(2R,4R)-1-[(2S)-5-carbamimidamido-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl]-4-methylpiperidine-2-carboxylic acid hydrate

$$$$
Bazedoxifene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.6497 -4.0133 0 0
M  V30 2 C 2.1256 -2.5487 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 C -0.3196 -1.3028 0 0
M  V30 5 C -1.0896 -2.6365 0 0
M  V30 6 C -2.6296 -2.6365 0 0
M  V30 7 C -3.3996 -1.3028 0 0
M  V30 8 O -4.9396 -1.3028 0 0
M  V30 9 C -2.6296 0.0309 0 0
M  V30 10 C -1.0896 0.0309 0 0
M  V30 11 N 2.1256 -0.0569 0 0
M  V30 12 C 1.6497 1.4077 0 0
M  V30 13 C 2.6802 2.5521 0 0
M  V30 14 C 2.2043 4.0168 0 0
M  V30 15 C 3.2348 5.1612 0 0
M  V30 16 C 4.7411 4.841 0 0
M  V30 17 O 5.7716 5.9855 0 0
M  V30 18 C 7.2779 5.6653 0 0
M  V30 19 C 8.3084 6.8097 0 0
M  V30 20 N 9.8147 6.4895 0 0
M  V30 21 C 10.7568 7.7078 0 0
M  V30 22 C 12.2966 7.7308 0 0
M  V30 23 C 13.2747 6.5413 0 0
M  V30 24 C 12.9545 5.035 0 0
M  V30 25 C 11.5772 4.3461 0 0
M  V30 26 C 10.1798 4.9934 0 0
M  V30 27 C 5.217 3.3764 0 0
M  V30 28 C 4.1865 2.2319 0 0
M  V30 29 C 3.5902 -0.5328 0 0
M  V30 30 C 4.9239 0.2372 0 0
M  V30 31 C 6.2576 -0.5328 0 0
M  V30 32 C 6.2576 -2.0728 0 0
M  V30 33 O 7.5913 -2.8428 0 0
M  V30 34 C 4.9239 -2.8428 0 0
M  V30 35 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 20 26
M  V30 28 2 16 27
M  V30 29 1 27 28
M  V30 30 2 13 28
M  V30 31 1 11 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 2 32 34
M  V30 37 1 34 35
M  V30 38 1 2 35
M  V30 39 2 29 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588063492

>  <MW>
470.603

>  <MW (desalted)>
470.603

>  <ClogP>
7.148

>  <logS>
-5.363

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
57.86

>  <RotBonds>
7

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
Protein degradation percentage Active

>  <CAS>
198481-32-2

>  <Description>
Bazedoxifene is an indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. It is used to treat moderate to severe vasomotor symptoms in menopause and osteoporosis alone or in combination with conjugated estrogens.

>  <EBC_ID>
EBC-27177

>  <IUPAC Name>
1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol

>  <Main Tar all refs>
Breast Cancer Res. Treat., 2020, vol. 180, # 3, p. 635 - 646

>  <Main tar all>
nuclear estrogen receptor pX=12.0

$$$$
Vardenafil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.3325 -5.7982 0 0
M  V30 2 C 0.1434 -4.3335 0 0
M  V30 3 C 1.6497 -4.0133 0 0
M  V30 4 C 2.1256 -2.5487 0 0
M  V30 5 N 1.2204 -1.3028 0 0
M  V30 6 C 2.1256 -0.0569 0 0
M  V30 7 C 1.6497 1.4077 0 0
M  V30 8 C 3.5902 -0.5328 0 0
M  V30 9 C 4.9239 0.2372 0 0
M  V30 10 O 4.9239 1.7772 0 0
M  V30 11 N 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 N 4.9239 -2.8428 0 0
M  V30 14 N 3.5902 -2.0728 0 0
M  V30 15 C 7.5913 -2.8428 0 0
M  V30 16 C 8.925 -2.0728 0 0
M  V30 17 C 10.2586 -2.8428 0 0
M  V30 18 C 10.2586 -4.3828 0 0
M  V30 19 C 8.925 -5.1528 0 0
M  V30 20 C 7.5913 -4.3828 0 0
M  V30 21 O 6.2576 -5.1528 0 0
M  V30 22 C 6.2576 -6.6928 0 0
M  V30 23 C 4.9239 -7.4628 0 0
M  V30 24 S 11.5923 -2.0728 0 0
M  V30 25 O 12.3623 -3.4065 0 0
M  V30 26 O 10.8223 -0.7391 0 0
M  V30 27 N 12.926 -1.3028 0 0
M  V30 28 C 12.926 0.2372 0 0
M  V30 29 C 14.2597 1.0072 0 0
M  V30 30 N 15.5934 0.2372 0 0
M  V30 31 C 16.927 1.0072 0 0
M  V30 32 C 16.927 2.5472 0 0
M  V30 33 C 15.5934 -1.3028 0 0
M  V30 34 C 14.2597 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 4 14
M  V30 15 1 8 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 17 24
M  V30 27 2 24 25
M  V30 28 2 24 26
M  V30 29 1 24 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 30 33
M  V30 36 1 33 34
M  V30 37 1 27 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038957

>  <MW>
488.603

>  <MW (desalted)>
488.603

>  <ClogP>
1.797

>  <logS>
-4.176

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
109.13

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.029 nM

>  <CAS>
224785-90-4

>  <Description>
Vardenafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction.

>  <EBC_ID>
EBC-11313

>  <IUPAC Name>
2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one

>  <Main Tar all refs>
ChemMedChem, 2017, vol. 12, # 7, p. 487 - 501

>  <Main tar all>
phosphodiesterase 5A pX=10.5

$$$$
Tenofovir alafenamide fumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 42 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -6.9663 -7.4637 0 0
M  V30 2 C -5.46 -7.1435 0 0
M  V30 3 C -4.4295 -8.2879 0 0
M  V30 4 O -4.9841 -5.6789 0 0
M  V30 5 C -3.4777 -5.3587 0 0
M  V30 6 O -2.4473 -6.5031 0 0
M  V30 7 C -3.0018 -3.8941 0 0 CFG=2
M  V30 8 C -4.0323 -2.7496 0 0
M  V30 9 N -1.4955 -3.5739 0 0
M  V30 10 P -1.0196 -2.1092 0 0 CFG=2
M  V30 11 O 0.445 -2.5851 0 0
M  V30 12 C -0.5437 -0.6446 0 0
M  V30 13 O 0.9626 -0.3244 0 0
M  V30 14 C 1.4385 1.1402 0 0 CFG=2
M  V30 15 C 0.4081 2.2846 0 0
M  V30 16 C 2.9449 1.4604 0 0
M  V30 17 N 3.4208 2.925 0 0
M  V30 18 C 2.5156 4.1709 0 0
M  V30 19 N 3.4208 5.4168 0 0
M  V30 20 C 4.8854 4.9409 0 0
M  V30 21 C 6.2191 5.7109 0 0
M  V30 22 N 6.2191 7.2509 0 0
M  V30 23 N 7.5527 4.9409 0 0
M  V30 24 C 7.5527 3.4009 0 0
M  V30 25 N 6.2191 2.6309 0 0
M  V30 26 C 4.8854 3.4009 0 0
M  V30 27 O -2.4842 -1.6334 0 0
M  V30 28 C -2.8044 -0.127 0 0
M  V30 29 C -4.269 0.3489 0 0
M  V30 30 C -4.5892 1.8552 0 0
M  V30 31 C -3.4448 2.8857 0 0
M  V30 32 C -1.9802 2.4098 0 0
M  V30 33 C -1.66 0.9034 0 0
M  V30 34 O 17.2327 1.3337 0 0
M  V30 35 C 15.6927 1.3337 0 0
M  V30 36 O 14.9227 2.6674 0 0
M  V30 37 C 14.9227 -0 0 0
M  V30 38 C 13.3827 -0 0 0
M  V30 39 C 12.6127 -1.3337 0 0
M  V30 40 O 13.3827 -2.6674 0 0
M  V30 41 O 11.0727 -1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=1
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=3
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 21 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 1 17 26
M  V30 27 2 20 26
M  V30 28 1 10 27 CFG=3
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 28 33
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 35 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 39 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2636644167

>  <MW>
592.205

>  <MW (desalted)>
476.466

>  <ClogP>
2.18

>  <logS>
-3.78

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
143.48

>  <RotBonds>
14

>  <CAS>
379270-38-9

>  <Description>
Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor.

>  <EBC_ID>
EBC-79035

>  <IUPAC Name>
(2E)-but-2-enedioic acid; propan-2-yl (2S)-2-{[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl]amino}propanoate

$$$$
Cisplatin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 2 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 0 0 0
M  V30 2 N 4.4 0 0 0
M  V30 3 Cl -1.54 -3.08 0 0
M  V30 4 Pt 0 -3.08 0 0
M  V30 5 Cl 1.54 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3182781436

>  <MW>
298.956

>  <MW (desalted)>
283.015

>  <ClogP>
-1.316

>  <logS>
-0.172

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.03 ?M | IC50 = 74.9 nM | IC50  0.2 ?M | IC50 = 0.73 ?M

>  <CAS>
15663-27-1

>  <Description>
Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. It is used for the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

>  <EBC_ID>
EBC-17049

>  <IUPAC Name>
dichloroplatinum diamine

>  <Main Tar all refs>
CYCLACEL PHARMACEUTICALS, INC. - EP1519932, 2007, B1 | J. Med. Chem., 2013, vol. 56, # 4, p. 1455 - 1466 | MAYO FOUNDATION - WO2011/130429, 2011, A2 | J. Med. Chem., 2010, vol. 53, # 14, p. 5144 - 5154

>  <Main tar all>
Cellular tumor antigen p53 pX=7.52 | Peroxiredoxin-5 pX=7.13 | protein kinase C iota pX=6.7 | Peripheral-type benzodiazepine receptor-associated protein 1 pX=6.14

$$$$
Piperazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 N 2.6674 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 0 0 0 0
M  V30 6 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 1 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1245537944

>  <MW>
86.084

>  <MW (desalted)>
86.136

>  <ClogP>
-1.484

>  <logS>
1.02

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
24.06

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  82 nM

>  <CAS>
110-85-0

>  <Description>
Piperazine is a GABA receptor agonist. Piperzine binds directly and selectively to muscle membrane GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm.

>  <EBC_ID>
EBC-03034

>  <IUPAC Name>
piperazine

>  <Main Tar all refs>
H. LUNDBECK A/S - US2003/105318, 2003, A1

>  <Main tar all>
TA1 receptor pX=7.09

$$$$
M-Cresol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O -1.3337 -0.77 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473820

>  <MW>
108.058

>  <MW (desalted)>
108.138

>  <ClogP>
1.974

>  <logS>
-1.46

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
pIC50  7.34  | Km (Michaelis constant)  0.24 ?M

>  <CAS>
108-39-4

>  <Description>
M-Cresol is an inhibitor of acetylcholinesterase.

>  <EBC_ID>
EBC-03069

>  <IUPAC Name>
3-methylphenol

>  <Main Tar all refs>
J. MED. CHEM., 1992, vol. 35, # 3, p. 584 - 589 | XENOBIOTICA, 1991, vol. 21, # 2, p. 171 - 177

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=7.34 |  UDP glucuronosyltransferase pX=6.62

$$$$
Amantadine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 5.7728 -2.2047 0 0
M  V30 3 C 5.7727 -0.6647 0 0
M  V30 4 C 4.4 -1.3622 0 0
M  V30 5 C 5.2389 0.113 0 0
M  V30 6 C 5.2389 1.5081 0 0
M  V30 7 C 6.6118 2.2057 0 0
M  V30 8 C 7.9849 1.5081 0 0
M  V30 9 C 7.9849 0.113 0 0
M  V30 10 C 6.6118 -0.5846 0 0
M  V30 11 C 7.1459 -1.3622 0 0
M  V30 12 C 5.7727 0.7305 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 7 12
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 3 11
M  V30 8 1 9 10
M  V30 9 1 5 10
M  V30 10 1 9 11
M  V30 11 1 8 9
M  V30 12 1 3 12
M  V30 13 1 5 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1522567174

>  <MW>
187.113

>  <MW (desalted)>
151.249

>  <ClogP>
1.995

>  <logS>
-2.84

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
26.02

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 20.25 nM | IC50  0.1 ?M | IC50  0.1 ?M | EC50  0.25 ?M | IC50  370.7 nM | IC50  553.5 nM

>  <CAS>
665-66-7

>  <Description>
Amantadine hydrochloride is an NMDA receptor antagonist. It is used for the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

>  <EBC_ID>
EBC-00003

>  <IUPAC Name>
adamantan-1-amine hydrochloride

>  <Main Tar all refs>
BIOORG. MED. CHEM. LETT., 1996, vol. 6, # 6, p. 595 - 600 | Eur. J. Med. Chem., 2016, vol. 120, p. 64 - 73 | Antiviral Res., 2017, vol. 140, p. 45 - 54 | ACS Chem. Biol., 2020, vol. 15, # 9, p. 2331 - 2337 | Microb. Pathog., 2016, vol. 91, p. 35 - 40 | Microb. Pathog., 2016, vol. 91, p. 35 - 40

>  <Main tar all>
sigma non-opioid intracellular receptor 1 pX=7.69 | M2 proton channel pX=7.0 | Matrix?M2 pX=7.0 | Matrix?protein pX=6.6 | Matrix?M2?(I28V,?N82S) pX=6.43 | Matrix?M2 pX=6.26

$$$$
Etidronate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.08 -1.54 0 0
M  V30 2 C 1.54 -1.54 0 0
M  V30 3 O 0 -1.54 0 0
M  V30 4 P 1.54 -3.08 0 0
M  V30 5 O 1.54 -4.62 0 0
M  V30 6 O 3.08 -3.08 0 0
M  V30 7 O 0 -3.08 0 0
M  V30 8 P 1.54 0 0 0
M  V30 9 O 1.54 1.54 0 0
M  V30 10 O 3.08 -0 0 0
M  V30 11 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 4 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269201561

>  <MW>
205.975

>  <MW (desalted)>
206.028

>  <ClogP>
-2.543

>  <logS>
3.401

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
135.29

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50 = 2E-07 M | IC50 = 2E-06 M | Kd (dissociation constant) = 2.4 ?M | IC50  6.3 ?M

>  <CAS>
2809-21-4

>  <Description>
Etidronate is a non-aminobisphosphonate. It shows protein tyrosine phosphatase inhibitory activity. Etidronate is indicated to treat Paget's disease of bone, as well as the treatment and prevention of heterotropic ossification after total hip replacement of spinal cord injury.

>  <EBC_ID>
EBC-02025

>  <IUPAC Name>
(1-hydroxy-1-phosphonoethyl)phosphonic acid

>  <Main Tar all refs>
Curr. Pharm. Des., 2003, vol. 9, # 32, p. 2643 - 2658 | Curr. Pharm. Des., 2003, vol. 9, # 32, p. 2643 - 2658 | Arch. Biochem. Biophys., 2011, vol. 507, # 2, p. 248 - 253 | Proc. Natl. Acad. Sci. U. S. A., 2017, vol. 114, # 31, p. E6297 - E6305

>  <Main tar all>
RTP Type S pX=6.7 | RTP Type E pX=5.7 | RTP Type A pX=5.62 | Vesicular glutamate transporter 3 pX=5.2

$$$$
N-Acetyl-L-leucine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 C 4.62 2.6674 0 0
M  V30 3 C 4.62 1.1274 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 7.2874 2.6674 0 0 CFG=2
M  V30 6 N 8.621 3.4374 0 0
M  V30 7 C 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 9 C 9.9547 1.1274 0 0
M  V30 10 C 7.2874 1.1274 0 0
M  V30 11 O 8.621 0.3574 0 0
M  V30 12 O 5.9537 0.3574 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 5 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756438860

>  <MW>
173.105

>  <MW (desalted)>
173.21

>  <ClogP>
0.859

>  <logS>
-1.531

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Substrate | Inhibitor

>  <Activity coefficients and valu>
IC50  0.7 mM | IC50  0.74 mM | Km (Michaelis constant)  3 mM | IC50  6.2 mM

>  <CAS>
1188-21-2

>  <Description>
N-Acetyl-L-leucine is an endogenous metabolite. It accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus.

>  <EBC_ID>
EBC-46236

>  <IUPAC Name>
(2S)-2-acetamido-4-methylpentanoic acid

>  <Main Tar all refs>
INTRABIO INC - WO2022/264037, 2022, A1 | INTRABIO INC - WO2022/264037, 2022, A1 | INTRABIO INC - WO2022/264037, 2022, A1 | INTRABIO INC - WO2022/264037, 2022, A1

>  <Main tar all>
Organic anion transporter 3 pX=3.15 | Peptide transporter 1 pX=3.13 | Monocarboxylate transporter 1 pX=2.52 | Organic anion transporter 1 pX=2.21

$$$$
7-Chloroquinolin-4-ol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 N 2.6674 0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 Cl 8.0021 -0 0 0
M  V30 10 C 6.6684 -2.31 0 0
M  V30 11 C 5.3347 -3.08 0 0
M  V30 12 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 2 12
M  V30 13 1 6 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255464975

>  <MW>
179.014

>  <MW (desalted)>
179.603

>  <ClogP>
3.126

>  <logS>
-2.394

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <CAS>
86-99-7

>  <Description>
An antibiotic agent, it inhibits Serratia marcescens ATCC.

>  <EBC_ID>
EBC-50114

>  <IUPAC Name>
7-chloroquinolin-4-ol

$$$$
Pivagabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.3584 0.5637 0 0
M  V30 2 C -3.0247 1.3337 0 0
M  V30 3 C -2.2547 0 0 0
M  V30 4 C -3.7947 2.6674 0 0
M  V30 5 C -1.691 2.1037 0 0
M  V30 6 O -1.691 3.6437 0 0
M  V30 7 N -0.3574 1.3337 0 0
M  V30 8 C 0.9763 2.1037 0 0
M  V30 9 C 2.31 1.3337 0 0
M  V30 10 C 3.6437 2.1037 0 0
M  V30 11 C 4.9774 1.3337 0 0
M  V30 12 O 6.311 2.1037 0 0
M  V30 13 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z85888809

>  <MW>
187.121

>  <MW (desalted)>
187.236

>  <ClogP>
0.556

>  <logS>
-0.68

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
5

>  <CAS>
69542-93-4

>  <Description>
Pivagabine has been used in trials studying the treatment of Stress and Anxiety.

>  <EBC_ID>
EBC-12535

>  <IUPAC Name>
4-(2,2-dimethylpropanamido)butanoic acid

$$$$
Menadione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 O 2.6674 1.54 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 O 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 1 2 12
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255430959

>  <MW>
172.052

>  <MW (desalted)>
172.18

>  <ClogP>
2.446

>  <logS>
-3.067

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
34.14

>  <RotBonds>
0

>  <Action on targets>
-

>  <Activity coefficients and valu>
Km (Michaelis constant) = 67 pM

>  <CAS>
58-27-5

>  <Description>
Menadione is a synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.

>  <EBC_ID>
EBC-11022

>  <IUPAC Name>
2-methyl-1,4-dihydronaphthalene-1,4-dione

>  <Main Tar all refs>
Chem.-Biol. Interact., 2009, vol. 178, # 1-3, p. 211 - 214

>  <Main tar all>
Carbonyl reductase [NADPH] 3 pX=10.2

$$$$
Methazolamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.2739 5.93 0 0
M  V30 2 C -0.2739 4.39 0 0
M  V30 3 O -1.6075 3.62 0 0
M  V30 4 N 1.0598 3.62 0 0
M  V30 5 C 1.0598 2.08 0 0
M  V30 6 S 2.3057 1.1748 0 0
M  V30 7 C 1.8298 -0.2898 0 0
M  V30 8 N 0.2898 -0.2898 0 0
M  V30 9 N -0.1861 1.1748 0 0
M  V30 10 C -1.6507 1.6507 0 0
M  V30 11 S 2.735 -1.5357 0 0
M  V30 12 O 3.6402 -2.7816 0 0
M  V30 13 O 1.4891 -2.4409 0 0
M  V30 14 N 3.9809 -0.6305 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2 CFG=2
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 9 10
M  V30 11 1 7 11
M  V30 12 2 11 12
M  V30 13 2 11 13
M  V30 14 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z728800602

>  <MW>
236.004

>  <MW (desalted)>
236.272

>  <ClogP>
0.088

>  <logS>
-1.968

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
105.19

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.1 nM | KI (concentration required for half-maximal inactivation)  2.4 nM | Ki (inhibition constant)  3.4 nM | Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  8 nM | Ki (inhibition constant)  10 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  19 nM | Ki (inhibition constant)  19 nM | Ki (inhibition constant)  19 nM | Ki (inhibition constant)  27 nM | Ki (inhibition constant)  50 nM | Ki (inhibition constant)  62 nM | Ki (inhibition constant)  65 nM | Ki (inhibition constant)  65 nM

>  <CAS>
554-57-4

>  <Description>
Methazolamide is a carbonic anhydrase inhibitor. It is used to treat open angle glaucoma and acute angle closure glaucoma.

>  <EBC_ID>
EBC-06359

>  <IUPAC Name>
N-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 971 - 976 | Bioorg. Med. Chem., 2013, vol. 21, # 15, p. 4521 - 4525 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 963 - 969 | Bioorg. Med. Chem., 2016, vol. 24, # 5, p. 1115 - 1120 | Eur. J. Med. Chem., 2000, vol. 35, # 9, p. 859 - 865 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 1149 - 1154 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 4, p. 1253 - 1259 | J. Med. Chem., 2012, vol. 55, # 7, p. 3513 - 3520 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | J. Med. Chem., 2012, vol. 55, # 7, p. 3513 - 3520 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 1149 - 1154 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 15, p. 4201 - 4207 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 15, p. 4201 - 4207 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 15, p. 4201 - 4207 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | Bioorg. Med. Chem. Lett., 2015, vol. 24, # 1, p. 240 - 244 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | J. Med. Chem., 2009, vol. 52, # 3, p. 646 - 654 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506

>  <Main tar all>
carbonic anhydrase 7 pX=8.68 | carbonic anhydrase pX=8.62 | carbonic anhydrase 12 pX=8.47 | ?-carbonic anhydrases pX=8.44 | Extracellular calcium-sensing receptor (isoform 2) pX=8.1 | carbonic anhydrase 6 pX=8.0 | ?-carbonic anhydrase pX=7.85 | Alpha carbonic anhydrase 2 pX=7.85 | carbonic anhydrase 1 pX=7.85 | carbonic anhydrase 2 pX=7.85 | carbonic anhydrase 2 pX=7.85 | carbonic anhydrase 4 pX=7.85 | ?-carbonic anhydrases pX=7.72 | carbonic anhydrase 13 pX=7.72 | carbonic anhydrase 14 pX=7.72 | carbonic anhydrase 9 pX=7.57 | carbonic anhydrase 1 pX=7.3 | Carbonic anhydrase 5B, mitochondrial pX=7.21 | carbonic anhydrase 15 pX=7.19 | carbonic anhydrase 5A pX=7.19

$$$$
D-Panthenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.2547 0 0 0
M  V30 2 C -3.0247 1.3337 0 0
M  V30 3 C -3.7947 2.6674 0 0
M  V30 4 C -4.3584 0.5637 0 0
M  V30 5 O -5.6921 1.3337 0 0
M  V30 6 C -1.691 2.1037 0 0 CFG=1
M  V30 7 O -1.691 3.6437 0 0
M  V30 8 C -0.3574 1.3337 0 0
M  V30 9 O -0.3574 -0.2063 0 0
M  V30 10 N 0.9763 2.1037 0 0
M  V30 11 C 2.31 1.3337 0 0
M  V30 12 C 3.6437 2.1037 0 0
M  V30 13 C 4.9774 1.3337 0 0
M  V30 14 O 6.311 2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 2
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269224929

>  <MW>
205.131

>  <MW (desalted)>
205.251

>  <ClogP>
-1.648

>  <logS>
0.159

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
89.79

>  <RotBonds>
6

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
81-13-0

>  <Description>
D-Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. It is used as a supplement or application to support a healthy epithelium and is also used to prevent vitamin deficiency in patients receiving total parenteral nutrition.

>  <EBC_ID>
EBC-26197

>  <IUPAC Name>
(2R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide

$$$$
Etofylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 N 2.1256 4.0887 0 0
M  V30 11 C 1.6497 5.5533 0 0
M  V30 12 C 2.6802 6.6978 0 0
M  V30 13 O 2.2043 8.1624 0 0
M  V30 14 C 3.5902 3.6128 0 0
M  V30 15 C 4.9239 4.3828 0 0
M  V30 16 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 10 14
M  V30 14 2 7 14
M  V30 15 1 14 15
M  V30 16 1 2 15
M  V30 17 2 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104493598

>  <MW>
224.091

>  <MW (desalted)>
224.217

>  <ClogP>
-0.87

>  <logS>
-0.502

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
78.67

>  <RotBonds>
2

>  <Action on targets>
Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
stimulation rate  43 % | inhibition percentage  89.4 % | Ki (inhibition constant)  17400 nM | Ki (inhibition constant) = 17400 nM | Ki (inhibition constant)  17300 nM

>  <CAS>
519-37-9

>  <Description>
Etofylline is a N-7-substituted derivative of theophylline, a smooth muscle relaxant. Etofylline is used to relieve bronchoconstriction. It may act as a phosphodiesterase inhibitor and adenosine receptor antagonist.

>  <EBC_ID>
EBC-03635

>  <IUPAC Name>
7-(2-hydroxyethyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
J. Med. Chem., 1999, vol. 42, # 14, p. 2527 - 2534 | Antiviral Res., 2019, vol. 163, p. 59 - 69 |  - WO2009/502604, 1995, A1 | GOVERNMENT OF THE UNITED STATES - WO1995/2604, 1995, A1 | J. Med. Chem., 2002, vol. 45, # 11, p. 2131 - 2138

>  <Main tar all>
Ryanodine receptor pX=5.58 | Nonstructural protein 1 pX=5.23 | A2A receptor pX=4.76 | A2A receptor pX=4.76 | Adenosine A2B receptor pX=4.76

$$$$
Clozapine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.6575 7.299 0 0
M  V30 2 N 4.3256 5.9116 0 0
M  V30 3 C 5.8613 5.7965 0 0
M  V30 4 C 6.5295 4.409 0 0
M  V30 5 N 5.662 3.1366 0 0
M  V30 6 C 4.1263 3.2517 0 0
M  V30 7 C 3.4581 4.6391 0 0
M  V30 8 C 6.3302 1.7491 0 0
M  V30 9 N 7.8702 1.7491 0 0
M  V30 10 C 8.8304 0.5451 0 0
M  V30 11 C 10.3019 0.999 0 0
M  V30 12 C 11.4308 -0.0485 0 0
M  V30 13 Cl 12.9024 0.4054 0 0
M  V30 14 C 11.0882 -1.5499 0 0
M  V30 15 C 9.6166 -2.0038 0 0
M  V30 16 C 8.4877 -0.9563 0 0
M  V30 17 N 7.1002 -1.6245 0 0
M  V30 18 C 5.7127 -0.9563 0 0
M  V30 19 C 4.5838 -2.0038 0 0
M  V30 20 C 3.1122 -1.5499 0 0
M  V30 21 C 2.7695 -0.0485 0 0
M  V30 22 C 3.8984 0.999 0 0
M  V30 23 C 5.37 0.5451 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 10 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 8 23
M  V30 26 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741982569

>  <MW>
326.823

>  <MW (desalted)>
326.823

>  <ClogP>
3.714

>  <logS>
-3.977

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
30.87

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.0377 nM | EC50  0.056 nM | Kd (dissociation constant)  0.1 nM | Kd (dissociation constant)  0.1 nM | Kd (dissociation constant)  0.14 nM | pKb  9.8  | pKi = 9.5  | Kd (dissociation constant)  0.35 nM | Kd (dissociation constant)  0.44 nM | Ki (inhibition constant)  0.5 nM | Ki (inhibition constant)  0.5 nM | pKi  9.26  | pKi  9.26  | Ki (inhibition constant) = 0.98 nM | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | Ki (inhibition constant)  1.1 nM | Ki (inhibition constant)  1.1 nM

>  <CAS>
5786-21-0

>  <Description>
Clozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the 5HT2, dopamine 2, 1 and 2 adrenergic, and H1 histaminergic receptors.

>  <EBC_ID>
EBC-00671

>  <IUPAC Name>
6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene

>  <Main Tar all refs>
THE JOHNS HOPKINS UNIVERSITY - WO2019/157083, 2019, A1 | THE JOHNS HOPKINS UNIVERSITY - WO2019/157083, 2019, A1 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | ABBVIE INC - US2010/145042, 2010, A1 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Eur. J. Pharmacol., 2007, vol. 573, # 1-3, p. 148 - 160 | Eur. J. Pharmacol., 2007, vol. 573, # 1-3, p. 148 - 160 | J. Pharmacol. Exp. Ther., 2006, vol. 317, # 2, p. 910 - 918 | J. Pharmacol. Exp. Ther., 2006, vol. 317, # 2, p. 910 - 918 | J. Med. Chem., 2001, vol. 44, # 4, p. 477 - 501 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | J. Pharmacol. Exp. Ther., 2008, vol. 324, # 2, p. 587 - 599 | J. Pharmacol. Exp. Ther., 2008, vol. 324, # 2, p. 587 - 599

>  <Main tar all>
M3Dq receptor? pX=10.4 | muscarinic acetylcholine receptor M4Di pX=10.3 | ?2-adrenoceptor pX=10.0 | ?2-adrenoceptor pX=10.0 | 5-HT7B?receptor pX=9.85 | H1 receptor pX=9.8 | 5-HT6 receptor pX=9.5 | 5-HT7A?receptor pX=9.46 | 5-HT7D?receptor pX=9.36 | ?1A-adrenoceptor pX=9.3 | ?1A-adrenoceptor pX=9.3 | 5-HT2A receptor pX=9.26 | 5-HT2A receptor pX=9.26 | M1 receptor pX=9.01 | ?1-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | ?1B-adrenoceptor pX=9.0 | 5-HT2A receptor pX=9.0 | 5-HT2B receptor pX=9.0 | 5-HT2B receptor pX=9.0 | 5-HT2B receptor pX=9.0 | ?1B-adrenoceptor pX=8.96 | ?1B-adrenoceptor pX=8.96

$$$$
Flubendazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.3996 -3.9702 0 0
M  V30 2 O -2.6296 -2.6365 0 0
M  V30 3 C -1.0896 -2.6365 0 0
M  V30 4 O -0.3196 -3.9702 0 0
M  V30 5 N -0.3196 -1.3028 0 0
M  V30 6 C 1.2204 -1.3028 0 0
M  V30 7 N 2.1256 -0.0569 0 0
M  V30 8 C 3.5902 -0.5328 0 0
M  V30 9 C 4.9239 0.2372 0 0
M  V30 10 C 6.2576 -0.5328 0 0
M  V30 11 C 6.2576 -2.0728 0 0
M  V30 12 C 4.9239 -2.8428 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 14 N 2.1256 -2.5487 0 0
M  V30 15 C 7.5913 0.2372 0 0
M  V30 16 O 7.5913 1.7772 0 0
M  V30 17 C 8.925 -0.5328 0 0
M  V30 18 C 10.2586 0.2372 0 0
M  V30 19 C 11.5923 -0.5328 0 0
M  V30 20 C 11.5923 -2.0728 0 0
M  V30 21 F 12.926 -2.8428 0 0
M  V30 22 C 10.2586 -2.8428 0 0
M  V30 23 C 8.925 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 10 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 22 23
M  V30 25 2 17 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280409

>  <MW>
313.283

>  <MW (desalted)>
313.283

>  <ClogP>
3.246

>  <logS>
-5.207

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
84.08

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
cell proliferation decrease Active   | phosphorylation level increase Active   | thermal stability increase Active   | IC90  5 ?M | inhibition percentage Active   | inhibition percentage  61.9 %

>  <CAS>
31430-15-6

>  <Description>
Flubendazole is an anthelmintic that is used to treat worm infection in humans. It has anticancer activities. Flubendazole induces p53-mediated apoptosis and arrests G2/M cell cycle.

>  <EBC_ID>
EBC-12784

>  <IUPAC Name>
methyl N-[5-(4-fluorobenzoyl)-1H-1,3-benzodiazol-2-yl]carbamate

>  <Main Tar all refs>
UNIVERSITY OF NEW SOUTH WALES - WO2021/184059, 2021, A1 | Cell Death Dis., 2022, vol. 13, # 4 | Pharmacol. Res., 2021, vol. 164 | ACS Infect. Dis., 2021 | OncoTargets Ther., 2019, vol. 12, p. 471 - 478 | PAIRNOMIX; PETROVSKI SLAVE; ANDRESEN J MICHAEL - WO2019/18119, 2019, A1

>  <Main tar all>
Transcription factor AP-1 pX=6.7 | Protein eva-1 homolog A pX=6.6 | Cellular tumor antigen p53 pX=6.3 | Tubulin beta chain pX=6.26 | Transcription factor p65 pX=6.0 | KNa1.1 pX=5.21

$$$$
Ketanserin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -5.3347 -13.86 0 0
M  V30 2 C -5.3347 -12.32 0 0
M  V30 3 C -6.6684 -11.55 0 0
M  V30 4 C -6.6684 -10.01 0 0
M  V30 5 C -5.3347 -9.24 0 0
M  V30 6 C -4.001 -10.01 0 0
M  V30 7 C -4.001 -11.55 0 0
M  V30 8 C -5.3347 -7.7 0 0
M  V30 9 O -6.6684 -6.93 0 0
M  V30 10 C -4.001 -6.93 0 0
M  V30 11 C -4.001 -5.39 0 0
M  V30 12 C -2.6674 -4.62 0 0
M  V30 13 N -1.3337 -5.39 0 0
M  V30 14 C 0 -4.62 0 0
M  V30 15 C 0 -3.08 0 0
M  V30 16 N 1.3337 -2.31 0 0
M  V30 17 C 1.3337 -0.77 0 0
M  V30 18 O 0 0 0 0
M  V30 19 N 2.6674 0 0 0
M  V30 20 C 4.001 -0.77 0 0
M  V30 21 C 5.3347 0 0 0
M  V30 22 C 6.6684 -0.77 0 0
M  V30 23 C 6.6684 -2.31 0 0
M  V30 24 C 5.3347 -3.08 0 0
M  V30 25 C 4.001 -2.31 0 0
M  V30 26 C 2.6674 -3.08 0 0
M  V30 27 O 2.6674 -4.62 0 0
M  V30 28 C -1.3337 -6.93 0 0
M  V30 29 C -2.6674 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 20 25
M  V30 27 1 25 26
M  V30 28 1 16 26
M  V30 29 2 26 27
M  V30 30 1 13 28
M  V30 31 1 28 29
M  V30 32 1 10 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216887910

>  <MW>
395.427

>  <MW (desalted)>
395.427

>  <ClogP>
3.003

>  <logS>
-4.73

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
69.72

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.006 nM | Ki (inhibition constant) = 0.06 nM | Ki (inhibition constant) = 0.2 nM

>  <CAS>
74050-98-9

>  <Description>
Ketanserin is a specific 5-hydroxytryptamine receptor 2a (5-HT2A) serotonin receptor antagonist. It is used as an antihypertensive drug.

>  <EBC_ID>
EBC-08725

>  <IUPAC Name>
3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione

>  <Main Tar all refs>
J. Cardiovasc. Pharmacol., 2008, vol. 51, # 2, p. 154 - 161 | Curr. Med. Chem., 2005, vol. 12, # 7, p. 877 - 885 | Eur. J. Med. Chem., 1999, vol. 34, # 5, p. 441 - 447

>  <Main tar all>
5-HT2A receptor pX=11.2 | D2 receptor pX=10.2 | 5-HT2A receptor pX=9.7

$$$$
Tiapride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -2.31 0 0
M  V30 2 C -5.3347 -3.08 0 0
M  V30 3 N -4.001 -2.31 0 0
M  V30 4 C -4.001 -0.77 0 0
M  V30 5 C -5.3347 -0 0 0
M  V30 6 C -2.6674 -3.08 0 0
M  V30 7 C -1.3337 -2.31 0 0
M  V30 8 N 0 -3.08 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 O 2.6674 -3.08 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 -0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 16 C 2.6674 -0 0 0
M  V30 17 O 4.001 -0.77 0 0
M  V30 18 C 4.001 -2.31 0 0
M  V30 19 S -1.3337 2.31 0 0
M  V30 20 O -2.6674 3.08 0 0
M  V30 21 O -0.5637 3.6437 0 0
M  V30 22 C -2.1037 0.9763 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 19
M  V30 20 2 19 20
M  V30 21 2 19 21
M  V30 22 1 19 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1545310764

>  <MW>
328.427

>  <MW (desalted)>
328.427

>  <ClogP>
1.297

>  <logS>
-2.119

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
75.71

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Antagonist | Inverse agonist | Inhibitor | Inhibitor | - | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  5.68 nM | Ki (inhibition constant)  14 nM | IC50  31 nM | Ki (inhibition constant)  39.5 nM | Ki (inhibition constant)  49.1 nM | Km (Michaelis constant) <= 50 nM | Km (Michaelis constant) <= 50 nM | Ki (inhibition constant)  95 nM

>  <CAS>
51012-32-9

>  <Description>
Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain. Tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.

>  <EBC_ID>
EBC-07458

>  <IUPAC Name>
N-[2-(diethylamino)ethyl]-5-methanesulfonyl-2-methoxybenzamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 1998, vol. 287, # 1, p. 167 - 186 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. NEUROCHEM., 1996, vol. 66, # 1, p. 394 - 402 | J. Pharmacol. Exp. Ther., 1998, vol. 287, # 2, p. 725 - 732 | Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287

>  <Main tar all>
D4.4 receptor pX=8.25 | D4.2 receptor pX=7.85 | D2S receptor pX=7.51 | D2L receptor pX=7.4 | D2 receptor pX=7.31 | ?2 pX=7.3 | sigma non-opioid intracellular receptor 1 pX=7.3 | D3 receptor pX=7.02

$$$$
Imatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.6705 -10.01 0 0
M  V30 2 N 14.6705 -11.55 0 0
M  V30 3 C 16.0041 -12.32 0 0
M  V30 4 C 16.0041 -13.86 0 0
M  V30 5 N 14.6705 -14.63 0 0
M  V30 6 C 14.6705 -16.17 0 0
M  V30 7 C 13.3368 -16.94 0 0
M  V30 8 C 13.3368 -18.48 0 0
M  V30 9 C 12.0031 -19.25 0 0
M  V30 10 C 10.6694 -18.48 0 0
M  V30 11 C 10.6694 -16.94 0 0
M  V30 12 C 12.0031 -16.17 0 0
M  V30 13 C 9.3358 -19.25 0 0
M  V30 14 O 9.3358 -20.79 0 0
M  V30 15 N 8.0021 -18.48 0 0
M  V30 16 C 6.6684 -19.25 0 0
M  V30 17 C 6.6684 -20.79 0 0
M  V30 18 C 5.3347 -21.56 0 0
M  V30 19 C 4.001 -20.79 0 0
M  V30 20 C 2.6674 -21.56 0 0
M  V30 21 C 4.001 -19.25 0 0
M  V30 22 N 2.6674 -18.48 0 0
M  V30 23 C 1.3337 -19.25 0 0
M  V30 24 N 1.3337 -20.79 0 0
M  V30 25 C -0 -21.56 0 0
M  V30 26 C -1.3337 -20.79 0 0
M  V30 27 C -1.3337 -19.25 0 0
M  V30 28 N -0 -18.48 0 0
M  V30 29 C -2.6674 -18.48 0 0
M  V30 30 C -4.001 -19.25 0 0
M  V30 31 C -5.3347 -18.48 0 0
M  V30 32 C -5.3347 -16.94 0 0
M  V30 33 N -4.001 -16.17 0 0
M  V30 34 C -2.6674 -16.94 0 0
M  V30 35 C 5.3347 -18.48 0 0
M  V30 36 C 13.3368 -13.86 0 0
M  V30 37 C 13.3368 -12.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 10 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 23 28
M  V30 30 1 27 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 29 34
M  V30 37 1 21 35
M  V30 38 2 16 35
M  V30 39 1 5 36
M  V30 40 1 36 37
M  V30 41 1 2 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546624232

>  <MW>
493.603

>  <MW (desalted)>
493.603

>  <ClogP>
4.529

>  <logS>
-4.92

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
86.28

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4 pM | IC50 = 0.03 nM | IC50 = 0.038 nM | IC50 = 0.05 nM | IC50  0.06 nM | IC50 = 0.1 nM

>  <CAS>
152459-95-5

>  <Description>
Imatinib is an oral chemotherapy medication used to treat cancer. It is a tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

>  <EBC_ID>
EBC-06061

>  <IUPAC Name>
N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide

>  <Main Tar all refs>
BRISTOL-MYERS SQUIBB CO - WO2007/53452, 2007, A1 | Annu. Rep. Med. Chem., 1996, vol. 31, p. 151 - 160 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600 | Pharmaceuticals, 2021, vol. 14, # 1, p. 1 - 21 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600

>  <Main tar all>
FIP1L1-PDGFR-alpha pX=11.4 | epidermal growth factor receptor pX=10.5 | Tyrosine-protein kinase ABL pX=10.4 | platelet derived growth factor receptor alpha pX=10.3 | erb-b2 receptor tyrosine kinase 2 pX=10.2 | Mast/stem cell growth factor receptor Kit pX=10.0

$$$$
Azelastine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -5.6002 0 0
M  V30 3 N 5.2675 -4.3278 0 0
M  V30 4 C 4.4975 -2.9941 0 0
M  V30 5 C 5.0601 -1.5606 0 0
M  V30 6 C 6.5317 -1.1067 0 0
M  V30 7 C 7.8041 -1.9742 0 0
M  V30 8 C 7.9192 -3.5099 0 0
M  V30 9 C 6.7903 -4.5573 0 0
M  V30 10 N 9.1378 -1.2042 0 0
M  V30 11 N 9.1378 0.3358 0 0
M  V30 12 C 10.4715 1.1058 0 0
M  V30 13 C 10.4715 2.6458 0 0
M  V30 14 C 11.8052 3.4158 0 0
M  V30 15 C 11.8052 4.9558 0 0
M  V30 16 C 13.1388 5.7258 0 0
M  V30 17 C 14.4725 4.9558 0 0
M  V30 18 Cl 15.8062 5.7258 0 0
M  V30 19 C 14.4725 3.4158 0 0
M  V30 20 C 13.1388 2.6458 0 0
M  V30 21 C 11.8052 0.3358 0 0
M  V30 22 C 13.1388 1.1058 0 0
M  V30 23 C 14.4725 0.3358 0 0
M  V30 24 C 14.4725 -1.2042 0 0
M  V30 25 C 13.1388 -1.9742 0 0
M  V30 26 C 11.8052 -1.2042 0 0
M  V30 27 C 10.4715 -1.9742 0 0
M  V30 28 O 10.4715 -3.5142 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 3 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 19 20
M  V30 20 2 14 20
M  V30 21 1 12 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 21 26
M  V30 28 1 26 27
M  V30 29 1 10 27
M  V30 30 2 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2074910255

>  <MW>
418.359

>  <MW (desalted)>
381.898

>  <ClogP>
4.008

>  <logS>
-4.846

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
35.91

>  <RotBonds>
3

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
pA2  9.7

>  <CAS>
79307-93-0

>  <Description>
Azelastine is primarily a selective antagonist of histamine H1-receptors, with a lesser affinity for H2-receptors. It is used intranasally to treat allergic and vasomotor rhinitis and in an ophthalmic solution to treat allergic conjunctivitis.

>  <EBC_ID>
EBC-11202

>  <IUPAC Name>
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)-1,2-dihydrophthalazin-1-one hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2011, vol. 54, # 7, p. 2183 - 2195

>  <Main tar all>
H1 receptor pX=9.7

$$$$
Caramiphen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.7387 -4.3189 0 0
M  V30 2 C -6.4051 -5.0889 0 0
M  V30 3 N -5.0714 -4.3189 0 0
M  V30 4 C -5.0714 -2.7789 0 0
M  V30 5 C -3.7377 -2.0089 0 0
M  V30 6 C -3.7377 -5.0889 0 0
M  V30 7 C -2.404 -4.3189 0 0
M  V30 8 O -1.0704 -5.0889 0 0
M  V30 9 C 0.2633 -4.3189 0 0
M  V30 10 O 0.2633 -2.7789 0 0
M  V30 11 C 1.597 -5.0889 0 0
M  V30 12 C 3.0616 -5.5647 0 0
M  V30 13 C 3.0616 -7.1047 0 0
M  V30 14 C 1.597 -7.5806 0 0
M  V30 15 C 0.6918 -6.3347 0 0
M  V30 16 C 2.2234 -3.682 0 0
M  V30 17 C 1.3182 -2.4361 0 0
M  V30 18 C 1.9446 -1.0292 0 0
M  V30 19 C 3.4761 -0.8683 0 0
M  V30 20 C 4.3813 -2.1142 0 0
M  V30 21 C 3.7549 -3.521 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 11 15
M  V30 16 1 11 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z252849348

>  <MW>
289.412

>  <MW (desalted)>
289.412

>  <ClogP>
4.639

>  <logS>
-3.442

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
29.54

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.2 nM | IC50  4 nM | Ki (inhibition constant)  7.2 nM | Ki (inhibition constant)  15.5 nM | Ki (inhibition constant) = 26 nM | Ki (inhibition constant)  31.7 nM

>  <CAS>
77-22-5

>  <Description>
Caramiphen is a cholinergic antagonist. It is used in Parkinson's disease.

>  <EBC_ID>
EBC-07616

>  <IUPAC Name>
2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate

>  <Main Tar all refs>
J. MED. CHEM., 1994, vol. 37, # 13, p. 1964 - 1970 | Eur. J. Pharmacol., 1991, vol. 193, # 1, p. 21 - 27 | EUR. J. PHARMACOL., 1993, vol. 231, # 3, p. 485 - 488 | J. Med. Chem., 2003, vol. 46, # 13, p. 2589 - 2598 | J. Med. Chem., 1998, vol. 41, # 4, p. 468 - 477 | J. MED. CHEM., 1991, vol. 34, # 10, p. 2984 - 2989

>  <Main tar all>
M1 receptor pX=8.92 | Sigma receptor pX=8.4 | M3 receptor pX=8.14 | sigma non-opioid intracellular receptor 1 pX=7.81 | GluN2D pX=7.59 | M2 receptor pX=7.5

$$$$
Digoxin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 55 62 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6627 13.6275 0 0
M  V30 2 C 7.6554 12.4502 0 0 CFG=1
M  V30 3 O 9.1714 12.7212 0 0
M  V30 4 C 10.1641 11.5439 0 0 CFG=2
M  V30 5 C 9.6409 10.0955 0 0
M  V30 6 C 8.1249 9.8245 0 0 CFG=2
M  V30 7 O 7.6017 8.3761 0 0
M  V30 8 C 7.1322 11.0018 0 0 CFG=2
M  V30 9 O 5.6162 10.7307 0 0
M  V30 10 O 11.68 11.815 0 0
M  V30 11 C 12.6728 10.6377 0 0 CFG=2
M  V30 12 C 14.1887 10.9087 0 0 CFG=1
M  V30 13 C 14.712 12.3571 0 0
M  V30 14 O 15.1815 9.7314 0 0
M  V30 15 C 14.6582 8.283 0 0 CFG=2
M  V30 16 C 13.1423 8.012 0 0
M  V30 17 C 12.1495 9.1893 0 0 CFG=2
M  V30 18 O 10.6336 8.9182 0 0
M  V30 19 O 15.651 7.1057 0 0
M  V30 20 C 15.1277 5.6573 0 0 CFG=2
M  V30 21 C 16.1205 4.48 0 0 CFG=1
M  V30 22 C 17.6364 4.7511 0 0
M  V30 23 O 15.5972 3.0316 0 0
M  V30 24 C 14.0813 2.7605 0 0 CFG=2
M  V30 25 C 13.0886 3.9378 0 0
M  V30 26 C 13.6118 5.3862 0 0 CFG=2
M  V30 27 O 12.6191 6.5636 0 0
M  V30 28 O 13.5581 1.3121 0 0
M  V30 29 C 12.0421 1.0411 0 0 CFG=1
M  V30 30 C 11.5189 -0.4073 0 0
M  V30 31 C 10.0029 -0.6784 0 0
M  V30 32 C 9.0102 0.4989 0 0 CFG=1
M  V30 33 C 8.487 -0.9495 0 0
M  V30 34 C 9.5334 1.9473 0 0 CFG=2
M  V30 35 C 8.5407 3.1246 0 0
M  V30 36 C 7.0247 2.8536 0 0
M  V30 37 C 6.5015 1.4052 0 0 CFG=2
M  V30 38 C 7.4942 0.2279 0 0 CFG=2
M  V30 39 C 6.971 -1.2205 0 0
M  V30 40 C 5.4551 -1.4916 0 0 CFG=1
M  V30 41 O 4.9318 -2.94 0 0
M  V30 42 C 4.4623 -0.3143 0 0 CFG=2
M  V30 43 C 3.7906 -1.7 0 0
M  V30 44 C 2.9231 -0.2642 0 0 CFG=2
M  V30 45 C 2.4951 1.2151 0 0
M  V30 46 C 3.7697 2.0793 0 0
M  V30 47 C 4.9856 1.1341 0 0 CFG=2
M  V30 48 O 5.3545 2.6293 0 0
M  V30 49 C 1.9779 -1.4801 0 0
M  V30 50 C 2.406 -2.9594 0 0
M  V30 51 C 1.1314 -3.8236 0 0
M  V30 52 O 1.0813 -5.3628 0 0
M  V30 53 O -0.0845 -2.8784 0 0
M  V30 54 C 0.4388 -1.43 0 0
M  V30 55 C 11.0494 2.2184 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 8 6
M  V30 8 1 8 2
M  V30 9 1 8 9 CFG=3
M  V30 10 1 4 10 CFG=1
M  V30 11 1 11 10 CFG=3
M  V30 12 1 11 12
M  V30 13 1 12 13 CFG=1
M  V30 14 1 12 14
M  V30 15 1 15 14
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 11 17
M  V30 19 1 17 18 CFG=3
M  V30 20 1 15 19 CFG=1
M  V30 21 1 20 19 CFG=3
M  V30 22 1 20 21
M  V30 23 1 21 22 CFG=1
M  V30 24 1 21 23
M  V30 25 1 24 23
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 20 26
M  V30 29 1 26 27 CFG=3
M  V30 30 1 24 28 CFG=1
M  V30 31 1 29 28 CFG=1
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 32 31
M  V30 35 1 32 33 CFG=1
M  V30 36 1 32 34
M  V30 37 1 34 35 CFG=3
M  V30 38 1 35 36
M  V30 39 1 37 36 CFG=3
M  V30 40 1 37 38
M  V30 41 1 38 32
M  V30 42 1 38 39 CFG=1
M  V30 43 1 40 39
M  V30 44 1 40 41 CFG=1
M  V30 45 1 42 40
M  V30 46 1 42 43 CFG=1
M  V30 47 1 42 44
M  V30 48 1 44 45
M  V30 49 1 45 46
M  V30 50 1 47 46
M  V30 51 1 47 37
M  V30 52 1 42 47
M  V30 53 1 47 48 CFG=1
M  V30 54 1 44 49 CFG=1
M  V30 55 2 49 50
M  V30 56 1 50 51
M  V30 57 2 51 52
M  V30 58 1 51 53
M  V30 59 1 53 54
M  V30 60 1 49 54
M  V30 61 1 34 55
M  V30 62 1 29 55
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2108699066

>  <MW>
780.938

>  <MW (desalted)>
780.938

>  <ClogP>
1.423

>  <logS>
-2.836

>  <HBD>
6

>  <HBA>
13

>  <TPSA>
203.06

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  3.47 nM | IC50  3.47 nM | inhibition percentage Active   | concentration (parameter)  7.51 ng/ml | IC50 = 10 nM | IC50  28.98 nM

>  <CAS>
20830-75-5

>  <Description>
Digoxin is a Na/K-ATPase inhibitor, with selectivity for the alpha2beta3 isoform, used in the treatment of atrial fibrillation and heart failure.

>  <EBC_ID>
EBC-08615

>  <IUPAC Name>
4-[(1R,3aS,3bR,5aR,7S,9aS,9bS,11R,11aS)-7-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a,11-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-2,5-dihydrofuran-2-one

>  <Main Tar all refs>
Br. J. Pharmacol., 2017, vol. 174, # 18, p. 3094 - 3106 | Drug Dev. Res., 2022, vol. 83, # 5, p. 1097 - 1110 | Drug Dev. Res., 2022, vol. 83, # 5, p. 1097 - 1110 | Cell Death Dis., 2018, vol. 9, # 10 | Drug Metab. Dispos., 2018, vol. 46, # 5, p. 652 - 657 | J. Med. Chem., 2006, vol. 49, # 2, p. 600 - 606 | WHISPERGENICS - WO2023/59687, 2023, A1

>  <Main tar all>
sodium:potassium-exchanging ATPase pX=9.0 | epoxide hydrolase 2 pX=8.46 | epoxide hydrolase 2 pX=8.46 | P-type sodium:potassium-exchanging transporter pX=8.4 | OATP1A2 pX=8.02 | Thyroid hormone receptor-? pX=8.0 | Baculoviral IAP repeat-containing protein 5 pX=7.54

$$$$
Finasteride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3663 -8.0839 0 0
M  V30 2 C 2.3115 -6.868 0 0
M  V30 3 C 3.5273 -7.8132 0 0
M  V30 4 C 1.0957 -5.9228 0 0
M  V30 5 N 3.2567 -5.6522 0 0
M  V30 6 C 4.7822 -5.8629 0 0
M  V30 7 O 5.3626 -7.2893 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 C 5.2994 -3.1677 0 0
M  V30 10 C 6.574 -2.3035 0 0
M  V30 11 C 7.7898 -3.2487 0 0 CFG=1
M  V30 12 C 9.3058 -2.9776 0 0 CFG=2
M  V30 13 C 9.829 -1.5293 0 0
M  V30 14 C 11.345 -1.2582 0 0
M  V30 15 C 12.3377 -2.4355 0 0 CFG=1
M  V30 16 N 13.8537 -2.1644 0 0
M  V30 17 C 14.8464 -3.3418 0 0
M  V30 18 O 16.3624 -3.0707 0 0
M  V30 19 C 14.3232 -4.7901 0 0
M  V30 20 C 12.8072 -5.0612 0 0
M  V30 21 C 11.8145 -3.8839 0 0 CFG=1
M  V30 22 C 11.2913 -5.3323 0 0
M  V30 23 C 10.2985 -4.155 0 0 CFG=1
M  V30 24 C 9.7753 -5.6034 0 0
M  V30 25 C 8.2593 -5.8744 0 0
M  V30 26 C 7.2666 -4.6971 0 0 CFG=2
M  V30 27 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13 CFG=3
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 15 16 CFG=1
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 2 19 20
M  V30 20 1 21 20
M  V30 21 1 21 15
M  V30 22 1 21 22 CFG=1
M  V30 23 1 23 21
M  V30 24 1 12 23
M  V30 25 1 23 24 CFG=1
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 26 8
M  V30 29 1 11 26
M  V30 30 1 26 27 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501475008

>  <MW>
372.544

>  <MW (desalted)>
372.544

>  <ClogP>
3.013

>  <logS>
-4.808

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 < 0.1 nM | IC50 = 0.18 nM | IC50  0.19 nM

>  <CAS>
98319-26-7

>  <Description>
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5?-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5?-dihydrotestosterone. It is used for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.

>  <EBC_ID>
EBC-07651

>  <IUPAC Name>
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-1H,2H,4aH,4bH,5H,6H,6aH,7H,8H,9H,9aH,9bH,10H,11H,11aH-indeno[5,4-f]quinoline-7-carboxamide

>  <Main Tar all refs>
J. STEROID BIOCHEM. MOL. BIOL., 1997, vol. 60, # 5-6, p. 303 - 309 | J. MED. CHEM., 1994, vol. 37, # 15, p. 2352 - 2360 | J. Steroid Biochem. Mol. Biol., 2011, vol. 127, # 3-5, p. 367 - 373

>  <Main tar all>
steroid 5 alpha-reductase 2 pX=10.0 | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 pX=9.74 | 5-Alpha reductase pX=9.72

$$$$
Maprotiline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.8537 6.4533 0 0
M  V30 3 N 4.8537 4.9133 0 0
M  V30 4 C 6.1874 4.1433 0 0
M  V30 5 C 6.1874 2.6033 0 0
M  V30 6 C 7.521 1.8333 0 0
M  V30 7 C 7.521 0.2933 0 0
M  V30 8 C 7.7777 -0.7333 0 0
M  V30 9 C 7.7777 -1.76 0 0
M  V30 10 C 7.521 -2.7867 0 0
M  V30 11 C 8.8547 -2.0167 0 0
M  V30 12 C 10.1884 -2.7867 0 0
M  V30 13 C 11.5221 -2.0167 0 0
M  V30 14 C 11.5221 -0.4767 0 0
M  V30 15 C 10.1884 0.2933 0 0
M  V30 16 C 8.8547 -0.4767 0 0
M  V30 17 C 6.1874 -0.4767 0 0
M  V30 18 C 4.8537 0.2933 0 0
M  V30 19 C 3.52 -0.4767 0 0
M  V30 20 C 3.52 -2.0167 0 0
M  V30 21 C 4.8537 -2.7867 0 0
M  V30 22 C 6.1874 -2.0167 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 2 11 16
M  V30 16 1 7 16
M  V30 17 1 7 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 10 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2311574250

>  <MW>
313.864

>  <MW (desalted)>
277.403

>  <ClogP>
4.524

>  <logS>
-4.474

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.67 nM | IC50  24.9 nM

>  <CAS>
10347-81-6

>  <Description>
Maprotiline is a selective noradrenalin re-uptake inhibitor that binds the norepinephrine transporter.  It is used to treat depressive illness, major depressive disorder, bipolar disorder, and anxiety associated with depression.

>  <EBC_ID>
EBC-09124

>  <IUPAC Name>
methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2009, vol. 19, # 2, p. 538 - 542 | Br. J. Pharmacol., 2010, vol. 159, # 1, p. 129 - 141

>  <Main tar all>
H1 receptor pX=8.78 | ?2-adrenoceptor pX=7.6

$$$$
Salicylic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954801710

>  <MW>
138.032

>  <MW (desalted)>
138.121

>  <ClogP>
2.187

>  <logS>
-1.071

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 254 pM | Ki (inhibition constant) = 1.08 nM | pIC50  8.14

>  <CAS>
69-72-7

>  <Description>
Salicylic acid directly irreversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes. Salicylic acid is an acid used to treat acne, psoriasis, calluses, corns, keratosis pilaris, and warts.

>  <EBC_ID>
EBC-03133

>  <IUPAC Name>
2-hydroxybenzoic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1 | Nat. Chem. Biol., 2005, vol. 1, # 1, p. 29 - 32 | J. Med. Chem., 1972, vol. 15, # 8, p. 787 - 789

>  <Main tar all>
COX-1  pX=9.6 | Yersiniabactin Synthetase pX=8.97 | Serum albumin pX=8.14

$$$$
Mebrophenhydramine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.4137 3.4374 0 0
M  V30 2 N 2.8737 3.4374 0 0
M  V30 3 C 2.1037 4.771 0 0
M  V30 4 C 2.1037 2.1037 0 0
M  V30 5 C 0.5637 2.1037 0 0
M  V30 6 O -0.2063 0.77 0 0
M  V30 7 C -1.7463 0.77 0 0
M  V30 8 C -1.7463 2.31 0 0
M  V30 9 C -1.7463 -0.77 0 0
M  V30 10 C -0.4126 -1.54 0 0
M  V30 11 C -0.4126 -3.08 0 0
M  V30 12 C -1.7463 -3.85 0 0
M  V30 13 C -3.08 -3.08 0 0
M  V30 14 C -3.08 -1.54 0 0
M  V30 15 C -3.2863 0.77 0 0
M  V30 16 C -4.0563 -0.5637 0 0
M  V30 17 C -5.5963 -0.5637 0 0
M  V30 18 C -6.3663 0.77 0 0
M  V30 19 Br -7.9063 0.77 0 0
M  V30 20 C -5.5963 2.1037 0 0
M  V30 21 C -4.0563 2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 7 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 20 21
M  V30 22 2 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2574931930

>  <MW>
347.088

>  <MW (desalted)>
348.277

>  <ClogP>
4.714

>  <logS>
-4.157

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
6

>  <CAS>
3565-72-8

>  <Description>
Mebrophenhydramine is a monoethanolamine used as an antihistamine and anticholinergic.

>  <EBC_ID>
EBC-12125

>  <IUPAC Name>
{2-[1-(4-bromophenyl)-1-phenylethoxy]ethyl}dimethylamine

$$$$
Cytisine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.5545 3.8421 0 0
M  V30 2 C -1.4441 2.306 0 0
M  V30 3 C -2.7191 1.4424 0 0
M  V30 4 C -2.6087 -0.0937 0 0
M  V30 5 C -1.2232 -0.766 0 0
M  V30 6 C 0.0518 0.0976 0 0
M  V30 7 C 1.216 -0.9104 0 0 CFG=1
M  V30 8 C 2.752 -0.8 0 0
M  V30 9 N 3.7601 0.3642 0 0
M  V30 10 C 3.6497 1.9003 0 0
M  V30 11 C 2.4854 2.9083 0 0 CFG=2
M  V30 12 C 1.3734 1.1576 0 0
M  V30 13 C 0.9494 2.7979 0 0
M  V30 14 N -0.0587 1.6337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 7 12 CFG=1
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1203159860

>  <MW>
190.111

>  <MW (desalted)>
190.242

>  <ClogP>
0.007

>  <logS>
-0.81

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
IC50  0.05 nM | IC50  0.05 nM | Kd (dissociation constant)  0.1 nM | Ki (inhibition constant) = 0.1 nM | Ki (inhibition constant) = 0.1 nM | Ki (inhibition constant) = 0.1 nM | Ki (inhibition constant) = 0.1 nM | Ki (inhibition constant)  0.091 nM | Ki (inhibition constant)  0.122 nM | Kd (dissociation constant)  0.376 nM | Ki (inhibition constant)  0.38 nM | Kd (dissociation constant) = 0.75 nM | Ki (inhibition constant)  1.27 nM | Ki (inhibition constant)  1.27 nM | EC50  1.3 nM

>  <CAS>
485-35-8

>  <Description>
Cytisine is a partial agonist of nicotinic acetylcholine receptors (nAChRs), it inhibits current induced by acetylcholine. Cytisine has been used as a smoking cessation treatment.

>  <EBC_ID>
EBC-09113

>  <IUPAC Name>
(1R,9S)-7,11-diazatricyclo[7.3.1.0,2,7]trideca-2,4-dien-6-one

>  <Main Tar all refs>
Br. J. Pharmacol., 2010, vol. 160, # 2, p. 334 - 345 | Br. J. Pharmacol., 2010, vol. 160, # 2, p. 334 - 345 | J. PHARMACOL. EXP. THER., 1995, vol. 273, # 3, p. 1434 - 1441 | Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, # 4, p. 337 - 348 | Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, # 4, p. 337 - 348 | Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, # 4, p. 337 - 348 | Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, # 4, p. 337 - 348 | Neuropharmacology, 2003, vol. 44, # 4, p. 503 - 515 | Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7309 - 7329 | Neuropharmacology, 2003, vol. 45, # 3, p. 345 - 354 | Mol. Pharmacol., 1998, vol. 54, # 6, p. 1132 - 1139 | Curr. Top. Med. Chem., 2004, vol. 4, # 3, p. 361 - 368 | UNIVERSITY OF BRISTOL - WO2018/33742, 2018, A2 | UNIVERSITY OF BRISTOL - WO2018/33742, 2018, A2 | J. Am. Chem. Soc., 2019

>  <Main tar all>
nicotinic acetylcholine receptor ?4 subunit pX=10.3 | nicotinic acetylcholine receptor ?2 subunit pX=10.3 | nicotinic acetylcholine receptor pX=10.0 | nicotinic acetylcholine receptor ?-like 1 pX=10.0 | nicotinic acetylcholine receptor ?-like 1 pX=10.0 | nicotinic acetylcholine receptor ?1 subunit pX=10.0 | nicotinic acetylcholine receptor ?1 subunit pX=10.0 | nicotinic acetylcholine receptor ?4 subunit pX=10.0 | nicotinic acetylcholine receptor ?4 subunit pX=9.91 | Nicotinic acetylcholine receptor (Alpha 4 isoform A529) pX=9.42 | nicotinic acetylcholine receptor ?-like 2 pX=9.42 | Neuronal Nicotinic Acetylcholine Receptor pX=9.12 | nicotinic acetylcholine receptor ?4 subunit pX=8.9 | nicotinic acetylcholine receptor ?2 subunit pX=8.9 | nicotinic acetylcholine receptor ?3 subunit pX=8.89

$$$$
Medroxyprogesterone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7959 4.573 0 0
M  V30 2 C 3.3191 3.1246 0 0 CFG=1
M  V30 3 C 4.8351 2.8536 0 0
M  V30 4 C 5.3583 1.4052 0 0 CFG=1
M  V30 5 C 6.8743 1.1341 0 0 CFG=2
M  V30 6 C 8.0901 2.0793 0 0
M  V30 7 C 9.3647 1.2151 0 0
M  V30 8 C 8.9367 -0.2642 0 0 CFG=2
M  V30 9 O 8.8256 -1.8002 0 0
M  V30 10 C 10.4526 -0.5353 0 0
M  V30 11 O 10.9759 -1.9837 0 0
M  V30 12 C 11.4454 0.642 0 0
M  V30 13 C 7.3975 -0.3143 0 0 CFG=2
M  V30 14 C 8.0693 -1.7 0 0
M  V30 15 C 6.4048 -1.4916 0 0
M  V30 16 C 4.8888 -1.2205 0 0
M  V30 17 C 4.3656 0.2279 0 0 CFG=2
M  V30 18 C 2.8496 0.4989 0 0 CFG=1
M  V30 19 C 3.3729 -0.9495 0 0
M  V30 20 C 1.8569 -0.6784 0 0
M  V30 21 C 0.3409 -0.4073 0 0
M  V30 22 C -0.1823 1.0411 0 0
M  V30 23 O -1.6982 1.3121 0 0
M  V30 24 C 0.8105 2.2184 0 0
M  V30 25 C 2.3264 1.9473 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10 CFG=3
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 13 8
M  V30 13 1 5 13
M  V30 14 1 13 14 CFG=3
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 17 16 CFG=3
M  V30 18 1 4 17
M  V30 19 1 17 18
M  V30 20 1 18 19 CFG=3
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 2 24 25
M  V30 27 1 2 25
M  V30 28 1 18 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485367

>  <MW>
344.235

>  <MW (desalted)>
344.488

>  <ClogP>
3.659

>  <logS>
-4.954

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
1

>  <Action on targets>
Agonist | Opener

>  <Activity coefficients and valu>
EC50  23 nM | pEC50  6.33

>  <CAS>
520-85-4

>  <Description>
Medroxyprogesterone is a progesterone receptor agonist and a metabolite of medroxyprogesterone 17-acetate.

>  <EBC_ID>
EBC-04399

>  <IUPAC Name>
(1R,3aS,3bR,5S,9aR,9bS,11aS)-1-acetyl-1-hydroxy-5,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Steroids, 2006, vol. 71, # 9, p. 792 - 798 | Mol. Pharmacol., 2022, vol. 101, # 1, p. 56 - 67

>  <Main tar all>
Progesterone receptor pX=7.64 | CatSper1 pX=6.33

$$$$
Cefamandole nafate sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na -5.6312 5.5569 0 0 CHG=1
M  V30 2 C -3.1141 -5.1898 0 0
M  V30 3 N -4.4863 -4.4907 0 0
M  V30 4 N -5.8584 -5.1898 0 0
M  V30 5 N -6.9474 -4.1009 0 0
M  V30 6 N -6.2482 -2.7287 0 0
M  V30 7 C -4.7272 -2.9696 0 0
M  V30 8 S -3.6383 -1.8807 0 0
M  V30 9 C -4.0368 -0.3932 0 0
M  V30 10 C -2.9479 0.6958 0 0
M  V30 11 C -3.3465 2.1833 0 0
M  V30 12 N -2.2575 3.2723 0 0
M  V30 13 C -0.77 2.8737 0 0 CFG=2
M  V30 14 S -0.3714 1.3862 0 0
M  V30 15 C -1.4604 0.2972 0 0
M  V30 16 C -0.3714 4.3612 0 0 CFG=2
M  V30 17 N 0.9623 5.1312 0 0
M  V30 18 C 2.2959 4.3612 0 0
M  V30 19 O 2.2959 2.8212 0 0
M  V30 20 C 3.6296 5.1312 0 0 CFG=2
M  V30 21 O 4.9633 4.3612 0 0
M  V30 22 C 6.297 5.1312 0 0
M  V30 23 O 7.6307 4.3612 0 0
M  V30 24 C 3.6296 6.6712 0 0
M  V30 25 C 2.2959 7.4412 0 0
M  V30 26 C 2.2959 8.9812 0 0
M  V30 27 C 3.6296 9.7512 0 0
M  V30 28 C 4.9633 8.9812 0 0
M  V30 29 C 4.9633 7.4412 0 0
M  V30 30 C -1.8589 4.7598 0 0
M  V30 31 O -2.6289 6.0935 0 0
M  V30 32 C -4.834 2.5819 0 0
M  V30 33 O -5.9229 1.493 0 0
M  V30 34 O -5.2326 4.0694 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 13 12 CFG=1
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 13 16
M  V30 17 1 16 17 CFG=1
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 20 18
M  V30 21 1 20 21 CFG=1
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 20 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 24 29
M  V30 31 1 16 30
M  V30 32 1 12 30
M  V30 33 2 30 31
M  V30 34 1 11 32
M  V30 35 2 32 33
M  V30 36 1 32 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041521791

>  <MW>
512.055

>  <MW (desalted)>
490.513

>  <ClogP>
-2.923

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
159.44

>  <RotBonds>
9

>  <CAS>
42540-40-9

>  <Description>
Cefamandole nafate is a second generation cephalosporin indicated in the prevention of infections during surgery.

>  <EBC_ID>
EBC-101066

>  <IUPAC Name>
sodium (6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

$$$$
Baricitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5356 13.2107 0 0
M  V30 2 C 6.9733 12.6589 0 0
M  V30 3 S 7.2142 11.1378 0 0
M  V30 4 O 5.6932 10.8969 0 0
M  V30 5 O 8.7353 11.3787 0 0
M  V30 6 N 7.4552 9.6168 0 0
M  V30 7 C 8.701 8.7116 0 0
M  V30 8 C 7.7959 7.4657 0 0
M  V30 9 C 9.0417 6.5605 0 0
M  V30 10 C 8.8808 5.0289 0 0
M  V30 11 N 8.7198 3.4974 0 0
M  V30 12 C 6.55 8.3709 0 0
M  V30 13 N 6.8907 6.2198 0 0
M  V30 14 C 7.3666 4.7552 0 0
M  V30 15 C 6.1207 3.85 0 0
M  V30 16 C 4.8748 4.7552 0 0
M  V30 17 N 5.3507 6.2198 0 0
M  V30 18 C 6.1207 2.31 0 0
M  V30 19 N 7.4543 1.54 0 0
M  V30 20 C 7.4543 0 0 0
M  V30 21 N 6.1207 -0.77 0 0
M  V30 22 C 4.787 0 0 0
M  V30 23 N 3.3224 -0.4759 0 0
M  V30 24 C 2.4172 0.77 0 0
M  V30 25 C 3.3224 2.0159 0 0
M  V30 26 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 3 10 11
M  V30 11 1 8 12
M  V30 12 1 6 12
M  V30 13 1 8 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 13 17
M  V30 19 1 15 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 18 26
M  V30 29 1 22 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2724205326

>  <MW>
371.116

>  <MW (desalted)>
371.417

>  <ClogP>
0.372

>  <logS>
-3.588

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
120.56

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.092 nM | IC50  0.47 nM | Kd (dissociation constant)  1.3 nM

>  <CAS>
1187594-09-7

>  <Description>
Baricitinib is a Janus kinase inhibitor. It is used to treat moderate to severe rheumatoid arthritis.

>  <EBC_ID>
EBC-11468

>  <IUPAC Name>
2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile

>  <Main Tar all refs>
ST. JUDE CHILDRENS RESEARCH HOSPITAL; ST JUDE CHILDRENSS RES HOSPITAL - WO2021/22076, 2021, A1 | MERCK & CO INC - WO2018/108969, 2018, A1 | ST. JUDE CHILDRENS RESEARCH HOSPITAL; ST JUDE CHILDRENSS RES HOSPITAL - WO2021/22076, 2021, A1

>  <Main tar all>
Janus kinase 2 pX=10.0 | Janus kinase 1 pX=9.33 | tyrosine kinase 2 pX=8.89

$$$$
Orlistat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -12.1258 -0.9534 0 0
M  V30 2 C -11.058 0.1563 0 0
M  V30 3 C -9.563 -0.2136 0 0
M  V30 4 C -8.4952 0.8961 0 0
M  V30 5 C -7.0003 0.5262 0 0
M  V30 6 C -5.9325 1.6359 0 0
M  V30 7 C -4.4376 1.266 0 0
M  V30 8 C -3.3698 2.3757 0 0
M  V30 9 C -1.8749 2.0058 0 0
M  V30 10 C -0.8071 3.1155 0 0
M  V30 11 C 0.6878 2.7456 0 0
M  V30 12 C 1.7556 3.8553 0 0 CFG=1
M  V30 13 C 1.3285 5.3348 0 0
M  V30 14 C -0.1664 5.7047 0 0 CFG=2
M  V30 15 O -1.485 4.9092 0 0
M  V30 16 C -2.2806 6.2278 0 0
M  V30 17 O -3.7755 6.5977 0 0
M  V30 18 C -0.9619 7.0234 0 0 CFG=1
M  V30 19 C -0.592 8.5183 0 0
M  V30 20 C -1.7017 9.5861 0 0
M  V30 21 C -1.3318 11.081 0 0
M  V30 22 C -2.4415 12.1488 0 0
M  V30 23 C -2.0716 13.6437 0 0
M  V30 24 C -3.1813 14.7115 0 0
M  V30 25 O 3.2505 3.4854 0 0
M  V30 26 C 3.6777 2.0058 0 0
M  V30 27 O 2.6099 0.8961 0 0
M  V30 28 C 5.1726 1.6359 0 0 CFG=2
M  V30 29 C 6.2404 2.7456 0 0
M  V30 30 C 5.8132 4.2252 0 0
M  V30 31 C 4.3183 4.595 0 0
M  V30 32 C 6.881 5.3348 0 0
M  V30 33 N 5.5997 0.1563 0 0
M  V30 34 C 7.0946 -0.2136 0 0
M  V30 35 O 8.1624 0.8961 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13
M  V30 13 1 14 13 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 18 16
M  V30 18 1 14 18
M  V30 19 1 18 19 CFG=1
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 12 25 CFG=1
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 28 26
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 30 32
M  V30 33 1 28 33 CFG=3
M  V30 34 1 33 34
M  V30 35 2 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2379810072

>  <MW>
495.735

>  <MW (desalted)>
495.735

>  <ClogP>
8.609

>  <logS>
-10.182

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
81.7

>  <RotBonds>
23

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.19 ng/ml | IC50  0.7 nM | IC50  0.75 nM | IC50  0.85 nM | IC50 = 1 nM | IC50  1.2 nM | IC50  1.83 nM | IC50  3 nM | IC50 ~ 3 nM | IC50  4 nM | IC50  4.65 nM | IC50  6 nM | IC50 ~ 10 nM

>  <CAS>
96829-58-2

>  <Description>
Orlistat is a reversible inhibitor of gastrointestinal lipases indicated for weight loss and weight maintenance.

>  <EBC_ID>
EBC-11225

>  <IUPAC Name>
(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate

>  <Main Tar all refs>
Phytother. Res., 2016, vol. 30, # 2, p. 260 - 266 | Life Sci., 2021, vol. 284 | Int. J. Biol. Macromol., 2020, vol. 145, p. 620 - 633 | J. Heterocycl. Chem., 2017, vol. 54, # 3, p. 1785 - 1805 | Bioorg. Med. Chem., 2016, vol. 24, # 7, p. 1455 - 1468 | J. Lipid Res., 2016, vol. 57, # 1, p. 131 - 141 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 629 - 640 | ACS Med. Chem. Lett., 2018, vol. 9, # 12, p. 1263 - 1268 | J. Lipid Res., 2016, vol. 57, # 1, p. 131 - 141 | ACS Med. Chem. Lett., 2018, vol. 9, # 3, p. 274 - 278 | Ecotoxicol. Environ. Saf., 2020, vol. 192 | ACS Med. Chem. Lett., 2018, vol. 9, # 12, p. 1263 - 1268 | NORTHEASTERN UNIVERSITY IN BOSTON, MASSACHUSETTS - WO2013/177492, 2013, A2

>  <Main tar all>
pancreatic lipase pX=9.42 | Arylacetamide deacetylase pX=9.15 | pancreatic lipase pX=9.12 | Lipase (gene LIP) pX=9.07 | Diacylglycerol lipase ? pX=9.0 | Adipose triglyceride lipase (ATGL) pX=8.92 | Pyrethroid hydrolase Ces2a pX=8.74 | Hepatic lipase pX=8.52 | Sn1-specific diacylglycerol lipase alpha pX=8.52 | pancreatic lipase type II pX=8.4 | lipase G, endothelial type pX=8.33 | Endothelial lipase pX=8.22 | Lipoprotein lipase pX=8.0

$$$$
Eltrombopag
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.8029 -3.195 0 0
M  V30 2 C 7.8029 -4.735 0 0
M  V30 3 N 9.0488 -5.6402 0 0
M  V30 4 N 8.5729 -7.1048 0 0
M  V30 5 C 9.4781 -8.3507 0 0
M  V30 6 C 11.0096 -8.1897 0 0
M  V30 7 C 11.9148 -9.4356 0 0
M  V30 8 C 11.2885 -10.8425 0 0
M  V30 9 C 12.1936 -12.0884 0 0
M  V30 10 C 9.7569 -11.0034 0 0
M  V30 11 C 9.1305 -12.4103 0 0
M  V30 12 C 8.8517 -9.7576 0 0
M  V30 13 C 7.0329 -7.1048 0 0
M  V30 14 O 6.1277 -8.3507 0 0
M  V30 15 C 6.557 -5.6402 0 0
M  V30 16 N 5.0924 -5.1643 0 0
M  V30 17 N 3.9479 -6.1948 0 0
M  V30 18 C 2.4833 -5.7189 0 0
M  V30 19 C 1.3389 -6.7493 0 0
M  V30 20 C -0.1258 -6.2735 0 0
M  V30 21 C -0.4459 -4.7671 0 0
M  V30 22 C 0.6985 -3.7366 0 0
M  V30 23 C 2.1631 -4.2125 0 0
M  V30 24 O 3.3076 -3.1821 0 0
M  V30 25 C 0.3783 -2.2303 0 0
M  V30 26 C -1.0863 -1.7544 0 0
M  V30 27 C -1.4065 -0.2481 0 0
M  V30 28 C -0.2621 0.7824 0 0
M  V30 29 C 1.2026 0.3065 0 0
M  V30 30 C 1.5228 -1.1998 0 0
M  V30 31 C 2.347 1.337 0 0
M  V30 32 O 2.0268 2.8433 0 0
M  V30 33 O 3.8116 0.8611 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 5 12
M  V30 13 1 4 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 2 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 18 23
M  V30 26 2 23 24
M  V30 27 1 22 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 25 30
M  V30 34 1 29 31
M  V30 35 2 31 32
M  V30 36 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568748600

>  <MW>
442.164

>  <MW (desalted)>
442.467

>  <ClogP>
3.985

>  <logS>
-6.261

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
111.1

>  <RotBonds>
5

>  <CAS>
496775-61-2

>  <Description>
Eltrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia or aplastic anemia associated with various etiologies.

>  <EBC_ID>
EBC-13607

>  <IUPAC Name>
3-[(5Z)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid

$$$$
Propiolactone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.77 3.3989 0 0
M  V30 2 C 0.77 1.8589 0 0
M  V30 3 C 1.8589 0.77 0 0
M  V30 4 C 0.77 -0.3189 0 0
M  V30 5 O -0.3189 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 2 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1089877620

>  <MW>
72.021

>  <MW (desalted)>
72.063

>  <ClogP>
-1.362

>  <logS>
-0.02

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
26.3

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.0006 mM

>  <CAS>
57-57-8

>  <Description>
Propiolactone is an alkylating agent that acts through alkylation of carboxyl- and hydroxyl- groups. It is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes.

>  <EBC_ID>
EBC-26030

>  <IUPAC Name>
oxetan-2-one

>  <Main Tar all refs>
STATE UNIVERSITY SYSTEM OF FLORIDA - US2002/151582, 2002, A1

>  <Main tar all>
proteasome 20S pX=6.22

$$$$
4-Amino-n-butyric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.3574 1.3337 0 0
M  V30 2 C 0.9763 2.1037 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 C 3.6437 2.1037 0 0
M  V30 5 C 4.9774 1.3337 0 0
M  V30 6 O 6.311 2.1037 0 0
M  V30 7 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104475620

>  <MW>
103.063

>  <MW (desalted)>
103.12

>  <ClogP>
-2.771

>  <logS>
0.76

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
3

>  <Action on targets>
Allosteric Modulator | Allosteric Modulator | Allosteric Modulator | Agonist | Inhibitor | Modulator | Inhibitor | Inhibitor | - | Activator | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
stimulation rate  175 % | stimulation rate  175 % | stimulation rate  175 % | inhibition rate Active   | Ki (inhibition constant) = 2.8 nM | EC50 = 3.28 nM | IC50 ~ 3.5 nM | Ki (inhibition constant)  4.4 nM | Kd (dissociation constant)  6 nM | EC50  7 nM | EC50  7 nM | pKi  8.06  | pKi  8.06  | pIC50  8.06026  | pIC50  8.06026  | IC50  15 nM | EC50  16.7 nM | EC50  16.7 nM | EC50  16.7 nM

>  <CAS>
56-12-2

>  <Description>
4-amino-n-butyric acid is a stimulator of GABA receptors.

>  <EBC_ID>
EBC-03052

>  <IUPAC Name>
4-aminobutanoic acid

>  <Main Tar all refs>
J. Biol. Chem., 2000, vol. 275, # 19, p. 14198 - 14204 | J. Biol. Chem., 2000, vol. 275, # 19, p. 14198 - 14204 | J. Biol. Chem., 2000, vol. 275, # 19, p. 14198 - 14204 | MERTIVA AB - WO2019/164446, 2019, A1 | MERCK & CO INC - WO1995/11894, 1995, A1 | J. Med. Chem., 2013, vol. 56, # 9, p. 3620 - 3635 | Eur. J. Pharmacol., 2011, vol. 650, # 1, p. 94 - 101 | J. Med. Chem., 2022, vol. 65, # 14, p. 9735 - 9749 | J. NEUROCHEM., 1982, vol. 38, # 4, p. 1123 - 1129 | Mol. Pharmacol., 2014, vol. 86, # 6, p. 647 - 656 | Mol. Pharmacol., 2014, vol. 86, # 6, p. 647 - 656 | Mol. Pharmacol., 1997, vol. 52, # 6, p. 1150 - 1156 | Mol. Pharmacol., 1997, vol. 52, # 6, p. 1150 - 1156 | JOHNSON & JOHNSON INC - WO2005/26208, 2005, A2 | JOHNSON & JOHNSON INC - WO2005/26208, 2005, A2 | J. Med. Chem., 2021, vol. 64, # 19, p. 14175 - 14191 | MERCK & CO INC - US6555341, 2003, B1 | MERCK & CO INC - US6555341, 2003, B1 | MERCK & CO INC - US6555341, 2003, B1

>  <Main tar all>
GABAA receptor ?1 subunit pX=9.28 | GABAA receptor ?2 subunit pX=9.28 | GABAA receptor ?2 subunit pX=9.28 | GABA receptor pX=9.0 | GABAA receptor pX=8.55 | GPCR family 3, GABA-B receptor pX=8.48 | GABAA receptor pX=8.46 | Kallikrein 1-related peptidase b5 pX=8.36 | GABAA receptor pX=8.22 | GABAA receptor ?4 subunit pX=8.15 | GABAA receptor ? subunit pX=8.15 | GABAA receptor ?5 subunit pX=8.06 | GABAA receptor ?3 subunit pX=8.06 | GABAB1a pX=8.06 | GABAB2 pX=8.06 | 4-aminobutyrate transaminase pX=7.82 | GABAA receptor ?2 subunit pX=7.78 | GABAA receptor ?1 subunit pX=7.78 | GABAA receptor ?1 subunit pX=7.78

$$$$
Betaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.77 4.001 0 0
M  V30 2 N 1.54 2.6674 0 0 CHG=1
M  V30 3 C 0.2063 1.8974 0 0
M  V30 4 C 2.8737 3.4374 0 0
M  V30 5 C 2.31 1.3337 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 O 2.31 -1.3337 0 0
M  V30 8 O 0 0 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289798098

>  <MW>
117.079

>  <MW (desalted)>
118.154

>  <ClogP>
-8.173

>  <logS>
0.468

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
40.13

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Agonist | Agonist | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  16.41 ?M | EC50  25 ?M | EC50  41 ?M | IC50  96 ?M | Km (Michaelis constant) = 138.5 ?M | Km (Michaelis constant) = 0.17 mM | IC50 = 206 ?M | IC50 = 206 ?M | IC50 = 206 ?M | inhibition percentage  87 % | inhibition percentage  87 % | inhibition percentage  59.5 % | IC50  41.9 ?g/ml | IC50 = 398 ?M

>  <CAS>
107-43-7

>  <Description>
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. It is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels.

>  <EBC_ID>
EBC-26047

>  <IUPAC Name>
2-(trimethylazaniumyl)acetate

>  <Main Tar all refs>
PLoS ONE, 2022, vol. 17, # 3 March | Mol. Pharmacol., 2015, vol. 87, # 1, p. 96 - 102 | Mol. Pharmacol., 2015, vol. 87, # 1, p. 96 - 102 | JOSEPH FOURIER UNIVERSITY; UNIVERSITY OF POITIERS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - WO2005/39589, 2005, A2 | Biochem. J., 2003, vol. 370, # 3, p. 945 - 952 | Chem.-Biol. Interact., 2009, vol. 177, # 3, p. 234 - 241 | H. LUNDBECK A/S - US5766848, 1998, A | H. LUNDBECK A/S - US5712148, 1998, A | H. LUNDBECK A/S - US5712148, 1998, A | Arch. Biochem. Biophys., 1999, vol. 364, # 1, p. 99 - 106 | Arch. Biochem. Biophys., 1999, vol. 364, # 1, p. 99 - 106 | Pharm. Res., 2009, vol. 26, # 8, p. 1890 - 1900 | Front. Pharmacol., 2020, vol. 11 | H. LUNDBECK A/S - US5766848, 1998, A

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=4.79 | nicotinic acetylcholine receptor pX=4.6 | Ligand-Gated Ion Channel pX=4.39 | CFTR pX=4.02 | betaine-homocysteine S-methyltransferase pX=3.86 | SIT1 pX=3.77 | BGT1 pX=3.69 | GAT pX=3.69 | Glycine N-acyltransferase pX=3.69 | OCT pX=3.52 | Plexin-A2 pX=3.52 | Organic cation/carnitine transporter 2 pX=3.47 | Beta-lactamase NDM-1 pX=3.45 | Vesicular glutamate transporter 1 pX=3.4

$$$$
Benzoic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127480

>  <MW>
122.037

>  <MW (desalted)>
122.121

>  <ClogP>
1.885

>  <logS>
-1.5

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
pIC50  6.61  | pIC50  6.61  | Ki (inhibition constant)  0.98 ?M | Kd (dissociation constant)  2.3 ?M | Km (Michaelis constant) = 7 ?M | Ki (inhibition constant)  7.12 ?M

>  <CAS>
65-85-0

>  <Description>
Benzoic acid is an antimicrobial food additive. It is conjugated to GLYCINE in the liver and excreted as hippuric acid. As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.

>  <EBC_ID>
EBC-04017

>  <IUPAC Name>
Benzoic acid

>  <Main Tar all refs>
J. Med. Chem., 1972, vol. 15, # 8, p. 787 - 789 | J. Med. Chem., 1972, vol. 15, # 8, p. 787 - 789 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 485 - 495 | J. Med. Chem., 2013, vol. 56, # 9, p. 3710 - 3724 | Biochem. J., 2001, vol. 357, # 1, p. 283 - 288 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 485 - 495

>  <Main tar all>
Albumin pX=6.61 | Serum albumin pX=6.61 | carbonic anhydrase 14 pX=6.01 | D-amino-acid oxidase pX=5.64 | Acyl-CoA Synthetase Medium-Chain pX=5.15 | carbonic anhydrase 5A pX=5.15

$$$$
L-Aspartic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.6437 3.6437 0 0
M  V30 2 C 3.6437 2.1037 0 0 CFG=1
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 C 0.9763 2.1037 0 0
M  V30 5 O -0.3574 1.3337 0 0
M  V30 6 O 0.9763 3.6437 0 0
M  V30 7 C 4.9774 1.3337 0 0
M  V30 8 O 6.311 2.1037 0 0
M  V30 9 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 2 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z995084132

>  <MW>
133.038

>  <MW (desalted)>
133.103

>  <ClogP>
-2.412

>  <logS>
0.35

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
100.62

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.1 ?M | Km (Michaelis constant) = 0.97 ?M | Ki (inhibition constant) > 1 ?M | Ki (inhibition constant) > 1 ?M | Ki (inhibition constant) > 1 ?M | IC50 = 1.18 ?M | IC50  1.638 ?M | Km (Michaelis constant) = 1.73 ?M | Ki (inhibition constant) = 2 ?M

>  <CAS>
56-84-8

>  <Description>
L-Aspartic acid is an amino acid commonly found as a component in total parenteral nutrition. It serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. It can also promote energy production via its metabolism in the Krebs cycle.

>  <EBC_ID>
EBC-03203

>  <IUPAC Name>
(2S)-2-aminobutanedioic acid

>  <Main Tar all refs>
Br. J. Pharmacol., 1988, vol. 95, # 3, p. 932 - 938 | OREGON HEALTH & SCIENCE UNIVERSITY - US5912171, 1999, A | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, vol. 362, # 6, p. 546 - 554 | Curr. Med. Chem., 2011, vol. 18, # 36, p. 5483 - 5506 | J. MED. CHEM., 1992, vol. 35, # 24, p. 4608 - 4612 | J. Biol. Chem., 2011, vol. 286, # 48, p. 41381 - 41390 | Curr. Pharm. Des., 2003, vol. 9, # 8, p. 599 - 625

>  <Main tar all>
NMDA receptor pX=7.0 | Excitatory amino acid transporter 4 pX=6.01 | mGlu6 receptor pX=6.0 | mGlu7a receptor pX=6.0 | mGlu8a receptor pX=6.0 | GluN2D pX=5.93 | GluN2C pX=5.79 | Excitatory amino acid transporter pX=5.76 | kainate selective glutamate receptor pX=5.7

$$$$
Gimeracil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 N 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201624655

>  <MW>
144.993

>  <MW (desalted)>
145.544

>  <ClogP>
-0.163

>  <logS>
-1.205

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
0

>  <CAS>
103766-25-2

>  <Description>
Gimeracil is used as an adjunct to antineoplastic therapy. It functions by reversibly blocking the enzyme dihydropyrimidine dehydrogenase, which is involved in the degradation of 5-FU 1.

>  <EBC_ID>
EBC-17025

>  <IUPAC Name>
5-chloro-4-hydroxy-1,2-dihydropyridin-2-one

$$$$
Pyridoxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 N 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 O 2.6674 -3.08 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C -1.3337 -0.77 0 0
M  V30 10 O -2.6674 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 5 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 11
M  V30 11 2 2 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z382721012

>  <MW>
169.074

>  <MW (desalted)>
169.178

>  <ClogP>
-0.345

>  <logS>
0.87

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
73.58

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | - | -

>  <Activity coefficients and valu>
inhibition percentage  40 % | Km (Michaelis constant) = 0.043 mM | Km (Michaelis constant) = 0.18 mM

>  <CAS>
65-23-6

>  <Description>
Pyridoxine is a 4-methanol form of vitamin B6 that is converted to pyridoxal 5?-phosphate, the active form of vitamin B6 and an important cofactor for metabolism. It has been used in cell culture media as a precursor to pyridoxal 5?-phosphate. Pyridoxine is indicated for the treatment of vitamin B6 deficiency and for the prophylaxis of Isoniazid-induced peripheral neuropathy.

>  <EBC_ID>
EBC-04089

>  <IUPAC Name>
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol

>  <Main Tar all refs>
Toxicol. Vitro, 2017, vol. 44, p. 206 - 212 | J. Biol. Chem., 1969, vol. 244, # 10, p. 2577 - 2584 | J. Biol. Chem., 1986, vol. 261, # 32, p. 15102 - 15105

>  <Main tar all>
Probable alanine aminotransferase pX=5.12 | Pyridoxine 4-Dehydrogenase pX=4.37 | pyridoxine 5-dehydrogenase pX=3.74

$$$$
Synephrine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 4.5558 0 0
M  V30 3 N 5.7337 3.7858 0 0
M  V30 4 C 5.7337 2.2458 0 0
M  V30 5 C 7.0674 1.4758 0 0
M  V30 6 O 8.401 2.2458 0 0
M  V30 7 C 7.0674 -0.0642 0 0
M  V30 8 C 8.401 -0.8342 0 0
M  V30 9 C 8.401 -2.3742 0 0
M  V30 10 C 7.0674 -3.1442 0 0
M  V30 11 O 7.0674 -4.6842 0 0
M  V30 12 C 5.7337 -2.3742 0 0
M  V30 13 C 5.7337 -0.8342 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 10 12
M  V30 11 1 12 13
M  V30 12 2 7 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977143

>  <MW>
203.071

>  <MW (desalted)>
167.205

>  <ClogP>
-0.088

>  <logS>
-1.011

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
52.49

>  <RotBonds>
3

>  <CAS>
5985-28-4

>  <Description>
Synephrine is naturally occurring alkaloid with vasoconstrictor and metabolic activities. It is an ?-adrenergic and ?-adrenergic agonist. Synephrine also has binding affinity towards insect neuronal octopamine OA3 receptor.

>  <EBC_ID>
EBC-152216

>  <IUPAC Name>
4-[1-hydroxy-2-(methylamino)ethyl]phenol hydrochloride

$$$$
Sulfaguanidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 7.7 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 N 1.3337 5.39 0 0
M  V30 4 S 1.3337 3.85 0 0
M  V30 5 O -0.2063 3.85 0 0
M  V30 6 O 2.8737 3.85 0 0
M  V30 7 C 1.3337 2.31 0 0
M  V30 8 C 2.6674 1.54 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 N 1.3337 -2.31 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 N -1.3337 5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275534804

>  <MW>
214.052

>  <MW (desalted)>
214.245

>  <ClogP>
-2.128

>  <logS>
-1.371

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
124.56

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 95 nM | Ki (inhibition constant) = 1350 nM | Ki (inhibition constant) = 1350 nM

>  <CAS>
57-67-0

>  <Description>
Sulphaguanidine is a thrombin inhibitor.

>  <EBC_ID>
EBC-02027

>  <IUPAC Name>
N''-(4-aminobenzenesulfonyl)guanidine

>  <Main Tar all refs>
J. Med. Chem., 2000, vol. 43, # 9, p. 1793 - 1806 | J. Med. Chem., 2000, vol. 43, # 9, p. 1793 - 1806 | J. Med. Chem., 2000, vol. 43, # 9, p. 1793 - 1806

>  <Main tar all>
coagulation factor II, thrombin pX=7.02 | serine protease 1 pX=5.87 | serine protease 1 pX=5.87

$$$$
Carbaryl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -7.7 0 0
M  V30 2 N 1.3337 -6.93 0 0
M  V30 3 C 1.3337 -5.39 0 0
M  V30 4 O 0 -4.62 0 0
M  V30 5 O 2.6674 -4.62 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 C 5.3347 0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 C 5.3347 -3.08 0 0
M  V30 15 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 6 15
M  V30 16 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z90123586

>  <MW>
201.079

>  <MW (desalted)>
201.221

>  <ClogP>
2.385

>  <logS>
-3.63

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
38.33

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  2.31E-09 M | IC50  0.0031 ?M | Ki (inhibition constant) = 1.51E-08 M | IC50  9 - 13.8 ng/ml | Ki (inhibition constant)  0.07 ?M

>  <CAS>
63-25-2

>  <Description>
Incecticide. Carbaryl is a carbamate insecticide that inhibits acetylcholinesterase. Carbaryl has been used to control insects in agriculture.

>  <EBC_ID>
EBC-04127

>  <IUPAC Name>
naphthalen-1-yl N-methylcarbamate

>  <Main Tar all refs>
J. Hazard. Mater., 2022, vol. 426 | J. Enzyme Inhib. Med. Chem., 2017, vol. 32, # 1, p. 47 - 50 | Phytochemistry, 1968, vol. 7, # 6, p. 913 - 920 | J. Hazard. Mater., 2021, vol. 412 | Chem. Res. Toxicol., 2017, vol. 30, # 2, p. 574 - 582

>  <Main tar all>
anti-carbofuran monoclonal antibody (mAb) 6G pX=8.64 | carbonic anhydrase pX=8.51 | Aryl Acylamidase pX=7.82 | anti-carbaryl antibody pX=7.35 | MT2 receptor pX=7.15

$$$$
Proguanil hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 6.6129 0 0
M  V30 3 C 5.7337 5.0729 0 0
M  V30 4 C 4.4 4.3029 0 0
M  V30 5 N 7.0674 4.3029 0 0
M  V30 6 C 7.0674 2.7629 0 0
M  V30 7 N 5.7337 1.9929 0 0
M  V30 8 N 8.401 1.9929 0 0
M  V30 9 C 8.401 0.4529 0 0
M  V30 10 N 7.0674 -0.3171 0 0
M  V30 11 N 9.7347 -0.3171 0 0
M  V30 12 C 9.7347 -1.8571 0 0
M  V30 13 C 11.0684 -2.6271 0 0
M  V30 14 C 11.0684 -4.1671 0 0
M  V30 15 C 9.7347 -4.9371 0 0
M  V30 16 Cl 9.7347 -6.4771 0 0
M  V30 17 C 8.401 -4.1671 0 0
M  V30 18 C 8.401 -2.6271 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 5 3 CFG=2
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 8 6 CFG=2
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 15 17
M  V30 16 1 17 18
M  V30 17 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1558572526

>  <MW>
290.192

>  <MW (desalted)>
253.731

>  <ClogP>
1.16

>  <logS>
-3.25

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
88.79

>  <RotBonds>
2

>  <CAS>
637-32-1

>  <Description>
Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.

>  <EBC_ID>
EBC-13182

>  <IUPAC Name>
1-({amino[(4-chlorophenyl)amino]methylidene}amino)-N'-(propan-2-yl)methanimidamide hydrochloride

$$$$
Levodropropizine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 2.31 0 0
M  V30 2 C 0 1.54 0 0
M  V30 3 C 0 0 0 0 CFG=1
M  V30 4 O -1.3337 -0.77 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 N 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 2.6674 -4.62 0 0
M  V30 9 N 1.3337 -5.39 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 C 0 -3.08 0 0
M  V30 12 C 1.3337 -6.93 0 0
M  V30 13 C 2.6674 -7.7 0 0
M  V30 14 C 2.6674 -9.24 0 0
M  V30 15 C 1.3337 -10.01 0 0
M  V30 16 C 0 -9.24 0 0
M  V30 17 C 0 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z301111588

>  <MW>
236.152

>  <MW (desalted)>
236.31

>  <ClogP>
1.335

>  <logS>
-1.027

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
46.94

>  <RotBonds>
4

>  <CAS>
99291-25-5

>  <Description>
Levodropropizine is a histamine receptor inhibitor. It is a peripherally-acting antitussive agent.

>  <EBC_ID>
EBC-03709

>  <IUPAC Name>
(2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol

$$$$
Carprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.9295 1.2741 0 0
M  V30 2 C 8.8991 0.1296 0 0
M  V30 3 C 9.375 -1.335 0 0
M  V30 4 O 10.8813 -1.6552 0 0
M  V30 5 O 8.3445 -2.4794 0 0
M  V30 6 C 7.3927 0.4498 0 0
M  V30 7 C 6.9168 1.9144 0 0
M  V30 8 C 5.4105 2.2346 0 0
M  V30 9 C 4.38 1.0902 0 0
M  V30 10 C 4.8559 -0.3744 0 0
M  V30 11 C 6.3623 -0.6946 0 0
M  V30 12 N 3.61 -1.2796 0 0
M  V30 13 C 2.3641 -0.3744 0 0
M  V30 14 C 0.8578 -0.6946 0 0
M  V30 15 C -0.1727 0.4498 0 0
M  V30 16 C 0.3032 1.9144 0 0
M  V30 17 Cl -0.7272 3.0589 0 0
M  V30 18 C 1.8096 2.2346 0 0
M  V30 19 C 2.84 1.0902 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 18 19
M  V30 20 2 13 19
M  V30 21 1 9 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530425063

>  <MW>
273.056

>  <MW (desalted)>
273.714

>  <ClogP>
3.978

>  <logS>
-4.87

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
53.09

>  <RotBonds>
2

>  <Action on targets>
Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
pEC50  8.93 | IC50 = 0.027 ?M

>  <CAS>
53716-49-7

>  <Description>
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen inhibits canine COX2.

>  <EBC_ID>
EBC-03775

>  <IUPAC Name>
2-(6-chloro-9H-carbazol-2-yl)propanoic acid

>  <Main Tar all refs>
Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | Biochem. J., 2004, vol. 377, # 3, p. 675 - 684

>  <Main tar all>
MC3 receptor pX=8.93 | COX-2  pX=7.57

$$$$
Teriflunomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 8.47 0 0
M  V30 2 C 1.3337 6.93 0 0
M  V30 3 C 0 6.16 0 0
M  V30 4 C -1.3337 6.93 0 0
M  V30 5 N -2.6674 7.7 0 0
M  V30 6 C 0 4.62 0 0
M  V30 7 O -1.3337 3.85 0 0
M  V30 8 N 1.3337 3.85 0 0
M  V30 9 C 1.3337 2.31 0 0
M  V30 10 C 2.6674 1.54 0 0
M  V30 11 C 2.6674 -0 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 C 0 0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 15 C 1.3337 -2.31 0 0
M  V30 16 F 1.3337 -3.85 0 0
M  V30 17 F -0.2063 -2.31 0 0
M  V30 18 F 2.8737 -2.31 0 0
M  V30 19 O 2.6674 6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 3 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 19 1 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1878131003

>  <MW>
270.062

>  <MW (desalted)>
270.207

>  <ClogP>
2.132

>  <logS>
-2.91

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
73.12

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  96.6 % | IC50  26 nM

>  <CAS>
163451-81-8

>  <Description>
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. Teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.

>  <EBC_ID>
EBC-03781

>  <IUPAC Name>
2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide

>  <Main Tar all refs>
Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA202992, Owner: SANOFI AVENTIS US, Number: 000, 2012 | Bioorg. Med. Chem. Lett., 2011, vol. 21, # 24, p. 7268 - 7272

>  <Main tar all>
Cytochrome P450 2C19 pX=8.98 | Dihydroorotate dehydrogenase (quinone), mitochondrial pX=7.59

$$$$
Pomalidomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 C 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 C 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 C 3.3224 -0.4759 0 0
M  V30 8 O 2.8465 -1.9405 0 0
M  V30 9 N 2.4172 0.77 0 0
M  V30 10 C 0.8772 0.77 0 0
M  V30 11 C 0.1072 -0.5637 0 0
M  V30 12 C -1.4328 -0.5637 0 0
M  V30 13 C -2.2028 0.77 0 0
M  V30 14 O -3.7428 0.77 0 0
M  V30 15 N -1.4328 2.1037 0 0
M  V30 16 C 0.1072 2.1037 0 0
M  V30 17 O 0.8772 3.4374 0 0
M  V30 18 C 3.3224 2.0159 0 0
M  V30 19 O 2.8465 3.4805 0 0
M  V30 20 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 10 16
M  V30 17 2 16 17
M  V30 18 1 9 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 6 20
M  V30 22 2 2 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269642575

>  <MW>
273.075

>  <MW (desalted)>
273.244

>  <ClogP>
-0.189

>  <logS>
-2.765

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
109.57

>  <RotBonds>
1

>  <Action on targets>
Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
induction rate Active   | IC50 = 3.9 nM | EC50  8.7 nM | IC50  9.38 nM | increase rate Active

>  <CAS>
19171-19-8

>  <Description>
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. It is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib.

>  <EBC_ID>
EBC-11137

>  <IUPAC Name>
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 13, p. 6648 - 6676 | Bioorg. Med. Chem. Lett., 1999, vol. 9, # 11, p. 1625 - 1630 | ChemMedChem, 2018, vol. 13, # 15, p. 1508 - 1512 | SHANGHAITECH UNIVERSITY - EP3778590, 2021, A1 | DANA-FARBER CANCER INSTITUTE - WO2021/67546, 2021, A1

>  <Main tar all>
Protein cereblon pX=9.0 | Tumor necrosis factor pX=8.41 | Zinc?finger?protein?Aiolos pX=8.06 | Cullin-4A pX=8.03 | zeta chain of T cell receptor associated protein kinase 70 pX=8.0

$$$$
Hydroflumethiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -3.4374 -1.7463 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -4.001 -3.85 0 0
M  V30 4 O -1.8974 -4.4137 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 N 4.001 -2.31 0 0
M  V30 12 S 2.6674 -3.08 0 0
M  V30 13 O 3.3903 -4.4397 0 0
M  V30 14 O 1.9444 -4.4397 0 0
M  V30 15 C 0 -0 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 17 C -2.6674 -0 0 0
M  V30 18 F -4.001 0.77 0 0
M  V30 19 F -3.8118 -1.0305 0 0
M  V30 20 F -1.8974 1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 2 8 15
M  V30 16 1 15 16
M  V30 17 2 5 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575271347

>  <MW>
330.991

>  <MW (desalted)>
331.292

>  <ClogP>
-0.21

>  <logS>
-2.087

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
118.36

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 305 nM | Ki (inhibition constant) = 360 nM | Ki (inhibition constant) = 412 nM | Ki (inhibition constant) = 429 nM | Ki (inhibition constant)  429 nM | Ki (inhibition constant) = 435 nM | Ki (inhibition constant) = 433 nM | Kd (dissociation constant)  470 nM | Ki (inhibition constant) = 2840 nM | Ki (inhibition constant) = 4780 nM | Ki (inhibition constant) = 8250 nM

>  <CAS>
135-09-1

>  <Description>
Hydroflumethiazide is a thiazide diuretic that also inhibits carbonic anhydrase. It is used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

>  <EBC_ID>
EBC-06827

>  <IUPAC Name>
1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | PLoS ONE, 2021, vol. 16, # 6 June | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506

>  <Main tar all>
carbonic anhydrase 12 pX=6.52 | carbonic anhydrase 14 pX=6.44 | carbonic anhydrase 9 pX=6.39 | Carbonic anhydrase 5B, mitochondrial pX=6.37 | carbonic anhydrase 3 pX=6.37 | carbonic anhydrase 2 pX=6.36 | carbonic anhydrase 7 pX=6.36 | carbonic anhydrase 13 pX=6.33 | carbonic anhydrase 1 pX=5.55 | carbonic anhydrase 4 pX=5.32 | carbonic anhydrase 6 pX=5.08

$$$$
Linezolid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -2.31 0 0
M  V30 2 C 0 -3.08 0 0
M  V30 3 O 1.3337 -2.31 0 0
M  V30 4 N 0 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 C 1.3337 -6.93 0 0 CFG=1
M  V30 7 C 2.5796 -7.8352 0 0
M  V30 8 N 2.1037 -9.2998 0 0
M  V30 9 C 0.5637 -9.2998 0 0
M  V30 10 O -0.3415 -10.5457 0 0
M  V30 11 O 0.0878 -7.8352 0 0
M  V30 12 C 3.0089 -10.5457 0 0
M  V30 13 C 4.5404 -10.3847 0 0
M  V30 14 C 5.4456 -11.6306 0 0
M  V30 15 C 4.8192 -13.0375 0 0
M  V30 16 N 5.7244 -14.2834 0 0
M  V30 17 C 7.256 -14.1224 0 0
M  V30 18 C 8.1612 -15.3683 0 0
M  V30 19 O 7.5348 -16.7751 0 0
M  V30 20 C 6.0033 -16.9361 0 0
M  V30 21 C 5.0981 -15.6902 0 0
M  V30 22 C 3.2877 -13.1984 0 0
M  V30 23 F 2.6613 -14.6053 0 0
M  V30 24 C 2.3825 -11.9526 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 23 2 15 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 2 12 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385084

>  <MW>
337.144

>  <MW (desalted)>
337.346

>  <ClogP>
0.168

>  <logS>
-3.169

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
71.11

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC90  1 ?g/ml | MIC90  1 ?g/ml | MIC90  1 ?g/ml | IC50  0.35 ?M | MIC  0.125 - 2 ?g/ml | EC50  0.42 ?M | MIC95  3.1 ?g/ml | MIC  0.5 ?g/ml | MIC  0.5 - 2 ?g/ml | MIC  0.5 - 2 ?g/ml | MIC  0.5 ?g/ml | MIC  0.5 - 16 ?g/ml | MIC <= 0.5 ?g/ml | MIC <= 0.5 ?g/ml | MIC  1.51 ?M | IC50 = 0.61 ?g/mL | MIC  0.625 ?g/ml | IC50 = 2.4 ?M | MIC  2.6 ?M | MIC  2.6 ?M | MIC  0.87 ?g/ml | MIC  2.6 ?M | MIC  1 ?g/ml | MIC  1 ?g/ml | Ki (inhibition constant)  4.3 ?M | MIC  1.75 ?g/ml | MIC  2 ?g/mL | MIC  2 mg/l | MIC  2 mg/l | Ki (inhibition constant) = 6.96 ?M

>  <CAS>
165800-03-3

>  <Description>
Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid works by inhibiting the initiation of bacterial protein synthesis.

>  <EBC_ID>
EBC-08517

>  <IUPAC Name>
N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide

>  <Main Tar all refs>
PLoS ONE, 2020, vol. 15, # 2 | PLoS ONE, 2020, vol. 15, # 2 | Antimicrob. Agents Chemother., 2023, vol. 67, # 4 | Chem. Res. Toxicol., 2021, vol. 34, # 5, p. 1348 - 1354 | Eur. J. Med. Chem., 2021, vol. 221 | J. Biol. Chem., 2021, vol. 296 | Nat. Commun., 2022, vol. 13, # 1 | Eur. J. Med. Chem., 2018, vol. 157, p. 610 - 621 | Antimicrob. Agents Chemother., 2018, vol. 62, # 6 | Antimicrob. Agents Chemother., 2018, vol. 62, # 6 | Eur. J. Med. Chem., 2018, vol. 157, p. 610 - 621 | ACS Infect. Dis., 2020, vol. 6, # 2, p. 324 - 337 | Eur. J. Med. Chem., 2019, vol. 175, p. 49 - 62 | PURDUE UNIVERSITY SYSTEM - WO2020/131980, 2020, A1 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Curr. Med. Chem., 2012, vol. 19, # 4, p. 488 - 517 | UNIVERSITY OF WASHINGTON - WO2018/237349, 2018, A1 | J. Med. Chem., 2015, vol. 58, # 7, p. 3156 - 3171 | Bioorg. Chem., 2020, vol. 102 | Bioorg. Chem., 2020, vol. 102 | Eur. J. Med. Chem., 2020, vol. 201 | Bioorg. Chem., 2020, vol. 102 | REDX PHARMA PLC - WO2017/93747, 2017, A1 | Bioorg. Chem., 2022, vol. 126 | LEGOCHEM BIOSCIENCES INC. - WO2010/36000, 2010, A2 | Bioorg. Med. Chem., 2022, vol. 54 | Antimicrob. Agents Chemother., 2013, vol. 57, # 12, p. 6131 - 6140 | J. Antibiot., 2021, vol. 74, # 12, p. 874 - 883 | ATRIVA THERAPEUTICS GMBH - WO2020/212478, 2020, A1 | FERRER INTERNACIONAL SA - EP2072514, 2009, A1

>  <Main tar all>
DNA supercoiling protein pX=6.48 | DNA topoisomerase II pX=6.48 | peptidyltransferase pX=6.48 | Monoamine oxidase B pX=6.46 | Cell division protein FtsZ pX=6.43 | SRC proto-oncogene, non-receptor tyrosine kinase pX=6.38 | Multidrug?efflux?pump?subunit?AcrB pX=6.32 | DNA topoisomerase IV subunit B pX=5.83 | DNA?gyrase subunit A pX=5.83 | DNA?gyrase subunit B pX=5.83 | DNA?gyrase subunit B (C-terminal domain) pX=5.83 | Trehalose?monomycolate?exporter?MmpL3 pX=5.83 | Undecaprenyl-diphosphatase (gene uppP) pX=5.83 | carbonic anhydrase pX=5.83 | DNA?gyrase pX=5.82 | 30S ribosomal protein pX=5.74 | methionine-tRNA ligase pX=5.73 | RNA polymerase pX=5.62 | UDP-N-acetylenolpyruvoylglucosamine reductase pX=5.59 | UDP-N-acetylenolpyruvoylglucosamine reductase (gene murB) pX=5.59 | non-proton translocating type II NADH dehydrogenase pX=5.59 | udp-n-acetylenolpyruvoylglucosamine reductase pX=5.59 | DNA topoisomerase II pX=5.53 | Transcriptional Regulatory Repressor Protein Ethr pX=5.53 | amine oxidase copper containing 3 pX=5.37 | Efflux pump NorA pX=5.28 | Exfoliative toxin B pX=5.23 | Sensor histidine kinase WalK pX=5.23 | mitogen-activated protein kinase kinase 1 pX=5.23 | Monoamine oxidase A pX=5.16

$$$$
Etofylline clofibrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 N 2.1256 4.0887 0 0
M  V30 11 C 1.6497 5.5533 0 0
M  V30 12 C 2.6802 6.6978 0 0
M  V30 13 O 2.2043 8.1624 0 0
M  V30 14 C 3.2348 9.3069 0 0
M  V30 15 O 4.7411 8.9867 0 0
M  V30 16 C 2.7589 10.7715 0 0
M  V30 17 C 4.2235 11.2474 0 0
M  V30 18 C 1.2942 10.2956 0 0
M  V30 19 O 2.283 12.2361 0 0
M  V30 20 C 3.3135 13.3805 0 0
M  V30 21 C 2.8376 14.8452 0 0
M  V30 22 C 3.868 15.9896 0 0
M  V30 23 C 5.3744 15.6694 0 0
M  V30 24 Cl 6.4048 16.8139 0 0
M  V30 25 C 5.8503 14.2048 0 0
M  V30 26 C 4.8198 13.0604 0 0
M  V30 27 C 3.5902 3.6128 0 0
M  V30 28 C 4.9239 4.3828 0 0
M  V30 29 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 23 25
M  V30 25 1 25 26
M  V30 26 2 20 26
M  V30 27 1 10 27
M  V30 28 2 7 27
M  V30 29 1 27 28
M  V30 30 1 2 28
M  V30 31 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z51093246

>  <MW>
420.847

>  <MW (desalted)>
420.847

>  <ClogP>
3

>  <logS>
-4.214

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
93.97

>  <RotBonds>
7

>  <CAS>
54504-70-0

>  <Description>
An antioxidant with ypolipidemic and antithrombotic effect.

>  <EBC_ID>
EBC-13569

>  <IUPAC Name>
2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)ethyl 2-(4-chlorophenoxy)-2-methylpropanoate

$$$$
Nisoldipine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.3124 -6.7889 0 0
M  V30 2 O -6.6684 -5.39 0 0
M  V30 3 C -5.1656 -5.2511 0 0
M  V30 4 O -3.8319 -6.0211 0 0
M  V30 5 C -5.3347 -3.08 0 0
M  V30 6 C -6.6684 -2.31 0 0
M  V30 7 C -8.0021 -3.08 0 0
M  V30 8 N -6.6684 -0.77 0 0
M  V30 9 C -5.3347 -0 0 0
M  V30 10 C -4.001 -0.77 0 0
M  V30 11 C -4.001 -2.31 0 0
M  V30 12 C -2.6674 -3.08 0 0
M  V30 13 C -1.3337 -2.31 0 0
M  V30 14 C 0 -3.08 0 0
M  V30 15 C 0 -4.62 0 0
M  V30 16 C -1.3337 -5.39 0 0
M  V30 17 C -2.6674 -4.62 0 0
M  V30 18 N -4.001 -5.39 0 0 CHG=1
M  V30 19 O -5.3347 -4.62 0 0
M  V30 20 O -4.001 -6.93 0 0 CHG=-1
M  V30 21 C -2.6674 -0 0 0
M  V30 22 O -2.6674 1.54 0 0
M  V30 23 O -1.3337 -0.77 0 0
M  V30 24 C 0 -0 0 0
M  V30 25 C 1.3337 -0.77 0 0
M  V30 26 C 2.6674 -0 0 0
M  V30 27 C 1.3337 -2.31 0 0
M  V30 28 C -5.3347 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 5 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 10 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 1 9 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z277942268

>  <MW>
388.414

>  <MW (desalted)>
388.414

>  <ClogP>
4.582

>  <logS>
-3.52

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
107.77

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) < 0.01 nM | Ki (inhibition constant) = 0.08 nM | Ki (inhibition constant) = 0.24 nM | Ki (inhibition constant) = 0.24 nM

>  <CAS>
63675-72-9

>  <Description>
Nisoldipine is a dihydropyridine calcium-channel blocker. It is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum.

>  <EBC_ID>
EBC-13348

>  <IUPAC Name>
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1982, vol. 77, # 2-3, p. 201 - 202 | Curr. Pharm. Des., 2006, vol. 12, # 4, p. 443 - 457 | Eur. J. Med. Chem., 1996, vol. 31, # 4, p. 311 - 318 | Eur. J. Med. Chem., 1996, vol. 31, # 4, p. 311 - 318

>  <Main tar all>
Cav1.1 pX=11.0 | Cav1.2 pX=10.1 | Cav1.2 pX=9.62 | Cav1.2 pX=9.62

$$$$
2,2'-Dibenzothiazyl disulfide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S -0.3196 -1.3028 0 0
M  V30 2 S -1.0896 -2.6365 0 0
M  V30 3 C -2.6296 -2.6365 0 0
M  V30 4 N -3.5348 -3.8824 0 0
M  V30 5 C -4.9994 -3.4065 0 0
M  V30 6 C -6.3331 -4.1765 0 0
M  V30 7 C -7.6668 -3.4065 0 0
M  V30 8 C -7.6668 -1.8665 0 0
M  V30 9 C -6.3331 -1.0965 0 0
M  V30 10 C -4.9994 -1.8665 0 0
M  V30 11 S -3.5348 -1.3906 0 0
M  V30 12 C 1.2204 -1.3028 0 0
M  V30 13 N 2.1256 -0.0569 0 0
M  V30 14 C 3.5902 -0.5328 0 0
M  V30 15 C 4.9239 0.2372 0 0
M  V30 16 C 6.2576 -0.5328 0 0
M  V30 17 C 6.2576 -2.0728 0 0
M  V30 18 C 4.9239 -2.8428 0 0
M  V30 19 C 3.5902 -2.0728 0 0
M  V30 20 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 3 11
M  V30 13 1 1 12
M  V30 14 2 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 22 1 19 20
M  V30 23 1 12 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56754489

>  <MW>
332.487

>  <MW (desalted)>
332.487

>  <ClogP>
4.606

>  <logS>
-7.73

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
25.78

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.098 ?M | IC50  0.16 ?M | IC50  0.31 ?M | IC50  0.379 ?M | IC50  0.625 ?M

>  <CAS>
120-78-5

>  <Description>
2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. It is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis.

>  <EBC_ID>
EBC-03858

>  <IUPAC Name>
2-(1,3-benzothiazol-2-yldisulfanyl)-1,3-benzothiazole

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 7, p. 2712 - 2717 | DOMPE' FARMACEUTICI - S.P.A.; FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - EP4011367, 2022, A1 | Eur. J. Med. Chem., 2020, vol. 203 | J. Med. Chem., 2017, vol. 60, # 6, p. 2227 - 2244 | J. Enzyme Inhib. Med. Chem., 2023, vol. 38, # 1, p. 24 - 35

>  <Main tar all>
mitogen-activated protein kinase 8 pX=7.01 | main protease pX=6.8 | Fructose-1,6-bisphosphatase 1 pX=6.51 | [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial pX=6.42 | 3C-like protease pX=6.2

$$$$
Vecuronium bromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0 CHG=-1
M  V30 2 C 7.8581 -4.2195 0 0
M  V30 3 C 8.8033 -3.0037 0 0
M  V30 4 O 10.3288 -3.2143 0 0
M  V30 5 O 8.2229 -1.5772 0 0
M  V30 6 C 9.1681 -0.3614 0 0 CFG=1
M  V30 7 C 8.7401 1.1179 0 0 CFG=2
M  V30 8 C 10.0147 1.9822 0 0
M  V30 9 C 11.2306 1.037 0 0 CFG=1
M  V30 10 C 12.7465 1.308 0 0 CFG=2
M  V30 11 C 13.2697 2.7564 0 0
M  V30 12 C 14.7857 3.0275 0 0
M  V30 13 C 15.7784 1.8502 0 0 CFG=1
M  V30 14 C 17.2944 2.1212 0 0
M  V30 15 C 18.2871 0.9439 0 0 CFG=2
M  V30 16 O 19.8031 1.215 0 0
M  V30 17 C 20.3263 2.6634 0 0
M  V30 18 O 21.8422 2.9344 0 0
M  V30 19 C 19.3336 3.8407 0 0
M  V30 20 C 17.7639 -0.5045 0 0 CFG=2
M  V30 21 C 16.2479 -0.7756 0 0
M  V30 22 C 15.2552 0.4018 0 0 CFG=1
M  V30 23 C 14.732 -1.0466 0 0
M  V30 24 C 13.7392 0.1307 0 0 CFG=1
M  V30 25 C 13.216 -1.3177 0 0
M  V30 26 C 11.7001 -1.5888 0 0
M  V30 27 C 10.7073 -0.4114 0 0 CFG=2
M  V30 28 C 10.0356 -1.7972 0 0
M  V30 29 N 18.7566 -1.6818 0 0
M  V30 30 C 20.2726 -1.4107 0 0
M  V30 31 C 21.2653 -2.5881 0 0
M  V30 32 C 20.7421 -4.0364 0 0
M  V30 33 C 19.2261 -4.3075 0 0
M  V30 34 C 18.2334 -3.1302 0 0
M  V30 35 N 7.2917 1.6411 0 0 CHG=1
M  V30 36 C 8.0585 2.9767 0 0
M  V30 37 C 7.0279 0.1239 0 0
M  V30 38 C 5.5821 -0.4063 0 0
M  V30 39 C 4.4 0.5808 0 0
M  V30 40 C 4.6638 2.098 0 0
M  V30 41 C 6.1096 2.6282 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 6 5 CFG=1
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 9 8 CFG=1
M  V30 8 1 9 10
M  V30 9 1 10 11 CFG=3
M  V30 10 1 11 12
M  V30 11 1 13 12 CFG=1
M  V30 12 1 13 14
M  V30 13 1 15 14
M  V30 14 1 15 16 CFG=3
M  V30 15 1 16 17
M  V30 16 2 17 18
M  V30 17 1 17 19
M  V30 18 1 15 20
M  V30 19 1 20 21
M  V30 20 1 22 21
M  V30 21 1 22 13
M  V30 22 1 22 23 CFG=1
M  V30 23 1 24 22
M  V30 24 1 10 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 25 26
M  V30 27 1 27 26
M  V30 28 1 6 27
M  V30 29 1 27 9
M  V30 30 1 27 28 CFG=1
M  V30 31 1 20 29 CFG=1
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 29 34
M  V30 38 1 7 35 CFG=1
M  V30 39 1 35 36
M  V30 40 1 35 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 1 35 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759894

>  <MW>
637.731

>  <MW (desalted)>
557.827

>  <ClogP>
4.334

>  <logS>
-4.55

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
55.84

>  <RotBonds>
6

>  <Action on targets>
Allosteric Modulator | Antagonist | Antagonist | Antagonist | Antagonist | Blocker

>  <Activity coefficients and valu>
inhibition percentage  88 % | IC50  0.0115 ?M | IC50  0.0115 ?M | IC50  0.0115 ?M | IC50  0.0115 ?M | IC90  0.44 ?M

>  <CAS>
50700-72-6

>  <Description>
Vecuronium is a nondepolarizing neuromuscular blocking agent used to relax muscles or as an adjunct in general anesthesia during surgical procedures.

>  <EBC_ID>
EBC-11164

>  <IUPAC Name>
1-[(1R,2S,3aS,3bR,5aS,7S,8S,9aS,9bS,11aS)-1,7-bis(acetyloxy)-9a,11a-dimethyl-8-(piperidin-1-yl)-hexadecahydro-1H-cyclopenta[a]phenanthren-2-yl]-1-methylpiperidin-1-ium bromide

>  <Main Tar all refs>
Eur. J. Pharmacol., 2007, vol. 569, # 1-2, p. 37 - 40 | Eur. J. Pharmacol., 2010, vol. 630, # 1-3, p. 29 - 33 | Eur. J. Pharmacol., 2010, vol. 630, # 1-3, p. 29 - 33 | Eur. J. Pharmacol., 2010, vol. 630, # 1-3, p. 29 - 33 | Eur. J. Pharmacol., 2010, vol. 630, # 1-3, p. 29 - 33 | Eur. J. Med. Chem., 2012, vol. 56, p. 332 - 347

>  <Main tar all>
M2 receptor pX=8.07 | nicotinic acetylcholine receptor ?1 subunit pX=7.94 | nicotinic acetylcholine receptor ?1 subunit pX=7.94 | nicotinic acetylcholine receptor ? subunit pX=7.94 | nicotinic acetylcholine receptor ? subunit pX=7.94 | nicotinic acetylcholine receptor pX=7.31

$$$$
Cinoxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -5.39 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 N 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O -1.3337 -0.77 0 0
M  V30 8 O 0 1.54 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 O 2.6674 1.54 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 O 8.133 -0.2941 0 0
M  V30 15 C 9.0382 -1.54 0 0
M  V30 16 O 8.133 -2.7859 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 C 5.3347 -3.08 0 0
M  V30 19 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 13 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 3 19
M  V30 21 2 11 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671138

>  <MW>
262.218

>  <MW (desalted)>
262.218

>  <ClogP>
1.735

>  <logS>
-2.443

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
88.43

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.32 ?M | Ki (inhibition constant) = 0.32 ?M

>  <CAS>
28657-80-9

>  <Description>
Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics. It has activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family.  It is used in urinary tract infections.

>  <EBC_ID>
EBC-07472

>  <IUPAC Name>
1-ethyl-4-oxo-1H,4H,7H-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid

>  <Main Tar all refs>
STATE UNIVERSITY SYSTEM OF FLORIDA - US2012/156212, 2012, A1 | STATE UNIVERSITY SYSTEM OF FLORIDA - US2012/156212, 2012, A1

>  <Main tar all>
Thymidylate synthase pX=6.49 | Thymidylate synthase (gene TYMS) pX=6.49

$$$$
Erythromycin ethylsuccinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 60 62 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -9.5143 -7.409 0 0
M  V30 2 C -8.0021 -7.7 0 0
M  V30 3 O -6.9939 -6.5359 0 0
M  V30 4 C -5.4817 -6.8269 0 0
M  V30 5 O -4.9776 -8.2821 0 0
M  V30 6 C -4.4735 -5.6628 0 0
M  V30 7 C -2.9612 -5.9538 0 0
M  V30 8 C -2.4572 -7.409 0 0
M  V30 9 O -3.4653 -8.5731 0 0
M  V30 10 O -0.9449 -7.7 0 0
M  V30 11 C -0.4408 -9.1552 0 0 CFG=2
M  V30 12 C -1.449 -10.3193 0 0 CFG=2
M  V30 13 C -0.9449 -11.7745 0 0
M  V30 14 C 0.5673 -12.0655 0 0 CFG=1
M  V30 15 C 1.6039 -13.2044 0 0
M  V30 16 O 0.9238 -10.9481 0 0
M  V30 17 C 1.0714 -9.4462 0 0 CFG=1
M  V30 18 O 2.0796 -8.2821 0 0
M  V30 19 C 3.5918 -8.5731 0 0 CFG=2
M  V30 20 C 3.0878 -7.1179 0 0 CFG=1
M  V30 21 C 1.5755 -6.8269 0 0
M  V30 22 C 4.0959 -5.9538 0 0 CFG=2
M  V30 23 O 3.5918 -4.4986 0 0
M  V30 24 C 4.6 -3.3345 0 0 CFG=1
M  V30 25 C 6.1123 -3.6255 0 0
M  V30 26 C 7.1204 -2.4614 0 0 CFG=1
M  V30 27 C 8.0918 -3.6564 0 0
M  V30 28 O 8.4659 -1.7123 0 0
M  V30 29 C 9.7875 -2.503 0 0
M  V30 30 C 6.6163 -1.0062 0 0 CFG=1
M  V30 31 O 7.6245 0.1579 0 0
M  V30 32 C 5.1041 -0.7152 0 0 CFG=2
M  V30 33 C 4.6 0.7399 0 0
M  V30 34 O 4.0959 -1.8793 0 0
M  V30 35 C 5.6082 -6.2448 0 0 CFG=1
M  V30 36 C 6.6163 -5.0807 0 0
M  V30 37 C 6.1123 -7.7 0 0
M  V30 38 O 5.1041 -8.8641 0 0
M  V30 39 O 7.6245 -7.991 0 0
M  V30 40 C 8.1286 -9.4462 0 0 CFG=2
M  V30 41 C 9.6408 -9.7372 0 0
M  V30 42 C 10.649 -8.5731 0 0
M  V30 43 C 7.1204 -10.6103 0 0 CFG=1
M  V30 44 C 8.641 -10.3666 0 0
M  V30 45 O 8.4419 -11.401 0 0
M  V30 46 C 7.6245 -12.0655 0 0 CFG=2
M  V30 47 O 9.1368 -12.3565 0 0
M  V30 48 C 6.6163 -13.2296 0 0 CFG=1
M  V30 49 C 7.1204 -14.6848 0 0
M  V30 50 C 5.1041 -12.9386 0 0
M  V30 51 O 4.0959 -14.1027 0 0
M  V30 52 C 4.6 -11.4834 0 0 CFG=2
M  V30 53 C 5.6082 -10.3193 0 0
M  V30 54 C 3.0878 -11.1924 0 0
M  V30 55 C 2.5837 -9.7372 0 0 CFG=2
M  V30 56 C 1.3238 -10.6229 0 0
M  V30 57 O 2.0345 -11.176 0 0
M  V30 58 N -2.9612 -10.0283 0 0
M  V30 59 C -4.2244 -9.1473 0 0
M  V30 60 C -3.9694 -11.1924 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=3
M  V30 15 1 14 16
M  V30 16 1 17 16
M  V30 17 1 11 17
M  V30 18 1 17 18 CFG=3
M  V30 19 1 19 18 CFG=1
M  V30 20 1 19 20 CFG=3
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 22 23 CFG=3
M  V30 24 1 24 23 CFG=3
M  V30 25 1 24 25
M  V30 26 1 26 25
M  V30 27 1 26 27 CFG=1
M  V30 28 1 26 28 CFG=3
M  V30 29 1 28 29
M  V30 30 1 30 26
M  V30 31 1 30 31 CFG=3
M  V30 32 1 30 32
M  V30 33 1 32 33 CFG=1
M  V30 34 1 32 34
M  V30 35 1 24 34
M  V30 36 1 22 35
M  V30 37 1 35 36 CFG=1
M  V30 38 1 35 37
M  V30 39 2 37 38
M  V30 40 1 37 39
M  V30 41 1 40 39
M  V30 42 1 40 41 CFG=3
M  V30 43 1 41 42
M  V30 44 1 43 40
M  V30 45 1 43 44 CFG=3
M  V30 46 1 43 45 CFG=1
M  V30 47 1 43 46
M  V30 48 1 46 47 CFG=3
M  V30 49 1 46 48
M  V30 50 1 48 49 CFG=1
M  V30 51 1 48 50
M  V30 52 2 50 51
M  V30 53 1 52 50
M  V30 54 1 52 53 CFG=1
M  V30 55 1 52 54
M  V30 56 1 55 54
M  V30 57 1 19 55
M  V30 58 1 55 56 CFG=3
M  V30 59 1 55 57 CFG=1
M  V30 60 1 12 58 CFG=3
M  V30 61 1 58 59
M  V30 62 1 58 60
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z608353986

>  <MW>
862.053

>  <MW (desalted)>
862.053

>  <ClogP>
3.232

>  <logS>
-3.32

>  <HBD>
4

>  <HBA>
14

>  <TPSA>
226.28

>  <RotBonds>
14

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  111.6 ?M

>  <CAS>
1264-62-6

>  <Description>
Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.

>  <EBC_ID>
EBC-08961

>  <IUPAC Name>
(2S,3R,4S,6R)-4-(dimethylamino)-2-{[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-2,10-dioxo-1-oxacyclotetradecan-6-yl]oxy}-6-methyloxan-3-yl 1-ethyl butanedioate

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=3.95

$$$$
Capecitabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -10.01 0 0
M  V30 2 C 5.3347 -9.24 0 0
M  V30 3 C 6.6684 -10.01 0 0
M  V30 4 C 8.0021 -9.24 0 0
M  V30 5 C 9.3358 -10.01 0 0
M  V30 6 O 10.6694 -9.24 0 0
M  V30 7 C 12.0031 -10.01 0 0
M  V30 8 O 12.0031 -11.55 0 0
M  V30 9 N 13.3368 -9.24 0 0
M  V30 10 C 14.6705 -10.01 0 0
M  V30 11 N 16.0041 -9.24 0 0
M  V30 12 C 17.3378 -10.01 0 0
M  V30 13 O 18.6715 -9.24 0 0
M  V30 14 N 17.3378 -11.55 0 0
M  V30 15 C 16.0041 -12.32 0 0
M  V30 16 C 14.6705 -11.55 0 0
M  V30 17 F 13.3368 -12.32 0 0
M  V30 18 C 18.6715 -12.32 0 0 CFG=2
M  V30 19 O 20.0784 -11.6936 0 0
M  V30 20 C 21.1088 -12.8381 0 0 CFG=2
M  V30 21 C 22.6404 -12.6771 0 0
M  V30 22 C 20.3388 -14.1717 0 0 CFG=1
M  V30 23 O 20.9652 -15.5786 0 0
M  V30 24 C 18.8325 -13.8516 0 0 CFG=1
M  V30 25 O 17.688 -14.882 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 10 16
M  V30 17 1 16 17
M  V30 18 1 18 14 CFG=3
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 20 21 CFG=3
M  V30 22 1 22 20
M  V30 23 1 22 23 CFG=1
M  V30 24 1 22 24
M  V30 25 1 24 18
M  V30 26 1 24 25 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480421

>  <MW>
359.35

>  <MW (desalted)>
359.35

>  <ClogP>
0.841

>  <logS>
-3.1

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
120.69

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | - | - | - | -

>  <Activity coefficients and valu>
inhibition percentage > 50 % | Km (Michaelis constant)  1 mM | Km (Michaelis constant)  1.5 mM | Km (Michaelis constant)  4 mM | Km (Michaelis constant)  4 mM

>  <CAS>
154361-50-9

>  <Description>
Capecitabine is a prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. Capecitabine is an anti-cancer chemotherapy drug, antimetabolite.

>  <EBC_ID>
EBC-07649

>  <IUPAC Name>
pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate

>  <Main Tar all refs>
Drug Metab. Dispos., 2009, vol. 37, # 5, p. 956 - 961 | J. Pharmacol. Exp. Ther., 2005, vol. 313, # 3, p. 1011 - 1016 | Drug Metab. Dispos., 2004, vol. 32, # 7, p. 762 - 767 | Drug Metab. Dispos., 2004, vol. 32, # 7, p. 762 - 767 | Drug Metab. Dispos., 2004, vol. 32, # 7, p. 762 - 767

>  <Main tar all>
carboxylesterase 1 pX=3.52 | Carboxylesterase 2 pX=3.0 | Carboxylesterase pX=2.82 | Thymidine phosphorylase pX=2.4 | cytidine deaminase pX=2.4

$$$$
Vandetanib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 O 0 -0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 C 5.3347 0 0 0
M  V30 7 N 5.3347 1.54 0 0
M  V30 8 C 6.6684 2.31 0 0
M  V30 9 C 6.6684 3.85 0 0
M  V30 10 C 8.0021 4.62 0 0
M  V30 11 C 9.3358 3.85 0 0
M  V30 12 Br 10.6694 4.62 0 0
M  V30 13 C 9.3358 2.31 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 F 8.0021 -0 0 0
M  V30 16 N 6.6684 -0.77 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 N 5.3347 -3.08 0 0
M  V30 19 C 4.001 -2.31 0 0
M  V30 20 C 2.6674 -3.08 0 0
M  V30 21 C 1.3337 -2.31 0 0
M  V30 22 O 0 -3.08 0 0
M  V30 23 C 0 -4.62 0 0
M  V30 24 C -1.3337 -5.39 0 0
M  V30 25 C -1.3337 -6.93 0 0
M  V30 26 C -2.6674 -7.7 0 0
M  V30 27 N -4.001 -6.93 0 0
M  V30 28 C -5.3347 -7.7 0 0
M  V30 29 C -4.001 -5.39 0 0
M  V30 30 C -2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 14 15
M  V30 16 2 6 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 5 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 3 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 1 29 30
M  V30 33 1 24 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2512943095

>  <MW>
475.354

>  <MW (desalted)>
475.354

>  <ClogP>
5.836

>  <logS>
-5.557

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
59.51

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | - | - | Inhibitor | - | - | - | - | - | - | - | - | - | - | - | - | Inhibitor | - | - | - | - | - | - | - | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter)  379.9 pg/ml | IC50  1.2 nM | IC50  4 nM | IC50  4 nM | Kd (dissociation constant)  4.6 nM | Kd (dissociation constant)  4.8 nM | inhibition percentage Active   | IC50 = 5 nM | Kd (dissociation constant)  5.9 nM | Kd (dissociation constant)  5.9 nM | IC50  7 nM | Kd (dissociation constant)  7.9 nM | Kd (dissociation constant)  8.7 nM | Kd (dissociation constant)  8.9 nM | Kd (dissociation constant)  9 nM | Kd (dissociation constant)  9.5 nM | Kd (dissociation constant)  9.6 nM | Kd (dissociation constant)  9.6 nM | Kd (dissociation constant)  9.5 nM | Kd (dissociation constant)  9.5 nM | Kd (dissociation constant)  9.5 nM | Kd (dissociation constant)  9.8 nM | Kd (dissociation constant)  11 nM | IC50  12 nmol/l | Kd (dissociation constant)  13 nM | Kd (dissociation constant)  14 nM | Kd (dissociation constant)  15 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  17 nM | IC50  20 nM | Kd (dissociation constant)  20 nM | IC50  19.76 nmol/l | IC50  21.4 nM

>  <CAS>
443913-73-3

>  <Description>
Vandetanib is a potent, orally active  multi-kinase inhibitor. Vandetanib have been used in the treatment of medullary thyroid cancer.

>  <EBC_ID>
EBC-07806

>  <IUPAC Name>
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

>  <Main Tar all refs>
J. Enzyme Inhib. Med. Chem., 2017, vol. 32, # 1, p. 893 - 907 | BLUEPRINT MEDICINES CORP - WO2018/17983, 2018, A1 | BLUEPRINT MEDICINES CORP - WO2018/213329, 2018, A1 | BLUEPRINT MEDICINES CORP - WO2017/79140, 2017, A1 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | GOVERNMENT OF THE UNITED STATES - WO2015/183956, 2015, A1 | Curr. Med. Chem., 2013, vol. 20, # 16, p. 2043 - 2067 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | BLUEPRINT MEDICINES CORP - WO2018/213329, 2018, A1 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | BLUEPRINT MEDICINES CORP - WO2018/213329, 2018, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Eur. J. Med. Chem., 2019, vol. 181 | CSPC PHARMACEUTICAL GROUP LIMITED - EP3181554, 2017, A1

>  <Main tar all>
kinase insert domain receptor pX=9.1 | ret proto-oncogene pX=8.92 | kinase insert domain receptor pX=8.4 | transmembrane receptor protein tyrosine kinase pX=8.4 | receptor interacting serine/threonine kinase 2 pX=8.34 | Epidermal growth factor receptor (delE746-A750) pX=8.32 | Nuclear factor erythroid 2-related factor 2 (Nrf2) pX=8.3 | epidermal growth factor receptor pX=8.3 | Epidermal growth factor receptor (G719S) pX=8.23 | Epidermal growth factor receptor (G719S) pX=8.23 | ret proto-oncogene (M918T) pX=8.15 | Epidermal growth factor receptor (L747-P753del, insS) pX=8.1 | Epidermal growth factor receptor (L858R) pX=8.06 | Epidermal growth factor receptor (L747-T751del, Sins) pX=8.05 | Tyrosine-protein?kinase?ABL1?(Y253F) phosphorylated pX=8.05 | Epidermal growth factor receptor (Del S752-I759) pX=8.02 | Epidermal growth factor receptor (G719C) pX=8.02 | Epidermal growth factor receptor (G719C) pX=8.02 | Epidermal growth factor receptor (L747-A750del, insP) pX=8.02 | Epidermal growth factor receptor (L861Q) pX=8.02 | Epidermal growth factor receptor (L861Q) pX=8.02 | Tyrosine-protein?kinase?ABL1?(H396P) phosphorylated pX=8.01 | discoidin domain receptor tyrosine kinase 1 pX=7.96 | Vascular endothelial growth factor receptor 2 (VEGFR2) pX=7.92 | Tyrosine-protein?kinase?ABL1?(E255K) phosphorylated pX=7.89 | ret proto-oncogene (M918T) pX=7.85 | Tyrosine-protein?kinase?ABL1?(M351T) pX=7.82 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=7.8 | Tyrosine-protein kinase ABL pX=7.8 | Tyrosine-protein?kinase?ABL1?(Q252H) phosphorylated pX=7.8 | LCK proto-oncogene, Src family tyrosine kinase pX=7.77 | CCDC6-Proto-oncogene tyrosine-protein kinase receptor Ret pX=7.7 | Tyrosine-protein?kinase?ABL1?(T315I)?phosphorylated pX=7.7 | epidermal growth factor receptor pX=7.7 | ret proto-oncogene (A432E) pX=7.67

$$$$
Phenyl Salicylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -3.08 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 C 4.001 -6.93 0 0
M  V30 5 C 2.6674 -7.7 0 0
M  V30 6 C 1.3337 -6.93 0 0
M  V30 7 C 1.3337 -5.39 0 0
M  V30 8 C 0 -4.62 0 0
M  V30 9 O 0 -3.08 0 0
M  V30 10 O -1.3337 -5.39 0 0
M  V30 11 C -2.6674 -4.62 0 0
M  V30 12 C -4.001 -5.39 0 0
M  V30 13 C -5.3347 -4.62 0 0
M  V30 14 C -5.3347 -3.08 0 0
M  V30 15 C -4.001 -2.31 0 0
M  V30 16 C -2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57206005

>  <MW>
214.063

>  <MW (desalted)>
214.217

>  <ClogP>
3.844

>  <logS>
-3.27

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
118-55-8

>  <Description>
Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate.

>  <EBC_ID>
EBC-14449

>  <IUPAC Name>
phenyl 2-hydroxybenzoate

$$$$
Tropisetron
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0359 -6.2043 0 0
M  V30 2 N -0.8693 -7.4502 0 0
M  V30 3 C -2.6484 -7.3269 0 0 CFG=1
M  V30 4 C -2.1073 -8.7687 0 0
M  V30 5 C -0.6427 -9.2446 0 0
M  V30 6 C 0.6426 -8.3962 0 0 CFG=2
M  V30 7 C 0.7806 -6.8624 0 0
M  V30 8 C -0.3325 -5.7982 0 0 CFG=1
M  V30 9 C -1.8586 -6.0049 0 0
M  V30 10 O 0.1434 -4.3335 0 0
M  V30 11 C 1.6497 -4.0133 0 0
M  V30 12 O 2.6802 -5.1578 0 0
M  V30 13 C 2.1256 -2.5487 0 0
M  V30 14 C 1.2204 -1.3028 0 0
M  V30 15 N 2.1256 -0.0569 0 0
M  V30 16 C 3.5902 -0.5328 0 0
M  V30 17 C 4.9239 0.2372 0 0
M  V30 18 C 6.2576 -0.5328 0 0
M  V30 19 C 6.2576 -2.0728 0 0
M  V30 20 C 4.9239 -2.8428 0 0
M  V30 21 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 2 CFG=3
M  V30 7 1 6 7
M  V30 8 1 8 7
M  V30 9 1 8 9
M  V30 10 1 3 9
M  V30 11 1 8 10 CFG=1
M  V30 12 1 10 11
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 13 21
M  V30 24 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891229

>  <MW>
284.152

>  <MW (desalted)>
284.353

>  <ClogP>
2.881

>  <logS>
-3.187

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
45.33

>  <RotBonds>
3

>  <Action on targets>
Antagonist | - | Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
pA2  10.63  | concentration (parameter)  14.52 pg/ml | Ki (inhibition constant)  0.2 nM | EC50  0.0006 ?M | EC50  0.0006 ?M

>  <CAS>
89565-68-4

>  <Description>
Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. It is used as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting.

>  <EBC_ID>
EBC-09042

>  <IUPAC Name>
(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate

>  <Main Tar all refs>
NATURE, 1985, vol. 316, # 6024, p. 126 - 131 | Life Sci., 2020, vol. 248 | Eur. J. Pharmacol., 1989, vol. 166, # 1, p. 107 - 110 | HOWARD HUGHES MEDICAL INSTITUTE - WO2019/94778, 2019, A1 | HOWARD HUGHES MEDICAL INSTITUTE - WO2019/94778, 2019, A1

>  <Main tar all>
5-HT3A pX=10.6 | NAD-dependent protein deacetylase sirtuin-1 pX=10.3 | 5-HT3A pX=9.7 | glycine receptor ?1 subunit pX=9.22 | nicotinic acetylcholine receptor ?7 subunit pX=9.22

$$$$
Ropivacaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -0.77 0 0
M  V30 2 C 4.001 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 C 2.6674 -7.7 0 0
M  V30 8 C 1.3337 -6.93 0 0
M  V30 9 C 1.3337 -5.39 0 0 CFG=1
M  V30 10 C 0 -4.62 0 0
M  V30 11 O 0 -3.08 0 0
M  V30 12 N -1.3337 -5.39 0 0
M  V30 13 C -2.6674 -4.62 0 0
M  V30 14 C -4.001 -5.39 0 0
M  V30 15 C -4.001 -6.93 0 0
M  V30 16 C -5.3347 -4.62 0 0
M  V30 17 C -5.3347 -3.08 0 0
M  V30 18 C -4.001 -2.31 0 0
M  V30 19 C -2.6674 -3.08 0 0
M  V30 20 C -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 4
M  V30 10 1 9 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 13 19
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811359

>  <MW>
274.205

>  <MW (desalted)>
274.401

>  <ClogP>
3.162

>  <logS>
-3.201

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | -

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.76 ?M | IC50 < 10 ?M | Km (Michaelis constant)  16 ?M

>  <CAS>
84057-95-4

>  <Description>
Ropivacaine block the sodium-channel and decrease chances of depolarization and consequent action potentials. Ropivacaine is an aminoamide local anaesthetic drug used for the research of regional anesthesia and neuropathic pain management.

>  <EBC_ID>
EBC-03920

>  <IUPAC Name>
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide

>  <Main Tar all refs>
Biol. Pharm. Bull., 2010, vol. 33, # 1, p. 95 - 99 | Eur. J. Med. Chem., 2013, vol. 65, p. 304 - 314 | DRUG METAB. DISPOS., 1996, vol. 24, # 9, p. 955 - 961

>  <Main tar all>
Alpha-1-acid glycoprotein pX=6.12 | Kv11.1 pX=5.0 | CYP1A pX=4.8

$$$$
Prucalopride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -11.55 0 0
M  V30 2 O 2.6674 -12.32 0 0
M  V30 3 C 4.001 -11.55 0 0
M  V30 4 C 5.3347 -12.32 0 0
M  V30 5 C 6.6684 -11.55 0 0
M  V30 6 N 8.0021 -12.32 0 0
M  V30 7 C 9.3358 -11.55 0 0
M  V30 8 C 10.6694 -12.32 0 0
M  V30 9 C 10.6694 -13.86 0 0
M  V30 10 C 9.3358 -14.63 0 0
M  V30 11 C 8.0021 -13.86 0 0
M  V30 12 N 12.0031 -14.63 0 0
M  V30 13 C 13.3368 -13.86 0 0
M  V30 14 O 13.3368 -12.32 0 0
M  V30 15 C 14.6705 -14.63 0 0
M  V30 16 C 16.0041 -13.86 0 0
M  V30 17 C 17.3378 -14.63 0 0
M  V30 18 Cl 18.6715 -13.86 0 0
M  V30 19 C 17.3378 -16.17 0 0
M  V30 20 N 18.6715 -16.94 0 0
M  V30 21 C 16.0041 -16.94 0 0
M  V30 22 C 15.684 -18.4463 0 0
M  V30 23 C 14.1524 -18.6073 0 0
M  V30 24 O 13.526 -17.2005 0 0
M  V30 25 C 14.6705 -16.17 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 21 25
M  V30 27 2 15 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801852

>  <MW>
367.166

>  <MW (desalted)>
367.87

>  <ClogP>
1.414

>  <logS>
-3.039

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
76.82

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 7E-06 ?M

>  <CAS>
179474-81-8

>  <Description>
Prucalopride acts as a selective stimulator of the 5-HT4 receptors. It is used to treat adults with chronic idiopathic constipation.

>  <EBC_ID>
EBC-11291

>  <IUPAC Name>
4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide

>  <Main Tar all refs>
JACS Meeting, 1997, 1997

>  <Main tar all>
5-HT4 receptor pX=11.2

$$$$
Trospium chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 O 13.2219 2.676 0 0
M  V30 3 C 13.2219 1.136 0 0
M  V30 4 C 11.6819 1.136 0 0
M  V30 5 O 10.9119 2.4697 0 0
M  V30 6 O 10.9119 -0.1977 0 0
M  V30 7 C 9.3719 -0.1977 0 0 CFG=2
M  V30 8 C 8.7037 1.1898 0 0
M  V30 9 C 7.2024 1.5325 0 0 CFG=2
M  V30 10 C 6.0703 0.3668 0 0
M  V30 11 C 5.9264 -0.7621 0 0
M  V30 12 C 7.2024 -1.9278 0 0 CFG=2
M  V30 13 C 8.7037 -1.5852 0 0
M  V30 14 N 6.7698 -0.1977 0 0 CHG=1
M  V30 15 C 5.8646 -1.4436 0 0
M  V30 16 C 4.4 -0.9677 0 0
M  V30 17 C 4.4 0.5723 0 0
M  V30 18 C 5.8646 1.0482 0 0
M  V30 19 C 14.7619 1.136 0 0
M  V30 20 C 15.5319 2.4697 0 0
M  V30 21 C 17.0719 2.4697 0 0
M  V30 22 C 17.8419 1.136 0 0
M  V30 23 C 17.0719 -0.1977 0 0
M  V30 24 C 15.5319 -0.1977 0 0
M  V30 25 C 13.2219 -0.404 0 0
M  V30 26 C 14.5556 -1.174 0 0
M  V30 27 C 14.5556 -2.714 0 0
M  V30 28 C 13.2219 -3.484 0 0
M  V30 29 C 11.8883 -2.714 0 0
M  V30 30 C 11.8883 -1.174 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 4 6
M  V30 5 1 7 6 CFG=1
M  V30 6 1 7 8
M  V30 7 1 9 8
M  V30 8 1 9 10 CFG=1
M  V30 9 1 10 11
M  V30 10 1 12 11 CFG=1
M  V30 11 1 12 13
M  V30 12 1 7 13
M  V30 13 1 12 14
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 20 1 3 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 27 1 3 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1980444595

>  <MW>
427.964

>  <MW (desalted)>
392.511

>  <ClogP>
-1.155

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  9.3  | pKi  9.2  | pKi  9.1  | Ki (inhibition constant)  0.82 nM | pKi  9  | pKi  8.54  | pKi  8.22

>  <CAS>
10405-02-4

>  <Description>
Trospium is a specific and competitive antagonist of muscarinic cholinergic receptors, with antimuscarinic activity. It is used to manage overactive bladder by relieving urgency, frequency, and incontinence.

>  <EBC_ID>
EBC-08827

>  <IUPAC Name>
(1S,3S,5R)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8lambda5-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium chloride

>  <Main Tar all refs>
BRIDGE PHARMACEUTICAL INC - US2005/43342, 2005, A1 | BRIDGE PHARMACEUTICAL INC - US2005/43342, 2005, A1 | BRIDGE PHARMACEUTICAL INC - US2005/43342, 2005, A1 | Biol. Pharm. Bull., 2016, vol. 39, # 7, p. 1167 - 1171 | BRIDGE PHARMACEUTICAL INC - US2005/43342, 2005, A1 | J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899 | J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899

>  <Main tar all>
M3 receptor pX=9.3 | M2 receptor pX=9.2 | M1 receptor pX=9.1 | mAChR pX=9.09 | M4 receptor pX=9.0 | mAChR pX=8.54 | M5 receptor pX=8.22

$$$$
Simeprevir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 52 58 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -5.7017 -6.4936 0 0
M  V30 2 O -5.7017 -4.9536 0 0
M  V30 3 C -4.3681 -4.1836 0 0
M  V30 4 C -4.3681 -2.6436 0 0
M  V30 5 C -3.0344 -1.8736 0 0
M  V30 6 C -1.7007 -2.6436 0 0
M  V30 7 C -0.367 -1.8736 0 0
M  V30 8 O -0.367 -0.3336 0 0
M  V30 9 C -1.7007 0.4364 0 0 CFG=2
M  V30 10 C -1.8617 1.9679 0 0
M  V30 11 C -3.368 2.2881 0 0 CFG=2
M  V30 12 C -4.138 0.9544 0 0 CFG=1
M  V30 13 C -3.1076 -0.19 0 0
M  V30 14 C -5.678 0.9544 0 0
M  V30 15 O -6.448 2.2881 0 0
M  V30 16 N -6.448 -0.3793 0 0
M  V30 17 C -5.678 -1.7129 0 0
M  V30 18 C -7.988 -0.3793 0 0
M  V30 19 C -8.758 0.9544 0 0
M  V30 20 C -7.988 2.2881 0 0
M  V30 21 C -8.758 3.6218 0 0
M  V30 22 C -7.988 4.9555 0 0
M  V30 23 C -6.448 4.9555 0 0
M  V30 24 C -5.678 6.2891 0 0 CFG=2
M  V30 25 C -4.908 7.6228 0 0
M  V30 26 C -4.138 6.2891 0 0 CFG=1
M  V30 27 N -3.368 4.9555 0 0
M  V30 28 C -4.138 3.6218 0 0
M  V30 29 O -5.678 3.6218 0 0
M  V30 30 C -2.8044 7.0591 0 0
M  V30 31 O -2.8044 8.5991 0 0
M  V30 32 N -1.4707 6.2891 0 0
M  V30 33 S -0.137 7.0591 0 0
M  V30 34 O -0.907 8.3928 0 0
M  V30 35 O 0.633 5.7255 0 0
M  V30 36 C 1.1967 7.8291 0 0
M  V30 37 C 1.9667 9.1628 0 0
M  V30 38 C 2.7367 7.8291 0 0
M  V30 39 C 0.9666 -2.6436 0 0
M  V30 40 C 0.9666 -4.1836 0 0
M  V30 41 N -0.367 -4.9536 0 0
M  V30 42 C -1.7007 -4.1836 0 0
M  V30 43 C -3.0344 -4.9536 0 0
M  V30 44 C -3.0344 -6.4936 0 0
M  V30 45 C 2.3003 -4.9536 0 0
M  V30 46 N 3.7072 -4.3273 0 0
M  V30 47 C 4.7376 -5.4717 0 0
M  V30 48 C 3.9676 -6.8054 0 0
M  V30 49 S 2.4613 -6.4852 0 0
M  V30 50 C 6.2692 -5.3107 0 0
M  V30 51 C 6.8956 -3.9039 0 0
M  V30 52 C 7.1744 -6.5566 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=3
M  V30 11 1 11 12
M  V30 12 1 12 13 CFG=1
M  V30 13 1 9 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 22 21 CFG=2
M  V30 23 2 22 23
M  V30 24 1 24 23
M  V30 25 1 24 25 CFG=3
M  V30 26 1 26 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 11 28
M  V30 31 2 28 29
M  V30 32 1 26 30 CFG=3
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 2 33 35
M  V30 38 1 33 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 36 38
M  V30 42 2 7 39
M  V30 43 1 39 40
M  V30 44 2 40 41
M  V30 45 1 41 42
M  V30 46 2 6 42
M  V30 47 1 42 43
M  V30 48 2 3 43
M  V30 49 1 43 44
M  V30 50 1 40 45
M  V30 51 2 45 46
M  V30 52 1 46 47
M  V30 53 2 47 48
M  V30 54 1 48 49
M  V30 55 1 45 49
M  V30 56 1 47 50
M  V30 57 1 50 51
M  V30 58 1 50 52
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3025867248

>  <MW>
749.292

>  <MW (desalted)>
749.939

>  <ClogP>
5.297

>  <logS>
-5.909

>  <HBD>
2

>  <HBA>
9

>  <TPSA>
156.89

>  <RotBonds>
7

>  <CAS>
1217263-04-1

>  <Description>
Simeprevir is a direct-acting antiviral agent that inhibits HCV NS3/4A protease to treat chronic hepatitis C virus infection in adults with HCV genotype 1 or 4.

>  <EBC_ID>
EBC-47509

>  <IUPAC Name>
(1R,4R,6S,15R,17R)-N-(cyclopropanesulfonyl)-17-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0,4,6]octadec-7-ene-4-carboxamide

$$$$
Saxagliptin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 2.9236 -5.4058 0 0
M  V30 2 C 1.5899 -4.6359 0 0 CFG=2
M  V30 3 C 0.2563 -5.4059 0 0
M  V30 4 O -1.0774 -4.636 0 0
M  V30 5 N 0.2564 -6.9459 0 0
M  V30 6 C 1.5023 -7.8511 0 0 CFG=1
M  V30 7 C 2.5328 -8.9954 0 0
M  V30 8 C 1.0265 -9.3157 0 0 CFG=1
M  V30 9 C -0.5135 -9.3158 0 0
M  V30 10 C -0.9895 -7.8512 0 0 CFG=1
M  V30 11 C -2.4541 -7.3754 0 0
M  V30 12 N -3.9188 -6.8996 0 0
M  V30 13 C 1.5898 -3.0959 0 0
M  V30 14 C 0.2171 -3.7934 0 0
M  V30 15 C 1.056 -2.3182 0 0
M  V30 16 C 1.056 -0.9231 0 0
M  V30 17 C 2.4289 -0.2255 0 0
M  V30 18 C 3.802 -0.9231 0 0
M  V30 19 C 3.802 -2.3182 0 0
M  V30 20 O 5.2908 -2.712 0 0
M  V30 21 C 2.4289 -3.0158 0 0
M  V30 22 C 2.963 -3.7934 0 0
M  V30 23 C 1.5898 -1.7007 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 8 7 CFG=1
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 10 9
M  V30 11 1 10 5
M  V30 12 1 10 11 CFG=1
M  V30 13 3 11 12
M  V30 14 1 2 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 17 23
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 13 22
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 15 21
M  V30 24 1 19 22
M  V30 25 1 18 19
M  V30 26 1 13 23
M  V30 27 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802036

>  <MW>
315.41

>  <MW (desalted)>
315.41

>  <ClogP>
-0.023

>  <logS>
-2.721

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
90.35

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.45 nM | IC50  1 nM

>  <CAS>
361442-04-8

>  <Description>
Saxagliptin is a dipeptidyl peptidase-4 inhibitor. It is an antidiabetic drug used for the treatment of type 2 diabetes.

>  <EBC_ID>
EBC-02059

>  <IUPAC Name>
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

>  <Main Tar all refs>
Annu. Rep. Med. Chem., 2005, vol. 40, p. 149 - 165 | BACH BIOSCIENCES - EP2400976, 2016, B1

>  <Main tar all>
dipeptidyl peptidase 4 pX=9.35 | Probable dipeptidyl peptidase 4 pX=9.0

$$$$
Diethylstilbestrol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C -2.6674 -3.08 0 0
M  V30 7 C 0 -4.62 0 0
M  V30 8 C 1.3337 -5.39 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 0 -7.7 0 0
M  V30 11 O 0 -9.24 0 0
M  V30 12 C -1.3337 -6.93 0 0
M  V30 13 C -1.3337 -5.39 0 0
M  V30 14 C 1.3337 -0.77 0 0
M  V30 15 C 0 0 0 0
M  V30 16 C 0 1.54 0 0
M  V30 17 C 1.3337 2.31 0 0
M  V30 18 O 1.3337 3.85 0 0
M  V30 19 C 2.6674 1.54 0 0
M  V30 20 C 2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 3 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 19 20
M  V30 21 2 14 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568587997

>  <MW>
268.146

>  <MW (desalted)>
268.35

>  <ClogP>
4.956

>  <logS>
-5.071

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
4

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
stimulation rate  234 % | stimulation rate  234 % | EC50  0.007 nM | EC50  0.01 nM

>  <CAS>
56-53-1

>  <Description>
Diethylstilbestrol is a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders, and in the treatment of prostate cancer.

>  <EBC_ID>
EBC-11048

>  <IUPAC Name>
4-[(3E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol

>  <Main Tar all refs>
BIOL. PHARM. BULL., 1996, vol. 19, # 8, p. 1018 - 1022 | BIOL. PHARM. BULL., 1996, vol. 19, # 8, p. 1018 - 1022 | J. Med. Chem., 2001, vol. 44, # 11, p. 1654 - 1657 | J. Biol. Chem., 2003, vol. 278, # 14, p. 12255 - 12262

>  <Main tar all>
Estrogen receptor pX=11.3 | Estrogen receptor pX=11.3 | nuclear estrogen receptor pX=11.2 | Estrogen receptor-? pX=11.0

$$$$
Cyclosporine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 85 85 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.6159 5.1209 0 0
M  V30 2 C -0.9102 3.7521 0 0
M  V30 3 C 0.628 3.6788 0 0 CFG=2
M  V30 4 N 1.3337 2.31 0 0
M  V30 5 C 0 1.54 0 0
M  V30 6 O -1.3337 2.31 0 0
M  V30 7 C 0 0 0 0 CFG=2
M  V30 8 C -1.3337 -0.77 0 0 CFG=2
M  V30 9 O -1.3337 -2.31 0 0
M  V30 10 C -2.6674 0 0 0 CFG=2
M  V30 11 C -4.001 -0.77 0 0
M  V30 12 C -2.6674 1.54 0 0
M  V30 13 C -4.001 2.31 0 0
M  V30 14 C -4.001 3.85 0 0
M  V30 15 C -5.3347 4.62 0 0
M  V30 16 N 1.3337 -0.77 0 0
M  V30 17 C 2.8113 -0.3361 0 0
M  V30 18 C 0.628 -2.1388 0 0
M  V30 19 O -0.8123 -2.6838 0 0
M  V30 20 C 1.4606 -3.4343 0 0 CFG=2
M  V30 21 C 0.7549 -4.8031 0 0
M  V30 22 C 1.5875 -6.0987 0 0
M  V30 23 C -0.7833 -4.8764 0 0
M  V30 24 N 2.9989 -3.3611 0 0
M  V30 25 C 4.0073 -2.1972 0 0
M  V30 26 C 3.1452 -4.8941 0 0
M  V30 27 O 2.2282 -6.1313 0 0
M  V30 28 C 4.5461 -5.5338 0 0 CFG=2
M  V30 29 C 4.6925 -7.0669 0 0
M  V30 30 C 3.438 -7.9601 0 0
M  V30 31 C 3.5844 -9.4932 0 0
M  V30 32 C 2.0372 -7.3204 0 0
M  V30 33 N 5.8005 -4.6405 0 0
M  V30 34 C 6.0197 -3.1162 0 0
M  V30 35 C 6.7525 -5.8511 0 0
M  V30 36 O 6.1801 -7.2807 0 0
M  V30 37 C 8.2768 -5.6319 0 0 CFG=2
M  V30 38 C 9.2288 -6.8424 0 0
M  V30 39 C 8.6564 -8.2721 0 0
M  V30 40 C 9.6084 -9.4826 0 0
M  V30 41 C 7.1321 -8.4913 0 0
M  V30 42 N 8.8492 -4.2022 0 0
M  V30 43 C 8.2094 -2.8014 0 0
M  V30 44 C 10.3045 -4.7059 0 0
M  V30 45 O 10.5959 -6.2181 0 0
M  V30 46 C 11.4683 -3.6974 0 0 CFG=1
M  V30 47 C 12.9236 -4.2011 0 0
M  V30 48 N 11.1769 -2.1852 0 0
M  V30 49 C 12.6735 -1.8222 0 0
M  V30 50 O 13.7362 -2.9367 0 0
M  V30 51 C 13.1073 -0.3446 0 0 CFG=2
M  V30 52 C 14.6039 0.0185 0 0
M  V30 53 N 12.0446 0.77 0 0
M  V30 54 C 13.1073 1.8846 0 0
M  V30 55 O 14.6039 1.5215 0 0
M  V30 56 C 12.6735 3.3622 0 0 CFG=2
M  V30 57 C 13.7362 4.4767 0 0
M  V30 58 C 15.2328 4.1137 0 0
M  V30 59 C 16.2955 5.2282 0 0
M  V30 60 C 15.6666 2.636 0 0
M  V30 61 N 11.1769 3.7252 0 0
M  V30 62 C 9.8813 2.8927 0 0
M  V30 63 C 11.4683 5.2374 0 0
M  V30 64 O 12.9236 5.7411 0 0
M  V30 65 C 10.3045 6.2459 0 0 CFG=1
M  V30 66 N 8.8492 5.7422 0 0
M  V30 67 C 8.2768 7.1719 0 0
M  V30 68 O 9.2288 8.3824 0 0
M  V30 69 C 6.7525 7.3911 0 0 CFG=2
M  V30 70 C 6.1801 8.8207 0 0
M  V30 71 C 7.1321 10.0313 0 0
M  V30 72 C 6.5597 11.461 0 0
M  V30 73 C 8.6564 9.8121 0 0
M  V30 74 N 5.8005 6.1805 0 0
M  V30 75 C 6.0197 4.6562 0 0
M  V30 76 C 4.5461 7.0738 0 0
M  V30 77 O 4.6925 8.6069 0 0
M  V30 78 C 3.1452 6.4341 0 0
M  V30 79 N 2.9989 4.9011 0 0
M  V30 80 C 4.0073 3.7372 0 0
M  V30 81 C 1.4606 4.9743 0 0
M  V30 82 O 0.7549 6.3431 0 0
M  V30 83 C 10.5959 7.7581 0 0
M  V30 84 C 9.8007 9.0768 0 0
M  V30 85 C 12.0512 8.2617 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 7 16 CFG=1
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 20 18
M  V30 20 1 20 21 CFG=1
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 20 24
M  V30 24 1 24 25
M  V30 25 1 24 26
M  V30 26 2 26 27
M  V30 27 1 28 26
M  V30 28 1 28 29 CFG=1
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 30 32
M  V30 32 1 28 33
M  V30 33 1 33 34
M  V30 34 1 33 35
M  V30 35 2 35 36
M  V30 36 1 37 35
M  V30 37 1 37 38 CFG=1
M  V30 38 1 38 39
M  V30 39 1 39 40
M  V30 40 1 39 41
M  V30 41 1 37 42
M  V30 42 1 42 43
M  V30 43 1 42 44
M  V30 44 2 44 45
M  V30 45 1 46 44
M  V30 46 1 46 47 CFG=3
M  V30 47 1 46 48
M  V30 48 1 48 49
M  V30 49 2 49 50
M  V30 50 1 51 49
M  V30 51 1 51 52 CFG=1
M  V30 52 1 51 53
M  V30 53 1 53 54
M  V30 54 2 54 55
M  V30 55 1 56 54
M  V30 56 1 56 57 CFG=1
M  V30 57 1 57 58
M  V30 58 1 58 59
M  V30 59 1 58 60
M  V30 60 1 56 61
M  V30 61 1 61 62
M  V30 62 1 61 63
M  V30 63 2 63 64
M  V30 64 1 65 63
M  V30 65 1 65 66
M  V30 66 1 66 67
M  V30 67 2 67 68
M  V30 68 1 69 67
M  V30 69 1 69 70 CFG=1
M  V30 70 1 70 71
M  V30 71 1 71 72
M  V30 72 1 71 73
M  V30 73 1 69 74
M  V30 74 1 74 75
M  V30 75 1 74 76
M  V30 76 2 76 77
M  V30 77 1 76 78
M  V30 78 1 78 79
M  V30 79 1 79 80
M  V30 80 1 79 81
M  V30 81 1 3 81
M  V30 82 2 81 82
M  V30 83 1 65 83 CFG=1
M  V30 84 1 83 84
M  V30 85 1 83 85
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568648411

>  <MW>
1201.841

>  <MW (desalted)>
1202.611

>  <ClogP>
14.36

>  <logS>
-6.458

>  <HBD>
5

>  <HBA>
12

>  <TPSA>
278.8

>  <RotBonds>
15

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.026 nM | IC50  0.05 nM | inhibition percentage Active

>  <CAS>
59865-13-3

>  <Description>
Cyclosporine is a steroid-sparing immunosuppressant used in organ and bone marrow transplants as well as inflammatory conditions such as ulcerative colitis, rheumatoid arthritis, and atopic dermatitis.

>  <EBC_ID>
EBC-27538

>  <IUPAC Name>
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone

>  <Main Tar all refs>
Phytochemistry, 2014, vol. 98, p. 160 - 163 | LUDWIG-MAXIMILIANS-UNIVERSIT?T M?NCHEN - WO2015/161908, 2015, A1 | UNIVERSITY OF KANSAS - US2016/75669, 2016, A1

>  <Main tar all>
Calcium release-activated calcium channel pX=10.6 | PP2B (Alpha) pX=10.3 | Peptidyl-prolyl?cis-trans?isomerase?D pX=10.0

$$$$
Daprodustat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -5.39 0 0
M  V30 2 C 5.3347 -6.16 0 0
M  V30 3 O 5.3347 -7.7 0 0
M  V30 4 C 6.6684 -5.39 0 0
M  V30 5 N 8.0021 -6.16 0 0
M  V30 6 C 9.3358 -5.39 0 0
M  V30 7 O 9.3358 -3.85 0 0
M  V30 8 C 10.6694 -6.16 0 0
M  V30 9 C 12.0031 -5.39 0 0
M  V30 10 O 12.0031 -3.85 0 0
M  V30 11 N 13.3368 -6.16 0 0
M  V30 12 C 14.6705 -5.39 0 0
M  V30 13 C 14.6705 -3.85 0 0
M  V30 14 C 16.0041 -3.08 0 0
M  V30 15 C 17.3378 -3.85 0 0
M  V30 16 C 17.3378 -5.39 0 0
M  V30 17 C 16.0041 -6.16 0 0
M  V30 18 C 13.3368 -7.7 0 0
M  V30 19 O 14.6705 -8.47 0 0
M  V30 20 N 12.0031 -8.47 0 0
M  V30 21 C 12.0031 -10.01 0 0
M  V30 22 C 13.3368 -10.78 0 0
M  V30 23 C 13.3368 -12.32 0 0
M  V30 24 C 12.0031 -13.09 0 0
M  V30 25 C 10.6694 -12.32 0 0
M  V30 26 C 10.6694 -10.78 0 0
M  V30 27 C 10.6694 -7.7 0 0
M  V30 28 O 9.3358 -8.47 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 1 11 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 21 26
M  V30 28 1 20 27
M  V30 29 1 8 27
M  V30 30 2 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2654188035

>  <MW>
393.19

>  <MW (desalted)>
393.434

>  <ClogP>
3.613

>  <logS>
-4.167

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
124.09

>  <RotBonds>
5

>  <CAS>
960539-70-2

>  <Description>
Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor.

>  <EBC_ID>
EBC-251095

$$$$
Mesna
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 6.93 -1.3337 0 0 CHG=1
M  V30 2 O 5.39 -1.3337 0 0 CHG=-1
M  V30 3 S 3.85 -1.3337 0 0
M  V30 4 O 3.85 0.2063 0 0
M  V30 5 O 3.85 -2.8737 0 0
M  V30 6 C 2.31 -1.3337 0 0
M  V30 7 C 1.54 0 0 0
M  V30 8 S 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 2 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z594284202

>  <MW>
163.958

>  <MW (desalted)>
142.197

>  <ClogP>
-4.292

>  <logS>
-0.52

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
57.2

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 ~ 9.08 ?M | inhibition rate Active   | inhibition rate Active

>  <CAS>
19767-45-4

>  <Description>
Mesna is a cofactor found in methanogenic archaea that is essential for the final step of methanogenesis and is also important for alkene metabolism. It functions as an antioxidant and cytoprotective agent and is widely used as a systemic protective agent against chemotherapy toxicity, but is primarily used to reduce hemorrhagic cystitis induced by cyclophosphamide.

>  <EBC_ID>
EBC-00013

>  <IUPAC Name>
sodium 2-sulfanylethane-1-sulfonate

>  <Main Tar all refs>
J. Inorg. Biochem., 2020, vol. 203 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1

>  <Main tar all>
Lactoperoxidase pX=5.04 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3

$$$$
Uracil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 N 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O -1.3337 -0.77 0 0
M  V30 8 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56889474

>  <MW>
112.027

>  <MW (desalted)>
112.087

>  <ClogP>
-1.056

>  <logS>
-0.88

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | - | - | Inhibitor | -

>  <Activity coefficients and valu>
IC50  0.236 ?M | Km (Michaelis constant) = 0.31 ?M | Km (Michaelis constant) = 0.39 ?M | Ki (inhibition constant) ~ 0.8 ?M | Km (Michaelis constant)  1.7 ?M

>  <CAS>
66-22-8

>  <Description>
Uracil is one of the four nucleobases in the nucleic acid of RNA. Uracil readily undergoes addition to ribose sugars and phosphates to partake in synthesis and further reactions in the body. It can be used for drug delivery and as a pharmaceutical.

>  <EBC_ID>
EBC-13197

>  <IUPAC Name>
1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
Nat. Prod. Res., 2023, vol. 37, # 7, p. 1082 - 1091 | Curr. Pharm. Des., 2007, vol. 13, # 6, p. 555 - 567 | Biol. Pharm. Bull., 2009, vol. 32, # 3, p. 450 - 455 | Curr. Top. Med. Chem., 2003, vol. 3, # 1, p. 81 - 97 | Cancer Lett., 1998, vol. 122, # 1-2, p. 107 - 113

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=6.63 | Snurportin-1 pX=6.51 | OAT pX=6.41 | mitogen-activated protein kinase 10 pX=6.1 | dihydropyrimidine dehydrogenase pX=5.77

$$$$
DL-4-Amino-3-hydroxybutyric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.3574 1.3337 0 0
M  V30 2 C 0.9763 2.1037 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 O 2.31 -0.2063 0 0
M  V30 5 C 3.6437 2.1037 0 0
M  V30 6 C 4.9774 1.3337 0 0
M  V30 7 O 6.311 2.1037 0 0
M  V30 8 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255390571

>  <MW>
119.058

>  <MW (desalted)>
119.119

>  <ClogP>
-3.969

>  <logS>
0.71

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.1 ?M | IC50 = 300 nM | IC50 = 300 nM | IC50 = 300 nM | IC50  0.7 ?M

>  <CAS>
924-49-2

>  <Description>
DL-4-amino-3-hydroxybutyric acid is an inhibitor of [3H]GABA binding to postsynaptic receptors.

>  <EBC_ID>
EBC-03099

>  <IUPAC Name>
4-amino-3-hydroxybutanoic acid

>  <Main Tar all refs>
J. NEUROCHEM., 1979, vol. 32, # 1, p. 249 - 252 | J. MED. CHEM., 1985, vol. 28, # 11, p. 1612 - 1617 | J. MED. CHEM., 1985, vol. 28, # 11, p. 1612 - 1617 | J. MED. CHEM., 1985, vol. 28, # 11, p. 1612 - 1617 | Eur. J. Pharmacol., 1993, vol. 244, # 3, p. 293 - 301

>  <Main tar all>
GABA receptor pX=7.0 | GABAA receptor ?1 subunit pX=6.52 | GABAA receptor ?2 subunit pX=6.52 | GABAA receptor ? subunit pX=6.52 | GABAA receptor pX=6.15

$$$$
6-Methyl-2-thiouracil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 N 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 S -1.3337 -0.77 0 0
M  V30 9 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 2 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z203045042

>  <MW>
142.02

>  <MW (desalted)>
142.179

>  <ClogP>
1.808

>  <logS>
-1.743

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
46.01

>  <RotBonds>
0

>  <CAS>
56-04-2

>  <Description>
6-Methyl-2-thiouracil is an antithyroid agent. It inhibits lactoperoxidase.

>  <EBC_ID>
EBC-04268

>  <IUPAC Name>
6-methyl-2-sulfanylpyrimidin-4-ol

$$$$
D-Methionine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 S 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0
M  V30 4 C 7.2874 2.6674 0 0
M  V30 5 C 8.621 3.4374 0 0 CFG=1
M  V30 6 N 8.621 4.9774 0 0
M  V30 7 C 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 9 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1147215595

>  <MW>
149.051

>  <MW (desalted)>
149.211

>  <ClogP>
-1.731

>  <logS>
-0.527

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  120 ?M | IC50  120 ?M

>  <CAS>
348-67-4

>  <Description>
D-Methionine is an amino acid found in mixture products used for nutrient supplementation. It is an effective chemoprotective agent.

>  <EBC_ID>
EBC-26092

>  <IUPAC Name>
(2R)-2-amino-4-(methylsulfanyl)butanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2018, vol. 61, # 16, p. 7358 - 7373 | J. Med. Chem., 2018, vol. 61, # 16, p. 7358 - 7373

>  <Main tar all>
4F2hc pX=3.92 | L-type amino acid transporter 1 pX=3.92

$$$$
L-Glutamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.621 4.9774 0 0
M  V30 2 C 8.621 3.4374 0 0 CFG=1
M  V30 3 C 7.2874 2.6674 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 4.62 2.6674 0 0
M  V30 6 O 3.2863 3.4374 0 0
M  V30 7 N 4.62 1.1274 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 O 11.2884 3.4374 0 0
M  V30 10 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440074

>  <MW>
146.069

>  <MW (desalted)>
146.145

>  <ClogP>
-3.375

>  <logS>
0.37

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
106.41

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Agonist | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
IC50  0.171 ?M | EC50  286 nM | Ki (inhibition constant)  0.32 ?M | Ki (inhibition constant) = 870 nM | EC50  5.4 ?M

>  <CAS>
56-85-9

>  <Description>
L-Glutamine is an amino acid commonly found as a component in total parenteral nutrition. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-13843

>  <IUPAC Name>
(2S)-2-amino-4-carbamoylbutanoic acid

>  <Main Tar all refs>
J. MED. CHEM., 1990, vol. 33, # 10, p. 2916 - 2924 | J. Pharmacol. Exp. Ther., 2014, vol. 351, # 3, p. 642 - 653 | Neuron, 1999, vol. 23, # 3, p. 487 - 498 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 9, p. 2279 - 2283 | J. Pharmacol. Exp. Ther., 2014, vol. 351, # 3, p. 642 - 653

>  <Main tar all>
NMDA receptor pX=6.77 | mGlu3 receptor pX=6.54 | GPRC6 receptor pX=6.49 | GluN2D pX=6.06 | mGlu2 receptor pX=5.27

$$$$
Acetaminophen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 O -1.3337 3.85 0 0
M  V30 4 N 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56946051

>  <MW>
151.063

>  <MW (desalted)>
151.163

>  <ClogP>
0.494

>  <logS>
-1.14

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
1

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50  1.2E-10 M

>  <CAS>
103-90-2

>  <Description>
Acetaminophen is an analgesic drug used alone or in combination with opioids for pain management, and as an antipyretic agent. It is categorized alongside NSAIDs due to its ability to inhibit the cyclooxygenase pathways.

>  <EBC_ID>
EBC-04043

>  <IUPAC Name>
N-(4-hydroxyphenyl)acetamide

>  <Main Tar all refs>
Toxicol. Lett., 2018, vol. 294, p. 95 - 104

>  <Main tar all>
Androgen receptor pX=9.92

$$$$
Levamisole hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0 0 0
M  V30 3 C 5.3052 1.2459 0 0
M  V30 4 N 6.7698 0.77 0 0
M  V30 5 C 8.2344 1.2459 0 0
M  V30 6 C 9.1396 -0 0 0 CFG=1
M  V30 7 N 8.2344 -1.2459 0 0
M  V30 8 C 6.7698 -0.77 0 0
M  V30 9 S 5.3052 -1.2459 0 0
M  V30 10 C 10.6796 0 0 0
M  V30 11 C 11.4496 1.3337 0 0
M  V30 12 C 12.9896 1.3337 0 0
M  V30 13 C 13.7596 0 0 0
M  V30 14 C 12.9896 -1.3337 0 0
M  V30 15 C 11.4496 -1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 6 5
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 4 8
M  V30 8 1 8 9
M  V30 9 1 2 9
M  V30 10 1 6 10 CFG=3
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1550648764

>  <MW>
240.049

>  <MW (desalted)>
204.291

>  <ClogP>
1.844

>  <logS>
-3.71

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
15.6

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  97.5 % | Ki (inhibition constant)  16 ?M | inhibition percentage  75 % | IC50 = 40000 nM | mRNA expression level decrease Active   | inhibition percentage  65 % | inhibition percentage  25.4 %

>  <CAS>
16595-80-5

>  <Description>
Levamisole is levamisole is a nicotinic receptor agonist. It was commonly used for the treatment of parasitic, viral, and bacterial infections. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. Levamisole has also been used in combination with other drugs for the treatment of various cancers.

>  <EBC_ID>
EBC-06511

>  <IUPAC Name>
(6S)-6-phenyl-2H,3H,5H,6H-imidazo[2,1-b][1,3]thiazole hydrochloride

>  <Main Tar all refs>
Antiviral Res., 2019, vol. 163, p. 59 - 69 | Bioorg. Med. Chem., 2009, vol. 17, # 20, p. 7290 - 7300 | J. MED. CHEM., 1978, vol. 21, # 5, p. 496 - 498 | J. MED. CHEM., 1979, vol. 22, # 9, p. 1030 - 1033 | Exp. Parasitol., 2018, vol. 184, p. 46 - 56 | J. MED. CHEM., 1978, vol. 21, # 5, p. 496 - 498 | UNIVERSITY OF ROCHESTER - WO2011/57204, 2011, A2

>  <Main tar all>
Nonstructural protein 1 pX=5.58 | Alkaline phosphatase, tissue-nonspecific isozyme pX=4.8 | Alkaline phosphatase, placental type pX=4.54 | Alkaline phosphatase pX=4.4 | Trehalose-phosphate phosphatase pX=4.38 | Intestinal-type alkaline phosphatase pX=4.33 | leucine rich repeat kinase 2 pX=4.33

$$$$
Dermatol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.3196 -1.3028 0 0
M  V30 2 Bi 1.2204 -1.3028 0 0
M  V30 3 O 2.1256 -0.0569 0 0
M  V30 4 C 3.5902 -0.5328 0 0
M  V30 5 C 4.9239 0.2372 0 0
M  V30 6 C 6.2576 -0.5328 0 0
M  V30 7 C 6.2576 -2.0728 0 0
M  V30 8 C 4.9239 -2.8428 0 0
M  V30 9 O 4.9239 -4.3828 0 0
M  V30 10 C 3.5902 -2.0728 0 0
M  V30 11 O 2.1256 -2.5487 0 0
M  V30 12 C 7.5913 0.2372 0 0
M  V30 13 O 7.5913 1.7772 0 0
M  V30 14 O 8.925 -0.5328 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 4 10
M  V30 11 1 10 11
M  V30 12 1 2 11
M  V30 13 1 6 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269175922

>  <MW>
393.989

>  <MW (desalted)>
394.091

>  <ClogP>
-0.246

>  <logS>
-0.409

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
96.22

>  <RotBonds>
1

>  <CAS>
99-26-3

>  <Description>
Bismuth subgallate is a medication used to deodorize flatulence and stools as well as hemostasis in soft tissue surgery.

>  <EBC_ID>
EBC-26927

>  <IUPAC Name>
2,7-dihydroxy-2H-benzo[d]1,3-dioxa-2-bismacyclopentane-5-carboxylic acid

$$$$
Triacetin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5963 4.771 0 0
M  V30 2 C 6.93 4.001 0 0
M  V30 3 O 6.93 2.461 0 0
M  V30 4 O 8.2637 4.771 0 0
M  V30 5 C 9.5974 4.001 0 0
M  V30 6 C 10.931 4.771 0 0
M  V30 7 C 12.2647 4.001 0 0
M  V30 8 O 13.5984 4.771 0 0
M  V30 9 C 14.9321 4.001 0 0
M  V30 10 O 16.2658 4.771 0 0
M  V30 11 C 14.9321 2.461 0 0
M  V30 12 O 10.931 6.311 0 0
M  V30 13 C 9.5974 7.081 0 0
M  V30 14 O 8.2637 6.311 0 0
M  V30 15 C 9.5974 8.621 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473192

>  <MW>
218.079

>  <MW (desalted)>
218.204

>  <ClogP>
0.446

>  <logS>
-0.49

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
78.9

>  <RotBonds>
8

>  <CAS>
102-76-1

>  <Description>
Triacetin is a triglyceride that is used as an antifungal agent.

>  <EBC_ID>
EBC-47025

>  <IUPAC Name>
1,3-bis(acetyloxy)propan-2-yl acetate

$$$$
Prilocaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -6.93 0 0
M  V30 2 C 2.6674 -7.7 0 0
M  V30 3 C 4.001 -6.93 0 0
M  V30 4 N 5.3347 -7.7 0 0
M  V30 5 C 6.6684 -6.93 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 C 8.0021 -7.7 0 0
M  V30 8 O 8.0021 -9.24 0 0
M  V30 9 N 9.3358 -6.93 0 0
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 12.0031 -6.93 0 0
M  V30 12 C 13.3368 -7.7 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 C 12.0031 -10.01 0 0
M  V30 15 C 10.6694 -9.24 0 0
M  V30 16 C 9.3358 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z44530398

>  <MW>
220.158

>  <MW (desalted)>
220.311

>  <ClogP>
1.807

>  <logS>
-2.682

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
41.13

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  4.27  | pIC50  4.27  | IC50  54 ?M

>  <CAS>
721-50-6

>  <Description>
Prilocaine is a local anesthetic that is similar pharmacologically to lidocaine. It is used most often for infiltration anesthesia in dentistry.

>  <EBC_ID>
EBC-11101

>  <IUPAC Name>
N-(2-methylphenyl)-2-(propylamino)propanamide

>  <Main Tar all refs>
Chem. Rev., 1991, vol. 91, # 6, p. 1109 - 1119 | Chem. Rev., 1991, vol. 91, # 6, p. 1109 - 1119 | J. Med. Chem., 1985, vol. 28, # 3, p. 381 - 388

>  <Main tar all>
Nav?1 pX=4.27 | Nav1.7 pX=4.27 | Voltage-gated?sodium?channel pX=4.27

$$$$
Acefylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 N 2.1256 4.0887 0 0
M  V30 11 C 1.6497 5.5533 0 0
M  V30 12 C 2.6802 6.6978 0 0
M  V30 13 O 2.2043 8.1624 0 0
M  V30 14 O 4.1865 6.3776 0 0
M  V30 15 C 3.5902 3.6128 0 0
M  V30 16 C 4.9239 4.3828 0 0
M  V30 17 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 10 15
M  V30 15 2 7 15
M  V30 16 1 15 16
M  V30 17 1 2 16
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104477882

>  <MW>
238.07

>  <MW (desalted)>
238.2

>  <ClogP>
-0.658

>  <logS>
-0.71

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
95.74

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  27600 nM | Ki (inhibition constant)  110 ?M | Ki (inhibition constant)  250 ?M

>  <CAS>
652-37-9

>  <Description>
Acefylline acting as an adenosine receptor antagonist, is a stimulant drug of the xanthine chemical class.

>  <EBC_ID>
EBC-12312

>  <IUPAC Name>
2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)acetic acid

>  <Main Tar all refs>
J. Med. Chem., 2002, vol. 45, # 11, p. 2131 - 2138 | PHARMACOLOGY, 1991, vol. 42, # 6, p. 309 - 321 | BIOCHEM. PHARMACOL., 1981, vol. 30, # 4, p. 325 - 333

>  <Main tar all>
Adenosine A2B receptor pX=4.56 | A2A receptor pX=3.96 | Adenosine receptor pX=3.6

$$$$
Gemfibrozil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C -1.3337 -2.31 0 0
M  V30 10 C -2.6674 -3.08 0 0
M  V30 11 C -2.6674 -4.62 0 0
M  V30 12 C -4.001 -5.39 0 0
M  V30 13 C -4.771 -4.0563 0 0
M  V30 14 C -3.231 -6.7237 0 0
M  V30 15 C -5.3347 -6.16 0 0
M  V30 16 O -5.3347 -7.7 0 0
M  V30 17 O -6.6684 -5.39 0 0
M  V30 18 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 7 18
M  V30 18 2 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1259021151

>  <MW>
250.157

>  <MW (desalted)>
250.333

>  <ClogP>
3.937

>  <logS>
-3.31

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
46.53

>  <RotBonds>
6

>  <Action on targets>
- | - | -

>  <Activity coefficients and valu>
pKb  9.04  | pKb  9.04  | concentration (parameter) < 0.0025 ?g/mL

>  <CAS>
25812-30-0

>  <Description>
Gemfibrozil is  used as a lipid-lowering drug. It is an activator of alfa-Peroxisome proliferator-activated receptor. Gemfibrozil is also a nonselective inhibitor of Aldose reductase and  P450 isoforms CYP2C9, 2C19 and 2C8. Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides, elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.

>  <EBC_ID>
EBC-06088

>  <IUPAC Name>
5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid

>  <Main Tar all refs>
Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | Drug Metab. Dispos., 2009, vol. 37, # 12, p. 2359 - 2366

>  <Main tar all>
Aldo-keto reductase family 1 member B1 pX=9.04 | Aldose reductase pX=9.04 | Cytochrome P450 2C8 pX=8.0

$$$$
Bupranolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 Cl 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C -1.3337 -2.31 0 0
M  V30 10 C -2.6674 -3.08 0 0
M  V30 11 O -4.001 -2.31 0 0
M  V30 12 C -2.6674 -4.62 0 0
M  V30 13 N -4.001 -5.39 0 0
M  V30 14 C -4.001 -6.93 0 0
M  V30 15 C -4.001 -8.47 0 0
M  V30 16 C -5.541 -6.93 0 0
M  V30 17 C -2.461 -6.93 0 0
M  V30 18 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 7 18
M  V30 18 2 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1497043450

>  <MW>
271.134

>  <MW (desalted)>
271.783

>  <ClogP>
3.1

>  <logS>
-3.26

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
41.49

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.1 nM | IC50  0.1 nM | pKi  9.85  | pA2  9.3  | pKi  8.65

>  <CAS>
14556-46-8

>  <Description>
Bupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity. Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.

>  <EBC_ID>
EBC-08355

>  <IUPAC Name>
1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol

>  <Main Tar all refs>
GPCR THERAPEUTICS - WO2020/234698, 2020, A1 | GPCR THERAPEUTICS - WO2020/234698, 2020, A1 | Br. J. Pharmacol., 2005, vol. 144, # 3, p. 317 - 322 | Eur. J. Med. Chem., 2002, vol. 37, # 1, p. 11 - 22 | Mol. Pharmacol., 2008, vol. 74, # 5, p. 1417 - 1428

>  <Main tar all>
?2-adrenoceptor pX=10.0 | CXCR4 pX=10.0 | ?2-adrenoceptor pX=9.85 | ?1-adrenoceptor pX=9.3 | ?3-adrenoceptor pX=8.65

$$$$
Trimetozine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 O 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 O 1.3337 -5.39 0 0
M  V30 9 C 0 -4.62 0 0
M  V30 10 C 2.6674 -3.08 0 0
M  V30 11 O 1.3337 -2.31 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 C 6.6684 -5.39 0 0
M  V30 14 O 8.0021 -4.62 0 0
M  V30 15 N 6.6684 -6.93 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 C 8.0021 -9.24 0 0
M  V30 18 O 6.6684 -10.01 0 0
M  V30 19 C 5.3347 -9.24 0 0
M  V30 20 C 5.3347 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z28251506

>  <MW>
281.126

>  <MW (desalted)>
281.304

>  <ClogP>
0.275

>  <logS>
-2.223

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
57.23

>  <RotBonds>
4

>  <CAS>
635-41-6

>  <Description>
Trimetozine is a sedative agent, which has been used in the treatment of anxiety.

>  <EBC_ID>
EBC-06817

>  <IUPAC Name>
4-(3,4,5-trimethoxybenzoyl)morpholine

$$$$
Meloxicam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 0 0 0 0
M  V30 5 O -1.3337 -0.77 0 0
M  V30 6 N 0 1.54 0 0
M  V30 7 C -1.3337 2.31 0 0
M  V30 8 N -2.7405 1.6836 0 0
M  V30 9 C -3.771 2.8281 0 0
M  V30 10 C -3.001 4.1617 0 0
M  V30 11 C -3.6274 5.5686 0 0
M  V30 12 S -1.4947 3.8416 0 0
M  V30 13 C 2.6674 0 0 0
M  V30 14 O 2.6674 1.54 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 21 S 2.6674 -3.08 0 0
M  V30 22 O 3.3903 -4.4397 0 0
M  V30 23 O 1.9444 -4.4397 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 7 12
M  V30 13 1 3 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 1 2 21
M  V30 24 2 21 22
M  V30 25 2 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2241984977

>  <MW>
351.401

>  <MW (desalted)>
351.401

>  <ClogP>
1.731

>  <logS>
-4.366

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
96.44

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.00017 nM | IC50 = 0.00021 nM

>  <CAS>
71125-38-7

>  <Description>
Meloxicam inhibits prostaglandin synthetase enzymes leading to a decreased synthesis of prostaglandins, which normally mediate painful inflammatory symptoms. Meloxicam is a nonsteroidal anti-inflammatory drug used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.

>  <EBC_ID>
EBC-11186

>  <IUPAC Name>
2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1,4-trioxo-3,4-dihydro-2H-1lambda6,2-benzothiazine-3-carboxamide

>  <Main Tar all refs>
Curr. Med. Chem., 2000, vol. 7, # 11, p. 1101 - 1112 | Curr. Med. Chem., 2000, vol. 7, # 11, p. 1101 - 1112

>  <Main tar all>
COX-2  pX=12.8 | COX-1  pX=12.7

$$$$
Lansoprasole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6296 2.6982 0 0
M  V30 2 C -3.3996 1.3645 0 0
M  V30 3 C -2.6296 0.0309 0 0
M  V30 4 C -1.0896 0.0309 0 0
M  V30 5 S -0.3196 -1.3028 0 0
M  V30 6 O -1.0896 -2.6365 0 0
M  V30 7 C 1.2204 -1.3028 0 0
M  V30 8 N 2.1256 -0.0569 0 0
M  V30 9 C 3.5902 -0.5328 0 0
M  V30 10 C 4.9239 0.2372 0 0
M  V30 11 C 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 C 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 N 2.1256 -2.5487 0 0
M  V30 16 N -3.3996 -1.3028 0 0
M  V30 17 C -4.9396 -1.3028 0 0
M  V30 18 C -5.7096 0.0309 0 0
M  V30 19 C -4.9396 1.3645 0 0
M  V30 20 O -5.7096 2.6982 0 0
M  V30 21 C -4.9396 4.0319 0 0
M  V30 22 C -5.7096 5.3656 0 0
M  V30 23 F -6.4796 6.6992 0 0
M  V30 24 F -4.3759 6.1356 0 0
M  V30 25 F -7.0433 4.5956 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 1 7 15
M  V30 17 2 3 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 2 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 22 24
M  V30 27 1 22 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485356

>  <MW>
369.076

>  <MW (desalted)>
369.361

>  <ClogP>
2.597

>  <logS>
-4.79

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
67.87

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 2.5 nM | Ki (inhibition constant) = 2.5 nM | Ki (inhibition constant) = 2.7 nM

>  <CAS>
103577-45-3

>  <Description>
Lansoprazole decreases gastric acid secretion by targeting H+,K+-ATPase. Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers.

>  <EBC_ID>
EBC-01057

>  <IUPAC Name>
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole

>  <Main Tar all refs>
J. Med. Chem., 2015, vol. 58, # 11, p. 4365 - 4382 | ACS Med. Chem. Lett., 2012, vol. 3, # 11, p. 936 - 941 | SERVICIOS CIENTIFICOS NEUROINNOVATION LTDA - EP2438918, 2012, A1

>  <Main tar all>
Microtubule-associated protein Tau pX=8.6 | tau tubulin kinase pX=8.6 | Microtubule-associated protein tau pX=8.57

$$$$
Triflupromazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.3529 0 0
M  V30 3 N 5.7337 0.4171 0 0
M  V30 4 C 5.7337 1.9571 0 0
M  V30 5 C 7.0674 -0.3529 0 0
M  V30 6 C 8.401 0.4171 0 0
M  V30 7 C 9.7347 -0.3529 0 0
M  V30 8 N 11.0684 0.4171 0 0
M  V30 9 C 11.0684 1.9571 0 0
M  V30 10 C 9.7347 2.7271 0 0
M  V30 11 C 9.7347 4.2671 0 0
M  V30 12 C 11.0684 5.0371 0 0
M  V30 13 C 12.4021 4.2671 0 0
M  V30 14 C 12.4021 2.7271 0 0
M  V30 15 S 13.7358 1.9571 0 0
M  V30 16 C 13.7358 0.4171 0 0
M  V30 17 C 15.0694 -0.3529 0 0
M  V30 18 C 15.0694 -1.8929 0 0
M  V30 19 C 13.7358 -2.6629 0 0
M  V30 20 C 12.4021 -1.8929 0 0
M  V30 21 C 12.4021 -0.3529 0 0
M  V30 22 C 13.7358 -4.2029 0 0
M  V30 23 F 13.7358 -5.7429 0 0
M  V30 24 F 12.1958 -4.2029 0 0
M  V30 25 F 15.2758 -4.2029 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 8 21
M  V30 22 2 16 21
M  V30 23 1 19 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 22 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1631505638

>  <MW>
388.099

>  <MW (desalted)>
352.417

>  <ClogP>
5.61

>  <logS>
-5.65

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
5

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
inhibition percentage  88 %

>  <CAS>
1098-60-8

>  <Description>
Triflupromazine hydrochloride is a phenothiazine with diverse biological activities. It is an antagonist of dopamine D2 receptor, also blocks sodium channel protein type 8 subunit alpha.

>  <EBC_ID>
EBC-08619

>  <IUPAC Name>
dimethyl({3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl})amine hydrochloride

>  <Main Tar all refs>
PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3

>  <Main tar all>
D2 receptor pX=5.87

$$$$
Penciclovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -3.5909 10.9898 0 0
M  V30 2 C -4.6213 9.8454 0 0
M  V30 3 N -4.1454 8.3807 0 0
M  V30 4 C -5.1759 7.2363 0 0
M  V30 5 N -5.0149 5.7047 0 0
M  V30 6 C -3.6813 4.9347 0 0
M  V30 7 C -3.6813 3.3947 0 0
M  V30 8 C -2.3476 2.6247 0 0
M  V30 9 C -2.3476 1.0847 0 0
M  V30 10 O -1.0139 0.3147 0 0
M  V30 11 C -1.0139 3.3947 0 0
M  V30 12 O 0.3198 2.6247 0 0
M  V30 13 C -6.4218 5.0783 0 0
M  V30 14 N -7.4523 6.2228 0 0
M  V30 15 C -6.6823 7.5565 0 0
M  V30 16 C -7.1581 9.0211 0 0
M  V30 17 O -8.6645 9.3413 0 0
M  V30 18 N -6.1277 10.1655 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 1 5 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 4 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2025569265

>  <MW>
253.258

>  <MW (desalted)>
253.258

>  <ClogP>
-2.716

>  <logS>
-1.271

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
125.76

>  <RotBonds>
5

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 = 0.6 ?M | Ki (inhibition constant) = 1.5 ?M | IC50  2 ?M | IC50  2 ?M

>  <CAS>
39809-25-1

>  <Description>
Penciclovir is a nucleoside polymerase inhibitor. It is used in the treatment of recurrent herpes labialis.

>  <EBC_ID>
EBC-13567

>  <IUPAC Name>
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-1H-purin-6-one

>  <Main Tar all refs>
Curr. Med. Chem. Anti-infec. Agents., 2003, vol. 2, # 3, p. 227 - 240 | J. MED. CHEM., 1987, vol. 30, # 5, p. 943 - 947 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 22 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 22

>  <Main tar all>
DNA pX=6.22 | thymidine kinase pX=5.82 | DNA polymerase catalytic subunit BALF5 pX=5.7 | DNA polymerase processivity factor BMRF1 pX=5.7

$$$$
Pramiracetam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.014 -4.2688 0 0
M  V30 2 C 9.5018 -4.5598 0 0
M  V30 3 C 8.9977 -6.015 0 0
M  V30 4 N 8.4936 -3.3957 0 0
M  V30 5 C 6.9813 -3.6867 0 0
M  V30 6 C 5.9732 -2.5226 0 0
M  V30 7 N 4.4609 -2.8136 0 0
M  V30 8 C 3.4528 -1.6495 0 0
M  V30 9 O 3.9568 -0.1943 0 0
M  V30 10 C 1.9405 -1.9405 0 0
M  V30 11 N 0.9323 -0.7764 0 0
M  V30 12 C -0.602 -0.9077 0 0
M  V30 13 C -1.2011 0.5109 0 0
M  V30 14 C -0.037 1.5191 0 0
M  V30 15 C 1.2816 0.7235 0 0
M  V30 16 O 2.7003 1.3226 0 0
M  V30 17 C 8.9977 -1.9405 0 0
M  V30 18 C 7.9895 -0.7764 0 0
M  V30 19 C 10.5099 -1.6495 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 11 15
M  V30 16 2 15 16
M  V30 17 1 4 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z221101674

>  <MW>
269.383

>  <MW (desalted)>
269.383

>  <ClogP>
1.405

>  <logS>
-1.185

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
52.65

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  10000 nM | Ki (inhibition constant)  10000 nM | Ki (inhibition constant) = 11 ?M

>  <CAS>
68497-62-1

>  <Description>
Pramiracetam is a potent nootropic drug derived from piracetam. Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression.

>  <EBC_ID>
EBC-03875

>  <IUPAC Name>
N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-oxopyrrolidin-1-yl)acetamide

>  <Main Tar all refs>
VIRGINIA COMMONWEALTH UNIVERSITY - US6057371, 2000, A | VIRGINIA COMMONWEALTH UNIVERSITY - US6057371, 2000, A | Curr. Pharm. Des., 2002, vol. 8, # 2, p. 125 - 138

>  <Main tar all>
Sigma 2 receptor pX=5.0 | sigma non-opioid intracellular receptor 1 pX=5.0 | prolyl endopeptidase pX=4.96

$$$$
Ezetemibe
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.9441 -0.2255 0 0
M  V30 2 C 6.2778 -0.9955 0 0 CFG=1
M  V30 3 C 6.2778 -2.5355 0 0
M  V30 4 C 4.9441 -3.3055 0 0
M  V30 5 C 4.9441 -4.8455 0 0 CFG=2
M  V30 6 C 6.033 -5.9345 0 0 CFG=2
M  V30 7 N 4.9441 -7.0234 0 0
M  V30 8 C 3.8551 -5.9345 0 0
M  V30 9 O 2.3151 -5.9345 0 0
M  V30 10 C 4.9441 -8.5634 0 0
M  V30 11 C 6.2778 -9.3334 0 0
M  V30 12 C 6.2778 -10.8734 0 0
M  V30 13 C 4.9441 -11.6434 0 0
M  V30 14 F 4.9441 -13.1834 0 0
M  V30 15 C 3.6104 -10.8734 0 0
M  V30 16 C 3.6104 -9.3334 0 0
M  V30 17 C 7.573 -5.9345 0 0
M  V30 18 C 8.343 -4.6008 0 0
M  V30 19 C 9.883 -4.6008 0 0
M  V30 20 C 10.653 -5.9345 0 0
M  V30 21 O 12.193 -5.9345 0 0
M  V30 22 C 9.883 -7.2682 0 0
M  V30 23 C 8.343 -7.2682 0 0
M  V30 24 C 7.6114 -0.2255 0 0
M  V30 25 C 7.6114 1.3145 0 0
M  V30 26 C 8.9451 2.0845 0 0
M  V30 27 C 10.2788 1.3145 0 0
M  V30 28 F 11.6125 2.0845 0 0
M  V30 29 C 10.2788 -0.2255 0 0
M  V30 30 C 8.9451 -0.9955 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 15 16
M  V30 17 2 10 16
M  V30 18 1 6 17 CFG=1
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 22 23
M  V30 25 2 17 23
M  V30 26 1 2 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 27 29
M  V30 32 1 29 30
M  V30 33 2 24 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759501

>  <MW>
409.425

>  <MW (desalted)>
409.425

>  <ClogP>
3.958

>  <logS>
-5.56

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
60.77

>  <RotBonds>
6

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  3.3 pmol/l

>  <CAS>
163222-33-1

>  <Description>
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The primary target of ezetimibe is the cholesterol transport protein Niemann-Pick C1-Like 1 (NPC1L1) protein. Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor.

>  <EBC_ID>
EBC-09095

>  <IUPAC Name>
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one

>  <Main Tar all refs>
J. Steroid Biochem. Mol. Biol., 2020, vol. 197

>  <Main tar all>
NPC1 like intracellular cholesterol transporter 1 pX=11.5

$$$$
Trazodone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 6.6 -7.2823 0 0
M  V30 3 C 5.83 -5.9486 0 0
M  V30 4 C 4.29 -5.9486 0 0
M  V30 5 C 3.52 -4.6149 0 0
M  V30 6 C 4.29 -3.2812 0 0
M  V30 7 C 5.83 -3.2812 0 0
M  V30 8 C 6.6 -4.6149 0 0
M  V30 9 N 6.6 -1.9476 0 0
M  V30 10 C 5.83 -0.6139 0 0
M  V30 11 C 6.6 0.7198 0 0
M  V30 12 N 8.14 0.7198 0 0
M  V30 13 C 8.91 2.0535 0 0
M  V30 14 C 10.45 2.0535 0 0
M  V30 15 C 11.22 3.3872 0 0
M  V30 16 N 12.76 3.3872 0 0
M  V30 17 N 13.6652 4.633 0 0
M  V30 18 C 15.1298 4.1572 0 0
M  V30 19 C 16.4635 4.9272 0 0
M  V30 20 C 17.7972 4.1572 0 0
M  V30 21 C 17.7972 2.6172 0 0
M  V30 22 C 16.4635 1.8472 0 0
M  V30 23 N 15.1298 2.6172 0 0
M  V30 24 C 13.6652 2.1413 0 0
M  V30 25 O 13.1893 0.6766 0 0
M  V30 26 C 8.91 -0.6139 0 0
M  V30 27 C 8.14 -1.9476 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 1 18 23
M  V30 24 1 23 24
M  V30 25 1 16 24
M  V30 26 2 24 25
M  V30 27 1 12 26
M  V30 28 1 26 27
M  V30 29 1 9 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759504

>  <MW>
408.325

>  <MW (desalted)>
371.864

>  <ClogP>
3.85

>  <logS>
-4.4

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
42.39

>  <RotBonds>
5

>  <Action on targets>
Antagonist | Antagonist

>  <Activity coefficients and valu>
percentage increase Active   | percentage increase Active

>  <CAS>
25332-39-2

>  <Description>
Trazodone hydrochloride is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders. It inhibits 5-HT receptors: 5-HT 2A, 1A and 2C.

>  <EBC_ID>
EBC-07539

>  <IUPAC Name>
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride

>  <Main Tar all refs>
ACS Chem. Neurosci., 2017, vol. 8, # 9, p. 2027 - 2038 | ACS Chem. Neurosci., 2017, vol. 8, # 9, p. 2027 - 2038

>  <Main tar all>
5-HT2A receptor pX=9.0 | 5-HT2A receptor pX=9.0

$$$$
Pazufloxacin mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.4795 -4.1411 0 0
M  V30 2 C -1.4795 -2.6011 0 0 CFG=1
M  V30 3 C -2.8132 -1.8311 0 0
M  V30 4 O -2.8132 -0.2911 0 0
M  V30 5 C -1.4795 0.4789 0 0
M  V30 6 C -1.4795 2.0189 0 0
M  V30 7 C -0.1459 2.7889 0 0
M  V30 8 F -0.1459 4.3289 0 0
M  V30 9 C 1.1878 2.0189 0 0
M  V30 10 C 1.1878 0.4789 0 0
M  V30 11 C 2.5215 -0.2911 0 0
M  V30 12 O 3.8552 0.4789 0 0
M  V30 13 C 2.5215 -1.8311 0 0
M  V30 14 C 1.1878 -2.6011 0 0
M  V30 15 N -0.1459 -1.8311 0 0
M  V30 16 C -0.1459 -0.2911 0 0
M  V30 17 C 3.8552 -2.6011 0 0
M  V30 18 O 3.8552 -4.1411 0 0
M  V30 19 O 5.1888 -1.8311 0 0
M  V30 20 C -2.8132 2.7889 0 0
M  V30 21 N -2.2865 4.236 0 0
M  V30 22 C -3.8031 1.6092 0 0
M  V30 23 C -4.3298 3.0563 0 0
M  V30 24 C 10.2488 -1.54 0 0
M  V30 25 S 10.2488 0 0 0
M  V30 26 O 10.2488 1.54 0 0
M  V30 27 O 11.7888 -0 0 0
M  V30 28 O 8.7088 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 2 15
M  V30 16 1 15 16
M  V30 17 2 5 16
M  V30 18 1 10 16
M  V30 19 1 13 17
M  V30 20 2 17 18
M  V30 21 1 17 19
M  V30 22 1 6 20
M  V30 23 1 20 21
M  V30 24 1 20 22
M  V30 25 1 22 23
M  V30 26 1 20 23
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 2 25 27
M  V30 30 1 25 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3234818655

>  <MW>
414.09

>  <MW (desalted)>
318.3

>  <ClogP>
-1.185

>  <logS>
-1.816

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
92.86

>  <RotBonds>
2

>  <CAS>
163680-77-1

>  <Description>
Pazufloxacin Mesylate is a quinolone antibacterial agent used for the intravenous therapy of several infections.

>  <EBC_ID>
EBC-13812

>  <IUPAC Name>
(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; methanesulfonic acid

$$$$
Quercetin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 O 2.6674 1.54 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 O 5.3347 1.54 0 0
M  V30 9 C 6.6684 -0.77 0 0
M  V30 10 O 8.0021 -0 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 O 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 14 C 2.6674 -3.08 0 0
M  V30 15 C 8.0021 -3.08 0 0
M  V30 16 C 9.3358 -2.31 0 0
M  V30 17 C 10.6694 -3.08 0 0
M  V30 18 C 10.6694 -4.62 0 0
M  V30 19 O 12.0031 -5.39 0 0
M  V30 20 C 9.3358 -5.39 0 0
M  V30 21 O 9.3358 -6.93 0 0
M  V30 22 C 8.0021 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 6 13
M  V30 14 1 13 14
M  V30 15 2 2 14
M  V30 16 1 11 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57176222

>  <MW>
302.043

>  <MW (desalted)>
302.236

>  <ClogP>
1.504

>  <logS>
-2.488

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
127.45

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  3.7 pM | enzyme activity decrease Active   | concentration (parameter)  22.3 pM

>  <CAS>
117-39-5

>  <Description>
Quercetin is a natural flavonoid found in foods and natural supplement products. It is the most prominent dietary antioxidant. Quercetin inhibits sulfotransferase, IC50=12 pM.

>  <EBC_ID>
EBC-11067

>  <IUPAC Name>
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one

>  <Main Tar all refs>
Xenobiotica, 2000, vol. 30, # 9, p. 857 - 866 | Front. Pharmacol., 2021, vol. 12 | Biochim. Biophys. Acta, 2008, vol. 1780, # 5, p. 819 - 25

>  <Main tar all>
Sulfotransferase pX=11.4 | dipeptidyl peptidase 4 pX=11.0 | beta-secretase 1 pX=10.7

$$$$
Artesunate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.4263 -1.6873 0 0
M  V30 2 C 7.1412 -0.8386 0 0 CFG=2
M  V30 3 C 5.7987 -1.6435 0 0
M  V30 4 C 4.7468 -0.4871 0 0
M  V30 5 C 4.9262 1.1088 0 0 CFG=1
M  V30 6 C 3.372 1.5431 0 0 CFG=1
M  V30 7 C 2.3262 0.4127 0 0
M  V30 8 C 2.8334 3.018 0 0 CFG=2
M  V30 9 O 1.3728 3.506 0 0
M  V30 10 C 0.2198 2.4851 0 0
M  V30 11 O 0.5274 0.9762 0 0
M  V30 12 C -1.2408 2.9732 0 0
M  V30 13 C -2.3938 1.9523 0 0
M  V30 14 C -3.8544 2.4404 0 0
M  V30 15 O -5.0074 1.4195 0 0
M  V30 16 O -4.162 3.9493 0 0
M  V30 17 O 4.1497 3.8722 0 0
M  V30 18 C 5.6707 3.367 0 0 CFG=2
M  V30 19 O 7.4117 2.9551 0 0
M  V30 20 C 8.9648 3.3526 0 0 CFG=1
M  V30 21 C 10.2443 4.2096 0 0
M  V30 22 C 9.8715 2.0501 0 0
M  V30 23 C 8.9591 0.7639 0 0
M  V30 24 C 7.3585 0.743 0 0 CFG=2
M  V30 25 C 6.312 2.0411 0 0 CFG=1
M  V30 26 O 6.7573 3.816 0 0
M  V30 27 O 8.1128 4.6753 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 8 17
M  V30 17 1 18 17 CFG=3
M  V30 18 1 18 19
M  V30 19 1 20 19
M  V30 20 1 20 21 CFG=1
M  V30 21 1 20 22
M  V30 22 1 22 23
M  V30 23 1 24 23 CFG=1
M  V30 24 1 24 2
M  V30 25 1 25 24
M  V30 26 1 25 5
M  V30 27 1 25 18
M  V30 28 1 25 26 CFG=3
M  V30 29 1 26 27
M  V30 30 1 20 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040194

>  <MW>
384.421

>  <MW (desalted)>
384.421

>  <ClogP>
2.934

>  <logS>
-3.929

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
100.52

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.53 nM | IC50  1.3 nM | IC50  0.002 ?M | IC50  0.003 ?M | EC50  6.2 nM

>  <CAS>
88495-63-0

>  <Description>
Artesunate is artesunate is an artemesinin derivative indicated for the initial treatment of severe malaria.

>  <EBC_ID>
EBC-17081

>  <IUPAC Name>
4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-yl]oxy}butanoic acid

>  <Main Tar all refs>
BMC Compl. Med.Therapies, 2022, vol. 22, # 1 | Antimicrob. Agents Chemother., 2018, vol. 62, # 9 | ACS Infect. Dis., 2021, vol. 7, # 6, p. 1680 - 1689 | Eur. J. Med. Chem., 2018, vol. 158, p. 801 - 813 | CORNELL UNIVERSITY - WO2022/159581, 2022, A2

>  <Main tar all>
L-lactate?dehydrogenase pX=9.28 | phosphatidylinositol 4-kinase alpha pX=8.89 | Proline-tRNA ligase, cytoplasmic pX=8.7 | Histone?deacetylase pX=8.52 | proteasome 20S pX=8.21

$$$$
Chlorprothixene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 8.47 0 0
M  V30 2 N 1.3337 6.93 0 0
M  V30 3 C -0 6.16 0 0
M  V30 4 C 2.6674 6.16 0 0
M  V30 5 C 2.6674 4.62 0 0
M  V30 6 C 4.001 3.85 0 0
M  V30 7 C 4.001 2.31 0 0
M  V30 8 C 5.3347 1.54 0 0
M  V30 9 C 6.6684 2.31 0 0
M  V30 10 C 8.0021 1.54 0 0
M  V30 11 C 8.0021 -0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 5.3347 0 0 0
M  V30 14 S 4.001 -0.77 0 0
M  V30 15 C 2.6674 0 0 0
M  V30 16 C 1.3337 -0.77 0 0
M  V30 17 C -0 0 0 0
M  V30 18 C 0 1.54 0 0
M  V30 19 Cl -1.3337 2.31 0 0
M  V30 20 C 1.3337 2.31 0 0
M  V30 21 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 20 21
M  V30 22 1 7 21
M  V30 23 2 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315576239

>  <MW>
315.085

>  <MW (desalted)>
315.86

>  <ClogP>
5.482

>  <logS>
-4.937

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.43 nM | Ki (inhibition constant)  0.43 nM | IC50  1.2 nM | IC50  1.2 nM | Ki (inhibition constant)  1.4 nM | Ki (inhibition constant)  1.4 nM | Ki (inhibition constant)  1.8 nM | pIC50  8.7  | pIC50  8.7  | Ki (inhibition constant)  2.8 nM | Ki (inhibition constant)  2.8 nM | Ki (inhibition constant)  3 nM | pIC50  8.39  | Ki (inhibition constant)  4.4 nM | IC50  5.2 nM | Ki (inhibition constant)  5.6 nM | pKi  8.25  | pIC50  8

>  <CAS>
113-59-7

>  <Description>
Chlorprothixene is a typical antipsychotic drug of the thioxanthene class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

>  <EBC_ID>
EBC-12051

>  <IUPAC Name>
{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}dimethylamine

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1987, vol. 143, # 2, p. 279 - 282 | EUR. J. PHARMACOL., 1987, vol. 143, # 2, p. 279 - 282 | PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3 | J. Pharmacol. Exp. Ther., 2015, vol. 352, # 1, p. 53 - 60 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154 | J. Neural Transm., 1987, vol. 68, # 3-4, p. 171 - 189 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154 | J. PHARMACOL. EXP. THER., 1994, vol. 268, # 3, p. 1403 - 1410 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | Mol. Pharmacol., 1976, vol. 12, # 5, p. 800 - 812 | Life Sci., 1978, vol. 23, # 6, p. 551 - 555 | J. PHARMACOL. EXP. THER., 1994, vol. 268, # 3, p. 1403 - 1410 | Curr. Med. Chem., 2004, vol. 11, # 5, p. 629 - 661 | J. PHYSIOL., 1981, vol. 77, # 2-3, p. 351 - 362

>  <Main tar all>
5-HT2A receptor pX=9.37 | 5-HT2A receptor pX=9.37 | D2 receptor pX=8.92 | D2- like receptor pX=8.92 | ?1-adrenoceptor pX=8.85 | ?1-adrenoceptor pX=8.85 | D1 receptor pX=8.74 | D2L receptor pX=8.7 | D2L receptor pX=8.7 | D2 receptor pX=8.55 | D2 receptor pX=8.55 | 5-HT6 receptor pX=8.52 | H1 receptor pX=8.39 | Dopamine receptor pX=8.36 | Dopamine receptor pX=8.28 | 5-HT7 receptor pX=8.25 | 5-HT7 receptor pX=8.25 | 5-HT receptor pX=8.0

$$$$
Molsidomine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.2877 -8.5784 0 0
M  V30 2 C -1.954 -9.3484 0 0
M  V30 3 O -0.6203 -8.5784 0 0
M  V30 4 C 0.7134 -9.3484 0 0
M  V30 5 O 0.7134 -10.8884 0 0
M  V30 6 N 2.047 -8.5784 0 0 CHG=-1
M  V30 7 C 3.3807 -9.3484 0 0
M  V30 8 C 4.7876 -8.7221 0 0
M  V30 9 N 5.818 -9.8665 0 0 CHG=1
M  V30 10 N 5.048 -11.2002 0 0
M  V30 11 O 3.5417 -10.88 0 0
M  V30 12 N 7.3496 -9.7055 0 0
M  V30 13 C 7.976 -8.2987 0 0
M  V30 14 C 9.5075 -8.1377 0 0
M  V30 15 O 10.4127 -9.3836 0 0
M  V30 16 C 9.7864 -10.7905 0 0
M  V30 17 C 8.2548 -10.9514 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040198

>  <MW>
242.232

>  <MW (desalted)>
243.24

>  <ClogP>
1.331

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
77.91

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  41.1 %

>  <CAS>
25717-80-0

>  <Description>
Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. It is used to treat angina pectoris, including in association with left heart failure and acute myocardial infarction.

>  <EBC_ID>
EBC-26286

>  <IUPAC Name>
5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3lambda5-oxadiazol-3-ylium

>  <Main Tar all refs>
PLoS ONE, 2015, vol. 10, # 9

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=4.54

$$$$
Roxithromycin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 58 60 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -8.47 0 0
M  V30 2 C -2.6674 -7.7 0 0
M  V30 3 C -2.6674 -6.16 0 0 CFG=1
M  V30 4 O -4.001 -6.93 0 0
M  V30 5 C -5.3347 -6.16 0 0
M  V30 6 O -6.6684 -6.93 0 0
M  V30 7 C -5.3347 -4.62 0 0 CFG=2
M  V30 8 C -6.8663 -4.781 0 0
M  V30 9 C -4.001 -3.85 0 0 CFG=1
M  V30 10 O -5.3347 -3.08 0 0
M  V30 11 C -6.6684 -3.85 0 0 CFG=1
M  V30 12 C -6.6684 -5.39 0 0
M  V30 13 C -8.0021 -6.16 0 0 CFG=1
M  V30 14 C -7.0122 -7.3397 0 0
M  V30 15 O -8.992 -7.3397 0 0
M  V30 16 C -8.4653 -8.7868 0 0
M  V30 17 C -9.3358 -5.39 0 0 CFG=1
M  V30 18 O -10.6694 -6.16 0 0
M  V30 19 C -9.3358 -3.85 0 0 CFG=2
M  V30 20 C -10.6694 -3.08 0 0
M  V30 21 O -8.0021 -3.08 0 0
M  V30 22 C -4.001 -2.31 0 0 CFG=2
M  V30 23 C -5.3347 -1.54 0 0
M  V30 24 C -2.6674 -1.54 0 0 CFG=1
M  V30 25 O -2.6674 0 0 0
M  V30 26 C -4.001 0.77 0 0 CFG=2
M  V30 27 O -5.3347 0 0 0
M  V30 28 C -6.6684 0.77 0 0 CFG=2
M  V30 29 C -8.0021 0 0 0
M  V30 30 C -6.6684 2.31 0 0
M  V30 31 C -5.3347 3.08 0 0 CFG=1
M  V30 32 C -4.001 2.31 0 0 CFG=1
M  V30 33 O -2.6674 3.08 0 0
M  V30 34 N -5.3347 4.62 0 0
M  V30 35 C -4.001 5.39 0 0
M  V30 36 C -6.6684 5.39 0 0
M  V30 37 C -1.3337 -2.31 0 0 CFG=2
M  V30 38 C -1.8604 -0.8629 0 0
M  V30 39 O -0.807 -0.8629 0 0
M  V30 40 C -0 -1.54 0 0
M  V30 41 C 1.3337 -2.31 0 0 CFG=1
M  V30 42 C 2.6674 -1.54 0 0
M  V30 43 C 1.3337 -3.85 0 0
M  V30 44 N 2.6674 -4.62 0 0
M  V30 45 O 2.6674 -6.16 0 0
M  V30 46 C 4.001 -6.93 0 0
M  V30 47 O 5.3347 -6.16 0 0
M  V30 48 C 6.6684 -6.93 0 0
M  V30 49 C 8.0021 -6.16 0 0
M  V30 50 O 9.3358 -6.93 0 0
M  V30 51 C 10.6694 -6.16 0 0
M  V30 52 C -0 -4.62 0 0 CFG=2
M  V30 53 C -1.3337 -3.85 0 0
M  V30 54 C -0 -6.16 0 0 CFG=1
M  V30 55 O 1.3337 -6.93 0 0
M  V30 56 C -1.3337 -6.93 0 0 CFG=1
M  V30 57 C -0.6107 -8.2897 0 0
M  V30 58 O -2.0567 -8.2897 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7 CFG=1
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 17 13
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 19 21
M  V30 21 1 11 21
M  V30 22 1 9 22
M  V30 23 1 22 23 CFG=3
M  V30 24 1 22 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 32 31
M  V30 33 1 32 26
M  V30 34 1 32 33 CFG=1
M  V30 35 1 31 34 CFG=3
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 24 37
M  V30 39 1 37 38 CFG=1
M  V30 40 1 37 39 CFG=3
M  V30 41 1 37 40
M  V30 42 1 41 40
M  V30 43 1 41 42 CFG=1
M  V30 44 1 41 43
M  V30 45 2 43 44
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 1 46 47
M  V30 49 1 47 48
M  V30 50 1 48 49
M  V30 51 1 49 50
M  V30 52 1 50 51
M  V30 53 1 52 43
M  V30 54 1 52 53 CFG=1
M  V30 55 1 54 52
M  V30 56 1 54 55 CFG=1
M  V30 57 1 54 56
M  V30 58 1 56 3
M  V30 59 1 56 57 CFG=1
M  V30 60 1 56 58 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2583141806

>  <MW>
836.525

>  <MW (desalted)>
837.047

>  <ClogP>
2.292

>  <logS>
-1.404

>  <HBD>
5

>  <HBA>
16

>  <TPSA>
216.89

>  <RotBonds>
13

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  3 - 6 nM | MIC  0.04 ?g/ml

>  <CAS>
80214-83-1

>  <Description>
Roxithromycin is an antibiotic used to treat a variety of susceptible bacterial infections.

>  <EBC_ID>
EBC-66070

>  <IUPAC Name>
(3R,4S,5S,6R,7R,9R,10Z,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1-oxacyclotetradecan-2-one

>  <Main Tar all refs>
Eur. J. Med. Chem., 2014, vol. 90, p. 809 - 821 | Eur. J. Med. Chem., 2019, vol. 166, p. 224 - 231

>  <Main tar all>
Angiomotin pX=8.52 | DNA supercoiling protein pX=7.32

$$$$
Fomepizole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 C 1.0598 2.08 0 0
M  V30 3 C 2.3057 1.1748 0 0
M  V30 4 N 1.8298 -0.2898 0 0
M  V30 5 N 0.2898 -0.2898 0 0
M  V30 6 C -0.1861 1.1748 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z600419582

>  <MW>
82.053

>  <MW (desalted)>
82.104

>  <ClogP>
0.51

>  <logS>
-0.39

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
28.68

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 10 nM | IC50  0.02 ?M | Kic  0.062 ?M | IC50 < 100 nM

>  <CAS>
7554-65-6

>  <Description>
Fomepizole is an inhibitor of alcohol dehydrogenase.

>  <EBC_ID>
EBC-03035

>  <IUPAC Name>
4-methyl-1H-pyrazole

>  <Main Tar all refs>
J. MED. CHEM., 1979, vol. 22, # 4, p. 356 - 359 | Regul. Toxicol. Pharmacol., 2020, vol. 111 | Chem.-Biol. Interact., 2011, vol. 191, # 1-3, p. 26 - 31 | Drug Metab. Dispos., 2001, vol. 29, # 6, p. 813 - 820

>  <Main tar all>
Alcohol dehydrogenase (Beta 2) pX=8.0 | CYP2E1 pX=7.7 | Aldo-keto reductase family 1 member B10 pX=7.21 | Chlorzoxazone 6-Hydroxylase pX=7.0

$$$$
Cycloserine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.0598 3.62 0 0
M  V30 2 C 1.0598 2.08 0 0 CFG=2
M  V30 3 C 2.3057 1.1748 0 0
M  V30 4 O 1.8298 -0.2898 0 0
M  V30 5 N 0.2898 -0.2898 0 0
M  V30 6 C -0.1861 1.1748 0 0
M  V30 7 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 2 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198154206

>  <MW>
102.043

>  <MW (desalted)>
102.092

>  <ClogP>
-1.192

>  <logS>
-0.01

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
64.35

>  <RotBonds>
0

>  <Action on targets>
Allosteric Modulator | -

>  <Activity coefficients and valu>
stimulation rate  80 % | MIC = 7.8 ng/mL

>  <CAS>
68-41-7

>  <Description>
Cycloserine is a broad-spectrum antibiotic used in the treatment of tuberculosis and certain urinary tract infections. Cycloserine is an analog of the amino acid D-alanine. It interferes with an early step in bacterial cell wall synthesis in the cytoplasm by competitive inhibition of two enzymes, L-alanine racemase, which forms D-alanine from L-alanine, and D-alanylalanine synthetase, which incorporates D-alanine into the pentapeptide necessary for peptidoglycan formation and bacterial cell wall synthesis.

>  <EBC_ID>
EBC-03937

>  <IUPAC Name>
(4R)-4-amino-1,2-oxazolidin-3-one

>  <Main Tar all refs>
SANOFI - US5856335, 1999, A | Chem. Biol., 2012, vol. 19, # 7, p. 844 - 854

>  <Main tar all>
NMDA receptor pX=8.6 | Isocitrate lyase pX=7.12

$$$$
Mequinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 O 1.3337 -2.31 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 3 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474598

>  <MW>
124.052

>  <MW (desalted)>
124.137

>  <ClogP>
1.574

>  <logS>
-0.99

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  15.8 nM

>  <CAS>
150-76-5

>  <Description>
Mequinol is indicated for the treatment of solar lentigines and related hyperpigmented lesions resulting from chronic sun exposure.

>  <EBC_ID>
EBC-03183

>  <IUPAC Name>
4-methoxyphenol

>  <Main Tar all refs>
Chem. Pharm. Bull., 2008, vol. 56, # 5, p. 723 - 726

>  <Main tar all>
myeloperoxidase pX=7.8

$$$$
Chlorocresol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104477910

>  <MW>
142.019

>  <MW (desalted)>
142.583

>  <ClogP>
2.984

>  <logS>
-2.01

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
IC50 = 27 nM | IC50  380 nM | EC50  500 nM | EC50  500 nM

>  <CAS>
59-50-7

>  <Description>
Chlorocresol possesses disinfectant and antiseptic properties.

>  <EBC_ID>
EBC-03201

>  <IUPAC Name>
4-chloro-3-methylphenol

>  <Main Tar all refs>
Curr. Drug Metab., 2008, vol. 9, # 4, p. 269 - 275 | JOHNSON & JOHNSON INC - US2006/270836, 2006, A1 | JOHNSON & JOHNSON INC - US2006/270836, 2006, A1 | J. Steroid Biochem. Mol. Biol., 2008, vol. 108, # 1-2, p. 44 - 54

>  <Main tar all>
Estrogen sulfotransferase pX=7.57 | Estrogen-related receptor-? pX=6.42 | RNA-binding motif, single-stranded-interacting protein 1 pX=6.3 | nuclear receptor coactivator 2 pX=6.3

$$$$
Allantoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.2739 5.93 0 0
M  V30 2 C -0.2739 4.39 0 0
M  V30 3 O -1.6075 3.62 0 0
M  V30 4 N 1.0598 3.62 0 0
M  V30 5 C 1.0598 2.08 0 0
M  V30 6 N 2.3057 1.1748 0 0
M  V30 7 C 1.8298 -0.2898 0 0
M  V30 8 O 2.735 -1.5357 0 0
M  V30 9 N 0.2898 -0.2898 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104486690

>  <MW>
158.044

>  <MW (desalted)>
158.115

>  <ClogP>
-2.235

>  <logS>
-0.28

>  <HBD>
4

>  <HBA>
3

>  <TPSA>
113.32

>  <RotBonds>
1

>  <CAS>
97-59-6

>  <Description>
Allantoin is a substance that is endogenous to the human body and also found as a normal component of human diets. It is commonly applied in a variety of topical vehicles or applications such as cosmetic creams, toothpastes, mouthwashes, shampoos, lipsticks, anti-acne products, and lotions for the purpose of moisturizing skin, enhancing the smoothness of skin, stimulating the healing of wounds, and soothing irritated skin.

>  <EBC_ID>
EBC-12265

>  <IUPAC Name>
(2,5-dioxoimidazolidin-4-yl)urea

$$$$
Oxyquinoline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 2.6674 0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 N 5.3347 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 2 11
M  V30 12 1 6 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56926518

>  <MW>
145.053

>  <MW (desalted)>
145.158

>  <ClogP>
2.077

>  <logS>
-1.62

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | EC50  6.6E-08 M | EC50  0.08 ?M

>  <CAS>
148-24-3

>  <Description>
Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It  is used as a biocidal component of several over the counter products. These products are marketed for the purposes of inhibiting abnormal biological growth in the vagina and restoring natural pH.

>  <EBC_ID>
EBC-03241

>  <IUPAC Name>
quinolin-8-ol

>  <Main Tar all refs>
Bioorg. Med. Chem., 2017, vol. 25, # 3, p. 813 - 824 | Water Res., 2016, vol. 93, p. 110 - 120 | Sham, Yuk Yin;Muthyala, Ramaiah;Shin, Woo-Shik - US2022/401432, 2022, A1

>  <Main tar all>
Methionyl aminopeptidase 1 pX=8.52 | nuclear estrogen receptor pX=7.18 | Beta-lactamase class B VIM-2 pX=7.1

$$$$
Isoeugenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 4.001 -2.31 0 0
M  V30 8 C 5.3347 -3.08 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8 CFG=2
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 3 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57953030

>  <MW>
164.084

>  <MW (desalted)>
164.201

>  <ClogP>
2.577

>  <logS>
-2.35

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
2

>  <Action on targets>
Antagonist | Inhibitor | - | Substrate

>  <Activity coefficients and valu>
IC30  1.67E-07 M | IC50  3.72 ?M | EC50  7 ?M | Ki (inhibition constant)  11.17 ?M

>  <CAS>
97-54-1

>  <Description>
Isoeugenol is a commonly used fragrance added to many commercially available products, and occurs naturally in the essential oils of plants such as ylang-ylang. Isoeugenol is approved by the FDA for use within allergenic epicutaneous patch tests.

>  <EBC_ID>
EBC-26115

>  <IUPAC Name>
2-methoxy-4-(prop-1-en-1-yl)phenol

>  <Main Tar all refs>
Environ. Pollut., 2021, vol. 286 | BioMed Res. Int., 2019, vol. 2019 | Biochemistry, 2011, vol. 50, # 5, p. 843 - 853 | Food Chem. Toxicol., 2016, vol. 90, p. 55 - 63

>  <Main tar all>
Androgen receptor pX=6.41 | Monoamine oxidase A pX=5.43 | Estrogen receptor pX=5.15 | UDP-glucuronosyltransferase 1-1 pX=4.95

$$$$
Debrisoquin  hydriodide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0
M  V30 2 N 4.8537 -2.6654 0 0
M  V30 3 C 4.8537 -1.1254 0 0
M  V30 4 N 3.52 -0.3554 0 0
M  V30 5 N 6.1874 -0.3554 0 0
M  V30 6 C 6.1874 1.1846 0 0
M  V30 7 C 7.521 1.9546 0 0
M  V30 8 C 8.8547 1.1846 0 0
M  V30 9 C 10.1884 1.9546 0 0
M  V30 10 C 11.5221 1.1846 0 0
M  V30 11 C 11.5221 -0.3554 0 0
M  V30 12 C 10.1884 -1.1254 0 0
M  V30 13 C 8.8547 -0.3554 0 0
M  V30 14 C 7.521 -1.1254 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 1 5 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z118438370

>  <MW>
303.023

>  <MW (desalted)>
175.23

>  <ClogP>
0.895

>  <logS>
-3.28

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
53.11

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Substrate

>  <Activity coefficients and valu>
Ki (inhibition constant)  369 nM | Ki (inhibition constant)  0.56 ?M | percentage increase Active   | IC50  1 ?M | IC50  2.1 ?M | IC50  3.9 ?M | IC50  4.8 ?M | Km (Michaelis constant)  6.87 ?M | Km (Michaelis constant)  11.4 ?M

>  <CAS>
1052540-65-4

>  <Description>
Debrisoquine is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. It is used for the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.

>  <EBC_ID>
EBC-15022

>  <IUPAC Name>
1,2,3,4-tetrahydroisoquinoline-2-carboximidamide hydroiodide

>  <Main Tar all refs>
Life Sci., 2002, vol. 71, # 23, p. 2691 - 2700 | Drug Metab. Dispos., 2012, vol. 40, # 1, p. 47 - 53 | SOUTHWEST RESEARCH INSTITUTE INC - US9216181, 2015, B2 | Br. J. Pharmacol., 2021, vol. 178, # 6, p. 1459 - 1474 | Br. J. Pharmacol., 2021, vol. 178, # 6, p. 1459 - 1474 | Br. J. Pharmacol., 2021, vol. 178, # 6, p. 1459 - 1474 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 2, p. 539 - 546 | Drug Metab. Dispos., 2002, vol. 30, # 9, p. 970 - 976 | Br. J. Pharmacol., 2021, vol. 178, # 6, p. 1459 - 1474

>  <Main tar all>
D2- like receptor pX=6.43 | Cytochrome P450 2D6 pX=6.25 | H1 receptor pX=6.0 | Multidrug and toxin extrusion pX=6.0 | Organic cation transporter 1 pX=5.68 | Organic cation/carnitine transporter 3 pX=5.41 | Monoamine oxidase A pX=5.32 | CYP2D26 pX=5.16 | Organic cation transporter 1 (R61C) pX=4.94

$$$$
Chlorphenesin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 O 2.6674 -3.08 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 O 5.3347 -4.62 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 Cl 10.6694 -7.7 0 0
M  V30 12 C 8.0021 -7.7 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z995094004

>  <MW>
202.04

>  <MW (desalted)>
202.635

>  <ClogP>
1.216

>  <logS>
-1.98

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.69

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
ED50 = 0.00033 M | inhibition percentage  47 %

>  <CAS>
104-29-0

>  <Description>
Chlorphenesin is a phenol ether used to treat painful muscular conditions.

>  <EBC_ID>
EBC-14344

>  <IUPAC Name>
3-(4-chlorophenoxy)propane-1,2-diol

>  <Main Tar all refs>
VIATRIS INC - US3879544, 1975, A | J. Med. Chem., 2013, vol. 56, # 21, p. 8377 - 8388

>  <Main tar all>
Histamine receptor pX=3.48 | COX-2  pX=3.25

$$$$
Phenazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.5796 -3.2152 0 0
M  V30 4 C 2.1037 -4.6798 0 0
M  V30 5 O 3.0089 -5.9257 0 0
M  V30 6 N 0.5637 -4.6798 0 0
M  V30 7 C -0.3415 -5.9257 0 0
M  V30 8 C 0.2849 -7.3326 0 0
M  V30 9 C -0.6203 -8.5784 0 0
M  V30 10 C -2.1519 -8.4175 0 0
M  V30 11 C -2.7783 -7.0106 0 0
M  V30 12 C -1.8731 -5.7647 0 0
M  V30 13 N 0.0878 -3.2152 0 0
M  V30 14 C -1.3768 -2.7393 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 6 13
M  V30 14 1 2 13
M  V30 15 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56869297

>  <MW>
188.095

>  <MW (desalted)>
188.226

>  <ClogP>
0.204

>  <logS>
-1.5

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
23.55

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  7.32E-08 M

>  <CAS>
60-80-0

>  <Description>
Phenazone is an analgesic and antipyretic that has been given by mouth and as ear drops. It is a  selective COX-3 inhibitor. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.

>  <EBC_ID>
EBC-03511

>  <IUPAC Name>
1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one

>  <Main Tar all refs>
TOTTORI UNIVERSITY - US2018/338899, 2018, A1

>  <Main tar all>
Homeobox-leucine zipper protein HAT1 pX=7.14

$$$$
Chloroquinaldol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 C 5.3347 0 0 0
M  V30 7 Cl 5.3347 1.54 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 Cl 8.0021 -3.08 0 0
M  V30 11 C 5.3347 -3.08 0 0
M  V30 12 O 5.3347 -4.62 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 14 N 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 5 13
M  V30 14 1 13 14
M  V30 15 2 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104475058

>  <MW>
226.99

>  <MW (desalted)>
228.075

>  <ClogP>
3.838

>  <logS>
-3.33

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
72-80-0

>  <Description>
Chlorquinaldol is bacteriocidal in both gram positive and gram negative bacteria. It is more effective in targeting gram positive bacteria, particularly staphylococci. Chlorquinaldol was used historically as a topical antiseptic agent for skin infections. It is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.

>  <EBC_ID>
EBC-03432

>  <IUPAC Name>
5,7-dichloro-2-methylquinolin-8-ol

>  <Main Tar all refs>
ACS Synth. Biol., 2022, vol. 11, # 8, p. 2820 - 2828

>  <Main tar all>
H2 receptor pX=9.0

$$$$
Nitrofural
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.7272 8.24 0 0
M  V30 2 C 3.7272 6.7 0 0
M  V30 3 O 5.0609 5.93 0 0
M  V30 4 N 2.3935 5.93 0 0
M  V30 5 N 2.3935 4.39 0 0
M  V30 6 C 1.0598 3.62 0 0
M  V30 7 C 1.0598 2.08 0 0
M  V30 8 C 2.3057 1.1748 0 0
M  V30 9 C 1.8298 -0.2898 0 0
M  V30 10 C 0.2898 -0.2898 0 0
M  V30 11 O -0.1861 1.1748 0 0
M  V30 12 N -0.6154 -1.5357 0 0 CHG=1
M  V30 13 O 0.011 -2.9426 0 0
M  V30 14 O -2.1469 -1.3747 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=2
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 1 10 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z49560608

>  <MW>
198.039

>  <MW (desalted)>
198.136

>  <ClogP>
0.204

>  <logS>
-2.813

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
123.76

>  <RotBonds>
3

>  <CAS>
59-87-0

>  <Description>
Nitrofural is a topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial wounds, burns, ulcers, and skin infections.

>  <EBC_ID>
EBC-71031

>  <IUPAC Name>
{[(5-nitrofuran-2-yl)methylidene]amino}urea

$$$$
Ornidazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 C 1.0598 2.08 0 0
M  V30 3 N 2.3057 1.1748 0 0
M  V30 4 C 1.8298 -0.2898 0 0
M  V30 5 C 0.2898 -0.2898 0 0
M  V30 6 N -0.6154 -1.5357 0 0 CHG=1
M  V30 7 O -2.1469 -1.3747 0 0
M  V30 8 O 0.011 -2.9426 0 0 CHG=-1
M  V30 9 N -0.1861 1.1748 0 0
M  V30 10 C -1.6507 1.6507 0 0
M  V30 11 C -1.9709 3.157 0 0
M  V30 12 O -3.4355 3.6329 0 0
M  V30 13 C -0.8264 4.1875 0 0
M  V30 14 Cl -1.1466 5.6939 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269240018

>  <MW>
219.041

>  <MW (desalted)>
219.626

>  <ClogP>
0.065

>  <logS>
-1.452

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
81.19

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  1.82 ?M | inhibition percentage  98 - 100 % | inhibition percentage  98 - 100 %

>  <CAS>
16773-42-5

>  <Description>
Ornidazole is an orally bioavailable 5-nitroimidazole derivative with antibacterial and antiprotozoal activities. It is a nitroimidazole agent indicated in the treatment of infections such as trichomoniasis, amebiasis, and giardiasis.

>  <EBC_ID>
EBC-04176

>  <IUPAC Name>
1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2022, vol. 66, # 7 | TEL AVIV UNIVERSITY - US2015/189881, 2015, A1 | TEL AVIV UNIVERSITY - US2015/189881, 2015, A1

>  <Main tar all>
epidermal growth factor receptor pX=5.74 | Glyceraldehyde-3-phosphate dehydrogenase pX=4.28 | Triosephosphate isomerase (gene tpi1) pX=4.28

$$$$
Disulfiram
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.2104 -5.7953 0 0
M  V30 2 C 1.3018 -5.5043 0 0
M  V30 3 N 2.31 -6.6684 0 0
M  V30 4 C 1.8059 -8.1236 0 0
M  V30 5 C 0.2937 -8.4146 0 0
M  V30 6 C 3.8222 -6.3774 0 0
M  V30 7 S 4.3263 -4.9222 0 0
M  V30 8 S 4.8304 -7.5415 0 0
M  V30 9 S 6.3427 -7.2505 0 0
M  V30 10 C 7.3508 -8.4146 0 0
M  V30 11 S 6.8467 -9.8698 0 0
M  V30 12 N 8.8631 -8.1236 0 0
M  V30 13 C 9.8712 -9.2877 0 0
M  V30 14 C 11.3835 -8.9967 0 0
M  V30 15 C 9.3672 -6.6684 0 0
M  V30 16 C 10.8794 -6.3774 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 12 15
M  V30 15 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473910

>  <MW>
296.051

>  <MW (desalted)>
296.539

>  <ClogP>
3.88

>  <logS>
-5.36

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
6.48

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
binding rate increase Active   | inhibition rate Active   | cell age score decrease Active   | cell age score decrease Active   | IC50  0.02 ?M | IC50  30.6 nM | IC50  42 nM | IC50  42 nM | IC50  0.059 ?M | IC50  72.91 nM

>  <CAS>
97-77-8

>  <Description>
Disulfiram is a carbamate derivative used as an alcohol deterrent. Disulfiram is a copper and zinc chelator and an irreversible inhibitor of aldehyde dehydrogenase. It also inhibits the copper-dependent enzyme dopamine beta-hydroxylase, which prevents the breakdown of dopamine and has been considered as a treatment for cocaine dependence.

>  <EBC_ID>
EBC-03638

>  <IUPAC Name>
N,N-diethyl[(diethylcarbamothioyl)disulfanyl]carbothioamide

>  <Main Tar all refs>
ACS Chem. Biol., 2022, vol. 17, # 12, p. 3389 - 3406 | PLoS ONE, 2020, vol. 15, # 7 | SPRING DISCOVERY - WO2021/257880, 2021, A1 | SPRING DISCOVERY - WO2021/257880, 2021, A1 | J. Med. Chem., 2022, vol. 65, # 13, p. 9126 - 9143 | Front. Oncol., 2022, vol. 12 | TOKYO UNIVERSITY OF SCIENCE - US10722480, 2020, B2 | TOKYO UNIVERSITY OF SCIENCE - US10722480, 2020, B2 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 18, p. 3113 - 3118 | Int. J. Mol. Sci., 2023, vol. 24, # 4

>  <Main tar all>
Glutathione peroxidase 4 (U46C) pX=8.61 | Nuclear protein localization protein 4 pX=8.0 | Aldehyde dehydrogenase 1 pX=7.7 | Gasdermin-D pX=7.7 | Glyceraldehyde-3-phosphate dehydrogenase pX=7.7 | Aldehyde dehydrogenase pX=7.51 | CCR2 pX=7.38 | Nuclear pore complex protein Nup85 pX=7.38 | Lysyl oxidase homolog 4 pX=7.23 | B-Raf proto-oncogene, serine/threonine kinase (V600E) pX=7.14

$$$$
Carbamazepine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.7665 2.9297 0 0
M  V30 2 C 7.1002 2.1597 0 0
M  V30 3 O 8.4339 2.9297 0 0
M  V30 4 N 7.1002 0.6197 0 0
M  V30 5 C 8.4877 -0.0485 0 0
M  V30 6 C 9.6166 0.999 0 0
M  V30 7 C 11.0882 0.5451 0 0
M  V30 8 C 11.4308 -0.9563 0 0
M  V30 9 C 10.3019 -2.0038 0 0
M  V30 10 C 8.8304 -1.5499 0 0
M  V30 11 C 7.8702 -2.7539 0 0
M  V30 12 C 6.3302 -2.7539 0 0
M  V30 13 C 5.37 -1.5499 0 0
M  V30 14 C 3.8984 -2.0038 0 0
M  V30 15 C 2.7695 -0.9563 0 0
M  V30 16 C 3.1122 0.5451 0 0
M  V30 17 C 4.5838 0.999 0 0
M  V30 18 C 5.7127 -0.0485 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 4 18
M  V30 20 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104508594

>  <MW>
236.095

>  <MW (desalted)>
236.269

>  <ClogP>
2.38

>  <logS>
-3.67

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
46.33

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
298-46-4

>  <Description>
Carbamazepine is an anticonvulsant drug and analgesic drug. It is used to control seizures and to treat pain resulting from trigeminal neuralgia.

>  <EBC_ID>
EBC-11073

>  <IUPAC Name>
2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide

>  <Main Tar all refs>
NATIONWIDE CHILDREN'S HOSPITAL INC - WO2020/61649, 2020, A1

>  <Main tar all>
integrin, alpha M subunit (complement component 3 receptor 3 subunit) pX=10.0

$$$$
Triamterene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 N 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 N 2.6674 1.54 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 N 5.3347 0 0 0
M  V30 8 C 6.6684 -0.77 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 N 8.0021 -3.08 0 0
M  V30 11 N 5.3347 -3.08 0 0
M  V30 12 C 4.001 -2.31 0 0
M  V30 13 N 2.6674 -3.08 0 0
M  V30 14 C 8.0021 -0 0 0
M  V30 15 C 8.0021 1.54 0 0
M  V30 16 C 9.3358 2.31 0 0
M  V30 17 C 10.6694 1.54 0 0
M  V30 18 C 10.6694 -0 0 0
M  V30 19 C 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 13 1 12 13
M  V30 14 2 2 13
M  V30 15 1 8 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275128596

>  <MW>
253.108

>  <MW (desalted)>
253.263

>  <ClogP>
1.608

>  <logS>
-3.93

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
129.62

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 6E-09 M | Ki (inhibition constant) = 6E-09 M | pKi  7.9

>  <CAS>
396-01-0

>  <Description>
Triamterene is an inhibitor of the epithelial sodium channel ENaC that increases renal sodium excretion and decreases potassium excretion. It is used in the treatment of edema and in the management of hypertension.

>  <EBC_ID>
EBC-03774

>  <IUPAC Name>
6-Phenylpteridine-2,4,7-triamine

>  <Main Tar all refs>
J. Med. Chem., 1969, vol. 12, # 4, p. 662 - 668 | J. Med. Chem., 1969, vol. 12, # 4, p. 662 - 668 | Chem. Rev., 1984, vol. 84, # 4, p. 333 - 407

>  <Main tar all>
dihydrofolate reductase pX=8.22 | dihydrofolate reductase pX=8.22 | dihydrofolate reductase pX=7.9

$$$$
Chlorpromazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.4667 0 0
M  V30 3 N 5.7337 0.6967 0 0
M  V30 4 C 5.7337 -0.8433 0 0
M  V30 5 C 7.0674 1.4667 0 0
M  V30 6 C 8.401 0.6967 0 0
M  V30 7 C 9.7347 1.4667 0 0
M  V30 8 N 11.0684 0.6967 0 0
M  V30 9 C 12.4021 1.4667 0 0
M  V30 10 C 12.4021 3.0067 0 0
M  V30 11 C 13.7358 3.7767 0 0
M  V30 12 C 15.0694 3.0067 0 0
M  V30 13 C 15.0694 1.4667 0 0
M  V30 14 C 13.7358 0.6967 0 0
M  V30 15 S 13.7358 -0.8433 0 0
M  V30 16 C 12.4021 -1.6133 0 0
M  V30 17 C 12.4021 -3.1533 0 0
M  V30 18 C 11.0684 -3.9233 0 0
M  V30 19 C 9.7347 -3.1533 0 0
M  V30 20 Cl 8.401 -3.9233 0 0
M  V30 21 C 9.7347 -1.6133 0 0
M  V30 22 C 11.0684 -0.8433 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 21 22
M  V30 22 1 8 22
M  V30 23 2 16 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104477466

>  <MW>
354.072

>  <MW (desalted)>
318.864

>  <ClogP>
5.3

>  <logS>
-5.4

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.55 nM | Ki (inhibition constant) = 0.75 nM | Ki (inhibition constant) = 1.1 nM | Ki (inhibition constant) = 1.14 nM | Ki (inhibition constant) = 1.16 nM | Ki (inhibition constant) = 1.2 nM | Ki (inhibition constant)  2.1 nM | Ki (inhibition constant) = 4 nM | Ki (inhibition constant)  4.8 nM | Ki (inhibition constant) = 4.9 nM | IC50  5.1 nM | Ki (inhibition constant)  8.01 nM | Ki (inhibition constant) = 9.7 nM | Ki (inhibition constant)  13 nM | Ki (inhibition constant)  16 nM

>  <CAS>
69-09-0

>  <Description>
Chlorpromazine is a phenothiazine antipsychotic used to treat nausea, vomiting, preoperative anxiety, schizophrenia, bipolar disorder, and severe behavioral problems in children.

>  <EBC_ID>
EBC-11054

>  <IUPAC Name>
[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine hydrochloride

>  <Main Tar all refs>
Pharmacol. Rev., 2001, vol. 53, # 1, p. 119 - 133 | Bioorg. Med. Chem., 1999, vol. 7, # 7, p. 1263 - 1271 | Bioorg. Med. Chem., 1999, vol. 7, # 7, p. 1263 - 1271 | Pharmacol. Rev., 1997, vol. 49, # 3, p. 231 - 252 | Pharmacol. Rev., 1997, vol. 49, # 3, p. 231 - 252 | Pharmacol. Rev., 2001, vol. 53, # 1, p. 119 - 133 | Eur. J. Pharmacol., 1993, vol. 237, # 2-3, p. 183 - 189 | Bioorg. Med. Chem., 2004, vol. 12, # 14, p. 3815 - 3824 | MOL. PHARMACOL., 1992, vol. 42, # 1, p. 1 - 5 | Bioorg. Med. Chem., 1999, vol. 7, # 7, p. 1263 - 1271 | Br. J. Pharmacol., 1980, vol. 68, # 4, p. 687 - 696 | J. PHARMACOL. EXP. THER., 1997, vol. 282, # 1, p. 56 - 63 | Pharmacol. Rev., 2001, vol. 53, # 1, p. 119 - 133 | J. PHARMACOL. EXP. THER., 1997, vol. 282, # 1, p. 56 - 63 | Endocrinology, 1979, vol. 104, # 2, p. 307 - 312

>  <Main tar all>
D2 receptor pX=9.26 | ?1-adrenoceptor pX=9.12 | D2A receptor pX=8.96 | D2 receptor pX=8.94 | D3 receptor pX=8.94 | D3 receptor pX=8.92 | D2L receptor pX=8.68 | 5-HT6 receptor pX=8.4 | ?2B-adrenoceptor pX=8.32 | 5-HT2A receptor pX=8.31 | H1 receptor pX=8.29 | D1 receptor pX=8.1 | D4 receptor pX=8.01 | 5-HT2A receptor pX=7.89 | Dopamine receptor pX=7.8

$$$$
Lidocaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7947 -1.9526 0 0
M  V30 2 C 5.3347 -1.9526 0 0
M  V30 3 N 6.1047 -3.2863 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 3.7947 -4.62 0 0
M  V30 6 C 7.6447 -3.2863 0 0
M  V30 7 C 8.4147 -4.62 0 0
M  V30 8 O 7.6447 -5.9537 0 0
M  V30 9 N 9.9547 -4.62 0 0
M  V30 10 C 10.7247 -5.9537 0 0
M  V30 11 C 12.2647 -5.9537 0 0
M  V30 12 C 13.0347 -4.62 0 0
M  V30 13 C 13.0347 -7.2874 0 0
M  V30 14 C 12.2647 -8.621 0 0
M  V30 15 C 10.7247 -8.621 0 0
M  V30 16 C 9.9547 -7.2874 0 0
M  V30 17 C 8.4147 -7.2874 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z55135799

>  <MW>
234.337

>  <MW (desalted)>
234.337

>  <ClogP>
1.954

>  <logS>
-2.638

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
5

>  <Action on targets>
Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50  0.017 ?M | IC50  3.7E-07 M

>  <CAS>
137-58-6

>  <Description>
Lidocaine is a local anesthetic of the amide type used in a wide variety of superficial and invasive procedures. The lidocaine agent acts on sodium ion channels located on the internal surface of nerve cell membranes.

>  <EBC_ID>
EBC-03844

>  <IUPAC Name>
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide

>  <Main Tar all refs>
J. Med. Chem., 2010, vol. 53, # 12, p. 4668 - 4677 | Br. J. Pharmacol., 2001, vol. 133, # 1, p. 207 - 216

>  <Main tar all>
Voltage-gated?sodium?channel pX=7.77 | M3 receptor pX=6.43

$$$$
Oseltamivir acid tartrate salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6007 5.1975 0 0
M  V30 2 C 1.267 4.4275 0 0
M  V30 3 C 1.267 2.8875 0 0
M  V30 4 C 2.6007 2.1175 0 0
M  V30 5 C 2.6007 0.5775 0 0
M  V30 6 O -0.0667 2.1175 0 0
M  V30 7 C -0.0667 0.5775 0 0 CFG=2
M  V30 8 C 1.267 -0.1925 0 0
M  V30 9 C 1.267 -1.7325 0 0
M  V30 10 C -0.0667 -2.5025 0 0
M  V30 11 C -1.4004 -1.7325 0 0 CFG=2
M  V30 12 N -2.734 -2.5025 0 0
M  V30 13 C -1.4004 -0.1925 0 0 CFG=1
M  V30 14 N -2.734 0.5775 0 0
M  V30 15 C -4.0677 -0.1925 0 0
M  V30 16 O -4.0677 -1.7325 0 0
M  V30 17 C -5.4014 0.5775 0 0
M  V30 18 C 2.6007 -2.5025 0 0
M  V30 19 O 2.6007 -4.0425 0 0
M  V30 20 O 3.9344 -1.7325 0 0
M  V30 21 O 11.2354 1.925 0 0
M  V30 22 C 11.2354 0.385 0 0
M  V30 23 C 9.9017 -0.385 0 0
M  V30 24 O 9.9017 -1.925 0 0
M  V30 25 C 8.568 0.385 0 0
M  V30 26 O 7.2344 -0.385 0 0
M  V30 27 O 8.568 1.925 0 0
M  V30 28 C 12.5691 -0.385 0 0
M  V30 29 O 13.9027 0.385 0 0
M  V30 30 O 12.5691 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 13 11
M  V30 13 1 13 7
M  V30 14 1 13 14 CFG=1
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 9 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 23 25
M  V30 25 2 25 26
M  V30 26 1 25 27
M  V30 27 1 22 28
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759893

>  <MW>
434.438

>  <MW (desalted)>
284.351

>  <ClogP>
-1.237

>  <logS>
-1.7

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
101.65

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.01 nM | IC50  0.05 nM | Ki (inhibition constant) = 0.12 nM | IC50  0.13 nM | IC50  0.0002 ?M | IC50 = 0.2 nM

>  <CAS>
1215211-48-5

>  <Description>
Oseltamivir acid is an antiviral prodrug targeted against the influenza viruses. It is an inhibitor of influenza neuraminidase.

>  <EBC_ID>
EBC-50044

>  <IUPAC Name>
(3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid; 2,3-dihydroxybutanedioic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2001, vol. 45, # 4, p. 1162 - 1167 | Antimicrob. Agents Chemother., 2013, vol. 57, # 11, p. 5209 - 5215 | Bioorg. Med. Chem. Lett., 2014, vol. 24, # 7, p. 1805 - 1807 | Antimicrob. Agents Chemother., 2014, vol. 58, # 4, p. 2045 - 2051 | J. Nat. Prod., 2014, vol. 77, # 3, p. 563 - 570 | Bioorg. Med. Chem., 2012, vol. 20, # 6, p. 2152 - 2157

>  <Main tar all>
Sialidase pX=11.0 | Neuraminidase pX=10.3 | Neuraminidase N2 pX=9.92 | Neuraminidase?(S245N) pX=9.89 | Neurofibromin pX=9.7 | Sialidase-3 pX=9.7

$$$$
Levonorgestrel
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.4591 -7.3575 0 0
M  V30 2 C 6.5949 -6.0829 0 0
M  V30 3 C 7.2666 -4.6971 0 0 CFG=2
M  V30 4 C 8.2593 -5.8744 0 0
M  V30 5 C 9.7753 -5.6034 0 0
M  V30 6 C 10.2985 -4.155 0 0 CFG=1
M  V30 7 C 9.3058 -2.9776 0 0 CFG=1
M  V30 8 C 9.829 -1.5293 0 0
M  V30 9 C 11.345 -1.2582 0 0
M  V30 10 C 12.3377 -2.4355 0 0
M  V30 11 C 13.8537 -2.1644 0 0
M  V30 12 C 14.8464 -3.3418 0 0
M  V30 13 O 16.3624 -3.0707 0 0
M  V30 14 C 14.3232 -4.7901 0 0
M  V30 15 C 12.8072 -5.0612 0 0
M  V30 16 C 11.8145 -3.8839 0 0 CFG=2
M  V30 17 C 7.7898 -3.2487 0 0 CFG=2
M  V30 18 C 6.574 -2.3035 0 0
M  V30 19 C 5.2994 -3.1677 0 0
M  V30 20 C 5.7274 -4.6471 0 0 CFG=2
M  V30 21 O 4.3071 -5.2423 0 0
M  V30 22 C 5.5008 -6.1703 0 0
M  V30 23 C 5.2742 -7.6935 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 6 16
M  V30 17 1 16 10
M  V30 18 1 17 7
M  V30 19 1 3 17
M  V30 20 1 17 18 CFG=1
M  V30 21 1 18 19
M  V30 22 1 20 19
M  V30 23 1 3 20
M  V30 24 1 20 21 CFG=1
M  V30 25 1 20 22 CFG=3
M  V30 26 3 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404028

>  <MW>
312.446

>  <MW (desalted)>
312.446

>  <ClogP>
3.499

>  <logS>
-5.35

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
1

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  0.16 pM

>  <CAS>
797-63-7

>  <Description>
Levonorgestrel is a synthetic progestogen similar to Progesterone. It is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device.

>  <EBC_ID>
EBC-11102

>  <IUPAC Name>
(1R,3aS,3bR,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-1-hydroxy-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Mol. Pharmacol., 2009, vol. 75, # 6, p. 1317 - 1324

>  <Main tar all>
Progesterone receptor pX=12.8

$$$$
Prazosin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 O 0 -0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 N 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 N 6.6684 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 N 5.3347 -4.62 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 1.3337 -2.31 0 0
M  V30 14 O 0 -3.08 0 0
M  V30 15 C -1.3337 -2.31 0 0
M  V30 16 N 8.0021 -0 0 0
M  V30 17 C 8.0021 1.54 0 0
M  V30 18 C 9.3358 2.31 0 0
M  V30 19 N 10.6694 1.54 0 0
M  V30 20 C 10.6694 -0 0 0
M  V30 21 C 9.3358 -0.77 0 0
M  V30 22 C 12.0031 2.31 0 0
M  V30 23 O 12.0031 3.85 0 0
M  V30 24 C 13.3368 1.54 0 0
M  V30 25 C 14.7437 2.1664 0 0
M  V30 26 C 15.7741 1.0219 0 0
M  V30 27 C 15.0041 -0.3117 0 0
M  V30 28 O 13.4978 0.0084 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 3 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 7 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 1 24 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275127478

>  <MW>
383.401

>  <MW (desalted)>
383.401

>  <ClogP>
2.028

>  <logS>
-4.829

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
106.95

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Antagonist | Antagonist | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  11.8  | pKi  11.8  | pA2  11.72  | Kb (antagonist dissociation constant)  0.004 nM | Kb (antagonist dissociation constant)  0.004 nM | Kb (antagonist dissociation constant)  0.005 nM | Kb (antagonist dissociation constant)  0.005 nM | pKi  11.11  | pKi  11.11  | pKb  10.95 | Ki (inhibition constant) = 2.7E-11 M | Ki (inhibition constant)  46 pM

>  <CAS>
19216-56-9

>  <Description>
Prazosin inhibits the postsynaptic alpha-1 adrenoceptors. This drug is indicated for the treatment of hypertension (high blood pressure).

>  <EBC_ID>
EBC-07720

>  <IUPAC Name>
2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine

>  <Main Tar all refs>
Biol. Pharm. Bull., 2008, vol. 31, # 4, p. 598 - 601 | Biol. Pharm. Bull., 2008, vol. 31, # 4, p. 598 - 601 | JPN. J. PHARMACOL., 1985, vol. 37, # 2, p. 181 - 187 | MedChemComm, 2018, vol. 9, # 3, p. 576 - 582 | MedChemComm, 2018, vol. 9, # 3, p. 576 - 582 | IPSEN SA - US6300499, 2001, B1 | IPSEN SA - US6300499, 2001, B1 | Biochemistry, 1998, vol. 37, # 16, p. 5730 - 5737 | Biochemistry, 1998, vol. 37, # 16, p. 5730 - 5737 | Br. J. Pharmacol., 2014, vol. 171, # 21, p. 4890 - 4901 | Nat. Chem. Biol., 2012, vol. 8, # 11, p. 890 - 896 | Mol. Pharmacol., 1997, vol. 52, # 2, p. 306 - 313

>  <Main tar all>
?1A-adrenoceptor pX=11.8 | ?1A-adrenoceptor pX=11.8 | ?-adrenoceptor pX=11.7 | ?1B-adrenoceptor pX=11.4 | ?1B-adrenoceptor pX=11.4 | ?1-adrenoceptor pX=11.3 | ?1-adrenoceptor pX=11.3 | ?1D-adrenoceptor pX=11.1 | ?1D-adrenoceptor pX=11.1 | alpha1-adrenergic receptor (Beta) pX=11.0 | ?1-adrenoceptor pX=10.6 | ?1B-adrenoceptor pX=10.3

$$$$
Biotin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 9.0521 2.5269 0 0
M  V30 2 C 10.3858 1.7569 0 0
M  V30 3 O 10.3858 0.2169 0 0
M  V30 4 C 11.7195 2.5269 0 0
M  V30 5 C 13.0532 1.7569 0 0
M  V30 6 C 14.3869 2.5269 0 0
M  V30 7 C 15.7205 1.7569 0 0
M  V30 8 C 17.0542 2.5269 0 0 CFG=2
M  V30 9 S 17.2152 4.0585 0 0
M  V30 10 C 18.7215 4.3787 0 0
M  V30 11 C 19.4915 3.045 0 0 CFG=2
M  V30 12 N 20.8984 2.4186 0 0
M  V30 13 C 20.7374 0.8871 0 0
M  V30 14 O 21.8819 -0.1434 0 0
M  V30 15 N 19.2311 0.5669 0 0
M  V30 16 C 18.4611 1.9006 0 0 CFG=2
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 16 8
M  V30 17 1 16 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z210803762

>  <MW>
244.311

>  <MW (desalted)>
244.311

>  <ClogP>
-0.075

>  <logS>
-1.87

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
78.43

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.026 nM

>  <CAS>
58-85-5

>  <Description>
Biotin is a B-complex vitamin found in many multivitamin products. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-11051

>  <IUPAC Name>
5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]pentanoic acid

>  <Main Tar all refs>
MedChemComm, 2011, vol. 2, # 9, p. 886 - 888

>  <Main tar all>
biotinidase pX=10.6

$$$$
iloperidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.7297 -11.3365 0 0
M  V30 2 O -1.2056 -12.8011 0 0
M  V30 3 C -2.7119 -13.1213 0 0
M  V30 4 C -3.1878 -14.5859 0 0
M  V30 5 C -4.6942 -14.9061 0 0
M  V30 6 C -5.7246 -13.7617 0 0
M  V30 7 C -5.2487 -12.297 0 0
M  V30 8 C -3.7424 -11.9768 0 0
M  V30 9 O -3.2665 -10.5122 0 0
M  V30 10 C -1.7602 -10.192 0 0
M  V30 11 C -1.2843 -8.7274 0 0
M  V30 12 C 0.2221 -8.4072 0 0
M  V30 13 N 0.698 -6.9426 0 0
M  V30 14 C -0.3325 -5.7982 0 0
M  V30 15 C 0.1434 -4.3335 0 0
M  V30 16 C 1.6497 -4.0133 0 0
M  V30 17 C 2.6802 -5.1578 0 0
M  V30 18 C 2.2043 -6.6224 0 0
M  V30 19 C 2.1256 -2.5487 0 0
M  V30 20 N 1.2204 -1.3028 0 0
M  V30 21 O 2.1256 -0.0569 0 0
M  V30 22 C 3.5902 -0.5328 0 0
M  V30 23 C 4.9239 0.2372 0 0
M  V30 24 C 6.2576 -0.5328 0 0
M  V30 25 F 7.5913 0.2372 0 0
M  V30 26 C 6.2576 -2.0728 0 0
M  V30 27 C 4.9239 -2.8428 0 0
M  V30 28 C 3.5902 -2.0728 0 0
M  V30 29 C -5.1701 -16.3707 0 0
M  V30 30 O -4.1396 -17.5152 0 0
M  V30 31 C -6.6764 -16.6909 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 19 28
M  V30 31 2 22 28
M  V30 32 1 5 29
M  V30 33 2 29 30
M  V30 34 1 29 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553906

>  <MW>
426.481

>  <MW (desalted)>
426.481

>  <ClogP>
3.916

>  <logS>
-4.21

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
64.8

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.043 nM | pKi = 9.6  | pKi = 9.6  | pKi  9.56  | pKi  9.56

>  <CAS>
133454-47-4

>  <Description>
Iloperidone is an atypical antipsychotic agent used for the acute treatment of schizophrenia in adults.

>  <EBC_ID>
EBC-11258

>  <IUPAC Name>
1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one

>  <Main Tar all refs>
Drugs Future, 2000, vol. 25, # 1, p. 29 - 40 | AVACTA GROUP PLC - US2006/229299, 2006, A1 | AVACTA GROUP PLC - US2006/229299, 2006, A1 | CNS Neurol. Disord. Drug Targets, 2006, vol. 5, # 4, p. 445 - 452 | CNS Neurol. Disord. Drug Targets, 2006, vol. 5, # 4, p. 445 - 452

>  <Main tar all>
5-HT6 receptor pX=10.4 | ?1-adrenoceptor pX=9.6 | ?1-adrenoceptor pX=9.6 | 5-HT2A receptor pX=9.56 | 5-HT2A receptor pX=9.56

$$$$
Oxyphenbutazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 C 2.6674 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 2.5796 -3.2152 0 0
M  V30 7 O 4.0442 -2.7393 0 0
M  V30 8 N 2.1037 -4.6798 0 0
M  V30 9 N 0.5637 -4.6798 0 0
M  V30 10 C 0.0878 -3.2152 0 0
M  V30 11 O -1.3768 -2.7393 0 0
M  V30 12 C -0.3415 -5.9257 0 0
M  V30 13 C 0.2849 -7.3326 0 0
M  V30 14 C -0.6203 -8.5784 0 0
M  V30 15 C -2.1519 -8.4175 0 0
M  V30 16 O -3.0571 -9.6634 0 0
M  V30 17 C -2.7783 -7.0106 0 0
M  V30 18 C -1.8731 -5.7647 0 0
M  V30 19 C 3.0089 -5.9257 0 0
M  V30 20 C 4.5404 -5.7647 0 0
M  V30 21 C 5.4456 -7.0106 0 0
M  V30 22 C 4.8192 -8.4175 0 0
M  V30 23 C 3.2877 -8.5784 0 0
M  V30 24 C 2.3825 -7.3326 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 2 12 18
M  V30 20 1 8 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2379810069

>  <MW>
324.147

>  <MW (desalted)>
324.374

>  <ClogP>
2.718

>  <logS>
-4.375

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
60.85

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
Kd (dissociation constant) = 6.4E-08 M

>  <CAS>
129-20-4

>  <Description>
Oxyphenbutazone is a metabolite of phenylbutazone. It inhibits phospholipase A2, tyrosine-protein kinase. Oxyphenbutazone is a nonsteroidal anti-inflammatory drug no longer commonly used for the symptomatic relief of musculoskeletal pain.

>  <EBC_ID>
EBC-00680

>  <IUPAC Name>
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione

>  <Main Tar all refs>
Biochemistry, 2004, vol. 43, # 46, p. 14577 - 14583

>  <Main tar all>
Phospholipase A2 pX=7.19

$$$$
Salbutamol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 7.7 0 0
M  V30 2 C -1.3337 6.93 0 0
M  V30 3 C -2.1037 5.5963 0 0
M  V30 4 C -0.5637 8.2637 0 0
M  V30 5 N 0 6.16 0 0
M  V30 6 C 0 4.62 0 0
M  V30 7 C 1.3337 3.85 0 0
M  V30 8 O 2.6674 4.62 0 0
M  V30 9 C 1.3337 2.31 0 0
M  V30 10 C 2.6674 1.54 0 0
M  V30 11 C 2.6674 -0 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 O 1.3337 -2.31 0 0
M  V30 14 C 0 0 0 0
M  V30 15 C -1.3337 -0.77 0 0
M  V30 16 O -2.6674 0 0 0
M  V30 17 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 14 17
M  V30 17 2 9 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301287926

>  <MW>
239.152

>  <MW (desalted)>
239.311

>  <ClogP>
0.061

>  <logS>
-0.796

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
5

>  <Action on targets>
Agonist | -

>  <Activity coefficients and valu>
pEC50  10.81  | Kd (dissociation constant) = 193.6 pM

>  <CAS>
18559-94-9

>  <Description>
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder.

>  <EBC_ID>
EBC-04430

>  <IUPAC Name>
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol

>  <Main Tar all refs>
Mol. Pharmacol., 2014, vol. 85, # 3, p. 492 - 509 | INVION - WO2005/34871, 2005, A2

>  <Main tar all>
?2-adrenoceptor pX=10.8 | ?-adrenoceptor pX=9.71

$$$$
Strontium ranelate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Sr -1.1568 -5.9851 0 0 CHG=2
M  V30 2 Sr 8.4208 -6.8582 0 0 CHG=2
M  V30 3 O 0.3555 -5.694 0 0 CHG=-1
M  V30 4 C 1.8677 -5.403 0 0
M  V30 5 O 2.8759 -6.5671 0 0
M  V30 6 C 2.3718 -3.9478 0 0
M  V30 7 N 3.8841 -3.6568 0 0
M  V30 8 C 4.8922 -4.8209 0 0
M  V30 9 C 6.4045 -4.5299 0 0
M  V30 10 O 7.3336 -3.3017 0 0
M  V30 11 O 7.4126 -5.694 0 0 CHG=-1
M  V30 12 C 4.3881 -2.2016 0 0
M  V30 13 S 3.5072 -0.9385 0 0
M  V30 14 C 4.4363 0.2897 0 0
M  V30 15 C 3.9888 1.7632 0 0
M  V30 16 O 5.0411 2.8875 0 0
M  V30 17 O 2.4889 2.1124 0 0 CHG=-1
M  V30 18 C 5.8914 -0.2144 0 0
M  V30 19 C 7.1546 0.6665 0 0
M  V30 20 C 8.5491 0.0131 0 0
M  V30 21 O 9.8122 0.8941 0 0
M  V30 22 O 8.6804 -1.5213 0 0 CHG=-1
M  V30 23 C 5.8617 -1.7541 0 0
M  V30 24 C 7.0899 -2.6832 0 0
M  V30 25 N 8.318 -3.6123 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 2 4 5
M  V30 3 1 4 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 2 9 10
M  V30 8 1 9 11
M  V30 9 1 7 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 2 15 16
M  V30 14 1 15 17
M  V30 15 2 14 18
M  V30 16 1 18 19
M  V30 17 1 19 20
M  V30 18 2 20 21
M  V30 19 1 20 22
M  V30 20 1 18 23
M  V30 21 2 12 23
M  V30 22 1 23 24
M  V30 23 3 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040192

>  <MW>
513.796

>  <MW (desalted)>
342.281

>  <ClogP>
-13.703

>  <HBD>
0

>  <HBA>
10

>  <TPSA>
187.55

>  <RotBonds>
8

>  <CAS>
135459-87-9

>  <Description>
Strontium ranelate is a medication used for the management of severe osteoporosis in high-risk postmenopausal women and adult men.

>  <EBC_ID>
EBC-27257

>  <IUPAC Name>
distrontium(2+) 5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate

$$$$
Moxifloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -5.39 0 0
M  V30 2 O 2.6674 -4.62 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 N 0 -3.08 0 0
M  V30 6 C -0.161 -4.6116 0 0
M  V30 7 C -1.6673 -4.9317 0 0 CFG=2
M  V30 8 C -2.4373 -6.2654 0 0
M  V30 9 C -3.9773 -6.2654 0 0
M  V30 10 C -4.7473 -4.9317 0 0
M  V30 11 N -3.9773 -3.5981 0 0
M  V30 12 C -2.4373 -3.5981 0 0 CFG=2
M  V30 13 C -1.4069 -2.4536 0 0
M  V30 14 C 1.3337 -0.77 0 0
M  V30 15 F 0 0 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 C 5.3347 0 0 0
M  V30 19 O 5.3347 1.54 0 0
M  V30 20 C 6.6684 -0.77 0 0
M  V30 21 C 6.6684 -2.31 0 0
M  V30 22 N 5.3347 -3.08 0 0
M  V30 23 C 5.3347 -4.62 0 0
M  V30 24 C 6.1047 -5.9537 0 0
M  V30 25 C 4.5647 -5.9537 0 0
M  V30 26 C 4.001 -2.31 0 0
M  V30 27 C 8.0021 -0 0 0
M  V30 28 O 8.0021 1.54 0 0
M  V30 29 O 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 7 12
M  V30 13 1 12 13 CFG=3
M  V30 14 1 5 13
M  V30 15 2 4 14
M  V30 16 1 14 15
M  V30 17 1 14 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 23 25
M  V30 28 1 22 26
M  V30 29 2 3 26
M  V30 30 1 17 26
M  V30 31 1 20 27
M  V30 32 2 27 28
M  V30 33 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996957

>  <MW>
401.431

>  <MW (desalted)>
401.431

>  <ClogP>
-0.082

>  <logS>
-3.099

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
82.11

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
inhibition percentage Active   | pIC50  8.1 | MIC90  0.2 ?M | MIC90  0.2 ?M | MIC90  0.24 ?M | MIC  0.015 ?g/ml | MIC50  0.041 ?M | IC50  43 nM | IC50  43 nM | MIC90  0.49 ?M | MIC < 0.03 ?g/ml | MIC  0.03 ?g/ml | MIC  0.11 ?M | MIC  0.12 ?M | MIC  0.125 ?M | MIC  0.125 ?M | MIC  0.125 ?M | MIC  0.125 ?M | MIC  0.125 ?M | MIC  0.13 ?M | MIC90  0.5 ?g/ml | MIC  0.06 ?g/mL | MIC  0.06 ?g/ml

>  <CAS>
151096-09-2

>  <Description>
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. It is used for the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis.

>  <EBC_ID>
EBC-12282

>  <IUPAC Name>
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2017, vol. 27, # 5, p. 1162 - 1168 | Int. J. Mol. Sci., 2022, vol. 23, # 23 | ACS Med. Chem. Lett., 2022, vol. 13, # 3, p. 417 - 427 | ACS Med. Chem. Lett., 2022, vol. 13, # 3, p. 417 - 427 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Bioconjugate Chem., 2019, vol. 30, # 3, p. 751 - 759 | J. Med. Chem., 2022 | Chem. Pharm. Bull., 2019, vol. 67, # 2, p. 125 - 129 | Chem. Pharm. Bull., 2019, vol. 67, # 2, p. 125 - 129 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Int. J. Mol. Sci., 2022, vol. 23, # 11 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 17, p. 2998 - 3003 | Chem. Pharm. Bull., 2019, vol. 67, # 2, p. 125 - 129 | ACS Infect. Dis., 2022, vol. 8, # 2, p. 330 - 342 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | ACS Med. Chem. Lett., 2014, vol. 5, # 7, p. 820 - 825 | Antimicrob. Agents Chemother., 2018, vol. 62, # 4 | J. Med. Chem., 2014, vol. 57, # 11, p. 4889 - 4905 | J. Med. Chem., 2021, vol. 64, # 9, p. 6329 - 6357

>  <Main tar all>
DNA topoisomerase II pX=8.31 | Cysteine ligase pX=8.1 | DNA?gyrase subunit A pX=7.65 | DNA?gyrase subunit A pX=7.65 | DNA?gyrase pX=7.57 | Nitroreductase pX=7.43 | DNA?gyrase subunit A pX=7.39 | DNA?gyrase subunit B pX=7.37 | DNA?gyrase subunit B pX=7.37 | DNA?gyrase subunit A?(G88C) pX=7.26 | DNA negative supercoiling pX=7.13 | DNA topoisomerase II pX=7.13 | Enoyl-[acyl-carrier-protein] reductase pX=6.96 | DNA topoisomerase II pX=6.92 | DprE1 C387G pX=6.9 | DprE1 C387S pX=6.9 | DprE1 Y314H pX=6.9 | DprE1 Y314H,F426C pX=6.9 | Probable decaprenylphosphoryl-beta-D-ribose oxidase pX=6.9 | DNA?gyrase pX=6.89 | DNA topoisomerase IV subunit A pX=6.86 | DNA gyrase A74V pX=6.83 | DNA topoisomerase pX=6.83

$$$$
Oxybutynin chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 8.085 0 0
M  V30 3 C 4.4 6.545 0 0
M  V30 4 N 5.7337 5.775 0 0
M  V30 5 C 7.0674 6.545 0 0
M  V30 6 C 8.401 5.775 0 0
M  V30 7 C 5.7337 4.235 0 0
M  V30 8 C 7.0674 3.465 0 0
M  V30 9 C 8.401 2.695 0 0
M  V30 10 C 9.7347 1.925 0 0
M  V30 11 O 9.7347 0.385 0 0
M  V30 12 C 11.0684 -0.385 0 0
M  V30 13 O 12.4021 0.385 0 0
M  V30 14 C 11.0684 -1.925 0 0
M  V30 15 O 9.5284 -1.925 0 0
M  V30 16 C 11.0684 -3.465 0 0
M  V30 17 C 12.4021 -4.235 0 0
M  V30 18 C 12.4021 -5.775 0 0
M  V30 19 C 11.0684 -6.545 0 0
M  V30 20 C 9.7347 -5.775 0 0
M  V30 21 C 9.7347 -4.235 0 0
M  V30 22 C 12.6084 -1.925 0 0
M  V30 23 C 13.3784 -0.5913 0 0
M  V30 24 C 14.9184 -0.5913 0 0
M  V30 25 C 15.6884 -1.925 0 0
M  V30 26 C 14.9184 -3.2587 0 0
M  V30 27 C 13.3784 -3.2587 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 4 7
M  V30 6 1 7 8
M  V30 7 3 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 12 14
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 1 16 21
M  V30 21 1 14 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 22 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616198

>  <MW>
393.207

>  <MW (desalted)>
357.486

>  <ClogP>
4.867

>  <logS>
-5.736

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
49.77

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.3 nM | Ki (inhibition constant)  3.4E-10 M | pKi  8.9  | Ki (inhibition constant)  2.5 nM | pKi  8.4  | Ki (inhibition constant) = 5 nM

>  <CAS>
1508-65-2

>  <Description>
Oxybutynin is an antagonist of muscarinic acetylcholine receptors. Oxybutynin have been used in the treatment of overactive bladder.

>  <EBC_ID>
EBC-04400

>  <IUPAC Name>
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1986, vol. 123, # 1, p. 133 - 143 | EUR. J. PHARMACOL., 1986, vol. 123, # 1, p. 133 - 143 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2002, vol. 366, # 2, p. 97 - 103 | EUR. J. PHARMACOL., 1986, vol. 123, # 1, p. 133 - 143 | BJU Int., 2008, vol. 101, # 8, p. 1036 - 1042 | Annu. Rep. Med. Chem., 1993, vol. 28, p. 1 - 10

>  <Main tar all>
M1 receptor pX=9.52 | mAChR pX=9.47 | M3 receptor pX=8.9 | M2 receptor pX=8.6 | M4 receptor pX=8.4 | sigma non-opioid intracellular receptor 1 pX=8.3

$$$$
Cefadroxil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.0529 1.0518 0 0
M  V30 2 C 3.7192 1.8218 0 0
M  V30 3 C 2.3855 1.0518 0 0
M  V30 4 N 1.0518 1.8218 0 0
M  V30 5 C 1.0518 3.3618 0 0 CFG=2
M  V30 6 S 2.3855 4.1318 0 0
M  V30 7 C 3.7192 3.3618 0 0
M  V30 8 C -0.4882 3.3618 0 0 CFG=2
M  V30 9 N -1.5771 4.4508 0 0
M  V30 10 C -1.1785 5.9383 0 0
M  V30 11 O 0.309 6.3369 0 0
M  V30 12 C -2.2675 7.0273 0 0 CFG=2
M  V30 13 N -3.755 6.6287 0 0
M  V30 14 C -1.8689 8.5148 0 0
M  V30 15 C -2.9578 9.6037 0 0
M  V30 16 C -2.5592 11.0913 0 0
M  V30 17 C -1.0717 11.4898 0 0
M  V30 18 O -0.6731 12.9774 0 0
M  V30 19 C 0.0172 10.4009 0 0
M  V30 20 C -0.3814 8.9134 0 0
M  V30 21 C -0.4882 1.8218 0 0
M  V30 22 O -1.5771 0.7329 0 0
M  V30 23 C 2.3855 -0.4882 0 0
M  V30 24 O 1.0518 -1.2582 0 0
M  V30 25 O 3.7192 -1.2582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 19 20
M  V30 21 2 14 20
M  V30 22 1 8 21
M  V30 23 1 4 21
M  V30 24 2 21 22
M  V30 25 1 3 23
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996508

>  <MW>
363.089

>  <MW (desalted)>
363.388

>  <ClogP>
-2.507

>  <logS>
-3.521

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
132.96

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.5 ?M | EC50  3.5 ?M | Ki (inhibition constant)  6.14 ?M | Ki (inhibition constant)  8.62 ?M | IC50  0.03 mM

>  <CAS>
50370-12-2

>  <Description>
Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. Cefadroxil binds to specific penicillin-binding proteins located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis.

>  <EBC_ID>
EBC-04401

>  <IUPAC Name>
(6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
J. BIOL. CHEM., 1995, vol. 270, # 43, p. 25672 - 25677 | THE JOHNS HOPKINS UNIVERSITY - WO2005/41978, 2005, A1 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | BioMed Res. Int., 2022, vol. 2022

>  <Main tar all>
Peptide transporter 2 pX=5.6 | Glucose transporter  1 pX=5.46 | Organic anion transporter 1 pX=5.21 | Organic anion transporter 3 pX=5.06 | tyrosinase pX=4.52

$$$$
Everolimus
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 68 71 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.8417 -9.8707 0 0
M  V30 2 O 5.3272 -9.5916 0 0
M  V30 3 C 4.8116 -8.1405 0 0 CFG=2
M  V30 4 C 3.2971 -7.8615 0 0
M  V30 5 C 2.7815 -6.4103 0 0 CFG=2
M  V30 6 C 1.267 -6.1313 0 0
M  V30 7 C 0.7514 -4.6802 0 0 CFG=1
M  V30 8 C -0.7631 -4.4011 0 0
M  V30 9 C 1.7503 -3.5081 0 0 CFG=2
M  V30 10 C 1.1517 -1.9327 0 0
M  V30 11 C -0.1862 -1.1701 0 0
M  V30 12 O -1.5896 -1.8043 0 0
M  V30 13 C 0.1256 0.3379 0 0 CFG=2
M  V30 14 C -0.9111 1.4767 0 0
M  V30 15 C 1.6563 0.5074 0 0
M  V30 16 C 2.8306 1.7161 0 0
M  V30 17 C 2.3785 3.1882 0 0
M  V30 18 C 4.3387 1.4042 0 0 CFG=1
M  V30 19 O 5.5895 0.506 0 0
M  V30 20 C 5.3628 2.5544 0 0 CFG=1
M  V30 21 O 4.8788 4.0163 0 0
M  V30 22 C 3.3707 4.3282 0 0
M  V30 23 C 6.8709 2.2425 0 0
M  V30 24 O 7.3549 0.7805 0 0
M  V30 25 C 7.895 3.3926 0 0 CFG=2
M  V30 26 C 7.411 4.8546 0 0
M  V30 27 C 9.4031 3.0808 0 0
M  V30 28 C 10.4272 4.2309 0 0 CFG=2
M  V30 29 C 9.9432 5.6929 0 0
M  V30 30 C 11.9353 3.919 0 0
M  V30 31 C 12.9594 5.0692 0 0
M  V30 32 C 14.4675 4.7573 0 0
M  V30 33 C 14.9515 3.2953 0 0
M  V30 34 C 16.4596 2.9835 0 0
M  V30 35 C 16.9436 1.5215 0 0
M  V30 36 C 18.4517 1.2097 0 0
M  V30 37 C 15.9194 0.3714 0 0 CFG=2
M  V30 38 C 14.4114 0.6832 0 0
M  V30 39 C 13.3872 -0.4669 0 0 CFG=2
M  V30 40 C 13.8712 -1.9289 0 0
M  V30 41 C 12.8471 -3.079 0 0
M  V30 42 C 11.339 -2.7671 0 0 CFG=1
M  V30 43 C 10.3149 -3.9172 0 0
M  V30 44 C 10.855 -1.3051 0 0 CFG=1
M  V30 45 O 9.8309 -2.4553 0 0
M  V30 46 O 11.8791 -0.155 0 0
M  V30 47 C 9.3469 -0.9933 0 0
M  V30 48 O 8.863 0.4687 0 0
M  V30 49 C 8.3228 -2.1434 0 0
M  V30 50 O 8.8068 -3.6054 0 0
M  V30 51 N 6.8147 -1.8316 0 0
M  V30 52 C 6.3307 -0.3696 0 0
M  V30 53 C 4.8226 -0.0577 0 0
M  V30 54 C 3.7985 -1.2078 0 0
M  V30 55 C 3.9891 -3.2536 0 0
M  V30 56 C 5.7906 -2.9817 0 0 CFG=1
M  V30 57 C 4.2825 -2.6698 0 0
M  V30 58 O 3.0316 -1.7715 0 0
M  V30 59 O 3.2584 -3.8199 0 0
M  V30 60 O 16.4034 -1.0906 0 0
M  V30 61 C 17.9115 -1.4024 0 0
M  V30 62 C 3.7804 -5.2382 0 0
M  V30 63 C 5.2949 -5.5173 0 0
M  V30 64 C 5.8105 -6.9684 0 0 CFG=1
M  V30 65 O 7.325 -7.2474 0 0
M  V30 66 C 8.3239 -6.0754 0 0
M  V30 67 C 9.8384 -6.3544 0 0
M  V30 68 O 10.354 -7.8055 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 13 11
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17 CFG=2
M  V30 17 1 18 16
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 20 21 CFG=1
M  V30 21 1 21 22
M  V30 22 1 20 23
M  V30 23 2 23 24
M  V30 24 1 25 23
M  V30 25 1 25 26 CFG=3
M  V30 26 1 25 27
M  V30 27 1 28 27
M  V30 28 1 28 29 CFG=3
M  V30 29 1 28 30
M  V30 30 2 30 31
M  V30 31 1 31 32 CFG=2
M  V30 32 2 32 33
M  V30 33 1 33 34 CFG=2
M  V30 34 2 34 35
M  V30 35 1 35 36 CFG=2
M  V30 36 1 37 35
M  V30 37 1 37 38
M  V30 38 1 39 38
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 1 42 41
M  V30 42 1 42 43 CFG=1
M  V30 43 1 42 44
M  V30 44 1 44 45 CFG=1
M  V30 45 1 44 46
M  V30 46 1 39 46 CFG=3
M  V30 47 1 44 47
M  V30 48 2 47 48
M  V30 49 1 47 49
M  V30 50 2 49 50
M  V30 51 1 49 51
M  V30 52 1 51 52
M  V30 53 1 52 53
M  V30 54 1 53 54
M  V30 55 1 54 55
M  V30 56 1 56 55
M  V30 57 1 56 51 CFG=1
M  V30 58 1 56 57
M  V30 59 2 57 58
M  V30 60 1 57 59
M  V30 61 1 9 59 CFG=3
M  V30 62 1 37 60 CFG=1
M  V30 63 1 60 61
M  V30 64 1 5 62
M  V30 65 1 62 63
M  V30 66 1 64 63
M  V30 67 1 3 64
M  V30 68 1 64 65 CFG=1
M  V30 69 1 65 66
M  V30 70 1 66 67
M  V30 71 1 67 68
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289798859

>  <MW>
957.581

>  <MW (desalted)>
958.224

>  <ClogP>
7.103

>  <logS>
-6.828

>  <HBD>
3

>  <HBA>
13

>  <TPSA>
204.66

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 < 0.001 nM | inhibition percentage Active

>  <CAS>
159351-69-6

>  <Description>
Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12. Everolimus is a derivative of Rapamycin. It is currently used as an immunosuppressant to prevent rejection of organ transplants.

>  <EBC_ID>
EBC-00688

>  <IUPAC Name>
(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0,4,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

>  <Main Tar all refs>
Eur. J. Med. Chem., 2023, vol. 248 | Med. Sci. Monit., 2018, vol. 24, p. 2735 - 2743

>  <Main tar all>
Serine/threonine-protein kinase mTOR pX=12.0 | Target of rapamycin complex 1 pX=12.0

$$$$
Indoramin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7766 -11.0163 0 0
M  V30 2 C -0.7297 -11.3365 0 0
M  V30 3 N -1.7602 -10.192 0 0
M  V30 4 C -1.2843 -8.7274 0 0
M  V30 5 C -2.3147 -7.583 0 0
M  V30 6 C -1.8389 -6.1183 0 0
M  V30 7 N -0.3325 -5.7982 0 0
M  V30 8 C 0.1434 -4.3335 0 0
M  V30 9 C 1.6497 -4.0133 0 0
M  V30 10 C 2.1256 -2.5487 0 0
M  V30 11 C 1.2204 -1.3028 0 0
M  V30 12 N 2.1256 -0.0569 0 0
M  V30 13 C 3.5902 -0.5328 0 0
M  V30 14 C 4.9239 0.2372 0 0
M  V30 15 C 6.2576 -0.5328 0 0
M  V30 16 C 6.2576 -2.0728 0 0
M  V30 17 C 4.9239 -2.8428 0 0
M  V30 18 C 3.5902 -2.0728 0 0
M  V30 19 C 0.698 -6.9426 0 0
M  V30 20 C 0.2221 -8.4072 0 0
M  V30 21 C -1.2056 -12.8011 0 0
M  V30 22 C -0.1751 -13.9455 0 0
M  V30 23 C -0.651 -15.4102 0 0
M  V30 24 C -2.1574 -15.7304 0 0
M  V30 25 C -3.1878 -14.5859 0 0
M  V30 26 C -2.7119 -13.1213 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 10 18
M  V30 19 2 13 18
M  V30 20 1 7 19
M  V30 21 1 19 20
M  V30 22 1 4 20
M  V30 23 1 2 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2574927887

>  <MW>
347.2

>  <MW (desalted)>
347.453

>  <ClogP>
2.836

>  <logS>
-4.584

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
48.13

>  <RotBonds>
5

>  <Action on targets>
Antagonist | Inhibitor | Antagonist | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pA2  8.7  | pKi = 8.53  | pA2  8.5  | pKi  8.4  | Ki (inhibition constant)  5 nM | pA2  8.2  | pKi  8  | pKi < 8  | Ki (inhibition constant) = 25 nM | pKi  7.37  | pKi  7.3

>  <CAS>
26844-12-2

>  <Description>
Indoramin is a discontinued piperidine antiadrenergic drug. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

>  <EBC_ID>
EBC-26681

>  <IUPAC Name>
N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide

>  <Main Tar all refs>
J. MED. CHEM., 1997, vol. 40, # 9, p. 1293 - 1315 | H. LUNDBECK A/S - US2003/113771, 2003, A1 | MOL. PHARMACOL., 1996, vol. 49, # 2, p. 209 - 215 | Curr. Med. Chem., 2006, vol. 13, # 28, p. 3395 - 3416 | Eur. J. Pharmacol., 1979, vol. 55, # 3, p. 323 - 326 | J. MED. CHEM., 1974, vol. 17, # 7, p. 739 - 744 | BR. J. PHARMACOL., 1995, vol. 115, # 6, p. 981 - 986 | H. LUNDBECK A/S - US5403847, 1995, A | J. MED. CHEM., 1995, vol. 38, # 18, p. 3415 - 3444 | H. LUNDBECK A/S - US5403847, 1995, A | MOL. PHARMACOL., 1996, vol. 49, # 2, p. 209 - 215

>  <Main tar all>
?1-adrenoceptor pX=8.7 | ?1A-adrenoceptor pX=8.53 | Alpha 1l adrenergic receptor pX=8.5 | ?1A-adrenoceptor pX=8.4 | ?-adrenoceptor pX=8.3 | Histamine receptor pX=8.2 | ?1B-adrenoceptor pX=8.0 | D2 receptor pX=8.0 | ?1B-adrenoceptor pX=7.6 | H1 receptor pX=7.37 | ?1D-adrenoceptor pX=7.3

$$$$
Telbivudine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1992 8.895 0 0
M  V30 2 C -1.1345 8.125 0 0
M  V30 3 C -1.1345 6.585 0 0
M  V30 4 N -2.4682 5.815 0 0
M  V30 5 C -2.4682 4.275 0 0 CFG=2
M  V30 6 C -1.2223 3.3698 0 0
M  V30 7 C -1.6982 1.9052 0 0 CFG=1
M  V30 8 O -0.793 0.6593 0 0
M  V30 9 C -3.2382 1.9052 0 0 CFG=2
M  V30 10 C -4.1434 0.6593 0 0
M  V30 11 O -3.517 -0.7476 0 0
M  V30 12 O -3.7141 3.3698 0 0
M  V30 13 C -3.8019 6.585 0 0
M  V30 14 O -5.1355 5.815 0 0
M  V30 15 N -3.8019 8.125 0 0
M  V30 16 C -2.4682 8.895 0 0
M  V30 17 O -2.4682 10.435 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 1 9 12
M  V30 12 1 5 12
M  V30 13 1 4 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 2 16
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610488

>  <MW>
242.09

>  <MW (desalted)>
242.229

>  <ClogP>
-1.385

>  <logS>
-1.003

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
99.1

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.15 ?M | Km (Michaelis constant)  0.65 ?M | Km (Michaelis constant) = 1.8 ?M | Km (Michaelis constant) = 1.8 ?M

>  <CAS>
3424-98-4

>  <Description>
Telbivudine is a thymidine nucleoside analog used for the treatment of chronic hepatitis B with clinical evidence of viral replication or persistent elevations in serum aminotransferases.

>  <EBC_ID>
EBC-11110

>  <IUPAC Name>
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
MOL. PHARMACOL., 1995, vol. 47, # 6, p. 1231 - 1238 | Antimicrob. Agents Chemother., 2007, vol. 51, # 6, p. 2028 - 2034 | Bioorg. Med. Chem., 2010, vol. 18, # 9, p. 3261 - 3269 | Bioorg. Med. Chem., 2010, vol. 18, # 9, p. 3261 - 3269

>  <Main tar all>
thymidine kinase pX=6.82 | Thymidine kinase (gene tdk) pX=6.19 | Thymidine kinase 1 pX=5.74 | Thymidine kinase, cytosolic pX=5.74

$$$$
Lurasidone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 10.4571 -4.0533 0 0
M  V30 3 C 10.6181 -2.5217 0 0
M  V30 4 C 11.9517 -1.7517 0 0 CFG=1
M  V30 5 C 13.4164 -2.2276 0 0 CFG=2
M  V30 6 C 14.5608 -1.1972 0 0
M  V30 7 C 14.2406 0.3092 0 0
M  V30 8 C 12.776 0.7851 0 0 CFG=1
M  V30 9 C 12.7196 -0.8013 0 0
M  V30 10 C 11.6316 -0.2454 0 0 CFG=1
M  V30 11 C 10.1 -0.0844 0 0
M  V30 12 O 9.33 1.2493 0 0
M  V30 13 N 9.4736 -1.4913 0 0
M  V30 14 C 7.9673 -1.8114 0 0
M  V30 15 C 7.4914 -3.2761 0 0 CFG=2
M  V30 16 C 8.5218 -4.4205 0 0
M  V30 17 C 8.046 -5.8851 0 0
M  V30 18 C 6.5396 -6.2053 0 0
M  V30 19 C 5.5091 -5.0609 0 0
M  V30 20 C 5.985 -3.5963 0 0 CFG=1
M  V30 21 C 4.9546 -2.4518 0 0
M  V30 22 N 5.4305 -0.9872 0 0
M  V30 23 C 4.4 0.1573 0 0
M  V30 24 C 4.8759 1.6219 0 0
M  V30 25 N 6.3822 1.9421 0 0
M  V30 26 C 7.4127 0.7976 0 0
M  V30 27 C 6.9368 -0.667 0 0
M  V30 28 C 6.8581 3.4067 0 0
M  V30 29 N 5.9529 4.6526 0 0
M  V30 30 S 6.8581 5.8985 0 0
M  V30 31 C 8.3227 5.4226 0 0
M  V30 32 C 9.6564 6.1926 0 0
M  V30 33 C 10.9901 5.4226 0 0
M  V30 34 C 10.9901 3.8826 0 0
M  V30 35 C 9.6564 3.1126 0 0
M  V30 36 C 8.3227 3.8826 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 2 3
M  V30 2 1 4 3 CFG=3
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 8 7
M  V30 7 1 8 9 CFG=3
M  V30 8 1 5 9 CFG=3
M  V30 9 1 10 8
M  V30 10 1 4 10
M  V30 11 1 10 11 CFG=3
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 3 13
M  V30 15 1 13 14
M  V30 16 1 15 14 CFG=3
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 20 19
M  V30 22 1 15 20
M  V30 23 1 20 21 CFG=1
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 22 27
M  V30 31 1 25 28
M  V30 32 2 28 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 2 32 33
M  V30 37 1 33 34
M  V30 38 2 34 35
M  V30 39 1 35 36
M  V30 40 1 28 36
M  V30 41 2 31 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3241270511

>  <MW>
528.233

>  <MW (desalted)>
492.676

>  <ClogP>
5.614

>  <logS>
-7.1

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
56.75

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1 nM

>  <CAS>
367514-88-3

>  <Description>
Lurasidone is an atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder. It binds with high affinity to dopamine-2 receptor.

>  <EBC_ID>
EBC-28061

>  <IUPAC Name>
(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0,2,6]decane-3,5-dione hydrochloride

>  <Main Tar all refs>
Sumitomo Chemical (w/o Dongwoo Fine-Chem); Sumitomo Pharma (in: Sumitomo Chemical); SUMITOMO CHEMICAL COMPANY LIMITED - US5532372, 1996, A

>  <Main tar all>
D2 receptor pX=9.0

$$$$
Parecoxib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 8.47 0 0
M  V30 2 C -0 7.7 0 0
M  V30 3 C 0 6.16 0 0
M  V30 4 O -1.3337 5.39 0 0
M  V30 5 N 1.3337 5.39 0 0
M  V30 6 S 1.3337 3.85 0 0
M  V30 7 O -0.2063 3.85 0 0
M  V30 8 O 2.8737 3.85 0 0
M  V30 9 C 1.3337 2.31 0 0
M  V30 10 C 2.6674 1.54 0 0
M  V30 11 C 2.6674 -0 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 C 0 -0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 15 C 1.3337 -2.31 0 0
M  V30 16 C 2.5796 -3.2152 0 0
M  V30 17 C 4.0442 -2.7393 0 0
M  V30 18 O 2.1037 -4.6798 0 0
M  V30 19 N 0.5637 -4.6798 0 0
M  V30 20 C 0.0878 -3.2152 0 0
M  V30 21 C -1.3768 -2.7393 0 0
M  V30 22 C -2.5213 -3.7698 0 0
M  V30 23 C -3.9859 -3.2939 0 0
M  V30 24 C -4.3061 -1.7875 0 0
M  V30 25 C -3.1616 -0.7571 0 0
M  V30 26 C -1.697 -1.233 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 2 6 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 12 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040125

>  <MW>
370.422

>  <MW (desalted)>
370.422

>  <ClogP>
2.046

>  <logS>
-5.049

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
89.27

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 <= 0.1 nM

>  <CAS>
198470-84-7

>  <Description>
Parecoxib is a selective COX-2 inhibitor and NSAID used for the short-term management of perioperative pain.

>  <EBC_ID>
EBC-26824

>  <IUPAC Name>
N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide

>  <Main Tar all refs>
MERCK & CO INC - WO2003/86314, 2003, A2

>  <Main tar all>
Insulin receptor pX=10.0

$$$$
Belinostat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.0021 3.08 0 0
M  V30 2 N 8.0021 1.54 0 0
M  V30 3 C 6.6684 0.77 0 0
M  V30 4 O 5.3347 1.54 0 0
M  V30 5 C 6.6684 -0.77 0 0
M  V30 6 C 5.3347 -1.54 0 0
M  V30 7 C 5.3347 -3.08 0 0
M  V30 8 C 6.6684 -3.85 0 0
M  V30 9 C 6.6684 -5.39 0 0
M  V30 10 C 5.3347 -6.16 0 0
M  V30 11 C 4.001 -5.39 0 0
M  V30 12 C 4.001 -3.85 0 0
M  V30 13 S 2.6674 -6.16 0 0
M  V30 14 O 1.8974 -4.8263 0 0
M  V30 15 O 3.4374 -7.4937 0 0
M  V30 16 N 1.3337 -6.93 0 0
M  V30 17 C 0 -6.16 0 0
M  V30 18 C -1.3337 -6.93 0 0
M  V30 19 C -2.6674 -6.16 0 0
M  V30 20 C -2.6674 -4.62 0 0
M  V30 21 C -1.3337 -3.85 0 0
M  V30 22 C 0 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 2 13 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2311825421

>  <MW>
318.067

>  <MW (desalted)>
318.348

>  <ClogP>
1.177

>  <logS>
-3.748

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
95.5

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.47 nM | Ki (inhibition constant)  0.00085 ?M | Ki (inhibition constant)  0.00085 ?M | Ki (inhibition constant)  0.0015 ?M | Ki (inhibition constant)  0.0016 ?M | Ki (inhibition constant)  0.0016 ?M

>  <CAS>
866323-14-0

>  <Description>
Belinostat is a novel agent that inhibits the enzyme histone deacetylase with a sulfonamide-hydroxamide structure. It is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

>  <EBC_ID>
EBC-11342

>  <IUPAC Name>
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2021, vol. 12, # 4, p. 540 - 547 | HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE - WO2011/19393, 2011, A2 | HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE - WO2011/19393, 2011, A2 | HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE - WO2011/19393, 2011, A2 | HARVARD UNIVERSITY; DANA-FARBER CANCER INSTITUTE - WO2011/19393, 2011, A2 | Nat. Chem. Biol., 2010, vol. 6, # 3, p. 238 - 243

>  <Main tar all>
Histone?deacetylase pX=9.33 | histone deacetylase 1 pX=9.07 | histone deacetylase 2 pX=9.07 | histone deacetylase 3 pX=8.82 | histone deacetylase 5 pX=8.8 | histone deacetylase 6 pX=8.8

$$$$
Cinnarizine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -5.39 0 0
M  V30 2 C -4.001 -6.93 0 0
M  V30 3 C -2.6674 -7.7 0 0
M  V30 4 C -2.6674 -9.24 0 0
M  V30 5 C -1.3337 -10.01 0 0
M  V30 6 C -1.3337 -11.55 0 0
M  V30 7 C -2.6674 -12.32 0 0
M  V30 8 C -4.001 -11.55 0 0
M  V30 9 C -4.001 -10.01 0 0
M  V30 10 N -2.6674 -4.62 0 0
M  V30 11 C -2.6674 -3.08 0 0
M  V30 12 C -1.3337 -2.31 0 0
M  V30 13 N 0 -3.08 0 0
M  V30 14 C 0 -4.62 0 0
M  V30 15 C -1.3337 -5.39 0 0
M  V30 16 C 1.3337 -2.31 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 18 C 4.001 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 5.3347 -4.62 0 0
M  V30 21 C 4.001 -5.39 0 0
M  V30 22 C 2.6674 -4.62 0 0
M  V30 23 C 1.3337 -0.77 0 0
M  V30 24 C 0 -0 0 0
M  V30 25 C 0 1.54 0 0
M  V30 26 C 1.3337 2.31 0 0
M  V30 27 C 2.6674 1.54 0 0
M  V30 28 C 2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 1 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 10 15
M  V30 17 1 13 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 25 1 16 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 23 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568613921

>  <MW>
368.225

>  <MW (desalted)>
368.514

>  <ClogP>
6.051

>  <logS>
-4.757

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Blocker | Inhibitor | Blocker | Blocker

>  <Activity coefficients and valu>
Ki (inhibition constant) = 19.5 nM | pA2  7.7  | Ki (inhibition constant) = 60 nM | Ki (inhibition constant) = 76.4 nM | IC50  7.9E-08 M | protein expression level decrease Active   | Ki (inhibition constant)  141.6 nM | Ki (inhibition constant)  169 nM | Ki (inhibition constant) = 290 nM | Ki (inhibition constant)  345 nM | Ki (inhibition constant)  0.36 ?M | Ki (inhibition constant)  0.36 ?M | Km (Michaelis constant)  400 nM | inhibition percentage Active   | inhibition percentage  110.5 %

>  <CAS>
298-57-7

>  <Description>
Cinnarizine is an antihistamine and a calcium channel blocker. It is used for the management of labyrinthine disorder symptoms, including vertigo, tinnitus, nystagmus, nausea, and vomiting.

>  <EBC_ID>
EBC-85024

>  <IUPAC Name>
1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine

>  <Main Tar all refs>
PFIZER INC - WO2002/36562, 2002, A2 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1982, vol. 318, # 3, p. 234 - 240 | Therapeutic Drugs by Colin Dollery, 2nd edition, 1999, 1999, vol. 6 | Biopharm. Drug Dispos., 2000, vol. 21, # 4, p. 129 - 138 | BR. J. PHARMACOL., 1986, vol. 89, # 4, p. 641 - 646 | Biochem. Pharmacol., 2018, vol. 155, p. 298 - 304 | Mol. Pharmacol., 2001, vol. 59, # 3, p. 427 - 433 | Life Sci., 1992, vol. 50, # 9, p. PL65-70 | Biopharm. Drug Dispos., 2000, vol. 21, # 4, p. 129 - 138 | Arzneimittelforschung, 1984, vol. 34, # 7, p. 754 - 758 | 7TM PHARMA AS - WO2004/52370, 2004, A2 | 7TM PHARMA AS - WO2004/52370, 2004, A2 | Biochem. Pharmacol., 2018, vol. 155, p. 298 - 304 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2005, vol. 371, # 6, p. 441 - 448 | Pharm. Res., 2019, vol. 36, # 9

>  <Main tar all>
5-HT6 receptor pX=7.71 | Cav1.1 pX=7.7 | H1 receptor pX=7.22 | D2 receptor pX=7.12 | Voltage-gated?sodium?channel pX=7.1 | mechanistic target of rapamycin complex 1 pX=7.0 | H4 receptor pX=6.85 | Sigma receptor pX=6.77 | M5 receptor pX=6.54 | ?1-adrenoceptor pX=6.46 | Kv11.1 pX=6.44 | Potassium voltage-gated channel subfamily E member 1 pX=6.44 | Serine/threonine-protein kinase mTOR pX=6.4 | KCa pX=6.3 | Nav1.8 pX=6.28

$$$$
3-Pyridylmethanol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 N 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104495622

>  <MW>
109.053

>  <MW (desalted)>
109.126

>  <ClogP>
0.057

>  <logS>
0.309

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
1

>  <Action on targets>
Allosteric Modulator | -

>  <Activity coefficients and valu>
inhibition percentage  36 % | Km (Michaelis constant) = 690 ?M

>  <CAS>
100-55-0

>  <Description>
3-Pyridylmethanol  is a small-molecule modulator of adenylyl cyclase.

>  <EBC_ID>
EBC-14602

>  <IUPAC Name>
(Pyridin-3-yl)methanol

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2013, vol. 347, # 2, p. 276 - 287 | Arch. Biochem. Biophys., 2010, vol. 503, # 2, p. 230 - 237

>  <Main tar all>
adenylyl cyclase 2 pX=4.35 | Aldo-keto reductase family 1 member B10 pX=3.16

$$$$
Hydroxyisovaleric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.77 4.001 0 0
M  V30 2 C 1.54 2.6674 0 0
M  V30 3 C 0.2063 1.8974 0 0
M  V30 4 O 2.8737 3.4374 0 0
M  V30 5 C 2.31 1.3337 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 O 2.31 -1.3337 0 0
M  V30 8 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z982131798

>  <MW>
118.063

>  <MW (desalted)>
118.131

>  <ClogP>
-0.239

>  <logS>
0.248

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
2

>  <CAS>
625-08-1

>  <Description>
A normal endogenous metabolite excreted in the urine, an active metabolite of L-leucine. It is used as dietary supplements.

>  <EBC_ID>
EBC-04386

>  <IUPAC Name>
3-hydroxy-3-methylbutanoic acid

$$$$
Piracetam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.2739 5.93 0 0
M  V30 2 C -0.2739 4.39 0 0
M  V30 3 O -1.6075 3.62 0 0
M  V30 4 C 1.0598 3.62 0 0
M  V30 5 N 1.0598 2.08 0 0
M  V30 6 C 2.3057 1.1748 0 0
M  V30 7 C 1.8298 -0.2898 0 0
M  V30 8 C 0.2898 -0.2898 0 0
M  V30 9 C -0.1861 1.1748 0 0
M  V30 10 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56865289

>  <MW>
142.074

>  <MW (desalted)>
142.156

>  <ClogP>
-1.182

>  <logS>
-0.15

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
63.4

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  47 % | Ki (inhibition constant)  56.05 ?M | IC50  58.69 ?M | Ki (inhibition constant) = 63.8 ?M

>  <CAS>
7491-74-9

>  <Description>
Piracetam is a nootropic drug in the racetams group. It is a cyclic derivative of ?-aminobutyric acid (GABA). Piracetam modulates the cholinergic, serotonergic, noradrenergic, and glutamatergic neurotransmission. It is indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.

>  <EBC_ID>
EBC-04296

>  <IUPAC Name>
2-(2-oxopyrrolidin-1-yl)acetamide

>  <Main Tar all refs>
Eur. J. Pharm. Sci., 2010, vol. 40, # 4, p. 282 - 288 | Biomolecules, 2019, vol. 9, # 9 | J. Biomol. Struct. Dyn., 2017, vol. 35, # 11, p. 2382 - 2394 | ChemMedChem, 2012, vol. 7, # 8, p. 1369 - 1374

>  <Main tar all>
OATP1A2 pX=4.65 | acetylcholinesterase (Cartwright blood group) pX=4.25 | acetylcholinesterase (Cartwright blood group) pX=4.23 | synaptic vesicle glycoprotein 2A pX=4.2

$$$$
Glutamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.621 4.9774 0 0
M  V30 2 C 8.621 3.4374 0 0 CFG=1
M  V30 3 C 7.2874 2.6674 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 4.62 2.6674 0 0
M  V30 6 O 3.2863 3.4374 0 0
M  V30 7 O 4.62 1.1274 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 O 11.2884 3.4374 0 0
M  V30 10 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440052

>  <MW>
147.053

>  <MW (desalted)>
147.129

>  <ClogP>
-2.694

>  <logS>
0.43

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
100.62

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  1.2 nM | IC50  1.6 nM

>  <CAS>
56-86-0

>  <Description>
Glutamic acid is an amino acid commonly found as a component in total parenteral nutrition. It activates both ionotropic and metabotropic glutamate receptors.

>  <EBC_ID>
EBC-03159

>  <IUPAC Name>
(2S)-2-aminopentanedioic acid

>  <Main Tar all refs>
Mol. Pharmacol., 2003, vol. 63, # 5, p. 1082 - 1093 | Mol. Brain Res., 2000, vol. 76, # 1, p. 180 - 190 | BR. J. PHARMACOL., 1995, vol. 116, # 8, p. 3279 - 3287

>  <Main tar all>
mGlu1a receptor pX=9.4 | mGlu8a receptor pX=8.92 | mGlu4a receptor pX=8.8

$$$$
Sulfanilamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 S 1.3337 -2.31 0 0
M  V30 9 O 1.3337 -3.85 0 0
M  V30 10 O -0.2063 -2.31 0 0
M  V30 11 N 2.8737 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56851240

>  <MW>
172.031

>  <MW (desalted)>
172.205

>  <ClogP>
-0.572

>  <logS>
-1.16

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
86.18

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 2.4771 nM | Ki (inhibition constant) = 2.643 nM | Ki (inhibition constant) = 28 nM | Ki (inhibition constant) = 32 nM | Ki (inhibition constant)  37 nM | Ki (inhibition constant)  0.037 ?M | Ki (inhibition constant) = 70 nM

>  <CAS>
63-74-1

>  <Description>
Sulfanilamide is a competitive inhibitor for bacterial enzyme dihydropteroate synthetase, is a sulfonamide antibiotic. It is used for the treatment of vulvovaginitis caused by Candida albicans.

>  <EBC_ID>
EBC-04045

>  <IUPAC Name>
4-aminobenzene-1-sulfonamide

>  <Main Tar all refs>
Bioorg. Med. Chem., 2006, vol. 14, # 4, p. 1108 - 1114 | Bioorg. Med. Chem., 2013, vol. 21, # 6, p. 1495 - 1502 | Eur. J. Med. Chem., 1997, vol. 32, # 5, p. 445 - 452 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 14, p. 3757 - 3762 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 963 - 969 | J. Enzyme Inhib. Med. Chem., 2012, vol. 27, # 6, p. 886 - 891 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 4, p. 971 - 976

>  <Main tar all>
carbonic anhydrase 2 pX=8.61 | carbonic anhydrase pX=8.58 | carbonic anhydrase 1 pX=7.55 | carbonic anhydrase 13 pX=7.49 | carbonic anhydrase 12 pX=7.43 | carbonic anhydrase 9 pX=7.43 | carbonic anhydrase 7 pX=7.15

$$$$
Oteracil potassium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 K -1.3337 5.39 0 0 CHG=1
M  V30 2 O 0 4.62 0 0 CHG=-1
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 N 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 O 4.001 -0.77 0 0
M  V30 9 N 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 O -1.3337 -0.77 0 0
M  V30 12 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 10 12
M  V30 11 1 5 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3066893590

>  <MW>
194.968

>  <MW (desalted)>
157.084

>  <ClogP>
-6.13

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
110.69

>  <RotBonds>
1

>  <CAS>
2207-75-2

>  <Description>
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. It functions by blocking the enzyme orotate phosphoribosyltransferase, which is involved in the production of 5-FU.

>  <EBC_ID>
EBC-12850

>  <IUPAC Name>
potassium 4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxylate

$$$$
Fructose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 C 4.62 2.6674 0 0 CFG=1
M  V30 4 O 4.62 1.1274 0 0
M  V30 5 C 5.9537 3.4374 0 0 CFG=1
M  V30 6 O 5.9537 4.9774 0 0
M  V30 7 C 7.2874 2.6674 0 0 CFG=2
M  V30 8 O 7.2874 1.1274 0 0
M  V30 9 C 8.621 3.4374 0 0
M  V30 10 O 8.621 4.9774 0 0
M  V30 11 C 9.9547 2.6674 0 0
M  V30 12 O 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255372738

>  <MW>
180.063

>  <MW (desalted)>
180.156

>  <ClogP>
-2.832

>  <logS>
0.647

>  <HBD>
5

>  <HBA>
6

>  <TPSA>
118.22

>  <RotBonds>
5

>  <Action on targets>
Substrate | Substrate | Substrate | -

>  <Activity coefficients and valu>
amount increase Active   | Km (Michaelis constant) ~ 0.25 mM | increase rate Active   | Km (Michaelis constant) = 0.4 mM

>  <CAS>
57-48-7

>  <Description>
Fructose is a simple ketonic monosaccharide found in many plants, where it is often bonded to glucose to form the disaccharide sucrose.

>  <EBC_ID>
EBC-44227

>  <IUPAC Name>
(3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one

>  <Main Tar all refs>
J. Nutr. Biochem., 2017, vol. 47, p. 120 - 131 | SCIENTIST OF FORTUNE SA. - WO2015/181074, 2015, A1 | JIA (inventors) - US2018/133192, 2018, A1 | Biochem. J., 2004, vol. 379, # 2, p. 375 - 383

>  <Main tar all>
Phylloquinone omega-hydroxylase CYP4F2 pX=4.52 | phosphoketolase pX=3.6 | Glucose transporter  5 pX=3.43 | Monosaccharide transporter pX=3.4

$$$$
L-Tyrosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -1.3337 3.85 0 0
M  V30 2 C 0 4.62 0 0 CFG=1
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 O 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 C 0 6.16 0 0
M  V30 12 O -1.3337 6.93 0 0
M  V30 13 O 1.3337 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 2 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440046

>  <MW>
181.074

>  <MW (desalted)>
181.189

>  <ClogP>
-2.223

>  <logS>
-0.96

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
3

>  <Action on targets>
- | Activator | - | -

>  <Activity coefficients and valu>
Ka (association constant) = 0.001 ?M | Ka (association constant)  0.003 ?M | Ka (association constant) = 0.011 ?M | Ka (association constant) = 0.02 ?M

>  <CAS>
60-18-4

>  <Description>
L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.

>  <EBC_ID>
EBC-04166

>  <IUPAC Name>
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 25 - 30 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327

>  <Main tar all>
carbonic anhydrase pX=9.0 | ?-carbonic anhydrase pX=8.52 | carbonic anhydrase 2 pX=7.96 | carbonic anhydrase 1 pX=7.7

$$$$
Betamipron
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 O 4.001 -5.39 0 0
M  V30 4 C 5.3347 -7.7 0 0
M  V30 5 C 6.6684 -6.93 0 0
M  V30 6 N 8.0021 -7.7 0 0
M  V30 7 C 9.3358 -6.93 0 0
M  V30 8 O 9.3358 -5.39 0 0
M  V30 9 C 10.6694 -7.7 0 0
M  V30 10 C 12.0031 -6.93 0 0
M  V30 11 C 13.3368 -7.7 0 0
M  V30 12 C 13.3368 -9.24 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56854345

>  <MW>
193.074

>  <MW (desalted)>
193.199

>  <ClogP>
0.722

>  <logS>
-1.76

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4.5 ?M | Ki (inhibition constant)  48.3 ?M

>  <CAS>
3440-28-6

>  <Description>
Betamipron is a renal anionic transport inhibitor and decreases nephrotoxicity caused by high doses of carbapenems, anionic drugs, by inhibiting the drug accumulation in the renal cortex.

>  <EBC_ID>
EBC-04009

>  <IUPAC Name>
3-(phenylformamido)propanoic acid

>  <Main Tar all refs>
J. Am. Soc. Nephrol., 2000, vol. 11, # 3, p. 383 - 393 | Eur. J. Pharmacol., 2001, vol. 419, # 2-3, p. 113 - 120

>  <Main tar all>
Organic anion transporter 1 pX=5.35 | Organic anion transporter 3 pX=4.32

$$$$
Clonidine HCl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 4.8537 -1.2921 0 0
M  V30 3 C 4.8537 0.2479 0 0
M  V30 4 C 3.52 1.0179 0 0
M  V30 5 C 3.52 2.5579 0 0
M  V30 6 C 4.8537 3.3279 0 0
M  V30 7 C 6.1874 2.5579 0 0
M  V30 8 Cl 7.521 3.3279 0 0
M  V30 9 C 6.1874 1.0179 0 0
M  V30 10 N 7.521 0.2479 0 0
M  V30 11 C 7.521 -1.2921 0 0
M  V30 12 N 8.7669 -2.1973 0 0
M  V30 13 C 8.291 -3.662 0 0
M  V30 14 C 6.751 -3.662 0 0
M  V30 15 N 6.2752 -2.1973 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 2 3 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 11 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1695759754

>  <MW>
264.994

>  <MW (desalted)>
230.094

>  <ClogP>
1.727

>  <logS>
-3.59

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
36.42

>  <RotBonds>
1

>  <CAS>
4205-91-8

>  <Description>
Clonidine hydrochloride is an agonist of alpha-2-adrenoceptor and potent antihypertensive agent. It is used to treat hypertension and severe cancer pain, among other conditions, and to treat withdrawal symptoms from various substances. It is also used to aid in the diagnosis of pheochromocytoma and to prevent migraines.

>  <EBC_ID>
EBC-08213

>  <IUPAC Name>
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

$$$$
Guanadrel hydroiodide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0
M  V30 2 N 4.4 -0.6949 0 0
M  V30 3 C 5.8069 -1.3213 0 0
M  V30 4 N 5.9678 -2.8528 0 0
M  V30 5 N 7.0527 -0.4161 0 0
M  V30 6 C 8.4596 -1.0424 0 0
M  V30 7 C 9.7055 -0.1373 0 0
M  V30 8 C 9.7055 1.4027 0 0
M  V30 9 O 11.1701 1.8786 0 0
M  V30 10 C 12.0753 0.6327 0 0
M  V30 11 C 12.8453 1.9664 0 0
M  V30 12 C 14.3853 1.9664 0 0
M  V30 13 C 15.1553 0.6327 0 0
M  V30 14 C 14.3853 -0.7009 0 0
M  V30 15 C 12.8453 -0.7009 0 0
M  V30 16 O 11.1701 -0.6131 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 10 15
M  V30 15 1 10 16
M  V30 16 1 7 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1592709025

>  <MW>
341.06

>  <MW (desalted)>
213.277

>  <ClogP>
0.635

>  <logS>
-3.4

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
80.36

>  <RotBonds>
2

>  <CAS>
1443980-00-4

>  <Description>
Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

>  <EBC_ID>
EBC-15024

>  <IUPAC Name>
N-({1,4-dioxaspiro[4.5]decan-2-yl}methyl)guanidine hydroiodide

$$$$
Enfenamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.6684 -2.31 0 0
M  V30 2 C 5.3347 -3.08 0 0
M  V30 3 O 4.001 -2.31 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 6.6684 -5.39 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 C 5.3347 -7.7 0 0
M  V30 8 C 4.001 -6.93 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 N 2.6674 -4.62 0 0
M  V30 11 C 2.6674 -3.08 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 0 0 0 0
M  V30 15 C 0 1.54 0 0
M  V30 16 C 1.3337 2.31 0 0
M  V30 17 C 2.6674 1.54 0 0
M  V30 18 C 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z381346304

>  <MW>
241.11

>  <MW (desalted)>
241.285

>  <ClogP>
4.457

>  <logS>
-3.2

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.33

>  <RotBonds>
5

>  <CAS>
23049-93-6

>  <Description>
Enfenamic acid has antiviral activity against Flavivirus infections.

>  <EBC_ID>
EBC-13947

>  <IUPAC Name>
2-[(2-phenylethyl)amino]benzoic acid

$$$$
Sulfamethazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -3.85 0 0
M  V30 3 C 5.3347 -4.62 0 0
M  V30 4 C 5.3347 -6.16 0 0
M  V30 5 C 6.6684 -6.93 0 0
M  V30 6 N 4.001 -6.93 0 0
M  V30 7 C 2.6674 -6.16 0 0
M  V30 8 N 1.3337 -6.93 0 0
M  V30 9 S 0 -6.16 0 0
M  V30 10 O 0.77 -4.8263 0 0
M  V30 11 O -0.77 -7.4937 0 0
M  V30 12 C -1.3337 -5.39 0 0
M  V30 13 C -2.6674 -6.16 0 0
M  V30 14 C -4.001 -5.39 0 0
M  V30 15 C -4.001 -3.85 0 0
M  V30 16 N -5.3347 -3.08 0 0
M  V30 17 C -2.6674 -3.08 0 0
M  V30 18 C -1.3337 -3.85 0 0
M  V30 19 N 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 12 18
M  V30 19 1 7 19
M  V30 20 2 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56791687

>  <MW>
278.084

>  <MW (desalted)>
278.33

>  <ClogP>
1.097

>  <logS>
-2.77

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
97.97

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
pKa (association)  7.58 | Km (Michaelis constant)  0.8 ?M | Ki (inhibition constant)  0.8 ?M

>  <CAS>
57-68-1

>  <Description>
Sulfamethazine is an antibacterial sulfonamide. Sulfamethazine inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydrofolate synthetase. It is used for the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections.

>  <EBC_ID>
EBC-03813

>  <IUPAC Name>
4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Hazard. Mater., 2018, vol. 341, p. 438 - 447 | Drug Metab. Dispos., 2005, vol. 33, # 7, p. 969 - 976 | FEBS J., 2020, vol. 287, # 15, p. 3273 - 3297

>  <Main tar all>
dihydrofolate synthase pX=7.58 | Arylamine N-acetyltransferase 2 pX=6.1 | Folate synthesis bifunctional protein pX=6.1

$$$$
Trimetazidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 O 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 N 2.6674 -7.7 0 0
M  V30 9 C 2.6674 -9.24 0 0
M  V30 10 C 1.3337 -10.01 0 0
M  V30 11 N -0 -9.24 0 0
M  V30 12 C 0 -7.7 0 0
M  V30 13 C 1.3337 -6.93 0 0
M  V30 14 C 2.6674 -4.62 0 0
M  V30 15 O 1.3337 -5.39 0 0
M  V30 16 C 0 -4.62 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 18 O 1.3337 -2.31 0 0
M  V30 19 C 1.3337 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 14 17
M  V30 18 2 3 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z99601262

>  <MW>
266.163

>  <MW (desalted)>
266.336

>  <ClogP>
1.175

>  <logS>
-0.82

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
42.96

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Activator

>  <Activity coefficients and valu>
IC50 = 75 nM | glucose uptake increase Active

>  <CAS>
5011-34-7

>  <Description>
Trimetazidine is a selective long chain 3-ketoyl CoA thiolase inhibitor. Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. It is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.

>  <EBC_ID>
EBC-03819

>  <IUPAC Name>
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine

>  <Main Tar all refs>
Curr. Pharm. Des., 2002, vol. 8, # 14, p. 1199 - 1227 | Front. Pharmacol., 2021, vol. 12

>  <Main tar all>
3-ketoacyl-CoA thiolase, mitochondrial pX=7.12 | AMP kinase pX=6.0

$$$$
Phenythoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.9846 -5.757 0 0
M  V30 2 C -0.0794 -4.5111 0 0
M  V30 3 N 1.4606 -4.5111 0 0
M  V30 4 C 1.9365 -3.0465 0 0
M  V30 5 O 3.4011 -2.5706 0 0
M  V30 6 C 0.6906 -2.1413 0 0
M  V30 7 N -0.5553 -3.0465 0 0
M  V30 8 C 1.8242 -1.0989 0 0
M  V30 9 C 1.4882 0.404 0 0
M  V30 10 C 2.6218 1.4464 0 0
M  V30 11 C 4.0914 0.9859 0 0
M  V30 12 C 4.4273 -0.517 0 0
M  V30 13 C 3.2937 -1.5594 0 0
M  V30 14 C -0.0654 -0.7996 0 0
M  V30 15 C -1.6053 -0.7835 0 0
M  V30 16 C -2.3613 0.5582 0 0
M  V30 17 C -1.5774 1.8837 0 0
M  V30 18 C -0.0375 1.8676 0 0
M  V30 19 C 0.7185 0.5259 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 6 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56786458

>  <MW>
252.09

>  <MW (desalted)>
252.268

>  <ClogP>
2.085

>  <logS>
-3.39

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.05 nM

>  <CAS>
57-41-0

>  <Description>
Phenytoin is an inactive voltage-gated sodium channel stabilizer. Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. It is indicated to treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery.

>  <EBC_ID>
EBC-04217

>  <IUPAC Name>
5,5-diphenylimidazolidine-2,4-dione

>  <Main Tar all refs>
MERCK & CO INC - WO1995/11894, 1995, A1

>  <Main tar all>
Voltage-gated potassium channel pX=10.3

$$$$
Carbinoxamine maleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.4683 -1.0395 0 0
M  V30 2 N -5.1347 -0.2695 0 0
M  V30 3 C -5.1347 1.2705 0 0
M  V30 4 C -3.801 -1.0395 0 0
M  V30 5 C -2.4673 -0.2695 0 0
M  V30 6 O -1.1336 -1.0395 0 0
M  V30 7 C 0.2001 -0.2695 0 0
M  V30 8 C 1.5337 -1.0395 0 0
M  V30 9 C 2.8674 -0.2695 0 0
M  V30 10 C 4.2011 -1.0395 0 0
M  V30 11 C 4.2011 -2.5795 0 0
M  V30 12 Cl 5.5348 -3.3495 0 0
M  V30 13 C 2.8674 -3.3495 0 0
M  V30 14 C 1.5337 -2.5795 0 0
M  V30 15 C 0.2001 1.2705 0 0
M  V30 16 C -1.1336 2.0405 0 0
M  V30 17 C -1.1336 3.5805 0 0
M  V30 18 C 0.2001 4.3505 0 0
M  V30 19 C 1.5337 3.5805 0 0
M  V30 20 N 1.5337 2.0405 0 0
M  V30 21 O 15.2148 -0 0 0
M  V30 22 C 13.6748 -0 0 0
M  V30 23 O 12.9048 -1.3337 0 0
M  V30 24 C 12.9048 1.3337 0 0
M  V30 25 C 11.3648 1.3337 0 0
M  V30 26 C 10.5948 -0 0 0
M  V30 27 O 11.3648 -1.3337 0 0
M  V30 28 O 9.0548 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 7 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315582665

>  <MW>
406.13

>  <MW (desalted)>
290.788

>  <ClogP>
2.668

>  <logS>
-2.879

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
25.36

>  <RotBonds>
8

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
3505-38-2

>  <Description>
Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. It is used to treat allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, allergic reactions, and mild allergic reactions.

>  <EBC_ID>
EBC-13285

>  <IUPAC Name>
(2Z)-but-2-enedioic acid; {2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine

$$$$
Troxipide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -2.31 0 0
M  V30 2 O 2.6674 -3.08 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 4.001 -5.39 0 0
M  V30 5 C 4.001 -6.93 0 0
M  V30 6 C 2.6674 -7.7 0 0
M  V30 7 C 1.3337 -6.93 0 0
M  V30 8 O 0 -7.7 0 0
M  V30 9 C -1.3337 -6.93 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 O 0 -4.62 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C 5.3347 -7.7 0 0
M  V30 14 O 5.3347 -9.24 0 0
M  V30 15 N 6.6684 -6.93 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 C 9.3358 -6.93 0 0
M  V30 18 C 10.6694 -7.7 0 0
M  V30 19 C 10.6694 -9.24 0 0
M  V30 20 N 9.3358 -10.01 0 0
M  V30 21 C 8.0021 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z285140914

>  <MW>
294.158

>  <MW (desalted)>
294.346

>  <ClogP>
0.782

>  <logS>
-1.961

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
68.82

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  186 ?M

>  <CAS>
30751-05-4

>  <Description>
Tripoxide is a gastric cytoprotective agent used for the treatment of gastritis and gastric uclers.  It exerts its activity by increasing mucus production, cytoprotective prostaglandin secretion, regeneration of collagen fibers, reducing inflammatory mediator induced neutrophil migration and reactive oxygen species generation in gastric mucosa, enhancing gastric mucosal metabolism and microcirculation.

>  <EBC_ID>
EBC-12563

>  <IUPAC Name>
3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=3.73

$$$$
Trimethoprim
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 O 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 C 6.6684 -6.93 0 0
M  V30 8 C 8.0021 -7.7 0 0
M  V30 9 N 8.0021 -9.24 0 0
M  V30 10 C 6.6684 -10.01 0 0
M  V30 11 N 6.6684 -11.55 0 0
M  V30 12 N 5.3347 -9.24 0 0
M  V30 13 C 5.3347 -7.7 0 0
M  V30 14 N 4.001 -6.93 0 0
M  V30 15 C 4.001 -5.39 0 0
M  V30 16 C 2.6674 -4.62 0 0
M  V30 17 O 1.3337 -5.39 0 0
M  V30 18 C 0 -4.62 0 0
M  V30 19 C 2.6674 -3.08 0 0
M  V30 20 O 1.3337 -2.31 0 0
M  V30 21 C 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 13 14
M  V30 15 1 5 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 16 19
M  V30 20 2 3 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385071

>  <MW>
290.138

>  <MW (desalted)>
290.318

>  <ClogP>
0.981

>  <logS>
-2.68

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
105.51

>  <RotBonds>
5

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 20 pM | Ki (inhibition constant)  129 pM | Ki (inhibition constant)  138 pM | Ki (inhibition constant)  0.22 nM

>  <CAS>
738-70-5

>  <Description>
Trimethoprim is a synthetic antibiotic that inhibits dihydrofolate reductase (DHFR), which is necessary for the synthesis of purines, amino acids, and thymidylic acid. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria, also has the potential for urinary tract infections, Shigellosis and Pneumocystis pneumonia treatment.

>  <EBC_ID>
EBC-03787

>  <IUPAC Name>
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine

>  <Main Tar all refs>
Chem. Biol., 2012, vol. 19, # 5, p. 629 - 637 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1449 - 1467 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1449 - 1467 | ACS Med. Chem. Lett., 2016, vol. 7, # 7, p. 692 - 696

>  <Main tar all>
dihydrofolate reductase pX=10.7 | dihydrofolate reductase pX=9.89 | Dihydrofolate reductase-NanoLuc fusion protein pX=9.86 | Dihydrofolate?reductase FolM pX=9.66

$$$$
Duloxetine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.3852 0 0
M  V30 3 N 5.7337 -1.1552 0 0
M  V30 4 C 7.0674 -0.3852 0 0
M  V30 5 C 8.401 -1.1552 0 0
M  V30 6 C 9.7347 -0.3852 0 0 CFG=2
M  V30 7 O 11.0684 -1.1552 0 0
M  V30 8 C 12.4021 -0.3852 0 0
M  V30 9 C 12.4021 1.1548 0 0
M  V30 10 C 13.7358 1.9248 0 0
M  V30 11 C 15.0694 1.1548 0 0
M  V30 12 C 15.0694 -0.3852 0 0
M  V30 13 C 16.4031 -1.1552 0 0
M  V30 14 C 16.4031 -2.6952 0 0
M  V30 15 C 15.0694 -3.4652 0 0
M  V30 16 C 13.7358 -2.6952 0 0
M  V30 17 C 13.7358 -1.1552 0 0
M  V30 18 C 9.7347 1.1548 0 0
M  V30 19 C 8.4888 2.06 0 0
M  V30 20 C 8.9647 3.5246 0 0
M  V30 21 C 10.5047 3.5246 0 0
M  V30 22 S 10.9806 2.06 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 6 5
M  V30 5 1 6 7 CFG=1
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 2 8 17
M  V30 17 1 12 17
M  V30 18 1 6 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 18 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575081875

>  <MW>
333.095

>  <MW (desalted)>
297.415

>  <ClogP>
4.258

>  <logS>
-5.394

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
21.26

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKi  10.64

>  <CAS>
136434-34-9

>  <Description>
Duloxetine is a serotonin norepinephrine reuptake inhibitor used to treat generalized anxiety disorder, neuropathic pain, osteoarthritis, and stress incontinence.

>  <EBC_ID>
EBC-12367

>  <IUPAC Name>
methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166

>  <Main tar all>
SERT pX=10.6

$$$$
Tegaserod
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.1317 -3.2373 0 0
M  V30 2 C 15.4654 -4.0073 0 0
M  V30 3 C 16.7991 -3.2373 0 0
M  V30 4 C 18.1327 -4.0073 0 0
M  V30 5 C 19.4664 -3.2373 0 0
M  V30 6 N 20.8001 -4.0073 0 0
M  V30 7 C 22.1338 -3.2373 0 0
M  V30 8 N 22.1338 -1.6973 0 0
M  V30 9 N 23.4675 -4.0073 0 0
M  V30 10 N 24.8011 -3.2373 0 0
M  V30 11 C 26.1348 -4.0073 0 0
M  V30 12 C 27.4685 -3.2373 0 0
M  V30 13 C 27.6295 -1.7057 0 0
M  V30 14 N 29.1358 -1.3856 0 0
M  V30 15 C 29.9058 -2.7192 0 0
M  V30 16 C 31.4122 -3.0394 0 0
M  V30 17 C 31.888 -4.5041 0 0
M  V30 18 C 30.8576 -5.6485 0 0
M  V30 19 O 31.3335 -7.1131 0 0
M  V30 20 C 32.8398 -7.4333 0 0
M  V30 21 C 29.3512 -5.3283 0 0
M  V30 22 C 28.8754 -3.8637 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=2
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 18 21
M  V30 21 1 21 22
M  V30 22 1 12 22
M  V30 23 2 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480423

>  <MW>
301.19

>  <MW (desalted)>
301.387

>  <ClogP>
2.807

>  <logS>
-4.779

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
85.29

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.5 ?M | IC50  2.5 ?M

>  <CAS>
145158-71-0

>  <Description>
Tegaserod is a serotonin-4 (5-HT4) receptor agonist.

>  <EBC_ID>
EBC-04413

>  <IUPAC Name>
N'-{[(5-methoxy-1H-indol-3-yl)methylidene]amino}-N-pentylguanidine

>  <Main Tar all refs>
MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO LTD - US2022/218666, 2022, A1 | MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO LTD - US2022/218666, 2022, A1

>  <Main tar all>
5-HT4 receptor pX=5.6 | Janus kinase pX=5.6

$$$$
Olanzapine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0572 7.3469 0 0
M  V30 2 N 3.7409 5.967 0 0
M  V30 3 C 5.2778 5.8691 0 0
M  V30 4 C 5.9614 4.4892 0 0
M  V30 5 N 5.1082 3.2071 0 0
M  V30 6 C 3.5713 3.305 0 0
M  V30 7 C 2.8876 4.685 0 0
M  V30 8 C 5.7918 1.8272 0 0
M  V30 9 N 7.3317 1.8444 0 0
M  V30 10 C 8.3053 0.6512 0 0
M  V30 11 C 9.7717 1.1215 0 0
M  V30 12 C 10.9123 0.0868 0 0
M  V30 13 C 10.5864 -1.4184 0 0
M  V30 14 C 9.12 -1.8887 0 0
M  V30 15 C 7.9794 -0.8539 0 0
M  V30 16 N 6.5995 -1.5376 0 0
M  V30 17 C 5.2046 -0.8849 0 0
M  V30 18 S 3.8915 -1.6895 0 0
M  V30 19 C 2.7205 -0.6893 0 0
M  V30 20 C 1.2231 -1.0488 0 0
M  V30 21 C 3.3099 0.7334 0 0
M  V30 22 C 4.8452 0.6125 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 1 21 22
M  V30 24 1 8 22
M  V30 25 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553472

>  <MW>
312.141

>  <MW (desalted)>
312.433

>  <ClogP>
3.009

>  <logS>
-3.89

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
30.87

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.04 nM | Kd (dissociation constant)  0.04 nM | pKi = 10  | pKb  10  | Ki (inhibition constant)  0.42 nM | pKb  9.3  | pKb  9.3  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | IC50  1 - 10 nM | IC50  1 - 10 nM | pKi  8 - 9

>  <CAS>
132539-06-1

>  <Description>
Olanzapine is an atypical antipsychotic that binds to dopamine D1, D2, and D4 receptors and the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2C, and 5-HT3. It inhibits Histamine H1 receptor. It is used in the management of schizophrenia, bipolar 1 disorder, and agitation associated with these disorders.

>  <EBC_ID>
EBC-06991

>  <IUPAC Name>
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),5,8,11,13-hexaene

>  <Main Tar all refs>
Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | ABBVIE INC - US2010/145042, 2010, A1 | SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | Bioorg. Med. Chem. Lett., 2020, vol. 30, # 21 | SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | angolul : Chemical Works of Gedeon Richter Plc. Gedeon Richter Plc. - WO2005/12266, 2005, A1 | angolul : Chemical Works of Gedeon Richter Plc. Gedeon Richter Plc. - WO2005/12266, 2005, A1 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583

>  <Main tar all>
?2-adrenoceptor pX=10.4 | ?2-adrenoceptor pX=10.4 | 5-HT6 receptor pX=10.0 | H1 receptor pX=10.0 | 5-HT2A receptor pX=9.38 | 5-HT2A receptor pX=9.3 | 5-HT2A receptor pX=9.3 | 5-HT2B receptor pX=9.0 | 5-HT2B receptor pX=9.0 | 5-HT2B receptor pX=9.0 | 5-HT2C receptor pX=9.0 | 5-HT2C receptor pX=9.0 | 5-HT2C receptor pX=9.0 | 5-HT6 receptor pX=9.0 | D3 receptor pX=9.0 | D3 receptor pX=9.0 | M5 receptor pX=9.0

$$$$
Omeprazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.925 3.6128 0 0
M  V30 2 O 7.5913 4.3828 0 0
M  V30 3 C 6.2576 3.6128 0 0
M  V30 4 C 6.2576 2.0728 0 0
M  V30 5 C 4.9239 1.3028 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 N 2.1256 1.5969 0 0
M  V30 8 C 1.2204 2.8428 0 0
M  V30 9 N 2.1256 4.0887 0 0
M  V30 10 C 3.5902 3.6128 0 0
M  V30 11 C 4.9239 4.3828 0 0
M  V30 12 S -0.3196 2.8428 0 0
M  V30 13 O -1.0896 4.1765 0 0
M  V30 14 C -1.0896 1.5091 0 0
M  V30 15 C -2.6296 1.5091 0 0
M  V30 16 N -3.3996 0.1755 0 0
M  V30 17 C -4.9396 0.1755 0 0
M  V30 18 C -5.7096 1.5091 0 0
M  V30 19 C -7.2496 1.5091 0 0
M  V30 20 C -4.9396 2.8428 0 0
M  V30 21 O -5.7096 4.1765 0 0
M  V30 22 C -4.9396 5.5102 0 0
M  V30 23 C -3.3996 2.8428 0 0
M  V30 24 C -2.6296 4.1765 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 2 3 11
M  V30 13 1 8 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 20 23
M  V30 25 2 15 23
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501475006

>  <MW>
345.115

>  <MW (desalted)>
345.416

>  <ClogP>
2.565

>  <logS>
-3.24

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
77.1

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | - | Inhibitor | Inhibitor | Stimulator | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  141 nM | IC50 ~ 154 nM | Ki (inhibition constant)  0.3 ?M | increase rate Active   | Kd (dissociation constant)  318 nM | inhibition rate Active   | inhibition percentage Active   | Ki (inhibition constant)  0.4 ?M | IC50 = 0.4 ?M | EC50  0.56 ?M | IC50 = 0.6 ?M | EC50  0.65 ?M | inhibition percentage Active   | inhibition rate Active   | inhibition percentage  94.9 % | IC50 >= 1.3 - 49.4 ?M | Ki (inhibition constant)  1.37 ?M | Km (Michaelis constant)  1.46 ?M | Km (Michaelis constant)  1.46 ?M | Km (Michaelis constant)  1.59 ?M | IC50  1.72 ?M | IC50 = 1.84 ?M | concentration (parameter) <= 2.2 ?M | IC50 = 2.3 ?M

>  <CAS>
73590-58-6

>  <Description>
Omeprazole is a member of a class of antisecretory compounds, the substituted benzimidazoles, that stop gastric acid secretion by selective inhibition of the H+/K+ ATPase enzyme system.

>  <EBC_ID>
EBC-04404

>  <IUPAC Name>
5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole

>  <Main Tar all refs>
Naunyn-Schmiedeberg's Arch. Pharmacol., 2009, vol. 379, # 1, p. 11 - 26 | Antimicrob. Agents Chemother., 2014, vol. 58, # 12, p. 7072 - 7082 | Biochem. Pharmacol., 2020, vol. 182 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1966 - 1975 | Drug Metab. Pharmacokinet., 2019, vol. 34, # 5, p. 325 - 333 | Free Radic. Biol. Med., 2022, vol. 181, p. 221 - 234 | Invest. New Drugs, 2021, vol. 39, # 2, p. 337 - 347 | Antimicrob. Agents Chemother., 2016, vol. 60, # 12, p. 7364 - 7371 | Xenobiotica, 2001, vol. 31, # 1, p. 1 - 10 | Biochem. Pharmacol., 2006, vol. 71, # 6, p. 837 - 849 | Xenobiotica, 2015, vol. 45, # 3, p. 218 - 229 | Curr. Med. Chem., 2002, vol. 9, # 14, p. 1323 - 1348 | J. Pharmacol. Exp. Ther., 2018, vol. 365, # 2, p. 262 - 271 | Xenobiotica, 2012, vol. 42, # 7, p. 633 - 640 | Cancers, 2020, vol. 12, # 3 | PLoS ONE, 2015, vol. 10, # 9 | Cancer Lett., 2021, vol. 509, p. 1 - 12 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 44, p. 27381 - 27387 | Basic Clin. Pharmacol. Toxicol., 2008, vol. 102, # 4, p. 388 - 393 | Basic Clin. Pharmacol. Toxicol., 2008, vol. 102, # 4, p. 388 - 393 | Drug Metab. Dispos., 2000, vol. 28, # 8, p. 966 - 972 | Xenobiotica, 2011, vol. 41, # 9, p. 826 - 835 | Annu. Rep. Med. Chem., 1985, vol. 20, p. 93 - 105 | Xenobiotica, 2018, vol. 48, # 6, p. 555 - 564 | Bioorg. Med. Chem. Lett., 2014, vol. 24, # 4, p. 1080 - 1084

>  <Main tar all>
ABCB1 pX=7.1 | triosephosphate isomerase (uniprot p36186) pX=6.85 | choline O-acetyltransferase pX=6.81 | CYP2C9*3 pX=6.52 | Cytochrome P450 2C9 pX=6.52 | MMP2 pX=6.5 | legumain pX=6.48 | Cytochrome P450 2C19 pX=6.47 | CYP1A1 pX=6.4 | hydrogen:potassium-exchanging ATPase pX=6.4 | CYP1A2 pX=6.25 | Urease (peptide) pX=6.22 | Aryl hydrocarbon receptor pX=6.19 | Cytochrome P450 3A4 pX=6.0 | potassium-transporting ATPase pX=6.0 | Organic cation/carnitine transporter 2 pX=5.97 | Fatty acid synthase (peptide) pX=5.89 | CoV 3C-like (main) protease pX=5.86 | CYP2C19*18 pX=5.84 | CYP2C19*19 pX=5.84 | CYP19A1 pX=5.8 | CYP2C19*15 pX=5.76 | P-type potassium:proton transporter pX=5.74 | CYP1A1 pX=5.66 | Unh pX=5.64

$$$$
Torasemide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 5.39 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 2.6674 3.08 0 0
M  V30 4 N 0 3.08 0 0
M  V30 5 C 0 1.54 0 0
M  V30 6 O 1.3337 0.77 0 0
M  V30 7 N -1.3337 0.77 0 0
M  V30 8 S -1.3337 -0.77 0 0
M  V30 9 O -2.8737 -0.77 0 0
M  V30 10 O 0.2063 -0.77 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 N 0 -4.62 0 0
M  V30 14 C -1.3337 -5.39 0 0
M  V30 15 C -2.6674 -4.62 0 0
M  V30 16 C -2.6674 -3.08 0 0
M  V30 17 N -4.001 -2.31 0 0
M  V30 18 C -5.3347 -3.08 0 0
M  V30 19 C -5.3347 -4.62 0 0
M  V30 20 C -6.6684 -5.39 0 0
M  V30 21 C -8.0021 -4.62 0 0
M  V30 22 C -8.0021 -3.08 0 0
M  V30 23 C -9.3358 -2.31 0 0
M  V30 24 C -6.6684 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 18 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385087

>  <MW>
348.126

>  <MW (desalted)>
348.42

>  <ClogP>
3.358

>  <logS>
-3.28

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
100.19

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.3 ?M | Kd (dissociation constant)  0.79 ?M | Kd (dissociation constant)  0.89 ?M | Kd (dissociation constant)  0.89 ?M | IC50 = 1 ?M | inhibition percentage  44.3 % | inhibition percentage  44.3 %

>  <CAS>
56211-40-6

>  <Description>
Torasemide is a high-ceiling loop diuretic. It is used as an antihypertensive agent. It acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface.

>  <EBC_ID>
EBC-06044

>  <IUPAC Name>
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea

>  <Main Tar all refs>
UNIVERSITY OF CALIFORNIA - US5585401, 1996, A | Drug Metab. Dispos., 2009, vol. 37, # 7, p. 1395 - 1403 | Drug Metab. Dispos., 2009, vol. 37, # 7, p. 1395 - 1403 | Drug Metab. Dispos., 2009, vol. 37, # 7, p. 1395 - 1403 | J. Enzyme Inhib. Med. Chem., 2011, vol. 26, # 5, p. 603 - 609 | Pharm. Pharmacol. Commun., 2000, vol. 6, # 2, p. 77 - 82 | Pharm. Pharmacol. Commun., 2000, vol. 6, # 2, p. 77 - 82

>  <Main tar all>
Solute Carrier Family 12 (Sodium/Potassium/Chloride Transporters) pX=6.52 | fatty acid binding protein 2 pX=6.1 | Albumin pX=6.05 | Serum albumin pX=6.05 | heat shock protein 90 beta family member 1 pX=6.0 | TP receptor pX=5.9 | TP receptor pX=5.9

$$$$
Pretomanid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.0896 -2.6365 0 0 CHG=-1
M  V30 2 N -0.3196 -1.3028 0 0 CHG=1
M  V30 3 O -1.0896 0.0309 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 C 2.1256 -0.0569 0 0
M  V30 6 N 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0 CFG=1
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 O 4.9239 -2.8428 0 0
M  V30 11 C 3.5902 -2.0728 0 0
M  V30 12 N 2.1256 -2.5487 0 0
M  V30 13 O 7.5913 0.2372 0 0
M  V30 14 C 7.5913 1.7772 0 0
M  V30 15 C 8.925 2.5472 0 0
M  V30 16 C 8.925 4.0872 0 0
M  V30 17 C 10.2586 4.8572 0 0
M  V30 18 C 11.5923 4.0872 0 0
M  V30 19 O 12.926 4.8572 0 0
M  V30 20 C 12.926 6.3972 0 0
M  V30 21 F 12.926 7.9372 0 0
M  V30 22 F 14.466 6.3972 0 0
M  V30 23 F 11.386 6.3972 0 0
M  V30 24 C 11.5923 2.5472 0 0
M  V30 25 C 10.2586 1.7772 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 4 12
M  V30 14 1 8 13 CFG=3
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 20 23
M  V30 25 2 18 24
M  V30 26 1 24 25
M  V30 27 2 15 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1650127771

>  <MW>
359.073

>  <MW (desalted)>
359.257

>  <ClogP>
2.792

>  <logS>
-5.309

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
88.65

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.031 ?g/ml | MIC  0.1 ?M

>  <CAS>
187235-37-6

>  <Description>
Pretomanid kills the actively replicating bacteria causing tuberculosis, known as Mycobacterium tuberculosis, and shortens the duration of treatment in patients who suffer from resistant forms of pulmonary TB by killing dormant bacteria. Pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrug-resistant, extensively drug-resistant, and treatment-intolerant forms of pulmonary tuberculosis.

>  <EBC_ID>
EBC-06939

>  <IUPAC Name>
(6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-5H,6H,7H-imidazo[2,1-b][1,3]oxazine

>  <Main Tar all refs>
J. Antibiot., 2022, vol. 75, # 6, p. 333 - 340 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - WO2019/46467, 2019, A1

>  <Main tar all>
Aspartate-semialdehyde dehydrogenase pX=7.06 | 3-oxoacyl-[acyl-carrier-protein] synthase 1 pX=7.0

$$$$
Netupitant
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 1.54 0 0
M  V30 2 N -5.3347 -0 0 0
M  V30 3 C -4.001 -0.77 0 0
M  V30 4 O -2.6674 -0 0 0
M  V30 5 C -4.001 -2.31 0 0
M  V30 6 C -2.461 -2.31 0 0
M  V30 7 C -5.541 -2.31 0 0
M  V30 8 C -4.001 -3.85 0 0
M  V30 9 C -2.6674 -4.62 0 0
M  V30 10 C -2.6674 -6.16 0 0
M  V30 11 C -4.001 -6.93 0 0
M  V30 12 C -5.3347 -6.16 0 0
M  V30 13 C -5.3347 -4.62 0 0
M  V30 14 C -6.6684 -6.93 0 0
M  V30 15 F -8.0021 -7.7 0 0
M  V30 16 F -5.8984 -8.2637 0 0
M  V30 17 F -7.4384 -5.5963 0 0
M  V30 18 C -1.3337 -6.93 0 0
M  V30 19 F 0 -7.7 0 0
M  V30 20 F -2.1037 -8.2637 0 0
M  V30 21 F -0.5637 -5.5963 0 0
M  V30 22 C -6.6684 -0.77 0 0
M  V30 23 C -6.6684 -2.31 0 0
M  V30 24 N -8.0021 -3.08 0 0
M  V30 25 C -9.3358 -2.31 0 0
M  V30 26 C -9.3358 -0.77 0 0
M  V30 27 C -8.0021 -0 0 0
M  V30 28 C -8.0021 1.54 0 0
M  V30 29 C -6.6684 2.31 0 0
M  V30 30 C -6.6684 3.85 0 0
M  V30 31 C -8.0021 4.62 0 0
M  V30 32 C -9.3358 3.85 0 0
M  V30 33 C -9.3358 2.31 0 0
M  V30 34 C -10.6694 1.54 0 0
M  V30 35 N -10.6694 -3.08 0 0
M  V30 36 C -10.6694 -4.62 0 0
M  V30 37 C -12.0031 -5.39 0 0
M  V30 38 N -13.3368 -4.62 0 0
M  V30 39 C -14.6705 -5.39 0 0
M  V30 40 C -13.3368 -3.08 0 0
M  V30 41 C -12.0031 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 10 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 2 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 22 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 28 33
M  V30 36 1 33 34
M  V30 37 1 25 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 38 40
M  V30 43 1 40 41
M  V30 44 1 35 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037279612

>  <MW>
578.592

>  <MW (desalted)>
578.592

>  <ClogP>
6.505

>  <logS>
-7.195

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
39.68

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  9.8  | pKi  9.8  | pKi = 9.8

>  <CAS>
290297-26-6

>  <Description>
Netupitant is an antiemetic agent used in combination with palonosetron to prevent acute and delayed vomiting and nausea caused by chemotherapy.  It is a neurokinin 1 receptor antagonist.

>  <EBC_ID>
EBC-27345

>  <IUPAC Name>
2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide

>  <Main Tar all refs>
ROCHE HOLDING AG - US2003/4157, 2003, A1 | ROCHE HOLDING AG - US2003/4157, 2003, A1 | ROCHE HOLDING AG - EP1621195, 2006, A2

>  <Main tar all>
NK1 receptor pX=9.8 | NK1 receptor pX=9.8 | NK1 receptor pX=9.8

$$$$
Prochlorperazine dimaleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 42 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.1213 5.9136 0 0
M  V30 2 N -3.7876 5.1436 0 0
M  V30 3 C -2.454 5.9136 0 0
M  V30 4 C -1.1203 5.1436 0 0
M  V30 5 N -1.1203 3.6036 0 0
M  V30 6 C 0.2134 2.8336 0 0
M  V30 7 C 0.2134 1.2936 0 0
M  V30 8 C 1.5471 0.5236 0 0
M  V30 9 N 1.5471 -1.0164 0 0
M  V30 10 C 2.8807 -1.7864 0 0
M  V30 11 C 4.2144 -1.0164 0 0
M  V30 12 C 5.5481 -1.7864 0 0
M  V30 13 C 5.5481 -3.3264 0 0
M  V30 14 C 4.2144 -4.0964 0 0
M  V30 15 C 2.8807 -3.3264 0 0
M  V30 16 S 1.5471 -4.0964 0 0
M  V30 17 C 0.2134 -3.3264 0 0
M  V30 18 C -1.1203 -4.0964 0 0
M  V30 19 C -2.454 -3.3264 0 0
M  V30 20 C -2.454 -1.7864 0 0
M  V30 21 Cl -3.7876 -1.0164 0 0
M  V30 22 C -1.1203 -1.0164 0 0
M  V30 23 C 0.2134 -1.7864 0 0
M  V30 24 C -2.454 2.8336 0 0
M  V30 25 C -3.7876 3.6036 0 0
M  V30 26 O 15.2281 -0 0 0
M  V30 27 C 13.6881 -0 0 0
M  V30 28 O 12.9181 -1.3337 0 0
M  V30 29 C 12.9181 1.3337 0 0
M  V30 30 C 11.3781 1.3337 0 0
M  V30 31 C 10.6081 -0 0 0
M  V30 32 O 11.3781 -1.3337 0 0
M  V30 33 O 9.0681 -0 0 0
M  V30 34 O 3.08 -8.5101 0 0
M  V30 35 C 1.54 -8.5101 0 0
M  V30 36 O 0.77 -9.8438 0 0
M  V30 37 C 0.77 -7.1764 0 0
M  V30 38 C -0.77 -7.1764 0 0
M  V30 39 C -1.54 -8.5101 0 0
M  V30 40 O -0.77 -9.8438 0 0
M  V30 41 O -3.08 -8.5101 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 22 23
M  V30 24 1 9 23
M  V30 25 2 17 23
M  V30 26 1 5 24
M  V30 27 1 24 25
M  V30 28 1 2 25
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 35 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 39 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568619526

>  <MW>
605.16

>  <MW (desalted)>
373.943

>  <ClogP>
4.382

>  <logS>
-4.198

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
9.72

>  <RotBonds>
8

>  <Action on targets>
Antagonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.37 ?M | number of tumor nodules decrease Active   | pKi  5.68

>  <CAS>
84-02-6

>  <Description>
Prochlorperazine is a phenothiazine derivative used in the treatment of schizophrenia and anxiety and to relieve severe nausea and vomiting. Prochlorperazine blocks the D2 dopamine receptors. It also inhibits histaminergic, cholinergic and alpha-1 adrenergic receptors.

>  <EBC_ID>
EBC-15048

>  <IUPAC Name>
bis((2Z)-but-2-enedioic acid); 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine

>  <Main Tar all refs>
PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3 | Biomed. Pharmacother., 2021, vol. 140 | J. Pharmacol. Sci., 2019, vol. 140, # 2, p. 197 - 200

>  <Main tar all>
D2 receptor pX=6.43 | D2 receptor pX=6.0 | mAChR pX=5.68

$$$$
Paromomycin sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 47 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -3.004 3.2623 0 0
M  V30 2 C -3.004 4.8023 0 0
M  V30 3 C -1.6703 5.5723 0 0 CFG=2
M  V30 4 O -0.3367 4.8023 0 0
M  V30 5 C 0.997 5.5723 0 0 CFG=2
M  V30 6 O 2.3307 4.8023 0 0
M  V30 7 C 2.3307 3.2623 0 0 CFG=1
M  V30 8 C 1.0848 2.3571 0 0 CFG=1
M  V30 9 O -0.3798 2.833 0 0
M  V30 10 C 1.5607 0.8925 0 0 CFG=2
M  V30 11 O 0.6555 -0.3534 0 0
M  V30 12 C 1.2819 -1.7602 0 0 CFG=2
M  V30 13 C 2.8134 -1.9212 0 0 CFG=1
M  V30 14 O 3.7186 -0.6753 0 0
M  V30 15 C 3.4398 -3.3281 0 0 CFG=2
M  V30 16 N 4.9714 -3.489 0 0
M  V30 17 C 2.5346 -4.574 0 0
M  V30 18 C 1.0031 -4.413 0 0 CFG=2
M  V30 19 N 0.0979 -5.6589 0 0
M  V30 20 C 0.3767 -3.0061 0 0 CFG=1
M  V30 21 O -1.1549 -2.8451 0 0
M  V30 22 C -2.0601 -4.091 0 0 CFG=1
M  V30 23 O -1.4337 -5.4979 0 0
M  V30 24 C -2.3389 -6.7438 0 0 CFG=2
M  V30 25 C -1.7125 -8.1506 0 0
M  V30 26 O -0.1809 -8.3116 0 0
M  V30 27 C -3.8704 -6.5828 0 0 CFG=1
M  V30 28 O -4.7756 -7.8287 0 0
M  V30 29 C -4.4968 -5.1759 0 0 CFG=2
M  V30 30 O -6.0284 -5.015 0 0
M  V30 31 C -3.5916 -3.9301 0 0 CFG=1
M  V30 32 N -4.218 -2.5232 0 0
M  V30 33 O 3.1007 0.8925 0 0
M  V30 34 C 3.5766 2.3571 0 0 CFG=2
M  V30 35 C 5.0412 2.833 0 0
M  V30 36 O 5.3614 4.3394 0 0
M  V30 37 C 0.997 7.1123 0 0 CFG=2
M  V30 38 N 2.3307 7.8823 0 0
M  V30 39 C -0.3367 7.8823 0 0 CFG=1
M  V30 40 O -0.3367 9.4223 0 0
M  V30 41 C -1.6703 7.1123 0 0 CFG=2
M  V30 42 O -3.004 7.8823 0 0
M  V30 43 O 10.4214 -1.54 0 0
M  V30 44 S 10.4214 0 0 0
M  V30 45 O 10.4214 1.54 0 0
M  V30 46 O 11.9614 -0 0 0
M  V30 47 O 8.8814 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=1
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16 CFG=3
M  V30 16 1 15 17
M  V30 17 1 18 17
M  V30 18 1 18 19 CFG=3
M  V30 19 1 20 18
M  V30 20 1 12 20
M  V30 21 1 20 21 CFG=1
M  V30 22 1 22 21 CFG=1
M  V30 23 1 22 23
M  V30 24 1 24 23
M  V30 25 1 24 25 CFG=3
M  V30 26 1 25 26
M  V30 27 1 27 24
M  V30 28 1 27 28 CFG=1
M  V30 29 1 27 29
M  V30 30 1 29 30 CFG=3
M  V30 31 1 29 31
M  V30 32 1 31 22
M  V30 33 1 31 32 CFG=1
M  V30 34 1 10 33
M  V30 35 1 34 33
M  V30 36 1 7 34
M  V30 37 1 34 35 CFG=1
M  V30 38 1 35 36
M  V30 39 1 37 5
M  V30 40 1 37 38 CFG=1
M  V30 41 1 37 39
M  V30 42 1 39 40 CFG=3
M  V30 43 1 39 41
M  V30 44 1 41 3
M  V30 45 1 41 42 CFG=1
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 2 44 46
M  V30 49 1 44 47
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551627167

>  <MW>
713.707

>  <MW (desalted)>
615.629

>  <ClogP>
-6.523

>  <logS>
1.59

>  <HBD>
13

>  <HBA>
19

>  <TPSA>
347.32

>  <RotBonds>
9

>  <CAS>
1263-89-4

>  <Description>
Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. It is used in the treatment of acute and chronic intestinal amebiasis, and as an adjunct for the management of hepatic coma.

>  <EBC_ID>
EBC-13181

>  <IUPAC Name>
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol; sulfuric acid

$$$$
Tolnaftate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -4.62 0 0
M  V30 2 N -2.6674 -3.08 0 0
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 S -1.3337 -0.77 0 0
M  V30 5 O 0 -3.08 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 2.6674 0 0 0
M  V30 9 C 4.001 -0.77 0 0
M  V30 10 C 5.3347 0 0 0
M  V30 11 C 6.6684 -0.77 0 0
M  V30 12 C 6.6684 -2.31 0 0
M  V30 13 C 5.3347 -3.08 0 0
M  V30 14 C 4.001 -2.31 0 0
M  V30 15 C 2.6674 -3.08 0 0
M  V30 16 C -4.001 -2.31 0 0
M  V30 17 C -5.3347 -3.08 0 0
M  V30 18 C -6.6684 -2.31 0 0
M  V30 19 C -6.6684 -0.77 0 0
M  V30 20 C -5.3347 0 0 0
M  V30 21 C -5.3347 1.54 0 0
M  V30 22 C -4.001 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 2 6 15
M  V30 17 1 2 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 16 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671220

>  <MW>
307.409

>  <MW (desalted)>
307.409

>  <ClogP>
5.339

>  <logS>
-7.168

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
12.47

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 51.5 nM

>  <CAS>
2398-96-1

>  <Description>
Tolnaftate is a synthetic over-the-counter anti-fungal agent. It is used to treat various skin infections caused by fungi.

>  <EBC_ID>
EBC-17054

>  <IUPAC Name>
N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide

>  <Main Tar all refs>
ANTIMICROB. AGENTS CHEMOTHER., 1996, vol. 40, # 2, p. 443 - 447

>  <Main tar all>
squalene monooxygenase pX=7.29

$$$$
podofilox
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.5902 -11.3128 0 0
M  V30 2 O 3.5902 -9.7728 0 0
M  V30 3 C 4.9239 -9.0028 0 0
M  V30 4 C 4.9239 -7.4628 0 0
M  V30 5 C 6.2576 -6.6928 0 0
M  V30 6 C 7.5913 -7.4628 0 0
M  V30 7 C 7.5913 -9.0028 0 0
M  V30 8 O 8.925 -9.7728 0 0
M  V30 9 C 8.925 -11.3128 0 0
M  V30 10 C 6.2576 -9.7728 0 0
M  V30 11 O 6.2576 -11.3128 0 0
M  V30 12 C 4.9239 -12.0828 0 0
M  V30 13 C 6.2576 -5.1528 0 0 CFG=1
M  V30 14 C 4.9239 -4.3828 0 0 CFG=2
M  V30 15 C 4.9239 -2.8428 0 0 CFG=2
M  V30 16 C 3.4593 -2.3669 0 0
M  V30 17 O 2.5541 -3.6128 0 0
M  V30 18 C 3.4593 -4.8587 0 0
M  V30 19 O 2.9834 -6.3233 0 0
M  V30 20 C 6.2576 -2.0728 0 0 CFG=1
M  V30 21 O 6.2576 -0.5328 0 0
M  V30 22 C 7.5913 -2.8428 0 0
M  V30 23 C 8.925 -2.0728 0 0
M  V30 24 C 10.2586 -2.8428 0 0
M  V30 25 O 11.7233 -2.3669 0 0
M  V30 26 C 12.6285 -3.6128 0 0
M  V30 27 O 11.7233 -4.8587 0 0
M  V30 28 C 10.2586 -4.3828 0 0
M  V30 29 C 8.925 -5.1528 0 0
M  V30 30 C 7.5913 -4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 13 5 CFG=1
M  V30 14 1 14 13
M  V30 15 1 14 15
M  V30 16 1 15 16 CFG=3
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18 CFG=1
M  V30 20 2 18 19
M  V30 21 1 15 20
M  V30 22 1 20 21 CFG=1
M  V30 23 1 20 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 24 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 13 30
M  V30 34 2 22 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z759291658

>  <MW>
414.405

>  <MW (desalted)>
414.405

>  <ClogP>
1.444

>  <logS>
-3.83

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
92.68

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.53892E-06 ?M

>  <CAS>
518-28-5

>  <Description>
Podofilox is a topical agent used for the treatment of external genital warts and perianal warts.

>  <EBC_ID>
EBC-12795

>  <IUPAC Name>
(10R,11R,15R,16R)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one

>  <Main Tar all refs>
Chem. Biol. Drug Des., 2012, vol. 80, # 4, p. 616 - 624

>  <Main tar all>
Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2 (P49/P100) pX=11.8

$$$$
Palonosetron
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.001 3.85 0 0
M  V30 2 C 4.001 2.31 0 0
M  V30 3 N 5.3347 1.54 0 0
M  V30 4 C 5.3347 0 0 0
M  V30 5 C 4.001 -0.77 0 0 CFG=1
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C -0 0 0 0
M  V30 11 C -0 1.54 0 0
M  V30 12 C 1.3337 2.31 0 0
M  V30 13 C 2.6674 1.54 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 6.6684 2.31 0 0 CFG=2
M  V30 16 C 6.6684 3.85 0 0
M  V30 17 N 8.0021 4.62 0 0
M  V30 18 C 9.3358 3.85 0 0
M  V30 19 C 9.3358 2.31 0 0
M  V30 20 C 8.0021 1.54 0 0
M  V30 21 C 8.2587 2.5667 0 0
M  V30 22 C 8.2587 3.5933 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 1 5 14
M  V30 16 2 9 14
M  V30 17 1 15 3 CFG=3
M  V30 18 1 15 16
M  V30 19 1 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 15 20
M  V30 24 1 20 21
M  V30 25 1 21 22
M  V30 26 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2185274784

>  <MW>
296.407

>  <MW (desalted)>
296.407

>  <ClogP>
2.176

>  <logS>
-3.83

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
23.55

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.18 nM | Kd (dissociation constant)  0.18 nM | Kd (dissociation constant)  0.32 nM | Kd (dissociation constant)  0.32 nM

>  <CAS>
135729-61-2

>  <Description>
Palonosetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3. Palonosetron has been used in the treatment of postoperative or chemotherapy-induced nausea and vomiting.

>  <EBC_ID>
EBC-07664

>  <IUPAC Name>
(5S)-3-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.0,5,13]trideca-1(12),9(13),10-trien-2-one

>  <Main Tar all refs>
Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7523 - 7528 | Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7523 - 7528 | Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7523 - 7528 | Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7523 - 7528

>  <Main tar all>
5-HT3B pX=9.74 | 5-HT3B pX=9.74 | 5-HT3A pX=9.49 | 5-HT3A pX=9.49

$$$$
Benzylparaben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3347 -3.08 0 0
M  V30 2 C 5.3347 -4.62 0 0
M  V30 3 C 6.6684 -5.39 0 0
M  V30 4 C 6.6684 -6.93 0 0
M  V30 5 C 5.3347 -7.7 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 C 4.001 -5.39 0 0
M  V30 8 C 5.3347 -9.24 0 0
M  V30 9 O 6.6684 -10.01 0 0
M  V30 10 O 4.001 -10.01 0 0
M  V30 11 C 4.001 -11.55 0 0
M  V30 12 C 2.6674 -12.32 0 0
M  V30 13 C 2.6674 -13.86 0 0
M  V30 14 C 1.3337 -14.63 0 0
M  V30 15 C 0 -13.86 0 0
M  V30 16 C 0 -12.32 0 0
M  V30 17 C 1.3337 -11.55 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z19674825

>  <MW>
228.079

>  <MW (desalted)>
228.243

>  <ClogP>
3.813

>  <logS>
-3.171

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
4

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  3.39 nM | Ki (inhibition constant)  54 nM

>  <CAS>
94-18-8

>  <Description>
Benzylparaben is a type of parabens being used as a preservative agent in cosmetics, food, and pharmaceutical products. Benzylparaben is used in allergenic testing.

>  <EBC_ID>
EBC-26250

>  <IUPAC Name>
benzyl 4-hydroxybenzoate

>  <Main Tar all refs>
Toxicology, 2022, vol. 471 | Toxicol. Lett., 2016, vol. 262, p. 92 - 99

>  <Main tar all>
Nuclear receptor ROR-gamma (isoform 2) pX=8.47 | Fatty acid amide hydrolase-2 pX=7.27

$$$$
Monomethyl fumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.62 2.6674 0 0
M  V30 2 O 3.85 1.3337 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 O 1.54 2.6674 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C -0.77 -1.3337 0 0
M  V30 8 O 0 -2.6674 0 0
M  V30 9 O -2.31 -1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315585555

>  <MW>
130.027

>  <MW (desalted)>
130.099

>  <ClogP>
0.28

>  <logS>
-0.465

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.6

>  <RotBonds>
3

>  <Action on targets>
Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  70 nM | Ki (inhibition constant) = 98 nM | Ki (inhibition constant) = 103 nM

>  <CAS>
2756-87-8

>  <Description>
Monomethyl fumarate is a metabolite of dimethyl fumarate. It is a potent immunosuppressants. It is a nuclear factor-like 2 pathway activator. Also, monomethyl fumarate exhibits agonist activity at GPR109A. Monomethyl fumarate suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases.

>  <EBC_ID>
EBC-26060

>  <IUPAC Name>
(2E)-4-methoxy-4-oxobut-2-enoic acid

>  <Main Tar all refs>
Biochem. Biophys. Res. Commun., 2008, vol. 375, # 4, p. 562 - 565 | Bioorg. Med. Chem., 2010, vol. 18, # 1, p. 14 - 18 | Bioorg. Med. Chem., 2010, vol. 18, # 1, p. 14 - 18

>  <Main tar all>
Hydroxycarboxylic acid receptor 2 pX=7.15 | Carbonic anhydrase 5B, mitochondrial pX=7.01 | carbonic anhydrase 5 pX=6.99

$$$$
Metyrapone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1047 -2.8737 0 0
M  V30 2 C 5.3347 -1.54 0 0
M  V30 3 C 4.5647 -0.2063 0 0
M  V30 4 C 4.001 -2.31 0 0
M  V30 5 O 2.6674 -1.54 0 0
M  V30 6 C 4.001 -3.85 0 0
M  V30 7 C 5.3347 -4.62 0 0
M  V30 8 C 5.3347 -6.16 0 0
M  V30 9 C 4.001 -6.93 0 0
M  V30 10 N 2.6674 -6.16 0 0
M  V30 11 C 2.6674 -4.62 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 6.6684 0.77 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 9.3358 0.77 0 0
M  V30 16 N 9.3358 -0.77 0 0
M  V30 17 C 8.0021 -1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289798161

>  <MW>
226.111

>  <MW (desalted)>
226.274

>  <ClogP>
1.459

>  <logS>
-1.628

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
42.85

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.14 nM | IC50 = 0.5 nM | IC50 = 0.0039 ?M

>  <CAS>
54-36-4

>  <Description>
Metyrapone is a steroid 11-beta-monooxygenase inhibitor. It is used to test hypothalamic-pituitary ACTH function.

>  <EBC_ID>
EBC-26244

>  <IUPAC Name>
2-methyl-1,2-bis(pyridin-3-yl)propan-1-one

>  <Main Tar all refs>
Curr. Top. Med. Chem., 2013, vol. 13, # 12, p. 1385 - 1401 | Curr. Top. Med. Chem., 2013, vol. 13, # 12, p. 1385 - 1401 | ARCH. BIOCHEM. BIOPHYS., 1990, vol. 276, # 1, p. 219 - 226

>  <Main tar all>
CYP11B1 pX=9.85 | CYP11B2 pX=9.3 | Limonene Hydroxylase pX=8.41

$$$$
Succinylcholine chloride dihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 Cl 8.8 0 0 0 CHG=-1
M  V30 4 Cl 0 -5.005 0 0 CHG=-1
M  V30 5 C 4.4 -6.16 0 0
M  V30 6 N 5.7337 -5.39 0 0 CHG=1
M  V30 7 C 6.5037 -6.7237 0 0
M  V30 8 C 4.9637 -4.0563 0 0
M  V30 9 C 7.0674 -4.62 0 0
M  V30 10 C 8.401 -5.39 0 0
M  V30 11 O 9.7347 -4.62 0 0
M  V30 12 C 11.0684 -5.39 0 0
M  V30 13 O 11.0684 -6.93 0 0
M  V30 14 C 12.4021 -4.62 0 0
M  V30 15 C 13.7358 -5.39 0 0
M  V30 16 C 15.0694 -4.62 0 0
M  V30 17 O 15.0694 -3.08 0 0
M  V30 18 O 16.4031 -5.39 0 0
M  V30 19 C 17.7368 -4.62 0 0
M  V30 20 C 19.0705 -5.39 0 0
M  V30 21 N 20.4041 -4.62 0 0 CHG=1
M  V30 22 C 21.7378 -3.85 0 0
M  V30 23 C 21.1741 -5.9537 0 0
M  V30 24 C 19.6341 -3.2863 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 6
M  V30 2 1 6 7
M  V30 3 1 6 8
M  V30 4 1 6 9
M  V30 5 1 9 10
M  V30 6 1 10 11
M  V30 7 1 11 12
M  V30 8 2 12 13
M  V30 9 1 12 14
M  V30 10 1 14 15
M  V30 11 1 15 16
M  V30 12 2 16 17
M  V30 13 1 16 18
M  V30 14 1 18 19
M  V30 15 1 19 20
M  V30 16 1 20 21
M  V30 17 1 21 22
M  V30 18 1 21 23
M  V30 19 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041510496

>  <MW>
396.179

>  <MW (desalted)>
290.399

>  <ClogP>
-6.874

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
52.6

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 26 nM | Ki (inhibition constant) = 26 nM | Ki (inhibition constant) = 26 nM | Ki (inhibition constant) = 26 nM

>  <CAS>
6101-15-1

>  <Description>
Succinylcholine chloride is an agonist of muscle-type nicotinic acetylcholine receptors. Succinylcholine is a depolarizing skeletal muscle relaxant used adjunctly to anesthesia and for skeletal muscle relaxation during intubation, mechanical ventilation, and surgical procedures.

>  <EBC_ID>
EBC-118024

>  <IUPAC Name>
trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium dihydrate dichloride

>  <Main Tar all refs>
Curr. Med. Chem., 2000, vol. 7, # 8, p. 749 - 800 | Curr. Med. Chem., 2000, vol. 7, # 8, p. 749 - 800 | Curr. Med. Chem., 2000, vol. 7, # 8, p. 749 - 800 | Curr. Med. Chem., 2000, vol. 7, # 8, p. 749 - 800

>  <Main tar all>
nicotinic acetylcholine receptor ?-like 1 pX=7.59 | nicotinic acetylcholine receptor ?-like 1 pX=7.59 | nicotinic acetylcholine receptor ?1 subunit pX=7.59 | nicotinic acetylcholine receptor ?1 subunit pX=7.59

$$$$
Rupatadine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7655 6.7797 0 0
M  V30 2 C 3.0991 7.5497 0 0
M  V30 3 C 3.0991 9.0897 0 0
M  V30 4 N 4.4328 9.8597 0 0
M  V30 5 C 5.7665 9.0897 0 0
M  V30 6 C 5.7665 7.5497 0 0
M  V30 7 C 7.1002 6.7797 0 0
M  V30 8 N 7.1002 5.2397 0 0
M  V30 9 C 8.4339 4.4697 0 0
M  V30 10 C 8.4339 2.9297 0 0
M  V30 11 C 7.1002 2.1597 0 0
M  V30 12 C 7.1002 0.6197 0 0
M  V30 13 C 8.4877 -0.0485 0 0
M  V30 14 C 9.6166 0.999 0 0
M  V30 15 C 11.0882 0.5451 0 0
M  V30 16 C 11.4308 -0.9563 0 0
M  V30 17 Cl 12.9024 -1.4103 0 0
M  V30 18 C 10.3019 -2.0038 0 0
M  V30 19 C 8.8304 -1.5499 0 0
M  V30 20 C 7.8702 -2.7539 0 0
M  V30 21 C 6.3302 -2.7539 0 0
M  V30 22 C 5.37 -1.5499 0 0
M  V30 23 C 3.8984 -2.0038 0 0
M  V30 24 C 2.7695 -0.9563 0 0
M  V30 25 C 3.1122 0.5451 0 0
M  V30 26 N 4.5838 0.999 0 0
M  V30 27 C 5.7127 -0.0485 0 0
M  V30 28 C 5.7665 2.9297 0 0
M  V30 29 C 5.7665 4.4697 0 0
M  V30 30 C 4.4328 6.7797 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 1 18 19
M  V30 19 2 13 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 1 12 27
M  V30 29 2 22 27
M  V30 30 1 11 28
M  V30 31 1 28 29
M  V30 32 1 8 29
M  V30 33 1 6 30
M  V30 34 2 2 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891941

>  <MW>
415.958

>  <MW (desalted)>
415.958

>  <ClogP>
5.062

>  <logS>
-4.379

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
29.02

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.0039 ?M

>  <CAS>
158876-82-5

>  <Description>
Rupatadine is a selective histamine H1 receptor antagonist and platelet activating factor antagonist used to treat allergic rhinitis.

>  <EBC_ID>
EBC-27019

>  <IUPAC Name>
13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaene

>  <Main Tar all refs>
Curr. Med. Chem., 2012, vol. 19, # 20, p. 3353 - 3387

>  <Main tar all>
H1 receptor pX=8.41

$$$$
Fluvoxamine maleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.3658 -0.28 0 0
M  V30 2 O -7.0321 0.49 0 0
M  V30 3 C -5.6984 -0.28 0 0
M  V30 4 C -4.3648 0.49 0 0
M  V30 5 C -3.0311 -0.28 0 0
M  V30 6 C -1.6974 0.49 0 0
M  V30 7 C -0.3637 -0.28 0 0
M  V30 8 N -0.3637 -1.82 0 0
M  V30 9 O -1.6974 -2.59 0 0
M  V30 10 C -1.6974 -4.13 0 0
M  V30 11 C -0.3637 -4.9 0 0
M  V30 12 N -0.3637 -6.44 0 0
M  V30 13 C 0.9699 0.49 0 0
M  V30 14 C 0.9699 2.03 0 0
M  V30 15 C 2.3036 2.8 0 0
M  V30 16 C 3.6373 2.03 0 0
M  V30 17 C 3.6373 0.49 0 0
M  V30 18 C 2.3036 -0.28 0 0
M  V30 19 C 4.971 2.8 0 0
M  V30 20 F 6.3047 3.57 0 0
M  V30 21 F 5.741 1.4663 0 0
M  V30 22 F 4.201 4.1337 0 0
M  V30 23 O 15.9847 -0 0 0
M  V30 24 C 14.4447 -0 0 0
M  V30 25 O 13.6747 -1.3337 0 0
M  V30 26 C 13.6747 1.3337 0 0
M  V30 27 C 12.1347 1.3337 0 0
M  V30 28 C 11.3647 -0 0 0
M  V30 29 O 12.1347 -1.3337 0 0
M  V30 30 O 9.8247 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 16 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 19 22
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568647847

>  <MW>
434.166

>  <MW (desalted)>
318.335

>  <ClogP>
3.025

>  <logS>
-2.977

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
56.84

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.46 nM | Ki (inhibition constant)  3.57 nM | IC50 = 3.8 nM | Ki (inhibition constant) = 36 nM

>  <CAS>
61718-82-9

>  <Description>
Fluvoxamine is a selective serotonin-reuptake inhibitor used to treat obsessive-compulsive disorder.

>  <EBC_ID>
EBC-13000

>  <IUPAC Name>
(2Z)-but-2-enedioic acid; (E)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine

>  <Main Tar all refs>
J. Med. Chem., 2003, vol. 46, # 6, p. 925 - 935 | Neuropharmacology, 1993, vol. 32, # 8, p. 737 - 743 | Curr. Med. Chem., 2002, vol. 9, # 8, p. 799 - 810 | PLoS ONE, 2008, vol. 3, # 7

>  <Main tar all>
DAT pX=8.84 | SERT pX=8.45 | 5-HT receptor pX=8.42 | sigma non-opioid intracellular receptor 1 pX=7.44

$$$$
Vitamin K1
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 20.0052 -2.31 0 0
M  V30 2 C 21.3389 -1.54 0 0
M  V30 3 C 21.3389 0 0 0
M  V30 4 C 22.6725 -2.31 0 0
M  V30 5 C 24.0062 -1.54 0 0
M  V30 6 C 25.3399 -2.31 0 0
M  V30 7 C 26.6736 -1.54 0 0 CFG=1
M  V30 8 C 26.6736 -0 0 0
M  V30 9 C 28.0073 -2.31 0 0
M  V30 10 C 29.3409 -1.54 0 0
M  V30 11 C 30.6746 -2.31 0 0
M  V30 12 C 32.0083 -1.54 0 0 CFG=1
M  V30 13 C 32.0083 -0 0 0
M  V30 14 C 33.342 -2.31 0 0
M  V30 15 C 34.6757 -1.54 0 0
M  V30 16 C 36.0093 -2.31 0 0
M  V30 17 C 37.343 -1.54 0 0
M  V30 18 C 38.6767 -2.31 0 0
M  V30 19 C 40.0104 -1.54 0 0
M  V30 20 C 41.3441 -2.31 0 0
M  V30 21 C 42.6777 -1.54 0 0
M  V30 22 C 42.6777 0 0 0
M  V30 23 C 44.0114 -2.31 0 0
M  V30 24 O 45.3451 -1.54 0 0
M  V30 25 C 44.0114 -3.85 0 0
M  V30 26 C 45.3451 -4.62 0 0
M  V30 27 C 45.3451 -6.16 0 0
M  V30 28 C 44.0114 -6.93 0 0
M  V30 29 C 42.6777 -6.16 0 0
M  V30 30 C 42.6777 -4.62 0 0
M  V30 31 C 41.3441 -3.85 0 0
M  V30 32 O 40.0104 -4.62 0 0
M  V30 33 C 37.343 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 29 30
M  V30 30 2 25 30
M  V30 31 1 30 31
M  V30 32 1 20 31
M  V30 33 2 31 32
M  V30 34 1 17 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568644345

>  <MW>
450.35

>  <MW (desalted)>
450.696

>  <ClogP>
12.012

>  <logS>
-12.043

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
34.14

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | - | - | Substrate | Substrate | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  1.99 ?M | Km (Michaelis constant)  8.3 ?M | Km (Michaelis constant)  8.3 ?M | qualitative Active   | qualitative Active   | Ki (inhibition constant)  40 ?M

>  <CAS>
84-80-0

>  <Description>
Vitamin K1 a fat-soluble, naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.

>  <EBC_ID>
EBC-09051

>  <IUPAC Name>
2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione

>  <Main Tar all refs>
Front. Microbiol., 2022, vol. 13 | Mol. Pharmacol., 2009, vol. 75, # 6, p. 1337 - 1346 | Mol. Pharmacol., 2009, vol. 75, # 6, p. 1337 - 1346 | Cells, 2021, vol. 10, # 7 | Cells, 2021, vol. 10, # 7 | UNIVERSITY OF BRITISH COLUMBIA - WO2006/5185, 2006, A1

>  <Main tar all>
Aryl hydrocarbon receptor pX=5.7 | Cytochrome P450 4F2 pX=5.08 | Phylloquinone omega-hydroxylase CYP4F2 pX=5.08 | UbiA prenyltransferase domain-containing protein 1 pX=5.0 | ubia prenyltransferase domain-containing protein 1 pX=5.0 | indoleamine 2,3-dioxygenase pX=4.4

$$$$
Cefmenoxime
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.5374 1.0989 0 0
M  V30 2 O -2.0499 1.4975 0 0
M  V30 3 N -1.6513 2.985 0 0
M  V30 4 C -0.1638 3.3836 0 0
M  V30 5 C 0.9252 2.2946 0 0
M  V30 6 O 2.4127 2.6932 0 0
M  V30 7 N 0.5266 0.8071 0 0
M  V30 8 C 1.6155 -0.2818 0 0 CFG=1
M  V30 9 C 3.1555 -0.2818 0 0 CFG=1
M  V30 10 S 4.4892 0.4882 0 0
M  V30 11 C 5.8229 -0.2818 0 0
M  V30 12 C 5.8229 -1.8218 0 0
M  V30 13 C 4.4892 -2.5918 0 0
M  V30 14 N 3.1555 -1.8218 0 0
M  V30 15 C 1.6155 -1.8218 0 0
M  V30 16 O 0.5266 -2.9108 0 0
M  V30 17 C 4.4892 -4.1318 0 0
M  V30 18 O 3.1555 -4.9018 0 0
M  V30 19 O 5.8229 -4.9018 0 0
M  V30 20 C 7.1566 -2.5918 0 0
M  V30 21 S 7.1566 -4.1318 0 0
M  V30 22 C 8.4902 -4.9018 0 0
M  V30 23 N 9.8971 -4.2755 0 0
M  V30 24 N 10.9276 -5.4199 0 0
M  V30 25 N 10.1576 -6.7536 0 0
M  V30 26 N 8.6512 -6.4334 0 0
M  V30 27 C 7.5068 -7.4639 0 0
M  V30 28 C 0.2348 4.8711 0 0
M  V30 29 C -0.7344 6.0679 0 0
M  V30 30 S 0.1044 7.3595 0 0
M  V30 31 C 1.5919 6.9609 0 0
M  V30 32 N 2.7887 7.93 0 0
M  V30 33 N 1.6725 5.423 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14 CFG=1
M  V30 15 1 14 15
M  V30 16 1 8 15
M  V30 17 2 15 16
M  V30 18 1 13 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 12 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 22 26
M  V30 29 1 26 27
M  V30 30 1 4 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 2 31 33
M  V30 36 1 28 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2583154272

>  <MW>
511.051

>  <MW (desalted)>
511.558

>  <ClogP>
0.252

>  <logS>
-4.973

>  <HBD>
3

>  <HBA>
11

>  <TPSA>
190.81

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.7 ?M | Km (Michaelis constant) = 21 ?M

>  <CAS>
65085-01-0

>  <Description>
Cefmenoxime is a broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.

>  <EBC_ID>
EBC-12395

>  <IUPAC Name>
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 1998, vol. 42, # 1, p. 176 - 179 | Antimicrob. Agents Chemother., 1999, vol. 43, # 2, p. 307 - 313

>  <Main tar all>
Beta-Lactamase AmpC pX=5.77 | Beta-lactamase pX=4.68

$$$$
Chlorobutanol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.54 -3.08 0 0
M  V30 2 C 1.54 -1.54 0 0
M  V30 3 C 3.08 -1.54 0 0
M  V30 4 O 0 -1.54 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 Cl 1.54 1.54 0 0
M  V30 7 Cl 3.08 -0 0 0
M  V30 8 Cl 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473554

>  <MW>
175.956

>  <MW (desalted)>
177.457

>  <ClogP>
2.252

>  <logS>
-2.26

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
IC50  0.0044 ?M

>  <CAS>
57-15-8

>  <Description>
Chlorobutanol is a detergent preservative with a broad spectrum of antimicrobial activity. Chlorobutanol disrupts the lipid structure of the cell membrane and increases the cell permeability, leading to cell lysis. It inhibits potassium voltage-gated channel subfamily H member 2.

>  <EBC_ID>
EBC-13267

>  <IUPAC Name>
1,1,1-trichloro-2-methylpropan-2-ol

>  <Main Tar all refs>
Pain, 2003, vol. 105, # 3, p. 499 - 506

>  <Main tar all>
Kv11.1 pX=8.36

$$$$
Mandelic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 O 0 6.16 0 0
M  V30 5 O -1.3337 3.85 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473974

>  <MW>
152.047

>  <MW (desalted)>
152.147

>  <ClogP>
0.502

>  <logS>
-1.24

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  2.4  | pIC50  2.31  | IC50 = 8.3 mM

>  <CAS>
90-64-2

>  <Description>
Mandelic acid is an approved aromatic, alpha hydroxy acid. Mandelic acid exerts its antibacterial effect mainly by increasing urine acidity. It is used for the treatment of urinary tract infections. It is also used as an ingredient in cosmetics and drug products applied topically for the treatment of wrinkles.

>  <EBC_ID>
EBC-26103

>  <IUPAC Name>
2-hydroxy-2-phenylacetic acid

>  <Main Tar all refs>
J. MED. CHEM., 1979, vol. 22, # 6, p. 608 - 614 | Bioorg. Med. Chem., 2005, vol. 13, # 4, p. 1101 - 1109 | J. Med. Chem., 1960, vol. 2, # 6, p. 633 - 657

>  <Main tar all>
Hydroxyacid oxidase pX=2.4 | RTP Type A pX=2.31 | L-lactate dehydrogenase (gene ImpL3) pX=2.08

$$$$
Camphoris
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.3892 0.6833 0 0
M  V30 2 C 1.8644 0.2413 0 0
M  V30 3 C 0.3892 -0.2007 0 0
M  V30 4 C 2.2494 1.7813 0 0
M  V30 5 C 0.9157 1.0113 0 0
M  V30 6 C 0.9157 -0.5287 0 0
M  V30 7 C 2.2494 -1.2987 0 0
M  V30 8 C 2.2494 -2.8387 0 0
M  V30 9 C 3.5831 -0.5287 0 0
M  V30 10 O 4.9167 -1.2987 0 0
M  V30 11 C 3.5831 1.0113 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 4 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473074

>  <MW>
152.12

>  <MW (desalted)>
152.233

>  <ClogP>
2.177

>  <logS>
-1.89

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.07

>  <RotBonds>
0

>  <Action on targets>
- | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Km (Michaelis constant) = 1.7 ?M | Kd (dissociation constant) = 2.1 ?M | Km (Michaelis constant) = 2.9 ?M | pIC50  5.4  | IC50 = 19 ?M | IC50 = 19 ?M | IC50 = 19 ?M | IC50 = 19 ?M | IC50 = 19000 nM | Km (Michaelis constant) = 23 ?M

>  <CAS>
76-22-2

>  <Description>
Camphoris a bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora.  It has been used to treat warts, cold sores, hemorrhoids, and osteoarthritis. It is used topically as a skin antipruritic and as an anti-infective agent. It is approved by the FDA as a topical antitussive.

>  <EBC_ID>
EBC-26105

>  <IUPAC Name>
1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

>  <Main Tar all refs>
ChemBioChem, 2011, vol. 12, # 1, p. 88 - 99 | Curr. Drug Metab., 2007, vol. 8, # 6, p. 594 - 611 | ChemBioChem, 2011, vol. 12, # 1, p. 88 - 99 | Br. J. Pharmacol., 2006, vol. 147, # sppl3 | GENOMINE INC; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - WO2001/58436, 2001, A1 | GENOMINE INC; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - WO2001/58436, 2001, A1 | GENOMINE INC; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - WO2001/58436, 2001, A1 | GENOMINE INC; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - WO2001/58436, 2001, A1 | GENOMINE INC; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - WO2001/58436, 2001, A1 | Biol. Pharm. Bull., 2007, vol. 30, # 2, p. 230 - 233

>  <Main tar all>
CYP101D2 pX=5.77 | Cytochrome P450, Family 101, Subfamily A, Polypeptide 1 pX=5.68 | CYP101D1 pX=5.54 | TRPV1 pX=5.4 | nicotinic acetylcholine receptor ?-like 1 pX=4.72 | nicotinic acetylcholine receptor ?-like 1 pX=4.72 | nicotinic acetylcholine receptor ?1 subunit pX=4.72 | nicotinic acetylcholine receptor ?1 subunit pX=4.72 | nicotinic acetylcholine receptor ?1 subunit pX=4.72 | Cytochrome P450 2A6 pX=4.64

$$$$
Edaravone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 N 2.5796 -3.2152 0 0
M  V30 4 N 2.1037 -4.6798 0 0
M  V30 5 C 0.5637 -4.6798 0 0
M  V30 6 O -0.3415 -5.9257 0 0
M  V30 7 C 0.0878 -3.2152 0 0
M  V30 8 C 3.0089 -5.9257 0 0
M  V30 9 C 4.5404 -5.7647 0 0
M  V30 10 C 5.4456 -7.0106 0 0
M  V30 11 C 4.8192 -8.4175 0 0
M  V30 12 C 3.2877 -8.5784 0 0
M  V30 13 C 2.3825 -7.3326 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 7
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z50145861

>  <MW>
174.079

>  <MW (desalted)>
174.199

>  <ClogP>
1.33

>  <logS>
-1.35

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
32.67

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | - | Inhibitor | - | - | - | - | - | Activator | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 > 1000 nM | rate increase Active   | rate increase Active   | IC50  5.57 ?M | Km (Michaelis constant)  6 ?M | Km (Michaelis constant)  6 ?M | Km (Michaelis constant)  7.4 ?M | Km (Michaelis constant) = 9.8 ?M | Km (Michaelis constant) = 9.8 ?M | percentage decrease Active   | IC50  10 ?M | inhibition percentage  43 % | EC50 < 20 ?M | inhibition percentage  24 - 100 % | MMP increase Active

>  <CAS>
89-25-8

>  <Description>
Edaravone is a strongl free radical scavenger. Edaravone reduces damage due to ischemia-reperfusion injury in lung, liver, and brain in animal models of transplant, infection, traumatic brain injury, and stroke. It is used for the treatment of amyotrophic lateral scleorosis.

>  <EBC_ID>
EBC-03526

>  <IUPAC Name>
3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one

>  <Main Tar all refs>
J. Med. Chem., 2007, vol. 50, # 21, p. 5053 - 5056 | Free Radic. Biol. Med., 2019, vol. 143, p. 422 - 432 | Free Radic. Biol. Med., 2019, vol. 143, p. 422 - 432 | NIPPON SODA COMPANY LIMITED - EP1650206, 2006, A1 | Drug Metab. Dispos., 2012, vol. 40, # 4, p. 734 - 741 | Drug Metab. Dispos., 2012, vol. 40, # 4, p. 734 - 741 | Drug Metab. Dispos., 2012, vol. 40, # 4, p. 734 - 741 | Trends Pharmacol. Sci., 2008, vol. 29, # 4, p. 200 - 207 | Trends Pharmacol. Sci., 2008, vol. 29, # 4, p. 200 - 207 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 7, p. 1616 - 1619 | NIPPON SODA COMPANY LIMITED - EP1650206, 2006, A1 | DARTMOUTH COLLEGE; UNIVERSITY OF CALIFORNIA - WO2013/155047, 2013, A2 | NORTHWESTERN UNIVERSITY (ILLINOIS) - US2015/18388, 2015, A1 | Antioxid. Redox Signal., 2010, vol. 12, # 3, p. 381 - 392 | Cell. Mol. Neurobiol., 2022, vol. 42, # 4, p. 1189 - 1210

>  <Main tar all>
Major prion protein pX=6.0 | Myeloperoxidase (uncleaved) pX=6.0 | myeloperoxidase pX=6.0 | Polyunsaturated fatty acid lipoxygenase ALOX15 pX=5.25 |  UDP glucuronosyltransferase family 1 member A9 pX=5.22 |  UDP glucuronosyltransferase family 1 member A9 pX=5.22 |  UDP glucuronosyltransferase pX=5.13 | ABCC4 pX=5.01 | ATP-binding cassette sub-family C member 4 pX=5.01 | Glutamate-cysteine ligase catalytic subunit pX=5.0 | Polyunsaturated fatty acid 5-lipoxygenase pX=5.0 | Cif pX=4.88 | superoxide dismutase pX=4.7 | Hemoglobin pX=4.61 | Haem oxygenase 1 pX=4.6

$$$$
Chromocarb
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -4.62 0 0
M  V30 2 C 0 -3.08 0 0
M  V30 3 O -1.3337 -2.31 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 2.6674 0 0 0
M  V30 7 O 2.6674 1.54 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 14 O 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 4 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56922101

>  <MW>
190.027

>  <MW (desalted)>
190.152

>  <ClogP>
1.3

>  <logS>
-2.6

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
63.6

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 > 100 nM

>  <CAS>
4940-39-0

>  <Description>
Chromocarb is benzo-?-pyrone derivative with vasoprotection activity used to eliminate lipoperoxidation post-vitrectomy.

>  <EBC_ID>
EBC-03478

>  <IUPAC Name>
4-oxo-4H-chromene-2-carboxylic acid

>  <Main Tar all refs>
J. Med. Chem., 2015, vol. 58, # 17, p. 6717 - 6732

>  <Main tar all>
Monoamine oxidase B pX=7.0

$$$$
P-nitrobiphenyl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0 CHG=-1
M  V30 2 N 1.3337 -0.77 0 0 CHG=1
M  V30 3 O 2.6674 0 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 2.6674 -3.08 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 1.3337 -5.39 0 0
M  V30 8 C 0 -4.62 0 0
M  V30 9 C 0 -3.08 0 0
M  V30 10 C 1.3337 -6.93 0 0
M  V30 11 C 2.6674 -7.7 0 0
M  V30 12 C 2.6674 -9.24 0 0
M  V30 13 C 1.3337 -10.01 0 0
M  V30 14 C 0 -9.24 0 0
M  V30 15 C 0 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127477

>  <MW>
199.063

>  <MW (desalted)>
199.205

>  <ClogP>
3.773

>  <logS>
-4.552

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
43.14

>  <RotBonds>
2

>  <CAS>
92-93-3

>  <Description>
P-nitrobiphenyl (Pnb) has been used in trials studying the treatment of Pelvic Organ Prolapse.

>  <EBC_ID>
EBC-71032

>  <IUPAC Name>
1-nitro-4-phenylbenzene

$$$$
Anagrelide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.52 -1.2513 0 0
M  V30 3 C 4.8537 -0.4813 0 0
M  V30 4 C 4.8537 1.0588 0 0
M  V30 5 C 6.1874 1.8288 0 0
M  V30 6 C 7.521 1.0588 0 0
M  V30 7 N 8.8547 1.8288 0 0
M  V30 8 C 10.1884 1.0587 0 0
M  V30 9 N 11.653 1.5346 0 0
M  V30 10 C 12.5582 0.2887 0 0
M  V30 11 O 14.0982 0.2887 0 0
M  V30 12 C 11.653 -0.9571 0 0
M  V30 13 N 10.1884 -0.4813 0 0
M  V30 14 C 8.8547 -1.2512 0 0
M  V30 15 C 7.521 -0.4812 0 0
M  V30 16 C 6.1874 -1.2512 0 0
M  V30 17 Cl 6.1874 -2.7912 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 10 12
M  V30 11 1 12 13
M  V30 12 1 8 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 6 15
M  V30 16 1 15 16
M  V30 17 2 3 16
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1888397835

>  <MW>
290.973

>  <MW (desalted)>
256.088

>  <ClogP>
1.022

>  <logS>
-4.11

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
44.7

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  23.7 nmol/l | enzyme activity decrease Active

>  <CAS>
58579-51-4

>  <Description>
Anagrelide is a platelet-reducing agent. It is an inhibitor of phosphodiesterase 3A. Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis.

>  <EBC_ID>
EBC-06567

>  <IUPAC Name>
6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one hydrochloride

>  <Main Tar all refs>
Clin. Cancer Res., 2019, vol. 25, # 5, p. 1676 - 1687 | Cell Chem. Biol., 2022, vol. 29, # 6, p. 958 - 5,969

>  <Main tar all>
cGMP-specific 3',5'-cGMP phosphodiesterase 3 pX=7.63 | phosphodiesterase 3A pX=7.0

$$$$
Ropinirole hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 6.6203 0 0
M  V30 3 C 5.7337 5.0803 0 0
M  V30 4 C 7.0674 4.3103 0 0
M  V30 5 N 7.0674 2.7703 0 0
M  V30 6 C 5.7337 2.0003 0 0
M  V30 7 C 5.7337 0.4603 0 0
M  V30 8 C 4.4 -0.3097 0 0
M  V30 9 C 8.401 2.0003 0 0
M  V30 10 C 8.401 0.4603 0 0
M  V30 11 C 9.7347 -0.3097 0 0
M  V30 12 C 11.0684 0.4603 0 0
M  V30 13 C 12.4021 -0.3097 0 0
M  V30 14 C 12.4021 -1.8497 0 0
M  V30 15 C 11.0684 -2.6197 0 0
M  V30 16 N 10.7482 -4.1261 0 0
M  V30 17 C 9.2166 -4.2871 0 0
M  V30 18 O 8.4466 -5.6207 0 0
M  V30 19 C 8.5903 -2.8802 0 0
M  V30 20 C 9.7347 -1.8497 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 5 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 2 17 18
M  V30 17 1 17 19
M  V30 18 1 19 20
M  V30 19 1 15 20
M  V30 20 2 11 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553578

>  <MW>
296.166

>  <MW (desalted)>
260.375

>  <ClogP>
2.796

>  <logS>
-2.99

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | - | - | Inhibitor | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 7.2 nM | EC50 = 8 nM | EC50 = 16.1 nM | Ki (inhibition constant) = 19 nM | EC50  100 nM

>  <CAS>
91374-20-8

>  <Description>
Ropinirole is a non-ergoline dopamine agonist. It is used for the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome.

>  <EBC_ID>
EBC-03833

>  <IUPAC Name>
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1997, vol. 40, # 5, p. 639 - 646 | PFIZER INC - WO2003/51370, 2003, A1 | PFIZER INC - WO2003/51370, 2003, A1 | J. MED. CHEM., 1997, vol. 40, # 5, p. 639 - 646 | J. MED. CHEM., 1986, vol. 29, # 6, p. 939 - 947

>  <Main tar all>
D2 receptor pX=8.14 | D3 receptor pX=8.1 | D2 receptor pX=7.79 | D3 receptor pX=7.72 | Dopamine receptor pX=7.0

$$$$
Chlorambucil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -6.93 0 0
M  V30 2 C 4.001 -5.39 0 0
M  V30 3 O 5.3347 -4.62 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 2.6674 -3.08 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 C 1.3337 2.31 0 0
M  V30 11 C 2.6674 1.54 0 0
M  V30 12 C 2.6674 0 0 0
M  V30 13 N 1.3337 3.85 0 0
M  V30 14 C -0 4.62 0 0
M  V30 15 C -0 6.16 0 0
M  V30 16 Cl -1.3337 6.93 0 0
M  V30 17 C 2.6674 4.62 0 0
M  V30 18 C 2.6674 6.16 0 0
M  V30 19 Cl 4.001 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 13 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552153009

>  <MW>
303.079

>  <MW (desalted)>
304.212

>  <ClogP>
3.631

>  <logS>
-3.78

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
40.54

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.156 ?M | IC50 > 1 ?M | IC50  1.96 ?M

>  <CAS>
305-03-3

>  <Description>
Chlorambucil is an antineoplastic in the class of alkylating agents that is used to treat various forms of cancer. It inhibits tyrosine-protein kinase Abl.

>  <EBC_ID>
EBC-06733

>  <IUPAC Name>
4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2013, vol. 20, # 13, p. 1694 - 1714 | Front. Pharmacol., 2023, vol. 13 | Cells, 2023, vol. 12, # 6

>  <Main tar all>
Tyrosine-protein kinase ABL pX=6.81 | Poly pX=6.0 | epidermal growth factor receptor pX=5.71

$$$$
Dantrolene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0 13.4 0 0 CHG=-1
M  V30 2 N 1.3337 12.63 0 0 CHG=1
M  V30 3 O 2.6674 13.4 0 0
M  V30 4 C 1.3337 11.09 0 0
M  V30 5 C 2.6674 10.32 0 0
M  V30 6 C 2.6674 8.78 0 0
M  V30 7 C 1.3337 8.01 0 0
M  V30 8 C 0 8.78 0 0
M  V30 9 C 0 10.32 0 0
M  V30 10 C 1.3337 6.47 0 0
M  V30 11 C 2.5796 5.5648 0 0
M  V30 12 C 2.1037 4.1002 0 0
M  V30 13 C 0.5637 4.1002 0 0
M  V30 14 C -0.3415 2.8543 0 0
M  V30 15 N 0.2849 1.4474 0 0
M  V30 16 N -0.6203 0.2016 0 0
M  V30 17 C -0.1444 -1.2631 0 0
M  V30 18 C -1.3903 -2.1683 0 0
M  V30 19 O -1.3903 -3.7083 0 0
M  V30 20 N -2.6362 -1.2631 0 0
M  V30 21 C -2.1603 0.2016 0 0
M  V30 22 O -3.0655 1.4474 0 0
M  V30 23 O 0.0878 5.5648 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 14 13 CFG=2
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 23 2 21 22
M  V30 24 1 13 23
M  V30 25 1 10 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z91274084

>  <MW>
314.065

>  <MW (desalted)>
314.253

>  <ClogP>
1.631

>  <logS>
-5.021

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
118.05

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  0.278 ?M | IC50  0.302 ?M | IC50  0.3 ?M

>  <CAS>
7261-97-4

>  <Description>
Dantrolene is classified as a direct-acting skeletal muscle relaxant. Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. It is used for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages.

>  <EBC_ID>
EBC-08773

>  <IUPAC Name>
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 1, p. 722 - 730 | J. Pharm. Sci., 2018, vol. 107, # 11, p. 2742 - 2747 | J. Pharm. Sci., 2018, vol. 107, # 11, p. 2742 - 2747 | J. Pharmacol. Exp. Ther., 2017, vol. 362, # 3, p. 450 - 458

>  <Main tar all>
Ryanodine receptor 1 (R2163C) pX=8.0 | ABCG2 pX=6.56 | ABCC4 pX=6.52 | Organic anion transporter 3 pX=6.52

$$$$
Trihexyphenidyl hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 4.1937 0.805 0 0
M  V30 3 C 5.7337 0.805 0 0
M  V30 4 C 5.7337 -0.735 0 0
M  V30 5 C 7.0674 -1.505 0 0
M  V30 6 N 7.0674 -3.045 0 0
M  V30 7 C 8.401 -3.815 0 0
M  V30 8 C 8.401 -5.355 0 0
M  V30 9 C 7.0674 -6.125 0 0
M  V30 10 C 5.7337 -5.355 0 0
M  V30 11 C 5.7337 -3.815 0 0
M  V30 12 C 5.7337 2.345 0 0
M  V30 13 C 4.4 3.115 0 0
M  V30 14 C 4.4 4.655 0 0
M  V30 15 C 5.7337 5.425 0 0
M  V30 16 C 7.0674 4.655 0 0
M  V30 17 C 7.0674 3.115 0 0
M  V30 18 C 7.2737 0.805 0 0
M  V30 19 C 8.0437 2.1387 0 0
M  V30 20 C 9.5837 2.1387 0 0
M  V30 21 C 10.3537 0.805 0 0
M  V30 22 C 9.5837 -0.5287 0 0
M  V30 23 C 8.0437 -0.5287 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 6 11
M  V30 11 1 3 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 1 3 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616204

>  <MW>
337.217

>  <MW (desalted)>
301.466

>  <ClogP>
5.151

>  <logS>
-4.6

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
23.47

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.6 nM | pA2  9.02  | Ki (inhibition constant)  3.2 nM | pKi  8.48  | pKi  8.04  | IC50  10.3 nM

>  <CAS>
52-49-3

>  <Description>
Trihexyphenidyl is an antagonist of M1 muscarinic acetylcholine receptors. Formulations containing trihexyphenidyl have been used in the symptomatic treatment of Parkinson's disease.

>  <EBC_ID>
EBC-07023

>  <IUPAC Name>
1-cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride

>  <Main Tar all refs>
Psychopharmacology, 1995, vol. 117, # 2, p. 208 - 215 | Eur. J. Pharmacol., 1988, vol. 151, # 2, p. 205 - 221 | Psychopharmacology, 1995, vol. 117, # 2, p. 208 - 215 | EUR. J. PHARMACOL., 1993, vol. 250, # 2, p. 223 - 230 | EUR. J. PHARMACOL., 1993, vol. 250, # 2, p. 223 - 230 | Bioorg. Med. Chem. Lett., 1998, vol. 8, # 15, p. 1991 - 1996

>  <Main tar all>
mAChR pX=9.22 | M1 receptor pX=9.02 | M2 receptor pX=8.49 | M4 receptor pX=8.48 | M3 receptor pX=8.04 | M5 receptor pX=7.99

$$$$
Phenylbutazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 C 2.6674 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 2.5796 -3.2152 0 0
M  V30 7 O 4.0442 -2.7393 0 0
M  V30 8 N 2.1037 -4.6798 0 0
M  V30 9 N 0.5637 -4.6798 0 0
M  V30 10 C 0.0878 -3.2152 0 0
M  V30 11 O -1.3768 -2.7393 0 0
M  V30 12 C -0.3415 -5.9257 0 0
M  V30 13 C 0.2849 -7.3326 0 0
M  V30 14 C -0.6203 -8.5784 0 0
M  V30 15 C -2.1519 -8.4175 0 0
M  V30 16 C -2.7783 -7.0106 0 0
M  V30 17 C -1.8731 -5.7647 0 0
M  V30 18 C 3.0089 -5.9257 0 0
M  V30 19 C 4.5404 -5.7647 0 0
M  V30 20 C 5.4456 -7.0106 0 0
M  V30 21 C 4.8192 -8.4175 0 0
M  V30 22 C 3.2877 -8.5784 0 0
M  V30 23 C 2.3825 -7.3326 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 8 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57355370

>  <MW>
308.152

>  <MW (desalted)>
308.374

>  <ClogP>
3.385

>  <logS>
-4.972

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
40.62

>  <RotBonds>
5

>  <Action on targets>
Agonist | Agonist | Antagonist

>  <Activity coefficients and valu>
concentration (parameter)  2.4 nM | concentration (parameter)  2.4 nM | concentration (parameter)  12.7 nM

>  <CAS>
50-33-9

>  <Description>
Phenylbutazone  is an efficient reducing cofactor for the peroxidase activity of COX. It is used as a non-steroidal anti-inflammatory agent for the treatment of chronic pain, including the symptoms of arthritis.

>  <EBC_ID>
EBC-03849

>  <IUPAC Name>
4-butyl-1,2-diphenylpyrazolidine-3,5-dione

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425 | CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425 | CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425

>  <Main tar all>
FPR1 pX=8.62 | FPR1 pX=8.62 | C5a anaphylatoxin chemotactic receptor 1 pX=7.9

$$$$
Flavoxate hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 6.1874 -4.5403 0 0
M  V30 3 C 7.521 -3.7703 0 0
M  V30 4 C 7.521 -2.2303 0 0
M  V30 5 O 8.8547 -1.4603 0 0
M  V30 6 C 10.1884 -2.2303 0 0
M  V30 7 C 11.5221 -1.4603 0 0
M  V30 8 C 12.8558 -2.2303 0 0
M  V30 9 C 12.8558 -3.7703 0 0
M  V30 10 C 11.5221 -4.5403 0 0
M  V30 11 C 10.1884 -3.7703 0 0
M  V30 12 C 8.8547 -4.5403 0 0
M  V30 13 O 8.8547 -6.0803 0 0
M  V30 14 C 11.5221 0.0797 0 0
M  V30 15 O 10.1884 0.8497 0 0
M  V30 16 O 12.8558 0.8497 0 0
M  V30 17 C 12.8558 2.3897 0 0
M  V30 18 C 14.1894 3.1597 0 0
M  V30 19 N 14.1894 4.6997 0 0
M  V30 20 C 12.8558 5.4697 0 0
M  V30 21 C 12.8558 7.0097 0 0
M  V30 22 C 14.1894 7.7797 0 0
M  V30 23 C 15.5231 7.0097 0 0
M  V30 24 C 15.5231 5.4697 0 0
M  V30 25 C 6.1874 -1.4603 0 0
M  V30 26 C 4.8537 -2.2303 0 0
M  V30 27 C 3.52 -1.4603 0 0
M  V30 28 C 3.52 0.0797 0 0
M  V30 29 C 4.8537 0.8497 0 0
M  V30 30 C 6.1874 0.0797 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 11 12
M  V30 12 1 3 12
M  V30 13 2 12 13
M  V30 14 1 7 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 19 24
M  V30 26 1 4 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2768134941

>  <MW>
427.155

>  <MW (desalted)>
391.46

>  <ClogP>
4.97

>  <logS>
-5.851

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
55.84

>  <RotBonds>
6

>  <Action on targets>
Blocker | Blocker

>  <Activity coefficients and valu>
inhibition percentage Active   | inhibition percentage  77.5 - 77.51 %

>  <CAS>
3717-88-2

>  <Description>
Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. It is used for the symptomatic relief of conditions associated with lack of muscle control in the bladder, such as dysuria, urgency, and nocturia.

>  <EBC_ID>
EBC-12087

>  <IUPAC Name>
2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2005, vol. 146, # 1, p. 25 - 32 | PAIRNOMIX - WO2018/64498, 2018, A1

>  <Main tar all>
L-type calcium channel pX=7.0 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=5.54

$$$$
Rofecoxib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 5.39 0 0
M  V30 2 S 1.3337 3.85 0 0
M  V30 3 O -0.2063 3.85 0 0
M  V30 4 O 2.8737 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 C 1.3337 -2.31 0 0
M  V30 12 C 2.5796 -3.2152 0 0
M  V30 13 C 2.1037 -4.6798 0 0
M  V30 14 O 3.0089 -5.9257 0 0
M  V30 15 O 0.5637 -4.6798 0 0
M  V30 16 C 0.0878 -3.2152 0 0
M  V30 17 C 4.0442 -2.7393 0 0
M  V30 18 C 4.3644 -1.233 0 0
M  V30 19 C 5.829 -0.7571 0 0
M  V30 20 C 6.9734 -1.7875 0 0
M  V30 21 C 6.6533 -3.2939 0 0
M  V30 22 C 5.1886 -3.7698 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 11 16
M  V30 18 1 12 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037279770

>  <MW>
314.356

>  <MW (desalted)>
314.356

>  <ClogP>
1.798

>  <logS>
-4.008

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
60.44

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 <= 0.1 nM | IC50 = 369 pM | inhibition percentage  100 %

>  <CAS>
162011-90-7

>  <Description>
Rofecoxib is a selective cyclooxygenase-2 inhibitor, a nonsteroidal anti-inflammatory drug. It is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.

>  <EBC_ID>
EBC-17057

>  <IUPAC Name>
4-(4-methanesulfonylphenyl)-3-phenyl-2,5-dihydrofuran-2-one

>  <Main Tar all refs>
MERCK & CO INC - WO2003/86314, 2003, A2 | EURO CELTIQUE S.A. - US2002/99049, 2002, A1 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 1, p. 85 - 89

>  <Main tar all>
Insulin receptor pX=10.0 | COX-1  pX=9.43 | COX-2  pX=9.28

$$$$
Dexamethasone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.851 -2.6445 0 0
M  V30 2 C 5.2994 -3.1677 0 0 CFG=2
M  V30 3 C 6.574 -2.3035 0 0
M  V30 4 C 7.7898 -3.2487 0 0 CFG=1
M  V30 5 C 9.3058 -2.9776 0 0 CFG=2
M  V30 6 C 9.829 -1.5293 0 0
M  V30 7 C 11.345 -1.2582 0 0
M  V30 8 C 12.3377 -2.4355 0 0
M  V30 9 C 13.8537 -2.1644 0 0
M  V30 10 C 14.8464 -3.3418 0 0
M  V30 11 O 16.3624 -3.0707 0 0
M  V30 12 C 14.3232 -4.7901 0 0
M  V30 13 C 12.8072 -5.0612 0 0
M  V30 14 C 11.8145 -3.8839 0 0 CFG=1
M  V30 15 C 11.2913 -5.3323 0 0
M  V30 16 C 10.2985 -4.155 0 0 CFG=2
M  V30 17 F 10.4097 -5.6909 0 0
M  V30 18 C 9.7753 -5.6034 0 0 CFG=1
M  V30 19 O 10.768 -6.7807 0 0
M  V30 20 C 8.2593 -5.8744 0 0
M  V30 21 C 7.2666 -4.6971 0 0 CFG=1
M  V30 22 C 6.5949 -6.0829 0 0
M  V30 23 C 5.7274 -4.6471 0 0 CFG=2
M  V30 24 O 5.5008 -6.1703 0 0
M  V30 25 C 4.3071 -5.2423 0 0
M  V30 26 O 4.1124 -6.7699 0 0
M  V30 27 C 3.0815 -4.3099 0 0
M  V30 28 O 1.6612 -4.9051 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 16 5
M  V30 18 1 16 17 CFG=3
M  V30 19 1 16 18
M  V30 20 1 18 19 CFG=1
M  V30 21 1 18 20
M  V30 22 1 21 20
M  V30 23 1 4 21
M  V30 24 1 21 22 CFG=1
M  V30 25 1 21 23
M  V30 26 1 23 2
M  V30 27 1 23 24 CFG=3
M  V30 28 1 23 25 CFG=1
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756391748

>  <MW>
392.461

>  <MW (desalted)>
392.461

>  <ClogP>
1.785

>  <logS>
-3.96

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
94.83

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | - | Agonist | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.007 nM | concentration (parameter) = 8.7 pg/mL | stimulation rate  100 % | concentration (parameter)  15.31 pg/ml | IC50 = 0.05 nM

>  <CAS>
50-02-2

>  <Description>
Dexamethasone is a glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders. Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.

>  <EBC_ID>
EBC-13183

>  <IUPAC Name>
(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Int. Immunopharmacol., 2018, vol. 65, p. 108 - 118 | Biochem. Pharmacol., 2006, vol. 71, # 4, p. 530 - 539 | Sumitomo Pharma (in: Sumitomo Chemical); SUMITOMO CHEMICAL COMPANY LIMITED; Sumitomo Chemical (w/o Dongwoo Fine-Chem) - EP1930320, 2008, A1 | Eur. J. Pharmacol., 2016, vol. 788, p. 152 - 159 | Br. J. Pharmacol., 2005, vol. 145, # 1, p. 123 - 131

>  <Main tar all>
phosphodiesterase 4 pX=11.2 | Concanavalin-A pX=10.7 | Glucocorticoid receptor pX=10.6 | Bradykinin pX=10.4 | Interleukin-1 alpha pX=10.3

$$$$
Mefloquine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 9.7347 -3.3169 0 0
M  V30 3 C 8.401 -2.5469 0 0 CFG=1
M  V30 4 C 7.0674 -3.3169 0 0 CFG=2
M  V30 5 C 7.0674 -4.8569 0 0
M  V30 6 C 5.7337 -5.6269 0 0
M  V30 7 C 4.4 -4.8569 0 0
M  V30 8 C 4.4 -3.3169 0 0
M  V30 9 N 5.7337 -2.5469 0 0
M  V30 10 C 8.401 -1.0069 0 0
M  V30 11 C 7.0674 -0.2369 0 0
M  V30 12 C 7.0674 1.3031 0 0
M  V30 13 N 8.401 2.0731 0 0
M  V30 14 C 9.7347 1.3031 0 0
M  V30 15 C 11.0684 2.0731 0 0
M  V30 16 C 12.4021 1.3031 0 0
M  V30 17 C 12.4021 -0.2369 0 0
M  V30 18 C 11.0684 -1.0069 0 0
M  V30 19 C 9.7347 -0.2369 0 0
M  V30 20 C 11.0684 3.6131 0 0
M  V30 21 F 11.0684 5.1531 0 0
M  V30 22 F 12.6084 3.6131 0 0
M  V30 23 F 9.5284 3.6131 0 0
M  V30 24 C 5.7337 2.0731 0 0
M  V30 25 F 4.4 2.8431 0 0
M  V30 26 F 6.5037 3.4068 0 0
M  V30 27 F 4.9637 0.7394 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=1
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 4 9 CFG=3
M  V30 9 1 3 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 10 19
M  V30 20 1 14 19
M  V30 21 1 15 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 20 23
M  V30 25 1 12 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 1 24 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1532363097

>  <MW>
414.773

>  <MW (desalted)>
378.312

>  <ClogP>
3.669

>  <logS>
-5.06

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
45.15

>  <RotBonds>
4

>  <Action on targets>
Antagonist | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
pIC50  6.18  | Ki (inhibition constant)  1.53 ?M | pIC50  5.57  | Ki (inhibition constant)  17 ?M

>  <CAS>
51773-92-3

>  <Description>
Mefloquine hydrochloride is a quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine.

>  <EBC_ID>
EBC-08959

>  <IUPAC Name>
(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2008, vol. 153, # 8, p. 1686 - 1696 | J. PHARM. PHARMACOL., 1990, vol. 42, # 4, p. 267 - 271 | Br. J. Pharmacol., 2008, vol. 153, # 8, p. 1686 - 1696 | Mol. Pharmacol., 2002, vol. 62, # 6, p. 1364 - 1372

>  <Main tar all>
5-HT3A pX=6.18 | CYP2D1 pX=5.82 | 5-HT3B pX=5.57 | Ribosyldihydronicotinamide dehydrogenase [quinone] pX=4.77

$$$$
Trifluoperazine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C 6.2873 -3.08 0 0
M  V30 4 N 4.9537 -3.85 0 0
M  V30 5 C 4.9537 -5.39 0 0
M  V30 6 C 3.62 -6.16 0 0
M  V30 7 N 2.2863 -5.39 0 0
M  V30 8 C 0.9526 -6.16 0 0
M  V30 9 C 0.9526 -7.7 0 0
M  V30 10 C -0.3811 -8.47 0 0
M  V30 11 N -0.3811 -10.01 0 0
M  V30 12 C 0.9526 -10.78 0 0
M  V30 13 C 2.2863 -10.01 0 0
M  V30 14 C 3.62 -10.78 0 0
M  V30 15 C 3.62 -12.32 0 0
M  V30 16 C 2.2863 -13.09 0 0
M  V30 17 C 0.9526 -12.32 0 0
M  V30 18 S -0.3811 -13.09 0 0
M  V30 19 C -1.7147 -12.32 0 0
M  V30 20 C -3.0484 -13.09 0 0
M  V30 21 C -4.3821 -12.32 0 0
M  V30 22 C -4.3821 -10.78 0 0
M  V30 23 C -3.0484 -10.01 0 0
M  V30 24 C -1.7147 -10.78 0 0
M  V30 25 C -5.7158 -10.01 0 0
M  V30 26 F -7.0494 -9.24 0 0
M  V30 27 F -4.9458 -8.6763 0 0
M  V30 28 F -6.4858 -11.3437 0 0
M  V30 29 C 2.2863 -3.85 0 0
M  V30 30 C 3.62 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 2 13 14
M  V30 12 1 14 15
M  V30 13 2 15 16
M  V30 14 1 16 17
M  V30 15 2 12 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 2 20 21
M  V30 20 1 21 22
M  V30 21 2 22 23
M  V30 22 1 23 24
M  V30 23 1 11 24
M  V30 24 2 19 24
M  V30 25 1 22 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 25 28
M  V30 29 1 7 29
M  V30 30 1 29 30
M  V30 31 1 4 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1565440332

>  <MW>
480.417

>  <MW (desalted)>
407.496

>  <ClogP>
4.692

>  <logS>
-5.5

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
9.72

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.5322 nM | Kd (dissociation constant) = 1.043 nM | Ki (inhibition constant)  1.2 nM | Ki (inhibition constant) = 9.3 nM | pIC50  8

>  <CAS>
440-17-5

>  <Description>
Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

>  <EBC_ID>
EBC-13185

>  <IUPAC Name>
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine dihydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1986, vol. 29, # 3, p. 359 - 369 | J. MED. CHEM., 1986, vol. 29, # 3, p. 359 - 369 | Mol. Pharmacol., 1985, vol. 28, # 5, p. 391 - 399 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | BIOCHEM. PHARMACOL., 1978, vol. 27, # 3, p. 307 - 316

>  <Main tar all>
D2 receptor pX=9.27 | 5-HT2A receptor pX=8.98 | D2L receptor pX=8.92 | D2 receptor pX=8.03 | Dopamine receptor pX=8.0

$$$$
Nitrendipine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 O 2.6674 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 O 0 0 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 4.001 -2.31 0 0
M  V30 9 N 2.6674 -4.62 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 C 0 -4.62 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C -1.3337 -2.31 0 0
M  V30 14 C -2.6674 -3.08 0 0
M  V30 15 C -4.001 -2.31 0 0
M  V30 16 C -4.001 -0.77 0 0
M  V30 17 C -2.6674 0 0 0
M  V30 18 C -1.3337 -0.77 0 0
M  V30 19 N -2.6674 1.54 0 0 CHG=1
M  V30 20 O -4.001 2.31 0 0
M  V30 21 O -1.3337 2.31 0 0 CHG=-1
M  V30 22 C -1.3337 -5.39 0 0
M  V30 23 O -2.6674 -4.62 0 0
M  V30 24 O -1.3337 -6.93 0 0
M  V30 25 C -2.6674 -7.7 0 0
M  V30 26 C 1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 6 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 11 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 1 10 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z239859926

>  <MW>
360.361

>  <MW (desalted)>
360.361

>  <ClogP>
3.734

>  <logS>
-3.213

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
107.77

>  <RotBonds>
7

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
pA2  10.19  | Ki (inhibition constant)  0.08 nM | Ki (inhibition constant)  0.11 nM | Ki (inhibition constant)  1.2E-10 M | pA2  9.7  | IC50 = 0.285 nM | Ki (inhibition constant) = 4.4E-10 M | IC50  0.4709 nM

>  <CAS>
39562-70-4

>  <Description>
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is indicated for the treatment of mild to moderate hypertension.

>  <EBC_ID>
EBC-11160

>  <IUPAC Name>
3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

>  <Main Tar all refs>
JPN. J. PHARMACOL., 1992, vol. 58, # 1, p. 75 - 78 | Biochem. Biophys. Res. Commun., 1982, vol. 104, # 3, p. 937 - 943 | Arzneimittelforschung, 1989, vol. 39, # 10, p. 1185 - 1189 | J. Med. Chem., 2020, vol. 63, # 7, p. 3610 - 3633 | J. PHARMACOL. EXP. THER., 1992, vol. 263, # 3, p. 1241 - 1247 | Bioorg. Med. Chem. Lett., 2013, vol. 23, # 6, p. 1834 - 1838 | J. Med. Chem., 2011, vol. 54, # 14, p. 5070 - 5081 | J. Med. Chem., 2020, vol. 63, # 13, p. 7033 - 7051

>  <Main tar all>
Cav1.1 pX=10.2 | voltage-gated calcium channel pX=10.1 | L-type calcium channel pX=9.96 | calcium activated cation channel pX=9.92 | Voltage-gated potassium channel pX=9.7 | Cav1.2 pX=9.55 | Cav1.2 pX=9.36 | L-type calcium channel pX=9.33

$$$$
Bunazosin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.343 -7.7483 0 0
M  V30 2 C -5.8073 -7.8634 0 0
M  V30 3 C -4.9398 -6.591 0 0
M  V30 4 C -3.4041 -6.706 0 0
M  V30 5 O -2.7359 -8.0935 0 0
M  V30 6 N -2.5366 -5.4336 0 0
M  V30 7 C -3.3066 -4.1 0 0
M  V30 8 C -2.744 -2.6664 0 0
M  V30 9 C -1.2724 -2.2125 0 0
M  V30 10 N 0 -3.08 0 0
M  V30 11 C 0.1151 -4.6157 0 0
M  V30 12 C -1.0138 -5.6632 0 0
M  V30 13 C 1.3337 -2.31 0 0
M  V30 14 N 1.3337 -0.77 0 0
M  V30 15 C 2.6674 0 0 0
M  V30 16 N 2.6674 1.54 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 C 5.3347 0 0 0
M  V30 19 C 6.6684 -0.77 0 0
M  V30 20 O 8.0021 -0 0 0
M  V30 21 C 8.0021 1.54 0 0
M  V30 22 C 6.6684 -2.31 0 0
M  V30 23 O 8.0021 -3.08 0 0
M  V30 24 C 8.0021 -4.62 0 0
M  V30 25 C 5.3347 -3.08 0 0
M  V30 26 C 4.001 -2.31 0 0
M  V30 27 N 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 6 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 19 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 22 25
M  V30 26 1 25 26
M  V30 27 2 17 26
M  V30 28 1 26 27
M  V30 29 2 13 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1172912933

>  <MW>
373.449

>  <MW (desalted)>
373.449

>  <ClogP>
2.098

>  <logS>
-4.51

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
93.81

>  <RotBonds>
5

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pA2  9.86  | pKi  9.71  | pKi  9.53  | pKi  9.37  | pKi  9.35

>  <CAS>
80755-51-7

>  <Description>
Bunazosin is a quinazoline derivative with a1-adrenoceptor blocking activity. It has been used in trials studying the treatment of High Blood Pressure.

>  <EBC_ID>
EBC-14148

>  <IUPAC Name>
1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one

>  <Main Tar all refs>
J. PHARMACOBIO-DYN., 1989, vol. 12, # 3, p. 170 - 174 | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149 | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149 | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149 | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149

>  <Main tar all>
?1-adrenoceptor pX=9.86 | ?1A-adrenoceptor pX=9.71 | ?1B-adrenoceptor pX=9.53 | ?1D-adrenoceptor pX=9.37 | ?1B-adrenoceptor pX=9.35

$$$$
Griseofulvin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.8072 4.771 0 0
M  V30 2 O 5.0372 3.4374 0 0
M  V30 3 C 5.8072 2.1037 0 0
M  V30 4 C 7.3472 2.1037 0 0
M  V30 5 C 8.1172 0.77 0 0
M  V30 6 O 9.6572 0.77 0 0
M  V30 7 C 7.3472 -0.5637 0 0
M  V30 8 C 5.8072 -0.5637 0 0 CFG=1
M  V30 9 C 5.0372 -1.8974 0 0
M  V30 10 C 5.0372 0.77 0 0 CFG=2
M  V30 11 O 4.132 2.0159 0 0
M  V30 12 C 2.6674 1.54 0 0
M  V30 13 C 2.6674 -0 0 0
M  V30 14 C 4.132 -0.4759 0 0
M  V30 15 O 4.132 -2.0159 0 0
M  V30 16 C 1.3337 -0.77 0 0
M  V30 17 O 1.3337 -2.31 0 0
M  V30 18 C 0 -3.08 0 0
M  V30 19 C 0 -0 0 0
M  V30 20 C 0 1.54 0 0
M  V30 21 O -1.3337 2.31 0 0
M  V30 22 C -2.6674 1.54 0 0
M  V30 23 C 1.3337 2.31 0 0
M  V30 24 Cl 1.3337 3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 3
M  V30 11 1 10 11 CFG=3
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 10 14
M  V30 16 2 14 15
M  V30 17 2 13 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 20 23
M  V30 25 2 12 23
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756424454

>  <MW>
352.766

>  <MW (desalted)>
352.766

>  <ClogP>
2.053

>  <logS>
-4.76

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
71.06

>  <RotBonds>
3

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50 (unbound)  0.96 ?M | IC50  13.87 ?M

>  <CAS>
126-07-8

>  <Description>
Griseofulvin is an antifungal agent used to treat a variety of superficial tinea infections and fungal infections of the fingernails and toes.

>  <EBC_ID>
EBC-14149

>  <IUPAC Name>
(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione

>  <Main Tar all refs>
Drug Metab. Dispos., 2008, vol. 36, # 8, p. 1689 - 1697 | Chem. Biodivers., 2023, vol. 20, # 6

>  <Main tar all>
Pregnane X receptor pX=6.02 | Transcription factor p65 pX=4.86

$$$$
Quinindine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8489 -2.7691 0 0
M  V30 2 O 9.5153 -1.9991 0 0
M  V30 3 C 8.1816 -2.7691 0 0
M  V30 4 C 8.1816 -4.3091 0 0
M  V30 5 C 6.8479 -5.0791 0 0
M  V30 6 C 5.5142 -4.3091 0 0
M  V30 7 N 4.1805 -5.0791 0 0
M  V30 8 C 2.8469 -4.3091 0 0
M  V30 9 C 2.8469 -2.7691 0 0
M  V30 10 C 4.1805 -1.9991 0 0
M  V30 11 C 4.1805 -0.4591 0 0 CFG=2
M  V30 12 O 2.8469 0.3109 0 0
M  V30 13 C 5.5142 0.3109 0 0 CFG=1
M  V30 14 C 5.5142 1.8509 0 0
M  V30 15 C 6.8479 2.6209 0 0 CFG=2
M  V30 16 C 7.1046 1.5942 0 0
M  V30 17 C 7.1046 0.5676 0 0
M  V30 18 N 6.8479 -0.4591 0 0
M  V30 19 C 8.1816 0.3109 0 0
M  V30 20 C 8.1816 1.8509 0 0 CFG=2
M  V30 21 C 9.5153 2.6209 0 0
M  V30 22 C 9.5153 4.1609 0 0
M  V30 23 C 5.5142 -2.7691 0 0
M  V30 24 C 6.8479 -1.9991 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 11 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 15 14 CFG=1
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 15 20
M  V30 22 1 20 21 CFG=1
M  V30 23 2 21 22
M  V30 24 1 10 23
M  V30 25 2 6 23
M  V30 26 1 23 24
M  V30 27 2 3 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741976976

>  <MW>
324.417

>  <MW (desalted)>
324.417

>  <ClogP>
2.785

>  <logS>
-2.803

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
45.59

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.0073 nM

>  <CAS>
56-54-2

>  <Description>
Quinidine is a stereoisomer of the antimalarial agent quinine. Quinidine blocks the potassium voltage-gated channel. It is used to restore normal sinus rhythm, treat atrial fibrillation and flutter, and treat ventricular arrhythmias.

>  <EBC_ID>
EBC-03886

>  <IUPAC Name>
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 14, p. 7721 - 7739

>  <Main tar all>
Cytochrome P450 2D6 pX=11.1

$$$$
Meropenem trihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 O 0 -7.227 0 0
M  V30 4 C 4.4 -6.7786 0 0
M  V30 5 C 5.8875 -6.38 0 0 CFG=1
M  V30 6 O 6.2861 -4.8925 0 0
M  V30 7 C 6.9765 -7.4689 0 0 CFG=2
M  V30 8 C 8.5165 -7.4689 0 0 CFG=1
M  V30 9 C 9.9811 -6.9931 0 0 CFG=1
M  V30 10 C 10.457 -5.5284 0 0
M  V30 11 C 10.8863 -8.2389 0 0
M  V30 12 C 9.9811 -9.4848 0 0
M  V30 13 N 8.5165 -9.0089 0 0
M  V30 14 C 6.9765 -9.0089 0 0
M  V30 15 O 5.8875 -10.0979 0 0
M  V30 16 C 10.457 -10.9495 0 0
M  V30 17 O 9.4265 -12.0939 0 0
M  V30 18 O 11.9633 -11.2696 0 0
M  V30 19 S 12.4263 -8.2389 0 0
M  V30 20 C 13.1963 -6.9053 0 0 CFG=2
M  V30 21 C 12.5699 -5.4984 0 0
M  V30 22 N 13.7144 -4.4679 0 0
M  V30 23 C 15.048 -5.2379 0 0 CFG=1
M  V30 24 C 14.7279 -6.7443 0 0
M  V30 25 C 16.4549 -4.6116 0 0
M  V30 26 O 16.6159 -3.08 0 0
M  V30 27 N 17.7008 -5.5168 0 0
M  V30 28 C 19.1076 -4.8904 0 0
M  V30 29 C 17.5398 -7.0483 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 4
M  V30 2 1 5 6 CFG=1
M  V30 3 1 7 5 CFG=3
M  V30 4 1 7 8
M  V30 5 1 8 9
M  V30 6 1 9 10 CFG=1
M  V30 7 1 9 11
M  V30 8 2 11 12
M  V30 9 1 12 13
M  V30 10 1 8 13 CFG=1
M  V30 11 1 13 14
M  V30 12 1 7 14
M  V30 13 2 14 15
M  V30 14 1 12 16
M  V30 15 2 16 17
M  V30 16 1 16 18
M  V30 17 1 11 19
M  V30 18 1 20 19 CFG=3
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 1 23 22
M  V30 22 1 23 24
M  V30 23 1 20 24
M  V30 24 1 23 25 CFG=3
M  V30 25 2 25 26
M  V30 26 1 25 27
M  V30 27 1 27 28
M  V30 28 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3243814856

>  <MW>
437.183

>  <MW (desalted)>
383.463

>  <ClogP>
-3.278

>  <logS>
-1.99

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
110.18

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 10000 nM | Km (Michaelis constant) = 85000 nM

>  <CAS>
119478-56-7

>  <Description>
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

>  <EBC_ID>
EBC-15047

>  <IUPAC Name>
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 1999, vol. 43, # 4, p. 902 - 906 | Antimicrob. Agents Chemother., 2001, vol. 45, # 4, p. 1254 - 1262

>  <Main tar all>
Beta-lactamase NDM-1 pX=5.0 | Beta-lactamase CcrA pX=4.07

$$$$
Imiqimod
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.9955 -6.8692 0 0
M  V30 2 C 4.6285 -5.3736 0 0
M  V30 3 C 3.1497 -4.9436 0 0
M  V30 4 C 5.7402 -4.3079 0 0
M  V30 5 N 5.3731 -2.8122 0 0
M  V30 6 C 3.9474 -2.2301 0 0
M  V30 7 N 4.0604 -0.6943 0 0
M  V30 8 C 5.556 -0.3272 0 0
M  V30 9 C 6.284 1.0299 0 0
M  V30 10 N 5.4728 2.3389 0 0
M  V30 11 N 7.8233 1.078 0 0
M  V30 12 C 8.6345 -0.231 0 0
M  V30 13 C 10.1738 -0.1829 0 0
M  V30 14 C 10.9851 -1.4919 0 0
M  V30 15 C 10.2571 -2.849 0 0
M  V30 16 C 8.7178 -2.8971 0 0
M  V30 17 C 7.9066 -1.5881 0 0
M  V30 18 C 6.3673 -1.6362 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 17 18
M  V30 19 1 5 18
M  V30 20 2 8 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038940

>  <MW>
240.137

>  <MW (desalted)>
240.304

>  <ClogP>
3.236

>  <logS>
-3.587

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
56.73

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.646 ?M | accumulation rate increase Active   | accumulation rate increase Active   | EC50  1.5 ?M | Ki (inhibition constant) = 2.16 ?M | Ki (inhibition constant) = 2.94 ?M | IC50  11 ?M | IC50  13.9 ?M | IC50  19.1 ?M

>  <CAS>
99011-02-6

>  <Description>
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. It is used for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

>  <EBC_ID>
EBC-07888

>  <IUPAC Name>
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine

>  <Main Tar all refs>
J. Med. Chem., 2016, vol. 59, # 6, p. 2346 - 2361 | Pharmaceuticals, 2021, vol. 14, # 12 | Pharmaceuticals, 2021, vol. 14, # 12 | Antimicrob. Agents Chemother., 2018, vol. 62, # 5 | Curr. Med. Chem., 2007, vol. 14, # 6, p. 681 - 687 | Curr. Med. Chem., 2007, vol. 14, # 6, p. 681 - 687 | Biochem. Pharmacol., 2020, vol. 182 | J. Pharmacol. Exp. Ther., 2012, vol. 341, # 3, p. 743 - 755 | J. Pharmacol. Exp. Ther., 2012, vol. 341, # 3, p. 743 - 755

>  <Main tar all>
Protein MTH1 pX=6.19 | ABCB1 pX=6.0 | ATP-dependent translocase ABCB1 pX=6.0 | TLR7 pX=5.82 | Adenosine A2A receptor pX=5.67 | Adenosine A1 receptor pX=5.53 | phosphodiesterase 4B pX=4.96 | Multidrug and toxin extrusion pX=4.86 | MATE2 pX=4.72

$$$$
Isoxaflutole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.1627 3.8825 0 0
M  V30 2 S 9.6273 3.4066 0 0
M  V30 3 O 9.1514 1.9419 0 0
M  V30 4 O 10.1032 4.8712 0 0
M  V30 5 C 11.0919 2.9307 0 0
M  V30 6 C 12.2364 3.9611 0 0
M  V30 7 C 13.701 3.4853 0 0
M  V30 8 C 14.0212 1.9789 0 0
M  V30 9 C 12.8767 0.9484 0 0
M  V30 10 C 11.4121 1.4243 0 0
M  V30 11 C 10.2677 0.3939 0 0
M  V30 12 O 10.5879 -1.1125 0 0
M  V30 13 C 8.803 0.8698 0 0
M  V30 14 C 8.3272 2.3344 0 0
M  V30 15 N 6.7872 2.3344 0 0
M  V30 16 O 6.3113 0.8698 0 0
M  V30 17 C 7.5572 -0.0354 0 0
M  V30 18 C 7.5572 -1.5754 0 0
M  V30 19 C 8.3272 -2.9091 0 0
M  V30 20 C 6.7872 -2.9091 0 0
M  V30 21 C 14.8454 4.5157 0 0
M  V30 22 F 15.9899 5.5462 0 0
M  V30 23 F 15.8759 3.3713 0 0
M  V30 24 F 13.815 5.6602 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 13 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 18 20
M  V30 23 1 7 21
M  V30 24 1 21 22
M  V30 25 1 21 23
M  V30 26 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3234892128

>  <MW>
359.044

>  <MW (desalted)>
359.32

>  <ClogP>
1.767

>  <logS>
-3.733

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
77.24

>  <RotBonds>
5

>  <CAS>
141112-29-0

>  <Description>
Isoxaflutole has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.

>  <EBC_ID>
EBC-13247

>  <IUPAC Name>
5-cyclopropyl-4-[2-methanesulfonyl-4-(trifluoromethyl)benzoyl]-1,2-oxazole

$$$$
Cortisone acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1331 -8.357 0 0
M  V30 2 C 1.6491 -8.086 0 0
M  V30 3 O 2.6418 -9.2633 0 0
M  V30 4 O 2.1723 -6.6376 0 0
M  V30 5 C 3.6883 -6.3665 0 0
M  V30 6 C 4.2115 -4.9181 0 0
M  V30 7 O 3.2187 -3.7408 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 O 5.8386 -6.183 0 0
M  V30 10 C 5.2994 -3.1677 0 0
M  V30 11 C 6.574 -2.3035 0 0
M  V30 12 C 7.7898 -3.2487 0 0 CFG=1
M  V30 13 C 9.3058 -2.9776 0 0 CFG=2
M  V30 14 C 9.829 -1.5293 0 0
M  V30 15 C 11.345 -1.2582 0 0
M  V30 16 C 12.3377 -2.4355 0 0
M  V30 17 C 13.8537 -2.1644 0 0
M  V30 18 C 14.8464 -3.3418 0 0
M  V30 19 O 16.3624 -3.0707 0 0
M  V30 20 C 14.3232 -4.7901 0 0
M  V30 21 C 12.8072 -5.0612 0 0
M  V30 22 C 11.8145 -3.8839 0 0 CFG=1
M  V30 23 C 11.2913 -5.3323 0 0
M  V30 24 C 10.2985 -4.155 0 0 CFG=1
M  V30 25 C 9.7753 -5.6034 0 0
M  V30 26 O 10.768 -6.7807 0 0
M  V30 27 C 8.2593 -5.8744 0 0
M  V30 28 C 7.2666 -4.6971 0 0 CFG=2
M  V30 29 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 13 24
M  V30 26 1 24 25 CFG=1
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 28 27
M  V30 30 1 12 28
M  V30 31 1 28 8
M  V30 32 1 28 29 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2238899644

>  <MW>
402.204

>  <MW (desalted)>
402.481

>  <ClogP>
2.022

>  <logS>
-3.341

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
97.74

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.91 mM

>  <CAS>
50-04-4

>  <Description>
Cortisone acetate is a steroid hormone used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and endocrine disorders associated with inadequate production of steroid hormones.

>  <EBC_ID>
EBC-12901

>  <IUPAC Name>
2-[(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-9a,11a-dimethyl-7,10-dioxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

>  <Main Tar all refs>
FEBS J., 2019, vol. 286, # 20, p. 4135 - 4155

>  <Main tar all>
Arginase I pX=3.04

$$$$
Atovaquone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 0 0 0 0 CFG=1
M  V30 5 C -1.3337 -0.77 0 0
M  V30 6 C -2.6674 0 0 0
M  V30 7 C -2.6674 1.54 0 0 CFG=1
M  V30 8 C -1.3337 2.31 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 C -4.001 2.31 0 0
M  V30 11 C -5.3347 1.54 0 0
M  V30 12 C -6.6684 2.31 0 0
M  V30 13 C -6.6684 3.85 0 0
M  V30 14 Cl -8.0021 4.62 0 0
M  V30 15 C -5.3347 4.62 0 0
M  V30 16 C -4.001 3.85 0 0
M  V30 17 C 2.6674 0 0 0
M  V30 18 O 2.6674 1.54 0 0
M  V30 19 C 4.001 -0.77 0 0
M  V30 20 C 5.3347 0 0 0
M  V30 21 C 6.6684 -0.77 0 0
M  V30 22 C 6.6684 -2.31 0 0
M  V30 23 C 5.3347 -3.08 0 0
M  V30 24 C 4.001 -2.31 0 0
M  V30 25 C 2.6674 -3.08 0 0
M  V30 26 O 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10 CFG=3
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 15 16
M  V30 17 2 10 16
M  V30 18 1 3 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 27 1 24 25
M  V30 28 1 2 25
M  V30 29 2 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038997

>  <MW>
366.102

>  <MW (desalted)>
366.837

>  <ClogP>
6.351

>  <logS>
-6.931

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.3 nM | EC50  0.56 nM | EC50  0.7 nM | IC50 = 1 nM | IC50  0.001 ?M | IC50  1.42 nM | IC50  0.0015 ?M | EC50  1.9 nM | EC50  1.9 nM

>  <CAS>
95233-18-4

>  <Description>
Atovaquone is a potent, selective and orally active inhibitor of the parasite?s mitochondrial cytochrome bc1 complex. Atovaquone is a broad-spectrum antiprotozoal agent that is active against Plasmodium, Toxoplasma, and Babesia, among other protozoa.Atovaquone have been used in the treatment of Pneumocystis pneumonia and toxoplasmosis as well as in combination with proguanil in the treatment of malaria and babesiosis.

>  <EBC_ID>
EBC-06068

>  <IUPAC Name>
2-hydroxy-3-[(1r,4r)-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydronaphthalene-1,4-dione

>  <Main Tar all refs>
Cell Chem. Biol., 2022, vol. 29, # 2, p. 191 - 8,201 | Pharmaceuticals, 2022, vol. 15, # 7 | J. Med. Chem., 2023, vol. 66, # 5, p. 3540 - 3565 | Antimicrob. Agents Chemother., 1999, vol. 43, # 3, p. 651 - 654 | GLAXOSMITHKLINE PLC - WO2022/263557, 2022, A1 | Antimicrob. Agents Chemother., 2017, vol. 61, # 8 | Parasitol. Int., 2020, vol. 75 | Proc. Natl. Acad. Sci. U. S. A., 2018, vol. 115, # 29, p. E6863 - E6870 | Proc. Natl. Acad. Sci. U. S. A., 2018, vol. 115, # 29, p. E6863 - E6870

>  <Main tar all>
acetate-CoA ligase pX=9.52 | Sulfide-quinone reductase pX=9.25 | ATP synthase subunit 4, mitochondrial pX=9.15 | Cytochrome C Reductase pX=9.0 | Cytochrome bc1 complex, cytochrome c subunit pX=9.0 | Cytochrome b6 pX=8.85 | Succinate cytochrome c reductase (complexes II and III) pX=8.82 | proteasome 20S subunit beta 2 pX=8.72 | proteasome 20S subunit beta 5 pX=8.72

$$$$
Fludarabine phosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 F 8.788 -0.77 0 0
M  V30 6 N 6.1207 -0.77 0 0
M  V30 7 C 4.787 0 0 0
M  V30 8 N 3.3224 -0.4759 0 0
M  V30 9 C 2.4172 0.77 0 0
M  V30 10 N 3.3224 2.0159 0 0
M  V30 11 C 4.787 1.54 0 0
M  V30 12 C 2.8465 -1.9405 0 0 CFG=2
M  V30 13 O 3.7517 -3.1864 0 0
M  V30 14 C 2.8465 -4.4323 0 0 CFG=2
M  V30 15 C 3.3224 -5.8969 0 0
M  V30 16 O 2.2919 -7.0414 0 0
M  V30 17 P 2.7678 -8.506 0 0
M  V30 18 O 3.2437 -9.9706 0 0
M  V30 19 O 1.3032 -8.9819 0 0
M  V30 20 O 4.2324 -8.0301 0 0
M  V30 21 C 1.3818 -3.9564 0 0 CFG=1
M  V30 22 O 0.136 -4.8616 0 0
M  V30 23 C 1.3818 -2.4164 0 0 CFG=2
M  V30 24 O 0.136 -1.5112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 2 11
M  V30 12 1 7 11
M  V30 13 1 12 8 CFG=3
M  V30 14 1 12 13
M  V30 15 1 14 13
M  V30 16 1 14 15 CFG=3
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 17 20
M  V30 22 1 21 14
M  V30 23 1 21 22 CFG=1
M  V30 24 1 21 23
M  V30 25 1 23 12
M  V30 26 1 23 24 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802254

>  <MW>
365.054

>  <MW (desalted)>
365.212

>  <ClogP>
-3.073

>  <logS>
-1.444

>  <HBD>
5

>  <HBA>
10

>  <TPSA>
186.07

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.245 ?M | EC50  0.93 ?M

>  <CAS>
75607-67-9

>  <Description>
Fludarabine?is a purine analog antimetabolite that inhibits DNA synthesis. Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia.

>  <EBC_ID>
EBC-07862

>  <IUPAC Name>
{[(2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

>  <Main Tar all refs>
FEBS J., 2021, vol. 288, # 3, p. 945 - 960 | Antiviral Res., 2022, vol. 198

>  <Main tar all>
endoplasmic reticulum to nucleus signaling 1 pX=6.61 | RNA-dependent RNA polymerase 2 pX=6.03

$$$$
Abacavir sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 47 52 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.1956 0.7783 0 0
M  V30 2 C 2.8619 0.0083 0 0
M  V30 3 N 2.8619 -1.5317 0 0
M  V30 4 C 1.5282 -2.3017 0 0
M  V30 5 N 1.5282 -3.8417 0 0
M  V30 6 C 2.8619 -4.6117 0 0
M  V30 7 C 4.4019 -4.6117 0 0
M  V30 8 C 3.6319 -5.9454 0 0
M  V30 9 C 0.1946 -1.5317 0 0
M  V30 10 N -1.2701 -2.0076 0 0
M  V30 11 C -2.1753 -0.7617 0 0
M  V30 12 N -1.2701 0.4842 0 0
M  V30 13 C -1.746 1.9488 0 0 CFG=2
M  V30 14 C -3.2106 2.4247 0 0
M  V30 15 C -3.2106 3.9647 0 0 CFG=2
M  V30 16 C -4.4565 4.8699 0 0
M  V30 17 O -5.8633 4.2435 0 0
M  V30 18 C -1.746 4.4406 0 0
M  V30 19 C -0.8408 3.1947 0 0
M  V30 20 C 0.1946 0.0083 0 0
M  V30 21 N 1.5282 0.7783 0 0
M  V30 22 N 17.9808 0.7783 0 0
M  V30 23 C 16.6472 0.0083 0 0
M  V30 24 N 16.6472 -1.5317 0 0
M  V30 25 C 15.3135 -2.3017 0 0
M  V30 26 N 15.3135 -3.8417 0 0
M  V30 27 C 16.6472 -4.6117 0 0
M  V30 28 C 18.1872 -4.6117 0 0
M  V30 29 C 17.4172 -5.9454 0 0
M  V30 30 C 13.9798 -1.5317 0 0
M  V30 31 N 12.5152 -2.0076 0 0
M  V30 32 C 11.61 -0.7617 0 0
M  V30 33 N 12.5152 0.4842 0 0
M  V30 34 C 12.0393 1.9488 0 0 CFG=2
M  V30 35 C 10.5747 2.4247 0 0
M  V30 36 C 10.5747 3.9647 0 0 CFG=2
M  V30 37 C 9.3288 4.8699 0 0
M  V30 38 O 7.9219 4.2435 0 0
M  V30 39 C 12.0393 4.4406 0 0
M  V30 40 C 12.9445 3.1947 0 0
M  V30 41 C 13.9798 0.0083 0 0
M  V30 42 N 15.3135 0.7783 0 0
M  V30 43 O 0 -12.1054 0 0
M  V30 44 S 0 -10.5654 0 0
M  V30 45 O 0 -9.0254 0 0
M  V30 46 O 1.54 -10.5654 0 0
M  V30 47 O -1.54 -10.5654 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 6 8
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 13 12 CFG=3
M  V30 14 1 13 14
M  V30 15 1 15 14
M  V30 16 1 15 16 CFG=3
M  V30 17 1 16 17
M  V30 18 1 15 18
M  V30 19 2 18 19
M  V30 20 1 13 19
M  V30 21 1 12 20
M  V30 22 2 9 20
M  V30 23 1 20 21
M  V30 24 2 2 21
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 27 29
M  V30 33 1 25 30
M  V30 34 1 30 31
M  V30 35 2 31 32
M  V30 36 1 32 33
M  V30 37 1 34 33 CFG=3
M  V30 38 1 34 35
M  V30 39 1 36 35
M  V30 40 1 36 37 CFG=3
M  V30 41 1 37 38
M  V30 42 1 36 39
M  V30 43 2 39 40
M  V30 44 1 34 40
M  V30 45 1 33 41
M  V30 46 2 30 41
M  V30 47 1 41 42
M  V30 48 2 23 42
M  V30 49 1 43 44
M  V30 50 2 44 45
M  V30 51 2 44 46
M  V30 52 1 44 47
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2471178866

>  <MW>
670.276

>  <MW (desalted)>
286.332

>  <ClogP>
0.806

>  <logS>
-3.952

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
101.88

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.006 nM | IC50  0.05 nM | IC50  0.072 nM

>  <CAS>
188062-50-2

>  <Description>
Abacavir is an antiviral nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV.

>  <EBC_ID>
EBC-14802

>  <IUPAC Name>
bis([(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol); sulfuric acid

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261

>  <Main tar all>
Organic cation transporter 2 pX=11.2 | Organic cation transporter 3 pX=10.3 | Organic cation transporter 1 pX=10.1

$$$$
Lumacaftor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.0573 -1.2483 0 0
M  V30 2 C 13.0675 -0.0686 0 0
M  V30 3 C 11.5508 -0.336 0 0
M  V30 4 C 10.561 0.8437 0 0
M  V30 5 C 11.0877 2.2908 0 0
M  V30 6 N 10.0978 3.4705 0 0
M  V30 7 C 8.5812 3.2031 0 0
M  V30 8 O 8.0545 1.756 0 0
M  V30 9 C 7.5913 4.3828 0 0
M  V30 10 C 7.0646 5.83 0 0
M  V30 11 C 8.5812 5.5625 0 0
M  V30 12 C 6.2576 3.6128 0 0
M  V30 13 C 6.2576 2.0728 0 0
M  V30 14 C 4.9239 1.3028 0 0
M  V30 15 C 3.5902 2.0728 0 0
M  V30 16 O 2.1256 1.5969 0 0
M  V30 17 C 1.2204 2.8428 0 0
M  V30 18 F 0.076 1.8124 0 0
M  V30 19 F 0.076 3.8733 0 0
M  V30 20 O 2.1256 4.0887 0 0
M  V30 21 C 3.5902 3.6128 0 0
M  V30 22 C 4.9239 4.3828 0 0
M  V30 23 N 12.6043 2.5582 0 0
M  V30 24 C 13.5942 1.3785 0 0
M  V30 25 C 15.1108 1.646 0 0
M  V30 26 C 15.6375 3.0931 0 0
M  V30 27 C 17.1541 3.3605 0 0
M  V30 28 C 18.144 2.1808 0 0
M  V30 29 C 17.6173 0.7337 0 0
M  V30 30 C 16.1007 0.4662 0 0
M  V30 31 C 18.6072 -0.446 0 0
M  V30 32 O 20.1238 -0.1786 0 0
M  V30 33 O 18.0804 -1.8932 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 20 21
M  V30 22 2 15 21
M  V30 23 1 21 22
M  V30 24 2 12 22
M  V30 25 2 5 23
M  V30 26 1 23 24
M  V30 27 2 2 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 2 26 27
M  V30 31 1 27 28
M  V30 32 2 28 29
M  V30 33 1 29 30
M  V30 34 2 25 30
M  V30 35 1 29 31
M  V30 36 2 31 32
M  V30 37 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801884

>  <MW>
452.118

>  <MW (desalted)>
452.407

>  <ClogP>
6.054

>  <logS>
-6.913

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
97.75

>  <RotBonds>
5

>  <Action on targets>
Activator | Inhibitor | Stimulator | Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
stimulation rate  100 % | Ki (inhibition constant)  79 nM | EC50  87 nM | protein expression level increase Active   | Kd (dissociation constant)  1.51 ?M

>  <CAS>
936727-05-8

>  <Description>
Lumacaftor is a protein chaperone. It is used for the treatment of cystic fibrosis. It is an allosteric modulator of cystic fibrosis transmembrane conductance regulator.

>  <EBC_ID>
EBC-11433

>  <IUPAC Name>
3-{6-[1-(2,2-difluoro-1,3-dioxaindan-5-yl)cyclopropaneamido]-3-methylpyridin-2-yl}benzoic acid

>  <Main Tar all refs>
YUMANITY THERAPEUTICS INC - WO2016/105477, 2016, A1 | ERJ Open Res., 2018, vol. 4, # 1 | Br. J. Pharmacol., 2017, vol. 174, # 7, p. 525 - 539 | Eur. J. Med. Chem., 2020, vol. 208 | mBio, 2021, vol. 12, # 2

>  <Main tar all>
CFTR pX=7.28 | benzodiazepine receptor pX=7.1 | Red Fluorescent Protein pHTomato pX=7.06 | CFTR (delF508) pX=6.3 | CoV Spike glycoprotein pX=5.82

$$$$
Darolutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.2537 -10.1814 0 0
M  V30 2 C -3.3486 -8.9355 0 0
M  V30 3 O -3.9749 -7.5287 0 0
M  V30 4 C -1.817 -9.0965 0 0
M  V30 5 C -0.7865 -7.9521 0 0
M  V30 6 C 0.6203 -8.5784 0 0
M  V30 7 N 0.4594 -10.11 0 0
M  V30 8 N -1.047 -10.4302 0 0
M  V30 9 C 1.954 -7.8084 0 0
M  V30 10 O 1.954 -6.2684 0 0
M  V30 11 N 3.2877 -8.5784 0 0
M  V30 12 C 4.6214 -7.8084 0 0 CFG=1
M  V30 13 C 4.6214 -6.2684 0 0
M  V30 14 C 5.955 -8.5784 0 0
M  V30 15 N 7.2887 -7.8084 0 0
M  V30 16 C 7.4497 -6.2769 0 0
M  V30 17 C 8.956 -5.9567 0 0
M  V30 18 C 9.726 -7.2904 0 0
M  V30 19 N 8.6956 -8.4348 0 0
M  V30 20 C 11.2576 -7.4514 0 0
M  V30 21 C 12.1628 -6.2055 0 0
M  V30 22 C 13.6944 -6.3664 0 0
M  V30 23 C 14.3207 -7.7733 0 0
M  V30 24 C 15.8523 -7.9343 0 0
M  V30 25 N 17.3839 -8.0952 0 0
M  V30 26 C 13.4155 -9.0192 0 0
M  V30 27 Cl 14.0419 -10.426 0 0
M  V30 28 C 11.884 -8.8582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 6 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 12 11
M  V30 13 1 12 13 CFG=1
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 15 19
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 3 24 25
M  V30 27 2 23 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 2 20 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2512157889

>  <MW>
398.126

>  <MW (desalted)>
398.846

>  <ClogP>
1.935

>  <logS>
-4.441

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
119.62

>  <RotBonds>
6

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50  0.037 ?M

>  <CAS>
1297538-32-9

>  <Description>
Darolutamide is a nonsteroidal androgen receptor antagonist. It is used for castration-resistant, non-metastatic prostate cancer.

>  <EBC_ID>
EBC-17092

>  <IUPAC Name>
N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide

>  <Main Tar all refs>
J. Med. Chem., 2022, vol. 65, # 19, p. 13074 - 13093

>  <Main tar all>
Androgen receptor pX=7.43

$$$$
Hydroxyurea
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.85 -1.3337 0 0
M  V30 2 C 2.31 -1.3337 0 0
M  V30 3 O 1.54 -2.6674 0 0
M  V30 4 N 1.54 0 0 0
M  V30 5 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1203577934

>  <MW>
76.027

>  <MW (desalted)>
76.055

>  <ClogP>
-1.8

>  <logS>
0.61

>  <HBD>
3

>  <HBA>
2

>  <TPSA>
75.35

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.84 ?M | GI85 > 25000 nM | Ki (inhibition constant)  5.38 ?M | IC50 = 14.29 ?M | IC50  22.3 ?M | IC50  22.3 ?M | Ki (inhibition constant) = 23000 nM | Ki (inhibition constant) = 28000 nM | IC50  29.82 ?M | IC50  29.82 ?M | Ki (inhibition constant) = 31 ?M | pIC50  4.36  | pIC50  4.36

>  <CAS>
127-07-1

>  <Description>
Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy.

>  <EBC_ID>
EBC-03024

>  <IUPAC Name>
hydroxyurea

>  <Main Tar all refs>
Biosci. Biotechnol. Biochem., 2010, vol. 74, # 6, p. 1256 - 1260 | Chem. Biol., 2012, vol. 19, # 12, p. 1620 - 1630 | Biosci. Biotechnol. Biochem., 2010, vol. 74, # 6, p. 1256 - 1260 | J. Enzyme Inhib. Med. Chem., 2013, vol. 28, # 1, p. 89 - 94 | Chem. Pharm. Bull., 2002, vol. 50, # 9, p. 1280 - 1282 | Chem. Pharm. Bull., 2002, vol. 50, # 9, p. 1280 - 1282 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 6, p. 1538 - 1543 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 6, p. 1538 - 1543 | Int. J. Environ. Res. Public Health, 2022, vol. 19, # 19 | Cancers, 2022, vol. 14, # 19 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 16, p. 4316 - 4320 | J. MED. CHEM., 1984, vol. 27, # 3, p. 347 - 357 | J. MED. CHEM., 1984, vol. 27, # 3, p. 347 - 357

>  <Main tar all>
Membrane primary amine oxidase pX=5.74 | ribonucleoside-diphosphate reductase pX=5.36 | amine oxidase copper containing 3 pX=5.27 | Urease (peptide) pX=4.84 | Urease pX=4.65 | urease pX=4.65 | carbonic anhydrase 9 pX=4.64 | carbonic anhydrase 2 pX=4.55 | Ribonucleoside-diphosphate reductase large subunit (peptide) pX=4.53 | Ribonucleoside-diphosphate reductase subunit M2 pX=4.53 | carbonic anhydrase 5 pX=4.51 | dihydrofolate reductase pX=4.36 | dihydrofolate reductase pX=4.36

$$$$
Pyruvic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.54 2.6674 0 0
M  V30 2 C 2.31 1.3337 0 0
M  V30 3 O 3.85 1.3337 0 0
M  V30 4 C 1.54 0 0 0
M  V30 5 O 2.31 -1.3337 0 0
M  V30 6 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104495240

>  <MW>
88.016

>  <MW (desalted)>
88.062

>  <ClogP>
-1.244

>  <logS>
0.08

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor | - | Inhibitor | Inhibitor | Substrate | - | - | - | - | -

>  <Activity coefficients and valu>
Km (Michaelis constant) = 18.6 ?M | Kic = 0.021 mM | Km (Michaelis constant)  48 - 95 ?M | IC50  4.8 ?g/ml | Ki (inhibition constant)  105.7 ?M | Km (Michaelis constant)  0.2 mM | Km (Michaelis constant) = 0.21 mM | Km (Michaelis constant) = 0.3 mM | Km (Michaelis constant) = 0.3 mM | Km (Michaelis constant) = 460 ?M | Km (Michaelis constant) = 0.5 mM

>  <CAS>
127-17-3

>  <Description>
Pyruvic acid is an ingredient of a blood cell processing solution used to rejuvenate a unit of red blood cells in preparation for transfusion.

>  <EBC_ID>
EBC-03029

>  <IUPAC Name>
2-oxopropanoic acid

>  <Main Tar all refs>
Biochem. J., 2002, vol. 363, # 3, p. 769 - 776 | BIOCHEMISTRY, 1990, vol. 29, # 7, p. 1749 - 1756 | J. BIOL. CHEM., 1994, vol. 269, # 24, p. 16726 - 16732 | Antimicrob. Agents Chemother., 2015, vol. 59, # 9, p. 5581 - 5594 | Bioorg. Med. Chem., 2009, vol. 17, # 7, p. 2654 - 2657 | Enzyme Microb. Technol., 2018, vol. 108, p. 1 - 10 | Biochem. J., 2007, vol. 408, # 1, p. 39 - 50 | ChemBioChem, 2008, vol. 9, # 10, p. 1591 - 1602 | ChemBioChem, 2008, vol. 9, # 10, p. 1591 - 1602 | J. BIOL. CHEM., 1994, vol. 269, # 24, p. 16726 - 16732 | EUR. J. BIOCHEM., 1997, vol. 244, # 3, p. 862 - 868

>  <Main tar all>
pyruvate dehydrogenase pX=4.73 | Tartrate dehydrogenase pX=4.68 | Ferredoxin pX=4.32 | Malate synthase (gene mls) pX=4.26 | carbonic anhydrase pX=3.97 | lactate dehydrogenase pX=3.7 | Serine-pyruvate aminotransferase pX=3.68 | 4-hydroxy-tetrahydrodipicolinate synthase (gene dapA) pX=3.52 | Molybdenum Storage Protein Subunit A pX=3.52 | Pyruvate synthase (gene POR) pX=3.34 | Pyruvate-Ferredoxin Oxidoreductase pX=3.3

$$$$
Methimazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 N 1.0598 2.08 0 0
M  V30 3 C 2.3057 1.1748 0 0
M  V30 4 C 1.8298 -0.2898 0 0
M  V30 5 N 0.2898 -0.2898 0 0
M  V30 6 C -0.1861 1.1748 0 0
M  V30 7 S -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57901905

>  <MW>
114.025

>  <MW (desalted)>
114.169

>  <ClogP>
0.819

>  <logS>
-0.72

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
17.82

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 45 ?M | Ki (inhibition constant) = 0.47 mM | IC50 = 754 ?M | IC50 = 754 ?M

>  <CAS>
60-56-0

>  <Description>
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. Methimazole is indicated for the treatment of hyperthyroidism in patients with Graves' disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options.

>  <EBC_ID>
EBC-11031

>  <IUPAC Name>
1-methyl-1H-imidazole-2-thiol

>  <Main Tar all refs>
J. MED. CHEM., 1986, vol. 29, # 12, p. 2465 - 2472 | Bioorg. Med. Chem., 2014, vol. 22, # 9, p. 2809 - 2815 | J. MED. CHEM., 1986, vol. 29, # 12, p. 2465 - 2472 | J. MED. CHEM., 1986, vol. 29, # 12, p. 2465 - 2472

>  <Main tar all>
Dopamine beta-hydroxylase (dopamine beta-monooxygenase) pX=4.35 | tyrosinase pX=3.33 | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) pX=3.12 | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) pX=3.12

$$$$
Hydroquinone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 O 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127551

>  <MW>
110.037

>  <MW (desalted)>
110.111

>  <ClogP>
0.808

>  <logS>
-0.56

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.09 ?M | Ki (inhibition constant) = 0.09 ?M | Ki (inhibition constant)  0.1 ?M | inhibition percentage  45.1 % | IC50  0.1 ?g/mL | protein expression level decrease Active   | IC50 = 1.9 ?M | Ki (inhibition constant)  2.2 ?M | IC50 = 2.5 ?M

>  <CAS>
123-31-9

>  <Description>
Hydroquinone is a topical brightening agent used for the treatment of skin disorders associated with hyperpigmentation including melasma, post-inflammatory hyperpigmentation, sunspots, and freckles. Hydroquinone reduces melanin pigment production through inhibition of the tyrosinase enzyme, which is involved in the initial step of the melanin pigment biosynthesis pathway.

>  <EBC_ID>
EBC-00526

>  <IUPAC Name>
benzene-1,4-diol

>  <Main Tar all refs>
Bioorg. Med. Chem., 2008, vol. 16, # 15, p. 7424 - 7428 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 12, p. 3593 - 3596 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 2417 - 2422 | Biol. Pharm. Bull., 2018, vol. 41, # 5, p. 806 - 810 | BEHRINGWERKE AG - US5519018, 1996, A | Chem.-Biol. Interact., 2022, vol. 355 | Curr. Top. Med. Chem., 2006, vol. 6, # 11, p. 1173 - 1182 | Bioorg. Chem., 2019, vol. 93 | Arch. Pharm., 2011, vol. 344, # 9, p. 557 - 563

>  <Main tar all>
Extracellular calcium-sensing receptor (isoform 2) pX=7.05 | carbonic anhydrase 2 pX=7.05 | carbonic anhydrase pX=7.0 | tyrosinase pX=6.22 | epidermal growth factor receptor pX=6.04 | Aryl hydrocarbon receptor pX=6.0 | heat shock protein 90 beta family member 1 pX=5.72 | ?-carbonic anhydrase pX=5.66 | MMP14 pX=5.6

$$$$
Pyrazinamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 N 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z33546644

>  <MW>
123.043

>  <MW (desalted)>
123.113

>  <ClogP>
-0.676

>  <logS>
0.47

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
68.87

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  49.31 ng/ml | MIC  3.12 ?M

>  <CAS>
98-96-4

>  <Description>
Pyrazinamide is an antituberculosis agent used as a component of tuberculosis (TB) treatment.

>  <EBC_ID>
EBC-03189

>  <IUPAC Name>
pyrazine-2-carboxamide

>  <Main Tar all refs>
Bioorg. Chem., 2023, vol. 131 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 8, p. 1859 - 1866

>  <Main tar all>
Thymidylate kinase pX=6.4 | DNA topoisomerase II pX=5.51

$$$$
Propylthiouracil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 O 4.001 -0.77 0 0
M  V30 8 N 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 S -1.3337 -0.77 0 0
M  V30 11 N 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 4 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56922173

>  <MW>
170.051

>  <MW (desalted)>
170.232

>  <ClogP>
1.198

>  <logS>
-2.62

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
41.46

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.67 ?M | IC50  0.79 ?M | EC50 = 2 ?M | IC50 = 5.7 ?M | IC50 = 5.7 ?M | IC50  12 ?M

>  <CAS>
51-52-5

>  <Description>
Propylthiouracil is a thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.

>  <EBC_ID>
EBC-11046

>  <IUPAC Name>
6-propyl-2-sulfanyl-3,4-dihydropyrimidin-4-one

>  <Main Tar all refs>
ChemMedChem, 2009, vol. 4, # 4, p. 512 - 516 | Regul. Toxicol. Pharmacol., 2020, vol. 117 | Leibniz Association - WO2004/29087, 2004, A2 | J. Med. Chem., 2015, vol. 58, # 21, p. 8513 - 8528 | J. Med. Chem., 2015, vol. 58, # 21, p. 8513 - 8528 | MCMASTER UNIVERSITY - WO2017/106974, 2017, A1

>  <Main tar all>
Lactoperoxidase pX=6.17 | thyroid peroxidase pX=6.1 | TAS2R38 pX=5.7 | Myeloperoxidase (uncleaved) pX=5.24 | myeloperoxidase pX=5.24 | Thyroid hormone receptor-?1 pX=4.92

$$$$
Thioguanin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 7.5913 4.3828 0 0
M  V30 2 C 6.2576 3.6128 0 0
M  V30 3 N 6.2576 2.0728 0 0
M  V30 4 C 4.9239 1.3028 0 0
M  V30 5 S 4.9239 -0.2372 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 N 2.1256 1.5969 0 0
M  V30 8 C 1.2204 2.8428 0 0
M  V30 9 N 2.1256 4.0887 0 0
M  V30 10 C 3.5902 3.6128 0 0
M  V30 11 N 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 1 2 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2299468139

>  <MW>
167.027

>  <MW (desalted)>
167.192

>  <ClogP>
-1.882

>  <logS>
-3.755

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
79.09

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active

>  <CAS>
154-42-7

>  <Description>
Tioguanine is a purine analogue antineoplastic agent used for the induction of remission, and for remission consolidation in patients with acute nonlymphocytic anemias.

>  <EBC_ID>
EBC-11072

>  <IUPAC Name>
2-amino-6,7-dihydro-3H-purine-6-thione

>  <Main Tar all refs>
Viruses, 2021, vol. 13, # 8

>  <Main tar all>
Programmed -1 ribosomal frameshift pX=8.0

$$$$
Mafenide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 4.4275 0 0
M  V30 3 C 5.7337 3.6575 0 0
M  V30 4 C 5.7337 2.1175 0 0
M  V30 5 C 7.0674 1.3475 0 0
M  V30 6 C 7.0674 -0.1925 0 0
M  V30 7 C 5.7337 -0.9625 0 0
M  V30 8 C 4.4 -0.1925 0 0
M  V30 9 C 4.4 1.3475 0 0
M  V30 10 S 5.7337 -2.5025 0 0
M  V30 11 O 5.7337 -4.0425 0 0
M  V30 12 O 4.1937 -2.5025 0 0
M  V30 13 N 7.2737 -2.5025 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 4 9
M  V30 9 1 7 10
M  V30 10 2 10 11
M  V30 11 2 10 12
M  V30 12 1 10 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57103974

>  <MW>
222.023

>  <MW (desalted)>
186.232

>  <ClogP>
-0.743

>  <logS>
-1.569

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
86.18

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  103 nM | Ki (inhibition constant)  170 nM | Ki (inhibition constant) = 170 nM

>  <CAS>
138-37-4

>  <Description>
Mafenide is a sulfonamide antibiotic that inhibits growth of bacteria. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. Mafenide is used as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.

>  <EBC_ID>
EBC-69049

>  <IUPAC Name>
4-(aminomethyl)benzene-1-sulfonamide hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2004, vol. 14, # 21, p. 5427 - 5433 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 21, p. 5427 - 5433 | Bioorg. Med. Chem., 2014, vol. 22, # 10, p. 2867 - 2874

>  <Main tar all>
carbonic anhydrase 9 pX=6.99 | Extracellular calcium-sensing receptor (isoform 2) pX=6.77 | carbonic anhydrase 2 pX=6.77

$$$$
Calcium gluconate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Ca 5.3347 1.21 0 0 CHG=2
M  V30 2 O -5.3347 -0.33 0 0
M  V30 3 C -4.001 0.44 0 0
M  V30 4 C -2.6674 -0.33 0 0 CFG=1
M  V30 5 O -2.6674 -1.87 0 0
M  V30 6 C -1.3337 0.44 0 0 CFG=1
M  V30 7 O -1.3337 1.98 0 0
M  V30 8 C 0 -0.33 0 0 CFG=2
M  V30 9 O 0 -1.87 0 0
M  V30 10 C 1.3337 0.44 0 0 CFG=1
M  V30 11 O 1.3337 1.98 0 0
M  V30 12 C 2.6674 -0.33 0 0
M  V30 13 O 2.6674 -1.87 0 0
M  V30 14 O 4.001 0.44 0 0 CHG=-1
M  V30 15 O 8.8547 -0.2369 0 0
M  V30 16 C 10.1884 0.5331 0 0
M  V30 17 C 11.5221 -0.2369 0 0 CFG=1
M  V30 18 O 11.5221 -1.7769 0 0
M  V30 19 C 12.8558 0.5331 0 0 CFG=1
M  V30 20 O 12.8558 2.0731 0 0
M  V30 21 C 14.1894 -0.2369 0 0 CFG=2
M  V30 22 O 14.1894 -1.7769 0 0
M  V30 23 C 15.5231 0.5331 0 0 CFG=1
M  V30 24 O 15.5231 2.0731 0 0
M  V30 25 C 16.8568 -0.2369 0 0
M  V30 26 O 18.1905 0.5331 0 0
M  V30 27 O 16.8568 -1.7769 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3
M  V30 3 1 4 5 CFG=3
M  V30 4 1 6 4
M  V30 5 1 6 7 CFG=1
M  V30 6 1 6 8
M  V30 7 1 8 9 CFG=1
M  V30 8 1 8 10
M  V30 9 1 10 11 CFG=1
M  V30 10 1 10 12
M  V30 11 2 12 13
M  V30 12 1 12 14
M  V30 13 1 15 16
M  V30 14 1 17 16
M  V30 15 1 17 18 CFG=3
M  V30 16 1 19 17
M  V30 17 1 19 20 CFG=1
M  V30 18 1 19 21
M  V30 19 1 21 22 CFG=1
M  V30 20 1 21 23
M  V30 21 1 23 24 CFG=1
M  V30 22 1 23 25
M  V30 23 2 25 26
M  V30 24 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2768168188

>  <MW>
430.064

>  <MW (desalted)>
196.155

>  <ClogP>
-5.424

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
141.28

>  <RotBonds>
10

>  <CAS>
299-28-5

>  <Description>
Calcium gluconate is an ingredient found in a variety of supplements and vitamins, and is used to lower potassium in the blood or treat magnesium poisoning.

>  <EBC_ID>
EBC-27072

>  <IUPAC Name>
calcium bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)

$$$$
Pyridoxal phosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 N 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 O -0 -3.08 0 0
M  V30 8 P -0 -4.62 0 0
M  V30 9 O -0 -6.16 0 0
M  V30 10 O -1.54 -4.62 0 0
M  V30 11 O 1.54 -4.62 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C -1.3337 -0.77 0 0
M  V30 14 O -2.6674 0 0 0
M  V30 15 C 0 1.54 0 0
M  V30 16 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 2 5 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 12 15
M  V30 15 2 2 15
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741970251

>  <MW>
247.025

>  <MW (desalted)>
247.142

>  <ClogP>
0.545

>  <logS>
1.103

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
116.95

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  1 nM

>  <CAS>
54-47-7

>  <Description>
Pyridoxal phosphate is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters, sphingolipids, aminolevulinic acid. It is used for nutritional supplementation and for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26309

>  <IUPAC Name>
[(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methoxy]phosphonic acid

>  <Main Tar all refs>
J. Mol. Catal. B Enzym., 2014, vol. 110, p. 171 - 177

>  <Main tar all>
Serine hydroxymethyltransferase pX=9.0

$$$$
Mebhydrolin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.9473 -1.5189 0 0
M  V30 2 N 6.9168 -0.3744 0 0
M  V30 3 C 7.3927 1.0902 0 0
M  V30 4 C 6.3623 2.2346 0 0
M  V30 5 C 4.8559 1.9144 0 0
M  V30 6 C 4.38 0.4498 0 0
M  V30 7 C 5.4105 -0.6946 0 0
M  V30 8 C 2.84 0.4498 0 0
M  V30 9 C 1.8096 -0.6946 0 0
M  V30 10 C 0.3032 -0.3744 0 0
M  V30 11 C -0.1727 1.0902 0 0
M  V30 12 C 0.8578 2.2346 0 0
M  V30 13 C 2.3641 1.9144 0 0
M  V30 14 N 3.61 2.8196 0 0
M  V30 15 C 3.61 4.3596 0 0
M  V30 16 C 4.9437 5.1296 0 0
M  V30 17 C 4.9437 6.6696 0 0
M  V30 18 C 6.2774 7.4396 0 0
M  V30 19 C 7.6111 6.6696 0 0
M  V30 20 C 7.6111 5.1296 0 0
M  V30 21 C 6.2774 4.3596 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 13 14
M  V30 16 1 5 14
M  V30 17 1 14 15
M  V30 18 1 15 16
M  V30 19 1 16 17
M  V30 20 2 17 18
M  V30 21 1 18 19
M  V30 22 2 19 20
M  V30 23 1 20 21
M  V30 24 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56841337

>  <MW>
276.163

>  <MW (desalted)>
276.376

>  <ClogP>
4.015

>  <logS>
-3.15

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
8.17

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 30 nM | Ki (inhibition constant)  655 nM

>  <CAS>
524-81-2

>  <Description>
Mebhydrolin is a histamine H1 receptor antagonist.

>  <EBC_ID>
EBC-03753

>  <IUPAC Name>
5-benzyl-2-methyl-1H,2H,3H,4H,5H-pyrido[4,3-b]indole

>  <Main Tar all refs>
Pharm. Chem. J., 2012, vol. 46, # 2, p. 103 - 113 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951

>  <Main tar all>
H1 receptor pX=7.52 | ?2B-adrenoceptor pX=6.18

$$$$
Mefenamic Acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 C -1.3337 -2.31 0 0
M  V30 3 C -2.6674 -3.08 0 0
M  V30 4 C -2.6674 -4.62 0 0
M  V30 5 C -1.3337 -5.39 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 N 1.3337 -5.39 0 0
M  V30 8 C 2.6674 -4.62 0 0
M  V30 9 C 2.6674 -3.08 0 0
M  V30 10 C 4.001 -2.31 0 0
M  V30 11 C 5.3347 -3.08 0 0
M  V30 12 C 5.3347 -4.62 0 0
M  V30 13 C 4.001 -5.39 0 0
M  V30 14 C 4.001 -6.93 0 0
M  V30 15 O 2.6674 -7.7 0 0
M  V30 16 O 5.3347 -7.7 0 0
M  V30 17 C 0 -3.08 0 0
M  V30 18 C 1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 6 17
M  V30 18 2 2 17
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56755828

>  <MW>
241.11

>  <MW (desalted)>
241.285

>  <ClogP>
5.287

>  <logS>
-4.09

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.33

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.3 nM | Ki (inhibition constant)  0.5 nM | Ki (inhibition constant)  1.1 nM | IC50  6.6 nM

>  <CAS>
61-68-7

>  <Description>
Mefenamic acid is a non-steroidal anti-inflammatory drug and a prostaglandin G/H synthase 2 (COX-2) inhibitor. It is used for  the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

>  <EBC_ID>
EBC-03713

>  <IUPAC Name>
2-[(2,3-dimethylphenyl)amino]benzoic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2011, vol. 18, # 17, p. 2554 - 2565 | Toxicol. Appl. Pharmacol., 2021, vol. 425 | Toxicol. Appl. Pharmacol., 2021, vol. 425 | Eur. J. Clin. Pharmacol., 2000, vol. 56, # 6-7, p. 477 - 479

>  <Main tar all>
AKR1C3 pX=9.52 | Sulfotransferase 1A1*2 pX=9.3 | Sulfotransferase 1A1 pX=8.96 | Sulfotransferase pX=8.18

$$$$
Zolimidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.4796 -1.3028 0 0
M  V30 2 S -4.9396 -1.3028 0 0
M  V30 3 O -4.9396 -2.8428 0 0
M  V30 4 O -4.9396 0.2372 0 0
M  V30 5 C -3.3996 -1.3028 0 0
M  V30 6 C -2.6296 0.0309 0 0
M  V30 7 C -1.0896 0.0309 0 0
M  V30 8 C -0.3196 -1.3028 0 0
M  V30 9 C -1.0896 -2.6365 0 0
M  V30 10 C -2.6296 -2.6365 0 0
M  V30 11 C 1.2204 -1.3028 0 0
M  V30 12 C 2.1256 -0.0569 0 0
M  V30 13 N 3.5902 -0.5328 0 0
M  V30 14 C 4.9239 0.2372 0 0
M  V30 15 C 6.2576 -0.5328 0 0
M  V30 16 C 6.2576 -2.0728 0 0
M  V30 17 C 4.9239 -2.8428 0 0
M  V30 18 C 3.5902 -2.0728 0 0
M  V30 19 N 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 2 18 19
M  V30 21 1 11 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z82177056

>  <MW>
272.062

>  <MW (desalted)>
272.322

>  <ClogP>
1.951

>  <logS>
-3.06

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
51.44

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  12.1 ?M | IC50  12.1 ?M

>  <CAS>
1222-57-7

>  <Description>
Zolimidine is a derivate of imidazopyridine with a gastroprotective effect. It is used in the treatment of peptic ulcer and gastro-oesophageal reflux disease. It has inhibitory activity against flavivirus non-structural protein.

>  <EBC_ID>
EBC-06864

>  <IUPAC Name>
2-(4-methanesulfonylphenyl)imidazo[1,2-a]pyridine

>  <Main Tar all refs>
GOVERNMENT OF THE UNITED STATES; HEALTH RESEARCH, INC - WO2017/223491, 2017, A1 | GOVERNMENT OF THE UNITED STATES; HEALTH RESEARCH, INC - WO2017/223491, 2017, A1

>  <Main tar all>
Flavivirus non-structural protein NS2B pX=4.92 | Nonstructural protein 3 pX=4.92

$$$$
Flutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 1.3337 6.93 0 0
M  V30 4 C 0 4.62 0 0
M  V30 5 O -1.3337 3.85 0 0
M  V30 6 N 1.3337 3.85 0 0
M  V30 7 C 1.3337 2.31 0 0
M  V30 8 C 2.6674 1.54 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 N 1.3337 -2.31 0 0 CHG=1
M  V30 12 O 2.6674 -3.08 0 0
M  V30 13 O -0 -3.08 0 0 CHG=-1
M  V30 14 C 0 0 0 0
M  V30 15 C 0 1.54 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 17 F -2.6674 -1.54 0 0
M  V30 18 F -2.1037 0.5637 0 0
M  V30 19 F -0.5637 -2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 10 14
M  V30 14 1 14 15
M  V30 15 2 7 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56755651

>  <MW>
276.072

>  <MW (desalted)>
276.212

>  <ClogP>
3.335

>  <logS>
-4.157

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
72.24

>  <RotBonds>
4

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
luciferase reporter activity decrease Active

>  <CAS>
13311-84-7

>  <Description>
Flutamide is a nonsteroidal antiandrogen. It blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. It is used for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.

>  <EBC_ID>
EBC-03834

>  <IUPAC Name>
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

>  <Main Tar all refs>
Environ. Pollut., 2021, vol. 272

>  <Main tar all>
Androgen receptor pX=9.0

$$$$
Fasudil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.2074 -4.62 0 0
M  V30 2 S 2.6674 -4.62 0 0
M  V30 3 O 1.1274 -4.62 0 0
M  V30 4 N 2.6674 -6.16 0 0
M  V30 5 C 4.0549 -6.8282 0 0
M  V30 6 C 4.3975 -8.3296 0 0
M  V30 7 C 3.4374 -9.5336 0 0
M  V30 8 N 1.8974 -9.5336 0 0
M  V30 9 C 0.9372 -8.3296 0 0
M  V30 10 C 1.2799 -6.8282 0 0
M  V30 11 C 2.6674 -3.08 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 N 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 4 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 11 20
M  V30 22 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z432085130

>  <MW>
291.104

>  <MW (desalted)>
291.369

>  <ClogP>
1.038

>  <logS>
-2.38

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
62.3

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
amount  13.3 pg/ml | increase rate Active

>  <CAS>
103745-39-7

>  <Description>
Fasudil is a nonspecific ROCK inhibitor and also has an inhibitory effect on protein kinases. Fasudil is also a potent Ca2+channel antagonist and vasodilator.

>  <EBC_ID>
EBC-00589

>  <IUPAC Name>
5-(1,4-diazepane-1-sulfonyl)isoquinoline

>  <Main Tar all refs>
Life Sci., 2020, vol. 254 | J. Control. Release, 2021, vol. 334, p. 237 - 247

>  <Main tar all>
Rho-dependent protein serine/threonine kinase pX=10.3 | Rho associated coiled-coil containing protein kinase 2 pX=9.0

$$$$
Etodolac
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.1779 -6.9326 0 0
M  V30 2 C 1.3285 -6.6125 0 0
M  V30 3 C 1.8044 -5.1478 0 0
M  V30 4 C 0.7739 -4.0034 0 0
M  V30 5 C 1.2498 -2.5388 0 0
M  V30 6 C 2.7561 -2.2186 0 0
M  V30 7 C 3.7866 -3.363 0 0
M  V30 8 C 5.3266 -3.363 0 0
M  V30 9 C 6.357 -2.2186 0 0
M  V30 10 C 7.8634 -2.5388 0 0
M  V30 11 O 8.3393 -4.0034 0 0
M  V30 12 C 7.3088 -5.1478 0 0
M  V30 13 C 8.6148 -5.9639 0 0
M  V30 14 C 9.9746 -5.2409 0 0
M  V30 15 C 6.7319 -6.5757 0 0
M  V30 16 C 7.68 -7.7892 0 0
M  V30 17 O 9.2051 -7.5749 0 0
M  V30 18 O 7.1031 -9.2171 0 0
M  V30 19 C 5.8025 -4.8277 0 0
M  V30 20 N 4.5566 -5.7328 0 0
M  V30 21 C 3.3107 -4.8277 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 12 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 12 19
M  V30 19 2 8 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 3 21
M  V30 23 1 7 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521549186

>  <MW>
287.152

>  <MW (desalted)>
287.354

>  <ClogP>
3.432

>  <logS>
-4.03

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
62.32

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.01 ?M | IC50 = 2.3E-08 M | IC50 = 0.07 ?M

>  <CAS>
41340-25-4

>  <Description>
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

>  <EBC_ID>
EBC-11162

>  <IUPAC Name>
2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid

>  <Main Tar all refs>
Med. Res. Rev., 2011, vol. 31, # 2, p. 161 - 201 | J. MED. CHEM., 1989, vol. 32, # 9, p. 2134 - 2137 | Med. Res. Rev., 2011, vol. 31, # 2, p. 161 - 201

>  <Main tar all>
COX-2  pX=8.0 | EP2 receptor pX=7.64 | COX-1  pX=7.15

$$$$
Phenprocoumon
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 2.31 0 0
M  V30 2 C 0 1.54 0 0
M  V30 3 C 0 -0 0 0
M  V30 4 C -1.3337 -0.77 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C -2.6674 -3.08 0 0
M  V30 7 C -4.001 -2.31 0 0
M  V30 8 C -4.001 -0.77 0 0
M  V30 9 C -2.6674 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 C 2.6674 0 0 0
M  V30 12 O 2.6674 1.54 0 0
M  V30 13 C 4.001 -0.77 0 0
M  V30 14 C 5.3347 0 0 0
M  V30 15 C 6.6684 -0.77 0 0
M  V30 16 C 6.6684 -2.31 0 0
M  V30 17 C 5.3347 -3.08 0 0
M  V30 18 C 4.001 -2.31 0 0
M  V30 19 O 2.6674 -3.08 0 0
M  V30 20 C 1.3337 -2.31 0 0
M  V30 21 O 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 3 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 10 20
M  V30 23 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2177958148

>  <MW>
280.11

>  <MW (desalted)>
280.318

>  <ClogP>
4.711

>  <logS>
-4.83

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  4.2 nM

>  <CAS>
435-97-2

>  <Description>
Phenprocoumon inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K. Phenprocoumon used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation.

>  <EBC_ID>
EBC-06784

>  <IUPAC Name>
4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one

>  <Main Tar all refs>
Blood, 2018, vol. 132, # 18, p. 1974 - 1984

>  <Main tar all>
Vitamin K epoxide reductase homolog pX=8.38

$$$$
Ciprofloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -4.62 0 0
M  V30 2 C 0 -3.08 0 0
M  V30 3 O -1.3337 -2.31 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 N 2.6674 0 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 1.8974 2.8737 0 0
M  V30 9 C 3.4374 2.8737 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 C 5.3347 0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 N 8.0021 -0 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 9.3358 2.31 0 0
M  V30 16 N 10.6694 1.54 0 0
M  V30 17 C 10.6694 -0 0 0
M  V30 18 C 9.3358 -0.77 0 0
M  V30 19 C 6.6684 -2.31 0 0
M  V30 20 F 8.0021 -3.08 0 0
M  V30 21 C 5.3347 -3.08 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 23 C 2.6674 -3.08 0 0
M  V30 24 O 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 9
M  V30 10 1 6 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 1 12 19
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 1 21 22
M  V30 24 2 10 22
M  V30 25 1 22 23
M  V30 26 1 4 23
M  V30 27 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56933707

>  <MW>
331.133

>  <MW (desalted)>
331.342

>  <ClogP>
-0.725

>  <logS>
-2.32

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
72.88

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.0006 ?M | MIC = 0.0004 ?g/mL | MIC90 <= 0.006 ?g/ml | MIC90 <= 0.006 ?g/ml | MIC  0.002 ?M | MIC90 <= 0.006 ?g/ml | MIC95  0.013 ?g/ml | MIC  0.000725 ?g/ml | MIC  1.05 ?g/l | MIC  1.6 ng/ml | MIC  1.6 ng/ml | MIC  1.6 ng/ml | MIC90  0.015 ?g/ml | MIC90 <= 0.016 ?g/ml | MIC  0.002 ?g/ml | MIC  2.1 ng/ml | Ki (inhibition constant) = 6.5E-06 mM | MIC  3.2 ng/ml | MIC  3.2 ng/ml | MIC  3.2 ng/ml | MIC  3.2 ng/ml | MIC  0.004 ?g/ml | MIC  0.004 ?g/ml | MIC  0.004 ?g/ml | MIC  0.004 ?g/ml | IC50  0.0149 ?M

>  <CAS>
85721-33-1

>  <Description>
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is only indicated in infections caused by susceptible bacteria.

>  <EBC_ID>
EBC-12960

>  <IUPAC Name>
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
Mol. Diversity, 2022, vol. 26, # 3, p. 1743 - 1759 | Antimicrob. Agents Chemother., 2006, vol. 50, # 11, p. 3717 - 3723 | BUGWORKS RESEARCH - WO2019/106693, 2019, A1 | BUGWORKS RESEARCH - WO2019/106693, 2019, A1 | Med. Chem. Res., 2022, vol. 31, # 7, p. 1176 - 1191 | BUGWORKS RESEARCH - WO2019/106693, 2019, A1 | Nat. Commun., 2022, vol. 13, # 1 | Bioconjugate Chem., 2019, vol. 30, # 3, p. 751 - 759 | J. Heterocycl. Chem., 2020 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | Antimicrob. Agents Chemother., 2019, vol. 63, # 12 | J. Med. Chem., 2020, vol. 63, # 1, p. 88 - 102 | J. Med. Chem., 2018, vol. 61, # 8, p. 3325 - 3349 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | Biol. Pharm. Bull., 2006, vol. 29, # 8, p. 1559 - 1563 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | MedChemComm, 2017, vol. 8, # 5, p. 942 - 951 | ACS Infect. Dis., 2020 | ACS Infect. Dis., 2020, vol. 6, # 12, p. 3163 - 3173 | ACS Infect. Dis., 2020 | Infect. Drug Resist., 2020, vol. 13, p. 749 - 759 | Chem. Biodivers., 2018, vol. 15, # 9

>  <Main tar all>
DNA negative supercoiling pX=9.22 | Norm, Na+-Driven Multidrug Efflux Pump pX=8.92 | DNA supercoiling protein pX=8.7 | DNA topoisomerase II pX=8.7 | DNA topoisomerase type II (double strand cut ATP-hydrolyzing) activator pX=8.7 | DNA?gyrase pX=8.7 | Multidrug?efflux?pump?subunit?AcrB pX=8.69 | Nitroreductase pX=8.66 | DNA?gyrase subunit A pX=8.5 | DNA?gyrase subunit A (P35T) pX=8.32 | DNA?gyrase subunit A (S97P) pX=8.32 | DNA?gyrase subunit B?(R136V) pX=8.32 | DNA topoisomerase II pX=8.3 | UDP-3-O-acyl N-acetylglucosamine deacetylase pX=8.27 | Bifunctional coenzyme A synthase pX=8.22 | DNA?gyrase subunit B pX=8.2 | Serum paraoxonase/arylesterase 1 pX=8.19 | DNA?gyrase subunit A (F96L) pX=8.02 | DNA?gyrase subunit A?(H45Y) pX=8.02 | DNA?gyrase subunit B (T508M) pX=8.02 | DNA?gyrase subunit B?(R136S) pX=8.02 | DNA topoisomerase II pX=7.92 | Elongation factor Tu pX=7.92 | RNA polymerase pX=7.92 | aac(6')-Ib-cr pX=7.92 | Dihydromonapterin reductase (peptide) pX=7.83

$$$$
Dipyridamole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 -11.55 0 0
M  V30 2 C -2.6674 -10.78 0 0
M  V30 3 C -2.6674 -9.24 0 0
M  V30 4 N -4.001 -8.47 0 0
M  V30 5 C -5.3347 -9.24 0 0
M  V30 6 C -5.3347 -10.78 0 0
M  V30 7 O -6.6684 -11.55 0 0
M  V30 8 C -4.001 -6.93 0 0
M  V30 9 N -5.3347 -6.16 0 0
M  V30 10 C -5.3347 -4.62 0 0
M  V30 11 N -6.6684 -3.85 0 0
M  V30 12 C -8.0021 -4.62 0 0
M  V30 13 C -9.3358 -3.85 0 0
M  V30 14 C -9.3358 -2.31 0 0
M  V30 15 C -8.0021 -1.54 0 0
M  V30 16 C -6.6684 -2.31 0 0
M  V30 17 C -4.001 -3.85 0 0
M  V30 18 N -4.001 -2.31 0 0
M  V30 19 C -2.6674 -1.54 0 0
M  V30 20 N -1.3337 -2.31 0 0
M  V30 21 C -1.3337 -3.85 0 0
M  V30 22 N 0 -4.62 0 0
M  V30 23 C 1.3337 -3.85 0 0
M  V30 24 C 2.6674 -4.62 0 0
M  V30 25 C 2.6674 -6.16 0 0
M  V30 26 C 1.3337 -6.93 0 0
M  V30 27 C 0 -6.16 0 0
M  V30 28 C -2.6674 -4.62 0 0
M  V30 29 N -2.6674 -6.16 0 0
M  V30 30 N -2.6674 0 0 0
M  V30 31 C -4.001 0.77 0 0
M  V30 32 C -4.001 2.31 0 0
M  V30 33 O -5.3347 3.08 0 0
M  V30 34 C -1.3337 0.77 0 0
M  V30 35 C -1.3337 2.31 0 0
M  V30 36 O 0 3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 11 16
M  V30 17 1 10 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 22 27
M  V30 29 1 21 28
M  V30 30 2 17 28
M  V30 31 1 28 29
M  V30 32 2 8 29
M  V30 33 1 19 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 30 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1137167676

>  <MW>
504.626

>  <MW (desalted)>
504.626

>  <ClogP>
1.492

>  <logS>
-3.31

>  <HBD>
4

>  <HBA>
12

>  <TPSA>
145.44

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.6 nM | Kd (dissociation constant)  4 nM | IC50  7.3 nM | Ki (inhibition constant) = 8.79 nM | Ki (inhibition constant) = 8.79 nM | Ki (inhibition constant)  0.04 ?M

>  <CAS>
58-32-2

>  <Description>
Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. It is used for as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.

>  <EBC_ID>
EBC-00632

>  <IUPAC Name>
2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol

>  <Main Tar all refs>
Biochem. J., 2005, vol. 386, # 2, p. 281 - 289 | CANCER CHEMOTHER. PHARMACOL., 1991, vol. 29, # 2, p. 127 - 132 | Biochem. J., 2004, vol. 380, # 1, p. 131 - 137 | Proc. Natl. Acad. Sci. U. S. A., 2012, vol. 109, # 28, p. 11178 - 11183 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 9, p. 2257 - 2260 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 44, p. 27381 - 27387

>  <Main tar all>
casein kinase 2, alpha 1 polypeptide subunit pX=8.8 | ABCB1 pX=8.4 | Equilibrative nucleoside transporter 1 pX=8.14 | Equilibrative nucleoside transporter pX=8.06 | Equilibrative nucleoside transporter 2 pX=8.06 | CoV 3C-like (main) protease pX=7.4

$$$$
Niraparib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 7.4543 4.62 0 0
M  V30 2 C 6.1207 3.85 0 0
M  V30 3 O 4.787 4.62 0 0
M  V30 4 C 6.1207 2.31 0 0
M  V30 5 C 7.4543 1.54 0 0
M  V30 6 C 7.4543 0 0 0
M  V30 7 C 6.1207 -0.77 0 0
M  V30 8 C 4.787 0 0 0
M  V30 9 C 3.3224 -0.4759 0 0
M  V30 10 N 2.4172 0.77 0 0
M  V30 11 N 3.3224 2.0159 0 0
M  V30 12 C 4.787 1.54 0 0
M  V30 13 C 0.8772 0.77 0 0
M  V30 14 C 0.1072 -0.5637 0 0
M  V30 15 C -1.4328 -0.5637 0 0
M  V30 16 C -2.2028 0.77 0 0
M  V30 17 C -1.4328 2.1037 0 0
M  V30 18 C 0.1072 2.1037 0 0
M  V30 19 C -3.7428 0.77 0 0 CFG=2
M  V30 20 C -4.5128 -0.5637 0 0
M  V30 21 C -6.0528 -0.5637 0 0
M  V30 22 C -6.8228 0.77 0 0
M  V30 23 N -6.0528 2.1037 0 0
M  V30 24 C -4.5128 2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 4 12
M  V30 13 1 8 12
M  V30 14 1 10 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 13 18
M  V30 21 1 19 16 CFG=3
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2724205341

>  <MW>
320.164

>  <MW (desalted)>
320.388

>  <ClogP>
2.722

>  <logS>
-3.484

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
72.94

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 ~ 7E-05 ?M | IC50  1 nM | IC50  1 - 100 nM | IC50  1 nM

>  <CAS>
1038915-60-4

>  <Description>
Niraparib is an orally active PARP inhibitor. It is used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy.

>  <EBC_ID>
EBC-17059

>  <IUPAC Name>
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide

>  <Main Tar all refs>
REPARE THERAPEUTICS INC - WO2021/119523, 2021, A1 | SHANGHAITECH UNIVERSITY - EP3778590, 2021, A1 | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL; HUMANWELL HEALTHCARE (GROUP) CO., LTD. - US2017/29430, 2017, A1 | SHANGHAITECH UNIVERSITY - EP3778590, 2021, A1

>  <Main tar all>
NAD+ ADP-ribosyltransferase pX=10.2 | Cullin-4A pX=9.0 | Poly pX=9.0 | Protein cereblon pX=9.0

$$$$
Diaveridine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 O 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 C 2.6674 -7.7 0 0
M  V30 9 C 2.6674 -9.24 0 0
M  V30 10 N 1.3337 -10.01 0 0
M  V30 11 C -0 -9.24 0 0
M  V30 12 N -1.3337 -10.01 0 0
M  V30 13 N 0 -7.7 0 0
M  V30 14 C 1.3337 -6.93 0 0
M  V30 15 N 1.3337 -5.39 0 0
M  V30 16 C 2.6674 -4.62 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 18 O 1.3337 -2.31 0 0
M  V30 19 C 1.3337 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 14 15
M  V30 16 2 6 16
M  V30 17 1 16 17
M  V30 18 2 3 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681892420

>  <MW>
260.127

>  <MW (desalted)>
260.292

>  <ClogP>
1.339

>  <logS>
-2.803

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
96.28

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 11.5 nM | pKi  6.92

>  <CAS>
5355-16-8

>  <Description>
Diaveridine is an antiprotozoal agent. It inhibits dihydrofolate reductase activity.  In veterinary it is used for the treatment of coccidiosis.

>  <EBC_ID>
EBC-07775

>  <IUPAC Name>
5-[(3,4-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine

>  <Main Tar all refs>
J. Med. Chem., 2004, vol. 47, # 2, p. 345 - 354 | J. MED. CHEM., 1982, vol. 25, # 7, p. 777 - 784

>  <Main tar all>
dihydrofolate reductase pX=7.94 | dihydrofolate reductase pX=6.92

$$$$
Ibuprofen piconol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -2.31 0 0
M  V30 2 C -5.3347 -3.08 0 0
M  V30 3 C -5.3347 -4.62 0 0
M  V30 4 C -4.001 -2.31 0 0
M  V30 5 C -2.6674 -3.08 0 0
M  V30 6 C -1.3337 -2.31 0 0
M  V30 7 C 0 -3.08 0 0
M  V30 8 C 0 -4.62 0 0
M  V30 9 C -1.3337 -5.39 0 0
M  V30 10 C -2.6674 -4.62 0 0
M  V30 11 C 1.3337 -5.39 0 0
M  V30 12 C 1.3337 -6.93 0 0
M  V30 13 C 2.6674 -4.62 0 0
M  V30 14 O 2.6674 -3.08 0 0
M  V30 15 O 4.001 -5.39 0 0
M  V30 16 C 5.3347 -4.62 0 0
M  V30 17 C 6.6684 -5.39 0 0
M  V30 18 C 8.0021 -4.62 0 0
M  V30 19 C 9.3358 -5.39 0 0
M  V30 20 C 9.3358 -6.93 0 0
M  V30 21 C 8.0021 -7.7 0 0
M  V30 22 N 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1537603096

>  <MW>
297.391

>  <MW (desalted)>
297.391

>  <ClogP>
4.356

>  <logS>
-4.532

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
39.19

>  <RotBonds>
7

>  <CAS>
64622-45-3

>  <Description>
Ibuprofen piconol is a non-steroidal, anti-inflammatory agent, used for the topical relief of primary thermal burns and sunburns.

>  <EBC_ID>
EBC-50107

>  <IUPAC Name>
(pyridin-2-yl)methyl 2-[4-(2-methylpropyl)phenyl]propanoate

$$$$
Ofloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -0.77 0 0
M  V30 3 C 2.6674 0 0 0
M  V30 4 O 2.6674 1.54 0 0
M  V30 5 C 4.001 2.31 0 0
M  V30 6 C 4.001 3.85 0 0
M  V30 7 N 2.6674 4.62 0 0
M  V30 8 C 1.3337 3.85 0 0
M  V30 9 C -0 4.62 0 0
M  V30 10 N -0 6.16 0 0
M  V30 11 C -1.3337 6.93 0 0
M  V30 12 C 1.3337 6.93 0 0
M  V30 13 C 2.6674 6.16 0 0
M  V30 14 C 5.3347 4.62 0 0
M  V30 15 F 5.3347 6.16 0 0
M  V30 16 C 6.6684 3.85 0 0
M  V30 17 C 6.6684 2.31 0 0
M  V30 18 C 8.0021 1.54 0 0
M  V30 19 O 9.3358 2.31 0 0
M  V30 20 C 8.0021 0 0 0
M  V30 21 C 6.6684 -0.77 0 0
M  V30 22 N 5.3347 0 0 0
M  V30 23 C 5.3347 1.54 0 0
M  V30 24 C 9.3358 -0.77 0 0
M  V30 25 O 10.6694 -0 0 0
M  V30 26 O 9.3358 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 2 22
M  V30 24 1 22 23
M  V30 25 2 5 23
M  V30 26 1 17 23
M  V30 27 1 20 24
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56761309

>  <MW>
361.368

>  <MW (desalted)>
361.368

>  <ClogP>
-0.508

>  <logS>
-2.41

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
73.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | - | - | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC90  0.25 mg/l | MIC  0.125 ?M | MIC  0.125 ?M | MIC = 0.063 ?g/mL | IC50 = 0.18 ?M | CC25 = 0.2 ?M | MIC  0.25 ?g/ml | MIC  0.25 ?g/ml | MIC = 0.25 ?g/mL | MIC  0.25 ?g/ml | MIC  0.7 ?M | CC50 (cytotoxic concentration) = 0.3 ?g/mL | MIC = 0.5 ?g/mL | MIC  0.5 ?g/ml

>  <CAS>
82419-36-1

>  <Description>
Ofloxacin is a broad spectrum fluoroquinolone antibiotic that prevents supercoiling of bacterial chromosomes by DNA gyrase. It is active against Gram-positive and Gram-negative bacteria

>  <EBC_ID>
EBC-08557

>  <IUPAC Name>
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

>  <Main Tar all refs>
J. Antibiot., 2021, vol. 74, # 5, p. 324 - 329 | Eur. J. Med. Chem., 2018, vol. 154, p. 144 - 154 | Eur. J. Med. Chem., 2018, vol. 154, p. 144 - 154 | Antimicrob. Agents Chemother., 1998, vol. 42, # 5, p. 1284 - 1287 | Antimicrob. Agents Chemother., 2006, vol. 50, # 1, p. 385 - 387 | Antimicrob. Agents Chemother., 2008, vol. 52, # 8, p. 2909 - 2914 | Antimicrob. Agents Chemother., 2021, vol. 65, # 1 | DUKE UNIVERSITY - US2023/95547, 2023, A1 | Antimicrob. Agents Chemother., 2000, vol. 44, # 2, p. 311 - 315 | Antimicrob. Agents Chemother., 2021, vol. 65, # 1 | ACS Med. Chem. Lett., 2014, vol. 5, # 5, p. 491 - 495 | Med. Res. Rev., 2000, vol. 20, # 4, p. 231 - 293 | Antimicrob. Agents Chemother., 1998, vol. 42, # 5, p. 1284 - 1287 | Eur. J. Med. Chem., 2023, vol. 255

>  <Main tar all>
Organic hydroperoxide resistance protein OhrB pX=7.11 | DNA?gyrase subunit A pX=6.9 | DNA?gyrase subunit A pX=6.9 | DNA?gyrase pX=6.76 | DNA?gyrase subunit A pX=6.74 | DNA?gyrase subunit B pX=6.22 | DNA supercoiling protein pX=6.16 | Glycine-tRNA ligase pX=6.16 | Outer membrane protein F pX=6.16 | Reverse gyrase pX=6.16 | Alkyl hydroperoxide reductase subunit C pX=6.15 | DNA negative supercoiling pX=6.08 | DNA topoisomerase IV subunit A pX=5.86 | Trehalose?monomycolate?exporter?MmpL3 pX=5.86

$$$$
Sulpiride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.4692 -2.425 0 0
M  V30 2 C 5.1355 -3.195 0 0
M  V30 3 N 5.1355 -4.735 0 0
M  V30 4 C 6.3814 -5.6402 0 0
M  V30 5 C 5.9055 -7.1048 0 0
M  V30 6 C 4.3655 -7.1048 0 0
M  V30 7 C 3.8896 -5.6402 0 0
M  V30 8 C 2.425 -5.1643 0 0
M  V30 9 N 2.1048 -3.658 0 0
M  V30 10 C 0.6402 -3.1821 0 0
M  V30 11 O -0.5042 -4.2125 0 0
M  V30 12 C 0.32 -1.6757 0 0
M  V30 13 C -1.1446 -1.1998 0 0
M  V30 14 C -1.4648 0.3065 0 0
M  V30 15 C -0.3203 1.337 0 0
M  V30 16 C 1.1443 0.8611 0 0
M  V30 17 C 1.4645 -0.6453 0 0
M  V30 18 O 2.9291 -1.1211 0 0
M  V30 19 C 3.2493 -2.6275 0 0
M  V30 20 S -2.9294 0.7824 0 0
M  V30 21 O -4.394 1.2583 0 0
M  V30 22 O -2.4535 2.247 0 0
M  V30 23 N -3.4053 -0.6822 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 3 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 14 20
M  V30 22 2 20 21
M  V30 23 2 20 22
M  V30 24 1 20 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z84655412

>  <MW>
341.426

>  <MW (desalted)>
341.426

>  <ClogP>
1.11

>  <logS>
-2.062

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
101.73

>  <RotBonds>
6

>  <Action on targets>
Antagonist | Inhibitor | Antagonist | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | - | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.7 nM | Ki (inhibition constant) = 0.8 nM | Kb (antagonist dissociation constant)  0.92 nM | pKi  8.67  | IC50  2.4 nM | Ki (inhibition constant) = 2.5 nM | Ki (inhibition constant) = 2.5 nM | Ki (inhibition constant) = 3.6 nM | Ki (inhibition constant)  3.9 nM | Ki (inhibition constant)  5.51 nM | Ki (inhibition constant) = 6.3 nM | Kb (antagonist dissociation constant) = 7 nM | Ki (inhibition constant) = 8 nM | Kb (antagonist dissociation constant) = 8.8 nM | Ki (inhibition constant)  18 nM | pIC50  7.68

>  <CAS>
15676-16-1

>  <Description>
Sulpiride is a dopamine D2-receptor antagonist, an atypical antipsychotic drug of the benzamide class. It is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.

>  <EBC_ID>
EBC-09094

>  <IUPAC Name>
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | Chem. Biol. Drug Des., 2009, vol. 74, # 6, p. 636 - 639 | ACS Chem. Neurosci., 2020, vol. 11, # 20, p. 3309 - 3320 | J. Pharmacol. Sci., 2008, vol. 108, # 1, p. 63 - 70 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Pharmacol. Rev., 2001, vol. 53, # 1, p. 119 - 133 | Bioorg. Med. Chem., 2013, vol. 21, # 15, p. 4521 - 4525 | Eur. J. Med. Chem., 2014, vol. 71, p. 105 - 111 | Bioorg. Med. Chem., 2014, vol. 22, # 5, p. 1586 - 1595 | J. Med. Chem., 1989, vol. 32, # 4, p. 874 - 880 | Pharmacol. Rev., 1997, vol. 49, # 3, p. 231 - 252 | J. MED. CHEM., 1985, vol. 28, # 10, p. 1533 - 1536 | Pharmacol. Rev., 2001, vol. 53, # 1, p. 119 - 133 | J. MED. CHEM., 1983, vol. 26, # 7, p. 933 - 935 | Bioorg. Chem., 2020, vol. 100 | Mol. Pharmacol., 2010, vol. 78, # 5, p. 925 - 934

>  <Main tar all>
D2 receptor pX=9.15 | carbonic anhydrase 6 pX=9.1 | D2 receptor (isoform?1) pX=9.04 | D1 receptor pX=8.67 | D2S receptor pX=8.62 | D2 receptor pX=8.6 | carbonic anhydrase pX=8.6 | carbonic anhydrase 7 pX=8.44 | carbonic anhydrase 12 pX=8.41 | D2L receptor pX=8.26 | D3 receptor pX=8.2 | Dopamine receptor pX=8.15 | D3 receptor pX=8.1 | Dopamine receptor pX=8.06 | Carbonic anhydrase 5B, mitochondrial pX=7.74 | Beta-arrestin-2 pX=7.68

$$$$
Zafirlukast
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.2221 -8.4072 0 0
M  V30 2 O 0.698 -6.9426 0 0
M  V30 3 C 2.2043 -6.6224 0 0
M  V30 4 C 3.2348 -7.7669 0 0
M  V30 5 C 4.7411 -7.4467 0 0
M  V30 6 C 5.217 -5.982 0 0
M  V30 7 C 4.1865 -4.8376 0 0
M  V30 8 C 2.6802 -5.1578 0 0
M  V30 9 C 1.6497 -4.0133 0 0
M  V30 10 C 2.1256 -2.5487 0 0
M  V30 11 C 1.2204 -1.3028 0 0
M  V30 12 N 2.1256 -0.0569 0 0
M  V30 13 C 1.6497 1.4077 0 0
M  V30 14 C 3.5902 -0.5328 0 0
M  V30 15 C 4.9239 0.2372 0 0
M  V30 16 C 6.2576 -0.5328 0 0
M  V30 17 C 6.2576 -2.0728 0 0
M  V30 18 N 7.5913 -2.8428 0 0
M  V30 19 C 8.925 -2.0728 0 0
M  V30 20 O 8.925 -0.5328 0 0
M  V30 21 O 10.2586 -2.8428 0 0
M  V30 22 C 11.5923 -2.0728 0 0
M  V30 23 C 11.7533 -0.5413 0 0
M  V30 24 C 13.2596 -0.2211 0 0
M  V30 25 C 14.0296 -1.5548 0 0
M  V30 26 C 12.9992 -2.6992 0 0
M  V30 27 C 4.9239 -2.8428 0 0
M  V30 28 C 3.5902 -2.0728 0 0
M  V30 29 C 5.7716 -8.5911 0 0
M  V30 30 O 7.2779 -8.2709 0 0
M  V30 31 N 5.2957 -10.0557 0 0
M  V30 32 S 3.7893 -10.3759 0 0
M  V30 33 O 3.4692 -8.8696 0 0
M  V30 34 O 4.1095 -11.8823 0 0
M  V30 35 C 2.283 -10.6961 0 0
M  V30 36 C 1.8071 -12.1607 0 0
M  V30 37 C 0.3008 -12.4809 0 0
M  V30 38 C -0.7297 -11.3365 0 0
M  V30 39 C -0.2538 -9.8718 0 0
M  V30 40 C 1.2525 -9.5517 0 0
M  V30 41 C 1.7284 -8.087 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 22 26
M  V30 28 2 17 27
M  V30 29 1 27 28
M  V30 30 1 10 28
M  V30 31 2 14 28
M  V30 32 1 5 29
M  V30 33 2 29 30
M  V30 34 1 29 31
M  V30 35 1 31 32
M  V30 36 2 32 33
M  V30 37 2 32 34
M  V30 38 1 32 35
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 2 38 39
M  V30 43 1 39 40
M  V30 44 2 35 40
M  V30 45 1 40 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616205

>  <MW>
575.675

>  <MW (desalted)>
575.675

>  <ClogP>
7.092

>  <logS>
-6.59

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
115.73

>  <RotBonds>
8

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
pA2  11.4

>  <CAS>
107753-78-6

>  <Description>
Zafirlukast is a leukotriene receptor antagonist used for prophylaxis and chronic treatment of asthma.

>  <EBC_ID>
EBC-11230

>  <IUPAC Name>
cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate

>  <Main Tar all refs>
J. Med. Chem., 2018, vol. 61, # 13, p. 5758 - 5764

>  <Main tar all>
CysLT1 receptor pX=11.4

$$$$
Chloramphenicol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 9.3358 -10.01 0 0
M  V30 2 C 8.0021 -9.24 0 0
M  V30 3 C 8.0021 -7.7 0 0 CFG=1
M  V30 4 N 6.6684 -6.93 0 0
M  V30 5 C 5.3347 -7.7 0 0
M  V30 6 O 5.3347 -9.24 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 Cl 2.6674 -7.7 0 0
M  V30 9 Cl 4.001 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0 CFG=2
M  V30 11 O 9.3358 -5.39 0 0
M  V30 12 C 10.6694 -7.7 0 0
M  V30 13 C 12.0031 -6.93 0 0
M  V30 14 C 13.3368 -7.7 0 0
M  V30 15 C 13.3368 -9.24 0 0
M  V30 16 C 12.0031 -10.01 0 0
M  V30 17 C 10.6694 -9.24 0 0
M  V30 18 N 14.6705 -10.01 0 0 CHG=1
M  V30 19 O 16.0041 -9.24 0 0
M  V30 20 O 14.6705 -11.55 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 3 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 15 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671241

>  <MW>
323.129

>  <MW (desalted)>
323.129

>  <ClogP>
1.283

>  <logS>
-3.238

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
112.7

>  <RotBonds>
6

>  <Action on targets>
Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC95  0.5 ?g/ml | EC90 rate decrease Active   | Ki (inhibition constant)  0.65 ?mol/l | IC50  0.88 ?M | MIC  0.49 ?g/ml | MIC  0.5 ?g/ml | MIC  0.5 ?g/ml

>  <CAS>
56-75-7

>  <Description>
Chloramphenicol, a broad-spectrum antibiotic, acts as a potent inhibitor of bacterial protein biosynthesis. Chloramphenicol acts primarily on the 50S subunit of bacterial 70S rihosomes and inhibits peptide bond formation by suppressing peptidyl transferase activity. It is used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea.

>  <EBC_ID>
EBC-07470

>  <IUPAC Name>
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide

>  <Main Tar all refs>
Nat. Commun., 2022, vol. 13, # 1 | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES - WO2018/111934, 2018, A1 | ChemBioChem, 2015, vol. 16, # 16, p. 2304 - 2308 | Drug Metab. Dispos., 2016, vol. 44, # 12, p. 1963 - 1972 | Bioorg. Chem., 2020, vol. 102 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5

>  <Main tar all>
Multidrug?efflux?pump?subunit?AcrB pX=7.09 | Efflux Pump pX=6.4 | 70S Ribosomal Protein pX=6.19 | CYP2B11 pX=6.06 | Tyrosine-tRNA ligase (gene tyrS) pX=5.82 | DNA?gyrase subunit A pX=5.81 | DNA?gyrase subunit A?(D87Y) pX=5.81

$$$$
Amphotericin B
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 65 67 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.1287 8.5576 0 0
M  V30 2 C -0.3126 7.0287 0 0 CFG=1
M  V30 3 O 0.9195 6.1049 0 0
M  V30 4 C 0.7356 4.5759 0 0 CFG=1
M  V30 5 O 1.9678 3.6522 0 0
M  V30 6 C 1.7839 2.1232 0 0 CFG=2
M  V30 7 C 0.3678 1.518 0 0
M  V30 8 C 0.1839 -0.011 0 0 CFG=2
M  V30 9 O 1.4161 -0.9348 0 0
M  V30 10 C 1.2322 -2.4638 0 0 CFG=1
M  V30 11 O 1.0483 -3.9927 0 0
M  V30 12 C -0.1839 -3.069 0 0
M  V30 13 C -1.4161 -2.1452 0 0 CFG=2
M  V30 14 O -2.8322 -2.7504 0 0
M  V30 15 C -1.2322 -0.6162 0 0 CFG=1
M  V30 16 C -2.4644 0.3075 0 0
M  V30 17 O -2.2805 1.8365 0 0
M  V30 18 O -3.8805 -0.2977 0 0
M  V30 19 C 2.4644 -3.3875 0 0
M  V30 20 C 3.8805 -2.7823 0 0 CFG=1
M  V30 21 O 4.0644 -1.2533 0 0
M  V30 22 C 5.1126 -3.7061 0 0
M  V30 23 C 6.5287 -3.1008 0 0 CFG=1
M  V30 24 O 6.7126 -1.5719 0 0
M  V30 25 C 7.7609 -4.0246 0 0 CFG=2
M  V30 26 O 7.577 -5.5536 0 0
M  V30 27 C 9.177 -3.4194 0 0
M  V30 28 C 10.4092 -4.3431 0 0
M  V30 29 C 11.8253 -3.7379 0 0 CFG=1
M  V30 30 O 12.0092 -2.2089 0 0
M  V30 31 C 13.0574 -4.6617 0 0
M  V30 32 C 14.4735 -4.0564 0 0 CFG=1
M  V30 33 O 14.6574 -2.5275 0 0
M  V30 34 C 15.7057 -4.9802 0 0
M  V30 35 C 17.1218 -4.375 0 0
M  V30 36 O 17.3057 -2.846 0 0
M  V30 37 O 18.354 -5.2987 0 0
M  V30 38 C 19.7701 -4.6935 0 0 CFG=1
M  V30 39 C 21.0023 -5.6173 0 0
M  V30 40 C 19.954 -3.1645 0 0 CFG=2
M  V30 41 C 18.7218 -2.2408 0 0
M  V30 42 C 21.3701 -2.5593 0 0 CFG=2
M  V30 43 O 22.6022 -3.4831 0 0
M  V30 44 C 21.554 -1.0303 0 0 CFG=1
M  V30 45 C 22.9701 -0.4251 0 0
M  V30 46 C 20.3218 -0.1066 0 0
M  V30 47 C 18.9057 -0.7118 0 0
M  V30 48 C 17.6735 0.212 0 0
M  V30 49 C 16.2574 -0.3933 0 0
M  V30 50 C 15.0253 0.5305 0 0
M  V30 51 C 13.6092 -0.0747 0 0
M  V30 52 C 12.377 0.849 0 0
M  V30 53 C 10.9609 0.2438 0 0
M  V30 54 C 9.7287 1.1676 0 0
M  V30 55 C 8.3126 0.5623 0 0
M  V30 56 C 7.0804 1.4861 0 0
M  V30 57 C 5.6644 0.8809 0 0
M  V30 58 C 4.4322 1.8046 0 0
M  V30 59 C 3.0161 1.1994 0 0
M  V30 60 C -0.6805 3.9707 0 0 CFG=1
M  V30 61 O -0.8644 2.4417 0 0
M  V30 62 C -1.9126 4.8945 0 0 CFG=1
M  V30 63 N -3.3287 4.2892 0 0
M  V30 64 C -1.7287 6.4234 0 0 CFG=2
M  V30 65 O -2.9609 7.3472 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=1
M  V30 11 1 10 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 15 13
M  V30 15 1 15 8
M  V30 16 1 15 16 CFG=1
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 10 19
M  V30 20 1 20 19
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 23 22
M  V30 24 1 23 24 CFG=1
M  V30 25 1 23 25
M  V30 26 1 25 26 CFG=1
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 1 29 28
M  V30 30 1 29 30 CFG=1
M  V30 31 1 29 31
M  V30 32 1 32 31
M  V30 33 1 32 33 CFG=1
M  V30 34 1 32 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 1 38 37
M  V30 39 1 38 39 CFG=3
M  V30 40 1 40 38
M  V30 41 1 40 41 CFG=3
M  V30 42 1 40 42
M  V30 43 1 42 43 CFG=1
M  V30 44 1 42 44
M  V30 45 1 44 45 CFG=3
M  V30 46 1 44 46
M  V30 47 2 46 47
M  V30 48 1 47 48 CFG=2
M  V30 49 2 48 49
M  V30 50 1 49 50 CFG=2
M  V30 51 2 50 51
M  V30 52 1 51 52 CFG=2
M  V30 53 2 52 53
M  V30 54 1 53 54 CFG=2
M  V30 55 2 54 55
M  V30 56 1 55 56 CFG=2
M  V30 57 2 56 57
M  V30 58 1 57 58 CFG=2
M  V30 59 2 58 59 CFG=2
M  V30 60 1 6 59
M  V30 61 1 60 4
M  V30 62 1 60 61 CFG=1
M  V30 63 1 60 62
M  V30 64 1 62 63 CFG=1
M  V30 65 1 62 64
M  V30 66 1 64 2
M  V30 67 1 64 65 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741982549

>  <MW>
924.079

>  <MW (desalted)>
924.079

>  <ClogP>
-3.654

>  <logS>
-2.135

>  <HBD>
12

>  <HBA>
17

>  <TPSA>
319.61

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.007 ?g/ml | IC80  0.03 ?g/ml | Kd (dissociation constant)  1.11E-08 M | MIC  0.02 ?M | EC50  0.02 ?g/ml | IC50  30 nM | MIC  0.03 - 1 mg/l | MIC  0.03 - 1 mg/l | MIC  0.03 - 1 mg/l | EC50  0.036 ?M | IC90  0.42 ?g/ml | IC90  0.42 ?g/ml | IC50  0.05 ?M | EC50  53 nM | EC50  0.054 ?M | IC50  0.0508 ?g/ml | IC50  0.0508 ?g/ml | MIC90  0.5 ?g/ml | IC50  0.0614 ?M | MIC < 0.06 ?g/mL | IC50  0.068 ?M | IC50  0.068 ?M | IC50  0.07 - 9.17 ?M | EC50  0.07 ?M | IC50  80 nM | EC50  0.1 ?M | EC50  0.1 ?M | IC50  0.106 ?M | MIC  0.125 ?g/ml | MIC  0.14 ?g/ml | IC50  0.16 ?M | MIC  0.18 ?M | EC50  0.19 ?M | IC50  0.23 ?M | MIC90  2 ?g/ml | MIC90  2 ?g/ml

>  <CAS>
1397-89-3

>  <Description>
Amphotericin B is an antifungal used to treat fungal infections in neutropenic patients, cryptococcal meningitis in HIV infection, fungal infections, and leishmaniasis.

>  <EBC_ID>
EBC-27506

>  <IUPAC Name>
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid

>  <Main Tar all refs>
Bioorg. Med. Chem., 2020, vol. 28, # 9 | J. Med. Chem., 2021 | Mol. Neurobiol., 2018, p. 1 - 11 | PLoS ONE, 2018, vol. 13, # 1 | Bioorg. Chem., 2020, vol. 102 | Parasitol. Res., 2022 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | PLoS. Negl. Trop. Dis., 2018, vol. 12, # 11 | Antimicrob. Agents Chemother., 2018, vol. 62, # 5 | Antimicrob. Agents Chemother., 2018, vol. 62, # 5 | Front. Microbiol., 2021, vol. 12 | ACS Infect. Dis., 2020, vol. 6, # 8, p. 2057 - 2072 | J. Mol. Graph. Model., 2019, vol. 91, p. 164 - 171 | Arch. Pharm., 2022, vol. 355, # 4 | Arch. Pharm., 2022, vol. 355, # 4 | Int. J. Mol. Sci., 2022, vol. 23, # 14 | BioMed Res. Int., 2017, vol. 2017 | MIRATI THERAPEUTICS, INC. - US2014/81017, 2014, A1 | J. Biomol. Struct. Dyn., 2022, vol. 40, # 7, p. 3213 - 3222 | J. Biomol. Struct. Dyn., 2022, vol. 40, # 7, p. 3213 - 3222 | Arch. Pharm., 2020, vol. 353, # 8 | J. Med. Chem., 2021, vol. 64, # 9, p. 6137 - 6160 | J. Biomol. Struct. Dyn., 2021, vol. 39, # 16, p. 6056 - 6069 | Int. J. Mol. Sci., 2021, vol. 22, # 19 | J. Enzyme Inhib. Med. Chem., 2020, vol. 35, # 1, p. 1345 - 1358 | BMC Pharmacol. Toxicol., 2021, vol. 22, # 1 | Microb. Pathog., 2023, vol. 175 | ACS Infect. Dis., 2022, vol. 8, # 9, p. 1851 - 1868 | Biomolecules, 2021, vol. 11, # 1, p. 1 - 22 | Bioorg. Med. Chem., 2018, vol. 26, # 20, p. 5408 - 5419 | Science, 2021, vol. 373, # 6557, p. 931 - 936 | Bioorg. Med. Chem. Lett., 2021, vol. 32 | Biochim. Biophys. Acta Gen. Subj., 2020, vol. 1864, # 11 | Biochim. Biophys. Acta Gen. Subj., 2020, vol. 1864, # 11

>  <Main tar all>
Dihydropteroate synthase pX=8.12 | desaturase pX=8.09 | Alternative prion protein pX=7.95 | Plasma Membrane ATPase 1 pX=7.7 | squalene monooxygenase pX=7.67 | 3-Mercaptopyruvate sulfurtransferase pX=7.52 | 1,3-beta-glucan synthase component FKS1 pX=7.49 | 1,3-beta-glucan synthase component GSC2 pX=7.49 | GTP-binding protein RHO1 pX=7.49 | protein tyrosine kinase 2 pX=7.44 | CYP51A1 pX=7.3 | Sterol 14-demethylase (CYP51B) pX=7.3 | Subtilisin pX=7.3 | tubulin alpha 1a pX=7.28 | Multifunctional alkaline phosphatase superfamily protein PehA pX=7.27 | Pteridine reductase 1 pX=7.26 | dihydrofolate reductase pX=7.26 | Homoserine O-acetyltransferase pX=7.22 | Calcium/calmodulin-dependent nitric oxide synthase pX=7.21 | Histone?deacetylase pX=7.19 | Arginase I pX=7.17 | Trypanothione reductase pX=7.17 | E3?ubiquitin-protein?ligase?UBR1 pX=7.15 | trypanothione-disulfide reductase pX=7.15 | Enoyl-[acyl-carrier-protein] reductase pX=7.1 | BRCT-containing protein pX=7.0 | Trypanothione synthetase pX=7.0 | dihydrofolate reductase pX=6.97 | Dihydropteroate synthase (activity) pX=6.87 | Pre-mRNA-processing-splicing factor 8 pX=6.82 | heat shock protein 90 beta family member 1 pX=6.8 | Inosine-5'-monophosphate dehydrogenase pX=6.74 | Replicase polyprotein 1a pX=6.72 | Ribose 5-phosphate isomerase B pX=6.64 | NADP-specific glutamate dehydrogenase 1 pX=6.62 | NADP-specific glutamate dehydrogenase 2 pX=6.62

$$$$
Metrizoate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 4.62 0 0
M  V30 2 N 1.3337 3.85 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 O 0 6.16 0 0
M  V30 5 C -1.3337 3.85 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 I 4.001 2.31 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 N 4.001 -0.77 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 O 5.3347 -3.08 0 0
M  V30 13 C 2.6674 -3.08 0 0
M  V30 14 C 1.3337 -0.77 0 0
M  V30 15 I 1.3337 -2.31 0 0
M  V30 16 C 0 0 0 0
M  V30 17 C -1.3337 -0.77 0 0
M  V30 18 O -2.6674 0 0 0
M  V30 19 O -1.3337 -2.31 0 0
M  V30 20 C 0 1.54 0 0
M  V30 21 I -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 9 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 16 20
M  V30 20 2 6 20
M  V30 21 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417556930

>  <MW>
627.785

>  <MW (desalted)>
627.94

>  <ClogP>
0.878

>  <logS>
-3.849

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
86.71

>  <RotBonds>
3

>  <CAS>
1949-45-7

>  <Description>
Metrizoate is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality.

>  <EBC_ID>
EBC-13248

>  <IUPAC Name>
3-acetamido-2,4,6-triiodo-5-(N-methylacetamido)benzoic acid

$$$$
Lornoxicam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 C 4.9239 1.3028 0 0
M  V30 5 O 4.9239 -0.2372 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 S 2.1256 1.5969 0 0
M  V30 8 C 1.2204 2.8428 0 0
M  V30 9 Cl -0.3196 2.8428 0 0
M  V30 10 C 2.1256 4.0887 0 0
M  V30 11 C 3.5902 3.6128 0 0
M  V30 12 S 4.9239 4.3828 0 0
M  V30 13 O 4.2009 5.7426 0 0
M  V30 14 O 5.6469 5.7426 0 0
M  V30 15 C 7.5913 1.3028 0 0
M  V30 16 O 7.5913 -0.2372 0 0
M  V30 17 N 8.925 2.0728 0 0
M  V30 18 C 10.2586 1.3028 0 0
M  V30 19 C 11.5923 2.0728 0 0
M  V30 20 C 12.926 1.3028 0 0
M  V30 21 C 12.926 -0.2372 0 0
M  V30 22 C 11.5923 -1.0072 0 0
M  V30 23 N 10.2586 -0.2372 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 1 2 12
M  V30 14 2 12 13
M  V30 15 2 12 14
M  V30 16 1 3 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801980

>  <MW>
370.98

>  <MW (desalted)>
371.819

>  <ClogP>
2.337

>  <logS>
-4.56

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
99.6

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.003 ?M | Ki (inhibition constant)  3.43 nM | IC50 = 0.008 ?M | Ki (inhibition constant)  9.19 nM | Kd (dissociation constant)  0.016 ?M | IC50 = 0.02 ?M

>  <CAS>
70374-39-9

>  <Description>
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID). It potently inhibits both COX-1 and COX-2.

>  <EBC_ID>
EBC-03924

>  <IUPAC Name>
6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1lambda6-thieno[2,3-e][1,2]thiazine-3-carboxamide

>  <Main Tar all refs>
EVA BINDER - WO2004/105766, 2004, A2 | Curr. Med. Chem., 2015, vol. 22, # 24, p. 2812 - 2818 | EVA BINDER - WO2004/105766, 2004, A2 | Curr. Med. Chem., 2015, vol. 22, # 24, p. 2812 - 2818 | Chem. Phys. Lipids, 2011, vol. 164, # 4, p. 292 - 299 | BINDER (inventors) - EP658559, 1995, A1

>  <Main tar all>
COX-1  pX=8.52 | carbonic anhydrase 4 pX=8.46 | COX-2  pX=8.1 | carbonic anhydrase 2 pX=8.04 | Phospholipase A2 pX=7.8 | Cyclooxygenase pX=7.7

$$$$
Gatifloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -5.39 0 0
M  V30 2 O 2.6674 -4.62 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 N 0 -3.08 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 C -1.3337 -5.39 0 0
M  V30 8 N -2.6674 -4.62 0 0
M  V30 9 C -2.6674 -3.08 0 0
M  V30 10 C -4.001 -2.31 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 F 0 0 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 O 5.3347 1.54 0 0
M  V30 18 C 6.6684 -0.77 0 0
M  V30 19 C 6.6684 -2.31 0 0
M  V30 20 N 5.3347 -3.08 0 0
M  V30 21 C 5.3347 -4.62 0 0
M  V30 22 C 6.1047 -5.9537 0 0
M  V30 23 C 4.5647 -5.9537 0 0
M  V30 24 C 4.001 -2.31 0 0
M  V30 25 C 8.0021 -0 0 0
M  V30 26 O 8.0021 1.54 0 0
M  V30 27 O 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 5 11
M  V30 12 2 4 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 21 23
M  V30 25 1 20 24
M  V30 26 2 3 24
M  V30 27 1 15 24
M  V30 28 1 18 25
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1824566854

>  <MW>
375.159

>  <MW (desalted)>
375.394

>  <ClogP>
-0.266

>  <logS>
-2.601

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
82.11

>  <RotBonds>
4

>  <Action on targets>
- | - | Inhibitor | - | - | Inhibitor | -

>  <Activity coefficients and valu>
CC90  0.3 ?g/mL | CC50 (cytotoxic concentration) = 0.22 ?M | MIC  0.47 ?M | CC50 (cytotoxic concentration) = 0.7 ?M | CC50 (cytotoxic concentration) = 0.7 ?M | IC50 = 0.8 ?g/mL | MIC  1 ?g/mL

>  <CAS>
112811-59-3

>  <Description>
Gatifloxacin is a fourth generation fluoroquinolone used to treat a wide variety of infections in the body. The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

>  <EBC_ID>
EBC-11236

>  <IUPAC Name>
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2008, vol. 52, # 2, p. 745 - 747 | Antimicrob. Agents Chemother., 2008, vol. 52, # 7, p. 2313 - 2323 | New J. Chem., 2020, vol. 44, # 31, p. 13308 - 13318 | Antimicrob. Agents Chemother., 2008, vol. 52, # 7, p. 2313 - 2323 | Antimicrob. Agents Chemother., 2008, vol. 52, # 7, p. 2313 - 2323 | Antimicrob. Agents Chemother., 2006, vol. 50, # 1, p. 104 - 112 | Z. Anorg. Allg. Chem., 2011, vol. 637, # 11, p. 1602 - 1611

>  <Main tar all>
DNA?gyrase pX=7.05 | DNA topoisomerase IV subunit A pX=6.66 | DNA?gyrase pX=6.33 | DNA?gyrase subunit A pX=6.15 | DNA?gyrase subunit A pX=6.15 | DNA?gyrase subunit A pX=5.67 | DNA negative supercoiling pX=5.58

$$$$
Retinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 6.16 0 0
M  V30 2 C 10.6694 4.62 0 0
M  V30 3 C 12.0031 3.85 0 0
M  V30 4 C 13.3368 4.62 0 0
M  V30 5 O 14.6705 3.85 0 0
M  V30 6 C 9.3358 3.85 0 0
M  V30 7 C 8.0021 4.62 0 0
M  V30 8 C 6.6684 3.85 0 0
M  V30 9 C 5.3347 4.62 0 0
M  V30 10 C 5.3347 6.16 0 0
M  V30 11 C 4.001 3.85 0 0
M  V30 12 C 4.001 2.31 0 0
M  V30 13 C 2.6674 1.54 0 0
M  V30 14 C 2.6674 -0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 1.3337 -0.77 0 0
M  V30 17 C 0 0 0 0
M  V30 18 C 0 1.54 0 0
M  V30 19 C 1.3337 2.31 0 0
M  V30 20 C 0.6107 3.6697 0 0
M  V30 21 C 2.0567 3.6697 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 2 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 13 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315574891

>  <MW>
286.23

>  <MW (desalted)>
286.452

>  <ClogP>
6.403

>  <logS>
-6.808

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.0056 ?M | Kd (dissociation constant)  18.5 nM | Kd (dissociation constant) = 70 nM | IC50  120 nM

>  <CAS>
68-26-8

>  <Description>
Retinol is a vitamin important for retinal function that is used clinically to correct vitamin A deficiency.

>  <EBC_ID>
EBC-26456

>  <IUPAC Name>
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol

>  <Main Tar all refs>
FEBS Lett., 2016, vol. 590, # 9, p. 1304 - 1312 | J. Biol. Chem., 2016, vol. 291, # 16, p. 8528 - 8540 | Bioorg. Med. Chem. Lett., 2000, vol. 10, # 18, p. 2129 - 2132 | MASS GENERAL BRIGHAM INC - US6596500, 2003, B1

>  <Main tar all>
CYP27C1 pX=8.25 | retinol binding protein 1 pX=7.73 | retinoic acid binding protein pX=7.15 | Cation-independent mannose-6-phosphate receptor pX=6.92

$$$$
Ditiocarb sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 6.311 0.5637 0 0 CHG=1
M  V30 2 C -0.3574 1.3337 0 0
M  V30 3 C 0.9763 2.1037 0 0
M  V30 4 N 2.31 1.3337 0 0
M  V30 5 C 2.31 -0.2063 0 0
M  V30 6 C 0.9763 -0.9763 0 0
M  V30 7 C 3.6437 2.1037 0 0
M  V30 8 S 3.6437 3.6437 0 0
M  V30 9 S 4.9774 1.3337 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 4 7
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1522566622

>  <MW>
171.015

>  <MW (desalted)>
149.278

>  <ClogP>
1.609

>  <logS>
-2.55

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
3.24

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.004 nM

>  <CAS>
148-18-5

>  <Description>
Ditiocarb sodium inhibits carbonic anhydrases from Porphyromonas gingivalis and Burkholderia pseudomallei. It also reduces the incidence of HIV infection.

>  <EBC_ID>
EBC-50109

>  <IUPAC Name>
sodium (diethylcarbamothioyl)sulfanide

>  <Main Tar all refs>
Bioorg. Med. Chem., 2016, vol. 24, # 4, p. 835 - 840

>  <Main tar all>
carbonic anhydrase pX=11.4

$$$$
Isoniazid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 6.16 0 0
M  V30 2 N 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 N 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z58981801

>  <MW>
137.059

>  <MW (desalted)>
137.139

>  <ClogP>
-0.668

>  <logS>
-0.51

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
68.01

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
MIC = 0.0125 ng/mL | Ki (inhibition constant) = 0.75 nM

>  <CAS>
54-85-3

>  <Description>
Isoniazid is an antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor.

>  <EBC_ID>
EBC-11047

>  <IUPAC Name>
pyridine-4-carbohydrazide

>  <Main Tar all refs>
Chem. Biol., 2012, vol. 19, # 7, p. 844 - 854 | Curr. Top. Med. Chem., 2012, vol. 12, # 7, p. 672 - 693

>  <Main tar all>
Isocitrate lyase pX=10.0 | Enoyl-[acyl-carrier-protein] reductase pX=9.12

$$$$
Hydralazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 -3.2725 0 0
M  V30 3 N 5.7337 -2.5025 0 0
M  V30 4 C 5.7337 -0.9625 0 0
M  V30 5 N 4.4 -0.1925 0 0
M  V30 6 N 4.4 1.3475 0 0
M  V30 7 C 5.7337 2.1175 0 0
M  V30 8 C 7.0674 1.3475 0 0
M  V30 9 C 8.401 2.1175 0 0
M  V30 10 C 9.7347 1.3475 0 0
M  V30 11 C 9.7347 -0.1925 0 0
M  V30 12 C 8.401 -0.9625 0 0
M  V30 13 C 7.0674 -0.1925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 4 13
M  V30 13 1 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57980178

>  <MW>
196.052

>  <MW (desalted)>
160.176

>  <ClogP>
1.173

>  <logS>
-3

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
63.83

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 = 0.45 ?M | Ki (inhibition constant) = 1900 nM | Ki (inhibition constant) = 7 ?M | Ki (inhibition constant) = 7000 nM

>  <CAS>
304-20-1

>  <Description>
Hydralazine is an antihypertensive agent used for the management of essential hypertension or severe hypertension associated with conditions requiring immediate action, heart failure, and pre-eclampsia or eclampsia. It may interfere with calcium transport in vascular smooth muscle to relax arteriolar smooth muscle and lower blood pressure.

>  <EBC_ID>
EBC-04151

>  <IUPAC Name>
1-hydrazinylphthalazine hydrochloride

>  <Main Tar all refs>
Drug Metab. Dispos., 2011, vol. 39, # 1, p. 151 - 159 | Curr. Med. Chem., 2007, vol. 14, # 25, p. 2654 - 2679 | Med. Chem. Res., 2005, vol. 14, # 5, p. 297 - 308 | Curr. Med. Chem., 2007, vol. 14, # 25, p. 2654 - 2679

>  <Main tar all>
Pregnane X receptor pX=6.35 | butyrylcholinesterase pX=5.72 | acetylcholinesterase (Cartwright blood group) pX=5.15 | acetylcholinesterase (Cartwright blood group) pX=5.15

$$$$
Rasagiline mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 -1.54 0 0
M  V30 2 S 0 0 0 0
M  V30 3 O 0 1.54 0 0
M  V30 4 O 1.54 -0 0 0
M  V30 5 O -1.54 0 0 0
M  V30 6 C 5.06 -4.7141 0 0
M  V30 7 C 5.5359 -3.2494 0 0
M  V30 8 C 6.0118 -1.7848 0 0
M  V30 9 N 7.5181 -1.4646 0 0
M  V30 10 C 7.994 -0 0 0 CFG=2
M  V30 11 C 7.0888 1.2459 0 0
M  V30 12 C 7.994 2.4918 0 0
M  V30 13 C 9.4586 2.0159 0 0
M  V30 14 C 10.7923 2.7859 0 0
M  V30 15 C 12.126 2.0159 0 0
M  V30 16 C 12.126 0.4759 0 0
M  V30 17 C 10.7923 -0.2941 0 0
M  V30 18 C 9.4586 0.4759 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 3 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 10 9 CFG=3
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 1 10 18
M  V30 18 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1820079046

>  <MW>
267.093

>  <MW (desalted)>
171.238

>  <ClogP>
2.524

>  <logS>
-1.74

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 4 nM

>  <CAS>
161735-79-1

>  <Description>
Rasagiline mesylate is an amine oxidase B inhibitor. It is used for the treatment of idiopathic Parkinson's disease.

>  <EBC_ID>
EBC-03768

>  <IUPAC Name>
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; methanesulfonic acid

>  <Main Tar all refs>
J. Neurochem., 2005, vol. 95, # 1, p. 68 - 78

>  <Main tar all>
Monoamine oxidase B pX=8.4

$$$$
Sulfathiazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -2.8665 13.515 0 0
M  V30 2 C -1.5329 12.745 0 0
M  V30 3 C -0.1992 13.515 0 0
M  V30 4 C 1.1345 12.745 0 0
M  V30 5 C 1.1345 11.205 0 0
M  V30 6 C -0.1992 10.435 0 0
M  V30 7 C -1.5329 11.205 0 0
M  V30 8 S 2.4682 10.435 0 0
M  V30 9 O 1.6982 9.1013 0 0
M  V30 10 O 3.2382 11.7687 0 0
M  V30 11 N 3.8019 9.665 0 0
M  V30 12 C 3.8019 8.125 0 0
M  V30 13 N 5.0477 7.2198 0 0
M  V30 14 C 4.5719 5.7552 0 0
M  V30 15 C 3.0319 5.7552 0 0
M  V30 16 S 2.556 7.2198 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 12 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57198680

>  <MW>
255.014

>  <MW (desalted)>
255.317

>  <ClogP>
0.726

>  <logS>
-2.74

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
85.08

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Activator | Inhibitor

>  <Activity coefficients and valu>
IC50  8.02 nM | cell viability increase Active   | Ki (inhibition constant) = 10.5 nM

>  <CAS>
72-14-0

>  <Description>
Sulfathiazole is a short-acting sulfa drug. Sulfathiazole is effective against a wide range of gram positive and gram negative pathogenic microorganisms. Although no longer used in humans, it is used in cattle.

>  <EBC_ID>
EBC-04202

>  <IUPAC Name>
4-Amino-N-(1,3-thiazol-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540 | Biochim. Biophys. Acta Gen. Subj., 2023, vol. 1867, # 3 | ANTIMICROB. AGENTS CHEMOTHER., 1995, vol. 39, # 8, p. 1756 - 1763

>  <Main tar all>
sepiapterin reductase pX=8.1 | Aromatase 1 pX=8.0 | Dihydropteroate synthase pX=7.98

$$$$
Antazoline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.8547 -0.3655 0 0
M  V30 3 N 7.521 0.4045 0 0
M  V30 4 C 7.521 1.9445 0 0
M  V30 5 C 8.8547 2.7145 0 0
M  V30 6 C 8.8547 4.2545 0 0
M  V30 7 C 10.1884 5.0245 0 0
M  V30 8 C 11.5221 4.2545 0 0
M  V30 9 C 11.5221 2.7145 0 0
M  V30 10 C 10.1884 1.9445 0 0
M  V30 11 C 6.1874 -0.3655 0 0
M  V30 12 C 6.1874 -1.9055 0 0
M  V30 13 C 4.8537 -2.6755 0 0
M  V30 14 C 3.52 -1.9055 0 0
M  V30 15 C 3.52 -0.3655 0 0
M  V30 16 C 4.8537 0.4045 0 0
M  V30 17 C 8.8547 -1.9055 0 0
M  V30 18 N 10.1006 -2.8107 0 0
M  V30 19 C 9.6247 -4.2753 0 0
M  V30 20 C 8.0847 -4.2753 0 0
M  V30 21 N 7.6088 -2.8107 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 3 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 2 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 17 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516821

>  <MW>
301.135

>  <MW (desalted)>
265.353

>  <ClogP>
4.112

>  <logS>
-3.806

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
27.63

>  <RotBonds>
5

>  <CAS>
2508-72-7

>  <Description>
Antazoline hydrochloride is a 1st generation antihistamine with also anticholinergic properties. It is used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.

>  <EBC_ID>
EBC-03693

>  <IUPAC Name>
N-benzyl-N-[(4,5-dihydro-1H-imidazol-2-yl)methyl]aniline hydrochloride

$$$$
Neostigmine methyl sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.1114 -1.925 0 0
M  V30 2 O 0.2223 -1.155 0 0
M  V30 3 S 0.2223 0.385 0 0
M  V30 4 O 0.2223 1.925 0 0
M  V30 5 O 1.7623 0.385 0 0
M  V30 6 O -1.3177 0.385 0 0 CHG=-1
M  V30 7 C 12.8307 4.8606 0 0
M  V30 8 N 11.497 4.0906 0 0
M  V30 9 C 10.1633 4.8606 0 0
M  V30 10 C 11.497 2.5506 0 0
M  V30 11 O 12.8307 1.7806 0 0
M  V30 12 O 10.1633 1.7806 0 0
M  V30 13 C 10.1633 0.2406 0 0
M  V30 14 C 11.497 -0.5294 0 0
M  V30 15 C 11.497 -2.0694 0 0
M  V30 16 C 10.1633 -2.8394 0 0
M  V30 17 C 8.8296 -2.0694 0 0
M  V30 18 C 8.8296 -0.5294 0 0
M  V30 19 N 7.496 -2.8394 0 0 CHG=1
M  V30 20 C 6.1623 -3.6094 0 0
M  V30 21 C 6.726 -1.5057 0 0
M  V30 22 C 8.266 -4.1731 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 8 10
M  V30 9 2 10 11
M  V30 10 1 10 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 2 13 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 1 19 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037281404

>  <MW>
334.12

>  <MW (desalted)>
223.291

>  <ClogP>
-2.812

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
29.54

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.94 nM | IC50 = 18.8 nM

>  <CAS>
51-60-5

>  <Description>
Neostigmine methylsulfonate is a reversible inhibitor of acetylcholinesterase. It is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.

>  <EBC_ID>
EBC-08150

>  <IUPAC Name>
3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium methyl sulfate

>  <Main Tar all refs>
Phytochem. Lett., 2019, vol. 29, p. 195 - 198 | Bioorg. Med. Chem., 2010, vol. 18, # 13, p. 4687 - 4693

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=9.03 | acetylcholinesterase (Cartwright blood group) pX=7.73

$$$$
Cycloguanil hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 11.1783 1.5392 0 0
M  V30 3 C 10.1884 0.3594 0 0
M  V30 4 C 9.1985 1.5392 0 0
M  V30 5 N 11.5221 -0.4106 0 0
M  V30 6 C 11.5221 -1.9506 0 0
M  V30 7 N 12.8558 -2.7206 0 0
M  V30 8 N 10.1884 -2.7206 0 0
M  V30 9 C 8.8547 -1.9506 0 0
M  V30 10 N 7.521 -2.7206 0 0
M  V30 11 N 8.8547 -0.4106 0 0
M  V30 12 C 7.521 0.3594 0 0
M  V30 13 C 6.1874 -0.4106 0 0
M  V30 14 C 4.8537 0.3594 0 0
M  V30 15 C 4.8537 1.8994 0 0
M  V30 16 Cl 3.52 2.6694 0 0
M  V30 17 C 6.1874 2.6694 0 0
M  V30 18 C 7.521 1.8994 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 9 11
M  V30 10 1 3 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z87001357

>  <MW>
288.176

>  <MW (desalted)>
251.715

>  <ClogP>
1.066

>  <logS>
-4.071

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
80

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  1.5 nM

>  <CAS>
152-53-4

>  <Description>
Cycloguanil hydrochloride is an inhibitor of plasmodium falciparum dihydrofolate reductase.

>  <EBC_ID>
EBC-07548

>  <IUPAC Name>
1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2017, vol. 25, # 24, p. 6467 - 6478

>  <Main tar all>
Dihydrofolate?reductase (PfDHFR) pX=8.82

$$$$
Phenindione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.6497 -4.0133 0 0
M  V30 2 C 2.1256 -2.5487 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 C 2.1256 -0.0569 0 0
M  V30 5 O 1.6497 1.4077 0 0
M  V30 6 C 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 3.5902 -2.0728 0 0
M  V30 12 C -0.3196 -1.3028 0 0
M  V30 13 C -1.0896 -2.6365 0 0
M  V30 14 C -2.6296 -2.6365 0 0
M  V30 15 C -3.3996 -1.3028 0 0
M  V30 16 C -2.6296 0.0309 0 0
M  V30 17 C -1.0896 0.0309 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 2 11
M  V30 12 2 6 11
M  V30 13 1 3 12
M  V30 14 1 12 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z276115700

>  <MW>
222.068

>  <MW (desalted)>
222.239

>  <ClogP>
2.81

>  <logS>
-3.914

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
34.14

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator | Activator

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.01E-07 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M | EC50 >= 1.69E-07 - 3.53E-05 M

>  <CAS>
83-12-5

>  <Description>
Phenindione is an anticoagulant and vitamin K antagonist. It has been used for the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. It is also used for anticoagulant prophylaxis.

>  <EBC_ID>
EBC-03704

>  <IUPAC Name>
2-phenyl-2,3-dihydro-1H-indene-1,3-dione

>  <Main Tar all refs>
UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NEW MEXICO; UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico) - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1 | UNIVERSITY OF NORTH CAROLINA SYSTEM; STC.UNM (in: University of New Mexico); UNIVERSITY OF NEW MEXICO - WO2019/173683, 2019, A1

>  <Main tar all>
Ras-related C3 botulinum toxin substrate 1 (Q61L) pX=7.0 | CDC42 (Q61L) pX=6.77 | Cdc42 pX=6.77 | Cell division control protein 42 homolog pX=6.77 | GTPase HRas pX=6.77 | GTPase HRas (G12V) pX=6.77 | GTPase KRas (G12D) pX=6.77 | GTPase KRas (Q61R) pX=6.77 | KRAS (G12A) pX=6.77 | KRAS (G12C) pX=6.77 | KRAS (G12V) pX=6.77 | KRAS (G13D) pX=6.77 | KRAS (Q61H) pX=6.77 | KRAS (Q61L) pX=6.77 | Ras-related C3 botulinum toxin substrate 1 pX=6.77 | Ras-related protein Rab-5A pX=6.77 | Ras-related protein rab7 pX=6.77

$$$$
Palmitic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.8363 10.1058 0 0
M  V30 2 C 16.17 9.3358 0 0
M  V30 3 C 17.5037 10.1058 0 0
M  V30 4 C 18.8374 9.3358 0 0
M  V30 5 C 20.171 10.1058 0 0
M  V30 6 C 21.5047 9.3358 0 0
M  V30 7 C 22.8384 10.1058 0 0
M  V30 8 C 24.1721 9.3358 0 0
M  V30 9 C 25.5058 10.1058 0 0
M  V30 10 C 26.8394 9.3358 0 0
M  V30 11 C 28.1731 10.1058 0 0
M  V30 12 C 29.5068 9.3358 0 0
M  V30 13 C 30.8405 10.1058 0 0
M  V30 14 C 32.1741 9.3358 0 0
M  V30 15 C 33.5078 10.1058 0 0
M  V30 16 C 34.8415 9.3358 0 0
M  V30 17 O 36.1752 10.1058 0 0
M  V30 18 O 34.8415 7.7958 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474418

>  <MW>
256.24

>  <MW (desalted)>
256.424

>  <ClogP>
7.212

>  <logS>
-6.65

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.54 nM | Ki (inhibition constant) = 0.024 ?M

>  <CAS>
57-10-3

>  <Description>
Palmitic acid is the first fatty acid produced during lipogenesis and from which longer fatty acids can be produced. Palmitate negatively feeds back on acetyl-CoA carboxylase which is responsible for converting acetyl-ACP to malonyl-ACP on the growing acyl chain, thus preventing further palmitate generation. It is used as a food additive and emollient or surfactant in cosmetics.

>  <EBC_ID>
EBC-26344

>  <IUPAC Name>
hexadecanoic acid

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2012, vol. 109, # 2, p. 370 - 377 | Chem. Biol., 2007, vol. 14, # 4, p. 453 - 465

>  <Main tar all>
Secreted Wg-Interacting Molecule pX=8.81 | fatty acid binding protein 2 pX=7.62

$$$$
Dyphylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 N 2.1256 4.0887 0 0
M  V30 11 C 1.6497 5.5533 0 0
M  V30 12 C 0.1434 5.8735 0 0
M  V30 13 O -0.8871 4.7291 0 0
M  V30 14 C -0.3325 7.3382 0 0
M  V30 15 O -1.8389 7.6583 0 0
M  V30 16 C 3.5902 3.6128 0 0
M  V30 17 C 4.9239 4.3828 0 0
M  V30 18 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 10 16
M  V30 16 2 7 16
M  V30 17 1 16 17
M  V30 18 1 2 17
M  V30 19 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57664072

>  <MW>
254.102

>  <MW (desalted)>
254.243

>  <ClogP>
-1.286

>  <logS>
-0.225

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
98.9

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 <= 1 ?M

>  <CAS>
479-18-5

>  <Description>
Dyphylline, a xanthine derivative, is a bronchodilator used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. It is a competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of bronchial smooth muscle as well as antagonism of adenosine receptors.

>  <EBC_ID>
EBC-26332

>  <IUPAC Name>
7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
PFIZER INC - WO2003/97050, 2003, A2

>  <Main tar all>
phosphodiesterase 4 pX=6.0

$$$$
Chlormidazole hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.5761 1.4893 0 0
M  V30 3 C 9.1161 1.4893 0 0
M  V30 4 N 10.0213 2.7352 0 0
M  V30 5 C 11.4859 2.2593 0 0
M  V30 6 C 12.8196 3.0293 0 0
M  V30 7 C 14.1533 2.2593 0 0
M  V30 8 C 14.1533 0.7193 0 0
M  V30 9 C 12.8196 -0.0507 0 0
M  V30 10 C 11.4859 0.7193 0 0
M  V30 11 N 10.0213 0.2434 0 0
M  V30 12 C 9.5454 -1.2212 0 0
M  V30 13 C 8.039 -1.5414 0 0
M  V30 14 C 7.5632 -3.006 0 0
M  V30 15 C 6.0568 -3.3262 0 0
M  V30 16 C 5.0263 -2.1818 0 0
M  V30 17 Cl 3.52 -2.502 0 0
M  V30 18 C 5.5022 -0.7172 0 0
M  V30 19 C 7.0086 -0.397 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 10 11
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 18 19
M  V30 20 2 13 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z111872342

>  <MW>
293.191

>  <MW (desalted)>
256.73

>  <ClogP>
4.081

>  <logS>
-4.17

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.82

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 200 nM

>  <CAS>
74298-63-8

>  <Description>
An antifungal agent with inhibitory activity against many fungi and some gram-positive cocci.

>  <EBC_ID>
EBC-50125

>  <IUPAC Name>
1-[(4-chlorophenyl)methyl]-2-methyl-1H-1,3-benzodiazole hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2014, vol. 24, # 3, p. 911 - 916

>  <Main tar all>
GAL3 receptor pX=6.7

$$$$
Anisindione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.7096 -2.6365 0 0
M  V30 2 O -4.9396 -1.3028 0 0
M  V30 3 C -3.3996 -1.3028 0 0
M  V30 4 C -2.6296 0.0309 0 0
M  V30 5 C -1.0896 0.0309 0 0
M  V30 6 C -0.3196 -1.3028 0 0
M  V30 7 C -1.0896 -2.6365 0 0
M  V30 8 C -2.6296 -2.6365 0 0
M  V30 9 C 1.2204 -1.3028 0 0
M  V30 10 C 2.1256 -0.0569 0 0
M  V30 11 O 1.6497 1.4077 0 0
M  V30 12 C 3.5902 -0.5328 0 0
M  V30 13 C 4.9239 0.2372 0 0
M  V30 14 C 6.2576 -0.5328 0 0
M  V30 15 C 6.2576 -2.0728 0 0
M  V30 16 C 4.9239 -2.8428 0 0
M  V30 17 C 3.5902 -2.0728 0 0
M  V30 18 C 2.1256 -2.5487 0 0
M  V30 19 O 1.6497 -4.0133 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 20 1 9 18
M  V30 21 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56175413

>  <MW>
252.079

>  <MW (desalted)>
252.265

>  <ClogP>
2.729

>  <logS>
-4

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
43.37

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 9.1 ?M | IC50 = 9.1 ?M | binding rate Active   | binding rate Active

>  <CAS>
117-37-3

>  <Description>
Anisindione is a synthetic anticoagulant and an indanedione derivative.

>  <EBC_ID>
EBC-26326

>  <IUPAC Name>
2-(4-methoxyphenyl)-2,3-dihydro-1H-indene-1,3-dione

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 1992, vol. 2, # 10, p. 1309 - 1314 | Bioorg. Med. Chem. Lett., 1992, vol. 2, # 10, p. 1309 - 1314 | VANDERBILT UNIVERSITY - US2021/11008, 2021, A1 | VANDERBILT UNIVERSITY - US2021/11008, 2021, A1

>  <Main tar all>
5-LOX pX=5.04 | Polyunsaturated fatty acid 5-lipoxygenase pX=5.04 | Amyloid-beta precursor protein pX=4.52 | amyloid-beta a4 protein pX=4.52

$$$$
Molindon
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.1434 -4.3335 0 0
M  V30 2 C 1.6497 -4.0133 0 0
M  V30 3 C 2.1256 -2.5487 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 C -0.3196 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 3.5902 -0.5328 0 0
M  V30 8 C 4.9239 0.2372 0 0
M  V30 9 C 6.2576 -0.5328 0 0
M  V30 10 C 6.2576 -2.0728 0 0
M  V30 11 C 7.5913 -2.8428 0 0
M  V30 12 N 7.5913 -4.3828 0 0
M  V30 13 C 8.925 -5.1528 0 0
M  V30 14 C 8.925 -6.6928 0 0
M  V30 15 O 7.5913 -7.4628 0 0
M  V30 16 C 6.2576 -6.6928 0 0
M  V30 17 C 6.2576 -5.1528 0 0
M  V30 18 C 4.9239 -2.8428 0 0
M  V30 19 O 4.9239 -4.3828 0 0
M  V30 20 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 1 10 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 3 20
M  V30 22 2 7 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z802671522

>  <MW>
276.184

>  <MW (desalted)>
276.374

>  <ClogP>
2.572

>  <logS>
-2.24

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
45.33

>  <RotBonds>
3

>  <Action on targets>
Inverse agonist | Inverse agonist | Antagonist | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50  3.8 nM | IC50  3.8 nM | Ki (inhibition constant)  4.4 nM | Ki (inhibition constant)  4.4 nM | Ki (inhibition constant)  5.6 nM | Ki (inhibition constant)  14 nM | Ki (inhibition constant)  24 nM | pKi  7.48  | pKi  7.48  | pKi  7.48  | Ki (inhibition constant)  51 nM | Ki (inhibition constant)  51 nM

>  <CAS>
7416-34-4

>  <Description>
Molindone acts by antagonizing dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Molindone is an indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder.

>  <EBC_ID>
EBC-08260

>  <IUPAC Name>
3-ethyl-2-methyl-5-[(morpholin-4-yl)methyl]-4,5,6,7-tetrahydro-1H-indol-4-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | Mol. Pharmacol., 1976, vol. 12, # 5, p. 800 - 812 | J. Neurochem., 1981, vol. 36, # 1, p. 201 - 219 | AFECTA PHARMACEUTICALS - US6897212, 2005, B2 | BIOORG. MED. CHEM. LETT., 1997, vol. 7, # 7, p. 913 - 918 | BIOORG. MED. CHEM. LETT., 1997, vol. 7, # 7, p. 913 - 918 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287

>  <Main tar all>
D2 receptor (isoform 2) pX=8.42 | D2S receptor pX=8.42 | D2 receptor pX=8.36 | D2 receptor pX=8.36 | D4.2 receptor pX=8.25 | Dopamine receptor pX=7.85 | Dopamine receptor pX=7.62 | D2 receptor pX=7.48 | D2L receptor pX=7.48 | D2L receptor pX=7.48 | D3 receptor pX=7.29 | D3 receptor pX=7.29

$$$$
Cetrimonium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0 CHG=-1
M  V30 2 C 4.4 0.2695 0 0
M  V30 3 C 5.7337 -0.5005 0 0
M  V30 4 C 7.0674 0.2695 0 0
M  V30 5 C 8.401 -0.5005 0 0
M  V30 6 C 9.7347 0.2695 0 0
M  V30 7 C 11.0684 -0.5005 0 0
M  V30 8 C 12.4021 0.2695 0 0
M  V30 9 C 13.7358 -0.5005 0 0
M  V30 10 C 15.0694 0.2695 0 0
M  V30 11 C 16.4031 -0.5005 0 0
M  V30 12 C 17.7368 0.2695 0 0
M  V30 13 C 19.0705 -0.5005 0 0
M  V30 14 C 20.4041 0.2695 0 0
M  V30 15 C 21.7378 -0.5005 0 0
M  V30 16 C 23.0715 0.2695 0 0
M  V30 17 C 24.4052 -0.5005 0 0
M  V30 18 N 25.7389 0.2695 0 0 CHG=1
M  V30 19 C 27.0725 1.0395 0 0
M  V30 20 C 26.5089 -1.0642 0 0
M  V30 21 C 24.9689 1.6032 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 18 20
M  V30 19 1 18 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417556873

>  <MW>
363.25

>  <MW (desalted)>
284.543

>  <ClogP>
2.679

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
15

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
IC50  14.5 nM

>  <CAS>
57-09-0

>  <Description>
Cetrimonium is a quaternary ammonium salt that can be used as a topical antiseptic.

>  <EBC_ID>
EBC-28044

>  <IUPAC Name>
hexadecyltrimethylazanium bromide

>  <Main Tar all refs>
Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258

>  <Main tar all>
Kv11.1 pX=7.84

$$$$
Warfarin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 3.85 0 0
M  V30 2 C -1.3337 2.31 0 0
M  V30 3 O -2.6674 1.54 0 0
M  V30 4 C 0 1.54 0 0
M  V30 5 C 0 -0 0 0
M  V30 6 C -1.3337 -0.77 0 0
M  V30 7 C -1.3337 -2.31 0 0
M  V30 8 C -2.6674 -3.08 0 0
M  V30 9 C -4.001 -2.31 0 0
M  V30 10 C -4.001 -0.77 0 0
M  V30 11 C -2.6674 -0 0 0
M  V30 12 C 1.3337 -0.77 0 0
M  V30 13 C 2.6674 0 0 0
M  V30 14 O 2.6674 1.54 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 21 O 2.6674 -3.08 0 0
M  V30 22 C 1.3337 -2.31 0 0
M  V30 23 O 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 5 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 12 22
M  V30 25 2 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z732250592

>  <MW>
308.105

>  <MW (desalted)>
308.328

>  <ClogP>
2.901

>  <logS>
-3.68

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.6

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  5.1 nM | IC50  0.00832 ?M | IC50  8.8 nM | IC50  24.7 nM | IC50  24.7 nM | IC50  125 nM

>  <CAS>
81-81-2

>  <Description>
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is a vitamin K antagonist which acts to inhibit the production of vitamin K by vitamin K epoxide reductase.

>  <EBC_ID>
EBC-02047

>  <IUPAC Name>
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one

>  <Main Tar all refs>
Blood, 2018, vol. 132, # 18, p. 1974 - 1984 | J. Nat. Prod., 2011, vol. 74, # 6, p. 1353 - 1357 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 15, p. 1954 - 1956 | Blood, 2013, vol. 122, # 15, p. 2743 - 2750 | Blood, 2013, vol. 122, # 15, p. 2743 - 2750 | Blood, 2014, vol. 123, # 4, p. 582 - 589

>  <Main tar all>
Vitamin K epoxide reductase homolog pX=8.29 | Pepsin A pX=8.08 | Thiol-disulfide oxidoreductase LTO1 pX=8.06 | coagulation factor IX pX=7.61 | vitamin K epoxide reductase complex subunit 1 pX=7.61 | Proline rich Gla (G-carboxyglutamic acid) 2 pX=6.9

$$$$
Fenofibrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 4.62 0 0
M  V30 2 C -5.3347 3.08 0 0
M  V30 3 C -6.6684 2.31 0 0
M  V30 4 O -4.001 2.31 0 0
M  V30 5 C -4.001 0.77 0 0
M  V30 6 O -5.3347 -0 0 0
M  V30 7 C -2.6674 -0 0 0
M  V30 8 C -3.4374 -1.3337 0 0
M  V30 9 C -1.8974 1.3337 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C 0 -4.62 0 0
M  V30 14 C -1.3337 -5.39 0 0
M  V30 15 C -2.6674 -4.62 0 0
M  V30 16 C -2.6674 -3.08 0 0
M  V30 17 C -1.3337 -6.93 0 0
M  V30 18 O -2.6674 -7.7 0 0
M  V30 19 C 0 -7.7 0 0
M  V30 20 C 1.3337 -6.93 0 0
M  V30 21 C 2.6674 -7.7 0 0
M  V30 22 C 2.6674 -9.24 0 0
M  V30 23 Cl 4.001 -10.01 0 0
M  V30 24 C 1.3337 -10.01 0 0
M  V30 25 C 0 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 14 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 1 24 25
M  V30 26 2 19 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485369

>  <MW>
360.113

>  <MW (desalted)>
360.831

>  <ClogP>
5.233

>  <logS>
-5.878

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
52.6

>  <RotBonds>
7

>  <Action on targets>
- | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKb  8.95  | pKb  8.95  | Ki (inhibition constant) = 0.024 ?M | Ki (inhibition constant) = 0.024 ?M

>  <CAS>
49562-28-9

>  <Description>
Fenofibrate is a fibrate that activates peroxisome proliferator activated receptor alpha (PPAR?) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.

>  <EBC_ID>
EBC-06049

>  <IUPAC Name>
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate

>  <Main Tar all refs>
Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | Biochem. Pharmacol., 2005, vol. 70, # 11, p. 1653 - 1663 | J. Med. Chem., 2008, vol. 51, # 13, p. 3755 - 3764 | J. Med. Chem., 2009, vol. 52, # 17, p. 5344 - 5355

>  <Main tar all>
Aldo-keto reductase family 1 member B1 pX=8.95 | Aldose reductase pX=8.95 | Aspartate aminotransferase, mitochondrial pX=7.62 | Fatty acid-binding protein pX=7.62

$$$$
Dicoumarol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3347 -9.24 0 0
M  V30 2 C 5.3347 -7.7 0 0
M  V30 3 C 4.001 -6.93 0 0
M  V30 4 C 2.6674 -7.7 0 0
M  V30 5 C 1.3337 -6.93 0 0
M  V30 6 C 0 -7.7 0 0
M  V30 7 O 0 -9.24 0 0
M  V30 8 C -1.3337 -6.93 0 0
M  V30 9 C -2.6674 -7.7 0 0
M  V30 10 C -4.001 -6.93 0 0
M  V30 11 C -4.001 -5.39 0 0
M  V30 12 C -2.6674 -4.62 0 0
M  V30 13 C -1.3337 -5.39 0 0
M  V30 14 O 0 -4.62 0 0
M  V30 15 C 1.3337 -5.39 0 0
M  V30 16 O 2.6674 -4.62 0 0
M  V30 17 C 4.001 -5.39 0 0
M  V30 18 O 3.3747 -3.9831 0 0
M  V30 19 O 5.3347 -4.62 0 0
M  V30 20 C 6.6684 -5.39 0 0
M  V30 21 C 8.0021 -4.62 0 0
M  V30 22 C 9.3358 -5.39 0 0
M  V30 23 C 9.3358 -6.93 0 0
M  V30 24 C 8.0021 -7.7 0 0
M  V30 25 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 5 15
M  V30 17 2 15 16
M  V30 18 1 3 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 2 25
M  V30 28 2 20 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57170530

>  <MW>
336.063

>  <MW (desalted)>
336.295

>  <ClogP>
3.658

>  <logS>
-4.6

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
93.06

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.6 nM | Ki (inhibition constant) = 0.01 ?M | Ki (inhibition constant)  0.039 ?M | Ki (inhibition constant) = 0.06 ?M | IC50  80.16 nM | IC50  80.16 nM

>  <CAS>
66-76-2

>  <Description>
Dicumarol inhibits vitamin K reductase. It is used for decreasing blood clotting.

>  <EBC_ID>
EBC-13674

>  <IUPAC Name>
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]-2H-chromen-2-one

>  <Main Tar all refs>
J. Med. Chem., 2009, vol. 52, # 22, p. 7142 - 7156 | Arch. Biochem. Biophys., 2012, vol. 528, # 1, p. 50 - 56 | J. Med. Chem., 2013, vol. 56, # 17, p. 7084 - 7099 | Arch. Biochem. Biophys., 2012, vol. 528, # 1, p. 50 - 56 | J. Biomol. Struct. Dyn., 2019, vol. 37, # 7, p. 1750 - 1765 | New J. Chem., 2019, vol. 43, # 47, p. 18713 - 18725

>  <Main tar all>
NAD(P)H dehydrogenase [quinone] 1 pX=8.59 | NAD(P)H dehydrogenase pX=8.0 | GPR35 pX=7.41 | Nitroreductase pX=7.22 | acetylcholinesterase (Cartwright blood group) pX=7.1 | acetylcholinesterase (acetyl.beta-methylcholinesterase) pX=7.1

$$$$
Indobufen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.2496 -2.6365 0 0
M  V30 2 C -5.7096 -2.6365 0 0
M  V30 3 C -4.9396 -1.3028 0 0
M  V30 4 C -5.7096 0.0309 0 0
M  V30 5 O -4.9396 1.3645 0 0
M  V30 6 O -7.2496 0.0309 0 0
M  V30 7 C -3.3996 -1.3028 0 0
M  V30 8 C -2.6296 0.0309 0 0
M  V30 9 C -1.0896 0.0309 0 0
M  V30 10 C -0.3196 -1.3028 0 0
M  V30 11 C -1.0896 -2.6365 0 0
M  V30 12 C -2.6296 -2.6365 0 0
M  V30 13 N 1.2204 -1.3028 0 0
M  V30 14 C 2.1256 -0.0569 0 0
M  V30 15 C 3.5902 -0.5328 0 0
M  V30 16 C 4.9239 0.2372 0 0
M  V30 17 C 6.2576 -0.5328 0 0
M  V30 18 C 6.2576 -2.0728 0 0
M  V30 19 C 4.9239 -2.8428 0 0
M  V30 20 C 3.5902 -2.0728 0 0
M  V30 21 C 2.1256 -2.5487 0 0
M  V30 22 O 1.6497 -4.0133 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 1 13 21
M  V30 24 2 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56804486

>  <MW>
295.332

>  <MW (desalted)>
295.332

>  <ClogP>
3.272

>  <logS>
-4.51

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
57.61

>  <RotBonds>
4

>  <CAS>
63610-08-2

>  <Description>
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase activity inhibitor.

>  <EBC_ID>
EBC-07422

>  <IUPAC Name>
2-[4-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)phenyl]butanoic acid

$$$$
Bupivacaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 N 0 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0
M  V30 7 C -1.3337 -6.93 0 0
M  V30 8 C 0 -7.7 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 C 2.6674 -4.62 0 0
M  V30 12 O 2.6674 -3.08 0 0
M  V30 13 N 4.001 -5.39 0 0
M  V30 14 C 5.3347 -4.62 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 C 4.001 -2.31 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 C 8.0021 -3.08 0 0
M  V30 19 C 8.0021 -4.62 0 0
M  V30 20 C 6.6684 -5.39 0 0
M  V30 21 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 14 20
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57479431

>  <MW>
288.428

>  <MW (desalted)>
288.428

>  <ClogP>
3.691

>  <logS>
-3.711

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  7.14 nM

>  <CAS>
38396-39-3

>  <Description>
Bupivacaine is a sodium channel blocker and local anesthetic. It is used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.

>  <EBC_ID>
EBC-04397

>  <IUPAC Name>
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

>  <Main Tar all refs>
- WO2001/47508, 2001, A1

>  <Main tar all>
Nav1.1 pX=8.15

$$$$
Naltrexone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 O 11.731 4.2564 0 0
M  V30 3 C 11.139 2.8347 0 0
M  V30 4 C 12.1105 1.6105 0 0
M  V30 5 C 11.5294 0.1812 0 0
M  V30 6 C 9.9899 0.0193 0 0
M  V30 7 C 9.4312 -1.378 0 0
M  V30 8 C 7.9032 -1.3967 0 0 CFG=1
M  V30 9 N 6.8883 -2.4943 0 0
M  V30 10 C 7.1447 -4.0128 0 0
M  V30 11 C 5.9578 -4.9941 0 0
M  V30 12 C 5.4206 -6.4373 0 0
M  V30 13 C 4.4393 -5.2505 0 0
M  V30 14 C 5.5423 -1.7764 0 0
M  V30 15 C 5.8093 -0.1198 0 0
M  V30 16 C 7.3869 0.9964 0 0 CFG=1
M  V30 17 C 6.9849 2.5481 0 0 CFG=1
M  V30 18 O 8.2272 3.4865 0 0
M  V30 19 C 9.5556 2.6584 0 0
M  V30 20 C 9.0138 1.2253 0 0
M  V30 21 C 6.8024 0.0694 0 0 CFG=2
M  V30 22 O 6.0135 -1.2532 0 0
M  V30 23 C 4.983 0.3422 0 0
M  V30 24 C 4.4 1.726 0 0
M  V30 25 C 5.4431 2.8471 0 0
M  V30 26 O 4.9661 4.3114 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 8 7
M  V30 7 1 8 9 CFG=1
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 11 13
M  V30 13 1 9 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 17
M  V30 17 1 17 18 CFG=3
M  V30 18 1 18 19
M  V30 19 2 3 19
M  V30 20 1 19 20
M  V30 21 2 6 20
M  V30 22 1 16 20 CFG=1
M  V30 23 1 16 21
M  V30 24 1 21 8
M  V30 25 1 21 22 CFG=1
M  V30 26 1 21 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 17 25
M  V30 30 2 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552161470

>  <MW>
377.862

>  <MW (desalted)>
341.401

>  <ClogP>
0.359

>  <logS>
-2.81

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
70

>  <RotBonds>
2

>  <Action on targets>
Antagonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.042 nM | Ke (antagonist potency)  0.05 nM | Ki (inhibition constant)  1.08 nM

>  <CAS>
16676-29-2

>  <Description>
Naltrexone is an opioid receptor antagonist. It is used in the treatment of alcohol dependence and in the prevention of relapse to opioid dependence.

>  <EBC_ID>
EBC-09166

>  <IUPAC Name>
(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 18, p. 6671 - 6681 | J. Med. Chem., 2008, vol. 51, # 6, p. 1913 - 1924 | BR. J. PHARMACOL., 1980, vol. 70, # 3, p. 481 - 490

>  <Main tar all>
? receptor pX=10.4 | ? receptor pX=10.3 | ? receptor pX=8.97

$$$$
Itraconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 49 55 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 23.1524 -3.6549 0 0
M  V30 2 C 23.1524 -5.1949 0 0
M  V30 3 C 21.8187 -5.9649 0 0
M  V30 4 C 20.485 -5.1949 0 0
M  V30 5 N 21.8187 -7.5049 0 0
M  V30 6 N 23.0646 -8.4101 0 0
M  V30 7 C 22.5887 -9.8747 0 0
M  V30 8 N 21.0487 -9.8747 0 0
M  V30 9 C 20.1435 -11.1206 0 0
M  V30 10 C 20.7699 -12.5275 0 0
M  V30 11 C 19.8647 -13.7733 0 0
M  V30 12 C 18.3331 -13.6124 0 0
M  V30 13 C 17.7068 -12.2055 0 0
M  V30 14 C 18.6119 -10.9596 0 0
M  V30 15 N 17.4279 -14.8583 0 0
M  V30 16 C 18.0543 -16.2651 0 0
M  V30 17 C 17.1491 -17.511 0 0
M  V30 18 N 15.6176 -17.35 0 0
M  V30 19 C 14.9912 -15.9432 0 0
M  V30 20 C 15.8964 -14.6973 0 0
M  V30 21 C 14.7124 -18.5959 0 0
M  V30 22 C 15.3387 -20.0028 0 0
M  V30 23 C 14.4336 -21.2487 0 0
M  V30 24 C 12.902 -21.0877 0 0
M  V30 25 O 11.9968 -22.3336 0 0
M  V30 26 C 10.4652 -22.1726 0 0
M  V30 27 C 9.5601 -23.4185 0 0 CFG=1
M  V30 28 C 10.0359 -24.8831 0 0
M  V30 29 O 8.7901 -25.7883 0 0
M  V30 30 C 7.5442 -24.8831 0 0 CFG=1
M  V30 31 C 6.7742 -26.2168 0 0
M  V30 32 N 7.5442 -27.5505 0 0
M  V30 33 C 6.9178 -28.9573 0 0
M  V30 34 N 8.0622 -29.9878 0 0
M  V30 35 C 9.3959 -29.2178 0 0
M  V30 36 N 9.0757 -27.7114 0 0
M  V30 37 O 8.0201 -23.4185 0 0
M  V30 38 C 6.1373 -24.2567 0 0
M  V30 39 C 4.8914 -25.1619 0 0
M  V30 40 C 3.4846 -24.5356 0 0
M  V30 41 C 3.3236 -23.004 0 0
M  V30 42 Cl 1.9167 -22.3776 0 0
M  V30 43 C 4.5695 -22.0988 0 0
M  V30 44 C 5.9763 -22.7252 0 0
M  V30 45 Cl 7.2222 -21.82 0 0
M  V30 46 C 12.2756 -19.6808 0 0
M  V30 47 C 13.1808 -18.4349 0 0
M  V30 48 C 20.5728 -8.4101 0 0
M  V30 49 O 19.1082 -7.9342 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 15 20
M  V30 22 1 18 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 27 26 CFG=1
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 30 29
M  V30 32 1 30 31 CFG=1
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 32 36
M  V30 39 1 30 37
M  V30 40 1 27 37
M  V30 41 1 30 38 CFG=3
M  V30 42 1 38 39
M  V30 43 2 39 40
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 2 41 43
M  V30 47 1 43 44
M  V30 48 2 38 44
M  V30 49 1 44 45
M  V30 50 2 24 46
M  V30 51 1 46 47
M  V30 52 2 21 47
M  V30 53 1 8 48
M  V30 54 1 5 48
M  V30 55 2 48 49
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404944

>  <MW>
705.633

>  <MW (desalted)>
705.633

>  <ClogP>
5.99

>  <logS>
-8.49

>  <HBD>
0

>  <HBA>
9

>  <TPSA>
100.79

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
MIC  0.0039 ?g/ml | MIC  0.015 - 0.031 ?g/ml | IC50  23 nM | MIC  0.02 ?g/ml | IC50  0.029 ?M | EC50  0.0292 ?M | IC50  0.04 ?M | Ki (inhibition constant) = 41 nM | MIC  0.03 ?g/ml | Ki (inhibition constant) = 45 nM | MIC80  0.125 ?g/ml | MIC80  0.13 ?g/ml | IC50  0.048 ?M | Ki (inhibition constant) = 76 nM | Ki (inhibition constant) = 82 nM | IC50  0.121 ?M | MIC  0.088 ?g/ml | IC50  0.125 ?M | MIC  0.09 ?g/ml

>  <CAS>
84625-61-6

>  <Description>
Itraconazole is an antifungal agent used for the treatment of various fungal infections in immunocompromised and non-immunocompromised patients, such as pulmonary and extrapulmonary blastomycosis, histoplasmosis, and onychomycosis.

>  <EBC_ID>
EBC-13184

>  <IUPAC Name>
1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one

>  <Main Tar all refs>
Appl. Microbiol. Biotechnol., 2018, vol. 102, # 12, p. 5255 - 5264 | Microb. Pathog., 2023, vol. 175 | J. Steroid Biochem. Mol. Biol., 2020, vol. 199 | PLoS ONE, 2020, vol. 15, # 7 July | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | J. Membr. Biol., 2015, vol. 248, # 6, p. 967 - 977 | Eur. J. Med. Chem., 2019, vol. 163, p. 320 - 332 | Drug Metab. Dispos., 2011, vol. 39, # 4, p. 724 - 728 | Med. Chem. Res., 2020 | Drug Metab. Dispos., 2011, vol. 39, # 4, p. 724 - 728 | J. Med. Chem., 2020, vol. 63, # 10, p. 5341 - 5359 | J. Med. Chem., 2021, vol. 64, # 2, p. 1116 - 1126 | Drug Metab. Dispos., 2016, vol. 44, # 3, p. 453 - 459 | Drug Metab. Dispos., 2011, vol. 39, # 4, p. 724 - 728 | Drug Metab. Dispos., 2011, vol. 39, # 4, p. 724 - 728 | Toxicol. Appl. Pharmacol., 2021, vol. 412 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 2 | Bioorg. Med. Chem. Lett., 2022, vol. 76 | PLoS ONE, 2020, vol. 15, # 7 July

>  <Main tar all>
CYP51A1 pX=8.26 | Dihydropteroate synthase (activity) pX=7.67 | CYP11B2 pX=7.64 | Protein ARV1 pX=7.55 | Sterol 14-demethylase (gene CYP51G1) pX=7.54 | ATP-dependent translocase ABCB1 pX=7.53 | Cytochrome P450 3A4 pX=7.4 | CYP3A4*16 pX=7.39 | hydroxymethylglutaryl-CoA reductase pX=7.37 | Cytochrome P450, Family 3, Subfamily A, Polypeptide 4.2 pX=7.35 | histone deacetylase 1 pX=7.35 | Histone?deacetylase pX=7.34 | ABCB1 pX=7.32 | CYP3A4*1 pX=7.12 | CYP3A4*18 pX=7.09 | hydroxysteroid 11-beta dehydrogenase 2 pX=6.92 | Pre-mRNA-processing-splicing factor 8 pX=6.9 | SMO pX=6.9 | arv1 homolog domain pX=6.89

$$$$
Flecainide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 F 12.4021 8.1675 0 0
M  V30 3 C 12.4021 6.6275 0 0
M  V30 4 F 10.8621 6.6275 0 0
M  V30 5 F 13.9421 6.6275 0 0
M  V30 6 C 12.4021 5.0875 0 0
M  V30 7 O 11.0684 4.3175 0 0
M  V30 8 C 11.0684 2.7775 0 0
M  V30 9 C 12.4021 2.0075 0 0
M  V30 10 C 12.4021 0.4675 0 0
M  V30 11 C 11.0684 -0.3025 0 0
M  V30 12 O 11.0684 -1.8425 0 0
M  V30 13 C 9.7347 -2.6125 0 0
M  V30 14 C 9.7347 -4.1525 0 0
M  V30 15 F 8.1947 -4.1525 0 0
M  V30 16 F 11.2747 -4.1525 0 0
M  V30 17 F 9.7347 -5.6925 0 0
M  V30 18 C 9.7347 0.4675 0 0
M  V30 19 C 9.7347 2.0075 0 0
M  V30 20 C 8.401 -0.3025 0 0
M  V30 21 O 8.401 -1.8425 0 0
M  V30 22 N 7.0674 0.4675 0 0
M  V30 23 C 5.7337 -0.3025 0 0
M  V30 24 C 5.7337 -1.8425 0 0
M  V30 25 C 7.0674 -2.6125 0 0
M  V30 26 C 7.0674 -4.1525 0 0
M  V30 27 C 5.7337 -4.9225 0 0
M  V30 28 C 4.4 -4.1525 0 0
M  V30 29 N 4.4 -2.6125 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 14 16
M  V30 15 1 14 17
M  V30 16 2 11 18
M  V30 17 1 18 19
M  V30 18 2 8 19
M  V30 19 1 18 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 24 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255523427

>  <MW>
450.804

>  <MW (desalted)>
414.343

>  <ClogP>
3.66

>  <logS>
-5.58

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
59.59

>  <RotBonds>
9

>  <CAS>
57415-44-8

>  <Description>
Flecainide is a class Ic antiarrhythmic agent used to manage atrial fibrillation and paroxysmal supraventricular tachycardias. It inhibits the action of sodium and potassium ion channels in the heart, raising the threshold for depolarization and correcting arrhythmias.

>  <EBC_ID>
EBC-12376

>  <IUPAC Name>
N-[(piperidin-2-yl)methyl]-2,5-bis(2,2,2-trifluoroethoxy)benzamide hydrochloride

$$$$
Pentoxifylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 O 4.001 -5.39 0 0
M  V30 4 C 5.3347 -7.7 0 0
M  V30 5 C 6.6684 -6.93 0 0
M  V30 6 C 8.0021 -7.7 0 0
M  V30 7 C 9.3358 -6.93 0 0
M  V30 8 N 10.6694 -7.7 0 0
M  V30 9 C 12.0031 -6.93 0 0
M  V30 10 O 12.0031 -5.39 0 0
M  V30 11 N 13.3368 -7.7 0 0
M  V30 12 C 14.6705 -6.93 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 N 14.4812 -10.2705 0 0
M  V30 15 C 13.8549 -11.6773 0 0
M  V30 16 N 12.3233 -11.5163 0 0
M  V30 17 C 11.2928 -12.6608 0 0
M  V30 18 C 12.0031 -10.01 0 0
M  V30 19 C 10.6694 -9.24 0 0
M  V30 20 O 9.3358 -10.01 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 13 18
M  V30 19 1 18 19
M  V30 20 1 8 19
M  V30 21 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741982628

>  <MW>
278.307

>  <MW (desalted)>
278.307

>  <ClogP>
0.116

>  <logS>
-1.07

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
75.51

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3.42 nM | IC50 = 0.0039 ?M

>  <CAS>
6493-05-6

>  <Description>
Pentoxifylline is a methylxanthine derivative used to treat intermittent claudication caused by chronic occlusive arterial disease of the limbs. It exhibits hemorheological, anti-oxidative, and anti-inflammatory properties. It acts as a non-specific cyclic-3',5'-phosphodiesterase inhibitor.

>  <EBC_ID>
EBC-12154

>  <IUPAC Name>
3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
SICHUAN UNIVERSITY - CN115772130, 2023, A | UNIVERSITY OF BERN; UNIVERSITY OF WASHINGTON - US2005/58998, 2005, A1

>  <Main tar all>
tubulin alpha 1a pX=8.47 | phosphodiesterase 5A pX=8.41

$$$$
Bortezomib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -9.24 0 0
M  V30 2 C 4.001 -10.01 0 0
M  V30 3 C 4.001 -11.55 0 0
M  V30 4 C 5.3347 -9.24 0 0
M  V30 5 C 6.6684 -10.01 0 0 CFG=2
M  V30 6 N 8.0021 -9.24 0 0
M  V30 7 C 9.3358 -10.01 0 0
M  V30 8 O 9.3358 -11.55 0 0
M  V30 9 C 10.6694 -9.24 0 0 CFG=2
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 9.3358 -6.93 0 0
M  V30 12 C 8.0021 -7.7 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 14 C 6.6684 -5.39 0 0
M  V30 15 C 8.0021 -4.62 0 0
M  V30 16 C 9.3358 -5.39 0 0
M  V30 17 N 12.0031 -10.01 0 0
M  V30 18 C 13.3368 -9.24 0 0
M  V30 19 O 13.3368 -7.7 0 0
M  V30 20 C 14.6705 -10.01 0 0
M  V30 21 C 16.0041 -9.24 0 0
M  V30 22 N 17.3378 -10.01 0 0
M  V30 23 C 17.3378 -11.55 0 0
M  V30 24 C 16.0041 -12.32 0 0
M  V30 25 N 14.6705 -11.55 0 0
M  V30 26 B 6.6684 -11.55 0 0
M  V30 27 O 8.0021 -12.32 0 0
M  V30 28 O 5.3347 -12.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 9 17 CFG=3
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 20 25
M  V30 27 1 5 26 CFG=3
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2213886907

>  <MW>
384.237

>  <MW (desalted)>
384.237

>  <ClogP>
0.777

>  <logS>
-2.673

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
124.44

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50 = 0.161 nM | IC50 = 0.161 nM | IC50  0.161 nM | IC50  0.0006 ?M | Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant) = 0.6 nM | percentage of late apoptotic cells increase Active   | IC50  0.0006 ?M | IC50  0.0009 ?M | EC50  0.001 ?M | IC50  1.07 - 2.1 nM | IC50  0.00106296 ?M | IC50  0.00106296 ?M | IC50  1.07 - 2.1 nM | IC50  1.3 nM | IC50  1.43 nM | IC50  1.5 nM | IC50  1.5 nM | IC50  1.5 nM | IC50  1.5 nM | IC50  0.0016 ?M | LD50  0.0017 ?M | IC50  0.002 ?M | EC50  0.002 ?M | IC50  2 nM | IC50  2.4 nM | IC (inhibitory concentration)  2.4 - 7.9 nM | pIC50  8.55 | IC50  3 nM | IC50  3 nM

>  <CAS>
179324-69-7

>  <Description>
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor. It  used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.

>  <EBC_ID>
EBC-11290

>  <IUPAC Name>
[(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid

>  <Main Tar all refs>
THE UNIVERSITY OF TEXAS SYSTEM - US2018/140578, 2018, A1 | PEKING UNIVERSITY - WO2010/145376, 2010, A1 | MedChemComm, 2010, vol. 1, # 3, p. 183 - 198 | Bioorg. Med. Chem., 2009, vol. 17, # 19, p. 6851 - 6861 | CORNELL UNIVERSITY - US2017/121366, 2017, A1 | Curr. Pharm. Des., 2007, vol. 13, # 5, p. 471 - 485 | Annu. Rep. Med. Chem., 2004, vol. 39, p. 337 - 368 | J. Med. Chem., 2020, vol. 63, # 18, p. 10339 - 10351 | CORNELL UNIVERSITY - WO2015/106200, 2015, A2 | THE JOHNS HOPKINS UNIVERSITY - WO2021/113743, 2021, A1 | Nat. Commun., 2019, vol. 10, # 1 | Front. Pharmacol., 2022, vol. 12 | BIOMEA FUSION, INC; BIOMEA FUSION INC - WO2023/22912, 2023, A1 | BIOMEA FUSION, INC; BIOMEA FUSION INC - WO2023/22912, 2023, A1 | Front. Pharmacol., 2022, vol. 12 | J. Med. Chem., 2021, vol. 64, # 14, p. 10230 - 10245 | J. Med. Chem., 2020, vol. 63, # 9, p. 4701 - 4715 | PLoS ONE, 2021, vol. 16, # 9 September | Cells, 2021, vol. 10, # 3, p. 1 - 15 | Cells, 2021, vol. 10, # 3, p. 1 - 15 | Cells, 2021, vol. 10, # 3, p. 1 - 15 | J. Med. Chem., 2019, vol. 62, # 15, p. 7032 - 7041 | CORNELL UNIVERSITY - US2017/121366, 2017, A1 | J. Med. Chem., 2018, vol. 61, # 22, p. 10053 - 10066 | J. Med. Chem., 2023, vol. 66, # 2, p. 1172 - 1185 | Chem. Biol. Drug Des., 2022, vol. 100, # 5, p. 623 - 638 | J. Nat. Prod., 2021, vol. 84, # 8, p. 2321 - 2335 | DUKE UNIVERSITY - US8809282, 2014, B2 | J. Med. Chem., 2022, vol. 65, # 18, p. 11985 - 12001 | Eur. J. Med. Chem., 2019, vol. 164, p. 423 - 439 | MAYO FOUNDATION - WO2021/72212, 2021, A1

>  <Main tar all>
proteasome 20S subunit beta 5 pX=10.0 | Chymotrypsin B pX=9.79 | Proteasome pX=9.79 | proteasome 20S pX=9.79 | 20s immunoproteosome subunit beta 5i pX=9.22 | 26S Proteasome pX=9.22 | Ubiquitin Proteasome pX=9.22 | histone deacetylase 6 pX=9.22 | proteasome 20S subunit beta 5 pX=9.22 | Proteasomal ubiquitin receptor ADRM1 homolog pX=9.05 | Janus kinase pX=9.0 | Glutamate receptor ionotropic, NMDA 1 pX=8.97 | Histone-lysine N-methyltransferase 2A pX=8.97 | Menin pX=8.97 | Tumor necrosis factor pX=8.97 | proteasome 20S subunit beta 8 pX=8.89 | histone deacetylase 1 pX=8.84 | 26S proteasome regulatory subunit RPN13 pX=8.82 | proteasome 20S subunit beta 1 pX=8.82 | proteasome 20S subunit beta 5 pX=8.82 | proteasome 20S subunit beta 9 pX=8.82 | Proteasome subunit beta 5-c pX=8.8 | 20S immunoproteosome pX=8.77 | 20S immunoproteasome subunit beta 5 pX=8.7 | Constitutive 20S proteasome subunit beta 5 pX=8.7 | proteasome 20S subunit beta 1 pX=8.7 | NFkB pX=8.62 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 5 (Beta 5) pX=8.62 | proteasome 20S subunit beta 5 pX=8.55 | Proteasome subunit beta type-1-i pX=8.52 | proteasome 20S subunit beta 9 pX=8.52

$$$$
Flurbiprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 0 0 0 0
M  V30 4 O 0 1.54 0 0
M  V30 5 O -1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 2.6674 -4.62 0 0
M  V30 9 C 1.3337 -5.39 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 F -1.3337 -5.39 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C 1.3337 -6.93 0 0
M  V30 14 C 2.6674 -7.7 0 0
M  V30 15 C 2.6674 -9.24 0 0
M  V30 16 C 1.3337 -10.01 0 0
M  V30 17 C 0 -9.24 0 0
M  V30 18 C 0 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 6 12
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216885233

>  <MW>
244.261

>  <MW (desalted)>
244.261

>  <ClogP>
3.754

>  <logS>
-4.236

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.001 ?M | pEC50  8.9 | IC50 = 3E-09 M | cell viability decrease Active   | cell viability decrease Active

>  <CAS>
5104-49-4

>  <Description>
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. It is used to treat the signs and symptoms of osteoarthritis and rheumatoid arthritis.

>  <EBC_ID>
EBC-26294

>  <IUPAC Name>
2-(3-fluoro-4-phenylphenyl)propanoic acid

>  <Main Tar all refs>
Curr. Top. Med. Chem., 2012, vol. 12, # 11, p. 1282 - 1290 | Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | Biochem. Biophys. Res. Commun., 2007, vol. 361, # 1, p. 37 - 42 | Eur. J. Med. Res., 2022, vol. 27, # 1 | Eur. J. Med. Res., 2022, vol. 27, # 1

>  <Main tar all>
COX-1  pX=9.0 | MC3 receptor pX=8.9 | COX-2  pX=8.52 | Huntingtin-interacting protein 1-related protein pX=8.0 | phosphatase and tensin homolog pX=8.0

$$$$
alpha-Tocopherol succinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.3929 0.8043 0 0
M  V30 2 C 15.7266 1.5743 0 0
M  V30 3 C 15.7266 3.1143 0 0
M  V30 4 C 17.0602 0.8043 0 0
M  V30 5 C 18.3939 1.5743 0 0
M  V30 6 C 19.7276 0.8043 0 0
M  V30 7 C 21.0613 1.5743 0 0 CFG=1
M  V30 8 C 21.0613 3.1143 0 0
M  V30 9 C 22.3949 0.8043 0 0
M  V30 10 C 23.7286 1.5743 0 0
M  V30 11 C 25.0623 0.8043 0 0
M  V30 12 C 26.396 1.5743 0 0 CFG=1
M  V30 13 C 26.396 3.1143 0 0
M  V30 14 C 27.7297 0.8043 0 0
M  V30 15 C 29.0633 1.5743 0 0
M  V30 16 C 30.397 0.8043 0 0
M  V30 17 C 30.397 -0.7357 0 0 CFG=2
M  V30 18 C 28.8804 -0.4683 0 0
M  V30 19 C 31.9136 -0.4683 0 0
M  V30 20 C 32.9035 -1.648 0 0
M  V30 21 C 32.3768 -3.0951 0 0
M  V30 22 C 33.3667 -4.2748 0 0
M  V30 23 C 34.8833 -4.0074 0 0
M  V30 24 C 32.84 -5.7219 0 0
M  V30 25 O 33.8299 -6.9016 0 0
M  V30 26 C 35.3465 -6.6342 0 0
M  V30 27 O 35.8732 -5.1871 0 0
M  V30 28 C 36.3364 -7.8139 0 0
M  V30 29 C 37.853 -7.5465 0 0
M  V30 30 C 38.8429 -8.7262 0 0
M  V30 31 O 40.3595 -8.4588 0 0
M  V30 32 O 38.3162 -10.1733 0 0
M  V30 33 C 31.3234 -5.9893 0 0
M  V30 34 C 30.7967 -7.4365 0 0
M  V30 35 C 30.3335 -4.8096 0 0
M  V30 36 C 28.8169 -5.0771 0 0
M  V30 37 C 30.8602 -3.3625 0 0
M  V30 38 O 29.8703 -2.1828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16 CFG=3
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 2 30 31
M  V30 31 1 30 32
M  V30 32 1 24 33
M  V30 33 1 33 34
M  V30 34 2 33 35
M  V30 35 1 35 36
M  V30 36 1 35 37
M  V30 37 2 21 37
M  V30 38 1 37 38
M  V30 39 1 17 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216889767

>  <MW>
530.779

>  <MW (desalted)>
530.779

>  <ClogP>
11.851

>  <logS>
-10.157

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
72.83

>  <RotBonds>
17

>  <Action on targets>
Stimulator | Inhibitor | Stimulator | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  7 ?M | inhibition percentage Active   | substrate hydrolysis increase Active   | IC50  2.505E-05 M | EC50  38 ?M | IC50  42 ?M

>  <CAS>
4345-03-3

>  <Description>
alpha-Tocopherol succinate is a form of vitamin E used to treat and prevent vitamin deficiencies.

>  <EBC_ID>
EBC-27284

>  <IUPAC Name>
4-oxo-4-{[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl]oxy}butanoic acid

>  <Main Tar all refs>
PURDUE UNIVERSITY SYSTEM - US11092596, 2021, B2 | Int. J. Nanomed., 2017, vol. 12, p. 5701 - 5715 | PURDUE UNIVERSITY SYSTEM - US11092596, 2021, B2 | MedChemComm, 2017, vol. 8, # 6, p. 1220 - 1224 | UNIVERSITY SYSTEM OF MARYLAND - WO2008/76918, 2008, A2 | Bioorg. Med. Chem., 2014, vol. 22, # 2, p. 684 - 691

>  <Main tar all>
proteasome 20S pX=5.15 | Folate receptor pX=4.82 | Immunoproteasome pX=4.6 | Tyrosine-protein phosphatase non-receptor type 1 pX=4.6 | Androgen receptor (T877A) pX=4.42 | Succinate:DCPIP oxidoreductase pX=4.38

$$$$
Haloperidol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -2.0848 -10.2834 0 0
M  V30 2 C -1.5581 -8.8363 0 0
M  V30 3 C -1.5581 -7.2963 0 0
M  V30 4 C -0.2244 -6.5263 0 0
M  V30 5 N 1.1093 -7.2963 0 0
M  V30 6 C 2.443 -6.5263 0 0
M  V30 7 C 3.7766 -7.2963 0 0
M  V30 8 C 5.1103 -6.5263 0 0
M  V30 9 C 6.444 -7.2963 0 0
M  V30 10 O 6.444 -8.8363 0 0
M  V30 11 C 7.7777 -6.5263 0 0
M  V30 12 C 7.7777 -4.9863 0 0
M  V30 13 C 9.1114 -4.2163 0 0
M  V30 14 C 10.445 -4.9863 0 0
M  V30 15 F 11.7787 -4.2163 0 0
M  V30 16 C 10.445 -6.5263 0 0
M  V30 17 C 9.1114 -7.2963 0 0
M  V30 18 C 1.1093 -8.8363 0 0
M  V30 19 C -0.2244 -9.6063 0 0
M  V30 20 C -3.0747 -8.5688 0 0
M  V30 21 C -4.0646 -9.7485 0 0
M  V30 22 C -5.5812 -9.4811 0 0
M  V30 23 C -6.1079 -8.034 0 0
M  V30 24 Cl -7.6245 -7.7666 0 0
M  V30 25 C -5.118 -6.8543 0 0
M  V30 26 C -3.6014 -7.1217 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 5 18
M  V30 19 1 18 19
M  V30 20 1 2 19
M  V30 21 1 2 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 25 26
M  V30 28 2 20 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1590789254

>  <MW>
375.864

>  <MW (desalted)>
375.864

>  <ClogP>
3.849

>  <logS>
-4.396

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
40.54

>  <RotBonds>
6

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor | Antagonist | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKb  10.47  | IC50 = 0.07 nM | IC50 = 0.07 nM | IC50 = 0.06 nM | IC50 = 0.06 nM | IC50  0.0874 nM | pKi = 10  | Ki (inhibition constant)  0.09 nM | pKi = 9.94  | pKi = 9.7  | Ki (inhibition constant) = 0.2 nM | Kb (antagonist dissociation constant)  0.29 nM | Ki (inhibition constant)  0.42 nM | Ki (inhibition constant)  0.44 nM | Ki (inhibition constant) = 0.5 nM | Ki (inhibition constant)  0.56 nM | Ki (inhibition constant)  0.57 nM | Ki (inhibition constant)  0.65 nM | Ki (inhibition constant)  0.68 nM | Ki (inhibition constant)  0.68 nM | Ki (inhibition constant)  0.74 nM | Ki (inhibition constant) ~ 0.8 nM | Ki (inhibition constant) ~ 0.8 nM | pKi  9.06  | Ki (inhibition constant)  1 nM | Ki (inhibition constant)  1 nM | pKi  8 - 9  | pKi  8 - 9  | pKi  8 - 9  | pKi  9  | pKi  8 - 9  | pKi  8 - 9

>  <CAS>
52-86-8

>  <Description>
Haloperidol is a potent dopamine D2 receptor antagonist. Formulations containing haloperidol have been used as an antipsychotic and butyrophenone,  in the treatment of schizophrenia and Tourette syndrome.

>  <EBC_ID>
EBC-03897

>  <IUPAC Name>
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2010, vol. 333, # 1, p. 328 - 340 | Bioorg. Med. Chem. Lett., 2003, vol. 13, # 22, p. 4015 - 4017 | Bioorg. Med. Chem. Lett., 2003, vol. 13, # 22, p. 4015 - 4017 | J. Med. Chem., 2014, vol. 57, # 16, p. 7042 - 7060 | J. Med. Chem., 2014, vol. 57, # 16, p. 7042 - 7060 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | ACADIA PHARMACEUTICALS INC - US2006/194831, 2006, A1 | Eur. J. Pharmacol., 1978, vol. 50, # 3, p. 283 - 284 | ASTRAZENECA PLC - US2009/215841, 2009, A1 | ACADIA PHARMACEUTICALS INC - US2006/194831, 2006, A1 | J. Med. Chem., 2005, vol. 48, # 15, p. 4754 - 4764 | Eur. J. Med. Chem., 2023, vol. 252 | Bioorg. Med. Chem., 2017, vol. 25, # 19, p. 5084 - 5094 | Synapse, 2000, vol. 38, # 4, p. 438 - 449 | J. Med. Chem., 2005, vol. 48, # 15, p. 4754 - 4764 | Eur. J. Pharmacol., 1992, vol. 227, # 4, p. 371 - 378 | Bioorg. Med. Chem. Lett., 2008, vol. 18, # 6, p. 2183 - 2187 | Curr. Top. Med. Chem., 2011, vol. 11, # 9, p. 1128 - 1150 | ACS Chem. Neurosci., 2011, vol. 2, # 6, p. 308 - 316 | ACS Chem. Neurosci., 2011, vol. 2, # 6, p. 308 - 316 | J. Med. Chem., 2002, vol. 45, # 26, p. 5727 - 5735 | PSYCHOGENCIS - WO2004/69339, 2004, A1 | PSYCHOGENCIS - WO2004/69339, 2004, A1 | J. MED. CHEM., 1994, vol. 37, # 4, p. 519 - 525 | J. Med. Chem., 1998, vol. 41, # 12, p. 1997 - 2009 | J. Med. Chem., 1998, vol. 41, # 12, p. 1997 - 2009 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - EP1541197, 2005, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1

>  <Main tar all>
D2L receptor pX=10.5 | D2 receptor pX=10.2 | D2 receptor pX=10.2 | D3 receptor pX=10.2 | D3 receptor pX=10.2 | D2S receptor pX=10.1 | D2 receptor pX=10.0 | Dopamine receptor pX=10.0 | D2 receptor (isoform 2) pX=9.94 | D3 receptor pX=9.7 | sigma non-opioid intracellular receptor 1 pX=9.7 | 5-HT2C receptor pX=9.54 | D2L receptor pX=9.38 | D2- like receptor pX=9.36 | C-8 sterol isomerase pX=9.3 | Sigma receptor pX=9.25 | Sigma 2 receptor pX=9.24 | ?2 pX=9.19 | NTS1 receptor pX=9.17 | NTS1 receptor pX=9.17 | D4.4 receptor pX=9.13 | D4 receptor pX=9.1 | D4 receptor pX=9.1 | D2 receptor (isoform?1) pX=9.06 | ?1-adrenoceptor pX=9.0 | ?1-adrenoceptor pX=9.0 | ?1-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | D1 receptor pX=9.0 | D4 receptor pX=9.0

$$$$
Idrocilamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 -6.93 0 0
M  V30 2 C 2.6674 -7.7 0 0
M  V30 3 C 4.001 -6.93 0 0
M  V30 4 N 5.3347 -7.7 0 0
M  V30 5 C 6.6684 -6.93 0 0
M  V30 6 O 6.6684 -5.39 0 0
M  V30 7 C 8.0021 -7.7 0 0
M  V30 8 C 9.3358 -6.93 0 0
M  V30 9 C 10.6694 -7.7 0 0
M  V30 10 C 12.0031 -6.93 0 0
M  V30 11 C 13.3368 -7.7 0 0
M  V30 12 C 13.3368 -9.24 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891576

>  <MW>
191.095

>  <MW (desalted)>
191.226

>  <ClogP>
1.195

>  <logS>
-1.889

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
4

>  <CAS>
35241-61-3

>  <Description>
A member of cinnamamides and a secondary carboxamide. It is a medication with skeletal muscle relaxant and anti-inflammatory actions used as a topical cream to treat lumbago and other kinds of muscular pain.

>  <EBC_ID>
EBC-50030

>  <IUPAC Name>
(2E)-N-(2-hydroxyethyl)-3-phenylprop-2-enamide

$$$$
Trolox
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 2.6674 0 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 O 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 7.1951 0.6771 0 0
M  V30 9 C 6.6684 -2.31 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 2.6674 -4.62 0 0
M  V30 14 C 1.3337 -2.31 0 0
M  V30 15 O 0 -3.08 0 0
M  V30 16 C 8.185 -1.0374 0 0
M  V30 17 O 9.1749 0.1423 0 0
M  V30 18 O 8.7117 -2.4845 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 2 14
M  V30 16 1 14 15
M  V30 17 1 7 16
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3013814504

>  <MW>
250.121

>  <MW (desalted)>
250.29

>  <ClogP>
3.089

>  <logS>
-2.924

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
66.76

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  20 - 400 nM | Ki (inhibition constant)  109.75 nM | IC50  0.13 ?M | IC50  0.15 ?M

>  <CAS>
53188-07-1

>  <Description>
Trolox is a cell-permeable, water-soluble derivative of vitamin E with potent antioxidant properties. It is effective as adjunctive therapy in the treatment of certain cancers. It shows anti-inflammatory activity against COX-1 (IC50= 0.13?M), COX-2 ( IC50= 0.15?M).

>  <EBC_ID>
EBC-13681

>  <IUPAC Name>
6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2011, vol. 18, # 32, p. 4949 - 4975 | J. Enzyme Inhib. Med. Chem., 2020, vol. 35, # 1, p. 950 - 962 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 9, p. 2558 - 2560 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 9, p. 2558 - 2560

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=7.7 | Acetylcholinesterase 1 pX=6.96 | COX-1  pX=6.89 | COX-2  pX=6.82

$$$$
Distearyldimonium chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 4.4 0 0 0
M  V30 3 C 5.7337 0.77 0 0
M  V30 4 C 7.0674 0 0 0
M  V30 5 C 8.401 0.77 0 0
M  V30 6 C 9.7347 0 0 0
M  V30 7 C 11.0684 0.77 0 0
M  V30 8 C 12.4021 0 0 0
M  V30 9 C 13.7358 0.77 0 0
M  V30 10 C 15.0694 0 0 0
M  V30 11 C 16.4031 0.77 0 0
M  V30 12 C 17.7368 0 0 0
M  V30 13 C 19.0705 0.77 0 0
M  V30 14 C 20.4041 0 0 0
M  V30 15 C 21.7378 0.77 0 0
M  V30 16 C 23.0715 0 0 0
M  V30 17 C 24.4052 0.77 0 0
M  V30 18 C 25.7389 0 0 0
M  V30 19 C 27.0725 0.77 0 0
M  V30 20 N 28.4062 0 0 0 CHG=1
M  V30 21 C 27.6362 -1.3337 0 0
M  V30 22 C 29.1762 1.3337 0 0
M  V30 23 C 29.7399 -0.77 0 0
M  V30 24 C 31.0736 0 0 0
M  V30 25 C 32.4073 -0.77 0 0
M  V30 26 C 33.7409 0 0 0
M  V30 27 C 35.0746 -0.77 0 0
M  V30 28 C 36.4083 0 0 0
M  V30 29 C 37.742 -0.77 0 0
M  V30 30 C 39.0757 0 0 0
M  V30 31 C 40.4093 -0.77 0 0
M  V30 32 C 41.743 0 0 0
M  V30 33 C 43.0767 -0.77 0 0
M  V30 34 C 44.4104 0 0 0
M  V30 35 C 45.7441 -0.77 0 0
M  V30 36 C 47.0777 0 0 0
M  V30 37 C 48.4114 -0.77 0 0
M  V30 38 C 49.7451 0 0 0
M  V30 39 C 51.0788 -0.77 0 0
M  V30 40 C 52.4124 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 1 20 22
M  V30 21 1 20 23
M  V30 22 1 23 24
M  V30 23 1 24 25
M  V30 24 1 25 26
M  V30 25 1 26 27
M  V30 26 1 27 28
M  V30 27 1 28 29
M  V30 28 1 29 30
M  V30 29 1 30 31
M  V30 30 1 31 32
M  V30 31 1 32 33
M  V30 32 1 33 34
M  V30 33 1 34 35
M  V30 34 1 35 36
M  V30 35 1 36 37
M  V30 36 1 37 38
M  V30 37 1 38 39
M  V30 38 1 39 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3234799722

>  <MW>
585.598

>  <MW (desalted)>
551.049

>  <ClogP>
12.73

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
34

>  <CAS>
107-64-2

>  <Description>
Distearyldimonium chloride is a cationic amphipathic lipid. It is used in the synthesis of a lipid bilayer which may be used in photosensitizer studies.

>  <EBC_ID>
EBC-102107

>  <IUPAC Name>
dimethyldioctadecylazanium chloride

$$$$
Carvedilol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.1099 1.3909 0 0
M  V30 2 O 11.1099 2.9309 0 0
M  V30 3 C 9.7762 3.7009 0 0
M  V30 4 C 8.4425 2.9309 0 0
M  V30 5 C 7.1088 3.7009 0 0
M  V30 6 C 7.1088 5.2409 0 0
M  V30 7 C 8.4425 6.0109 0 0
M  V30 8 C 9.7762 5.2409 0 0
M  V30 9 O 11.1099 6.0109 0 0
M  V30 10 C 12.4436 5.2409 0 0
M  V30 11 C 13.7772 6.0109 0 0
M  V30 12 N 15.1109 5.2409 0 0
M  V30 13 C 16.4446 6.0109 0 0
M  V30 14 C 17.7783 5.2409 0 0
M  V30 15 O 17.7783 3.7009 0 0
M  V30 16 C 19.1119 6.0109 0 0
M  V30 17 O 20.4456 5.2409 0 0
M  V30 18 C 21.7793 6.0109 0 0
M  V30 19 C 21.7793 7.5509 0 0
M  V30 20 C 23.113 8.3209 0 0
M  V30 21 C 24.4467 7.5509 0 0
M  V30 22 C 24.4467 6.0109 0 0
M  V30 23 N 25.5911 4.9804 0 0
M  V30 24 C 24.9647 3.5736 0 0
M  V30 25 C 25.5911 2.1667 0 0
M  V30 26 C 24.6859 0.9208 0 0
M  V30 27 C 23.1544 1.0818 0 0
M  V30 28 C 22.528 2.4886 0 0
M  V30 29 C 23.4332 3.7345 0 0
M  V30 30 C 23.113 5.2409 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 24 29
M  V30 31 1 29 30
M  V30 32 2 18 30
M  V30 33 1 22 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515383337

>  <MW>
406.189

>  <MW (desalted)>
406.474

>  <ClogP>
4.041

>  <logS>
-5.705

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
75.74

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  10.88  | pKi  10.88  | pKd  10.36 | pKd  10.36 | pKd  9.97 M | pIC50  9.79 | Ki (inhibition constant) = 0.39 nM | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.4 nM

>  <CAS>
72956-09-3

>  <Description>
Carvedilol is a non selective beta-adrenergic antagonist used to treat mild to severe chronic heart failure, hypertension, and left ventricular dysfunction following myocardial infarction in clinically stable patients.

>  <EBC_ID>
EBC-00687

>  <IUPAC Name>
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol

>  <Main Tar all refs>
Mol. Pharmacol., 2014, vol. 85, # 4, p. 608 - 617 | Mol. Pharmacol., 2014, vol. 85, # 4, p. 608 - 617 | Pharmacol. Res. Perspect., 2022, vol. 10, # 4 | Pharmacol. Res. Perspect., 2022, vol. 10, # 4 | J. Med. Chem., 2019, vol. 62, # 17, p. 7806 - 7839 | Mol. Pharmacol., 2021, vol. 100, # 6, p. 568 - 579 | J. Pharmacol. Exp. Ther., 1999, vol. 289, # 1, p. 48 - 53 | J. Pharmacol. Exp. Ther., 1999, vol. 290, # 2, p. 649 - 655 | J. Pharmacol. Exp. Ther., 1999, vol. 290, # 2, p. 649 - 655

>  <Main tar all>
?2-adrenoceptor pX=10.9 | ?2-adrenoceptor pX=10.9 | ?1-adrenoceptor pX=10.4 | ?1-adrenoceptor pX=10.4 | ?2-adrenoceptor pX=9.97 | ?1-adrenoceptor pX=9.79 | ?-adrenoceptor pX=9.41 | ?3-adrenoceptor pX=9.4 | ?3-adrenoceptor pX=9.4

$$$$
Tafluprost
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.624 -4.7622 0 0
M  V30 2 C 7.164 -4.7622 0 0
M  V30 3 C 7.934 -6.0958 0 0
M  V30 4 O 7.934 -3.4285 0 0
M  V30 5 C 9.474 -3.4285 0 0
M  V30 6 O 10.244 -4.7622 0 0
M  V30 7 C 10.244 -2.0948 0 0
M  V30 8 C 11.784 -2.0948 0 0
M  V30 9 C 12.554 -3.4285 0 0
M  V30 10 C 14.094 -3.4285 0 0
M  V30 11 C 14.864 -4.7622 0 0
M  V30 12 C 14.094 -6.0958 0 0
M  V30 13 C 14.864 -7.4295 0 0 CFG=1
M  V30 14 C 16.3956 -7.5905 0 0 CFG=1
M  V30 15 O 17.426 -6.4461 0 0
M  V30 16 C 16.7157 -9.0968 0 0
M  V30 17 C 15.3821 -9.8668 0 0 CFG=1
M  V30 18 O 15.2211 -11.3984 0 0
M  V30 19 C 14.2376 -8.8364 0 0 CFG=2
M  V30 20 C 12.7313 -9.1566 0 0
M  V30 21 C 11.7008 -8.0121 0 0
M  V30 22 C 10.1945 -8.3323 0 0
M  V30 23 F 9.8743 -6.826 0 0
M  V30 24 F 10.5147 -9.8387 0 0
M  V30 25 C 8.6881 -8.6525 0 0
M  V30 26 O 8.2122 -10.1171 0 0
M  V30 27 C 6.7059 -10.4373 0 0
M  V30 28 C 6.23 -11.9019 0 0
M  V30 29 C 4.7237 -12.2221 0 0
M  V30 30 C 3.6932 -11.0777 0 0
M  V30 31 C 4.1691 -9.613 0 0
M  V30 32 C 5.6754 -9.2929 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 13 12 CFG=1
M  V30 13 1 13 14
M  V30 14 1 14 15 CFG=1
M  V30 15 1 14 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=1
M  V30 18 1 19 17
M  V30 19 1 13 19
M  V30 20 1 19 20 CFG=3
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 22 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 27 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568721846

>  <MW>
452.237

>  <MW (desalted)>
452.531

>  <ClogP>
4.26

>  <logS>
-5.154

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
75.99

>  <RotBonds>
13

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.4 nM

>  <CAS>
209860-87-7

>  <Description>
Tafluprost is an ophthalmic prostaglandin analog used to lower intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

>  <EBC_ID>
EBC-27132

>  <IUPAC Name>
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoate

>  <Main Tar all refs>
Annual Reports in Medicinal Chemistry, 2009, vol. 44, # 1, p. 577 - 632

>  <Main tar all>
FP receptor pX=9.4

$$$$
Ivermectin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 123 135 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.5299 1.6608 0 0
M  V30 2 C 11.3145 2.6064 0 0
M  V30 3 C 9.8878 2.0266 0 0 CFG=1
M  V30 4 C 9.6766 0.5012 0 0
M  V30 5 C 8.6723 2.9722 0 0 CFG=1
M  V30 6 O 7.2456 2.3924 0 0
M  V30 7 C 6.0301 3.338 0 0 CFG=2
M  V30 8 C 6.2413 4.8635 0 0
M  V30 9 C 7.668 5.4433 0 0
M  V30 10 C 8.8835 4.4977 0 0 CFG=2
M  V30 11 C 10.3102 5.0775 0 0
M  V30 12 C 4.8147 4.2837 0 0
M  V30 13 C 3.388 3.7038 0 0 CFG=2
M  V30 14 C 3.1768 2.1784 0 0
M  V30 15 C 4.3923 1.2328 0 0 CFG=1
M  V30 16 C 4.1811 -0.2927 0 0
M  V30 17 C 2.7544 -0.8725 0 0
M  V30 18 C 2.5432 -2.398 0 0
M  V30 19 C 3.7587 -3.3436 0 0
M  V30 20 C 1.1165 -2.9778 0 0 CFG=1
M  V30 21 O 0.9053 -4.5032 0 0
M  V30 22 C -0.5213 -5.0831 0 0 CFG=1
M  V30 23 C -0.7325 -6.6085 0 0
M  V30 24 C -2.1592 -7.1883 0 0 CFG=2
M  V30 25 O -2.3704 -8.7138 0 0
M  V30 26 C -3.7971 -9.2936 0 0
M  V30 27 C -3.3747 -6.2427 0 0 CFG=1
M  V30 28 O -4.8014 -6.8225 0 0
M  V30 29 C -6.0168 -5.8769 0 0 CFG=1
M  V30 30 C -7.4435 -6.4567 0 0
M  V30 31 C -8.659 -5.5111 0 0 CFG=2
M  V30 32 O -10.0857 -6.0909 0 0
M  V30 33 C -10.2969 -7.6164 0 0
M  V30 34 C -8.4478 -3.9857 0 0 CFG=1
M  V30 35 O -9.6633 -3.04 0 0
M  V30 36 C -7.0211 -3.4058 0 0 CFG=2
M  V30 37 C -6.8099 -1.8804 0 0
M  V30 38 O -5.8056 -4.3515 0 0
M  V30 39 C -3.1635 -4.7173 0 0 CFG=2
M  V30 40 C -4.379 -3.7716 0 0
M  V30 41 O -1.7368 -4.1374 0 0
M  V30 42 C -0.0989 -2.0322 0 0 CFG=1
M  V30 43 C -1.5256 -2.612 0 0
M  V30 44 C 0.1123 -0.5067 0 0
M  V30 45 C -1.1032 0.4389 0 0
M  V30 46 C -0.892 1.9644 0 0
M  V30 47 C -2.1075 2.91 0 0
M  V30 48 C -3.6435 2.7994 0 0
M  V30 49 O -4.2234 4.2261 0 0
M  V30 50 C -3.0457 5.2184 0 0 CFG=2
M  V30 51 C -2.9951 6.7576 0 0 CFG=2
M  V30 52 O -4.3028 7.571 0 0
M  V30 53 C -1.6369 7.4833 0 0
M  V30 54 C -0.3292 6.6699 0 0
M  V30 55 C -0.4696 5.0153 0 0 CFG=1
M  V30 56 C 0.7458 4.0696 0 0
M  V30 57 O 0.5346 2.5442 0 0
M  V30 58 O 2.1725 4.6495 0 0
M  V30 59 C -1.8963 4.4354 0 0 CFG=2
M  V30 60 O -1.7334 5.9668 0 0
M  V30 61 C -1.5863 9.0225 0 0
M  V30 62 O 5.819 1.8126 0 0
M  V30 63 C 16.9299 -7.5892 0 0
M  V30 64 O 17.1411 -6.0637 0 0
M  V30 65 C 18.5678 -5.4839 0 0 CFG=1
M  V30 66 C 19.7833 -6.4295 0 0
M  V30 67 C 21.21 -5.8497 0 0 CFG=2
M  V30 68 O 22.4254 -6.7953 0 0
M  V30 69 C 23.8521 -6.2155 0 0 CFG=1
M  V30 70 C 24.0633 -4.69 0 0 CFG=2
M  V30 71 C 22.8478 -3.7444 0 0
M  V30 72 O 25.49 -4.1102 0 0
M  V30 73 C 26.7055 -5.0558 0 0 CFG=2
M  V30 74 C 26.4943 -6.5813 0 0
M  V30 75 C 25.0676 -7.1611 0 0 CFG=2
M  V30 76 O 24.8564 -8.6866 0 0
M  V30 77 C 23.4297 -9.2664 0 0
M  V30 78 O 28.1322 -4.476 0 0
M  V30 79 C 28.3433 -2.9506 0 0 CFG=1
M  V30 80 C 27.1279 -2.0049 0 0 CFG=1
M  V30 81 C 25.7012 -2.5848 0 0
M  V30 82 C 27.3391 -0.4795 0 0
M  V30 83 C 26.1236 0.4661 0 0
M  V30 84 C 26.3348 1.9916 0 0
M  V30 85 C 25.1193 2.9372 0 0
M  V30 86 C 23.5833 2.8266 0 0
M  V30 87 O 23.0034 4.2533 0 0
M  V30 88 C 24.1811 5.2456 0 0 CFG=2
M  V30 89 C 24.2317 6.7848 0 0 CFG=2
M  V30 90 O 22.924 7.5982 0 0
M  V30 91 C 25.59 7.5106 0 0
M  V30 92 C 26.8976 6.6972 0 0
M  V30 93 C 26.7572 5.0425 0 0 CFG=1
M  V30 94 C 27.9726 4.0969 0 0
M  V30 95 O 27.7614 2.5714 0 0
M  V30 96 O 29.3993 4.6767 0 0
M  V30 97 C 30.6148 3.7311 0 0 CFG=1
M  V30 98 C 30.4036 2.2056 0 0
M  V30 99 C 31.6191 1.26 0 0 CFG=1
M  V30 100 C 31.4079 -0.2655 0 0
M  V30 101 C 29.9812 -0.8453 0 0
M  V30 102 C 29.77 -2.3707 0 0
M  V30 103 C 30.9855 -3.3164 0 0
M  V30 104 O 33.0458 1.8398 0 0
M  V30 105 C 33.257 3.3653 0 0 CFG=2
M  V30 106 C 33.4681 4.8907 0 0
M  V30 107 C 34.8948 5.4705 0 0
M  V30 108 C 36.1103 4.5249 0 0 CFG=2
M  V30 109 C 37.537 5.1047 0 0
M  V30 110 C 35.8991 2.9995 0 0 CFG=2
M  V30 111 O 34.4724 2.4196 0 0
M  V30 112 C 37.1146 2.0538 0 0
M  V30 113 C 36.9034 0.5284 0 0
M  V30 114 C 38.5413 2.6337 0 0
M  V30 115 C 32.0415 4.3109 0 0
M  V30 116 C 25.3305 4.4627 0 0 CFG=2
M  V30 117 O 25.4934 5.994 0 0
M  V30 118 C 25.6405 9.0497 0 0
M  V30 119 O 21.4212 -4.3242 0 0
M  V30 120 C 20.2057 -3.3786 0 0 CFG=1
M  V30 121 C 20.4169 -1.8532 0 0
M  V30 122 C 18.779 -3.9584 0 0 CFG=2
M  V30 123 O 17.5635 -3.0128 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 5 3 CFG=1
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 5 10
M  V30 11 1 10 11 CFG=3
M  V30 12 1 7 12
M  V30 13 1 13 12
M  V30 14 1 13 14 CFG=3
M  V30 15 1 15 14 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 20 18
M  V30 21 1 20 21 CFG=1
M  V30 22 1 22 21 CFG=1
M  V30 23 1 22 23
M  V30 24 1 24 23
M  V30 25 1 24 25 CFG=3
M  V30 26 1 25 26
M  V30 27 1 27 24
M  V30 28 1 27 28 CFG=1
M  V30 29 1 29 28 CFG=1
M  V30 30 1 29 30
M  V30 31 1 31 30
M  V30 32 1 31 32 CFG=3
M  V30 33 1 32 33
M  V30 34 1 34 31
M  V30 35 1 34 35 CFG=1
M  V30 36 1 34 36
M  V30 37 1 36 37 CFG=3
M  V30 38 1 36 38
M  V30 39 1 29 38
M  V30 40 1 27 39
M  V30 41 1 39 40 CFG=3
M  V30 42 1 39 41
M  V30 43 1 22 41
M  V30 44 1 20 42
M  V30 45 1 42 43 CFG=1
M  V30 46 1 42 44
M  V30 47 2 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 1 48 49
M  V30 52 1 50 49 CFG=3
M  V30 53 1 50 51
M  V30 54 1 51 52 CFG=3
M  V30 55 1 51 53
M  V30 56 2 53 54
M  V30 57 1 55 54 CFG=1
M  V30 58 1 55 56
M  V30 59 2 56 57
M  V30 60 1 56 58
M  V30 61 1 13 58
M  V30 62 1 59 55
M  V30 63 1 50 59
M  V30 64 1 59 47
M  V30 65 1 59 60 CFG=1
M  V30 66 1 53 61
M  V30 67 1 15 62
M  V30 68 1 7 62
M  V30 69 1 63 64
M  V30 70 1 65 64 CFG=3
M  V30 71 1 65 66
M  V30 72 1 67 66
M  V30 73 1 67 68 CFG=1
M  V30 74 1 69 68 CFG=1
M  V30 75 1 69 70
M  V30 76 1 70 71 CFG=3
M  V30 77 1 70 72
M  V30 78 1 73 72
M  V30 79 1 73 74
M  V30 80 1 75 74
M  V30 81 1 69 75
M  V30 82 1 75 76 CFG=3
M  V30 83 1 76 77
M  V30 84 1 73 78 CFG=1
M  V30 85 1 79 78 CFG=1
M  V30 86 1 79 80
M  V30 87 1 80 81 CFG=1
M  V30 88 1 80 82
M  V30 89 2 82 83
M  V30 90 1 83 84 CFG=2
M  V30 91 2 84 85
M  V30 92 1 85 86 CFG=2
M  V30 93 1 86 87
M  V30 94 1 88 87 CFG=3
M  V30 95 1 88 89
M  V30 96 1 89 90 CFG=3
M  V30 97 1 89 91
M  V30 98 2 91 92
M  V30 99 1 93 92 CFG=1
M  V30 100 1 93 94
M  V30 101 2 94 95
M  V30 102 1 94 96
M  V30 103 1 97 96
M  V30 104 1 97 98 CFG=3
M  V30 105 1 99 98 CFG=3
M  V30 106 1 99 100
M  V30 107 1 101 100 CFG=2
M  V30 108 2 101 102
M  V30 109 1 79 102
M  V30 110 1 102 103
M  V30 111 1 99 104
M  V30 112 1 105 104 CFG=3
M  V30 113 1 105 106
M  V30 114 1 106 107
M  V30 115 1 108 107
M  V30 116 1 108 109 CFG=3
M  V30 117 1 108 110
M  V30 118 1 110 111
M  V30 119 1 105 111
M  V30 120 1 110 112 CFG=1
M  V30 121 1 112 113
M  V30 122 1 112 114
M  V30 123 1 105 115
M  V30 124 1 97 115
M  V30 125 1 116 93
M  V30 126 1 88 116
M  V30 127 1 116 85
M  V30 128 1 116 117 CFG=1
M  V30 129 1 91 118
M  V30 130 1 67 119
M  V30 131 1 120 119
M  V30 132 1 120 121 CFG=3
M  V30 133 1 122 120
M  V30 134 1 122 65
M  V30 135 1 122 123 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z8781773424

>  <MW>
1736.15894

>  <MW (desalted)>
875.09276

>  <ClogP>
5.388

>  <logS>
1.957

>  <HBD>
3

>  <HBA>
13

>  <TPSA>
170.06

>  <RotBonds>
15

>  <CAS>
70288-86-7

>  <EBC_ID>
EBC-387071

>  <IUPAC Name>
(1'R,2R,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2R)-butan-2-yl]-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one; (1'R,2R,4'S,5S,6R,8'R,12'S,13'S,20'R,21'R,24'S)-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-6-(propan-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one

$$$$
Propylene glycol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.85 -1.3337 0 0
M  V30 2 C 2.31 -1.3337 0 0
M  V30 3 O 1.54 -2.6674 0 0
M  V30 4 C 1.54 0 0 0
M  V30 5 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z106938868

>  <MW>
76.052

>  <MW (desalted)>
76.094

>  <ClogP>
-1.06

>  <logS>
0.7

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
1

>  <Action on targets>
- | - | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 2.8 mM | Km (Michaelis constant) = 0.011 M | IC50  20 mM

>  <CAS>
57-55-6

>  <Description>
Propylene glycol is a viscous organic solvent and diluent used in pharmaceutical preparations.

>  <EBC_ID>
EBC-26033

>  <IUPAC Name>
propane-1,2-diol

>  <Main Tar all refs>
J. BIOL. CHEM., 1984, vol. 259, # 4, p. 2124 - 2129 | Biochim. Biophys. Acta, 1964, vol. 89, p. 217 - 225 | BR. J. CLIN. PHARMACOL., 1995, vol. 39, # 2, p. 151 - 159

>  <Main tar all>
acetoin dehydrogenase pX=2.55 | NADH dehydrogenase pX=1.96 | CYP2E1 pX=1.7

$$$$
p-Phenylenediamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 N 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104472524

>  <MW>
108.069

>  <MW (desalted)>
108.141

>  <ClogP>
-0.312

>  <logS>
-1

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
52.04

>  <RotBonds>
0

>  <CAS>
106-50-3

>  <Description>
p-Phenylenediamine is one of the simplest aromatic diamine primarily used as a component of engineering polymers, composites, dye intermediate and as a hair dye.

>  <EBC_ID>
EBC-26044

>  <IUPAC Name>
benzene-1,4-diamine

$$$$
Flucytosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 N 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 N 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 F -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201621875

>  <MW>
129.034

>  <MW (desalted)>
129.092

>  <ClogP>
-1.635

>  <logS>
-1.234

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
67.48

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC50  0.5 - 1 ?g/ml | IC50  55.3 ?M | IC50  55.3 ?M

>  <CAS>
2022-85-7

>  <Description>
Flucytosine is an antifungal indicated only to treat severe infections throughout the body caused by susceptible strains of Candida or Cryptococcus.

>  <EBC_ID>
EBC-04031

>  <IUPAC Name>
6-amino-5-fluoro-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
CIDARA THERAPEUTICS INC - WO2018/85200, 2018, A1 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Callose synthase pX=5.41 | Organic cation/carnitine transporter 2 pX=4.26 | Organic cation/carnitine transporter 2 pX=4.26

$$$$
Valproic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 C 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0
M  V30 4 C 7.2874 2.6674 0 0
M  V30 5 C 8.621 3.4374 0 0
M  V30 6 C 9.9547 2.6674 0 0
M  V30 7 C 11.2884 3.4374 0 0
M  V30 8 C 7.2874 1.1274 0 0
M  V30 9 O 8.621 0.3574 0 0
M  V30 10 O 5.9537 0.3574 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756391526

>  <MW>
144.115

>  <MW (desalted)>
144.211

>  <ClogP>
2.76

>  <logS>
-2.45

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  214.2 pg/ml

>  <CAS>
99-66-1

>  <Description>
Valproic acid is a fatty acid derivative and anticonvulsant. It is used to control complex partial seizures and both simple and complex absence seizures. It acts as a direct histone deactylase (HDAC) inhibitor.

>  <EBC_ID>
EBC-13795

>  <IUPAC Name>
2-propylpentanoic acid

>  <Main Tar all refs>
IUBMB Life, 2018, vol. 70, # 6, p. 511 - 518

>  <Main tar all>
histone deacetylase 1 pX=8.83

$$$$
Valnoctamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.9763 0.9763 0 0
M  V30 2 C 2.31 0.2063 0 0
M  V30 3 C 2.31 -1.3337 0 0
M  V30 4 C 0.9763 -2.1037 0 0
M  V30 5 C 3.6437 -2.1037 0 0
M  V30 6 C 3.6437 -3.6437 0 0
M  V30 7 C 4.9774 -4.4137 0 0
M  V30 8 C 4.9774 -1.3337 0 0
M  V30 9 O 4.9774 0.2063 0 0
M  V30 10 N 6.311 -2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155509

>  <MW>
143.131

>  <MW (desalted)>
143.227

>  <ClogP>
1.71

>  <logS>
-2.42

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
43.09

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
decrease rate Active   | Ki (inhibition constant) = 0.55 mM | IC50  1 mM

>  <CAS>
4171-13-5

>  <Description>
Valnocatmide is a human microsomal epoxide hydrolase inhibitor.

>  <EBC_ID>
EBC-07957

>  <IUPAC Name>
2-ethyl-3-methylpentanamide

>  <Main Tar all refs>
YALE UNIVERSITY - WO2017/192799, 2017, A1 | Pharmacol. Rep., 2007, vol. 59, # 4, p. 402 - 407 | Int. J. Mol. Sci., 2017, vol. 18, # 9

>  <Main tar all>
histone deacetylase 2 pX=4.0 | Inositol-3-phosphate synthase 1 pX=3.26 | pyruvate dehydrogenase pX=3.0

$$$$
Iodoquinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 I 0 -3.08 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 2.6674 0 0 0
M  V30 7 I 2.6674 1.54 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 N 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 2 13
M  V30 14 1 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57825347

>  <MW>
396.846

>  <MW (desalted)>
396.951

>  <ClogP>
4.139

>  <logS>
-3.47

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
83-73-8

>  <Description>
Iodoquinol is a topical therapeutic agent, with satisfactory antibacterial properties.

>  <EBC_ID>
EBC-00547

>  <IUPAC Name>
5,7-diiodoquinolin-8-ol

>  <Main Tar all refs>
ACS Synth. Biol., 2022, vol. 11, # 8, p. 2820 - 2828

>  <Main tar all>
H2 receptor pX=9.0

$$$$
Chloroxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 Cl 0 -3.08 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 2.6674 0 0 0
M  V30 7 Cl 2.6674 1.54 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 N 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 2 13
M  V30 14 1 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z111781330

>  <MW>
212.975

>  <MW (desalted)>
214.048

>  <ClogP>
3.339

>  <logS>
-3.15

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
773-76-2

>  <Description>
Chloroxine is one of the important 8-hydroxyquinoline derivative. Chloroxine has effective antibacterial, antifungal, antiprotozoal and antiamoebic activities, especially used in treating the intestinal amebiasis. It is also used in the treatment of dandruff and seborrheic dermatitis of the scalp.

>  <EBC_ID>
EBC-00554

>  <IUPAC Name>
5,7-dichloroquinolin-8-ol

>  <Main Tar all refs>
ACS Synth. Biol., 2022, vol. 11, # 8, p. 2820 - 2828

>  <Main tar all>
H2 receptor pX=9.0

$$$$
Phensuximide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 2.5796 -3.2152 0 0
M  V30 4 O 4.0442 -2.7393 0 0
M  V30 5 C 2.1037 -4.6798 0 0
M  V30 6 C 0.5637 -4.6798 0 0
M  V30 7 C 0.0878 -3.2152 0 0
M  V30 8 O -1.3768 -2.7393 0 0
M  V30 9 C -0.3415 -5.9257 0 0
M  V30 10 C 0.2849 -7.3326 0 0
M  V30 11 C -0.6203 -8.5784 0 0
M  V30 12 C -2.1519 -8.4175 0 0
M  V30 13 C -2.7783 -7.0106 0 0
M  V30 14 C -1.8731 -5.7647 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 7 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z360145318

>  <MW>
189.079

>  <MW (desalted)>
189.211

>  <ClogP>
0.942

>  <logS>
-1.62

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
37.38

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  559 ?M

>  <CAS>
86-34-0

>  <Description>
Phensuximide is an anticonvulsant and antiepileptic agent. It inhibits seizures induced by maximal electroshock (MES) and pentylenetetrazole. Phensuximide is used for the treatment of epilepsy.

>  <EBC_ID>
EBC-06368

>  <IUPAC Name>
1-methyl-3-phenylpyrrolidine-2,5-dione

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1987, vol. 240, # 1, p. 216 - 222

>  <Main tar all>
CYP1A1 pX=3.25

$$$$
Alendronic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.16 -4.2074 0 0
M  V30 2 C 5.39 -2.8737 0 0
M  V30 3 C 3.85 -2.8737 0 0
M  V30 4 C 3.08 -1.54 0 0
M  V30 5 C 1.54 -1.54 0 0
M  V30 6 O 0 -1.54 0 0
M  V30 7 P 1.54 -3.08 0 0
M  V30 8 O 0 -3.08 0 0
M  V30 9 O 3.08 -3.08 0 0
M  V30 10 O 1.54 -4.62 0 0
M  V30 11 P 1.54 0 0 0
M  V30 12 O 1.54 1.54 0 0
M  V30 13 O 3.08 0 0 0
M  V30 14 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 5 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56771118

>  <MW>
249.017

>  <MW (desalted)>
249.096

>  <ClogP>
-5.642

>  <logS>
4.05

>  <HBD>
6

>  <HBA>
8

>  <TPSA>
161.31

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 10 nM | Ki (inhibition constant) = 44.2 nM | IC50 < 50 nM | IC50 = 90 nM | IC50 = 90 nM

>  <CAS>
66376-36-1

>  <Description>
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. Alendronic acid binds to bone hydroxyapatite.

>  <EBC_ID>
EBC-04173

>  <IUPAC Name>
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid

>  <Main Tar all refs>
Curr. Pharm. Des., 2004, vol. 10, # 13, p. 1439 - 1455 | J. Med. Chem., 2008, vol. 51, # 7, p. 2187 - 2195 | Curr. Med. Chem. Anti-inflam. Agents., 2002, vol. 1, # 1, p. 15 - 28 | J. Med. Chem., 2002, vol. 45, # 11, p. 2185 - 2196 | J. Med. Chem., 2002, vol. 45, # 11, p. 2185 - 2196

>  <Main tar all>
integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor) pX=8.0 | farnesyl diphosphate synthase pX=7.35 | MMP13 pX=7.3 | geranylgeranyl diphosphate synthase pX=7.05 | geranylgeranyl diphosphate synthase pX=7.05

$$$$
Anethole trithione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0 13.4 0 0
M  V30 2 O 1.3337 12.63 0 0
M  V30 3 C 1.3337 11.09 0 0
M  V30 4 C 2.6674 10.32 0 0
M  V30 5 C 2.6674 8.78 0 0
M  V30 6 C 1.3337 8.01 0 0
M  V30 7 C 0 8.78 0 0
M  V30 8 C 0 10.32 0 0
M  V30 9 C 1.3337 6.47 0 0
M  V30 10 C 2.5796 5.5648 0 0
M  V30 11 C 2.1037 4.1002 0 0
M  V30 12 S 3.0089 2.8543 0 0
M  V30 13 S 0.5637 4.1002 0 0
M  V30 14 S 0.0878 5.5648 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 6 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269145528

>  <MW>
239.974

>  <MW (desalted)>
240.365

>  <ClogP>
3.621

>  <logS>
-5.393

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
9.23

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Activator | Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50 ~ 0.5 ?M | increase rate Active   | inhibition percentage  78.5 % | EC50  10.2 ?M

>  <CAS>
532-11-6

>  <Description>
Anethole trithione is a medication used to treat dry mouth associated with medication or radiotherapy of the head and neck. It appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia to demonstrating an ability to inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes.

>  <EBC_ID>
EBC-17037

>  <IUPAC Name>
5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione

>  <Main Tar all refs>
ABBOTT LABORATORIES INC - US2006/194971, 2006, A1 | Acta Pharmacol. Sin., 2022, vol. 43, # 4, p. 811 - 828 | Pharm. Res., 2019, vol. 36, # 9 | PLoS ONE, 2019, vol. 14, # 5

>  <Main tar all>
Amine oxidase [flavin-containing] pX=6.3 | Uncoupling protein 2 pX=6.3 | Nav1.8 pX=5.56 | ubiquinone complex 1 pX=4.99

$$$$
Dexibuprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C -1.3337 3.85 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 C 1.3337 -2.31 0 0 CFG=2
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C -0 -3.08 0 0
M  V30 14 O -0 -4.62 0 0
M  V30 15 O -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 11 8
M  V30 12 1 11 12 CFG=3
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1508914616

>  <MW>
206.131

>  <MW (desalted)>
206.281

>  <ClogP>
3.679

>  <logS>
-3.535

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
4

>  <Action on targets>
Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  30 % | IC50 = 98.65 nM

>  <CAS>
51146-56-6

>  <Description>
Dexibuprofen is a non-steroidal anti-inflammatory drug. It is a pharmacologically effective S-enantiomer of racemic ibuprofen that differs in physicochemical properties. It suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX.

>  <EBC_ID>
EBC-04181

>  <IUPAC Name>
(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2005, vol. 48, # 13, p. 4312 - 4331 | Bioorg. Med. Chem. Lett., 2011, vol. 21, # 12, p. 3578 - 3582

>  <Main tar all>
CXCR1 pX=7.63 | COX-1  pX=7.01

$$$$
Vanillyl butyl ether
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 C 5.3347 -7.7 0 0
M  V30 4 C 6.6684 -6.93 0 0
M  V30 5 O 8.0021 -7.7 0 0
M  V30 6 C 9.3358 -6.93 0 0
M  V30 7 C 10.6694 -7.7 0 0
M  V30 8 C 12.0031 -6.93 0 0
M  V30 9 C 13.3368 -7.7 0 0
M  V30 10 C 13.3368 -9.24 0 0
M  V30 11 O 14.6705 -10.01 0 0
M  V30 12 C 12.0031 -10.01 0 0
M  V30 13 O 12.0031 -11.55 0 0
M  V30 14 C 10.6694 -12.32 0 0
M  V30 15 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 12 15
M  V30 15 2 7 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509562802

>  <MW>
210.126

>  <MW (desalted)>
210.27

>  <ClogP>
2.569

>  <logS>
-2.134

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
38.69

>  <RotBonds>
6

>  <Action on targets>
Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
EC50  14.1 ?M | IC50  87.9 ?M

>  <CAS>
82654-98-6

>  <Description>
Vanillyl butyl ether is an ether of monohydroxybenzoic acid. It is added to food products as a flavoring agent. It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.

>  <EBC_ID>
EBC-26207

>  <IUPAC Name>
4-(butoxymethyl)-2-methoxyphenol

>  <Main Tar all refs>
Biochem. Biophys. Rep., 2022, vol. 30 | MARS, INCORPORATED - US2014/271949, 2014, A1

>  <Main tar all>
TRPV1 pX=4.85 | 5-HT3A pX=4.06

$$$$
Tinidazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7272 8.24 0 0
M  V30 2 C 2.3935 7.47 0 0
M  V30 3 S 2.3935 5.93 0 0
M  V30 4 O 0.8535 5.93 0 0
M  V30 5 O 3.9335 5.93 0 0
M  V30 6 C 2.3935 4.39 0 0
M  V30 7 C 1.0598 3.62 0 0
M  V30 8 N 1.0598 2.08 0 0
M  V30 9 C 2.3057 1.1748 0 0
M  V30 10 C 3.7703 1.6507 0 0
M  V30 11 N 1.8298 -0.2898 0 0
M  V30 12 C 0.2898 -0.2898 0 0
M  V30 13 C -0.1861 1.1748 0 0
M  V30 14 N -1.6507 1.6507 0 0 CHG=1
M  V30 15 O -2.7951 0.6202 0 0
M  V30 16 O -1.9709 3.157 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56763819

>  <MW>
247.063

>  <MW (desalted)>
247.272

>  <ClogP>
-0.319

>  <logS>
-1.183

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
95.1

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  89 % | inhibition percentage  88 % | inhibition percentage  88 % | inhibition percentage  86.5 % | inhibition percentage  71 % | inhibition percentage  68.5 % | IC50  96 nM

>  <CAS>
19387-91-8

>  <Description>
Tinidazole is a 5-nitroimidazole derivative with antiparasitic and antibiotic activity. It is used to treat trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis.

>  <EBC_ID>
EBC-08203

>  <IUPAC Name>
1-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole

>  <Main Tar all refs>
Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021618-021681-021682, Owner: MISSION PHARMA, Number: 000, Revision: 17.05.2004 00:00:00, 2004 | ANGIOTECH PHARMACEUTICALS, INC. - WO2006/121518, 2006, A2

>  <Main tar all>
Cytochrome P450 2B6 pX=8.43 | CYP1A2 pX=8.39 | Cytochrome P450 2C9 pX=8.39 | Cytochrome P450 2D6 pX=8.33 | CYP2E1 pX=7.91 | Cytochrome P450 3A4 pX=7.86 | Interleukin-1 beta pX=7.02

$$$$
Benznidazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -3.1917 -7.2286 0 0 CHG=-1
M  V30 2 N -1.727 -6.7527 0 0 CHG=1
M  V30 3 O -0.5826 -7.7832 0 0
M  V30 4 C -1.4069 -5.2464 0 0
M  V30 5 N -2.4373 -4.1019 0 0
M  V30 6 C -1.6673 -2.7683 0 0
M  V30 7 C -0.161 -3.0884 0 0
M  V30 8 N 0 -4.62 0 0
M  V30 9 C 1.3337 -5.39 0 0
M  V30 10 C 2.6674 -4.62 0 0
M  V30 11 O 2.6674 -3.08 0 0
M  V30 12 N 4.001 -5.39 0 0
M  V30 13 C 5.3347 -4.62 0 0
M  V30 14 C 6.6684 -5.39 0 0
M  V30 15 C 8.0021 -4.62 0 0
M  V30 16 C 9.3358 -5.39 0 0
M  V30 17 C 9.3358 -6.93 0 0
M  V30 18 C 8.0021 -7.7 0 0
M  V30 19 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2044771577

>  <MW>
260.091

>  <MW (desalted)>
260.249

>  <ClogP>
0.9

>  <logS>
-2.758

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
90.06

>  <RotBonds>
5

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 = 110 nM | IC50  0.9 ?M | EC50  1.23 ?M | IC50  1.7 ?M | IC50  1.7 ?M | EC50  2.2 ?M | EC50  2.2 ?M | IC50  2.2 ?M | EC50  2.63 ?M

>  <CAS>
22994-85-0

>  <Description>
Benznidazole is a nitroimidazole derivative having an antiprotozoal activity. Benznidazole is an antiparasitic medication for trypanosoma cruzi strains, and has been used in the treatment of Chagas disease.

>  <EBC_ID>
EBC-03694

>  <IUPAC Name>
N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2001, vol. 45, # 4, p. 1210 - 1215 | Eur. J. Med. Chem., 2019, vol. 182 | PLoS. Negl. Trop. Dis., 2018, vol. 12, # 1 | ACS Med. Chem. Lett., 2019, vol. 10, # 4, p. 413 - 418 | Eur. J. Med. Chem., 2016, vol. 109, p. 173 - 186 | ACS Med. Chem. Lett., 2020, vol. 11, # 6, p. 1250 - 1256 | ACS Infect. Dis., 2021, vol. 7, # 8, p. 2455 - 2471 | J. Med. Chem., 2012, vol. 55, # 11, p. 5554 - 5565 | Eur. J. Med. Chem., 2018, vol. 149, p. 257 - 268

>  <Main tar all>
lanosterol synthase pX=6.96 | Cruzipain pX=6.05 | NAD-dependent protein deacetylase SIR2rp1 pX=5.91 | ?-carbonic anhydrases pX=5.77 | Beta-galactosidase (gene GLB1) pX=5.77 | Glucose-6-phosphate dehydrogenase pX=5.66 | Malic enzyme, cytosolic pX=5.66 | Nitroreductase pX=5.66 | Lanosterol 14-alpha demethylase erg11 pX=5.58

$$$$
Cimetidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.905 -8.5901 0 0
M  V30 2 N 4.5713 -7.8201 0 0
M  V30 3 C 4.5713 -6.2801 0 0
M  V30 4 N 3.2376 -5.5101 0 0
M  V30 5 C 1.9039 -6.2801 0 0
M  V30 6 N 0.5703 -7.0501 0 0
M  V30 7 N 5.905 -5.5101 0 0
M  V30 8 C 7.2387 -6.2801 0 0
M  V30 9 C 8.5723 -5.5101 0 0
M  V30 10 S 9.906 -6.2801 0 0
M  V30 11 C 11.2397 -5.5101 0 0
M  V30 12 C 12.5734 -6.2801 0 0
M  V30 13 N 13.9802 -5.6538 0 0
M  V30 14 C 15.0107 -6.7982 0 0
M  V30 15 N 14.2407 -8.1319 0 0
M  V30 16 C 12.7343 -7.8117 0 0
M  V30 17 C 11.5899 -8.8422 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5 CFG=2
M  V30 5 3 5 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 12 16
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1162463430

>  <MW>
252.116

>  <MW (desalted)>
252.339

>  <ClogP>
0.38

>  <logS>
-1.89

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
88.89

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1.3 nM

>  <CAS>
51481-61-9

>  <Description>
Cimetidine is a histamine-2 (H2) receptor antagonist. It is used to manage GERD, peptic ulcer disease, and indigestion.

>  <EBC_ID>
EBC-04238

>  <IUPAC Name>
N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine

>  <Main Tar all refs>
ELI LILLY & CO - WO2003/32912, 2003, A2

>  <Main tar all>
H1 receptor pX=8.89

$$$$
Ticlopidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 4.9239 5.9228 0 0
M  V30 2 C 6.2576 6.6928 0 0
M  V30 3 C 6.2576 8.2328 0 0
M  V30 4 C 7.5913 9.0028 0 0
M  V30 5 C 8.925 8.2328 0 0
M  V30 6 C 8.925 6.6928 0 0
M  V30 7 C 7.5913 5.9228 0 0
M  V30 8 C 7.5913 4.3828 0 0
M  V30 9 N 6.2576 3.6128 0 0
M  V30 10 C 6.2576 2.0728 0 0
M  V30 11 C 4.9239 1.3028 0 0
M  V30 12 C 3.5902 2.0728 0 0
M  V30 13 S 2.1256 1.5969 0 0
M  V30 14 C 1.2204 2.8428 0 0
M  V30 15 C 2.1256 4.0887 0 0
M  V30 16 C 3.5902 3.6128 0 0
M  V30 17 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 12 16
M  V30 18 1 16 17
M  V30 19 1 9 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z231745614

>  <MW>
263.786

>  <MW (desalted)>
263.786

>  <ClogP>
4.388

>  <logS>
-3.518

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.16 nM

>  <CAS>
55142-85-3

>  <Description>
Ticlopidine is an antiplatelet drug in the thienopyridine family. It is used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks. Ticlopyridine inhibits Cytochrome P450 2B6.

>  <EBC_ID>
EBC-06095

>  <IUPAC Name>
5-[(2-chlorophenyl)methyl]-4H,5H,6H,7H-thieno[3,2-c]pyridine

>  <Main Tar all refs>
Regul. Toxicol. Pharmacol., 2021, vol. 122

>  <Main tar all>
Cytochrome P450 2B6 pX=9.8

$$$$
Febuxostat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 15.71 0 0
M  V30 2 C -0 14.94 0 0
M  V30 3 C 1.3337 15.71 0 0
M  V30 4 C -0 13.4 0 0
M  V30 5 O 1.3337 12.63 0 0
M  V30 6 C 1.3337 11.09 0 0
M  V30 7 C 2.6674 10.32 0 0
M  V30 8 C 2.6674 8.78 0 0
M  V30 9 C 1.3337 8.01 0 0
M  V30 10 C 0 8.78 0 0
M  V30 11 C 0 10.32 0 0
M  V30 12 C -1.3337 11.09 0 0
M  V30 13 N -2.6674 11.86 0 0
M  V30 14 C 1.3337 6.47 0 0
M  V30 15 N 2.5796 5.5648 0 0
M  V30 16 C 2.1037 4.1002 0 0
M  V30 17 C 3.0089 2.8543 0 0
M  V30 18 C 0.5637 4.1002 0 0
M  V30 19 S 0.0878 5.5648 0 0
M  V30 20 C -0.3415 2.8543 0 0
M  V30 21 O 0.2849 1.4474 0 0
M  V30 22 O -1.8731 3.0153 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 3 12 13
M  V30 14 1 9 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 18 19
M  V30 20 1 14 19
M  V30 21 1 18 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759499

>  <MW>
316.088

>  <MW (desalted)>
316.375

>  <ClogP>
4.097

>  <logS>
-4.73

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
83.21

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Blocker | Inhibitor | Blocker

>  <Activity coefficients and valu>
Ki (inhibition constant) = 120 pM | pIC50  8.9  | IC50  0.0016 ?M | IC50 = 1.8 nM | EC50  0.003 ?M

>  <CAS>
144060-53-7

>  <Description>
Febuxostat is a xanthine oxidase inhibitor, it achieves its therapeutic effect by decreasing serum uric acid.  It is used for the management of chronic hyperuricemia in adults with gout who have an inadequate response or intolerance to allopurinol.

>  <EBC_ID>
EBC-08698

>  <IUPAC Name>
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid

>  <Main Tar all refs>
J. Nat. Prod., 2014, vol. 77, # 7, p. 1693 - 1699 | Bioorg. Med. Chem. Lett., 2014, vol. 24, # 5, p. 1315 - 1321 | Biopharm. Drug Dispos., 2022, vol. 43, # 2, p. 57 - 65 | ASTELLAS PHARMA INC. - EP1992361, 2008, A1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED - WO2007/62028, 2007, A2

>  <Main tar all>
Xanthine dehydrogenase (gene ry) pX=9.92 | xanthine dehydrogenase pX=8.9 | Organic anion transporter 3 pX=8.8 | Xanthine dehydrogenase (peptide) pX=8.74 | Kv11.1 pX=8.52

$$$$
Loperamide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -1.5253 0 0
M  V30 3 N 5.94 -1.5253 0 0
M  V30 4 C 6.71 -0.1916 0 0
M  V30 5 C 6.71 -2.859 0 0
M  V30 6 O 5.94 -4.1927 0 0
M  V30 7 C 8.25 -2.859 0 0
M  V30 8 C 8.25 -1.319 0 0
M  V30 9 C 9.5837 -0.549 0 0
M  V30 10 N 9.5837 0.991 0 0
M  V30 11 C 8.25 1.761 0 0
M  V30 12 C 8.25 3.301 0 0
M  V30 13 C 9.5837 4.071 0 0
M  V30 14 O 8.5938 5.2507 0 0
M  V30 15 C 10.9174 3.301 0 0
M  V30 16 C 10.9174 1.761 0 0
M  V30 17 C 10.5736 5.2507 0 0
M  V30 18 C 10.0469 6.6978 0 0
M  V30 19 C 11.0368 7.8775 0 0
M  V30 20 C 12.5534 7.6101 0 0
M  V30 21 Cl 13.5433 8.7898 0 0
M  V30 22 C 13.0801 6.163 0 0
M  V30 23 C 12.0902 4.9833 0 0
M  V30 24 C 8.25 -4.399 0 0
M  V30 25 C 9.5837 -5.169 0 0
M  V30 26 C 9.5837 -6.709 0 0
M  V30 27 C 8.25 -7.479 0 0
M  V30 28 C 6.9163 -6.709 0 0
M  V30 29 C 6.9163 -5.169 0 0
M  V30 30 C 9.79 -2.859 0 0
M  V30 31 C 10.56 -1.5253 0 0
M  V30 32 C 12.1 -1.5253 0 0
M  V30 33 C 12.87 -2.859 0 0
M  V30 34 C 12.1 -4.1927 0 0
M  V30 35 C 10.56 -4.1927 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 15 1 10 16
M  V30 16 1 13 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 17 23
M  V30 24 1 7 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 24 29
M  V30 31 1 7 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 2 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610490

>  <MW>
513.498

>  <MW (desalted)>
477.038

>  <ClogP>
4.662

>  <logS>
-5.28

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
43.78

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.16 nM | Ki (inhibition constant) = 0.16 nM

>  <CAS>
34552-83-5

>  <Description>
Loperamide is a long acting antidiarrheal used to control nonspecific diarrhea and chronic diarrhea caused by inflammatory bowel disease, or gastroenteritis.

>  <EBC_ID>
EBC-11156

>  <IUPAC Name>
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2004, vol. 47, # 21, p. 5009 - 5020 | J. Med. Chem., 2004, vol. 47, # 21, p. 5009 - 5020

>  <Main tar all>
? receptor pX=9.8 | ? receptor pX=9.8

$$$$
Nefazodone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.7866 3.6593 0 0
M  V30 3 C 10.1203 2.8893 0 0
M  V30 4 C 10.1203 1.3493 0 0
M  V30 5 N 11.3662 0.4441 0 0
M  V30 6 N 10.8903 -1.0205 0 0
M  V30 7 C 11.7955 -2.2664 0 0
M  V30 8 C 13.3271 -2.1054 0 0
M  V30 9 C 14.2323 -3.3513 0 0
M  V30 10 N 15.7638 -3.1904 0 0
M  V30 11 C 16.3902 -1.7835 0 0
M  V30 12 C 17.9218 -1.6225 0 0
M  V30 13 N 18.827 -2.8684 0 0
M  V30 14 C 18.2006 -4.2753 0 0
M  V30 15 C 16.669 -4.4362 0 0
M  V30 16 C 20.3585 -2.7074 0 0
M  V30 17 C 20.9849 -1.3006 0 0
M  V30 18 C 22.5165 -1.1396 0 0
M  V30 19 C 23.4216 -2.3855 0 0
M  V30 20 C 22.7953 -3.7923 0 0
M  V30 21 Cl 23.7005 -5.0382 0 0
M  V30 22 C 21.2637 -3.9533 0 0
M  V30 23 C 9.3503 -1.0205 0 0
M  V30 24 O 8.4451 -2.2664 0 0
M  V30 25 N 8.8744 0.4441 0 0
M  V30 26 C 7.4098 0.92 0 0
M  V30 27 C 7.0896 2.4263 0 0
M  V30 28 O 5.625 2.9022 0 0
M  V30 29 C 5.3048 4.4086 0 0
M  V30 30 C 3.8402 4.8844 0 0
M  V30 31 C 3.52 6.3908 0 0
M  V30 32 C 4.6644 7.4213 0 0
M  V30 33 C 6.1291 6.9454 0 0
M  V30 34 C 6.4493 5.439 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 10 15
M  V30 15 1 13 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 20 22
M  V30 22 2 16 22
M  V30 23 1 6 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 4 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 29 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037281001

>  <MW>
506.468

>  <MW (desalted)>
470.007

>  <ClogP>
5.725

>  <logS>
-4.613

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
51.62

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1E-08 M | IC50  17 nM | IC50 = 17 nM | IC50 = 17 nM | Ki (inhibition constant) = 137 nM | IC50  160 nM

>  <CAS>
82752-99-6

>  <Description>
Nefazodone hydrochloride is an antidepressant drug. It acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake.

>  <EBC_ID>
EBC-12785

>  <IUPAC Name>
1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one hydrochloride

>  <Main Tar all refs>
ASSEMBLY BIOSCIENCES, INC. - EP684816, 2004, B1 | ASSEMBLY BIOSCIENCES, INC. - EP684816, 2004, B1 | ASSEMBLY BIOSCIENCES, INC. - US5605902, 1997, A | ASSEMBLY BIOSCIENCES, INC. - US5605902, 1997, A | MAYO FOUNDATION - US6069177, 2000, A | ASSEMBLY BIOSCIENCES, INC. - EP684816, 2004, B1

>  <Main tar all>
5-HT receptor pX=8.0 | 5-HT2A receptor pX=7.77 | 5-HT2A receptor pX=7.77 | 5-HT2A receptor pX=7.77 | SERT pX=6.86 | ?-adrenoceptor pX=6.8

$$$$
Cinoxate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -9.24 0 0
M  V30 2 C 4.001 -10.01 0 0
M  V30 3 O 5.3347 -9.24 0 0
M  V30 4 C 6.6684 -10.01 0 0
M  V30 5 C 8.0021 -9.24 0 0
M  V30 6 O 9.3358 -10.01 0 0
M  V30 7 C 10.6694 -9.24 0 0
M  V30 8 O 10.6694 -7.7 0 0
M  V30 9 C 12.0031 -10.01 0 0
M  V30 10 C 13.3368 -9.24 0 0
M  V30 11 C 14.6705 -10.01 0 0
M  V30 12 C 16.0041 -9.24 0 0
M  V30 13 C 17.3378 -10.01 0 0
M  V30 14 C 17.3378 -11.55 0 0
M  V30 15 O 18.6715 -12.32 0 0
M  V30 16 C 20.0052 -11.55 0 0
M  V30 17 C 16.0041 -12.32 0 0
M  V30 18 C 14.6705 -11.55 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7 CFG=2
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 14 17
M  V30 17 1 17 18
M  V30 18 2 11 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53833825

>  <MW>
250.29

>  <MW (desalted)>
250.29

>  <ClogP>
2.754

>  <logS>
-2.512

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
44.76

>  <RotBonds>
8

>  <CAS>
104-28-9

>  <Description>
Cinoxate is a potent ultraviolet absorber. It is approved by FDA as the active ingredient in sunscreen compositions.

>  <EBC_ID>
EBC-12068

>  <IUPAC Name>
2-ethoxyethyl 3-(4-methoxyphenyl)prop-2-enoate

$$$$
Methotrexate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -8.47 0 0
M  V30 2 N 5.3347 -9.24 0 0
M  V30 3 C 5.3347 -10.78 0 0
M  V30 4 C 4.001 -11.55 0 0
M  V30 5 C 4.001 -13.09 0 0
M  V30 6 N 2.6674 -13.86 0 0
M  V30 7 C 1.3337 -13.09 0 0
M  V30 8 N 0 -13.86 0 0
M  V30 9 C -1.3337 -13.09 0 0
M  V30 10 N -2.6674 -13.86 0 0
M  V30 11 N -1.3337 -11.55 0 0
M  V30 12 C 0 -10.78 0 0
M  V30 13 N 0 -9.24 0 0
M  V30 14 C 1.3337 -11.55 0 0
M  V30 15 N 2.6674 -10.78 0 0
M  V30 16 C 6.6684 -8.47 0 0
M  V30 17 C 6.6684 -6.93 0 0
M  V30 18 C 8.0021 -6.16 0 0
M  V30 19 C 9.3358 -6.93 0 0
M  V30 20 C 9.3358 -8.47 0 0
M  V30 21 C 8.0021 -9.24 0 0
M  V30 22 C 10.6694 -6.16 0 0
M  V30 23 O 10.6694 -4.62 0 0
M  V30 24 N 12.0031 -6.93 0 0
M  V30 25 C 13.3368 -6.16 0 0 CFG=1
M  V30 26 C 14.6705 -6.93 0 0
M  V30 27 C 16.0041 -6.16 0 0
M  V30 28 C 17.3378 -6.93 0 0
M  V30 29 O 18.6715 -6.16 0 0
M  V30 30 O 17.3378 -8.47 0 0
M  V30 31 C 13.3368 -4.62 0 0
M  V30 32 O 14.6705 -3.85 0 0
M  V30 33 O 12.0031 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 7 14
M  V30 15 1 14 15
M  V30 16 2 4 15
M  V30 17 1 2 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 25 24 CFG=3
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 25 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553982

>  <MW>
454.439

>  <MW (desalted)>
454.439

>  <ClogP>
-0.529

>  <logS>
-3.44

>  <HBD>
5

>  <HBA>
12

>  <TPSA>
210.54

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  3E-06 ?M | Ki (inhibition constant)  3E-06 ?M | Ki (inhibition constant) = 4.42E-06 ?M | Ki (inhibition constant) = 0.038 nM | Ki (inhibition constant) = 0.058 nM

>  <CAS>
59-05-2

>  <Description>
Methotrexate is an antineoplastic agent used the treatment of a wide variety of cancers.

>  <EBC_ID>
EBC-12158

>  <IUPAC Name>
(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 20, p. 7324 - 7336 | Bioorg. Med. Chem., 2009, vol. 17, # 20, p. 7324 - 7336 | Eur. J. Med. Chem., 2008, vol. 43, # 1, p. 189 - 203 | Chem. Rev., 2005, vol. 105, # 2, p. 593 - 620 | Bioorg. Med. Chem., 2012, vol. 20, # 3, p. 1281 - 1290

>  <Main tar all>
dihydrofolate reductase pX=11.5 | dihydrofolate reductase pX=11.5 | dihydrofolate reductase pX=11.4 | Bifunctional dihydrofolate reductase-thymidylate synthase pX=10.4 | dihydrofolate reductase pX=10.2

$$$$
Docetaxel
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 58 63 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.5984 3.9756 0 0
M  V30 2 C 9.0751 3.7497 0 0
M  V30 3 O 8.1178 4.956 0 0
M  V30 4 O 8.509 2.3175 0 0
M  V30 5 C 9.4663 1.1112 0 0 CFG=1
M  V30 6 C 10.3838 2.3481 0 0
M  V30 7 O 11.6206 1.4306 0 0
M  V30 8 C 10.7032 0.1937 0 0 CFG=2
M  V30 9 C 10.5271 -1.3362 0 0
M  V30 10 C 9.1141 -1.9486 0 0 CFG=2
M  V30 11 O 8.938 -3.4785 0 0
M  V30 12 C 7.8772 -1.0312 0 0 CFG=2
M  V30 13 C 7.8736 -2.5712 0 0
M  V30 14 C 8.0533 0.4987 0 0 CFG=2
M  V30 15 C 7.0272 1.7505 0 0 CFG=2
M  V30 16 O 7.8015 3.0817 0 0
M  V30 17 C 7.0357 4.4179 0 0
M  V30 18 O 5.4958 4.4228 0 0
M  V30 19 C 7.81 5.7491 0 0
M  V30 20 C 7.0443 7.0852 0 0
M  V30 21 C 7.8185 8.4164 0 0
M  V30 22 C 9.3585 8.4115 0 0
M  V30 23 C 10.1243 7.0754 0 0
M  V30 24 C 9.35 5.7442 0 0
M  V30 25 C 5.4208 2.0253 0 0 CFG=2
M  V30 26 O 5.9126 3.4847 0 0
M  V30 27 C 3.9869 2.7732 0 0
M  V30 28 C 2.591 2.0373 0 0 CFG=2
M  V30 29 O 1.2591 2.8104 0 0
M  V30 30 C -0.0763 2.0436 0 0
M  V30 31 O -0.0799 0.5036 0 0
M  V30 32 C -1.4082 2.8167 0 0 CFG=2
M  V30 33 O -1.4046 4.3567 0 0
M  V30 34 C -2.7437 2.0498 0 0 CFG=1
M  V30 35 N -4.0756 2.8229 0 0
M  V30 36 C -5.411 2.056 0 0
M  V30 37 O -5.4146 0.516 0 0
M  V30 38 O -6.7429 2.8292 0 0
M  V30 39 C -8.0784 2.0623 0 0
M  V30 40 C -9.4139 1.2954 0 0
M  V30 41 C -8.8453 3.3978 0 0
M  V30 42 C -7.3115 0.7268 0 0
M  V30 43 C -2.7473 0.5098 0 0
M  V30 44 C -1.4154 -0.2633 0 0
M  V30 45 C -1.419 -1.8033 0 0
M  V30 46 C -2.7545 -2.5702 0 0
M  V30 47 C -4.0864 -1.7971 0 0
M  V30 48 C -4.0828 -0.2571 0 0
M  V30 49 C 2.6443 0.4602 0 0
M  V30 50 C 4.0048 -0.414 0 0
M  V30 51 C 5.0402 -1.6726 0 0 CFG=1
M  V30 52 O 4.259 -2.9998 0 0
M  V30 53 C 6.6114 -1.9609 0 0
M  V30 54 O 6.9566 -3.4618 0 0
M  V30 55 C 4.8205 0.7432 0 0
M  V30 56 C 5.762 -0.4755 0 0
M  V30 57 C 6.3457 0.53 0 0
M  V30 58 C 1.3054 -0.3006 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 10 9
M  V30 11 1 10 11 CFG=3
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 1 14 12
M  V30 15 1 14 5 CFG=3
M  V30 16 1 14 15
M  V30 17 1 15 16 CFG=1
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 27 1 15 25
M  V30 28 1 25 26 CFG=3
M  V30 29 1 25 27
M  V30 30 1 28 27
M  V30 31 1 28 29 CFG=1
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 32 30
M  V30 35 1 32 33 CFG=1
M  V30 36 1 32 34
M  V30 37 1 34 35 CFG=3
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 36 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 1 39 41
M  V30 44 1 39 42
M  V30 45 1 34 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 2 43 48
M  V30 52 1 28 49
M  V30 53 2 49 50
M  V30 54 1 51 50
M  V30 55 1 51 52 CFG=3
M  V30 56 1 51 53
M  V30 57 1 12 53
M  V30 58 2 53 54
M  V30 59 1 50 55
M  V30 60 1 25 55
M  V30 61 1 55 56
M  V30 62 1 55 57
M  V30 63 1 49 58
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546621742

>  <MW>
807.879

>  <MW (desalted)>
807.879

>  <ClogP>
4.084

>  <logS>
-6.5

>  <HBD>
5

>  <HBA>
10

>  <TPSA>
224.45

>  <RotBonds>
13

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | IC50  0.1 nM | EC50  0.35 nM | IC50  0.39 nM | inhibition percentage Active   | IC50  5.7E-10 mol/l | IC50  0.6 nM | IC50  0.74 nM | IC50  0.74 nM | IC50  0.92 nM | percentage decrease Active   | inhibition rate Active   | IC50  1.2 nM | IC50  0.0012 ?M | IC50  0.0012 ?M | IC50  0.0012 ?M | IC50  1.2 nM | IC50  1.2 nM | IC50  1.9 nmol/l

>  <CAS>
114977-28-5

>  <Description>
Docetaxel is a taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.

>  <EBC_ID>
EBC-11238

>  <IUPAC Name>
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate

>  <Main Tar all refs>
WASHINGTON STATE UNIVERSITY - WO2020/205458, 2020, A1 | J. Med. Chem., 2019, vol. 62, # 14, p. 6734 - 6750 | Front. Pharmacol., 2021, vol. 12 | Theranostics, 2021, vol. 11, # 14, p. 6873 - 6890 | Chem. Biol. Drug Des., 2017, vol. 90, # 4, p. 561 - 571 | Clin. Cancer Res., 2019, vol. 25, # 4, p. 1404 - 1414 | Nat. Commun., 2020, vol. 11, # 1 | Cancers, 2022, vol. 14, # 11 | Cancers, 2022, vol. 14, # 11 | J. Drug Deliv. Sci. Technol., 2021, vol. 61 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 11, p. 2286 - 2291 | Cell Death Dis., 2022, vol. 13, # 9 | VERU INC - WO2019/222385, 2019, A1 | Front. Oncol., 2022, vol. 12 | Front. Oncol., 2022, vol. 12 | Front. Oncol., 2022, vol. 12 | VERU INC - WO2019/222385, 2019, A1 | VERU INC - WO2019/222385, 2019, A1 | Mol. Cancer Ther., 2017, vol. 16, # 9, p. 1819 - 1830

>  <Main tar all>
nicotinic acetylcholine receptor pX=10.0 | tubulin alpha 1a pX=10.0 | Desmocollin-1 pX=9.46 | embryonic ectoderm development pX=9.41 | DNA-(apurinic or apyrimidinic site) lyase pX=9.3 | Checkpoint serine/threonine-protein kinase bub1 pX=9.24 | ABCB1 pX=9.22 | Folate hydrolase (prostate-specific membrane antigen) 1 pX=9.13 | Galectin-3 pX=9.13 | SRC proto-oncogene, non-receptor tyrosine kinase pX=9.04 | Androgen receptor pX=9.0 | Kinesin-like protein KIF11 pX=9.0 |  tubulin alpha pX=8.92 | Phosphatidylinositol 3-kinase 1 pX=8.92 | Putative multidrug resistance protein pX=8.92 | Serine/threonine-protein kinase mTOR pX=8.92 | Tubulin beta-1 chain pX=8.92 | Tubulin beta-2 chain pX=8.92 | Fatty acid synthase (gene FASN) pX=8.72

$$$$
Floxuridine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 1.3337 -2.31 0 0 CFG=1
M  V30 4 O 2.5796 -3.2152 0 0
M  V30 5 C 2.1037 -4.6798 0 0 CFG=2
M  V30 6 C 0.5637 -4.6798 0 0
M  V30 7 C 0.0878 -3.2152 0 0 CFG=2
M  V30 8 O -1.3768 -2.7393 0 0
M  V30 9 N 3.0089 -5.9257 0 0
M  V30 10 C 4.5404 -5.7647 0 0
M  V30 11 C 5.4456 -7.0106 0 0
M  V30 12 F 6.9772 -6.8496 0 0
M  V30 13 C 4.8192 -8.4175 0 0
M  V30 14 O 5.7244 -9.6634 0 0
M  V30 15 N 3.2877 -8.5784 0 0
M  V30 16 C 2.3825 -7.3326 0 0
M  V30 17 O 0.8509 -7.4935 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 5 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 9 16
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756475348

>  <MW>
246.192

>  <MW (desalted)>
246.192

>  <ClogP>
-1.405

>  <logS>
-1.01

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
99.1

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.0003 ?M | IC50  0.0007 ?M | EC90  0.0268 ?M

>  <CAS>
50-91-9

>  <Description>
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. It is an inhibitor of thymidylate synthase. It is used for palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means.

>  <EBC_ID>
EBC-07483

>  <IUPAC Name>
5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
NUCANA PLC - WO2012/117246, 2012, A1 | NUCANA PLC - US2014/57866, 2014, A1 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4

>  <Main tar all>
Thymidylate synthase (gene TYMS) pX=9.52 | Thymidylate synthase pX=9.15 | methionine-tRNA ligase pX=8.53

$$$$
Prednisolone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0 CFG=2
M  V30 5 O 10.768 -6.7807 0 0
M  V30 6 C 10.2985 -4.155 0 0 CFG=1
M  V30 7 C 9.3058 -2.9776 0 0 CFG=1
M  V30 8 C 9.829 -1.5293 0 0
M  V30 9 C 11.345 -1.2582 0 0
M  V30 10 C 12.3377 -2.4355 0 0
M  V30 11 C 13.8537 -2.1644 0 0
M  V30 12 C 14.8464 -3.3418 0 0
M  V30 13 O 16.3624 -3.0707 0 0
M  V30 14 C 14.3232 -4.7901 0 0
M  V30 15 C 12.8072 -5.0612 0 0
M  V30 16 C 11.8145 -3.8839 0 0 CFG=2
M  V30 17 C 11.2913 -5.3323 0 0
M  V30 18 C 7.7898 -3.2487 0 0 CFG=2
M  V30 19 C 6.574 -2.3035 0 0
M  V30 20 C 5.2994 -3.1677 0 0
M  V30 21 C 5.7274 -4.6471 0 0 CFG=1
M  V30 22 O 4.3071 -5.2423 0 0
M  V30 23 C 5.5008 -6.1703 0 0
M  V30 24 O 6.7067 -7.1282 0 0
M  V30 25 C 4.0683 -6.7357 0 0
M  V30 26 O 3.8417 -8.2589 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 4 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 16 15
M  V30 16 1 6 16
M  V30 17 1 16 10
M  V30 18 1 16 17 CFG=1
M  V30 19 1 7 18
M  V30 20 1 18 2
M  V30 21 1 18 19 CFG=1
M  V30 22 1 19 20
M  V30 23 1 21 20
M  V30 24 1 2 21
M  V30 25 1 21 22 CFG=3
M  V30 26 1 21 23 CFG=1
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z778141968

>  <MW>
360.444

>  <MW (desalted)>
360.444

>  <ClogP>
1.423

>  <logS>
-3.43

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
94.83

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.29 nM | EC50 = 0.4 nM | IC50  0.4 nM | IC50  0.526 nM | Ki (inhibition constant)  1.5 nM | Ki (inhibition constant)  1.5 nM | EC50 = 1.5 nM | EC50 = 2 nM | IC50  3.72 nM

>  <CAS>
50-24-8

>  <Description>
Prednisolone is a glucocorticoid used to treat adrenocortical insufficiency, inflammatory conditions, and some cancers. Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.

>  <EBC_ID>
EBC-12796

>  <IUPAC Name>
(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
J. Med. Chem., 2014, vol. 57, # 3, p. 849 - 860 | Curr. Med. Chem., 2005, vol. 12, # 9, p. 1017 - 1075 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 7, p. 1721 - 1727 | PFIZER INC - US2008/188443, 2008, A1 | J. Med. Chem., 2010, vol. 53, # 23, p. 8241 - 8251 | J. Med. Chem., 2010, vol. 53, # 23, p. 8241 - 8251 | Curr. Top. Med. Chem., 2008, vol. 8, # 9, p. 750 - 765 | Curr. Med. Chem., 2005, vol. 12, # 9, p. 1017 - 1075 | ALEMBIC PHARMACEUTICALS LIMITED - WO2011/42797, 2011, A1

>  <Main tar all>
Mineralocorticoid receptor pX=9.54 | Collagenase pX=9.4 | Glucocorticoid receptor pX=9.4 | nuclear glucocorticoid receptor pX=9.28 | Glucocorticoid receptor (isoform Alpha) pX=8.82 | Glucocorticoid receptor alpha pX=8.82 | Tyrosine aminotransferase pX=8.82 | EP2 receptor pX=8.7 | Calcium release-activated calcium channel pX=8.43

$$$$
Benzthiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -3.85 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -1.8974 -4.4137 0 0
M  V30 4 O -3.4374 -1.7463 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 C 5.3347 -0 0 0
M  V30 12 S 6.6684 -0.77 0 0
M  V30 13 C 8.0021 -0 0 0
M  V30 14 C 9.3358 -0.77 0 0
M  V30 15 C 10.6694 -0 0 0
M  V30 16 C 12.0031 -0.77 0 0
M  V30 17 C 12.0031 -2.31 0 0
M  V30 18 C 10.6694 -3.08 0 0
M  V30 19 C 9.3358 -2.31 0 0
M  V30 20 N 4.001 -2.31 0 0
M  V30 21 S 2.6674 -3.08 0 0
M  V30 22 O 3.3903 -4.4397 0 0
M  V30 23 O 1.9444 -4.4397 0 0
M  V30 24 C 0 -0 0 0
M  V30 25 C -1.3337 -0.77 0 0
M  V30 26 Cl -2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 20 1 10 20
M  V30 21 1 20 21
M  V30 22 1 7 21
M  V30 23 2 21 22
M  V30 24 2 21 23
M  V30 25 2 8 24
M  V30 26 1 24 25
M  V30 27 2 5 25
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575268710

>  <MW>
431.937

>  <MW (desalted)>
431.937

>  <ClogP>
2.172

>  <logS>
-4.57

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
118.69

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 16 nM

>  <CAS>
91-33-8

>  <Description>
Benzthiazide is a long-acting diuretic and a hypertension agent. It is an inhibitor of carbonic anhydrase.

>  <EBC_ID>
EBC-07702

>  <IUPAC Name>
3-[(benzylsulfanyl)methyl]-6-chloro-1,1-dioxo-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 1997, vol. 32, # 4, p. 311 - 319

>  <Main tar all>
carbonic anhydrase pX=7.8

$$$$
Paclitaxel
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 62 68 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3236 5.0346 0 0
M  V30 2 C 2.1108 3.711 0 0
M  V30 3 O 1.3581 2.3675 0 0
M  V30 4 O 3.6507 3.7309 0 0
M  V30 5 C 4.4378 2.4073 0 0 CFG=2
M  V30 6 C 3.4083 1.1439 0 0
M  V30 7 C 2.0518 0.2635 0 0
M  V30 8 C 0.7094 1.0182 0 0
M  V30 9 C 2.0057 -1.3138 0 0 CFG=2
M  V30 10 C 3.405 -2.0433 0 0
M  V30 11 C 4.8354 -1.2889 0 0 CFG=1
M  V30 12 O 5.3339 -2.7459 0 0
M  V30 13 C 6.4406 -1.0067 0 0 CFG=1
M  V30 14 O 7.2118 -2.3397 0 0
M  V30 15 C 6.443 -3.6741 0 0
M  V30 16 O 4.903 -3.6755 0 0
M  V30 17 C 7.2142 -5.007 0 0
M  V30 18 C 8.7542 -5.0057 0 0
M  V30 19 C 9.5254 -6.3386 0 0
M  V30 20 C 8.7566 -7.673 0 0
M  V30 21 C 7.2166 -7.6744 0 0
M  V30 22 C 6.4454 -6.3414 0 0
M  V30 23 C 7.4646 0.2194 0 0 CFG=2
M  V30 24 C 8.8803 -0.3865 0 0 CFG=2
M  V30 25 C 9.8034 -1.6192 0 0
M  V30 26 O 11.0361 -0.6961 0 0
M  V30 27 C 10.113 0.5366 0 0 CFG=2
M  V30 28 C 9.9299 2.0656 0 0
M  V30 29 C 8.5141 2.6716 0 0 CFG=2
M  V30 30 O 8.3311 4.2007 0 0
M  V30 31 C 7.2815 1.7485 0 0 CFG=2
M  V30 32 C 7.2817 3.2885 0 0
M  V30 33 C 6.0078 2.7028 0 0
M  V30 34 O 6.3566 4.2028 0 0
M  V30 35 O 7.9286 -1.5972 0 0
M  V30 36 C 8.5012 -3.0268 0 0
M  V30 37 O 10.0255 -3.2457 0 0
M  V30 38 C 7.5494 -4.2375 0 0
M  V30 39 C 4.2292 -0.0095 0 0
M  V30 40 C 5.7534 0.2107 0 0
M  V30 41 C 5.1652 1.2135 0 0
M  V30 42 O 0.6774 -2.093 0 0
M  V30 43 C 0.688 -3.633 0 0
M  V30 44 O 2.027 -4.3937 0 0
M  V30 45 C -0.6403 -4.4122 0 0 CFG=2
M  V30 46 O -1.9793 -3.6514 0 0
M  V30 47 C -0.6296 -5.9522 0 0 CFG=1
M  V30 48 N -1.958 -6.7314 0 0
M  V30 49 C -1.9473 -8.2713 0 0
M  V30 50 O -0.6083 -9.0321 0 0
M  V30 51 C -3.2756 -9.0505 0 0
M  V30 52 C -3.265 -10.5905 0 0
M  V30 53 C -4.5933 -11.3697 0 0
M  V30 54 C -5.9323 -10.6089 0 0
M  V30 55 C -5.9429 -9.069 0 0
M  V30 56 C -4.6146 -8.2898 0 0
M  V30 57 C 0.7093 -6.7129 0 0
M  V30 58 C 2.0377 -5.9337 0 0
M  V30 59 C 3.3766 -6.6945 0 0
M  V30 60 C 3.3873 -8.2344 0 0
M  V30 61 C 2.059 -9.0136 0 0
M  V30 62 C 0.72 -8.2529 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 13 11
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 17 22
M  V30 23 1 23 13
M  V30 24 1 23 24 CFG=1
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 27 26 CFG=1
M  V30 28 1 24 27
M  V30 29 1 27 28
M  V30 30 1 29 28
M  V30 31 1 29 30 CFG=1
M  V30 32 1 31 29
M  V30 33 1 23 31
M  V30 34 1 31 32 CFG=1
M  V30 35 1 31 33
M  V30 36 1 5 33
M  V30 37 2 33 34
M  V30 38 1 24 35 CFG=3
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 36 38
M  V30 42 1 11 39
M  V30 43 1 6 39
M  V30 44 1 39 40
M  V30 45 1 39 41
M  V30 46 1 9 42 CFG=3
M  V30 47 1 42 43
M  V30 48 2 43 44
M  V30 49 1 45 43
M  V30 50 1 45 46 CFG=1
M  V30 51 1 45 47
M  V30 52 1 47 48 CFG=3
M  V30 53 1 48 49
M  V30 54 2 49 50
M  V30 55 1 49 51
M  V30 56 1 51 52
M  V30 57 2 52 53
M  V30 58 1 53 54
M  V30 59 2 54 55
M  V30 60 1 55 56
M  V30 61 2 51 56
M  V30 62 1 47 57
M  V30 63 1 57 58
M  V30 64 2 58 59
M  V30 65 1 59 60
M  V30 66 2 60 61
M  V30 67 1 61 62
M  V30 68 2 57 62
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485366

>  <MW>
853.906

>  <MW (desalted)>
853.906

>  <ClogP>
4.731

>  <logS>
-6.773

>  <HBD>
4

>  <HBA>
10

>  <TPSA>
221.29

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0007827 nM | tumor cell density decrease Active   | tumor cell density decrease Active   | GI50  0.0045 nM

>  <CAS>
33069-62-4

>  <Description>
Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. It initiates apoptosis of cancer cells through multiple mechanisms. Paclitaxel can cause both mitotic arrest and apoptotic cell death

>  <EBC_ID>
EBC-06097

>  <IUPAC Name>
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate

>  <Main Tar all refs>
BROAD INSTITUTE; DANA-FARBER CANCER INSTITUTE - WO2021/183881, 2021, A1 | Bioorg. Med. Chem. Lett., 2022, vol. 71 | Bioorg. Med. Chem. Lett., 2022, vol. 71 | ChemMedChem, 2021, vol. 16, # 19, p. 3003 - 3016

>  <Main tar all>
glutaminase pX=12.1 | 1-phosphatidylinositol-3-kinase pX=11.8 | Histone?deacetylase pX=11.8 | tubulin alpha 1a pX=11.3

$$$$
Tolmetin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.2002 11.205 0 0
M  V30 2 C 2.8665 10.435 0 0
M  V30 3 C 2.8665 8.895 0 0
M  V30 4 C 1.5329 8.125 0 0
M  V30 5 C 0.1992 8.895 0 0
M  V30 6 C 0.1992 10.435 0 0
M  V30 7 C 1.5329 11.205 0 0
M  V30 8 C -1.1345 8.125 0 0
M  V30 9 O -2.4682 8.895 0 0
M  V30 10 C -1.1345 6.585 0 0
M  V30 11 C 0.1114 5.6798 0 0
M  V30 12 C -0.3645 4.2152 0 0
M  V30 13 C -1.9045 4.2152 0 0
M  V30 14 C -2.8097 2.9693 0 0
M  V30 15 C -4.3412 3.1303 0 0
M  V30 16 O -5.2464 1.8844 0 0
M  V30 17 O -4.9676 4.5371 0 0
M  V30 18 N -2.3804 5.6798 0 0
M  V30 19 C -3.845 6.1557 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 13 18
M  V30 19 1 10 18
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741975772

>  <MW>
257.285

>  <MW (desalted)>
257.285

>  <ClogP>
2.206

>  <logS>
-2.897

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
59.3

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Allosteric Modulator | Allosteric Modulator

>  <Activity coefficients and valu>
IC50  19.5 nM | IC50  50 nM | IC50  90 nM | IC50  90 nM

>  <CAS>
26171-23-3

>  <Description>
Tolmetin is a potent COX inhibitor. It is a non-steroidal anti-inflammatory drug (NSAID) and also exhibits analgesic and antipyretic activity.

>  <EBC_ID>
EBC-03893

>  <IUPAC Name>
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1997, vol. 75, # 9, p. 1088 - 1095 | JOHNSON & JOHNSON INC - WO2006/39704, 2006, A2 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 15, p. 4026 - 4030 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 15, p. 4026 - 4030

>  <Main tar all>
COX-1  pX=7.71 | COX-2  pX=7.3 | CXCR1 pX=7.05 | CXCR1 pX=7.05

$$$$
Sodium nitroprusside
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 0 0 0 0 CHG=1
M  V30 2 Na 2.09 0 0 0 CHG=1
M  V30 3 O 2.2508 -4.4137 0 0
M  V30 4 N 0.7108 -4.4137 0 0
M  V30 5 Fe -0.0592 -5.7474 0 0 CHG=-2
M  V30 6 C -0.8292 -7.081 0 0
M  V30 7 N -1.5992 -8.4147 0 0
M  V30 8 C 0.7108 -7.081 0 0
M  V30 9 N 1.4808 -8.4147 0 0
M  V30 10 C 1.4808 -5.7474 0 0
M  V30 11 N 3.0208 -5.7474 0 0
M  V30 12 C -0.8292 -4.4137 0 0
M  V30 13 N -1.5992 -3.08 0 0
M  V30 14 C -1.5992 -5.7474 0 0
M  V30 15 N -3.1392 -5.7474 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 3 6 7
M  V30 5 1 5 8
M  V30 6 3 8 9
M  V30 7 1 5 10
M  V30 8 3 10 11
M  V30 9 1 5 12
M  V30 10 3 12 13
M  V30 11 1 5 14
M  V30 12 3 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996978

>  <MW>
261.928

>  <MW (desalted)>
238.928

>  <ClogP>
-1.316

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
148.38

>  <RotBonds>
1

>  <CAS>
14402-89-2

>  <Description>
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles).

>  <EBC_ID>
EBC-71118

>  <IUPAC Name>
disodium pentacyano(nitroso)irondiuide

$$$$
Zolmitriptan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.8389 -6.1183 0 0
M  V30 2 N -0.3325 -5.7982 0 0
M  V30 3 C 0.698 -6.9426 0 0
M  V30 4 C 0.1434 -4.3335 0 0
M  V30 5 C 1.6497 -4.0133 0 0
M  V30 6 C 2.1256 -2.5487 0 0
M  V30 7 C 1.2204 -1.3028 0 0
M  V30 8 N 2.1256 -0.0569 0 0
M  V30 9 C 3.5902 -0.5328 0 0
M  V30 10 C 4.9239 0.2372 0 0
M  V30 11 C 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 C 7.5913 -2.8428 0 0
M  V30 14 C 8.925 -2.0728 0 0 CFG=1
M  V30 15 C 9.0859 -0.5413 0 0
M  V30 16 O 10.5923 -0.2211 0 0
M  V30 17 C 11.3623 -1.5548 0 0
M  V30 18 O 12.8938 -1.7157 0 0
M  V30 19 N 10.3318 -2.6992 0 0
M  V30 20 C 4.9239 -2.8428 0 0
M  V30 21 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 14 19
M  V30 20 2 12 20
M  V30 21 1 20 21
M  V30 22 1 6 21
M  V30 23 2 9 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801890

>  <MW>
287.163

>  <MW (desalted)>
287.357

>  <ClogP>
1.288

>  <logS>
-2.342

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
57.36

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
pKi  9.97 | pKi  9.97 | pEC50  9.5  | pEC50  9.5  | pKi  8.53

>  <CAS>
139264-17-8

>  <Description>
Zolmitriptan is a member of the triptan class of 5-HT(1B/1D/1F) receptor agonist drugs. It is used for the acute treatment of migraine with or without aura in adults.

>  <EBC_ID>
EBC-26462

>  <IUPAC Name>
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

>  <Main Tar all refs>
Br. J. Pharmacol., 2019, vol. 176, # 24, p. 4681 - 4695 | Br. J. Pharmacol., 2019, vol. 176, # 24, p. 4681 - 4695 | BR. J. PHARMACOL., 1997, vol. 121, # 2, p. 157 - 164 | BR. J. PHARMACOL., 1997, vol. 121, # 2, p. 157 - 164 | BR. J. PHARMACOL., 1997, vol. 120, # 1, p. 153 - 159

>  <Main tar all>
5-HT1D receptor pX=9.97 | 5-HT1D receptor pX=9.97 | 5-HT1B receptor pX=9.5 | 5-HT1B receptor pX=9.5 | 5-HT1B receptor pX=8.53

$$$$
Pregnenolone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.2567 -5.6522 0 0
M  V30 2 C 4.7822 -5.8629 0 0
M  V30 3 O 5.3626 -7.2893 0 0
M  V30 4 C 5.7274 -4.6471 0 0 CFG=1
M  V30 5 C 5.2994 -3.1677 0 0
M  V30 6 C 6.574 -2.3035 0 0
M  V30 7 C 7.7898 -3.2487 0 0 CFG=1
M  V30 8 C 9.3058 -2.9776 0 0 CFG=2
M  V30 9 C 9.829 -1.5293 0 0
M  V30 10 C 11.345 -1.2582 0 0
M  V30 11 C 12.3377 -2.4355 0 0
M  V30 12 C 13.8537 -2.1644 0 0
M  V30 13 C 14.8464 -3.3418 0 0 CFG=1
M  V30 14 O 16.3624 -3.0707 0 0
M  V30 15 C 14.3232 -4.7901 0 0
M  V30 16 C 12.8072 -5.0612 0 0
M  V30 17 C 11.8145 -3.8839 0 0 CFG=1
M  V30 18 C 11.2913 -5.3323 0 0
M  V30 19 C 10.2985 -4.155 0 0 CFG=1
M  V30 20 C 9.7753 -5.6034 0 0
M  V30 21 C 8.2593 -5.8744 0 0
M  V30 22 C 7.2666 -4.6971 0 0 CFG=2
M  V30 23 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 11
M  V30 18 1 17 18 CFG=1
M  V30 19 1 19 17
M  V30 20 1 8 19
M  V30 21 1 19 20 CFG=1
M  V30 22 1 20 21
M  V30 23 1 22 21
M  V30 24 1 22 4
M  V30 25 1 7 22
M  V30 26 1 22 23 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801892

>  <MW>
316.24

>  <MW (desalted)>
316.478

>  <ClogP>
4.027

>  <logS>
-4.819

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
1

>  <Action on targets>
Antagonist | Antagonist | Agonist | Substrate | Inhibitor | Substrate | Activator | Activator | Inhibitor | Substrate | Inhibitor

>  <Activity coefficients and valu>
stimulation rate  34.6 % | stimulation rate  34.6 % | EC50  205 nM | Km (Michaelis constant)  0.373 ?M | Ki (inhibition constant) = 0.38 ?M | Km (Michaelis constant)  0.99 ?M | EC50  1.4 ?M | EC50  1.4 ?M | Kd (dissociation constant) = 1.7 ?M | Km (Michaelis constant)  2.742 ?M | pKi  5.23

>  <CAS>
145-13-1

>  <Description>
Pregnenolone is a 21-carbon steroid, derived from cholesterol and found in steroid hormone-producing tissues. Pregnenolone is the precursor to gonadal steroid hormones and the adrenal corticosteroids.

>  <EBC_ID>
EBC-26770

>  <IUPAC Name>
1-[(1S,3aS,3bS,7S,9aR,9bS,11aS)-7-hydroxy-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]ethan-1-one

>  <Main Tar all refs>
UNIVERSITY OF BORDEAUX 1; NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH - WO2012/160006, 2012, A1 | UNIVERSITY OF BORDEAUX 1; NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH - WO2012/160006, 2012, A1 | EUR. J. PHARMACOL., 1996, vol. 303, # 3, p. 227 - 234 | J. Ethnopharmacol., 2023, vol. 317 | J. BIOCHEM., 1985, vol. 98, # 6, p. 1519 - 1526 | Xenobiotica, 2018, p. 1 - 6 | Neuropharmacology, 2001, vol. 41, # 3, p. 369 - 376 | Neuropharmacology, 2001, vol. 41, # 3, p. 369 - 376 | Curr. Drug Metab., 2007, vol. 8, # 6, p. 594 - 611 | J. Ethnopharmacol., 2023, vol. 317 | J. Med. Chem., 2004, vol. 47, # 11, p. 2732 - 2742

>  <Main tar all>
CB1 receptor pX=6.72 | CB1 receptor pX=6.72 | Progesterone receptor (isoform B) pX=6.69 | 3-beta-Hydroxysteroid dehydrogenase 1 pX=6.43 | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta-  Steroid Delta-Isomerase 1 pX=6.42 | Cytosolic sulfotransferase 14 pX=6.0 | glycine receptor ?1 subunit pX=5.85 | glycine receptor ?1 subunit pX=5.85 | CYP11A1 pX=5.77 | 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 2 pX=5.56 | Corticosteroid-binding globulin pX=5.23

$$$$
Obeticholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.28 4.8441 0 0
M  V30 2 C 2.7959 4.573 0 0
M  V30 3 C 3.3191 3.1246 0 0 CFG=1
M  V30 4 C 4.8351 2.8536 0 0 CFG=1
M  V30 5 O 5.8278 4.0309 0 0
M  V30 6 C 5.3583 1.4052 0 0 CFG=1
M  V30 7 C 6.8743 1.1341 0 0 CFG=2
M  V30 8 C 8.0901 2.0793 0 0
M  V30 9 C 9.3647 1.2151 0 0
M  V30 10 C 8.9367 -0.2642 0 0 CFG=2
M  V30 11 C 9.8819 -1.4801 0 0 CFG=2
M  V30 12 C 9.3016 -2.9065 0 0
M  V30 13 C 11.4074 -1.2694 0 0
M  V30 14 C 12.3526 -2.4852 0 0
M  V30 15 C 13.8781 -2.2746 0 0
M  V30 16 O 14.8233 -3.4904 0 0
M  V30 17 O 14.4585 -0.8481 0 0
M  V30 18 C 7.3975 -0.3143 0 0 CFG=2
M  V30 19 C 8.0693 -1.7 0 0
M  V30 20 C 6.4048 -1.4916 0 0
M  V30 21 C 4.8888 -1.2205 0 0
M  V30 22 C 4.3656 0.2279 0 0 CFG=2
M  V30 23 C 2.8496 0.4989 0 0 CFG=1
M  V30 24 C 3.3729 -0.9495 0 0
M  V30 25 C 1.8569 -0.6784 0 0
M  V30 26 C 0.3409 -0.4073 0 0
M  V30 27 C -0.1823 1.0411 0 0 CFG=1
M  V30 28 O -1.6982 1.3121 0 0
M  V30 29 C 0.8105 2.2184 0 0
M  V30 30 C 2.3264 1.9473 0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=3
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 18 10
M  V30 18 1 7 18
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 22 21 CFG=3
M  V30 23 1 6 22
M  V30 24 1 22 23
M  V30 25 1 23 24 CFG=3
M  V30 26 1 23 25
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 28 CFG=1
M  V30 30 1 27 29
M  V30 31 1 30 29 CFG=1
M  V30 32 1 3 30
M  V30 33 1 23 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2077740507

>  <MW>
420.324

>  <MW (desalted)>
420.625

>  <ClogP>
5.362

>  <logS>
-5.984

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
77.76

>  <RotBonds>
5

>  <Action on targets>
Agonist | Inhibitor | Agonist

>  <Activity coefficients and valu>
binding rate decrease Active   | EC50  10 nM | EC50  0.0237 ?M

>  <CAS>
459789-99-2

>  <Description>
Obeticholic acid is a bile acid analog and farnesoid X receptor agonist used to treat primary biliary cholangitis in adult patients with inadequate clinical response or intolerance to UDCA.

>  <EBC_ID>
EBC-27035

>  <IUPAC Name>
(4R)-4-[(1R,3aS,3bS,4R,5R,5aS,7R,9aS,9bS,11aR)-5-ethyl-4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
J. Am. Chem. Soc., 2022, vol. 2, # 12, p. 2830 - 2838 | J. Med. Chem., 2017, vol. 60, # 24, p. 9960 - 9973 | J. Med. Chem., 2020, vol. 63, # 21, p. 12748 - 12772

>  <Main tar all>
Farnesoid X receptor pX=9.0 | Farnesoid X receptor pX=8.0 | GPBA receptor pX=7.63

$$$$
Dihydroartemisinin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.4263 -1.6873 0 0
M  V30 2 C 7.1412 -0.8386 0 0 CFG=2
M  V30 3 C 5.7987 -1.6435 0 0
M  V30 4 C 4.7468 -0.4871 0 0
M  V30 5 C 4.9262 1.1088 0 0
M  V30 6 C 3.372 1.5431 0 0 CFG=1
M  V30 7 C 2.3262 0.4127 0 0
M  V30 8 C 2.8334 3.018 0 0 CFG=1
M  V30 9 O 1.3728 3.506 0 0
M  V30 10 O 4.1497 3.8722 0 0
M  V30 11 C 5.6707 3.367 0 0 CFG=2
M  V30 12 O 7.4117 2.9551 0 0
M  V30 13 C 8.9648 3.3526 0 0
M  V30 14 C 10.2443 4.2096 0 0
M  V30 15 C 9.8715 2.0501 0 0
M  V30 16 C 8.9591 0.7639 0 0
M  V30 17 C 7.3585 0.743 0 0 CFG=2
M  V30 18 C 6.312 2.0411 0 0 CFG=1
M  V30 19 O 6.7573 3.816 0 0
M  V30 20 O 8.1128 4.6753 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=3
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 16 CFG=1
M  V30 17 1 17 2
M  V30 18 1 17 18
M  V30 19 1 18 5
M  V30 20 1 18 11
M  V30 21 1 18 19 CFG=3
M  V30 22 1 19 20
M  V30 23 1 13 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2379810087

>  <MW>
284.348

>  <MW (desalted)>
284.348

>  <ClogP>
2.451

>  <logS>
-4.071

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
57.15

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50  4.11 nM

>  <CAS>
71939-50-9

>  <Description>
Dihydroartemisinin is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections.

>  <EBC_ID>
EBC-11036

>  <IUPAC Name>
(4S,5R,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-ol

>  <Main Tar all refs>
Eur. J. Med. Chem., 2021, vol. 220

>  <Main tar all>
Falcipain-2 pX=8.39

$$$$
Terbinafine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 N 1.3337 -5.39 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 C 0 -7.7 0 0
M  V30 5 C -1.3337 -6.93 0 0
M  V30 6 C -2.6674 -7.7 0 0
M  V30 7 C -4.001 -8.47 0 0
M  V30 8 C -5.3347 -9.24 0 0
M  V30 9 C -6.6684 -10.01 0 0
M  V30 10 C -4.5647 -10.5737 0 0
M  V30 11 C -6.1047 -7.9063 0 0
M  V30 12 C 2.6674 -4.62 0 0
M  V30 13 C 2.6674 -3.08 0 0
M  V30 14 C 1.3337 -2.31 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 C 5.3347 0 0 0
M  V30 19 C 6.6684 -0.77 0 0
M  V30 20 C 6.6684 -2.31 0 0
M  V30 21 C 5.3347 -3.08 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 3 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 1 2 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 13 22
M  V30 23 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315576259

>  <MW>
291.199

>  <MW (desalted)>
291.43

>  <ClogP>
5.96

>  <logS>
-6.142

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
6

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  12.8 nM | IC50 = 0.006 ?g/mL | Ki (inhibition constant)  22.4 nM | IC50 = 0.03 ?M

>  <CAS>
91161-71-6

>  <Description>
Terbinafine is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase, an enzyme that is part of the fungal cell wall synthesis pathway. It is used to treat dermatophyte infections of toenails and fingernails as well as other fungal skin infections.

>  <EBC_ID>
EBC-12634

>  <IUPAC Name>
[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine

>  <Main Tar all refs>
BECKLEY PSYTECH LIMITED; BECKLEY PSYTECH LTD - WO2021/250435, 2021, A1 | Antimicrob. Agents Chemother., 2006, vol. 50, # 6, p. 2234 - 2236 | Drug Metab. Dispos., 1999, vol. 27, # 7, p. 770 - 775 | Bioorg. Med. Chem. Lett., 2000, vol. 10, # 13, p. 1459 - 1462

>  <Main tar all>
Kv11.1 pX=7.89 | squalene monooxygenase pX=7.69 | Cytochrome P450 2D6 pX=7.65 | Squalene monooxygenase (peptide) pX=7.52

$$$$
Sunitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.31 -6.9904 0 0
M  V30 2 C 12.6437 -6.2204 0 0
M  V30 3 N 13.9774 -6.9904 0 0
M  V30 4 C 13.9774 -8.5304 0 0
M  V30 5 C 12.6437 -9.3004 0 0
M  V30 6 C 15.311 -6.2204 0 0
M  V30 7 C 16.6447 -6.9904 0 0
M  V30 8 N 17.9784 -6.2204 0 0
M  V30 9 C 19.3121 -6.9904 0 0
M  V30 10 O 19.3121 -8.5304 0 0
M  V30 11 C 20.6458 -6.2204 0 0
M  V30 12 C 20.8067 -4.6888 0 0
M  V30 13 C 19.6623 -3.6584 0 0
M  V30 14 N 22.3131 -4.3687 0 0
M  V30 15 C 23.0831 -5.7023 0 0
M  V30 16 C 24.6146 -5.8633 0 0
M  V30 17 C 25.5198 -4.6174 0 0
M  V30 18 C 25.0439 -3.1528 0 0
M  V30 19 O 23.5793 -2.6769 0 0
M  V30 20 N 26.2898 -2.2476 0 0
M  V30 21 C 27.5357 -3.1528 0 0
M  V30 22 C 29.0421 -2.8326 0 0
M  V30 23 C 30.0725 -3.9771 0 0
M  V30 24 C 29.5966 -5.4417 0 0
M  V30 25 F 30.6271 -6.5861 0 0
M  V30 26 C 28.0903 -5.7619 0 0
M  V30 27 C 27.0598 -4.6174 0 0
M  V30 28 C 22.0526 -6.8468 0 0
M  V30 29 C 22.3728 -8.3531 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 2 24 26
M  V30 26 1 26 27
M  V30 27 1 17 27
M  V30 28 2 21 27
M  V30 29 2 15 28
M  V30 30 1 11 28
M  V30 31 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568722545

>  <MW>
398.212

>  <MW (desalted)>
398.474

>  <ClogP>
2.998

>  <logS>
-4.742

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
77.23

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.008 nM | Ki (inhibition constant) = 0.009 nM | inhibition percentage  66.84 % | Kd (dissociation constant)  0.075 nM | Kd (dissociation constant)  0.21 nM | IC50  0.00022 ?M | IC50 = 0.000219 ?M | Kd (dissociation constant)  0.22 nM

>  <CAS>
557795-19-4

>  <Description>
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase inhibitor. It is used fhe treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

>  <EBC_ID>
EBC-12065

>  <IUPAC Name>
N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide

>  <Main Tar all refs>
PFIZER INC - US7125905, 2006, B2 | PFIZER INC - US7125905, 2006, B2 | AMOREPACIFIC CORP. - WO2007/52882, 2007, A1 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | TACTOGEN - WO2022/61242, 2022, A1 | Novartis (w/o Sandoz); NOVARTIS AG - WO2006/124413, 2006, A2 | Blood, 2009, vol. 114, # 14, p. 2984 - 2992

>  <Main tar all>
platelet derived growth factor receptor alpha pX=11.1 | kinase insert domain receptor pX=11.0 | Mast/stem cell growth factor receptor Kit pX=10.3 | platelet derived growth factor receptor beta pX=10.1 | KIT (V559D, V654A) pX=9.68 | Vascular endothelial growth factor receptor 2 (VEGFR2) pX=9.66 | fms related receptor tyrosine kinase 3 pX=9.66 | fms related receptor tyrosine kinase 3 (K663Q) pX=9.66

$$$$
Pyrithione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0 CHG=-1
M  V30 2 N 1.3337 2.31 0 0 CHG=1
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 S -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104343004

>  <MW>
127.009

>  <MW (desalted)>
127.164

>  <ClogP>
-0.592

>  <logS>
-1.7

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
26.94

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.05 ?M | inhibition percentage Active

>  <CAS>
1121-31-9

>  <Description>
Pyrithione is an antimicrobial agent used for the treatment of dandruff and seborrheic dermatitis. Pyrithione zinc has a broad antimicrobial spectrum of activity, including fungi, gram-positive and gram-negative bacteria

>  <EBC_ID>
EBC-26056

>  <IUPAC Name>
2-sulfanylpyridin-1-ium-1-olate

>  <Main Tar all refs>
DOMPE' FARMACEUTICI - S.P.A.; FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - EP4011367, 2022, A1 | BioMetals, 2018, vol. 31, # 1, p. 29 - 43

>  <Main tar all>
main protease pX=7.3 | 26S Proteasome pX=6.2

$$$$
Caprylic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5963 4.771 0 0
M  V30 2 C 6.93 4.001 0 0
M  V30 3 C 8.2637 4.771 0 0
M  V30 4 C 9.5974 4.001 0 0
M  V30 5 C 10.931 4.771 0 0
M  V30 6 C 12.2647 4.001 0 0
M  V30 7 C 13.5984 4.771 0 0
M  V30 8 C 14.9321 4.001 0 0
M  V30 9 O 16.2658 4.771 0 0
M  V30 10 O 14.9321 2.461 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104495238

>  <MW>
144.115

>  <MW (desalted)>
144.211

>  <ClogP>
2.98

>  <logS>
-2.48

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
6

>  <Action on targets>
Agonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.2 ?M | Kd (dissociation constant)  1.109 ?M | Ki (inhibition constant)  5.41 ?M

>  <CAS>
124-07-2

>  <Description>
Caprylic acid is found naturally in coconuts and breast milk.

>  <EBC_ID>
EBC-03109

>  <IUPAC Name>
octanoic acid

>  <Main Tar all refs>
J. Biol. Chem., 2005, vol. 280, # 12, p. 11807 - 11815 | Int. J. Mol. Sci., 2023, vol. 24, # 6 | Life Sci., 2001, vol. 69, # 18, p. 2123 - 2135

>  <Main tar all>
Olfactory receptor 544 pX=6.7 | Fatty acid-binding protein, heart pX=5.95 | Organic anion transporter 1 pX=5.27

$$$$
Ethosuximide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5966 2.9043 0 0
M  V30 2 C 2.0903 3.2244 0 0
M  V30 3 C 1.0598 2.08 0 0
M  V30 4 C 0.0294 3.2244 0 0
M  V30 5 C 2.3057 1.1748 0 0
M  V30 6 C 1.8298 -0.2898 0 0
M  V30 7 O 2.735 -1.5357 0 0
M  V30 8 N 0.2898 -0.2898 0 0
M  V30 9 C -0.1861 1.1748 0 0
M  V30 10 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z384975088

>  <MW>
141.079

>  <MW (desalted)>
141.168

>  <ClogP>
0.395

>  <logS>
-0.767

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.17

>  <RotBonds>
1

>  <Action on targets>
- | - | - | - | Inhibitor | Inhibitor | Activator | Activator

>  <Activity coefficients and valu>
Kd (dissociation constant) = 7 ?M | Kd (dissociation constant) = 7 ?M | Kd (dissociation constant) = 15000 nM | Kd (dissociation constant) = 15000 nM | inhibition percentage  43 % | inhibition percentage  36 % | increase rate Active   | increase rate Active

>  <CAS>
77-67-8

>  <Description>
Ethosuximide is an anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. It is a potent and selective T-type calcium channel modulator.

>  <EBC_ID>
EBC-03155

>  <IUPAC Name>
3-ethyl-3-methylpyrrolidine-2,5-dione

>  <Main Tar all refs>
JOHNSON & JOHNSON INC - US6358706, 2002, B1 | CNS Neurol. Disord. Drug Targets, 2006, vol. 5, # 6, p. 587 - 603 | JOHNSON & JOHNSON INC - US6358706, 2002, B1 | JOHNSON & JOHNSON INC - US6358706, 2002, B1 | Eur. J. Pharm. Sci., 2010, vol. 40, # 4, p. 282 - 288 | Eur. J. Pharm. Sci., 2010, vol. 40, # 4, p. 282 - 288 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1

>  <Main tar all>
Cav3.1 pX=5.15 | Cav3.1 pX=5.15 | Cav1.2 pX=4.82 | Cav1.2 pX=4.82 | OATP1A2 pX=4.58 | Organic cation transporter 1 pX=4.45 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3

$$$$
Chloroxylenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C -1.3337 -0.77 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 2 9
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z405702410

>  <MW>
156.034

>  <MW (desalted)>
156.609

>  <ClogP>
3.483

>  <logS>
-2.3

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | - | - | Inhibitor | - | - | Blocker

>  <Activity coefficients and valu>
IC50  0.79 ?M | percentage increase  381.06 % | percentage increase  326.69 % | IC50  9.9 ?M | EC50  11 ?M | EC50  11 ?M | induction percentage  33 % | EC50  13 ?M | Ki (inhibition constant)  14 ?M | Kd (dissociation constant) = 14 ?M | Kd (dissociation constant) = 14 ?M | Kd (dissociation constant)  14 ?M

>  <CAS>
88-04-0

>  <Description>
Chloroxylenol is an antiseptic and disinfectant agent used for skin disinfection and surgical instruments. It is used in antibacterial soaps, wound-cleansing applications, and household antiseptics. The halophenol is shown to be most effective against Gram positive bacteria where it disrupts the cell wall due to its phenolic nature.

>  <EBC_ID>
EBC-04299

>  <IUPAC Name>
4-chloro-3,5-dimethylphenol

>  <Main Tar all refs>
Science, 2020, vol. 369, # 6502, p. 403 - 413 | PROCTER & GAMBLE CO; Gillette (in: P&G) - US2017/713, 2017, A1 | PROCTER & GAMBLE CO; Gillette (in: P&G) - US2017/713, 2017, A1 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | DUNDEE CORP; UNIVERSITY OF LIVERPOOL (THE); UNIVERSITY OF DUNDEE; HANNOVER MEDICAL SCHOOL - US2007/142477, 2007, A1 | DUNDEE CORP; UNIVERSITY OF LIVERPOOL (THE); UNIVERSITY OF DUNDEE; HANNOVER MEDICAL SCHOOL - US2007/142477, 2007, A1 | Environ. Pollut., 2018, vol. 235, p. 814 - 824 | DUNDEE CORP; UNIVERSITY OF LIVERPOOL (THE); UNIVERSITY OF DUNDEE; HANNOVER MEDICAL SCHOOL - US2007/142477, 2007, A1 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | B. Braun Melsungen Aktiengesellschaft - WO2002/40005, 2002, A2 | B. Braun Melsungen Aktiengesellschaft - EP1206934, 2002, A1 | Br. J. Pharmacol., 2001, vol. 132, # 8, p. 1916 - 1924

>  <Main tar all>
Vesicular monoamine transporter 2 pX=6.1 | TRPA1 pX=5.28 | TRPV1 pX=5.28 | M1 receptor pX=5.0 | glycine receptor ?1 subunit pX=4.96 | glycine receptor ? subunit pX=4.96 | F1 capsule-anchoring protein pX=4.89 | Glycine receptor (Alpha) pX=4.89 | ?1A-adrenoceptor pX=4.85 | Nav1.1 pX=4.85 | Voltage-gated?sodium?channel pX=4.85 | sodium channel (Alpha) pX=4.85

$$$$
L-tartaric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 3.6437 3.6437 0 0
M  V30 2 C 3.6437 2.1037 0 0 CFG=2
M  V30 3 C 2.31 1.3337 0 0 CFG=1
M  V30 4 O 2.31 -0.2063 0 0
M  V30 5 C 0.9763 2.1037 0 0
M  V30 6 O -0.3574 1.3337 0 0
M  V30 7 O 0.9763 3.6437 0 0
M  V30 8 C 4.9774 1.3337 0 0
M  V30 9 O 6.311 2.1037 0 0
M  V30 10 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1147451717

>  <MW>
150.016

>  <MW (desalted)>
150.087

>  <ClogP>
-3.22

>  <logS>
0.36

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
115.06

>  <RotBonds>
3

>  <Action on targets>
Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
activation percentage  60.4 % | activation percentage  38.4 % | Ki (inhibition constant)  2.1 mM

>  <CAS>
87-69-4

>  <Description>
Tartaric acid is primarily indicated in conditions like antiscorbutic, antiseptic.

>  <EBC_ID>
EBC-48063

>  <IUPAC Name>
(2R,3R)-2,3-dihydroxybutanedioic acid

>  <Main Tar all refs>
PROCTER & GAMBLE CO - WO2015/153184, 2015, A1 | PROCTER & GAMBLE CO - WO2015/153184, 2015, A1 | Arch. Biochem. Biophys., 2022, vol. 718

>  <Main tar all>
TRPV1 pX=4.18 | TRPA1 pX=3.79 | Mandelate racemase pX=2.68

$$$$
Paramethadione
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5966 2.9043 0 0
M  V30 2 C 2.0903 3.2244 0 0
M  V30 3 C 1.0598 2.08 0 0
M  V30 4 C 0.0294 3.2244 0 0
M  V30 5 O 2.3057 1.1748 0 0
M  V30 6 C 1.8298 -0.2898 0 0
M  V30 7 O 2.735 -1.5357 0 0
M  V30 8 N 0.2898 -0.2898 0 0
M  V30 9 C -0.6154 -1.5357 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 3 10
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155421

>  <MW>
157.074

>  <MW (desalted)>
157.167

>  <ClogP>
0.412

>  <logS>
-1.52

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
46.61

>  <RotBonds>
1

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
115-67-3

>  <Description>
Paramethadione is an anticonvulsant in the oxazolidinedione class. It is used for the control of absence seizures that are refractory to treatment with other medications. Paramethadione reduces T-type calcium currents in thalamic neurons.

>  <EBC_ID>
EBC-14841

>  <IUPAC Name>
5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione

$$$$
Acamprosate calcium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Ca 5.39 1.1114 0 0 CHG=2
M  V30 2 C -4.62 -2.8896 0 0
M  V30 3 C -3.85 -1.556 0 0
M  V30 4 O -4.62 -0.2223 0 0
M  V30 5 N -2.31 -1.556 0 0
M  V30 6 C -1.54 -0.2223 0 0
M  V30 7 C 0 -0.2223 0 0
M  V30 8 C 0.77 1.1114 0 0
M  V30 9 S 2.31 1.1114 0 0
M  V30 10 O 2.31 2.6514 0 0
M  V30 11 O 2.31 -0.4286 0 0
M  V30 12 O 3.85 1.1114 0 0 CHG=-1
M  V30 13 C 9.79 -4.13 0 0
M  V30 14 C 11.1237 -3.36 0 0
M  V30 15 O 12.4574 -4.13 0 0
M  V30 16 N 11.1237 -1.82 0 0
M  V30 17 C 12.4574 -1.05 0 0
M  V30 18 C 12.4574 0.49 0 0
M  V30 19 C 13.791 1.26 0 0
M  V30 20 S 13.791 2.8 0 0
M  V30 21 O 13.791 4.34 0 0
M  V30 22 O 15.331 2.8 0 0
M  V30 23 O 12.251 2.8 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 2 9 11
M  V30 10 1 9 12
M  V30 11 1 13 14
M  V30 12 2 14 15
M  V30 13 1 14 16
M  V30 14 1 16 17
M  V30 15 1 17 18
M  V30 16 1 18 19
M  V30 17 1 19 20
M  V30 18 2 20 21
M  V30 19 2 20 22
M  V30 20 1 20 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1696861853

>  <MW>
400.029

>  <MW (desalted)>
181.21

>  <ClogP>
-5.425

>  <logS>
-0.11

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
86.3

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 645 ?M

>  <CAS>
77337-73-6

>  <Description>
Acamprosate is a medication used to maintain alcohol abstinence in patients with alcohol dependence. It acts on the CNS, aiding in the restoration of normal glutaminergic neuron activity. Acamprosate calcium reduces alcohol intake in alcohol-dependent individuals, likely through effects on NMDA receptors and calcium channels.

>  <EBC_ID>
EBC-12310

>  <IUPAC Name>
calcium bis(3-acetamidopropane-1-sulfonate)

>  <Main Tar all refs>
Alcohol. Clin. Exp. Res., 1998, vol. 22, # 4, p. 802 - 809

>  <Main tar all>
GluN2D pX=3.19

$$$$
Phenylalanine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -1.3337 3.85 0 0
M  V30 2 C 0 4.62 0 0 CFG=1
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 C 0 6.16 0 0
M  V30 11 O -1.3337 6.93 0 0
M  V30 12 O 1.3337 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 2 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756430566

>  <MW>
165.079

>  <MW (desalted)>
165.189

>  <ClogP>
-1.556

>  <logS>
-1.35

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
3

>  <Action on targets>
- | - | Inhibitor | - | Substrate | Substrate | -

>  <Activity coefficients and valu>
Ka (association constant) = 0.008 ?M | Ka (association constant) = 0.013 ?M | Ki (inhibition constant) = 0.03 ?M | Ka (association constant) = 0.07 ?M | Km (Michaelis constant)  0.2 ?M | Km (Michaelis constant)  0.2 ?M | Ka (association constant) = 0.24 ?M

>  <CAS>
63-91-2

>  <Description>
Phenylalanine is an amino acid commonly found as a component of total parenteral nutrition. Phenylalanine is a precursor of melanin, dopamine, noradrenalin, and thyroxine.

>  <EBC_ID>
EBC-13702

>  <IUPAC Name>
(2S)-2-amino-3-phenylpropanoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327 | Curr. Top. Med. Chem., 2006, vol. 6, # 4, p. 361 - 376 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 20, p. 6324 - 6327 | EISAI CO LTD; BROAD INSTITUTE; HARVARD UNIVERSITY - WO2022/67060, 2022, A1 | EISAI CO LTD; BROAD INSTITUTE; HARVARD UNIVERSITY - WO2022/67060, 2022, A1 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 15, p. 4107 - 4112

>  <Main tar all>
carbonic anhydrase pX=8.1 | carbonic anhydrase 2 pX=7.89 | 3C-like proteinase (cleavage product of Replicase polyprotein 1ab) pX=7.52 | carbonic anhydrase 1 pX=7.15 | Phenylalanine-tRNA ligase alpha subunit pX=6.7 | Phenylalanine-tRNA ligase beta subunit pX=6.7 | carbonic anhydrase 14 pX=6.62

$$$$
Serotonin hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 -3.5894 0 0
M  V30 3 C 4.8759 -2.1248 0 0
M  V30 4 C 6.3822 -1.8046 0 0
M  V30 5 C 6.8581 -0.34 0 0
M  V30 6 C 5.9529 0.9059 0 0
M  V30 7 N 6.8581 2.1518 0 0
M  V30 8 C 8.3227 1.6759 0 0
M  V30 9 C 9.6564 2.4459 0 0
M  V30 10 C 10.9901 1.6759 0 0
M  V30 11 C 10.9901 0.1359 0 0
M  V30 12 O 12.3238 -0.6341 0 0
M  V30 13 C 9.6564 -0.6341 0 0
M  V30 14 C 8.3227 0.1359 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 11 13
M  V30 12 1 13 14
M  V30 13 1 5 14
M  V30 14 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741979085

>  <MW>
212.072

>  <MW (desalted)>
176.215

>  <ClogP>
0.756

>  <logS>
-2.085

>  <HBD>
3

>  <HBA>
2

>  <TPSA>
62.04

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Agonist | Agonist | Inhibitor | Agonist | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.12 nM | EC50  0.0002 ?M | EC50 > 0.0002 ?M | pKi  9.6  | EC50  0.32 nM | EC50  0.35 nM | EC50  0.36 nM | pKi  9.35 | Kd (dissociation constant)  0.51 nM | Kd (dissociation constant)  0.66 nM | Kd (dissociation constant)  0.66 nM | pEC50  9 | pEC50  8.94 | EC50  0.00263 ?M

>  <CAS>
153-98-0

>  <Description>
Serotonin hydrochloride is an endogenous agonist at 5-HT receptors and endogenous substrate for 5-HT transporters. It is a neurotransmitter that has roles in regulation of mood, emesis, sexuality, sleep and appetite.

>  <EBC_ID>
EBC-13726

>  <IUPAC Name>
3-(2-aminoethyl)-1H-indol-5-ol hydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 1997, vol. 283, # 3, p. 1305 - 1322 | TACTOGEN - WO2022/10937, 2022, A1 | TACTOGEN - WO2022/61242, 2022, A1 | BR. J. PHARMACOL., 1995, vol. 115, # 1, p. 107 - 116 | ACS Med. Chem. Lett., 2022, vol. 13, # 4, p. 648 - 657 | ACS Med. Chem. Lett., 2022, vol. 13, # 4, p. 648 - 657 | ACS Med. Chem. Lett., 2022, vol. 13, # 4, p. 648 - 657 | Br. J. Pharmacol., 2019, vol. 176, # 24, p. 4681 - 4695 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2015, vol. 172, # 15, p. 3846 - 3860 | Br. J. Pharmacol., 2019, vol. 176, # 24, p. 4681 - 4695 | Br. J. Pharmacol., 2019, vol. 176, # 24, p. 4681 - 4695 | ACS Chem. Neurosci., 2020, vol. 11, # 17, p. 2577 - 2589

>  <Main tar all>
5-HT1A receptor pX=9.92 | 5-HT1B receptor pX=9.7 | 5-HT1B receptor pX=9.7 | 5-HT7 receptor pX=9.6 | 5-HT2C receptor pX=9.49 | 5-HT2A receptor pX=9.46 | 5-HT2B receptor pX=9.44 | 5-HT1D receptor pX=9.35 | 5-HT7A?receptor pX=9.29 | 5-HT7B?receptor pX=9.18 | 5-HT7D?receptor pX=9.18 | 5-ht1e receptor pX=9.0 | 5-HT1F receptor pX=8.94 | 5-HT2B receptor pX=8.58

$$$$
Pramipexole dihydrochloride monohydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 Cl 0 -4.29 0 0
M  V30 4 C 16.3119 -3.85 0 0
M  V30 5 C 14.9782 -3.08 0 0
M  V30 6 C 13.6445 -3.85 0 0
M  V30 7 N 12.3109 -3.08 0 0
M  V30 8 C 10.9772 -3.85 0 0 CFG=1
M  V30 9 C 10.9772 -5.39 0 0
M  V30 10 C 9.6435 -6.16 0 0
M  V30 11 C 8.3098 -5.39 0 0
M  V30 12 N 6.8452 -5.8659 0 0
M  V30 13 C 5.94 -4.62 0 0
M  V30 14 N 4.4 -4.62 0 0
M  V30 15 S 6.8452 -3.3741 0 0
M  V30 16 C 8.3098 -3.85 0 0
M  V30 17 C 9.6435 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 1 6 7
M  V30 4 1 8 7 CFG=1
M  V30 5 1 8 9
M  V30 6 1 9 10
M  V30 7 1 10 11
M  V30 8 1 11 12
M  V30 9 2 12 13
M  V30 10 1 13 14
M  V30 11 1 13 15
M  V30 12 1 15 16
M  V30 13 2 11 16
M  V30 14 1 16 17
M  V30 15 1 8 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551900340

>  <MW>
301.078

>  <MW (desalted)>
211.327

>  <ClogP>
1.168

>  <logS>
-3.11

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
50.94

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.5 nM | Kd (dissociation constant) = 1.6 nM | pKb  8.24  | Ki (inhibition constant) = 8.5 nM | EC50 = 9.2 nM | EC50 = 12 nM | EC50 = 15 nM

>  <CAS>
191217-81-9

>  <Description>
Pramipexole is a non-ergot dopamine agonist. It is indicated for the symptomatic treatment of Parkinson?s disease.

>  <EBC_ID>
EBC-11296

>  <IUPAC Name>
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrate dihydrochloride

>  <Main Tar all refs>
Pharmacol. Rev., 1997, vol. 49, # 3, p. 231 - 252 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 17, p. 2377 - 2380 | J. Pharmacol. Exp. Ther., 2002, vol. 303, # 2, p. 805 - 814 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 17, p. 2377 - 2380 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 17, p. 2377 - 2380 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 17, p. 2377 - 2380 | Bioorg. Med. Chem. Lett., 2002, vol. 12, # 17, p. 2377 - 2380

>  <Main tar all>
D3 receptor pX=9.3 | D2 receptor pX=8.8 | ?1A-adrenoceptor pX=8.24 | D4.4 receptor pX=8.07 | D2L receptor pX=8.04 | D2S receptor pX=7.92 | D4.2 receptor pX=7.82

$$$$
Ciclopirox
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 6.6684 -6.93 0 0
M  V30 9 C 5.3347 -7.7 0 0
M  V30 10 C 4.001 -6.93 0 0
M  V30 11 N 1.3337 -5.39 0 0
M  V30 12 O 1.3337 -6.93 0 0
M  V30 13 C 0 -4.62 0 0
M  V30 14 O -1.3337 -5.39 0 0
M  V30 15 C 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 2 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509504366

>  <MW>
207.126

>  <MW (desalted)>
207.269

>  <ClogP>
2.027

>  <logS>
-2.93

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
40.54

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.2 ?mol/l | IC50  445 nM | percentage of cells in G0/G1 phase  48.1 % | inhibition percentage Active   | percentage decrease > 60 % | IC50  4.5 ?M | IC50 = 5 ?M | IC50 = 5 ?M | cell viability decrease Active

>  <CAS>
29342-05-0

>  <Description>
Ciclopirox is a broad-spectrum topical antifungal agent. It is used to treat mild to moderate onychomycosis of fingernails and toenails in immunocompetent patients.

>  <EBC_ID>
EBC-00572

>  <IUPAC Name>
6-cyclohexyl-1-hydroxy-4-methyl-1,2-dihydropyridin-2-one

>  <Main Tar all refs>
Cancer Res., 2017, vol. 77, # 17, p. 4626 - 4638 | Nat. Commun., 2019, vol. 10, # 1 | Biomolecules, 2019, vol. 9, # 11 | Clin. Cancer Res., 2019, vol. 25, # 2, p. 844 - 855 | BIOTHERYX INC - US2015/342942, 2015, A1 | CORNELL UNIVERSITY - WO2011/106226, 2011, A2 | Mini-Rev. Med. Chem., 2006, vol. 6, # 11, p. 1231 - 1241 | Mini-Rev. Med. Chem., 2006, vol. 6, # 11, p. 1231 - 1241 | Cell Death Dis., 2022, vol. 13, # 11

>  <Main tar all>
Lysine-specific demethylase 4B pX=6.7 | Nucleoprotein pX=6.35 | High mobility group protein HMGI-C pX=6.27 | Hexokinase-2 pX=6.0 | Baculoviral IAP repeat-containing protein 5 pX=5.48 | Egl nine homolog 1 pX=5.35 | Deoxyhypusine hydroxylase pX=5.3 | Monooxygenase pX=5.3 | signal transducer and activator of transcription 3 pX=5.3

$$$$
Lamotrigine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 N -1.3337 -5.39 0 0
M  V30 8 N 0 -3.08 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 2.6674 -7.7 0 0
M  V30 11 C 2.6674 -9.24 0 0
M  V30 12 C 1.3337 -10.01 0 0
M  V30 13 C 0 -9.24 0 0
M  V30 14 Cl -1.3337 -10.01 0 0
M  V30 15 C 0 -7.7 0 0
M  V30 16 Cl -1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 9 1 5 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 9 15
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1532338577

>  <MW>
255.008

>  <MW (desalted)>
256.091

>  <ClogP>
2.534

>  <logS>
-4.09

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
90.71

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor | Inhibitor | Blocker | Blocker | Blocker | Blocker

>  <Activity coefficients and valu>
Km (Michaelis constant) <= 50 nM | Km (Michaelis constant) <= 50 nM | Kd (dissociation constant)  417 nM | IC50  0.724 ?M | percentage decrease Active   | percentage decrease Active   | IC50  1.26 ?M

>  <CAS>
84057-84-1

>  <Description>
Lamotrigine is a novel anticonvulsant drug which inhibits 5-HT and sodium channel. It is used to treat some types of epilepsy and bipolar I disorder.

>  <EBC_ID>
EBC-03614

>  <IUPAC Name>
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine

>  <Main Tar all refs>
Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | Corporacion Quimico Farmaceutica Esteve SA - US2006/19968, 2006, A1 | THE JOHNS HOPKINS UNIVERSITY - US2023/228738, 2023, A1 | XENON PHARMACEUTICALS INC - WO2007/109324, 2007, A2 | STEM CELL THERANOSTICS - WO2016/191316, 2016, A1 | STEM CELL THERANOSTICS - WO2016/191316, 2016, A1 | XENON PHARMACEUTICALS INC - WO2007/109324, 2007, A2

>  <Main tar all>
?2 pX=7.3 | sigma non-opioid intracellular receptor 1 pX=7.3 | Mas-related G-protein coupled receptor member X4 pX=6.38 | Nav1.5 pX=6.14 | Cav1.1 pX=6.0 | Nav1.1 pX=6.0 | Nav1.4 pX=5.9

$$$$
Oxitriptan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.1865 -4.8376 0 0
M  V30 2 C 2.6802 -5.1578 0 0 CFG=1
M  V30 3 C 1.6497 -4.0133 0 0
M  V30 4 C 2.1256 -2.5487 0 0
M  V30 5 C 1.2204 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 3.5902 -0.5328 0 0
M  V30 8 C 4.9239 0.2372 0 0
M  V30 9 C 6.2576 -0.5328 0 0
M  V30 10 C 6.2576 -2.0728 0 0
M  V30 11 O 7.5913 -2.8428 0 0
M  V30 12 C 4.9239 -2.8428 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 14 C 2.2043 -6.6224 0 0
M  V30 15 O 3.2348 -7.7669 0 0
M  V30 16 O 0.698 -6.9426 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 4 13
M  V30 14 2 7 13
M  V30 15 1 2 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2044741046

>  <MW>
220.085

>  <MW (desalted)>
220.225

>  <ClogP>
-2.233

>  <logS>
-1.816

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
99.34

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  4.4 nM | Ki (inhibition constant) = 10.9 nM | pEC40  8.01  | inhibition percentage  83 %

>  <CAS>
4350-09-8

>  <Description>
Oxitriptan is a naturally occurring amino acid that is used to manage post-hypoxic myoclonus. It is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin.

>  <EBC_ID>
EBC-01052

>  <IUPAC Name>
(2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2022, vol. 65, # 14, p. 9735 - 9749 | H. LUNDBECK A/S - US5476782, 1995, A | Bioorg. Med. Chem. Lett., 1993, vol. 3, # 4, p. 633 - 634 | Eur. J. Clin. Pharmacol., 2000, vol. 56, # 2, p. 145 - 151

>  <Main tar all>
Kallikrein 1-related peptidase b5 pX=8.36 | 5-ht1e receptor pX=7.96 | 5-HT4 receptor pX=7.83 | CYP3A pX=7.69

$$$$
Trioxsalen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0141 -3.6128 0 0
M  V30 2 C 2.5541 -3.6128 0 0
M  V30 3 C 3.4593 -2.3669 0 0
M  V30 4 C 4.9239 -2.8428 0 0
M  V30 5 C 6.2576 -2.0728 0 0
M  V30 6 C 7.5913 -2.8428 0 0
M  V30 7 C 8.925 -2.0728 0 0
M  V30 8 C 8.925 -0.5328 0 0
M  V30 9 C 10.2586 -2.8428 0 0
M  V30 10 C 10.2586 -4.3828 0 0
M  V30 11 O 11.5923 -5.1528 0 0
M  V30 12 O 8.925 -5.1528 0 0
M  V30 13 C 7.5913 -4.3828 0 0
M  V30 14 C 6.2576 -5.1528 0 0
M  V30 15 C 6.2576 -6.6928 0 0
M  V30 16 C 4.9239 -4.3828 0 0
M  V30 17 O 3.4593 -4.8587 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 6 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 4 16
M  V30 18 1 16 17
M  V30 19 1 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404499

>  <MW>
228.079

>  <MW (desalted)>
228.243

>  <ClogP>
3.469

>  <logS>
-4.36

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
39.44

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  53.7 %

>  <CAS>
3902-71-4

>  <Description>
Trioxsalen is a derivative of the photoactive probe psoralen. Trioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo.

>  <EBC_ID>
EBC-06587

>  <IUPAC Name>
2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one

>  <Main Tar all refs>
PAIRNOMIX; PETROVSKI SLAVE; ANDRESEN J MICHAEL - WO2019/18119, 2019, A1

>  <Main tar all>
KNa1.1 pX=5.06

$$$$
Fenbufen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -9.24 0 0
M  V30 2 C 1.3337 -10.01 0 0
M  V30 3 O 1.3337 -11.55 0 0
M  V30 4 C 2.6674 -9.24 0 0
M  V30 5 C 4.001 -10.01 0 0
M  V30 6 C 5.3347 -9.24 0 0
M  V30 7 O 5.3347 -7.7 0 0
M  V30 8 C 6.6684 -10.01 0 0
M  V30 9 C 8.0021 -9.24 0 0
M  V30 10 C 9.3358 -10.01 0 0
M  V30 11 C 9.3358 -11.55 0 0
M  V30 12 C 8.0021 -12.32 0 0
M  V30 13 C 6.6684 -11.55 0 0
M  V30 14 C 10.6694 -12.32 0 0
M  V30 15 C 12.0031 -11.55 0 0
M  V30 16 C 13.3368 -12.32 0 0
M  V30 17 C 13.3368 -13.86 0 0
M  V30 18 C 12.0031 -14.63 0 0
M  V30 19 C 10.6694 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 11 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z99599540

>  <MW>
254.094

>  <MW (desalted)>
254.281

>  <ClogP>
3.143

>  <logS>
-3.93

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.97 ?M | IC50 = 0.001 mM | IC50  1000 nM | IC50 = 1000 nM | IC50  3.9 ?M | IC50  8.1 ?M | EC50  10.379 ?M | pKi  4.71

>  <CAS>
36330-85-5

>  <Description>
Fenbufen is a non-steroidal anti-inflammatory drug and a prodrug form of 4-biphenylacetic acid. Fenbufen was previously used in the treatment of osteoarthritis and inflammatory pain.

>  <EBC_ID>
EBC-02045

>  <IUPAC Name>
4-Oxo-4-(4-phenylphenyl)butanoic acid

>  <Main Tar all refs>
Chem. Biodivers., 2021, vol. 18, # 2 | ARCH. BIOCHEM. BIOPHYS., 1992, vol. 296, # 1, p. 17 - 26 | BAYER AG - US5789434, 1998, A | BAYER AG - US6166082, 2000, A | Eur. J. Med. Chem., 2009, vol. 44, # 9, p. 3798 - 3804 | Eur. J. Med. Chem., 2009, vol. 44, # 9, p. 3798 - 3804 | Eur. J. Med. Chem., 2023, vol. 245 | J. Med. Chem., 2008, vol. 51, # 24, p. 8088 - 8095

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=6.01 | AKR1C3 pX=6.0 | MMP2 pX=6.0 | MMP2 pX=6.0 | COX-1  pX=5.41 | COX-2  pX=5.09 | FFA1 receptor pX=4.98 | GPCR family 3, GABA-B receptor pX=4.71

$$$$
Probenecid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -3.85 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 N 4.001 -3.85 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 C 5.3347 -1.54 0 0
M  V30 7 C 5.3347 0 0 0
M  V30 8 S 5.3347 -4.62 0 0
M  V30 9 O 4.5647 -5.9537 0 0
M  V30 10 O 6.1047 -3.2863 0 0
M  V30 11 C 6.6684 -5.39 0 0
M  V30 12 C 8.0021 -4.62 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 9.3358 -6.93 0 0
M  V30 15 C 8.0021 -7.7 0 0
M  V30 16 C 6.6684 -6.93 0 0
M  V30 17 C 10.6694 -7.7 0 0
M  V30 18 O 12.0031 -6.93 0 0
M  V30 19 O 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 8
M  V30 8 2 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 14 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53037954

>  <MW>
285.103

>  <MW (desalted)>
285.359

>  <ClogP>
3.371

>  <logS>
-2.898

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
74.68

>  <RotBonds>
6

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  1.6 nM | IC90  0.27 ?M

>  <CAS>
57-66-9

>  <Description>
Probenecid is a potent and selective agonist of transient receptor potential vanilloid 2 (TRPV2) channels. It is the prototypical uricosuric agent and is primarily used in treating gout and hyperuricemia. Probenecid is also a clinically used broad-spectrum Pannexin1 blocker. I it used to treat gouty arthritis, tophaceous gout, and hyperuricemia.

>  <EBC_ID>
EBC-03820

>  <IUPAC Name>
4-(dipropylsulfamoyl)benzoic acid

>  <Main Tar all refs>
UNIVERSITY SYSTEM OF OHIO - EP2882431, 2020, B1 | Viruses, 2022, vol. 14, # 5

>  <Main tar all>
TRPV2 pX=8.8 | Organic anion transporter 3 pX=7.52

$$$$
Sulfamethoxydiazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -1.54 0 0
M  V30 2 O 4.001 -2.31 0 0
M  V30 3 C 4.001 -3.85 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 N 5.3347 -6.16 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 N 4.001 -8.47 0 0
M  V30 8 S 2.6674 -9.24 0 0
M  V30 9 O 1.8974 -7.9063 0 0
M  V30 10 O 3.4374 -10.5737 0 0
M  V30 11 C 1.3337 -10.01 0 0
M  V30 12 C 1.3337 -11.55 0 0
M  V30 13 C -0 -12.32 0 0
M  V30 14 C -1.3337 -11.55 0 0
M  V30 15 N -2.6674 -12.32 0 0
M  V30 16 C -1.3337 -10.01 0 0
M  V30 17 C 0 -9.24 0 0
M  V30 18 N 2.6674 -6.16 0 0
M  V30 19 C 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 2 6 18
M  V30 19 1 18 19
M  V30 20 2 3 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1511483974

>  <MW>
280.063

>  <MW (desalted)>
280.303

>  <ClogP>
0.648

>  <logS>
-2.43

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
107.2

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKa (association)  6.69

>  <CAS>
651-06-9

>  <Description>
Sulfamethoxydiazine is a long acting sulfonamide used in leprosy, urinary, and respiratory tract infections. It has binding affinity to dihydrofolate synthase.

>  <EBC_ID>
EBC-08507

>  <IUPAC Name>
4-amino-N-(5-methoxypyrimidin-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Hazard. Mater., 2018, vol. 341, p. 438 - 447

>  <Main tar all>
dihydrofolate synthase pX=6.69

$$$$
Ketoprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 C 4.001 -0.77 0 0
M  V30 3 C 5.3347 0 0 0
M  V30 4 O 5.3347 1.54 0 0
M  V30 5 O 6.6684 -0.77 0 0
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 C 5.3347 -3.08 0 0
M  V30 8 C 5.3347 -4.62 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 C 2.6674 -4.62 0 0
M  V30 11 C 2.6674 -3.08 0 0
M  V30 12 C 1.3337 -5.39 0 0
M  V30 13 O 1.3337 -6.93 0 0
M  V30 14 C 0 -4.62 0 0
M  V30 15 C -1.3337 -5.39 0 0
M  V30 16 C -2.6674 -4.62 0 0
M  V30 17 C -2.6674 -3.08 0 0
M  V30 18 C -1.3337 -2.31 0 0
M  V30 19 C 0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 10 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532758

>  <MW>
254.094

>  <MW (desalted)>
254.281

>  <ClogP>
2.761

>  <logS>
-3.9

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
54.37

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Allosteric Modulator | Inhibitor | Inhibitor | Allosteric Modulator | Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.001 ?M | pEC50  8.87 | IC50  1.7 nM | Ki (inhibition constant) = 1.84 nM | inhibition percentage  64 % | inhibition percentage  64 % | Ki (inhibition constant) <= 10 nM | Kd (dissociation constant)  1.23E-08 M | IC50  0.031 ?M

>  <CAS>
22071-15-4

>  <Description>
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID). It is a non-selective COX inhibitor. It is used used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, mild to moderate muscle pain, postoperative pain, and postpartum pain.

>  <EBC_ID>
EBC-06731

>  <IUPAC Name>
2-(3-Benzoylphenyl)propanoic acid

>  <Main Tar all refs>
ZOETIS INC. - WO2015/95045, 2015, A1 | Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | CAN. J. PHYSIOL. PHARMACOL., 1997, vol. 75, # 9, p. 1088 - 1095 | J. Pharmacol. Exp. Ther., 2001, vol. 298, # 3, p. 1179 - 1184 | J. Med. Chem., 2005, vol. 48, # 13, p. 4312 - 4331 | J. Med. Chem., 2005, vol. 48, # 13, p. 4312 - 4331 | GLAXOSMITHKLINE PLC - WO2005/68414, 2005, A1 | Mol. Neurobiol., 2018, p. 1 - 11 | Lett. Drug Des. Discov., 2020, vol. 17, # 9, p. 1117 - 1125

>  <Main tar all>
COX-2  pX=9.0 | MC3 receptor pX=8.87 | COX-1  pX=8.77 | Organic anion transporter 2 pX=8.74 | CXCR1 pX=8.25 | CXCR1 pX=8.25 | TRPV1 pX=8.0 | Alternative prion protein pX=7.91 | Cytochrome c oxidase subunit 1 pX=7.51

$$$$
Boscalid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 6.6684 -0.77 0 0
M  V30 2 C 6.6684 -2.31 0 0
M  V30 3 C 8.0021 -3.08 0 0
M  V30 4 C 8.0021 -4.62 0 0
M  V30 5 C 6.6684 -5.39 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 C 5.3347 -3.08 0 0
M  V30 8 C 6.6684 -6.93 0 0
M  V30 9 C 8.0021 -7.7 0 0
M  V30 10 C 8.0021 -9.24 0 0
M  V30 11 C 6.6684 -10.01 0 0
M  V30 12 C 5.3347 -9.24 0 0
M  V30 13 C 5.3347 -7.7 0 0
M  V30 14 N 4.001 -6.93 0 0
M  V30 15 C 2.6674 -7.7 0 0
M  V30 16 O 2.6674 -9.24 0 0
M  V30 17 C 1.3337 -6.93 0 0
M  V30 18 C -0 -7.7 0 0
M  V30 19 C -1.3337 -6.93 0 0
M  V30 20 C -1.3337 -5.39 0 0
M  V30 21 N 0 -4.62 0 0
M  V30 22 C 1.3337 -5.39 0 0
M  V30 23 Cl 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1948010801

>  <MW>
342.033

>  <MW (desalted)>
343.207

>  <ClogP>
3.437

>  <logS>
-6.872

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
41.99

>  <RotBonds>
3

>  <CAS>
188425-85-6

>  <Description>
Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.

>  <EBC_ID>
EBC-04344

>  <IUPAC Name>
2-chloro-N-{4'-chloro-[1,1'-biphenyl]-2-yl}pyridine-3-carboxamide

$$$$
Tazarotene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 -10.78 0 0
M  V30 2 C -8.0021 -9.24 0 0
M  V30 3 O -6.6684 -8.47 0 0
M  V30 4 C -6.6684 -6.93 0 0
M  V30 5 O -8.0021 -6.16 0 0
M  V30 6 C -5.3347 -6.16 0 0
M  V30 7 C -5.3347 -4.62 0 0
M  V30 8 C -4.001 -3.85 0 0
M  V30 9 C -2.6674 -4.62 0 0
M  V30 10 C -1.3337 -3.85 0 0
M  V30 11 C 0 -3.08 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 S 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 6.3246 -4.2597 0 0
M  V30 21 C 4.3448 -4.2597 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 23 C 2.6674 -3.08 0 0
M  V30 24 N -2.6674 -6.16 0 0
M  V30 25 C -4.001 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 3 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 1 19 22
M  V30 22 2 15 22
M  V30 23 1 22 23
M  V30 24 2 12 23
M  V30 25 2 9 24
M  V30 26 1 24 25
M  V30 27 2 6 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1424590960

>  <MW>
351.129

>  <MW (desalted)>
351.462

>  <ClogP>
6.075

>  <logS>
-5.798

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
39.19

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
ID80 = 0.8 nM | EC50  0.8 nM | EC50  2.5 nM | IC50  5.1 nM

>  <CAS>
118292-40-3

>  <Description>
Tazarotene is an acetylenic retinoid used to treat fine wrinkles, mottled pigmentation of the skin, acne vulgaris, and plaque psoriasis. It binds to all three members of the retinoic acid receptor (RAR) family.

>  <EBC_ID>
EBC-11242

>  <IUPAC Name>
ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1997, vol. 282, # 2, p. 528 - 534 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 2, p. 489 - 492 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 10, p. 1736 - 1741 | Antiviral Res., 2019, vol. 168, p. 146 - 155

>  <Main tar all>
Ornithine decarboxylase pX=9.7 | Retinoic acid receptor-? pX=9.1 | Regulatory protein GAL4 pX=8.6 | Retinoic acid receptor-? pX=8.29

$$$$
Valdecoxib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 O 2.5796 -3.2152 0 0
M  V30 4 N 2.1037 -4.6798 0 0
M  V30 5 C 0.5637 -4.6798 0 0
M  V30 6 C 0.0878 -3.2152 0 0
M  V30 7 C -1.3768 -2.7393 0 0
M  V30 8 C -2.5213 -3.7698 0 0
M  V30 9 C -3.9859 -3.2939 0 0
M  V30 10 C -4.3061 -1.7875 0 0
M  V30 11 C -3.1616 -0.7571 0 0
M  V30 12 C -1.697 -1.233 0 0
M  V30 13 S -5.7707 -1.3116 0 0
M  V30 14 O -7.2353 -0.8358 0 0
M  V30 15 O -6.2466 -2.7763 0 0
M  V30 16 N -5.2948 0.153 0 0
M  V30 17 C -0.3415 -5.9257 0 0
M  V30 18 C 0.2849 -7.3326 0 0
M  V30 19 C -0.6203 -8.5784 0 0
M  V30 20 C -2.1519 -8.4175 0 0
M  V30 21 C -2.7783 -7.0106 0 0
M  V30 22 C -1.8731 -5.7647 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 7 12
M  V30 14 1 10 13
M  V30 15 2 13 14
M  V30 16 2 13 15
M  V30 17 1 13 16
M  V30 18 1 5 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671687

>  <MW>
314.359

>  <MW (desalted)>
314.359

>  <ClogP>
1.832

>  <logS>
-4.461

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
86.19

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
IC50 <= 0.1 nM | Kd (dissociation constant) = 2.3 nM

>  <CAS>
181695-72-7

>  <Description>
Valdecoxib is a COX-2 inhibitor used to treat osteoarthritis and dysmenorrhoea.

>  <EBC_ID>
EBC-26753

>  <IUPAC Name>
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
MERCK & CO INC - WO2003/86314, 2003, A2 | Mini-Rev. Med. Chem., 2004, vol. 4, # 6, p. 597 - 601

>  <Main tar all>
Insulin receptor pX=10.0 | COX-2  pX=8.64

$$$$
Flumequine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -0.77 0 0
M  V30 3 C 2.6674 0 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 4.001 2.31 0 0
M  V30 6 C 4.001 3.85 0 0
M  V30 7 C 5.3347 4.62 0 0
M  V30 8 F 5.3347 6.16 0 0
M  V30 9 C 6.6684 3.85 0 0
M  V30 10 C 6.6684 2.31 0 0
M  V30 11 C 8.0021 1.54 0 0
M  V30 12 O 9.3358 2.31 0 0
M  V30 13 C 8.0021 0 0 0
M  V30 14 C 6.6684 -0.77 0 0
M  V30 15 N 5.3347 0 0 0
M  V30 16 C 5.3347 1.54 0 0
M  V30 17 C 9.3358 -0.77 0 0
M  V30 18 O 9.3358 -2.31 0 0
M  V30 19 O 10.6694 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 2 15
M  V30 16 1 15 16
M  V30 17 2 5 16
M  V30 18 1 10 16
M  V30 19 1 13 17
M  V30 20 2 17 18
M  V30 21 1 17 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671185

>  <MW>
261.248

>  <MW (desalted)>
261.248

>  <ClogP>
2.432

>  <logS>
-2.583

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
57.61

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  7.8 ?M | inhibition percentage > 30 % | IC50  40.3 ?M

>  <CAS>
42835-25-6

>  <Description>
Flumequine  is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. It is an inhibitor of DNA gyrase, which is a topoisomerase II inhibitor found only in bacteria. It was used to treat urinary tract infections until toxicity studies were reported.

>  <EBC_ID>
EBC-03872

>  <IUPAC Name>
7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0,5,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid

>  <Main Tar all refs>
Protein Sci., 2022, vol. 31, # 10 | Clin. Cancer Res., 2019, vol. 25, # 2, p. 844 - 855 | J. Inorg. Biochem., 2011, vol. 105, # 10, p. 1273 - 1285

>  <Main tar all>
Fragilysin pX=5.11 | Hexokinase-2 pX=4.63 | Lipoxygenase pX=4.39

$$$$
Bicalutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.7721 -4.4137 0 0
M  V30 2 C 8.0021 -3.08 0 0
M  V30 3 O 7.2321 -1.7463 0 0
M  V30 4 C 6.6684 -3.85 0 0
M  V30 5 S 6.6684 -5.39 0 0
M  V30 6 O 8.2084 -5.39 0 0
M  V30 7 O 5.1284 -5.39 0 0
M  V30 8 C 6.6684 -6.93 0 0
M  V30 9 C 8.0021 -7.7 0 0
M  V30 10 C 8.0021 -9.24 0 0
M  V30 11 C 6.6684 -10.01 0 0
M  V30 12 F 6.6684 -11.55 0 0
M  V30 13 C 5.3347 -9.24 0 0
M  V30 14 C 5.3347 -7.7 0 0
M  V30 15 C 9.3358 -2.31 0 0
M  V30 16 O 10.6694 -3.08 0 0
M  V30 17 N 9.3358 -0.77 0 0
M  V30 18 C 10.6694 0 0 0
M  V30 19 C 10.6694 1.54 0 0
M  V30 20 C 12.0031 2.31 0 0
M  V30 21 C 13.3368 1.54 0 0
M  V30 22 C 14.6705 2.31 0 0
M  V30 23 N 16.0041 3.08 0 0
M  V30 24 C 13.3368 -0 0 0
M  V30 25 C 12.0031 -0.77 0 0
M  V30 26 C 14.6705 -0.77 0 0
M  V30 27 F 16.0041 -1.54 0 0
M  V30 28 F 13.9005 -2.1037 0 0
M  V30 29 F 15.4405 0.5637 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 2 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 3 22 23
M  V30 24 2 21 24
M  V30 25 1 24 25
M  V30 26 2 18 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 1 26 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2108698963

>  <MW>
430.373

>  <MW (desalted)>
430.373

>  <ClogP>
2.707

>  <logS>
-4.918

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
107.26

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 6.19E-06 ?M

>  <CAS>
90357-06-5

>  <Description>
Bicalutamide is an androgen receptor inhibitor used to treat Stage D2 metastatic carcinoma of the prostate.

>  <EBC_ID>
EBC-00668

>  <IUPAC Name>
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide

>  <Main Tar all refs>
Chem. Pharm. Bull., 2011, vol. 59, # 11, p. 1363 - 1368

>  <Main tar all>
Androgen receptor pX=11.2

$$$$
Adenosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 C 2.4172 0.77 0 0
M  V30 9 N 3.3224 2.0159 0 0
M  V30 10 C 4.787 1.54 0 0
M  V30 11 C 2.8465 -1.9405 0 0 CFG=2
M  V30 12 O 3.7517 -3.1864 0 0
M  V30 13 C 2.8465 -4.4323 0 0 CFG=2
M  V30 14 C 3.3224 -5.8969 0 0
M  V30 15 O 4.8287 -6.2171 0 0
M  V30 16 C 1.3818 -3.9564 0 0 CFG=1
M  V30 17 O 0.136 -4.8616 0 0
M  V30 18 C 1.3818 -2.4164 0 0 CFG=1
M  V30 19 O 0.136 -1.5112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 2 10
M  V30 11 1 6 10
M  V30 12 1 11 7 CFG=3
M  V30 13 1 11 12
M  V30 14 1 13 12
M  V30 15 1 13 14 CFG=3
M  V30 16 1 14 15
M  V30 17 1 16 13
M  V30 18 1 16 17 CFG=1
M  V30 19 1 16 18
M  V30 20 1 18 11
M  V30 21 1 18 19 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1341543331

>  <MW>
267.241

>  <MW (desalted)>
267.241

>  <ClogP>
-2.158

>  <logS>
-1.38

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
139.54

>  <RotBonds>
2

>  <Action on targets>
- | - | Inhibitor | Agonist | Agonist | - | Inhibitor | Agonist

>  <Activity coefficients and valu>
EC50 = 0.8 nM | Kd (dissociation constant) = 0.95 nM | Ki (inhibition constant) = 1 nM | pIC50  8.94 | EC50  0.006 ?M | Km (Michaelis constant)  8.1 nM | IC50 = 0.01 ?M | EC50  20.6 nM

>  <CAS>
58-61-7

>  <Description>
Adenosine is a medication used in myocardial perfusion scintigraphy and to treat supraventricular tachycardia. It is an agonist of adenosine receptors A1 and A2.

>  <EBC_ID>
EBC-11050

>  <IUPAC Name>
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

>  <Main Tar all refs>
Biochem. Pharmacol., 2005, vol. 70, # 4, p. 598 - 605 | Curr. Med. Chem., 2000, vol. 7, # 12, p. 1269 - 1288 | J. MED. CHEM., 1988, vol. 31, # 9, p. 1798 - 1804 | J. Med. Chem., 2016, vol. 59, # 3, p. 947 - 964 | Cell. Signal., 2016, vol. 28, # 6, p. 552 - 560 | Biochemistry, 2011, vol. 50, # 11, p. 1885 - 1893 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 14, p. 3642 - 3645 | J. Pharmacol. Exp. Ther., 2006, vol. 317, # 1, p. 172 - 180

>  <Main tar all>
Growth hormone secretagogue receptor type 1 (isoform 1A) pX=9.1 | A1 receptor pX=9.02 | S-Adenosylhomocysteine hydrolase pX=9.0 | A3 receptor pX=8.94 | A2A receptor pX=8.22 | Adenosine kinase pX=8.09 | Adenosine A2A receptor pX=8.0 | A2B receptor pX=7.69

$$$$
(-)-Paroxetine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 F 6.7698 5.0371 0 0
M  V30 3 C 8.1035 4.2671 0 0
M  V30 4 C 9.4372 5.0371 0 0
M  V30 5 C 10.7709 4.2671 0 0
M  V30 6 C 10.7709 2.7271 0 0
M  V30 7 C 9.4372 1.9571 0 0
M  V30 8 C 8.1035 2.7271 0 0
M  V30 9 C 12.1045 1.9571 0 0 CFG=2
M  V30 10 C 13.4382 2.7271 0 0
M  V30 11 C 14.7719 1.9571 0 0
M  V30 12 N 14.7719 0.4171 0 0
M  V30 13 C 13.4382 -0.3529 0 0
M  V30 14 C 12.1045 0.4171 0 0 CFG=1
M  V30 15 C 10.7709 -0.3529 0 0
M  V30 16 O 10.7709 -1.8929 0 0
M  V30 17 C 9.4372 -2.6629 0 0
M  V30 18 C 9.4372 -4.2029 0 0
M  V30 19 C 8.1035 -4.9729 0 0
M  V30 20 C 6.7698 -4.2029 0 0
M  V30 21 O 5.3052 -4.6788 0 0
M  V30 22 C 4.4 -3.4329 0 0
M  V30 23 O 5.3052 -2.187 0 0
M  V30 24 C 6.7698 -2.6629 0 0
M  V30 25 C 8.1035 -1.8929 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 9 6 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 9 14
M  V30 15 1 14 15 CFG=1
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 20 24
M  V30 26 1 24 25
M  V30 27 2 17 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557492145

>  <MW>
365.826

>  <MW (desalted)>
329.365

>  <ClogP>
4.238

>  <logS>
-4.623

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
39.72

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Ka (association constant) = 0.085 nM | IC50 = 0.29 nM

>  <CAS>
78246-49-8

>  <Description>
Paroxetine is a selective serotonin reuptake inhibitor used to treat major depressive disorder, panic disorder, OCD, social phobia, generalized anxiety disorder, the vasomotor symptoms of menopause, and premenstrual dysphoric disorder.

>  <EBC_ID>
EBC-12122

>  <IUPAC Name>
(3S,4R)-3-[(1,3-dioxaindan-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2002, vol. 303, # 1, p. 211 - 217 | Curr. Med. Chem., 2002, vol. 9, # 8, p. 799 - 810

>  <Main tar all>
SERT pX=10.1 | 5-HT receptor pX=9.54

$$$$
Abiraterone acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.7374 -6.1116 0 0
M  V30 2 C -2.2215 -5.8405 0 0
M  V30 3 O -1.2287 -7.0178 0 0
M  V30 4 O -1.6982 -4.3921 0 0
M  V30 5 C -0.1823 -4.1211 0 0 CFG=1
M  V30 6 C 0.3409 -2.6727 0 0
M  V30 7 C 1.8569 -2.4016 0 0
M  V30 8 C 2.8496 -3.5789 0 0 CFG=2
M  V30 9 C 3.3729 -2.1305 0 0
M  V30 10 C 4.3656 -3.3079 0 0 CFG=1
M  V30 11 C 4.8888 -1.8595 0 0
M  V30 12 C 6.4048 -1.5884 0 0
M  V30 13 C 7.3975 -2.7657 0 0 CFG=1
M  V30 14 C 8.0693 -1.38 0 0
M  V30 15 C 6.8743 -4.2141 0 0 CFG=1
M  V30 16 C 8.0901 -5.1593 0 0
M  V30 17 C 9.3647 -4.2951 0 0
M  V30 18 C 8.9367 -2.8158 0 0
M  V30 19 C 9.8819 -1.5999 0 0
M  V30 20 C 9.3016 -0.1735 0 0
M  V30 21 C 10.2467 1.0423 0 0
M  V30 22 C 11.7723 0.8317 0 0
M  V30 23 N 12.3526 -0.5948 0 0
M  V30 24 C 11.4074 -1.8106 0 0
M  V30 25 C 5.3583 -4.4852 0 0 CFG=2
M  V30 26 C 4.8351 -5.9336 0 0
M  V30 27 C 3.3191 -6.2046 0 0
M  V30 28 C 2.3264 -5.0273 0 0
M  V30 29 C 0.8105 -5.2984 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 10 8
M  V30 10 1 10 11 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 15 13
M  V30 15 1 15 16 CFG=1
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 26 1 25 15
M  V30 27 1 10 25
M  V30 28 1 25 26 CFG=3
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 8 28
M  V30 32 1 28 29
M  V30 33 1 5 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741979782

>  <MW>
391.546

>  <MW (desalted)>
391.546

>  <ClogP>
6.111

>  <logS>
-5.942

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
39.19

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0025 ?M | IC50 = 2.9 nM

>  <CAS>
154229-18-2

>  <Description>
Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) with antiandrogen activity. Abiraterone acetate is a prodrug form of abiraterone.

>  <EBC_ID>
EBC-23629

>  <IUPAC Name>
(3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl acetate

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2014, vol. 24, # 11, p. 2444 - 2447 | Annual Reports in Medicinal Chemistry, 2012, vol. 47, p. 499 - 569

>  <Main tar all>
CYP17A1 pX=8.6 | CYP17A1 pX=8.54

$$$$
Cilastatine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -13.3021 10.344 0 0
M  V30 2 C -13.0347 8.8274 0 0
M  V30 3 C -14.4818 8.3006 0 0
M  V30 4 C -11.4947 8.8274 0 0
M  V30 5 C -12.2647 7.4937 0 0 CFG=2
M  V30 6 C -12.2647 5.9537 0 0
M  V30 7 O -13.5984 5.1837 0 0
M  V30 8 N -10.931 5.1837 0 0
M  V30 9 C -10.931 3.6437 0 0
M  V30 10 C -9.5974 2.8737 0 0
M  V30 11 C -8.2637 3.6437 0 0
M  V30 12 C -6.93 2.8737 0 0
M  V30 13 C -5.5963 3.6437 0 0
M  V30 14 C -4.2626 2.8737 0 0
M  V30 15 S -2.929 3.6437 0 0
M  V30 16 C -1.5953 2.8737 0 0
M  V30 17 C -0.2616 3.6437 0 0 CFG=2
M  V30 18 N -0.2616 5.1837 0 0
M  V30 19 C 1.0721 2.8737 0 0
M  V30 20 O 2.4058 3.6437 0 0
M  V30 21 O 1.0721 1.3337 0 0
M  V30 22 C -12.2647 2.8737 0 0
M  V30 23 O -12.2647 1.3337 0 0
M  V30 24 O -13.5984 3.6437 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 2
M  V30 6 1 5 6 CFG=3
M  V30 7 2 6 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 17 18 CFG=3
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 9 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2312626081

>  <MW>
358.156

>  <MW (desalted)>
358.453

>  <ClogP>
0.474

>  <logS>
-3.258

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
129.72

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1E-07 M | IC50  0.3 ?M

>  <CAS>
82009-34-5

>  <Description>
Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Cilastatin is indicated, in combination with imipenem with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.

>  <EBC_ID>
EBC-12881

>  <IUPAC Name>
(2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-{[(1S)-2,2-dimethylcyclopropyl]formamido}hept-2-enoic acid

>  <Main Tar all refs>
MERCK & CO INC - US4988681, 1991, A | ANTIMICROB. AGENTS CHEMOTHER., 1995, vol. 39, # 7, p. 1629 - 1631

>  <Main tar all>
Dipeptidase 1 pX=7.0 | Beta-lactamase NDM-1 pX=6.52

$$$$
Levobupivacaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 N 0 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0
M  V30 7 C -1.3337 -6.93 0 0
M  V30 8 C 0 -7.7 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 1.3337 -5.39 0 0 CFG=1
M  V30 11 C 2.6674 -4.62 0 0
M  V30 12 O 2.6674 -3.08 0 0
M  V30 13 N 4.001 -5.39 0 0
M  V30 14 C 5.3347 -4.62 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 C 4.001 -2.31 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 C 8.0021 -3.08 0 0
M  V30 19 C 8.0021 -4.62 0 0
M  V30 20 C 6.6684 -5.39 0 0
M  V30 21 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 5
M  V30 11 1 10 11 CFG=3
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 14 20
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242128693

>  <MW>
288.22

>  <MW (desalted)>
288.428

>  <ClogP>
3.691

>  <logS>
-3.798

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
32.34

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Blocker | Blocker | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.42 ?M | IC50  2.8 ?M | inhibition percentage  67.5 % | IC50  43 ?M

>  <CAS>
27262-47-1

>  <Description>
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is used for the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management

>  <EBC_ID>
EBC-03922

>  <IUPAC Name>
(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2003, vol. 304, # 1, p. 71 - 80 | Mol. Pharmacol., 2003, vol. 63, # 6, p. 1398 - 1406 | Br. J. Pharmacol., 2002, vol. 137, # 8, p. 1269 - 1279 | J. Pharmacol. Exp. Ther., 2003, vol. 306, # 1, p. 84 - 92

>  <Main tar all>
Alpha-1-acid glycoprotein pX=5.85 | Nav1.4 pX=5.55 | Kv11.1 pX=5.02 | KNa1.1 pX=4.37

$$$$
R-Salbutamol sulphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.8243 4.8012 0 0
M  V30 2 C -1.4906 4.0312 0 0
M  V30 3 C -2.2606 2.6975 0 0
M  V30 4 C -0.7206 5.3649 0 0
M  V30 5 N -0.1569 3.2612 0 0
M  V30 6 C -0.1569 1.7212 0 0
M  V30 7 C 1.1768 0.9512 0 0 CFG=2
M  V30 8 O 2.5105 1.7212 0 0
M  V30 9 C 1.1768 -0.5888 0 0
M  V30 10 C 2.5105 -1.3588 0 0
M  V30 11 C 2.5105 -2.8988 0 0
M  V30 12 C 1.1768 -3.6688 0 0
M  V30 13 O 1.1768 -5.2088 0 0
M  V30 14 C -0.1569 -2.8988 0 0
M  V30 15 C -1.4906 -3.6688 0 0
M  V30 16 O -2.8243 -2.8988 0 0
M  V30 17 C -0.1569 -1.3588 0 0
M  V30 18 O 7.5705 -1.54 0 0
M  V30 19 S 7.5705 0 0 0
M  V30 20 O 7.5705 1.54 0 0
M  V30 21 O 9.1105 -0 0 0
M  V30 22 O 6.0305 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 14 17
M  V30 17 2 9 17
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 2 19 21
M  V30 21 1 19 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3071621361

>  <MW>
337.12

>  <MW (desalted)>
239.311

>  <ClogP>
0.061

>  <logS>
0.166

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
5

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
EC50 = 100 nM | Kd (dissociation constant) = 1540 nM

>  <CAS>
324000-04-6

>  <Description>
R-Salbutamol sulphate  is a short-acting beta2-adrenergic receptor agonist. It has the potential for the treatment of COPD.

>  <EBC_ID>
EBC-08750

>  <IUPAC Name>
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; sulfuric acid

>  <Main Tar all refs>
COURAGE (unclear) - US2005/20692, 2005, A1 | COURAGE (unclear) - US2005/20692, 2005, A1

>  <Main tar all>
?2-adrenoceptor pX=7.0 | ?1-adrenoceptor pX=5.81

$$$$
Dehydrocholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.3016 -2.9065 0 0
M  V30 2 C 9.8819 -1.4801 0 0 CFG=2
M  V30 3 C 11.4074 -1.2694 0 0
M  V30 4 C 12.3526 -2.4852 0 0
M  V30 5 C 13.8781 -2.2746 0 0
M  V30 6 O 14.8233 -3.4904 0 0
M  V30 7 O 14.4585 -0.8481 0 0
M  V30 8 C 8.9367 -0.2642 0 0
M  V30 9 C 9.3647 1.2151 0 0
M  V30 10 C 8.0901 2.0793 0 0
M  V30 11 C 6.8743 1.1341 0 0 CFG=1
M  V30 12 C 5.3583 1.4052 0 0 CFG=1
M  V30 13 C 4.3656 0.2279 0 0 CFG=2
M  V30 14 C 4.8888 -1.2205 0 0
M  V30 15 C 6.4048 -1.4916 0 0
M  V30 16 O 6.928 -2.94 0 0
M  V30 17 C 7.3975 -0.3143 0 0 CFG=2
M  V30 18 C 8.0693 -1.7 0 0
M  V30 19 C 2.8496 0.4989 0 0 CFG=1
M  V30 20 C 3.3729 -0.9495 0 0
M  V30 21 C 1.8569 -0.6784 0 0
M  V30 22 C 0.3409 -0.4073 0 0
M  V30 23 C -0.1823 1.0411 0 0
M  V30 24 O -1.6982 1.3121 0 0
M  V30 25 C 0.8105 2.2184 0 0
M  V30 26 C 2.3264 1.9473 0 0 CFG=1
M  V30 27 C 3.3191 3.1246 0 0
M  V30 28 C 4.8351 2.8536 0 0
M  V30 29 O 5.8278 4.0309 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=3
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 17 15
M  V30 17 1 17 8
M  V30 18 1 11 17
M  V30 19 1 17 18 CFG=3
M  V30 20 1 13 19
M  V30 21 1 19 20 CFG=3
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 26 25 CFG=1
M  V30 28 1 19 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 12 28 CFG=1
M  V30 32 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3407753879

>  <MW>
402.241

>  <MW (desalted)>
402.524

>  <ClogP>
2.325

>  <logS>
-3.357

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
88.51

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | Allosteric Modulator

>  <Activity coefficients and valu>
Km (Michaelis constant) = 7 ?M | Ki (inhibition constant)  29.7 ?M | Ki (inhibition constant)  53.9 ?M | Ki (inhibition constant)  57.8 ?M | inhibition percentage  28 %

>  <CAS>
81-23-2

>  <Description>
Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid. It has been used for stimulation of biliary lipid secretion.

>  <EBC_ID>
EBC-12273

>  <IUPAC Name>
(4R)-4-[(3aS,3bR,5aS,9aS,9bS,11aR)-9a,11a-dimethyl-4,7,11-trioxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
Biol. Pharm. Bull., 2006, vol. 29, # 3, p. 539 - 542 | Pharmacol. Res., 2009, vol. 60, # 1, p. 50 - 56 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 1453 - 1459 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 1453 - 1459 | J. Pharmacol. Exp. Ther., 2013, vol. 347, # 2, p. 276 - 287

>  <Main tar all>
Aldo-Keto Reductase Family 1, Member C20 pX=5.15 | OATP1B1 pX=4.53 | carbonic anhydrase 9 pX=4.27 | carbonic anhydrase 2 pX=4.24 | adenylyl cyclase 2 pX=4.19

$$$$
Progesterone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.2567 -5.6522 0 0
M  V30 2 C 4.7822 -5.8629 0 0
M  V30 3 O 5.3626 -7.2893 0 0
M  V30 4 C 5.7274 -4.6471 0 0 CFG=1
M  V30 5 C 5.2994 -3.1677 0 0
M  V30 6 C 6.574 -2.3035 0 0
M  V30 7 C 7.7898 -3.2487 0 0 CFG=1
M  V30 8 C 9.3058 -2.9776 0 0 CFG=2
M  V30 9 C 9.829 -1.5293 0 0
M  V30 10 C 11.345 -1.2582 0 0
M  V30 11 C 12.3377 -2.4355 0 0
M  V30 12 C 13.8537 -2.1644 0 0
M  V30 13 C 14.8464 -3.3418 0 0
M  V30 14 O 16.3624 -3.0707 0 0
M  V30 15 C 14.3232 -4.7901 0 0
M  V30 16 C 12.8072 -5.0612 0 0
M  V30 17 C 11.8145 -3.8839 0 0 CFG=1
M  V30 18 C 11.2913 -5.3323 0 0
M  V30 19 C 10.2985 -4.155 0 0 CFG=1
M  V30 20 C 9.7753 -5.6034 0 0
M  V30 21 C 8.2593 -5.8744 0 0
M  V30 22 C 7.2666 -4.6971 0 0 CFG=2
M  V30 23 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 11
M  V30 18 1 17 18 CFG=1
M  V30 19 1 19 17
M  V30 20 1 8 19
M  V30 21 1 19 20 CFG=1
M  V30 22 1 20 21
M  V30 23 1 22 21
M  V30 24 1 22 4
M  V30 25 1 7 22
M  V30 26 1 22 23 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485353

>  <MW>
314.225

>  <MW (desalted)>
314.462

>  <ClogP>
3.965

>  <logS>
-5.627

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
34.14

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  4.3 pM | stimulation rate  100 % | Ki (inhibition constant)  0.09 nM

>  <CAS>
57-83-0

>  <Description>
Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR); An agonist of the membrane progesterone receptors(mPRs).

>  <EBC_ID>
EBC-06111

>  <IUPAC Name>
(1S,3aS,3bS,9aR,9bS,11aS)-1-acetyl-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Front. Endocrinol., 2022, vol. 13 | Steroids, 2005, vol. 70, # 14, p. 946 - 953 | EUR. J. PHARMACOL., 1996, vol. 303, # 3, p. 227 - 234

>  <Main tar all>
Progesterone receptor pX=11.4 | Progesterone receptor (isoform A) pX=10.1 | Progesterone receptor (isoform B) pX=10.0

$$$$
Cefradin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.0529 1.0518 0 0
M  V30 2 C 3.7192 1.8218 0 0
M  V30 3 C 2.3855 1.0518 0 0
M  V30 4 N 1.0518 1.8218 0 0
M  V30 5 C 1.0518 3.3618 0 0 CFG=2
M  V30 6 S 2.3855 4.1318 0 0
M  V30 7 C 3.7192 3.3618 0 0
M  V30 8 C -0.4882 3.3618 0 0 CFG=2
M  V30 9 N -1.5771 4.4508 0 0
M  V30 10 C -1.1785 5.9383 0 0
M  V30 11 O 0.309 6.3369 0 0
M  V30 12 C -2.2675 7.0273 0 0 CFG=2
M  V30 13 N -3.755 6.6287 0 0
M  V30 14 C -1.8689 8.5148 0 0
M  V30 15 C -2.9578 9.6037 0 0
M  V30 16 C -2.5592 11.0913 0 0
M  V30 17 C -1.0717 11.4898 0 0
M  V30 18 C 0.0172 10.4009 0 0
M  V30 19 C -0.3814 8.9134 0 0
M  V30 20 C -0.4882 1.8218 0 0
M  V30 21 O -1.5771 0.7329 0 0
M  V30 22 C 2.3855 -0.4882 0 0
M  V30 23 O 1.0518 -1.2582 0 0
M  V30 24 O 3.7192 -1.2582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 14 19
M  V30 21 1 8 20
M  V30 22 1 4 20
M  V30 23 2 20 21
M  V30 24 1 3 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811518

>  <MW>
349.11

>  <MW (desalted)>
349.405

>  <ClogP>
-1.727

>  <logS>
-4.113

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
112.73

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Substrate | Substrate | Agonist | - | - | Substrate | - | - | - | Substrate | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50  3 ?M | Km (Michaelis constant)  12 ?M | Km (Michaelis constant)  13 ?M | EC50 (unbound)  20.7 ?M | Km (Michaelis constant)  27 ?M | Km (Michaelis constant)  39 ?M | Km (Michaelis constant)  48 ?M | percentage decrease Active   | percentage decrease Active   | percentage decrease Active   | Km (Michaelis constant)  54 ?M | Ki (inhibition constant)  0.065 mM | Km (Michaelis constant)  69 ?M | IC50  0.07 mM

>  <CAS>
38821-53-3

>  <Description>
Cefradine is a first-generation cephalosporin antibiotic used in the treatment of bacterial infections of the respiratory and urinary tracts and of the skin and soft tissues.

>  <EBC_ID>
EBC-14619

>  <IUPAC Name>
(6R,7R)-7-[(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2017, vol. 61, # 9 | Antimicrob. Agents Chemother., 2014, vol. 58, # 6, p. 3538 - 3540 | Antimicrob. Agents Chemother., 2014, vol. 58, # 6, p. 3538 - 3540 | Drug Metab. Dispos., 2008, vol. 36, # 8, p. 1689 - 1697 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4427 - 4432 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4427 - 4432 | Antimicrob. Agents Chemother., 2017, vol. 61, # 3 | COMMONWEALTH SYSTEM OF HIGHER EDUCATION - US2016/361319, 2016, A1 | COMMONWEALTH SYSTEM OF HIGHER EDUCATION - US2016/361319, 2016, A1 | COMMONWEALTH SYSTEM OF HIGHER EDUCATION - US2016/361319, 2016, A1 | Antimicrob. Agents Chemother., 2017, vol. 61, # 3 | Eur. J. Pharm. Biopharm., 2005, vol. 59, # 1, p. 17 - 24 | Antimicrob. Agents Chemother., 2013, vol. 57, # 9, p. 4427 - 4432 | BioMed Res. Int., 2022, vol. 2022

>  <Main tar all>
Penicillin-binding?protein?3 pX=5.52 | NDM-3 pX=4.92 | Beta-lactamase NDM-1 pX=4.89 | Pregnane X receptor pX=4.68 | Beta-lactamase IMP-7 pX=4.57 | Beta-lactamase IMP-11 pX=4.41 | Beta-lactamase PER-8 pX=4.32 | Alpha-1-antitrypsin pX=4.3 | Green fluorescent protein pX=4.3 | alpha-1-antitrypsin pX=4.3 | Beta-lactamase PER-7 pX=4.27 | Peptide transporter 2 pX=4.19 | Beta-lactamase IMP-43 pX=4.16 | tyrosinase pX=4.15

$$$$
Regorafenib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 -3.08 0 0
M  V30 2 N -8.0021 -4.62 0 0
M  V30 3 C -6.6684 -5.39 0 0
M  V30 4 O -5.3347 -4.62 0 0
M  V30 5 C -6.6684 -6.93 0 0
M  V30 6 C -5.3347 -7.7 0 0
M  V30 7 C -5.3347 -9.24 0 0
M  V30 8 O -4.001 -10.01 0 0
M  V30 9 C -4.001 -11.55 0 0
M  V30 10 C -2.6674 -12.32 0 0
M  V30 11 C -2.6674 -13.86 0 0
M  V30 12 C -4.001 -14.63 0 0
M  V30 13 N -4.001 -16.17 0 0
M  V30 14 C -5.3347 -16.94 0 0
M  V30 15 O -6.6684 -16.17 0 0
M  V30 16 N -5.3347 -18.48 0 0
M  V30 17 C -4.001 -19.25 0 0
M  V30 18 C -2.6674 -18.48 0 0
M  V30 19 C -1.3337 -19.25 0 0
M  V30 20 C -1.3337 -20.79 0 0
M  V30 21 Cl -0 -21.56 0 0
M  V30 22 C -2.6674 -21.56 0 0
M  V30 23 C -4.001 -20.79 0 0
M  V30 24 C -2.6674 -23.1 0 0
M  V30 25 F -2.6674 -24.64 0 0
M  V30 26 F -4.2074 -23.1 0 0
M  V30 27 F -1.1274 -23.1 0 0
M  V30 28 C -5.3347 -13.86 0 0
M  V30 29 F -6.6684 -14.63 0 0
M  V30 30 C -5.3347 -12.32 0 0
M  V30 31 C -6.6684 -10.01 0 0
M  V30 32 C -8.0021 -9.24 0 0
M  V30 33 N -8.0021 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 17 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 2 12 28
M  V30 29 1 28 29
M  V30 30 1 28 30
M  V30 31 2 9 30
M  V30 32 1 7 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 5 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801830

>  <MW>
482.815

>  <MW (desalted)>
482.815

>  <ClogP>
5.185

>  <logS>
-6.359

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
92.35

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.5 nM | IC50  1.5 nM | IC50  2.5 nM | IC50 = 2.6 nM | IC50  2.6 nM | IC50  7 nM | IC50 ~ 10 nM | IC50  12 - 130 nM | IC50  12 - 130 nM | IC50  12 - 130 nM | IC50  12 nM | IC50  13 nM | IC50  15 nmol/l

>  <CAS>
755037-03-7

>  <Description>
Regorafenib is a kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma.

>  <EBC_ID>
EBC-11382

>  <IUPAC Name>
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2013, vol. 23, # 13, p. 3732 - 3737 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Curr. Pharm. Des., 2012, vol. 18, # 20, p. 2921 - 2935 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | BLUEPRINT MEDICINES CORP - WO2017/79140, 2017, A1 | Int. J. Cancer, 2011, vol. 129, # 1, p. 245 - 255 | Mol. Cancer Ther., 2019, vol. 18, # 11, p. 1985 - 1996

>  <Main tar all>
epoxide hydrolase 2 pX=9.3 | ret proto-oncogene pX=8.82 | Raf-1 proto-oncogene, serine/threonine kinase pX=8.6 | kinase insert domain receptor pX=8.59 | vascular endothelial growth factor-activated receptor pX=8.59 | Mast/stem cell growth factor receptor Kit pX=8.15 | ret proto-oncogene (C634W) pX=8.0 | KIT (W557-K558-del, D816G) pX=7.92 | KIT (W557-K558-del, T670I) pX=7.92 | KIT (W557-K558-del, V654A) pX=7.92 | transmembrane receptor protein tyrosine kinase pX=7.92 | fms related receptor tyrosine kinase 1 pX=7.89 | KIT (V560-Y578del) pX=7.82

$$$$
Diethylamino hydroxybenzoyl hexyl benzoate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -1.54 0 0
M  V30 2 C -1.3337 -0.77 0 0
M  V30 3 C 0 -1.54 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 C 1.3337 -3.85 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 O 2.6674 -1.54 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 O 5.3347 -1.54 0 0
M  V30 10 C 4.001 0.77 0 0
M  V30 11 C 5.3347 1.54 0 0
M  V30 12 C 5.3347 3.08 0 0
M  V30 13 C 4.001 3.85 0 0
M  V30 14 C 2.6674 3.08 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 16 C 1.3337 0.77 0 0
M  V30 17 O 1.3337 -0.77 0 0
M  V30 18 C 0 1.54 0 0
M  V30 19 C -1.3337 0.77 0 0
M  V30 20 C -2.6674 1.54 0 0
M  V30 21 C -2.6674 3.08 0 0
M  V30 22 C -1.3337 3.85 0 0
M  V30 23 C 0 3.08 0 0
M  V30 24 O 1.3337 3.85 0 0
M  V30 25 N -4.001 3.85 0 0
M  V30 26 C -5.3347 3.08 0 0
M  V30 27 C -5.3347 1.54 0 0
M  V30 28 C -4.001 5.39 0 0
M  V30 29 C -5.3347 6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 18 23
M  V30 25 1 23 24
M  V30 26 1 21 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 25 28
M  V30 30 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3243814745

>  <MW>
397.225

>  <MW (desalted)>
397.507

>  <ClogP>
7.082

>  <logS>
-6.234

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
66.84

>  <RotBonds>
12

>  <CAS>
302776-68-7

>  <Description>
Diethylamino hydroxybenzoyl hexyl benzoate is a UV filter with high absorption in the UV-A range. It is indicated for use as a sunscreen agent.

>  <EBC_ID>
EBC-26939

>  <IUPAC Name>
hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate

$$$$
Silodosin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 0 -3.08 0 0 CFG=2
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 C -2.6674 -3.08 0 0
M  V30 5 C -2.6674 -4.62 0 0
M  V30 6 C -4.001 -5.39 0 0
M  V30 7 C -4.3212 -6.8963 0 0
M  V30 8 C -5.8528 -7.0573 0 0
M  V30 9 N -6.4792 -5.6505 0 0
M  V30 10 C -7.9855 -5.3303 0 0
M  V30 11 C -9.016 -6.4747 0 0
M  V30 12 C -10.5223 -6.1545 0 0
M  V30 13 O -11.5528 -7.299 0 0
M  V30 14 C -5.3347 -4.62 0 0
M  V30 15 C -5.3347 -3.08 0 0
M  V30 16 C -4.001 -2.31 0 0
M  V30 17 C -6.6684 -2.31 0 0
M  V30 18 O -6.6684 -0.77 0 0
M  V30 19 N -8.0021 -3.08 0 0
M  V30 20 N 1.3337 -2.31 0 0
M  V30 21 C 2.6674 -3.08 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 23 O 5.3347 -3.08 0 0
M  V30 24 C 6.6684 -2.31 0 0
M  V30 25 C 6.6684 -0.77 0 0
M  V30 26 C 8.0021 -0 0 0
M  V30 27 C 9.3358 -0.77 0 0
M  V30 28 C 9.3358 -2.31 0 0
M  V30 29 C 8.0021 -3.08 0 0
M  V30 30 O 8.0021 -4.62 0 0
M  V30 31 C 9.3358 -5.39 0 0
M  V30 32 C 10.6694 -4.62 0 0
M  V30 33 F 12.0031 -3.85 0 0
M  V30 34 F 11.4394 -5.9537 0 0
M  V30 35 F 9.8994 -3.2863 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 9 14
M  V30 14 1 6 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 4 16
M  V30 18 1 15 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 2 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 24 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 32 34
M  V30 37 1 32 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802137

>  <MW>
495.234

>  <MW (desalted)>
495.534

>  <ClogP>
2.968

>  <logS>
-4.705

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
97.05

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  11.14  | pKi  11.14  | pKi  10.4  | pKi  10.4  | IC50 = 0.07 nM | pKi  10  | pKi  10

>  <CAS>
160970-54-7

>  <Description>
Silodosin is an alpha-1 adrenergic receptor antagonist used to treat symptoms associated with benign prostatic hyperplasia (BPH).

>  <EBC_ID>
EBC-27231

>  <IUPAC Name>
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide

>  <Main Tar all refs>
Biol. Pharm. Bull., 2008, vol. 31, # 4, p. 598 - 601 | Biol. Pharm. Bull., 2008, vol. 31, # 4, p. 598 - 601 | Eur. J. Pharmacol., 2008, vol. 584, # 2-3, p. 222 - 228 | Eur. J. Pharmacol., 2008, vol. 584, # 2-3, p. 222 - 228 | CHINESE ACADEMY OF SCIENCES; Shanghai Institute of Materia Medica (in: CAS) - WO2014/177065, 2014, A1 | Br. J. Pharmacol., 2008, vol. 153, # 7, p. 1485 - 1494 | Br. J. Pharmacol., 2008, vol. 153, # 7, p. 1485 - 1494

>  <Main tar all>
?1A-adrenoceptor pX=11.1 | ?1A-adrenoceptor pX=11.1 | ?1B-adrenoceptor pX=10.4 | ?1B-adrenoceptor pX=10.4 | ?1A-adrenoceptor pX=10.2 | ?1-adrenoceptor pX=10.0 | ?1-adrenoceptor pX=10.0

$$$$
Nintedanib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.925 6.6928 0 0
M  V30 2 O 7.5913 5.9228 0 0
M  V30 3 C 7.5913 4.3828 0 0
M  V30 4 O 8.925 3.6128 0 0
M  V30 5 C 6.2576 3.6128 0 0
M  V30 6 C 6.2576 2.0728 0 0
M  V30 7 C 4.9239 1.3028 0 0
M  V30 8 C 3.5902 2.0728 0 0
M  V30 9 C 2.1256 1.5969 0 0
M  V30 10 C 1.6497 0.1323 0 0
M  V30 11 N 0.1434 -0.1879 0 0
M  V30 12 C -0.3325 -1.6525 0 0
M  V30 13 C 0.698 -2.7969 0 0
M  V30 14 C 0.2221 -4.2616 0 0
M  V30 15 C -1.2843 -4.5818 0 0
M  V30 16 C -2.3147 -3.4373 0 0
M  V30 17 C -1.8389 -1.9727 0 0
M  V30 18 N -1.7602 -6.0464 0 0
M  V30 19 C -0.7297 -7.1908 0 0
M  V30 20 C -3.2665 -6.3666 0 0
M  V30 21 O -4.297 -5.2221 0 0
M  V30 22 C -3.7424 -7.8312 0 0
M  V30 23 N -2.7119 -8.9756 0 0
M  V30 24 C -1.2056 -8.6554 0 0
M  V30 25 C -0.1751 -9.7999 0 0
M  V30 26 N -0.651 -11.2645 0 0
M  V30 27 C 0.3794 -12.409 0 0
M  V30 28 C -2.1574 -11.5847 0 0
M  V30 29 C -3.1878 -10.4403 0 0
M  V30 30 C 2.6802 -1.0121 0 0
M  V30 31 C 4.1865 -0.6919 0 0
M  V30 32 C 5.217 -1.8364 0 0
M  V30 33 C 4.7411 -3.301 0 0
M  V30 34 C 3.2348 -3.6212 0 0
M  V30 35 C 2.2043 -2.4768 0 0
M  V30 36 C 1.2204 2.8428 0 0
M  V30 37 O -0.3196 2.8428 0 0
M  V30 38 N 2.1256 4.0887 0 0
M  V30 39 C 3.5902 3.6128 0 0
M  V30 40 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 1 28 29
M  V30 30 1 23 29
M  V30 31 1 10 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 2 30 35
M  V30 38 1 9 36
M  V30 39 2 36 37
M  V30 40 1 36 38
M  V30 41 1 38 39
M  V30 42 2 8 39
M  V30 43 1 39 40
M  V30 44 2 5 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516920

>  <MW>
539.625

>  <MW (desalted)>
539.625

>  <ClogP>
3.083

>  <logS>
-4.564

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
94.22

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.594 nM | IC50  1.8 nM | IC50  2 nmol/l | IC50  3 nmol/l | IC50 = 3 nM | IC50  3 nmol/l | IC50  4 nmol/l | IC50  0.004 ?M | IC50  5 nmol/l | IC50  5 nM | Ki (inhibition constant)  5.9 nM | IC50  6 nmol/l | IC50  7 nM | IC50  11 nmol/l | IC50  12 nmol/l | IC50  14 nmol/l | IC50  16 nM | IC50  16 nmol/l | IC50  17 nmol/l | IC50 = 18 nM

>  <CAS>
656247-17-5

>  <Description>
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer.

>  <EBC_ID>
EBC-11367

>  <IUPAC Name>
methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate

>  <Main Tar all refs>
JOHNSON & JOHNSON INC - WO2017/109513, 2017, A1 | ACS Med. Chem. Lett., 2017, vol. 8, # 11, p. 1142 - 1147 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | C.H. Boehringer Sohn AG & Co. KG - WO2007/57397, 2007, A1 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | Eur. J. Med. Chem., 2013, vol. 65, p. 477 - 486 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Med. Chem., 2009, vol. 52, # 14, p. 4466 - 4480 | JOHNSON & JOHNSON INC - WO2017/109513, 2017, A1 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | Cancer Res., 2008, vol. 68, # 12, p. 4774 - 4782 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | Cancer Res., 2008, vol. 68, # 12, p. 4774 - 4782 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | J. Pharmacol. Exp. Ther., 2018, vol. 364, # 3, p. 494 - 503 | C.H. Boehringer Sohn AG & Co. KG - WO2007/57397, 2007, A1

>  <Main tar all>
kinase insert domain receptor pX=9.23 | platelet derived growth factor receptor beta pX=8.74 | ret proto-oncogene pX=8.7 | Vascular endothelial growth factor receptor 2 (VEGFR2) pX=8.52 | fibroblast growth factor receptor 1 pX=8.52 | maternal embryonic leucine zipper kinase pX=8.52 | Vascular endothelial growth factor receptor 3 (VEGFR3) pX=8.4 | platelet derived growth factor receptor alpha pX=8.4 | colony stimulating factor 1 receptor pX=8.3 | fms related receptor tyrosine kinase 4 pX=8.3 | fibroblast growth factor receptor 3 pX=8.23 | Mast/stem cell growth factor receptor Kit pX=8.22 | vascular endothelial growth factor-activated receptor pX=8.15 | Serine/threonine-protein kinase SIK2 pX=7.96 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=7.92 | YES proto-oncogene 1, Src family tyrosine kinase pX=7.85 | LCK proto-oncogene, Src family tyrosine kinase pX=7.8 | discoidin domain receptor tyrosine kinase 2 pX=7.8 | discoidin domain receptor tyrosine kinase 1 pX=7.77 | fms related receptor tyrosine kinase 1 pX=7.74

$$$$
Dolutegravir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -6.93 0 0
M  V30 2 C 4.001 -5.39 0 0 CFG=2
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 2.6674 -3.08 0 0
M  V30 5 O 4.001 -2.31 0 0
M  V30 6 C 5.3347 -3.08 0 0 CFG=1
M  V30 7 C 6.6684 -2.31 0 0
M  V30 8 N 8.0021 -3.08 0 0
M  V30 9 C 9.3358 -2.31 0 0
M  V30 10 C 10.6694 -3.08 0 0
M  V30 11 C 12.0031 -2.31 0 0
M  V30 12 O 12.0031 -0.77 0 0
M  V30 13 N 13.3368 -3.08 0 0
M  V30 14 C 14.6705 -2.31 0 0
M  V30 15 C 16.0041 -3.08 0 0
M  V30 16 C 17.3378 -2.31 0 0
M  V30 17 C 18.6715 -3.08 0 0
M  V30 18 C 18.6715 -4.62 0 0
M  V30 19 F 20.0052 -5.39 0 0
M  V30 20 C 17.3378 -5.39 0 0
M  V30 21 C 16.0041 -4.62 0 0
M  V30 22 F 14.6705 -5.39 0 0
M  V30 23 C 10.6694 -4.62 0 0
M  V30 24 O 12.0031 -5.39 0 0
M  V30 25 C 9.3358 -5.39 0 0
M  V30 26 O 9.3358 -6.93 0 0
M  V30 27 C 8.0021 -4.62 0 0
M  V30 28 C 6.6684 -5.39 0 0
M  V30 29 O 6.6684 -6.93 0 0
M  V30 30 N 5.3347 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 20 21
M  V30 21 2 15 21
M  V30 22 1 21 22
M  V30 23 1 10 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 25 26
M  V30 27 2 25 27
M  V30 28 1 8 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 2 30
M  V30 33 1 6 30 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801952

>  <MW>
419.129

>  <MW (desalted)>
419.379

>  <ClogP>
-0.407

>  <logS>
-3.143

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
99.18

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.2 nM | EC50  0.5 nM | EC50 < 0.51 nM | EC50  0.0006 ?M | Ki (inhibition constant)  0.78 nM | EC50  1.3 nM | EC50  1.8 nM | EC50  1.8 nM | EC50  1.9 nM | EC50  1.9 nM | IC50  2.4 nM | EC50  3.3 nM | EC50  3.4 nM | EC50  3.5 nM | EC50  3.8 nM | EC50  4.2 nM | EC50  5.1 nM | EC50  5.4 nM | EC50  5.6 nM | EC50  5.8 nM

>  <CAS>
1051375-16-6

>  <Description>
Dolutegravir is an antiviral agent used for the treatment of HIV-1 infections in combination with other antiretroviral agents.

>  <EBC_ID>
EBC-27030

>  <IUPAC Name>
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2019, vol. 63, # 8 | ACS Infect. Dis., 2021, vol. 7, # 6, p. 1469 - 1482 | Virol. J., 2021, vol. 18, # 1 | Lett. Drug Des. Discov., 2020, vol. 17, # 4, p. 416 - 425 | Antimicrob. Agents Chemother., 2013, vol. 57, # 12, p. 6223 - 6235 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Nat. Commun., 2022, vol. 13, # 1 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9 | Antimicrob. Agents Chemother., 2020, vol. 64, # 9

>  <Main tar all>
Protease pX=9.7 | Integrase pX=9.3 | Integrase pX=9.29 | Integrase pX=9.22 | Integrase pX=9.11 | Integrase (T66I/R263K) pX=8.89 | Integrase (G140S/G149A) pX=8.74 | Integrase (M154I) pX=8.74 | Integrase (Q146R) pX=8.72 | Integrase (T66I/L74M/E138K/S147G/M154I) pX=8.72 | Integrase homolog pX=8.62 | Integrase (C56S) pX=8.48 | Integrase (L74I) pX=8.47 | Integrase (G149A) pX=8.46 | Integrase (Q95K/Q146R) pX=8.42 | Integrase?(L74I/E138K/G140S/Q148R) pX=8.38 | Integrase (E157Q) pX=8.29 | Integrase?(M50I/R263K) pX=8.27 | Integrase (E157Q/R263K) pX=8.25 | Integrase (S119R/R263K) pX=8.24

$$$$
Lopinavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 46 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.691 -8.2637 0 0
M  V30 2 C 2.461 -6.93 0 0
M  V30 3 C 1.691 -5.5963 0 0
M  V30 4 C 4.001 -6.93 0 0 CFG=2
M  V30 5 N 4.771 -8.2637 0 0
M  V30 6 C 6.311 -8.2637 0 0
M  V30 7 C 7.081 -9.5974 0 0
M  V30 8 C 6.311 -10.931 0 0
M  V30 9 N 4.771 -10.931 0 0
M  V30 10 C 4.001 -9.5974 0 0
M  V30 11 O 2.461 -9.5974 0 0
M  V30 12 C 4.771 -5.5963 0 0
M  V30 13 O 6.311 -5.5963 0 0
M  V30 14 N 4.001 -4.2626 0 0
M  V30 15 C 4.771 -2.929 0 0 CFG=2
M  V30 16 C 6.311 -2.929 0 0
M  V30 17 C 7.081 -4.2626 0 0 CFG=2
M  V30 18 O 7.242 -5.7942 0 0
M  V30 19 C 8.621 -4.2626 0 0 CFG=2
M  V30 20 C 9.7655 -3.2322 0 0
M  V30 21 C 9.4453 -1.7258 0 0
M  V30 22 C 7.9807 -1.2499 0 0
M  V30 23 C 7.6605 0.2564 0 0
M  V30 24 C 8.8049 1.2869 0 0
M  V30 25 C 10.2696 0.811 0 0
M  V30 26 C 10.5897 -0.6954 0 0
M  V30 27 N 9.391 -5.5963 0 0
M  V30 28 C 10.931 -5.5963 0 0
M  V30 29 O 11.701 -4.2626 0 0
M  V30 30 C 11.701 -6.93 0 0
M  V30 31 O 13.241 -6.93 0 0
M  V30 32 C 14.011 -8.2637 0 0
M  V30 33 C 15.551 -8.2637 0 0
M  V30 34 C 16.321 -6.93 0 0
M  V30 35 C 16.321 -9.5974 0 0
M  V30 36 C 15.551 -10.931 0 0
M  V30 37 C 14.011 -10.931 0 0
M  V30 38 C 13.241 -9.5974 0 0
M  V30 39 C 11.701 -9.5974 0 0
M  V30 40 C 4.001 -1.5953 0 0
M  V30 41 C 4.771 -0.2616 0 0
M  V30 42 C 4.001 1.0721 0 0
M  V30 43 C 4.771 2.4058 0 0
M  V30 44 C 6.311 2.4058 0 0
M  V30 45 C 7.081 1.0721 0 0
M  V30 46 C 6.311 -0.2616 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 12 1 4 12 CFG=1
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 15 14 CFG=1
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 17 18 CFG=1
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 21 26
M  V30 28 1 19 27 CFG=3
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 33 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 2 32 38
M  V30 41 1 38 39
M  V30 42 1 15 40
M  V30 43 1 40 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 45 46
M  V30 49 2 41 46
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801862

>  <MW>
628.362

>  <MW (desalted)>
628.801

>  <ClogP>
6.095

>  <logS>
-6.786

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
120

>  <RotBonds>
15

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.3 pM | Ki (inhibition constant)  1.3 pM | Ki (inhibition constant)  1.3 pM | Ki (inhibition constant)  0.005 nM | Ki (inhibition constant)  0.029 nM | Ki (inhibition constant)  0.03 nM | inhibition percentage  93.2 % | Ki (inhibition constant)  0.04 nM

>  <CAS>
192725-17-0

>  <Description>
Lopinavir is a potent HIV protease inhibitor. It is used in combination with other antiretrovirals in the treatment of HIV-1 infection.

>  <EBC_ID>
EBC-06069

>  <IUPAC Name>
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide

>  <Main Tar all refs>
Curr. Pharm. Des., 2007, vol. 13, # 3, p. 271 - 285 | Antimicrob. Agents Chemother., 1998, vol. 42, # 12, p. 3218 - 3224 | Antimicrob. Agents Chemother., 1998, vol. 42, # 12, p. 3218 - 3224 | J. Med. Chem., 2010, vol. 53, # 21, p. 7699 - 7708 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | Viruses, 2015, vol. 7, # 12, p. 6152 - 6162 | ABBVIE INC - US5914332, 1999, A | Chem. Biol. Drug Des., 2007, vol. 69, # 5, p. 298 - 313

>  <Main tar all>
Protease pX=11.9 | Gag-Pol polyprotein pX=11.9 | HIV-1 protease pX=11.9 | HIV-1?protease?(Q7K) pX=11.3 | HIV-1 protease (L10I, I15V, E35D, N37S, R41K, I62V, L63P, A71V, G73S, L90M) pX=10.5 | HIV-2?protease pX=10.5 | HIV protease pX=10.4 | HIV-1 protease (D30N, L63P, N88D) pX=10.4

$$$$
Cefuroxime
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.2348 4.8711 0 0
M  V30 2 O -0.1638 3.3836 0 0
M  V30 3 N -1.6513 2.985 0 0
M  V30 4 C -2.0499 1.4975 0 0
M  V30 5 C -0.961 0.4085 0 0
M  V30 6 O -1.3595 -1.079 0 0
M  V30 7 N 0.5266 0.8071 0 0
M  V30 8 C 1.6155 -0.2818 0 0 CFG=1
M  V30 9 C 3.1555 -0.2818 0 0 CFG=1
M  V30 10 S 4.4892 0.4882 0 0
M  V30 11 C 5.8229 -0.2818 0 0
M  V30 12 C 5.8229 -1.8218 0 0
M  V30 13 C 4.4892 -2.5918 0 0
M  V30 14 N 3.1555 -1.8218 0 0
M  V30 15 C 1.6155 -1.8218 0 0
M  V30 16 O 0.5266 -2.9108 0 0
M  V30 17 C 4.4892 -4.1318 0 0
M  V30 18 O 3.1555 -4.9018 0 0
M  V30 19 O 5.8229 -4.9018 0 0
M  V30 20 C 7.1566 -2.5918 0 0
M  V30 21 O 8.4902 -1.8218 0 0
M  V30 22 C 9.8239 -2.5918 0 0
M  V30 23 O 11.1576 -1.8218 0 0
M  V30 24 N 9.8239 -4.1318 0 0
M  V30 25 C -3.5374 1.0989 0 0
M  V30 26 C -4.0893 -0.3388 0 0
M  V30 27 C -5.6272 -0.2582 0 0
M  V30 28 C -6.0258 1.2293 0 0
M  V30 29 O -4.7342 2.068 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14 CFG=1
M  V30 15 1 14 15
M  V30 16 1 8 15
M  V30 17 2 15 16
M  V30 18 1 13 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 12 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 4 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 1 25 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2382058334

>  <MW>
424.069

>  <MW (desalted)>
424.385

>  <ClogP>
0.229

>  <logS>
-3.951

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
173.76

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0031 ?g/ml | IC50  0.02 ?M | IC50  0.02 ?g/ml | IC50  0.053 ?g/ml | Km (Michaelis constant) = 0.13 ?M | Km (Michaelis constant) = 0.13 ?M | Km (Michaelis constant) = 0.15 ?M

>  <CAS>
55268-75-2

>  <Description>
Cefuroxime is a cephalosporin indicated for the treatment of a variety of infections including acute bacterial otitis media, several upper respiratory tract infections, skin infections, urinary tract infections, gonorrhea, early Lyme disease, and impetigo.

>  <EBC_ID>
EBC-27046

>  <IUPAC Name>
(6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | ACS Infect. Dis., 2022, vol. 8, # 7, p. 1241 - 1252 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | THERIVA BIOLOGICS - WO2011/148041, 2011, A1 | THERIVA BIOLOGICS INC - WO2011/148041, 2011, A1 | Antimicrob. Agents Chemother., 2000, vol. 44, # 5, p. 1387 - 1390

>  <Main tar all>
Penicillin-binding?protein 2X pX=8.14 | Penicillin-binding?protein?3 pX=7.7 | Penicillin-binding?protein?3 pX=7.33 | Penicillin-binding?protein 2A pX=6.9 | Beta-lactamase pX=6.89 | Beta-lactamase pX=6.89 | Beta-Lactamase AmpC pX=6.82

$$$$
Siponimod
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.9441 -17.1655 0 0
M  V30 2 C -3.6104 -16.3955 0 0
M  V30 3 C -3.6104 -14.8555 0 0
M  V30 4 C -4.9441 -14.0855 0 0
M  V30 5 C -4.9441 -12.5455 0 0
M  V30 6 C -3.6104 -11.7755 0 0
M  V30 7 C -2.2767 -12.5455 0 0
M  V30 8 C -2.2767 -14.0855 0 0
M  V30 9 C -0.9431 -14.8555 0 0
M  V30 10 N -0.9431 -16.3955 0 0
M  V30 11 C 0.1459 -17.4845 0 0
M  V30 12 C -0.9431 -18.5734 0 0
M  V30 13 C -2.032 -17.4845 0 0
M  V30 14 C -0.9431 -20.1134 0 0
M  V30 15 O -2.2767 -20.8834 0 0
M  V30 16 O 0.3906 -20.8834 0 0
M  V30 17 C -6.2778 -11.7755 0 0
M  V30 18 N -6.2778 -10.2355 0 0
M  V30 19 O -7.6114 -9.4655 0 0
M  V30 20 C -8.9451 -10.2355 0 0
M  V30 21 C -10.2788 -9.4655 0 0
M  V30 22 C -11.6125 -10.2355 0 0
M  V30 23 C -12.9462 -9.4655 0 0
M  V30 24 C -12.9462 -7.9255 0 0
M  V30 25 C -14.2798 -7.1555 0 0
M  V30 26 C -15.6135 -7.9255 0 0
M  V30 27 C -16.9472 -7.1555 0 0
M  V30 28 C -16.9472 -5.6155 0 0
M  V30 29 C -15.6135 -4.8455 0 0
M  V30 30 C -14.2798 -5.6155 0 0
M  V30 31 C -11.6125 -7.1555 0 0
M  V30 32 C -10.2788 -7.9255 0 0
M  V30 33 C -11.6125 -5.6155 0 0
M  V30 34 F -11.6125 -4.0755 0 0
M  V30 35 F -10.0725 -5.6155 0 0
M  V30 36 F -13.1525 -5.6155 0 0
M  V30 37 C -7.6114 -12.5455 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 10 13
M  V30 15 1 12 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 5 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 25 30
M  V30 33 2 24 31
M  V30 34 1 31 32
M  V30 35 2 21 32
M  V30 36 1 31 33
M  V30 37 1 33 34
M  V30 38 1 33 35
M  V30 39 1 33 36
M  V30 40 1 17 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568751224

>  <MW>
516.26

>  <MW (desalted)>
516.595

>  <ClogP>
6.001

>  <logS>
-7.647

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
62.13

>  <RotBonds>
10

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.167 nM | EC50  0.3 nM

>  <CAS>
1230487-00-9

>  <Description>
Siponimod is classified as a sphingosine-1-phosphate (S1P) receptor modulator. Siponimod binds with high affinity to both S1P receptors 1 and 5. It is used to treat relapsing multiple sclerosis.

>  <EBC_ID>
EBC-27261

>  <IUPAC Name>
1-({4-[(1E)-1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid

>  <Main Tar all refs>
FEBS Open Bio, 2020, vol. 10, # 10, p. 2010 - 2020 | Front. Pharmacol., 2022, vol. 13

>  <Main tar all>
S1P1 receptor pX=9.78 | S1P5 receptor pX=9.52

$$$$
Rosuvastatin sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 14.6705 -3.85 0 0 CHG=1
M  V30 2 C 5.3347 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 C 4.001 -6.93 0 0
M  V30 5 C 2.6674 -4.62 0 0
M  V30 6 N 1.3337 -5.39 0 0
M  V30 7 C 0 -4.62 0 0
M  V30 8 N 0 -3.08 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C 2.6674 -3.08 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 C 6.6684 -2.31 0 0 CFG=1
M  V30 14 O 6.6684 -0.77 0 0
M  V30 15 C 8.0021 -3.08 0 0
M  V30 16 C 9.3358 -2.31 0 0 CFG=1
M  V30 17 O 9.3358 -0.77 0 0
M  V30 18 C 10.6694 -3.08 0 0
M  V30 19 C 12.0031 -2.31 0 0
M  V30 20 O 12.0031 -0.77 0 0
M  V30 21 O 13.3368 -3.08 0 0 CHG=-1
M  V30 22 C 1.3337 -0.77 0 0
M  V30 23 C 0 0 0 0
M  V30 24 C 0 1.54 0 0
M  V30 25 C 1.3337 2.31 0 0
M  V30 26 F 1.3337 3.85 0 0
M  V30 27 C 2.6674 1.54 0 0
M  V30 28 C 2.6674 0 0 0
M  V30 29 N -1.3337 -5.39 0 0
M  V30 30 C -1.3337 -6.93 0 0
M  V30 31 S -2.6674 -4.62 0 0
M  V30 32 O -1.8974 -3.2863 0 0
M  V30 33 O -3.4374 -5.9537 0 0
M  V30 34 C -4.001 -3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 16 15
M  V30 16 1 16 17 CFG=1
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 9 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 25 27
M  V30 27 1 27 28
M  V30 28 2 22 28
M  V30 29 1 7 29
M  V30 30 1 29 30
M  V30 31 1 29 31
M  V30 32 2 31 32
M  V30 33 2 31 33
M  V30 34 1 31 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2583154880

>  <MW>
503.15

>  <MW (desalted)>
481.538

>  <ClogP>
-1.062

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
143.75

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  89 ?M

>  <CAS>
147098-18-8

>  <Description>
Rosuvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis. It is used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.

>  <EBC_ID>
EBC-13301

>  <IUPAC Name>
sodium (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate

>  <Main Tar all refs>
Int. J. Mol. Sci., 2021, vol. 22, # 11

>  <Main tar all>
adenylate?kinase 1 pX=4.05

$$$$
Metformin hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 10.56 1.4819 0 0
M  V30 3 N 9.02 1.4819 0 0
M  V30 4 C 8.25 2.8155 0 0
M  V30 5 C 8.25 0.1482 0 0
M  V30 6 N 6.71 0.1482 0 0
M  V30 7 C 5.94 -1.1855 0 0
M  V30 8 N 6.71 -2.5192 0 0
M  V30 9 N 4.4 -1.1855 0 0
M  V30 10 N 9.02 -1.1855 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 6 7 CFG=2
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 8 1 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2244578658

>  <MW>
165.078

>  <MW (desalted)>
129.164

>  <ClogP>
-1.633

>  <logS>
-0.453

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
91.49

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  2.55 pg/ml

>  <CAS>
1115-70-4

>  <Description>
Metformin is a biguanide drug used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus and used off-label for insulin resistance in polycystic ovary syndrome.

>  <EBC_ID>
EBC-11106

>  <IUPAC Name>
N-[amino(dimethylamino)methylidene]guanidine hydrochloride

>  <Main Tar all refs>
Int. J. Nanomed., 2021, vol. 16, p. 1005 - 1019

>  <Main tar all>
CD44 antigen pX=10.8

$$$$
Theophylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 N 2.1256 4.0887 0 0
M  V30 11 C 3.5902 3.6128 0 0
M  V30 12 C 4.9239 4.3828 0 0
M  V30 13 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 7 11
M  V30 12 1 11 12
M  V30 13 1 2 12
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z203045518

>  <MW>
180.065

>  <MW (desalted)>
180.164

>  <ClogP>
-0.034

>  <logS>
-1.39

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
69.3

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant) = 0.6 nM | Ki (inhibition constant) = 14 nM | Ki (inhibition constant) = 14 nM

>  <CAS>
58-55-9

>  <Description>
Theophylline is a xanthine used to manage the symptoms of asthma, COPD, and other lung conditions caused by reversible airflow obstruction. Theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen.

>  <EBC_ID>
EBC-13437

>  <IUPAC Name>
1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 609 - 612

>  <Main tar all>
A1 receptor pX=9.22 | A1 receptor pX=9.22 | A2A receptor pX=9.22 | A2A receptor pX=9.22 | A3 receptor pX=7.85 | A3 receptor pX=7.85

$$$$
Aceglutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 O 3.2863 4.9774 0 0
M  V30 4 N 4.62 2.6674 0 0
M  V30 5 C 5.9537 3.4374 0 0 CFG=1
M  V30 6 C 7.2874 2.6674 0 0
M  V30 7 C 8.621 3.4374 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 O 11.2884 3.4374 0 0
M  V30 10 N 9.9547 1.1274 0 0
M  V30 11 C 5.9537 4.9774 0 0
M  V30 12 O 7.2874 5.7474 0 0
M  V30 13 O 4.62 5.7474 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 5 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756456072

>  <MW>
188.08

>  <MW (desalted)>
188.181

>  <ClogP>
-2.406

>  <logS>
-0.119

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
109.49

>  <RotBonds>
5

>  <CAS>
2490-97-3

>  <Description>
Aceglutamide is a psychostimulant, nootropic agent which functions as a prodrug to glutamine. It is used to improve memory and concentration.

>  <EBC_ID>
EBC-47163

>  <IUPAC Name>
(2S)-4-carbamoyl-2-acetamidobutanoic acid

$$$$
L-Carglumic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 O 3.2863 4.9774 0 0
M  V30 4 N 4.62 2.6674 0 0
M  V30 5 C 5.9537 3.4374 0 0 CFG=1
M  V30 6 C 7.2874 2.6674 0 0
M  V30 7 C 8.621 3.4374 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 O 11.2884 3.4374 0 0
M  V30 10 O 9.9547 1.1274 0 0
M  V30 11 C 5.9537 4.9774 0 0
M  V30 12 O 7.2874 5.7474 0 0
M  V30 13 O 4.62 5.7474 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 5 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756468010

>  <MW>
190.059

>  <MW (desalted)>
190.154

>  <ClogP>
-1.935

>  <logS>
0.01

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
129.72

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
1188-38-1

>  <Description>
Carglumic acid is an analog of N-acetylglutamate used for the treatment of acute and chronic hyperammonemia in patients with N-acetylglutamate synthase deficiency. It is an essential allosteric activator of the liver enzyme carbamoyl phosphate synthetase 1.

>  <EBC_ID>
EBC-12537

>  <IUPAC Name>
(2S)-2-(carbamoylamino)pentanedioic acid

$$$$
Amylmetacresol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 C 4.001 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 C 8.0021 -4.62 0 0
M  V30 8 C 9.3358 -5.39 0 0
M  V30 9 C 9.3358 -6.93 0 0
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 8.0021 -7.7 0 0
M  V30 12 C 6.6684 -6.93 0 0
M  V30 13 O 5.3347 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255446224

>  <MW>
178.136

>  <MW (desalted)>
178.271

>  <ClogP>
4.539

>  <logS>
-3.881

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
4

>  <CAS>
1300-94-3

>  <Description>
Amylmetacresol is an antiseptic used to treat infections in the mouth and throat. Amylmetacresol is an antibacterial and antiviral agent, and blocks voltage-gated Na channels in a local anesthetic-like manner.

>  <EBC_ID>
EBC-26137

>  <IUPAC Name>
5-methyl-2-pentylphenol

$$$$
Phenibut
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0 -4.62 0 0
M  V30 2 C 1.3337 -3.85 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 2.6674 -1.54 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 O 5.3347 -1.54 0 0
M  V30 7 O 4.001 -3.85 0 0
M  V30 8 C 0 -1.54 0 0
M  V30 9 C -1.3337 -2.31 0 0
M  V30 10 C -2.6674 -1.54 0 0
M  V30 11 C -2.6674 0 0 0
M  V30 12 C -1.3337 0.77 0 0
M  V30 13 C 0 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 3 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255487817

>  <MW>
179.095

>  <MW (desalted)>
179.216

>  <ClogP>
-1.333

>  <logS>
-0.89

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <CAS>
1078-21-3

>  <Description>
Phenibut is a GABA receptor agonist. It is a central nervous system depressant with anxiolytic and sedative effects.

>  <EBC_ID>
EBC-44072

>  <IUPAC Name>
4-amino-3-phenylbutanoic acid

$$$$
Carboplatinum
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1187 -0.2199 0 0
M  V30 2 Pt 4.9389 0.77 0 0
M  V30 3 N 6.1187 1.7599 0 0
M  V30 4 O 4.1689 -0.5637 0 0
M  V30 5 C 2.6289 -0.5637 0 0
M  V30 6 O 1.8589 -1.8974 0 0
M  V30 7 C 1.8589 0.77 0 0
M  V30 8 C 0.77 -0.3189 0 0
M  V30 9 C -0.3189 0.77 0 0
M  V30 10 C 0.77 1.8589 0 0
M  V30 11 C 2.6289 2.1037 0 0
M  V30 12 O 1.8589 3.4374 0 0
M  V30 13 O 4.1689 2.1037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 7 10
M  V30 11 1 7 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 2 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546624241

>  <MW>
369.029

>  <MW (desalted)>
369.233

>  <ClogP>
-2.338

>  <logS>
-0.55

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
104.64

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1.8 ?M | IC50  1.8 ?M | IC50  1.8 ?M | IC50  1.8 ?M | IC50  2.87 - 10 ?mol/l | IC50  2.87 - 10 ?mol/l | EC50  3.38 ?M | GI50  3.91 ?M | decrease rate Active   | IC50  6.72 ?M | IC50  9 ?M | IC50  18.1 - 21.04 ?mol/l | inhibition rate Active   | IC50  28.8 ?M | IC50  32.04 ?M | IC50  33.2 ?M | IC50  40.76 ?M | inhibition percentage  61 % | IC50  46.5 ?M

>  <CAS>
41575-94-4

>  <Description>
Carboplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer.

>  <EBC_ID>
EBC-00556

>  <IUPAC Name>
7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione

>  <Main Tar all refs>
Bioorg. Chem., 2019, vol. 88 | Bioorg. Chem., 2019, vol. 88 | Bioorg. Chem., 2019, vol. 88 | Bioorg. Chem., 2019, vol. 88 | Mol. Cancer Ther., 2019, vol. 18, # 7, p. 1205 - 1216 | Mol. Cancer Ther., 2019, vol. 18, # 7, p. 1205 - 1216 | RENOTARGET THERAPEUTICS - US2018/127383, 2018, A1 | J. Cell. Biochem., 2018, vol. 119, # 8, p. 6501 - 6513 | LIXTE BIOTECHNOLOGY - WO2022/159150, 2022, A1 | Cells, 2019, vol. 8, # 10 | Cell Chem. Biol., 2021, vol. 28, # 6, p. 835 - 5,847 | Cancer Res., 2017, vol. 77, # 14, p. 3834 - 3845 | Cancers, 2020, vol. 12, # 2 | Biochem. Pharmacol., 2020, vol. 175 | Biochem. Pharmacol., 2021, vol. 193 | Oncogene, 2021, vol. 40, # 8, p. 1409 - 1424 | Mol. Biol. Rep., 2022, vol. 49, # 1, p. 363 - 372 | UNIVERSITY OF NEBRASKA SYSTEM - US2016/310528, 2016, A1 | J. Inorg. Biochem., 2021, vol. 218

>  <Main tar all>
Ectonucleotide pyrophosphatase/phosphodiesterase 1 pX=5.74 | Ectonucleotide pyrophosphatase/phosphodiesterase 3 pX=5.74 | Intestinal-type alkaline phosphatase pX=5.74 | Tissue Nonspecific Alkaline Phosphatase pX=5.74 | NEDD8-activating enzyme E1 regulatory subunit pX=5.54 | Ubiquitin-activating enzyme E1 3 pX=5.54 | epidermal growth factor receptor pX=5.47 | Alkaline phosphatase, tissue-nonspecific isozyme pX=5.41 | PP2A (Catalytic subunit) pX=5.4 | Transforming growth factor, beta 1 pX=5.17 | DNA repair protein RAD51 pX=5.05 | cyclin dependent kinase 7 pX=4.74 | DAT pX=4.7 | Thioredoxin reductase 1 pX=4.54 | Tryptophan 2,3-dioxygenase (gene Tdo2) pX=4.49 | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 pX=4.48 | Histone?deacetylase pX=4.39 | UDP-glucose 6-dehydrogenase (peptide) pX=4.37 | COX-2  pX=4.33

$$$$
Lauric acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.2163 7.4384 0 0
M  V30 2 C 11.55 6.6684 0 0
M  V30 3 C 12.8837 7.4384 0 0
M  V30 4 C 14.2174 6.6684 0 0
M  V30 5 C 15.551 7.4384 0 0
M  V30 6 C 16.8847 6.6684 0 0
M  V30 7 C 18.2184 7.4384 0 0
M  V30 8 C 19.5521 6.6684 0 0
M  V30 9 C 20.8858 7.4384 0 0
M  V30 10 C 22.2194 6.6684 0 0
M  V30 11 C 23.5531 7.4384 0 0
M  V30 12 C 24.8868 6.6684 0 0
M  V30 13 O 26.2205 7.4384 0 0
M  V30 14 O 24.8868 5.1284 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104476194

>  <MW>
200.178

>  <MW (desalted)>
200.318

>  <ClogP>
5.096

>  <logS>
-4.58

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
10

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
Kd (dissociation constant) = 171 pM | Kd (dissociation constant) = 498 pM

>  <CAS>
143-07-7

>  <Description>
Lauric acid is the main acid in coconut oil and in palm kernel oil, and is believed to have antimicrobial properties. It might be used as an alternative treatment for antibiotic therapy of acne vulgaris. Lauric acid is used in the manufacture of soaps, detergents, cosmetics, and lauryl alcohol.

>  <EBC_ID>
EBC-26189

>  <IUPAC Name>
dodecanoic acid

>  <Main Tar all refs>
Biol. Pharm. Bull., 2009, vol. 32, # 4, p. 646 - 650 | Biol. Pharm. Bull., 2009, vol. 32, # 4, p. 646 - 650

>  <Main tar all>
?1-adrenoceptor pX=9.77 | mAChR pX=9.3

$$$$
Diethylcarbamazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 N 0 4.62 0 0
M  V30 4 C -1.3337 3.85 0 0
M  V30 5 C -1.3337 2.31 0 0
M  V30 6 C 1.3337 3.85 0 0
M  V30 7 O 2.6674 4.62 0 0
M  V30 8 N 1.3337 2.31 0 0
M  V30 9 C 2.6674 1.54 0 0
M  V30 10 C 2.6674 -0 0 0
M  V30 11 N 1.3337 -0.77 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 0 0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z641623606

>  <MW>
199.168

>  <MW (desalted)>
199.293

>  <ClogP>
1.616

>  <logS>
-0.37

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
26.79

>  <RotBonds>
2

>  <Action on targets>
Allosteric Modulator | Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  33.49 % | inhibition percentage  33.49 % | inhibition percentage = 45 %

>  <CAS>
90-89-1

>  <Description>
Diethylcarbamazine is an anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa. The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis.

>  <EBC_ID>
EBC-03464

>  <IUPAC Name>
N,N-diethyl-4-methylpiperazine-1-carboxamide

>  <Main Tar all refs>
Drug Metab. Dispos., 2017, vol. 45, # 6, p. 604 - 611 | Drug Metab. Dispos., 2017, vol. 45, # 6, p. 604 - 611 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 1, p. 47 - 50

>  <Main tar all>
ABCC2 pX=4.4 | ABCC2 pX=4.4 | DNA topoisomerase II pX=3.61

$$$$
Primidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.8604 0.6771 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 2.3236 -1.9497 0 0
M  V30 4 C 3.6573 -2.7197 0 0
M  V30 5 O 4.9909 -1.9497 0 0
M  V30 6 N 3.6573 -4.2597 0 0
M  V30 7 C 2.3236 -5.0297 0 0
M  V30 8 N 0.9899 -4.2597 0 0
M  V30 9 C 0.9899 -2.7197 0 0
M  V30 10 O -0.3438 -1.9497 0 0
M  V30 11 C 3.3135 -0.77 0 0
M  V30 12 C 2.7868 0.6771 0 0
M  V30 13 C 3.7766 1.8568 0 0
M  V30 14 C 5.2933 1.5894 0 0
M  V30 15 C 5.82 0.1423 0 0
M  V30 16 C 4.8301 -1.0374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 2 9 10
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509139960

>  <MW>
218.106

>  <MW (desalted)>
218.252

>  <ClogP>
0.882

>  <logS>
-1.89

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
2

>  <Action on targets>
Antagonist | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  705 nM | IC50  7.4 ?M | inhibition percentage  28 % | inhibition percentage  28 %

>  <CAS>
125-33-7

>  <Description>
Primidone is an anticonvulsant of the pyrimidinedione class that can be detected in urine. It is presumed to be a modulator of GABAA receptors. Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures.

>  <EBC_ID>
EBC-04191

>  <IUPAC Name>
5-ethyl-5-phenyl-1,3-diazinane-4,6-dione

>  <Main Tar all refs>
Br. J. Pharmacol., 2020, vol. 177, # 12, p. 2683 - 2695 | PAIRNOMIX - WO2018/64498, 2018, A1 | DRUG METAB. DISPOS., 1990, vol. 18, # 5, p. 595 - 606 | DRUG METAB. DISPOS., 1990, vol. 18, # 5, p. 595 - 606

>  <Main tar all>
TRPM3 pX=6.15 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=5.13 | CYP3A pX=4.89 | Cytochrome P450, E-class, CYP3A pX=4.89

$$$$
Sulfamethoxazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8019 -2.425 0 0
M  V30 2 C 3.8019 -3.965 0 0
M  V30 3 C 5.0477 -4.8702 0 0
M  V30 4 C 4.5719 -6.3348 0 0
M  V30 5 N 5.477 -7.5807 0 0
M  V30 6 S 4.8507 -8.9876 0 0
M  V30 7 O 3.4438 -8.3612 0 0
M  V30 8 O 6.2575 -9.6139 0 0
M  V30 9 C 4.2243 -10.3944 0 0
M  V30 10 C 5.1295 -11.6403 0 0
M  V30 11 C 4.5031 -13.0472 0 0
M  V30 12 C 2.9715 -13.2081 0 0
M  V30 13 N 2.3452 -14.615 0 0
M  V30 14 C 2.0664 -11.9623 0 0
M  V30 15 C 2.6927 -10.5554 0 0
M  V30 16 N 3.0319 -6.3348 0 0
M  V30 17 O 2.556 -4.8702 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 2 6 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 14 15
M  V30 15 2 9 15
M  V30 16 2 4 16
M  V30 17 1 16 17
M  V30 18 1 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57198677

>  <MW>
253.052

>  <MW (desalted)>
253.278

>  <ClogP>
0.563

>  <logS>
-2.25

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
98.22

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 10.1 nM | IC50  10.97 nM | IC50 = 0.1 ?M | IC50 = 0.1 ?M | IC50  0.23 ?M

>  <CAS>
723-46-6

>  <Description>
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. In combination with trimethoprim it has been used to treat bronchitis, prostatitis, and urinary tract infections among other infectious conditions.

>  <EBC_ID>
EBC-03728

>  <IUPAC Name>
4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Med. Chem., 2004, vol. 47, # 24, p. 5953 - 5961 | J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540 | J. MED. CHEM., 1995, vol. 38, # 24, p. 4739 - 4759 | J. MED. CHEM., 1995, vol. 38, # 24, p. 4739 - 4759 | ANTIMICROB. AGENTS CHEMOTHER., 1996, vol. 40, # 3, p. 727 - 733

>  <Main tar all>
Protease pX=8.0 | sepiapterin reductase pX=7.96 | dihydrofolate reductase pX=7.0 | dihydrofolate reductase pX=7.0 | Dihydropteroate synthase pX=6.64

$$$$
Xylometazoline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.401 -2.0744 0 0
M  V30 3 C 8.401 -0.5344 0 0
M  V30 4 C 7.0674 0.2356 0 0
M  V30 5 C 7.0674 1.7756 0 0
M  V30 6 C 8.401 2.5456 0 0
M  V30 7 C 9.7347 1.7756 0 0
M  V30 8 C 11.0684 2.5456 0 0
M  V30 9 C 9.7347 0.2356 0 0
M  V30 10 C 11.0684 -0.5344 0 0
M  V30 11 C 11.0684 -2.0744 0 0
M  V30 12 N 12.3143 -2.9796 0 0
M  V30 13 C 11.8384 -4.4443 0 0
M  V30 14 C 10.2984 -4.4443 0 0
M  V30 15 N 9.8225 -2.9796 0 0
M  V30 16 C 5.7337 2.5456 0 0
M  V30 17 C 4.4 3.3156 0 0
M  V30 18 C 6.5037 3.8792 0 0
M  V30 19 C 4.9637 1.2119 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 2 3 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 11 15
M  V30 16 1 5 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242061948

>  <MW>
280.171

>  <MW (desalted)>
244.375

>  <ClogP>
5.376

>  <logS>
-4.409

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.39

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.7 nM | Ki (inhibition constant) = 4.8 nM | Ki (inhibition constant) = 14 nM

>  <CAS>
1218-35-5

>  <Description>
Xylometazoline is an imidazoline derivative with sympathomimetic and nasal decongestant activity. It works by binding to alpha (?)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. Xylometazoline is indicated for the temporary relief of nasal congestion due to cold, hay fever or other respiratory allergies.

>  <EBC_ID>
EBC-04431

>  <IUPAC Name>
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 1998, vol. 41, # 13, p. 2243 - 2251 | J. MED. CHEM., 1979, vol. 22, # 11, p. 1290 - 1295 | J. Med. Chem., 1998, vol. 41, # 13, p. 2243 - 2251

>  <Main tar all>
5-HT1D receptor pX=9.15 | ?-adrenoceptor pX=8.32 | 5-HT1B receptor pX=7.85

$$$$
Fenoprofen calcium dihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 Ca 2.8779 -3.08 0 0 CHG=2
M  V30 4 C 0.2106 -6.16 0 0
M  V30 5 C 1.5443 -6.93 0 0
M  V30 6 C 2.8779 -6.16 0 0
M  V30 7 O 4.2116 -6.93 0 0
M  V30 8 O 2.8779 -4.62 0 0 CHG=-1
M  V30 9 C 1.5443 -8.47 0 0
M  V30 10 C 2.8779 -9.24 0 0
M  V30 11 C 2.8779 -10.78 0 0
M  V30 12 C 1.5443 -11.55 0 0
M  V30 13 C 0.2106 -10.78 0 0
M  V30 14 O -1.1231 -11.55 0 0
M  V30 15 C -2.4568 -10.78 0 0
M  V30 16 C -3.7905 -11.55 0 0
M  V30 17 C -5.1241 -10.78 0 0
M  V30 18 C -5.1241 -9.24 0 0
M  V30 19 C -3.7905 -8.47 0 0
M  V30 20 C -2.4568 -9.24 0 0
M  V30 21 C 0.2106 -9.24 0 0
M  V30 22 C 13.0663 -5.847 0 0
M  V30 23 C 14.4 -6.617 0 0
M  V30 24 C 15.7337 -5.847 0 0
M  V30 25 O 15.7337 -4.307 0 0
M  V30 26 O 17.0674 -6.617 0 0 CHG=-1
M  V30 27 C 14.4 -8.157 0 0
M  V30 28 C 15.7337 -8.927 0 0
M  V30 29 C 15.7337 -10.467 0 0
M  V30 30 C 14.4 -11.237 0 0
M  V30 31 C 13.0663 -10.467 0 0
M  V30 32 O 11.7327 -11.237 0 0
M  V30 33 C 10.399 -10.467 0 0
M  V30 34 C 9.0653 -11.237 0 0
M  V30 35 C 7.7316 -10.467 0 0
M  V30 36 C 7.7316 -8.927 0 0
M  V30 37 C 9.0653 -8.157 0 0
M  V30 38 C 10.399 -8.927 0 0
M  V30 39 C 13.0663 -8.927 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 2 6 7
M  V30 4 1 6 8
M  V30 5 1 5 9
M  V30 6 1 9 10
M  V30 7 2 10 11
M  V30 8 1 11 12
M  V30 9 2 12 13
M  V30 10 1 13 14
M  V30 11 1 14 15
M  V30 12 1 15 16
M  V30 13 2 16 17
M  V30 14 1 17 18
M  V30 15 2 18 19
M  V30 16 1 19 20
M  V30 17 2 15 20
M  V30 18 1 13 21
M  V30 19 2 9 21
M  V30 20 1 22 23
M  V30 21 1 23 24
M  V30 22 2 24 25
M  V30 23 1 24 26
M  V30 24 1 23 27
M  V30 25 1 27 28
M  V30 26 2 28 29
M  V30 27 1 29 30
M  V30 28 2 30 31
M  V30 29 1 31 32
M  V30 30 1 32 33
M  V30 31 1 33 34
M  V30 32 2 34 35
M  V30 33 1 35 36
M  V30 34 2 36 37
M  V30 35 1 37 38
M  V30 36 2 33 38
M  V30 37 1 31 39
M  V30 38 2 27 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552187007

>  <MW>
558.157

>  <MW (desalted)>
242.27

>  <ClogP>
-0.019

>  <logS>
-7.524

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
49.36

>  <RotBonds>
8

>  <Action on targets>
Agonist | Agonist | Allosteric Modulator | Agonist

>  <Activity coefficients and valu>
pEC50  10.47 | pEC50  9.86 | pEC50  9.46 | pEC50  9.06

>  <CAS>
71720-56-4

>  <Description>
Fenoprofen is an anti-inflammatory analgesic agent.

>  <EBC_ID>
EBC-12986

>  <IUPAC Name>
calcium bis(2-(3-phenoxyphenyl)propanoate) dihydrate

>  <Main Tar all refs>
Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345 | Cell. Mol. Life Sci., 2017, vol. 74, # 7, p. 1335 - 1345

>  <Main tar all>
MC4 receptor pX=10.5 | MC3 receptor pX=9.86 | MC3 receptor pX=9.46 | MC5 receptor pX=9.06

$$$$
Sumatriptan succinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.0147 -0.4956 0 0
M  V30 2 N 5.681 -1.2656 0 0
M  V30 3 S 4.3474 -0.4956 0 0
M  V30 4 O 5.1174 0.8381 0 0
M  V30 5 O 3.5774 -1.8293 0 0
M  V30 6 C 3.0137 0.2744 0 0
M  V30 7 C 1.68 -0.4956 0 0
M  V30 8 C 1.68 -2.0356 0 0
M  V30 9 C 0.3463 -2.8056 0 0
M  V30 10 C -0.9874 -2.0356 0 0
M  V30 11 N -2.452 -2.5115 0 0
M  V30 12 C -3.3572 -1.2656 0 0
M  V30 13 C -2.452 -0.0197 0 0
M  V30 14 C -2.9279 1.4449 0 0
M  V30 15 C -4.4342 1.7651 0 0
M  V30 16 N -4.9101 3.2297 0 0
M  V30 17 C -6.4165 3.5499 0 0
M  V30 18 C -3.8796 4.3742 0 0
M  V30 19 C -0.9874 -0.4956 0 0
M  V30 20 C 0.3463 0.2744 0 0
M  V30 21 O 10.5347 -0.385 0 0
M  V30 22 C 11.8684 0.385 0 0
M  V30 23 O 11.8684 1.925 0 0
M  V30 24 C 13.2021 -0.385 0 0
M  V30 25 C 14.5358 0.385 0 0
M  V30 26 C 15.8694 -0.385 0 0
M  V30 27 O 17.2031 0.385 0 0
M  V30 28 O 15.8694 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 13 19
M  V30 19 2 10 19
M  V30 20 1 19 20
M  V30 21 2 7 20
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404947

>  <MW>
413.162

>  <MW (desalted)>
295.4

>  <ClogP>
0.743

>  <logS>
-1.11

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
65.2

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  9.3  | pKi  8.79  | pKi  8.4  | pKi  8.4  | pKi  8.19

>  <CAS>
103628-48-4

>  <Description>
Sumatriptan succinate is an agonist of the serotonin (5-HT) receptor. It is used in the treatment of migraine headache.

>  <EBC_ID>
EBC-03803

>  <IUPAC Name>
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; butanedioic acid

>  <Main Tar all refs>
J. Med. Chem., 2001, vol. 44, # 5, p. 681 - 693 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, vol. 346, # 3, p. 243 - 248 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, vol. 346, # 3, p. 249 - 254 | Arch. Pharm., 1998, vol. 331, # 2, p. 59 - 71 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, vol. 346, # 3, p. 249 - 254

>  <Main tar all>
5-HT1B receptor pX=9.3 | 5-HT1D receptor pX=8.79 | 5-HT receptor pX=8.4 | 5-HT1D receptor pX=8.4 | 5-HT1B receptor pX=8.19

$$$$
Prozac(R)
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.4 0 0
M  V30 3 N 5.7337 2.17 0 0
M  V30 4 C 7.0674 1.4 0 0
M  V30 5 C 8.401 2.17 0 0
M  V30 6 C 9.7347 1.4 0 0
M  V30 7 O 11.0684 2.17 0 0
M  V30 8 C 12.4021 1.4 0 0
M  V30 9 C 13.7358 2.17 0 0
M  V30 10 C 15.0694 1.4 0 0
M  V30 11 C 15.0694 -0.14 0 0
M  V30 12 C 13.7358 -0.91 0 0
M  V30 13 C 12.4021 -0.14 0 0
M  V30 14 C 16.4031 -0.91 0 0
M  V30 15 F 17.7368 -1.68 0 0
M  V30 16 F 15.6331 -2.2437 0 0
M  V30 17 F 17.1731 0.4237 0 0
M  V30 18 C 9.7347 -0.14 0 0
M  V30 19 C 11.0684 -0.91 0 0
M  V30 20 C 11.0684 -2.45 0 0
M  V30 21 C 9.7347 -3.22 0 0
M  V30 22 C 8.401 -2.45 0 0
M  V30 23 C 8.401 -0.91 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 11 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 6 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741982921

>  <MW>
345.111

>  <MW (desalted)>
309.326

>  <ClogP>
4.566

>  <logS>
-4.7

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
21.26

>  <RotBonds>
7

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
Lipid peroxidation increase Active   | Kd (dissociation constant) = 0.121 nM

>  <CAS>
56296-78-7

>  <Description>
Fluoxetine HCl is a selective serotonin reuptake inhibitor. Fluoxetine HCl have been used in the treatment of major depression as well as other psychiatric disorders.

>  <EBC_ID>
EBC-03850

>  <IUPAC Name>
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine hydrochloride

>  <Main Tar all refs>
Sci. Total Environ., 2022, vol. 807 | J. PHARMACOL. EXP. THER., 1997, vol. 282, # 1, p. 132 - 147

>  <Main tar all>
SERT pX=10.8 | ?-adrenoceptor pX=9.92

$$$$
Azatadine dimaleat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0 5.9587 0 0
M  V30 2 N -0 4.4187 0 0
M  V30 3 C 1.3337 3.6487 0 0
M  V30 4 C 1.3337 2.1087 0 0
M  V30 5 C 0 1.3387 0 0
M  V30 6 C 0 -0.2013 0 0
M  V30 7 C 1.3875 -0.8694 0 0
M  V30 8 C 2.5164 0.178 0 0
M  V30 9 C 3.988 -0.2759 0 0
M  V30 10 C 4.3307 -1.7773 0 0
M  V30 11 C 3.2018 -2.8247 0 0
M  V30 12 C 1.7302 -2.3708 0 0
M  V30 13 C 0.77 -3.5748 0 0
M  V30 14 C -0.77 -3.5748 0 0
M  V30 15 C -1.7302 -2.3708 0 0
M  V30 16 C -3.2018 -2.8247 0 0
M  V30 17 C -4.3307 -1.7773 0 0
M  V30 18 C -3.988 -0.2759 0 0
M  V30 19 N -2.5164 0.178 0 0
M  V30 20 C -1.3875 -0.8694 0 0
M  V30 21 C -1.3337 2.1087 0 0
M  V30 22 C -1.3337 3.6487 0 0
M  V30 23 O 14.0107 1.3337 0 0
M  V30 24 C 12.4707 1.3337 0 0
M  V30 25 O 11.7007 2.6674 0 0
M  V30 26 C 11.7007 -0 0 0
M  V30 27 C 10.1607 -0 0 0
M  V30 28 C 9.3907 -1.3337 0 0
M  V30 29 O 10.1607 -2.6674 0 0
M  V30 30 O 7.8507 -1.3337 0 0
M  V30 31 O 3.08 -7.9885 0 0
M  V30 32 C 1.54 -7.9885 0 0
M  V30 33 O 0.77 -6.6548 0 0
M  V30 34 C 0.77 -9.3222 0 0
M  V30 35 C -0.77 -9.3222 0 0
M  V30 36 C -1.54 -10.6559 0 0
M  V30 37 O -0.77 -11.9896 0 0
M  V30 38 O -3.08 -10.6559 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 6 20
M  V30 22 2 15 20
M  V30 23 1 5 21
M  V30 24 1 21 22
M  V30 25 1 2 22
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 26 24 CFG=2
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 34 32 CFG=2
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 36 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1623942918

>  <MW>
522.546

>  <MW (desalted)>
290.402

>  <ClogP>
3.559

>  <logS>
-2.85

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
16.13

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 3.9 nM

>  <CAS>
3978-86-7

>  <Description>
Azatadine is an H1 receptor antagonist used to treat perennial and allergic rhinitis as well as eustachian tube congestion.

>  <EBC_ID>
EBC-15032

>  <IUPAC Name>
2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaene; bis(but-2-enedioic acid)

>  <Main Tar all refs>
J. MED. CHEM., 1991, vol. 34, # 1, p. 457 - 461

>  <Main tar all>
H1 receptor pX=8.41

$$$$
Ruxolitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.9799 11.3643 0 0
M  V30 2 C 8.0747 10.1184 0 0
M  V30 3 C 7.1695 8.8726 0 0
M  V30 4 C 7.7959 7.4657 0 0 CFG=2
M  V30 5 C 9.3274 7.3047 0 0
M  V30 6 C 10.3579 8.4492 0 0
M  V30 7 C 11.7647 7.8228 0 0
M  V30 8 C 11.6038 6.2912 0 0
M  V30 9 C 10.0974 5.971 0 0
M  V30 10 N 6.8907 6.2198 0 0
M  V30 11 C 7.3666 4.7552 0 0
M  V30 12 C 6.1207 3.85 0 0
M  V30 13 C 4.8748 4.7552 0 0
M  V30 14 N 5.3507 6.2198 0 0
M  V30 15 C 6.1207 2.31 0 0
M  V30 16 N 7.4543 1.54 0 0
M  V30 17 C 7.4543 0 0 0
M  V30 18 N 6.1207 -0.77 0 0
M  V30 19 C 4.787 0 0 0
M  V30 20 N 3.3224 -0.4759 0 0
M  V30 21 C 2.4172 0.77 0 0
M  V30 22 C 3.3224 2.0159 0 0
M  V30 23 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 10 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 15 23
M  V30 26 1 19 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301683487

>  <MW>
306.159

>  <MW (desalted)>
306.365

>  <ClogP>
2.177

>  <logS>
-4.452

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
83.18

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.026 nM | Ki (inhibition constant)  0.2 nM | Kd (dissociation constant)  0.25 nM

>  <CAS>
941678-49-5

>  <Description>
Ruxolitinib is an antineoplastic agent that inhibits cell proliferation, induces apoptosis of malignant cells, and reduces pro-inflammatory cytokine plasma levels by inhibiting JAK-induced phosphorylation of signal transducer and activator of transcription (STAT). It is used to treat various types of myelofibrosis, polycythemia vera.

>  <EBC_ID>
EBC-17053

>  <IUPAC Name>
(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile

>  <Main Tar all refs>
Front. Immunol., 2022, vol. 13 | J. Med. Chem., 2012, vol. 55, # 13, p. 6176 - 6193 | Nat. Commun., 2019, vol. 10, # 1

>  <Main tar all>
Janus kinase 2 pX=10.6 | Janus kinase 1 pX=9.7 | tyrosine kinase 2 pX=9.6

$$$$
Melatonin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0749 -5.9641 0 0
M  V30 2 O 4.5507 -4.4994 0 0
M  V30 3 C 3.5203 -3.355 0 0
M  V30 4 C 2.0139 -3.6752 0 0
M  V30 5 C 0.9835 -2.5307 0 0
M  V30 6 C 1.4594 -1.0661 0 0
M  V30 7 N 0.6894 0.2676 0 0
M  V30 8 C 1.7198 1.412 0 0
M  V30 9 C 3.1267 0.7857 0 0
M  V30 10 C 4.4604 1.5557 0 0
M  V30 11 C 5.794 0.7857 0 0
M  V30 12 N 7.1277 1.5557 0 0
M  V30 13 C 8.4614 0.7857 0 0
M  V30 14 O 9.7951 1.5557 0 0
M  V30 15 C 8.4614 -0.7543 0 0
M  V30 16 C 2.9657 -0.7459 0 0
M  V30 17 C 3.9962 -1.8904 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 9 16
M  V30 16 2 6 16
M  V30 17 1 16 17
M  V30 18 2 3 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1191880499

>  <MW>
232.278

>  <MW (desalted)>
232.278

>  <ClogP>
1.03

>  <logS>
-2.27

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
54.12

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Agonist | Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
IC50 = 0.23 pM | EC50  1.2 pM | IC50 = 1.6 pM | Ki (inhibition constant)  2.995 pM | pEC50  11.38

>  <CAS>
73-31-4

>  <Description>
Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. It is used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind, and benzodiazepine and nicotine withdrawal.

>  <EBC_ID>
EBC-08635

>  <IUPAC Name>
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide

>  <Main Tar all refs>
J. Med. Chem., 2009, vol. 52, # 3, p. 826 - 833 | J. Pharmacol. Exp. Ther., 1998, vol. 285, # 3, p. 1239 - 1245 | Arch. Pharm., 2011, vol. 344, # 10, p. 666 - 674 | Mol. Pharmacol., 2019, vol. 96, # 2, p. 272 - 296 | eLife, 2020, vol. 9

>  <Main tar all>
MT1 receptor pX=12.6 | MT receptor pX=11.9 | MT2 receptor pX=11.8 | MT1 receptor pX=11.5 | MT1A?receptor  pX=11.4

$$$$
Clofarabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 Cl 8.788 -0.77 0 0
M  V30 6 N 6.1207 -0.77 0 0
M  V30 7 C 4.787 0 0 0
M  V30 8 N 3.3224 -0.4759 0 0
M  V30 9 C 2.4172 0.77 0 0
M  V30 10 N 3.3224 2.0159 0 0
M  V30 11 C 4.787 1.54 0 0
M  V30 12 C 2.8465 -1.9405 0 0 CFG=2
M  V30 13 O 3.7517 -3.1864 0 0
M  V30 14 C 2.8465 -4.4323 0 0 CFG=2
M  V30 15 C 3.3224 -5.8969 0 0
M  V30 16 O 4.8287 -6.2171 0 0
M  V30 17 C 1.3818 -3.9564 0 0 CFG=1
M  V30 18 O 0.136 -4.8616 0 0
M  V30 19 C 1.3818 -2.4164 0 0 CFG=2
M  V30 20 F 0.136 -1.5112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 2 11
M  V30 12 1 7 11
M  V30 13 1 12 8 CFG=3
M  V30 14 1 12 13
M  V30 15 1 14 13
M  V30 16 1 14 15 CFG=3
M  V30 17 1 15 16
M  V30 18 1 17 14
M  V30 19 1 17 18 CFG=1
M  V30 20 1 17 19
M  V30 21 1 19 12
M  V30 22 1 19 20 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551900487

>  <MW>
303.677

>  <MW (desalted)>
303.677

>  <ClogP>
-0.462

>  <logS>
-3.22

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
119.31

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.005 ?M | inhibition percentage  54.2 % | EC50  0.043 ?mol/l | IC50 ~ 50 nM | insertion-deletion mutation rate increase Active   | insertion-deletion mutation rate increase Active   | IC50  0.12 ?M | IC50  0.15 ?mol/l

>  <CAS>
123318-82-1

>  <Description>
Clofarabine is metabolized intracellularly to the active 5'-monophosphate metabolite by deoxycytidine kinase and 5'-triphosphate metabolite by mono- and di-phospho-kinases. It is used for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic leukemia after at least two prior regimens.

>  <EBC_ID>
EBC-11026

>  <IUPAC Name>
(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol

>  <Main Tar all refs>
Nat. Commun., 2019, vol. 10, # 1 | Int. J. Mol. Sci., 2018, vol. 19, # 12 | Cancer Res., 2022, vol. 82, # 4, p. 721 - 733 | Bioorg. Med. Chem., 2015, vol. 23, # 21, p. 6912 - 6921 | PHOREMOST - WO2020/79433, 2020, A1 | PHOREMOST - WO2020/79433, 2020, A1 | J. Med. Chem., 2020, vol. 63, # 24, p. 15852 - 15863 | GEORGETOWN UNIVERSITY - WO2018/71675, 2018, A1

>  <Main tar all>
Janus kinase pX=8.3 | Retinoic acid receptor-? pX=7.37 | Vitamin B12-dependent ribonucleoside-diphosphate reductase pX=7.37 | ribonucleoside-diphosphate reductase pX=7.3 | Ribonucleoside-diphosphate reductase large chain pX=7.0 | Ribonucleoside-diphosphate reductase small chain 1 pX=7.0 | phosphodiesterase 8A pX=6.92 | CD99 antigen pX=6.82

$$$$
Olmesartan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.4692 -5.505 0 0
M  V30 2 C 5.1355 -4.735 0 0
M  V30 3 C 3.8019 -5.505 0 0
M  V30 4 C 3.8019 -7.045 0 0
M  V30 5 N 5.0477 -7.9502 0 0
M  V30 6 C 4.5719 -9.4148 0 0
M  V30 7 C 3.0319 -9.4148 0 0
M  V30 8 C 2.1267 -10.6607 0 0
M  V30 9 O 0.5951 -10.4997 0 0
M  V30 10 O 2.753 -12.0676 0 0
M  V30 11 N 2.556 -7.9502 0 0
M  V30 12 C 1.0913 -7.4743 0 0
M  V30 13 C 0.7712 -5.968 0 0
M  V30 14 C -0.6935 -5.4921 0 0
M  V30 15 C -1.0137 -3.9857 0 0
M  V30 16 C 0.1308 -2.9553 0 0
M  V30 17 C 1.5954 -3.4311 0 0
M  V30 18 C 1.9156 -4.9375 0 0
M  V30 19 C -0.1894 -1.4489 0 0
M  V30 20 C -1.654 -0.973 0 0
M  V30 21 C -1.9742 0.5333 0 0
M  V30 22 C -0.8298 1.5638 0 0
M  V30 23 C 0.6349 1.0879 0 0
M  V30 24 C 0.955 -0.4185 0 0
M  V30 25 C 2.4197 -0.8943 0 0
M  V30 26 N 3.6656 0.0109 0 0
M  V30 27 N 4.9114 -0.8943 0 0
M  V30 28 N 4.4356 -2.359 0 0
M  V30 29 N 2.8956 -2.359 0 0
M  V30 30 C 5.477 -10.6607 0 0
M  V30 31 C 6.3822 -11.9066 0 0
M  V30 32 C 4.2312 -11.5659 0 0
M  V30 33 O 6.7229 -9.7555 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 7 11
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 16 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 1 25 29
M  V30 33 1 6 30
M  V30 34 1 30 31
M  V30 35 1 30 32
M  V30 36 1 30 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541758605

>  <MW>
446.502

>  <MW (desalted)>
446.502

>  <ClogP>
2.5

>  <logS>
-6.2

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
129.81

>  <RotBonds>
8

>  <Action on targets>
Antagonist | Inhibitor

>  <Activity coefficients and valu>
pD'2  9.9  | Kd (dissociation constant)  2.1 nM

>  <CAS>
144689-24-7

>  <Description>
Olmesartan is an angiotensin receptor blocker. It is used in the treatment of hypertension. It belongs to the angiotensin II receptor blocker family of drugs, which selectively bind to angiotensin receptor 1 and prevent the protein angiotensin II from binding and exerting its hypertensive effects.

>  <EBC_ID>
EBC-13061

>  <IUPAC Name>
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1995, vol. 285, # 2, p. 181 - 188 | J. Biol. Chem., 2015, vol. 290, # 49, p. 29127 - 29139

>  <Main tar all>
AT1 receptor pX=9.9 | AT1 receptor pX=8.68

$$$$
Candesartan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6296 0.0309 0 0
M  V30 2 C -1.0896 0.0309 0 0
M  V30 3 O -0.3196 -1.3028 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 N 2.1256 -0.0569 0 0
M  V30 6 C 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 4.9239 -4.3828 0 0
M  V30 12 O 3.5902 -5.1528 0 0
M  V30 13 O 6.2576 -5.1528 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 N 2.1256 -2.5487 0 0
M  V30 16 C 1.6497 -4.0133 0 0
M  V30 17 C 0.1434 -4.3335 0 0
M  V30 18 C -0.3325 -5.7982 0 0
M  V30 19 C -1.8389 -6.1183 0 0
M  V30 20 C -2.8693 -4.9739 0 0
M  V30 21 C -2.3934 -3.5093 0 0
M  V30 22 C -0.8871 -3.1891 0 0
M  V30 23 C -4.3757 -5.2941 0 0
M  V30 24 C -4.8515 -6.7587 0 0
M  V30 25 C -6.3579 -7.0789 0 0
M  V30 26 C -7.3884 -5.9344 0 0
M  V30 27 C -6.9125 -4.4698 0 0
M  V30 28 C -5.4061 -4.1496 0 0
M  V30 29 C -4.9302 -2.685 0 0
M  V30 30 N -5.8354 -1.4391 0 0
M  V30 31 N -4.9302 -0.1932 0 0
M  V30 32 N -3.4656 -0.6691 0 0
M  V30 33 N -3.4656 -2.2091 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 10 14
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 1 4 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 25 1 20 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 23 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 30 31
M  V30 35 2 31 32
M  V30 36 1 32 33
M  V30 37 1 29 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741968269

>  <MW>
440.454

>  <MW (desalted)>
440.454

>  <ClogP>
5.181

>  <logS>
-7.532

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
118.81

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.06 nM | Kd (dissociation constant)  0.087 nM | Kd (dissociation constant)  1.04 nM | Ki (inhibition constant)  1.8 nM

>  <CAS>
139481-59-7

>  <Description>
Candesartan is an inhibitor of the angiotensin II type 1 (AT1) receptor. It is used for the treatment of hypertension.

>  <EBC_ID>
EBC-06094

>  <IUPAC Name>
2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid

>  <Main Tar all refs>
Curr. Med. Chem.: Cardiovasc. Hematol. Agents, 2004, vol. 2, # 1, p. 69 - 77 | Biochem. Pharmacol., 2003, vol. 65, # 8, p. 1329 - 1338 | J. Biol. Chem., 2004, vol. 279, # 15, p. 15248 - 15257 | J. Med. Chem., 2016, vol. 59, # 5, p. 1925 - 1945

>  <Main tar all>
AT1 receptor pX=10.2 | AT1 receptor pX=10.1 | AT1 receptor pX=8.98 | AT1 receptor pX=8.74

$$$$
Cefalothin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.0539 1.8218 0 0
M  V30 2 C 7.7202 1.0518 0 0
M  V30 3 O 7.7202 -0.4882 0 0
M  V30 4 O 6.3866 1.8218 0 0
M  V30 5 C 5.0529 1.0518 0 0
M  V30 6 C 3.7192 1.8218 0 0
M  V30 7 C 2.3855 1.0518 0 0
M  V30 8 N 1.0518 1.8218 0 0
M  V30 9 C 1.0518 3.3618 0 0 CFG=2
M  V30 10 S 2.3855 4.1318 0 0
M  V30 11 C 3.7192 3.3618 0 0
M  V30 12 C -0.4882 3.3618 0 0 CFG=2
M  V30 13 N -1.5771 4.4508 0 0
M  V30 14 C -1.1785 5.9383 0 0
M  V30 15 O 0.309 6.3369 0 0
M  V30 16 C -2.2675 7.0273 0 0
M  V30 17 C -1.8689 8.5148 0 0
M  V30 18 C -2.838 9.7116 0 0
M  V30 19 C -1.9993 11.0031 0 0
M  V30 20 C -0.5118 10.6046 0 0
M  V30 21 S -0.4312 9.0667 0 0
M  V30 22 C -0.4882 1.8218 0 0
M  V30 23 O -1.5771 0.7329 0 0
M  V30 24 C 2.3855 -0.4882 0 0
M  V30 25 O 1.0518 -1.2582 0 0
M  V30 26 O 3.7192 -1.2582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13 CFG=1
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 17 21
M  V30 23 1 12 22
M  V30 24 1 8 22
M  V30 25 2 22 23
M  V30 26 1 7 24
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977144

>  <MW>
396.438

>  <MW (desalted)>
396.438

>  <ClogP>
-0.283

>  <logS>
-3.498

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
113.01

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.006 ?g/ml | IC50  0.013 ?g/ml | Ki (inhibition constant)  0.04 ?M | IC50 = 42 nM | IC50  0.018 ?g/ml | IC50  0.018 ?g/ml | IC50  0.043 ?g/ml | IC50  0.043 ?g/ml | Ki (inhibition constant)  0.2 ?M | Ki (inhibition constant)  0.22 ?M | IC50  0.27 ?M | Ki (inhibition constant) = 320 nM | IC50  0.13 ?g/ml

>  <CAS>
153-61-7

>  <Description>
Cefalotin is a cephalosporin antibiotic. It is used to prevent infection during surgery and to treat many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract. The bactericidal activity of cefalotin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins.

>  <EBC_ID>
EBC-03891

>  <IUPAC Name>
(6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | J. Antibiot., 2009, vol. 62, # 10, p. 575 - 580 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | Eur. J. Pharmacol., 2002, vol. 438, # 3, p. 137 - 142 | STATE UNIVERSITY SYSTEM OF FLORIDA - US2023/2381, 2023, A1 | MedChemComm, 2010, vol. 1, # 3, p. 183 - 198 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555

>  <Main tar all>
Penicillin-binding?protein?3 pX=7.82 | Penicillin-binding?protein 1B pX=7.48 | Organic anion transporter 3 pX=7.4 | D-alanyl-D-alanine carboxypeptidase pX=7.38 | Penicillin-binding?protein 1A pX=7.34 | Penicillin-binding?protein 1A pX=7.34 | Penicillin-binding?protein 2X pX=6.97 | Penicillin-binding?protein 2X pX=6.97 | Solute carrier family 22 member 11 pX=6.7 | Organic anion transporter 1 pX=6.66 | Stage V sporulation protein D pX=6.57 | Beta-lactamase pX=6.49 | Penicillin-binding?protein 2A pX=6.48

$$$$
Amoxicillin sesquihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 O 0 -7.3306 0 0
M  V30 4 C 18.1898 -7.9654 0 0
M  V30 5 C 17.0453 -6.935 0 0
M  V30 6 C 18.1898 -5.9045 0 0
M  V30 7 S 16.1401 -8.1808 0 0
M  V30 8 C 14.6755 -7.705 0 0 CFG=2
M  V30 9 C 13.1355 -7.705 0 0 CFG=2
M  V30 10 N 12.0466 -8.7939 0 0
M  V30 11 C 10.559 -8.3953 0 0
M  V30 12 O 10.1605 -6.9078 0 0
M  V30 13 C 9.4701 -9.4843 0 0 CFG=2
M  V30 14 N 9.8687 -10.9718 0 0
M  V30 15 C 7.9826 -9.0857 0 0
M  V30 16 C 6.8936 -10.1746 0 0
M  V30 17 C 5.4061 -9.776 0 0
M  V30 18 C 5.0075 -8.2885 0 0
M  V30 19 O 3.52 -7.8899 0 0
M  V30 20 C 6.0965 -7.1996 0 0
M  V30 21 C 7.584 -7.5982 0 0
M  V30 22 C 13.1355 -6.165 0 0
M  V30 23 O 12.0466 -5.076 0 0
M  V30 24 N 14.6755 -6.165 0 0
M  V30 25 C 16.1401 -5.6891 0 0 CFG=1
M  V30 26 C 16.616 -4.2244 0 0
M  V30 27 O 15.5856 -3.08 0 0
M  V30 28 O 18.1224 -3.9043 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 5
M  V30 2 1 5 6
M  V30 3 1 5 7
M  V30 4 1 8 7
M  V30 5 1 8 9
M  V30 6 1 9 10 CFG=3
M  V30 7 1 10 11
M  V30 8 2 11 12
M  V30 9 1 13 11
M  V30 10 1 13 14 CFG=3
M  V30 11 1 13 15
M  V30 12 1 15 16
M  V30 13 2 16 17
M  V30 14 1 17 18
M  V30 15 1 18 19
M  V30 16 2 18 20
M  V30 17 1 20 21
M  V30 18 2 15 21
M  V30 19 1 9 22
M  V30 20 2 22 23
M  V30 21 1 22 24
M  V30 22 1 8 24 CFG=3
M  V30 23 1 25 24
M  V30 24 1 25 5
M  V30 25 1 25 26 CFG=1
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041510078

>  <MW>
419.136

>  <MW (desalted)>
365.404

>  <ClogP>
-1.872

>  <logS>
-4.017

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
132.96

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4 pM | IC50 = 0.03 nM | IC50 = 0.038 nM | IC50 = 0.05 nM | IC50  0.06 nM | IC50 = 0.1 nM

>  <CAS>
61336-70-7

>  <Description>
Amoxicillin is a penicillin derivative used for the treatment of infections caused by gram-positive bacteria, in particular streptococcal bacteria causing upper respiratory tract infections.

>  <EBC_ID>
EBC-15035

>  <IUPAC Name>
(2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate

>  <Main Tar all refs>
BRISTOL-MYERS SQUIBB CO - WO2007/53452, 2007, A1 | Annu. Rep. Med. Chem., 1996, vol. 31, p. 151 - 160 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600 | Pharmaceuticals, 2021, vol. 14, # 1, p. 1 - 21 | Curr. Pharm. Des., 2009, vol. 15, # 6, p. 587 - 600

>  <Main tar all>
FIP1L1-PDGFR-alpha pX=11.4 | epidermal growth factor receptor pX=10.5 | Tyrosine-protein kinase ABL pX=10.4 | platelet derived growth factor receptor alpha pX=10.3 | erb-b2 receptor tyrosine kinase 2 pX=10.2 | Mast/stem cell growth factor receptor Kit pX=10.0

$$$$
Propylparaben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 O 4.001 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 O 5.3347 -3.08 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 O 10.6694 -7.7 0 0
M  V30 12 C 8.0021 -7.7 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53833638

>  <MW>
180.079

>  <MW (desalted)>
180.2

>  <ClogP>
3.043

>  <logS>
-2.046

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
4

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
percentage increase Active

>  <CAS>
94-13-3

>  <Description>
Propylparaben is an antimicrobial preservative which can be produced naturally by plants and bacteria. Propylparaben disrupts antral follicle growth and steroidogenic function by altering the cell-cycle, apoptosis, and steroidogenesis pathways. It is prevalently used in cosmetics, pharmaceuticals, foods and in allergenic testing.

>  <EBC_ID>
EBC-26146

>  <IUPAC Name>
propyl 4-hydroxybenzoate

>  <Main Tar all refs>
Environ. Sci. Technol., 2017, vol. 51, # 11, p. 6452 - 6460

>  <Main tar all>
Androgen receptor pX=11.3

$$$$
Oxybenzone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 0 0 0
M  V30 2 O 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 O 5.3347 -7.7 0 0
M  V30 9 C 2.6674 -7.7 0 0
M  V30 10 C 2.6674 -9.24 0 0
M  V30 11 C 1.3337 -10.01 0 0
M  V30 12 C -0 -9.24 0 0
M  V30 13 C 0 -7.7 0 0
M  V30 14 C 1.3337 -6.93 0 0
M  V30 15 C 2.6674 -4.62 0 0
M  V30 16 O 1.3337 -5.39 0 0
M  V30 17 C 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 2 6 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 3 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104500700

>  <MW>
228.079

>  <MW (desalted)>
228.243

>  <ClogP>
3.586

>  <logS>
-3.39

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Agonist | Inhibitor | Agonist | Blocker | Agonist | Antagonist | Agonist

>  <Activity coefficients and valu>
inhibition percentage Active   | DNA damage increase Active   | IC50 = 3.25 ?M | R-loop formation increase Active   | inhibition percentage  57.4 % | increase rate Active   | IC50  11.81 ?M | EC50  25.05 ?M

>  <CAS>
131-57-7

>  <Description>
Oxybenzone is a benzophenone derivative used as a sunscreen agent. Oxybenzone absorbs UV-A ultraviolet rays, preventing them from reaching the skin.

>  <EBC_ID>
EBC-03702

>  <IUPAC Name>
2-benzoyl-5-methoxyphenol

>  <Main Tar all refs>
Ecotoxicology, 2016, vol. 25, # 7, p. 1318 - 1326 | UNIVERSITY OF MASSACHUSETTS - US2021/109085, 2021, A1 | J. Med. Chem., 2008, vol. 51, # 20, p. 6478 - 6494 | UNIVERSITY OF MASSACHUSETTS - US2021/109085, 2021, A1 | Pharm. Res., 2019, vol. 36, # 9 | Toxicology, 2022, vol. 471 | Water Res., 2020, vol. 185 | Toxicol. Vitro, 2020, vol. 67

>  <Main tar all>
ABCG2 pX=6.0 | nuclear estrogen receptor pX=6.0 | Hormone-sensitive lipase (gene Lipe) pX=5.49 | Estrogen receptor pX=5.3 | Kv7.1 pX=5.13 | Nuclear receptor ROR-gamma (isoform 2) pX=5.0 | Progesterone receptor pX=4.93 | Peroxisome proliferator-activated receptor-? pX=4.6

$$$$
Pentostatin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.2397 -8.9852 0 0
M  V30 2 C -1.4007 -7.4537 0 0
M  V30 3 C -0.1548 -6.5485 0 0 CFG=1
M  V30 4 O -0.1548 -5.0085 0 0
M  V30 5 C 1.3098 -4.5326 0 0 CFG=2
M  V30 6 C 2.215 -5.7785 0 0
M  V30 7 C 1.3098 -7.0244 0 0 CFG=2
M  V30 8 O 1.7857 -8.489 0 0
M  V30 9 N 1.7857 -3.068 0 0
M  V30 10 C 0.8805 -1.8221 0 0
M  V30 11 N 1.7857 -0.5762 0 0
M  V30 12 C 3.2504 -1.0521 0 0
M  V30 13 C 4.4544 -0.0919 0 0 CFG=2
M  V30 14 O 4.1117 1.4095 0 0
M  V30 15 C 5.9558 -0.4346 0 0
M  V30 16 N 6.624 -1.8221 0 0
M  V30 17 C 5.9558 -3.2096 0 0
M  V30 18 N 4.4544 -3.5522 0 0
M  V30 19 C 3.2504 -2.5921 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 5 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 13 12
M  V30 14 1 13 14 CFG=3
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 12 19
M  V30 21 1 9 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2204459563

>  <MW>
268.269

>  <MW (desalted)>
268.269

>  <ClogP>
-2.546

>  <logS>
-0.73

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
112.13

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) < 0.2 nM | inhibition rate Active   | Ki (inhibition constant)  1.2 nM

>  <CAS>
53910-25-1

>  <Description>
Pentostatin is a potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

>  <EBC_ID>
EBC-08665

>  <IUPAC Name>
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol

>  <Main Tar all refs>
Curr. Top. Med. Chem., 2006, vol. 6, # 13, p. 1375 - 1399 | UNIVERSITY OF CAMBRIDGE - WO2020/120410, 2020, A1 | ChemBioChem, 2019, vol. 20, # 5, p. 718 - 726

>  <Main tar all>
AMP deaminase pX=9.7 | Purine nucleoside phosphorylase LACC1 pX=9.0 | Adenosine deaminase pX=8.92

$$$$
Berberine chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 4.4 -0.293 0 0
M  V30 3 O 5.1496 1.0522 0 0
M  V30 4 C 6.6895 1.0757 0 0
M  V30 5 C 7.4391 2.4209 0 0
M  V30 6 C 8.9789 2.4443 0 0
M  V30 7 C 9.7691 1.1225 0 0
M  V30 8 C 11.3089 1.1459 0 0
M  V30 9 C 12.0991 -0.1759 0 0
M  V30 10 C 13.6389 -0.1525 0 0
M  V30 11 C 14.3886 1.1928 0 0
M  V30 12 C 15.9284 1.2162 0 0
M  V30 13 O 16.9413 2.3762 0 0
M  V30 14 C 18.3575 1.7713 0 0
M  V30 15 O 18.2199 0.2374 0 0
M  V30 16 C 16.7186 -0.1056 0 0
M  V30 17 C 15.9689 -1.4509 0 0
M  V30 18 C 14.4291 -1.4743 0 0
M  V30 19 C 13.6795 -2.8195 0 0
M  V30 20 C 12.1397 -2.8429 0 0
M  V30 21 N 11.3495 -1.5211 0 0 CHG=1
M  V30 22 C 9.8097 -1.5445 0 0
M  V30 23 C 9.0195 -0.2227 0 0
M  V30 24 C 7.4796 -0.2462 0 0
M  V30 25 O 6.73 -1.5914 0 0
M  V30 26 C 5.1902 -1.6148 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 12 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 10 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 9 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 7 23
M  V30 26 1 23 24
M  V30 27 2 4 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1494829513

>  <MW>
371.092

>  <MW (desalted)>
336.361

>  <ClogP>
-0.771

>  <logS>
-5.48

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
40.8

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | - | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50 = 13.98 nM | IC50 = 0.04 ?M | protein expression level decrease Active   | protein aggregation decrease Active   | protein expression level decrease Active   | Ki (inhibition constant) = 0.289 ?M

>  <CAS>
633-65-8

>  <Description>
Berberine chloride is a quaternary ammonium salt from the group of isoquinoline alkaloid that has antibacterial, anti-inflammatory, antitumor, anti-obesity, and hypercholesterolemic activity. Berberine has been reported as an acetylcholinesterase (AChE) inhibitor.

>  <EBC_ID>
EBC-07791

>  <IUPAC Name>
16,17-dimethoxy-5,7-dioxa-13lambda5-azapentacyclo[11.8.0.0^{2,10}.0^{4,8}.0^{15,20}]henicosa-1(21),2(10),3,8,13,15(20),16,18-octaen-13-ylium chloride

>  <Main Tar all refs>
Curr. Med. Chem., 2006, vol. 13, # 10, p. 1203 - 1218 | Bioorg. Med. Chem. Lett., 2011, vol. 21, # 21, p. 6603 - 6607 | Int. J. Mol. Sci., 2020, vol. 21, # 10 | Int. J. Mol. Sci., 2020, vol. 21, # 10 | Int. J. Mol. Sci., 2020, vol. 21, # 10 | Bioorg. Med. Chem., 2010, vol. 18, # 3, p. 1244 - 1251

>  <Main tar all>
Aldo-keto reductase family 1 member B1 pX=7.85 | acetylcholinesterase (Cartwright blood group) pX=7.4 | Androgen receptor (polyglutamine Q46) pX=7.3 | Androgen receptor (polyglutamine Q48) pX=6.7 | TAR DNA-binding protein 43 pX=6.7 | acetylcholinesterase (Cartwright blood group) pX=6.54

$$$$
Vancomycin hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 102 110 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.1057 -8.6447 0 0
M  V30 3 N 7.9906 -9.9051 0 0
M  V30 4 C 9.5246 -9.769 0 0 CFG=2
M  V30 5 C 10.4094 -11.0294 0 0
M  V30 6 C 9.7603 -12.4259 0 0
M  V30 7 C 10.6452 -13.6863 0 0
M  V30 8 C 8.2263 -12.562 0 0
M  V30 9 C 10.1737 -8.3724 0 0
M  V30 10 O 11.7076 -8.2363 0 0
M  V30 11 N 9.2888 -7.112 0 0
M  V30 12 C 9.9379 -5.7155 0 0 CFG=2
M  V30 13 C 8.6966 -4.7336 0 0 CFG=2
M  V30 14 O 7.3861 -5.5425 0 0
M  V30 15 C 8.3713 -3.1648 0 0
M  V30 16 C 9.877 -2.7454 0 0
M  V30 17 C 10.317 -1.2729 0 0
M  V30 18 C 9.2625 -0.1169 0 0
M  V30 19 O 10.2337 1.1452 0 0
M  V30 20 C 11.7045 1.7408 0 0
M  V30 21 C 12.7452 0.5742 0 0
M  V30 22 C 14.2919 0.7519 0 0
M  V30 23 C 14.7997 2.2303 0 0
M  V30 24 C 13.8502 3.4856 0 0
M  V30 25 O 14.6932 4.85 0 0
M  V30 26 C 16.1256 5.5604 0 0
M  V30 27 C 17.0029 6.8628 0 0
M  V30 28 C 18.5588 6.7996 0 0
M  V30 29 C 19.2957 5.4115 0 0
M  V30 30 C 18.4206 4.1213 0 0
M  V30 31 C 16.8828 4.1983 0 0
M  V30 32 Cl 16.069 2.8909 0 0
M  V30 33 C 20.6998 4.6629 0 0 CFG=1
M  V30 34 O 21.6969 5.8365 0 0
M  V30 35 C 21.6599 3.4056 0 0 CFG=2
M  V30 36 N 20.9224 2.0122 0 0
M  V30 37 C 20.1068 0.676 0 0
M  V30 38 O 18.675 1.2428 0 0
M  V30 39 C 19.7837 -0.8715 0 0 CFG=2
M  V30 40 N 18.2223 -1.0898 0 0
M  V30 41 C 16.7402 -0.5915 0 0
M  V30 42 O 16.9905 0.928 0 0
M  V30 43 C 15.1653 -0.588 0 0 CFG=2
M  V30 44 N 14.9615 -2.158 0 0
M  V30 45 C 15.1077 -3.7144 0 0
M  V30 46 O 16.6174 -4.0186 0 0
M  V30 47 C 14.3771 -5.0799 0 0 CFG=2
M  V30 48 C 15.4766 -6.1582 0 0
M  V30 49 C 15.0925 -7.6495 0 0
M  V30 50 O 16.1919 -8.7278 0 0
M  V30 51 N 13.6089 -8.0625 0 0
M  V30 52 N 13.0246 -5.8377 0 0
M  V30 53 C 11.4762 -6.0289 0 0
M  V30 54 O 11.4161 -7.5677 0 0
M  V30 55 C 20.8669 -2.0507 0 0
M  V30 56 C 20.5992 -3.5929 0 0
M  V30 57 C 21.7579 -4.6246 0 0
M  V30 58 C 23.2287 -4.1166 0 0
M  V30 59 O 24.3761 -5.1437 0 0
M  V30 60 C 23.5741 -2.5873 0 0
M  V30 61 C 22.3639 -1.5932 0 0
M  V30 62 C 24.9887 -1.8645 0 0
M  V30 63 C 25.9511 -3.0668 0 0
M  V30 64 O 25.391 -4.5013 0 0
M  V30 65 C 27.4734 -2.8345 0 0
M  V30 66 C 28.0335 -1.3999 0 0
M  V30 67 O 29.5558 -1.1676 0 0
M  V30 68 C 27.0711 -0.1976 0 0
M  V30 69 C 25.5487 -0.4299 0 0
M  V30 70 C 25.034 1.0613 0 0 CFG=2
M  V30 71 N 24.5234 2.5369 0 0
M  V30 72 C 23.2364 3.4299 0 0
M  V30 73 O 23.685 4.9031 0 0
M  V30 74 C 26.4895 1.5643 0 0
M  V30 75 O 26.7817 3.0764 0 0
M  V30 76 O 27.6529 0.5553 0 0
M  V30 77 C 12.3046 3.1893 0 0
M  V30 78 O 11.3318 4.3831 0 0
M  V30 79 C 9.8115 4.1375 0 0 CFG=2
M  V30 80 O 9.2641 2.6981 0 0
M  V30 81 C 7.7438 2.4526 0 0
M  V30 82 C 7.1963 1.0132 0 0
M  V30 83 O 5.676 0.7676 0 0
M  V30 84 C 6.771 3.6464 0 0 CFG=1
M  V30 85 O 5.2507 3.4009 0 0
M  V30 86 C 7.3184 5.0858 0 0 CFG=2
M  V30 87 O 6.3456 6.2796 0 0
M  V30 88 C 8.8387 5.3314 0 0 CFG=1
M  V30 89 O 9.3862 6.7708 0 0
M  V30 90 C 8.4134 7.9646 0 0 CFG=1
M  V30 91 C 8.9609 9.404 0 0
M  V30 92 C 7.9881 10.5978 0 0 CFG=2
M  V30 93 C 9.3327 11.3486 0 0
M  V30 94 N 7.4822 12.0524 0 0
M  V30 95 C 6.4678 10.3523 0 0 CFG=2
M  V30 96 O 5.495 11.5461 0 0
M  V30 97 C 5.9203 8.9129 0 0 CFG=2
M  V30 98 C 4.4 8.6673 0 0
M  V30 99 O 6.8931 7.719 0 0
M  V30 100 C 7.7309 -0.4967 0 0
M  V30 101 Cl 6.6576 0.6077 0 0
M  V30 102 C 7.3132 -1.9964 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3 CFG=1
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 4 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 12 11 CFG=3
M  V30 11 1 12 13
M  V30 12 1 13 14 CFG=3
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 2 21 22
M  V30 21 1 22 23
M  V30 22 2 23 24
M  V30 23 1 24 25
M  V30 24 1 25 26
M  V30 25 1 26 27
M  V30 26 2 27 28
M  V30 27 1 28 29
M  V30 28 2 29 30
M  V30 29 1 30 31
M  V30 30 2 26 31
M  V30 31 1 31 32
M  V30 32 1 33 29
M  V30 33 1 33 34 CFG=1
M  V30 34 1 33 35
M  V30 35 1 35 36 CFG=1
M  V30 36 1 36 37
M  V30 37 2 37 38
M  V30 38 1 39 37
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 2 41 42
M  V30 42 1 43 41
M  V30 43 1 43 22 CFG=3
M  V30 44 1 43 44
M  V30 45 1 44 45
M  V30 46 2 45 46
M  V30 47 1 47 45
M  V30 48 1 47 48 CFG=3
M  V30 49 1 48 49
M  V30 50 2 49 50
M  V30 51 1 49 51
M  V30 52 1 47 52
M  V30 53 1 52 53
M  V30 54 1 12 53
M  V30 55 2 53 54
M  V30 56 1 39 55 CFG=1
M  V30 57 1 55 56
M  V30 58 2 56 57
M  V30 59 1 57 58
M  V30 60 1 58 59
M  V30 61 2 58 60
M  V30 62 1 60 61
M  V30 63 2 55 61
M  V30 64 1 60 62
M  V30 65 1 62 63
M  V30 66 1 63 64
M  V30 67 2 63 65
M  V30 68 1 65 66
M  V30 69 1 66 67
M  V30 70 2 66 68
M  V30 71 1 68 69
M  V30 72 2 62 69
M  V30 73 1 70 69
M  V30 74 1 70 71
M  V30 75 1 71 72
M  V30 76 1 35 72
M  V30 77 2 72 73
M  V30 78 1 70 74 CFG=3
M  V30 79 2 74 75
M  V30 80 1 74 76
M  V30 81 1 24 77
M  V30 82 2 20 77
M  V30 83 1 77 78
M  V30 84 1 79 78 CFG=3
M  V30 85 1 79 80
M  V30 86 1 80 81
M  V30 87 1 81 82
M  V30 88 1 82 83
M  V30 89 1 84 81
M  V30 90 1 84 85 CFG=1
M  V30 91 1 86 84
M  V30 92 1 86 87 CFG=3
M  V30 93 1 86 88
M  V30 94 1 88 79
M  V30 95 1 88 89 CFG=1
M  V30 96 1 90 89 CFG=3
M  V30 97 1 90 91
M  V30 98 1 92 91
M  V30 99 1 92 93 CFG=3
M  V30 100 1 92 94 CFG=1
M  V30 101 1 95 92
M  V30 102 1 95 96 CFG=1
M  V30 103 1 95 97
M  V30 104 1 97 98 CFG=1
M  V30 105 1 97 99
M  V30 106 1 90 99
M  V30 107 2 18 100
M  V30 108 1 100 101
M  V30 109 1 100 102
M  V30 110 2 15 102
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3223135042

>  <MW>
1483.407

>  <MW (desalted)>
1449.254

>  <ClogP>
-1.142

>  <logS>
-1.604

>  <HBD>
19

>  <HBA>
24

>  <TPSA>
530.49

>  <RotBonds>
13

>  <CAS>
1404-93-9

>  <Description>
Vancomycin is a glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA.

>  <EBC_ID>
EBC-68041

>  <IUPAC Name>
(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S,3R,4S,5S)-3-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-22-(carbamoylmethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid hydrochloride

$$$$
Gilteritinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 0 0 0
M  V30 2 C 4.001 -0.77 0 0
M  V30 3 C 4.001 -2.31 0 0
M  V30 4 N 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 O 8.0021 -4.62 0 0
M  V30 8 N 6.6684 -6.93 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 N 4.001 -6.93 0 0
M  V30 11 C 2.6674 -7.7 0 0
M  V30 12 C 2.6674 -9.24 0 0
M  V30 13 C 1.3337 -10.01 0 0
M  V30 14 C 0 -9.24 0 0
M  V30 15 N -1.3337 -10.01 0 0
M  V30 16 C -1.3337 -11.55 0 0
M  V30 17 C -2.6674 -12.32 0 0
M  V30 18 C -4.001 -11.55 0 0
M  V30 19 C -4.001 -10.01 0 0
M  V30 20 C -2.6674 -9.24 0 0
M  V30 21 N -5.3347 -12.32 0 0
M  V30 22 C -5.3347 -13.86 0 0
M  V30 23 C -6.6684 -14.63 0 0
M  V30 24 N -8.0021 -13.86 0 0
M  V30 25 C -9.3358 -14.63 0 0
M  V30 26 C -8.0021 -12.32 0 0
M  V30 27 C -6.6684 -11.55 0 0
M  V30 28 C 0 -7.7 0 0
M  V30 29 O -1.3337 -6.93 0 0
M  V30 30 C -1.3337 -5.39 0 0
M  V30 31 C 1.3337 -6.93 0 0
M  V30 32 N 2.6674 -4.62 0 0
M  V30 33 C 2.6674 -3.08 0 0
M  V30 34 N 1.3337 -2.31 0 0
M  V30 35 C 1.3337 -0.77 0 0
M  V30 36 C 0 0 0 0
M  V30 37 C 0 1.54 0 0
M  V30 38 O 1.3337 2.31 0 0
M  V30 39 C 2.6674 1.54 0 0
M  V30 40 C 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 15 20
M  V30 21 1 18 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 26 27
M  V30 28 1 21 27
M  V30 29 2 14 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 28 31
M  V30 33 2 11 31
M  V30 34 2 9 32
M  V30 35 1 32 33
M  V30 36 2 3 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 35 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3026628192

>  <MW>
552.354

>  <MW (desalted)>
552.711

>  <ClogP>
2.271

>  <logS>
-2.925

>  <HBD>
3

>  <HBA>
10

>  <TPSA>
121.11

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.29 nM | IC50  0.31 nM | IC50  0.34 nM | IC50  0.38 nM | IC50  0.41 nM | Kd (dissociation constant)  0.41 nmol/l | Kd (dissociation constant)  0.41 nmol/l | IC50  0.43 nM | IC50  0.576 nM | IC50  0.7 nM | Kd (dissociation constant)  0.76 nmol/l | IC50  1.37 nmol/l | IC50  1.5 nM | IC50  1.64 nM | Kd (dissociation constant)  1.7 nmol/l | EC50  1.8 nM | EC50  1.8 nM | IC50  2.5 nM | IC50  2.86 nM | IC50 ~ 3 nM | IC50  3.15 nM | Kd (dissociation constant)  3.2 nmol/l | GI50  3.29 nM | IC50  3.57 nM | IC50  4.85 nM | GI50  5 nM | IC50  6.8 - 10.59 nM | IC50  6.95 nM | Kd (dissociation constant)  8.2 nmol/l | IC50  9 nmol/l

>  <CAS>
1254053-43-4

>  <Description>
Gilteritinib is a potent selective inhibitor of both of the mutations, internal tandem duplication and tyrosine kinase domain, of the FLT3 receptor. It is used to treat relapsed or refractory acute myeloid leukemia.

>  <EBC_ID>
EBC-17149

>  <IUPAC Name>
6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2019, vol. 29, # 6, p. 836 - 838 | J. Med. Chem., 2022, vol. 65, # 4, p. 3229 - 3248 | Nat. Commun., 2021, vol. 12, # 1 | Nat. Commun., 2021, vol. 12, # 1 | Nat. Commun., 2021, vol. 12, # 1 | WUXI APPTEC CO., LTD. - EP3858819, 2021, A1 | WUXI APPTEC CO., LTD. - US2023/141887, 2023, A1 | J. Med. Chem., 2022, vol. 65, # 4, p. 3229 - 3248 | Biomed. Pharmacother., 2023, vol. 165 | ASTELLAS PHARMA INC. - EP3103453, 2016, A1 | WUXI APPTEC CO., LTD. - EP3858819, 2021, A1 | WUXI APPTEC CO., LTD. - US2023/141887, 2023, A1 | ASTELLAS PHARMA INC.; KOTOBUKI PHARMACEUTICAL CO.,LTD - WO2010/128659, 2010, A1 | Nat. Commun., 2021, vol. 12, # 1 | WUXI APPTEC CO., LTD. - EP3858819, 2021, A1 | BRISTOL-MYERS SQUIBB CO - WO2020/257671, 2020, A1 | BRISTOL-MYERS SQUIBB CO - WO2020/257671, 2020, A1 | UNIVERSITY OF TORONTO - US2019/91205, 2019, A1 | Nat. Commun., 2021, vol. 12, # 1 | Nat. Chem. Biol., 2020 | Nat. Commun., 2021, vol. 12, # 1 | WUXI APPTEC CO., LTD. - EP3858819, 2021, A1 | Eur. J. Med. Chem., 2020, vol. 195 | Biomed. Pharmacother., 2023, vol. 165 | Biomed. Pharmacother., 2023, vol. 165 | J. Med. Chem., 2021, vol. 64, # 16, p. 11934 - 11957 | CRYSTAL GENOMICS INC; APTOS BIOSCIENCES; APTOSE BIOSCIENCES INC. - WO2018/156578, 2018, A1 | Nat. Commun., 2021, vol. 12, # 1 | WUXI APPTEC CO., LTD. - EP3858819, 2021, A1 | , 2022, vol. 21, # 7, p. 1125 - 1135

>  <Main tar all>
fms related receptor tyrosine kinase 3 pX=9.54 | fms related receptor tyrosine kinase 3 (D835V) pX=9.51 | EML4-ALK tyrosine kinase (L1256F) pX=9.47 | ALK receptor tyrosine kinase pX=9.42 | EML4-ALK tyrosine kinase (I1171N, L1256F) pX=9.39 | fms related receptor tyrosine kinase 3 (ITD) pX=9.39 | fms related receptor tyrosine kinase 3 (ITD) pX=9.39 | fms related receptor tyrosine kinase 3 (ITD) pX=9.37 | fms related receptor tyrosine kinase 3 (ITD) pX=9.24 | AXL receptor tyrosine kinase pX=9.15 | fms related receptor tyrosine kinase 3 (F691L) pX=9.12 | NEDD8-activating enzyme E1 regulatory subunit AXL pX=8.86 | EML4-ALK tyrosine kinase variant 1 pX=8.82 | EML4-ALK tyrosine kinase (I1171N, L1198F) pX=8.79 | fms related receptor tyrosine kinase 3 (D835Y) pX=8.77 | fms related receptor tyrosine kinase 3 (D538Y) pX=8.74 | fms related receptor tyrosine kinase 3 (ITD) pX=8.74 | Epidermal growth factor receptor (Del19/T790M/C797S) pX=8.6 | EML4-ALK tyrosine kinase (I1171S) pX=8.54 | epidermal growth factor receptor pX=8.52 | EML4-ALK tyrosine kinase (I1171N, F1174L) pX=8.5 | fms related receptor tyrosine kinase 3 (D835H) pX=8.49 | fms related receptor tyrosine kinase 3 (ITD) pX=8.48 | ret proto-oncogene pX=8.45 | ret proto-oncogene (M918T) pX=8.31 | fms related receptor tyrosine kinase 3 (ITD,?D835Y) pX=8.3 | fms related receptor tyrosine kinase 3 (ITD,?D835Y) pX=8.17 | EML4-ALK tyrosine kinase (I1171N, L1198H) pX=8.16 | fms related receptor tyrosine kinase 3 (N841I) pX=8.09 | fms related receptor tyrosine kinase 3 (ITD,?D835Y) pX=8.05

$$$$
Enzacamene
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.4091 -6.9294 0 0
M  V30 2 C -1.384 -5.3896 0 0
M  V30 3 C -2.7049 -4.5979 0 0
M  V30 4 C -2.6798 -3.0581 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C -1.3099 -0.8538 0 0
M  V30 7 C 0.154 -0.154 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 C 2.6674 1.54 0 0
M  V30 11 C 1.3337 2.31 0 0
M  V30 12 C 1.3956 3.9195 0 0
M  V30 13 C 0.154 1.694 0 0
M  V30 14 O -0.9561 2.9859 0 0
M  V30 15 C 0.9487 0.77 0 0
M  V30 16 C -0.8248 1.448 0 0
M  V30 17 C -0.9126 0.1836 0 0
M  V30 18 C -0.0127 -3.1017 0 0
M  V30 19 C -0.0379 -4.6415 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 7 13
M  V30 14 2 13 14
M  V30 15 1 11 15
M  V30 16 1 8 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 2 5 18
M  V30 20 1 18 19
M  V30 21 2 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2312380068

>  <MW>
254.167

>  <MW (desalted)>
254.367

>  <ClogP>
5.019

>  <logS>
-4.699

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.07

>  <RotBonds>
1

>  <CAS>
36861-47-9

>  <Description>
Enzacamene is an ingredient used in sunscreen to block UVB radiation.

>  <EBC_ID>
EBC-26337

>  <IUPAC Name>
(3E)-1,7,7-trimethyl-3-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-2-one

$$$$
Mycophenolic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.5315 2.0728 0 0
M  V30 2 O 5.1978 1.3028 0 0
M  V30 3 C 3.8641 2.0728 0 0
M  V30 4 C 2.5304 1.3028 0 0
M  V30 5 C 2.5304 -0.2372 0 0
M  V30 6 C 1.1967 2.0728 0 0
M  V30 7 C -0.2679 1.5969 0 0
M  V30 8 O -1.1731 2.8428 0 0
M  V30 9 C -0.2679 4.0887 0 0
M  V30 10 O -0.7438 5.5533 0 0
M  V30 11 C 1.1967 3.6128 0 0
M  V30 12 C 2.5304 4.3828 0 0
M  V30 13 O 2.5304 5.9228 0 0
M  V30 14 C 3.8641 3.6128 0 0
M  V30 15 C 5.1978 4.3828 0 0
M  V30 16 C 5.1978 5.9228 0 0
M  V30 17 C 6.5315 6.6928 0 0
M  V30 18 C 7.8651 5.9228 0 0
M  V30 19 C 6.5315 8.2328 0 0
M  V30 20 C 5.1978 9.0028 0 0
M  V30 21 C 5.1978 10.5428 0 0
M  V30 22 O 3.8641 11.3128 0 0
M  V30 23 O 6.5315 11.3128 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 3 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315575694

>  <MW>
320.126

>  <MW (desalted)>
320.337

>  <ClogP>
2.291

>  <logS>
-3.157

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
93.06

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage >= 80 % | Ki (inhibition constant) = 10 nM | stimulation rate Active   | Ki (inhibition constant)  11 - 33 nM | IC50 = 13 nM | IC50 = 45 nM | Km (Michaelis constant)  0.06 ?M | inhibition percentage Active

>  <CAS>
24280-93-1

>  <Description>
Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor and prednisolone.

>  <EBC_ID>
EBC-11149

>  <IUPAC Name>
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid

>  <Main Tar all refs>
J. Asian Nat. Prod. Res., 2016, vol. 18, # 5, p. 475 - 485 | Curr. Top. Med. Chem., 2011, vol. 11, # 22, p. 2749 - 2787 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 17, p. 4767 - 4770 | Curr. Med. Chem., 2011, vol. 18, # 13, p. 1909 - 1918 | J. Biol. Chem., 2011, vol. 286, # 47, p. 40595 - 40600 | J. Biol. Chem., 2011, vol. 286, # 47, p. 40595 - 40600 | Drug Metab. Dispos., 2005, vol. 33, # 1, p. 139 - 146 | YUMANITY THERAPEUTICS INC - WO2018/81167, 2018, A1

>  <Main tar all>
inosine monophosphate dehydrogenase 2 pX=8.43 | IMP dehydrogenase pX=8.0 | Peroxisome proliferator-activated receptor-? pX=8.0 | inosine monophosphate dehydrogenase 1 pX=7.96 | Inosine-5'-monophosphate dehydrogenase pX=7.89 | Inosine-5'-Monophosphate Dehydrogenase A pX=7.35 |  UDP glucuronosyltransferase pX=7.22 | Acyl-CoA desaturase (gene SCD) pX=7.2

$$$$
Anethole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C -0 -3.08 0 0
M  V30 9 C -0 -4.62 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 6 10
M  V30 10 1 10 11
M  V30 11 2 3 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315575049

>  <MW>
148.089

>  <MW (desalted)>
148.202

>  <ClogP>
3.314

>  <logS>
-2.849

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
9.23

>  <RotBonds>
2

>  <Action on targets>
Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50  1.84E-07 M | Ki (inhibition constant)  5.656 ?M

>  <CAS>
4180-23-8

>  <Description>
Anethole is a flavoring agent in foods and beverages. It has antimicrobial properties and also an estrogenic activity.

>  <EBC_ID>
EBC-26090

>  <IUPAC Name>
1-methoxy-4-[(1E)-prop-1-en-1-yl]benzene

>  <Main Tar all refs>
Life Sci., 2007, vol. 81, # 13, p. 1085 - 1093 | Khan, Muhammad Imran;Wang, Depeng;Ullah, Najeeb;Shah, Fawad Ali;Fahad, Shah;Khan, Shahid Ullah;Wahab, Abdul;Khan, Arif Ullah - US2022/304946, 2022, A1

>  <Main tar all>
Cav1.1 pX=6.74 | prolyl endopeptidase pX=5.25

$$$$
Afatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.001 6.93 0 0
M  V30 2 N -2.6674 6.16 0 0
M  V30 3 C -1.3337 6.93 0 0
M  V30 4 C -2.6674 4.62 0 0
M  V30 5 C -1.3337 3.85 0 0
M  V30 6 C -1.3337 2.31 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 O 1.3337 2.31 0 0
M  V30 9 N 0 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 C 2.6674 0 0 0
M  V30 12 C 4.001 -0.77 0 0
M  V30 13 C 5.3347 0 0 0
M  V30 14 N 5.3347 1.54 0 0
M  V30 15 C 6.6684 2.31 0 0
M  V30 16 C 6.6684 3.85 0 0
M  V30 17 C 8.0021 4.62 0 0
M  V30 18 C 9.3358 3.85 0 0
M  V30 19 F 10.6694 4.62 0 0
M  V30 20 C 9.3358 2.31 0 0
M  V30 21 Cl 10.6694 1.54 0 0
M  V30 22 C 8.0021 1.54 0 0
M  V30 23 N 6.6684 -0.77 0 0
M  V30 24 C 6.6684 -2.31 0 0
M  V30 25 N 5.3347 -3.08 0 0
M  V30 26 C 4.001 -2.31 0 0
M  V30 27 C 2.6674 -3.08 0 0
M  V30 28 C 1.3337 -2.31 0 0
M  V30 29 O 0 -3.08 0 0
M  V30 30 C -1.3337 -2.31 0 0 CFG=1
M  V30 31 C -1.4947 -0.7784 0 0
M  V30 32 C -3.001 -0.4583 0 0
M  V30 33 O -3.771 -1.7919 0 0
M  V30 34 C -2.7405 -2.9364 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 20 21
M  V30 21 1 20 22
M  V30 22 2 15 22
M  V30 23 2 13 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 12 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 10 28
M  V30 31 1 28 29
M  V30 32 1 30 29 CFG=3
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 30 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568727518

>  <MW>
485.163

>  <MW (desalted)>
485.938

>  <ClogP>
4.49

>  <logS>
-6.366

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
88.61

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | - | - | - | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.01 nM | IC50  0.01 nM | IC50  0.02 nM | IC50  0.09 nM | Kd (dissociation constant)  0.1 nM | Kd (dissociation constant)  0.1 nM | IC50  0.09 nM | Kd (dissociation constant)  0.11 nM | Kd (dissociation constant)  0.12 nM | Kd (dissociation constant)  0.12 nM | IC50  0.12 nM | IC50  0.13 nM | Kd (dissociation constant)  0.14 nM | Kd (dissociation constant)  0.14 nM | IC50  0.17 nM | IC50  0.18 nM | Kd (dissociation constant)  0.19 nM | Kd (dissociation constant)  0.19 nM | IC50 = 0.19 nM | IC50  0.19 nM | IC50  0.2 nM | IC50  0.22 nM | Kd (dissociation constant)  0.23 nM | IC50  0.26 nM | IC50  0.29 nM | IC50  0.29 nM

>  <CAS>
850140-72-6

>  <Description>
Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. It is a 4-anilinoquinazoline tyrosine kinase inhibitor.

>  <EBC_ID>
EBC-12394

>  <IUPAC Name>
(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 20, p. 11725 - 11755 | J. Med. Chem., 2020, vol. 63, # 20, p. 11725 - 11755 | C.H. Boehringer Sohn AG & Co. KG - WO2022/90481, 2022, A1 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | JAPANESE FOUNDATION FOR CANCER RESEARCH - US2021/122759, 2021, A1 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Bioorg. Med. Chem., 2013, vol. 21, # 24, p. 7988 - 7998 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | DANA-FARBER CANCER INSTITUTE - WO2008/121467, 2008, A2 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP4205746, 2023, A1 | JAPANESE FOUNDATION FOR CANCER RESEARCH - US2021/122759, 2021, A1

>  <Main tar all>
Epidermal growth factor receptor (L858R) pX=11.0 | epidermal growth factor receptor pX=11.0 | Epidermal growth factor receptor (Del19) pX=10.7 | Epidermal growth factor receptor (D770GY) pX=10.0 | Epidermal growth factor receptor (G719C) pX=10.0 | Epidermal growth factor receptor (G719C) pX=10.0 | epidermal growth factor receptor (D761Y) pX=10.0 | Epidermal growth factor receptor (delE746-A750) pX=9.96 | Epidermal growth factor receptor (L747-P753del, insS) pX=9.92 | Epidermal growth factor receptor (L747-T751del, Sins) pX=9.92 | Epidermal growth factor receptor (L861Q) pX=9.92 | Epidermal growth factor receptor (G719D) pX=9.89 | Epidermal growth factor receptor (Del S752-I759) pX=9.85 | Epidermal growth factor receptor (L747-A750del, insP) pX=9.85 | Epidermal growth factor receptor (T790M/del19) pX=9.77 | epidermal growth factor receptor (d747-749/A750P) pX=9.74 | Epidermal growth factor receptor (G719S) pX=9.72 | Epidermal growth factor receptor (G719S) pX=9.72 | epidermal growth factor receptor pX=9.72 | epidermal growth factor receptor (A763_Y764insFHEA) pX=9.72 | Epidermal growth factor receptor (Del E746-S752) pX=9.7 | erb-b2 receptor tyrosine kinase 2 (V777_G778insGSP) pX=9.66 | Epidermal growth factor receptor (L861Q) pX=9.64 | epidermal growth factor receptor (A763_Y764insFQEA) pX=9.59 | Epidermal growth factor receptor (D770-N771, insNPG) pX=9.54 | Epidermal growth factor receptor (T790M/L858R) pX=9.54

$$$$
Phenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473830

>  <MW>
94.042

>  <MW (desalted)>
94.111

>  <ClogP>
1.475

>  <logS>
-0.895

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.05 ?M | Ki (inhibition constant)  0.8 ?M

>  <CAS>
108-95-2

>  <Description>
Phenol is an antiseptic and disinfectant. It is active against a wide range of micro-organisms including some fungi and viruses. Phenol is primarily indicated for minor sore throat pain, sore mouth, minor mouth irritation, and pain associated with canker sores. Additionally, phenol is indicated in the treatment of focal spasticity.

>  <EBC_ID>
EBC-26037

>  <IUPAC Name>
phenol

>  <Main Tar all refs>
XENOBIOTICA, 1991, vol. 21, # 2, p. 171 - 177 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 666 - 671

>  <Main tar all>
UDP glucuronosyltransferase pX=7.3 | ?-carbonic anhydrases pX=6.1

$$$$
Allopurinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 N 2.4172 0.77 0 0
M  V30 9 C 3.3224 2.0159 0 0
M  V30 10 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 2 10
M  V30 11 2 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954804966

>  <MW>
136.039

>  <MW (desalted)>
136.111

>  <ClogP>
-0.736

>  <logS>
-1.599

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
70.14

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.24 ?M | IC (inhibitory concentration) = 2.2 ?M

>  <CAS>
315-30-0

>  <Description>
Allopurinol is a xanthine oxidase inhibitor. It is used to reduce urinary and serum uric acid concentrations in patients with gout, recurrent calcium oxalate calculi, and various malignancies.

>  <EBC_ID>
EBC-03149

>  <IUPAC Name>
1H,4H,7H-pyrazolo[3,4-d]pyrimidin-4-one

>  <Main Tar all refs>
J. Pharm. Pharmacol., 2001, vol. 53, # 5, p. 757 - 761 | Kailash Chandra Agarwal - US8808768, 2014, B2

>  <Main tar all>
xanthine dehydrogenase pX=6.62 | Xanthine dehydrogenase (peptide) pX=5.66

$$$$
Dichlorobenzyl alcohol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 Cl 1.3337 -2.31 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 3 9
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z111479786

>  <MW>
175.98

>  <MW (desalted)>
177.028

>  <ClogP>
2.53

>  <logS>
-2.46

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
IC50  5.2 ?M

>  <CAS>
1777-82-8

>  <Description>
Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. It is used to treat a sore throat.

>  <EBC_ID>
EBC-03968

>  <IUPAC Name>
(2,4-dichlorophenyl)methanol

>  <Main Tar all refs>
RECKITT BENCKISER GROUP PLC - WO2009/63223, 2009, A1

>  <Main tar all>
Nav1.2 pX=5.28

$$$$
L-Lysine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 -0.385 0 0
M  V30 3 C 5.7337 0.385 0 0
M  V30 4 C 7.0674 -0.385 0 0
M  V30 5 C 8.401 0.385 0 0
M  V30 6 C 9.7347 -0.385 0 0
M  V30 7 C 11.0684 0.385 0 0 CFG=2
M  V30 8 N 11.0684 1.925 0 0
M  V30 9 C 12.4021 -0.385 0 0
M  V30 10 O 13.7358 0.385 0 0
M  V30 11 O 12.4021 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 7 6
M  V30 6 1 7 8 CFG=3
M  V30 7 1 7 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z812534818

>  <MW>
182.082

>  <MW (desalted)>
146.188

>  <ClogP>
-3.424

>  <logS>
-0.49

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
89.34

>  <RotBonds>
5

>  <CAS>
657-27-2

>  <Description>
L-Lysine is an amino acid commonly found as a component of total parenteral nutrition. It has putative anti-herpes simplex virus activity. There is preliminary research suggesting that it may have some anti-osteoporotic activity.

>  <EBC_ID>
EBC-14434

>  <IUPAC Name>
(2S)-2,6-diaminohexanoic acid hydrochloride

$$$$
Methyl aminolevulinate hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.385 0 0
M  V30 3 O 5.7337 0.385 0 0
M  V30 4 C 7.0674 -0.385 0 0
M  V30 5 O 7.0674 -1.925 0 0
M  V30 6 C 8.401 0.385 0 0
M  V30 7 C 9.7347 -0.385 0 0
M  V30 8 C 11.0684 0.385 0 0
M  V30 9 O 11.0684 1.925 0 0
M  V30 10 C 12.4021 -0.385 0 0
M  V30 11 N 13.7358 0.385 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 4 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 9 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3015912776

>  <MW>
181.051

>  <MW (desalted)>
145.156

>  <ClogP>
-0.67

>  <logS>
-0.273

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
69.39

>  <RotBonds>
5

>  <CAS>
79416-27-6

>  <Description>
Methyl aminolevulinate hydrochloride is an agent used as a sensitizer in photodynamic therapy. It is s a prodrug that can be metabolized to Protoporphyrin IX.

>  <EBC_ID>
EBC-14842

>  <IUPAC Name>
methyl 5-amino-4-oxopentanoate hydrochloride

$$$$
Enflurane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 3.08 5.3347 0 0
M  V30 2 C 2.31 4.001 0 0
M  V30 3 F 0.77 4.001 0 0
M  V30 4 O 3.08 2.6674 0 0
M  V30 5 C 2.31 1.3337 0 0
M  V30 6 F 0.9763 2.1037 0 0
M  V30 7 F 3.6437 0.5637 0 0
M  V30 8 C 1.54 0 0 0
M  V30 9 F 2.31 -1.3337 0 0
M  V30 10 Cl 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255360592

>  <MW>
183.971

>  <MW (desalted)>
184.492

>  <ClogP>
2.459

>  <logS>
-2.23

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
9.23

>  <RotBonds>
3

>  <Action on targets>
- | Blocker | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.12 mM | inhibition percentage  75 % | inhibition percentage  75 % | IC50  1 mM | IC50 = 2930 ?M

>  <CAS>
13838-16-9

>  <Description>
Enflurane is a halogenated inhalational anesthetic agent used for the induction and maintenance of anesthesia and for analgesia during labor and delivery.

>  <EBC_ID>
EBC-14062

>  <IUPAC Name>
2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1995, vol. 274, # 3, p. 1355 - 1361 | Br. J. Pharmacol., 2005, vol. 144, # 1, p. 59 - 70 | Br. J. Pharmacol., 2005, vol. 144, # 1, p. 59 - 70 | PHARMACOLOGY, 1995, vol. 50, # 3, p. 154 - 161 | Anesthesiology, 2001, vol. 95, # 4, p. 954 - 958

>  <Main tar all>
ion channel pX=3.92 | Cav3.3 pX=3.76 | Cav3.3 pX=3.76 | GluN2C pX=3.0 | Kv9.1 pX=2.53

$$$$
Coumarin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 C 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 6.6684 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 C 4.001 -2.31 0 0
M  V30 11 O 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 2 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57169486

>  <MW>
146.037

>  <MW (desalted)>
146.143

>  <ClogP>
1.412

>  <logS>
-2.55

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
26.3

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 R 0.8 nM

>  <CAS>
91-64-5

>  <Description>
Coumarin is a pharmaceutic aid (flavor) that is found in tonka beans, levender oil, woodruff, sweet clover. It has many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.

>  <EBC_ID>
EBC-44176

>  <IUPAC Name>
2H-chromen-2-one

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2013, vol. 13, # 6, p. 870 - 887

>  <Main tar all>
amine oxidase copper containing 3 pX=9.1

$$$$
Hydroxyamphetamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 N -1.3337 3.85 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57102382

>  <MW>
151.1

>  <MW (desalted)>
151.206

>  <ClogP>
1.075

>  <logS>
-0.97

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
46.25

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
EC50 = 0.05 ?M

>  <CAS>
103-86-6

>  <Description>
Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is an indirect acting sympathomimetic agent which causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis.

>  <EBC_ID>
EBC-06307

>  <IUPAC Name>
4-(2-aminopropyl)phenol

>  <Main Tar all refs>
Bioorg. Med. Chem., 2011, vol. 19, # 23, p. 7044 - 7048

>  <Main tar all>
TA1 receptor pX=7.3

$$$$
Thiram
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.9526 2.6674 0 0
M  V30 2 N 3.2863 3.4374 0 0
M  V30 3 C 3.2863 4.9774 0 0
M  V30 4 C 4.62 2.6674 0 0
M  V30 5 S 4.62 1.1274 0 0
M  V30 6 S 5.9537 3.4374 0 0
M  V30 7 S 7.2874 2.6674 0 0
M  V30 8 C 8.621 3.4374 0 0
M  V30 9 S 8.621 4.9774 0 0
M  V30 10 N 9.9547 2.6674 0 0
M  V30 11 C 11.2884 3.4374 0 0
M  V30 12 C 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56754480

>  <MW>
239.988

>  <MW (desalted)>
240.433

>  <ClogP>
1.764

>  <logS>
-4.02

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
6.48

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.018 ?M | IC50  0.02 ?M | IC50  0.05 ?M | EC50 < 0.08 ?M | EC50 < 0.08 ?M | EC50 < 0.08 ?M | IC50  0.11 ?M | IC50  0.17 ?M | IC50  0.18 ?M | IC50  0.32 ?M | IC50  0.55 ?M

>  <CAS>
137-26-8

>  <Description>
Thiram is the simplest thiuram disulfide and the oxidized dimer of dimethyldithiocarbamate. It is used as a fungicide, ectoparasiticide to prevent fungal diseases in seed and crops and similarly as an animal repellent to protect fruit trees and ornamentals from damage by rabbits, rodents and deer. Thiram may be used in dermatology as a scabicide.

>  <EBC_ID>
EBC-04333

>  <IUPAC Name>
N,N-dimethyl[(dimethylcarbamothioyl)disulfanyl]carbothioamide

>  <Main Tar all refs>
Toxicology, 2023, vol. 487 | Bioorg. Med. Chem. Lett., 2021, vol. 40 | DOMPE' FARMACEUTICI - S.P.A.; FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - EP4011367, 2022, A1 | Pharmaceuticals, 2022, vol. 15, # 6 | Pharmaceuticals, 2022, vol. 15, # 6 | Pharmaceuticals, 2022, vol. 15, # 6 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 18, p. 3113 - 3118 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 18, p. 3113 - 3118 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 18, p. 3113 - 3118 | Bioorg. Med. Chem. Lett., 2021, vol. 40 | Bioorg. Med. Chem. Lett., 2018, vol. 28, # 7, p. 1234 - 1238

>  <Main tar all>
Parkinson disease protein 7 homolog pX=7.74 | Aldehyde dehydrogenase 1A1 pX=7.7 | main protease pX=7.3 | cathepsin L pX=7.1 | main protease Mpro pX=7.1 | papain-like protease PLpro pX=7.1 | Lysyl oxidase homolog 3 pX=6.96 | lysyl oxidase like 2 pX=6.77 | Lysyl oxidase homolog 4 pX=6.74 | aldehyde dehydrogenase 2 family member pX=6.49 | Histone-lysine N-methyltransferase EHMT2 pX=6.26

$$$$
Pyridoxal hydrocloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.301 3.465 0 0
M  V30 3 C 7.301 1.925 0 0
M  V30 4 N 8.6347 1.155 0 0
M  V30 5 C 8.6347 -0.385 0 0
M  V30 6 C 7.301 -1.155 0 0
M  V30 7 C 7.301 -2.695 0 0
M  V30 8 O 8.6347 -3.465 0 0
M  V30 9 C 5.9674 -0.385 0 0
M  V30 10 C 4.6337 -1.155 0 0
M  V30 11 O 3.3 -0.385 0 0
M  V30 12 C 5.9674 1.155 0 0
M  V30 13 O 4.6337 1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 6 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 9 12
M  V30 11 2 3 12
M  V30 12 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2575039413

>  <MW>
203.035

>  <MW (desalted)>
167.162

>  <ClogP>
1.179

>  <logS>
-0.068

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
70.42

>  <RotBonds>
2

>  <CAS>
65-22-5

>  <Description>
Pyridoxal is the 4-carboxyaldehyde form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. It is used for nutritional supplementation and for treating dietary shortage or imbalances.

>  <EBC_ID>
EBC-14609

>  <IUPAC Name>
3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde hydrochloride

$$$$
Benzocaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 O 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 O 2.6674 4.62 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 N 1.3337 -2.31 0 0
M  V30 11 C 0 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z54178706

>  <MW>
165.079

>  <MW (desalted)>
165.189

>  <ClogP>
1.923

>  <logS>
-1.87

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
52.32

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  6.2  | IC50  1399 nM | cell proliferation decrease Active

>  <CAS>
94-09-7

>  <Description>
Benzocaine is a topical local anesthetic used for the temporary relief of pain and itching associated with minor burns, sunburn, scrapes and insect bites or minor skin irritations.

>  <EBC_ID>
EBC-13558

>  <IUPAC Name>
ethyl 4-aminobenzoate

>  <Main Tar all refs>
ASTRAZENECA PLC - WO2001/85146, 2001, A1 | J. Enzyme Inhib. Med. Chem., 2017, vol. 32, # 1, p. 1209 - 1215 | Cancers, 2021, vol. 13, # 21

>  <Main tar all>
myeloperoxidase pX=6.2 | S-Adenosylhomocysteine hydrolase pX=5.85 | Voltage-gated?sodium?channel pX=5.1

$$$$
D-Glucose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 C 4.62 2.6674 0 0 CFG=1
M  V30 4 O 4.62 1.1274 0 0
M  V30 5 C 5.9537 3.4374 0 0 CFG=1
M  V30 6 O 5.9537 4.9774 0 0
M  V30 7 C 7.2874 2.6674 0 0 CFG=2
M  V30 8 O 7.2874 1.1274 0 0
M  V30 9 C 8.621 3.4374 0 0 CFG=1
M  V30 10 O 8.621 4.9774 0 0
M  V30 11 C 9.9547 2.6674 0 0
M  V30 12 O 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201619321

>  <MW>
180.063

>  <MW (desalted)>
180.156

>  <ClogP>
-2.899

>  <logS>
0.98

>  <HBD>
5

>  <HBA>
6

>  <TPSA>
118.22

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pKi  9.54

>  <CAS>
50-99-7

>  <Description>
D-Glucose is a most commonly occurring isomer of glucose used as a carbohydrate supplementation in case of nutrient deprivation and metabolic disorders, such as hypoglycemia. Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis.

>  <EBC_ID>
EBC-11045

>  <IUPAC Name>
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

>  <Main Tar all refs>
LIFE SCI., 1993, vol. 53, # 6, p. 517 - 525

>  <Main tar all>
somatostatin receptor pX=9.54

$$$$
(Rac)-Telmesteine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7272 6.7 0 0
M  V30 2 C 2.3935 5.93 0 0
M  V30 3 O 2.3935 4.39 0 0
M  V30 4 C 1.0598 3.62 0 0
M  V30 5 O -0.2739 4.39 0 0
M  V30 6 N 1.0598 2.08 0 0
M  V30 7 C 2.3057 1.1748 0 0
M  V30 8 S 1.8298 -0.2898 0 0
M  V30 9 C 0.2898 -0.2898 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 C -1.6507 1.6507 0 0
M  V30 12 O -2.7951 0.6202 0 0
M  V30 13 O -1.9709 3.157 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 6 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z316101664

>  <MW>
205.041

>  <MW (desalted)>
205.232

>  <ClogP>
1.103

>  <logS>
-1.804

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
66.84

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 11 mM

>  <CAS>
127657-29-8

>  <Description>
It has mucoactive activity.

>  <EBC_ID>
EBC-14668

>  <IUPAC Name>
3-(ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid

>  <Main Tar all refs>
YASON; YASON MAILAND MILANO IT - US4874776, 1989, A

>  <Main tar all>
chymotrypsin like elastase 1 pX=1.96

$$$$
Selegiline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.8547 -1.54 0 0
M  V30 3 C 8.8547 0 0 0 CFG=2
M  V30 4 C 7.521 0.77 0 0
M  V30 5 C 6.1874 0 0 0
M  V30 6 C 6.1874 -1.54 0 0
M  V30 7 C 4.8537 -2.31 0 0
M  V30 8 C 3.52 -1.54 0 0
M  V30 9 C 3.52 0 0 0
M  V30 10 C 4.8537 0.77 0 0
M  V30 11 N 10.1884 0.77 0 0
M  V30 12 C 10.1884 2.31 0 0
M  V30 13 C 11.5221 0 0 0
M  V30 14 C 12.8558 0.77 0 0
M  V30 15 C 14.1894 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 3 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 3 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2768168341

>  <MW>
223.113

>  <MW (desalted)>
187.281

>  <ClogP>
3.024

>  <logS>
-2.967

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
percentage decrease Active   | IC50  0.011 ?M | IC50  0.017 ?M | IC50  0.18 ?M

>  <CAS>
14611-52-0

>  <Description>
Selegilinel is a selective, reversible inhibitor of monoamine oxide.  In addition to finding use against depression, selegiline provides neuroprotection which may be relevant to Parkinson?s disease, Alzheimer?s disease, Huntington?s disease, and stroke.

>  <EBC_ID>
EBC-04192

>  <IUPAC Name>
methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine hydrochloride

>  <Main Tar all refs>
Eur. J. Pharmacol., 2018, vol. 818, p. 254 - 262 | Biochem. Pharmacol., 2000, vol. 59, # 12, p. 1611 - 1621 | ChemMedChem, 2014, vol. 9, # 8, p. 1672 - 1676 | Mar. Drugs, 2019, vol. 17, # 6

>  <Main tar all>
amine oxidase copper containing 3 pX=8.0 | Monoamine oxidase A pX=7.96 | Monoamine oxidase B pX=7.77 | Probable flavin-containing monoamine oxidase B pX=6.74

$$$$
alpha-Amyl cinnamaldehyde
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 5.3347 -1.54 0 0
M  V30 3 C 6.6684 -2.31 0 0
M  V30 4 C 8.0021 -1.54 0 0
M  V30 5 C 9.3358 -2.31 0 0
M  V30 6 C 10.6694 -1.54 0 0
M  V30 7 C 12.0031 -2.31 0 0
M  V30 8 C 12.0031 -3.85 0 0
M  V30 9 C 13.3368 -4.62 0 0
M  V30 10 C 13.3368 -6.16 0 0
M  V30 11 C 12.0031 -6.93 0 0
M  V30 12 C 10.6694 -6.16 0 0
M  V30 13 C 10.6694 -4.62 0 0
M  V30 14 C 10.6694 0 0 0
M  V30 15 O 12.0031 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8 CFG=2
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 6 14
M  V30 15 2 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104476282

>  <MW>
202.136

>  <MW (desalted)>
202.292

>  <ClogP>
4.474

>  <logS>
-4.194

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.07

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.7 ?M

>  <CAS>
122-40-7

>  <Description>
alpha-Amyl cinnamaldehyde has a jasmine-like odor and is a widely used synthetic fragrance & suspected allergen. It is used in allergenic testing.

>  <EBC_ID>
EBC-71034

>  <IUPAC Name>
2-(phenylmethylidene)heptanal

>  <Main Tar all refs>
Cell. Mol. Life Sci., 2011, vol. 68, # 10, p. 1799 - 1813

>  <Main tar all>
OBP4 pX=5.57

$$$$
Hexaminolevulinate hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 0.3593 0 0
M  V30 3 C 5.7337 -0.4107 0 0
M  V30 4 C 7.0674 0.3593 0 0
M  V30 5 C 8.401 -0.4107 0 0
M  V30 6 C 9.7347 0.3593 0 0
M  V30 7 C 11.0684 -0.4107 0 0
M  V30 8 O 12.4021 0.3593 0 0
M  V30 9 C 13.7358 -0.4107 0 0
M  V30 10 O 13.7358 -1.9507 0 0
M  V30 11 C 15.0694 0.3593 0 0
M  V30 12 C 16.4031 -0.4107 0 0
M  V30 13 C 17.7368 0.3593 0 0
M  V30 14 O 17.7368 1.8993 0 0
M  V30 15 C 19.0705 -0.4107 0 0
M  V30 16 N 20.4041 0.3593 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509470545

>  <MW>
251.129

>  <MW (desalted)>
215.289

>  <ClogP>
1.975

>  <logS>
-2.563

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
69.39

>  <RotBonds>
10

>  <CAS>
140898-91-5

>  <Description>
Hexaminolevulinate is an optical imaging agent used to perform Blue Light Cystoscopy in order to detect carcinoma of the bladder.

>  <EBC_ID>
EBC-28042

>  <IUPAC Name>
hexyl 5-amino-4-oxopentanoate hydrochloride

$$$$
Varenicline tartrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0.6668 1.925 0 0
M  V30 2 C 0.6668 0.385 0 0 CFG=2
M  V30 3 C -0.6668 -0.385 0 0 CFG=1
M  V30 4 O -0.6668 -1.925 0 0
M  V30 5 C -2.0005 0.385 0 0
M  V30 6 O -3.3342 -0.385 0 0
M  V30 7 O -2.0005 1.925 0 0
M  V30 8 C 2.0005 -0.385 0 0
M  V30 9 O 3.3342 0.385 0 0
M  V30 10 O 2.0005 -1.925 0 0
M  V30 11 C 9.6681 -0 0 0
M  V30 12 C 9.2356 1.7302 0 0 CFG=1
M  V30 13 C 7.7342 1.3875 0 0
M  V30 14 N 7.066 0 0 0
M  V30 15 C 7.7342 -1.3875 0 0
M  V30 16 C 9.2356 -1.7302 0 0 CFG=2
M  V30 17 C 10.4396 -0.77 0 0
M  V30 18 C 11.7733 -1.54 0 0
M  V30 19 C 13.107 -0.77 0 0
M  V30 20 N 14.4406 -1.54 0 0
M  V30 21 C 15.7743 -0.77 0 0
M  V30 22 C 15.7743 0.77 0 0
M  V30 23 N 14.4406 1.54 0 0
M  V30 24 C 13.107 0.77 0 0
M  V30 25 C 11.7733 1.54 0 0
M  V30 26 C 10.4396 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 12 11 CFG=3
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 16 15
M  V30 15 1 16 11 CFG=3
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 1 19 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 12 26
M  V30 28 2 17 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2044783305

>  <MW>
361.127

>  <MW (desalted)>
211.262

>  <ClogP>
0.899

>  <logS>
-0.488

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
37.81

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Agonist | - | - | - | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 350 nM | Ki (inhibition constant) >= 0.5 ?M | Ki (inhibition constant) > 1 ?M | infection rate decrease Active   | EC50 = 2.3 ?M | EC50 = 2.3 ?M | EC50 = 2.3 ?M | EC50  5.02 ?M | EC50  5.02 ?M | EC50  5.02 ?M

>  <CAS>
375815-87-5

>  <Description>
Varenicline tartrate  is a nicotinic acetylcholine receptor partial agonist. It is used to treat nicotine addiction.

>  <EBC_ID>
EBC-07819

>  <IUPAC Name>
(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene; (2R,3R)-2,3-dihydroxybutanedioic acid

>  <Main Tar all refs>
Pfizer Inc., Chantix"" (Varenicline), Product leaflet | Behav. Pharmacol., 2011, vol. 22, # 4, p. 291 - 299 | Behav. Pharmacol., 2011, vol. 22, # 4, p. 291 - 299 | VIATRIS INC - WO2021/222230, 2021, A1 | Mol. Pharmacol., 2006, vol. 70, # 3, p. 801 - 805 | Mol. Pharmacol., 2006, vol. 70, # 3, p. 801 - 805 | Mol. Pharmacol., 2006, vol. 70, # 3, p. 801 - 805 | VIATRIS INC - WO2021/222230, 2021, A1 | VIATRIS INC - WO2021/222230, 2021, A1 | VIATRIS INC - WO2021/222230, 2021, A1

>  <Main tar all>
5-HT3A pX=6.46 | nicotinic acetylcholine receptor ?-like 1 pX=6.3 | nicotinic acetylcholine receptor ?7 subunit pX=6.0 | nicotinic acetylcholine receptor pX=5.92 | nicotinic acetylcholine receptor ?-like 1 pX=5.64 | nicotinic acetylcholine receptor ?1 subunit pX=5.64 | nicotinic acetylcholine receptor ?1 subunit pX=5.64 | nicotinic acetylcholine receptor ?4 subunit pX=5.3 | nicotinic acetylcholine receptor ?6 subunit pX=5.3 | nicotinic acetylcholine receptor ?2 subunit pX=5.3

$$$$
Risedronic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 5.39 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 N 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 P 0.77 5.9537 0 0
M  V30 11 O 1.54 7.2874 0 0
M  V30 12 O 2.1037 5.1837 0 0
M  V30 13 O -0.5637 6.7237 0 0
M  V30 14 P -0.77 3.2863 0 0
M  V30 15 O 0.5637 2.5163 0 0
M  V30 16 O -1.54 1.9526 0 0
M  V30 17 O -2.1037 4.0563 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 2 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 1 2 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485357

>  <MW>
283.001

>  <MW (desalted)>
283.112

>  <ClogP>
-2.622

>  <logS>
3.422

>  <HBD>
5

>  <HBA>
8

>  <TPSA>
148.18

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active

>  <CAS>
105462-24-6

>  <Description>
Risedronic acid  is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It inhibits farnesyl pyrophosphate synthase, Ki = 0.36 nM.

>  <EBC_ID>
EBC-06663

>  <IUPAC Name>
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid

>  <Main Tar all refs>
MONE ZAIDI CONSULTING - US2016/38516, 2016, A1

>  <Main tar all>
erb-b2 receptor tyrosine kinase 2 pX=11.0

$$$$
Benzoyl Peroxide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 -5.39 0 0
M  V30 2 C 1.3337 -3.85 0 0
M  V30 3 O 2.6674 -3.08 0 0
M  V30 4 O 4.001 -3.85 0 0
M  V30 5 C 5.3347 -3.08 0 0
M  V30 6 O 5.3347 -1.54 0 0
M  V30 7 C 6.6684 -3.85 0 0
M  V30 8 C 8.0021 -3.08 0 0
M  V30 9 C 9.3358 -3.85 0 0
M  V30 10 C 9.3358 -5.39 0 0
M  V30 11 C 8.0021 -6.16 0 0
M  V30 12 C 6.6684 -5.39 0 0
M  V30 13 C 0 -3.08 0 0
M  V30 14 C -1.3337 -3.85 0 0
M  V30 15 C -2.6674 -3.08 0 0
M  V30 16 C -2.6674 -1.54 0 0
M  V30 17 C -1.3337 -0.77 0 0
M  V30 18 C 0 -1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104489074

>  <MW>
242.058

>  <MW (desalted)>
242.227

>  <ClogP>
2.78

>  <logS>
-4.279

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
52.6

>  <RotBonds>
5

>  <CAS>
94-36-0

>  <Description>
Benzoyl Peroxide is used in acne treatments, bleaching and polymerizing polyester. It inhibits protein kinase C.

>  <EBC_ID>
EBC-47359

>  <IUPAC Name>
benzoyl benzenecarboperoxoate

$$$$
Cinchophen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.001 -5.39 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 O 1.3337 -5.39 0 0
M  V30 4 C 2.6674 -3.08 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 N 2.6674 0 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 14 C 0 0 0 0
M  V30 15 C -1.3337 -0.77 0 0
M  V30 16 C -2.6674 0 0 0
M  V30 17 C -2.6674 1.54 0 0
M  V30 18 C -1.3337 2.31 0 0
M  V30 19 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 4 13
M  V30 14 1 8 13
M  V30 15 1 6 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56782585

>  <MW>
249.079

>  <MW (desalted)>
249.264

>  <ClogP>
4.281

>  <logS>
-4.48

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
50.19

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  4.4  | Kd (dissociation constant) = 127 ?M | IC50  144 ?M | IC50  295.8 ?M

>  <CAS>
132-60-5

>  <Description>
Cinchophen has an analgetic activity. It is used in combination with prednisolone, by veterinarians to treat arthritis in animals.

>  <EBC_ID>
EBC-03816

>  <IUPAC Name>
2-phenylquinoline-4-carboxylic acid

>  <Main Tar all refs>
J. Med. Chem., 1973, vol. 16, # 5, p. 484 - 486 | J. Med. Chem., 2013, vol. 56, # 8, p. 3228 - 3234 | J. Med. Chem., 2018, vol. 61, # 12, p. 5162 - 5186 | Drug Metab. Dispos., 2012, vol. 40, # 1, p. 130 - 138

>  <Main tar all>
Serum albumin pX=4.4 | phosphodiesterase 10A pX=3.9 | Dihydroorotate dehydrogenase (quinone), mitochondrial pX=3.84 | ABCB11 pX=3.53

$$$$
Primaquine monophosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.0183 4.4174 0 0
M  V30 2 O -1.6846 3.6474 0 0
M  V30 3 C -1.6846 2.1074 0 0
M  V30 4 C -0.351 1.3374 0 0
M  V30 5 C -0.351 -0.2026 0 0
M  V30 6 N 0.9827 -0.9726 0 0
M  V30 7 C 2.3164 -0.2026 0 0
M  V30 8 C 2.3164 1.3374 0 0
M  V30 9 C 3.6501 -0.9726 0 0
M  V30 10 C 4.9837 -0.2026 0 0
M  V30 11 C 6.3174 -0.9726 0 0
M  V30 12 N 7.6511 -0.2026 0 0
M  V30 13 C -1.6846 -0.9726 0 0
M  V30 14 N -1.6846 -2.5126 0 0
M  V30 15 C -3.0183 -3.2826 0 0
M  V30 16 C -4.352 -2.5126 0 0
M  V30 17 C -4.352 -0.9726 0 0
M  V30 18 C -3.0183 -0.2026 0 0
M  V30 19 C -3.0183 1.3374 0 0
M  V30 20 O 12.7111 -1.54 0 0
M  V30 21 P 12.7111 0 0 0
M  V30 22 O 12.7111 1.54 0 0
M  V30 23 O 14.2511 -0 0 0
M  V30 24 O 11.1711 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 5 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 18 19
M  V30 20 2 3 19
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z732242096

>  <MW>
357.145

>  <MW (desalted)>
259.347

>  <ClogP>
2.598

>  <logS>
0.141

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
60.17

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.59 - 400 nM | IC50  6 nM

>  <CAS>
66616-84-0

>  <Description>
Primaquine phosphate inhibits integrase (HIV).

>  <EBC_ID>
EBC-06855

>  <IUPAC Name>
N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; phosphoric acid

>  <Main Tar all refs>
Curr. Med. Chem., 2013, vol. 20, # 25, p. 3049 - 3068 | J. Chem. Inf. Model., 2010, vol. 50, # 9, p. 1706 - 1723

>  <Main tar all>
Plasmepsin-2 pX=9.23 | Heat shock protein HSP 90-alpha pX=8.22

$$$$
Sulfalen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -1.54 0 0
M  V30 2 O 4.001 -2.31 0 0
M  V30 3 C 4.001 -3.85 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 2.6674 -6.16 0 0
M  V30 6 C 4.001 -6.93 0 0
M  V30 7 N 5.3347 -6.16 0 0
M  V30 8 C 5.3347 -4.62 0 0
M  V30 9 N 6.6684 -3.85 0 0
M  V30 10 S 8.0021 -4.62 0 0
M  V30 11 O 7.2321 -5.9537 0 0
M  V30 12 O 8.7721 -3.2863 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 10.6694 -4.62 0 0
M  V30 15 C 12.0031 -5.39 0 0
M  V30 16 C 12.0031 -6.93 0 0
M  V30 17 N 13.3368 -7.7 0 0
M  V30 18 C 10.6694 -7.7 0 0
M  V30 19 C 9.3358 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 18 19
M  V30 20 2 13 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z277559098

>  <MW>
280.063

>  <MW (desalted)>
280.303

>  <ClogP>
1.048

>  <logS>
-1.93

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
107.2

>  <RotBonds>
3

>  <CAS>
152-47-6

>  <Description>
Sulfalene is a long-acting sulfonamide antibacterial with a wide spectrum against most gram-positive and many gram-negative organisms.  Sulfalene inhibits multiplication of bacteria by acting as competitive inhibitor of p-aminobenzoic acid in the folic acid metabolism cycle. Sulfalene is also an antimalarial agent.

>  <EBC_ID>
EBC-03778

>  <IUPAC Name>
4-amino-N-(3-methoxypyrazin-2-yl)benzene-1-sulfonamide

$$$$
Mirtazapine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.6402 5.7501 0 0
M  V30 2 N 7.8702 4.4164 0 0
M  V30 3 C 6.3302 4.4164 0 0
M  V30 4 C 5.5602 3.0828 0 0
M  V30 5 N 6.3302 1.7491 0 0
M  V30 6 C 7.8702 1.7491 0 0
M  V30 7 C 8.6402 3.0828 0 0
M  V30 8 C 8.8304 0.5451 0 0
M  V30 9 C 10.3019 0.999 0 0
M  V30 10 C 11.4308 -0.0485 0 0
M  V30 11 C 11.0882 -1.5499 0 0
M  V30 12 C 9.6166 -2.0038 0 0
M  V30 13 C 8.4877 -0.9563 0 0
M  V30 14 C 7.1002 -1.6245 0 0
M  V30 15 C 5.7127 -0.9563 0 0
M  V30 16 C 4.5838 -2.0038 0 0
M  V30 17 C 3.1122 -1.5499 0 0
M  V30 18 C 2.7695 -0.0485 0 0
M  V30 19 N 3.8984 0.999 0 0
M  V30 20 C 5.37 0.5451 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 5 20
M  V30 23 2 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z905065772

>  <MW>
265.158

>  <MW (desalted)>
265.353

>  <ClogP>
2.814

>  <logS>
-2.55

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
19.37

>  <RotBonds>
0

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pA2  9.94  | Ki (inhibition constant)  2 nM | Ki (inhibition constant)  2 nM

>  <CAS>
85650-52-8

>  <Description>
Mirtazapine is indicated for the treatment of major depressive disorder and its associated symptoms. It has been shown that both noradrenergic and serotonergic activity increase following mirtazapine administration.

>  <EBC_ID>
EBC-08263

>  <IUPAC Name>
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene

>  <Main Tar all refs>
NEUROPHARMACOLOGY, 1988, vol. 27, # 4, p. 399 - 408 | J. Med. Chem., 2002, vol. 45, # 15, p. 3280 - 3285 | J. Med. Chem., 2002, vol. 45, # 15, p. 3280 - 3285

>  <Main tar all>
H1 receptor pX=9.94 | 5-HT2A receptor pX=8.7 | 5-HT2A receptor pX=8.7

$$$$
Metoclopramide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -2.31 0 0
M  V30 2 C -5.3347 -3.08 0 0
M  V30 3 N -4.001 -2.31 0 0
M  V30 4 C -4.001 -0.77 0 0
M  V30 5 C -2.6674 -0 0 0
M  V30 6 C -2.6674 -3.08 0 0
M  V30 7 C -1.3337 -2.31 0 0
M  V30 8 N 0 -3.08 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 O 2.6674 -3.08 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 -0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 Cl -1.3337 2.31 0 0
M  V30 15 C 1.3337 2.31 0 0
M  V30 16 N 1.3337 3.85 0 0
M  V30 17 C 2.6674 1.54 0 0
M  V30 18 C 2.6674 -0 0 0
M  V30 19 O 4.001 -0.77 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 11 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2196779550

>  <MW>
299.14

>  <MW (desalted)>
299.796

>  <ClogP>
2.229

>  <logS>
-2.87

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
67.59

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Antagonist | Blocker | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 < 1 nM | IC50 < 1 nM | Ki (inhibition constant)  2.1 nM | Ki (inhibition constant)  2.1 nM | IC50  2.25E-09 M | Ki (inhibition constant)  5 nM | IC50  5.232E-09 M | IC50  5.4 nM | IC50  9.151E-09 M | Ki (inhibition constant)  10.2 nM | Ki (inhibition constant)  10.2 nM | IC50  11 nM | IC50 = 12 nM | Kb (antagonist dissociation constant)  1.9E-08 M | Ki (inhibition constant)  21 nM | Ki (inhibition constant)  27 nM | Ki (inhibition constant)  27 nM

>  <CAS>
364-62-5

>  <Description>
Metoclopramide is an antiemetic agent and dopamine D2 antagonist. It is used in the treatment of gastroesophageal reflux disease, prevention of nausea and vomiting, and to stimulate gastric emptying.

>  <EBC_ID>
EBC-04213

>  <IUPAC Name>
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide

>  <Main Tar all refs>
Br. J. Pharmacol., 2005, vol. 146, # 4, p. 543 - 552 | Br. J. Pharmacol., 2005, vol. 146, # 4, p. 543 - 552 | J. NEUROCHEM., 1994, vol. 62, # 5, p. 1664 - 1669 | J. NEUROCHEM., 1994, vol. 62, # 5, p. 1664 - 1669 | J. Neurochem., 2014, vol. 129, # 2, p. 284 - 296 | Mol. Pharmacol., 1996, vol. 49, # 4, p. 692 - 698 | J. Neurochem., 2014, vol. 129, # 2, p. 284 - 296 | Pharmacology, 2005, vol. 74, # 1, p. 31 - 36 | J. Neurochem., 2014, vol. 129, # 2, p. 284 - 296 | JOHNSON MATTHEY PLC - US5863928, 1999, A | JOHNSON MATTHEY PLC - US5863928, 1999, A | Bioorg. Med. Chem. Lett., 1998, vol. 8, # 6, p. 619 - 624 | Curr. Pharm. Des., 2006, vol. 12, # 28, p. 3615 - 3630 | NEUROGASTRX - WO2015/200369, 2015, A1 | Bioorg. Med. Chem., 2000, vol. 8, # 2, p. 321 - 327 | Bioorg. Med. Chem., 2000, vol. 8, # 2, p. 321 - 327 | Bioorg. Med. Chem., 2000, vol. 8, # 2, p. 321 - 327

>  <Main tar all>
5-HT3A pX=9.0 | 5-HT3A pX=9.0 | D2L receptor pX=8.68 | D2L receptor pX=8.68 | Octopamine 2 receptor pX=8.65 | D2 receptor (isoform?1) pX=8.3 | Octopamine 3 receptor pX=8.28 | Kv11.1 pX=8.27 | Octopamine 4 receptor pX=8.04 | D2 receptor pX=7.99 | D2 receptor pX=7.99 | D2S receptor pX=7.96 | 5-HT3A pX=7.92 | D2 receptor pX=7.72 | D2 receptor (isoform 2) pX=7.68 | D3 receptor pX=7.57 | D3 receptor pX=7.57

$$$$
Methyclothiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 0 0 0 0
M  V30 5 Cl 0 1.54 0 0
M  V30 6 N 2.6674 0 0 0
M  V30 7 C 4.001 -0.77 0 0
M  V30 8 C 5.3347 0 0 0
M  V30 9 C 6.6684 -0.77 0 0
M  V30 10 Cl 8.0021 -0 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 C 4.001 -2.31 0 0
M  V30 14 S 2.6674 -3.08 0 0
M  V30 15 O 3.3903 -4.4397 0 0
M  V30 16 O 1.9444 -4.4397 0 0
M  V30 17 S 8.0021 -3.08 0 0
M  V30 18 O 9.3358 -3.85 0 0
M  V30 19 O 7.2321 -4.4137 0 0
M  V30 20 N 8.7721 -1.7463 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 13 14
M  V30 15 1 2 14
M  V30 16 2 14 15
M  V30 17 2 14 16
M  V30 18 1 11 17
M  V30 19 2 17 18
M  V30 20 2 17 19
M  V30 21 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759222

>  <MW>
358.957

>  <MW (desalted)>
360.237

>  <ClogP>
0.937

>  <logS>
-3.09

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
109.57

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
135-07-9

>  <Description>
Methyclothiazide is a diuretic drug used to treat hypertension and edema caused by heart failure, renal conditions, treatment with corticosteroids, and estrogen therapy.

>  <EBC_ID>
EBC-12729

>  <IUPAC Name>
6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

$$$$
Mebendazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.3996 1.3645 0 0
M  V30 2 O -2.6296 0.0309 0 0
M  V30 3 C -1.0896 0.0309 0 0
M  V30 4 O -0.3196 1.3645 0 0
M  V30 5 N -0.3196 -1.3028 0 0
M  V30 6 C 1.2204 -1.3028 0 0
M  V30 7 N 2.1256 -0.0569 0 0
M  V30 8 C 3.5902 -0.5328 0 0
M  V30 9 C 4.9239 0.2372 0 0
M  V30 10 C 6.2576 -0.5328 0 0
M  V30 11 C 6.2576 -2.0728 0 0
M  V30 12 C 4.9239 -2.8428 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 14 N 2.1256 -2.5487 0 0
M  V30 15 C 7.5913 -2.8428 0 0
M  V30 16 O 8.925 -2.0728 0 0
M  V30 17 C 7.5913 -4.3828 0 0
M  V30 18 C 8.925 -5.1528 0 0
M  V30 19 C 8.925 -6.6928 0 0
M  V30 20 C 7.5913 -7.4628 0 0
M  V30 21 C 6.2576 -6.6928 0 0
M  V30 22 C 6.2576 -5.1528 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 11 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z234895185

>  <MW>
295.096

>  <MW (desalted)>
295.293

>  <ClogP>
3.077

>  <logS>
-5.16

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
84.08

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | IC50  104.3 nM

>  <CAS>
31431-39-7

>  <Description>
Mebendazole is a synthetic benzimidazole derivate and anthelmintic agent. It is used to treat helminth infections. It also has antimyeloma activity.

>  <EBC_ID>
EBC-00598

>  <IUPAC Name>
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate

>  <Main Tar all refs>
GEORGETOWN UNIVERSITY - US2018/263987, 2018, A1 | GEORGETOWN UNIVERSITY - US2018/263987, 2018, A1 | Acta Pharmacol. Sin., 2019, vol. 40, # 12, p. 1568 - 1577 | Front. Pharmacol., 2022, vol. 13

>  <Main tar all>
B-Raf proto-oncogene, serine/threonine kinase pX=8.0 | B-Raf proto-oncogene, serine/threonine kinase (V600K) pX=8.0 | ubiquitin specific peptidase 5 pX=7.0 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=6.98

$$$$
Praziquantel
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.7237 4.771 0 0
M  V30 2 C 7.4937 3.4374 0 0
M  V30 3 C 9.0337 3.4374 0 0
M  V30 4 C 9.8037 4.771 0 0
M  V30 5 C 11.3437 4.771 0 0
M  V30 6 C 12.1137 3.4374 0 0
M  V30 7 C 11.3437 2.1037 0 0
M  V30 8 C 9.8037 2.1037 0 0
M  V30 9 N 6.7237 2.1037 0 0
M  V30 10 C 5.1837 2.1037 0 0
M  V30 11 C 4.4137 0.77 0 0
M  V30 12 N 5.1837 -0.5637 0 0
M  V30 13 C 4.4137 -1.8974 0 0
M  V30 14 C 2.8737 -1.8974 0 0
M  V30 15 C 2.1037 -0.5637 0 0
M  V30 16 C 0.5637 -0.5637 0 0
M  V30 17 C -0.2063 0.77 0 0
M  V30 18 C 0.5637 2.1037 0 0
M  V30 19 C 2.1037 2.1037 0 0
M  V30 20 C 2.8737 0.77 0 0
M  V30 21 C 6.7237 -0.5637 0 0
M  V30 22 O 7.4937 -1.8974 0 0
M  V30 23 C 7.4937 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 11 20
M  V30 22 2 15 20
M  V30 23 1 12 21
M  V30 24 2 21 22
M  V30 25 1 21 23
M  V30 26 1 9 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1554103331

>  <MW>
312.184

>  <MW (desalted)>
312.406

>  <ClogP>
3.36

>  <logS>
-4.63

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
40.62

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor | Agonist

>  <Activity coefficients and valu>
EC50  0.0107 ?M | IC50  0.1 ?M | EC50  177 - 619 nM

>  <CAS>
55268-74-1

>  <Description>
Praziquantel is an anthelmintic medication used to treat a number of parasitic worm infections such as schistosomiasis.

>  <EBC_ID>
EBC-11170

>  <IUPAC Name>
2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-pyrazino[2,1-a]isoquinolin-4-one

>  <Main Tar all refs>
ABERYSTWYTH UNIVERSITY - WO2021/1661, 2021, A1 | ChemMedChem, 2023, vol. 18, # 3 | PLoS. Negl. Trop. Dis., 2021, vol. 15, # 11

>  <Main tar all>
Smp 138030 pX=7.97 | histone deacetylase 8 pX=7.0 | TRPM pX=6.75

$$$$
Nimodipin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.2321 1.3337 0 0
M  V30 2 O 8.0021 0 0 0
M  V30 3 C 9.5421 0 0 0
M  V30 4 C 10.3121 -1.3337 0 0
M  V30 5 O 11.8521 -1.3337 0 0
M  V30 6 C 12.6221 0 0 0
M  V30 7 O 11.8521 1.3337 0 0
M  V30 8 C 14.1621 0 0 0
M  V30 9 C 14.9321 1.3337 0 0
M  V30 10 C 14.1621 2.6674 0 0
M  V30 11 N 16.4721 1.3337 0 0
M  V30 12 C 17.2421 0 0 0
M  V30 13 C 16.4721 -1.3337 0 0
M  V30 14 C 14.9321 -1.3337 0 0
M  V30 15 C 14.1621 -2.6674 0 0
M  V30 16 C 14.9321 -4.001 0 0
M  V30 17 C 14.1621 -5.3347 0 0
M  V30 18 C 12.6221 -5.3347 0 0
M  V30 19 C 11.8521 -4.001 0 0
M  V30 20 C 12.6221 -2.6674 0 0
M  V30 21 N 10.3121 -4.001 0 0 CHG=1
M  V30 22 O 9.5421 -5.3347 0 0
M  V30 23 O 9.5421 -2.6674 0 0 CHG=-1
M  V30 24 C 17.2421 -2.6674 0 0
M  V30 25 O 16.4721 -4.001 0 0
M  V30 26 O 18.7821 -2.6674 0 0
M  V30 27 C 19.5521 -4.001 0 0
M  V30 28 C 21.0921 -4.001 0 0
M  V30 29 C 18.7821 -5.3347 0 0
M  V30 30 C 18.7821 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 8 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 19 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 13 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 1 12 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53829207

>  <MW>
418.44

>  <MW (desalted)>
418.44

>  <ClogP>
4.003

>  <logS>
-3.293

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
117

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Blocker | Blocker | Blocker | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant) < 0.01 nM | Kapp (apparent dissociation constant)  16.4 pM | Kapp (apparent dissociation constant)  16.4 pM | inhibition percentage  93.4 % | IC50  1.3E-10 M

>  <CAS>
66085-59-4

>  <Description>
Nimodipine is a calcium channel blocker used to improve neurological outcomes in patients with subarachnoid hemorrhage due to a ruptured intracranial aneurysm.

>  <EBC_ID>
EBC-11180

>  <IUPAC Name>
3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1982, vol. 77, # 2-3, p. 201 - 202 | J. GEN. PHYSIOL., 1989, vol. 94, # 4, p. 669 - 692 | J. GEN. PHYSIOL., 1989, vol. 94, # 4, p. 669 - 692 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; GOVERNMENT OF THE UNITED STATES - WO2019/104041, 2019, A1 | Arzneimittelforschung, 1989, vol. 39, # 4, p. 445 - 450

>  <Main tar all>
Cav1.1 pX=11.0 | L-type calcium channel pX=10.8 | T-type calcium channel pX=10.8 | Voltage-dependent calcium channel, gamma-1 subunit pX=10.2 | glutamate?receptor pX=9.89

$$$$
Cytarabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 C 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=2
M  V30 7 O 2.5796 5.5648 0 0
M  V30 8 C 2.1037 4.1002 0 0 CFG=2
M  V30 9 C 3.0089 2.8543 0 0
M  V30 10 O 4.5404 3.0153 0 0
M  V30 11 C 0.5637 4.1002 0 0 CFG=1
M  V30 12 O -0.3415 2.8543 0 0
M  V30 13 C 0.0878 5.5648 0 0 CFG=2
M  V30 14 O -1.3768 6.0407 0 0
M  V30 15 C 0 8.78 0 0
M  V30 16 O -1.3337 8.01 0 0
M  V30 17 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 8
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 6
M  V30 14 1 13 14 CFG=3
M  V30 15 1 5 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1511499171

>  <MW>
243.217

>  <MW (desalted)>
243.217

>  <ClogP>
-2.195

>  <logS>
-0.42

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
128.61

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | IC50  0.002 ?M

>  <CAS>
147-94-4

>  <Description>
Cytarabine is a pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.

>  <EBC_ID>
EBC-13057

>  <IUPAC Name>
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
ASCENTAGE PHARMACEUTICAL GROUP CO LTD - WO2021/18032, 2021, A1 | GLAXOSMITHKLINE PLC - WO2019/165473, 2019, A1

>  <Main tar all>
MDM2 proto-oncogene pX=10.0 | Probable serine/threonine-protein kinase cdc7 pX=8.7

$$$$
Ribavirin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.679 0.4336 0 0
M  V30 2 C 2.3453 -0.3364 0 0
M  V30 3 O 1.0116 0.4336 0 0
M  V30 4 C 2.3453 -1.8764 0 0
M  V30 5 N 3.5912 -2.7816 0 0
M  V30 6 C 3.1153 -4.2462 0 0
M  V30 7 N 1.5753 -4.2462 0 0
M  V30 8 N 1.0994 -2.7816 0 0
M  V30 9 C 0.6701 -5.4921 0 0 CFG=2
M  V30 10 O 1.146 -6.9567 0 0
M  V30 11 C -0.0999 -7.8619 0 0 CFG=2
M  V30 12 C -0.0999 -9.4019 0 0
M  V30 13 O 1.2338 -10.1719 0 0
M  V30 14 C -1.3457 -6.9567 0 0 CFG=1
M  V30 15 O -2.8104 -7.4326 0 0
M  V30 16 C -0.8699 -5.4921 0 0 CFG=1
M  V30 17 O -1.7751 -4.2462 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 4 8
M  V30 9 1 9 7 CFG=3
M  V30 10 1 9 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=3
M  V30 13 1 12 13
M  V30 14 1 14 11
M  V30 15 1 14 15 CFG=1
M  V30 16 1 14 16
M  V30 17 1 16 9
M  V30 18 1 16 17 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z594284196

>  <MW>
244.205

>  <MW (desalted)>
244.205

>  <ClogP>
-2.849

>  <logS>
0.22

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
143.72

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC90  63.84 nM | EC50  9.91 nM | protein expression level decrease Active   | EC50  0.094 ?M

>  <CAS>
36791-04-5

>  <Description>
Ribavirin is an antiviral guanosine nucleoside analog. It producing a broad-spectrum activity against several RNA and DNA viruses. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers.

>  <EBC_ID>
EBC-00633

>  <IUPAC Name>
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide

>  <Main Tar all refs>
Antiviral Res., 2018, vol. 157, p. 151 - 158 | GILEAD SCIENCES INC - US2013/109647, 2013, A1 | Antiviral Res., 2023, vol. 209 | Arch. Pharm., 2019, vol. 352, # 11

>  <Main tar all>
Eukaryotic initiation factor 4A pX=8.15 | Nonstructural protein 5B pX=8.0 | Dihydroorotate dehydrogenase (quinone), mitochondrial pX=7.49 | Hemagglutinin pX=7.03

$$$$
Quinacrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6521 9.2583 0 0
M  V30 2 C 6.1643 9.5493 0 0
M  V30 3 N 7.1725 8.3852 0 0
M  V30 4 C 6.6684 6.93 0 0
M  V30 5 C 5.1561 6.639 0 0
M  V30 6 C 8.6847 8.6762 0 0
M  V30 7 C 9.6929 7.5121 0 0
M  V30 8 C 11.2051 7.8031 0 0
M  V30 9 C 12.2133 6.639 0 0
M  V30 10 C 11.7092 5.1838 0 0
M  V30 11 N 13.7256 6.93 0 0
M  V30 12 C 14.7337 5.7659 0 0
M  V30 13 C 16.246 6.0569 0 0
M  V30 14 C 16.7501 7.5121 0 0
M  V30 15 C 18.2623 7.8031 0 0
M  V30 16 C 19.2705 6.639 0 0
M  V30 17 Cl 20.7827 6.93 0 0
M  V30 18 C 18.7664 5.1838 0 0
M  V30 19 C 17.2541 4.8928 0 0
M  V30 20 N 16.7501 3.4376 0 0
M  V30 21 C 15.2378 3.1466 0 0
M  V30 22 C 14.7337 1.6914 0 0
M  V30 23 C 13.2215 1.4004 0 0
M  V30 24 C 12.2133 2.5645 0 0
M  V30 25 O 10.7011 2.2735 0 0
M  V30 26 C 9.6929 3.4376 0 0
M  V30 27 C 12.7174 4.0197 0 0
M  V30 28 C 14.2296 4.3107 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 1 18 19
M  V30 19 2 13 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 24 27
M  V30 28 1 27 28
M  V30 29 2 12 28
M  V30 30 1 21 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z31251611

>  <MW>
399.957

>  <MW (desalted)>
399.957

>  <ClogP>
6.723

>  <logS>
-5.51

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
37.39

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active

>  <CAS>
83-89-6

>  <Description>
Quinacrine binds to deoxyribonucleic acid (DNA) in vitro by intercalation between adjacent base pairs, inhibiting transcription and translation to ribonucleic acid (RNA).  Quinacrine inhibits succinate oxidation, also suppress the lupus erythematous cell factor and acts as a strong inhibitor of cholinesterase. Quinacrine has been used as an antimalarial drug and as an antibiotic. It is used to treat giardiasis, a protozoal infection of the intestinal tract, and certain types of lupus erythematosus, an inflammatory disease that affects the joints, tendons, and other connective tissues and organs.

>  <EBC_ID>
EBC-06109

>  <IUPAC Name>
6-chloro-N-[5-(diethylamino)pentan-2-yl]-2-methoxyacridin-9-amine

>  <Main Tar all refs>
INCURON - US9108916, 2015, B2

>  <Main tar all>
NF-kappa-B/Dorsal pX=9.0

$$$$
Phthalylsulfathiazole sodium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na -9.5349 9.665 0 0 CHG=1
M  V30 2 O -8.2013 10.435 0 0 CHG=-1
M  V30 3 C -6.8676 11.205 0 0
M  V30 4 O -5.5339 10.435 0 0
M  V30 5 C -6.8676 12.745 0 0
M  V30 6 C -8.2013 13.515 0 0
M  V30 7 C -8.2013 15.055 0 0
M  V30 8 C -6.8676 15.825 0 0
M  V30 9 C -5.5339 15.055 0 0
M  V30 10 C -5.5339 13.515 0 0
M  V30 11 C -4.2002 12.745 0 0
M  V30 12 O -4.2002 11.205 0 0
M  V30 13 N -2.8665 13.515 0 0
M  V30 14 C -1.5329 12.745 0 0
M  V30 15 C -0.1992 13.515 0 0
M  V30 16 C 1.1345 12.745 0 0
M  V30 17 C 1.1345 11.205 0 0
M  V30 18 C -0.1992 10.435 0 0
M  V30 19 C -1.5329 11.205 0 0
M  V30 20 S 2.4682 10.435 0 0
M  V30 21 O 1.6982 9.1013 0 0
M  V30 22 O 3.2382 11.7687 0 0
M  V30 23 N 3.8019 9.665 0 0
M  V30 24 C 3.8019 8.125 0 0
M  V30 25 N 5.0477 7.2198 0 0
M  V30 26 C 4.5719 5.7552 0 0
M  V30 27 C 3.0319 5.7552 0 0
M  V30 28 S 2.556 7.2198 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 20 1 17 20
M  V30 21 2 20 21
M  V30 22 2 20 22
M  V30 23 1 20 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 24 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3281948767

>  <MW>
425.414

>  <MW (desalted)>
403.432

>  <ClogP>
-1.824

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
128.29

>  <RotBonds>
5

>  <CAS>
63868-70-2

>  <Description>
Phthalylsulfathiazole is a broad spectrum antibiotic which is part of the drug class, sulfonamides. It is indicated in the treatment of gastrointestinal infections.

>  <EBC_ID>
EBC-28063

>  <IUPAC Name>
sodium 2-({4-[(1,3-thiazol-2-yl)sulfamoyl]phenyl}carbamoyl)benzoate

$$$$
Sulfadimethoxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -1.54 0 0
M  V30 2 O 4.001 -2.31 0 0
M  V30 3 C 4.001 -3.85 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 5.3347 -6.16 0 0
M  V30 6 N 6.6684 -6.93 0 0
M  V30 7 S 6.6684 -8.47 0 0
M  V30 8 O 5.1284 -8.47 0 0
M  V30 9 O 8.2084 -8.47 0 0
M  V30 10 C 6.6684 -10.01 0 0
M  V30 11 C 8.0021 -10.78 0 0
M  V30 12 C 8.0021 -12.32 0 0
M  V30 13 C 6.6684 -13.09 0 0
M  V30 14 N 6.6684 -14.63 0 0
M  V30 15 C 5.3347 -12.32 0 0
M  V30 16 C 5.3347 -10.78 0 0
M  V30 17 N 4.001 -6.93 0 0
M  V30 18 C 2.6674 -6.16 0 0
M  V30 19 O 1.3337 -6.93 0 0
M  V30 20 C 0 -6.16 0 0
M  V30 21 N 2.6674 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 2 7 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 5 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 18 21
M  V30 22 2 3 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56763920

>  <MW>
310.329

>  <MW (desalted)>
310.329

>  <ClogP>
1.981

>  <logS>
-3.53

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
116.43

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.8 ?M | IC50  13.5 ?M

>  <CAS>
122-11-2

>  <Description>
Sulfadimethoxine is a sulfonamide antibiotic that is active against Gram-negative and Gram-positive bacteria and other microorganisms. Sulfadimethoxine is used to treat many infections including treatment of respiratory, urinary tract, enteric, and soft tissue infections.

>  <EBC_ID>
EBC-04407

>  <IUPAC Name>
4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
FEBS J., 2020, vol. 287, # 15, p. 3273 - 3297 | Rapid Commun. Mass Spectrom., 2010, vol. 24, # 1, p. 147 - 154

>  <Main tar all>
Folate synthesis bifunctional protein pX=6.1 | Cytochrome P450 2D6 pX=4.87

$$$$
Auranofin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.6437 4.0563 0 0
M  V30 2 C -2.1037 4.0563 0 0
M  V30 3 P -1.3337 5.39 0 0
M  V30 4 Au 0 4.62 0 0
M  V30 5 S 1.3337 3.85 0 0
M  V30 6 C 1.3337 2.31 0 0 CFG=2
M  V30 7 O 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0 CFG=2
M  V30 9 C 4.001 -0.77 0 0
M  V30 10 O 5.3347 -0 0 0
M  V30 11 C 6.6684 -0.77 0 0
M  V30 12 O 8.0021 -0 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 C 1.3337 -0.77 0 0 CFG=1
M  V30 15 O 1.3337 -2.31 0 0
M  V30 16 C 2.6674 -3.08 0 0
M  V30 17 O 4.001 -2.31 0 0
M  V30 18 C 2.6674 -4.62 0 0
M  V30 19 C 0 0 0 0 CFG=2
M  V30 20 O -1.3337 -0.77 0 0
M  V30 21 C -1.3337 -2.31 0 0
M  V30 22 O -0 -3.08 0 0
M  V30 23 C -2.6674 -3.08 0 0
M  V30 24 C 0 1.54 0 0 CFG=1
M  V30 25 O -1.3337 2.31 0 0
M  V30 26 C -2.6674 1.54 0 0
M  V30 27 O -2.6674 0 0 0
M  V30 28 C -4.001 2.31 0 0
M  V30 29 C -0.5637 6.7237 0 0
M  V30 30 C 0.9763 6.7237 0 0
M  V30 31 C -2.6674 6.16 0 0
M  V30 32 C -2.6674 7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 14 8
M  V30 14 1 14 15 CFG=1
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 14 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 19 24
M  V30 24 1 24 6
M  V30 25 1 24 25 CFG=1
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 3 29
M  V30 30 1 29 30
M  V30 31 1 3 31
M  V30 32 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2178867076

>  <MW>
678.484

>  <MW (desalted)>
678.484

>  <ClogP>
3.791

>  <logS>
-1.06

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
114.43

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | inhibition rate Active   | IC50  0.9 nM | IC50  3 nM | IC50  3 nM

>  <CAS>
34031-32-8

>  <Description>
Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

>  <EBC_ID>
EBC-13193

>  <IUPAC Name>
[(2R,3R,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-{[(triethyl-lambda5-phosphanylidene)aurio]sulfanyl}oxan-2-yl]methyl acetate

>  <Main Tar all refs>
Int. J. Mol. Sci., 2022, vol. 23, # 13 | ACS Infect. Dis., 2019, vol. 5, # 10, p. 1682 - 1687 | Bioorg. Med. Chem., 2017, vol. 25, # 20, p. 5452 - 5460 | PLoS. Negl. Trop. Dis., 2015, vol. 9, # 2, p. 18 | Bioorg. Med. Chem., 2017, vol. 25, # 20, p. 5452 - 5460

>  <Main tar all>
Bifunctional thioredoxin reductase/thioredoxin pX=10.0 | Thioredoxin reductase pX=9.74 | Thioredoxin reductase 1 pX=9.05 | Peroxiredoxin-5 pX=8.52 | Thioredoxin reductase 2 pX=8.52

$$$$
Emtricitabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 N 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 O 4.001 8.01 0 0
M  V30 6 N 1.3337 8.01 0 0
M  V30 7 C 0 8.78 0 0
M  V30 8 C 0 10.32 0 0
M  V30 9 F -1.3337 11.09 0 0
M  V30 10 C 1.3337 6.47 0 0 CFG=2
M  V30 11 C 2.5796 5.5648 0 0
M  V30 12 S 2.1037 4.1002 0 0
M  V30 13 C 0.5637 4.1002 0 0 CFG=2
M  V30 14 C -0.3415 2.8543 0 0
M  V30 15 O 0.2849 1.4474 0 0
M  V30 16 O 0.0878 5.5648 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 10 6 CFG=3
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 13 12
M  V30 14 1 13 14 CFG=3
M  V30 15 1 14 15
M  V30 16 1 13 16
M  V30 17 1 10 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553474

>  <MW>
247.247

>  <MW (desalted)>
247.247

>  <ClogP>
-1.291

>  <logS>
-1.36

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
88.15

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.02 nM | IC50  0.53 nM

>  <CAS>
143491-57-0

>  <Description>
Emtricitabine is a nucleoside analog and an inhibitor of HIV-1 and hepatitis B reverse transcriptase with antiviral activity. It is indicated in combination with other medications for the treatment of HIV-1 infections.

>  <EBC_ID>
EBC-07648

>  <IUPAC Name>
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261

>  <Main tar all>
Organic cation transporter 1 pX=10.7 | Organic cation transporter 3 pX=9.28

$$$$
Simvastatin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 -9.24 0 0
M  V30 2 C 1.3337 -8.47 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 C 2.8737 -6.93 0 0
M  V30 5 C -0.2063 -6.93 0 0
M  V30 6 C 1.3337 -5.39 0 0
M  V30 7 O 0 -4.62 0 0
M  V30 8 O 2.6674 -4.62 0 0
M  V30 9 C 2.6674 -3.08 0 0 CFG=1
M  V30 10 C 1.3337 -2.31 0 0
M  V30 11 C 1.3337 -0.77 0 0 CFG=1
M  V30 12 C 0 0 0 0
M  V30 13 C 2.6674 0 0 0
M  V30 14 C 4.001 -0.77 0 0
M  V30 15 C 5.3347 0 0 0
M  V30 16 C 6.6684 -0.77 0 0
M  V30 17 C 6.6684 -2.31 0 0 CFG=2
M  V30 18 C 8.0021 -3.08 0 0
M  V30 19 C 5.3347 -3.08 0 0 CFG=2
M  V30 20 C 5.3347 -4.62 0 0
M  V30 21 C 6.6684 -5.39 0 0
M  V30 22 C 6.6684 -6.93 0 0 CFG=2
M  V30 23 C 5.3347 -7.7 0 0
M  V30 24 C 5.3347 -9.24 0 0 CFG=1
M  V30 25 O 4.001 -10.01 0 0
M  V30 26 C 6.6684 -10.01 0 0
M  V30 27 C 8.0021 -9.24 0 0
M  V30 28 O 9.3358 -10.01 0 0
M  V30 29 O 8.0021 -7.7 0 0
M  V30 30 C 4.001 -2.31 0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=3
M  V30 18 1 19 17
M  V30 19 1 19 20 CFG=3
M  V30 20 1 20 21
M  V30 21 1 22 21 CFG=1
M  V30 22 1 22 23
M  V30 23 1 24 23
M  V30 24 1 24 25 CFG=3
M  V30 25 1 24 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 27 29
M  V30 29 1 22 29
M  V30 30 1 19 30
M  V30 31 1 30 9
M  V30 32 1 30 14 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754918914

>  <MW>
418.566

>  <MW (desalted)>
418.566

>  <ClogP>
4.481

>  <logS>
-4.7

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
72.83

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.1 nM | inhibition percentage Active

>  <CAS>
79902-63-9

>  <Description>
Simvastatin is an oral antilipemic agent which inhibits HMG-CoA reductase. Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides, and to increase high-density lipoprotein cholesterol.

>  <EBC_ID>
EBC-00672

>  <IUPAC Name>
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2008, vol. 8, # 6, p. 609 - 618 | WENG, Ching-Feng;CHEN, Chin-piao;SHIVAJI, Sulake Rohidas;HUANG, Zi-Ling - WO2016/37566, 2016, A1

>  <Main tar all>
hydroxymethylglutaryl-CoA reductase pX=10.0 | Lipase (gene LIP) pX=9.3

$$$$
O-desmethylvenlafaxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.2701 1.316 0 0
M  V30 2 N 0.0635 0.546 0 0
M  V30 3 C 1.3972 1.316 0 0
M  V30 4 C 0.0635 -0.994 0 0
M  V30 5 C 1.3972 -1.764 0 0
M  V30 6 C 1.3972 -3.304 0 0
M  V30 7 C 2.7309 -4.074 0 0
M  V30 8 C 2.7309 -5.614 0 0
M  V30 9 C 1.3972 -6.384 0 0
M  V30 10 O 1.3972 -7.924 0 0
M  V30 11 C 0.0635 -5.614 0 0
M  V30 12 C 0.0635 -4.074 0 0
M  V30 13 C 2.7309 -0.994 0 0
M  V30 14 O 3.2576 -2.4411 0 0
M  V30 15 C 1.741 0.1857 0 0
M  V30 16 C 2.2677 1.6329 0 0
M  V30 17 C 3.7843 1.9003 0 0
M  V30 18 C 4.7742 0.7206 0 0
M  V30 19 C 4.2475 -0.7265 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 13 1 5 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 13 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977125

>  <MW>
263.375

>  <MW (desalted)>
263.375

>  <ClogP>
2.683

>  <logS>
-2.332

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
43.7

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  7.7 nM

>  <CAS>
93413-62-8

>  <Description>
Desvenlafaxine is an antidepressant agent and SNRI used for the treatment of major depressive disorders in adults.

>  <EBC_ID>
EBC-13155

>  <IUPAC Name>
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 1997, vol. 283, # 3, p. 1305 - 1322

>  <Main tar all>
SERT pX=8.11

$$$$
Tacrolimus
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 57 60 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 24.075 9.2175 0 0
M  V30 2 O 22.7473 8.4373 0 0
M  V30 3 C 21.4078 9.197 0 0 CFG=2
M  V30 4 C 20.08 8.4168 0 0
M  V30 5 C 18.7405 9.1766 0 0 CFG=1
M  V30 6 C 18.7287 10.7165 0 0
M  V30 7 C 20.0564 11.4967 0 0
M  V30 8 C 21.3959 10.737 0 0 CFG=1
M  V30 9 O 22.7237 11.5172 0 0
M  V30 10 C 17.4128 8.3963 0 0
M  V30 11 C 16.0732 9.1561 0 0
M  V30 12 C 16.0614 10.696 0 0
M  V30 13 C 14.7455 8.3759 0 0 CFG=1
M  V30 14 O 14.795 6.6914 0 0
M  V30 15 C 15.8093 5.5326 0 0
M  V30 16 O 17.343 5.6721 0 0
M  V30 17 C 15.0207 4.2098 0 0 CFG=2
M  V30 18 C 15.4759 2.7387 0 0
M  V30 19 C 14.4295 1.6088 0 0
M  V30 20 C 12.9278 1.9502 0 0
M  V30 21 C 12.4725 3.4213 0 0
M  V30 22 N 13.519 4.5512 0 0
M  V30 23 C 12.0135 3.7938 0 0
M  V30 24 O 11.9585 2.2547 0 0
M  V30 25 C 10.6908 4.5824 0 0
M  V30 26 O 10.7124 6.1223 0 0
M  V30 27 C 9.3464 3.8312 0 0 CFG=2
M  V30 28 O 10.6692 3.0426 0 0
M  V30 29 O 8.0237 4.6198 0 0
M  V30 30 C 6.6793 3.8686 0 0 CFG=1
M  V30 31 C 6.6577 2.3288 0 0 CFG=2
M  V30 32 C 7.9805 1.5402 0 0
M  V30 33 C 9.3248 2.2914 0 0 CFG=1
M  V30 34 C 10.6476 1.5027 0 0
M  V30 35 O 5.3134 1.5776 0 0
M  V30 36 C 5.2917 0.0377 0 0
M  V30 37 C 5.3566 4.6573 0 0 CFG=2
M  V30 38 C 5.3782 6.1971 0 0
M  V30 39 C 4.0555 6.9858 0 0 CFG=1
M  V30 40 C 2.7111 6.2346 0 0
M  V30 41 C 4.0771 8.5256 0 0
M  V30 42 C 5.4214 9.2768 0 0
M  V30 43 C 6.7442 8.4882 0 0
M  V30 44 C 8.0885 9.2394 0 0 CFG=1
M  V30 45 C 8.1102 10.7792 0 0
M  V30 46 C 6.7874 11.5679 0 0
M  V30 47 C 6.809 13.1077 0 0
M  V30 48 C 9.4113 8.4507 0 0
M  V30 49 O 9.3897 6.9109 0 0
M  V30 50 C 10.7556 9.202 0 0
M  V30 51 C 12.0784 8.4133 0 0 CFG=2
M  V30 52 O 12.0568 6.8735 0 0
M  V30 53 C 13.4227 9.1645 0 0 CFG=1
M  V30 54 C 13.4443 10.7044 0 0
M  V30 55 C 5.4431 10.8167 0 0
M  V30 56 O 4.0122 3.9061 0 0
M  V30 57 C 2.6895 4.6947 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 3 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 5 10 CFG=3
M  V30 11 2 10 11
M  V30 12 1 11 12 CFG=2
M  V30 13 1 13 11 CFG=1
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 17 15
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22 CFG=3
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 2 25 26
M  V30 28 1 27 25
M  V30 29 1 27 28 CFG=3
M  V30 30 1 27 29
M  V30 31 1 30 29 CFG=1
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 33 32
M  V30 35 1 27 33
M  V30 36 1 33 34 CFG=3
M  V30 37 1 31 35 CFG=3
M  V30 38 1 35 36
M  V30 39 1 30 37
M  V30 40 1 37 38
M  V30 41 1 39 38
M  V30 42 1 39 40 CFG=1
M  V30 43 1 39 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 44 43
M  V30 47 1 44 45 CFG=1
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 44 48
M  V30 51 2 48 49
M  V30 52 1 48 50
M  V30 53 1 51 50
M  V30 54 1 51 52 CFG=1
M  V30 55 1 53 51
M  V30 56 1 53 13
M  V30 57 1 53 54 CFG=1
M  V30 58 1 42 55 CFG=2
M  V30 59 1 37 56 CFG=1
M  V30 60 1 56 57
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242006187

>  <MW>
803.482

>  <MW (desalted)>
804.018

>  <ClogP>
5.776

>  <logS>
-6.476

>  <HBD>
3

>  <HBA>
11

>  <TPSA>
178.36

>  <RotBonds>
7

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
stimulation rate Active   | IC50  0.1 nM | Kd (dissociation constant) = 2E-10 M | IC50  0.25 nM | Ki (inhibition constant)  0.33 nM | Kd (dissociation constant) ~ 0.4 nM | IC50 = 0.5 nM | IC50 = 0.5 nM | Ki (inhibition constant)  0.55 nM | IC50  0.62 nM | Ki (inhibition constant)  0.72 nM | Kd (dissociation constant)  0.8 nM | inhibition percentage Active   | IC50  1.54 nM | Ki (inhibition constant)  2.17 nM | IC50 = 2.54 nM | IC50  2.64 nM

>  <CAS>
104987-11-3

>  <Description>
Tacrolimus is a calcineurin inhibitor used to prevent organ transplant rejection and to treat moderate to severe atopic dermatitis.

>  <EBC_ID>
EBC-14160

>  <IUPAC Name>
(1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-{1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0,4,9]octacos-18-ene-2,3,10,16-tetrone

>  <Main Tar all refs>
Cell Chem. Biol., 2019, vol. 26, # 5, p. 652 - 4,661 | J. Am. Chem. Soc., 2007, vol. 129, # 40, p. 12222 - 12231 | Bioorg. Med. Chem. Lett., 1993, vol. 3, # 10, p. 1947 - 1950 | J. PHARMACOL. EXP. THER., 1997, vol. 283, # 1, p. 321 - 327 | PFIZER INC - WO2008/94147, 2008, A1 | J. MED. CHEM., 1992, vol. 35, # 13, p. 2467 - 2473 | J. Med. Chem., 2002, vol. 45, # 6, p. 1151 - 1175 | J. Med. Chem., 2002, vol. 45, # 6, p. 1151 - 1175 | J. Med. Chem., 2018, vol. 61, # 8, p. 3660 - 3673 | J. PHARMACOL. EXP. THER., 1997, vol. 283, # 1, p. 321 - 327 | PFIZER INC - WO2008/94147, 2008, A1 | UNIVERSITY OF CALIFORNIA - WO2020/163594, 2020, A1 | ISOMERASE THERAPEUTICS - WO2015/4455, 2015, A2 | J. PHARMACOL. EXP. THER., 1997, vol. 283, # 1, p. 321 - 327 | J. Med. Chem., 2018, vol. 61, # 8, p. 3660 - 3673 | Bioorg. Med. Chem. Lett., 1998, vol. 8, # 8, p. 935 - 938 | J. PHARMACOL. EXP. THER., 1997, vol. 283, # 1, p. 321 - 327

>  <Main tar all>
12 kDa FK506-binding protein pX=10.0 | cytokine pX=10.0 | FKBP prolyl isomerase 1A pX=9.7 | Interleukin-2 pX=9.6 | Peptidyl-prolyl cis-trans isomerase FKBP12 pX=9.48 | Peptidyl-prolyl cis-trans isomerase (gene CYP1) pX=9.4 | Protein Phosphatase 2 (Formerly 2A), Catalytic Subunit, Beta Isoform (Catalytic subunit) pX=9.3 | Protein Phosphatase 3 (Formerly 2B), Catalytic Subunit, Alpha Isoform (Catalytic subunit) pX=9.3 | FKBP prolyl isomerase 1A pX=9.26 | Interferon-? receptor pX=9.21 | Peptidyl-prolyl?cis-trans?isomerase?FKBP4 pX=9.14 | Serine/threonine-protein kinase mTOR pX=9.1 | Macrophage infectivity potentiator [MIP] pX=9.0 | Interleukin-4 pX=8.81 | Peptidyl-prolyl cis-trans isomerase FKBP1B pX=8.66 | FK506-binding protein pX=8.6 | Interleukin-5 pX=8.58

$$$$
Tofacitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.1207 6.93 0 0
M  V30 2 C 4.787 6.16 0 0 CFG=2
M  V30 3 C 3.4533 6.93 0 0
M  V30 4 C 2.1196 6.16 0 0
M  V30 5 N 2.1196 4.62 0 0
M  V30 6 C 3.4533 3.85 0 0
M  V30 7 C 4.787 4.62 0 0 CFG=2
M  V30 8 N 6.1207 3.85 0 0
M  V30 9 C 7.4543 4.62 0 0
M  V30 10 C 6.1207 2.31 0 0
M  V30 11 N 7.4543 1.54 0 0
M  V30 12 C 7.4543 0 0 0
M  V30 13 N 6.1207 -0.77 0 0
M  V30 14 C 4.787 0 0 0
M  V30 15 N 3.3224 -0.4759 0 0
M  V30 16 C 2.4172 0.77 0 0
M  V30 17 C 3.3224 2.0159 0 0
M  V30 18 C 4.787 1.54 0 0
M  V30 19 C 0.7859 3.85 0 0
M  V30 20 O 0.7859 2.31 0 0
M  V30 21 C -0.5477 4.62 0 0
M  V30 22 C -1.8814 3.85 0 0
M  V30 23 N -3.2151 3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 2 7
M  V30 8 1 7 8 CFG=1
M  V30 9 1 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 10 18
M  V30 20 1 14 18
M  V30 21 1 5 19
M  V30 22 2 19 20
M  V30 23 1 19 21
M  V30 24 1 21 22
M  V30 25 3 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216896219

>  <MW>
312.37

>  <MW (desalted)>
312.37

>  <ClogP>
1.517

>  <logS>
-3.788

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
88.91

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.069 nM | Kd (dissociation constant)  0.07 nM | IC50  0.12 nM | Kd (dissociation constant)  0.16 nM | Kd (dissociation constant)  0.2 nM | Kd (dissociation constant)  0.67 - 1.8 nM

>  <CAS>
477600-75-2

>  <Description>
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is used for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs, when methotrexate alone is not sufficient.

>  <EBC_ID>
EBC-11351

>  <IUPAC Name>
3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile

>  <Main Tar all refs>
Front. Immunol., 2022, vol. 13 | Front. Immunol., 2022, vol. 13 | Front. Immunol., 2022, vol. 13 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Front. Immunol., 2022, vol. 13 | Front. Immunol., 2022, vol. 13

>  <Main tar all>
Janus kinase 2 pX=10.2 | Janus kinase 3 (domain JH1) pX=10.2 | Janus kinase 1 pX=9.92 | Janus kinase 3 pX=9.8 | Janus kinase 2 (domain JH1) pX=9.7 | Janus kinase 1 (domain JH1) pX=9.17

$$$$
Methyl salicylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 O 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z19703590

>  <MW>
152.047

>  <MW (desalted)>
152.147

>  <ClogP>
2.335

>  <logS>
-1.3

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  3.43 ?M | Ki (inhibition constant)  9.81 ?M | Kd (dissociation constant)  43.51 ?M | IC50  84.6 ?M

>  <CAS>
119-36-8

>  <Description>
Methyl salicylate relieve musculoskeletal pain in the muscles, joints, and tendons by causing irritation and reddening of the skin due to dilated capillaries and increased blood flow. It is pharmacologically similar to aspirin and other NSAIDs but as a topical agent it primarily acts as a rubefacient and skin irritant. It reversibly inhibits cyclooxygenase enzyme and locally and peripherally prevents the production of inflammatory mediators such as prostaglandin and thromboxane A2. Ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago, sciatica and rheumatic conditions. It is used as a local analgesic for human and veterinary medicine.

>  <EBC_ID>
EBC-12859

>  <IUPAC Name>
methyl 2-hydroxybenzoate

>  <Main Tar all refs>
Front. Physiol., 2022, vol. 13 | Front. Physiol., 2018, vol. 9 | Int. J. Mol. Sci., 2018, vol. 19, # 3 | Front. Physiol., 2021, vol. 12

>  <Main tar all>
Odorant-binding protein 9 pX=5.46 | Odorant-binding protein 7 pX=5.01 | General odorant-binding protein 2 pX=4.36 | Chemosensory protein 15 pX=4.07

$$$$
Deferasirox
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 -0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 N 1.3337 -2.31 0 0
M  V30 11 N 0.0878 -3.2152 0 0
M  V30 12 C 0.5637 -4.6798 0 0
M  V30 13 C -0.3415 -5.9257 0 0
M  V30 14 C -1.8731 -5.7647 0 0
M  V30 15 C -2.7783 -7.0106 0 0
M  V30 16 C -2.1519 -8.4175 0 0
M  V30 17 C -0.6203 -8.5784 0 0
M  V30 18 C 0.2849 -7.3326 0 0
M  V30 19 O 1.8164 -7.4935 0 0
M  V30 20 N 2.1037 -4.6798 0 0
M  V30 21 C 2.5796 -3.2152 0 0
M  V30 22 C 4.0442 -2.7393 0 0
M  V30 23 C 4.3644 -1.233 0 0
M  V30 24 C 5.829 -0.7571 0 0
M  V30 25 C 6.9734 -1.7875 0 0
M  V30 26 C 6.6533 -3.2939 0 0
M  V30 27 C 5.1886 -3.7698 0 0
M  V30 28 O 4.8685 -5.2761 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 1 12 11 CFG=2
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 2 18 19
M  V30 21 1 12 20
M  V30 22 1 21 20 CFG=2
M  V30 23 1 10 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 22 27
M  V30 31 2 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041510169

>  <MW>
373.362

>  <MW (desalted)>
373.362

>  <ClogP>
2.542

>  <logS>
-4.712

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
98.74

>  <RotBonds>
2

>  <CAS>
201530-41-8

>  <Description>
Deferasirox is an orally available iron chelator used for the management of transfusional iron overload.

>  <EBC_ID>
EBC-50057

>  <IUPAC Name>
4-[3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid

$$$$
Rifabutin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 61 66 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.4672 8.453 0 0
M  V30 2 O 2.6183 7.1681 0 0
M  V30 3 C 3.3066 5.7905 0 0 CFG=1
M  V30 4 C 4.7663 6.3063 0 0
M  V30 5 C 6.324 6.4593 0 0
M  V30 6 O 7.9196 6.4045 0 0
M  V30 7 C 9.147 5.3616 0 0 CFG=1
M  V30 8 C 10.6755 5.1742 0 0
M  V30 9 O 7.7675 4.6777 0 0
M  V30 10 C 7.8548 3.1521 0 0
M  V30 11 C 9.3824 2.8121 0 0
M  V30 12 C 10.1886 4.1737 0 0
M  V30 13 O 11.722 4.3162 0 0
M  V30 14 C 9.7707 1.2339 0 0
M  V30 15 C 11.2367 0.6681 0 0
M  V30 16 N 12.5969 1.3903 0 0
M  V30 17 C 13.7041 0.3198 0 0
M  V30 18 C 14.2316 1.7666 0 0
M  V30 19 C 15.7484 2.0332 0 0
M  V30 20 N 16.7376 0.8529 0 0
M  V30 21 C 18.2544 1.1194 0 0
M  V30 22 C 19.2435 -0.0609 0 0
M  V30 23 C 20.7603 0.2056 0 0
M  V30 24 C 18.716 -1.5077 0 0
M  V30 25 C 16.21 -0.5939 0 0
M  V30 26 C 14.6932 -0.8605 0 0
M  V30 27 N 13.0281 -1.0639 0 0
M  V30 28 C 11.5033 -0.8487 0 0
M  V30 29 C 10.3621 -1.9 0 0
M  V30 30 N 9.7091 -3.3754 0 0
M  V30 31 C 8.6659 -4.5688 0 0
M  V30 32 O 9.5933 -5.7983 0 0
M  V30 33 C 7.1891 -5.2643 0 0
M  V30 34 C 5.5762 -5.4401 0 0
M  V30 35 C 3.9521 -5.1375 0 0
M  V30 36 C 2.5679 -4.4436 0 0
M  V30 37 C 1.4101 -3.4125 0 0 CFG=2
M  V30 38 C 0.244 -4.4184 0 0
M  V30 39 C 0.5623 -2.1193 0 0 CFG=2
M  V30 40 O -0.8248 -2.7884 0 0
M  V30 41 C 0.078 -0.6508 0 0 CFG=1
M  V30 42 C -1.435 -0.9381 0 0
M  V30 43 C -0.0097 0.8929 0 0 CFG=1
M  V30 44 O -1.5454 1.007 0 0
M  V30 45 C 0.3051 2.4065 0 0 CFG=1
M  V30 46 C -1.1489 2.914 0 0
M  V30 47 C 1 3.7863 0 0 CFG=2
M  V30 48 O -0.2737 4.652 0 0
M  V30 49 C -1.6602 3.9818 0 0
M  V30 50 O -1.7731 2.446 0 0
M  V30 51 C -2.9339 4.8475 0 0
M  V30 52 C 2.0251 4.9379 0 0 CFG=2
M  V30 53 C 1.0152 6.1005 0 0
M  V30 54 C 7.6063 -6.7467 0 0
M  V30 55 C 8.9334 -1.3366 0 0
M  V30 56 O 7.7636 -2.3382 0 0
M  V30 57 C 8.5935 0.1761 0 0
M  V30 58 C 7.0949 0.6149 0 0
M  V30 59 O 5.9957 -0.4638 0 0
M  V30 60 C 6.6902 2.1004 0 0
M  V30 61 C 5.2124 2.5337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6 CFG=2
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 11 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 20 25
M  V30 26 1 25 26
M  V30 27 1 17 26
M  V30 28 1 17 27
M  V30 29 1 27 28
M  V30 30 1 15 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 36 2 33 34
M  V30 37 1 34 35 CFG=2
M  V30 38 2 35 36 CFG=2
M  V30 39 1 37 36
M  V30 40 1 37 38 CFG=3
M  V30 41 1 39 37
M  V30 42 1 39 40 CFG=3
M  V30 43 1 39 41
M  V30 44 1 41 42 CFG=1
M  V30 45 1 41 43
M  V30 46 1 43 44 CFG=1
M  V30 47 1 43 45
M  V30 48 1 45 46 CFG=1
M  V30 49 1 45 47
M  V30 50 1 47 48 CFG=3
M  V30 51 1 48 49
M  V30 52 2 49 50
M  V30 53 1 49 51
M  V30 54 1 47 52
M  V30 55 1 52 3
M  V30 56 1 52 53 CFG=3
M  V30 57 1 33 54
M  V30 58 1 29 55
M  V30 59 2 55 56
M  V30 60 1 55 57
M  V30 61 1 14 57
M  V30 62 2 57 58
M  V30 63 1 58 59
M  V30 64 1 58 60
M  V30 65 2 10 60
M  V30 66 1 60 61
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754926486

>  <MW>
847.005

>  <MW (desalted)>
847.005

>  <ClogP>
4.732

>  <logS>
-6.86

>  <HBD>
5

>  <HBA>
13

>  <TPSA>
205.55

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC90  2.3 nM | MIC  2.3 nM

>  <CAS>
72559-06-9

>  <Description>
Rifabutin is an antibiotic used to treat mycobacterium avium complex disease in patients with HIV.

>  <EBC_ID>
EBC-12322

>  <IUPAC Name>
(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate

>  <Main Tar all refs>
ACS Infect. Dis., 2022, vol. 8, # 8, p. 1408 - 1421 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1422 - 1438

>  <Main tar all>
DNA-directed RNA polymerase pX=9.59 | RNA polymerase pX=8.64

$$$$
Cloperastine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.52 3.4817 0 0
M  V30 3 C 4.8537 2.7117 0 0
M  V30 4 C 6.1874 3.4817 0 0
M  V30 5 C 7.521 2.7117 0 0
M  V30 6 C 7.521 1.1717 0 0
M  V30 7 C 6.1874 0.4017 0 0
M  V30 8 C 4.8537 1.1717 0 0
M  V30 9 C 8.8547 0.4017 0 0
M  V30 10 O 10.1884 1.1717 0 0
M  V30 11 C 11.5221 0.4017 0 0
M  V30 12 C 12.8558 1.1717 0 0
M  V30 13 N 14.1894 0.4017 0 0
M  V30 14 C 15.5231 1.1717 0 0
M  V30 15 C 16.8568 0.4017 0 0
M  V30 16 C 16.8568 -1.1383 0 0
M  V30 17 C 15.5231 -1.9083 0 0
M  V30 18 C 14.1894 -1.1383 0 0
M  V30 19 C 8.8547 -1.1383 0 0
M  V30 20 C 10.1884 -1.9083 0 0
M  V30 21 C 10.1884 -3.4483 0 0
M  V30 22 C 8.8547 -4.2183 0 0
M  V30 23 C 7.521 -3.4483 0 0
M  V30 24 C 7.521 -1.9083 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 9 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3234966609

>  <MW>
365.131

>  <MW (desalted)>
329.864

>  <ClogP>
5.376

>  <logS>
-4.612

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
6

>  <Action on targets>
Blocker | Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50  0.7 ?M | inhibition percentage  93.38 % | decrease rate Active

>  <CAS>
14984-68-0

>  <Description>
Cloperastine hydrochloride is a blocker of sodium channel protein type 8.

>  <EBC_ID>
EBC-03905

>  <IUPAC Name>
1-{2-[(4-chlorophenyl)(phenyl)methoxy]ethyl}piperidine hydrochloride

>  <Main Tar all refs>
PAIRNOMIX - WO2018/64498, 2018, A1 | PAIRNOMIX - WO2018/64498, 2018, A1 | INDIANA UNIVERSITY - WO2021/138578, 2021, A1

>  <Main tar all>
Nav1.6 pX=6.15 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=6.15 | protein arginine methyltransferase 5  pX=4.82

$$$$
Loxapine succinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.4913 5.9645 0 0
M  V30 2 N -1.8231 4.577 0 0
M  V30 3 C -0.2874 4.462 0 0
M  V30 4 C 0.3808 3.0745 0 0
M  V30 5 N -0.4867 1.8021 0 0
M  V30 6 C -2.0224 1.9172 0 0
M  V30 7 C -2.6906 3.3046 0 0
M  V30 8 C 0.1814 0.4146 0 0
M  V30 9 N 1.7214 0.4146 0 0
M  V30 10 C 2.6816 -0.7894 0 0
M  V30 11 C 4.1532 -0.3355 0 0
M  V30 12 C 5.2821 -1.383 0 0
M  V30 13 C 4.9394 -2.8844 0 0
M  V30 14 C 3.4678 -3.3383 0 0
M  V30 15 C 2.3389 -2.2908 0 0
M  V30 16 O 0.9514 -2.959 0 0
M  V30 17 C -0.4361 -2.2908 0 0
M  V30 18 C -1.565 -3.3383 0 0
M  V30 19 C -3.0365 -2.8844 0 0
M  V30 20 C -3.3792 -1.383 0 0
M  V30 21 Cl -4.8508 -0.9291 0 0
M  V30 22 C -2.2503 -0.3355 0 0
M  V30 23 C -0.7787 -0.7894 0 0
M  V30 24 O 8.8021 -0.385 0 0
M  V30 25 C 10.1358 0.385 0 0
M  V30 26 O 10.1358 1.925 0 0
M  V30 27 C 11.4695 -0.385 0 0
M  V30 28 C 12.8031 0.385 0 0
M  V30 29 C 14.1368 -0.385 0 0
M  V30 30 O 15.4705 0.385 0 0
M  V30 31 O 14.1368 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 22 23
M  V30 25 1 8 23
M  V30 26 2 17 23
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 25 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 29 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516768

>  <MW>
445.14

>  <MW (desalted)>
327.808

>  <ClogP>
3.981

>  <logS>
-3.662

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
28.07

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.8 nM | Ki (inhibition constant) = 4.2 nM | Ki (inhibition constant) = 4.9 nM | Ki (inhibition constant) = 5 nM | IC50 = 6 nM | IC50 = 14 nM | Ki (inhibition constant) = 15 nM | pKi  7.82  | IC50 = 18 nM | Ki (inhibition constant) = 21 nM | Ki (inhibition constant) = 21 nM | IC50 = 22 nM | Ki (inhibition constant) = 30 nM | Ki (inhibition constant) = 43 nM

>  <CAS>
27833-64-3

>  <Description>
Loxapine is a antipsychotic used for the treatment of schizophrenia. It is a dopamine antagonist, and also a serotonin 5-HT2 blocker.

>  <EBC_ID>
EBC-12876

>  <IUPAC Name>
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene; butanedioic acid

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. MED. CHEM., 1995, vol. 38, # 4, p. 708 - 714 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. Med. Chem., 1999, vol. 42, # 12, p. 2235 - 2244 | J. Med. Chem., 1999, vol. 42, # 12, p. 2235 - 2244 | J. Med. Chem., 2003, vol. 46, # 14, p. 2795 - 2812 | Bioorg. Med. Chem., 2004, vol. 12, # 14, p. 3815 - 3824 | J. Med. Chem., 1999, vol. 42, # 12, p. 2235 - 2244 | J. Med. Chem., 2004, vol. 47, # 1, p. 143 - 157 | J. MED. CHEM., 1995, vol. 38, # 4, p. 708 - 714 | J. Med. Chem., 1999, vol. 42, # 12, p. 2235 - 2244 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | J. Med. Chem., 2003, vol. 46, # 14, p. 2795 - 2812

>  <Main tar all>
D2 receptor pX=8.74 | 5-HT2A receptor pX=8.38 | D4 receptor pX=8.31 | H1 receptor pX=8.3 | 5-HT2A receptor pX=8.22 | D4.2 receptor pX=7.85 | 5-HT6 receptor pX=7.82 | 5-HT6 receptor pX=7.82 | ?1-adrenoceptor pX=7.74 | D2 receptor pX=7.68 | D2L receptor pX=7.68 | D3 receptor pX=7.66 | 5-HT2B receptor pX=7.52 | 5-HT7 receptor pX=7.37

$$$$
Lactose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -2.6674 -0 0 0
M  V30 2 C -1.3337 -0.77 0 0
M  V30 3 C -1.3337 -2.31 0 0 CFG=1
M  V30 4 O 0 -3.08 0 0
M  V30 5 C 0 -4.62 0 0 CFG=1
M  V30 6 O 1.3337 -5.39 0 0
M  V30 7 C 2.6674 -4.62 0 0 CFG=2
M  V30 8 C 2.6674 -3.08 0 0 CFG=1
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 4.001 -2.31 0 0 CFG=2
M  V30 11 O 4.001 -0.77 0 0
M  V30 12 C 5.3347 -3.08 0 0 CFG=1
M  V30 13 O 6.6684 -2.31 0 0
M  V30 14 O 5.3347 -4.62 0 0
M  V30 15 C 4.001 -5.39 0 0 CFG=1
M  V30 16 C 4.001 -6.93 0 0
M  V30 17 O 2.6674 -7.7 0 0
M  V30 18 C -1.3337 -5.39 0 0 CFG=2
M  V30 19 O -1.3337 -6.93 0 0
M  V30 20 C -2.6674 -4.62 0 0 CFG=1
M  V30 21 O -4.001 -5.39 0 0
M  V30 22 C -2.6674 -3.08 0 0 CFG=1
M  V30 23 O -4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 1 15 14
M  V30 15 1 7 15
M  V30 16 1 15 16 CFG=1
M  V30 17 1 16 17
M  V30 18 1 18 5
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 22 3
M  V30 24 1 22 23 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3031460626

>  <MW>
342.116

>  <MW (desalted)>
342.296

>  <ClogP>
-4.399

>  <logS>
0.315

>  <HBD>
8

>  <HBA>
11

>  <TPSA>
189.53

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 9500 ?M

>  <CAS>
63-42-3

>  <Description>
Lactose is a disaccharide naturally found in milk and dairy. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

>  <EBC_ID>
EBC-13808

>  <IUPAC Name>
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-{[(2S,3R,4S,5S,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxane-3,4,5-triol

>  <Main Tar all refs>
Curr. Med. Chem., 2006, vol. 13, # 1, p. 109 - 116

>  <Main tar all>
Glucoamylase (gene glaA) pX=2.02

$$$$
D-Myo-inositol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0 CFG=1
M  V30 3 C 2.6674 1.54 0 0 CFG=2
M  V30 4 O 4.001 2.31 0 0
M  V30 5 C 2.6674 -0 0 0 CFG=1
M  V30 6 O 4.001 -0.77 0 0
M  V30 7 C 1.3337 -0.77 0 0 CFG=2
M  V30 8 O 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0 CFG=2
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0 CFG=2
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 9
M  V30 11 1 2 11
M  V30 12 1 11 12 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1486007281

>  <MW>
180.063

>  <MW (desalted)>
180.156

>  <ClogP>
-1.427

>  <logS>
0.474

>  <HBD>
6

>  <HBA>
6

>  <TPSA>
121.38

>  <RotBonds>
0

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 0.2 mM | inhibition percentage  73.3 %

>  <CAS>
87-89-8

>  <Description>
D-myo-inositol have structural similarities to glucose and are involved in cellular signaling. It is used as a nutrient supplement in special dietary foods and infant formula. Inositol can stimulate glucose uptake in skeletal muscle cells which allows the decrease in blood sugar levels.

>  <EBC_ID>
EBC-04436

>  <IUPAC Name>
(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol

>  <Main Tar all refs>
J. Biol. Chem., 1981, vol. 256, # 16, p. 8519 - 8524 | Chem. Pap., 2014, vol. 68, # 1, p. 37 - 45

>  <Main tar all>
Inositol oxygenase pX=3.7 | Angiotensin-converting enzyme pX=3.69

$$$$
Glucosamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 6.1874 3.2725 0 0
M  V30 3 C 6.1874 1.7325 0 0 CFG=1
M  V30 4 C 7.521 0.9625 0 0 CFG=2
M  V30 5 O 8.8547 1.7325 0 0
M  V30 6 O 7.521 -0.5775 0 0
M  V30 7 C 6.1874 -1.3475 0 0 CFG=2
M  V30 8 C 6.1874 -2.8875 0 0
M  V30 9 O 7.521 -3.6575 0 0
M  V30 10 C 4.8537 -0.5775 0 0 CFG=1
M  V30 11 O 3.52 -1.3475 0 0
M  V30 12 C 4.8537 0.9625 0 0 CFG=2
M  V30 13 O 3.52 1.7325 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=1
M  V30 2 1 3 4
M  V30 3 1 4 5 CFG=3
M  V30 4 1 4 6
M  V30 5 1 7 6
M  V30 6 1 7 8 CFG=3
M  V30 7 1 8 9
M  V30 8 1 10 7
M  V30 9 1 10 11 CFG=1
M  V30 10 1 12 10
M  V30 11 1 3 12
M  V30 12 1 12 13 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3223588754

>  <MW>
215.056

>  <MW (desalted)>
179.171

>  <ClogP>
-2.184

>  <logS>
-0.336

>  <HBD>
5

>  <HBA>
6

>  <TPSA>
116.17

>  <RotBonds>
1

>  <CAS>
14131-63-6

>  <Description>
Glucosamine is a common ingredient in nutritional supplements. It is used over the counter in the symptomatic treatment of osteoarthritis and joint pain.

>  <EBC_ID>
EBC-67070

>  <IUPAC Name>
(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol hydrochloride

$$$$
Dabigatran
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.9855 5.3303 0 0
M  V30 2 N -6.4792 5.6505 0 0
M  V30 3 C -5.8528 7.0573 0 0
M  V30 4 C -6.6228 8.391 0 0
M  V30 5 N -8.1628 8.391 0 0
M  V30 6 C -8.9328 9.7247 0 0
M  V30 7 C -10.4728 9.7247 0 0
M  V30 8 C -11.2428 11.0584 0 0
M  V30 9 C -10.4728 12.392 0 0
M  V30 10 C -8.9328 12.392 0 0
M  V30 11 C -8.1628 11.0584 0 0
M  V30 12 C -11.2428 13.7257 0 0
M  V30 13 N -10.4728 15.0594 0 0
M  V30 14 N -12.7828 13.7257 0 0
M  V30 15 N -4.3212 6.8963 0 0
M  V30 16 C -4.001 5.39 0 0
M  V30 17 C -2.6674 4.62 0 0
M  V30 18 C -2.6674 3.08 0 0
M  V30 19 C -4.001 2.31 0 0
M  V30 20 C -5.3347 3.08 0 0
M  V30 21 C -5.3347 4.62 0 0
M  V30 22 C -1.3337 2.31 0 0
M  V30 23 O -1.3337 0.77 0 0
M  V30 24 N -0 3.08 0 0
M  V30 25 C 1.3337 2.31 0 0
M  V30 26 C 2.6674 3.08 0 0
M  V30 27 C 4.001 2.31 0 0
M  V30 28 O 5.3347 3.08 0 0
M  V30 29 O 4.001 0.77 0 0
M  V30 30 C -0 4.62 0 0
M  V30 31 C -1.3337 5.39 0 0
M  V30 32 C -1.3337 6.93 0 0
M  V30 33 C -0 7.7 0 0
M  V30 34 C 1.3337 6.93 0 0
M  V30 35 N 1.3337 5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 9 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 2 3 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 2 21
M  V30 23 2 16 21
M  V30 24 1 18 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 1 24 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 2 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891234

>  <MW>
471.202

>  <MW (desalted)>
471.511

>  <ClogP>
0.063

>  <logS>
-4.333

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
150.22

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  7E-10 M | Ki (inhibition constant)  2.4 nM | Ki (inhibition constant)  2.9 nM | Ki (inhibition constant)  3.6 nM | IC50  6.4 nM | Ki (inhibition constant)  7 nM

>  <CAS>
211914-51-1

>  <Description>
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate. It is a trombin inhibitor (Ki = 6.3 nM).

>  <EBC_ID>
EBC-14163

>  <IUPAC Name>
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid

>  <Main Tar all refs>
Thromb. Haemost., 2007, vol. 98, # 1, p. 155 - 162 | J. Med. Chem., 2013, vol. 56, # 23, p. 9441 - 9456 | J. Med. Chem., 2013, vol. 56, # 23, p. 9441 - 9456 | J. Med. Chem., 2013, vol. 56, # 23, p. 9441 - 9456 | ChemMedChem, 2021, vol. 16, # 24, p. 3672 - 3690 | J. Med. Chem., 2013, vol. 56, # 23, p. 9441 - 9456

>  <Main tar all>
coagulation factor II, thrombin pX=9.15 | Chymotrypsin B pX=8.62 | kallikrein B1 pX=8.54 | plasminogen activator, tissue type pX=8.44 | Coagulation factor IIa pX=8.19 | Trypsin pX=8.15

$$$$
Iopromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -2.31 0 0
M  V30 2 O -2.6674 -1.54 0 0
M  V30 3 C -2.6674 0 0 0
M  V30 4 C -1.3337 0.77 0 0
M  V30 5 O 0 0 0 0
M  V30 6 N -1.3337 2.31 0 0
M  V30 7 C 0 3.08 0 0
M  V30 8 C 0 4.62 0 0
M  V30 9 I -1.3337 5.39 0 0
M  V30 10 C 1.3337 5.39 0 0
M  V30 11 C 1.3337 6.93 0 0
M  V30 12 O 2.6674 7.7 0 0
M  V30 13 N 0 7.7 0 0
M  V30 14 C 0 9.24 0 0
M  V30 15 C -1.3337 10.01 0 0
M  V30 16 O -2.6674 9.24 0 0
M  V30 17 C -1.3337 11.55 0 0
M  V30 18 O -2.6674 12.32 0 0
M  V30 19 C 2.6674 4.62 0 0
M  V30 20 I 4.001 5.39 0 0
M  V30 21 C 2.6674 3.08 0 0
M  V30 22 C 4.001 2.31 0 0
M  V30 23 O 4.001 0.77 0 0
M  V30 24 N 5.3347 3.08 0 0
M  V30 25 C 5.3347 4.62 0 0
M  V30 26 C 6.6684 2.31 0 0
M  V30 27 C 8.0021 3.08 0 0
M  V30 28 O 8.0021 4.62 0 0
M  V30 29 C 9.3358 2.31 0 0
M  V30 30 O 10.6694 3.08 0 0
M  V30 31 C 1.3337 2.31 0 0
M  V30 32 I 1.3337 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 10 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 24 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 27 29
M  V30 29 1 29 30
M  V30 30 1 21 31
M  V30 31 2 7 31
M  V30 32 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681890595

>  <MW>
790.87

>  <MW (desalted)>
791.112

>  <ClogP>
-1.73

>  <logS>
-2.236

>  <HBD>
6

>  <HBA>
8

>  <TPSA>
168.66

>  <RotBonds>
11

>  <CAS>
73334-07-3

>  <Description>
Iopromide is an X-ray contrast agent used during various types of imaging tests such as angiography and contrast computed tomography (CT) imaging tests.

>  <EBC_ID>
EBC-23637

>  <IUPAC Name>
N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N1-methylbenzene-1,3-dicarboxamide

$$$$
Iguratimod
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 3.08 0 0
M  V30 2 S 0 1.54 0 0
M  V30 3 O 1.54 1.54 0 0
M  V30 4 O -1.54 1.54 0 0
M  V30 5 N 0 -0 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 2.6674 0 0 0
M  V30 8 C 4.001 -0.77 0 0
M  V30 9 O 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 N 8.0021 -3.08 0 0
M  V30 13 C 9.3358 -2.31 0 0
M  V30 14 O 10.6694 -3.08 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 O 5.3347 -4.62 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 18 C 2.6674 -3.08 0 0
M  V30 19 C 1.3337 -2.31 0 0
M  V30 20 O 0 -3.08 0 0
M  V30 21 C -1.3337 -2.31 0 0
M  V30 22 C -2.6674 -3.08 0 0
M  V30 23 C -4.001 -2.31 0 0
M  V30 24 C -4.001 -0.77 0 0
M  V30 25 C -2.6674 -0 0 0
M  V30 26 C -1.3337 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 11 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 8 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 6 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891323

>  <MW>
374.057

>  <MW (desalted)>
374.368

>  <ClogP>
1.931

>  <logS>
-3.769

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
110.8

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 <= 0.2 ?M | IC50 >~ 1 ?M

>  <CAS>
123663-49-0

>  <Description>
Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 7.7 ?M. Iguratimod also inhibits macrophage migration inhibitory factor with an IC50 of 6.81 ?M.

>  <EBC_ID>
EBC-46041

>  <IUPAC Name>
N-(7-methanesulfonamido-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide

>  <Main Tar all refs>
PFIZER INC - WO2005/16249, 2005, A2 | PFIZER INC - WO2005/294, 2005, A1

>  <Main tar all>
COX-2  pX=6.7 | COX-1  pX=6.0

$$$$
Cinnamyl alcohol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315574947

>  <MW>
134.073

>  <MW (desalted)>
134.175

>  <ClogP>
1.608

>  <logS>
-1.704

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Km (Michaelis constant) = 0.035 mM | Ki (inhibition constant) = 84 ?M | IC50 = 250 ?M | Km (Michaelis constant) = 0.436 mM

>  <CAS>
4407-36-7

>  <Description>
Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Cinnamyl alcohol is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older.

>  <EBC_ID>
EBC-26070

>  <IUPAC Name>
(2E)-3-phenylprop-2-en-1-ol

>  <Main Tar all refs>
Arch. Biochem. Biophys., 2011, vol. 506, # 2, p. 157 - 164 | EUR. J. BIOCHEM., 1992, vol. 208, # 3, p. 651 - 657 | Bioorg. Med. Chem. Lett., 2015, vol. 25, # 22, p. 5028 - 5031 | Biochem. J., 2002, vol. 361, # 1, p. 163 - 172

>  <Main tar all>
Alcohol Dehydrogenase 1C pX=4.46 | aryl-alcohol oxidase pX=4.08 | 1-lipoxygenase pX=3.6 | Alcohol Dehydrogenase 6 (Class V) pX=3.36

$$$$
Enasidenib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 3.08 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 C 4.2074 1.54 0 0
M  V30 4 O 1.1274 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 N 1.3337 -0.77 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 N 2.6674 -3.08 0 0
M  V30 9 C 2.6674 -4.62 0 0
M  V30 10 N 4.001 -5.39 0 0
M  V30 11 C 5.3347 -4.62 0 0
M  V30 12 C 5.3347 -3.08 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 N 8.0021 -3.08 0 0
M  V30 15 C 8.0021 -4.62 0 0
M  V30 16 C 6.6684 -5.39 0 0
M  V30 17 C 9.3358 -5.39 0 0
M  V30 18 F 10.6694 -6.16 0 0
M  V30 19 F 10.1058 -4.0563 0 0
M  V30 20 F 8.5658 -6.7237 0 0
M  V30 21 N 1.3337 -5.39 0 0
M  V30 22 C 0 -4.62 0 0
M  V30 23 N 0 -3.08 0 0
M  V30 24 C -1.3337 -5.39 0 0
M  V30 25 C -1.3337 -6.93 0 0
M  V30 26 C -2.6674 -7.7 0 0
M  V30 27 C -4.001 -6.93 0 0
M  V30 28 C -4.001 -5.39 0 0
M  V30 29 N -2.6674 -4.62 0 0
M  V30 30 C -5.3347 -4.62 0 0
M  V30 31 F -6.6684 -3.85 0 0
M  V30 32 F -4.5647 -3.2863 0 0
M  V30 33 F -6.1047 -5.9537 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 17 20
M  V30 21 1 9 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 7 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 24 29
M  V30 32 1 28 30
M  V30 33 1 30 31
M  V30 34 1 30 32
M  V30 35 1 30 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2512157873

>  <MW>
473.14

>  <MW (desalted)>
473.375

>  <ClogP>
3.906

>  <logS>
-5.665

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
108.74

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.009 ?M | IC50  35.9 nM | IC50  100 - 1000 nM | IC50  100 - 1000 nM | IC50  269.1 nM

>  <CAS>
1446502-11-9

>  <Description>
Enasidenib is an isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.

>  <EBC_ID>
EBC-17126

>  <IUPAC Name>
2-methyl-1-({4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl}amino)propan-2-ol

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2020, vol. 11, # 2, p. 101 - 107 | Eur. J. Med. Chem., 2020, vol. 203 | SERVIER MONDE - WO2013/102431, 2013, A1 | SERVIER MONDE - WO2013/102431, 2013, A1 | Eur. J. Med. Chem., 2020, vol. 203

>  <Main tar all>
Isocitrate dehydrogenase pX=8.05 | isocitrate dehydrogenase (NADP(+)) 2, (R140Q) pX=7.44 | isocitrate dehydrogenase (NADP(+)) 2, (R140Q) pX=7.0 | isocitrate dehydrogenase (NADP(+)) 2, (R172K) pX=7.0 | isocitrate dehydrogenase (NADP(+)) 2, (R172K) pX=6.57

$$$$
Eplerenone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.5277 -9.2727 0 0
M  V30 2 O 4.0645 -9.3716 0 0
M  V30 3 C 4.9186 -8.0902 0 0
M  V30 4 O 6.4554 -8.1891 0 0
M  V30 5 C 4.2359 -6.7098 0 0 CFG=2
M  V30 6 C 2.6991 -6.6108 0 0
M  V30 7 C 2.0164 -5.2304 0 0
M  V30 8 C 0.4796 -5.1314 0 0
M  V30 9 C -0.2031 -3.751 0 0
M  V30 10 O -1.74 -3.6521 0 0
M  V30 11 C 0.651 -2.4696 0 0
M  V30 12 C 2.1878 -2.5686 0 0
M  V30 13 C 2.8705 -3.949 0 0 CFG=1
M  V30 14 C 2.8083 -2.4102 0 0
M  V30 15 C 4.4073 -4.0479 0 0 CFG=1
M  V30 16 O 3.7246 -2.6675 0 0
M  V30 17 C 5.2614 -2.7665 0 0 CFG=2
M  V30 18 C 6.7982 -2.8655 0 0
M  V30 19 C 7.4809 -4.2459 0 0 CFG=1
M  V30 20 C 8.05 -2.8148 0 0
M  V30 21 C 6.6268 -5.5273 0 0 CFG=1
M  V30 22 C 7.5816 -6.7356 0 0
M  V30 23 C 9.0258 -6.2009 0 0
M  V30 24 C 8.9636 -4.6622 0 0 CFG=1
M  V30 25 C 8.9014 -3.1234 0 0
M  V30 26 C 10.3456 -2.5888 0 0
M  V30 27 C 11.3004 -3.7971 0 0
M  V30 28 O 12.8391 -3.7349 0 0
M  V30 29 O 10.4463 -5.0785 0 0
M  V30 30 C 5.09 -5.4283 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 5 3 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 7
M  V30 14 1 13 14 CFG=1
M  V30 15 1 15 13
M  V30 16 1 15 16 CFG=3
M  V30 17 1 17 16 CFG=3
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 19 18
M  V30 21 1 19 20 CFG=1
M  V30 22 1 19 21
M  V30 23 1 21 22 CFG=1
M  V30 24 1 22 23
M  V30 25 1 24 23
M  V30 26 1 19 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 1 24 29 CFG=1
M  V30 33 1 21 30
M  V30 34 1 5 30
M  V30 35 1 15 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588064174

>  <MW>
414.204

>  <MW (desalted)>
414.491

>  <ClogP>
0.475

>  <logS>
-3.216

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
82.2

>  <RotBonds>
2

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  7.4 | IC50  122 nM | pKi  6.9 | IC50  144 - 218 nM | inhibition percentage  26 % | inhibition percentage < 50 % | IC50 > 1 ?M | IC50 > 1 ?M | Ki (inhibition constant) > 1100 nM

>  <CAS>
107724-20-9

>  <Description>
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

>  <EBC_ID>
EBC-09057

>  <IUPAC Name>
methyl (1'R,2R,2'S,9'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate

>  <Main Tar all refs>
J. Med. Chem., 2019, vol. 62, # 3, p. 1385 - 1406 | J. Med. Chem., 2010, vol. 53, # 16, p. 5970 - 5978 | ChemMedChem, 2017, vol. 12, # 1, p. 50 - 65 | J. Med. Chem., 2022, vol. 65, # 12, p. 8127 - 8143 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021437, Owner: GD SEARLE LLC, Number: 000, Revision: 27.09.2002 00:00:00, 2002 | Xenobiotica, 2004, vol. 34, # 3, p. 215 - 228 | BAYER AG - US2014/288035, 2014, A1 | BAYER AG - US2014/288035, 2014, A1 | J. Med. Chem., 2007, vol. 50, # 26, p. 6443 - 6445

>  <Main tar all>
Mineralocorticoid receptor pX=7.4 | Mineralocorticoid receptor pX=6.91 | Regulatory protein GAL4 pX=6.9 | Mineralocorticoid receptor (S810L) pX=6.84 | Cytochrome P450 3A4 pX=6.55 | CYP3A pX=6.0 | Galectin-4 pX=6.0 | Progesterone receptor pX=6.0 | Estrogen receptor pX=5.96

$$$$
Rifapentine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 63 68 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.988 7.5525 0 0
M  V30 2 O 8.4673 7.3095 0 0
M  V30 3 C 7.9173 5.8711 0 0 CFG=1
M  V30 4 C 9.2841 5.144 0 0
M  V30 5 C 10.4498 4.0994 0 0
M  V30 6 O 11.4879 2.8866 0 0
M  V30 7 C 11.5491 1.2771 0 0 CFG=1
M  V30 8 C 12.4442 0.024 0 0
M  V30 9 O 10.1126 1.8314 0 0
M  V30 10 C 9.0473 0.7359 0 0
M  V30 11 C 9.8293 -0.6198 0 0
M  V30 12 C 11.3777 -0.2935 0 0
M  V30 13 O 12.5192 -1.3273 0 0
M  V30 14 C 8.9287 -1.9727 0 0
M  V30 15 C 9.5028 -3.4355 0 0
M  V30 16 O 11.0276 -3.6509 0 0
M  V30 17 C 8.5827 -4.6342 0 0
M  V30 18 C 9.2161 -6.038 0 0
M  V30 19 N 8.3171 -7.2883 0 0
M  V30 20 N 8.9504 -8.6921 0 0
M  V30 21 C 10.4827 -8.8455 0 0
M  V30 22 C 11.1161 -10.2492 0 0
M  V30 23 N 10.217 -11.4996 0 0
M  V30 24 C 8.6847 -11.3462 0 0
M  V30 25 C 8.0514 -9.9424 0 0
M  V30 26 C 10.8504 -12.9033 0 0
M  V30 27 C 12.3583 -13.216 0 0
M  V30 28 C 12.5268 -14.7468 0 0
M  V30 29 C 11.1231 -15.3801 0 0
M  V30 30 C 10.087 -14.2408 0 0
M  V30 31 C 7.019 -4.5269 0 0
M  V30 32 C 6.4684 -3.0932 0 0
M  V30 33 O 4.9396 -2.9081 0 0
M  V30 34 C 7.3535 -1.8201 0 0
M  V30 35 C 6.6638 -0.4192 0 0
M  V30 36 O 5.1259 -0.3382 0 0
M  V30 37 C 7.4851 0.8832 0 0
M  V30 38 C 6.8054 2.2651 0 0
M  V30 39 N 5.4903 -5.043 0 0
M  V30 40 C 3.9057 -5.0809 0 0
M  V30 41 O 3.6265 -6.5954 0 0
M  V30 42 C 2.3949 -4.4626 0 0
M  V30 43 C 1.175 -3.3929 0 0
M  V30 44 C 0.3003 -1.9914 0 0
M  V30 45 C -0.124 -0.5023 0 0
M  V30 46 C -0.1467 1.0479 0 0 CFG=2
M  V30 47 C -1.6762 1.2273 0 0
M  V30 48 C 0.2331 2.5468 0 0 CFG=2
M  V30 49 O -1.1975 3.1168 0 0
M  V30 50 C 0.988 3.8963 0 0 CFG=1
M  V30 51 C -0.2464 4.8171 0 0
M  V30 52 C 2.0664 5.0045 0 0 CFG=1
M  V30 53 O 1.1124 6.2133 0 0
M  V30 54 C 3.3946 5.7956 0 0 CFG=1
M  V30 55 C 2.7857 7.2102 0 0
M  V30 56 C 4.8811 6.2162 0 0 CFG=2
M  V30 57 O 4.6582 7.74 0 0
M  V30 58 C 3.2271 8.3088 0 0
M  V30 59 O 2.0189 7.3538 0 0
M  V30 60 C 3.0041 9.8325 0 0
M  V30 61 C 6.4227 6.2391 0 0 CFG=2
M  V30 62 C 6.5968 7.7693 0 0
M  V30 63 C 1.5844 -5.7721 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6 CFG=2
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 11 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 20 25
M  V30 27 1 23 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 26 30
M  V30 33 1 17 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 1 32 34
M  V30 37 1 14 34
M  V30 38 2 34 35
M  V30 39 1 35 36
M  V30 40 1 35 37
M  V30 41 2 10 37
M  V30 42 1 37 38
M  V30 43 1 31 39
M  V30 44 1 39 40
M  V30 45 2 40 41
M  V30 46 1 40 42
M  V30 47 2 42 43
M  V30 48 1 43 44
M  V30 49 2 44 45
M  V30 50 1 46 45
M  V30 51 1 46 47 CFG=3
M  V30 52 1 48 46
M  V30 53 1 48 49 CFG=3
M  V30 54 1 48 50
M  V30 55 1 50 51 CFG=1
M  V30 56 1 50 52
M  V30 57 1 52 53 CFG=1
M  V30 58 1 52 54
M  V30 59 1 54 55 CFG=1
M  V30 60 1 54 56
M  V30 61 1 56 57 CFG=3
M  V30 62 1 57 58
M  V30 63 2 58 59
M  V30 64 1 58 60
M  V30 65 1 56 61
M  V30 66 1 61 3
M  V30 67 1 61 62 CFG=3
M  V30 68 1 42 63
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z4670676681

>  <MW>
876.452

>  <MW (desalted)>
877.031

>  <ClogP>
5.413

>  <logS>
-5.717

>  <HBD>
6

>  <HBA>
14

>  <TPSA>
216.66

>  <RotBonds>
6

>  <Action on targets>
Agonist | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  1.63 ?M | EC50  2.2 ?M | inhibition rate increase Active   | IC50  26.7 ?M | IC50  36.1 ?M | inhibition percentage  52.1 % | inhibition percentage  52.1 %

>  <CAS>
61379-65-5

>  <Description>
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells.

>  <EBC_ID>
EBC-27499

>  <IUPAC Name>
(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-26-[(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate

>  <Main Tar all refs>
Curr. Drug Metab., 2006, vol. 7, # 4, p. 375 - 388 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1408 - 1421 | Eur. J. Pharm. Sci., 2023, vol. 181 | Antimicrob. Agents Chemother., 2016, vol. 60, # 5, p. 3096 - 3105 | Antimicrob. Agents Chemother., 2016, vol. 60, # 5, p. 3096 - 3105 | Chem. Pharm. Bull., 2018, vol. 66, # 8, p. 773 - 778 | Chem. Pharm. Bull., 2018, vol. 66, # 8, p. 773 - 778

>  <Main tar all>
Pregnane X receptor pX=5.79 | Cytochrome P450 3A4 pX=5.66 | ABCG2 pX=5.3 | OATP1B1 pX=4.57 | OATP2B1 pX=4.44 | Programmed cell death 1 ligand 1 pX=4.34 | Programmed cell death protein 1 pX=4.34

$$$$
Tromethamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.08 2.6674 0 0
M  V30 2 C 2.31 1.3337 0 0
M  V30 3 C 0.9763 2.1037 0 0
M  V30 4 O -0.3574 1.3337 0 0
M  V30 5 C 3.6437 0.5637 0 0
M  V30 6 O 4.9774 1.3337 0 0
M  V30 7 C 1.54 0 0 0
M  V30 8 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 2 7
M  V30 7 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104509094

>  <MW>
121.074

>  <MW (desalted)>
121.135

>  <ClogP>
-0.94

>  <logS>
1.09

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
86.71

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 7.65 ?M

>  <CAS>
77-86-1

>  <Description>
Tromethamine is a proton acceptor. It is indicated for the prevention and correction of metabolic acidosis associated with various clinical conditions, such as cardiac bypass surgery.

>  <EBC_ID>
EBC-02022

>  <IUPAC Name>
2-amino-2-(hydroxymethyl)propane-1,3-diol

>  <Main Tar all refs>
J. Biochem., 2012, vol. 151, # 5, p. 533 - 540

>  <Main tar all>
MMP7 pX=5.12

$$$$
D-Penicillamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.77 4.001 0 0
M  V30 2 C 1.54 2.6674 0 0
M  V30 3 C 0.2063 1.8974 0 0
M  V30 4 S 2.8737 3.4374 0 0
M  V30 5 C 2.31 1.3337 0 0 CFG=1
M  V30 6 N 3.85 1.3337 0 0
M  V30 7 C 1.54 0 0 0
M  V30 8 O 2.31 -1.3337 0 0
M  V30 9 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 2
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z234896485

>  <MW>
149.051

>  <MW (desalted)>
149.211

>  <ClogP>
-1.729

>  <logS>
-1.54

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
ID50  3 mg/L | MIC90  64 ?g/ml | IC50 = 50 ?M | inhibition percentage  100 % | ID50  14 mg/L | ID50  14 mg/L | IC50 = 152.5 ?M | inhibition percentage  81.13 % | inhibition percentage  81.13 %

>  <CAS>
52-67-5

>  <Description>
D-Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis.

>  <EBC_ID>
EBC-04281

>  <IUPAC Name>
(2S)-2-amino-3-methyl-3-sulfanylbutanoic acid

>  <Main Tar all refs>
INFLAMM. RES., 1995, vol. 44, # 12, p. 529 - 534 | Int. J. Mol. Sci., 2022, vol. 23, # 14 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 22, p. 6350 - 6352 | J. Mol. Catal. B Enzym., 2013, vol. 94, p. 15 - 22 | INFLAMM. RES., 1995, vol. 44, # 12, p. 529 - 534 | INFLAMM. RES., 1995, vol. 44, # 12, p. 529 - 534 | Chem. Pharm. Bull., 2011, vol. 59, # 2, p. 249 - 253 | PLoS ONE, 2018, vol. 13, # 1 | PLoS ONE, 2018, vol. 13, # 1

>  <Main tar all>
MMP9 pX=4.7 | Homoserine O-acetyltransferase pX=4.32 | Desuccinylase pX=4.3 | D-amino acid aminotransferase pX=4.28 | plasminogen activator, tissue type pX=4.03 | plasminogen activator, urokinase pX=4.03 | Cytochrome P450 2D6 pX=3.82 | Albumin pX=3.63 | Serum albumin pX=3.63

$$$$
Creatine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.6437 3.6437 0 0
M  V30 2 N 3.6437 2.1037 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 C 0.9763 2.1037 0 0
M  V30 5 O -0.3574 1.3337 0 0
M  V30 6 O 0.9763 3.6437 0 0
M  V30 7 C 4.9774 1.3337 0 0
M  V30 8 N 6.311 2.1037 0 0
M  V30 9 N 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 2 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1203577925

>  <MW>
131.069

>  <MW (desalted)>
131.133

>  <ClogP>
-1.511

>  <logS>
0.173

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
90.41

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage = 92 % | inhibition percentage  66 %

>  <CAS>
57-00-1

>  <Description>
Creatine is a essential, non-proteinaceous amino acid derivative found in all animals. It is synthesized in the kidney, liver, and pancreas from L-arginine, glycine and L-methionine. In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate. The reaction is catalysed by creatine kinase, and the result is phosphocreatine. Phosphocreatine binds with adenosine diphosphate to convert it back to ATP. Creatine is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26062

>  <IUPAC Name>
2-(N-methylcarbamimidamido)acetic acid

>  <Main Tar all refs>
J. Med. Chem., 2001, vol. 44, # 8, p. 1231 - 1248 | J. Med. Chem., 2013, vol. 56, # 21, p. 8377 - 8388

>  <Main tar all>
Creatine transporter pX=4.06 | Angiotensin-converting enzyme pX=3.59

$$$$
2-Mercaptobenzothiazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S -0.3196 -1.3028 0 0
M  V30 2 C 1.2204 -1.3028 0 0
M  V30 3 N 2.1256 -0.0569 0 0
M  V30 4 C 3.5902 -0.5328 0 0
M  V30 5 C 4.9239 0.2372 0 0
M  V30 6 C 6.2576 -0.5328 0 0
M  V30 7 C 6.2576 -2.0728 0 0
M  V30 8 C 4.9239 -2.8428 0 0
M  V30 9 C 3.5902 -2.0728 0 0
M  V30 10 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104499140

>  <MW>
166.986

>  <MW (desalted)>
167.251

>  <ClogP>
2.958

>  <logS>
-3.33

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.89

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.4 ?M | IC50 = 3 ?M | IC50  6.74 ?M | IC50 = 7 ?M | IC50 = 8 ?M | IC50 = 50 ?M

>  <CAS>
149-30-4

>  <Description>
2-Mercaptobenzothiazole is an endogenous metabolite. It is an inhibitor of thyroid peroxidase. It also inhibits indoleamine 2,3-dioxygenase.

>  <EBC_ID>
EBC-13269

>  <IUPAC Name>
1,3-benzothiazole-2-thiol

>  <Main Tar all refs>
Xenobiotica, 2020, vol. 50, # 3, p. 318 - 322 | ChemMedChem, 2007, vol. 2, # 4, p. 449 - 478 | New J. Chem., 2011, vol. 35, # 1, p. 213 - 224 | J. Med. Chem., 2010, vol. 53, # 3, p. 1172 - 1189 | MQT HOLDINGS - US2002/44914, 2002, A1 | LUDWIG INSTITUTE FOR CANCER RESEARCH - WO2009/127669, 2009, A2

>  <Main tar all>
thyroid peroxidase pX=5.62 | tyrosinase pX=5.52 | Lactoperoxidase pX=5.17 | indoleamine 2,3-dioxygenase pX=5.15 | Tyrosinase (peptide) pX=5.1 | Indoleamine 2,3-dioxygenase (gene BNA2) pX=4.3

$$$$
Xylose
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 3.2863 3.4374 0 0
M  V30 2 C 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0 CFG=1
M  V30 4 O 5.9537 4.9774 0 0
M  V30 5 C 7.2874 2.6674 0 0 CFG=2
M  V30 6 O 7.2874 1.1274 0 0
M  V30 7 C 8.621 3.4374 0 0 CFG=1
M  V30 8 O 8.621 4.9774 0 0
M  V30 9 C 9.9547 2.6674 0 0
M  V30 10 O 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255438834

>  <MW>
150.053

>  <MW (desalted)>
150.13

>  <ClogP>
-2.73

>  <logS>
0.954

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
97.99

>  <RotBonds>
4

>  <Action on targets>
- | - | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.27 mM | Km (Michaelis constant) = 0.3 mM | MIC  4 mM

>  <CAS>
58-86-6

>  <Description>
Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group.  It is isolated from wood. Xylose is a sugar widely used as a diabetic sweetener in food and beverage. It has also been used as a diagnostic agent to observe malabsorption.

>  <EBC_ID>
EBC-26098

>  <IUPAC Name>
(2R,3S,4R)-2,3,4,5-tetrahydroxypentanal

>  <Main Tar all refs>
J. Mol. Catal. B Enzym., 2013, vol. 94, p. 119 - 128 | Biochem. J., 2004, vol. 379, # 2, p. 375 - 383 | Anal. Biochem., 2021, vol. 635

>  <Main tar all>
Beta-glucosidase?(gene?abg) pX=3.57 | Monosaccharide transporter pX=3.52 | Hemagglutinin pX=2.4

$$$$
Dopamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.8537 4.69 0 0
M  V30 3 C 4.8537 3.15 0 0
M  V30 4 C 6.1874 2.38 0 0
M  V30 5 C 6.1874 0.84 0 0
M  V30 6 C 7.521 0.07 0 0
M  V30 7 C 7.521 -1.47 0 0
M  V30 8 C 6.1874 -2.24 0 0
M  V30 9 O 6.1874 -3.78 0 0
M  V30 10 C 4.8537 -1.47 0 0
M  V30 11 O 3.52 -2.24 0 0
M  V30 12 C 4.8537 0.07 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 8 10
M  V30 9 1 10 11
M  V30 10 1 10 12
M  V30 11 2 5 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474032

>  <MW>
189.056

>  <MW (desalted)>
153.178

>  <ClogP>
0.169

>  <logS>
-0.89

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
66.48

>  <RotBonds>
2

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.11 nM | stimulation rate  104 % | inhibition percentage  95 % | pIC50  9.2  | Ki (inhibition constant) = 1.2 nM | Ki (inhibition constant)  1.8 nM | Ki (inhibition constant) = 1.89 nM

>  <CAS>
62-31-7

>  <Description>
Dopamine is one of the catecholamine neurotransmitters in the brain. It is used to treat hemodynamic imbalances, poor perfusion of vital organs, low cardiac output, and hypotension. In the brain, dopamine acts as an agonist to the five dopamine receptor subtypes (D1, D2, D3, D4, D5).

>  <EBC_ID>
EBC-11052

>  <IUPAC Name>
4-(2-aminoethyl)benzene-1,2-diol hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 9, p. 4579 - 4602 | J. MED. CHEM., 1992, vol. 35, # 23, p. 4408 - 4414 | J. MED. CHEM., 1992, vol. 35, # 23, p. 4408 - 4414 | J. Med. Chem., 2014, vol. 57, # 2, p. 391 - 410 | Bioorg. Med. Chem., 2004, vol. 12, # 1, p. 113 - 117 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1979, vol. 308, # 3, p. 231 - 237 | Bioorg. Med. Chem. Lett., 1999, vol. 9, # 15, p. 2167 - 2172

>  <Main tar all>
D3 receptor pX=9.96 | D1 receptor pX=9.28 | D2 receptor pX=9.28 | D2L receptor pX=9.2 | D4.4 receptor pX=8.92 | Dopamine receptor pX=8.74 | D2A receptor pX=8.72

$$$$
Phenylephrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 N 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0 CFG=2
M  V30 5 O 2.6674 4.62 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 O -1.3337 -0.77 0 0
M  V30 12 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 6 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198723489

>  <MW>
167.095

>  <MW (desalted)>
167.205

>  <ClogP>
-0.088

>  <logS>
-0.414

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
52.49

>  <RotBonds>
3

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 8.9 pM | IC50 = 0.02 nM

>  <CAS>
59-42-7

>  <Description>
Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction and mydriasis depending on the route and location of administration. It is used in the management of hypotension, generally in the surgical setting associated with the use of anesthetics.

>  <EBC_ID>
EBC-26121

>  <IUPAC Name>
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol

>  <Main Tar all refs>
JOHNSON & JOHNSON INC - US2004/73043, 2004, A1 | JOHNSON & JOHNSON INC - US6664424, 2003, B2

>  <Main tar all>
?2-adrenoceptor pX=11.1 | ?2-adrenoceptor pX=10.7

$$$$
Memantine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7728 -2.4712 0 0
M  V30 3 C 5.7727 -0.9312 0 0
M  V30 4 C 4.4 -1.6288 0 0
M  V30 5 C 5.2389 -0.1535 0 0
M  V30 6 C 6.6118 -0.8511 0 0
M  V30 7 C 7.9849 -0.1535 0 0
M  V30 8 C 9.4737 -0.5473 0 0
M  V30 9 C 7.1459 -1.6288 0 0
M  V30 10 C 5.7727 0.4639 0 0
M  V30 11 C 6.6118 1.9392 0 0
M  V30 12 N 6.6118 3.4792 0 0
M  V30 13 C 5.2389 1.2416 0 0
M  V30 14 C 7.9849 1.2416 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 3 9
M  V30 9 1 11 14
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 5 13
M  V30 14 1 3 10
M  V30 15 1 7 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551429722

>  <MW>
215.144

>  <MW (desalted)>
179.302

>  <ClogP>
3.033

>  <logS>
-3.15

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
26.02

>  <RotBonds>
0

>  <Action on targets>
Antagonist | Antagonist | Antagonist | Antagonist | Antagonist | Substrate | Substrate | Blocker | Blocker | Antagonist | Antagonist | Inhibitor | Antagonist | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50  0.5 ?M | IC50  1 ?M | increase rate Active   | IC50  1 ?M | IC50  1 ?M | percentage increase Active   | uptake percentage Active   | IC50  1.2 ?M | IC50  1.2 ?M | IC50  2.3 ?M | IC50  6 ?M | IC50 = 9.52 ?M | apoptosis rate decrease Active   | apoptosis rate decrease Active   | apoptosis rate decrease Active

>  <CAS>
41100-52-1

>  <Description>
Memantine is an NMDA receptor antagonist that blocks NMDA-induced currents. It is used in the management of alzheimer's disease.

>  <EBC_ID>
EBC-06533

>  <IUPAC Name>
3,5-dimethyladamantan-1-amine hydrochloride

>  <Main Tar all refs>
SUPERNUS PHARMACEUTICALS INC - WO2007/65036, 2007, A2 | NIHON UNIVERSITY - EP2096106, 2009, A1 | Chem.-Biol. Interact., 2020, vol. 325 | NIHON UNIVERSITY - EP2096106, 2009, A1 | NIHON UNIVERSITY - EP2096106, 2009, A1 | Mol. Pharm., 2017, vol. 14, # 9, p. 2991 - 2998 | Mol. Pharm., 2017, vol. 14, # 9, p. 2991 - 2998 | Eur. J. Pharmacol., 2007, vol. 566, # 1-3, p. 11 - 19 | Eur. J. Pharmacol., 2007, vol. 566, # 1-3, p. 11 - 19 | Eur. J. Med. Chem., 2019, vol. 180, p. 111 - 120 | Br. J. Pharmacol., 2019, vol. 176, # 17, p. 3318 - 3335 | Curr. Med. Chem., 2011, vol. 18, # 28, p. 4299 - 4320 | J. Recept. Signal Transduction, 2021, vol. 41, # 3, p. 273 - 283 | J. Recept. Signal Transduction, 2021, vol. 41, # 3, p. 273 - 283 | J. Recept. Signal Transduction, 2021, vol. 41, # 3, p. 273 - 283

>  <Main tar all>
NMDA receptor pX=6.3 | GluN2B pX=6.0 | GluN2C pX=6.0 | Glutamate receptor ionotropic, NMDA 1 pX=6.0 | Glutamate receptor ionotropic, NMDA 2A pX=6.0 | Multidrug and toxin extrusion pX=6.0 | Organic cation/carnitine transporter 2 pX=6.0 | nicotinic acetylcholine receptor ?10 subunit pX=5.92 | nicotinic acetylcholine receptor ?9 subunit pX=5.92 | N-methyl-D-aspartate (GluN1-1a/GluN2A) receptor pX=5.64 | Glutamate pX=5.22 | GluN2D pX=5.02 | TRPA1 pX=5.0 | TRPM2 pX=5.0 | TRPV1 pX=5.0

$$$$
Guanfacine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 6.1874 5.1847 0 0
M  V30 3 C 6.1874 3.6447 0 0
M  V30 4 N 4.8537 2.8747 0 0
M  V30 5 C 4.8537 1.3347 0 0
M  V30 6 O 3.52 0.5647 0 0
M  V30 7 C 6.1874 0.5647 0 0
M  V30 8 C 6.1874 -0.9753 0 0
M  V30 9 C 7.521 -1.7453 0 0
M  V30 10 Cl 8.8547 -0.9753 0 0
M  V30 11 C 7.521 -3.2853 0 0
M  V30 12 C 6.1874 -4.0553 0 0
M  V30 13 C 4.8537 -3.2853 0 0
M  V30 14 C 4.8537 -1.7453 0 0
M  V30 15 Cl 3.52 -0.9753 0 0
M  V30 16 N 7.521 2.8747 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 9 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 8 14
M  V30 14 1 14 15
M  V30 15 1 3 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2696918787

>  <MW>
280.989

>  <MW (desalted)>
246.093

>  <ClogP>
1.254

>  <logS>
-3.433

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
81.47

>  <RotBonds>
2

>  <CAS>
29110-48-3

>  <Description>
Guanfacine is an alpha-2A adrenergic receptor agonist. It is indicated alone or as an adjunct with stimulants to treat ADHD.

>  <EBC_ID>
EBC-14320

>  <IUPAC Name>
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride

$$$$
Methsuximide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8854 -5.5892 0 0
M  V30 2 N 2.9802 -4.3433 0 0
M  V30 3 C 1.4402 -4.3433 0 0
M  V30 4 O 0.5351 -5.5892 0 0
M  V30 5 C 0.9644 -2.8787 0 0
M  V30 6 C 2.2102 -1.9735 0 0
M  V30 7 C 1.1798 -0.8291 0 0
M  V30 8 C 3.4561 -2.8787 0 0
M  V30 9 O 4.9208 -2.4028 0 0
M  V30 10 C 3.2407 -0.8291 0 0
M  V30 11 C 2.7648 0.6356 0 0
M  V30 12 C 3.7953 1.78 0 0
M  V30 13 C 5.3016 1.4598 0 0
M  V30 14 C 5.7775 -0.0048 0 0
M  V30 15 C 4.7471 -1.1493 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 2 8
M  V30 9 2 8 9
M  V30 10 1 6 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z649373426

>  <MW>
203.095

>  <MW (desalted)>
203.237

>  <ClogP>
1.461

>  <logS>
-1.79

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
37.38

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  68 % | Ki (inhibition constant)  269 ?M

>  <CAS>
77-41-8

>  <Description>
Methsuximide is a succinimide anticonvulsant that increases the seizure threshold. It is primarily used for childhood absence seizures. Functions by suppressing paroxysmal spike-and-wave patterns associated with lapses of consciousness in absence seizures.

>  <EBC_ID>
EBC-26193

>  <IUPAC Name>
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

>  <Main Tar all refs>
BR. J. CLIN. PHARMACOL., 1995, vol. 39, # 4, p. 441 - 444 | J. PHARMACOL. EXP. THER., 1987, vol. 240, # 1, p. 216 - 222

>  <Main tar all>
Cytochrome P450 2C19 pX=4.63 | CYP1A1 pX=3.57

$$$$
Ethoxzolamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.2586 4.3828 0 0
M  V30 2 C 8.925 3.6128 0 0
M  V30 3 O 7.5913 4.3828 0 0
M  V30 4 C 6.2576 3.6128 0 0
M  V30 5 C 6.2576 2.0728 0 0
M  V30 6 C 4.9239 1.3028 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 S 2.1256 4.0887 0 0
M  V30 11 C 3.5902 3.6128 0 0
M  V30 12 C 4.9239 4.3828 0 0
M  V30 13 S -0.3196 2.8428 0 0
M  V30 14 O -1.8596 2.8428 0 0
M  V30 15 O -0.3196 4.3828 0 0
M  V30 16 N -0.3196 1.3028 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 7 11
M  V30 12 1 11 12
M  V30 13 2 4 12
M  V30 14 1 9 13
M  V30 15 2 13 14
M  V30 16 2 13 15
M  V30 17 1 13 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z995241886

>  <MW>
258.013

>  <MW (desalted)>
258.317

>  <ClogP>
2.047

>  <logS>
-2.956

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
82.28

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.01 nM | Kd (dissociation constant) = 0.15 nM | IC50 = 0.25 nM

>  <CAS>
452-35-7

>  <Description>
Ethoxzolamide is a sulfonamide. It inhibits carbonic anhydrase activity. It was used in the treatment of glaucoma and duodenal ulcers, and as a diuretic, but is now withdrawn.

>  <EBC_ID>
EBC-03608

>  <IUPAC Name>
6-ethoxy-1,3-benzothiazole-2-sulfonamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 1997, vol. 32, # 5, p. 445 - 452 | Angew. Chem. Int. Ed. Engl., 2005, vol. 44, p. 116 - 120 | Eur. J. Med. Chem., 2013, vol. 62, p. 597 - 604

>  <Main tar all>
carbonic anhydrase 1 pX=11.0 | carbonic anhydrase 2 pX=9.82 | carbonic anhydrase 9 pX=9.6

$$$$
Chlorothiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -3.85 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -1.8974 -4.4137 0 0
M  V30 4 O -3.4374 -1.7463 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 N 4.001 -2.31 0 0
M  V30 12 S 2.6674 -3.08 0 0
M  V30 13 O 3.3903 -4.4397 0 0
M  V30 14 O 1.9444 -4.4397 0 0
M  V30 15 C 0 -0 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 17 Cl -2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 2 8 15
M  V30 16 1 15 16
M  V30 17 2 5 16
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480416

>  <MW>
294.949

>  <MW (desalted)>
295.723

>  <ClogP>
-0.294

>  <logS>
-2.66

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
118.69

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.06 nM | IC50 = 0.00024 ?M

>  <CAS>
58-94-6

>  <Description>
Chlorothiazide is a first-in-class thiazide diuretic initially discovered from its ability to inhibit carbonic anhydrase. Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

>  <EBC_ID>
EBC-08326

>  <IUPAC Name>
6-chloro-1,1-dioxo-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 1996, vol. 31, # 11, p. 843 - 846 | Br. J. Pharmacol., 2008, vol. 155, # 7, p. 1066 - 1075

>  <Main tar all>
carbonic anhydrase 2 pX=10.2 | ABCC4 pX=9.62

$$$$
Tafamidis
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 8.925 3.6128 0 0
M  V30 2 C 7.5913 4.3828 0 0
M  V30 3 O 7.5913 5.9228 0 0
M  V30 4 C 6.2576 3.6128 0 0
M  V30 5 C 6.2576 2.0728 0 0
M  V30 6 C 4.9239 1.3028 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 O 2.1256 4.0887 0 0
M  V30 11 C 3.5902 3.6128 0 0
M  V30 12 C 4.9239 4.3828 0 0
M  V30 13 C -0.3196 2.8428 0 0
M  V30 14 C -1.0896 1.5091 0 0
M  V30 15 C -2.6296 1.5091 0 0
M  V30 16 Cl -3.3996 0.1755 0 0
M  V30 17 C -3.3996 2.8428 0 0
M  V30 18 C -2.6296 4.1765 0 0
M  V30 19 Cl -3.3996 5.5102 0 0
M  V30 20 C -1.0896 4.1765 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 7 11
M  V30 12 1 11 12
M  V30 13 2 4 12
M  V30 14 1 9 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 1 18 20
M  V30 22 2 13 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1443584665

>  <MW>
306.98

>  <MW (desalted)>
308.116

>  <ClogP>
4.998

>  <logS>
-5.359

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.33

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
Kd (dissociation constant) = 2 nM

>  <CAS>
594839-88-0

>  <Description>
Tafamidis stabilizes transthyretin tetramers, reducing the amount of monomers available for amyloidogenesis. Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.

>  <EBC_ID>
EBC-06821

>  <IUPAC Name>
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 24, p. 10823 - 10843

>  <Main tar all>
transthyretin pX=8.7

$$$$
Norfloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -5.39 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O 0 1.54 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 O 2.6674 1.54 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 F 8.0021 -0 0 0
M  V30 15 C 6.6684 -2.31 0 0
M  V30 16 C 5.3347 -3.08 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 18 N 8.0021 -3.08 0 0
M  V30 19 C 9.3358 -2.31 0 0
M  V30 20 C 10.6694 -3.08 0 0
M  V30 21 N 10.6694 -4.62 0 0
M  V30 22 C 9.3358 -5.39 0 0
M  V30 23 C 8.0021 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 3 17
M  V30 18 2 11 17
M  V30 19 1 15 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56926638

>  <MW>
319.133

>  <MW (desalted)>
319.331

>  <ClogP>
-0.78

>  <logS>
-2.2

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
72.88

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  9E-05 ?M | MIC = 0.001 ?g/mL

>  <CAS>
70458-96-7

>  <Description>
Norfloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase. It is used for the treatment of urinary tract infection.

>  <EBC_ID>
EBC-04415

>  <IUPAC Name>
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2010, vol. 20, # 17, p. 5349 - 5352 | Antimicrob. Agents Chemother., 2006, vol. 50, # 11, p. 3717 - 3723

>  <Main tar all>
DNA?gyrase subunit B pX=10.0 | Norm, Na+-Driven Multidrug Efflux Pump pX=8.5

$$$$
Cetylpyridinium chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 4.4 -0.07 0 0
M  V30 3 C 5.7337 0.7 0 0
M  V30 4 C 7.0674 -0.07 0 0
M  V30 5 C 8.401 0.7 0 0
M  V30 6 C 9.7347 -0.07 0 0
M  V30 7 C 11.0684 0.7 0 0
M  V30 8 C 12.4021 -0.07 0 0
M  V30 9 C 13.7358 0.7 0 0
M  V30 10 C 15.0694 -0.07 0 0
M  V30 11 C 16.4031 0.7 0 0
M  V30 12 C 17.7368 -0.07 0 0
M  V30 13 C 19.0705 0.7 0 0
M  V30 14 C 20.4041 -0.07 0 0
M  V30 15 C 21.7378 0.7 0 0
M  V30 16 C 23.0715 -0.07 0 0
M  V30 17 C 24.4052 0.7 0 0
M  V30 18 N 25.7389 -0.07 0 0 CHG=1
M  V30 19 C 27.0725 0.7 0 0
M  V30 20 C 28.4062 -0.07 0 0
M  V30 21 C 28.4062 -1.61 0 0
M  V30 22 C 27.0725 -2.38 0 0
M  V30 23 C 25.7389 -1.61 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 2 19 20
M  V30 19 1 20 21
M  V30 20 2 21 22
M  V30 21 1 22 23
M  V30 22 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z89264780

>  <MW>
339.269

>  <MW (desalted)>
304.533

>  <ClogP>
3.736

>  <logS>
-7.87

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
3.88

>  <RotBonds>
15

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.1 ?M | IC50  0.25 ?M | Ki (inhibition constant)  0.55 ?M | IC50  0.55 ?M | IC50  0.73 ?M | inhibition rate Active   | IC50  1.3 ?M | IC50  2.5 ?M

>  <CAS>
123-03-5

>  <Description>
Cetylpyridinium chloride is considered a cationic disinfectant with properties and uses similar to other such cationic surfactants. Cetylpyridinium chloride is a quaternary ammonium with broad-spectrum antiseptic properties. It  is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays.

>  <EBC_ID>
EBC-26657

>  <IUPAC Name>
1-hexadecylpyridin-1-ium chloride

>  <Main Tar all refs>
RECKITT BENCKISER GROUP PLC - WO2009/63223, 2009, A1 | Virus Res., 2019, vol. 263, p. 102 - 111 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Mitochondrion, 2020, vol. 50, p. 19 - 24 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413

>  <Main tar all>
Nav1.2 pX=7.0 | Nucleoprotein pX=6.6 | D3 receptor pX=6.26 | DNA-directed RNA polymerase V subunit 1 pX=6.26 | Vesicular monoamine transporter 2 pX=6.14 | AMP kinase pX=6.0 | Kv11.1 pX=5.89 | COX-2  pX=5.6

$$$$
Valacyclovir Hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.4261 0 0
M  V30 3 C 5.7337 0.3439 0 0
M  V30 4 C 5.7337 1.8839 0 0
M  V30 5 C 7.0674 -0.4261 0 0 CFG=2
M  V30 6 N 7.0674 -1.9661 0 0
M  V30 7 C 8.401 0.3439 0 0
M  V30 8 O 8.401 1.8839 0 0
M  V30 9 O 9.7347 -0.4261 0 0
M  V30 10 C 11.0684 0.3439 0 0
M  V30 11 C 12.4021 -0.4261 0 0
M  V30 12 O 13.7358 0.3439 0 0
M  V30 13 C 15.0694 -0.4261 0 0
M  V30 14 N 16.4031 0.3439 0 0
M  V30 15 C 16.5641 1.8755 0 0
M  V30 16 N 18.0704 2.1956 0 0
M  V30 17 C 18.8404 0.862 0 0
M  V30 18 C 20.3468 0.5418 0 0
M  V30 19 O 21.3772 1.6862 0 0
M  V30 20 N 20.8227 -0.9229 0 0
M  V30 21 C 19.7922 -2.0673 0 0
M  V30 22 N 20.2681 -3.5319 0 0
M  V30 23 N 18.2859 -1.7471 0 0
M  V30 24 C 17.81 -0.2825 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 5 3
M  V30 4 1 5 6 CFG=1
M  V30 5 1 5 7
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 18 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 2 21 23
M  V30 22 1 23 24
M  V30 23 1 14 24
M  V30 24 2 17 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546624231

>  <MW>
360.131

>  <MW (desalted)>
324.336

>  <ClogP>
-1.219

>  <logS>
-3.516

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
146.85

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.09 ?M

>  <CAS>
124832-27-5

>  <Description>
Valaciclovir is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. Valacyclovir is the L-valine ester of aciclovir. It is classified as a nucleoside analog DNA polymerase enzyme inhibitor.

>  <EBC_ID>
EBC-11248

>  <IUPAC Name>
2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 44, p. 27381 - 27387

>  <Main tar all>
CoV 3C-like (main) protease pX=5.96

$$$$
Citalopram hydrobromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0
M  V30 2 C 4.4 -0.4785 0 0
M  V30 3 N 5.7337 0.2915 0 0
M  V30 4 C 5.7337 1.8315 0 0
M  V30 5 C 7.0674 -0.4785 0 0
M  V30 6 C 8.401 0.2915 0 0
M  V30 7 C 9.7347 -0.4785 0 0
M  V30 8 C 11.0684 0.2915 0 0
M  V30 9 O 12.2128 1.322 0 0
M  V30 10 C 13.5465 0.552 0 0
M  V30 11 C 13.2263 -0.9544 0 0
M  V30 12 C 14.1315 -2.2003 0 0
M  V30 13 C 13.5051 -3.6071 0 0
M  V30 14 C 14.4103 -4.853 0 0
M  V30 15 N 15.3155 -6.0989 0 0
M  V30 16 C 11.9736 -3.7681 0 0
M  V30 17 C 11.0684 -2.5222 0 0
M  V30 18 C 11.6948 -1.1153 0 0
M  V30 19 C 10.1632 1.5374 0 0
M  V30 20 C 8.6316 1.3764 0 0
M  V30 21 C 7.7265 2.6223 0 0
M  V30 22 C 8.3528 4.0292 0 0
M  V30 23 F 7.4476 5.2751 0 0
M  V30 24 C 9.8844 4.1901 0 0
M  V30 25 C 10.7896 2.9443 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 3 14 15
M  V30 14 1 13 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 2 11 18
M  V30 18 1 8 18
M  V30 19 1 8 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 1 24 25
M  V30 26 2 19 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1550648760

>  <MW>
404.09

>  <MW (desalted)>
324.392

>  <ClogP>
3.132

>  <logS>
-4.64

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
36.26

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.4 nM | concentration (parameter)  1.4 nM

>  <CAS>
59729-32-7

>  <Description>
Citalopram is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression.

>  <EBC_ID>
EBC-12781

>  <IUPAC Name>
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide

>  <Main Tar all refs>
TEL AVIV UNIVERSITY - WO2007/148341, 2007, A2 | Psychopharmacology, 1984, vol. 83, # 1, p. 20 - 27

>  <Main tar all>
SERT pX=9.4 | 5-HT receptor pX=8.85

$$$$
Halofantrine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.4082 7.461 0 0
M  V30 3 C 6.9204 7.17 0 0
M  V30 4 C 7.4245 5.7148 0 0
M  V30 5 C 8.9367 5.4238 0 0
M  V30 6 N 9.4408 3.9686 0 0
M  V30 7 C 8.4327 2.8045 0 0
M  V30 8 C 6.9204 3.0955 0 0
M  V30 9 C 5.9122 1.9314 0 0
M  V30 10 C 4.4 2.2224 0 0
M  V30 11 C 10.9531 3.6776 0 0
M  V30 12 C 11.4572 2.2224 0 0
M  V30 13 C 12.9694 1.9314 0 0
M  V30 14 O 13.9776 3.0955 0 0
M  V30 15 C 13.4735 0.4762 0 0
M  V30 16 C 14.9857 0.1852 0 0
M  V30 17 C 15.4898 -1.27 0 0
M  V30 18 C 17.0021 -1.561 0 0
M  V30 19 Cl 18.0102 -0.3969 0 0
M  V30 20 C 17.5062 -3.0162 0 0
M  V30 21 C 16.498 -4.1803 0 0
M  V30 22 Cl 17.0021 -5.6355 0 0
M  V30 23 C 14.9857 -3.8893 0 0
M  V30 24 C 14.4817 -2.4341 0 0
M  V30 25 C 12.9694 -2.1431 0 0
M  V30 26 C 11.9612 -3.3072 0 0
M  V30 27 C 10.449 -3.0162 0 0
M  V30 28 C 9.9449 -1.561 0 0
M  V30 29 C 10.9531 -0.3969 0 0
M  V30 30 C 12.4653 -0.6879 0 0
M  V30 31 C 9.4408 -4.1803 0 0
M  V30 32 F 8.4327 -5.3444 0 0
M  V30 33 F 8.2767 -3.1721 0 0
M  V30 34 F 10.605 -5.1885 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 6 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 2 18 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 2 21 23
M  V30 22 1 23 24
M  V30 23 1 17 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 29 30
M  V30 30 2 15 30
M  V30 31 1 25 30
M  V30 32 1 27 31
M  V30 33 1 31 32
M  V30 34 1 31 33
M  V30 35 1 31 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2285376546

>  <MW>
535.142

>  <MW (desalted)>
500.424

>  <ClogP>
9.31

>  <logS>
-10.09

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
23.47

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 6700 nM | IC50  19 ?M | IC50  19 ?M | IC50  19 ?M | IC50 = 22 ?M | IC50 = 22 ?M | IC50 = 184.5 ?M

>  <CAS>
36167-63-2

>  <Description>
Halofantrine is a synthetic antimalarial which acts as a blood schizonticide. It is effective against multi drug resistant P. falciparum malaria.

>  <EBC_ID>
EBC-13378

>  <IUPAC Name>
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2003, vol. 13, # 16, p. 2773 - 2775 | Drug Metab. Dispos., 1998, vol. 26, # 4, p. 313 - 317 | Drug Metab. Dispos., 1998, vol. 26, # 4, p. 313 - 317 | Drug Metab. Dispos., 1998, vol. 26, # 4, p. 313 - 317 | Curr. Med. Chem., 2001, vol. 8, # 2, p. 171 - 189 | Curr. Med. Chem., 2001, vol. 8, # 2, p. 171 - 189 | Bioorg. Med. Chem., 2004, vol. 12, # 12, p. 3313 - 3321

>  <Main tar all>
Kv11.1 pX=5.17 | Cytochrome P450 2B6 pX=4.72 | Cytochrome P450 3A4 pX=4.72 | Cytochrome P450 3A5 pX=4.72 | Haemoglobin pX=4.66 | Hemoglobin subunit alpha-1 pX=4.66 | Hematin pX=3.73

$$$$
Sitagliptin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.001 -5.39 0 0
M  V30 2 C 4.001 -3.85 0 0 CFG=1
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -3.85 0 0
M  V30 5 O 1.3337 -5.39 0 0
M  V30 6 N 0 -3.08 0 0
M  V30 7 C -1.3337 -3.85 0 0
M  V30 8 C -2.6674 -3.08 0 0
M  V30 9 N -2.6674 -1.54 0 0
M  V30 10 C -3.8118 -0.5095 0 0
M  V30 11 N -3.1854 0.8973 0 0
M  V30 12 N -1.6539 0.7363 0 0
M  V30 13 C -1.3337 -0.77 0 0
M  V30 14 C 0 -1.54 0 0
M  V30 15 C -5.3181 -0.8297 0 0
M  V30 16 F -6.8245 -1.1499 0 0
M  V30 17 F -4.998 -2.3361 0 0
M  V30 18 F -5.6383 0.6766 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 C 6.6684 -3.85 0 0
M  V30 21 C 8.0021 -3.08 0 0
M  V30 22 C 9.3358 -3.85 0 0
M  V30 23 F 10.6694 -3.08 0 0
M  V30 24 C 9.3358 -5.39 0 0
M  V30 25 F 10.6694 -6.16 0 0
M  V30 26 C 8.0021 -6.16 0 0
M  V30 27 C 6.6684 -5.39 0 0
M  V30 28 F 5.3347 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 10 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 15 18
M  V30 20 1 2 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 24 26
M  V30 28 1 26 27
M  V30 29 2 20 27
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553713

>  <MW>
407.314

>  <MW (desalted)>
407.314

>  <ClogP>
0.691

>  <logS>
-3.51

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
77.04

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  12.57 pmol/l

>  <CAS>
486460-32-6

>  <Description>
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus.

>  <EBC_ID>
EBC-13573

>  <IUPAC Name>
(3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

>  <Main Tar all refs>
Int. J. Mol. Sci., 2019, vol. 20, # 2

>  <Main tar all>
dipeptidyl peptidase 4 pX=10.9

$$$$
Paliperidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.9206 -16.5827 0 0
M  V30 2 C 12.4143 -16.9029 0 0
M  V30 3 N 11.9384 -18.3675 0 0
M  V30 4 C 10.4321 -18.6877 0 0
M  V30 5 C 9.9562 -20.1523 0 0
M  V30 6 O 10.9866 -21.2968 0 0
M  V30 7 C 8.4498 -20.4725 0 0
M  V30 8 C 7.4194 -19.3281 0 0
M  V30 9 C 7.8952 -17.8635 0 0
M  V30 10 N 9.4016 -17.5433 0 0
M  V30 11 C 9.8775 -16.0786 0 0
M  V30 12 O 8.847 -14.9342 0 0
M  V30 13 C 11.3838 -15.7585 0 0
M  V30 14 C 11.8597 -14.2938 0 0
M  V30 15 C 10.8292 -13.1494 0 0
M  V30 16 N 11.3051 -11.6848 0 0
M  V30 17 C 10.2747 -10.5403 0 0
M  V30 18 C 10.7506 -9.0757 0 0
M  V30 19 C 12.2569 -8.7555 0 0
M  V30 20 C 13.2874 -9.9 0 0
M  V30 21 C 12.8115 -11.3646 0 0
M  V30 22 C 12.7328 -7.2909 0 0
M  V30 23 N 11.8276 -6.045 0 0
M  V30 24 O 12.7328 -4.7991 0 0
M  V30 25 C 14.1974 -5.275 0 0
M  V30 26 C 15.5311 -4.505 0 0
M  V30 27 C 16.8648 -5.275 0 0
M  V30 28 F 18.1985 -4.505 0 0
M  V30 29 C 16.8648 -6.815 0 0
M  V30 30 C 15.5311 -7.585 0 0
M  V30 31 C 14.1974 -6.815 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 2 2 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 1 22 31
M  V30 35 2 25 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553597

>  <MW>
426.484

>  <MW (desalted)>
426.484

>  <ClogP>
1.074

>  <logS>
-2.14

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
82.17

>  <RotBonds>
4

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.1 nM | Ki (inhibition constant)  0.1 nM | Ki (inhibition constant) = 0.16 nM | Ki (inhibition constant)  0.25 nM | Ki (inhibition constant)  0.25 nM | Ki (inhibition constant) = 0.25 nM | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  1.3 nM

>  <CAS>
144598-75-4

>  <Description>
Paliperidone is an atypical antipsychotic used in the treatment of schizophrenia and other schizoaffective or delusional disorders.

>  <EBC_ID>
EBC-13192

>  <IUPAC Name>
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | Annu. Rep. Med. Chem., 2008, vol. 43, p. 455 - 497 | Psychopharmacology, 1996, vol. 124, # 1-2, p. 57 - 73 | Psychopharmacology, 1996, vol. 124, # 1-2, p. 57 - 73 | Annu. Rep. Med. Chem., 2008, vol. 43, p. 455 - 497 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | Psychopharmacology, 1996, vol. 124, # 1-2, p. 57 - 73

>  <Main tar all>
D3 receptor pX=10.0 | D3 receptor pX=10.0 | D2 receptor pX=9.8 | 5-HT2A receptor pX=9.6 | 5-HT2A receptor pX=9.6 | 5-HT2A receptor pX=9.6 | D2 receptor (isoform 2) pX=9.4 | D2S receptor pX=9.4 | 5-HT7 receptor pX=8.89

$$$$
Diltiazem HCl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 14.8934 -5.869 0 0
M  V30 3 O 13.3706 -6.0986 0 0
M  V30 4 C 12.4104 -4.8945 0 0
M  V30 5 C 10.8876 -5.1241 0 0
M  V30 6 C 9.9275 -3.92 0 0
M  V30 7 C 10.4901 -2.4865 0 0
M  V30 8 C 12.0129 -2.257 0 0
M  V30 9 C 12.9731 -3.461 0 0
M  V30 10 C 9.5299 -1.2825 0 0 CFG=2
M  V30 11 S 8.0285 -1.6252 0 0
M  V30 12 C 6.8245 -0.665 0 0
M  V30 13 C 5.4908 -1.435 0 0
M  V30 14 C 4.1571 -0.665 0 0
M  V30 15 C 4.1571 0.875 0 0
M  V30 16 C 5.4908 1.645 0 0
M  V30 17 C 6.8245 0.875 0 0
M  V30 18 N 8.0285 1.8352 0 0
M  V30 19 C 7.6858 3.3366 0 0
M  V30 20 C 6.2143 3.7905 0 0
M  V30 21 N 5.8716 5.2919 0 0
M  V30 22 C 4.4 5.7458 0 0
M  V30 23 C 7.0005 6.3394 0 0
M  V30 24 C 9.5299 1.4925 0 0
M  V30 25 O 10.4901 2.6965 0 0
M  V30 26 C 10.1981 0.105 0 0 CFG=2
M  V30 27 O 11.7381 0.105 0 0
M  V30 28 C 12.5081 1.4387 0 0
M  V30 29 O 11.7381 2.7724 0 0
M  V30 30 C 14.0481 1.4387 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 4 9
M  V30 9 1 10 7 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 18 24
M  V30 25 2 24 25
M  V30 26 1 26 24
M  V30 27 1 10 26
M  V30 28 1 26 27 CFG=3
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551967090

>  <MW>
450.138

>  <MW (desalted)>
414.518

>  <ClogP>
3.647

>  <logS>
-5.17

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
59.08

>  <RotBonds>
7

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.00011 nM

>  <CAS>
33286-22-5

>  <Description>
Diltiazem is a calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias.

>  <EBC_ID>
EBC-07790

>  <IUPAC Name>
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate hydrochloride

>  <Main Tar all refs>
Eur. J. Med. Chem., 1992, vol. 27, p. 571 - 579

>  <Main tar all>
Cav1.1 pX=13.0

$$$$
Atorvastatin hemicalcium salt trihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 86 88 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 O 8.8 0 0 0
M  V30 4 Ca 0 -7.9533 0 0
M  V30 5 C 12.4062 -12.3155 0 0
M  V30 6 C 11.2617 -11.285 0 0
M  V30 7 C 9.7971 -11.7609 0 0
M  V30 8 C 11.5819 -9.7787 0 0
M  V30 9 C 10.5514 -8.6343 0 0
M  V30 10 C 9.0199 -8.7952 0 0
M  V30 11 O 8.3935 -10.2021 0 0
M  V30 12 N 8.1147 -7.5493 0 0
M  V30 13 C 6.5831 -7.7103 0 0
M  V30 14 C 5.9568 -9.1172 0 0
M  V30 15 C 4.4252 -9.2782 0 0
M  V30 16 C 3.52 -8.0323 0 0
M  V30 17 C 4.1464 -6.6254 0 0
M  V30 18 C 5.6779 -6.4644 0 0
M  V30 19 C 11.3214 -7.3006 0 0
M  V30 20 C 12.8278 -7.6208 0 0
M  V30 21 C 13.9722 -6.5903 0 0
M  V30 22 C 13.6521 -5.084 0 0
M  V30 23 C 14.7965 -4.0535 0 0
M  V30 24 C 16.2611 -4.5294 0 0
M  V30 25 F 17.4056 -3.4989 0 0
M  V30 26 C 16.5813 -6.0357 0 0
M  V30 27 C 15.4369 -7.0662 0 0
M  V30 28 N 12.9888 -9.1523 0 0
M  V30 29 C 14.3224 -9.9223 0 0
M  V30 30 C 15.6561 -9.1523 0 0
M  V30 31 C 16.9898 -9.9223 0 0 CFG=1
M  V30 32 O 16.9898 -11.4623 0 0
M  V30 33 C 18.3235 -9.1523 0 0
M  V30 34 C 19.6572 -9.9223 0 0 CFG=1
M  V30 35 O 19.6572 -11.4623 0 0
M  V30 36 C 20.9908 -9.1523 0 0
M  V30 37 C 22.3245 -9.9223 0 0
M  V30 38 O 23.6582 -9.1523 0 0
M  V30 39 O 22.3245 -11.4623 0 0
M  V30 40 C 10.6951 -5.8937 0 0
M  V30 41 C 9.1635 -5.7327 0 0
M  V30 42 C 8.5371 -4.3259 0 0
M  V30 43 C 9.4423 -3.08 0 0
M  V30 44 C 10.9739 -3.241 0 0
M  V30 45 C 11.6003 -4.6478 0 0
M  V30 46 C 36.0644 -12.3155 0 0
M  V30 47 C 34.9199 -11.285 0 0
M  V30 48 C 33.4553 -11.7609 0 0
M  V30 49 C 35.2401 -9.7787 0 0
M  V30 50 C 34.2096 -8.6343 0 0
M  V30 51 C 32.6781 -8.7952 0 0
M  V30 52 O 32.0517 -10.2021 0 0
M  V30 53 N 31.7729 -7.5493 0 0
M  V30 54 C 30.2413 -7.7103 0 0
M  V30 55 C 29.615 -9.1172 0 0
M  V30 56 C 28.0834 -9.2782 0 0
M  V30 57 C 27.1782 -8.0323 0 0
M  V30 58 C 27.8046 -6.6254 0 0
M  V30 59 C 29.3361 -6.4644 0 0
M  V30 60 C 34.9796 -7.3006 0 0
M  V30 61 C 36.486 -7.6208 0 0
M  V30 62 C 37.6304 -6.5903 0 0
M  V30 63 C 37.3102 -5.084 0 0
M  V30 64 C 38.4547 -4.0535 0 0
M  V30 65 C 39.9193 -4.5294 0 0
M  V30 66 F 41.0638 -3.4989 0 0
M  V30 67 C 40.2395 -6.0357 0 0
M  V30 68 C 39.0951 -7.0662 0 0
M  V30 69 N 36.647 -9.1523 0 0
M  V30 70 C 37.9806 -9.9223 0 0
M  V30 71 C 39.3143 -9.1523 0 0
M  V30 72 C 40.648 -9.9223 0 0 CFG=1
M  V30 73 O 40.648 -11.4623 0 0
M  V30 74 C 41.9817 -9.1523 0 0
M  V30 75 C 43.3154 -9.9223 0 0 CFG=1
M  V30 76 O 43.3154 -11.4623 0 0
M  V30 77 C 44.649 -9.1523 0 0
M  V30 78 C 45.9827 -9.9223 0 0
M  V30 79 O 47.3164 -9.1523 0 0
M  V30 80 O 45.9827 -11.4623 0 0
M  V30 81 C 34.3533 -5.8937 0 0
M  V30 82 C 32.8217 -5.7327 0 0
M  V30 83 C 32.1953 -4.3259 0 0
M  V30 84 C 33.1005 -3.08 0 0
M  V30 85 C 34.6321 -3.241 0 0
M  V30 86 C 35.2585 -4.6478 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 5 6
M  V30 2 1 6 7
M  V30 3 1 6 8
M  V30 4 2 8 9
M  V30 5 1 9 10
M  V30 6 2 10 11
M  V30 7 1 10 12
M  V30 8 1 12 13
M  V30 9 1 13 14
M  V30 10 2 14 15
M  V30 11 1 15 16
M  V30 12 2 16 17
M  V30 13 1 17 18
M  V30 14 2 13 18
M  V30 15 1 9 19
M  V30 16 2 19 20
M  V30 17 1 20 21
M  V30 18 1 21 22
M  V30 19 2 22 23
M  V30 20 1 23 24
M  V30 21 1 24 25
M  V30 22 2 24 26
M  V30 23 1 26 27
M  V30 24 2 21 27
M  V30 25 1 20 28
M  V30 26 1 8 28
M  V30 27 1 28 29
M  V30 28 1 29 30
M  V30 29 1 31 30
M  V30 30 1 31 32 CFG=3
M  V30 31 1 31 33
M  V30 32 1 34 33
M  V30 33 1 34 35 CFG=3
M  V30 34 1 34 36
M  V30 35 1 36 37
M  V30 36 2 37 38
M  V30 37 1 37 39
M  V30 38 1 19 40
M  V30 39 1 40 41
M  V30 40 2 41 42
M  V30 41 1 42 43
M  V30 42 2 43 44
M  V30 43 1 44 45
M  V30 44 2 40 45
M  V30 45 1 46 47
M  V30 46 1 47 48
M  V30 47 1 47 49
M  V30 48 2 49 50
M  V30 49 1 50 51
M  V30 50 2 51 52
M  V30 51 1 51 53
M  V30 52 1 53 54
M  V30 53 1 54 55
M  V30 54 2 55 56
M  V30 55 1 56 57
M  V30 56 2 57 58
M  V30 57 1 58 59
M  V30 58 2 54 59
M  V30 59 1 50 60
M  V30 60 2 60 61
M  V30 61 1 61 62
M  V30 62 1 62 63
M  V30 63 2 63 64
M  V30 64 1 64 65
M  V30 65 1 65 66
M  V30 66 2 65 67
M  V30 67 1 67 68
M  V30 68 2 62 68
M  V30 69 1 61 69
M  V30 70 1 49 69
M  V30 71 1 69 70
M  V30 72 1 70 71
M  V30 73 1 72 71
M  V30 74 1 72 73 CFG=3
M  V30 75 1 72 74
M  V30 76 1 75 74
M  V30 77 1 75 76 CFG=3
M  V30 78 1 75 77
M  V30 79 1 77 78
M  V30 80 2 78 79
M  V30 81 1 78 80
M  V30 82 1 60 81
M  V30 83 1 81 82
M  V30 84 2 82 83
M  V30 85 1 83 84
M  V30 86 2 84 85
M  V30 87 1 85 86
M  V30 88 2 81 86
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610476

>  <MW>
1210.5

>  <MW (desalted)>
558.64

>  <ClogP>
4.457

>  <logS>
-8.022

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
111.79

>  <RotBonds>
24

>  <Action on targets>
-

>  <Activity coefficients and valu>
amount  13.8 pg/ml

>  <CAS>
344423-98-9

>  <Description>
Atorvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.

>  <EBC_ID>
EBC-13176

>  <IUPAC Name>
bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid) calcium trihydrate

>  <Main Tar all refs>
Life Sci., 2020, vol. 254

>  <Main tar all>
Rho-dependent protein serine/threonine kinase pX=10.6

$$$$
4'-Hydroxypropiophenone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 O 2.6674 4.62 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104499156

>  <MW>
150.068

>  <MW (desalted)>
150.175

>  <ClogP>
1.984

>  <logS>
-1.72

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
2

>  <Action on targets>
Agonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  8.32E-05 M | IC50 = 150.56 ?M | IC50 = 176 ?M | IC50 = 293 ?M

>  <CAS>
70-70-2

>  <Description>
A manufactured, nonsteroidal estrogen which has been used medically as an antigonadotropin.

>  <EBC_ID>
EBC-14444

>  <IUPAC Name>
1-(4-hydroxyphenyl)propan-1-one

>  <Main Tar all refs>
J. Chem. Inf. Comput. Sci., 2003, vol. 43, # 4, p. 1166 - 1176 | Lett. Drug Des. Discov., 2009, vol. 6, # 7, p. 518 - 523 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 3, p. 592 - 595 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 3, p. 592 - 595

>  <Main tar all>
Estrogen receptor pX=4.08 | Testosterone 17-beta-dehydrogenase 3 pX=3.82 | 4-aminobutyrate aminotransferase pX=3.75 | aldehyde dehydrogenase 5 family member A1 pX=3.53

$$$$
Tolcapone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -0.77 0 0
M  V30 2 C 4.001 -2.31 0 0
M  V30 3 C 5.3347 -3.08 0 0
M  V30 4 C 5.3347 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 4.001 -6.93 0 0
M  V30 9 O 5.3347 -7.7 0 0
M  V30 10 C 2.6674 -7.7 0 0
M  V30 11 C 2.6674 -9.24 0 0
M  V30 12 C 1.3337 -10.01 0 0
M  V30 13 O 1.3337 -11.55 0 0
M  V30 14 C -0 -9.24 0 0
M  V30 15 O -1.3337 -10.01 0 0
M  V30 16 C 0 -7.7 0 0
M  V30 17 C 1.3337 -6.93 0 0
M  V30 18 N -1.3337 -6.93 0 0 CHG=1
M  V30 19 O -1.3337 -5.39 0 0
M  V30 20 O -2.6674 -7.7 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 10 17
M  V30 19 1 16 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802071

>  <MW>
273.064

>  <MW (desalted)>
273.241

>  <ClogP>
3.245

>  <logS>
-4.158

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
100.67

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.2 nM | Ki (inhibition constant) = 0.27 nM | IC50  0.378 - 0.825 nM | IC50  6.83E-10 M | IC50  0.0009 ?M | IC50  0.0009 ?M | IC50  0.91 nM | IC50  0.0046 ?M

>  <CAS>
134308-13-7

>  <Description>
Tolcapone is a catechol-O-methyltransferase inhibitor. It is used as adjunct therapy in the symptomatic management of idiopathic Parkinson's disease.

>  <EBC_ID>
EBC-26395

>  <IUPAC Name>
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol

>  <Main Tar all refs>
Psychopharmacology, 2020, vol. 237, # 9, p. 2695 - 2707 | CNS Neurol. Disord. Drug Targets, 2012, vol. 11, # 3, p. 324 - 332 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - WO2022/165432, 2022, A1 | ALBERT-LUDWIGS-UNIVERSIT?T FREIBURG - WO2021/53158, 2021, A1 | THE UNIVERSITY OF TEXAS SYSTEM - WO2018/183668, 2018, A1 | THE UNIVERSITY OF TEXAS SYSTEM - WO2018/183668, 2018, A1 | J. Med. Chem., 2016, vol. 59, # 16, p. 7584 - 7597 | Xenobiotica, 2021, vol. 51, # 3, p. 268 - 278

>  <Main tar all>
Catechol O-methyltransferase (isoform Membrane-bound) pX=9.7 | Catechol-O-methyltransferase pX=9.57 | Catechol O-methyltransferase (isoform Soluble) pX=9.42 | Soluble Catechol-O-Methyltransferase (V108M) pX=9.17 | Catechol-O-methyltransferase pX=9.05 | Catechol-O-methyltransferase pX=9.05 | Catechol-O-methyltransferase pX=9.04 | Catechol O-methyltransferase B pX=8.34

$$$$
Mestranol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.2215 -5.8405 0 0
M  V30 2 O -1.6982 -4.3921 0 0
M  V30 3 C -0.1823 -4.1211 0 0
M  V30 4 C 0.3409 -2.6727 0 0
M  V30 5 C 1.8569 -2.4016 0 0
M  V30 6 C 2.8496 -3.5789 0 0
M  V30 7 C 4.3656 -3.3079 0 0 CFG=1
M  V30 8 C 4.8888 -1.8595 0 0
M  V30 9 C 6.4048 -1.5884 0 0
M  V30 10 C 7.3975 -2.7657 0 0 CFG=1
M  V30 11 C 8.0693 -1.38 0 0
M  V30 12 C 6.8743 -4.2141 0 0 CFG=1
M  V30 13 C 8.0901 -5.1593 0 0
M  V30 14 C 9.3647 -4.2951 0 0
M  V30 15 C 8.9367 -2.8158 0 0 CFG=2
M  V30 16 O 10.357 -2.2205 0 0
M  V30 17 C 9.1633 -1.2925 0 0
M  V30 18 C 9.3899 0.2307 0 0
M  V30 19 C 5.3583 -4.4852 0 0 CFG=2
M  V30 20 C 4.8351 -5.9336 0 0
M  V30 21 C 3.3191 -6.2046 0 0
M  V30 22 C 2.3264 -5.0273 0 0
M  V30 23 C 0.8105 -5.2984 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=1
M  V30 11 1 10 12
M  V30 12 1 12 13 CFG=1
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 10 15
M  V30 16 1 15 16 CFG=1
M  V30 17 1 15 17 CFG=3
M  V30 18 3 17 18
M  V30 19 1 12 19
M  V30 20 1 19 7
M  V30 21 1 19 20 CFG=3
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 6 22
M  V30 25 1 22 23
M  V30 26 2 3 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557501642

>  <MW>
310.193

>  <MW (desalted)>
310.43

>  <ClogP>
4.45

>  <logS>
-5.238

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
1

>  <Action on targets>
Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  9.1 nM | EC50  9.1 nM | IC50  30 nM

>  <CAS>
72-33-3

>  <Description>
Mestranol is the 3-methyl ether of ethinyl estradiol, which is a potent estrogen receptor agonist. It is used as oral contraceptives.

>  <EBC_ID>
EBC-07794

>  <IUPAC Name>
(1R,3aS,3bR,9bS,11aS)-1-ethynyl-7-methoxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-ol

>  <Main Tar all refs>
J. Steroid Biochem. Mol. Biol., 2004, vol. 91, # 3, p. 99 - 109 | J. Steroid Biochem. Mol. Biol., 2004, vol. 91, # 3, p. 99 - 109 | Pharm. Chem. J., 2019, vol. 52, # 10, p. 855 - 859

>  <Main tar all>
Estrogen receptor pX=8.04 | Estrogen receptor pX=8.04 | Estrogen receptor-? pX=7.52

$$$$
Isosorbide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.8939 -3.1864 0 0
M  V30 2 C 2.3698 -1.7218 0 0 CFG=1
M  V30 3 C 1.4646 -0.4759 0 0
M  V30 4 O 2.3698 0.77 0 0
M  V30 5 C 3.8344 0.2941 0 0 CFG=2
M  V30 6 C 5.2991 0.77 0 0 CFG=2
M  V30 7 O 5.775 2.2346 0 0
M  V30 8 C 6.2043 -0.4759 0 0
M  V30 9 O 5.2991 -1.7218 0 0
M  V30 10 C 3.8344 -1.2459 0 0 CFG=2
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 2
M  V30 11 1 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1216815730

>  <MW>
146.058

>  <MW (desalted)>
146.141

>  <ClogP>
-1.53

>  <logS>
-0.348

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
58.92

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.31 ?M | Ki (inhibition constant)  0.44 ?M | IC50  1.19 ?M | IC50  1.65 ?M | IC50  1.65 ?M | IC50  9.8 ?M

>  <CAS>
652-67-5

>  <Description>
Isosorbide is a vasodilator used for the prevention and treatment of angina pectoris due to coronary artery disease. It was previously used to reduce intraocular pressure. Isosorbide binds to the Bcl-2 protein and inhibits the tumor cell growth.

>  <EBC_ID>
EBC-04434

>  <IUPAC Name>
(3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2016, vol. 26, # 15, p. 3464 - 3467 | Bioorg. Med. Chem. Lett., 2016, vol. 26, # 15, p. 3464 - 3467 | Med. Chem. Res., 2023, vol. 32, # 1, p. 99 - 108 | Med. Chem. Res., 2023, vol. 32, # 1, p. 99 - 108 | Med. Chem. Res., 2023, vol. 32, # 1, p. 99 - 108 | Med. Chem. Res., 2023, vol. 32, # 1, p. 99 - 108

>  <Main tar all>
Bcl2-associated agonist of cell death pX=6.51 | Apoptosis regulator, Bcl-2 pX=6.36 | Apoptosis regulator, Mcl-1 pX=5.92 | Apoptosis regulator Bcl-2 pX=5.78 | apoptosis regulator bcl-2 pX=5.78 | Bcl-2-like protein 1 (isoform Bcl-X(L)) pX=5.01

$$$$
Ticagrelor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.925 8.2328 0 0
M  V30 2 C 8.925 6.6928 0 0
M  V30 3 C 7.5913 5.9228 0 0
M  V30 4 S 7.5913 4.3828 0 0
M  V30 5 C 6.2576 3.6128 0 0
M  V30 6 N 6.2576 2.0728 0 0
M  V30 7 C 4.9239 1.3028 0 0
M  V30 8 N 4.9239 -0.2372 0 0
M  V30 9 C 6.2576 -1.0072 0 0 CFG=2
M  V30 10 C 7.7976 -1.0072 0 0
M  V30 11 C 7.0276 -2.3409 0 0 CFG=1
M  V30 12 C 7.0276 -3.8809 0 0
M  V30 13 C 8.3613 -4.6509 0 0
M  V30 14 C 8.3613 -6.1909 0 0
M  V30 15 C 7.0276 -6.9609 0 0
M  V30 16 F 7.0276 -8.5009 0 0
M  V30 17 C 5.6939 -6.1909 0 0
M  V30 18 F 4.3602 -6.9609 0 0
M  V30 19 C 5.6939 -4.6509 0 0
M  V30 20 C 3.5902 2.0728 0 0
M  V30 21 N 2.1256 1.5969 0 0
M  V30 22 N 1.2204 2.8428 0 0
M  V30 23 N 2.1256 4.0887 0 0
M  V30 24 C 1.6497 5.5533 0 0 CFG=2
M  V30 25 C 0.1851 6.0292 0 0
M  V30 26 C 0.1851 7.5692 0 0 CFG=2
M  V30 27 O -1.0608 8.4744 0 0
M  V30 28 C -2.4676 7.848 0 0
M  V30 29 C -3.7135 8.7532 0 0
M  V30 30 O -5.1204 8.1269 0 0
M  V30 31 C 1.6497 8.0451 0 0 CFG=1
M  V30 32 O 2.1256 9.5097 0 0
M  V30 33 C 2.5549 6.7992 0 0 CFG=1
M  V30 34 O 4.0949 6.7992 0 0
M  V30 35 C 3.5902 3.6128 0 0
M  V30 36 N 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 9 11
M  V30 12 1 11 12 CFG=1
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 12 19
M  V30 21 1 7 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 24 23 CFG=3
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 26 27 CFG=3
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 31 26
M  V30 33 1 31 32 CFG=1
M  V30 34 1 31 33
M  V30 35 1 33 24
M  V30 36 1 33 34 CFG=1
M  V30 37 1 23 35
M  V30 38 2 20 35
M  V30 39 1 35 36
M  V30 40 2 5 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802088

>  <MW>
522.186

>  <MW (desalted)>
522.568

>  <ClogP>
2.546

>  <logS>
-5.421

>  <HBD>
4

>  <HBA>
9

>  <TPSA>
138.44

>  <RotBonds>
10

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1.8 nM | Ki (inhibition constant) = 2 nM | pKi  8.7

>  <CAS>
274693-27-5

>  <Description>
Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death.

>  <EBC_ID>
EBC-12279

>  <IUPAC Name>
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol

>  <Main Tar all refs>
Phytomedicine, 2019, vol. 64 | Bioorg. Med. Chem., 2015, vol. 23, # 14, p. 3880 - 3906 | Bioorg. Med. Chem. Lett., 2007, vol. 17, # 21, p. 6013 - 6018

>  <Main tar all>
P2Y12 receptor pX=8.74 | P2Y12 receptor pX=8.7 | P2Y12 receptor pX=8.7

$$$$
Bemotrizinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 46 49 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 5.39 0 0
M  V30 2 C -5.3347 4.62 0 0
M  V30 3 C -4.001 5.39 0 0
M  V30 4 C -2.6674 4.62 0 0
M  V30 5 C -1.3337 5.39 0 0
M  V30 6 C -1.3337 6.93 0 0
M  V30 7 C -0 7.7 0 0
M  V30 8 C -0 4.62 0 0
M  V30 9 O 1.3337 5.39 0 0
M  V30 10 C 2.6674 4.62 0 0
M  V30 11 C 4.001 5.39 0 0
M  V30 12 C 5.3347 4.62 0 0
M  V30 13 C 5.3347 3.08 0 0
M  V30 14 C 4.001 2.31 0 0
M  V30 15 O 4.001 0.77 0 0
M  V30 16 C 2.6674 3.08 0 0
M  V30 17 C 6.6684 2.31 0 0
M  V30 18 N 8.0021 3.08 0 0
M  V30 19 C 9.3358 2.31 0 0
M  V30 20 N 9.3358 0.77 0 0
M  V30 21 C 8.0021 0 0 0
M  V30 22 N 6.6684 0.77 0 0
M  V30 23 C 8.0021 -1.54 0 0
M  V30 24 C 9.3358 -2.31 0 0
M  V30 25 C 9.3358 -3.85 0 0
M  V30 26 C 8.0021 -4.62 0 0
M  V30 27 O 8.0021 -6.16 0 0
M  V30 28 C 9.3358 -6.93 0 0
M  V30 29 C 10.6694 -6.16 0 0
M  V30 30 C 10.6694 -4.62 0 0
M  V30 31 C 12.0031 -3.85 0 0
M  V30 32 C 12.0031 -6.93 0 0
M  V30 33 C 13.3368 -6.16 0 0
M  V30 34 C 14.6705 -6.93 0 0
M  V30 35 C 16.0041 -6.16 0 0
M  V30 36 C 6.6684 -3.85 0 0
M  V30 37 C 6.6684 -2.31 0 0
M  V30 38 O 5.3347 -1.54 0 0
M  V30 39 C 10.6694 3.08 0 0
M  V30 40 C 10.6694 4.62 0 0
M  V30 41 C 12.0031 5.39 0 0
M  V30 42 C 13.3368 4.62 0 0
M  V30 43 O 14.6705 5.39 0 0
M  V30 44 C 16.0041 4.62 0 0
M  V30 45 C 13.3368 3.08 0 0
M  V30 46 C 12.0031 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 10 16
M  V30 17 1 13 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 29 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 2 26 36
M  V30 38 1 36 37
M  V30 39 2 23 37
M  V30 40 1 37 38
M  V30 41 1 19 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 1 42 43
M  V30 46 1 43 44
M  V30 47 2 42 45
M  V30 48 1 45 46
M  V30 49 2 39 46
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891866

>  <MW>
627.367

>  <MW (desalted)>
627.813

>  <ClogP>
10.984

>  <logS>
-11.847

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
106.82

>  <RotBonds>
18

>  <CAS>
187393-00-6

>  <Description>
Bemotrizinol is an ingredient used in sunscreen to block UVA and UVB radiation.

>  <EBC_ID>
EBC-27398

>  <IUPAC Name>
5-[(2-ethylhexyl)oxy]-2-(4-{4-[(2-ethylhexyl)oxy]-2-hydroxyphenyl}-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl)phenol

$$$$
Ponatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0254 -22.597 0 0
M  V30 2 N 4.5013 -21.1324 0 0
M  V30 3 C 3.4708 -19.9879 0 0
M  V30 4 C 3.9467 -18.5233 0 0
M  V30 5 N 5.4531 -18.2031 0 0
M  V30 6 C 5.9289 -16.7385 0 0
M  V30 7 C 4.8985 -15.5941 0 0
M  V30 8 C 3.3921 -15.9142 0 0
M  V30 9 C 2.3617 -14.7698 0 0
M  V30 10 C 2.8376 -13.3052 0 0
M  V30 11 N 1.8071 -12.1607 0 0
M  V30 12 C 2.283 -10.6961 0 0
M  V30 13 O 3.7893 -10.3759 0 0
M  V30 14 C 1.2525 -9.5517 0 0
M  V30 15 C -0.2538 -9.8718 0 0
M  V30 16 C -1.2843 -8.7274 0 0
M  V30 17 C -0.8084 -7.2628 0 0
M  V30 18 C -1.8389 -6.1183 0 0
M  V30 19 C 0.698 -6.9426 0 0
M  V30 20 C 1.1738 -5.478 0 0
M  V30 21 C 1.6497 -4.0133 0 0
M  V30 22 C 2.1256 -2.5487 0 0
M  V30 23 C 1.2204 -1.3028 0 0
M  V30 24 N 2.1256 -0.0569 0 0
M  V30 25 C 3.5902 -0.5328 0 0
M  V30 26 C 4.9239 0.2372 0 0
M  V30 27 C 6.2576 -0.5328 0 0
M  V30 28 C 6.2576 -2.0728 0 0
M  V30 29 N 4.9239 -2.8428 0 0
M  V30 30 N 3.5902 -2.0728 0 0
M  V30 31 C 1.7284 -8.087 0 0
M  V30 32 C 4.3439 -12.985 0 0
M  V30 33 C 5.3744 -14.1294 0 0
M  V30 34 C 6.8807 -13.8093 0 0
M  V30 35 F 8.3871 -13.4891 0 0
M  V30 36 F 7.2009 -15.3156 0 0
M  V30 37 F 6.5605 -12.3029 0 0
M  V30 38 C 6.4835 -19.3476 0 0
M  V30 39 C 6.0076 -20.8122 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 19 20
M  V30 20 3 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 29 30
M  V30 30 1 22 30
M  V30 31 1 25 30
M  V30 32 1 19 31
M  V30 33 2 14 31
M  V30 34 2 10 32
M  V30 35 1 32 33
M  V30 36 2 7 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 34 37
M  V30 41 1 5 38
M  V30 42 1 38 39
M  V30 43 1 2 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1828098700

>  <MW>
532.22

>  <MW (desalted)>
532.559

>  <ClogP>
5.768

>  <logS>
-5.658

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
65.77

>  <RotBonds>
7

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
GI50 < 0.001 nM | IC50  0.0086 nM

>  <CAS>
943319-70-8

>  <Description>
Ponatinib is a kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML).

>  <EBC_ID>
EBC-11436

>  <IUPAC Name>
3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide

>  <Main Tar all refs>
J. Med. Chem., 2013, vol. 56, # 14, p. 5757 - 5772 | Cardiovasc. Toxicol., 2017, vol. 17, # 3, p. 297 - 306

>  <Main tar all>
BCR-ABL tyrosine kinase pX=12.0 | Tyrosine-protein kinase ABL pX=11.1

$$$$
Darunavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.4509 -7.3482 0 0
M  V30 2 C 4.6809 -6.0145 0 0
M  V30 3 C 3.1409 -6.0145 0 0
M  V30 4 C 5.4509 -4.6809 0 0
M  V30 5 N 6.9909 -4.6809 0 0
M  V30 6 C 7.7609 -3.3472 0 0
M  V30 7 C 9.3009 -3.3472 0 0 CFG=1
M  V30 8 O 10.0709 -4.6809 0 0
M  V30 9 C 10.0709 -2.0135 0 0 CFG=2
M  V30 10 C 9.3009 -0.6798 0 0
M  V30 11 C 7.7609 -0.6798 0 0
M  V30 12 C 6.9909 -2.0135 0 0
M  V30 13 C 5.4509 -2.0135 0 0
M  V30 14 C 4.6809 -0.6798 0 0
M  V30 15 C 5.4509 0.6539 0 0
M  V30 16 C 6.9909 0.6539 0 0
M  V30 17 N 11.6109 -2.0135 0 0
M  V30 18 C 12.3809 -0.6798 0 0
M  V30 19 O 11.6109 0.6539 0 0
M  V30 20 O 13.9209 -0.6798 0 0
M  V30 21 C 14.6909 0.6539 0 0 CFG=1
M  V30 22 C 14.0645 2.0607 0 0
M  V30 23 O 15.209 3.0912 0 0
M  V30 24 C 16.5427 2.3212 0 0 CFG=1
M  V30 25 O 18.0742 2.4822 0 0
M  V30 26 C 18.7006 1.0753 0 0
M  V30 27 C 17.5562 0.0448 0 0
M  V30 28 C 16.2225 0.8148 0 0 CFG=1
M  V30 29 S 7.7609 -6.0145 0 0
M  V30 30 O 6.4272 -6.7845 0 0
M  V30 31 O 9.0946 -5.2445 0 0
M  V30 32 C 8.5309 -7.3482 0 0
M  V30 33 C 10.0709 -7.3482 0 0
M  V30 34 C 10.8409 -8.6819 0 0
M  V30 35 C 10.0709 -10.0156 0 0
M  V30 36 N 10.8409 -11.3493 0 0
M  V30 37 C 8.5309 -10.0156 0 0
M  V30 38 C 7.7609 -8.6819 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 9 17 CFG=3
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 21 20 CFG=1
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 24 23 CFG=1
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 28 27 CFG=1
M  V30 29 1 28 21
M  V30 30 1 28 24
M  V30 31 1 5 29
M  V30 32 2 29 30
M  V30 33 2 29 31
M  V30 34 1 29 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 2 35 37
M  V30 40 1 37 38
M  V30 41 2 32 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301684748

>  <MW>
547.664

>  <MW (desalted)>
547.664

>  <ClogP>
2.887

>  <logS>
-4.769

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
140.42

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.0002 nM | Ki (inhibition constant) < 0.001 nM | Ki (inhibition constant)  0.001 nM | Ki (inhibition constant) < 0.001 nM | Ki (inhibition constant)  0.0043 nM | Ki (inhibition constant)  0.004 nM | Ki (inhibition constant) < 0.005 nM | Ki (inhibition constant)  0.005 nM | Ki (inhibition constant) < 5 pM

>  <CAS>
206361-99-1

>  <Description>
Darunavir is a HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies.

>  <EBC_ID>
EBC-27304

>  <IUPAC Name>
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | J. Med. Chem., 2009, vol. 52, # 22, p. 7132 - 7141 | J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | J. Med. Chem., 2012, vol. 55, # 14, p. 6328 - 6341 | UNIVERSITY OF MASSACHUSETTS - US2021/371439, 2021, A1 | J. Am. Chem. Soc., 2008, vol. 130, # 19, p. 6099 - 6113 | UNIVERSITY OF MASSACHUSETTS - US2021/371439, 2021, A1

>  <Main tar all>
HIV-1?protease?(Q7K) pX=12.7 | Protease pX=12.0 | HIV-1?protease?(I50V,?A71V) pX=12.0 | HIV-1?protease?(L10F,?L19I,?K20R,?L33F,?E35D,?M36I,?R41K,?F53L,?I54V,?L63P,?H69K,?A71V,?T74P,?I84V,?L89M,?L90M,?I93L) pX=12.0 | HIV-1 protease pX=11.4 | HIV-1 protease (L10I, G48V, I54V, L63P, V82A) pX=11.4 | Capsid scaffolding protein pX=11.3 | HIV-1?protease?(L10I,?G48V,?V82A) pX=11.3 | RNA-directed RNA polymerase pX=11.3

$$$$
Bacitracin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 100 103 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -18.7758 8.3113 0 0
M  V30 2 C -17.3277 7.7872 0 0
M  V30 3 C -17.0576 6.2711 0 0 CFG=2
M  V30 4 C -18.2356 5.2791 0 0
M  V30 5 C -15.6096 5.7469 0 0 CFG=2
M  V30 6 N -14.4316 6.7389 0 0
M  V30 7 C -15.3394 4.2308 0 0
M  V30 8 N -13.9541 3.5582 0 0
M  V30 9 C -14.1657 2.0328 0 0 CFG=1
M  V30 10 C -15.6818 1.7627 0 0
M  V30 11 S -16.4072 3.1211 0 0
M  V30 12 C -13.056 0.965 0 0
M  V30 13 O -13.4259 -0.5299 0 0
M  V30 14 N -11.5764 1.3921 0 0
M  V30 15 C -10.4667 0.3243 0 0 CFG=1
M  V30 16 C -10.8366 -1.1706 0 0
M  V30 17 C -9.727 -2.2384 0 0
M  V30 18 C -8.2474 -1.8113 0 0
M  V30 19 C -10.0968 -3.7333 0 0
M  V30 20 C -8.9872 0.7514 0 0
M  V30 21 O -8.6173 2.2464 0 0
M  V30 22 N -7.8775 -0.3164 0 0
M  V30 23 C -6.3979 0.1108 0 0 CFG=2
M  V30 24 C -6.028 1.6057 0 0
M  V30 25 C -4.5484 2.0328 0 0
M  V30 26 C -4.1785 3.5277 0 0
M  V30 27 O -5.2882 4.5955 0 0
M  V30 28 O -2.6989 3.9548 0 0
M  V30 29 C -5.2882 -0.957 0 0
M  V30 30 O -5.6581 -2.452 0 0
M  V30 31 N -3.8086 -0.5299 0 0
M  V30 32 C -2.6989 -1.5977 0 0 CFG=1
M  V30 33 C -3.0688 -3.0926 0 0 CFG=1
M  V30 34 C -4.5484 -3.5198 0 0
M  V30 35 C -1.9591 -4.1604 0 0
M  V30 36 C -2.329 -5.6554 0 0
M  V30 37 C -1.2193 -1.1706 0 0
M  V30 38 O -0.8494 0.3243 0 0
M  V30 39 N -0.1097 -2.2384 0 0
M  V30 40 C 1.3699 -1.8113 0 0 CFG=1
M  V30 41 C 0.4678 -0.5632 0 0
M  V30 42 C 1.3761 0.6805 0 0
M  V30 43 C 2.8395 0.2009 0 0
M  V30 44 C 4.4089 0.815 0 0
M  V30 45 N 5.6525 -0.0933 0 0
M  V30 46 C 7.061 0.5296 0 0
M  V30 47 O 7.2257 2.0607 0 0
M  V30 48 C 8.3046 -0.3787 0 0 CFG=2
M  V30 49 C 8.4694 1.1524 0 0
M  V30 50 C 9.8778 1.7753 0 0
M  V30 51 O 10.0426 3.3065 0 0
M  V30 52 N 11.1214 0.867 0 0
M  V30 53 N 9.713 0.2442 0 0
M  V30 54 C 10.9566 -0.6641 0 0
M  V30 55 O 10.7918 -2.1953 0 0
M  V30 56 C 12.365 -0.0412 0 0 CFG=1
M  V30 57 C 12.5298 1.4899 0 0
M  V30 58 C 13.9382 2.1128 0 0
M  V30 59 O 14.103 3.6439 0 0
M  V30 60 O 15.1819 1.2045 0 0
M  V30 61 N 13.6087 -0.9495 0 0
M  V30 62 C 13.4439 -2.4807 0 0
M  V30 63 O 12.0355 -3.1036 0 0
M  V30 64 C 14.6875 -3.389 0 0 CFG=2
M  V30 65 C 16.0959 -2.7661 0 0
M  V30 66 C 17.3396 -3.6744 0 0
M  V30 67 C 17.3357 -5.2144 0 0
M  V30 68 N 18.7992 -5.6939 0 0
M  V30 69 C 19.7075 -4.4503 0 0
M  V30 70 N 18.8054 -3.2021 0 0
M  V30 71 N 14.5227 -4.9201 0 0
M  V30 72 C 13.1143 -5.543 0 0
M  V30 73 O 12.9495 -7.0742 0 0
M  V30 74 C 11.8707 -4.6347 0 0 CFG=1
M  V30 75 C 12.1871 -6.1419 0 0
M  V30 76 C 11.0401 -7.1695 0 0
M  V30 77 C 11.3566 -8.6766 0 0
M  V30 78 C 10.2096 -9.7042 0 0
M  V30 79 C 8.7461 -9.2247 0 0
M  V30 80 C 8.4297 -7.7176 0 0
M  V30 81 C 9.5767 -6.6899 0 0
M  V30 82 N 10.4623 -5.2576 0 0
M  V30 83 C 9.2187 -4.3493 0 0
M  V30 84 O 9.3834 -2.8182 0 0
M  V30 85 C 7.8102 -4.9722 0 0 CFG=1
M  V30 86 N 6.5666 -4.0639 0 0
M  V30 87 C 5.1582 -4.6868 0 0
M  V30 88 O 4.9934 -6.2179 0 0
M  V30 89 C 3.9146 -3.7785 0 0 CFG=1
M  V30 90 C 3.7498 -5.3097 0 0
M  V30 91 C 2.3414 -5.9325 0 0
M  V30 92 C 2.1766 -7.4637 0 0
M  V30 93 N 0.7682 -8.0866 0 0
M  V30 94 N 2.5061 -4.4014 0 0
M  V30 95 C 1.2625 -3.4931 0 0
M  V30 96 O -0.132 -4.1464 0 0
M  V30 97 C 7.6455 -6.5033 0 0 CFG=1
M  V30 98 C 7.6416 -8.0433 0 0
M  V30 99 C 6.237 -7.1262 0 0
M  V30 100 C 6.0723 -8.6574 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 1 9 12 CFG=3
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 15 14 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 1 15 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 23 22 CFG=3
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 23 29
M  V30 30 2 29 30
M  V30 31 1 29 31
M  V30 32 1 32 31 CFG=3
M  V30 33 1 32 33
M  V30 34 1 33 34 CFG=3
M  V30 35 1 33 35
M  V30 36 1 35 36
M  V30 37 1 32 37
M  V30 38 2 37 38
M  V30 39 1 37 39
M  V30 40 1 40 39 CFG=3
M  V30 41 1 40 41 CFG=1
M  V30 42 1 41 42
M  V30 43 1 42 43
M  V30 44 1 43 44
M  V30 45 1 44 45
M  V30 46 1 45 46
M  V30 47 2 46 47
M  V30 48 1 48 46
M  V30 49 1 48 49 CFG=1
M  V30 50 1 49 50
M  V30 51 2 50 51
M  V30 52 1 50 52
M  V30 53 1 48 53 CFG=3
M  V30 54 1 53 54
M  V30 55 2 54 55
M  V30 56 1 56 54
M  V30 57 1 56 57 CFG=1
M  V30 58 1 57 58
M  V30 59 2 58 59
M  V30 60 1 58 60
M  V30 61 1 56 61
M  V30 62 1 61 62
M  V30 63 2 62 63
M  V30 64 1 64 62
M  V30 65 1 64 65 CFG=3
M  V30 66 1 65 66
M  V30 67 2 66 67
M  V30 68 1 67 68
M  V30 69 1 68 69
M  V30 70 2 69 70
M  V30 71 1 66 70
M  V30 72 1 64 71
M  V30 73 1 71 72
M  V30 74 2 72 73
M  V30 75 1 74 72
M  V30 76 1 74 75 CFG=3
M  V30 77 1 75 76
M  V30 78 1 76 77
M  V30 79 2 77 78
M  V30 80 1 78 79
M  V30 81 2 79 80
M  V30 82 1 80 81
M  V30 83 2 76 81
M  V30 84 1 74 82 CFG=1
M  V30 85 1 82 83
M  V30 86 2 83 84
M  V30 87 1 85 83
M  V30 88 1 85 86
M  V30 89 1 86 87
M  V30 90 2 87 88
M  V30 91 1 89 87
M  V30 92 1 89 90 CFG=3
M  V30 93 1 90 91
M  V30 94 1 91 92
M  V30 95 1 92 93
M  V30 96 1 89 94 CFG=1
M  V30 97 1 94 95
M  V30 98 1 40 95
M  V30 99 2 95 96
M  V30 100 1 85 97 CFG=3
M  V30 101 1 97 98 CFG=1
M  V30 102 1 97 99
M  V30 103 1 99 100
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038928

>  <MW>
1422.693

>  <MW (desalted)>
1422.693

>  <ClogP>
-2.056

>  <logS>
-2.042

>  <HBD>
17

>  <HBA>
20

>  <TPSA>
530.87

>  <RotBonds>
31

>  <CAS>
1405-87-4

>  <Description>
Bacitracin is a cyclic polypeptide antibiotic used to prevent wound infections, treat pneumonia and empyema in infants, and to treat skin and eye infections.

>  <EBC_ID>
EBC-27559

>  <IUPAC Name>
(4R)-4-[(2S)-2-{[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazol-4-yl]formamido}-4-methylpentanamido]-4-{[(1S,2S)-1-{[(3S,6R,9S,12R,15S,18R,21S)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-3-(carbamoylmethyl)-6-(carboxymethyl)-9-[(1H-imidazol-4-yl)methyl]-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid

$$$$
Urethane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.31 4.001 0 0
M  V30 2 C 1.54 2.6674 0 0
M  V30 3 O 2.31 1.3337 0 0
M  V30 4 C 1.54 0 0 0
M  V30 5 O 2.31 -1.3337 0 0
M  V30 6 N 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z33546369

>  <MW>
89.048

>  <MW (desalted)>
89.093

>  <ClogP>
-0.175

>  <logS>
-0.01

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
52.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  85 %

>  <CAS>
51-79-6

>  <Description>
Urethane is an ethyl ester of carbamic acid, that has been found in many fermented food products and alcoholic beverages. It has a potential to inhibit the growth of bacteria, plant tissue, and rat carcinoma. Urethane has been used for many years as an antineoplastic agent for medical purposes but this application ended after it was discovered to be carcinogenic.

>  <EBC_ID>
EBC-17024

>  <IUPAC Name>
ethyl carbamate

>  <Main Tar all refs>
TOXICOL. APPL. PHARMACOL., 1997, vol. 146, # 2, p. 245 - 254

>  <Main tar all>
CYP2E1 pX=3.75

$$$$
Dalfampridine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 N 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104495272

>  <MW>
94.053

>  <MW (desalted)>
94.115

>  <ClogP>
0.318

>  <logS>
-0.02

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.91

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Blocker | - | Inhibitor

>  <Activity coefficients and valu>
IC50 ~ 400 nM | IC50  1.33 ?M | EC50 = 5 ?M | IC50 < 10 ?M

>  <CAS>
504-24-5

>  <Description>
Dalfampridine is a potassium channel blocker. It is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis.

>  <EBC_ID>
EBC-03934

>  <IUPAC Name>
pyridin-4-amine

>  <Main Tar all refs>
Biochem. Pharmacol., 2009, vol. 77, # 2, p. 177 - 185 | Mol. Pharmacol., 2015, vol. 87, # 4, p. 595 - 605 | Curr. Med. Chem., 2011, vol. 18, # 24, p. 3737 - 3756 | Eur. J. Med. Chem., 2013, vol. 65, p. 304 - 314

>  <Main tar all>
Kv9.1 pX=6.4 | Voltage-gated potassium channel pX=5.88 | Kir pX=5.3 | Kv11.1 pX=5.0

$$$$
Choline chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 8.91 -0.3811 0 0
M  V30 3 N 7.37 -0.3811 0 0 CHG=1
M  V30 4 C 7.37 1.1589 0 0
M  V30 5 C 7.37 -1.9211 0 0
M  V30 6 C 5.83 -0.3811 0 0
M  V30 7 C 5.06 0.9526 0 0
M  V30 8 O 3.52 0.9526 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954802409

>  <MW>
139.076

>  <MW (desalted)>
104.171

>  <ClogP>
-4.364

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
2

>  <Action on targets>
Agonist | Activator

>  <Activity coefficients and valu>
EC50  0.43 ?M | percentage decrease  96 %

>  <CAS>
67-48-1

>  <Description>
Choline is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. It is needed for good nerve conduction throughout the CNS. Choline is also needed for gallbladder regulation, liver function and lecithin formation. It also aids in fat and cholesterol metabolism and prevents excessive fat build up in the liver. Choline has been used to mitigate the effects of Parkinsonism and tardive dyskinesia.

>  <EBC_ID>
EBC-04258

>  <IUPAC Name>
(2-hydroxyethyl)trimethylazanium chloride

>  <Main Tar all refs>
Eur. J. Pharmacol., 2014, vol. 726, # 1, p. 77 - 86 | Acta Pharmacol. Sin., 2016, vol. 37, # 3, p. 312 - 321

>  <Main tar all>
nicotinic acetylcholine receptor ?7 subunit pX=6.37 | GABAA receptor pX=5.28

$$$$
Asparagine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.6437 3.6437 0 0
M  V30 2 C 3.6437 2.1037 0 0 CFG=1
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 C 0.9763 2.1037 0 0
M  V30 5 O -0.3574 1.3337 0 0
M  V30 6 N 0.9763 3.6437 0 0
M  V30 7 C 4.9774 1.3337 0 0
M  V30 8 O 6.311 2.1037 0 0
M  V30 9 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 2 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1066276474

>  <MW>
132.053

>  <MW (desalted)>
132.118

>  <ClogP>
-3.544

>  <logS>
0.29

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
106.41

>  <RotBonds>
3

>  <Action on targets>
-

>  <Activity coefficients and valu>
Km (Michaelis constant) = 0.12 nM

>  <CAS>
70-47-3

>  <Description>
Asparagine is a non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26064

>  <IUPAC Name>
(2S)-2-amino-3-carbamoylpropanoic acid

>  <Main Tar all refs>
Biochem. J., 2002, vol. 364, # 1, p. 129 - 136

>  <Main tar all>
Isoaspartyl peptidase/L-asparaginase pX=9.92

$$$$
L-Ornithine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.4 0.3422 0 0
M  V30 3 C 5.7337 -0.4278 0 0
M  V30 4 C 7.0674 0.3422 0 0
M  V30 5 C 8.401 -0.4278 0 0
M  V30 6 C 9.7347 0.3422 0 0 CFG=2
M  V30 7 N 9.7347 1.8822 0 0
M  V30 8 C 11.0684 -0.4278 0 0
M  V30 9 O 12.4021 0.3422 0 0
M  V30 10 O 11.0684 -1.9678 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 6 5
M  V30 5 1 6 7 CFG=3
M  V30 6 1 6 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z991547388

>  <MW>
168.067

>  <MW (desalted)>
132.161

>  <ClogP>
-3.953

>  <logS>
-0.19

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
89.34

>  <RotBonds>
4

>  <CAS>
3184-13-2

>  <Description>
L-ornithine hydrochloride has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

>  <EBC_ID>
EBC-03972

>  <IUPAC Name>
(2S)-2,5-diaminopentanoic acid hydrochloride

$$$$
Clopidol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 N 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 Cl 1.3337 -2.31 0 0
M  V30 8 C 0 0 0 0
M  V30 9 O -1.3337 -0.77 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 2 10
M  V30 11 1 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155477

>  <MW>
190.99

>  <MW (desalted)>
192.043

>  <ClogP>
2.87

>  <logS>
-1.701

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
0

>  <CAS>
2971-90-6

>  <Description>
Clopidol is a coccidiostat. It prevents mortality of chickens infected with the parasites E. tenella, E. necatrix, E. acervuline, E. mivati, E. brunetti, and E. maxima.

>  <EBC_ID>
EBC-12490

>  <IUPAC Name>
3,5-dichloro-2,6-dimethylpyridin-4-ol

$$$$
4-Chloro-2-isopropyl-5-methylphenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 Cl 4.001 -0.77 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 4 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104485030

>  <MW>
184.065

>  <MW (desalted)>
184.663

>  <ClogP>
4.211

>  <logS>
-3.26

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  6.99  | pIC50  6.99

>  <CAS>
89-68-9

>  <Description>
4-Chloro-2-isopropyl-5-methylphenol has binding affinity to estrogen receptor.

>  <EBC_ID>
EBC-04087

>  <IUPAC Name>
4-chloro-5-methyl-2-(propan-2-yl)phenol

>  <Main Tar all refs>
Sci. Total Environ., 1999, vol. 233, # 1-3, p. 141 - 161 | Sci. Total Environ., 1999, vol. 233, # 1-3, p. 141 - 161

>  <Main tar all>
Estrogen receptor pX=6.99 | Estrogen receptor pX=6.99

$$$$
2-Ethoxybenzamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 O 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 C -1.3337 2.31 0 0
M  V30 11 O -1.3337 3.85 0 0
M  V30 12 N -2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z54953371

>  <MW>
165.079

>  <MW (desalted)>
165.189

>  <ClogP>
1.295

>  <logS>
-1.95

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
52.32

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  2.78 ?M

>  <CAS>
938-73-8

>  <Description>
2-Ethoxybenzamide is widely used as an antipyretic anodyne. It binds to the 5-hydroxytryptamine (5HT)2B receptor in concentration-dependent manner with modest inhibitory effects on monoamine oxidase-A and transient potential vanilloid 1 channel.

>  <EBC_ID>
EBC-44318

>  <IUPAC Name>
2-ethoxybenzamide

>  <Main Tar all refs>
Biol. Pharm. Bull., 2020, vol. 43, # 5, p. 839 - 847

>  <Main tar all>
5-HT2B receptor pX=5.56

$$$$
Creatinol phosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.85 1.3337 0 0
M  V30 2 N 2.31 1.3337 0 0
M  V30 3 C 1.54 2.6674 0 0
M  V30 4 C 2.31 4.001 0 0
M  V30 5 O 1.54 5.3347 0 0
M  V30 6 P 2.31 6.6684 0 0
M  V30 7 O 3.08 8.0021 0 0
M  V30 8 O 0.9763 7.4384 0 0
M  V30 9 O 3.6437 5.8984 0 0
M  V30 10 C 1.54 0 0 0
M  V30 11 N 2.31 -1.3337 0 0
M  V30 12 N 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 2 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155511

>  <MW>
197.057

>  <MW (desalted)>
197.13

>  <ClogP>
-1.771

>  <logS>
1.023

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
119.87

>  <RotBonds>
4

>  <CAS>
6903-79-3

>  <Description>
Creatinol phosphate is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease.

>  <EBC_ID>
EBC-12914

>  <IUPAC Name>
[2-(N-methylcarbamimidamido)ethoxy]phosphonic acid

$$$$
Rimantadine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4392 -2.5171 0 0
M  V30 3 C 5.7728 -1.747 0 0
M  V30 4 N 7.1066 -2.517 0 0
M  V30 5 C 5.7727 -0.207 0 0
M  V30 6 C 4.4 -0.9046 0 0
M  V30 7 C 5.2389 0.5706 0 0
M  V30 8 C 5.2389 1.9658 0 0
M  V30 9 C 6.6118 2.6633 0 0
M  V30 10 C 7.9849 1.9658 0 0
M  V30 11 C 7.9849 0.5706 0 0
M  V30 12 C 6.6118 -0.1269 0 0
M  V30 13 C 7.1459 -0.9046 0 0
M  V30 14 C 5.7727 1.1881 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 9 14
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 5 13
M  V30 10 1 11 12
M  V30 11 1 7 12
M  V30 12 1 11 13
M  V30 13 1 10 11
M  V30 14 1 5 14
M  V30 15 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56872184

>  <MW>
215.144

>  <MW (desalted)>
179.302

>  <ClogP>
3.963

>  <logS>
-3.7

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
26.02

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Blocker | Blocker | Blocker | Blocker

>  <Activity coefficients and valu>
inhibition percentage  97 % | IC50  0.7 nM | IC50  1.6 nM | IC50  1.7 nM | IC50  3 nM

>  <CAS>
1501-84-4

>  <Description>
Rimantadine hydrochloride is a derivative of amantadine with antiviral activity.  It inhibits recombinant influenza A matrix protein 2 and recombinant hepatitis C virus p7 protein expressed in HEK293 cells. Rimantadine is used for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults.

>  <EBC_ID>
EBC-06391

>  <IUPAC Name>
1-(adamantan-1-yl)ethan-1-amine hydrochloride

>  <Main Tar all refs>
Biochemistry, 2003, vol. 42, # 24, p. 7358 - 7370 | Drug Des. Dev. Ther., 2018, vol. 12, p. 1019 - 1031 | Drug Des. Dev. Ther., 2018, vol. 12, p. 1019 - 1031 | Drug Des. Dev. Ther., 2018, vol. 12, p. 1019 - 1031 | Drug Des. Dev. Ther., 2018, vol. 12, p. 1019 - 1031

>  <Main tar all>
nicotinic acetylcholine receptor pX=9.28 | Hepatitis?C?virus?p7?genotype?1a pX=9.15 | Hepatitis?C?virus?p7?genotype?3a pX=8.8 | Hepatitis?C?virus?p7?genotype?1b pX=8.77 | Hepatitis?C?virus?p7?genotype?4a pX=8.52

$$$$
Butamben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 C 5.3347 -7.7 0 0
M  V30 4 C 6.6684 -6.93 0 0
M  V30 5 O 8.0021 -7.7 0 0
M  V30 6 C 9.3358 -6.93 0 0
M  V30 7 O 9.3358 -5.39 0 0
M  V30 8 C 10.6694 -7.7 0 0
M  V30 9 C 12.0031 -6.93 0 0
M  V30 10 C 13.3368 -7.7 0 0
M  V30 11 C 13.3368 -9.24 0 0
M  V30 12 N 14.6705 -10.01 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57126994

>  <MW>
193.11

>  <MW (desalted)>
193.242

>  <ClogP>
2.981

>  <logS>
-2.68

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
52.32

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 60 nM

>  <CAS>
94-25-7

>  <Description>
Butamben is anesthesia of mucus membranes other than the eyes. It acts by inhibiting the voltage-gated calcium channels in dorsal root ganglion neurons.

>  <EBC_ID>
EBC-13392

>  <IUPAC Name>
butyl 4-aminobenzoate

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2005, vol. 314, # 3, p. 1177 - 1186

>  <Main tar all>
Kv9.1 pX=7.22

$$$$
Detomidine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 0.4679 0 0
M  V30 3 C 5.7337 1.2379 0 0
M  V30 4 C 5.7337 2.7779 0 0
M  V30 5 C 7.0674 3.5479 0 0
M  V30 6 C 8.401 2.7779 0 0
M  V30 7 C 8.401 1.2379 0 0
M  V30 8 C 9.7347 0.4679 0 0
M  V30 9 C 9.7347 -1.0721 0 0
M  V30 10 C 10.9806 -1.9773 0 0
M  V30 11 N 10.5047 -3.442 0 0
M  V30 12 C 8.9647 -3.442 0 0
M  V30 13 N 8.4888 -1.9773 0 0
M  V30 14 C 7.0674 0.4679 0 0
M  V30 15 C 7.0674 -1.0721 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 9 13
M  V30 13 1 7 14
M  V30 14 2 3 14
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516861

>  <MW>
222.092

>  <MW (desalted)>
186.253

>  <ClogP>
2.936

>  <logS>
-3.598

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
28.68

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.043 ?M

>  <CAS>
90038-01-0

>  <Description>
Detomidine is an ?2-adrenergic agonist that is used as a horse sedative.

>  <EBC_ID>
EBC-43028

>  <IUPAC Name>
4-[(2,3-dimethylphenyl)methyl]-1H-imidazole hydrochloride

>  <Main Tar all refs>
ROCHE HOLDING AG - US2007/197622, 2007, A1

>  <Main tar all>
TA1 receptor pX=7.37

$$$$
Guanabenz hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 4.8537 5.225 0 0
M  V30 3 C 4.8537 3.685 0 0
M  V30 4 N 3.52 2.915 0 0
M  V30 5 N 6.1874 2.915 0 0
M  V30 6 N 6.1874 1.375 0 0
M  V30 7 C 7.521 0.605 0 0
M  V30 8 C 7.521 -0.935 0 0
M  V30 9 C 8.8547 -1.705 0 0
M  V30 10 Cl 10.1884 -0.935 0 0
M  V30 11 C 8.8547 -3.245 0 0
M  V30 12 C 7.521 -4.015 0 0
M  V30 13 C 6.1874 -3.245 0 0
M  V30 14 C 6.1874 -1.705 0 0
M  V30 15 Cl 4.8537 -0.935 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 6 5 CFG=2
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 9 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 8 14
M  V30 14 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z49562666

>  <MW>
265.989

>  <MW (desalted)>
231.082

>  <ClogP>
2.979

>  <logS>
-4.43

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
74.26

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  86 nM

>  <CAS>
23113-43-1

>  <Description>
Guanabenz is an alpha-2-adrenergic receptor agonist with hypotensive effects. It is used for management of high blood pressure.

>  <EBC_ID>
EBC-06434

>  <IUPAC Name>
N-{[(2,6-dichlorophenyl)methylidene]amino}guanidine hydrochloride

>  <Main Tar all refs>
ACS Chemical Neuroscience, 2018

>  <Main tar all>
NPFF1 receptor pX=7.07

$$$$
N-Acetyltyrosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -6.93 0 0
M  V30 2 C 2.6674 -6.16 0 0
M  V30 3 O 4.001 -6.93 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 4.001 -3.85 0 0 CFG=1
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 C 5.3347 -1.54 0 0
M  V30 8 C 5.3347 0 0 0
M  V30 9 C 6.6684 0.77 0 0
M  V30 10 C 8.0021 0 0 0
M  V30 11 O 9.3358 0.77 0 0
M  V30 12 C 8.0021 -1.54 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 C 5.3347 -4.62 0 0
M  V30 15 O 6.6684 -3.85 0 0
M  V30 16 O 5.3347 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 5 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756442196

>  <MW>
223.084

>  <MW (desalted)>
223.225

>  <ClogP>
0.153

>  <logS>
-1.346

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
86.63

>  <RotBonds>
4

>  <CAS>
537-55-3

>  <Description>
N-Acetyltyrosine is used in place of as a tyrosine precursor. It is indicated as a peripherally administered source of nitrogen for nutritional support in patients with adequate stores of body fat in whom, for short periods, oral administration cannot be tolerated, is undesirable, or inadequate.

>  <EBC_ID>
EBC-26235

>  <IUPAC Name>
(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoic acid

$$$$
Ganciclovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.5954 -0.7802 0 0
M  V30 2 C 1.0713 0.6845 0 0
M  V30 3 N 0.0408 1.8289 0 0
M  V30 4 C 0.5167 3.2935 0 0
M  V30 5 O -0.5138 4.438 0 0
M  V30 6 C 2.023 3.6137 0 0
M  V30 7 N 2.793 4.9474 0 0
M  V30 8 C 4.2994 4.6272 0 0
M  V30 9 N 4.4604 3.0957 0 0
M  V30 10 C 5.794 2.3257 0 0
M  V30 11 O 5.794 0.7857 0 0
M  V30 12 C 7.1277 0.0157 0 0
M  V30 13 C 7.1277 -1.5243 0 0
M  V30 14 O 8.4614 -2.2943 0 0
M  V30 15 C 8.4614 0.7857 0 0
M  V30 16 O 9.7951 0.0157 0 0
M  V30 17 C 3.0535 2.4693 0 0
M  V30 18 N 2.5776 1.0046 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 12 15
M  V30 15 1 15 16
M  V30 16 1 9 17
M  V30 17 2 6 17
M  V30 18 1 17 18
M  V30 19 1 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z594284200

>  <MW>
255.097

>  <MW (desalted)>
255.231

>  <ClogP>
-2.728

>  <logS>
-1.8

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
134.99

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Substrate

>  <Activity coefficients and valu>
IC50  0.00037 ?M | Ki (inhibition constant) = 9 nM | IC50  0.01 ?M

>  <CAS>
82410-32-0

>  <Description>
Ganciclovir is a synthetic analog of 2'-deoxy-guanosine which is used to treat or prevent cytomegalovirus infections. It is is a DNA polymerase inhibitor. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

>  <EBC_ID>
EBC-13406

>  <IUPAC Name>
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one

>  <Main Tar all refs>
Bioorg. Med. Chem., 2005, vol. 13, # 6, p. 2089 - 2096 | J. MED. CHEM., 1993, vol. 36, # 22, p. 3455 - 3463 | UCB - WO1999/19466, 1999, A3

>  <Main tar all>
Thymidine kinase (gene tdk) pX=9.43 | Purine nucleoside phosphorylase (activity) pX=8.05 | thymidine kinase pX=8.0

$$$$
Nevirapine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5661 -5.0919 0 0
M  V30 2 C 1.9088 -3.5905 0 0
M  V30 3 C 0.7799 -2.543 0 0
M  V30 4 C 1.1226 -1.0416 0 0
M  V30 5 N 2.5942 -0.5877 0 0
M  V30 6 C 3.7231 -1.6352 0 0
M  V30 7 N 5.1106 -0.967 0 0
M  V30 8 C 5.1106 0.573 0 0
M  V30 9 C 4.3406 1.9067 0 0
M  V30 10 C 5.8806 1.9067 0 0
M  V30 11 C 6.4981 -1.6352 0 0
M  V30 12 N 7.627 -0.5877 0 0
M  V30 13 C 9.0985 -1.0416 0 0
M  V30 14 C 9.4412 -2.543 0 0
M  V30 15 C 8.3123 -3.5905 0 0
M  V30 16 C 6.8407 -3.1365 0 0
M  V30 17 C 5.8806 -4.3406 0 0
M  V30 18 O 6.5487 -5.7281 0 0
M  V30 19 N 4.3406 -4.3406 0 0
M  V30 20 C 3.3804 -3.1365 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 10
M  V30 11 1 7 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 2 2 20
M  V30 23 1 6 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553473

>  <MW>
266.117

>  <MW (desalted)>
266.298

>  <ClogP>
2.65

>  <logS>
-3.05

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
58.12

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
IC50 = 0.09 ng/mL | EC50  6.7 nM | EC50  6.7 nM | IC50  0.0019 ?g/ml | EC90 = 95 nM

>  <CAS>
129618-40-2

>  <Description>
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used as part of a management regimen for HIV-1 virus infection.

>  <EBC_ID>
EBC-11254

>  <IUPAC Name>
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

>  <Main Tar all refs>
Bioorg. Med. Chem., 2011, vol. 19, # 6, p. 2084 - 2089 | Eur. J. Med. Chem., 2020, vol. 188 | Eur. J. Med. Chem., 2020, vol. 188 | J. Ethnopharmacol., 2021, vol. 277 | Antiviral Res., 2006, vol. 70, # 2, p. 66 - 74

>  <Main tar all>
RNA-directed DNA polymerase pX=9.47 | Endogenous?retrovirus?group?K?member?9?Pol?protein pX=8.17 | p51 reverse transcriptase (p51 RT) pX=8.17 | Truncated surface protein pX=8.15 | Beta-galactosidase (gene GLB1) pX=7.98

$$$$
Tolazamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.0343 -5.0728 0 0
M  V30 2 C 5.0343 -6.6128 0 0
M  V30 3 C 6.3679 -7.3828 0 0
M  V30 4 C 6.3679 -8.9228 0 0
M  V30 5 C 5.0343 -9.6928 0 0
M  V30 6 C 3.7006 -8.9228 0 0
M  V30 7 C 3.7006 -7.3828 0 0
M  V30 8 S 5.0343 -11.2328 0 0
M  V30 9 O 3.4943 -11.2328 0 0
M  V30 10 O 6.5743 -11.2328 0 0
M  V30 11 N 5.0343 -12.7728 0 0
M  V30 12 C 3.7006 -13.5428 0 0
M  V30 13 O 2.3669 -12.7728 0 0
M  V30 14 N 3.7006 -15.0828 0 0
M  V30 15 N 2.3669 -15.8528 0 0
M  V30 16 C 2.482 -17.3885 0 0
M  V30 17 C 1.3531 -18.436 0 0
M  V30 18 C -0.1697 -18.2065 0 0
M  V30 19 C -0.9397 -16.8728 0 0
M  V30 20 C -0.3771 -15.4392 0 0
M  V30 21 C 1.0945 -14.9853 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575267190

>  <MW>
311.13

>  <MW (desalted)>
311.4

>  <ClogP>
1.338

>  <logS>
-3.492

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
78.51

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) > 100 nM | IC50 < 100 nM | Ki (inhibition constant)  2602 nM | Ki (inhibition constant)  2602 nM

>  <CAS>
1156-19-0

>  <Description>
Tolazamide is a sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. It is indicated for use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

>  <EBC_ID>
EBC-13624

>  <IUPAC Name>
1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea

>  <Main Tar all refs>
LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332

>  <Main tar all>
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=7.0 | Kir6.2 pX=7.0 | KATP?channel?SUR1 pX=5.59 | Kir6.2 pX=5.59

$$$$
Ondanserton
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.31 1.5418 0 0
M  V30 2 C 10.08 0.2082 0 0
M  V30 3 N 11.6116 0.0472 0 0
M  V30 4 C 11.9318 -1.4592 0 0
M  V30 5 C 10.5981 -2.2292 0 0
M  V30 6 N 9.4536 -1.1987 0 0
M  V30 7 C 7.9473 -1.5189 0 0
M  V30 8 C 6.9168 -0.3744 0 0
M  V30 9 C 7.3927 1.0902 0 0
M  V30 10 C 6.3623 2.2346 0 0
M  V30 11 C 4.8559 1.9144 0 0
M  V30 12 C 4.38 0.4498 0 0
M  V30 13 C 5.4105 -0.6946 0 0
M  V30 14 O 4.9346 -2.1593 0 0
M  V30 15 C 2.84 0.4498 0 0
M  V30 16 C 1.8096 -0.6946 0 0
M  V30 17 C 0.3032 -0.3744 0 0
M  V30 18 C -0.1727 1.0902 0 0
M  V30 19 C 0.8578 2.2346 0 0
M  V30 20 C 2.3641 1.9144 0 0
M  V30 21 N 3.61 2.8196 0 0
M  V30 22 C 3.61 4.3596 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 8 13
M  V30 15 2 13 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 20 21
M  V30 24 1 11 21
M  V30 25 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485364

>  <MW>
293.153

>  <MW (desalted)>
293.363

>  <ClogP>
2.716

>  <logS>
-2.25

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
39.82

>  <RotBonds>
2

>  <Action on targets>
Antagonist | Antagonist | Inhibitor

>  <Activity coefficients and valu>
pA2  10.1  | IC50  0.09 nM | pKi  8.7

>  <CAS>
99614-02-5

>  <Description>
Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

>  <EBC_ID>
EBC-06052

>  <IUPAC Name>
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one

>  <Main Tar all refs>
BIOORG. MED. CHEM. LETT., 1992, vol. 2, # 5, p. 461 - 466 | J. Med. Chem., 2011, vol. 54, # 9, p. 3206 - 3221 | J. Med. Chem., 1999, vol. 42, # 21, p. 4362 - 4379

>  <Main tar all>
5-HT3A pX=10.1 | 5-HT3A pX=10.0 | 5-HT2A receptor pX=8.7

$$$$
Cyclobenzaprine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 6.0592 0 0
M  V30 3 N 5.7337 4.5192 0 0
M  V30 4 C 4.4 3.7492 0 0
M  V30 5 C 7.0674 3.7492 0 0
M  V30 6 C 7.0674 2.2092 0 0
M  V30 7 C 8.401 1.4392 0 0
M  V30 8 C 8.401 -0.1008 0 0
M  V30 9 C 9.7885 -0.769 0 0
M  V30 10 C 10.9174 0.2784 0 0
M  V30 11 C 12.389 -0.1755 0 0
M  V30 12 C 12.7317 -1.6769 0 0
M  V30 13 C 11.6028 -2.7243 0 0
M  V30 14 C 10.1312 -2.2704 0 0
M  V30 15 C 9.171 -3.4744 0 0
M  V30 16 C 7.631 -3.4744 0 0
M  V30 17 C 6.6709 -2.2704 0 0
M  V30 18 C 5.1993 -2.7243 0 0
M  V30 19 C 4.0704 -1.6769 0 0
M  V30 20 C 4.4131 -0.1755 0 0
M  V30 21 C 5.8846 0.2784 0 0
M  V30 22 C 7.0135 -0.769 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 8 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575278780

>  <MW>
311.144

>  <MW (desalted)>
275.387

>  <ClogP>
5.097

>  <logS>
-4.918

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
3.24

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  29 nM | IC50  300 nM

>  <CAS>
6202-23-9

>  <Description>
Cyclobenzaprine is a skeletal muscle relaxant that works on the brainstem to treat muscle spasms of local origin. Cyclobenzaprine is indicated as a short-term adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

>  <EBC_ID>
EBC-12731

>  <IUPAC Name>
dimethyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}propyl)amine hydrochloride

>  <Main Tar all refs>
EISAI CO LTD - US6340759, 2002, B1 | GUJRAL; SINGH (inventors); LIFEBRANDZ LTD - WO2010/6432, 2010, A1

>  <Main tar all>
5-HT1A receptor pX=7.54 | ret proto-oncogene pX=6.52

$$$$
Disopyramide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7463 6.93 0 0
M  V30 2 C 1.7463 5.39 0 0
M  V30 3 C 0.4126 4.62 0 0
M  V30 4 N 3.08 4.62 0 0
M  V30 5 C 3.08 3.08 0 0
M  V30 6 C 4.4137 2.31 0 0
M  V30 7 C 4.4137 0.77 0 0
M  V30 8 C 2.8737 0.77 0 0
M  V30 9 O 2.1037 -0.5637 0 0
M  V30 10 N 2.1037 2.1037 0 0
M  V30 11 C 4.4137 -0.77 0 0
M  V30 12 C 5.7474 -1.54 0 0
M  V30 13 C 5.7474 -3.08 0 0
M  V30 14 C 4.4137 -3.85 0 0
M  V30 15 C 3.08 -3.08 0 0
M  V30 16 C 3.08 -1.54 0 0
M  V30 17 C 5.9537 0.77 0 0
M  V30 18 C 6.7237 2.1037 0 0
M  V30 19 C 8.2637 2.1037 0 0
M  V30 20 C 9.0337 0.77 0 0
M  V30 21 C 8.2637 -0.5637 0 0
M  V30 22 N 6.7237 -0.5637 0 0
M  V30 23 C 4.4137 5.39 0 0
M  V30 24 C 5.7474 4.62 0 0
M  V30 25 C 4.4137 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 7 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 4 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1556052559

>  <MW>
339.231

>  <MW (desalted)>
339.474

>  <ClogP>
2.576

>  <logS>
-2.54

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
59.22

>  <RotBonds>
8

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
EC50  7.78E-10 M | IC50 = 22 nM

>  <CAS>
3737-09-5

>  <Description>
Disopyramide is a Type 1A antiarrhythmic drug. It inhibits the fast sodium channels. It has a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. Disopyramide is used for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.

>  <EBC_ID>
EBC-12812

>  <IUPAC Name>
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide

>  <Main Tar all refs>
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - WO2007/112288, 2007, A2 | Curr. Med. Chem.: Cardiovasc. Hematol. Agents, 2003, vol. 1, # 3, p. 225 - 241

>  <Main tar all>
Amyloid-beta protein 40 pX=9.11 | Kv9.1 pX=7.66

$$$$
Bestatin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -9.24 0 0
M  V30 2 C 4.001 -10.01 0 0
M  V30 3 C 4.001 -11.55 0 0
M  V30 4 C 5.3347 -9.24 0 0
M  V30 5 C 6.6684 -10.01 0 0 CFG=2
M  V30 6 N 8.0021 -9.24 0 0
M  V30 7 C 9.3358 -10.01 0 0
M  V30 8 O 9.3358 -11.55 0 0
M  V30 9 C 10.6694 -9.24 0 0 CFG=1
M  V30 10 O 10.6694 -7.7 0 0
M  V30 11 C 12.0031 -10.01 0 0 CFG=2
M  V30 12 N 12.0031 -11.55 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 C 14.6705 -10.01 0 0
M  V30 15 C 16.0041 -9.24 0 0
M  V30 16 C 17.3378 -10.01 0 0
M  V30 17 C 17.3378 -11.55 0 0
M  V30 18 C 16.0041 -12.32 0 0
M  V30 19 C 14.6705 -11.55 0 0
M  V30 20 C 6.6684 -11.55 0 0
M  V30 21 O 8.0021 -12.32 0 0
M  V30 22 O 5.3347 -12.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 20 1 5 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242062173

>  <MW>
308.174

>  <MW (desalted)>
308.373

>  <ClogP>
-0.307

>  <logS>
-3.337

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
112.65

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.4 nM | Ki (inhibition constant)  0.0005 ?M | IC50  0.0016 ?M | IC50  0.0016 ?M | IC50  3.49 nM

>  <CAS>
58970-76-6

>  <Description>
Bestatin is a competitive protease inhibitor. It is an inhibitor of cytosol aminopeptidase (Ki= 0.4 nM), aminopeptidase B (Ki= 14 nM), leukotriene A4 hydrolase ( Km = 0.17 ?M), aminopeptidase N (Km = 14 nM). It is being studied for use in the treatment of acute myelocytic leukemia.

>  <EBC_ID>
EBC-17055

>  <IUPAC Name>
(2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid

>  <Main Tar all refs>
Med. Res. Rev., 2006, vol. 26, # 1, p. 88 - 130 | Bioorg. Med. Chem., 2012, vol. 20, # 16, p. 4942 - 4953 | Bioorg. Med. Chem., 2006, vol. 14, # 21, p. 7241 - 7257 | Bioorg. Med. Chem., 2011, vol. 19, # 4, p. 1434 - 1449 | Biochim. Biophys. Acta Gen. Subj., 2014, vol. 1840, # 6, p. 1872 - 1881

>  <Main tar all>
Leucine aminopeptidase 3 pX=9.4 | Aminopeptidase N pX=9.3 | APaero pX=8.8 | aminopeptidase pX=8.8 | Arginyl aminopeptidase pX=8.46

$$$$
Naftopidil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 -3.08 0 0
M  V30 2 O -6.6684 -2.31 0 0
M  V30 3 C -6.6684 -0.77 0 0
M  V30 4 C -8.0021 -0 0 0
M  V30 5 C -8.0021 1.54 0 0
M  V30 6 C -6.6684 2.31 0 0
M  V30 7 C -5.3347 1.54 0 0
M  V30 8 C -5.3347 -0 0 0
M  V30 9 N -4.001 -0.77 0 0
M  V30 10 C -2.6674 0 0 0
M  V30 11 C -1.3337 -0.77 0 0
M  V30 12 N -1.3337 -2.31 0 0
M  V30 13 C 0 -3.08 0 0
M  V30 14 C 0 -4.62 0 0
M  V30 15 O -1.3337 -5.39 0 0
M  V30 16 C 1.3337 -5.39 0 0
M  V30 17 O 2.6674 -4.62 0 0
M  V30 18 C 2.6674 -3.08 0 0
M  V30 19 C 1.3337 -2.31 0 0
M  V30 20 C 1.3337 -0.77 0 0
M  V30 21 C 2.6674 0 0 0
M  V30 22 C 4.001 -0.77 0 0
M  V30 23 C 5.3347 0 0 0
M  V30 24 C 6.6684 -0.77 0 0
M  V30 25 C 6.6684 -2.31 0 0
M  V30 26 C 5.3347 -3.08 0 0
M  V30 27 C 4.001 -2.31 0 0
M  V30 28 C -2.6674 -3.08 0 0
M  V30 29 C -4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 18 27
M  V30 29 1 22 27
M  V30 30 1 12 28
M  V30 31 1 28 29
M  V30 32 1 9 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z31369389

>  <MW>
392.491

>  <MW (desalted)>
392.491

>  <ClogP>
4.433

>  <logS>
-5.008

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
45.17

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.2 nM | Ki (inhibition constant) = 3.7 nM | pA2  8.15  | IC (inhibitory concentration)  0.01 ?M | Ki (inhibition constant) = 20 nM | pA2  7.52

>  <CAS>
57149-07-2

>  <Description>
Naftopidil is a selective alpha1-adrenoceptor antagonist, with antiproliferative effects. Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

>  <EBC_ID>
EBC-03851

>  <IUPAC Name>
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol

>  <Main Tar all refs>
Curr. Med. Chem., 2002, vol. 9, # 13, p. 1303 - 1321 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 3, p. 657 - 664 | JPN. J. PHARMACOL., 1991, vol. 55, # 3, p. 391 - 398 | Sumitomo Pharma (in: Sumitomo Chemical); Sumitomo Chemical (w/o Dongwoo Fine-Chem); SUMITOMO CHEMICAL COMPANY LIMITED - WO2018/26371, 2018, A1 | Curr. Med. Chem., 2002, vol. 9, # 13, p. 1303 - 1321 | JPN. J. PHARMACOL., 1991, vol. 55, # 3, p. 391 - 398

>  <Main tar all>
?1D-adrenoceptor pX=8.92 | ?1A-adrenoceptor pX=8.43 | ?1-adrenoceptor pX=8.15 | Nav1.2 pX=8.0 | ?1B-adrenoceptor pX=7.7 | ?1-adrenoceptor pX=7.52

$$$$
Epinastine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 10.5612 3.159 0 0
M  V30 3 C 9.0965 2.6831 0 0
M  V30 4 N 7.8507 3.5883 0 0
M  V30 5 C 6.6048 2.6831 0 0
M  V30 6 C 7.0807 1.2185 0 0
M  V30 7 N 8.6207 1.2185 0 0
M  V30 8 C 9.5808 0.0145 0 0
M  V30 9 C 11.0524 0.4684 0 0
M  V30 10 C 12.1813 -0.579 0 0
M  V30 11 C 11.8386 -2.0804 0 0
M  V30 12 C 10.367 -2.5344 0 0
M  V30 13 C 9.2381 -1.4869 0 0
M  V30 14 C 7.8507 -2.1551 0 0
M  V30 15 C 6.4632 -1.4869 0 0
M  V30 16 C 5.3343 -2.5344 0 0
M  V30 17 C 3.8627 -2.0804 0 0
M  V30 18 C 3.52 -0.579 0 0
M  V30 19 C 4.6489 0.4684 0 0
M  V30 20 C 6.1205 0.0145 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 6 20
M  V30 22 2 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516876

>  <MW>
285.103

>  <MW (desalted)>
249.31

>  <ClogP>
3.006

>  <logS>
-4.404

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
41.62

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  9.8 nM

>  <CAS>
108929-04-0

>  <Description>
Epinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response. Epinastine stabilizes mast cells by preventing mast cell degranulation to control the allergic response. It prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection. Epinastine prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.

>  <EBC_ID>
EBC-28051

>  <IUPAC Name>
2,4-diazatetracyclo[12.4.0.0^{2,6}.0^{7,12}]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine hydrochloride

>  <Main Tar all refs>
Arzneimittelforschung, 1990, vol. 40, # 4, p. 440 - 446

>  <Main tar all>
H1 receptor pX=8.01

$$$$
Nitrofurantoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.6612 -1.3512 0 0 CHG=-1
M  V30 2 N 4.3276 -2.1212 0 0 CHG=1
M  V30 3 O 2.9939 -1.3512 0 0
M  V30 4 C 4.3276 -3.6612 0 0
M  V30 5 C 5.5734 -4.5664 0 0
M  V30 6 C 5.0976 -6.031 0 0
M  V30 7 C 3.5576 -6.031 0 0
M  V30 8 C 2.6524 -7.2769 0 0
M  V30 9 N 3.2787 -8.6838 0 0
M  V30 10 N 2.3736 -9.9297 0 0
M  V30 11 C 2.8494 -11.3943 0 0
M  V30 12 C 1.6036 -12.2995 0 0
M  V30 13 O 1.6036 -13.8395 0 0
M  V30 14 N 0.3577 -11.3943 0 0
M  V30 15 C 0.8336 -9.9297 0 0
M  V30 16 O -0.0716 -8.6838 0 0
M  V30 17 O 3.0817 -4.5664 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 7 CFG=2
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 2 15 16
M  V30 17 1 7 17
M  V30 18 1 4 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57152561

>  <MW>
238.157

>  <MW (desalted)>
238.157

>  <ClogP>
-0.467

>  <logS>
-3.307

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
118.05

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor

>  <Activity coefficients and valu>
MIC  4 ?g/ml | MIC  4 ?g/ml | EC50  20 - 40 ?M | EC50  20 - 40 ?M | inhibition percentage  91 % | IC50  56.1 ?M | MIC  16 ?g/ml | MIC  16 ?g/ml | IC50  136.4 ?M | superoxide production rate Active   | inhibition percentage  66 %

>  <CAS>
67-20-9

>  <Description>
Nitrofurantoin is an antibiotic used to treat urinary tract infections.

>  <EBC_ID>
EBC-71080

>  <IUPAC Name>
1-{[(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione

>  <Main Tar all refs>
Front. Microbiol., 2020, vol. 11 | Front. Microbiol., 2020, vol. 11 | Bioorg. Med. Chem., 2020, vol. 28, # 22 | Bioorg. Med. Chem., 2020, vol. 28, # 22 | J. Med. Chem., 2003, vol. 46, # 21, p. 4477 - 4486 | J. Med. Chem., 2022, vol. 65, # 21, p. 14578 - 14588 | Int. J. Mol. Sci., 2021, vol. 22, # 8 | Int. J. Mol. Sci., 2021, vol. 22, # 8 | Toxicol. Appl. Pharmacol., 2020, vol. 401 | Toxicol. Appl. Pharmacol., 2020, vol. 401 | J. Med. Chem., 2013, vol. 56, # 21, p. 8377 - 8388

>  <Main tar all>
Outer membrane protein assembly factor BamA pX=4.77 | Outer membrane protein assembly factor BamD pX=4.77 | 10 kDa chaperonin pX=4.7 | 60 kDa chaperonin 1 pX=4.7 | Chymotrypsin B pX=4.61 | Organic anion transporter 2 pX=4.25 | DNA topoisomerase IV subunit A pX=4.17 | DNA topoisomerase IV subunit B pX=4.17 | H-PGDS pX=3.87 | NADPH-cytochrome P450 reductase pX=3.6 | COX-1  pX=3.59

$$$$
Fludarabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 F 8.788 -0.77 0 0
M  V30 6 N 6.1207 -0.77 0 0
M  V30 7 C 4.787 0 0 0
M  V30 8 N 3.3224 -0.4759 0 0
M  V30 9 C 2.4172 0.77 0 0
M  V30 10 N 3.3224 2.0159 0 0
M  V30 11 C 4.787 1.54 0 0
M  V30 12 C 2.8465 -1.9405 0 0 CFG=2
M  V30 13 O 3.7517 -3.1864 0 0
M  V30 14 C 2.8465 -4.4323 0 0 CFG=2
M  V30 15 C 3.3224 -5.8969 0 0
M  V30 16 O 4.8287 -6.2171 0 0
M  V30 17 C 1.3818 -3.9564 0 0 CFG=1
M  V30 18 O 0.136 -4.8616 0 0
M  V30 19 C 1.3818 -2.4164 0 0 CFG=2
M  V30 20 O 0.136 -1.5112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 2 11
M  V30 12 1 7 11
M  V30 13 1 12 8 CFG=3
M  V30 14 1 12 13
M  V30 15 1 14 13
M  V30 16 1 14 15 CFG=3
M  V30 17 1 15 16
M  V30 18 1 17 14
M  V30 19 1 17 18 CFG=1
M  V30 20 1 17 19
M  V30 21 1 19 12
M  V30 22 1 19 20 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756440078

>  <MW>
285.232

>  <MW (desalted)>
285.232

>  <ClogP>
-2.005

>  <logS>
-2.33

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
139.54

>  <RotBonds>
2

>  <Action on targets>
Activator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
stimulation rate >= 50 - 70 % | percentage increase Active   | EC50  1.06 ?M

>  <CAS>
21679-14-1

>  <Description>
Fludarabine is a purine analog antimetabolite that inhibits DNA synthesis. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.

>  <EBC_ID>
EBC-11027

>  <IUPAC Name>
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

>  <Main Tar all refs>
Mol. Ther. Oncolytics, 2019, vol. 13, p. 22 - 34 | ACS Chem. Biol., 2017, vol. 12, # 2, p. 444 - 455 | Antiviral Res., 2022, vol. 198

>  <Main tar all>
signal transducer and activator of transcription 1 pX=6.88 | Bcl-2-related protein A1 pX=6.0 | RNA-dependent RNA polymerase 2 pX=5.97

$$$$
Dutasterid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 C 10.2985 -4.155 0 0 CFG=1
M  V30 6 C 9.3058 -2.9776 0 0 CFG=1
M  V30 7 C 9.829 -1.5293 0 0
M  V30 8 C 11.345 -1.2582 0 0
M  V30 9 C 12.3377 -2.4355 0 0 CFG=1
M  V30 10 N 13.8537 -2.1644 0 0
M  V30 11 C 14.8464 -3.3418 0 0
M  V30 12 O 16.3624 -3.0707 0 0
M  V30 13 C 14.3232 -4.7901 0 0
M  V30 14 C 12.8072 -5.0612 0 0
M  V30 15 C 11.8145 -3.8839 0 0 CFG=2
M  V30 16 C 11.2913 -5.3323 0 0
M  V30 17 C 7.7898 -3.2487 0 0 CFG=2
M  V30 18 C 6.574 -2.3035 0 0
M  V30 19 C 5.2994 -3.1677 0 0
M  V30 20 C 5.7274 -4.6471 0 0 CFG=2
M  V30 21 C 4.7822 -5.8629 0 0
M  V30 22 O 3.2567 -5.6522 0 0
M  V30 23 N 5.3626 -7.2893 0 0
M  V30 24 C 4.4174 -8.5052 0 0
M  V30 25 C 2.8918 -8.2945 0 0
M  V30 26 C 1.9467 -9.5103 0 0
M  V30 27 C 2.527 -10.9368 0 0
M  V30 28 C 4.0525 -11.1474 0 0
M  V30 29 C 4.9977 -9.9316 0 0
M  V30 30 C 6.5232 -10.1423 0 0
M  V30 31 F 8.0488 -10.3529 0 0
M  V30 32 F 6.3126 -11.6678 0 0
M  V30 33 F 6.7339 -8.6168 0 0
M  V30 34 C 0.4211 -9.2997 0 0
M  V30 35 F -1.1044 -9.089 0 0
M  V30 36 F 0.6318 -7.7741 0 0
M  V30 37 F 0.2105 -10.8252 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=1
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 15 14
M  V30 15 1 15 9
M  V30 16 1 5 15
M  V30 17 1 15 16 CFG=1
M  V30 18 1 17 6
M  V30 19 1 2 17
M  V30 20 1 17 18 CFG=1
M  V30 21 1 18 19
M  V30 22 1 20 19
M  V30 23 1 2 20
M  V30 24 1 20 21 CFG=1
M  V30 25 2 21 22
M  V30 26 1 21 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 2 25 26
M  V30 30 1 26 27
M  V30 31 2 27 28
M  V30 32 1 28 29
M  V30 33 2 24 29
M  V30 34 1 29 30
M  V30 35 1 30 31
M  V30 36 1 30 32
M  V30 37 1 30 33
M  V30 38 1 26 34
M  V30 39 1 34 35
M  V30 40 1 34 36
M  V30 41 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1558504346

>  <MW>
528.53

>  <MW (desalted)>
528.53

>  <ClogP>
4.94

>  <logS>
-7.44

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
58.2

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 < 0.1 nM | IC50 = 2.4 nM

>  <CAS>
164656-23-9

>  <Description>
Dutasteride is an antiandrogenic compound that is used for the treatment of symptomatic benign prostatic hyperplasia (BPH) in adult males by inhibiting 5-alpha reductase.

>  <EBC_ID>
EBC-11281

>  <IUPAC Name>
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-1H,2H,4aH,4bH,5H,6H,6aH,7H,8H,9H,9aH,9bH,10H,11H,11aH-indeno[5,4-f]quinoline-7-carboxamide

>  <Main Tar all refs>
J. MED. CHEM., 1995, vol. 38, # 17, p. 3189 - 3192 | J. MED. CHEM., 1997, vol. 40, # 9, p. 1293 - 1315

>  <Main tar all>
steroid 5 alpha-reductase 2 pX=10.0 | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 pX=8.62

$$$$
Enalaprilat dihydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 O 4.4 0 0 0
M  V30 3 C 1.3669 -3.85 0 0
M  V30 4 C 1.3669 -5.39 0 0 CFG=2
M  V30 5 N 0.0332 -6.16 0 0
M  V30 6 C -1.3005 -5.39 0 0 CFG=1
M  V30 7 C -2.6342 -6.16 0 0
M  V30 8 C -3.9679 -5.39 0 0
M  V30 9 C -5.3015 -6.16 0 0
M  V30 10 C -5.3015 -7.7 0 0
M  V30 11 C -6.6352 -8.47 0 0
M  V30 12 C -7.9689 -7.7 0 0
M  V30 13 C -7.9689 -6.16 0 0
M  V30 14 C -6.6352 -5.39 0 0
M  V30 15 C -1.3005 -3.85 0 0
M  V30 16 O -2.6342 -3.08 0 0
M  V30 17 O 0.0332 -3.08 0 0
M  V30 18 C 2.7005 -6.16 0 0
M  V30 19 O 2.7005 -7.7 0 0
M  V30 20 N 4.0342 -5.39 0 0
M  V30 21 C 4.1952 -3.8584 0 0
M  V30 22 C 5.7015 -3.5383 0 0
M  V30 23 C 6.4715 -4.8719 0 0
M  V30 24 C 5.4411 -6.0164 0 0 CFG=1
M  V30 25 C 5.7613 -7.5227 0 0
M  V30 26 O 7.2259 -7.9986 0 0
M  V30 27 O 4.6168 -8.5532 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 3 CFG=1
M  V30 2 1 4 5
M  V30 3 1 6 5 CFG=1
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 2 10 11
M  V30 9 1 11 12
M  V30 10 2 12 13
M  V30 11 1 13 14
M  V30 12 2 9 14
M  V30 13 1 6 15
M  V30 14 2 15 16
M  V30 15 1 15 17
M  V30 16 1 4 18
M  V30 17 2 18 19
M  V30 18 1 18 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 1 22 23
M  V30 22 1 24 23
M  V30 23 1 24 20
M  V30 24 1 24 25 CFG=1
M  V30 25 2 25 26
M  V30 26 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2569864568

>  <MW>
384.19

>  <MW (desalted)>
348.394

>  <ClogP>
0.748

>  <logS>
-2.937

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
106.94

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.95 nM

>  <CAS>
84680-54-6

>  <Description>
Enalaprilat is an antihypertensive agent used for the management of hypertension when oral therapy is not practical. Enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme from transforming angiotensin I into angiotensin II.

>  <EBC_ID>
EBC-15039

>  <IUPAC Name>
(2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid dihydrate

>  <Main Tar all refs>
J. MED. CHEM., 1991, vol. 34, # 1, p. 439 - 447

>  <Main tar all>
Angiotensin-converting enzyme pX=9.02

$$$$
Lapatanib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.2359 -10.8811 0 0
M  V30 2 S -6.6096 -9.4743 0 0
M  V30 3 O -5.2027 -10.1006 0 0
M  V30 4 O -8.0164 -8.8479 0 0
M  V30 5 C -5.9832 -8.0674 0 0
M  V30 6 C -4.4516 -7.9064 0 0
M  V30 7 N -3.8253 -6.4996 0 0
M  V30 8 C -2.2937 -6.3386 0 0
M  V30 9 C -1.6673 -4.9317 0 0
M  V30 10 C -2.4373 -3.5981 0 0
M  V30 11 C -1.4069 -2.4536 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 O -0.161 -4.6116 0 0
M  V30 14 C 1.3337 -2.31 0 0
M  V30 15 C 1.3337 -0.77 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 17 C 4.001 -0.77 0 0
M  V30 18 N 5.3347 0 0 0
M  V30 19 C 6.6684 -0.77 0 0
M  V30 20 N 6.6684 -2.31 0 0
M  V30 21 C 5.3347 -3.08 0 0
M  V30 22 N 5.3347 -4.62 0 0
M  V30 23 C 4.001 -5.39 0 0
M  V30 24 C 2.6674 -4.62 0 0
M  V30 25 C 1.3337 -5.39 0 0
M  V30 26 C 1.3337 -6.93 0 0
M  V30 27 O -0 -7.7 0 0
M  V30 28 C -0 -9.24 0 0
M  V30 29 C -1.3337 -10.01 0 0
M  V30 30 C -2.6674 -9.24 0 0
M  V30 31 C -4.001 -10.01 0 0
M  V30 32 C -4.001 -11.55 0 0
M  V30 33 C -2.6674 -12.32 0 0
M  V30 34 F -2.6674 -13.86 0 0
M  V30 35 C -1.3337 -11.55 0 0
M  V30 36 C 2.6674 -7.7 0 0
M  V30 37 Cl 2.6674 -9.24 0 0
M  V30 38 C 4.001 -6.93 0 0
M  V30 39 C 4.001 -2.31 0 0
M  V30 40 C 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 9 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 1 33 35
M  V30 36 2 29 35
M  V30 37 2 26 36
M  V30 38 1 36 37
M  V30 39 1 36 38
M  V30 40 2 23 38
M  V30 41 1 21 39
M  V30 42 2 17 39
M  V30 43 1 39 40
M  V30 44 2 14 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480422

>  <MW>
581.058

>  <MW (desalted)>
581.058

>  <ClogP>
5.965

>  <logS>
-7.448

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
106.35

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.06 nM | IC50 = 8E-05 ?M | Ki (inhibition constant)  0.1 nM | IC50  0.182 nM | Ki (inhibition constant)  0.42 nM | Ki (inhibition constant)  0.42 nM | IC50  0.296 ng/ml | Ki (inhibition constant)  0.7 nM | Ki (inhibition constant)  0.7 nM | IC50  0.0009 ?M | inhibition percentage Active   | IC50  1.76 nM

>  <CAS>
231277-92-2

>  <Description>
Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2). Lapatinib is an anti-cancer drug, used for the treatment for solid tumours such as breast and lung cancer.

>  <EBC_ID>
EBC-00694

>  <IUPAC Name>
N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 20, p. 11725 - 11755 | EISAI CO LTD - WO2003/60799, 2003, A3 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Bioorg. Chem., 2021, vol. 110 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Bioorg. Chem., 2020, vol. 105 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 9, p. 2419 - 2422 | SCRIPPS RESEARCH; UNIVERSITY OF CALIFORNIA - WO2017/184775, 2017, A1 | THE UNIVERSITY OF TEXAS SYSTEM - WO2019/191279, 2019, A2

>  <Main tar all>
epidermal growth factor receptor pX=10.2 | B-Raf proto-oncogene, serine/threonine kinase pX=10.1 | epidermal growth factor receptor pX=10.0 | Epidermal growth factor receptor (L858R) pX=9.74 | Epidermal growth factor receptor (L861Q) pX=9.38 | Epidermal growth factor receptor (L861Q) pX=9.38 | epidermal growth factor receptor pX=9.29 | Epidermal growth factor receptor (G719C) pX=9.15 | Epidermal growth factor receptor (G719C) pX=9.15 | erb-b2 receptor tyrosine kinase 2 pX=9.05 | Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial pX=9.0 | erb-b2 receptor tyrosine kinase 2 (D769N) pX=8.75

$$$$
Valsartan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -6.847 -7.409 0 0
M  V30 2 C -5.3347 -7.7 0 0
M  V30 3 C -4.3265 -6.5359 0 0
M  V30 4 C -2.8143 -6.8269 0 0
M  V30 5 C -1.8061 -5.6628 0 0
M  V30 6 O -2.3102 -4.2076 0 0
M  V30 7 N -0.2939 -5.9538 0 0
M  V30 8 C 0.7143 -4.7897 0 0
M  V30 9 C 0.2102 -3.3345 0 0
M  V30 10 C -1.302 -3.0435 0 0
M  V30 11 C -1.8061 -1.5883 0 0
M  V30 12 C -0.798 -0.4242 0 0
M  V30 13 C 0.7143 -0.7152 0 0
M  V30 14 C 1.2184 -2.1704 0 0
M  V30 15 C -1.302 1.031 0 0
M  V30 16 C -2.8143 1.322 0 0
M  V30 17 C -3.3184 2.7772 0 0
M  V30 18 C -2.3102 3.9413 0 0
M  V30 19 C -0.798 3.6503 0 0
M  V30 20 C -0.2939 2.1951 0 0
M  V30 21 C 1.2184 1.9041 0 0
M  V30 22 N 2.3427 2.9564 0 0
M  V30 23 N 3.691 2.2123 0 0
M  V30 24 N 3.4 0.7001 0 0
M  V30 25 N 1.8718 0.5096 0 0
M  V30 26 C 0.2102 -7.409 0 0 CFG=1
M  V30 27 C -0.798 -8.5731 0 0
M  V30 28 C -0.2939 -10.0283 0 0
M  V30 29 C -2.3102 -8.2821 0 0
M  V30 30 C 1.7225 -7.7 0 0
M  V30 31 O 2.7306 -6.5359 0 0
M  V30 32 O 2.2265 -9.1552 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 21 25
M  V30 28 1 26 7 CFG=3
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 1 26 30
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1379303659

>  <MW>
435.519

>  <MW (desalted)>
435.519

>  <ClogP>
4.859

>  <logS>
-6.95

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
112.07

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.37 nM | Kd (dissociation constant)  9.12E-10 M | concentration (parameter) = 1.7 nM | IC50  1.9 nM | IC50  0.0023 ?M | IC50 ~ 5 nM

>  <CAS>
137862-53-4

>  <Description>
Valsartan belongs to the angiotensin II receptor blocker family of drugs, which selectively bind to angiotensin receptor 1 and prevent angiotensin II from binding and exerting its hypertensive effects. It is used to manage hypertension alone or in combination with other antihypertensive agents and to manage heart failure in patients who are intolerant to ACE inhibitors.

>  <EBC_ID>
EBC-11260

>  <IUPAC Name>
(2S)-3-methyl-2-(N-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid

>  <Main Tar all refs>
J. Pharmacol. Toxicol. Methods, 2020, vol. 102 | Int. J. Mol. Sci., 2022, vol. 23, # 19 | J. Med. Chem., 2005, vol. 48, # 13, p. 4389 - 4399 | J. Med. Chem., 2004, vol. 47, # 10, p. 2574 - 2586 | Toxicol. Appl. Pharmacol., 2017, vol. 323, p. 53 - 65 | Novartis (w/o Sandoz); NOVARTIS AG - EP443983, 1991, B1

>  <Main tar all>
AT1 receptor pX=9.43 | Protein X pX=9.04 | AT1 receptor pX=8.77 | AT1 receptor pX=8.72 | Neutral endopeptidase pX=8.64 | AT2 receptor pX=8.3

$$$$
Chlorthalidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.5428 -1.7787 0 0
M  V30 2 S -3.2091 -2.5487 0 0
M  V30 3 O -3.9791 -3.8824 0 0
M  V30 4 O -2.4391 -1.215 0 0
M  V30 5 C -1.8754 -3.3187 0 0
M  V30 6 C -0.5417 -2.5487 0 0
M  V30 7 C 0.7919 -3.3187 0 0
M  V30 8 C 0.7919 -4.8587 0 0
M  V30 9 C -0.5417 -5.6287 0 0
M  V30 10 C -1.8754 -4.8587 0 0
M  V30 11 Cl -3.2091 -5.6287 0 0
M  V30 12 C 2.1256 -2.5487 0 0
M  V30 13 O 2.752 -3.9556 0 0
M  V30 14 N 1.2204 -1.3028 0 0
M  V30 15 C 2.1256 -0.0569 0 0
M  V30 16 O 1.6497 1.4077 0 0
M  V30 17 C 3.5902 -0.5328 0 0
M  V30 18 C 4.9239 0.2372 0 0
M  V30 19 C 6.2576 -0.5328 0 0
M  V30 20 C 6.2576 -2.0728 0 0
M  V30 21 C 4.9239 -2.8428 0 0
M  V30 22 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 7 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 12 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741981513

>  <MW>
338.766

>  <MW (desalted)>
338.766

>  <ClogP>
0.448

>  <logS>
-3.674

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
109.49

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.8 nM | Ki (inhibition constant)  2.8 nM | Ki (inhibition constant)  4.5 nM | Ki (inhibition constant)  9 nM | Ki (inhibition constant)  15 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  19 nM | Ki (inhibition constant)  23 nM | Kd (dissociation constant)  35 nM

>  <CAS>
77-36-1

>  <Description>
Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl? symporter in the distal convoluted tubule cells in the kidney. The exact mechanism of chlorthalidone's anti-hypertensive effect is under debate, however, it is thought that increased diuresis results in decreased plasma and extracellular fluid volume, decreased cardiac output and therefore overall reduction in blood pressure.

>  <EBC_ID>
EBC-26647

>  <IUPAC Name>
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328 | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328 | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328 | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328 | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | J. Med. Chem., 2009, vol. 52, # 2, p. 322 - 328 | PLoS ONE, 2021, vol. 16, # 6 June

>  <Main tar all>
carbonic anhydrase 3 pX=8.55 | carbonic anhydrase 7 pX=8.55 | carbonic anhydrase 12 pX=8.35 | Carbonic anhydrase 5B, mitochondrial pX=8.05 | carbonic anhydrase 13 pX=7.82 | carbonic anhydrase 1 pX=7.8 | carbonic anhydrase 14 pX=7.72 | carbonic anhydrase 9 pX=7.64 | carbonic anhydrase 2 pX=7.46

$$$$
Tetracycline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 4.62 0 0
M  V30 2 N 9.3358 3.85 0 0
M  V30 3 C 8.0021 4.62 0 0
M  V30 4 C 9.3358 2.31 0 0 CFG=1
M  V30 5 C 8.0021 1.54 0 0 CFG=2
M  V30 6 C 6.6684 2.31 0 0
M  V30 7 C 5.3347 1.54 0 0 CFG=1
M  V30 8 C 5.3347 0 0 0
M  V30 9 C 6.6684 -0.77 0 0
M  V30 10 O 6.6684 -2.31 0 0
M  V30 11 C 8.0021 0 0 0 CFG=1
M  V30 12 O 8.0021 -1.54 0 0
M  V30 13 C 9.3358 -0.77 0 0
M  V30 14 O 9.3358 -2.31 0 0
M  V30 15 C 10.6694 -0 0 0
M  V30 16 C 10.6694 1.54 0 0
M  V30 17 O 12.0031 2.31 0 0
M  V30 18 C 12.0031 -0.77 0 0
M  V30 19 O 13.3368 -0 0 0
M  V30 20 N 12.0031 -2.31 0 0
M  V30 21 C 4.001 -0.77 0 0
M  V30 22 O 4.001 -2.31 0 0
M  V30 23 C 2.6674 0 0 0
M  V30 24 C 1.3337 -0.77 0 0
M  V30 25 O 1.3337 -2.31 0 0
M  V30 26 C -0 0 0 0
M  V30 27 C 0 1.54 0 0
M  V30 28 C 1.3337 2.31 0 0
M  V30 29 C 2.6674 1.54 0 0
M  V30 30 C 4.001 2.31 0 0 CFG=2
M  V30 31 C 3.2781 3.6697 0 0
M  V30 32 O 4.724 3.6697 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=3
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 11 9
M  V30 11 1 5 11
M  V30 12 1 11 12 CFG=3
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 4 16
M  V30 18 1 16 17
M  V30 19 1 15 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 8 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 24 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 23 29
M  V30 32 1 30 29
M  V30 33 1 7 30
M  V30 34 1 30 31 CFG=3
M  V30 35 1 30 32 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2144222809

>  <MW>
444.435

>  <MW (desalted)>
444.435

>  <ClogP>
-0.896

>  <logS>
-2.183

>  <HBD>
6

>  <HBA>
9

>  <TPSA>
181.62

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC  0.0078125 ?g/ml | MIC  0.0078125 ?g/ml | MIC95  0.25 ?g/ml | MIC  0.0325 ?M | MIC90  0.3125 mg/l | MIC  0.0625 ?g/ml | MIC90  1 ?g/mL | MIC90  1 ?g/mL | MIC90  1 ?g/mL | MIC90  1 ?g/mL | MIC90  1 ?g/mL | MIC50  0.12 ?g/mL | MIC50  0.12 ?g/ml | MIC50  0.12 ?g/ml | MIC  0.125 ?g/ml | IC50 > 0.4 ?M | MIC90  2 ?g/ml | inhibition percentage Active   | MIC  0.25 ?g/ml | MIC  0.25 ?g/ml | MIC  0.25 - 0.28 ?g/ml

>  <CAS>
60-54-8

>  <Description>
Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.

>  <EBC_ID>
EBC-12827

>  <IUPAC Name>
(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

>  <Main Tar all refs>
Int. J. Biol. Macromol., 2022, vol. 198, p. 1 - 10 | Int. J. Biol. Macromol., 2022, vol. 198, p. 1 - 10 | Nat. Commun., 2022, vol. 13, # 1 | Eur. J. Med. Chem., 2018, vol. 154, p. 144 - 154 | J. Antibiot., 2021, vol. 74, # 5, p. 324 - 329 | ACS Infect. Dis., 2022, vol. 8, # 2, p. 255 - 270 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | Antimicrob. Agents Chemother., 2014, vol. 58, # 2, p. 833 - 838 | PLoS ONE, 2020, vol. 15, # 2 | PLoS ONE, 2020, vol. 15, # 2 | Eur. J. Med. Chem., 2022, vol. 243 | Antimicrob. Agents Chemother., 1999, vol. 43, # 7, p. 1693 - 1699 | Antimicrob. Agents Chemother., 2018, vol. 62, # 4 | Jpn. J. Pharmacol., 2002, vol. 88, # 1, p. 69 - 76 | J. Med. Chem., 2018, vol. 61, # 8, p. 3325 - 3349 | REDX PHARMA PLC - WO2017/93747, 2017, A1 | Antimicrob. Agents Chemother., 2019, vol. 63, # 12

>  <Main tar all>
Bifunctional autolysin pX=7.75 | Efflux pump NorA pX=7.75 | Multidrug?efflux?pump?subunit?AcrB pX=7.53 | DNA?gyrase subunit A pX=7.49 | Organic hydroperoxide resistance protein OhrB pX=7.11 | Multidrug?efflux?pump?subunit?AcrA pX=6.85 | Beta-lactamase CTX-M-14 pX=6.6 | Beta-lactamase CTX-M-15 pX=6.6 | Beta-lactamase ESBL pX=6.6 | Beta-lactamase KPC pX=6.6 | Beta-lactamase SHV pX=6.6 | Beta-lactamase CMY-2 pX=6.57 | DNA topoisomerase II pX=6.57 | DNA?gyrase pX=6.57 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase pX=6.55 | Sporulation kinase A pX=6.4 | Isoleucine-tRNA ligase, cytoplasmic pX=6.3 | Organic anion transporter 2 pX=6.3 | Bifunctional coenzyme A synthase pX=6.25 | DNA topoisomerase II pX=6.25 | DNA topoisomerase II pX=6.25

$$$$
Nadolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -10.78 0 0
M  V30 2 C -1.3337 -10.01 0 0
M  V30 3 C -0.5637 -11.3437 0 0
M  V30 4 C -2.1037 -8.6763 0 0
M  V30 5 N 0 -9.24 0 0
M  V30 6 C 0 -7.7 0 0
M  V30 7 C 1.3337 -6.93 0 0
M  V30 8 O 2.6674 -7.7 0 0
M  V30 9 C 1.3337 -5.39 0 0
M  V30 10 O 2.6674 -4.62 0 0
M  V30 11 C 2.6674 -3.08 0 0
M  V30 12 C 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0 CFG=1
M  V30 18 O 8.0021 -0 0 0
M  V30 19 C 6.6684 -2.31 0 0 CFG=1
M  V30 20 O 8.0021 -3.08 0 0
M  V30 21 C 5.3347 -3.08 0 0
M  V30 22 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=1
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 2 11 22
M  V30 23 1 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z608060832

>  <MW>
309.401

>  <MW (desalted)>
309.401

>  <ClogP>
0.379

>  <logS>
-1.822

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
81.95

>  <RotBonds>
6

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  4E-06 ?M

>  <CAS>
1164498-31-0

>  <Description>
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.

>  <EBC_ID>
EBC-26725

>  <IUPAC Name>
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol

>  <Main Tar all refs>
NOVELYEAST BV - WO2023/79170, 2023, A1

>  <Main tar all>
?2-adrenoceptor pX=11.4

$$$$
Crystal violet
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 9.7347 6.93 0 0
M  V30 3 N 11.0684 6.16 0 0
M  V30 4 C 12.4021 6.93 0 0
M  V30 5 C 11.0684 4.62 0 0
M  V30 6 C 12.4021 3.85 0 0
M  V30 7 C 12.4021 2.31 0 0
M  V30 8 C 11.0684 1.54 0 0
M  V30 9 C 9.7347 2.31 0 0
M  V30 10 C 9.7347 3.85 0 0
M  V30 11 C 11.0684 0 0 0
M  V30 12 C 9.7347 -0.77 0 0
M  V30 13 C 9.7347 -2.31 0 0
M  V30 14 C 8.401 -3.08 0 0
M  V30 15 C 7.0674 -2.31 0 0
M  V30 16 N 5.7337 -3.08 0 0 CHG=1
M  V30 17 C 5.7337 -4.62 0 0
M  V30 18 C 4.4 -2.31 0 0
M  V30 19 C 7.0674 -0.77 0 0
M  V30 20 C 8.401 0 0 0
M  V30 21 C 12.4021 -0.77 0 0
M  V30 22 C 13.7358 -0 0 0
M  V30 23 C 15.0694 -0.77 0 0
M  V30 24 C 15.0694 -2.31 0 0
M  V30 25 C 13.7358 -3.08 0 0
M  V30 26 C 12.4021 -2.31 0 0
M  V30 27 N 16.4031 -3.08 0 0
M  V30 28 C 16.4031 -4.62 0 0
M  V30 29 C 17.7368 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 5 10
M  V30 10 1 8 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 15 19
M  V30 19 2 19 20
M  V30 20 1 12 20
M  V30 21 1 11 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 21 26
M  V30 28 1 24 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1465002628

>  <MW>
407.213

>  <MW (desalted)>
372.526

>  <ClogP>
0.63

>  <logS>
-4.389

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
9.49

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.05 ?M | MIC  0.125 ?g/ml | inhibition percentage >= 95 % | IC50 = 1280 nM | IC50  1280 nM | mRNA expression level increase Active   | IC50 = 1545 nM | IC50 = 1545 nM

>  <CAS>
548-62-9

>  <Description>
Crystal Violet has antiviral and prominent bactericidal activities. Crystal violet is a triarylmethane dye.

>  <EBC_ID>
EBC-03909

>  <IUPAC Name>
4-{bis[4-(dimethylamino)phenyl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium chloride

>  <Main Tar all refs>
Mol. Pharmacol., 1999, vol. 55, # 1, p. 159 - 167 | ACS Infect. Dis., 2021, vol. 7, # 6, p. 1833 - 1847 | J. Med. Chem., 2011, vol. 54, # 13, p. 4548 - 4558 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 24, p. 7667 - 7671 | ChemMedChem, 2013, vol. 8, # 6, p. 891 - 897 | J. Med. Chem., 2023, vol. 66, # 7, p. 5171 - 5184 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 24, p. 7667 - 7671 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 24, p. 7667 - 7671

>  <Main tar all>
nicotinic acetylcholine receptor pX=7.3 | multidrug?efflux?RND?transporter?permease?subunit?MtrD?(D405C) pX=6.51 | Organic cation transporter 2 pX=5.98 | Amyloid-beta precursor protein pX=5.89 | Amyloid-beta protein 40 pX=5.89 | GTPase NRas pX=5.84 | Microtubule-associated protein Tau pX=5.81 | Microtubule-associated protein tau pX=5.81

$$$$
Fluphenazine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 O 7.1574 -3.08 0 0
M  V30 4 C 5.8237 -3.85 0 0
M  V30 5 C 5.8237 -5.39 0 0
M  V30 6 N 4.4901 -6.16 0 0
M  V30 7 C 4.4901 -7.7 0 0
M  V30 8 C 3.1564 -8.47 0 0
M  V30 9 N 1.8227 -7.7 0 0
M  V30 10 C 0.489 -8.47 0 0
M  V30 11 C 0.489 -10.01 0 0
M  V30 12 C -0.8447 -10.78 0 0
M  V30 13 N -0.8447 -12.32 0 0
M  V30 14 C 0.489 -13.09 0 0
M  V30 15 C 1.8227 -12.32 0 0
M  V30 16 C 3.1564 -13.09 0 0
M  V30 17 C 3.1564 -14.63 0 0
M  V30 18 C 1.8227 -15.4 0 0
M  V30 19 C 0.489 -14.63 0 0
M  V30 20 S -0.8447 -15.4 0 0
M  V30 21 C -2.1783 -14.63 0 0
M  V30 22 C -3.512 -15.4 0 0
M  V30 23 C -4.8457 -14.63 0 0
M  V30 24 C -4.8457 -13.09 0 0
M  V30 25 C -3.512 -12.32 0 0
M  V30 26 C -2.1783 -13.09 0 0
M  V30 27 C -6.1794 -12.32 0 0
M  V30 28 F -7.5131 -11.55 0 0
M  V30 29 F -5.4094 -10.9863 0 0
M  V30 30 F -6.9494 -13.6537 0 0
M  V30 31 C 1.8227 -6.16 0 0
M  V30 32 C 3.1564 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 2 15 16
M  V30 14 1 16 17
M  V30 15 2 17 18
M  V30 16 1 18 19
M  V30 17 2 14 19
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 2 22 23
M  V30 22 1 23 24
M  V30 23 2 24 25
M  V30 24 1 25 26
M  V30 25 1 13 26
M  V30 26 2 21 26
M  V30 27 1 24 27
M  V30 28 1 27 28
M  V30 29 1 27 29
M  V30 30 1 27 30
M  V30 31 1 9 31
M  V30 32 1 31 32
M  V30 33 1 6 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1592690505

>  <MW>
509.128

>  <MW (desalted)>
437.522

>  <ClogP>
4.118

>  <logS>
-5.276

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
29.95

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.08 nM | Ki (inhibition constant) = 0.1 nM | Ki (inhibition constant)  0.49 nM | Ki (inhibition constant) = 1.44 nM | IC50  1.7 nM

>  <CAS>
146-56-5

>  <Description>
Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor. It also inhibits Histamine H1 Receptor.

>  <EBC_ID>
EBC-07795

>  <IUPAC Name>
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol dihydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1986, vol. 29, # 9, p. 1628 - 1637 | J. Pharmacol. Exp. Ther., 2001, vol. 299, # 1, p. 268 - 276 | Mol. Pharmacol., 1985, vol. 28, # 5, p. 391 - 399 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 2, p. 538 - 542 | DRUG DEV. RES., 1991, vol. 22, # 3, p. 239 - 250

>  <Main tar all>
Adenylate?cyclase?(gene?cya) pX=10.1 | D2 receptor pX=10.0 | D2L receptor pX=9.31 | D2 receptor pX=8.84 | D1 receptor pX=8.77

$$$$
Nafcillin sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 13.3347 -0.4964 0 0 CHG=1
M  V30 2 C -0.5962 1.6316 0 0
M  V30 3 C -0.1976 3.1191 0 0
M  V30 4 O 1.2899 3.5177 0 0
M  V30 5 C 1.6885 5.0052 0 0
M  V30 6 C 0.5996 6.0941 0 0
M  V30 7 C 0.9981 7.5817 0 0
M  V30 8 C 2.4857 7.9802 0 0
M  V30 9 C 2.8843 9.4678 0 0
M  V30 10 C 4.3718 9.8664 0 0
M  V30 11 C 5.4607 8.7774 0 0
M  V30 12 C 5.0621 7.2899 0 0
M  V30 13 C 3.5746 6.8913 0 0
M  V30 14 C 3.176 5.4038 0 0
M  V30 15 C 4.265 4.3148 0 0
M  V30 16 O 3.8664 2.8273 0 0
M  V30 17 N 5.7525 4.7134 0 0
M  V30 18 C 6.8414 3.6245 0 0 CFG=1
M  V30 19 C 8.3814 3.6245 0 0 CFG=1
M  V30 20 S 9.8461 4.1004 0 0
M  V30 21 C 10.7513 2.8545 0 0
M  V30 22 C 11.8957 3.8849 0 0
M  V30 23 C 11.8957 1.824 0 0
M  V30 24 C 9.8461 1.6086 0 0 CFG=1
M  V30 25 N 8.3814 2.0845 0 0
M  V30 26 C 6.8414 2.0845 0 0
M  V30 27 O 5.7525 0.9955 0 0
M  V30 28 C 10.322 0.144 0 0
M  V30 29 O 9.2915 -1.0005 0 0
M  V30 30 O 11.8283 -0.1762 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 13 14
M  V30 14 2 5 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 18 17 CFG=1
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 24 21
M  V30 25 1 24 25
M  V30 26 1 19 25 CFG=1
M  V30 27 1 25 26
M  V30 28 1 18 26
M  V30 29 2 26 27
M  V30 30 1 24 28 CFG=3
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3025678941

>  <MW>
436.107

>  <MW (desalted)>
414.475

>  <ClogP>
0.712

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
98.77

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.014 ?M | IC50  0.125 ?M

>  <CAS>
985-16-0

>  <Description>
Nafcillin is a semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

>  <EBC_ID>
EBC-28052

>  <IUPAC Name>
sodium (2S,5R,6R)-6-(2-ethoxynaphthalene-1-amido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

>  <Main Tar all refs>
Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443 | Biol. Chem., 2022, vol. 403, # 4, p. 433 - 443

>  <Main tar all>
Penicillin-binding?protein 2X pX=7.85 | Penicillin-binding?protein B pX=6.9

$$$$
Cefotaxime sodium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 1.8218 -5.6718 0 0 CHG=1
M  V30 2 C 0.4198 -4.7444 0 0
M  V30 3 O -0.6692 -3.6555 0 0
M  V30 4 N -0.2706 -2.1679 0 0
M  V30 5 C -1.3595 -1.079 0 0
M  V30 6 C -0.961 0.4085 0 0
M  V30 7 O -2.0499 1.4975 0 0
M  V30 8 N 0.5266 0.8071 0 0
M  V30 9 C 1.6155 -0.2818 0 0 CFG=1
M  V30 10 C 3.1555 -0.2818 0 0 CFG=1
M  V30 11 S 4.4892 0.4882 0 0
M  V30 12 C 5.8229 -0.2818 0 0
M  V30 13 C 5.8229 -1.8218 0 0
M  V30 14 C 4.4892 -2.5918 0 0
M  V30 15 N 3.1555 -1.8218 0 0
M  V30 16 C 1.6155 -1.8218 0 0
M  V30 17 O 0.5266 -2.9108 0 0
M  V30 18 C 4.4892 -4.1318 0 0
M  V30 19 O 5.8229 -4.9018 0 0
M  V30 20 O 3.1555 -4.9018 0 0 CHG=-1
M  V30 21 C 7.1566 -2.5918 0 0
M  V30 22 O 7.1566 -4.1318 0 0
M  V30 23 C 8.4902 -4.9018 0 0
M  V30 24 O 8.4902 -6.4418 0 0
M  V30 25 C 9.8239 -4.1318 0 0
M  V30 26 C -2.8471 -1.4776 0 0
M  V30 27 C -3.3989 -2.9153 0 0
M  V30 28 S -4.9368 -2.8347 0 0
M  V30 29 C -5.3354 -1.3472 0 0
M  V30 30 N -6.7731 -0.7953 0 0
M  V30 31 N -4.0439 -0.5084 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3 CFG=2
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 6 8
M  V30 7 1 9 8 CFG=1
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 10 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 9 16
M  V30 17 2 16 17
M  V30 18 1 14 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 13 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 5 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 29 31
M  V30 32 1 26 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404029

>  <MW>
477.039

>  <MW (desalted)>
455.465

>  <ClogP>
-2.777

>  <logS>
-4.254

>  <HBD>
2

>  <HBA>
9

>  <TPSA>
176.34

>  <RotBonds>
8

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 21 ?M | IC50  122.5 ?M

>  <CAS>
64485-93-4

>  <Description>
Cefotaxime is a third generation cephalosporin used to treat susceptible Gram negative and Gram positive bacterial infections.

>  <EBC_ID>
EBC-12276

>  <IUPAC Name>
sodium (6R,7R)-3-[(acetyloxy)methyl]-7-[2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2008, vol. 52, # 5, p. 1897 - 1898 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Beta-lactamase pX=4.68 | Organic cation/carnitine transporter 2 pX=3.91

$$$$
Betamethasone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.851 -2.6445 0 0
M  V30 2 C 5.2994 -3.1677 0 0 CFG=1
M  V30 3 C 6.574 -2.3035 0 0
M  V30 4 C 7.7898 -3.2487 0 0 CFG=1
M  V30 5 C 9.3058 -2.9776 0 0 CFG=2
M  V30 6 C 9.829 -1.5293 0 0
M  V30 7 C 11.345 -1.2582 0 0
M  V30 8 C 12.3377 -2.4355 0 0
M  V30 9 C 13.8537 -2.1644 0 0
M  V30 10 C 14.8464 -3.3418 0 0
M  V30 11 O 16.3624 -3.0707 0 0
M  V30 12 C 14.3232 -4.7901 0 0
M  V30 13 C 12.8072 -5.0612 0 0
M  V30 14 C 11.8145 -3.8839 0 0 CFG=1
M  V30 15 C 11.2913 -5.3323 0 0
M  V30 16 C 10.2985 -4.155 0 0 CFG=2
M  V30 17 F 10.4097 -5.6909 0 0
M  V30 18 C 9.7753 -5.6034 0 0 CFG=1
M  V30 19 O 10.768 -6.7807 0 0
M  V30 20 C 8.2593 -5.8744 0 0
M  V30 21 C 7.2666 -4.6971 0 0 CFG=1
M  V30 22 C 6.5949 -6.0829 0 0
M  V30 23 C 5.7274 -4.6471 0 0 CFG=2
M  V30 24 O 5.5008 -6.1703 0 0
M  V30 25 C 4.3071 -5.2423 0 0
M  V30 26 O 4.1124 -6.7699 0 0
M  V30 27 C 3.0815 -4.3099 0 0
M  V30 28 O 1.6612 -4.9051 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 16 5
M  V30 18 1 16 17 CFG=3
M  V30 19 1 16 18
M  V30 20 1 18 19 CFG=1
M  V30 21 1 18 20
M  V30 22 1 21 20
M  V30 23 1 4 21
M  V30 24 1 21 22 CFG=1
M  V30 25 1 21 23
M  V30 26 1 23 2
M  V30 27 1 23 24 CFG=3
M  V30 28 1 23 25 CFG=1
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553714

>  <MW>
392.2

>  <MW (desalted)>
392.461

>  <ClogP>
1.785

>  <logS>
-3.947

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
94.83

>  <RotBonds>
2

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  0.81 nM

>  <CAS>
378-44-9

>  <Description>
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It is used to relieve inflammation in various conditions, including but not limited to allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders.

>  <EBC_ID>
EBC-11078

>  <IUPAC Name>
(1R,2S,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
J. STEROID BIOCHEM. MOL. BIOL., 1992, vol. 41, # 3-8, p. 733 - 738

>  <Main tar all>
Glucocorticoid receptor pX=9.09

$$$$
Hydrocortisone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0 CFG=2
M  V30 5 O 10.768 -6.7807 0 0
M  V30 6 C 10.2985 -4.155 0 0 CFG=1
M  V30 7 C 9.3058 -2.9776 0 0 CFG=1
M  V30 8 C 9.829 -1.5293 0 0
M  V30 9 C 11.345 -1.2582 0 0
M  V30 10 C 12.3377 -2.4355 0 0
M  V30 11 C 13.8537 -2.1644 0 0
M  V30 12 C 14.8464 -3.3418 0 0
M  V30 13 O 16.3624 -3.0707 0 0
M  V30 14 C 14.3232 -4.7901 0 0
M  V30 15 C 12.8072 -5.0612 0 0
M  V30 16 C 11.8145 -3.8839 0 0 CFG=2
M  V30 17 C 11.2913 -5.3323 0 0
M  V30 18 C 7.7898 -3.2487 0 0 CFG=2
M  V30 19 C 6.574 -2.3035 0 0
M  V30 20 C 5.2994 -3.1677 0 0
M  V30 21 C 5.7274 -4.6471 0 0 CFG=1
M  V30 22 O 4.3071 -5.2423 0 0
M  V30 23 C 5.5008 -6.1703 0 0
M  V30 24 O 6.7067 -7.1282 0 0
M  V30 25 C 4.0683 -6.7357 0 0
M  V30 26 O 3.8417 -8.2589 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 4 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 6 16
M  V30 17 1 16 10
M  V30 18 1 16 17 CFG=1
M  V30 19 1 7 18
M  V30 20 1 18 2
M  V30 21 1 18 19 CFG=1
M  V30 22 1 19 20
M  V30 23 1 21 20
M  V30 24 1 2 21
M  V30 25 1 21 22 CFG=3
M  V30 26 1 21 23 CFG=1
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530425064

>  <MW>
362.209

>  <MW (desalted)>
362.46

>  <ClogP>
1.887

>  <logS>
-3.089

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
94.83

>  <RotBonds>
2

>  <Action on targets>
Agonist | - | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
mRNA expression level decrease Active   | EC50 = 0.6 nM | EC50 ~ 7E-10 M | EC50  2.7 nM | IC50  6.7E-09 M

>  <CAS>
50-23-7

>  <Description>
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. It is used to treat corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders.

>  <EBC_ID>
EBC-11040

>  <IUPAC Name>
(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Biomolecules, 2020, vol. 10, # 3 | VANANDEL RES INST; VAN ANDEL RESEARCH INSTITUTE - US2007/111265, 2007, A1 | Mol. Endocrinol., 2004, vol. 18, # 9, p. 2151 - 2165 | CHINESE ACADEMY OF SCIENCES; VANANDEL RES INST; Shanghai Institute of Materia Medica (in: CAS) - WO2015/48316, 2015, A1 | THE GOVERNMENT OF THE UNITED KINGDOM - WO2004/87215, 2004, A1

>  <Main tar all>
Glucocorticoid receptor pX=9.56 | Mineralocorticoid receptor pX=9.22 | Mineralocorticoid receptor pX=9.15 | nuclear glucocorticoid receptor pX=8.57 | Globuline pX=8.17

$$$$
trans-Sobrerol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0 CFG=2
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0 CFG=2
M  V30 8 O -1.3337 2.31 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C 1.3337 -3.85 0 0
M  V30 11 C -0.2063 -2.31 0 0
M  V30 12 O 2.8737 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 2
M  V30 8 1 7 8 CFG=3
M  V30 9 1 5 9 CFG=1
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1278926502

>  <MW>
170.131

>  <MW (desalted)>
170.249

>  <ClogP>
0.742

>  <logS>
-0.825

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
1

>  <CAS>
42370-41-2

>  <Description>
A natural product found in Boswellia sacra. It has antimicrobial activity.

>  <EBC_ID>
EBC-47424

>  <IUPAC Name>
(1S,5R)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol

$$$$
Udenafil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5902 8.2328 0 0
M  V30 2 C 3.5902 6.6928 0 0
M  V30 3 C 4.9239 5.9228 0 0
M  V30 4 O 6.2576 6.6928 0 0
M  V30 5 C 7.5913 5.9228 0 0
M  V30 6 C 8.925 6.6928 0 0
M  V30 7 C 10.2586 5.9228 0 0
M  V30 8 C 10.2586 4.3828 0 0
M  V30 9 C 8.925 3.6128 0 0
M  V30 10 C 7.5913 4.3828 0 0
M  V30 11 C 6.2576 3.6128 0 0
M  V30 12 N 6.2576 2.0728 0 0
M  V30 13 C 4.9239 1.3028 0 0
M  V30 14 O 4.9239 -0.2372 0 0
M  V30 15 C 3.5902 2.0728 0 0
M  V30 16 N 2.1256 1.5969 0 0
M  V30 17 C 1.6497 0.1323 0 0
M  V30 18 N 1.2204 2.8428 0 0
M  V30 19 C 2.1256 4.0887 0 0
M  V30 20 C 1.6497 5.5533 0 0
M  V30 21 C 0.1434 5.8735 0 0
M  V30 22 C -0.3325 7.3382 0 0
M  V30 23 C 3.5902 3.6128 0 0
M  V30 24 N 4.9239 4.3828 0 0
M  V30 25 S 11.5923 3.6128 0 0
M  V30 26 O 10.8223 2.2791 0 0
M  V30 27 O 12.3623 4.9465 0 0
M  V30 28 N 12.926 2.8428 0 0
M  V30 29 C 12.926 1.3028 0 0
M  V30 30 C 14.2597 0.5328 0 0
M  V30 31 C 14.2597 -1.0072 0 0
M  V30 32 C 15.5056 -1.9124 0 0
M  V30 33 C 15.0297 -3.377 0 0
M  V30 34 C 13.4897 -3.377 0 0
M  V30 35 N 13.0138 -1.9124 0 0
M  V30 36 C 11.5492 -1.4365 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 19 23
M  V30 24 2 15 23
M  V30 25 1 23 24
M  V30 26 1 11 24
M  V30 27 1 8 25
M  V30 28 2 25 26
M  V30 29 2 25 27
M  V30 30 1 25 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 31 35
M  V30 39 1 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811577

>  <MW>
516.656

>  <MW (desalted)>
516.656

>  <ClogP>
3.147

>  <logS>
-3.967

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
117.92

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.8 nM | IC50 = 5.8 nM | IC50 = 8.2 nM

>  <CAS>
268203-93-6

>  <Description>
Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor. It is used to treat erectile dysfunction.

>  <EBC_ID>
EBC-27262

>  <IUPAC Name>
3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide

>  <Main Tar all refs>
MEZZION PHARMA CO.,LTD. - WO2006/132460, 2006, A1 | Arch. Pharmacal Res., 2002, vol. 25, # 6, p. 873 - 878 | Arch. Pharmacal Res., 2002, vol. 25, # 6, p. 873 - 878

>  <Main tar all>
Collagen pX=9.1 | phosphodiesterase 5A pX=8.24 | phosphodiesterase 1 pX=8.09

$$$$
Linoleic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.5963 14.011 0 0
M  V30 2 C 4.2626 13.241 0 0
M  V30 3 C 4.2626 11.701 0 0
M  V30 4 C 2.929 10.931 0 0
M  V30 5 C 2.929 9.391 0 0
M  V30 6 C 1.5953 8.621 0 0
M  V30 7 C 1.5953 7.081 0 0
M  V30 8 C 2.929 6.311 0 0
M  V30 9 C 2.929 4.771 0 0
M  V30 10 C 4.2626 4.001 0 0
M  V30 11 C 5.5963 4.771 0 0
M  V30 12 C 6.93 4.001 0 0
M  V30 13 C 8.2637 4.771 0 0
M  V30 14 C 9.5974 4.001 0 0
M  V30 15 C 10.931 4.771 0 0
M  V30 16 C 12.2647 4.001 0 0
M  V30 17 C 13.5984 4.771 0 0
M  V30 18 C 14.9321 4.001 0 0
M  V30 19 O 16.2658 4.771 0 0
M  V30 20 O 14.9321 2.461 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2315575242

>  <MW>
280.24

>  <MW (desalted)>
280.445

>  <ClogP>
7.302

>  <logS>
-7.292

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | - | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  4.8 nM | Kd (dissociation constant) = 40 nM | Kd (dissociation constant) = 115 nM

>  <CAS>
60-33-3

>  <Description>
Linoleic acid is an essential ?-6 polyunsaturated fatty acid. It is the most abundant PUFA in a variety of foods, and dietary sources of linoleic acid include vegetable oils, meats, nuts, seeds, and eggs. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism.

>  <EBC_ID>
EBC-26431

>  <IUPAC Name>
(9Z,12Z)-octadeca-9,12-dienoic acid

>  <Main Tar all refs>
Biochemistry, 1999, vol. 38, # 1, p. 185 - 190 | Biochem. J., 2002, vol. 363, # 3, p. 809 - 815 | Curr. Pharm. Des., 2011, vol. 17, # 2, p. 168 - 175

>  <Main tar all>
Peroxisome proliferator-activated receptor-? pX=8.32 | Serum albumin pX=7.4 | fatty acid binding protein 7 pX=6.94

$$$$
Cysteine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.85 1.3337 0 0
M  V30 2 C 2.31 1.3337 0 0 CFG=1
M  V30 3 C 1.54 2.6674 0 0
M  V30 4 S 2.31 4.001 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 O 2.31 -1.3337 0 0
M  V30 7 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z760035162

>  <MW>
121.02

>  <MW (desalted)>
121.158

>  <ClogP>
-2.347

>  <logS>
-0.24

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
2

>  <Action on targets>
-

>  <Activity coefficients and valu>
Kd (dissociation constant) = 3.21 nM

>  <CAS>
52-90-4

>  <Description>
Cysteine can usually be synthesized by the human body under normal physiological conditions if a sufficient quantity of methionine is available. It exhibits antioxidant properties and participates in redox reactions. Cysteine is an amino acid commonly found as a component of total parenteral nutrition and used as an antidote for acetaminophen overdose.

>  <EBC_ID>
EBC-26052

>  <IUPAC Name>
(2R)-2-amino-3-sulfanylpropanoic acid

>  <Main Tar all refs>
J. Biol. Chem., 2011, vol. 286, # 45, p. 39100 - 39115

>  <Main tar all>
Poly(rC)-binding protein 1 pX=8.49

$$$$
Halothane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 3.08 2.6674 0 0
M  V30 2 C 2.31 1.3337 0 0
M  V30 3 F 0.9763 2.1037 0 0
M  V30 4 F 3.6437 0.5637 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 Cl 2.31 -1.3337 0 0
M  V30 7 Br 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201617125

>  <MW>
195.89

>  <MW (desalted)>
197.382

>  <ClogP>
2.272

>  <logS>
-2.479

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
1

>  <Action on targets>
- | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 = 121 nM | Kd (dissociation constant) = 1.6 ?M | Kd (dissociation constant) = 1.6 ?M

>  <CAS>
151-67-7

>  <Description>
Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. Halothane causes general anaethesia due to its actions on multiple ion channels, which ultimately depresses nerve conduction, breathing, cardiac contractility. Its immobilizing effects have been attributed to its binding to potassium channels in cholinergic neurons.

>  <EBC_ID>
EBC-03062

>  <IUPAC Name>
2-bromo-2-chloro-1,1,1-trifluoroethane

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2012, vol. 109, # 20, p. 7923 - 7928 | Biochem. J., 2004, vol. 380, # 1, p. 147 - 152 | Biochem. J., 2004, vol. 380, # 1, p. 147 - 152

>  <Main tar all>
Cav1.2 pX=6.92 | Albumin pX=5.8 | Serum albumin pX=5.8

$$$$
L-Valine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.31 4.001 0 0
M  V30 2 C 1.54 2.6674 0 0
M  V30 3 C -0 2.6674 0 0
M  V30 4 C 2.31 1.3337 0 0 CFG=2
M  V30 5 N 3.85 1.3337 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 O 2.31 -1.3337 0 0
M  V30 8 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756430564

>  <MW>
117.079

>  <MW (desalted)>
117.146

>  <ClogP>
-2.286

>  <logS>
-0.6

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.3 nM

>  <CAS>
72-18-4

>  <Description>
L-Valine is an amino acid commonly found as a component of total parenteral nutrition. It has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.

>  <EBC_ID>
EBC-03948

>  <IUPAC Name>
(2S)-2-amino-3-methylbutanoic acid

>  <Main Tar all refs>
Annu. Rep. Med. Chem., 1994, vol. 29, p. 133 - 144

>  <Main tar all>
Protease pX=8.89

$$$$
Vigabatrin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.621 4.9774 0 0
M  V30 2 C 8.621 3.4374 0 0
M  V30 3 C 7.2874 2.6674 0 0
M  V30 4 C 5.9537 3.4374 0 0
M  V30 5 C 4.62 2.6674 0 0
M  V30 6 O 3.2863 3.4374 0 0
M  V30 7 O 4.62 1.1274 0 0
M  V30 8 C 9.9547 2.6674 0 0
M  V30 9 C 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255431434

>  <MW>
129.079

>  <MW (desalted)>
129.157

>  <ClogP>
-2.217

>  <logS>
-0.04

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4.21 ?M | IC50  8.93 ?M | IC50 = 24000 nM | IC50  39.72 ?M

>  <CAS>
68506-86-5

>  <Description>
Vigabatrin is an analog of gamma-aminobutyric acid, the main inhibitory neurotransmitter in the central nervous system. It used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active.

>  <EBC_ID>
EBC-06162

>  <IUPAC Name>
4-aminohex-5-enoic acid

>  <Main Tar all refs>
BMC Pharmacol. Toxicol., 2021, vol. 22, # 1 | J. Enzyme Inhib. Med. Chem., 2021, vol. 36, # 1, p. 2016 - 2024 | PHARMACOL. REV., 1990, vol. 42, # 3, p. 223 - 286 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 14, p. 1825 - 1830

>  <Main tar all>
KCa3.1 pX=5.38 | 4-aminobutyrate aminotransferase pX=5.05 | 4-aminobutyrate aminotransferase pX=4.62 | 4-aminobutyrate aminotransferase GabT pX=4.4

$$$$
Betahistine dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C -2.1339 -3.08 0 0
M  V30 4 N -0.8002 -3.85 0 0
M  V30 5 C -0.8002 -5.39 0 0
M  V30 6 C 0.5335 -6.16 0 0
M  V30 7 C 0.5335 -7.7 0 0
M  V30 8 C 1.8672 -8.47 0 0
M  V30 9 C 1.8672 -10.01 0 0
M  V30 10 C 0.5335 -10.78 0 0
M  V30 11 C -0.8002 -10.01 0 0
M  V30 12 N -0.8002 -8.47 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 2 8 9
M  V30 7 1 9 10
M  V30 8 2 10 11
M  V30 9 1 11 12
M  V30 10 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2238930991

>  <MW>
208.053

>  <MW (desalted)>
136.194

>  <ClogP>
0.082

>  <logS>
-1.148

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.92

>  <RotBonds>
3

>  <Action on targets>
Inverse agonist | Inverse agonist

>  <Activity coefficients and valu>
EC50  0.05 nM | EC50  0.1 nM

>  <CAS>
5579-84-0

>  <Description>
Betahistine is an antivertigo agent used for the reduction of episodes of vertigo association with M?ni?re's disease.

>  <EBC_ID>
EBC-13651

>  <IUPAC Name>
methyl[2-(pyridin-2-yl)ethyl]amine dihydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2010, vol. 334, # 3, p. 945 - 954 | J. Pharmacol. Exp. Ther., 2010, vol. 334, # 3, p. 945 - 954

>  <Main tar all>
H3 receptor (isoform 2) pX=10.3 | H3 receptor (isoform 1) pX=10.0

$$$$
Carvacrol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 4 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104496566

>  <MW>
150.104

>  <MW (desalted)>
150.218

>  <ClogP>
3.351

>  <logS>
-2.73

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter)  10 - 18 pg/ml | concentration (parameter)  10 - 18 pg/ml | concentration (parameter)  10 - 18 pg/ml

>  <CAS>
499-75-2

>  <Description>
Carvacrol is a monoterpenoid phenol isolated from Lamiaceae family plants, with antibiotic, antioxidant, anti-inflammatory properties. Carvacrol has significant antimicrobial potential against ESBL E. coli.

>  <EBC_ID>
EBC-46271

>  <IUPAC Name>
2-methyl-5-(propan-2-yl)phenol

>  <Main Tar all refs>
Microb. Pathog., 2020, vol. 142 | Microb. Pathog., 2020, vol. 142 | Microb. Pathog., 2020, vol. 142

>  <Main tar all>
Beta-lactamase CTX-M-9 pX=10.7 | Beta-lactamase SHV-2 pX=10.7 | Beta-lactamase TEM-12 pX=10.7

$$$$
(+/-)-Methoxyphenamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.0674 4.1462 0 0
M  V30 3 N 8.401 3.3762 0 0
M  V30 4 C 8.401 1.8362 0 0
M  V30 5 C 9.7347 1.0662 0 0
M  V30 6 C 7.0674 1.0662 0 0
M  V30 7 C 7.0674 -0.4738 0 0
M  V30 8 C 8.401 -1.2438 0 0
M  V30 9 C 8.401 -2.7838 0 0
M  V30 10 C 7.0674 -3.5538 0 0
M  V30 11 C 5.7337 -2.7838 0 0
M  V30 12 C 5.7337 -1.2438 0 0
M  V30 13 O 4.4 -0.4738 0 0
M  V30 14 C 4.4 1.0662 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 7 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1691545280

>  <MW>
215.108

>  <MW (desalted)>
179.259

>  <ClogP>
1.807

>  <logS>
-1.96

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
21.26

>  <RotBonds>
4

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50  7.3 ?M

>  <CAS>
5588-10-3

>  <Description>
(+/-)-Methoxyphenamine hydrochloride exhibits an antagonistic effect on alpha- and beta-adrenergic receptor. It is used as a bronchodilator.

>  <EBC_ID>
EBC-04171

>  <IUPAC Name>
[1-(2-methoxyphenyl)propan-2-yl](methyl)amine hydrochloride

>  <Main Tar all refs>
J. Pharm. Sci., 1969, vol. 58, # 6, p. 760 - 761

>  <Main tar all>
?-adrenoceptor pX=5.14

$$$$
Pamidronic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.39 -0.2063 0 0
M  V30 2 C 3.85 -0.2063 0 0
M  V30 3 C 3.08 -1.54 0 0
M  V30 4 C 1.54 -1.54 0 0
M  V30 5 O 0 -1.54 0 0
M  V30 6 P 1.54 -3.08 0 0
M  V30 7 O 1.54 -4.62 0 0
M  V30 8 O 0 -3.08 0 0
M  V30 9 O 3.08 -3.08 0 0
M  V30 10 P 1.54 0 0 0
M  V30 11 O 1.54 1.54 0 0
M  V30 12 O 3.08 0 0 0
M  V30 13 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 4 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 10 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269196032

>  <MW>
235.001

>  <MW (desalted)>
235.069

>  <ClogP>
-6.171

>  <logS>
3.666

>  <HBD>
6

>  <HBA>
8

>  <TPSA>
161.31

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 30 nM | IC50  312 nM

>  <CAS>
40391-99-9

>  <Description>
Pamidronic acid is a second generation, nitrogen containing bisphosphonate that inhibits osteoclast mediated bone loss. It is used to treat Paget's disease, to treat hypercalcemia of malignancy, and to treat osteolytic bone lesions.

>  <EBC_ID>
EBC-13324

>  <IUPAC Name>
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2011, vol. 18, # 2, p. 220 - 233 | UNIVERSITY OF SHEFFIELD - WO2014/162123, 2014, A1

>  <Main tar all>
farnesyl diphosphate synthase pX=7.52 | prenyl synthase pX=6.51

$$$$
Acetazolamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3935 5.93 0 0
M  V30 2 C 2.3935 4.39 0 0
M  V30 3 O 3.7272 3.62 0 0
M  V30 4 N 1.0598 3.62 0 0
M  V30 5 C 1.0598 2.08 0 0
M  V30 6 N 2.3057 1.1748 0 0
M  V30 7 N 1.8298 -0.2898 0 0
M  V30 8 C 0.2898 -0.2898 0 0
M  V30 9 S -0.1861 1.1748 0 0
M  V30 10 S -0.6154 -1.5357 0 0
M  V30 11 O -1.5206 -2.7816 0 0
M  V30 12 O -1.8613 -0.6305 0 0
M  V30 13 N 0.6305 -2.4409 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 8 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z277559108

>  <MW>
221.988

>  <MW (desalted)>
222.245

>  <ClogP>
-0.981

>  <logS>
-2.09

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
115.04

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.004 nM | Ki (inhibition constant)  0.0056 nM | concentration (parameter) = 0.02 nM | Ki (inhibition constant) = 0.025 nM

>  <CAS>
59-66-5

>  <Description>
Acetazolamide is a carbonic anhydrase inhibitor. It is effective against absence seizures, useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance.

>  <EBC_ID>
EBC-03431

>  <IUPAC Name>
N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 1996, vol. 31, p. 843 - 846 | Eur. J. Med. Chem., 2020, vol. 201 | Phytochemistry, 1970, vol. 9, # 1, p. 25 - 32 | Bioorg. Med. Chem., 2009, vol. 17, # 2, p. 553 - 557

>  <Main tar all>
carbonic anhydrase 2 pX=11.4 | carbonic anhydrase 12 pX=11.3 | carbonic anhydrase pX=10.7 | carbonic anhydrase 9 pX=10.6

$$$$
Ethotoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 N 1.3337 -2.31 0 0
M  V30 4 C 2.5796 -3.2152 0 0
M  V30 5 O 4.0442 -2.7393 0 0
M  V30 6 N 2.1037 -4.6798 0 0
M  V30 7 C 0.5637 -4.6798 0 0
M  V30 8 C 0.0878 -3.2152 0 0
M  V30 9 O -1.3768 -2.7393 0 0
M  V30 10 C -0.3415 -5.9257 0 0
M  V30 11 C 0.2849 -7.3326 0 0
M  V30 12 C -0.6203 -8.5784 0 0
M  V30 13 C -2.1519 -8.4175 0 0
M  V30 14 C -2.7783 -7.0106 0 0
M  V30 15 C -1.8731 -5.7647 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 2 8 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53845223

>  <MW>
204.09

>  <MW (desalted)>
204.225

>  <ClogP>
1.482

>  <logS>
-2.332

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
49.41

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Blocker | Blocker | Blocker

>  <Activity coefficients and valu>
Ki (inhibition constant)  107 ?M | IC50  826.7 ?M | IC50  826.7 ?M | IC50  1125.7 ?M

>  <CAS>
86-35-1

>  <Description>
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. It is used for the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.

>  <EBC_ID>
EBC-14348

>  <IUPAC Name>
3-ethyl-5-phenylimidazolidine-2,4-dione

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1987, vol. 240, # 1, p. 216 - 222 | PAIRNOMIX - WO2018/64498, 2018, A1 | PAIRNOMIX - WO2018/64498, 2018, A1 | PAIRNOMIX - WO2018/64498, 2018, A1

>  <Main tar all>
CYP1A1 pX=3.97 | Nav1.6 pX=3.08 | Nav1.6 pX=3.08 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=2.95

$$$$
Tinazoline hydroiodide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 0 0 0 0
M  V30 2 C 4.7202 -2.9949 0 0
M  V30 3 C 4.4 -1.4885 0 0
M  V30 4 N 5.7337 -0.7185 0 0
M  V30 5 C 6.8781 -1.749 0 0
M  V30 6 N 6.2517 -3.1558 0 0
M  V30 7 S 8.3845 -1.4288 0 0
M  V30 8 C 8.8604 0.0358 0 0
M  V30 9 C 7.9552 1.2817 0 0
M  V30 10 N 8.8604 2.5276 0 0
M  V30 11 C 10.325 2.0517 0 0
M  V30 12 C 11.6587 2.8217 0 0
M  V30 13 C 12.9923 2.0517 0 0
M  V30 14 C 12.9923 0.5117 0 0
M  V30 15 C 11.6587 -0.2583 0 0
M  V30 16 C 10.325 0.5117 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 2 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 8 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301534047

>  <MW>
345.203

>  <MW (desalted)>
217.29

>  <ClogP>
0.942

>  <logS>
-4.598

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.18

>  <RotBonds>
2

>  <CAS>
55107-59-0

>  <Description>
Tinazoline is an imidazole derivative with potent and long-acting vasoconstrictor activity.

>  <EBC_ID>
EBC-105028

>  <IUPAC Name>
3-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)-1H-indole hydroiodide

$$$$
Nifenalol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 O 5.3347 -3.08 0 0
M  V30 8 C 6.6684 -5.39 0 0
M  V30 9 C 8.0021 -4.62 0 0
M  V30 10 C 9.3358 -5.39 0 0
M  V30 11 C 9.3358 -6.93 0 0
M  V30 12 C 8.0021 -7.7 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 14 N 10.6694 -7.7 0 0 CHG=1
M  V30 15 O 12.0031 -6.93 0 0
M  V30 16 O 10.6694 -9.24 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 11 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56755859

>  <MW>
224.116

>  <MW (desalted)>
224.256

>  <ClogP>
1.16

>  <logS>
-2.15

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
75.4

>  <RotBonds>
5

>  <Action on targets>
- | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 126 nM | pA2  6  | Ki (inhibition constant)  1.32 ?M

>  <CAS>
7413-36-7

>  <Description>
Nifenalol is an antagonist of beta-adrenergic receptor.

>  <EBC_ID>
EBC-08194

>  <IUPAC Name>
1-(4-nitrophenyl)-2-[(propan-2-yl)amino]ethan-1-ol

>  <Main Tar all refs>
Curr. Pharm. Des., 2004, vol. 10, # 13, p. 1519 - 1536 | J. Med. Chem., 1972, vol. 15, # 12, p. 1321 - 1324 | J. MED. CHEM., 1985, vol. 28, # 9, p. 1328 - 1334

>  <Main tar all>
?1-adrenoceptor pX=6.9 | ?-adrenoceptor pX=6.0 | ?2-adrenoceptor pX=5.88

$$$$
Acyclovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.5507 -4.4994 0 0
M  V30 2 C 3.5203 -3.355 0 0
M  V30 3 N 2.0139 -3.6752 0 0
M  V30 4 C 0.9835 -2.5307 0 0
M  V30 5 O -0.5229 -2.8509 0 0
M  V30 6 C 1.4594 -1.0661 0 0
M  V30 7 N 0.6894 0.2676 0 0
M  V30 8 C 1.7198 1.412 0 0
M  V30 9 N 3.1267 0.7857 0 0
M  V30 10 C 4.4604 1.5557 0 0
M  V30 11 O 5.794 0.7857 0 0
M  V30 12 C 7.1277 1.5557 0 0
M  V30 13 C 8.4614 0.7857 0 0
M  V30 14 O 9.7951 1.5557 0 0
M  V30 15 C 2.9657 -0.7459 0 0
M  V30 16 N 3.9962 -1.8904 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 9 15
M  V30 15 2 6 15
M  V30 16 1 15 16
M  V30 17 1 2 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610471

>  <MW>
225.086

>  <MW (desalted)>
225.205

>  <ClogP>
-2.605

>  <logS>
-1.394

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
114.76

>  <RotBonds>
4

>  <Action on targets>
Activator | Inhibitor | Substrate

>  <Activity coefficients and valu>
cell viability increase Active   | IC50  0.003 ?g/mL | IC50  0.025 ?M

>  <CAS>
59277-89-3

>  <Description>
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis.

>  <EBC_ID>
EBC-11172

>  <IUPAC Name>
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one

>  <Main Tar all refs>
Life Sci., 2022, vol. 304 | J. Med. Chem., 2000, vol. 43, # 4, p. 736 - 745 | UCB - WO1999/19466, 1999, A3

>  <Main tar all>
Pyruvate kinase PKM (isoform M1) pX=8.0 | Thymidine kinase (gene tdk) pX=7.88 | thymidine kinase pX=7.6

$$$$
Procaine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -1.4947 0 0
M  V30 3 C 5.7337 -2.2647 0 0
M  V30 4 N 7.0674 -1.4947 0 0
M  V30 5 C 7.0674 0.0453 0 0
M  V30 6 C 8.401 0.8153 0 0
M  V30 7 C 8.401 -2.2647 0 0
M  V30 8 C 9.7347 -1.4947 0 0
M  V30 9 O 11.0684 -2.2647 0 0
M  V30 10 C 12.4021 -1.4947 0 0
M  V30 11 O 13.7358 -2.2647 0 0
M  V30 12 C 12.4021 0.0453 0 0
M  V30 13 C 11.0684 0.8153 0 0
M  V30 14 C 11.0684 2.3553 0 0
M  V30 15 C 12.4021 3.1253 0 0
M  V30 16 N 12.4021 4.6653 0 0
M  V30 17 C 13.7358 2.3553 0 0
M  V30 18 C 13.7358 0.8153 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 4 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 10 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 15 17
M  V30 16 1 17 18
M  V30 17 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104476766

>  <MW>
272.129

>  <MW (desalted)>
236.31

>  <ClogP>
2.538

>  <logS>
-2.81

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
55.56

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  63 % | inhibition percentage  63 % | inhibition percentage  63 %

>  <CAS>
51-05-8

>  <Description>
Procaine hydrochloride is a  local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. Procaine acts by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. It also inhibits muscarinic acetylcholine receptor family and cholinergic receptor.

>  <EBC_ID>
EBC-03727

>  <IUPAC Name>
2-(diethylamino)ethyl 4-aminobenzoate hydrochloride

>  <Main Tar all refs>
GEORGETOWN UNIVERSITY; SAMARITAN PHARMACEUTICALS - WO2004/108076, 2004, A2 | GEORGETOWN UNIVERSITY; SAMARITAN PHARMACEUTICALS - WO2004/108076, 2004, A2 | GEORGETOWN UNIVERSITY; SAMARITAN PHARMACEUTICALS - WO2004/108076, 2004, A2

>  <Main tar all>
CCR5 pX=10.8 | CD4 pX=10.8 | CXCR4 pX=10.8

$$$$
Cetyl alcohol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 14.8363 10.1058 0 0
M  V30 2 C 16.17 9.3358 0 0
M  V30 3 C 17.5037 10.1058 0 0
M  V30 4 C 18.8374 9.3358 0 0
M  V30 5 C 20.171 10.1058 0 0
M  V30 6 C 21.5047 9.3358 0 0
M  V30 7 C 22.8384 10.1058 0 0
M  V30 8 C 24.1721 9.3358 0 0
M  V30 9 C 25.5058 10.1058 0 0
M  V30 10 C 26.8394 9.3358 0 0
M  V30 11 C 28.1731 10.1058 0 0
M  V30 12 C 29.5068 9.3358 0 0
M  V30 13 C 30.8405 10.1058 0 0
M  V30 14 C 32.1741 9.3358 0 0
M  V30 15 C 33.5078 10.1058 0 0
M  V30 16 C 34.8415 9.3358 0 0
M  V30 17 O 36.1752 10.1058 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473594

>  <MW>
242.261

>  <MW (desalted)>
242.441

>  <ClogP>
7.171

>  <logS>
-6.581

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
14

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
36653-82-4

>  <Description>
Cetyl alcohol exhibits skin protect properties against skin irritations caused by bites, rashes and stings. It has an inhibitory action against the growth of Mycoplasma gallisepticum and Mycopiasma pneumoniae. It is indicated to be used as an indirect additive in food contact substances, or an ingredient in commercial or cosmetic products.

>  <EBC_ID>
EBC-26290

>  <IUPAC Name>
hexadecan-1-ol

$$$$
Meclofenoxate hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -0.0453 0 0
M  V30 3 N 5.7337 0.7247 0 0
M  V30 4 C 5.7337 2.2647 0 0
M  V30 5 C 7.0674 -0.0453 0 0
M  V30 6 C 8.401 0.7247 0 0
M  V30 7 O 9.7347 -0.0453 0 0
M  V30 8 C 11.0684 0.7247 0 0
M  V30 9 O 11.0684 2.2647 0 0
M  V30 10 C 12.4021 -0.0453 0 0
M  V30 11 O 13.7358 0.7247 0 0
M  V30 12 C 15.0694 -0.0453 0 0
M  V30 13 C 16.4031 0.7247 0 0
M  V30 14 C 17.7368 -0.0453 0 0
M  V30 15 C 17.7368 -1.5853 0 0
M  V30 16 Cl 19.0705 -2.3553 0 0
M  V30 17 C 16.4031 -2.3553 0 0
M  V30 18 C 15.0694 -1.5853 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 15 17
M  V30 16 1 17 18
M  V30 17 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57281900

>  <MW>
293.059

>  <MW (desalted)>
257.713

>  <ClogP>
2.849

>  <logS>
-2.99

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
38.77

>  <RotBonds>
7

>  <CAS>
3685-84-5

>  <Description>
Meclofenoxate hydrochloride is a nootropic agent. It inhibits norepinephrine reuptake and serotonin (5-HT) reuptake. Meclofenoxate HCl is an anti-aging drug used to treat the symptoms of senile dementia and Alzheimer's disease.

>  <EBC_ID>
EBC-03732

>  <IUPAC Name>
2-(dimethylamino)ethyl 2-(4-chlorophenoxy)acetate hydrochloride

$$$$
Pyrimethamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 N 2.6674 -3.08 0 0
M  V30 5 C 2.6674 -4.62 0 0
M  V30 6 N 4.001 -5.39 0 0
M  V30 7 N 1.3337 -5.39 0 0
M  V30 8 C 0 -4.62 0 0
M  V30 9 N -1.3337 -5.39 0 0
M  V30 10 C 0 -3.08 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C -2.6674 -3.08 0 0
M  V30 13 C -4.001 -2.31 0 0
M  V30 14 C -4.001 -0.77 0 0
M  V30 15 Cl -5.3347 0 0 0
M  V30 16 C -2.6674 0 0 0
M  V30 17 C -1.3337 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385085

>  <MW>
248.083

>  <MW (desalted)>
248.711

>  <ClogP>
3.003

>  <logS>
-4.67

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
77.82

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  10.3  | Ki (inhibition constant)  0.3 nM | Ki (inhibition constant) = 1.5 nM

>  <CAS>
58-14-0

>  <Description>
Pyrimethamine is an antiparasitic drug used in the prevention and treatment of toxoplasmosis and malaria. It is a dihydrofolate reductase (DHFR) inhibitor.

>  <EBC_ID>
EBC-00583

>  <IUPAC Name>
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine

>  <Main Tar all refs>
Chem. Rev., 1984, vol. 84, # 4, p. 333 - 407 | ChemMedChem, 2022, vol. 17, # 22 | J. Med. Chem., 1998, vol. 41, # 9, p. 1367 - 1370

>  <Main tar all>
dihydrofolate reductase pX=10.3 | dihydrofolate reductase pX=9.52 | Thymidylate synthase (gene TYMS) pX=8.82

$$$$
Azathioprine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.1814 2.4873 0 0
M  V30 2 N 8.8612 3.9936 0 0
M  V30 3 C 9.8917 5.1381 0 0
M  V30 4 N 9.1217 6.4717 0 0
M  V30 5 C 7.6153 6.1516 0 0
M  V30 6 N 6.4709 7.182 0 0 CHG=1
M  V30 7 O 5.0062 6.7061 0 0
M  V30 8 O 6.7911 8.6884 0 0 CHG=-1
M  V30 9 C 7.4543 4.62 0 0
M  V30 10 S 6.1207 3.85 0 0
M  V30 11 C 6.1207 2.31 0 0
M  V30 12 N 7.4543 1.54 0 0
M  V30 13 C 7.4543 0 0 0
M  V30 14 N 6.1207 -0.77 0 0
M  V30 15 C 4.787 0 0 0
M  V30 16 N 3.3224 -0.4759 0 0
M  V30 17 C 2.4172 0.77 0 0
M  V30 18 N 3.3224 2.0159 0 0
M  V30 19 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 5 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 11 19
M  V30 21 1 15 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57063156

>  <MW>
277.038

>  <MW (desalted)>
277.263

>  <ClogP>
0.512

>  <logS>
-4.99

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
115.42

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 10 ?g/mL | Km (Michaelis constant) = 0.48 mM

>  <CAS>
446-86-6

>  <Description>
Azathioprine acts as a prodrug for 6-mercaptopurine, which alters purine processing and DNA synthesis, interfering with the proliferation of lymphocytes and other myeloid cells. Azathioprine is an immunosuppressant used to prevent renal transplant rejection, treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

>  <EBC_ID>
EBC-08508

>  <IUPAC Name>
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine

>  <Main Tar all refs>
J. MED. CHEM., 1974, vol. 17, # 7, p. 772 - 775 | Chem. Biol., 2012, vol. 19, # 3, p. 414 - 421

>  <Main tar all>
DNA pX=4.44 | glutathione S-transferase alpha 2 pX=3.32

$$$$
Niflumic Acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -0 0 0
M  V30 2 C -1.3337 -0.77 0 0
M  V30 3 O -2.6674 0 0 0
M  V30 4 C -1.3337 -2.31 0 0
M  V30 5 C 0 -3.08 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 C -1.3337 -5.39 0 0
M  V30 8 N -2.6674 -4.62 0 0
M  V30 9 C -2.6674 -3.08 0 0
M  V30 10 N -4.001 -2.31 0 0
M  V30 11 C -5.3347 -3.08 0 0
M  V30 12 C -5.3347 -4.62 0 0
M  V30 13 C -6.6684 -5.39 0 0
M  V30 14 C -8.0021 -4.62 0 0
M  V30 15 C -8.0021 -3.08 0 0
M  V30 16 C -6.6684 -2.31 0 0
M  V30 17 C -9.3358 -2.31 0 0
M  V30 18 F -10.6694 -1.54 0 0
M  V30 19 F -8.5658 -0.9763 0 0
M  V30 20 F -10.1058 -3.6437 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56922127

>  <MW>
282.062

>  <MW (desalted)>
282.218

>  <ClogP>
4.922

>  <logS>
-3.76

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
62.22

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  23.3 nM | Ki (inhibition constant)  0.0275 ?M | IC50 = 0.08 ?M | ID50 = 0.03 ?g/mL | Kd (dissociation constant) = 260 nM | IC50  0.28 ?M | Ki (inhibition constant)  0.368 ?M | IC50  0.38 ?M | IC50  0.402 ?M | inhibition percentage  83 % | inhibition percentage  100 %

>  <CAS>
4394-00-7

>  <Description>
Niflumic acid is a selective inhibitor of Prostaglandin G/H synthase 2. It is used to alleviate inflammation, pain, and edema associated with acute and chronic inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, post-operative inflammatory conditions, and physical trauma.

>  <EBC_ID>
EBC-03797

>  <IUPAC Name>
2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1997, vol. 75, # 9, p. 1088 - 1095 | Biopharm. Drug Dispos., 2006, vol. 27, # 1, p. 1 - 6 | Biochem. J., 2004, vol. 377, # 3, p. 675 - 684 | Annu. Rep. Med. Chem., 1974, vol. 9, p. 162 - 171 | J. Med. Chem., 2015, vol. 58, # 16, p. 6507 - 6515 | Xenobiotica, 2000, vol. 30, # 2, p. 111 - 116 | BAYLOR COLLEGE OF MEDICINE - WO2021/188296, 2021, A1 | Biopharm. Drug Dispos., 2015, vol. 36, # 4, p. 258 - 264 | Toxicol. Lett., 2016, vol. 259, p. 1 - 10 | Drug Metab. Dispos., 2012, vol. 40, # 3, p. 556 - 567 | Drug Metab. Dispos., 2011, vol. 39, # 4, p. 644 - 652

>  <Main tar all>
COX-1  pX=7.63 |  UDP glucuronosyltransferase family 1 member A9 pX=7.56 | COX-2  pX=7.1 | Cyclooxygenase pX=6.97 | transthyretin pX=6.59 | Sulfotransferase 1A1 pX=6.55 | xanthine dehydrogenase pX=6.43 |  UDP glucuronosyltransferase family 1 member A8 pX=6.42 |  UDP glucuronosyltransferase family 1 member A8 pX=6.4 |  UDP glucuronosyltransferase pX=6.29 |  UDP glucuronosyltransferase family 1 member A7 pX=6.28

$$$$
Trichlormethiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -3.85 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -1.8974 -4.4137 0 0
M  V30 4 O -3.4374 -1.7463 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 N 4.001 -2.31 0 0
M  V30 12 S 2.6674 -3.08 0 0
M  V30 13 O 3.3903 -4.4397 0 0
M  V30 14 O 1.9444 -4.4397 0 0
M  V30 15 C 5.3347 -0 0 0
M  V30 16 Cl 5.3347 1.54 0 0
M  V30 17 Cl 6.6684 -0.77 0 0
M  V30 18 C 0 -0 0 0
M  V30 19 C -1.3337 -0.77 0 0
M  V30 20 Cl -2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 8 18
M  V30 19 1 18 19
M  V30 20 2 5 19
M  V30 21 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1562203528

>  <MW>
378.902

>  <MW (desalted)>
380.656

>  <ClogP>
0.88

>  <logS>
-3.295

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
118.36

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 7.9 nM | Ki (inhibition constant)  65 - 138 nM | Ki (inhibition constant) = 87 nM | Ki (inhibition constant) = 134 nM

>  <CAS>
133-67-5

>  <Description>
Trichlormethiazide is a thiazide diuretic with properties similar to those of hydrochlorothiazide. Trichlormethiazide seemingly appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle. It is usually administered for the treatment of oedema and hypertension.

>  <EBC_ID>
EBC-03804

>  <IUPAC Name>
6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
Bioorg. Med. Chem., 2009, vol. 17, # 3, p. 1214 - 1221 | Bioorg. Med. Chem. Lett., 2010, vol. 20, # 12, p. 3467 - 3474 | Bioorg. Med. Chem., 2009, vol. 17, # 3, p. 1214 - 1221 | Bioorg. Med. Chem., 2009, vol. 17, # 3, p. 1214 - 1221

>  <Main tar all>
carbonic anhydrase 7 pX=8.1 | carbonic anhydrase 2 pX=7.19 | carbonic anhydrase 9 pX=7.06 | Carbonic anhydrase 5B, mitochondrial pX=6.87

$$$$
Sufadoxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 -1.54 0 0
M  V30 2 O 4.001 -2.31 0 0
M  V30 3 C 4.001 -3.85 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 2.6674 -6.16 0 0
M  V30 6 N 4.001 -6.93 0 0
M  V30 7 C 5.3347 -6.16 0 0
M  V30 8 N 6.6684 -6.93 0 0
M  V30 9 S 6.6684 -8.47 0 0
M  V30 10 O 5.1284 -8.47 0 0
M  V30 11 O 8.2084 -8.47 0 0
M  V30 12 C 6.6684 -10.01 0 0
M  V30 13 C 8.0021 -10.78 0 0
M  V30 14 C 8.0021 -12.32 0 0
M  V30 15 C 6.6684 -13.09 0 0
M  V30 16 N 6.6684 -14.63 0 0
M  V30 17 C 5.3347 -12.32 0 0
M  V30 18 C 5.3347 -10.78 0 0
M  V30 19 C 5.3347 -4.62 0 0
M  V30 20 O 6.6684 -3.85 0 0
M  V30 21 C 6.6684 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 12 18
M  V30 19 1 7 19
M  V30 20 2 3 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385080

>  <MW>
310.074

>  <MW (desalted)>
310.329

>  <ClogP>
1.231

>  <logS>
-3.115

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
116.43

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 11.97 nM

>  <CAS>
2447-57-6

>  <Description>
Sulfadoxin is a sulfonamide antibiotic that inhibits dihydropteroate synthetase. It is a long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

>  <EBC_ID>
EBC-03788

>  <IUPAC Name>
4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 1998, vol. 42, # 1, p. 164 - 169

>  <Main tar all>
dihydrofolate reductase pX=7.92

$$$$
Efavirenz
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 0.6876 -5.4394 0 0
M  V30 2 C 1.6775 -4.2597 0 0
M  V30 3 F 2.8572 -5.2496 0 0
M  V30 4 F 0.4978 -3.2698 0 0
M  V30 5 C 2.6674 -3.08 0 0 CFG=1
M  V30 6 O 1.3337 -2.31 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 O 0 0 0 0
M  V30 9 N 2.6674 0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 C 5.3347 0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 6.6684 -2.31 0 0
M  V30 14 Cl 8.0021 -3.08 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 C 4.001 -2.31 0 0
M  V30 17 C 3.6573 -4.2597 0 0
M  V30 18 C 4.6471 -5.4394 0 0
M  V30 19 C 5.637 -6.6191 0 0
M  V30 20 C 7.0842 -7.1458 0 0
M  V30 21 C 5.9045 -8.1357 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 2 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 5 16
M  V30 18 1 5 17 CFG=3
M  V30 19 3 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2177953192

>  <MW>
315.027

>  <MW (desalted)>
315.675

>  <ClogP>
3.726

>  <logS>
-5.51

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.33

>  <RotBonds>
3

>  <Action on targets>
- | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50 = 0.006 nM | IC50  0.0084 nM | IC90 = 1.7 nM

>  <CAS>
154598-52-4

>  <Description>
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection or prevent the spread of HIV.

>  <EBC_ID>
EBC-12705

>  <IUPAC Name>
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 23, p. 10601 - 10609 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 20, p. 5857 - 5860 | Bioorg. Med. Chem. Lett., 2001, vol. 11, # 2, p. 211 - 214

>  <Main tar all>
RNA-directed DNA polymerase pX=11.2 | HIV-1 protease pX=11.1 | RNA pX=9.72

$$$$
Rosiglitazone maleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2264 -0.1306 0 0
M  V30 2 N -4.2264 1.4094 0 0
M  V30 3 C -2.8927 2.1794 0 0
M  V30 4 C -1.559 1.4094 0 0
M  V30 5 O -0.2253 2.1794 0 0
M  V30 6 C 1.1084 1.4094 0 0
M  V30 7 C 2.442 2.1794 0 0
M  V30 8 C 3.7757 1.4094 0 0
M  V30 9 C 3.7757 -0.1306 0 0
M  V30 10 C 5.1094 -0.9006 0 0
M  V30 11 C 5.1094 -2.4406 0 0
M  V30 12 S 6.3553 -3.3458 0 0
M  V30 13 C 5.8794 -4.8104 0 0
M  V30 14 O 6.7846 -6.0563 0 0
M  V30 15 N 4.3394 -4.8104 0 0
M  V30 16 C 3.8635 -3.3458 0 0
M  V30 17 O 2.3989 -2.8699 0 0
M  V30 18 C 2.442 -0.9006 0 0
M  V30 19 C 1.1084 -0.1306 0 0
M  V30 20 C -5.56 2.1794 0 0
M  V30 21 C -6.8937 1.4094 0 0
M  V30 22 C -8.2274 2.1794 0 0
M  V30 23 C -8.2274 3.7194 0 0
M  V30 24 C -6.8937 4.4894 0 0
M  V30 25 N -5.56 3.7194 0 0
M  V30 26 O 16.4646 -0 0 0
M  V30 27 C 14.9246 -0 0 0
M  V30 28 O 14.1546 -1.3337 0 0
M  V30 29 C 14.1546 1.3337 0 0
M  V30 30 C 12.6146 1.3337 0 0
M  V30 31 C 11.8446 -0 0 0
M  V30 32 O 12.6146 -1.3337 0 0
M  V30 33 O 10.3046 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 11 16
M  V30 17 2 16 17
M  V30 18 2 9 18
M  V30 19 1 18 19
M  V30 20 2 6 19
M  V30 21 1 2 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 20 25
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568700088

>  <MW>
473.126

>  <MW (desalted)>
357.427

>  <ClogP>
3.02

>  <logS>
-4.383

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
71.53

>  <RotBonds>
9

>  <Action on targets>
Activator | Activator | Agonist | Inhibitor | -

>  <Activity coefficients and valu>
stimulation rate Active   | stimulation rate Active   | EC50  0.01 ?M | IC50 = 10 nM | EC50 = 20 nM

>  <CAS>
155141-29-0

>  <Description>
Rosiglitazone is used to maintain glycemic control in type 2 diabetes.

>  <EBC_ID>
EBC-11276

>  <IUPAC Name>
(2Z)-but-2-enedioic acid; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione

>  <Main Tar all refs>
NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3498279, 2019, A1 | NOVMETAPHARMA CO LTD; POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3498279, 2019, A1 | J. Mol. Endocrinol., 2004, vol. 32, # 2, p. 425 - 436 | J. Pharmacol. Exp. Ther., 1998, vol. 284, # 2, p. 751 - 759 | J. Med. Chem., 2004, vol. 47, # 12, p. 3255 - 3263

>  <Main tar all>
Peroxisome proliferator-activated receptor-? pX=9.0 | Regulatory protein GAL4 pX=9.0 | Peroxisome proliferator-activated receptor-?2 pX=8.0 | Peroxisome proliferator-activated receptor-? pX=8.0 | Peroxisome proliferator-activated receptor-? pX=7.7

$$$$
Pyrvinium pamoate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 87 96 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.3706 -3.9627 0 0
M  V30 2 N -8.3706 -2.4227 0 0
M  V30 3 C -9.7043 -1.6527 0 0
M  V30 4 C -7.0369 -1.6527 0 0
M  V30 5 C -7.0369 -0.1127 0 0
M  V30 6 C -5.7033 0.6573 0 0
M  V30 7 C -4.3696 -0.1127 0 0
M  V30 8 N -3.0359 0.6573 0 0 CHG=1
M  V30 9 C -3.0359 2.1973 0 0
M  V30 10 C -1.7022 -0.1127 0 0
M  V30 11 C -0.3685 0.6573 0 0
M  V30 12 C 0.9651 -0.1127 0 0
M  V30 13 C 2.2988 0.6573 0 0
M  V30 14 C 2.4598 2.1889 0 0
M  V30 15 C 3.9661 2.5091 0 0
M  V30 16 C 4.5925 3.9159 0 0
M  V30 17 N 4.7361 1.1754 0 0
M  V30 18 C 3.7057 0.0309 0 0
M  V30 19 C 4.0259 -1.4754 0 0
M  V30 20 C 6.2677 1.0144 0 0
M  V30 21 C 7.1729 2.2603 0 0
M  V30 22 C 8.7045 2.0993 0 0
M  V30 23 C 9.3308 0.6925 0 0
M  V30 24 C 8.4256 -0.5534 0 0
M  V30 25 C 6.8941 -0.3924 0 0
M  V30 26 C -1.7022 -1.6527 0 0
M  V30 27 C -3.0359 -2.4227 0 0
M  V30 28 C -4.3696 -1.6527 0 0
M  V30 29 C -5.7033 -2.4227 0 0
M  V30 30 C 15.0645 -3.9627 0 0
M  V30 31 N 15.0645 -2.4227 0 0
M  V30 32 C 13.7308 -1.6527 0 0
M  V30 33 C 16.3982 -1.6527 0 0
M  V30 34 C 16.3982 -0.1127 0 0
M  V30 35 C 17.7319 0.6573 0 0
M  V30 36 C 19.0655 -0.1127 0 0
M  V30 37 N 20.3992 0.6573 0 0 CHG=1
M  V30 38 C 20.3992 2.1973 0 0
M  V30 39 C 21.7329 -0.1127 0 0
M  V30 40 C 23.0666 0.6573 0 0
M  V30 41 C 24.4003 -0.1127 0 0
M  V30 42 C 25.7339 0.6573 0 0
M  V30 43 C 25.8949 2.1889 0 0
M  V30 44 C 27.4013 2.5091 0 0
M  V30 45 C 28.0276 3.9159 0 0
M  V30 46 N 28.1713 1.1754 0 0
M  V30 47 C 27.1408 0.0309 0 0
M  V30 48 C 27.461 -1.4754 0 0
M  V30 49 C 29.7028 1.0144 0 0
M  V30 50 C 30.608 2.2603 0 0
M  V30 51 C 32.1396 2.0993 0 0
M  V30 52 C 32.766 0.6925 0 0
M  V30 53 C 31.8608 -0.5534 0 0
M  V30 54 C 30.3292 -0.3924 0 0
M  V30 55 C 21.7329 -1.6527 0 0
M  V30 56 C 20.3992 -2.4227 0 0
M  V30 57 C 19.0655 -1.6527 0 0
M  V30 58 C 17.7319 -2.4227 0 0
M  V30 59 O -1.3025 -13.9727 0 0
M  V30 60 C 0.0312 -14.7427 0 0
M  V30 61 C 1.3649 -13.9727 0 0
M  V30 62 C 1.3649 -12.4327 0 0
M  V30 63 C 0.0312 -11.6627 0 0
M  V30 64 C -1.3025 -12.4327 0 0
M  V30 65 O -2.2077 -13.6786 0 0
M  V30 66 C -2.6361 -11.6627 0 0
M  V30 67 C -2.6361 -10.1227 0 0
M  V30 68 C -1.3025 -9.3527 0 0
M  V30 69 C -1.3025 -7.8127 0 0
M  V30 70 C 0.0312 -7.0427 0 0
M  V30 71 C 1.3649 -7.8127 0 0
M  V30 72 C 1.3649 -9.3527 0 0
M  V30 73 C 0.0312 -10.1227 0 0
M  V30 74 C -3.9698 -12.4327 0 0
M  V30 75 O -5.3035 -11.6627 0 0
M  V30 76 O -3.9698 -13.9727 0 0 CHG=-1
M  V30 77 C 2.6986 -14.7427 0 0
M  V30 78 C 4.0323 -13.9727 0 0
M  V30 79 C 5.3659 -14.7427 0 0
M  V30 80 C 5.3659 -16.2827 0 0
M  V30 81 C 4.0323 -17.0527 0 0
M  V30 82 C 2.6986 -16.2827 0 0
M  V30 83 C 1.3649 -17.0527 0 0
M  V30 84 C 0.0312 -16.2827 0 0
M  V30 85 C -1.3025 -17.0527 0 0
M  V30 86 O -2.6361 -16.2827 0 0
M  V30 87 O -1.3025 -18.5927 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 11 10 CFG=2
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 18 19
M  V30 20 1 17 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 20 25
M  V30 27 1 10 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 7 28
M  V30 31 1 28 29
M  V30 32 2 4 29
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 31 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 2 37 39
M  V30 42 1 40 39 CFG=2
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 1 42 43
M  V30 46 2 43 44
M  V30 47 1 44 45
M  V30 48 1 44 46
M  V30 49 1 46 47
M  V30 50 2 42 47
M  V30 51 1 47 48
M  V30 52 1 46 49
M  V30 53 1 49 50
M  V30 54 2 50 51
M  V30 55 1 51 52
M  V30 56 2 52 53
M  V30 57 1 53 54
M  V30 58 2 49 54
M  V30 59 1 39 55
M  V30 60 2 55 56
M  V30 61 1 56 57
M  V30 62 2 36 57
M  V30 63 1 57 58
M  V30 64 2 33 58
M  V30 65 1 59 60
M  V30 66 1 60 61
M  V30 67 1 61 62
M  V30 68 1 62 63
M  V30 69 1 63 64
M  V30 70 1 64 65
M  V30 71 2 64 66
M  V30 72 1 66 67
M  V30 73 2 67 68
M  V30 74 1 68 69
M  V30 75 2 69 70
M  V30 76 1 70 71
M  V30 77 2 71 72
M  V30 78 1 72 73
M  V30 79 2 63 73
M  V30 80 1 68 73
M  V30 81 1 66 74
M  V30 82 2 74 75
M  V30 83 1 74 76
M  V30 84 2 61 77
M  V30 85 1 77 78
M  V30 86 2 78 79
M  V30 87 1 79 80
M  V30 88 2 80 81
M  V30 89 1 81 82
M  V30 90 1 77 82
M  V30 91 2 82 83
M  V30 92 1 83 84
M  V30 93 2 60 84
M  V30 94 1 84 85
M  V30 95 2 85 86
M  V30 96 1 85 87
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2196311755

>  <MW>
1151.395

>  <MW (desalted)>
382.521

>  <ClogP>
2.786

>  <logS>
-13.32

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
12.05

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | - | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
inhibition percentage Active   | EC50 = 10 nM | EC50 ~ 20 nM | EC50 ~ 20 nM | amount increase Active   | enzyme activity decrease Active   | enzyme activity decrease Active   | enzyme activity decrease Active   | IC50  0.194 ?M | protein expression level increase Active

>  <CAS>
3546-41-6

>  <Description>
Pyrvinium is an anthelmintic agent used for the treatment of pinworm infestations.

>  <EBC_ID>
EBC-12083

>  <IUPAC Name>
bis(2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-6-(dimethylamino)-1-methylquinolin-1-ium) 4-[(3-carboxylato-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylate

>  <Main Tar all refs>
UMASS MEMORIAL HEALTH CARE INC - WO2018/222831, 2018, A1 | Annual Reports in Medicinal Chemistry, 2012, vol. 47, p. 393 - 409 | J. Biol. Chem., 2022, vol. 298, # 8 | J. Biol. Chem., 2022, vol. 298, # 8 | UNIVERSITY SYSTEM OF MARYLAND - WO2017/151786, 2017, A1 | Cancer Res., 2020, vol. 80, # 19 | Cancer Res., 2020, vol. 80, # 19 | Cancer Res., 2020, vol. 80, # 19 | UNIVERSITY OF BRITISH COLUMBIA - WO2015/120543, 2015, A1 | J. Biol. Chem., 2022, vol. 298, # 8

>  <Main tar all>
Histone lysine demethylase (KDM) pX=8.0 | Proto-oncogene Wnt-1 pX=8.0 | Protein cereblon pX=7.7 | casein kinase 1 alpha pX=7.7 | Wnt pX=7.6 | NADH dehydrogenase (ubiquinone) pX=7.0 | cytochrome-c oxidase pX=7.0 | succinate dehydrogenase (ubiquinone) pX=7.0 | Androgen receptor pX=6.71 | Casein kinase 1 alpha (G40N) pX=6.7

$$$$
Olaparib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -2.6674 -7.7 0 0
M  V30 2 C -1.3337 -6.93 0 0
M  V30 3 C -1.3337 -5.39 0 0
M  V30 4 C 0 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 N 1.3337 -2.31 0 0
M  V30 9 N 1.3337 -0.77 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 O 2.6674 1.54 0 0
M  V30 12 C 4.001 -0.77 0 0
M  V30 13 C 5.3347 0 0 0
M  V30 14 C 6.6684 -0.77 0 0
M  V30 15 C 6.6684 -2.31 0 0
M  V30 16 C 5.3347 -3.08 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 18 C 1.3337 -6.93 0 0
M  V30 19 C 0 -7.7 0 0
M  V30 20 C 0 -9.24 0 0
M  V30 21 O 1.3337 -10.01 0 0
M  V30 22 N -1.3337 -10.01 0 0
M  V30 23 C -1.3337 -11.55 0 0
M  V30 24 C -2.6674 -12.32 0 0
M  V30 25 N -4.001 -11.55 0 0
M  V30 26 C -4.001 -10.01 0 0
M  V30 27 C -2.6674 -9.24 0 0
M  V30 28 C -5.3347 -12.32 0 0
M  V30 29 O -5.3347 -13.86 0 0
M  V30 30 C -6.6684 -11.55 0 0
M  V30 31 C -8.2084 -11.55 0 0
M  V30 32 C -7.4384 -10.2163 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 7 17
M  V30 18 2 12 17
M  V30 19 2 5 18
M  V30 20 1 18 19
M  V30 21 2 2 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 22 27
M  V30 31 1 25 28
M  V30 32 2 28 29
M  V30 33 1 28 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 30 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2227698469

>  <MW>
434.463

>  <MW (desalted)>
434.463

>  <ClogP>
1.236

>  <logS>
-5.731

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
82.08

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.004 nM

>  <CAS>
763113-22-0

>  <Description>
Olaparib is a chemotherapeutic agent used to treat recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and prior history of chemotherapy.

>  <EBC_ID>
EBC-11384

>  <IUPAC Name>
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one

>  <Main Tar all refs>
, 2009

>  <Main tar all>
Poly pX=11.4

$$$$
Clevidipine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 -1.54 0 0
M  V30 2 C 12.0031 -2.31 0 0
M  V30 3 C 13.3368 -1.54 0 0
M  V30 4 C 14.6705 -2.31 0 0
M  V30 5 O 14.6705 -3.85 0 0
M  V30 6 O 16.0041 -1.54 0 0
M  V30 7 C 17.3378 -2.31 0 0
M  V30 8 O 18.6715 -1.54 0 0
M  V30 9 C 20.0052 -2.31 0 0
M  V30 10 O 20.0052 -3.85 0 0
M  V30 11 C 21.3389 -1.54 0 0
M  V30 12 C 21.3389 0 0 0
M  V30 13 C 20.0052 0.77 0 0
M  V30 14 N 22.6725 0.77 0 0
M  V30 15 C 24.0062 0 0 0
M  V30 16 C 24.0062 -1.54 0 0
M  V30 17 C 22.6725 -2.31 0 0
M  V30 18 C 22.6725 -3.85 0 0
M  V30 19 C 24.0062 -4.62 0 0
M  V30 20 C 24.0062 -6.16 0 0
M  V30 21 C 22.6725 -6.93 0 0
M  V30 22 C 21.3389 -6.16 0 0
M  V30 23 Cl 20.0052 -6.93 0 0
M  V30 24 C 21.3389 -4.62 0 0
M  V30 25 Cl 19.8073 -4.781 0 0
M  V30 26 C 25.3399 -2.31 0 0
M  V30 27 O 25.3399 -3.85 0 0
M  V30 28 O 26.6736 -1.54 0 0
M  V30 29 C 28.0073 -2.31 0 0
M  V30 30 C 25.3399 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 11 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 18 24
M  V30 26 1 24 25
M  V30 27 1 16 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 1 15 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553844

>  <MW>
456.316

>  <MW (desalted)>
456.316

>  <ClogP>
5.53

>  <logS>
-4.31

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
90.93

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.1 ?M | Ki (inhibition constant)  1.6 ?M | IC50  2.5 ?M | IC50  2.6 ?M

>  <CAS>
167221-71-8

>  <Description>
Clevidipine is a dihydropyridine L-type calcium channel blocker used to lower blood pressure when oral antihypertensive therapy is not feasible or not desirable.

>  <EBC_ID>
EBC-14153

>  <IUPAC Name>
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 93, # 2, p. 101 - 108 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA022156, Owner: MEDS CO, Number: 000, Revision: 01.08.2008 00:00:00, 2008 | Drug Metab. Dispos., 2006, vol. 34, # 5, p. 734 - 737 | Drug Metab. Dispos., 2006, vol. 34, # 5, p. 734 - 737

>  <Main tar all>
CYP27A1 pX=7.0 | Cytochrome P450 2C9 pX=5.8 | Cytochrome P450 2C19 pX=5.6 | Cytochrome P450 3A4 pX=5.59

$$$$
Gemcitabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 8.4381 7.4684 0 0
M  V30 2 C 6.9734 6.9925 0 0
M  V30 3 C 6.6533 5.4861 0 0
M  V30 4 C 5.1886 5.0102 0 0
M  V30 5 N 4.0442 6.0407 0 0
M  V30 6 C 2.5796 5.5648 0 0 CFG=2
M  V30 7 O 2.1037 4.1002 0 0
M  V30 8 C 0.5637 4.1002 0 0 CFG=2
M  V30 9 C -0.3415 2.8543 0 0
M  V30 10 O 0.2849 1.4474 0 0
M  V30 11 C 0.0878 5.5648 0 0 CFG=1
M  V30 12 O -1.3768 6.0407 0 0
M  V30 13 C 1.3337 6.47 0 0
M  V30 14 F 0.5777 7.8117 0 0
M  V30 15 F 2.0897 7.8117 0 0
M  V30 16 C 4.3644 7.547 0 0
M  V30 17 O 3.2199 8.5775 0 0
M  V30 18 N 5.829 8.0229 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 8 11
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 5 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 2 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741982024

>  <MW>
263.198

>  <MW (desalted)>
263.198

>  <ClogP>
-0.712

>  <logS>
-1.344

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
108.38

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
relative organoid volume decrease Active   | IC50  0.1 nM | inhibition percentage Active   | GI50  0.251 nM | IC50 = 1.1 nM | IC50  1.4 nM

>  <CAS>
95058-81-4

>  <Description>
Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.

>  <EBC_ID>
EBC-11028

>  <IUPAC Name>
4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
UNIVERSITY OF CALIFORNIA - WO2020/172467, 2020, A1 | Bioconjugate Chem., 2014, vol. 25, # 4, p. 813 - 823 | JAZZ PHARMACEUTICALS PLC - WO2017/123588, 2017, A1 | J. Med. Chem., 2018, vol. 61, # 3, p. 1061 - 1073 | MAYO FOUNDATION - WO2011/130429, 2011, A2 | , 2020, vol. 11, # 2, p. 268 - 273

>  <Main tar all>
RAR-related orphan receptor-? pX=10.3 | GnRH1 receptor pX=10.0 | ATR serine/threonine kinase pX=9.89 | checkpoint kinase 1 pX=9.6 | protein kinase C iota pX=8.96 | Thymidylate synthase pX=8.85

$$$$
Quetiapine hemifumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 62 67 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -10.4715 2.0579 0 0
M  V30 2 C -9.1378 2.8279 0 0
M  V30 3 C -7.8041 2.0579 0 0
M  V30 4 O -6.4704 2.8279 0 0
M  V30 5 C -5.1367 2.0579 0 0
M  V30 6 C -3.8031 2.8279 0 0
M  V30 7 N -2.4694 2.0579 0 0
M  V30 8 C -1.1357 2.8279 0 0
M  V30 9 C 0.198 2.0579 0 0
M  V30 10 N 0.198 0.5179 0 0
M  V30 11 C -1.1357 -0.2521 0 0
M  V30 12 C -2.4694 0.5179 0 0
M  V30 13 C 1.5316 -0.2521 0 0
M  V30 14 N 2.8041 0.6154 0 0
M  V30 15 C 4.2756 0.1615 0 0
M  V30 16 C 5.2358 1.3655 0 0
M  V30 17 C 6.7586 1.136 0 0
M  V30 18 C 7.3212 -0.2975 0 0
M  V30 19 C 6.3611 -1.5015 0 0
M  V30 20 C 4.8383 -1.272 0 0
M  V30 21 S 4.0683 -2.6057 0 0
M  V30 22 C 2.5455 -2.8352 0 0
M  V30 23 C 2.2028 -4.3366 0 0
M  V30 24 C 0.7312 -4.7905 0 0
M  V30 25 C -0.3977 -3.7431 0 0
M  V30 26 C -0.055 -2.2417 0 0
M  V30 27 C 1.4166 -1.7878 0 0
M  V30 28 O 10.8412 2.0579 0 0
M  V30 29 C 12.1749 2.8279 0 0
M  V30 30 C 13.5086 2.0579 0 0
M  V30 31 O 14.8423 2.8279 0 0
M  V30 32 C 16.176 2.0579 0 0
M  V30 33 C 17.5096 2.8279 0 0
M  V30 34 N 18.8433 2.0579 0 0
M  V30 35 C 20.177 2.8279 0 0
M  V30 36 C 21.5107 2.0579 0 0
M  V30 37 N 21.5107 0.5179 0 0
M  V30 38 C 20.177 -0.2521 0 0
M  V30 39 C 18.8433 0.5179 0 0
M  V30 40 C 22.8443 -0.2521 0 0
M  V30 41 N 24.1168 0.6154 0 0
M  V30 42 C 25.5883 0.1615 0 0
M  V30 43 C 26.5485 1.3655 0 0
M  V30 44 C 28.0713 1.136 0 0
M  V30 45 C 28.6339 -0.2975 0 0
M  V30 46 C 27.6738 -1.5015 0 0
M  V30 47 C 26.151 -1.272 0 0
M  V30 48 S 25.381 -2.6057 0 0
M  V30 49 C 23.8582 -2.8352 0 0
M  V30 50 C 23.5155 -4.3366 0 0
M  V30 51 C 22.0439 -4.7905 0 0
M  V30 52 C 20.915 -3.7431 0 0
M  V30 53 C 21.2577 -2.2417 0 0
M  V30 54 C 22.7293 -1.7878 0 0
M  V30 55 O 3.08 -9.2042 0 0
M  V30 56 C 1.54 -9.2042 0 0
M  V30 57 O 0.77 -7.8705 0 0
M  V30 58 C 0.77 -10.5379 0 0
M  V30 59 C -0.77 -10.5379 0 0
M  V30 60 C -1.54 -11.8716 0 0
M  V30 61 O -0.77 -13.2053 0 0
M  V30 62 O -3.08 -11.8716 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 13 27
M  V30 30 2 22 27
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 34 39
M  V30 43 1 37 40
M  V30 44 2 40 41
M  V30 45 1 41 42
M  V30 46 1 42 43
M  V30 47 2 43 44
M  V30 48 1 44 45
M  V30 49 2 45 46
M  V30 50 1 46 47
M  V30 51 2 42 47
M  V30 52 1 47 48
M  V30 53 1 48 49
M  V30 54 1 49 50
M  V30 55 2 50 51
M  V30 56 1 51 52
M  V30 57 2 52 53
M  V30 58 1 53 54
M  V30 59 1 40 54
M  V30 60 2 49 54
M  V30 61 1 55 56
M  V30 62 2 56 57
M  V30 63 1 56 58
M  V30 64 2 58 59
M  V30 65 1 59 60
M  V30 66 2 60 61
M  V30 67 1 60 62
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568699261

>  <MW>
882.344

>  <MW (desalted)>
383.507

>  <ClogP>
2.992

>  <logS>
-7.131

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
48.3

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  8 - 9  | Ki (inhibition constant) = 4.5 nM | pKi  8.17  | Ki (inhibition constant) = 7 nM | Ki (inhibition constant)  9.2 nM | pKi  7 - 8  | pKi  7 - 8  | pKi  7 - 8  | pKi  7 - 8  | pKi  8  | pKi  7 - 8  | Ki (inhibition constant) > 10 nM | Ki (inhibition constant) > 10 nM | Ki (inhibition constant) > 10 nM | Ki (inhibition constant) > 10 nM | Ki (inhibition constant) > 10 nM | concentration (parameter)  0.0125 ?M | Ki (inhibition constant)  28.9 nM | pKi  7.54 | Ki (inhibition constant) = 31 nM

>  <CAS>
111974-72-2

>  <Description>
Quetiapine hemifumarate is an atypical antipsychotic. It is used in the treatment of schizophrenia, bipolar mania, bipolar depression. It shows affinity for serotonin, dopamine, histamine, and adrenergic receptors.

>  <EBC_ID>
EBC-15049

>  <IUPAC Name>
(2E)-but-2-enedioic acid; bis(2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol)

>  <Main Tar all refs>
PHARMANEUROBOOST - US2005/203130, 2005, A1 | J. Med. Chem., 2001, vol. 44, # 4, p. 477 - 501 | Br. J. Pharmacol., 2005, vol. 145, # 1, p. 34 - 42 | Curr. Med. Chem., 2013, vol. 20, # 3, p. 448 - 461 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | ANIMA SRL - WO2010/112529, 2010, A1 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - EP1541197, 2005, A1 | MedChemComm, 2012, vol. 3, # 5, p. 580 - 583 | ELI LILLY & CO - US2006/94705, 2006, A1 | ELI LILLY & CO - US2006/94705, 2006, A1 | ELI LILLY & CO - US2006/94705, 2006, A1 | ELI LILLY & CO - US2006/94705, 2006, A1 | ELI LILLY & CO - US2006/94705, 2006, A1 | Drug Metab. Dispos., 2009, vol. 37, # 2, p. 254 - 258 | ASTRAZENECA PLC - WO2006/73360, 2006, A1 | Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | Curr. Top. Med. Chem., 2008, vol. 8, # 11, p. 969 - 976

>  <Main tar all>
H1 receptor pX=9.0 | ?1-adrenoceptor pX=8.35 | D2S receptor pX=8.17 | ?1-adrenoceptor pX=8.15 | D3 receptor pX=8.04 | ?1A-adrenoceptor pX=8.0 | ?1A-adrenoceptor pX=8.0 | ?1B-adrenoceptor pX=8.0 | ?2B-adrenoceptor pX=8.0 | ?2B-adrenoceptor pX=8.0 | ?2C-adrenoceptor pX=8.0 | D1 receptor pX=8.0 | D2 receptor pX=8.0 | M1 receptor pX=8.0 | M2 receptor pX=8.0 | M3 receptor pX=8.0 | Cytochrome P450 3A5 pX=7.9 | ?2C-adrenoceptor pX=7.54 | 5-HT2A receptor pX=7.54 | 5-HT2A receptor pX=7.51

$$$$
Ethylparaben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 O 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 O 2.6674 4.62 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 O 1.3337 -2.31 0 0
M  V30 11 C 0 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53833636

>  <MW>
166.063

>  <MW (desalted)>
166.174

>  <ClogP>
2.514

>  <logS>
-1.643

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
percentage increase Active

>  <CAS>
120-47-8

>  <Description>
Ethylparaben is the ethyl ester of p-hydroxybenzoic acid, used as an antifungal preservative and food additive. It is a standardized chemical allergen.

>  <EBC_ID>
EBC-03339

>  <IUPAC Name>
ethyl 4-hydroxybenzoate

>  <Main Tar all refs>
Environ. Sci. Technol., 2017, vol. 51, # 11, p. 6452 - 6460

>  <Main tar all>
Androgen receptor pX=11.3

$$$$
Glycol salicylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 2.6674 -4.62 0 0
M  V30 4 O 4.001 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 O 5.3347 -3.08 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 C 8.0021 -7.7 0 0
M  V30 12 C 6.6684 -6.93 0 0
M  V30 13 O 5.3347 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z147642460

>  <MW>
182.058

>  <MW (desalted)>
182.173

>  <ClogP>
1.449

>  <logS>
-1.157

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.76

>  <RotBonds>
4

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
87-28-5

>  <Description>
Glycol salicylate is a non-steroidal anti-inflammatory drug. It is used to treat mild to moderate muscle pain.

>  <EBC_ID>
EBC-26155

>  <IUPAC Name>
2-hydroxyethyl 2-hydroxybenzoate

$$$$
Solifenacin succinate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -3.3342 -0.385 0 0
M  V30 2 C -2.0005 0.385 0 0
M  V30 3 O -2.0005 1.925 0 0
M  V30 4 C -0.6668 -0.385 0 0
M  V30 5 C 0.6668 0.385 0 0
M  V30 6 C 2.0005 -0.385 0 0
M  V30 7 O 3.3342 0.385 0 0
M  V30 8 O 2.0005 -1.925 0 0
M  V30 9 O 14.8563 -1.8252 0 0
M  V30 10 C 13.5226 -1.0552 0 0
M  V30 11 O 13.5226 0.4848 0 0
M  V30 12 C 14.8563 1.2548 0 0 CFG=1
M  V30 13 C 14.8563 2.7948 0 0
M  V30 14 N 16.19 3.5648 0 0
M  V30 15 C 17.5236 2.7948 0 0
M  V30 16 C 17.5236 1.2548 0 0
M  V30 17 C 16.19 0.4848 0 0 CFG=1
M  V30 18 C 16.4466 1.5115 0 0
M  V30 19 C 16.4466 2.5381 0 0
M  V30 20 N 12.1889 -1.8252 0 0
M  V30 21 C 12.1889 -3.3652 0 0
M  V30 22 C 10.8552 -4.1352 0 0
M  V30 23 C 9.5216 -3.3652 0 0
M  V30 24 C 8.1879 -4.1352 0 0
M  V30 25 C 6.8542 -3.3652 0 0
M  V30 26 C 6.8542 -1.8252 0 0
M  V30 27 C 8.1879 -1.0552 0 0
M  V30 28 C 9.5216 -1.8252 0 0
M  V30 29 C 10.8552 -1.0552 0 0 CFG=2
M  V30 30 C 10.8552 0.4848 0 0
M  V30 31 C 9.5216 1.2548 0 0
M  V30 32 C 9.5216 2.7948 0 0
M  V30 33 C 10.8552 3.5648 0 0
M  V30 34 C 12.1889 2.7948 0 0
M  V30 35 C 12.1889 1.2548 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 12 11 CFG=1
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 17 16 CFG=3
M  V30 16 1 12 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 19
M  V30 20 1 10 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 23 28
M  V30 30 1 29 28
M  V30 31 1 29 20
M  V30 32 1 29 30 CFG=3
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 2 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3292113945

>  <MW>
480.226

>  <MW (desalted)>
362.465

>  <ClogP>
4.68

>  <logS>
-3.161

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
32.78

>  <RotBonds>
6

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.45 nM | Ki (inhibition constant)  1.72 nM

>  <CAS>
242478-38-2

>  <Description>
Solifenacin is a muscarinic antagonist with antispasmodic properties.

>  <EBC_ID>
EBC-70072

>  <IUPAC Name>
(3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate; butanedioic acid

>  <Main Tar all refs>
Biol. Pharm. Bull., 2006, vol. 29, # 7, p. 1397 - 1400 | LABORATORIOS SALVAT S.A. - EP1300407, 2003, A1

>  <Main tar all>
mAChR pX=9.35 | M3 receptor pX=8.76

$$$$
Abiraterone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 C 10.2985 -4.155 0 0 CFG=1
M  V30 6 C 9.3058 -2.9776 0 0 CFG=1
M  V30 7 C 9.829 -1.5293 0 0
M  V30 8 C 11.345 -1.2582 0 0
M  V30 9 C 12.3377 -2.4355 0 0
M  V30 10 C 13.8537 -2.1644 0 0
M  V30 11 C 14.8464 -3.3418 0 0 CFG=1
M  V30 12 O 16.3624 -3.0707 0 0
M  V30 13 C 14.3232 -4.7901 0 0
M  V30 14 C 12.8072 -5.0612 0 0
M  V30 15 C 11.8145 -3.8839 0 0 CFG=2
M  V30 16 C 11.2913 -5.3323 0 0
M  V30 17 C 7.7898 -3.2487 0 0 CFG=2
M  V30 18 C 6.574 -2.3035 0 0
M  V30 19 C 5.2994 -3.1677 0 0
M  V30 20 C 5.7274 -4.6471 0 0
M  V30 21 C 4.7822 -5.8629 0 0
M  V30 22 C 5.3626 -7.2893 0 0
M  V30 23 C 4.4174 -8.5052 0 0
M  V30 24 C 2.8918 -8.2945 0 0
M  V30 25 N 2.3115 -6.868 0 0
M  V30 26 C 3.2567 -5.6522 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 5 15
M  V30 16 1 15 9
M  V30 17 1 15 16 CFG=1
M  V30 18 1 6 17
M  V30 19 1 17 2
M  V30 20 1 17 18 CFG=1
M  V30 21 1 18 19
M  V30 22 2 19 20
M  V30 23 1 2 20
M  V30 24 1 20 21
M  V30 25 1 21 22
M  V30 26 2 22 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301684603

>  <MW>
349.241

>  <MW (desalted)>
349.509

>  <ClogP>
5.165

>  <logS>
-5.575

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
33.12

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.39 nM

>  <CAS>
154229-19-3

>  <Description>
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1. Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. It is used  in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.

>  <EBC_ID>
EBC-13814

>  <IUPAC Name>
(3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2020, vol. 374, # 3, p. 438 - 451

>  <Main tar all>
CYP17A1 pX=9.41

$$$$
Ceritinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 -3.08 0 0
M  V30 2 C -5.3347 -4.62 0 0
M  V30 3 C -6.6684 -5.39 0 0
M  V30 4 O -4.001 -5.39 0 0
M  V30 5 C -4.001 -6.93 0 0
M  V30 6 C -2.6674 -7.7 0 0
M  V30 7 C -2.6674 -9.24 0 0
M  V30 8 C -1.3337 -10.01 0 0
M  V30 9 C 0 -9.24 0 0
M  V30 10 C 1.3337 -10.01 0 0
M  V30 11 N 1.3337 -11.55 0 0
M  V30 12 C 0 -12.32 0 0
M  V30 13 C -1.3337 -11.55 0 0
M  V30 14 C -4.001 -10.01 0 0
M  V30 15 C -4.001 -11.55 0 0
M  V30 16 C -5.3347 -9.24 0 0
M  V30 17 C -5.3347 -7.7 0 0
M  V30 18 N -6.6684 -6.93 0 0
M  V30 19 C -8.0021 -7.7 0 0
M  V30 20 N -8.0021 -9.24 0 0
M  V30 21 C -9.3358 -10.01 0 0
M  V30 22 C -10.6694 -9.24 0 0
M  V30 23 Cl -12.0031 -10.01 0 0
M  V30 24 C -10.6694 -7.7 0 0
M  V30 25 N -12.0031 -6.93 0 0
M  V30 26 C -13.3368 -7.7 0 0
M  V30 27 C -13.3368 -9.24 0 0
M  V30 28 C -14.6705 -10.01 0 0
M  V30 29 C -16.0041 -9.24 0 0
M  V30 30 C -16.0041 -7.7 0 0
M  V30 31 C -14.6705 -6.93 0 0
M  V30 32 S -14.6705 -5.39 0 0
M  V30 33 O -13.1305 -5.39 0 0
M  V30 34 O -16.2105 -5.39 0 0
M  V30 35 C -14.6705 -3.85 0 0
M  V30 36 C -16.0041 -3.08 0 0
M  V30 37 C -13.3368 -3.08 0 0
M  V30 38 N -9.3358 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 5 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 22 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 26 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 2 32 34
M  V30 37 1 32 35
M  V30 38 1 35 36
M  V30 39 1 35 37
M  V30 40 1 24 38
M  V30 41 2 19 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802104

>  <MW>
557.223

>  <MW (desalted)>
558.135

>  <ClogP>
6.713

>  <logS>
-6.676

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
105.24

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 >= 0.1 - 50 nM | IC50 >= 0.1 - 50 nM | IC50  0.14 nM | IC50  0.25 nM | IC50  0.63 nM | inhibition percentage Active   | inhibition rate Active   | IC50  2 nM | IC50  2 nmol/l | IC50  2.5 nM | IC50  2.6 nM

>  <CAS>
1032900-25-6

>  <Description>
Ceritinib is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib.

>  <EBC_ID>
EBC-12909

>  <IUPAC Name>
5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

>  <Main Tar all refs>
PHARMA RESOURCES GMBH; NUVALENT; PHARMARESOURCES CO. - WO2021/226269, 2021, A1 | PHARMA RESOURCES GMBH; NUVALENT; PHARMARESOURCES CO. - WO2021/226269, 2021, A1 | J. Med. Chem., 2018, vol. 61, # 9, p. 4249 - 4255 | Eur. J. Med. Chem., 2021, vol. 224 | Eur. J. Med. Chem., 2017, vol. 126, p. 536 - 549 | eLife, 2017, vol. 6 | UNIVERSITY OF OSLO - WO2022/69684, 2022, A1 | Eur. J. Med. Chem., 2019, vol. 171, p. 297 - 309 | Eur. J. Med. Chem., 2016, vol. 123, p. 80 - 89 | Eur. J. Med. Chem., 2018, vol. 143, p. 123 - 136 | Acta Pharmacol. Sin., 2021, vol. 42, # 6, p. 998 - 1004

>  <Main tar all>
H-2 class II histocompatibility antigen gamma chain pX=10.0 | Proto-oncogene?tyrosine-protein?kinase?ROS?(G2032R) pX=10.0 | ALK receptor tyrosine kinase pX=9.85 | ALK tyrosine kinase receptor (L1196M) pX=9.6 | Alkaline phosphatase pX=9.2 | MDM2 proto-oncogene pX=9.0 | leukocyte receptor tyrosine kinase pX=9.0 | ALK tyrosine kinase receptor (L1196M) pX=8.7 | c-ros oncogene 1, receptor tyrosine kinase pX=8.7 | ALK tyrosine kinase receptor (T1151ins) pX=8.6 | General negative regulator of transcription subunit 1 pX=8.59

$$$$
Fluvastatin sodium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 12.1638 -7.2084 0 0 CHG=1
M  V30 2 C 9.3504 -0.3586 0 0
M  V30 3 C 8.2059 -1.3891 0 0
M  V30 4 C 8.5261 -2.8954 0 0
M  V30 5 N 6.7413 -0.9132 0 0
M  V30 6 C 5.4954 -1.8184 0 0
M  V30 7 C 5.4954 -3.3584 0 0
M  V30 8 C 4.1617 -4.1284 0 0
M  V30 9 C 4.1617 -5.6684 0 0 CFG=1
M  V30 10 O 2.8281 -6.4384 0 0
M  V30 11 C 5.4954 -6.4384 0 0
M  V30 12 C 6.8291 -5.6684 0 0 CFG=1
M  V30 13 O 6.8291 -4.1284 0 0
M  V30 14 C 8.1628 -6.4384 0 0
M  V30 15 C 9.4965 -5.6684 0 0
M  V30 16 O 9.4965 -4.1284 0 0
M  V30 17 O 10.8301 -6.4384 0 0 CHG=-1
M  V30 18 C 4.2495 -0.9132 0 0
M  V30 19 C 2.7849 -1.3891 0 0
M  V30 20 C 2.4647 -2.8954 0 0
M  V30 21 C 1.0001 -3.3713 0 0
M  V30 22 C -0.1443 -2.3408 0 0
M  V30 23 F -1.609 -2.8167 0 0
M  V30 24 C 0.1758 -0.8345 0 0
M  V30 25 C 1.6405 -0.3586 0 0
M  V30 26 C 4.7254 0.5515 0 0
M  V30 27 C 3.9554 1.8851 0 0
M  V30 28 C 4.7254 3.2188 0 0
M  V30 29 C 6.2654 3.2188 0 0
M  V30 30 C 7.0354 1.8851 0 0
M  V30 31 C 6.2654 0.5515 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 9 8
M  V30 8 1 9 10 CFG=3
M  V30 9 1 9 11
M  V30 10 1 12 11
M  V30 11 1 12 13 CFG=1
M  V30 12 1 12 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 15 17
M  V30 16 2 6 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 2 20 21
M  V30 20 1 21 22
M  V30 21 1 22 23
M  V30 22 2 22 24
M  V30 23 1 24 25
M  V30 24 2 19 25
M  V30 25 1 18 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 2 29 30
M  V30 30 1 30 31
M  V30 31 1 5 31
M  V30 32 2 26 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568666661

>  <MW>
433.167

>  <MW (desalted)>
411.466

>  <ClogP>
1.088

>  <logS>
-5.525

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
85.52

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 2.5 nM

>  <CAS>
93957-55-2

>  <Description>
Fluvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.

>  <EBC_ID>
EBC-13130

>  <IUPAC Name>
sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate

>  <Main Tar all refs>
J. MED. CHEM., 1991, vol. 34, # 10, p. 2962 - 2983

>  <Main tar all>
hydroxymethylglutaryl-CoA reductase pX=8.6

$$$$
P-Cresol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 O 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473818

>  <MW>
108.058

>  <MW (desalted)>
108.138

>  <ClogP>
1.974

>  <logS>
-1.439

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
pIC50  8.74

>  <CAS>
106-44-5

>  <Description>
p-Cresol is a potent acetylcholinesterase inhibitor.

>  <EBC_ID>
EBC-03068

>  <IUPAC Name>
4-methylphenol

>  <Main Tar all refs>
BIOORG. MED. CHEM., 1996, vol. 4, # 9, p. 1429 - 1446

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=8.74

$$$$
Thiotepa
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 1.3337 5.6282 0 0
M  V30 2 P 2.8737 5.6282 0 0
M  V30 3 N 2.8737 4.0882 0 0
M  V30 4 C 3.6437 2.7546 0 0
M  V30 5 C 2.1037 2.7546 0 0
M  V30 6 N 2.8737 7.1682 0 0
M  V30 7 C 2.1037 8.5019 0 0
M  V30 8 C 3.6437 8.5019 0 0
M  V30 9 N 4.4137 5.6282 0 0
M  V30 10 C 5.7474 6.3982 0 0
M  V30 11 C 5.7474 4.8582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 5
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 6 8
M  V30 10 1 2 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201619320

>  <MW>
189.049

>  <MW (desalted)>
189.218

>  <ClogP>
0.524

>  <logS>
-0.648

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
9.03

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.099 ?M | inhibition percentage  97.9 % | inhibition percentage  93.2 % | inhibition percentage < 50 % | IC50 = 1.06 ?M | inhibition percentage  89.7 % | inhibition percentage  85.6 % | IC50  2.7 ?M | IC50  2.7 ?M

>  <CAS>
52-24-4

>  <Description>
Thiotepa is an alkylating agent used to prevent graft rejection in stem cell transplantation and to treat a variety of malignancies including certain types of adenocarcinoma and superficial bladder carcinomas.

>  <EBC_ID>
EBC-06025

>  <IUPAC Name>
tris(aziridin-1-yl)-lambda5-phosphanethione

>  <Main Tar all refs>
Drug Metab. Dispos., 2007, vol. 35, # 2, p. 246 - 255 | J. Med. Chem., 2012, vol. 55, # 2, p. 812 - 823 | J. Med. Chem., 2012, vol. 55, # 2, p. 812 - 823 | PRINCETON BIOINNOVATION - WO2014/200816, 2014, A1 | Chem. Biol. Drug Des., 2011, vol. 78, # 2, p. 236 - 251 | J. Med. Chem., 2012, vol. 55, # 2, p. 812 - 823 | J. Med. Chem., 2012, vol. 55, # 2, p. 812 - 823 | Drug Metab. Dispos., 2007, vol. 35, # 2, p. 246 - 255 | Drug Metab. Dispos., 2007, vol. 35, # 2, p. 246 - 255

>  <Main tar all>
Cytochrome P450 2B6 pX=7.0 | Cytochrome P450 2C19 pX=6.28 | Cytochrome P450 2C9 pX=6.14 | ABCB11 pX=6.0 | Cytochrome P450 2D6 pX=5.97 | Cytochrome P450 3A4 pX=5.94 | CYP1A2 pX=5.77 | CYP3A pX=5.57 | Cytochrome P450, E-class, CYP3A pX=5.57

$$$$
Resorcinol monoacetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 O -1.3337 3.85 0 0
M  V30 4 O 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255485183

>  <MW>
152.047

>  <MW (desalted)>
152.147

>  <ClogP>
1.004

>  <logS>
-1.317

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
2

>  <CAS>
102-29-4

>  <Description>
Resorcinol monoacetate (Acetylresorcinol) is an antiseptic and a disinfectant.

>  <EBC_ID>
EBC-26101

>  <IUPAC Name>
3-hydroxyphenyl acetate

$$$$
Propofol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C -1.3337 -0.77 0 0
M  V30 10 C -1.3337 -2.31 0 0
M  V30 11 C -2.6674 0 0 0
M  V30 12 C 0 1.54 0 0
M  V30 13 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 8 12
M  V30 12 2 4 12
M  V30 13 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z752915492

>  <MW>
178.136

>  <MW (desalted)>
178.271

>  <ClogP>
3.929

>  <logS>
-3.46

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  100 % | IC50 = 5.9 nM

>  <CAS>
2078-54-8

>  <Description>
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid through GABA-A receptors.

>  <EBC_ID>
EBC-13390

>  <IUPAC Name>
2,6-bis(propan-2-yl)phenol

>  <Main Tar all refs>
J. NEUROCHEM., 1990, vol. 55, # 6, p. 2135 - 2138 | J. Pharmacol. Exp. Ther., 2003, vol. 307, # 3, p. 995 - 1000

>  <Main tar all>
GABAA receptor pX=9.28 | M1 receptor pX=8.23

$$$$
Secnidazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3935 5.93 0 0
M  V30 2 C 2.3935 4.39 0 0
M  V30 3 O 3.7272 3.62 0 0
M  V30 4 C 1.0598 3.62 0 0
M  V30 5 N 1.0598 2.08 0 0
M  V30 6 C 2.3057 1.1748 0 0
M  V30 7 C 3.7703 1.6507 0 0
M  V30 8 N 1.8298 -0.2898 0 0
M  V30 9 C 0.2898 -0.2898 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 N -1.6507 1.6507 0 0 CHG=1
M  V30 12 O -2.7951 0.6202 0 0
M  V30 13 O -1.9709 3.157 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155412

>  <MW>
185.08

>  <MW (desalted)>
185.181

>  <ClogP>
-0.148

>  <logS>
-0.828

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
81.19

>  <RotBonds>
3

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
EC50  6.57 ?M | IC50 = 28.5 ?M

>  <CAS>
3366-95-8

>  <Description>
Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including Metronidazole and Tinidazole. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. It is indicated for the treatment of bacterial vaginosis in adult women.

>  <EBC_ID>
EBC-03424

>  <IUPAC Name>
1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2022, vol. 66, # 7 | Bioorg. Med. Chem., 2011, vol. 19, # 15, p. 4513 - 4519

>  <Main tar all>
epidermal growth factor receptor pX=5.18 | beta-ketoacyl-acyl-carrier-protein synthase III pX=4.55

$$$$
Enprofylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.787 6.16 0 0
M  V30 2 C 4.787 4.62 0 0
M  V30 3 C 6.1207 3.85 0 0
M  V30 4 N 6.1207 2.31 0 0
M  V30 5 C 7.4543 1.54 0 0
M  V30 6 O 8.788 2.31 0 0
M  V30 7 N 7.4543 0 0 0
M  V30 8 C 6.1207 -0.77 0 0
M  V30 9 O 6.1207 -2.31 0 0
M  V30 10 C 4.787 0 0 0
M  V30 11 N 3.3224 -0.4759 0 0
M  V30 12 C 2.4172 0.77 0 0
M  V30 13 N 3.3224 2.0159 0 0
M  V30 14 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 4 14
M  V30 15 2 10 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198148417

>  <MW>
194.08

>  <MW (desalted)>
194.191

>  <ClogP>
0.396

>  <logS>
-1.95

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
78.09

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 <= 1 ?M | Ki (inhibition constant) = 4730 nM | Ki (inhibition constant) = 4730 nM | Ki (inhibition constant) = 7 ?M | EC50 = 19.1 ?M | Ki (inhibition constant) = 26000 nM | Ki (inhibition constant) = 26000 nM

>  <CAS>
41078-02-8

>  <Description>
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

>  <EBC_ID>
EBC-06370

>  <IUPAC Name>
3-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
PFIZER INC - WO2003/97050, 2003, A2 | Med. Res. Rev., 2006, vol. 26, # 5, p. 667 - 698 | Med. Res. Rev., 2006, vol. 26, # 5, p. 667 - 698 | ABBVIE INC - WO2011/5871, 2011, A1 | PFIZER INC - WO2002/83934, 2002, A1 | Med. Res. Rev., 2006, vol. 26, # 5, p. 667 - 698 | Med. Res. Rev., 2006, vol. 26, # 5, p. 667 - 698

>  <Main tar all>
phosphodiesterase 4 pX=6.0 | A3 receptor pX=5.33 | Adenosine A2B receptor pX=5.33 | A2B receptor pX=5.15 | P2Y12 receptor pX=4.72 | A1 receptor pX=4.59 | A2A receptor pX=4.59

$$$$
Metyrosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.4374 3.2863 0 0
M  V30 2 C 2.6674 4.62 0 0 CFG=2
M  V30 3 N 1.8974 5.9537 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 C 4.001 5.39 0 0
M  V30 13 O 4.001 6.93 0 0
M  V30 14 O 5.3347 4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 12 1 2 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255434943

>  <MW>
195.09

>  <MW (desalted)>
195.215

>  <ClogP>
-1.667

>  <logS>
-1.21

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Agonist | Agonist

>  <Activity coefficients and valu>
Ki (inhibition constant)  1 nM | EC50  11 nM | EC50  19 nM

>  <CAS>
672-87-7

>  <Description>
Metyrosine inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is indicated for use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.

>  <EBC_ID>
EBC-12576

>  <IUPAC Name>
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid

>  <Main Tar all refs>
J. Med. Chem., 2021, vol. 64, # 9, p. 5345 - 5364 | J. Med. Chem., 2021, vol. 64, # 9, p. 5345 - 5364 | J. Med. Chem., 2021, vol. 64, # 9, p. 5345 - 5364

>  <Main tar all>
APJ receptor pX=9.0 | Guanine?nucleotide-binding?protein?G(i)?subunit?alpha-2 pX=7.96 | Guanine?nucleotide-binding?protein?G(i)?subunit?alpha-1 pX=7.72

$$$$
Diazoxide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -0 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 N 2.6674 0 0 0
M  V30 4 C 4.001 -0.77 0 0
M  V30 5 C 5.3347 0 0 0
M  V30 6 C 6.6684 -0.77 0 0
M  V30 7 C 6.6684 -2.31 0 0
M  V30 8 Cl 8.0021 -3.08 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 C 4.001 -2.31 0 0
M  V30 11 S 2.6674 -3.08 0 0
M  V30 12 O 3.6573 -4.2597 0 0
M  V30 13 O 1.6775 -4.2597 0 0
M  V30 14 N 1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 2 11 13
M  V30 14 1 11 14
M  V30 15 1 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269122570

>  <MW>
229.992

>  <MW (desalted)>
230.671

>  <ClogP>
1.201

>  <logS>
-2.26

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
58.53

>  <RotBonds>
0

>  <Action on targets>
Activator | Activator | Activator | Opener | Inhibitor | Inhibitor | Inhibitor | - | Activator | Inhibitor

>  <Activity coefficients and valu>
membrane potential decrease Active   | membrane potential decrease Active   | migration rate increase Active   | inhibition percentage Active   | pKi  4.66  | IC50  32000 nM | Ki (inhibition constant) = 44.8 ?M | pulmonary vascular resistance decrease Active   | activation rate Active   | IC50  131.2 ?M

>  <CAS>
364-98-7

>  <Description>
Diazoxide is a non diuretic benzothiadiazine indicated for the management of hypoglycemia in patients who produce an excess of insulin caused by a variety of conditions.

>  <EBC_ID>
EBC-13327

>  <IUPAC Name>
7-chloro-3-methyl-2H-1lambda6,2,4-benzothiadiazine-1,1-dione

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2019, vol. 370, # 3, p. 350 - 359 | J. Pharmacol. Exp. Ther., 2019, vol. 370, # 3, p. 350 - 359 | Br. J. Pharmacol., 2019, vol. 176, # 22, p. 4373 - 4387 | Biochem. Biophys. Res. Commun., 2018, vol. 500, # 2, p. 504 - 510 | J. MED. CHEM., 1993, vol. 36, # 14, p. 2004 - 2010 | UNIVERSITY OF ROCHESTER - WO2019/217631, 2019, A1 | ABBOTT LABORATORIES INC - WO2003/11869, 2003, A1 | Cells, 2021, vol. 10, # 9 | Pharmacol. Res., 2020, vol. 158 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=5.3 | Kir6.2 pX=5.3 | mitochondrial ATP-sensitive potassium channel (mitoKATP) pX=5.0 | KATP?channel pX=4.7 | Kv9.1 pX=4.66 | respiratory complex II (CII) pX=4.49 | Kir6.2 pX=4.35 | mitochondrial ATP-gated potassium channel pX=4.0 | nuclear glucocorticoid receptor pX=4.0 | Organic cation/carnitine transporter 2 pX=3.88

$$$$
Baclofen hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 7.521 -2.915 0 0
M  V30 3 C 8.8547 -2.145 0 0
M  V30 4 C 8.8547 -0.605 0 0
M  V30 5 C 10.1884 0.165 0 0
M  V30 6 C 11.5221 -0.605 0 0
M  V30 7 O 12.8558 0.165 0 0
M  V30 8 O 11.5221 -2.145 0 0
M  V30 9 C 7.521 0.165 0 0
M  V30 10 C 6.1874 -0.605 0 0
M  V30 11 C 4.8537 0.165 0 0
M  V30 12 C 4.8537 1.705 0 0
M  V30 13 Cl 3.52 2.475 0 0
M  V30 14 C 6.1874 2.475 0 0
M  V30 15 C 7.521 1.705 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 6 8
M  V30 7 1 4 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 12 14
M  V30 13 1 14 15
M  V30 14 2 9 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2569257770

>  <MW>
249.032

>  <MW (desalted)>
213.661

>  <ClogP>
-0.62

>  <logS>
-2.262

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <CAS>
28311-31-1

>  <Description>
Baclofen is a GABA-ergic agonist used to manage severe spasticity of cerebral or spinal origin in adult and pediatric patients.

>  <EBC_ID>
EBC-08214

>  <IUPAC Name>
4-amino-3-(4-chlorophenyl)butanoic acid hydrochloride

$$$$
Nitromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6674 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 0 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 10 N -1.3337 -0.77 0 0 CHG=1
M  V30 11 O -1.3337 -2.31 0 0
M  V30 12 O -2.6674 0 0 0 CHG=-1
M  V30 13 N 4.001 -0.77 0 0 CHG=1
M  V30 14 O 4.001 -2.31 0 0
M  V30 15 O 5.3347 -0 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 8 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 6 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57117643

>  <MW>
211.023

>  <MW (desalted)>
211.132

>  <ClogP>
0.627

>  <logS>
-3.039

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
129.37

>  <RotBonds>
3

>  <CAS>
121-81-3

>  <Description>
An anti-parasitic agent.

>  <EBC_ID>
EBC-14125

>  <IUPAC Name>
3,5-dinitrobenzamide

$$$$
Proflavine sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -5.3347 -1.3475 0 0
M  V30 2 C -4.001 -0.5775 0 0
M  V30 3 C -4.001 0.9625 0 0
M  V30 4 C -2.6674 1.7325 0 0
M  V30 5 C -1.3337 0.9625 0 0
M  V30 6 C 0 1.7325 0 0
M  V30 7 C 1.3337 0.9625 0 0
M  V30 8 C 2.6674 1.7325 0 0
M  V30 9 C 4.001 0.9625 0 0
M  V30 10 C 4.001 -0.5775 0 0
M  V30 11 N 5.3347 -1.3475 0 0
M  V30 12 C 2.6674 -1.3475 0 0
M  V30 13 C 1.3337 -0.5775 0 0
M  V30 14 N -0 -1.3475 0 0
M  V30 15 C -1.3337 -0.5775 0 0
M  V30 16 C -2.6674 -1.3475 0 0
M  V30 17 O 10.3947 -1.54 0 0
M  V30 18 S 10.3947 0 0 0
M  V30 19 O 10.3947 1.54 0 0
M  V30 20 O 11.9347 -0 0 0
M  V30 21 O 8.8547 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 5 15
M  V30 17 1 15 16
M  V30 18 2 2 16
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 2 18 20
M  V30 22 1 18 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2768171875

>  <MW>
307.063

>  <MW (desalted)>
209.247

>  <ClogP>
2.309

>  <logS>
-2.535

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
64.93

>  <RotBonds>
0

>  <CAS>
553-30-0

>  <Description>
Proflavine is a topical antiseptic agent used in wound dressings to prevent infections.

>  <EBC_ID>
EBC-15026

>  <IUPAC Name>
acridine-3,6-diamine; sulfuric acid

$$$$
Metaxalone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.4692 11.205 0 0
M  V30 2 C 7.8029 10.435 0 0
M  V30 3 C 9.1366 11.205 0 0
M  V30 4 C 10.4702 10.435 0 0
M  V30 5 C 11.8039 11.205 0 0
M  V30 6 C 10.4702 8.895 0 0
M  V30 7 C 9.1366 8.125 0 0
M  V30 8 O 9.1366 6.585 0 0
M  V30 9 C 7.8029 5.815 0 0
M  V30 10 C 7.8029 4.275 0 0
M  V30 11 C 9.0488 3.3698 0 0
M  V30 12 N 8.5729 1.9052 0 0
M  V30 13 C 7.0329 1.9052 0 0
M  V30 14 O 6.1277 0.6593 0 0
M  V30 15 O 6.557 3.3698 0 0
M  V30 16 C 7.8029 8.895 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 10 15
M  V30 16 1 7 16
M  V30 17 2 2 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z106952910

>  <MW>
221.105

>  <MW (desalted)>
221.252

>  <ClogP>
2.145

>  <logS>
-3.01

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
47.56

>  <RotBonds>
3

>  <Action on targets>
- | - | - | - | - | - | - | - | -

>  <Activity coefficients and valu>
concentration (parameter) < 0.01 ?M | concentration (parameter) < 0.01 ?M | concentration (parameter) < 0.025 ?M | concentration (parameter) = 0.0323 ?M | concentration (parameter) = 0.05 ?M | concentration (parameter) < 0.05 ?M | concentration (parameter) < 0.1 ?M | concentration (parameter) = 0.126 ?M | concentration (parameter) < 0.3 ?M

>  <CAS>
1665-48-1

>  <Description>
Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions.

>  <EBC_ID>
EBC-06028

>  <IUPAC Name>
5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-one

>  <Main Tar all refs>
TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED; SUN PHARMACEUTICAL INDUSTRIES LIMITED - US7122566, 2006, B1

>  <Main tar all>
Cytochrome P450 2C9 pX=8.0 | Cytochrome P450 2D6 pX=8.0 | Cytochrome P450 2B6 pX=7.6 | CYP1A2 pX=7.49 | CYP2E1 pX=7.3 | Cytochrome P450 2C19 pX=7.3 | Cytochrome P450 3A4 pX=7.0 | Cytochrome P450 2C8 pX=6.9 | Cytochrome P450 2A6 pX=6.52

$$$$
Mephenytoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.3266 -1.1493 0 0
M  V30 2 C 1.1798 -0.8291 0 0
M  V30 3 C 2.2102 -1.9735 0 0
M  V30 4 N 3.4561 -2.8787 0 0
M  V30 5 C 2.9802 -4.3433 0 0
M  V30 6 O 3.8854 -5.5892 0 0
M  V30 7 N 1.4402 -4.3433 0 0
M  V30 8 C 0.5351 -5.5892 0 0
M  V30 9 C 0.9644 -2.8787 0 0
M  V30 10 O -0.5003 -2.4028 0 0
M  V30 11 C 3.2407 -0.8291 0 0
M  V30 12 C 2.7648 0.6356 0 0
M  V30 13 C 3.7953 1.78 0 0
M  V30 14 C 5.3016 1.4598 0 0
M  V30 15 C 5.7775 -0.0048 0 0
M  V30 16 C 4.7471 -1.1493 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 3 9
M  V30 10 2 9 10
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53843610

>  <MW>
218.106

>  <MW (desalted)>
218.252

>  <ClogP>
2.001

>  <logS>
-2.649

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
49.41

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.08 ?M | IC50  1.38 ?M

>  <CAS>
50-12-4

>  <Description>
Mephenytoin is an anticonvulsant. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin.

>  <EBC_ID>
EBC-06030

>  <IUPAC Name>
5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione

>  <Main Tar all refs>
Eur. J. Med. Chem., 2023, vol. 246 | Eur. J. Med. Chem., 2023, vol. 246

>  <Main tar all>
Cytochrome P450 3A4 pX=7.1 | Cytochrome P450 2C19 pX=5.86

$$$$
Sulfamethizole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8019 -2.425 0 0
M  V30 2 C 3.8019 -3.965 0 0
M  V30 3 N 5.0477 -4.8702 0 0
M  V30 4 N 4.5719 -6.3348 0 0
M  V30 5 C 3.0319 -6.3348 0 0
M  V30 6 N 2.1267 -7.5807 0 0
M  V30 7 S 0.5951 -7.4197 0 0
M  V30 8 O 0.7561 -5.8882 0 0
M  V30 9 O 0.4341 -8.9513 0 0
M  V30 10 C -0.9365 -7.2588 0 0
M  V30 11 C -1.8417 -8.5046 0 0
M  V30 12 C -3.3732 -8.3437 0 0
M  V30 13 C -3.9996 -6.9368 0 0
M  V30 14 N -5.5312 -6.7758 0 0
M  V30 15 C -3.0944 -5.6909 0 0
M  V30 16 C -1.5628 -5.8519 0 0
M  V30 17 S 2.556 -4.8702 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 2 7 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 5 17
M  V30 18 1 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1713449471

>  <MW>
270.025

>  <MW (desalted)>
270.331

>  <ClogP>
0.418

>  <logS>
-2.822

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
97.97

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2.22 ?M | Ki (inhibition constant)  3.87 ?M | IC50 = 50.1 ?M

>  <CAS>
144-82-1

>  <Description>
Sulfamethizole is a broad spectrum sulfonamide antibiotic. It inhibits dihydropteroate synthase, an enzyme involved in folate biosynthesis. Sulfamethizole have previously been used to treat urinary tract infections.

>  <EBC_ID>
EBC-03707

>  <IUPAC Name>
4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1966 - 1975 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1966 - 1975 | J. Enzyme Inhib. Med. Chem., 2011, vol. 26, # 5, p. 603 - 609

>  <Main tar all>
Cytochrome P450 2C9 pX=5.65 | CYP2C9*3 pX=5.41 | heat shock protein 90 beta family member 1 pX=4.3

$$$$
Etomidate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.1992 -0.115 0 0
M  V30 2 C 1.1345 -0.885 0 0
M  V30 3 O 2.4682 -0.115 0 0
M  V30 4 C 3.8019 -0.885 0 0
M  V30 5 O 5.1355 -0.115 0 0
M  V30 6 C 3.8019 -2.425 0 0
M  V30 7 C 2.556 -3.3302 0 0
M  V30 8 N 3.0319 -4.7948 0 0
M  V30 9 C 4.5719 -4.7948 0 0
M  V30 10 N 5.0477 -3.3302 0 0
M  V30 11 C 6.5124 -2.8543 0 0 CFG=2
M  V30 12 C 6.8326 -1.348 0 0
M  V30 13 C 7.6568 -3.8848 0 0
M  V30 14 C 9.1214 -3.4089 0 0
M  V30 15 C 10.2659 -4.4393 0 0
M  V30 16 C 9.9457 -5.9457 0 0
M  V30 17 C 8.4811 -6.4216 0 0
M  V30 18 C 7.3366 -5.3911 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 6 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741976844

>  <MW>
244.121

>  <MW (desalted)>
244.289

>  <ClogP>
2.417

>  <logS>
-2.502

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
44.12

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Blocker

>  <Activity coefficients and valu>
IC50 = 0.5 nM | IC50 = 1.7 nM | inhibition percentage  99 %

>  <CAS>
33125-97-2

>  <Description>
Etomidate is a GABAA receptors agonist. It is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia and supplementation of subpotent anesthesia during short operative procedures.

>  <EBC_ID>
EBC-06089

>  <IUPAC Name>
ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate

>  <Main Tar all refs>
EINDHOVEN UNIVERSITY OF TECHNOLOGY; NETHERLANDS ORGANISATION FOR SCIENTIFIC RESEARCH; MAASTRICHT UNIVERSITY - EP2095819, 2009, A1 | EINDHOVEN UNIVERSITY OF TECHNOLOGY; NETHERLANDS ORGANISATION FOR SCIENTIFIC RESEARCH; MAASTRICHT UNIVERSITY - EP2095819, 2009, A1 | Eur. J. Pharmacol., 2014, vol. 736, p. 55 - 62

>  <Main tar all>
CYP11B1 pX=9.3 | CYP11B2 pX=8.77 | Voltage-gated?sodium?channel pX=8.28

$$$$
Metoprolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 -1.54 0 0
M  V30 2 O -5.3347 -0 0 0
M  V30 3 C -4.001 0.77 0 0
M  V30 4 C -4.001 2.31 0 0
M  V30 5 C -2.6674 3.08 0 0
M  V30 6 C -2.6674 4.62 0 0
M  V30 7 C -1.3337 5.39 0 0
M  V30 8 C 0 4.62 0 0
M  V30 9 O 1.3337 5.39 0 0
M  V30 10 C 2.6674 4.62 0 0
M  V30 11 C 4.001 5.39 0 0
M  V30 12 O 4.001 6.93 0 0
M  V30 13 C 5.3347 4.62 0 0
M  V30 14 N 6.6684 5.39 0 0
M  V30 15 C 8.0021 4.62 0 0
M  V30 16 C 9.3358 5.39 0 0
M  V30 17 C 8.0021 3.08 0 0
M  V30 18 C 0 3.08 0 0
M  V30 19 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 8 18
M  V30 18 1 18 19
M  V30 19 2 5 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z398538014

>  <MW>
267.183

>  <MW (desalted)>
267.364

>  <ClogP>
1.486

>  <logS>
-1.656

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
50.72

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.08 nM | Ki (inhibition constant)  0.08 nM | IC50 = 5E-07 mM | Ki (inhibition constant)  2.41 nM | Ki (inhibition constant)  2.41 nM

>  <CAS>
51384-51-1

>  <Description>
Metoprolol is a beta-1-adrenergic receptor blocker specific to cardiac cells with negligible effect on beta-2 receptors. Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.

>  <EBC_ID>
EBC-03826

>  <IUPAC Name>
1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol

>  <Main Tar all refs>
NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | BRISTOL-MYERS SQUIBB CO - US4994476, 1991, A | NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202 | NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., 1985, vol. 330, # 3, p. 193 - 202

>  <Main tar all>
?1-adrenoceptor pX=10.1 | ?1-adrenoceptor pX=10.1 | ?-adrenoceptor pX=9.3 | ?2-adrenoceptor pX=8.62 | ?2-adrenoceptor pX=8.62

$$$$
Flumecinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.9763 -0.9763 0 0
M  V30 2 C -0.2063 -2.31 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 O 2.8737 -2.31 0 0
M  V30 5 C 1.3337 -3.85 0 0
M  V30 6 C 2.6674 -4.62 0 0
M  V30 7 C 2.6674 -6.16 0 0
M  V30 8 C 1.3337 -6.93 0 0
M  V30 9 C 0 -6.16 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 16 C 2.6674 -0 0 0
M  V30 17 C 4.001 2.31 0 0
M  V30 18 F 5.3347 3.08 0 0
M  V30 19 F 4.771 0.9763 0 0
M  V30 20 F 3.231 3.6437 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1020762628

>  <MW>
280.107

>  <MW (desalted)>
280.285

>  <ClogP>
4.263

>  <logS>
-4.49

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
4

>  <CAS>
56430-99-0

>  <Description>
Flumecinol, a benzhydrol derivative, is a hepatic microsomal drug-metabolizing enzyme inducer. It was in clinical development for the treatment of pruritus associated with primary biliary cirrhosis.

>  <EBC_ID>
EBC-13221

>  <IUPAC Name>
1-phenyl-1-[3-(trifluoromethyl)phenyl]propan-1-ol

$$$$
Imipramine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.2146 0 0
M  V30 3 N 5.7337 0.4446 0 0
M  V30 4 C 5.7337 -1.0954 0 0
M  V30 5 C 7.0674 1.2146 0 0
M  V30 6 C 8.401 0.4446 0 0
M  V30 7 C 9.7347 1.2146 0 0
M  V30 8 N 11.0684 0.4446 0 0
M  V30 9 C 12.3408 1.3121 0 0
M  V30 10 C 11.9981 2.8135 0 0
M  V30 11 C 13.127 3.8609 0 0
M  V30 12 C 14.5986 3.407 0 0
M  V30 13 C 14.9413 1.9056 0 0
M  V30 14 C 13.8124 0.8582 0 0
M  V30 15 C 14.375 -0.5754 0 0
M  V30 16 C 13.605 -1.9091 0 0
M  V30 17 C 12.0822 -2.1386 0 0
M  V30 18 C 11.7395 -3.64 0 0
M  V30 19 C 10.2679 -4.0939 0 0
M  V30 20 C 9.139 -3.0464 0 0
M  V30 21 C 9.4817 -1.545 0 0
M  V30 22 C 10.9533 -1.0911 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 8 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610478

>  <MW>
316.171

>  <MW (desalted)>
280.407

>  <ClogP>
5.037

>  <logS>
-4.4

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist

>  <Activity coefficients and valu>
pKi  9.44 | IC50  2.6 nM | Kb (antagonist dissociation constant)  8E-09 M

>  <CAS>
113-52-0

>  <Description>
Imipramine hydrochloride acts as an inhibitor of serotonin and norepinephrine transporters, also is an antagonist at histamine, muscarinic acetylcholine, and alpha-1-adrenergic receptors. Imipramine is a first generation tricyclic antidepressant.

>  <EBC_ID>
EBC-00601

>  <IUPAC Name>
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | BIOORG. MED. CHEM. LETT., 1997, vol. 7, # 20, p. 2559 - 2564 | BIOCHEM. PHARMACOL., 1986, vol. 35, # 24, p. 4493 - 4497

>  <Main tar all>
SERT pX=9.44 | NET pX=8.59 | H1 receptor pX=8.1

$$$$
Famciclovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.4222 -5.0432 0 0
M  V30 2 C 11.4222 -3.5032 0 0
M  V30 3 O 10.0885 -2.7332 0 0
M  V30 4 O 12.7559 -2.7332 0 0
M  V30 5 C 12.7559 -1.1932 0 0
M  V30 6 C 14.0896 -0.4232 0 0
M  V30 7 C 14.0896 1.1168 0 0
M  V30 8 C 15.4233 1.8868 0 0
M  V30 9 N 15.4233 3.4268 0 0
M  V30 10 C 14.1774 4.332 0 0
M  V30 11 N 14.6533 5.7966 0 0
M  V30 12 C 16.1933 5.7966 0 0
M  V30 13 C 17.2237 6.941 0 0
M  V30 14 N 18.7301 6.6208 0 0
M  V30 15 C 19.206 5.1562 0 0
M  V30 16 N 20.7123 4.836 0 0
M  V30 17 N 18.1755 4.0118 0 0
M  V30 18 C 16.6692 4.332 0 0
M  V30 19 C 15.4233 -1.1932 0 0
M  V30 20 O 15.4233 -2.7332 0 0
M  V30 21 C 16.7569 -3.5032 0 0
M  V30 22 O 18.0906 -2.7332 0 0
M  V30 23 C 16.7569 -5.0432 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 1 9 18
M  V30 19 2 12 18
M  V30 20 1 6 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532759

>  <MW>
321.144

>  <MW (desalted)>
321.332

>  <ClogP>
0.085

>  <logS>
-2.142

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
122.22

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  37 % | IC50  117.4 ?M | IC50 <= 200 ?M

>  <CAS>
104227-87-4

>  <Description>
Famciclovir is a nucleoside analog DNA polymerase inhibitor used for the treatment of recurrent cold sores and genital herpes in healthy patients and patients with HIV, and to manage herpes zoster.

>  <EBC_ID>
EBC-07021

>  <IUPAC Name>
2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate

>  <Main Tar all refs>
J. Clin. Pharmacol., 2004, vol. 44, # 1, p. 7 - 19 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | ASTRIA THERAPEUTICS INC - US2016/129122, 2016, A1

>  <Main tar all>
Aldehyde oxidase pX=4.07 | Organic cation/carnitine transporter 2 pX=3.93 | IkappaB kinase pX=3.7

$$$$
Triiodothyronine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 -0.77 0 0
M  V30 2 C 2.6674 0 0 0 CFG=1
M  V30 3 C 4.001 -0.77 0 0
M  V30 4 C 4.001 -2.31 0 0
M  V30 5 C 5.3347 -3.08 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 I 6.6684 -5.39 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 O 4.001 -6.93 0 0
M  V30 10 C 2.6674 -7.7 0 0
M  V30 11 C 2.6674 -9.24 0 0
M  V30 12 C 1.3337 -10.01 0 0
M  V30 13 C -0 -9.24 0 0
M  V30 14 O -1.3337 -10.01 0 0
M  V30 15 C 0 -7.7 0 0
M  V30 16 I -1.3337 -6.93 0 0
M  V30 17 C 1.3337 -6.93 0 0
M  V30 18 C 2.6674 -4.62 0 0
M  V30 19 I 1.3337 -5.39 0 0
M  V30 20 C 2.6674 -3.08 0 0
M  V30 21 C 2.6674 1.54 0 0
M  V30 22 O 1.3337 2.31 0 0
M  V30 23 O 4.001 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 10 17
M  V30 18 2 8 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 2 4 20
M  V30 22 1 2 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557400301

>  <MW>
650.79

>  <MW (desalted)>
650.973

>  <ClogP>
2.631

>  <logS>
-5.03

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
92.78

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Activator | Agonist | Inhibitor | Agonist | Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.018 nM | EC25  1.8E-05 ?M | EC50  0.066 nM | Ki (inhibition constant)  58 pM | EC50  0.06 nM | Ki (inhibition constant)  0.08 nM | IC50  0.103 nM | Ki (inhibition constant)  0.22 nM | EC50  0.25 - 0.44 nM | EC50  0.31 nM | IC50 = 0.5 nM

>  <CAS>
6893-02-3

>  <Description>
Liothyronine is a thyroid hormone replacement therapy used to treat hypothyroidism, to suppress TSH, and to help in the diagnosis of hyperthyroidism.

>  <EBC_ID>
EBC-13881

>  <IUPAC Name>
(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2013, vol. 23, # 6, p. 1834 - 1838 | Sci. Total Environ., 2019, vol. 677, p. 626 - 636 | CHENGDU FANXI BIOPHARMA - EP4201927, 2023, A1 | Chem. Biol., 1998, vol. 5, # 6, p. 299 - 306 | MOL. PHARMACOL., 1997, vol. 52, # 3, p. 542 - 547 | Bioorg. Med. Chem. Lett., 2003, vol. 13, # 3, p. 379 - 382 | Eur. J. Med. Chem., 2018, vol. 157, p. 791 - 804 | Proc. Natl. Acad. Sci. U. S. A., 2007, vol. 104, # 39, p. 15490 - 15495 | UNIVERSITY OF CALIFORNIA - US5883294, 1999, A | Steroids, 2009, vol. 74, # 2, p. 270 - 276 | J. MED. CHEM., 1989, vol. 32, # 2, p. 320 - 336

>  <Main tar all>
Thyroid hormone receptor-? pX=10.7 | Thyroid hormone receptor-? pX=10.3 | Glutamate receptor-interacting protein 1 pX=10.2 | Thyroid hormone receptor-?1 pX=10.2 | Thyroid hormone receptor-?1 pX=10.2 | Thyroid hormone receptor-? pX=10.1 | Regulatory protein GAL4 pX=9.99 | Retinoid X receptor-? pX=9.66 | Thyroid hormone receptor-?1 pX=9.6 | NCoR1-2 pX=9.51 | 3,5,3''-TrIIodo-L-Thyronine Receptor pX=9.3

$$$$
Phenolphthalein
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6311 -8.1762 0 0
M  V30 2 C 4.0047 -6.7693 0 0
M  V30 3 C 2.4732 -6.6083 0 0
M  V30 4 C 1.8468 -5.2015 0 0
M  V30 5 C 2.752 -3.9556 0 0
M  V30 6 C 4.2836 -4.1165 0 0
M  V30 7 C 4.9099 -5.5234 0 0
M  V30 8 C 2.1256 -2.5487 0 0
M  V30 9 O 1.2204 -1.3028 0 0
M  V30 10 C 2.1256 -0.0569 0 0
M  V30 11 O 1.6497 1.4077 0 0
M  V30 12 C 3.5902 -0.5328 0 0
M  V30 13 C 4.9239 0.2372 0 0
M  V30 14 C 6.2576 -0.5328 0 0
M  V30 15 C 6.2576 -2.0728 0 0
M  V30 16 C 4.9239 -2.8428 0 0
M  V30 17 C 3.5902 -2.0728 0 0
M  V30 18 C 0.7919 -3.3187 0 0
M  V30 19 C 0.7919 -4.8587 0 0
M  V30 20 C -0.5417 -5.6287 0 0
M  V30 21 C -1.8754 -4.8587 0 0
M  V30 22 O -3.2091 -5.6287 0 0
M  V30 23 C -1.8754 -3.3187 0 0
M  V30 24 C -0.5417 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 8 17
M  V30 20 1 8 18
M  V30 21 1 18 19
M  V30 22 2 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 2 21 23
M  V30 26 1 23 24
M  V30 27 2 18 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57233591

>  <MW>
318.089

>  <MW (desalted)>
318.323

>  <ClogP>
2.579

>  <logS>
-4.6

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.76

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
IC50 = 0.08 ?M | IC50 = 0.34 ?M | IC50 = 1 ?M | IC50 = 1 ?M | Ki (inhibition constant)  1.2 ?M | Ki (inhibition constant) = 1.3 ?M | inhibition percentage  27 % | Ki (inhibition constant)  2 ?M | Ki (inhibition constant)  2 ?M | IC50 = 2.1 ?M | Km (Michaelis constant) = 2.2 ?M

>  <CAS>
77-09-8

>  <Description>
Phenolphthalein inhibits aldo-keto reductase and estrogen receptor. It was used as a laxative, was withdrawn due to concerns with carcinogenicity.

>  <EBC_ID>
EBC-03839

>  <IUPAC Name>
3,3-bis(4-hydroxyphenyl)-1,3-dihydro-2-benzofuran-1-one

>  <Main Tar all refs>
Chem.-Biol. Interact., 2003, vol. 143-144, p. 503 - 513 | Chem.-Biol. Interact., 2003, vol. 143-144, p. 503 - 513 | Br. J. Pharmacol., 2005, vol. 145, # 3, p. 313 - 322 | Br. J. Pharmacol., 2005, vol. 145, # 3, p. 313 - 322 | J. Med. Chem., 2011, vol. 54, # 15, p. 5454 - 5467 | Curr. Med. Chem., 2005, vol. 12, # 19, p. 2241 - 2258 | Drug Metab. Dispos., 2010, vol. 38, # 4, p. 667 - 678 | Pharmacogenetics, 2002, vol. 12, # 8, p. 635 - 645 | Pharmacogenetics, 2002, vol. 12, # 8, p. 635 - 645 | Chem.-Biol. Interact., 2003, vol. 143-144, p. 503 - 513 | Biochem. Pharmacol., 2007, vol. 73, # 9, p. 1463 - 1473

>  <Main tar all>
Aldo-keto reductase family 1 member C4 pX=7.1 | Aldo-keto reductase family 1 member C1 pX=6.47 | P2X1 pX=6.0 | P2X1 pX=6.0 | Thymidylate synthase (gene TYMS) pX=5.92 | Thymidylate synthase pX=5.89 | Aldo-keto reductase family 1 member C2 pX=5.87 | UDP-glucuronosyltransferase 1-1 pX=5.7 | UDP-glucuronosyltransferase 1A1 pX=5.7 | AKR1C3 pX=5.68 |  UDP glucuronosyltransferase family 2 member B15 pX=5.66

$$$$
Nateglinide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -10.78 0 0
M  V30 2 C -2.6674 -9.24 0 0
M  V30 3 C -4.001 -8.47 0 0
M  V30 4 C -1.3337 -8.47 0 0 CFG=1
M  V30 5 C -1.3337 -6.93 0 0
M  V30 6 C 0 -6.16 0 0
M  V30 7 C 1.3337 -6.93 0 0 CFG=1
M  V30 8 C 1.3337 -8.47 0 0
M  V30 9 C 0 -9.24 0 0
M  V30 10 C 2.6674 -6.16 0 0
M  V30 11 O 4.001 -6.93 0 0
M  V30 12 N 2.6674 -4.62 0 0
M  V30 13 C 4.001 -3.85 0 0 CFG=2
M  V30 14 C 4.001 -2.31 0 0
M  V30 15 C 5.3347 -1.54 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 0.77 0 0
M  V30 18 C 8.0021 0 0 0
M  V30 19 C 8.0021 -1.54 0 0
M  V30 20 C 6.6684 -2.31 0 0
M  V30 21 C 5.3347 -4.62 0 0
M  V30 22 O 6.6684 -3.85 0 0
M  V30 23 O 5.3347 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10 CFG=3
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 13 12 CFG=3
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 13 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1514053266

>  <MW>
317.423

>  <MW (desalted)>
317.423

>  <ClogP>
4.298

>  <logS>
-5.358

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
6

>  <Action on targets>
Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  8 nM | concentration (parameter) > 10 nM | Ki (inhibition constant) = 75 nM | Ki (inhibition constant) = 75 nM | Ki (inhibition constant) = 105 nM | Ki (inhibition constant) = 105 nM | Ki (inhibition constant) = 170 nM

>  <CAS>
105816-04-4

>  <Description>
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus. It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release.

>  <EBC_ID>
EBC-11228

>  <IUPAC Name>
(2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid

>  <Main Tar all refs>
BIOCHEM. PHARMACOL., 1996, vol. 52, # 3, p. 407 - 411 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 3, p. 1025 - 1032 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 3, p. 1025 - 1032 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 3, p. 1025 - 1032 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 3, p. 1025 - 1032 | J. Pharmacol. Exp. Ther., 2003, vol. 304, # 3, p. 1025 - 1032 | J. Pharmacol. Exp. Ther., 2000, vol. 293, # 2, p. 444 - 452

>  <Main tar all>
Potassium channel ATP dependent pX=8.1 | Kv9.1 pX=8.0 | KATP?channel?SUR1 pX=7.12 | Kir6.1 pX=7.12 | KATP?channel?SUR1 pX=6.98 | Kir6.1 pX=6.98 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=6.77

$$$$
Apalutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.1216 9.6592 0 0
M  V30 2 N -0.6458 8.1946 0 0
M  V30 3 C 0.8606 7.8744 0 0
M  V30 4 O 1.8911 9.0188 0 0
M  V30 5 C 1.3365 6.4098 0 0
M  V30 6 C 2.8428 6.0896 0 0
M  V30 7 C 3.3187 4.625 0 0
M  V30 8 C 2.2882 3.4805 0 0
M  V30 9 C 0.7819 3.8007 0 0
M  V30 10 C 0.306 5.2653 0 0
M  V30 11 F -1.2003 5.5855 0 0
M  V30 12 N 2.7641 2.0159 0 0
M  V30 13 C 4.2288 1.54 0 0
M  V30 14 S 5.4746 2.4452 0 0
M  V30 15 N 4.2288 -0 0 0
M  V30 16 C 2.7641 -0.4759 0 0
M  V30 17 O 2.2882 -1.9405 0 0
M  V30 18 C 1.8589 0.77 0 0
M  V30 19 C 0.77 -0.3189 0 0
M  V30 20 C -0.3189 0.77 0 0
M  V30 21 C 0.77 1.8589 0 0
M  V30 22 C 5.4746 -0.9052 0 0
M  V30 23 C 6.8815 -0.2788 0 0
M  V30 24 N 8.1274 -1.184 0 0
M  V30 25 C 7.9664 -2.7156 0 0
M  V30 26 C 9.2123 -3.6208 0 0
M  V30 27 N 10.4582 -4.5259 0 0
M  V30 28 C 6.5596 -3.3419 0 0
M  V30 29 C 5.3137 -2.4368 0 0
M  V30 30 C 6.3986 -4.8735 0 0
M  V30 31 F 6.2376 -6.4051 0 0
M  V30 32 F 4.867 -4.7125 0 0
M  V30 33 F 7.9301 -5.0345 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 12 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 18 21
M  V30 24 1 15 22
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 3 26 27
M  V30 30 2 25 28
M  V30 31 1 28 29
M  V30 32 2 22 29
M  V30 33 1 28 30
M  V30 34 1 30 31
M  V30 35 1 30 32
M  V30 36 1 30 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280438

>  <MW>
477.435

>  <MW (desalted)>
477.435

>  <ClogP>
2.138

>  <logS>
-6.101

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
89.33

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.452 nM

>  <CAS>
956104-40-8

>  <Description>
Apalutamide is an androgen receptor inhibitor used to treat non metastatic, castration resistant prostate cancer.

>  <EBC_ID>
EBC-17127

>  <IUPAC Name>
4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-N-methylbenzamide

>  <Main Tar all refs>
UNIVERSITY OF TENNESSEE - WO2021/202936, 2021, A1

>  <Main tar all>
Androgen receptor pX=8.84

$$$$
Terazosin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 O 0 -0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 N 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 N 6.6684 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 N 5.3347 -4.62 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 1.3337 -2.31 0 0
M  V30 14 O 0 -3.08 0 0
M  V30 15 C -1.3337 -2.31 0 0
M  V30 16 N 8.0021 -0 0 0
M  V30 17 C 8.0021 1.54 0 0
M  V30 18 C 9.3358 2.31 0 0
M  V30 19 N 10.6694 1.54 0 0
M  V30 20 C 10.6694 -0 0 0
M  V30 21 C 9.3358 -0.77 0 0
M  V30 22 C 12.0031 2.31 0 0
M  V30 23 O 12.0031 3.85 0 0
M  V30 24 C 13.3368 1.54 0 0
M  V30 25 C 14.7437 2.1664 0 0
M  V30 26 C 15.7741 1.0219 0 0
M  V30 27 C 15.0041 -0.3117 0 0
M  V30 28 O 13.4978 0.0084 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 3 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 7 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 24 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1172269406

>  <MW>
387.433

>  <MW (desalted)>
387.433

>  <ClogP>
2.182

>  <logS>
-4.109

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
103.04

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Antagonist | Antagonist | Antagonist | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  10.3  | pKi  10.3  | pKi  9.912  | pKi  9.912  | pA2  9.91  | pA2  9.91  | Kb (antagonist dissociation constant)  0.33 nM | Kb (antagonist dissociation constant)  0.33 nM | EC50 = 0.5 nM | Ki (inhibition constant)  0.689 nM | Ki (inhibition constant) = 1.04 nM

>  <CAS>
63590-64-7

>  <Description>
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.

>  <EBC_ID>
EBC-07365

>  <IUPAC Name>
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine

>  <Main Tar all refs>
Eur. J. Pharmacol., 1997, vol. 327, # 1, p. 79 - 86 | Eur. J. Pharmacol., 1997, vol. 327, # 1, p. 79 - 86 | ABBOTT LABORATORIES INC - US5212176, 1993, A | ABBOTT LABORATORIES INC - US5212176, 1993, A | J. PHARMACOL. EXP. THER., 1996, vol. 278, # 1, p. 136 - 144 | J. PHARMACOL. EXP. THER., 1996, vol. 278, # 1, p. 136 - 144 | J. Med. Chem., 2000, vol. 43, # 15, p. 2775 - 2778 | J. Med. Chem., 2000, vol. 43, # 15, p. 2775 - 2778 | Bioorg. Med. Chem., 2015, vol. 23, # 9, p. 2104 - 2111 | ABBOTT LABORATORIES INC - US6153614, 2000, A | Br. J. Clin. Pharmacol., 2007, vol. 63, # 4, p. 394 - 403

>  <Main tar all>
?1B-adrenoceptor pX=10.3 | ?1B-adrenoceptor pX=10.3 | ?1-adrenoceptor pX=9.91 | ?1-adrenoceptor pX=9.91 | ?1D-adrenoceptor pX=9.91 | ?1D-adrenoceptor pX=9.91 | ?1A-adrenoceptor pX=9.48 | ?1A-adrenoceptor pX=9.48 | ?2-adrenoceptor pX=9.3 | ?1B-adrenoceptor pX=9.16 | ?1-adrenoceptor pX=8.98

$$$$
Oseltamivir phosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.8798 6.02 0 0
M  V30 2 C -2.5461 5.25 0 0
M  V30 3 O -2.5461 3.71 0 0
M  V30 4 C -1.2124 2.94 0 0
M  V30 5 O 0.1212 3.71 0 0
M  V30 6 C -1.2124 1.4 0 0
M  V30 7 C 0.1212 0.63 0 0
M  V30 8 C 0.1212 -0.91 0 0 CFG=1
M  V30 9 O 1.4549 -1.68 0 0
M  V30 10 C 2.7886 -0.91 0 0
M  V30 11 C 4.1223 -1.68 0 0
M  V30 12 C 5.456 -0.91 0 0
M  V30 13 C 2.7886 0.63 0 0
M  V30 14 C 4.1223 1.4 0 0
M  V30 15 C -1.2124 -1.68 0 0 CFG=2
M  V30 16 N -1.2124 -3.22 0 0
M  V30 17 C 0.1212 -3.99 0 0
M  V30 18 O 1.4549 -3.22 0 0
M  V30 19 C 0.1212 -5.53 0 0
M  V30 20 C -2.5461 -0.91 0 0 CFG=1
M  V30 21 N -3.8798 -1.68 0 0
M  V30 22 C -2.5461 0.63 0 0
M  V30 23 O 10.516 -1.54 0 0
M  V30 24 P 10.516 0 0 0
M  V30 25 O 10.516 1.54 0 0
M  V30 26 O 12.056 -0 0 0
M  V30 27 O 8.976 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 10 13
M  V30 13 1 13 14
M  V30 14 1 15 8
M  V30 15 1 15 16 CFG=3
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 15 20
M  V30 20 1 20 21 CFG=1
M  V30 21 1 20 22
M  V30 22 1 6 22
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 24 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759495

>  <MW>
410.4

>  <MW (desalted)>
312.405

>  <ClogP>
2.132

>  <logS>
-0.1

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
90.65

>  <RotBonds>
8

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 < 0.001 nM

>  <CAS>
204255-11-8

>  <Description>
Oseltamivir phosphate is an antiviral prodrug targeted against the influenza viruses. It is used for the treatment and prophylaxis of influenza A and B.

>  <EBC_ID>
EBC-03876

>  <IUPAC Name>
ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; phosphoric acid

>  <Main Tar all refs>
J. Med. Chem., 2001, vol. 44, # 25, p. 4379 - 4392

>  <Main tar all>
Sialidase pX=12.0

$$$$
Artemether
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.6534 0.7006 0 0
M  V30 2 O -1.5004 1.7215 0 0
M  V30 3 C -0.0398 1.2334 0 0 CFG=1
M  V30 4 O 1.2765 2.0876 0 0
M  V30 5 C 2.7975 1.5825 0 0 CFG=2
M  V30 6 O 4.5385 1.1705 0 0
M  V30 7 C 6.0916 1.568 0 0 CFG=1
M  V30 8 C 7.3711 2.425 0 0
M  V30 9 C 6.9984 0.2655 0 0
M  V30 10 C 6.0859 -1.0207 0 0
M  V30 11 C 4.4854 -1.0416 0 0 CFG=1
M  V30 12 C 4.268 -2.6232 0 0 CFG=2
M  V30 13 C 5.5531 -3.4718 0 0
M  V30 14 C 2.9255 -3.4281 0 0
M  V30 15 C 1.8736 -2.2716 0 0
M  V30 16 C 2.0531 -0.6758 0 0 CFG=1
M  V30 17 C 0.4988 -0.2415 0 0 CFG=1
M  V30 18 C -0.547 -1.3719 0 0
M  V30 19 C 3.4388 0.2565 0 0 CFG=1
M  V30 20 O 3.8841 2.0314 0 0
M  V30 21 O 5.2397 2.8908 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 16 15 CFG=1
M  V30 16 1 16 17
M  V30 17 1 17 3
M  V30 18 1 17 18 CFG=1
M  V30 19 1 19 16
M  V30 20 1 19 5
M  V30 21 1 19 11
M  V30 22 1 19 20 CFG=3
M  V30 23 1 20 21
M  V30 24 1 7 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759910

>  <MW>
298.375

>  <MW (desalted)>
298.375

>  <ClogP>
3.055

>  <logS>
-3.8

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
46.15

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
IC50  145 nM | IC50  1.3 ?M | IC50  2.4 ?M

>  <CAS>
71963-77-4

>  <Description>
Artemether is an antimalarial agent used in combination with lumefantrine for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum.

>  <EBC_ID>
EBC-11189

>  <IUPAC Name>
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane

>  <Main Tar all refs>
Biochemistry, 2017, vol. 56, # 33, p. 4335 - 4345 | J. Neurochem., 2021, vol. 157, # 3, p. 611 - 623 | Xenobiotica, 2014, vol. 44, # 7, p. 615 - 626

>  <Main tar all>
1-phosphatidylinositol-3-kinase pX=6.84 | myeloid differentiation protein 2 pX=5.89 | Cytochrome P450 2B6 pX=5.62

$$$$
Doxapram Hydrochloride Hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 C -1.9399 -12.1276 0 0
M  V30 4 C -2.5662 -10.7207 0 0
M  V30 5 N -1.6611 -9.4748 0 0
M  V30 6 C -0.1211 -9.4748 0 0
M  V30 7 C 0.3548 -8.0102 0 0
M  V30 8 C 1.8195 -7.5343 0 0
M  V30 9 C 2.9639 -8.5648 0 0
M  V30 10 N 2.6437 -10.0711 0 0
M  V30 11 C 3.7882 -11.1016 0 0
M  V30 12 C 3.468 -12.6079 0 0
M  V30 13 O 2.0033 -13.0838 0 0
M  V30 14 C 0.8589 -12.0534 0 0
M  V30 15 C 1.1791 -10.547 0 0
M  V30 16 C -0.8911 -7.105 0 0
M  V30 17 C -2.1369 -8.0102 0 0
M  V30 18 O -3.6016 -7.5343 0 0
M  V30 19 C 0.2425 -6.0626 0 0
M  V30 20 C -0.0934 -4.5597 0 0
M  V30 21 C 1.0402 -3.5173 0 0
M  V30 22 C 2.5097 -3.9778 0 0
M  V30 23 C 2.8457 -5.4808 0 0
M  V30 24 C 1.7121 -6.5231 0 0
M  V30 25 C -1.6471 -5.7633 0 0
M  V30 26 C -3.187 -5.7472 0 0
M  V30 27 C -3.943 -4.4055 0 0
M  V30 28 C -3.159 -3.08 0 0
M  V30 29 C -1.6191 -3.0961 0 0
M  V30 30 C -0.8631 -4.4378 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 1 10 15
M  V30 14 1 7 16
M  V30 15 1 16 17
M  V30 16 1 5 17
M  V30 17 2 17 18
M  V30 18 1 16 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 19 24
M  V30 25 1 16 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2569809969

>  <MW>
432.218

>  <MW (desalted)>
378.507

>  <ClogP>
3.24

>  <logS>
-3.612

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
32.78

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50 = 410 nM

>  <CAS>
7081-53-0

>  <Description>
Doxapram is a short acting respiratory stimulant used to treat acute respiratory insufficiency in COPD patients.

>  <EBC_ID>
EBC-15038

>  <IUPAC Name>
1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one hydrate hydrochloride

>  <Main Tar all refs>
Anesth. Analg., 2006, vol. 102, # 3, p. 779 - 785

>  <Main tar all>
K2P3.1 pX=6.39

$$$$
Crizotinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.8029 -0.115 0 0
M  V30 2 C 9.1366 -0.885 0 0 CFG=1
M  V30 3 O 9.1366 -2.425 0 0
M  V30 4 C 7.8029 -3.195 0 0
M  V30 5 C 7.8029 -4.735 0 0
M  V30 6 C 6.4692 -5.505 0 0
M  V30 7 C 5.1355 -4.735 0 0
M  V30 8 N 5.1355 -3.195 0 0
M  V30 9 C 6.4692 -2.425 0 0
M  V30 10 N 6.4692 -0.885 0 0
M  V30 11 C 6.4692 -7.045 0 0
M  V30 12 C 7.7151 -7.9502 0 0
M  V30 13 N 7.2392 -9.4148 0 0
M  V30 14 N 5.6992 -9.4148 0 0
M  V30 15 C 5.2233 -7.9502 0 0
M  V30 16 C 4.794 -10.6607 0 0
M  V30 17 C 5.4204 -12.0676 0 0
M  V30 18 C 4.5152 -13.3134 0 0
M  V30 19 N 2.9836 -13.1525 0 0
M  V30 20 C 2.3573 -11.7456 0 0
M  V30 21 C 3.2625 -10.4997 0 0
M  V30 22 C 10.4702 -0.115 0 0
M  V30 23 C 10.4702 1.425 0 0
M  V30 24 Cl 9.1366 2.195 0 0
M  V30 25 C 11.8039 2.195 0 0
M  V30 26 C 13.1376 1.425 0 0
M  V30 27 C 13.1376 -0.115 0 0
M  V30 28 F 14.4713 -0.885 0 0
M  V30 29 C 11.8039 -0.885 0 0
M  V30 30 Cl 11.8039 -2.425 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 11 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 2 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 2 23 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 2 22 29
M  V30 33 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065417924

>  <MW>
450.337

>  <MW (desalted)>
450.337

>  <ClogP>
4.288

>  <logS>
-4.825

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
77.99

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 >= 0.1 - 50 nM | IC50 >= 0.1 - 50 nM | Ki (inhibition constant)  0.097 nM | IC50  0.135 nM | GI50 < 0.0003 ?M | GI50 < 0.0003 ?M | GI50 < 0.0003 ?M | IC50  0.51 nM | Kd (dissociation constant)  0.55 nM | IC50  0.0006 ?M | IC50  0.842 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | inhibition rate Active   | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1 - 100 nM | IC50  1.22 nM | IC50  1.5 nM | Kd (dissociation constant)  1.5 nM | IC50  0.0015 ?M | IC50  2 nM | IC50  2 nM | IC50  2.6 nM | IC50  2.7 nM

>  <CAS>
877399-52-5

>  <Description>
Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.

>  <EBC_ID>
EBC-12789

>  <IUPAC Name>
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine

>  <Main Tar all refs>
PHARMA RESOURCES GMBH; NUVALENT; PHARMARESOURCES CO. - WO2021/226269, 2021, A1 | PHARMA RESOURCES GMBH; NUVALENT; PHARMARESOURCES CO. - WO2021/226269, 2021, A1 | PFIZER INC - WO2013/17989, 2013, A1 | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE - WO2015/179436, 2015, A1 | Eur. J. Med. Chem., 2017, vol. 139, p. 674 - 697 | Eur. J. Med. Chem., 2017, vol. 139, p. 674 - 697 | Eur. J. Med. Chem., 2017, vol. 139, p. 674 - 697 | Cancer Res., 2011, vol. 71, # 14, p. 4920 - 4931 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Eur. J. Med. Chem., 2015, vol. 90, p. 195 - 208 | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY - EP3782993, 2021, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | SINO BIOPHARMACEUTICAL LIMITED - EP4019021, 2022, A1 | UNIVERSITY OF OSLO - WO2022/69684, 2022, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | GLAXOSMITHKLINE PLC - WO2013/74518, 2013, A1 | CHEMBRIDGE CORPORATION - WO2009/117097, 2009, A1 | Acta Pharmacol. Sin., 2021, vol. 42, # 6, p. 998 - 1004 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | GRUENEBERG - US2016/31890, 2016, A1 | Cancer Res., 2007, vol. 67, # 9, p. 4408 - 4417 | Cancer Res., 2007, vol. 67, # 9, p. 4408 - 4417 | Cancer Lett., 2023, vol. 561 | GUANGDONG NEWOPP BIOPHARMACEUTICALS - WO2013/13308, 2013, A1

>  <Main tar all>
H-2 class II histocompatibility antigen gamma chain pX=10.0 | Proto-oncogene?tyrosine-protein?kinase?ROS?(G2032R) pX=10.0 | c-ros oncogene 1, receptor tyrosine kinase pX=10.0 | mitogen-activated protein kinase kinase kinase 3 pX=9.87 | Echinoderm microtubule-associated protein-like 4 pX=9.52 | Nucleophosmin pX=9.52 | activin A receptor type IL pX=9.52 | MET proto-oncogene, receptor tyrosine kinase pX=9.29 | MET (M1250T) pX=9.26 | ALK receptor tyrosine kinase pX=9.22 | Janus kinase 2 pX=9.07 | ALK tyrosine kinase receptor (F1174L) pX=9.0 | ALK tyrosine kinase receptor (L1196M) pX=9.0 | ALK tyrosine kinase receptor (R1275Q) pX=9.0 | EML4-ALK tyrosine kinase pX=9.0 | EML4-ALK tyrosine kinase pX=9.0 | leukocyte receptor tyrosine kinase pX=9.0 | neurotrophic receptor tyrosine kinase 1 pX=9.0 | neurotrophic receptor tyrosine kinase 2 pX=9.0 | neurotrophic receptor tyrosine kinase 3 pX=9.0 | protein tyrosine kinase 2 pX=9.0 | fms related receptor tyrosine kinase 3 (ITD) pX=8.91 | General negative regulator of transcription subunit 1 pX=8.82 | MET (Y1235D) pX=8.82 | ROS kinase pX=8.82 | MET (H1094R) pX=8.7 | MET (H1094R) pX=8.7 | proto-oncogene c-Met (exon 14 skipped) pX=8.59 | ALK tyrosine kinase receptor (F1174L) pX=8.57

$$$$
Estrone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.5949 -6.0829 0 0
M  V30 2 C 7.2666 -4.6971 0 0 CFG=2
M  V30 3 C 8.2593 -5.8744 0 0
M  V30 4 C 9.7753 -5.6034 0 0
M  V30 5 C 10.2985 -4.155 0 0 CFG=1
M  V30 6 C 9.3058 -2.9776 0 0 CFG=1
M  V30 7 C 9.829 -1.5293 0 0
M  V30 8 C 11.345 -1.2582 0 0
M  V30 9 C 12.3377 -2.4355 0 0
M  V30 10 C 13.8537 -2.1644 0 0
M  V30 11 C 14.8464 -3.3418 0 0
M  V30 12 O 16.3624 -3.0707 0 0
M  V30 13 C 14.3232 -4.7901 0 0
M  V30 14 C 12.8072 -5.0612 0 0
M  V30 15 C 11.8145 -3.8839 0 0
M  V30 16 C 7.7898 -3.2487 0 0 CFG=2
M  V30 17 C 6.574 -2.3035 0 0
M  V30 18 C 5.2994 -3.1677 0 0
M  V30 19 C 5.7274 -4.6471 0 0
M  V30 20 O 4.7822 -5.8629 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 5 15
M  V30 16 2 9 15
M  V30 17 1 6 16
M  V30 18 1 16 2
M  V30 19 1 16 17 CFG=1
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 2 19
M  V30 23 2 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530425070

>  <MW>
270.366

>  <MW (desalted)>
270.366

>  <ClogP>
3.382

>  <logS>
-4.12

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
0

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
stimulation rate  137 % | stimulation rate  137 % | pEC50  9.9  | EC50  0.15 nM

>  <CAS>
53-16-7

>  <Description>
Estrone is an estrogenic hormone, one of the three naturally occurring estrogens (estrone, estradiol and estriol). Estrone is used for management of perimenopausal and postmenopausal symptoms.

>  <EBC_ID>
EBC-04419

>  <IUPAC Name>
(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-trien-14-one

>  <Main Tar all refs>
BIOL. PHARM. BULL., 1996, vol. 19, # 8, p. 1018 - 1022 | BIOL. PHARM. BULL., 1996, vol. 19, # 8, p. 1018 - 1022 | Mol. Pharmacol., 2008, vol. 73, # 3, p. 900 - 908 | ACADIA PHARMACEUTICALS INC - WO2008/33894, 2008, A2

>  <Main tar all>
Estrogen receptor pX=11.3 | Estrogen receptor pX=11.3 | nuclear estrogen receptor pX=9.9 | Estrogen receptor-? pX=9.82

$$$$
(-)-Menthol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 C 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0 CFG=2
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0 CFG=1
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0 CFG=1
M  V30 11 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 10 9
M  V30 10 1 4 10
M  V30 11 1 10 11 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255438640

>  <MW>
156.265

>  <MW (desalted)>
156.265

>  <ClogP>
3.233

>  <logS>
-2.78

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Activator

>  <Activity coefficients and valu>
Kd (dissociation constant)  16.8 nM | EC50  101 nM

>  <CAS>
2216-51-5

>  <Description>
(-)-Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. It is used to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.

>  <EBC_ID>
EBC-07707

>  <IUPAC Name>
(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol

>  <Main Tar all refs>
Nat. Commun., 2022, vol. 13, # 1 | J. Neurosci., 2004, vol. 24, # 23, p. 5364 - 5369

>  <Main tar all>
Transcription factor HES-1 pX=7.77 | TRPM8 pX=7.0

$$$$
Rivaroxaban
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0.5389 -12.9521 0 0
M  V30 2 C 0.5389 -14.4921 0 0
M  V30 3 C 1.7848 -15.3972 0 0
M  V30 4 C 1.3089 -16.8619 0 0
M  V30 5 C -0.2311 -16.8619 0 0
M  V30 6 S -0.707 -15.3972 0 0
M  V30 7 C -1.1363 -18.1078 0 0
M  V30 8 O -0.5099 -19.5146 0 0
M  V30 9 N -2.6679 -17.9468 0 0
M  V30 10 C -3.5731 -19.1927 0 0
M  V30 11 C -5.1046 -19.0317 0 0 CFG=1
M  V30 12 C -6.1351 -20.1761 0 0
M  V30 13 N -7.542 -19.5498 0 0
M  V30 14 C -7.381 -18.0182 0 0
M  V30 15 O -8.5254 -16.9877 0 0
M  V30 16 O -5.8746 -17.698 0 0
M  V30 17 C -8.8756 -20.3198 0 0
M  V30 18 C -8.8756 -21.8598 0 0
M  V30 19 C -10.2093 -22.6298 0 0
M  V30 20 C -11.543 -21.8598 0 0
M  V30 21 C -11.543 -20.3198 0 0
M  V30 22 C -10.2093 -19.5498 0 0
M  V30 23 N -12.8767 -22.6298 0 0
M  V30 24 C -12.8767 -24.1698 0 0
M  V30 25 C -14.2103 -24.9398 0 0
M  V30 26 O -15.544 -24.1698 0 0
M  V30 27 C -15.544 -22.6298 0 0
M  V30 28 C -14.2103 -21.8598 0 0
M  V30 29 O -14.2103 -20.3198 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 11 10 CFG=1
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 11 16
M  V30 18 1 13 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 25 1 20 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 23 28
M  V30 32 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977097

>  <MW>
435.881

>  <MW (desalted)>
435.881

>  <ClogP>
2.394

>  <logS>
-6.279

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
88.18

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.04 nM | IC50  0.00021 ?M | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.48 nM | IC50  0.7 nM | IC50  0.0007 ?M | Ki (inhibition constant) = 1.11 nM

>  <CAS>
366789-02-8

>  <Description>
Rivaroxaban is a highly potent, selective and direct Factor Xa (FXa) inhibitor. It competitively inhibits free and clot bound factor Xa. Rivaroxaban is used to treat deep vein thrombosis and pulmonary embolism.

>  <EBC_ID>
EBC-07653

>  <IUPAC Name>
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

>  <Main Tar all refs>
Curr. Med. Chem., 2012, vol. 19, # 20, p. 3388 - 3416 | Pharm. Chem. J., 2018, vol. 51, # 11, p. 975 - 979 | J. Thromb. Haemost., 2005, vol. 3, # 3, p. 514 - 521 | J. Thromb. Thrombolysis, 2019, vol. 47, # 1, p. 80 - 86 | J. Med. Chem., 2020, vol. 63, # 21, p. 13159 - 13186 | Pharmaceutics, 2022, vol. 14, # 1 | NORTH CHINA PHARMACEUTICAL GROUP CORP. - WO2015/43364, 2015, A1

>  <Main tar all>
coagulation factor X pX=10.4 | Antistasin pX=9.68 | Activated factor Xa heavy chain pX=9.4 | coagulation factor thrombokinase (factor Xa) pX=9.32 | Coagulation factor Xa pX=9.15 | factor Xa pX=9.15 | coagulation factor II, thrombin pX=8.95

$$$$
Thioridazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.4784 0 0
M  V30 3 S 5.7337 0.7084 0 0
M  V30 4 C 7.0674 1.4784 0 0
M  V30 5 C 7.0674 3.0184 0 0
M  V30 6 C 8.401 3.7884 0 0
M  V30 7 C 9.7347 3.0184 0 0
M  V30 8 S 11.0684 3.7884 0 0
M  V30 9 C 12.4021 3.0184 0 0
M  V30 10 C 13.7358 3.7884 0 0
M  V30 11 C 15.0694 3.0184 0 0
M  V30 12 C 15.0694 1.4784 0 0
M  V30 13 C 13.7358 0.7084 0 0
M  V30 14 C 12.4021 1.4784 0 0
M  V30 15 N 11.0684 0.7084 0 0
M  V30 16 C 11.0684 -0.8316 0 0
M  V30 17 C 12.4021 -1.6016 0 0
M  V30 18 C 12.4021 -3.1416 0 0
M  V30 19 C 13.7358 -3.9116 0 0
M  V30 20 C 13.7358 -5.4516 0 0
M  V30 21 C 12.4021 -6.2216 0 0
M  V30 22 C 11.0684 -5.4516 0 0
M  V30 23 N 11.0684 -3.9116 0 0
M  V30 24 C 9.7347 -3.1416 0 0
M  V30 25 C 9.7347 1.4784 0 0
M  V30 26 C 8.401 0.7084 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 18 23
M  V30 24 1 23 24
M  V30 25 1 15 25
M  V30 26 2 7 25
M  V30 27 1 25 26
M  V30 28 2 4 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1592690502

>  <MW>
406.13

>  <MW (desalted)>
370.575

>  <ClogP>
6.003

>  <logS>
-5.726

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
4

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker

>  <Activity coefficients and valu>
IC50  0.003 ?M | Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  3.6 nM | Ki (inhibition constant)  5 nM | Ki (inhibition constant)  5 nM | Ki (inhibition constant)  8.2 nM | Ki (inhibition constant)  8.2 nM | IC50  39 nM | pIC50  7.4  | pIC50  7.4  | IC50  80.3 nM

>  <CAS>
130-61-0

>  <Description>
Thioridazine hydrochloride binds to dopamine D2, histamine H1, M3 muscarinic, and alpha1-adrenergic receptor. Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis.

>  <EBC_ID>
EBC-07856

>  <IUPAC Name>
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine hydrochloride

>  <Main Tar all refs>
PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3 | Eur. J. Pharmacol., 1993, vol. 237, # 2-3, p. 183 - 189 | Eur. J. Pharmacol., 1993, vol. 237, # 2-3, p. 183 - 189 | EUR. J. PHARMACOL., 1993, vol. 238, # 2-3, p. 407 - 410 | EUR. J. PHARMACOL., 1993, vol. 238, # 2-3, p. 407 - 410 | EUR. J. PHARMACOL., 1993, vol. 238, # 2-3, p. 407 - 410 | EUR. J. PHARMACOL., 1993, vol. 238, # 2-3, p. 407 - 410 | EUR. J. PHARMACOL., 1984, vol. 102, # 3-4, p. 459 - 474 | BIOCHEM. PHARMACOL., 1978, vol. 27, # 3, p. 307 - 316 | BIOCHEM. PHARMACOL., 1978, vol. 27, # 3, p. 307 - 316 | Biochem. Biophys. Res. Commun., 2006, vol. 351, # 1, p. 273 - 280

>  <Main tar all>
D2 receptor pX=8.52 | D2L receptor pX=8.44 | D2L receptor pX=8.44 | ?1-adrenoceptor pX=8.3 | ?1-adrenoceptor pX=8.3 | ?1B-adrenoceptor pX=8.09 | ?1B-adrenoceptor pX=8.09 | D1 receptor pX=7.41 | Dopamine receptor pX=7.4 | Dopamine receptor pX=7.4 | Kv11.1 pX=7.1

$$$$
Ibudilast
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.1865 -4.8376 0 0
M  V30 2 C 2.6802 -5.1578 0 0
M  V30 3 C 2.2043 -6.6224 0 0
M  V30 4 C 1.6497 -4.0133 0 0
M  V30 5 O 0.1434 -4.3335 0 0
M  V30 6 C 2.1256 -2.5487 0 0
M  V30 7 C 1.2204 -1.3028 0 0
M  V30 8 N 2.1256 -0.0569 0 0
M  V30 9 N 3.5902 -0.5328 0 0
M  V30 10 C 4.9239 0.2372 0 0
M  V30 11 C 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 C 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 C -0.3196 -1.3028 0 0
M  V30 16 C -1.0896 0.0309 0 0
M  V30 17 C -1.0896 -2.6365 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 6 14
M  V30 15 1 9 14
M  V30 16 1 7 15
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588063484

>  <MW>
230.142

>  <MW (desalted)>
230.306

>  <ClogP>
3.247

>  <logS>
-3.213

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
34.37

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter) = 0.0398 ?M | IC50 = 54 nM | IC50 = 65 nM | pIC50  7.05 | IC50 = 166 nM | IC50 = 239 nM | IC40  0.59 ?M | EC50 = 0.9 ?M | IC50 = 1 ?M

>  <CAS>
50847-11-5

>  <Description>
Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of nitric oxide synthesis and reduction in reactive oxygen species.

>  <EBC_ID>
EBC-47047

>  <IUPAC Name>
2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one

>  <Main Tar all refs>
Conference Paper, 469494131 | J. Med. Chem., 2008, vol. 51, # 18, p. 5471 - 5489 | J. Med. Chem., 2008, vol. 51, # 18, p. 5471 - 5489 | Biochem. Pharmacol., 2020, vol. 174 | J. Med. Chem., 2008, vol. 51, # 18, p. 5471 - 5489 | J. Med. Chem., 2008, vol. 51, # 18, p. 5471 - 5489 | Biochem. Pharmacol., 1999, vol. 58, # 6, p. 991 - 999 | J. Med. Chem., 2011, vol. 54, # 9, p. 3331 - 3347 | KYORIN HOLDINGS, INC. - EP1570847, 2005, A1

>  <Main tar all>
Cytochrome P450 2D6 pX=7.4 | phosphodiesterase 4A pX=7.27 | phosphodiesterase 4B pX=7.19 | phosphodiesterase 4 pX=7.05 | phosphodiesterase 4D pX=6.78 | phosphodiesterase 4C pX=6.62 | cytokine pX=6.05 | phosphodiesterase 4A1 pX=6.05 | phosphodiesterase 10A pX=6.0

$$$$
Dicloxacillin sodium hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Na 18.2754 -3.6699 0 0 CHG=1
M  V30 3 C 9.7299 4.4504 0 0
M  V30 4 C 8.3577 3.7513 0 0
M  V30 5 O 6.9856 4.4504 0 0
M  V30 6 N 5.8966 3.3615 0 0
M  V30 7 C 6.5958 1.9893 0 0
M  V30 8 C 8.1168 2.2302 0 0
M  V30 9 C 9.2058 1.1413 0 0
M  V30 10 O 8.8072 -0.3462 0 0
M  V30 11 N 10.6933 1.5399 0 0
M  V30 12 C 11.7822 0.4509 0 0 CFG=1
M  V30 13 C 13.3222 0.4509 0 0 CFG=1
M  V30 14 S 14.7869 0.9268 0 0
M  V30 15 C 15.692 -0.3191 0 0
M  V30 16 C 16.8365 -1.3495 0 0
M  V30 17 C 16.8365 0.7114 0 0
M  V30 18 C 14.7869 -1.5649 0 0 CFG=1
M  V30 19 N 13.3222 -1.0891 0 0
M  V30 20 C 11.7822 -1.0891 0 0
M  V30 21 O 10.6933 -2.178 0 0
M  V30 22 C 15.2627 -3.0296 0 0
M  V30 23 O 14.2323 -4.174 0 0
M  V30 24 O 16.7691 -3.3498 0 0 CHG=-1
M  V30 25 C 5.8966 0.6172 0 0
M  V30 26 C 6.7354 -0.6744 0 0
M  V30 27 Cl 8.2733 -0.5938 0 0
M  V30 28 C 6.0362 -2.0465 0 0
M  V30 29 C 4.4983 -2.1271 0 0
M  V30 30 C 3.6596 -0.8356 0 0
M  V30 31 C 4.3587 0.5366 0 0
M  V30 32 Cl 3.52 1.8281 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 2 6 7
M  V30 5 1 7 8
M  V30 6 2 4 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 12 11 CFG=1
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 15 17
M  V30 16 1 18 15
M  V30 17 1 18 19
M  V30 18 1 13 19 CFG=1
M  V30 19 1 19 20
M  V30 20 1 12 20
M  V30 21 2 20 21
M  V30 22 1 18 22 CFG=3
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 7 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 2 26 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 2 25 31
M  V30 33 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1554101876

>  <MW>
509.019

>  <MW (desalted)>
470.326

>  <ClogP>
0.165

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
115.57

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  31 %

>  <CAS>
13412-64-1

>  <Description>
Dicloxacillin is a penicillin used to treat penicillinase-producing bacterial infections that are susceptible to the drug.

>  <EBC_ID>
EBC-14164

>  <IUPAC Name>
sodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate

>  <Main Tar all refs>
Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109

>  <Main tar all>
carboxylesterase 1 pX=3.65

$$$$
Quinapril hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -2.3374 0 0
M  V30 3 C 5.9122 -2.6284 0 0
M  V30 4 O 6.9204 -1.4643 0 0
M  V30 5 C 8.4327 -1.7553 0 0
M  V30 6 O 8.9367 -3.2105 0 0
M  V30 7 C 9.4408 -0.5912 0 0 CFG=2
M  V30 8 C 8.9367 0.864 0 0
M  V30 9 C 7.4245 1.155 0 0
M  V30 10 C 6.9204 2.6102 0 0
M  V30 11 C 5.4082 2.9012 0 0
M  V30 12 C 4.9041 4.3564 0 0
M  V30 13 C 5.9122 5.5205 0 0
M  V30 14 C 7.4245 5.2295 0 0
M  V30 15 C 7.9286 3.7743 0 0
M  V30 16 N 10.9531 -0.8822 0 0
M  V30 17 C 11.4572 -2.3374 0 0 CFG=1
M  V30 18 C 10.449 -3.5015 0 0
M  V30 19 C 12.9694 -2.6284 0 0
M  V30 20 O 13.4735 -4.0836 0 0
M  V30 21 N 13.9776 -1.4643 0 0
M  V30 22 C 13.4735 -0.0091 0 0
M  V30 23 C 14.4817 1.155 0 0
M  V30 24 C 13.9776 2.6102 0 0
M  V30 25 C 14.9857 3.7743 0 0
M  V30 26 C 16.498 3.4833 0 0
M  V30 27 C 17.0021 2.0281 0 0
M  V30 28 C 15.9939 0.864 0 0
M  V30 29 C 16.498 -0.5912 0 0
M  V30 30 C 15.4898 -1.7553 0 0 CFG=1
M  V30 31 C 15.9939 -3.2105 0 0
M  V30 32 O 14.9857 -4.3746 0 0
M  V30 33 O 17.5062 -3.5015 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 7 5
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 10 15
M  V30 15 1 7 16 CFG=3
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=3
M  V30 18 1 17 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 23 28
M  V30 29 1 28 29
M  V30 30 1 30 29
M  V30 31 1 30 21
M  V30 32 1 30 31 CFG=1
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2240938942

>  <MW>
474.192

>  <MW (desalted)>
438.516

>  <ClogP>
1.736

>  <logS>
-5.111

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
95.94

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.0083 ?M

>  <CAS>
82586-55-8

>  <Description>
Quinapril HCl is a prodrug to the angiotensin converting enzyme inhibitor quinaprilat. ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.

>  <EBC_ID>
EBC-02086

>  <IUPAC Name>
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1986, vol. 29, # 10, p. 1953 - 1961

>  <Main tar all>
Angiotensin-converting enzyme pX=8.08

$$$$
Rifampicin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 59 63 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.988 7.5525 0 0
M  V30 2 O 8.4673 7.3095 0 0
M  V30 3 C 7.9173 5.8711 0 0 CFG=1
M  V30 4 C 9.2841 5.144 0 0
M  V30 5 C 10.4498 4.0994 0 0
M  V30 6 O 11.4879 2.8866 0 0
M  V30 7 C 11.5491 1.2771 0 0 CFG=1
M  V30 8 C 12.4442 0.024 0 0
M  V30 9 O 10.1126 1.8314 0 0
M  V30 10 C 9.0473 0.7359 0 0
M  V30 11 C 9.8293 -0.6198 0 0
M  V30 12 C 11.3777 -0.2935 0 0
M  V30 13 O 12.5192 -1.3273 0 0
M  V30 14 C 8.9287 -1.9727 0 0
M  V30 15 C 9.5028 -3.4355 0 0
M  V30 16 O 11.0276 -3.6509 0 0
M  V30 17 C 8.5827 -4.6342 0 0
M  V30 18 C 9.2161 -6.038 0 0
M  V30 19 N 8.3171 -7.2883 0 0
M  V30 20 N 8.9504 -8.6921 0 0
M  V30 21 C 10.4827 -8.8455 0 0
M  V30 22 C 11.1161 -10.2492 0 0
M  V30 23 N 10.217 -11.4996 0 0
M  V30 24 C 10.8504 -12.9033 0 0
M  V30 25 C 8.6847 -11.3462 0 0
M  V30 26 C 8.0514 -9.9424 0 0
M  V30 27 C 7.019 -4.5269 0 0
M  V30 28 N 5.4903 -5.043 0 0
M  V30 29 C 3.9057 -5.0809 0 0
M  V30 30 O 3.6265 -6.5954 0 0
M  V30 31 C 2.3949 -4.4626 0 0
M  V30 32 C 1.175 -3.3929 0 0
M  V30 33 C 0.3003 -1.9914 0 0
M  V30 34 C -0.124 -0.5023 0 0
M  V30 35 C -0.1467 1.0479 0 0 CFG=2
M  V30 36 C -1.6762 1.2273 0 0
M  V30 37 C 0.2331 2.5468 0 0 CFG=2
M  V30 38 O -1.1975 3.1168 0 0
M  V30 39 C 0.988 3.8963 0 0 CFG=1
M  V30 40 C -0.2464 4.8171 0 0
M  V30 41 C 2.0664 5.0045 0 0 CFG=1
M  V30 42 O 1.1124 6.2133 0 0
M  V30 43 C 3.3946 5.7956 0 0 CFG=1
M  V30 44 C 2.7857 7.2102 0 0
M  V30 45 C 4.8811 6.2162 0 0 CFG=2
M  V30 46 O 4.6582 7.74 0 0
M  V30 47 C 3.2271 8.3088 0 0
M  V30 48 O 2.0189 7.3538 0 0
M  V30 49 C 3.0041 9.8325 0 0
M  V30 50 C 6.4227 6.2391 0 0 CFG=2
M  V30 51 C 6.5968 7.7693 0 0
M  V30 52 C 1.5844 -5.7721 0 0
M  V30 53 C 6.4684 -3.0932 0 0
M  V30 54 O 4.9396 -2.9081 0 0
M  V30 55 C 7.3535 -1.8201 0 0
M  V30 56 C 6.6638 -0.4192 0 0
M  V30 57 O 5.1259 -0.3382 0 0
M  V30 58 C 7.4851 0.8832 0 0
M  V30 59 C 6.8054 2.2651 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6 CFG=2
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 11 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 18 17 CFG=2
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 1 25 26
M  V30 27 1 20 26
M  V30 28 1 17 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 2 31 32
M  V30 34 1 32 33 CFG=2
M  V30 35 2 33 34 CFG=2
M  V30 36 1 35 34
M  V30 37 1 35 36 CFG=3
M  V30 38 1 37 35
M  V30 39 1 37 38 CFG=3
M  V30 40 1 37 39
M  V30 41 1 39 40 CFG=1
M  V30 42 1 39 41
M  V30 43 1 41 42 CFG=1
M  V30 44 1 41 43
M  V30 45 1 43 44 CFG=1
M  V30 46 1 43 45
M  V30 47 1 45 46 CFG=3
M  V30 48 1 46 47
M  V30 49 2 47 48
M  V30 50 1 47 49
M  V30 51 1 45 50
M  V30 52 1 50 3
M  V30 53 1 50 51 CFG=3
M  V30 54 1 31 52
M  V30 55 2 27 53
M  V30 56 1 53 54
M  V30 57 1 53 55
M  V30 58 1 14 55
M  V30 59 2 55 56
M  V30 60 1 56 57
M  V30 61 1 56 58
M  V30 62 2 10 58
M  V30 63 1 58 59
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515376764

>  <MW>
822.405

>  <MW (desalted)>
822.94

>  <ClogP>
3.71

>  <logS>
-6.396

>  <HBD>
6

>  <HBA>
14

>  <TPSA>
220.15

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Activator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
MIC90  0.0008 ?g/ml | MIC90  0.001 ?M | MIC90  0.0023 ?M | MIC90  0.0023 ?M | IC90  0.0025 ?M | IC90  0.0034 ?M | MIC90  0.0045 ?M | MIC  0.00049 ?g/ml | IC90  0.0057 - 0.0082 ?M | MIC  0.001 ?M | EC50  1.35 nM | MIC90  0.013 - 0.023 ?M | MIC  0.0015 ?M | MIC90  15.85 nM | MIC90  15.85 nM | MIC  0.0018 ?M | MIC  0.002 ?M | IC50  2.4 nM | IC50  2.4 nM | MIC  0.002 - 0.003 ?g/ml | MIC90  27 nM

>  <CAS>
13292-46-1

>  <Description>
Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis.

>  <EBC_ID>
EBC-08482

>  <IUPAC Name>
(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate

>  <Main Tar all refs>
mBio, 2018, vol. 9, # 5 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Antimicrob. Agents Chemother., 2022, vol. 66, # 4 | Bioorg. Chem., 2021, vol. 115 | Chem. Biodiversity, 2020, vol. 17, # 8 | Eur. J. Med. Chem., 2021, vol. 225 | Antimicrob. Agents Chemother., 2021, vol. 65, # 1 | UNIVERSITY SYSTEM OF OHIO - WO2017/223160, 2017, A1 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - WO2019/46467, 2019, A1 | Drug Metab. Dispos., 2022, vol. 50, # 8, p. 1064 - 1076 | Eur. J. Med. Chem., 2022, vol. 230 | ACS Med. Chem. Lett., 2014, vol. 5, # 7, p. 820 - 825 | J. Med. Chem., 2022, vol. 65, # 6, p. 4893 - 4908 | J. Med. Chem., 2022, vol. 65, # 6, p. 4893 - 4908 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | J. Med. Chem., 2014, vol. 57, # 13, p. 5728 - 5737 | Drug Metab. Dispos., 2000, vol. 28, # 3, p. 268 - 278 | Drug Metab. Dispos., 2000, vol. 28, # 3, p. 268 - 278 | Biomolecules, 2022, vol. 12, # 11 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1408 - 1421

>  <Main tar all>
Cytochrome bc1 complex cytochrome b subunit pX=9.97 | DNA?gyrase pX=9.95 | DNA?gyrase subunit A (A190V) pX=9.59 | DNA?gyrase subunit A?(G88C) pX=9.59 | DNA?gyrase subunit B pX=9.56 | Probable UDP-N-acetylglucosamine pyrophosphorylase pX=9.42 | RNA polymerase, beta subunit pX=9.3 | RNA polymerase pX=9.23 | Diacylglycerol acyltransferase/mycolyltransferase Ag85C pX=9.2 | 3-oxoacyl-[acyl-carrier-protein] synthase 1 pX=9.0 | Pregnane X receptor pX=8.87 | Cytochrome P450 121 pX=8.84 | DNA gyrase subunit A (D89N) pX=8.82 | ATP-dependent Clp protease ATP-binding subunit ClpC1 pX=8.75 | ATP-dependent Clp protease proteolytic subunit 1 and 2 complex pX=8.75 | Enoyl-[acyl-carrier-protein] reductase (G96A) pX=8.74 | DprE1 Y314H pX=8.7 | Glucocorticoid receptor pX=8.62 | Mineralocorticoid receptor pX=8.62 | Probable proline-tRNA ligase, mitochondrial pX=8.61 | DNA-directed RNA polymerase pX=8.52

$$$$
Miglustat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 N 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0 CFG=2
M  V30 8 O 4.001 -0.77 0 0
M  V30 9 C 1.3337 -0.77 0 0 CFG=1
M  V30 10 O 1.3337 -2.31 0 0
M  V30 11 C 0 0 0 0 CFG=2
M  V30 12 O -1.3337 -0.77 0 0
M  V30 13 C 0 1.54 0 0 CFG=1
M  V30 14 C -1.3337 2.31 0 0
M  V30 15 O -1.3337 3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 12 CFG=3
M  V30 12 1 11 13
M  V30 13 1 13 5
M  V30 14 1 13 14 CFG=1
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2379810058

>  <MW>
219.147

>  <MW (desalted)>
219.278

>  <ClogP>
0.906

>  <logS>
-0.279

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
84.16

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.014 ?M | IC50 = 0.1 ?M | IC50  0.1 ?M | IC50 = 0.1 ?M | Ki (inhibition constant)  0.2 ?M | IC50 = 0.21 ?M | IC50 = 0.23 ?M | Ki (inhibition constant) = 0.26 ?M | Ki (inhibition constant)  0.326 ?M | IC50 = 0.34 ?M | IC50 = 420 nM | IC50  0.44 ?M

>  <CAS>
72599-27-0

>  <Description>
Miglustat is an inhibitor of glucosylceramide synthase. It is used for the management of mild to moderate type I Gaucher disease for patients who are not candidates for whole enzyme replacement.

>  <EBC_ID>
EBC-07860

>  <IUPAC Name>
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

>  <Main Tar all refs>
Eur. J. Med. Chem., 2019, vol. 175, p. 63 - 71 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 23, p. 6600 - 6603 | J. Org. Chem., 2007, vol. 72, # 4, p. 1088 - 1097 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 23, p. 6600 - 6603 | J. Med. Chem., 2022, vol. 65, # 3, p. 2329 - 2341 | ANTIMICROB. AGENTS CHEMOTHER., 1994, vol. 38, # 8, p. 1780 - 1787 | J. Med. Chem., 2010, vol. 53, # 2, p. 689 - 698 | Biochem. Pharmacol., 2007, vol. 73, # 9, p. 1376 - 1383 | J. Am. Chem. Soc., 2017, vol. 139, # 40, p. 14192 - 14197 | Biochem. Pharmacol., 2007, vol. 73, # 9, p. 1376 - 1383 | Bioorg. Med. Chem. Lett., 2004, vol. 14, # 24, p. 5991 - 5995 | PLoS. Negl. Trop. Dis., 2016, vol. 10, # 3

>  <Main tar all>
Non-lysosomal glucosylceramidase pX=7.85 | Alpha-glucosidase?(gene?aglA) pX=7.0 | Lysosomal?alpha-glucosidase pX=7.0 | maltase-glucoamylase pX=7.0 | Lysosomal?alpha-glucosidase pX=6.7 | Alpha-glucosidase?I pX=6.68 | Beta-glucosidase?(gene?abg) pX=6.64 | Oligo-1,6-glucosidase (peptide) pX=6.59 | Non-lysosomal glucosylceramidase (isoform 2) pX=6.49 | Isomaltase pX=6.47 | Alpha-glucosidase pX=6.38 | Sucrase pX=6.36

$$$$
Glimepiride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -16.8772 -6.867 0 0
M  V30 2 C -15.972 -8.1129 0 0
M  V30 3 C -14.4404 -7.9519 0 0
M  V30 4 C -13.6704 -6.6183 0 0
M  V30 5 C -14.2968 -5.2114 0 0
M  V30 6 C -12.1641 -6.9384 0 0
M  V30 7 N -12.0031 -8.47 0 0
M  V30 8 C -10.6694 -9.24 0 0
M  V30 9 O -10.6694 -10.78 0 0
M  V30 10 N -9.3358 -8.47 0 0
M  V30 11 C -8.0021 -9.24 0 0
M  V30 12 C -6.6684 -8.47 0 0
M  V30 13 C -5.3347 -9.24 0 0
M  V30 14 C -4.001 -8.47 0 0
M  V30 15 C -2.6674 -9.24 0 0
M  V30 16 C -2.6674 -10.78 0 0
M  V30 17 C -4.001 -11.55 0 0
M  V30 18 C -5.3347 -10.78 0 0
M  V30 19 S -1.3337 -11.55 0 0
M  V30 20 O -2.1037 -12.8837 0 0
M  V30 21 O -0.5637 -10.2163 0 0
M  V30 22 N 0 -12.32 0 0
M  V30 23 C 0 -13.86 0 0
M  V30 24 O -1.3337 -14.63 0 0
M  V30 25 N 1.3337 -14.63 0 0
M  V30 26 C 2.6674 -13.86 0 0 CFG=1
M  V30 27 C 2.6674 -12.32 0 0
M  V30 28 C 4.001 -11.55 0 0
M  V30 29 C 5.3347 -12.32 0 0 CFG=2
M  V30 30 C 6.6684 -11.55 0 0
M  V30 31 C 5.3347 -13.86 0 0
M  V30 32 C 4.001 -14.63 0 0
M  V30 33 C -13.41 -9.0964 0 0
M  V30 34 O -13.7302 -10.6027 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 16 19
M  V30 20 2 19 20
M  V30 21 2 19 21
M  V30 22 1 19 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 26 25 CFG=1
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 29 28
M  V30 30 1 29 30 CFG=3
M  V30 31 1 29 31
M  V30 32 1 31 32
M  V30 33 1 26 32
M  V30 34 1 7 33
M  V30 35 1 3 33
M  V30 36 2 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501475009

>  <MW>
490.225

>  <MW (desalted)>
490.616

>  <ClogP>
3.962

>  <logS>
-5.649

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
124.68

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 3 nM | IC50 = 5.4 nM | IC50  6.2 nM | IC50  8.3 nM

>  <CAS>
93479-97-1

>  <Description>
Glimepiride is a medication used to treat diabetes mellitus type 2. It is a potent Kir6.2/SUR1, SUR2A and SUR2B inhibitor.

>  <EBC_ID>
EBC-07868

>  <IUPAC Name>
3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide

>  <Main Tar all refs>
Br. J. Pharmacol., 2001, vol. 133, # 1, p. 193 - 199 | Br. J. Pharmacol., 2001, vol. 133, # 1, p. 193 - 199 | Br. J. Pharmacol., 2002, vol. 136, # 5, p. 746 - 752 | LUDWIG-MAXIMILIANS-UNIVERSIT?T M?NCHEN - WO2016/59093, 2016, A1

>  <Main tar all>
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=8.52 | ABCC9 pX=8.27 | ion channel pX=8.21 | S-alkyl-thiohydroximate lyase SUR1 pX=8.08

$$$$
Ritonavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 50 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -8.0021 4.62 0 0
M  V30 2 C -8.0021 3.08 0 0
M  V30 3 C -9.3358 2.31 0 0
M  V30 4 C -6.6684 2.31 0 0 CFG=2
M  V30 5 N -6.6684 0.77 0 0
M  V30 6 C -8.0021 -0 0 0
M  V30 7 O -9.3358 0.77 0 0
M  V30 8 N -8.0021 -1.54 0 0
M  V30 9 C -6.6684 -2.31 0 0
M  V30 10 C -9.3358 -2.31 0 0
M  V30 11 C -9.3358 -3.85 0 0
M  V30 12 C -8.0899 -4.7552 0 0
M  V30 13 S -8.5658 -6.2198 0 0
M  V30 14 C -10.1058 -6.2198 0 0
M  V30 15 N -10.5816 -4.7552 0 0
M  V30 16 C -11.0109 -7.4657 0 0
M  V30 17 C -10.3846 -8.8726 0 0
M  V30 18 C -12.5425 -7.3047 0 0
M  V30 19 C -5.3347 3.08 0 0
M  V30 20 O -4.001 2.31 0 0
M  V30 21 N -5.3347 4.62 0 0
M  V30 22 C -4.001 5.39 0 0 CFG=2
M  V30 23 C -2.6674 4.62 0 0
M  V30 24 C -2.6674 3.08 0 0 CFG=2
M  V30 25 O -3.2937 1.6731 0 0
M  V30 26 C -1.3337 2.31 0 0 CFG=2
M  V30 27 C 0 3.08 0 0
M  V30 28 C 0 4.62 0 0
M  V30 29 C -1.3337 5.39 0 0
M  V30 30 C -1.3337 6.93 0 0
M  V30 31 C 0 7.7 0 0
M  V30 32 C 1.3337 6.93 0 0
M  V30 33 C 1.3337 5.39 0 0
M  V30 34 N -1.3337 0.77 0 0
M  V30 35 C 0 -0 0 0
M  V30 36 O 1.3337 0.77 0 0
M  V30 37 O 0 -1.54 0 0
M  V30 38 C 1.3337 -2.31 0 0
M  V30 39 C 1.3337 -3.85 0 0
M  V30 40 C 0.0878 -4.7552 0 0
M  V30 41 N 0.5637 -6.2198 0 0
M  V30 42 C 2.1037 -6.2198 0 0
M  V30 43 S 2.5796 -4.7552 0 0
M  V30 44 C -4.001 6.93 0 0
M  V30 45 C -5.3347 7.7 0 0
M  V30 46 C -6.6684 6.93 0 0
M  V30 47 C -8.0021 7.7 0 0
M  V30 48 C -8.0021 9.24 0 0
M  V30 49 C -6.6684 10.01 0 0
M  V30 50 C -5.3347 9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5 CFG=1
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 11 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 4 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 22 21 CFG=1
M  V30 23 1 22 23
M  V30 24 1 24 23
M  V30 25 1 24 25 CFG=1
M  V30 26 1 24 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 2 28 33
M  V30 35 1 26 34 CFG=3
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 35 37
M  V30 39 1 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 40 41
M  V30 43 2 41 42
M  V30 44 1 42 43
M  V30 45 1 39 43
M  V30 46 1 22 44
M  V30 47 1 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 49 50
M  V30 53 2 45 50
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553599

>  <MW>
720.313

>  <MW (desalted)>
720.944

>  <ClogP>
4.937

>  <logS>
-6.236

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
145.78

>  <RotBonds>
18

>  <Action on targets>
-

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.00014 nM

>  <CAS>
155213-67-5

>  <Description>
Ritonavir is an inhibitor of HIV protease and Cytochrome P450, used to treat HIV infection and AIDS.

>  <EBC_ID>
EBC-06098

>  <IUPAC Name>
(1,3-thiazol-5-yl)methyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate

>  <Main Tar all refs>
J. Am. Chem. Soc., 2000, vol. 122, # 46, p. 11533 - 11534

>  <Main tar all>
Protease pX=12.9

$$$$
Fosinopril
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.93 2.8737 0 0
M  V30 2 C 6.16 4.2074 0 0
M  V30 3 C 4.62 4.2074 0 0
M  V30 4 O 3.85 5.541 0 0
M  V30 5 O 3.85 2.8737 0 0
M  V30 6 C 2.31 2.8737 0 0 CFG=1
M  V30 7 O 1.54 1.54 0 0
M  V30 8 P 0 1.54 0 0
M  V30 9 O -1.54 1.54 0 0
M  V30 10 C 0 3.08 0 0
M  V30 11 C -1.3337 3.85 0 0
M  V30 12 C -1.3337 5.39 0 0
M  V30 13 C -2.6674 6.16 0 0
M  V30 14 C -2.6674 7.7 0 0
M  V30 15 C -4.001 8.47 0 0
M  V30 16 C -4.001 10.01 0 0
M  V30 17 C -2.6674 10.78 0 0
M  V30 18 C -1.3337 10.01 0 0
M  V30 19 C -1.3337 8.47 0 0
M  V30 20 C 0 0 0 0
M  V30 21 C 1.3337 -0.77 0 0
M  V30 22 O 2.6674 -0 0 0
M  V30 23 N 1.3337 -2.31 0 0
M  V30 24 C 2.5796 -3.2152 0 0
M  V30 25 C 2.1037 -4.6798 0 0 CFG=1
M  V30 26 C 0.5637 -4.6798 0 0
M  V30 27 C 0.0878 -3.2152 0 0 CFG=1
M  V30 28 C -1.3768 -2.7393 0 0
M  V30 29 O -1.697 -1.233 0 0
M  V30 30 O -2.5213 -3.7698 0 0
M  V30 31 C 3.0089 -5.9257 0 0
M  V30 32 C 4.5404 -5.7647 0 0
M  V30 33 C 5.4456 -7.0106 0 0
M  V30 34 C 4.8192 -8.4175 0 0
M  V30 35 C 3.2877 -8.5784 0 0
M  V30 36 C 2.3825 -7.3326 0 0
M  V30 37 C 1.54 4.2074 0 0
M  V30 38 C 2.31 5.541 0 0
M  V30 39 C 0 4.2074 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 20 1 8 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 1 25 24
M  V30 26 1 25 26
M  V30 27 1 27 26
M  V30 28 1 27 23
M  V30 29 1 27 28 CFG=1
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 1 25 31 CFG=3
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 31 36
M  V30 39 1 6 37
M  V30 40 1 37 38
M  V30 41 1 37 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3207130728

>  <MW>
563.301

>  <MW (desalted)>
563.663

>  <ClogP>
7.445

>  <logS>
-6.521

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
110.21

>  <RotBonds>
15

>  <CAS>
98048-97-6

>  <Description>
Fosinopril is an ACE inhibitor used to treat mild to moderate hypertension, congestive heart failure, and to slow the progression of renal disease in hypertensive diabetics.

>  <EBC_ID>
EBC-15044

>  <IUPAC Name>
(2S,4S)-4-cyclohexyl-1-(2-{[(1S)-2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid

$$$$
Atazanavir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 51 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.7409 -14.0662 0 0
M  V30 2 O 10.7327 -15.2303 0 0
M  V30 3 C 9.2204 -14.9393 0 0
M  V30 4 O 8.7164 -13.4841 0 0
M  V30 5 N 8.2123 -16.1034 0 0
M  V30 6 C 6.7 -15.8124 0 0 CFG=2
M  V30 7 C 6.1959 -14.3572 0 0
M  V30 8 O 7.2041 -13.1931 0 0
M  V30 9 N 4.6837 -14.0662 0 0
M  V30 10 C 4.1796 -12.611 0 0 CFG=1
M  V30 11 C 2.6674 -12.32 0 0
M  V30 12 C 1.6592 -13.4841 0 0
M  V30 13 C 2.1633 -14.9393 0 0
M  V30 14 C 1.1551 -16.1034 0 0
M  V30 15 C -0.3571 -15.8124 0 0
M  V30 16 C -0.8612 -14.3572 0 0
M  V30 17 C 0.1469 -13.1931 0 0
M  V30 18 C 5.1878 -11.4469 0 0 CFG=1
M  V30 19 O 6.7 -11.7379 0 0
M  V30 20 C 4.6837 -9.9917 0 0
M  V30 21 N 5.6919 -8.8276 0 0
M  V30 22 C 5.1878 -7.3724 0 0
M  V30 23 C 6.1959 -6.2083 0 0
M  V30 24 C 5.6919 -4.7532 0 0
M  V30 25 C 6.7 -3.589 0 0
M  V30 26 C 8.2123 -3.8801 0 0
M  V30 27 C 8.7164 -5.3352 0 0
M  V30 28 C 7.7082 -6.4993 0 0
M  V30 29 C 9.2204 -2.7159 0 0
M  V30 30 C 8.7164 -1.2608 0 0
M  V30 31 C 9.7245 -0.0966 0 0
M  V30 32 C 11.2368 -0.3877 0 0
M  V30 33 C 11.7409 -1.8428 0 0
M  V30 34 N 10.7327 -3.007 0 0
M  V30 35 N 7.2041 -9.1186 0 0
M  V30 36 C 7.7082 -10.5738 0 0
M  V30 37 O 7.5768 -12.1082 0 0
M  V30 38 C 9.2204 -10.8648 0 0 CFG=1
M  V30 39 N 10.2286 -9.7007 0 0
M  V30 40 C 11.7409 -9.9917 0 0
M  V30 41 O 12.2449 -11.4469 0 0
M  V30 42 O 12.749 -8.8276 0 0
M  V30 43 C 14.2613 -9.1186 0 0
M  V30 44 C 9.7245 -12.32 0 0
M  V30 45 C 8.2694 -12.8241 0 0
M  V30 46 C 11.1797 -11.8159 0 0
M  V30 47 C 10.2286 -13.7752 0 0
M  V30 48 C 5.6919 -16.9765 0 0
M  V30 49 C 4.5277 -15.9684 0 0
M  V30 50 C 6.856 -17.9847 0 0
M  V30 51 C 4.6837 -18.1407 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=1
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 10 18
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 23 28
M  V30 30 1 26 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 29 34
M  V30 37 1 21 35
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 38 36
M  V30 41 1 38 39 CFG=1
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 40 42
M  V30 45 1 42 43
M  V30 46 1 38 44
M  V30 47 1 44 45
M  V30 48 1 44 46
M  V30 49 1 44 47
M  V30 50 1 6 48
M  V30 51 1 48 49
M  V30 52 1 48 50
M  V30 53 1 48 51
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1258932192

>  <MW>
704.855

>  <MW (desalted)>
704.855

>  <ClogP>
5.922

>  <logS>
-6.17

>  <HBD>
5

>  <HBA>
7

>  <TPSA>
171.22

>  <RotBonds>
18

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 10 pM | Ki (inhibition constant)  10 - 100 pM | Ki (inhibition constant)  0.009 nM | Ki (inhibition constant)  0.054 nM | Ki (inhibition constant)  0.046 nM | Ki (inhibition constant)  0.076 nM | Ki (inhibition constant) < 0.1 nM | IC50  0.3 nM

>  <CAS>
198904-31-3

>  <Description>
Atazanavir is an antiviral protease inhibitor used in combination with other antiretrovirals for the treatment of HIV.

>  <EBC_ID>
EBC-13816

>  <IUPAC Name>
methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate

>  <Main Tar all refs>
Curr. Pharm. Des., 2007, vol. 13, # 3, p. 271 - 285 | ALNYLAM PHARMACEUTICALS INC - US5783425, 1998, A | J. Med. Chem., 2007, vol. 50, # 18, p. 4316 - 4328 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | J. Med. Chem., 2007, vol. 50, # 18, p. 4316 - 4328 | J. Med. Chem., 2008, vol. 51, # 15, p. 4839 - 4843 | Bioorg. Med. Chem. Lett., 2012, vol. 22, # 15, p. 5078 - 5083 | J. Med. Chem., 2019, vol. 62, # 7, p. 3553 - 3574

>  <Main tar all>
Protease pX=11.0 | HIV-1 protease pX=11.0 | HIV-1 protease (D30N, L63P, N88D) pX=11.0 | HIV-1?protease?(L10F,?L19I,?K20R,?L33F,?E35D,?M36I,?R41K,?F53L,?I54V,?L63P,?H69K,?A71V,?T74P,?I84V,?L89M,?L90M,?I93L) pX=10.3 | HIV-1?protease?(Q7K) pX=10.3 | HIV-1 protease (L10I, I15V, E35D, N37S, R41K, I62V, L63P, A71V, G73S, L90M) pX=10.1 | HIV protease pX=10.0 | peptidase pX=9.52

$$$$
Tadalafil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.2971 -9.4438 0 0
M  V30 2 N 9.9634 -8.6738 0 0
M  V30 3 C 8.6297 -9.4438 0 0
M  V30 4 C 7.296 -8.6738 0 0
M  V30 5 O 5.9623 -9.4438 0 0
M  V30 6 N 7.296 -7.1338 0 0
M  V30 7 C 5.9623 -6.3638 0 0 CFG=1
M  V30 8 C 5.9623 -4.8238 0 0
M  V30 9 N 4.8179 -3.7933 0 0
M  V30 10 C 5.4443 -2.3865 0 0
M  V30 11 C 4.8179 -0.9796 0 0
M  V30 12 C 5.7231 0.2663 0 0
M  V30 13 C 7.2547 0.1053 0 0
M  V30 14 C 7.881 -1.3016 0 0
M  V30 15 C 6.9758 -2.5474 0 0
M  V30 16 C 7.296 -4.0538 0 0
M  V30 17 C 8.6297 -4.8238 0 0
M  V30 18 C 8.6297 -6.3638 0 0 CFG=2
M  V30 19 C 9.9634 -7.1338 0 0
M  V30 20 O 11.2971 -6.3638 0 0
M  V30 21 C 4.6287 -7.1338 0 0
M  V30 22 C 4.6287 -8.6738 0 0
M  V30 23 C 3.295 -9.4438 0 0
M  V30 24 C 1.9613 -8.6738 0 0
M  V30 25 O 0.4967 -9.1497 0 0
M  V30 26 C -0.4085 -7.9038 0 0
M  V30 27 O 0.4967 -6.6579 0 0
M  V30 28 C 1.9613 -7.1338 0 0
M  V30 29 C 3.295 -6.3638 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 16 1 15 16
M  V30 17 2 8 16
M  V30 18 1 16 17
M  V30 19 1 18 17
M  V30 20 1 18 6 CFG=3
M  V30 21 1 18 19
M  V30 22 1 2 19
M  V30 23 2 19 20
M  V30 24 1 7 21 CFG=3
M  V30 25 1 21 22
M  V30 26 2 22 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 2 24 28
M  V30 33 1 28 29
M  V30 34 2 21 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485354

>  <MW>
389.404

>  <MW (desalted)>
389.404

>  <ClogP>
2.584

>  <logS>
-5.342

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
74.87

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.9 nM | IC50  1.5 nM | IC50  0.004 ?M | IC50 = 10 nM | IC50 < 10 nM | pIC50  7.86  | IC50  22.1 nM

>  <CAS>
171596-29-5

>  <Description>
Tadalafil is a potent inhibitor of phosphodiesterase. Tadalafil is an orally administered drug used to treat male erectile dysfunction.

>  <EBC_ID>
EBC-09118

>  <IUPAC Name>
(2R,8R)-2-(1,3-dioxaindan-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1(10),11(16),12,14-tetraene-4,7-dione

>  <Main Tar all refs>
Int. J. Impotence Res., 2001, vol. 13, # Suppl. 4, p. 33 | Bioorg. Chem., 2020, vol. 98 | ACS Chem. Neurosci., 2018, vol. 9, # 2, p. 328 - 345 | Eur. J. Med. Chem., 2013, vol. 60, p. 285 - 294 | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA - WO2014/131855, 2014, A1 | Br. J. Pharmacol., 2008, vol. 154, # 4, p. 787 - 796 | J. Med. Chem., 2019, vol. 62, # 10, p. 4979 - 4990

>  <Main tar all>
phosphodiesterase 5A pX=9.05 | cGMP-dependent 3',5'-cGMP phosphodiesterase A pX=8.82 | cGMP-specific 3',5'-cyclic phosphodiesterase (isoform PDE5A1) pX=8.4 | phosphodiesterase 11A pX=8.0 | phosphodiesterase 5A1 pX=8.0 | voltage-gated calcium channel pX=7.86 | Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11 pX=7.66

$$$$
Montelukast sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na -9.821 -9.0483 0 0 CHG=1
M  V30 2 C 2.6674 -6.16 0 0
M  V30 3 C 2.6674 -7.7 0 0
M  V30 4 C 1.1274 -7.7 0 0
M  V30 5 O 4.2074 -7.7 0 0
M  V30 6 C 2.6674 -9.24 0 0
M  V30 7 C 4.001 -10.01 0 0
M  V30 8 C 4.001 -11.55 0 0
M  V30 9 C 2.6674 -12.32 0 0
M  V30 10 C 1.3337 -11.55 0 0
M  V30 11 C 1.3337 -10.01 0 0
M  V30 12 C 0 -9.24 0 0
M  V30 13 C -1.3337 -10.01 0 0
M  V30 14 C -2.6674 -9.24 0 0 CFG=1
M  V30 15 S -4.001 -10.01 0 0
M  V30 16 C -4.001 -11.55 0 0
M  V30 17 C -5.3347 -12.32 0 0
M  V30 18 C -6.3246 -11.1403 0 0
M  V30 19 C -7.8412 -11.4077 0 0
M  V30 20 O -8.3679 -12.8548 0 0
M  V30 21 O -8.8311 -10.228 0 0 CHG=-1
M  V30 22 C -4.808 -13.7671 0 0
M  V30 23 C -6.3246 -13.4997 0 0
M  V30 24 C -2.6674 -7.7 0 0
M  V30 25 C -4.001 -6.93 0 0
M  V30 26 C -4.001 -5.39 0 0
M  V30 27 C -2.6674 -4.62 0 0
M  V30 28 C -1.3337 -5.39 0 0
M  V30 29 C 0 -4.62 0 0
M  V30 30 C 0 -3.08 0 0
M  V30 31 C 1.3337 -2.31 0 0
M  V30 32 C 1.3337 -0.77 0 0
M  V30 33 C 2.6674 0 0 0
M  V30 34 C 4.001 -0.77 0 0
M  V30 35 C 5.3347 0 0 0
M  V30 36 C 6.6684 -0.77 0 0
M  V30 37 C 6.6684 -2.31 0 0
M  V30 38 Cl 8.0021 -3.08 0 0
M  V30 39 C 5.3347 -3.08 0 0
M  V30 40 C 4.001 -2.31 0 0
M  V30 41 N 2.6674 -3.08 0 0
M  V30 42 C -1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 3 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 17 22
M  V30 22 1 22 23
M  V30 23 1 17 23
M  V30 24 1 14 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 36 37
M  V30 38 1 37 38
M  V30 39 2 37 39
M  V30 40 1 39 40
M  V30 41 2 34 40
M  V30 42 1 40 41
M  V30 43 2 31 41
M  V30 44 1 28 42
M  V30 45 2 24 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568666690

>  <MW>
607.192

>  <MW (desalted)>
586.183

>  <ClogP>
5.272

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
73.25

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  9.31E-05 ?M | IC50 = 0.5 nM

>  <CAS>
151767-02-1

>  <Description>
Montelukast is a leukotriene receptor antagonist used as part of an asthma therapy regimen, to prevent exercise induced bronchoconstriction, and to treat seasonal allergic rhinitis.

>  <EBC_ID>
EBC-12447

>  <IUPAC Name>
sodium 2-[1-({[(1R)-1-{3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetate

>  <Main Tar all refs>
Drug Metab. Dispos., 2022, vol. 50, # 9, p. 1259 - 1271 | Drugs Future, 1997, vol. 22, # 10, p. 1103

>  <Main tar all>
Cytochrome P450 2C8 pX=10.0 | CysLT1 receptor pX=9.3

$$$$
Indocyanine green
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 54 58 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na -1.1615 -5.3849 0 0 CHG=1
M  V30 2 C 15.8501 2.2999 0 0
M  V30 3 C 16.5781 3.657 0 0
M  V30 4 C 17.8516 2.7911 0 0
M  V30 5 C 15.1524 4.2391 0 0
M  V30 6 C 13.8434 3.4278 0 0
M  V30 7 C 12.4863 4.1558 0 0
M  V30 8 C 11.1773 3.3445 0 0
M  V30 9 C 9.8203 4.0725 0 0
M  V30 10 C 8.5113 3.2612 0 0
M  V30 11 C 7.1542 3.9892 0 0
M  V30 12 C 5.8452 3.1779 0 0
M  V30 13 C 4.4881 3.9059 0 0
M  V30 14 N 3.1015 3.2359 0 0 CHG=1
M  V30 15 C 2.8285 1.7203 0 0
M  V30 16 C 1.3795 1.1989 0 0
M  V30 17 C 1.1065 -0.3167 0 0
M  V30 18 C -0.3426 -0.8381 0 0
M  V30 19 S -0.6155 -2.3537 0 0
M  V30 20 O 0.9001 -2.6267 0 0
M  V30 21 O -2.1312 -2.0807 0 0
M  V30 22 O -0.8885 -3.8693 0 0 CHG=-1
M  V30 23 C 2.0358 4.3476 0 0
M  V30 24 C 0.4966 4.2995 0 0
M  V30 25 C -0.3147 5.6085 0 0
M  V30 26 C 0.4133 6.9656 0 0
M  V30 27 C -0.398 8.2746 0 0
M  V30 28 C 0.33 9.6316 0 0
M  V30 29 C 1.8692 9.6797 0 0
M  V30 30 C 2.6805 8.3708 0 0
M  V30 31 C 1.9525 7.0137 0 0
M  V30 32 C 2.7638 5.7047 0 0
M  V30 33 C 4.2794 5.4317 0 0
M  V30 34 C 4.7248 6.9059 0 0
M  V30 35 C 5.7711 5.8144 0 0
M  V30 36 N 15.2654 5.7749 0 0
M  V30 37 C 14.0894 6.7692 0 0
M  V30 38 C 14.3624 8.2848 0 0
M  V30 39 C 13.1863 9.279 0 0
M  V30 40 C 13.4593 10.7946 0 0
M  V30 41 S 12.2832 11.7888 0 0
M  V30 42 O 11.1072 12.783 0 0
M  V30 43 O 13.2774 12.9649 0 0
M  V30 44 O 11.289 10.6128 0 0 CHG=-1
M  V30 45 C 16.761 6.142 0 0
M  V30 46 C 17.489 7.4991 0 0
M  V30 47 C 19.0283 7.5472 0 0
M  V30 48 C 19.8395 6.2382 0 0
M  V30 49 C 21.3788 6.2863 0 0
M  V30 50 C 22.1901 4.9773 0 0
M  V30 51 C 21.4621 3.6202 0 0
M  V30 52 C 19.9228 3.5721 0 0
M  V30 53 C 19.1116 4.8811 0 0
M  V30 54 C 17.5723 4.833 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 2 19 20
M  V30 19 2 19 21
M  V30 20 1 19 22
M  V30 21 1 14 23
M  V30 22 1 23 24
M  V30 23 2 24 25
M  V30 24 1 25 26
M  V30 25 1 26 27
M  V30 26 2 27 28
M  V30 27 1 28 29
M  V30 28 2 29 30
M  V30 29 1 30 31
M  V30 30 2 26 31
M  V30 31 1 31 32
M  V30 32 2 23 32
M  V30 33 1 32 33
M  V30 34 1 13 33
M  V30 35 1 33 34
M  V30 36 1 33 35
M  V30 37 1 5 36
M  V30 38 1 36 37
M  V30 39 1 37 38
M  V30 40 1 38 39
M  V30 41 1 39 40
M  V30 42 1 40 41
M  V30 43 2 41 42
M  V30 44 2 41 43
M  V30 45 1 41 44
M  V30 46 1 36 45
M  V30 47 1 45 46
M  V30 48 2 46 47
M  V30 49 1 47 48
M  V30 50 1 48 49
M  V30 51 2 49 50
M  V30 52 1 50 51
M  V30 53 2 51 52
M  V30 54 1 52 53
M  V30 55 2 48 53
M  V30 56 1 53 54
M  V30 57 2 45 54
M  V30 58 1 3 54
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587758505

>  <MW>
774.277

>  <MW (desalted)>
753.989

>  <ClogP>
-3.411

>  <HBD>
0

>  <HBA>
7

>  <TPSA>
120.65

>  <RotBonds>
14

>  <CAS>
3599-32-4

>  <Description>
Indocyanine green is a diagnostic agent used for the determination of cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography.

>  <EBC_ID>
EBC-27452

>  <IUPAC Name>
sodium 2-[(1E,3E,5E)-7-[(2Z)-1,1-dimethyl-3-(4-sulfonatobutyl)-1H,2H,3H-benzo[e]indol-2-ylidene]hepta-1,3,5-trien-1-yl]-1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-3-ium

$$$$
Remdesivir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 13.2535 12.857 0 0
M  V30 2 C 14.7935 12.857 0 0
M  V30 3 C 15.5635 11.5233 0 0
M  V30 4 C 14.7935 10.1896 0 0
M  V30 5 C 13.2535 10.1896 0 0
M  V30 6 C 17.1035 11.5233 0 0
M  V30 7 O 17.8735 10.1896 0 0
M  V30 8 C 19.4135 10.1896 0 0
M  V30 9 O 20.1835 11.5233 0 0
M  V30 10 C 20.1835 8.856 0 0 CFG=2
M  V30 11 C 19.4135 7.5223 0 0
M  V30 12 N 21.7235 8.856 0 0
M  V30 13 P 22.4935 7.5223 0 0 CFG=2
M  V30 14 O 21.1598 6.7523 0 0
M  V30 15 O 23.2635 6.1886 0 0
M  V30 16 C 24.8035 6.1886 0 0
M  V30 17 C 25.5735 4.8549 0 0 CFG=1
M  V30 18 O 27.105 4.6939 0 0
M  V30 19 C 27.4252 3.1876 0 0 CFG=2
M  V30 20 C 28.8898 3.6635 0 0
M  V30 21 N 30.3545 4.1394 0 0
M  V30 22 C 26.0915 2.4176 0 0 CFG=2
M  V30 23 O 25.9306 0.886 0 0
M  V30 24 C 24.9471 3.4481 0 0 CFG=2
M  V30 25 O 23.4407 3.1279 0 0
M  V30 26 C 28.0516 1.7807 0 0
M  V30 27 C 29.5579 1.4605 0 0
M  V30 28 C 29.7189 -0.071 0 0
M  V30 29 C 28.312 -0.6974 0 0
M  V30 30 C 27.8362 -2.162 0 0
M  V30 31 N 28.8666 -3.3065 0 0
M  V30 32 N 26.3298 -2.4822 0 0
M  V30 33 C 25.2994 -1.3378 0 0
M  V30 34 N 25.7752 0.1269 0 0
M  V30 35 N 27.2816 0.4471 0 0
M  V30 36 O 23.8271 8.2923 0 0
M  V30 37 C 23.8271 9.8323 0 0
M  V30 38 C 22.4935 10.6023 0 0
M  V30 39 C 22.4935 12.1423 0 0
M  V30 40 C 23.8271 12.9123 0 0
M  V30 41 C 25.1608 12.1423 0 0
M  V30 42 C 25.1608 10.6023 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 10 8
M  V30 10 1 10 11 CFG=1
M  V30 11 1 10 12
M  V30 12 1 13 12 CFG=1
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 17 16 CFG=1
M  V30 17 1 17 18
M  V30 18 1 19 18
M  V30 19 1 19 20 CFG=3
M  V30 20 3 20 21
M  V30 21 1 22 19
M  V30 22 1 22 23 CFG=3
M  V30 23 1 22 24
M  V30 24 1 24 17
M  V30 25 1 24 25 CFG=3
M  V30 26 1 19 26 CFG=1
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 2 30 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 34 35
M  V30 36 1 26 35
M  V30 37 1 29 35
M  V30 38 1 13 36 CFG=3
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 2 38 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 37 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3064247938

>  <MW>
602.576

>  <MW (desalted)>
602.576

>  <ClogP>
1.249

>  <logS>
-6.271

>  <HBD>
4

>  <HBA>
9

>  <TPSA>
203.55

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.16 - 1.2 nM | EC50  5.3 nM | EC90  0.17 ?M | EC50  0.02 ?M | EC50  0.034 ?M

>  <CAS>
1809249-37-3

>  <Description>
Remdesivir is a nucleoside analog used to treat RNA virus infections.

>  <EBC_ID>
EBC-27372

>  <IUPAC Name>
2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate

>  <Main Tar all refs>
Front. Pharmacol., 2021, vol. 12 | Nat. Commun., 2021, vol. 12, # 1 | Nat. Commun., 2021, vol. 12, # 1 | LEXICON PHARMACEUTICALS INC - WO2021/216441, 2021, A1 | Int. J. Mol. Sci., 2021, vol. 22, # 3, p. 1 - 17

>  <Main tar all>
RNA polymerase pX=8.67 | RNA-directed RNA polymerase pX=8.28 | RNA-dependent RNA polymerase pX=7.72 | AP2 associated kinase 1 pX=7.7 | M-protease pX=7.47

$$$$
Betazole dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 N -1.0003 -3.08 0 0
M  V30 4 C -1.0003 -4.62 0 0
M  V30 5 C 0.3334 -5.39 0 0
M  V30 6 C 0.3334 -6.93 0 0
M  V30 7 C 1.5793 -7.8352 0 0
M  V30 8 C 1.1034 -9.2998 0 0
M  V30 9 N -0.4366 -9.2998 0 0
M  V30 10 N -0.9125 -7.8352 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 2 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 2 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2867120994

>  <MW>
183.033

>  <MW (desalted)>
111.145

>  <ClogP>
-0.698

>  <logS>
-1.027

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
54.7

>  <RotBonds>
2

>  <CAS>
138-92-1

>  <Description>
Betazole is a histamine H2 agonist. It is used clinically to test gastric secretory function.

>  <EBC_ID>
EBC-12925

>  <IUPAC Name>
2-(1H-pyrazol-3-yl)ethan-1-amine dihydrochloride

$$$$
L-Threonine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.31 4.001 0 0
M  V30 2 C 1.54 2.6674 0 0 CFG=1
M  V30 3 O -0 2.6674 0 0
M  V30 4 C 2.31 1.3337 0 0 CFG=2
M  V30 5 N 3.85 1.3337 0 0
M  V30 6 C 1.54 0 0 0
M  V30 7 O 2.31 -1.3337 0 0
M  V30 8 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 2 4
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z813019058

>  <MW>
119.058

>  <MW (desalted)>
119.119

>  <ClogP>
-2.502

>  <logS>
0.3

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) = 1.2 ?M | Ki (inhibition constant)  3.2 ?M

>  <CAS>
72-19-5

>  <Description>
L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. It makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation.

>  <EBC_ID>
EBC-26050

>  <IUPAC Name>
(2S,3R)-2-amino-3-hydroxybutanoic acid

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2010, vol. 107, # 9, p. 4028 - 4033 | Neuron, 1999, vol. 23, # 3, p. 487 - 498

>  <Main tar all>
Threonine-tRNA ligase (gene thrS) pX=5.92 | GPRC6 receptor pX=5.49

$$$$
L-Proline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.2739 4.39 0 0
M  V30 2 C 1.0598 3.62 0 0
M  V30 3 O 2.3935 4.39 0 0
M  V30 4 C 1.0598 2.08 0 0 CFG=2
M  V30 5 C 2.3057 1.1748 0 0
M  V30 6 C 1.8298 -0.2898 0 0
M  V30 7 C 0.2898 -0.2898 0 0
M  V30 8 N -0.1861 1.1748 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756429958

>  <MW>
115.063

>  <MW (desalted)>
115.13

>  <ClogP>
-2.413

>  <logS>
0.21

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.33

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.5 ?M | Km (Michaelis constant) = 11.3 ?M | inhibition percentage  93 % | Ki (inhibition constant)  58 ?M

>  <CAS>
147-85-3

>  <Description>
L-Proline is one of non-essential amino acids and an essential component of collagen that is important for proper functioning of joints and tendons.

>  <EBC_ID>
EBC-44195

>  <IUPAC Name>
(2S)-pyrrolidine-2-carboxylic acid

>  <Main Tar all refs>
Eur. J. Med. Chem., 2022, vol. 232 | Biochem. J., 2002, vol. 363, # 3, p. 483 - 491 | J. Med. Chem., 2013, vol. 56, # 21, p. 8377 - 8388 | Neuron, 1999, vol. 23, # 3, p. 487 - 498

>  <Main tar all>
Glutamate 5-kinase pX=5.6 | D-amino-acid oxidase pX=4.95 | Angiotensin-converting enzyme pX=4.42 | GPRC6 receptor pX=4.24

$$$$
Phenoxyethanol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 O 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473570

>  <MW>
138.068

>  <MW (desalted)>
138.164

>  <ClogP>
1.188

>  <logS>
-1.26

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 360 ?M

>  <CAS>
122-99-6

>  <Description>
Phenoxyethanol has antibacterial properties and is effective against strains of Pseudomonas aeruginosa. It is an is an antiseptic used as a hand disinfectant or preservative in medications.

>  <EBC_ID>
EBC-26080

>  <IUPAC Name>
2-phenoxyethan-1-ol

>  <Main Tar all refs>
Arch. Toxicol., 1999, vol. 73, # 1, p. 55 - 59

>  <Main tar all>
GluN2D pX=3.44

$$$$
Isoflurane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -1.1274 -4.62 0 0
M  V30 2 C 0.2063 -3.85 0 0
M  V30 3 F 1.54 -4.62 0 0
M  V30 4 O 0.2063 -2.31 0 0
M  V30 5 C 1.54 -1.54 0 0
M  V30 6 Cl 2.8737 -2.31 0 0
M  V30 7 C 1.54 0 0 0
M  V30 8 F 1.54 1.54 0 0
M  V30 9 F 3.08 -0 0 0
M  V30 10 F 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1201618663

>  <MW>
183.971

>  <MW (desalted)>
184.492

>  <ClogP>
1.764

>  <logS>
-1.88

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
9.23

>  <RotBonds>
3

>  <Action on targets>
-

>  <Activity coefficients and valu>
EC50 = 120 nM

>  <CAS>
26675-46-7

>  <Description>
Isoflurane is a halogenated ether with anesthetic properties. It is used for induction and maintenance of general anesthesia.

>  <EBC_ID>
EBC-03166

>  <IUPAC Name>
2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane

>  <Main Tar all refs>
Proc. Natl. Acad. Sci. U. S. A., 2012, vol. 109, # 20, p. 7923 - 7928

>  <Main tar all>
Cav1.2 pX=6.92

$$$$
Mannitol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.9526 2.6674 0 0
M  V30 2 C 3.2863 3.4374 0 0
M  V30 3 C 4.62 2.6674 0 0 CFG=1
M  V30 4 O 4.62 1.1274 0 0
M  V30 5 C 5.9537 3.4374 0 0 CFG=1
M  V30 6 O 5.9537 4.9774 0 0
M  V30 7 C 7.2874 2.6674 0 0 CFG=2
M  V30 8 O 7.2874 1.1274 0 0
M  V30 9 C 8.621 3.4374 0 0 CFG=2
M  V30 10 O 8.621 4.9774 0 0
M  V30 11 C 9.9547 2.6674 0 0
M  V30 12 O 11.2884 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=3
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198149813

>  <MW>
182.079

>  <MW (desalted)>
182.172

>  <ClogP>
-2.046

>  <logS>
1.16

>  <HBD>
6

>  <HBA>
6

>  <TPSA>
121.38

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  30.1 % | IC50  191.57 ?M | inhibition percentage  70 %

>  <CAS>
69-65-8

>  <Description>
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. It  is a sugar alcohol used to test for asthma, to reduce intracranial and intraocular pressure, to measure glomerular filtration rate, and to manage pulmonary symptoms associated with cystic fibrosis.

>  <EBC_ID>
EBC-11056

>  <IUPAC Name>
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol

>  <Main Tar all refs>
SINEW PHARMA - WO2017/50298, 2017, A1 | J. Biomol. Struct. Dyn., 2023 | Chem. Pap., 2014, vol. 68, # 1, p. 37 - 45

>  <Main tar all>
CYP2E1 pX=4.89 | 3C-like protease pX=3.72 | Angiotensin-converting enzyme pX=3.63

$$$$
Epinephrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 N 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0 CFG=2
M  V30 5 O 2.6674 4.62 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 O 1.3337 -2.31 0 0
M  V30 11 C 0 0 0 0
M  V30 12 O -1.3337 -0.77 0 0
M  V30 13 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 6 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255449978

>  <MW>
183.09

>  <MW (desalted)>
183.204

>  <ClogP>
-0.685

>  <logS>
-0.085

>  <HBD>
4

>  <HBA>
4

>  <TPSA>
72.72

>  <RotBonds>
3

>  <Action on targets>
Agonist | Inhibitor | Agonist | Agonist | - | Inhibitor | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor

>  <Activity coefficients and valu>
EC50  0.1 nM | Ki (inhibition constant)  0.095 nM | IC50  108 pM | EC50  0.44 nM | pEC50  9.32  | pKi  9.22  | pEC50  9.19  | EC50  9.7E-10 M | Ki (inhibition constant)  9.8E-10 M | Ki (inhibition constant)  1.4 nM | Ki (inhibition constant)  2 nM | Ka (association constant)  0.002 ?M | pKi  8.57

>  <CAS>
51-43-4

>  <Description>
Epinephrine is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Epinephrine is used to treat allergic reactions, to restore cardiac rhythm, and to control mucosal congestion, glaucoma, and asthma.

>  <EBC_ID>
EBC-12200

>  <IUPAC Name>
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol

>  <Main Tar all refs>
MOL. PHARMACOL., 1996, vol. 49, # 1, p. 112 - 122 | BIOCHEMISTRY, 1990, vol. 29, # 9, p. 2335 - 2342 | Mol. Cell. Endocrinol., 2018, vol. 473, p. 136 - 145 | J. BIOL. CHEM., 1992, vol. 267, # 3, p. 1430 - 1433 | Mol. Pharmacol., 2011, vol. 79, # 2, p. 298 - 307 | BIOL. PHARM. BULL., 1997, vol. 20, # 2, p. 142 - 148 | J. PHARMACOL. EXP. THER., 1987, vol. 242, # 1, p. 121 - 130 | ChemMedChem, 2019, vol. 14, # 12, p. 1129 - 1134 | STANFORD UNIVERSITY; HUEBNER HARALD; FRIEDRICH-ALEXANDER-UNIVERSIT?T ERLANGEN-N?RNBERG; STOESSEL ANNE; UNIVERSITY OF CALIFORNIA - WO2019/204768, 2019, A1 | Mol. Pharmacol., 2001, vol. 59, # 5, p. 1343 - 1354 | Eur. J. Pharmacol., 1981, vol. 76, # 4, p. 461 - 464 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 25 - 30 | Eur. J. Pharmacol., 2010, vol. 640, # 1-3, p. 8 - 14

>  <Main tar all>
?1B-adrenoceptor pX=10.0 | ?2-adrenoceptor pX=10.0 | Androgen receptor pX=9.97 | ?1B-adrenoceptor pX=9.36 | ?1A-adrenoceptor pX=9.32 | ?-adrenoceptor pX=9.22 | ?-adrenoceptor pX=9.19 | ?2A-adrenoceptor pX=9.01 | ?2-adrenoceptor pX=9.01 | ?2A-adrenoceptor pX=8.85 | ?2-adrenoceptor pX=8.7 | ?-carbonic anhydrase pX=8.7 | ?2B-adrenoceptor pX=8.57

$$$$
Nicorandil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 -6.93 0 0 CHG=-1
M  V30 2 N 2.6674 -7.7 0 0 CHG=1
M  V30 3 O 2.6674 -9.24 0 0
M  V30 4 O 4.001 -6.93 0 0
M  V30 5 C 5.3347 -7.7 0 0
M  V30 6 C 6.6684 -6.93 0 0
M  V30 7 N 8.0021 -7.7 0 0
M  V30 8 C 9.3358 -6.93 0 0
M  V30 9 O 9.3358 -5.39 0 0
M  V30 10 C 10.6694 -7.7 0 0
M  V30 11 C 12.0031 -6.93 0 0
M  V30 12 C 13.3368 -7.7 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 N 12.0031 -10.01 0 0
M  V30 15 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57965636

>  <MW>
211.059

>  <MW (desalted)>
211.175

>  <ClogP>
-1.801

>  <logS>
-1.61

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
94.36

>  <RotBonds>
5

>  <Action on targets>
-

>  <Activity coefficients and valu>
concentration (parameter)  0.8 ng/ml

>  <CAS>
65141-46-0

>  <Description>
Nicorandil is a vasodilatory drug that functions through potassium channels and intracellular cGMP concentrations commonly used to treat angina.

>  <EBC_ID>
EBC-11178

>  <IUPAC Name>
2-[(pyridin-3-yl)formamido]ethyl nitrate

>  <Main Tar all refs>
Cardiovasc. Toxicol., 2020, vol. 20, # 1, p. 71 - 81

>  <Main tar all>
Kir3.4 pX=8.42

$$$$
Dinitolmide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 N -1.3337 2.31 0 0 CHG=1
M  V30 9 O -1.3337 3.85 0 0
M  V30 10 O -2.6674 1.54 0 0 CHG=-1
M  V30 11 N 1.3337 -2.31 0 0 CHG=1
M  V30 12 O 2.6674 -3.08 0 0
M  V30 13 O -0 -3.08 0 0 CHG=-1
M  V30 14 C 4.001 2.31 0 0
M  V30 15 O 5.3347 1.54 0 0
M  V30 16 N 4.001 3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 3 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z971222254

>  <MW>
225.039

>  <MW (desalted)>
225.158

>  <ClogP>
0.706

>  <logS>
-3.315

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
129.37

>  <RotBonds>
3

>  <CAS>
148-01-6

>  <Description>
Dinitolmide is a fodder additive for prophylaxis against coccidiosis infections in poultry.

>  <EBC_ID>
EBC-47247

>  <IUPAC Name>
2-methyl-3,5-dinitrobenzamide

$$$$
Benzyl benzoate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3347 0 0 0
M  V30 2 C 6.6684 -0.77 0 0
M  V30 3 O 6.6684 -2.31 0 0
M  V30 4 C 5.3347 -3.08 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 C 6.6684 -6.93 0 0
M  V30 8 C 5.3347 -7.7 0 0
M  V30 9 C 4.001 -6.93 0 0
M  V30 10 C 4.001 -5.39 0 0
M  V30 11 C 8.0021 0 0 0
M  V30 12 C 8.0021 1.54 0 0
M  V30 13 C 9.3358 2.31 0 0
M  V30 14 C 10.6694 1.54 0 0
M  V30 15 C 10.6694 -0 0 0
M  V30 16 C 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z19825582

>  <MW>
212.084

>  <MW (desalted)>
212.244

>  <ClogP>
3.939

>  <logS>
-3.572

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
26.3

>  <RotBonds>
4

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  8.16 nM

>  <CAS>
120-51-4

>  <Description>
Benzyl benzoate is used for treatment of paediatric scabies. Benzyl benzoate exerts toxic effects on the nervous system of the parasite, resulting in its death.

>  <EBC_ID>
EBC-03744

>  <IUPAC Name>
benzyl benzoate

>  <Main Tar all refs>
Toxicology, 2022, vol. 471

>  <Main tar all>
Nuclear receptor ROR-gamma (isoform 2) pX=8.09

$$$$
Moxonidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 O 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 N 0 0 0 0
M  V30 5 C 0 1.54 0 0
M  V30 6 C -1.3337 2.31 0 0
M  V30 7 N 1.3337 2.31 0 0
M  V30 8 C 2.6674 1.54 0 0
M  V30 9 Cl 4.001 2.31 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 N 4.001 -0.77 0 0
M  V30 12 C 4.001 -2.31 0 0
M  V30 13 N 2.7552 -3.2152 0 0
M  V30 14 C 3.231 -4.6798 0 0
M  V30 15 C 4.771 -4.6798 0 0
M  V30 16 N 5.2469 -3.2152 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 3 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 12 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040189

>  <MW>
241.073

>  <MW (desalted)>
241.677

>  <ClogP>
1.506

>  <logS>
-2.12

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
71.43

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.16 nM | pIC50  8.45

>  <CAS>
75438-57-2

>  <Description>
Moxonidine is an imidazoline/?-2 receptor agonist used to treat hypertension, especially in cases where ACE inhibitors, ?-blockers, calcium channel blockers, and thiazides are not appropriate or provide inadequate blood pressure control.

>  <EBC_ID>
EBC-26285

>  <IUPAC Name>
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine

>  <Main Tar all refs>
Eur. J. Pharmacol., 2013, vol. 720, # 1-3, p. 363 - 375 | J. Med. Chem., 2020, vol. 63, # 7, p. 3610 - 3633

>  <Main tar all>
Nischarin pX=9.8 | Imidazoline I1 receptors pX=8.45

$$$$
Nalidixic Acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -5.39 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 C 1.3337 -2.31 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O 0 1.54 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C 2.6674 0 0 0
M  V30 10 O 2.6674 1.54 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 C 6.6684 -2.31 0 0
M  V30 15 C 8.0021 -3.08 0 0
M  V30 16 N 5.3347 -3.08 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 1 3 17
M  V30 18 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104478940

>  <MW>
232.085

>  <MW (desalted)>
232.235

>  <ClogP>
1.024

>  <logS>
-1.98

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
70.5

>  <RotBonds>
2

>  <Action on targets>
- | - | - | - | Inhibitor | - | - | - | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Substrate | Substrate | Substrate | Inhibitor

>  <Activity coefficients and valu>
GI85 > 25000 nM | Kd (dissociation constant)  5.69 ?M | Kd (dissociation constant)  5.69 ?M | Kd (dissociation constant)  6.55 ?M | IC50  1.74 ?g/ml | glucose level decrease Active   | glucose level decrease Active   | MIC = 2.5 ?g/mL | IC50  10.8 ?M | MIC  4 mg/l | IC50  24.87 ?M | MIC  8 ?g/ml | inhibition percentage = 80 % | inhibition percentage  88 % | MIC  16 ?g/ml | MIC  16 ?g/ml | MIC  16 ?g/ml | IC50  101 ?M

>  <CAS>
389-08-2

>  <Description>
Nalidixic acid was the first quinolone-based antibiotic. It  is effective against both gram-positive and gram-negative bacteria. It inhibits DNA gyrase and topoisomerase IV activity in Gram-negative bacteria.  Nalidixic acid is used for the treatment of urinary tract infections.

>  <EBC_ID>
EBC-04219

>  <IUPAC Name>
1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

>  <Main Tar all refs>
Chem. Biol., 2012, vol. 19, # 12, p. 1620 - 1630 | Pharmaceuticals, 2022, vol. 15, # 8 | Pharmaceuticals, 2022, vol. 15, # 8 | Pharmaceuticals, 2022, vol. 15, # 8 | Bioorg. Chem., 2018, vol. 81, p. 599 - 611 | J. Biol. Chem., 2022, vol. 298, # 2 | J. Biol. Chem., 2022, vol. 298, # 2 | Bioorg. Med. Chem. Lett., 1992, vol. 2, # 7, p. 643 - 646 | J. Pharmacol. Exp. Ther., 2017, vol. 362, # 3, p. 450 - 458 | Bioorg. Chem., 2020, vol. 104 | J. Pharmacol. Exp. Ther., 2017, vol. 362, # 3, p. 450 - 458 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | Bioorg. Med. Chem. Lett., 2005, vol. 15, # 1, p. 47 - 50 | J. Med. Chem., 2013, vol. 56, # 21, p. 8377 - 8388 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | Antimicrob. Agents Chemother., 2021, vol. 65, # 5 | ACS Chem. Biol., 2017, vol. 12, # 10, p. 2563 - 2569

>  <Main tar all>
RNA-directed DNA polymerase pX=5.36 | Albumin pX=5.24 | Serum albumin pX=5.24 | Serotransferrin pX=5.18 | DNA?gyrase pX=5.13 | Mitochondrial pyruvate carrier 2-RLuc8 pX=5.0 | mitochondrial pyruvate carrier 1 pX=5.0 | DNA?gyrase pX=4.97 | Organic anion transporter 1 pX=4.97 | DNA supercoiling protein pX=4.76 | Organic anion transporter 3 pX=4.6 | Multidrug?efflux?pump?subunit?AcrB pX=4.46 | DNA topoisomerase II pX=4.37 | COX-2  pX=4.17 | Multidrug?efflux?pump?subunit?AcrB?(M78I) pX=4.16 | Multidrug?efflux?pump?subunit?AcrB?(M78I/P319L) pX=4.16 | Multidrug?efflux?pump?subunit?AcrB?(P319L) pX=4.16 | DNA topoisomerase II pX=4.0

$$$$
Chlormezanone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -5.39 0 0
M  V30 2 N 0 -4.62 0 0
M  V30 3 C 0 -3.08 0 0
M  V30 4 C -1.3337 -2.31 0 0
M  V30 5 C -2.6674 -3.08 0 0
M  V30 6 C -4.001 -2.31 0 0
M  V30 7 C -4.001 -0.77 0 0
M  V30 8 Cl -5.3347 0 0 0
M  V30 9 C -2.6674 0 0 0
M  V30 10 C -1.3337 -0.77 0 0
M  V30 11 S 1.3337 -2.31 0 0
M  V30 12 O 0.3438 -1.1303 0 0
M  V30 13 O 2.3236 -1.1303 0 0
M  V30 14 C 2.6674 -3.08 0 0
M  V30 15 C 2.6674 -4.62 0 0
M  V30 16 C 1.3337 -5.39 0 0
M  V30 17 O 1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 4 10
M  V30 11 1 3 11
M  V30 12 2 11 12
M  V30 13 2 11 13
M  V30 14 1 11 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 2 16
M  V30 18 2 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104493622

>  <MW>
273.023

>  <MW (desalted)>
273.736

>  <ClogP>
1.575

>  <logS>
-2.16

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
54.45

>  <RotBonds>
1

>  <Action on targets>
Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
EC50  5.42 nM | EC50  7 nM | EC50  14.1 nM

>  <CAS>
80-77-3

>  <Description>
Chlormezanone is a non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors.

>  <EBC_ID>
EBC-06625

>  <IUPAC Name>
2-(4-chlorophenyl)-3-methyl-1lambda6,3-thiazinane-1,1,4-trione

>  <Main Tar all refs>
CHROMOCELL CORP. - EP3009513, 2016, A1 | CHROMOCELL CORP. - EP3009513, 2016, A1 | CHROMOCELL CORP. - EP3009513, 2016, A1

>  <Main tar all>
GABAA receptor ?2 subunit pX=8.27 | GABAA receptor ?3 subunit pX=8.15 | GABAA receptor ?5 subunit pX=7.85

$$$$
Thalidomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.6497 -4.0133 0 0
M  V30 2 C 2.1256 -2.5487 0 0
M  V30 3 N 1.2204 -1.3028 0 0
M  V30 4 C -0.3196 -1.3028 0 0
M  V30 5 C -1.0896 -2.6365 0 0
M  V30 6 C -2.6296 -2.6365 0 0
M  V30 7 C -3.3996 -1.3028 0 0
M  V30 8 O -4.9396 -1.3028 0 0
M  V30 9 N -2.6296 0.0309 0 0
M  V30 10 C -1.0896 0.0309 0 0
M  V30 11 O -0.3196 1.3645 0 0
M  V30 12 C 2.1256 -0.0569 0 0
M  V30 13 O 1.6497 1.4077 0 0
M  V30 14 C 3.5902 -0.5328 0 0
M  V30 15 C 4.9239 0.2372 0 0
M  V30 16 C 6.2576 -0.5328 0 0
M  V30 17 C 6.2576 -2.0728 0 0
M  V30 18 C 4.9239 -2.8428 0 0
M  V30 19 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 4 10
M  V30 11 2 10 11
M  V30 12 1 3 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 2 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z905162656

>  <MW>
258.064

>  <MW (desalted)>
258.23

>  <ClogP>
0.528

>  <logS>
-2.94

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
1

>  <Action on targets>
- | - | Inhibitor | -

>  <Activity coefficients and valu>
concentration (parameter) = 17.5 pg/mL | concentration (parameter) = 21.8 pg/mL | percentage of viable cells decrease Active   | concentration (parameter) = 26.1 pg/mL

>  <CAS>
50-35-1

>  <Description>
Thalidomide is an immunomodulatory compound with diverse biological activities, including anticancer, anti-inflammatory, and teratogenic properties. Thalidomide is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

>  <EBC_ID>
EBC-04403

>  <IUPAC Name>
2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2003, vol. 47, # 8, p. 2445 - 2449 | Antimicrob. Agents Chemother., 2003, vol. 47, # 8, p. 2445 - 2449 | DANA-FARBER CANCER INSTITUTE - WO2020/6157, 2020, A1 | Antimicrob. Agents Chemother., 2003, vol. 47, # 8, p. 2445 - 2449

>  <Main tar all>
Interleukin-1 beta pX=10.2 | Interleukin-6 pX=10.1 | Histone-lysine N-methyltransferase, H3 lysine-79 specific pX=10.0 | Tumor necrosis factor pX=10.0

$$$$
Furosemide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -1.3337 18.79 0 0
M  V30 2 S -1.3337 17.25 0 0
M  V30 3 O -2.8737 17.25 0 0
M  V30 4 O 0.2063 17.25 0 0
M  V30 5 C -1.3337 15.71 0 0
M  V30 6 C -0 14.94 0 0
M  V30 7 C -0 13.4 0 0
M  V30 8 C 1.3337 12.63 0 0
M  V30 9 O 1.3337 11.09 0 0
M  V30 10 O 2.6674 13.4 0 0
M  V30 11 C -1.3337 12.63 0 0
M  V30 12 N -1.3337 11.09 0 0
M  V30 13 C -0 10.32 0 0
M  V30 14 C -0 8.78 0 0
M  V30 15 C 1.2459 7.8748 0 0
M  V30 16 C 0.77 6.4102 0 0
M  V30 17 C -0.77 6.4102 0 0
M  V30 18 O -1.2459 7.8748 0 0
M  V30 19 C -2.6674 13.4 0 0
M  V30 20 C -2.6674 14.94 0 0
M  V30 21 Cl -4.001 15.71 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 7 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 14 18
M  V30 19 2 11 19
M  V30 20 1 19 20
M  V30 21 2 5 20
M  V30 22 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275128584

>  <MW>
330.008

>  <MW (desalted)>
330.744

>  <ClogP>
1.9

>  <logS>
-3.165

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
122.63

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  7.25E-09 M | Ki (inhibition constant) = 18 nM | IC50  0.05 ?M | Ki (inhibition constant) = 52 nM | Ki (inhibition constant) = 65 nM | inhibition percentage  92.7 % | IC50 = 80 nM | Kd (dissociation constant)  120 nM | Kd (dissociation constant)  200 nM

>  <CAS>
54-31-9

>  <Description>
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body.

>  <EBC_ID>
EBC-06772

>  <IUPAC Name>
4-chloro-2-{[(furan-2-yl)methyl]amino}-5-sulfamoylbenzoic acid

>  <Main Tar all refs>
Mol. Neurobiol., 2018, p. 1 - 11 | J. MED. CHEM., 1975, vol. 18, # 11, p. 1152 - 1154 | Eur. J. Pharm. Sci., 2019, vol. 133, p. 95 - 103 | Bioorg. Med. Chem., 2009, vol. 17, # 3, p. 1214 - 1221 | J. Med. Chem., 2009, vol. 52, # 15, p. 4853 - 4859 | Br. J. Pharmacol., 2014, vol. 171, # 1, p. 265 - 278 | NAIA METABOLIC - WO2008/89521, 2008, A1 | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June

>  <Main tar all>
Alternative prion protein pX=8.14 | carbonic anhydrase 1 pX=7.74 | Organic anion transporter 3 pX=7.3 | carbonic anhydrase 14 pX=7.28 | carbonic anhydrase 2 pX=7.19 | CFTR pX=7.1 | carbonic anhydrase pX=7.1 | carbonic anhydrase 12 pX=6.92 | carbonic anhydrase 9 pX=6.7

$$$$
Nifenazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.5796 -3.2152 0 0
M  V30 4 N 4.0442 -2.7393 0 0
M  V30 5 C 4.3644 -1.233 0 0
M  V30 6 O 3.2199 -0.2025 0 0
M  V30 7 C 5.829 -0.7571 0 0
M  V30 8 C 6.1492 0.7493 0 0
M  V30 9 C 7.6138 1.2252 0 0
M  V30 10 C 8.7583 0.1947 0 0
M  V30 11 N 8.4381 -1.3116 0 0
M  V30 12 C 6.9734 -1.7875 0 0
M  V30 13 C 2.1037 -4.6798 0 0
M  V30 14 O 3.0089 -5.9257 0 0
M  V30 15 N 0.5637 -4.6798 0 0
M  V30 16 C -0.3415 -5.9257 0 0
M  V30 17 C 0.2849 -7.3326 0 0
M  V30 18 C -0.6203 -8.5784 0 0
M  V30 19 C -2.1519 -8.4175 0 0
M  V30 20 C -2.7783 -7.0106 0 0
M  V30 21 C -1.8731 -5.7647 0 0
M  V30 22 N 0.0878 -3.2152 0 0
M  V30 23 C -1.3768 -2.7393 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 3 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 23 1 15 22
M  V30 24 1 2 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z27661938

>  <MW>
308.335

>  <MW (desalted)>
308.335

>  <ClogP>
0.127

>  <logS>
-2.377

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
65.54

>  <RotBonds>
3

>  <CAS>
2139-47-1

>  <Description>
Nifenazone has been used as an analgesic for a number of rheumatic conditions. Nifenazone is an activator of the 20S proteasome.

>  <EBC_ID>
EBC-13986

>  <IUPAC Name>
N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)pyridine-3-carboxamide

$$$$
Fedratinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -21.1397 10.435 0 0
M  V30 2 C -21.1397 8.895 0 0
M  V30 3 C -19.806 8.125 0 0
M  V30 4 N -19.806 6.585 0 0
M  V30 5 C -21.1397 5.815 0 0
M  V30 6 N -21.1397 4.275 0 0
M  V30 7 C -19.806 3.505 0 0
M  V30 8 C -18.4723 4.275 0 0
M  V30 9 C -17.1386 3.505 0 0
M  V30 10 C -17.1386 1.965 0 0
M  V30 11 O -15.805 1.195 0 0
M  V30 12 C -15.805 -0.345 0 0
M  V30 13 C -14.4713 -1.115 0 0
M  V30 14 N -14.4713 -2.655 0 0
M  V30 15 C -13.2254 -3.5602 0 0
M  V30 16 C -13.7013 -5.0248 0 0
M  V30 17 C -15.2413 -5.0248 0 0
M  V30 18 C -15.7172 -3.5602 0 0
M  V30 19 C -18.4723 1.195 0 0
M  V30 20 C -19.806 1.965 0 0
M  V30 21 N -22.4734 6.585 0 0
M  V30 22 C -22.4734 8.125 0 0
M  V30 23 N -23.807 8.895 0 0
M  V30 24 C -25.1407 8.125 0 0
M  V30 25 C -25.1407 6.585 0 0
M  V30 26 C -26.4744 5.815 0 0
M  V30 27 C -27.8081 6.585 0 0
M  V30 28 C -27.8081 8.125 0 0
M  V30 29 C -26.4744 8.895 0 0
M  V30 30 S -29.1418 8.895 0 0
M  V30 31 O -28.3718 10.2287 0 0
M  V30 32 O -29.9118 7.5613 0 0
M  V30 33 N -30.4754 9.665 0 0
M  V30 34 C -31.8091 8.895 0 0
M  V30 35 C -33.1428 8.125 0 0
M  V30 36 C -32.5791 10.2287 0 0
M  V30 37 C -31.0391 7.5613 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 14 18
M  V30 19 2 10 19
M  V30 20 1 19 20
M  V30 21 2 7 20
M  V30 22 2 5 21
M  V30 23 1 21 22
M  V30 24 2 2 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 24 29
M  V30 33 1 28 30
M  V30 34 2 30 31
M  V30 35 2 30 32
M  V30 36 1 30 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280076

>  <MW>
524.678

>  <MW (desalted)>
524.678

>  <ClogP>
6.545

>  <logS>
-5.439

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
108.48

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | - | - | - | - | - | - | - | - | - | - | - | - | -

>  <Activity coefficients and valu>
IC50  0.75 nM | IC50  0.865 nM | IC50  0.865 nM | IC50  0.9 nM | IC50  0.9 nM | IC50  1.07 nM | Kd (dissociation constant)  1.1 nM | IC50  1.16 nM | Kd (dissociation constant)  1.2 nM | Kd (dissociation constant)  4.9 nM | Kd (dissociation constant)  4.9 nM | Kd (dissociation constant)  6.4 nM | Kd (dissociation constant)  6.6 nM | Kd (dissociation constant)  13 nM | Kd (dissociation constant)  13 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  16 nM | Kd (dissociation constant)  18 nM | Kd (dissociation constant)  19 nM | Kd (dissociation constant)  20 nM | Kd (dissociation constant)  21 nM

>  <CAS>
936091-26-8

>  <Description>
Fedratinib is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative.

>  <EBC_ID>
EBC-17140

>  <IUPAC Name>
N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide

>  <Main Tar all refs>
J. Med. Chem., 2021, vol. 64, # 4, p. 2228 - 2241 | Bioorg. Chem., 2023, vol. 134 | Bioorg. Chem., 2023, vol. 134 | Bioorg. Chem., 2023, vol. 134 | Bioorg. Chem., 2023, vol. 134 | Bioorg. Chem., 2023, vol. 134 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Bioorg. Chem., 2023, vol. 134 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051

>  <Main tar all>
Janus kinase 2 pX=9.12 | Janus kinase 3 pX=9.06 | fms related receptor tyrosine kinase 3 pX=9.06 | Janus kinase 2, V617F pX=9.05 | fms related receptor tyrosine kinase 3 (ITD) pX=9.05 | fms related receptor tyrosine kinase 3 (ITD,?D835Y) pX=8.97 | cyclin G associated kinase pX=8.96 | fms related receptor tyrosine kinase 3 (ITD,?F691L) pX=8.94 | death associated protein kinase 3 pX=8.92 | fms related receptor tyrosine kinase 3 (D835H) pX=8.31 | fms related receptor tyrosine kinase 3 (D835H) pX=8.31 | fms related receptor tyrosine kinase 3 (D835Y) pX=8.19 | serine/threonine kinase 16 pX=8.18 | doublecortin like kinase 3 pX=7.89 | fms related receptor tyrosine kinase 3 (K663Q) pX=7.89 | death associated protein kinase 1 pX=7.8 | fms related receptor tyrosine kinase 3 (ITD) pX=7.8 | Janus kinase 1 pX=7.74 | mitogen-activated protein kinase kinase kinase 8 pX=7.72 | fms related receptor tyrosine kinase 3 (N841I) pX=7.7 | tyrosine kinase 2 pX=7.68

$$$$
Dronedarone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -5.7193 0 0
M  V30 3 C 5.94 -5.7193 0 0
M  V30 4 C 6.71 -4.3856 0 0
M  V30 5 C 8.25 -4.3856 0 0
M  V30 6 N 9.02 -3.0519 0 0
M  V30 7 C 8.25 -1.7182 0 0
M  V30 8 C 9.02 -0.3846 0 0
M  V30 9 C 8.25 0.9491 0 0
M  V30 10 C 9.02 2.2828 0 0
M  V30 11 C 10.56 -3.0519 0 0
M  V30 12 C 11.33 -1.7182 0 0
M  V30 13 C 12.87 -1.7182 0 0
M  V30 14 O 13.64 -0.3846 0 0
M  V30 15 C 15.18 -0.3846 0 0
M  V30 16 C 15.95 0.9491 0 0
M  V30 17 C 17.49 0.9491 0 0
M  V30 18 C 18.26 -0.3846 0 0
M  V30 19 C 17.49 -1.7182 0 0
M  V30 20 C 15.95 -1.7182 0 0
M  V30 21 C 19.8 -0.3846 0 0
M  V30 22 O 20.57 -1.7182 0 0
M  V30 23 C 20.57 0.9491 0 0
M  V30 24 C 19.9436 2.356 0 0
M  V30 25 C 18.4373 2.6762 0 0
M  V30 26 C 17.9614 4.1408 0 0
M  V30 27 C 16.455 4.461 0 0
M  V30 28 C 15.9792 5.9256 0 0
M  V30 29 O 21.0881 3.3864 0 0
M  V30 30 C 22.4217 2.6164 0 0
M  V30 31 C 23.8864 3.0923 0 0
M  V30 32 C 25.0308 2.0619 0 0
M  V30 33 C 24.7106 0.5555 0 0
M  V30 34 N 25.8551 -0.4749 0 0
M  V30 35 S 27.3197 0.0009 0 0
M  V30 36 O 28.7843 0.4768 0 0
M  V30 37 O 27.7956 -1.4637 0 0
M  V30 38 C 26.8438 1.4656 0 0
M  V30 39 C 23.246 0.0796 0 0
M  V30 40 C 22.1016 1.1101 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 6 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 19 20
M  V30 19 2 15 20
M  V30 20 1 18 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 24 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 2 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 2 35 36
M  V30 36 2 35 37
M  V30 37 1 35 38
M  V30 38 2 33 39
M  V30 39 1 39 40
M  V30 40 1 23 40
M  V30 41 2 30 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759373

>  <MW>
593.217

>  <MW (desalted)>
556.756

>  <ClogP>
8.567

>  <logS>
-8.59

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
88.85

>  <RotBonds>
17

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.062 nM | IC50 R 1 nM

>  <CAS>
141625-93-6

>  <Description>
Dronedarone is a Class III antiarrhythmic drug used in the reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation. It restores normal sinus rhythm and reduces heart rate in atrial fibrillation.

>  <EBC_ID>
EBC-13577

>  <IUPAC Name>
N-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide hydrochloride

>  <Main Tar all refs>
BR. J. PHARMACOL., 1995, vol. 116, # 3, p. 1949 - 1956 | CHINA RESOURCES NATIONAL CORPORATION - WO2015/192672, 2015, A1

>  <Main tar all>
?-adrenoceptor pX=10.2 | Kv11.1 pX=9.0

$$$$
Piperacetazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 O 1.3337 -6.93 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 C 2.6674 -3.08 0 0
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 C 5.3347 -3.08 0 0
M  V30 8 S 6.6684 -2.31 0 0
M  V30 9 C 8.0021 -3.08 0 0
M  V30 10 C 9.3358 -2.31 0 0
M  V30 11 C 10.6694 -3.08 0 0
M  V30 12 C 10.6694 -4.62 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 8.0021 -4.62 0 0
M  V30 15 N 6.6684 -5.39 0 0
M  V30 16 C 6.6684 -6.93 0 0
M  V30 17 C 5.3347 -7.7 0 0
M  V30 18 C 5.3347 -9.24 0 0
M  V30 19 N 4.001 -10.01 0 0
M  V30 20 C 4.001 -11.55 0 0
M  V30 21 C 2.6674 -12.32 0 0
M  V30 22 C 1.3337 -11.55 0 0
M  V30 23 C -0 -12.32 0 0
M  V30 24 C -1.3337 -11.55 0 0
M  V30 25 O -2.6674 -12.32 0 0
M  V30 26 C 1.3337 -10.01 0 0
M  V30 27 C 2.6674 -9.24 0 0
M  V30 28 C 5.3347 -4.62 0 0
M  V30 29 C 4.001 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 22 26
M  V30 27 1 26 27
M  V30 28 1 19 27
M  V30 29 1 15 28
M  V30 30 2 7 28
M  V30 31 1 28 29
M  V30 32 2 4 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671295

>  <MW>
410.572

>  <MW (desalted)>
410.572

>  <ClogP>
4.449

>  <logS>
-4.27

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
43.78

>  <RotBonds>
7

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
inhibition percentage  62.17 - 62.2 %

>  <CAS>
3819-00-9

>  <Description>
Piperacetazine is an antipsychotic prodrug, most notably used for schizophrenia. It blocks sodium channel protein type 8 subunit alpha.

>  <EBC_ID>
EBC-07471

>  <IUPAC Name>
1-(10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-10H-phenothiazin-2-yl)ethan-1-one

>  <Main Tar all refs>
PAIRNOMIX - WO2018/64498, 2018, A1

>  <Main tar all>
Sodium channel protein type 8 subunit alpha (R1872Q) pX=5.22

$$$$
Amlodipine besylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.2168 2.7823 0 0
M  V30 2 C 2.8831 2.0123 0 0
M  V30 3 O 1.5495 2.7823 0 0
M  V30 4 C 0.2158 2.0123 0 0
M  V30 5 O -1.1179 2.7823 0 0
M  V30 6 C 0.2158 0.4723 0 0
M  V30 7 C 1.5495 -0.2977 0 0
M  V30 8 C 2.8831 0.4723 0 0
M  V30 9 O 4.2168 -0.2977 0 0
M  V30 10 C 5.5505 0.4723 0 0
M  V30 11 C 6.8842 -0.2977 0 0
M  V30 12 N 8.2179 0.4723 0 0
M  V30 13 N 1.5495 -1.8377 0 0
M  V30 14 C 0.2158 -2.6077 0 0
M  V30 15 C -1.1179 -1.8377 0 0
M  V30 16 C -1.1179 -0.2977 0 0
M  V30 17 C -2.4516 0.4723 0 0
M  V30 18 C -3.7853 -0.2977 0 0
M  V30 19 C -5.1189 0.4723 0 0
M  V30 20 C -5.1189 2.0123 0 0
M  V30 21 C -3.7853 2.7823 0 0
M  V30 22 C -2.4516 2.0123 0 0
M  V30 23 Cl -1.8252 3.4191 0 0
M  V30 24 C -2.4516 -2.6077 0 0
M  V30 25 O -3.7853 -1.8377 0 0
M  V30 26 O -2.4516 -4.1477 0 0
M  V30 27 C -3.7853 -4.9177 0 0
M  V30 28 C 0.2158 -4.1477 0 0
M  V30 29 O 13.0715 3.234 0 0
M  V30 30 S 13.0715 1.694 0 0
M  V30 31 O 11.5315 1.694 0 0
M  V30 32 O 14.6115 1.694 0 0
M  V30 33 C 13.0715 0.154 0 0
M  V30 34 C 14.4052 -0.616 0 0
M  V30 35 C 14.4052 -2.156 0 0
M  V30 36 C 13.0715 -2.926 0 0
M  V30 37 C 11.7379 -2.156 0 0
M  V30 38 C 11.7379 -0.616 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 6 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 22 23
M  V30 25 1 15 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 14 28
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 2 30 32
M  V30 33 1 30 33
M  V30 34 1 33 34
M  V30 35 2 34 35
M  V30 36 1 35 36
M  V30 37 2 36 37
M  V30 38 1 37 38
M  V30 39 2 33 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z199040762

>  <MW>
567.051

>  <MW (desalted)>
408.876

>  <ClogP>
3.434

>  <logS>
-3.33

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
99.88

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  8.7  | IC50  34.8 nM

>  <CAS>
111470-99-6

>  <Description>
Amlodipine is a calcium channel blocker used to treat hypertension and angina.

>  <EBC_ID>
EBC-11232

>  <IUPAC Name>
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; benzenesulfonic acid

>  <Main Tar all refs>
Eur. J. Med. Chem., 1993, vol. 28, p. 859 - 867 | Arzneimittelforschung, 2009, vol. 59, # 6, p. 283 - 288

>  <Main tar all>
Cav1.1 pX=8.7 | L-type calcium channel pX=7.46

$$$$
Chlorpropamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 10.78 0 0
M  V30 2 C -1.3337 10.01 0 0
M  V30 3 C -1.3337 8.47 0 0
M  V30 4 N 0 7.7 0 0
M  V30 5 C 0 6.16 0 0
M  V30 6 O -1.3337 5.39 0 0
M  V30 7 N 1.3337 5.39 0 0
M  V30 8 S 1.3337 3.85 0 0
M  V30 9 O -0.2063 3.85 0 0
M  V30 10 O 2.8737 3.85 0 0
M  V30 11 C 1.3337 2.31 0 0
M  V30 12 C 2.6674 1.54 0 0
M  V30 13 C 2.6674 -0 0 0
M  V30 14 C 1.3337 -0.77 0 0
M  V30 15 Cl 1.3337 -2.31 0 0
M  V30 16 C 0 0 0 0
M  V30 17 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 2 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z276509110

>  <MW>
276.74

>  <MW (desalted)>
276.74

>  <ClogP>
2.35

>  <logS>
-3.098

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
75.27

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.37 nM | Kd (dissociation constant)  3.59E-09 M

>  <CAS>
94-20-2

>  <Description>
Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide binds to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane.

>  <EBC_ID>
EBC-26409

>  <IUPAC Name>
1-(4-chlorobenzenesulfonyl)-3-propylurea

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540 | TOTTORI UNIVERSITY - US2018/338899, 2018, A1

>  <Main tar all>
sepiapterin reductase pX=9.43 | Homeobox-leucine zipper protein HAT1 pX=8.44

$$$$
Doxazosin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -16.17 0 0
M  V30 2 O -4.001 -14.63 0 0
M  V30 3 C -2.6674 -13.86 0 0
M  V30 4 C -2.6674 -12.32 0 0
M  V30 5 C -1.3337 -11.55 0 0
M  V30 6 N -1.3337 -10.01 0 0
M  V30 7 C 0 -9.24 0 0
M  V30 8 N 1.3337 -10.01 0 0
M  V30 9 C 1.3337 -11.55 0 0
M  V30 10 N 2.6674 -12.32 0 0
M  V30 11 C 0 -12.32 0 0
M  V30 12 C 0 -13.86 0 0
M  V30 13 C -1.3337 -14.63 0 0
M  V30 14 O -1.3337 -16.17 0 0
M  V30 15 C -2.6674 -16.94 0 0
M  V30 16 N 0 -7.7 0 0
M  V30 17 C -1.3337 -6.93 0 0
M  V30 18 C -1.3337 -5.39 0 0
M  V30 19 N 0 -4.62 0 0
M  V30 20 C 1.3337 -5.39 0 0
M  V30 21 C 1.3337 -6.93 0 0
M  V30 22 C 0 -3.08 0 0
M  V30 23 O -1.3337 -2.31 0 0
M  V30 24 C 1.3337 -2.31 0 0
M  V30 25 C 1.3337 -0.77 0 0
M  V30 26 O 2.6674 0 0 0
M  V30 27 C 4.001 -0.77 0 0
M  V30 28 C 5.3347 0 0 0
M  V30 29 C 6.6684 -0.77 0 0
M  V30 30 C 6.6684 -2.31 0 0
M  V30 31 C 5.3347 -3.08 0 0
M  V30 32 C 4.001 -2.31 0 0
M  V30 33 O 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 3 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 7 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 27 32
M  V30 36 1 32 33
M  V30 37 1 24 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z784767764

>  <MW>
451.475

>  <MW (desalted)>
451.475

>  <ClogP>
3.532

>  <logS>
-5.88

>  <HBD>
1

>  <HBA>
9

>  <TPSA>
112.27

>  <RotBonds>
4

>  <Action on targets>
Inverse agonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
pEC50  10.02  | pKi  9.71  | Ki (inhibition constant) = 0.23 nM | Ki (inhibition constant)  0.231 nM | pKi  9.4  | pA2  8.97  | pKi  8.5

>  <CAS>
74191-85-8

>  <Description>
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic alpha1-adrenergic receptors. It is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms.

>  <EBC_ID>
EBC-00685

>  <IUPAC Name>
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine

>  <Main Tar all refs>
Naunyn-Schmiedeberg's Arch. Pharmacol., 2001, vol. 363, # 1, p. 34 - 39 | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149 | Br. J. Clin. Pharmacol., 2007, vol. 63, # 4, p. 394 - 403 | ABBOTT LABORATORIES INC - US5891882, 1999, A | EUR. J. PHARMACOL. MOL. PHARMACOL. SECT., 1994, vol. 268, # 2, p. 141 - 149 | ABBOTT LABORATORIES INC - US5891882, 1999, A | Curr. Med. Chem., 2006, vol. 13, # 28, p. 3395 - 3416

>  <Main tar all>
?1B-adrenoceptor pX=10.0 | ?1B-adrenoceptor pX=9.71 | ?1-adrenoceptor pX=9.64 | ?1D-adrenoceptor pX=9.64 | ?1A-adrenoceptor pX=9.4 | ?1-adrenoceptor pX=8.97 | ?1A-adrenoceptor pX=8.5

$$$$
Escitalopram
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -5.8591 -0.4785 0 0
M  V30 2 N -4.5255 0.2915 0 0
M  V30 3 C -4.5255 1.8315 0 0
M  V30 4 C -3.1918 -0.4785 0 0
M  V30 5 C -1.8581 0.2915 0 0
M  V30 6 C -0.5244 -0.4785 0 0
M  V30 7 C 0.8092 0.2915 0 0 CFG=1
M  V30 8 O 1.9537 1.322 0 0
M  V30 9 C 3.2874 0.552 0 0
M  V30 10 C 2.9672 -0.9544 0 0
M  V30 11 C 3.8724 -2.2003 0 0
M  V30 12 C 3.246 -3.6071 0 0
M  V30 13 C 4.1512 -4.853 0 0
M  V30 14 N 5.0564 -6.0989 0 0
M  V30 15 C 1.7144 -3.7681 0 0
M  V30 16 C 0.8092 -2.5222 0 0
M  V30 17 C 1.4356 -1.1153 0 0
M  V30 18 C -0.0959 1.5374 0 0
M  V30 19 C -1.6275 1.3764 0 0
M  V30 20 C -2.5327 2.6223 0 0
M  V30 21 C -1.9063 4.0292 0 0
M  V30 22 F -2.8115 5.2751 0 0
M  V30 23 C -0.3748 4.1901 0 0
M  V30 24 C 0.5304 2.9443 0 0
M  V30 25 O 10.1164 2.0005 0 0
M  V30 26 C 10.8864 0.6668 0 0
M  V30 27 O 12.4264 0.6668 0 0
M  V30 28 C 10.1164 -0.6668 0 0
M  V30 29 O 10.8864 -2.0005 0 0
M  V30 30 O 8.5764 -0.6668 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 3 13 14
M  V30 14 1 12 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 10 17
M  V30 18 1 7 17
M  V30 19 1 7 18 CFG=3
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 1 23 24
M  V30 26 2 18 24
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3235136057

>  <MW>
414.159

>  <MW (desalted)>
324.392

>  <ClogP>
3.132

>  <logS>
-3.538

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
36.26

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.39 nM | IC50 = 0.9 nM | IC50 = 1.8 nM

>  <CAS>
219861-08-2

>  <Description>
Escitalopram is a selective serotonin re-uptake inhibitor used in the treatment of major depressive disorder, generalized anxiety disorder, and other select psychiatric disorders such as obsessive-compulsive disorder.

>  <EBC_ID>
EBC-80071

>  <IUPAC Name>
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; oxalic acid

>  <Main Tar all refs>
J. Pharm. Pharmacol., 2014, vol. 66, # 8, p. 1122 - 1132 | Bioorg. Med. Chem., 2003, vol. 11, # 6, p. 1007 - 1014 | Curr. Med. Chem., 2002, vol. 9, # 8, p. 799 - 810

>  <Main tar all>
SERT pX=9.41 | DAT pX=9.05 | 5-HT receptor pX=8.74

$$$$
Ethyl salicylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 O 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 O 2.6674 4.62 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 2.6674 1.54 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 0 0 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 O -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z53833295

>  <MW>
166.063

>  <MW (desalted)>
166.174

>  <ClogP>
2.864

>  <logS>
-1.643

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
3

>  <Action on targets>
Agonist | Substrate | Agonist

>  <Activity coefficients and valu>
activation percentage  41 % | Km (Michaelis constant) = 1.75 mM | activation percentage  28 %

>  <CAS>
118-61-6

>  <Description>
Ethyl salicylate is a salicylate indicated in the treatment of sports related pain.

>  <EBC_ID>
EBC-26118

>  <IUPAC Name>
ethyl 2-hydroxybenzoate

>  <Main Tar all refs>
PROCTER & GAMBLE CO - WO2015/153184, 2015, A1 | BOSTON SCIENTIFIC CORP - US5462868, 1995, A | PROCTER & GAMBLE CO - WO2015/153184, 2015, A1

>  <Main tar all>
TRPA1 pX=2.84 | Esterase pX=2.76 | TRPV1 pX=2.59

$$$$
Oxytetracycline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 4.62 0 0
M  V30 2 N 9.3358 3.85 0 0
M  V30 3 C 8.0021 4.62 0 0
M  V30 4 C 9.3358 2.31 0 0 CFG=1
M  V30 5 C 8.0021 1.54 0 0 CFG=2
M  V30 6 C 6.6684 2.31 0 0 CFG=1
M  V30 7 O 6.6684 3.85 0 0
M  V30 8 C 5.3347 1.54 0 0 CFG=1
M  V30 9 C 5.3347 0 0 0
M  V30 10 C 6.6684 -0.77 0 0
M  V30 11 O 6.6684 -2.31 0 0
M  V30 12 C 8.0021 0 0 0 CFG=1
M  V30 13 O 8.0021 -1.54 0 0
M  V30 14 C 9.3358 -0.77 0 0
M  V30 15 O 9.3358 -2.31 0 0
M  V30 16 C 10.6694 -0 0 0
M  V30 17 C 10.6694 1.54 0 0
M  V30 18 O 12.0031 2.31 0 0
M  V30 19 C 12.0031 -0.77 0 0
M  V30 20 O 13.3368 -0 0 0
M  V30 21 N 12.0031 -2.31 0 0
M  V30 22 C 4.001 -0.77 0 0
M  V30 23 O 4.001 -2.31 0 0
M  V30 24 C 2.6674 0 0 0
M  V30 25 C 1.3337 -0.77 0 0
M  V30 26 O 1.3337 -2.31 0 0
M  V30 27 C -0 0 0 0
M  V30 28 C 0 1.54 0 0
M  V30 29 C 1.3337 2.31 0 0
M  V30 30 C 2.6674 1.54 0 0
M  V30 31 C 4.001 2.31 0 0 CFG=2
M  V30 32 C 3.2781 3.6697 0 0
M  V30 33 O 4.724 3.6697 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=3
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=1
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 12 10
M  V30 12 1 5 12
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 4 17
M  V30 19 1 17 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 9 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 25 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 24 30
M  V30 33 1 31 30
M  V30 34 1 8 31
M  V30 35 1 31 32 CFG=3
M  V30 36 1 31 33 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385075

>  <MW>
460.148

>  <MW (desalted)>
460.434

>  <ClogP>
-1.266

>  <logS>
-1.93

>  <HBD>
7

>  <HBA>
10

>  <TPSA>
201.85

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
glucose level decrease Active   | Ki (inhibition constant)  0.99 ?M | EC50  1.18 mg/l

>  <CAS>
79-57-2

>  <Description>
Oxytetracycline is a tetracycline antibiotic used to treat a wide variety of susceptible bacterial infections. It inhibits cell growth by inhibiting translation. Oxytetracycline binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome.

>  <EBC_ID>
EBC-11061

>  <IUPAC Name>
(4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

>  <Main Tar all refs>
Chemosphere, 2019, vol. 226, p. 696 - 703 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 44, p. 27381 - 27387 | Ecotoxicol. Environ. Saf., 2020, vol. 195

>  <Main tar all>
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma pX=6.96 | CoV 3C-like (main) protease pX=6.0 | Laccase (family) pX=5.59

$$$$
Captopril
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.7272 3.62 0 0
M  V30 2 C 2.3935 4.39 0 0 CFG=2
M  V30 3 C 2.3935 5.93 0 0
M  V30 4 S 3.7272 6.7 0 0
M  V30 5 C 1.0598 3.62 0 0
M  V30 6 O -0.2739 4.39 0 0
M  V30 7 N 1.0598 2.08 0 0
M  V30 8 C 2.3057 1.1748 0 0
M  V30 9 C 1.8298 -0.2898 0 0
M  V30 10 C 0.2898 -0.2898 0 0
M  V30 11 C -0.1861 1.1748 0 0 CFG=1
M  V30 12 C -1.6507 1.6507 0 0
M  V30 13 O -2.7951 0.6202 0 0
M  V30 14 O -1.9709 3.157 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 7
M  V30 12 1 11 12 CFG=1
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269124804

>  <MW>
217.077

>  <MW (desalted)>
217.285

>  <ClogP>
0.89

>  <logS>
-1.694

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.61

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.06 nM | IC50  0.51 nM

>  <CAS>
62571-86-2

>  <Description>
Captopril is an ACE inhibitor used for the management of essential or renovascular hypertension, congestive heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy.

>  <EBC_ID>
EBC-02058

>  <IUPAC Name>
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

>  <Main Tar all refs>
Pharmacol. Biochem. Behav., 2013, vol. 110, p. 137 - 144 | Int. J. Pept. Res. Ther., 2023, vol. 29, # 1

>  <Main tar all>
Angiotensin-converting enzyme pX=10.2 | Angiotensin-converting enzyme 2 pX=9.29

$$$$
Polymyxin B1 sulphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 90 90 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -21.8753 2.7035 0 0
M  V30 2 C -20.6387 3.6214 0 0
M  V30 3 C -19.2255 3.0095 0 0
M  V30 4 C -19.0489 1.4796 0 0
M  V30 5 C -17.989 3.9274 0 0
M  V30 6 C -16.5758 3.3154 0 0
M  V30 7 C -15.3392 4.2333 0 0
M  V30 8 C -13.926 3.6214 0 0
M  V30 9 C -12.6894 4.5393 0 0
M  V30 10 O -12.8661 6.0691 0 0
M  V30 11 N -11.2762 3.9274 0 0
M  V30 12 C -10.0397 4.8453 0 0 CFG=1
M  V30 13 C -10.2163 6.3751 0 0
M  V30 14 C -8.9798 7.293 0 0
M  V30 15 N -7.5666 6.6811 0 0
M  V30 16 C -8.6265 4.2333 0 0
M  V30 17 O -8.4498 2.7035 0 0
M  V30 18 N -7.3899 5.1512 0 0
M  V30 19 C -5.9767 4.5393 0 0 CFG=1
M  V30 20 C -5.8001 3.0095 0 0 CFG=1
M  V30 21 C -5.0165 1.6837 0 0
M  V30 22 O -7.0366 2.0916 0 0
M  V30 23 C -4.7402 5.4572 0 0
M  V30 24 O -4.9168 6.987 0 0
M  V30 25 N -3.327 4.8453 0 0
M  V30 26 C -3.1503 3.3154 0 0 CFG=1
M  V30 27 C -4.3869 2.3975 0 0
M  V30 28 C -4.2102 0.8677 0 0
M  V30 29 N -2.797 0.2558 0 0
M  V30 30 C -1.7371 2.7035 0 0
M  V30 31 O -1.5605 1.1737 0 0
M  V30 32 N -0.5006 3.6214 0 0
M  V30 33 C 0.9126 3.0095 0 0 CFG=1
M  V30 34 C 1.0108 4.5463 0 0
M  V30 35 C 2.5028 4.9278 0 0
M  V30 36 N 3.3267 3.6267 0 0
M  V30 37 C 4.9281 3.1018 0 0
M  V30 38 O 6.0526 4.1541 0 0
M  V30 39 C 5.3096 1.6098 0 0 CFG=1
M  V30 40 N 6.7924 1.1942 0 0
M  V30 41 C 7.1739 -0.2978 0 0
M  V30 42 O 6.0725 -1.3742 0 0
M  V30 43 C 8.6567 -0.7134 0 0 CFG=2
M  V30 44 C 9.7581 0.3629 0 0
M  V30 45 C 11.241 -0.0527 0 0
M  V30 46 N 12.3424 1.0237 0 0
M  V30 47 N 9.0382 -2.2054 0 0
M  V30 48 C 10.5211 -2.6211 0 0
M  V30 49 O 11.6225 -1.5447 0 0
M  V30 50 C 10.9026 -4.1131 0 0 CFG=2
M  V30 51 C 12.3854 -4.5287 0 0
M  V30 52 C 12.7669 -6.0207 0 0
M  V30 53 N 14.2497 -6.4363 0 0
M  V30 54 N 9.8012 -5.1894 0 0
M  V30 55 C 8.3183 -4.7738 0 0
M  V30 56 O 7.9369 -3.2818 0 0
M  V30 57 C 7.217 -5.8502 0 0 CFG=2
M  V30 58 C 7.5984 -7.3422 0 0
M  V30 59 C 6.4971 -8.4185 0 0
M  V30 60 C 6.8785 -9.9106 0 0
M  V30 61 C 5.0531 -8.9539 0 0
M  V30 62 N 5.7341 -5.4345 0 0
M  V30 63 C 5.3526 -3.9425 0 0
M  V30 64 O 6.454 -2.8662 0 0
M  V30 65 C 3.8698 -3.5269 0 0 CFG=1
M  V30 66 C 2.7684 -4.6033 0 0
M  V30 67 C 3.1499 -6.0953 0 0
M  V30 68 C 4.6327 -6.5109 0 0
M  V30 69 C 5.0142 -8.0029 0 0
M  V30 70 C 3.9128 -9.0793 0 0
M  V30 71 C 2.43 -8.6637 0 0
M  V30 72 C 2.0485 -7.1717 0 0
M  V30 73 N 3.4883 -2.0349 0 0
M  V30 74 C 2.0054 -1.6193 0 0
M  V30 75 O 0.9041 -2.6956 0 0
M  V30 76 C 1.624 -0.1273 0 0 CFG=1
M  V30 77 C 0.5226 -1.2036 0 0
M  V30 78 C -0.9603 -0.788 0 0
M  V30 79 N -2.0616 -1.8644 0 0
M  V30 80 N 0.1411 0.2884 0 0
M  V30 81 C -0.2404 1.7804 0 0
M  V30 82 O -1.0658 0.4803 0 0
M  V30 83 C 6.4109 2.6862 0 0 CFG=1
M  V30 84 C 7.8938 2.2706 0 0
M  V30 85 O 6.9793 4.1175 0 0
M  V30 86 O 19.3097 -1.54 0 0
M  V30 87 S 19.3097 0 0 0
M  V30 88 O 19.3097 1.54 0 0
M  V30 89 O 20.8497 -0 0 0
M  V30 90 O 17.7697 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 12 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 19 18 CFG=3
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 20 22 CFG=1
M  V30 22 1 19 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 26 25 CFG=3
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 26 30
M  V30 30 2 30 31
M  V30 31 1 30 32
M  V30 32 1 33 32 CFG=3
M  V30 33 1 33 34 CFG=1
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 1 36 37
M  V30 37 2 37 38
M  V30 38 1 39 37
M  V30 39 1 39 40 CFG=3
M  V30 40 1 40 41
M  V30 41 2 41 42
M  V30 42 1 43 41
M  V30 43 1 43 44 CFG=3
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 43 47
M  V30 47 1 47 48
M  V30 48 2 48 49
M  V30 49 1 50 48
M  V30 50 1 50 51 CFG=3
M  V30 51 1 51 52
M  V30 52 1 52 53
M  V30 53 1 50 54
M  V30 54 1 54 55
M  V30 55 2 55 56
M  V30 56 1 57 55
M  V30 57 1 57 58 CFG=3
M  V30 58 1 58 59
M  V30 59 1 59 60
M  V30 60 1 59 61
M  V30 61 1 57 62
M  V30 62 1 62 63
M  V30 63 2 63 64
M  V30 64 1 65 63
M  V30 65 1 65 66 CFG=1
M  V30 66 1 66 67
M  V30 67 1 67 68
M  V30 68 2 68 69
M  V30 69 1 69 70
M  V30 70 2 70 71
M  V30 71 1 71 72
M  V30 72 2 67 72
M  V30 73 1 65 73
M  V30 74 1 73 74
M  V30 75 2 74 75
M  V30 76 1 76 74
M  V30 77 1 76 77 CFG=3
M  V30 78 1 77 78
M  V30 79 1 78 79
M  V30 80 1 76 80 CFG=1
M  V30 81 1 80 81
M  V30 82 1 33 81
M  V30 83 2 81 82
M  V30 84 1 39 83 CFG=1
M  V30 85 1 83 84
M  V30 86 1 83 85 CFG=3
M  V30 87 1 86 87
M  V30 88 2 87 88
M  V30 89 2 87 89
M  V30 90 1 87 90
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3244598618

>  <MW>
1300.717

>  <MW (desalted)>
1203.477

>  <ClogP>
-3.663

>  <logS>
0.865

>  <HBD>
18

>  <HBA>
18

>  <TPSA>
490.66

>  <RotBonds>
29

>  <CAS>
1405-20-5

>  <Description>
Polymyxin B is an antibiotic used to treat a wide variety of infections.

>  <EBC_ID>
EBC-28056

>  <IUPAC Name>
N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2-hydroxypropyl]carbamoyl}propyl]-6-methyloctanamide; sulfuric acid

$$$$
Carbocromen hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 2.7246 0 0
M  V30 3 C 5.7337 3.4946 0 0
M  V30 4 O 7.0674 2.7246 0 0
M  V30 5 C 8.401 3.4946 0 0
M  V30 6 O 8.401 5.0346 0 0
M  V30 7 C 9.7347 2.7246 0 0
M  V30 8 O 11.0684 3.4946 0 0
M  V30 9 C 12.4021 2.7246 0 0
M  V30 10 C 13.7358 3.4946 0 0
M  V30 11 C 15.0694 2.7246 0 0
M  V30 12 C 15.0694 1.1846 0 0
M  V30 13 C 16.4031 0.4146 0 0
M  V30 14 C 17.7368 1.1846 0 0
M  V30 15 C 16.4031 -1.1254 0 0
M  V30 16 C 17.7368 -1.8954 0 0
M  V30 17 C 17.7368 -3.4354 0 0
M  V30 18 N 19.0705 -4.2054 0 0
M  V30 19 C 19.0705 -5.7454 0 0
M  V30 20 C 20.4041 -6.5154 0 0
M  V30 21 C 20.4041 -3.4354 0 0
M  V30 22 C 21.7378 -4.2054 0 0
M  V30 23 C 15.0694 -1.8954 0 0
M  V30 24 O 15.0694 -3.4354 0 0
M  V30 25 O 13.7358 -1.1254 0 0
M  V30 26 C 13.7358 0.4146 0 0
M  V30 27 C 12.4021 1.1846 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 13 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 18 21
M  V30 20 1 21 22
M  V30 21 1 15 23
M  V30 22 2 23 24
M  V30 23 1 23 25
M  V30 24 1 25 26
M  V30 25 2 12 26
M  V30 26 1 26 27
M  V30 27 2 9 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041521404

>  <MW>
397.166

>  <MW (desalted)>
361.432

>  <ClogP>
3.373

>  <logS>
-4.546

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
65.07

>  <RotBonds>
10

>  <CAS>
655-35-6

>  <Description>
Carbocromen was marketed for use as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development.

>  <EBC_ID>
EBC-28057

>  <IUPAC Name>
ethyl 2-({3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-chromen-7-yl}oxy)acetate hydrochloride

$$$$
Telaprevir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 49 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.5917 -8.9508 0 0
M  V30 2 C 5.5917 -7.4108 0 0
M  V30 3 C 4.2581 -6.6408 0 0
M  V30 4 C 4.2581 -5.1008 0 0 CFG=2
M  V30 5 N 2.9244 -4.3308 0 0
M  V30 6 C 1.5907 -5.1008 0 0
M  V30 7 O 1.5907 -6.6408 0 0
M  V30 8 C 0.257 -4.3308 0 0 CFG=2
M  V30 9 C -1.1498 -4.9572 0 0 CFG=1
M  V30 10 C -1.9198 -6.2909 0 0
M  V30 11 C -3.4262 -5.9707 0 0
M  V30 12 C -3.5871 -4.4391 0 0
M  V30 13 C -2.1803 -3.8128 0 0 CFG=1
M  V30 14 C -1.4103 -2.4791 0 0
M  V30 15 N 0.0961 -2.7993 0 0
M  V30 16 C 1.2405 -1.7688 0 0
M  V30 17 O 2.7051 -2.2447 0 0
M  V30 18 C 0.9203 -0.2625 0 0 CFG=1
M  V30 19 N 2.0648 0.768 0 0
M  V30 20 C 1.7446 2.2743 0 0
M  V30 21 O 0.28 2.7502 0 0
M  V30 22 C 2.889 3.3048 0 0 CFG=1
M  V30 23 N 2.5688 4.8111 0 0
M  V30 24 C 3.7133 5.8416 0 0
M  V30 25 O 5.1779 5.3657 0 0
M  V30 26 C 3.3931 7.348 0 0
M  V30 27 C 1.9285 7.8238 0 0
M  V30 28 N 1.6083 9.3302 0 0
M  V30 29 C 2.7527 10.3606 0 0
M  V30 30 C 4.2174 9.8848 0 0
M  V30 31 N 4.5375 8.3784 0 0
M  V30 32 C 4.3536 2.8289 0 0
M  V30 33 C 5.4981 3.8594 0 0
M  V30 34 C 6.9627 3.3835 0 0
M  V30 35 C 7.2829 1.8771 0 0
M  V30 36 C 6.1385 0.8467 0 0
M  V30 37 C 4.6738 1.3226 0 0
M  V30 38 C -0.5443 0.2134 0 0
M  V30 39 C -2.0089 0.6893 0 0
M  V30 40 C -0.0684 1.678 0 0
M  V30 41 C -1.0202 -1.2512 0 0
M  V30 42 C 5.5917 -4.3308 0 0
M  V30 43 O 5.5917 -2.7908 0 0
M  V30 44 C 6.9254 -5.1008 0 0
M  V30 45 O 6.9254 -6.6408 0 0
M  V30 46 N 8.2591 -4.3308 0 0
M  V30 47 C 8.2591 -2.7908 0 0
M  V30 48 C 7.4891 -1.4572 0 0
M  V30 49 C 9.0291 -1.4572 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=3
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=1
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 13 12 CFG=1
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 8 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 18 16
M  V30 20 1 18 19 CFG=3
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 22 20
M  V30 24 1 22 23 CFG=1
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 26 31
M  V30 34 1 22 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 32 37
M  V30 41 1 18 38
M  V30 42 1 38 39
M  V30 43 1 38 40
M  V30 44 1 38 41
M  V30 45 1 4 42
M  V30 46 2 42 43
M  V30 47 1 42 44
M  V30 48 2 44 45
M  V30 49 1 44 46
M  V30 50 1 46 47
M  V30 51 1 47 48
M  V30 52 1 48 49
M  V30 53 1 47 49
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802141

>  <MW>
679.406

>  <MW (desalted)>
679.849

>  <ClogP>
5.351

>  <logS>
-7.397

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
179.56

>  <RotBonds>
14

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki*  3.8E-11 M | Ki*  3.8E-11 M

>  <CAS>
402957-28-2

>  <Description>
Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections.

>  <EBC_ID>
EBC-27428

>  <IUPAC Name>
(3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-[(pyrazin-2-yl)formamido]acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide

>  <Main Tar all refs>
Biochim. Biophys. Acta Gen. Subj., 2014, vol. 1840, # 12, p. 3292 - 3298 | Biochim. Biophys. Acta Gen. Subj., 2014, vol. 1840, # 12, p. 3292 - 3298

>  <Main tar all>
Nonstructural protein 3 pX=10.4 | Serine protease NS3 pX=10.4

$$$$
Linagliptin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.7421 -14.3767 0 0
M  V30 2 C 7.7117 -13.2322 0 0
M  V30 3 C 6.6812 -12.0878 0 0
M  V30 4 C 5.6508 -10.9433 0 0
M  V30 5 N 6.1267 -9.4787 0 0
M  V30 6 C 5.2215 -8.2328 0 0
M  V30 7 N 6.1267 -6.9869 0 0
M  V30 8 C 7.5913 -7.4628 0 0
M  V30 9 N 8.925 -6.6928 0 0
M  V30 10 C 8.925 -5.1528 0 0
M  V30 11 C 10.2586 -7.4628 0 0
M  V30 12 O 11.5923 -6.6928 0 0
M  V30 13 N 10.2586 -9.0028 0 0
M  V30 14 C 11.5923 -9.7728 0 0
M  V30 15 C 12.926 -9.0028 0 0
M  V30 16 N 12.926 -7.4628 0 0
M  V30 17 C 14.2597 -6.6928 0 0
M  V30 18 C 14.2597 -5.1528 0 0
M  V30 19 C 15.5934 -7.4628 0 0
M  V30 20 C 16.927 -6.6928 0 0
M  V30 21 C 18.2607 -7.4628 0 0
M  V30 22 C 18.2607 -9.0028 0 0
M  V30 23 C 16.927 -9.7728 0 0
M  V30 24 C 15.5934 -9.0028 0 0
M  V30 25 N 14.2597 -9.7728 0 0
M  V30 26 C 8.925 -9.7728 0 0
M  V30 27 O 8.925 -11.3128 0 0
M  V30 28 C 7.5913 -9.0028 0 0
M  V30 29 N 3.6815 -8.2328 0 0
M  V30 30 C 2.9115 -9.5665 0 0
M  V30 31 C 1.3715 -9.5665 0 0
M  V30 32 C 0.6015 -8.2328 0 0
M  V30 33 C 1.3715 -6.8991 0 0 CFG=1
M  V30 34 N 0.6015 -5.5655 0 0
M  V30 35 C 2.9115 -6.8991 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 19 24
M  V30 25 1 24 25
M  V30 26 2 15 25
M  V30 27 1 13 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 5 28
M  V30 31 2 8 28
M  V30 32 1 6 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 33 32
M  V30 37 1 33 34 CFG=1
M  V30 38 1 33 35
M  V30 39 1 29 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801970

>  <MW>
472.542

>  <MW (desalted)>
472.542

>  <ClogP>
1.909

>  <logS>
-4.563

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
113.48

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  0.0066 nM | IC50  0.1 nM

>  <CAS>
668270-12-0

>  <Description>
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus.

>  <EBC_ID>
EBC-13284

>  <IUPAC Name>
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
ChemMedChem, 2021, vol. 16, # 4, p. 630 - 639 | ACS Med. Chem. Lett., 2016, vol. 7, # 5, p. 498 - 501

>  <Main tar all>
dipeptidyl peptidase 4 pX=11.2 | Prolyl endopeptidase FAP pX=10.0

$$$$
Dexlansoprazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.6296 2.6982 0 0
M  V30 2 C -3.3996 1.3645 0 0
M  V30 3 C -2.6296 0.0309 0 0
M  V30 4 C -1.0896 0.0309 0 0
M  V30 5 S -0.3196 -1.3028 0 0 CFG=1
M  V30 6 O -1.0896 -2.6365 0 0
M  V30 7 C 1.2204 -1.3028 0 0
M  V30 8 N 2.1256 -0.0569 0 0
M  V30 9 C 3.5902 -0.5328 0 0
M  V30 10 C 4.9239 0.2372 0 0
M  V30 11 C 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 C 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 N 2.1256 -2.5487 0 0
M  V30 16 N -3.3996 -1.3028 0 0
M  V30 17 C -4.9396 -1.3028 0 0
M  V30 18 C -5.7096 0.0309 0 0
M  V30 19 C -4.9396 1.3645 0 0
M  V30 20 O -5.7096 2.6982 0 0
M  V30 21 C -4.9396 4.0319 0 0
M  V30 22 C -5.7096 5.3656 0 0
M  V30 23 F -6.4796 6.6992 0 0
M  V30 24 F -4.3759 6.1356 0 0
M  V30 25 F -7.0433 4.5956 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 1 7 15
M  V30 17 2 3 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 2 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 22 24
M  V30 27 1 22 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516862

>  <MW>
370.084

>  <MW (desalted)>
370.369

>  <ClogP>
1.354

>  <logS>
-4.646

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
67.87

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  2.2 ?M | Km (Michaelis constant)  2.9 ?M | IC50  3.36 ?M | IC50  5.7 ?M | IC50  5.7 ?M | Km (Michaelis constant)  6.55 ?M | IC50  7.1 ?M | IC50  18.8 ?M | IC50 ~ 25 ?M

>  <CAS>
138530-94-6

>  <Description>
Dexlansoprazole is a proton pump inhibitor that irreversibly inactivates the H+/K+-stimulated ATPase pumps in parietal cells, inhibiting gastric acid secretion and increasing intragastric pH.

>  <EBC_ID>
EBC-28062

>  <IUPAC Name>
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole

>  <Main Tar all refs>
Drug Metab. Dispos., 2012, vol. 40, # 9, p. 1698 - 1711 | Eur. J. Clin. Pharmacol., 2001, vol. 57, # 10, p. 709 - 715 | Front. Pharmacol., 2020, vol. 11 | Eur. J. Med. Chem., 2020, vol. 188 | Eur. J. Med. Chem., 2020, vol. 188 | Drug Metab. Dispos., 2005, vol. 33, # 2, p. 209 - 213 | Drug Metab. Dispos., 2012, vol. 40, # 9, p. 1698 - 1711 | Front. Pharmacol., 2020, vol. 11 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 13, p. 2962 - 2966

>  <Main tar all>
Cytochrome P450 2C19 pX=5.66 | Cytochrome P450 3A4 pX=5.54 | L-Tryptophan hydroxylase 2 pX=5.47 | Histone-lysine N-methyltransferase 2A pX=5.24 | WD repeat-containing protein 5 pX=5.24 | Cytochrome P450 2C9 pX=5.18 | CYP1A2 pX=5.15 | L-Tryptophan hydroxylase 1 pX=4.73 | Cytosolic endo-beta-N-acetylglucosaminidase pX=4.6

$$$$
Sodium feredetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 3.8971 4.6936 0 0 CHG=1
M  V30 2 O 2.5746 3.9045 0 0 CHG=-1
M  V30 3 C 1.2522 3.1154 0 0
M  V30 4 O -0.0924 3.8661 0 0
M  V30 5 C 1.2743 1.5756 0 0
M  V30 6 N 2.619 0.8248 0 0 CHG=1
M  V30 7 C 2.9174 2.3356 0 0
M  V30 8 C 4.4465 2.5186 0 0
M  V30 9 N 5.0931 1.1209 0 0 CHG=1
M  V30 10 C 6.9534 -0.1736 0 0
M  V30 11 C 7.0877 -1.8262 0 0
M  V30 12 O 8.1407 -2.95 0 0
M  V30 13 O 5.378 -1.5746 0 0
M  V30 14 Fe 3.9636 0.0741 0 0 CHG=-2
M  V30 15 O 3.6651 -1.4367 0 0
M  V30 16 C 2.136 -1.6197 0 0
M  V30 17 O 1.3853 -2.9643 0 0
M  V30 18 C 1.4895 -0.222 0 0
M  V30 19 O 4.6101 -1.3236 0 0
M  V30 20 C 6.1392 -1.1406 0 0
M  V30 21 O 6.7858 -2.5383 0 0
M  V30 22 C 6.4377 0.3702 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 11 13
M  V30 12 1 13 14
M  V30 13 1 6 14
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 6 18
M  V30 20 1 14 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 9 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z5060133256

>  <MW>
366.984

>  <MW (desalted)>
345.064

>  <ClogP>
-2.978

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
119.03

>  <RotBonds>
2

>  <CAS>
15708-41-5

>  <Description>
Sodium feredetate is used in children nutrition as a source of iron.

>  <EBC_ID>
EBC-26809

>  <IUPAC Name>
sodium 5-(carboxylatomethyl)-3,10,13-trioxo-2,11,12-trioxa-5,8lambda5-diaza-1-ferratetracyclo[6.3.3.0^{1,5}.0^{1,8}]tetradecan-5-ium-8-ylium-1,1-diuide

$$$$
Isotretinoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.6684 3.85 0 0
M  V30 2 C 5.3347 4.62 0 0
M  V30 3 C 5.3347 6.16 0 0
M  V30 4 C 6.6684 6.93 0 0
M  V30 5 C 6.6684 8.47 0 0
M  V30 6 C 8.0021 9.24 0 0
M  V30 7 C 8.0021 10.78 0 0
M  V30 8 C 6.6684 11.55 0 0
M  V30 9 O 6.6684 13.09 0 0
M  V30 10 O 5.3347 10.78 0 0
M  V30 11 C 9.3358 8.47 0 0
M  V30 12 C 4.001 3.85 0 0
M  V30 13 C 4.001 2.31 0 0
M  V30 14 C 2.6674 1.54 0 0
M  V30 15 C 2.6674 -0 0 0
M  V30 16 C 4.001 -0.77 0 0
M  V30 17 C 1.3337 -0.77 0 0
M  V30 18 C 0 0 0 0
M  V30 19 C 0 1.54 0 0
M  V30 20 C 1.3337 2.31 0 0
M  V30 21 C 0.6107 3.6697 0 0
M  V30 22 C 2.0567 3.6697 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 6 11
M  V30 11 1 2 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 14 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2311575452

>  <MW>
300.209

>  <MW (desalted)>
300.435

>  <ClogP>
6.744

>  <logS>
-6.701

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  3E-07 ?M

>  <CAS>
4759-48-2

>  <Description>
Isotretinoin is a retinoid that is converted in vivo into all-trans retinoic acid and has diverse biological activities. Isotretinoin produces its effects through altering progress through the cell cycle, cell differentiation, survival, and apoptosis.

>  <EBC_ID>
EBC-17199

>  <IUPAC Name>
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid

>  <Main Tar all refs>
UNIVERSITY OF DUNDEE - WO2008/12534, 2008, A2

>  <Main tar all>
Luciferin 4-monooxygenase pX=12.5

$$$$
Velpatasvir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 65 73 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -6.2625 -2.935 0 0
M  V30 2 O -4.7227 -2.9116 0 0
M  V30 3 C -3.9731 -1.5664 0 0
M  V30 4 C -2.4333 -1.543 0 0 CFG=1
M  V30 5 C -1.5092 -2.7749 0 0
M  V30 6 C -0.052 -2.2768 0 0 CFG=2
M  V30 7 N -0.0754 -0.737 0 0
M  V30 8 C -1.5471 -0.2835 0 0
M  V30 9 C 1.1565 0.187 0 0
M  V30 10 O 2.5728 -0.4179 0 0
M  V30 11 C 0.9723 1.716 0 0 CFG=2
M  V30 12 N 2.2043 2.64 0 0
M  V30 13 C 3.6205 2.0351 0 0
M  V30 14 O 3.8047 0.5061 0 0
M  V30 15 O 4.8525 2.9591 0 0
M  V30 16 C 6.2687 2.3542 0 0
M  V30 17 C -0.4439 2.3209 0 0
M  V30 18 C -1.6759 1.3968 0 0
M  V30 19 C -3.0921 2.0017 0 0
M  V30 20 C -3.2764 3.5307 0 0
M  V30 21 C -2.0444 4.4547 0 0
M  V30 22 C -0.6282 3.8498 0 0
M  V30 23 C 1.2075 -3.163 0 0
M  V30 24 N 1.2309 -4.7028 0 0
M  V30 25 C 2.7026 -5.1563 0 0
M  V30 26 C 3.5888 -3.8968 0 0
M  V30 27 N 2.6647 -2.6649 0 0
M  V30 28 C 5.1286 -3.8734 0 0
M  V30 29 C 5.9188 -5.1952 0 0
M  V30 30 C 7.4586 -5.1718 0 0
M  V30 31 C 8.2082 -3.8266 0 0
M  V30 32 C 7.418 -2.5048 0 0
M  V30 33 C 8.1677 -1.1595 0 0
M  V30 34 O 9.7075 -1.1361 0 0
M  V30 35 C 10.4977 -2.4579 0 0
M  V30 36 C 12.0375 -2.4345 0 0
M  V30 37 C 12.8277 -3.7563 0 0
M  V30 38 C 14.3675 -3.7329 0 0
M  V30 39 N 15.3804 -2.5729 0 0
M  V30 40 C 16.7967 -3.1778 0 0
M  V30 41 N 16.659 -4.7117 0 0
M  V30 42 C 15.1577 -5.0547 0 0
M  V30 43 C 14.4081 -6.3999 0 0
M  V30 44 C 12.8682 -6.4234 0 0
M  V30 45 C 12.0781 -5.1016 0 0
M  V30 46 C 10.5382 -5.125 0 0
M  V30 47 C 9.748 -3.8032 0 0
M  V30 48 C 18.1185 -2.3876 0 0 CFG=2
M  V30 49 C 19.5347 -2.9925 0 0
M  V30 50 C 20.5476 -1.8326 0 0
M  V30 51 C 19.7574 -0.5107 0 0 CFG=2
M  V30 52 C 20.3624 0.9055 0 0
M  V30 53 N 18.2561 -0.8538 0 0
M  V30 54 C 17.0962 0.1591 0 0
M  V30 55 O 15.6389 -0.339 0 0
M  V30 56 C 17.3934 1.6702 0 0 CFG=1
M  V30 57 N 18.8506 2.1683 0 0
M  V30 58 C 19.1479 3.6793 0 0
M  V30 59 O 17.9879 4.6923 0 0
M  V30 60 O 20.6051 4.1774 0 0
M  V30 61 C 20.9023 5.6885 0 0
M  V30 62 C 16.2334 2.6831 0 0
M  V30 63 C 14.7762 2.185 0 0
M  V30 64 C 16.5307 4.1942 0 0
M  V30 65 C 5.8782 -2.5282 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 11 9
M  V30 12 1 11 12 CFG=1
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 11 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 6 23 CFG=3
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 23 27
M  V30 30 1 26 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 38 42
M  V30 46 1 42 43
M  V30 47 2 43 44
M  V30 48 1 44 45
M  V30 49 1 37 45
M  V30 50 2 45 46
M  V30 51 1 46 47
M  V30 52 2 35 47
M  V30 53 1 31 47
M  V30 54 1 48 40 CFG=1
M  V30 55 1 48 49
M  V30 56 1 49 50
M  V30 57 1 51 50
M  V30 58 1 51 52 CFG=1
M  V30 59 1 51 53
M  V30 60 1 48 53
M  V30 61 1 53 54
M  V30 62 2 54 55
M  V30 63 1 56 54
M  V30 64 1 56 57 CFG=3
M  V30 65 1 57 58
M  V30 66 2 58 59
M  V30 67 1 58 60
M  V30 68 1 60 61
M  V30 69 1 56 62
M  V30 70 1 62 63
M  V30 71 1 62 64
M  V30 72 1 32 65
M  V30 73 2 28 65
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2327235567

>  <MW>
882.406

>  <MW (desalted)>
883.002

>  <ClogP>
5.705

>  <logS>
-9.064

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
193.1

>  <RotBonds>
13

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  0.001 - 0.99 nM | EC90  0.024 nM | EC90  0.027 nM | EC90  0.04 nM | EC90  0.05 nM | EC90  0.05 nM | EC50 = 0.007 nM | EC90  0.075 nM | EC90  0.18 nM | EC90  0.2 nM | EC90  0.2 nM | EC90  0.25 nM

>  <CAS>
1377049-84-7

>  <Description>
Velpatasvir is a NS5A inhibitor used to treat chronic hepatitis C infections in patients without cirrhosis or with compensated cirrhosis.

>  <EBC_ID>
EBC-27501

>  <IUPAC Name>
methyl N-[(1R)-2-[(2S,4S)-2-(5-{6-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.0^{3,11}.0^{4,8}.0^{14,19}]henicosa-1(13),2,4(8),6,9,11,14(19),15,17-nonaen-17-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate

>  <Main Tar all refs>
GILEAD SCIENCES INC - WO2012/68234, 2012, A2 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | GILEAD SCIENCES INC - WO2013/75029, 2013, A1 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4 | Antimicrob. Agents Chemother., 2019, vol. 63, # 4

>  <Main tar all>
Nonstructural?protein?5A pX=12.0 | Nonstructural protein 5A (R30S) pX=11.6 | Nonstructural protein 5A (R30N) pX=11.5 | Nonstructural protein 5B (R30A) pX=11.4 | Nonstructural protein 5A (T58S) pX=11.3 | Nonstructural?protein?5A (T58A) pX=11.3 | NS5A Polymerase pX=11.2 | Nonstructural?protein?5A?(R30E) pX=11.1 | Nonstructural protein 5A (L28V/R30A) pX=10.7 | Nonstructural?protein 5A (L28V/R30T) pX=10.7 | Nonstructural?protein?5A?(L28F) pX=10.7 | Nonstructural protein 5A (T93I) pX=10.6

$$$$
Glycine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.54 2.6674 0 0
M  V30 2 C 2.31 1.3337 0 0
M  V30 3 C 1.54 0 0 0
M  V30 4 O 2.31 -1.3337 0 0
M  V30 5 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z955123660

>  <MW>
75.032

>  <MW (desalted)>
75.067

>  <ClogP>
-3.21

>  <logS>
0.62

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
1

>  <Action on targets>
- | - | Stimulator

>  <Activity coefficients and valu>
EC50 = 1.1 nM | EC50 = 1.1 nM | EC50  0.016 ?M

>  <CAS>
56-40-6

>  <Description>
Glycine is an amino acid commonly used as a component of total parenteral nutrition and is also used as irrigation during surgery. Glycine is a subunit specific modulator of the N-methyl-D-aspartate (NMDA) receptor.

>  <EBC_ID>
EBC-00522

>  <IUPAC Name>
2-aminoacetic acid

>  <Main Tar all refs>
BOSTON UNIVERSITY - WO2001/16601, 2001, A1 | BOSTON UNIVERSITY - WO2001/16601, 2001, A1 | eLife, 2018, vol. 7

>  <Main tar all>
Glutamate receptor ionotropic, NMDA 1 pX=8.96 | Glutamate receptor ionotropic, NMDA 2A pX=8.96 | GluN2D pX=7.8

$$$$
Lactic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.54 2.6674 0 0
M  V30 2 C 2.31 1.3337 0 0
M  V30 3 O 3.85 1.3337 0 0
M  V30 4 C 1.54 0 0 0
M  V30 5 O 2.31 -1.3337 0 0
M  V30 6 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474158

>  <MW>
90.032

>  <MW (desalted)>
90.078

>  <ClogP>
-0.734

>  <logS>
0.373

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
1

>  <Action on targets>
Substrate | Substrate | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate

>  <Activity coefficients and valu>
uptake percentage Active   | inhibition percentage Active   | Km (Michaelis constant)  3 - 5 mM | Km (Michaelis constant) = 6.1 mM | IC50 <= 10 mM | IC50 <= 10 mM | IC50 <= 10 mM | IC50 <= 10 mM | Km (Michaelis constant)  15.8 mM

>  <CAS>
50-21-5

>  <Description>
Lactic acid is an emollient and keratolytic used agent in various cosmetic products and used as an additive in various pharmaceutical products for its antibacterial properties.

>  <EBC_ID>
EBC-04352

>  <IUPAC Name>
2-hydroxypropanoic acid

>  <Main Tar all refs>
BioMetals, 2017, vol. 30, # 5, p. 747 - 755 | Drug Metab. Pharmacokinet., 2019, vol. 34, # 1, p. 95 - 103 | Curr. Drug Metab., 2010, vol. 11, # 9, p. 730 - 742 | Bioorg. Chem., 2002, vol. 30, # 3, p. 145 - 162 | J. Biol. Chem., 2007, vol. 282, # 7, p. 4524 - 4532 | J. Biol. Chem., 2007, vol. 282, # 7, p. 4524 - 4532 | J. Biol. Chem., 2007, vol. 282, # 7, p. 4524 - 4532 | J. Biol. Chem., 2007, vol. 282, # 7, p. 4524 - 4532 | J. Mol. Catal. B Enzym., 2014, vol. 105, p. 41 - 48

>  <Main tar all>
AQP9 pX=3.0 | SMCT1 pX=3.0 | Monocarboxylate transporter 1 pX=2.52 | Hydroxyacid oxidase pX=2.21 | CaS receptor pX=2.0 | Egl Nine Homolog 2 (C. Elegans) pX=2.0 | Egl nine homolog 1 pX=2.0 | Prolyl hydroxylase EGLN3 pX=2.0 | Alcohol oxidase (gene MOX) pX=1.8

$$$$
Biguanide sulphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.88 2.6674 0 0
M  V30 2 C 0.11 1.3337 0 0
M  V30 3 N -1.43 1.3337 0 0
M  V30 4 N 0.88 0 0 0
M  V30 5 C 0.11 -1.3337 0 0
M  V30 6 N 0.88 -2.6674 0 0
M  V30 7 N -1.43 -1.3337 0 0
M  V30 8 O 5.94 -1.54 0 0
M  V30 9 S 5.94 0 0 0
M  V30 10 O 5.94 1.54 0 0
M  V30 11 O 7.48 -0 0 0
M  V30 12 O 4.4 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 2 9 11
M  V30 10 1 9 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2574927435

>  <MW>
199.038

>  <MW (desalted)>
101.11

>  <ClogP>
-2.571

>  <logS>
0.708

>  <HBD>
5

>  <HBA>
5

>  <TPSA>
111.77

>  <RotBonds>
0

>  <CAS>
6945-23-9

>  <Description>
Biguanide has been investigated for the treatment of Diabetes Mellitus.

>  <EBC_ID>
EBC-28040

>  <IUPAC Name>
carbamimidamidomethanimidamide; sulfuric acid

$$$$
Chlormethiazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0598 3.62 0 0
M  V30 2 C 1.0598 2.08 0 0
M  V30 3 N 2.3057 1.1748 0 0
M  V30 4 C 1.8298 -0.2898 0 0
M  V30 5 S 0.2898 -0.2898 0 0
M  V30 6 C -0.1861 1.1748 0 0
M  V30 7 C -1.6507 1.6507 0 0
M  V30 8 C -1.9709 3.157 0 0
M  V30 9 Cl -3.4355 3.6329 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z945806150

>  <MW>
161.007

>  <MW (desalted)>
161.652

>  <ClogP>
1.676

>  <logS>
-2.03

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
12.89

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
IC50  0.96 ?M | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | stimulation rate  100 % | IC50  19 ?M

>  <CAS>
533-45-9

>  <Description>
Chlormethiazole is an potent and orally active GABAA agonist. It inhibits cytochrome P450 isoform CYP2E. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus.

>  <EBC_ID>
EBC-00014

>  <IUPAC Name>
5-(2-chloroethyl)-4-methyl-1,3-thiazole

>  <Main Tar all refs>
Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430 | J. Med. Chem., 2012, vol. 55, # 15, p. 6784 - 6801 | Drug Metab. Dispos., 2016, vol. 44, # 8, p. 1424 - 1430

>  <Main tar all>
CYP2E1 pX=6.02 | CYP1A2 pX=6.0 | Cytochrome P450 2B6 pX=6.0 | Cytochrome P450 2C19 pX=6.0 | Cytochrome P450 2C8 pX=6.0 | Cytochrome P450 2C9 pX=6.0 | Cytochrome P450 2D6 pX=6.0 | Cytochrome P450 3A4 pX=6.0 | GABAA receptor pX=5.58 | CYP2A7 pX=4.72

$$$$
Deferiprone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 O 4.001 2.31 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 O 4.001 -0.77 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 0 0 0 0
M  V30 9 N 0 1.54 0 0
M  V30 10 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255390865

>  <MW>
139.063

>  <MW (desalted)>
139.152

>  <ClogP>
-0.903

>  <logS>
0.631

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
40.54

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Substrate

>  <Activity coefficients and valu>
inhibition percentage  97 % | IC50  3.87 ?M | IC50  4.2 ?M | inhibition percentage  84 % | inhibition rate Active   | inhibition rate Active   | inhibition rate Active   | IC50 = 30 ?M | IC50  30 ?M | IC50 = 40 ?M | EC50 = 64 ?M | EC50 = 64 ?M | metabolite formation rate Active

>  <CAS>
30652-11-0

>  <Description>
Deferiprone is an iron chelator. It is used to treat patients with transfusional iron overload caused by thalassemia syndromes.

>  <EBC_ID>
EBC-04014

>  <IUPAC Name>
3-hydroxy-1,2-dimethyl-1,4-dihydropyridin-4-one

>  <Main Tar all refs>
BioMetals, 2010, vol. 23, # 2, p. 231 - 245 | ACS Chem. Biol., 2019, vol. 14, # 8, p. 1737 - 1750 | GEORGIA INSTITUTE OF TECHNOLOGY - WO2019/183197, 2019, A1 | BioMetals, 2010, vol. 23, # 2, p. 231 - 245 | GOVERNMENT OF THE UNITED STATES - WO2022/251679, 2022, A1 | GOVERNMENT OF THE UNITED STATES - WO2022/251679, 2022, A1 | GOVERNMENT OF THE UNITED STATES - WO2022/251679, 2022, A1 | Curr. Med. Chem., 2013, vol. 20, # 21, p. 2697 - 2711 | J. Inorg. Biochem., 2022, vol. 234 | Curr. Med. Chem., 2013, vol. 20, # 21, p. 2697 - 2711 | Bioorg. Med. Chem., 2011, vol. 19, # 3, p. 1285 - 1297 | Bioorg. Med. Chem., 2011, vol. 19, # 3, p. 1285 - 1297 | Xenobiotica, 2021, vol. 51, # 11, p. 1282 - 1291

>  <Main tar all>
Serum albumin pX=5.5 | Lysine-specific demethylase 4A pX=5.41 | Lysine-specific demethylase 6A pX=5.38 | Alkaline phosphatase pX=4.94 | CoV Non-structural protein 8 pX=4.6 | Non-structural protein NSP7 superfamily, coronavirus pX=4.6 | Replicase polyprotein 1ab pX=4.6 | CaS receptor pX=4.52 | catechol oxidase pX=4.52 | Egl nine homolog 1 pX=4.4 | Lipoxygenase 1 pX=4.19 | Seed linoleate 13S-lipoxygenase-1 pX=4.19 | Cytochrome P450 2A6 pX=4.0

$$$$
Eflornithine monohydrochloride monohydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 N -2.2526 -10.3674 0 0
M  V30 4 C -2.2526 -8.8274 0 0
M  V30 5 C -0.9189 -8.0574 0 0
M  V30 6 C -0.9189 -6.5174 0 0
M  V30 7 C 0.4148 -5.7474 0 0
M  V30 8 N 1.1848 -7.081 0 0
M  V30 9 C 1.7485 -4.9774 0 0
M  V30 10 F 1.7485 -3.4374 0 0
M  V30 11 F 3.0821 -5.7474 0 0
M  V30 12 C -0.3552 -4.4137 0 0
M  V30 13 O 0.4148 -3.08 0 0
M  V30 14 O -1.8952 -4.4137 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 7 9
M  V30 7 1 9 10
M  V30 8 1 9 11
M  V30 9 1 7 12
M  V30 10 2 12 13
M  V30 11 1 12 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1550675464

>  <MW>
236.074

>  <MW (desalted)>
182.168

>  <ClogP>
-1.843

>  <logS>
-1.06

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
89.34

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 39000 nM

>  <CAS>
96020-91-6

>  <Description>
Eflornithine is a medication used topically to reduce unwanted facial hair growth in women. The postulated mechanism of action is through irreversible inhibition of ornithine decarboxylase (ODC) in the skin.

>  <EBC_ID>
EBC-14432

>  <IUPAC Name>
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrate hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1983, vol. 26, # 11, p. 1551 - 1556

>  <Main tar all>
Ornithine decarboxylase pX=4.41

$$$$
Theobromine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.6497 -4.0133 0 0
M  V30 2 N 2.1256 -2.5487 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 N 2.1256 -0.0569 0 0
M  V30 5 C 3.5902 -0.5328 0 0
M  V30 6 N 4.9239 0.2372 0 0
M  V30 7 C 4.9239 1.7772 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 O 7.5913 0.2372 0 0
M  V30 10 N 6.2576 -2.0728 0 0
M  V30 11 C 4.9239 -2.8428 0 0
M  V30 12 O 4.9239 -4.3828 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 2 13
M  V30 14 2 5 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56347209

>  <MW>
180.065

>  <MW (desalted)>
180.164

>  <ClogP>
-0.672

>  <logS>
-1.39

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
67.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
inhibition percentage  89 % | IC50 = 50 ?M | Ki (inhibition constant)  68000 nM | Ki (inhibition constant)  68000 nM | percentage decrease  55 % | inhibition percentage  51 % | Ki (inhibition constant)  130000 nM | Ki (inhibition constant)  130 ?M | IC50  138.9 ?M | Ki (inhibition constant) = 187000 nM | Ki (inhibition constant) = 187000 nM | Km (Michaelis constant) = 295 ?M

>  <CAS>
83-67-0

>  <Description>
Theobromine is the principle alkaloid in Theobroma cacao and other plants. It is a xanthine alkaloid that is used as a bronchodilator and as a vasodilator. Theobromine is used as a vasodilator, a diuretic, and heart stimulant. Theobromine acts as antagonist at adenosine-receptors.

>  <EBC_ID>
EBC-13222

>  <IUPAC Name>
3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
BIOCHEM. PHARMACOL., 1983, vol. 32, # 18, p. 2832 - 2834 | Curr. Top. Med. Chem., 2012, vol. 12, # 13, p. 1392 - 1407 | PROC. NATL. ACAD. SCI. U. S. A., 1983, vol. 80, # 7 I, p. 2077 - 2080 | PROC. NATL. ACAD. SCI. U. S. A., 1983, vol. 80, # 7 I, p. 2077 - 2080 | Eur. J. Pharmacol., 2014, vol. 745, p. 249 - 253 | NETHERLANDS ORGANISATION FOR SCIENTIFIC RESEARCH - WO2006/24545, 2006, A1 | PROC. NATL. ACAD. SCI. U. S. A., 1980, vol. 77, # 9 II, p. 5547 - 5551 | BIOCHEM. PHARMACOL., 1981, vol. 30, # 4, p. 325 - 333 | Biochim. Biophys. Acta, 2005, vol. 1714, p. 85 | GOVERNMENT OF THE UNITED STATES - WO1995/2604, 1995, A1 | GOVERNMENT OF THE UNITED STATES - WO1995/2604, 1995, A1 | Drug Metab. Dispos., 2011, vol. 39, # 1, p. 4 - 7

>  <Main tar all>
Ecto-5'-Nucleotidase pX=4.91 | phosphodiesterase 4 pX=4.3 | A1 receptor pX=4.17 | A1 receptor pX=4.17 | ABCC5 pX=4.09 | poly(ADP-ribose) polymerase 1 pX=4.02 | A2A receptor pX=3.89 | Adenosine receptor pX=3.89 | Organic anion transporter 1 pX=3.86 | A2A receptor pX=3.73 | A2A receptor pX=3.73 | CYP1A2 pX=3.53

$$$$
Meglumine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.5963 4.771 0 0
M  V30 2 N 6.93 4.001 0 0
M  V30 3 C 8.2637 4.771 0 0
M  V30 4 C 9.5974 4.001 0 0 CFG=2
M  V30 5 O 9.5974 2.461 0 0
M  V30 6 C 10.931 4.771 0 0 CFG=1
M  V30 7 O 10.931 6.311 0 0
M  V30 8 C 12.2647 4.001 0 0 CFG=2
M  V30 9 O 12.2647 2.461 0 0
M  V30 10 C 13.5984 4.771 0 0 CFG=2
M  V30 11 O 13.5984 6.311 0 0
M  V30 12 C 14.9321 4.001 0 0
M  V30 13 O 16.2658 4.771 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255485274

>  <MW>
195.111

>  <MW (desalted)>
195.214

>  <ClogP>
-1.565

>  <logS>
1.219

>  <HBD>
6

>  <HBA>
6

>  <TPSA>
113.18

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | inhibition rate Active   | inhibition rate Active   | inhibition rate Active   | inhibition rate Active   | inhibition rate Active   | inhibition rate Active

>  <CAS>
6284-40-8

>  <Description>
Meglumine is a poorly metabolized derivative of sorbitol that has regulatory acceptance as a benign excipient for drug formulation to increase aqueous solubility of lipophilic drugs and improve their absorption. In conjugated form meglumine is used as a contrast agent.

>  <EBC_ID>
EBC-26175

>  <IUPAC Name>
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol

>  <Main Tar all refs>
Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207 | Mol. Pharm., 2021, vol. 18, # 6, p. 2198 - 2207

>  <Main tar all>
CHT pX=2.99 | Organic cation transporter 1 pX=2.99 | Organic cation transporter 2 pX=2.99 | Plasma membrane monoamine transporter pX=2.99 | Pyrilamine-sensitive proton-coupled organic cation antiporter pX=2.99 | SERT pX=2.99 | Thiamine transporter 2 pX=2.99

$$$$
Benzoin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -3.08 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 O 4.001 -2.31 0 0
M  V30 5 C 2.6674 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 C 2.6674 -7.7 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 16 C 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57160197

>  <MW>
212.084

>  <MW (desalted)>
212.244

>  <ClogP>
2.379

>  <logS>
-3.48

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  2220 nM | Ki (inhibition constant)  7250 nM

>  <CAS>
119-53-9

>  <Description>
Benzoin is a white crystalline compound prepared by condensation of benzaldehyde in potassium cyanide, and is used in organic syntheses. Benzoin is an FDA-approved colour additive used for marking fruits and vegetables.

>  <EBC_ID>
EBC-14458

>  <IUPAC Name>
2-hydroxy-1,2-diphenylethan-1-one

>  <Main Tar all refs>
J. Med. Chem., 2005, vol. 48, # 17, p. 5543 - 5550 | J. Med. Chem., 2005, vol. 48, # 17, p. 5543 - 5550

>  <Main tar all>
Carboxylesterase 2 pX=5.65 | carboxylesterase 1 pX=5.14

$$$$
Naphazoline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 N 1.1727 -6.9216 0 0
M  V30 4 C -0.3336 -7.2417 0 0
M  V30 5 C -1.1036 -5.9081 0 0
M  V30 6 N -0.0732 -4.7636 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 1.3337 -0.77 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 C 6.6684 -2.31 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 1 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 7 16
M  V30 18 1 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56762888

>  <MW>
210.116

>  <MW (desalted)>
210.274

>  <ClogP>
3.826

>  <logS>
-2.93

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.39

>  <RotBonds>
2

>  <Action on targets>
Agonist | Agonist

>  <Activity coefficients and valu>
EC50  1.57E-11 M | EC50  2.31E-10 M

>  <CAS>
835-31-4

>  <Description>
Naphazoline is a sympathomimetic alpha adrenergic agonist. Naphazoline?is a sympathomimetic vasoconstrictor used for the symptomatic relief of redness and itching of the eye, and nasal congestion.

>  <EBC_ID>
EBC-06528

>  <IUPAC Name>
2-[(naphthalen-1-yl)methyl]-4,5-dihydro-1H-imidazole

>  <Main Tar all refs>
Int. J. Mol. Sci., 2022, vol. 23, # 23 | Int. J. Mol. Sci., 2022, vol. 23, # 23

>  <Main tar all>
Octopamine receptor beta-2R pX=10.8 | Octopamine receptor beta-1R pX=9.64

$$$$
Tizanidine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 9.6709 -0.1566 0 0
M  V30 3 C 8.3372 -0.9266 0 0
M  V30 4 C 8.3372 -2.4666 0 0
M  V30 5 C 7.0035 -3.2366 0 0
M  V30 6 C 5.6698 -2.4666 0 0
M  V30 7 N 4.2052 -2.9424 0 0
M  V30 8 S 3.3 -1.6966 0 0
M  V30 9 N 4.2052 -0.4507 0 0
M  V30 10 C 5.6698 -0.9266 0 0
M  V30 11 C 7.0035 -0.1566 0 0
M  V30 12 N 7.0035 1.3834 0 0
M  V30 13 C 8.3372 2.1534 0 0
M  V30 14 N 8.4981 3.685 0 0
M  V30 15 C 10.0045 4.0052 0 0
M  V30 16 C 10.7745 2.6715 0 0
M  V30 17 N 9.744 1.5271 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 2 3 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 13 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z594284192

>  <MW>
288.996

>  <MW (desalted)>
253.711

>  <ClogP>
2.093

>  <logS>
-3.216

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
62.2

>  <RotBonds>
1

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  1.2 nM | Ki (inhibition constant)  28.3 nM

>  <CAS>
64461-82-1

>  <Description>
Tizanidine hydrochloride is an alpha-2-adrenergic receptor agonist. It inhibits neurotransmitter release from CNS noradrenergic neurons. Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities.

>  <EBC_ID>
EBC-04245

>  <IUPAC Name>
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride

>  <Main Tar all refs>
Mol. Pharmacol., 2017, vol. 92, # 3, p. 297 - 309 | Bioorg. Med. Chem., 2008, vol. 16, # 15, p. 7134 - 7140

>  <Main tar all>
alpha-like octopamine receptor pX=8.92 | Nischarin pX=7.55

$$$$
Tolbutamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -8.47 0 0
M  V30 2 C 2.6674 -9.24 0 0
M  V30 3 C 4.001 -8.47 0 0
M  V30 4 C 5.3347 -9.24 0 0
M  V30 5 N 6.6684 -8.47 0 0
M  V30 6 C 8.0021 -9.24 0 0
M  V30 7 O 8.0021 -10.78 0 0
M  V30 8 N 9.3358 -8.47 0 0
M  V30 9 S 10.6694 -9.24 0 0
M  V30 10 O 9.8994 -10.5737 0 0
M  V30 11 O 11.4394 -7.9063 0 0
M  V30 12 C 12.0031 -10.01 0 0
M  V30 13 C 13.3368 -9.24 0 0
M  V30 14 C 14.6705 -10.01 0 0
M  V30 15 C 14.6705 -11.55 0 0
M  V30 16 C 16.0041 -12.32 0 0
M  V30 17 C 13.3368 -12.32 0 0
M  V30 18 C 12.0031 -11.55 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 12 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z44591715

>  <MW>
270.104

>  <MW (desalted)>
270.348

>  <ClogP>
2.497

>  <logS>
-3.37

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
75.27

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  4.58 nM | Kd (dissociation constant) > 100 nM | IC50 < 100 nM

>  <CAS>
64-77-7

>  <Description>
Tolbutamide is an oral antihyperglycemic agent. It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating ? cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. It is used for treatment of NIDDM in conjunction with diet and exercise.

>  <EBC_ID>
EBC-11053

>  <IUPAC Name>
3-butyl-1-(4-methylbenzenesulfonyl)urea

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1

>  <Main tar all>
sepiapterin reductase pX=8.34 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=7.0 | Kir6.2 pX=7.0

$$$$
Pinacidil hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 C 7.0674 2.6522 0 0
M  V30 3 C 7.0674 1.1122 0 0
M  V30 4 N 8.401 0.3422 0 0
M  V30 5 C 9.7347 1.1122 0 0
M  V30 6 N 11.0684 0.3422 0 0
M  V30 7 C 11.0684 -1.1978 0 0
M  V30 8 C 12.4021 -1.9678 0 0
M  V30 9 C 12.4021 -3.5078 0 0
M  V30 10 N 11.0684 -4.2778 0 0
M  V30 11 C 9.7347 -3.5078 0 0
M  V30 12 C 9.7347 -1.9678 0 0
M  V30 13 N 9.7347 2.6522 0 0
M  V30 14 C 11.0684 3.4222 0 0
M  V30 15 N 12.4021 4.1922 0 0
M  V30 16 C 5.7337 0.3422 0 0
M  V30 17 C 4.4 -0.4278 0 0
M  V30 18 C 4.9637 1.6759 0 0
M  V30 19 C 6.5037 -0.9915 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7 CFG=2
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 7 12
M  V30 12 1 5 13
M  V30 13 1 13 14
M  V30 14 3 14 15
M  V30 15 1 3 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1617901125

>  <MW>
263.339

>  <MW (desalted)>
245.323

>  <ClogP>
1.348

>  <logS>
-1.95

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
73.1

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
concentration (parameter) = 1000 nM

>  <CAS>
85371-64-8

>  <Description>
Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. The above processes result in reduced blood pressure.

>  <EBC_ID>
EBC-12121

>  <IUPAC Name>
N'-cyano-N-(3,3-dimethylbutan-2-yl)-N''-(pyridin-4-yl)guanidine hydrate

>  <Main Tar all refs>
OMEROS CORP - WO2004/43479, 2004, A1

>  <Main tar all>
Kv9.1 pX=6.0

$$$$
Doxepin hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 6.0592 0 0
M  V30 3 N 5.7337 4.5192 0 0
M  V30 4 C 4.4 3.7492 0 0
M  V30 5 C 7.0674 3.7492 0 0
M  V30 6 C 7.0674 2.2092 0 0
M  V30 7 C 8.401 1.4392 0 0
M  V30 8 C 8.401 -0.1008 0 0
M  V30 9 C 9.7885 -0.769 0 0
M  V30 10 C 10.9174 0.2784 0 0
M  V30 11 C 12.389 -0.1755 0 0
M  V30 12 C 12.7317 -1.6769 0 0
M  V30 13 C 11.6028 -2.7243 0 0
M  V30 14 C 10.1312 -2.2704 0 0
M  V30 15 C 9.171 -3.4744 0 0
M  V30 16 O 7.631 -3.4744 0 0
M  V30 17 C 6.6709 -2.2704 0 0
M  V30 18 C 5.1993 -2.7243 0 0
M  V30 19 C 4.0704 -1.6769 0 0
M  V30 20 C 4.4131 -0.1755 0 0
M  V30 21 C 5.8846 0.2784 0 0
M  V30 22 C 7.0135 -0.769 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 7 6 CFG=2
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 8 22
M  V30 23 2 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557407006

>  <MW>
315.139

>  <MW (desalted)>
279.376

>  <ClogP>
4.092

>  <logS>
-4.309

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  18 nM | Ki (inhibition constant)  115 nM | Ki (inhibition constant)  1.79E-07 M

>  <CAS>
1229-29-4

>  <Description>
Doxepin is a psychotropic agent used for the treatment of depression, anxiety, manic-depressive disorder, and insomnia. Doxepin is known to be a selective histamine H1 receptor blocker.

>  <EBC_ID>
EBC-13878

>  <IUPAC Name>
dimethyl(3-{9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}propyl)amine hydrochloride

>  <Main Tar all refs>
NEUROPHARMACOLOGY, 1996, vol. 35, # 1, p. 63 - 70 | J. PHARMACOL. EXP. THER., 1987, vol. 242, # 1, p. 364 - 371 | BR. J. PHARMACOL., 1980, vol. 68, # 3, p. 541 - 549

>  <Main tar all>
NET pX=7.74 | SERT pX=6.94 | mAChR pX=6.75

$$$$
Amiloxate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 10.78 0 0
M  V30 2 O -4.001 11.55 0 0
M  V30 3 C -2.6674 10.78 0 0
M  V30 4 C -1.3337 11.55 0 0
M  V30 5 C 0 10.78 0 0
M  V30 6 C 0 9.24 0 0
M  V30 7 C 1.3337 8.47 0 0
M  V30 8 C 1.3337 6.93 0 0
M  V30 9 C 2.6674 6.16 0 0
M  V30 10 O 2.6674 4.62 0 0
M  V30 11 O 4.001 6.93 0 0
M  V30 12 C 5.3347 6.16 0 0
M  V30 13 C 6.6684 6.93 0 0
M  V30 14 C 8.0021 6.16 0 0
M  V30 15 C 9.3358 6.93 0 0
M  V30 16 C 8.0021 4.62 0 0
M  V30 17 C -1.3337 8.47 0 0
M  V30 18 C -2.6674 9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=2
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 6 17
M  V30 17 1 17 18
M  V30 18 2 3 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z212714982

>  <MW>
248.318

>  <MW (desalted)>
248.318

>  <ClogP>
4.37

>  <logS>
-3.826

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
35.53

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  32.8 %

>  <CAS>
71617-10-2

>  <Description>
Amiloxate is an EMA-approved chemical UV-filter. It is indicated as an active sunscreen agent. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity

>  <EBC_ID>
EBC-80047

>  <IUPAC Name>
3-methylbutyl 3-(4-methoxyphenyl)prop-2-enoate

>  <Main Tar all refs>
Beiersdorf (in: maxingvest); MAXINGVEST AG - US2016/15614, 2016, A1

>  <Main tar all>
tyrosinase pX=3.35

$$$$
Folic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -22.6725 -0.77 0 0
M  V30 2 C -21.3389 -0 0 0
M  V30 3 N -21.3389 1.54 0 0
M  V30 4 C -20.0052 2.31 0 0
M  V30 5 O -20.0052 3.85 0 0
M  V30 6 C -18.6715 1.54 0 0
M  V30 7 N -17.3378 2.31 0 0
M  V30 8 C -16.0041 1.54 0 0
M  V30 9 C -14.6705 2.31 0 0
M  V30 10 N -14.6705 3.85 0 0
M  V30 11 C -13.3368 4.62 0 0
M  V30 12 C -13.3368 6.16 0 0
M  V30 13 C -12.0031 6.93 0 0
M  V30 14 C -10.6694 6.16 0 0
M  V30 15 C -10.6694 4.62 0 0
M  V30 16 C -12.0031 3.85 0 0
M  V30 17 C -9.3358 6.93 0 0
M  V30 18 O -9.3358 8.47 0 0
M  V30 19 N -8.0021 6.16 0 0
M  V30 20 C -6.6684 6.93 0 0 CFG=1
M  V30 21 C -5.3347 6.16 0 0
M  V30 22 C -4.001 6.93 0 0
M  V30 23 C -2.6674 6.16 0 0
M  V30 24 O -1.3337 6.93 0 0
M  V30 25 O -2.6674 4.62 0 0
M  V30 26 C -6.6684 8.47 0 0
M  V30 27 O -5.3347 9.24 0 0
M  V30 28 O -8.0021 9.24 0 0
M  V30 29 C -16.0041 0 0 0
M  V30 30 N -17.3378 -0.77 0 0
M  V30 31 C -18.6715 -0 0 0
M  V30 32 N -20.0052 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 14 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 20 19 CFG=3
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 20 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 8 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 2 6 31
M  V30 33 1 31 32
M  V30 34 2 2 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2042042504

>  <MW>
441.397

>  <MW (desalted)>
441.397

>  <ClogP>
-0.725

>  <logS>
-3.222

>  <HBD>
6

>  <HBA>
12

>  <TPSA>
213.54

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  7.7  | Kd (dissociation constant)  64 nM | pKi  7

>  <CAS>
59-30-3

>  <Description>
Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis.

>  <EBC_ID>
EBC-14140

>  <IUPAC Name>
(2S)-2-[(4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid

>  <Main Tar all refs>
Chem. Rev., 1984, vol. 84, # 4, p. 333 - 407 | ACS Chem. Biol., 2016, vol. 11, # 1, p. 211 - 221 | Chem. Rev., 1984, vol. 84, # 4, p. 333 - 407

>  <Main tar all>
dihydrofolate reductase pX=7.7 | Avidin 1 pX=7.19 | dihydrofolate reductase pX=7.0

$$$$
Irinotecan hydrochloirde
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 17.5599 3.647 0 0
M  V30 3 C 19.0663 3.3268 0 0
M  V30 4 C 19.5422 1.8622 0 0
M  V30 5 C 21.0485 1.542 0 0
M  V30 6 C 22.2944 2.4472 0 0
M  V30 7 N 23.5403 1.542 0 0
M  V30 8 C 23.0644 0.0773 0 0
M  V30 9 C 24.0949 -1.0671 0 0
M  V30 10 C 25.6012 -0.7469 0 0
M  V30 11 C 26.0771 0.7177 0 0
M  V30 12 C 27.5834 1.0379 0 0
M  V30 13 O 28.6139 -0.1065 0 0
M  V30 14 C 28.138 -1.5712 0 0
M  V30 15 O 29.1685 -2.7156 0 0
M  V30 16 C 26.6317 -1.8914 0 0 CFG=1
M  V30 17 O 26.8991 -3.408 0 0
M  V30 18 C 25.5239 -2.9611 0 0
M  V30 19 C 24.0435 -2.5366 0 0
M  V30 20 C 25.0466 1.8622 0 0
M  V30 21 O 25.5225 3.3268 0 0
M  V30 22 C 21.5244 0.0773 0 0
M  V30 23 N 20.4939 -1.0671 0 0
M  V30 24 C 18.9876 -0.7469 0 0
M  V30 25 C 17.9571 -1.8914 0 0
M  V30 26 C 16.4508 -1.5712 0 0
M  V30 27 C 15.9749 -0.1065 0 0
M  V30 28 O 14.4685 0.2136 0 0
M  V30 29 C 13.4381 -0.9308 0 0
M  V30 30 O 13.914 -2.3954 0 0
M  V30 31 N 11.9317 -0.6106 0 0
M  V30 32 C 10.9013 -1.7551 0 0
M  V30 33 C 9.3949 -1.4349 0 0
M  V30 34 C 8.919 0.0298 0 0
M  V30 35 C 9.9495 1.1742 0 0
M  V30 36 C 11.4559 0.854 0 0
M  V30 37 N 7.4127 0.3499 0 0
M  V30 38 C 6.3822 -0.7945 0 0
M  V30 39 C 4.8759 -0.4743 0 0
M  V30 40 C 4.4 0.9903 0 0
M  V30 41 C 5.4305 2.1347 0 0
M  V30 42 C 6.9368 1.8146 0 0
M  V30 43 C 17.0054 1.0379 0 0
M  V30 44 C 18.5117 0.7177 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 16 14
M  V30 15 1 16 10
M  V30 16 1 16 17 CFG=1
M  V30 17 1 16 18 CFG=3
M  V30 18 1 18 19
M  V30 19 1 11 20
M  V30 20 1 7 20
M  V30 21 2 20 21
M  V30 22 1 8 22
M  V30 23 2 5 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 31 36
M  V30 39 1 34 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 1 40 41
M  V30 44 1 41 42
M  V30 45 1 37 42
M  V30 46 2 27 43
M  V30 47 1 43 44
M  V30 48 2 4 44
M  V30 49 1 24 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541760033

>  <MW>
623.139

>  <MW (desalted)>
586.678

>  <ClogP>
2.728

>  <logS>
-6.5

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
112.51

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | - | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  1.75 ?M | IC50  2.3 - 3.2 ?g/ml | Km (Michaelis constant) = 6200 nM | IC50  7.1 ?M | Km (Michaelis constant)  29 ?M

>  <CAS>
100286-90-6

>  <Description>
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death.

>  <EBC_ID>
EBC-12141

>  <IUPAC Name>
(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride

>  <Main Tar all refs>
Cancer Res., 2009, vol. 69, # 4, p. 1494 - 1501 | Front. Pharmacol., 2022, vol. 13 | Mol. Pharmacol., 2001, vol. 60, # 2, p. 355 - 362 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Clin. Cancer Res., 2000, vol. 6, # 5, p. 2012 - 2020

>  <Main tar all>
Organic cation transporter 3 pX=5.76 | topoisomerase (DNA) I mitochondrial pX=5.43 | Carboxylesterase pX=5.21 | Organic cation/carnitine transporter 2 pX=5.15 | Cytochrome P450 3A4 pX=4.54

$$$$
Cinacalcet hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.8547 2.8135 0 0
M  V30 3 C 8.8547 1.2735 0 0 CFG=1
M  V30 4 N 10.1884 0.5035 0 0
M  V30 5 C 11.5221 1.2735 0 0
M  V30 6 C 12.8558 0.5035 0 0
M  V30 7 C 14.1894 1.2735 0 0
M  V30 8 C 15.5231 0.5035 0 0
M  V30 9 C 16.8568 1.2735 0 0
M  V30 10 C 18.1905 0.5035 0 0
M  V30 11 C 18.1905 -1.0365 0 0
M  V30 12 C 16.8568 -1.8065 0 0
M  V30 13 C 15.5231 -1.0365 0 0
M  V30 14 C 16.8568 -3.3465 0 0
M  V30 15 F 16.8568 -4.8865 0 0
M  V30 16 F 18.3968 -3.3465 0 0
M  V30 17 F 15.3168 -3.3465 0 0
M  V30 18 C 7.521 0.5035 0 0
M  V30 19 C 7.521 -1.0365 0 0
M  V30 20 C 6.1874 -1.8065 0 0
M  V30 21 C 4.8537 -1.0365 0 0
M  V30 22 C 4.8537 0.5035 0 0
M  V30 23 C 3.52 1.2735 0 0
M  V30 24 C 3.52 2.8135 0 0
M  V30 25 C 4.8537 3.5835 0 0
M  V30 26 C 6.1874 2.8135 0 0
M  V30 27 C 6.1874 1.2735 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=1
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 8 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 3 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 18 27
M  V30 28 1 22 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977003

>  <MW>
393.873

>  <MW (desalted)>
357.412

>  <ClogP>
6.352

>  <logS>
-6.76

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
12.03

>  <RotBonds>
7

>  <Action on targets>
Allosteric Modulator | Inhibitor

>  <Activity coefficients and valu>
pEC50  7.7  | IC50 ~ 70 nM

>  <CAS>
364782-34-3

>  <Description>
Cinacalcet is a calcimimetic and an allosteric agonist of the calcium-sensing receptor. Cinacalcet has been used in the treatment of secondary hyperparathyroidism due to end-stage renal disease and hypercalcemia in patients with parathyroid carcinoma.

>  <EBC_ID>
EBC-07704

>  <IUPAC Name>
[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2010, vol. 20, # 19, p. 5918 - 5921 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021688, Owner: AMGEN, Number: 000, Revision: 08.03.2004 00:00:00, 2004

>  <Main tar all>
CaS receptor pX=7.7 | Cytochrome P450 2D6 pX=7.15

$$$$
Stavudine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1992 8.895 0 0
M  V30 2 C -1.1345 8.125 0 0
M  V30 3 C -1.1345 6.585 0 0
M  V30 4 N -2.4682 5.815 0 0
M  V30 5 C -2.4682 4.275 0 0 CFG=2
M  V30 6 O -1.2223 3.3698 0 0
M  V30 7 C -1.6982 1.9052 0 0 CFG=2
M  V30 8 C -0.793 0.6593 0 0
M  V30 9 O -1.4194 -0.7476 0 0
M  V30 10 C -3.2382 1.9052 0 0
M  V30 11 C -3.7141 3.3698 0 0
M  V30 12 C -3.8019 6.585 0 0
M  V30 13 O -5.1355 5.815 0 0
M  V30 14 N -3.8019 8.125 0 0
M  V30 15 C -2.4682 8.895 0 0
M  V30 16 O -2.4682 10.435 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 10 11
M  V30 11 1 5 11
M  V30 12 1 4 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 2 15
M  V30 17 2 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530425068

>  <MW>
224.213

>  <MW (desalted)>
224.213

>  <ClogP>
-0.488

>  <logS>
-1.4

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
78.87

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.4 nM

>  <CAS>
3056-17-5

>  <Description>
Stavudine iis a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.

>  <EBC_ID>
EBC-07706

>  <IUPAC Name>
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2001, vol. 45, # 7, p. 2144 - 2146

>  <Main tar all>
RNA-directed DNA polymerase pX=9.4

$$$$
Etoricoxib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 1.54 0 0
M  V30 2 C 5.3347 0 0 0
M  V30 3 C 6.6684 -0.77 0 0
M  V30 4 C 6.6684 -2.31 0 0
M  V30 5 C 5.3347 -3.08 0 0
M  V30 6 C 4.001 -2.31 0 0
M  V30 7 N 4.001 -0.77 0 0
M  V30 8 C 5.3347 -4.62 0 0
M  V30 9 N 6.6684 -5.39 0 0
M  V30 10 C 6.6684 -6.93 0 0
M  V30 11 C 5.3347 -7.7 0 0
M  V30 12 Cl 5.3347 -9.24 0 0
M  V30 13 C 4.001 -6.93 0 0
M  V30 14 C 4.001 -5.39 0 0
M  V30 15 C 2.6674 -4.62 0 0
M  V30 16 C 1.3337 -5.39 0 0
M  V30 17 C 0 -4.62 0 0
M  V30 18 C 0 -3.08 0 0
M  V30 19 C 1.3337 -2.31 0 0
M  V30 20 C 2.6674 -3.08 0 0
M  V30 21 S -1.3337 -2.31 0 0
M  V30 22 O -2.6674 -1.54 0 0
M  V30 23 O -0.5637 -0.9763 0 0
M  V30 24 C -2.1037 -3.6437 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 13 14
M  V30 15 2 8 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 18 21
M  V30 24 2 21 22
M  V30 25 2 21 23
M  V30 26 1 21 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216907255

>  <MW>
358.842

>  <MW (desalted)>
358.842

>  <ClogP>
2.351

>  <logS>
-4.408

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
59.92

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 <= 0.1 nM

>  <CAS>
202409-33-4

>  <Description>
Etoricoxib is a COX-2 selective inhibito. Etoricoxib is a non steroidal anti-inflammatory agent, has antipyretic, analgesic, and potential antineoplastic properties.

>  <EBC_ID>
EBC-00675

>  <IUPAC Name>
5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-2,3'-bipyridine

>  <Main Tar all refs>
MERCK & CO INC - WO2003/86314, 2003, A2

>  <Main tar all>
Insulin receptor pX=10.0

$$$$
Tetracaine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.9047 0 0
M  V30 3 C 5.7337 1.1347 0 0
M  V30 4 C 7.0674 1.9047 0 0
M  V30 5 C 8.401 1.1347 0 0
M  V30 6 N 9.7347 1.9047 0 0
M  V30 7 C 11.0684 1.1347 0 0
M  V30 8 C 12.4021 1.9047 0 0
M  V30 9 C 13.7358 1.1347 0 0
M  V30 10 C 13.7358 -0.4053 0 0
M  V30 11 C 12.4021 -1.1753 0 0
M  V30 12 C 11.0684 -0.4053 0 0
M  V30 13 C 15.0694 -1.1753 0 0
M  V30 14 O 15.0694 -2.7153 0 0
M  V30 15 O 16.4031 -0.4053 0 0
M  V30 16 C 17.7368 -1.1753 0 0
M  V30 17 C 19.0705 -0.4053 0 0
M  V30 18 N 20.4041 -1.1753 0 0
M  V30 19 C 21.7378 -0.4053 0 0
M  V30 20 C 20.4041 -2.7153 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 7 12
M  V30 12 1 10 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516968

>  <MW>
300.16

>  <MW (desalted)>
264.363

>  <ClogP>
3.834

>  <logS>
-3.227

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
41.57

>  <RotBonds>
9

>  <Action on targets>
- | - | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Antagonist | Blocker | Blocker | Antagonist | Antagonist

>  <Activity coefficients and valu>
Kd (dissociation constant) = 310 nM | Kd (dissociation constant) = 310 nM | Kd (dissociation constant) = 310 nM | Kd (dissociation constant) = 310 nM | IC50  1E-06 M | IC50 = 1000 nM | pIC50  5.47  | pIC50  5.47  | inhibition percentage  73.6 - 73.65 % | pA2  5.35  | Kd (dissociation constant)  4.9 ?M | Kd (dissociation constant)  4.9 ?M | pA2  5.28  | Kb (antagonist dissociation constant)  6 ?M

>  <CAS>
136-47-0

>  <Description>
Tetracaine is a local anaesthetic agent used to induce local analgesia in the eyes and skin during medical procedures.

>  <EBC_ID>
EBC-28048

>  <IUPAC Name>
2-(dimethylamino)ethyl 4-(butylamino)benzoate hydrochloride

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2002, vol. 2, # 4, p. 385 - 410 | Mini-Rev. Med. Chem., 2002, vol. 2, # 4, p. 385 - 410 | Mini-Rev. Med. Chem., 2002, vol. 2, # 4, p. 385 - 410 | Mini-Rev. Med. Chem., 2002, vol. 2, # 4, p. 385 - 410 | Eur. J. Pharmacol., 1986, vol. 124, # 3, p. 291 - 298 | Mini-Rev. Med. Chem., 2002, vol. 2, # 4, p. 385 - 410 | Chem. Rev., 1991, vol. 91, # 6, p. 1109 - 1119 | Chem. Rev., 1991, vol. 91, # 6, p. 1109 - 1119 | PAIRNOMIX - WO2018/64498, 2018, A1 | Eur. J. Pharmacol., 1979, vol. 59, # 3-4, p. 195 - 210 | J. Med. Chem., 2011, vol. 54, # 13, p. 4904 - 4912 | J. Med. Chem., 2011, vol. 54, # 13, p. 4904 - 4912 | Eur. J. Pharmacol., 1979, vol. 59, # 3-4, p. 195 - 210 | BIOCHEM. PHARMACOL., 1978, vol. 27, # 16, p. 2039 - 2048

>  <Main tar all>
nicotinic acetylcholine receptor ?-like 1 pX=6.51 | nicotinic acetylcholine receptor ?-like 1 pX=6.51 | nicotinic acetylcholine receptor ?1 subunit pX=6.51 | nicotinic acetylcholine receptor ?1 subunit pX=6.51 | Voltage-gated?sodium?channel pX=6.0 | nicotinic acetylcholine receptor ?1 subunit pX=6.0 | Nav?1 pX=5.47 | Nav1.7 pX=5.47 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=5.45 | nicotinic acetylcholine receptor pX=5.35 | Cyclic nucleotide-gated cation channel (CNGA1) pX=5.31 | Cyclic nucleotide-gated cation channel (CNGB1) pX=5.31 | 5-HT receptor pX=5.28 | mAChR pX=5.22

$$$$
Butylparaben
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 C 5.3347 -7.7 0 0
M  V30 4 C 6.6684 -6.93 0 0
M  V30 5 O 8.0021 -7.7 0 0
M  V30 6 C 9.3358 -6.93 0 0
M  V30 7 O 9.3358 -5.39 0 0
M  V30 8 C 10.6694 -7.7 0 0
M  V30 9 C 12.0031 -6.93 0 0
M  V30 10 C 13.3368 -7.7 0 0
M  V30 11 C 13.3368 -9.24 0 0
M  V30 12 O 14.6705 -10.01 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 C 10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z291799028

>  <MW>
194.094

>  <MW (desalted)>
194.227

>  <ClogP>
3.572

>  <logS>
-2.46

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
5

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
percentage increase Active

>  <CAS>
94-26-8

>  <Description>
Butylparaben is an organic compound, has proven to be a highly successful antimicrobial preservative in cosmetics, also used in medication suspensions, and as a flavoring additive in food.

>  <EBC_ID>
EBC-03509

>  <IUPAC Name>
butyl 4-hydroxybenzoate

>  <Main Tar all refs>
Environ. Sci. Technol., 2017, vol. 51, # 11, p. 6452 - 6460

>  <Main tar all>
Androgen receptor pX=11.3

$$$$
Nicardipine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -1.562 0 0
M  V30 3 O 5.7337 -0.792 0 0
M  V30 4 C 5.7337 0.748 0 0
M  V30 5 O 4.4 1.518 0 0
M  V30 6 C 7.0674 1.518 0 0
M  V30 7 C 7.0674 3.058 0 0
M  V30 8 C 5.7337 3.828 0 0
M  V30 9 N 8.401 3.828 0 0
M  V30 10 C 9.7347 3.058 0 0
M  V30 11 C 9.7347 1.518 0 0
M  V30 12 C 8.401 0.748 0 0
M  V30 13 C 8.401 -0.792 0 0
M  V30 14 C 9.7347 -1.562 0 0
M  V30 15 C 9.7347 -3.102 0 0
M  V30 16 C 8.401 -3.872 0 0
M  V30 17 C 7.0674 -3.102 0 0
M  V30 18 C 7.0674 -1.562 0 0
M  V30 19 N 5.7337 -3.872 0 0 CHG=1
M  V30 20 O 5.7337 -5.412 0 0
M  V30 21 O 4.4 -3.102 0 0 CHG=-1
M  V30 22 C 11.0684 0.748 0 0
M  V30 23 O 11.0684 -0.792 0 0
M  V30 24 O 12.4021 1.518 0 0
M  V30 25 C 13.7358 0.748 0 0
M  V30 26 C 15.0694 1.518 0 0
M  V30 27 N 16.4031 0.748 0 0
M  V30 28 C 16.4031 -0.792 0 0
M  V30 29 C 17.7368 1.518 0 0
M  V30 30 C 19.0705 0.748 0 0
M  V30 31 C 20.4041 1.518 0 0
M  V30 32 C 21.7378 0.748 0 0
M  V30 33 C 21.7378 -0.792 0 0
M  V30 34 C 20.4041 -1.562 0 0
M  V30 35 C 19.0705 -0.792 0 0
M  V30 36 C 11.0684 3.828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 4 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 6 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 11 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 27 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 34 35
M  V30 36 2 30 35
M  V30 37 1 10 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551967349

>  <MW>
515.182

>  <MW (desalted)>
479.525

>  <ClogP>
5.23

>  <logS>
-4.677

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
111.01

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | Inhibitor | Blocker

>  <Activity coefficients and valu>
IC50 = 0.003 nM | Ki (inhibition constant)  0.1 nM | inhibition percentage Active

>  <CAS>
54527-84-3

>  <Description>
Nicardipine is a calcium channel blocker.

>  <EBC_ID>
EBC-12271

>  <IUPAC Name>
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride

>  <Main Tar all refs>
Eur. J. Med. Chem., 1996, vol. 31, p. 71 - 75 | Arzneimittelforschung, 1996, vol. 46, # 1, p. 15 - 24 | EUR. J. PHARMACOL., 1991, vol. 205, # 1, p. 49 - 54

>  <Main tar all>
Cav1.2 pX=11.5 | L-type calcium channel pX=10.0 | voltage-gated calcium channel pX=10.0

$$$$
Oleic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.4058 14.011 0 0
M  V30 2 C -1.0721 13.241 0 0
M  V30 3 C -1.0721 11.701 0 0
M  V30 4 C 0.2616 10.931 0 0
M  V30 5 C 0.2616 9.391 0 0
M  V30 6 C 1.5953 8.621 0 0
M  V30 7 C 1.5953 7.081 0 0
M  V30 8 C 2.929 6.311 0 0
M  V30 9 C 2.929 4.771 0 0
M  V30 10 C 4.2626 4.001 0 0
M  V30 11 C 5.5963 4.771 0 0
M  V30 12 C 6.93 4.001 0 0
M  V30 13 C 8.2637 4.771 0 0
M  V30 14 C 9.5974 4.001 0 0
M  V30 15 C 10.931 4.771 0 0
M  V30 16 C 12.2647 4.001 0 0
M  V30 17 C 13.5984 4.771 0 0
M  V30 18 C 14.9321 4.001 0 0
M  V30 19 O 16.2658 4.771 0 0
M  V30 20 O 14.9321 2.461 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2412194967

>  <MW>
282.256

>  <MW (desalted)>
282.461

>  <ClogP>
7.786

>  <logS>
-7.248

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
15

>  <Action on targets>
- | - | - | - | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 188 pM | Kd (dissociation constant) = 510 pM | Kd (dissociation constant) = 601 pM | Kd (dissociation constant) = 1.4 nM | Ki (inhibition constant)  5.9 nM

>  <CAS>
112-80-1

>  <Description>
Oleic acid is a naturally occurring fatty acid with antibacterial properties added to a variety of drug products.

>  <EBC_ID>
EBC-13253

>  <IUPAC Name>
(9Z)-octadec-9-enoic acid

>  <Main Tar all refs>
Biol. Pharm. Bull., 2009, vol. 32, # 4, p. 646 - 650 | Biol. Pharm. Bull., 2009, vol. 32, # 4, p. 646 - 650 | Biol. Pharm. Bull., 2009, vol. 32, # 4, p. 646 - 650 | Br. J. Pharmacol., 2006, vol. 149, # 1, p. 73 - 81 | Biochemistry, 1999, vol. 38, # 1, p. 185 - 190

>  <Main tar all>
?1-adrenoceptor pX=9.73 | mAChR pX=9.29 | Cav1.2 pX=9.22 | Serum albumin pX=8.85 | Peroxisome proliferator-activated receptor-? pX=8.23

$$$$
Reserpine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.7726 -3.7944 0 0
M  V30 2 O 3.2646 -5.2482 0 0
M  V30 3 C 4.2696 -6.415 0 0 CFG=1
M  V30 4 C 3.7616 -7.8688 0 0 CFG=1
M  V30 5 C 4.7666 -9.0356 0 0
M  V30 6 C 6.2796 -8.7487 0 0 CFG=2
M  V30 7 C 7.2847 -9.9155 0 0
M  V30 8 N 8.7977 -9.6286 0 0
M  V30 9 C 9.8027 -10.7954 0 0
M  V30 10 C 11.3158 -10.5085 0 0
M  V30 11 C 11.8238 -9.0547 0 0
M  V30 12 C 10.8187 -7.8878 0 0
M  V30 13 N 11.6179 -6.5714 0 0
M  V30 14 C 13.1168 -6.9247 0 0
M  V30 15 C 14.3823 -6.0471 0 0
M  V30 16 C 15.7751 -6.7043 0 0
M  V30 17 O 17.0406 -5.8267 0 0
M  V30 18 C 18.4333 -6.4839 0 0
M  V30 19 C 15.9023 -8.239 0 0
M  V30 20 C 14.6368 -9.1166 0 0
M  V30 21 C 13.2441 -8.4594 0 0
M  V30 22 C 9.3057 -8.1748 0 0 CFG=1
M  V30 23 C 8.3007 -7.0079 0 0
M  V30 24 C 6.7876 -7.2949 0 0 CFG=2
M  V30 25 C 5.7826 -6.128 0 0 CFG=2
M  V30 26 C 6.2906 -4.6742 0 0
M  V30 27 O 7.8037 -4.3873 0 0
M  V30 28 O 5.2856 -3.5074 0 0
M  V30 29 C 5.7936 -2.0536 0 0
M  V30 30 O 2.2486 -8.1558 0 0
M  V30 31 C 1.7406 -9.6096 0 0
M  V30 32 O 2.7456 -10.7764 0 0
M  V30 33 C 0.2275 -9.8965 0 0
M  V30 34 C -0.2805 -11.3503 0 0
M  V30 35 C -1.7935 -11.6373 0 0
M  V30 36 O -2.3015 -13.0911 0 0
M  V30 37 C -3.8145 -13.378 0 0
M  V30 38 C -2.7985 -10.4704 0 0
M  V30 39 O -4.3116 -10.7574 0 0
M  V30 40 C -4.8196 -12.2112 0 0
M  V30 41 C -2.2905 -9.0166 0 0
M  V30 42 O -3.2955 -7.8498 0 0
M  V30 43 C -2.7875 -6.396 0 0
M  V30 44 C -0.7775 -8.7297 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 16 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 11 21
M  V30 22 2 14 21
M  V30 23 1 22 12 CFG=3
M  V30 24 1 22 8
M  V30 25 1 22 23
M  V30 26 1 24 23 CFG=1
M  V30 27 1 24 6
M  V30 28 1 25 24
M  V30 29 1 3 25
M  V30 30 1 25 26 CFG=1
M  V30 31 2 26 27
M  V30 32 1 26 28
M  V30 33 1 28 29
M  V30 34 1 4 30 CFG=1
M  V30 35 1 30 31
M  V30 36 2 31 32
M  V30 37 1 31 33
M  V30 38 1 33 34
M  V30 39 2 34 35
M  V30 40 1 35 36
M  V30 41 1 36 37
M  V30 42 1 35 38
M  V30 43 1 38 39
M  V30 44 1 39 40
M  V30 45 2 38 41
M  V30 46 1 41 42
M  V30 47 1 42 43
M  V30 48 1 41 44
M  V30 49 2 33 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1251172867

>  <MW>
608.273

>  <MW (desalted)>
608.679

>  <ClogP>
3.859

>  <logS>
-4.323

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
117.78

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  1.79 nM | IC50  2.46 nM | EC50  3.17 nM | IC50  4.9 nM | Ki (inhibition constant)  5.5 nM | Ki (inhibition constant)  5.5 nM | IC50 ~ 0.01 ?M | Ki (inhibition constant) = 25 nM

>  <CAS>
50-55-5

>  <Description>
Reserpine is an alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals.

>  <EBC_ID>
EBC-11044

>  <IUPAC Name>
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate

>  <Main Tar all refs>
J. Med. Chem., 2018, vol. 61, # 20, p. 9121 - 9131 | Pharmacol. Res., 2022, vol. 186 | Pharmacol. Res., 2022, vol. 186 | Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258 | BR. J. PHARMACOL., 1986, vol. 89, # 1, p. 15 - 25 | BR. J. PHARMACOL., 1986, vol. 89, # 1, p. 15 - 25 | DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG - WO2008/145678, 2008, A1 | UNIVERSITY OF CALIFORNIA - US5688936, 1997, A

>  <Main tar all>
Vesicular monoamine transporter 2 pX=8.75 | epoxide hydrolase 2 pX=8.61 | epoxide hydrolase 2 pX=8.5 | Kv11.1 pX=8.31 | Dopamine receptor pX=8.26 | Dopamine receptor pX=8.26 | cyclin dependent kinase 1 pX=8.0 | DAT pX=7.6

$$$$
Quinine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8489 -2.7691 0 0
M  V30 2 O 9.5153 -1.9991 0 0
M  V30 3 C 8.1816 -2.7691 0 0
M  V30 4 C 8.1816 -4.3091 0 0
M  V30 5 C 6.8479 -5.0791 0 0
M  V30 6 C 5.5142 -4.3091 0 0
M  V30 7 N 4.1805 -5.0791 0 0
M  V30 8 C 2.8469 -4.3091 0 0
M  V30 9 C 2.8469 -2.7691 0 0
M  V30 10 C 4.1805 -1.9991 0 0
M  V30 11 C 4.1805 -0.4591 0 0 CFG=1
M  V30 12 O 2.8469 0.3109 0 0
M  V30 13 C 5.5142 0.3109 0 0 CFG=2
M  V30 14 C 5.5142 1.8509 0 0
M  V30 15 C 6.8479 2.6209 0 0 CFG=2
M  V30 16 C 7.1046 1.5942 0 0
M  V30 17 C 7.1046 0.5676 0 0
M  V30 18 N 6.8479 -0.4591 0 0
M  V30 19 C 8.1816 0.3109 0 0
M  V30 20 C 8.1816 1.8509 0 0 CFG=2
M  V30 21 C 9.5153 2.6209 0 0
M  V30 22 C 9.5153 4.1609 0 0
M  V30 23 C 5.5142 -2.7691 0 0
M  V30 24 C 6.8479 -1.9991 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 15 14 CFG=1
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 15 20
M  V30 22 1 20 21 CFG=1
M  V30 23 2 21 22
M  V30 24 1 10 23
M  V30 25 2 6 23
M  V30 26 1 23 24
M  V30 27 2 3 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235811384

>  <MW>
324.184

>  <MW (desalted)>
324.417

>  <ClogP>
2.785

>  <logS>
-2.792

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
45.59

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Substrate | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | IC50  179.04 nM | EC50  512 nM | uptake percentage < 200 % | uptake percentage < 200 % | IC50  0.7 ?M | IC50  0.26 - 0.268 ?g/ml | inhibition percentage > 90 % | IC50  1.89 ?M | Ki (inhibition constant)  2.03 ?M | Ki (inhibition constant) = 2.6 ?M | Ki (inhibition constant) = 2.6 ?M

>  <CAS>
130-95-0

>  <Description>
Quinine is an antimalarial agent. It inhibits cholinesterase, multidrug resistance protein 1, cytochrome P450. It is used to treat uncomplicated Plasmodium falciparum malaria.

>  <EBC_ID>
EBC-03912

>  <IUPAC Name>
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol

>  <Main Tar all refs>
Xenobiotica, 2019, vol. 49, # 11, p. 1323 - 1331 | Int. J. Parasitol Drugs Drug Resist., 2018, vol. 8, # 1, p. 31 - 35 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 3 | Malar. J., 2017, vol. 16, # 1 | Malar. J., 2017, vol. 16, # 1 | Drug Metab. Dispos., 2016, vol. 44, # 10, p. 1562 - 1568 | J. Heterocycl. Chem., 2019, vol. 56, # 8, p. 2235 - 2252 | Drug Metab. Dispos., 2014, vol. 42, # 5, p. 890 - 898 | Drug Metab. Dispos., 2018, vol. 46, # 9, p. 1251 - 1258 | Arch. Pharm., 2017, vol. 350, # 3-4 | J. Med. Chem., 2002, vol. 45, # 26, p. 5671 - 5686 | J. Med. Chem., 2002, vol. 45, # 26, p. 5671 - 5686

>  <Main tar all>
Cytochrome P450 (IPR:IPR001128) pX=7.0 | Oligopeptide-binding protein AliA pX=6.75 | Sugar transport protein 1 pX=6.29 | Organic cation transporter 1 pX=6.28 | Organic cation transporter 2 pX=6.28 | OATP1A2 pX=6.15 | Bifunctional dihydrofolate reductase/thymidylate synthase pX=6.1 | CYP2D26 pX=5.95 | OATP1A2 pX=5.72 | synaptic vesicle glycoprotein 2A pX=5.69 | ABCB1 pX=5.59 | ATP-dependent translocase ABCB1 pX=5.59

$$$$
Dinagest
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.5938 -3.4528 0 0
M  V30 2 C 3.2656 -4.8386 0 0 CFG=2
M  V30 3 C 4.2583 -3.6612 0 0
M  V30 4 C 5.7743 -3.9323 0 0
M  V30 5 C 6.2975 -5.3807 0 0
M  V30 6 C 7.8134 -5.6518 0 0
M  V30 7 C 8.8062 -4.4744 0 0
M  V30 8 C 10.3221 -4.7455 0 0
M  V30 9 C 10.8454 -6.1939 0 0
M  V30 10 O 12.3613 -6.465 0 0
M  V30 11 C 9.8526 -7.3712 0 0
M  V30 12 C 8.3367 -7.1001 0 0
M  V30 13 C 7.3439 -8.2775 0 0
M  V30 14 C 5.828 -8.0064 0 0
M  V30 15 C 5.3048 -6.558 0 0 CFG=1
M  V30 16 C 3.7888 -6.2869 0 0 CFG=2
M  V30 17 C 2.573 -7.2321 0 0
M  V30 18 C 1.2984 -6.3679 0 0
M  V30 19 C 1.7264 -4.8886 0 0 CFG=2
M  V30 20 O 0.3061 -4.2934 0 0
M  V30 21 C 1.4998 -3.3654 0 0
M  V30 22 C 0.0673 -2.8 0 0
M  V30 23 N -1.3652 -2.2346 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 6 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 15 14 CFG=1
M  V30 16 1 15 5
M  V30 17 1 16 15
M  V30 18 1 2 16
M  V30 19 1 16 17 CFG=3
M  V30 20 1 17 18
M  V30 21 1 19 18
M  V30 22 1 2 19
M  V30 23 1 19 20 CFG=3
M  V30 24 1 19 21 CFG=1
M  V30 25 1 21 22
M  V30 26 3 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801839

>  <MW>
311.189

>  <MW (desalted)>
311.418

>  <ClogP>
2.125

>  <logS>
-3.552

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
61.09

>  <RotBonds>
1

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  3.4 - 10.5 nM

>  <CAS>
65928-58-7

>  <Description>
Dienogest is a synthetic progestin and progesterone receptor agonist. It is indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.

>  <EBC_ID>
EBC-07864

>  <IUPAC Name>
2-[(1R,3aS,3bS,11aS)-1-hydroxy-11a-methyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]acetonitrile

>  <Main Tar all refs>
Steroids, 2008, vol. 73, # 2, p. 222 - 231

>  <Main tar all>
Progesterone receptor pX=8.47

$$$$
Azilsartan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6296 0.0309 0 0
M  V30 2 C -1.0896 0.0309 0 0
M  V30 3 O -0.3196 -1.3028 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 N 2.1256 -0.0569 0 0
M  V30 6 C 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 4.9239 -4.3828 0 0
M  V30 12 O 3.5902 -5.1528 0 0
M  V30 13 O 6.2576 -5.1528 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 N 2.1256 -2.5487 0 0
M  V30 16 C 1.6497 -4.0133 0 0
M  V30 17 C 0.1434 -4.3335 0 0
M  V30 18 C -0.3325 -5.7982 0 0
M  V30 19 C -1.8389 -6.1183 0 0
M  V30 20 C -2.8693 -4.9739 0 0
M  V30 21 C -2.3934 -3.5093 0 0
M  V30 22 C -0.8871 -3.1891 0 0
M  V30 23 C -4.3757 -5.2941 0 0
M  V30 24 C -4.8515 -6.7587 0 0
M  V30 25 C -6.3579 -7.0789 0 0
M  V30 26 C -7.3884 -5.9344 0 0
M  V30 27 C -6.9125 -4.4698 0 0
M  V30 28 C -5.4061 -4.1496 0 0
M  V30 29 C -4.9302 -2.685 0 0
M  V30 30 N -5.8354 -1.4391 0 0
M  V30 31 C -4.9302 -0.1932 0 0
M  V30 32 O -5.4061 1.2714 0 0
M  V30 33 O -3.4656 -0.6691 0 0
M  V30 34 N -3.4656 -2.2091 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 10 14
M  V30 14 2 6 14
M  V30 15 1 14 15
M  V30 16 1 4 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 17 22
M  V30 25 1 20 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 23 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 30 31
M  V30 35 2 31 32
M  V30 36 1 31 33
M  V30 37 1 33 34
M  V30 38 1 29 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575099375

>  <MW>
456.143

>  <MW (desalted)>
456.45

>  <ClogP>
5.293

>  <logS>
-7.682

>  <HBD>
2

>  <HBA>
7

>  <TPSA>
115.04

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 4.2E-07 M

>  <CAS>
147403-03-0

>  <Description>
Azilsartan is an analgesic and antiinflammatory drugs containing angiotensin II antagonists. It is an active metabolite of azilsartan medoxomil.

>  <EBC_ID>
EBC-12468

>  <IUPAC Name>
2-ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid

>  <Main Tar all refs>
J. MED. CHEM., 1996, vol. 39, # 26, p. 5228 - 5235

>  <Main tar all>
AT1 receptor pX=6.38

$$$$
Lenvatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -0.77 0 0
M  V30 2 O 0 -0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 N 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 6.6684 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 O 5.3347 -4.62 0 0
M  V30 11 C 4.001 -5.39 0 0
M  V30 12 C 2.6674 -4.62 0 0
M  V30 13 C 1.3337 -5.39 0 0
M  V30 14 C 1.3337 -6.93 0 0
M  V30 15 N -0 -7.7 0 0
M  V30 16 C -1.3337 -6.93 0 0
M  V30 17 O -1.3337 -5.39 0 0
M  V30 18 N -2.6674 -7.7 0 0
M  V30 19 C -2.6674 -9.24 0 0
M  V30 20 C -1.8974 -10.5737 0 0
M  V30 21 C -3.4374 -10.5737 0 0
M  V30 22 C 2.6674 -7.7 0 0
M  V30 23 Cl 2.6674 -9.24 0 0
M  V30 24 C 4.001 -6.93 0 0
M  V30 25 C 4.001 -2.31 0 0
M  V30 26 C 2.6674 -3.08 0 0
M  V30 27 C 1.3337 -2.31 0 0
M  V30 28 C 0 -3.08 0 0
M  V30 29 O -1.3337 -2.31 0 0
M  V30 30 N 0 -4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 19 21
M  V30 22 2 14 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 11 24
M  V30 26 1 9 25
M  V30 27 1 5 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 3 27
M  V30 31 1 27 28
M  V30 32 2 28 29
M  V30 33 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801899

>  <MW>
426.853

>  <MW (desalted)>
426.853

>  <ClogP>
3.347

>  <logS>
-5.55

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
115.57

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.36 nM | IC50  0.83 nM | IC50 = 0.91 nM | Ki (inhibition constant) = 1.5 nM | IC50  1.9 nM | IC50  4 - 100 nM | IC50  4 - 100 nM | IC50  4 - 100 nM | IC50  5.4 nM | IC50 < 10 nM

>  <CAS>
417716-92-8

>  <Description>
Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.

>  <EBC_ID>
EBC-11343

>  <IUPAC Name>
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide

>  <Main Tar all refs>
Clin. Cancer Res., 2008, vol. 14, # 17, p. 5459 - 5465 | Int. J. Cancer, 2008, vol. 122, # 3, p. 664 - 671 | EISAI CO LTD - WO2008/1956, 2008, A1 | J. Med. Chem., 2015, vol. 58, # 9, p. 3672 - 3681 | Int. J. Cancer, 2008, vol. 122, # 3, p. 664 - 671 | Anti-Cancer Agents Med. Chem., 2013, vol. 13, # 5, p. 748 - 761 | Anti-Cancer Agents Med. Chem., 2013, vol. 13, # 5, p. 748 - 761 | Anti-Cancer Agents Med. Chem., 2013, vol. 13, # 5, p. 748 - 761 | EISAI CO LTD; JPARIMOTO ITARU - US2004/53908, 2004, A1 | EISAI CO LTD - EP2065372, 2009, A1

>  <Main tar all>
fms related receptor tyrosine kinase 4 pX=9.44 | kinase insert domain receptor pX=9.08 | discoidin domain receptor tyrosine kinase 2 pX=9.04 | ret proto-oncogene pX=8.82 | Mast/stem cell growth factor receptor Kit pX=8.72 | fms related receptor tyrosine kinase 1 pX=8.4 | platelet derived growth factor receptor alpha pX=8.4 | platelet derived growth factor receptor beta pX=8.4 | vascular endothelial growth factor-activated receptor pX=8.27 | fibroblast growth factor receptor 2 pX=8.0

$$$$
Dapagliflozin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -3.08 0 0
M  V30 2 C -2.6674 -4.62 0 0
M  V30 3 O -1.3337 -5.39 0 0
M  V30 4 C -1.3337 -6.93 0 0
M  V30 5 C 0 -7.7 0 0
M  V30 6 C 0 -9.24 0 0
M  V30 7 C -1.3337 -10.01 0 0
M  V30 8 C -1.3337 -11.55 0 0
M  V30 9 C -2.6674 -12.32 0 0
M  V30 10 C -2.6674 -13.86 0 0
M  V30 11 C -4.001 -14.63 0 0
M  V30 12 C -5.3347 -13.86 0 0
M  V30 13 C -5.3347 -12.32 0 0
M  V30 14 C -4.001 -11.55 0 0
M  V30 15 Cl -4.001 -10.01 0 0
M  V30 16 C -4.001 -16.17 0 0 CFG=2
M  V30 17 O -2.6674 -16.94 0 0
M  V30 18 C -2.6674 -18.48 0 0 CFG=2
M  V30 19 C -1.3337 -19.25 0 0
M  V30 20 O -0 -18.48 0 0
M  V30 21 C -4.001 -19.25 0 0 CFG=1
M  V30 22 O -4.001 -20.79 0 0
M  V30 23 C -5.3347 -18.48 0 0 CFG=2
M  V30 24 O -6.6684 -19.25 0 0
M  V30 25 C -5.3347 -16.94 0 0 CFG=1
M  V30 26 O -6.6684 -16.17 0 0
M  V30 27 C -2.6674 -9.24 0 0
M  V30 28 C -2.6674 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 1 16 11 CFG=3
M  V30 17 1 16 17
M  V30 18 1 18 17
M  V30 19 1 18 19 CFG=3
M  V30 20 1 19 20
M  V30 21 1 21 18
M  V30 22 1 21 22 CFG=1
M  V30 23 1 21 23
M  V30 24 1 23 24 CFG=3
M  V30 25 1 23 25
M  V30 26 1 25 16
M  V30 27 1 25 26 CFG=1
M  V30 28 2 7 27
M  V30 29 1 27 28
M  V30 30 2 4 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801883

>  <MW>
408.873

>  <MW (desalted)>
408.873

>  <ClogP>
3.369

>  <logS>
-3.943

>  <HBD>
4

>  <HBA>
6

>  <TPSA>
99.38

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  9.84  | IC50  3 nM

>  <CAS>
461432-26-8

>  <Description>
Dapagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It is used in the management of type 2 diabetes mellitus.

>  <EBC_ID>
EBC-11348

>  <IUPAC Name>
(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol

>  <Main Tar all refs>
Curr. Top. Med. Chem., 2011, vol. 11, # 12, p. 1476 - 1512 | SHANGPHARMA VENTURE DEVELOPMENT JIANGSU - US2013/324464, 2013, A1

>  <Main tar all>
Sodium/glucose cotransporter 2 pX=9.84 | Sodium/glucose cotransporter 1 pX=8.52

$$$$
Brigatinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -4.62 0 0
M  V30 2 O 1.3337 -5.39 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 C 2.6674 -7.7 0 0
M  V30 5 C 2.6674 -9.24 0 0
M  V30 6 C 1.3337 -10.01 0 0
M  V30 7 C 0 -9.24 0 0
M  V30 8 C 0 -7.7 0 0
M  V30 9 N -1.3337 -6.93 0 0
M  V30 10 C -1.3337 -5.39 0 0
M  V30 11 N 0 -4.62 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C -1.3337 -2.31 0 0
M  V30 14 Cl -1.3337 -0.77 0 0
M  V30 15 C -2.6674 -3.08 0 0
M  V30 16 N -4.001 -2.31 0 0
M  V30 17 C -5.3347 -3.08 0 0
M  V30 18 C -5.3347 -4.62 0 0
M  V30 19 C -6.6684 -5.39 0 0
M  V30 20 C -8.0021 -4.62 0 0
M  V30 21 C -8.0021 -3.08 0 0
M  V30 22 C -6.6684 -2.31 0 0
M  V30 23 P -6.6684 -0.77 0 0
M  V30 24 O -6.6684 0.77 0 0
M  V30 25 C -5.1284 -0.77 0 0
M  V30 26 C -8.2084 -0.77 0 0
M  V30 27 N -2.6674 -4.62 0 0
M  V30 28 N 4.001 -10.01 0 0
M  V30 29 C 5.3347 -9.24 0 0
M  V30 30 C 6.6684 -10.01 0 0
M  V30 31 C 6.6684 -11.55 0 0
M  V30 32 C 5.3347 -12.32 0 0
M  V30 33 C 4.001 -11.55 0 0
M  V30 34 N 8.0021 -12.32 0 0
M  V30 35 C 9.3358 -11.55 0 0
M  V30 36 C 10.6694 -12.32 0 0
M  V30 37 N 10.6694 -13.86 0 0
M  V30 38 C 12.0031 -14.63 0 0
M  V30 39 C 9.3358 -14.63 0 0
M  V30 40 C 8.0021 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 23 26
M  V30 28 1 15 27
M  V30 29 2 10 27
M  V30 30 1 5 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 28 33
M  V30 37 1 31 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 37 39
M  V30 43 1 39 40
M  V30 44 1 34 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2512157852

>  <MW>
583.259

>  <MW (desalted)>
584.092

>  <ClogP>
2.024

>  <logS>
-3.361

>  <HBD>
2

>  <HBA>
9

>  <TPSA>
85.86

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 >= 0.1 - 50 nM | IC50 >= 0.1 - 50 nM | cell viability decrease Active   | IC50 = 0.5 nM | IC50  0.7 nM | IC50  0.82 nM | IC50  1 nM | inhibition rate Active   | IC50  1.5 nM | IC50  1.5 nM | IC50  1.6 nM | IC50  1.9 nM | IC50  1.9 nM | IC50  2 nM | IC50  2.1 nM | IC50  2.1 nM | IC50  2.1 nM | IC50  2.5 nM | IC50  2.7 nM

>  <CAS>
1197953-54-0

>  <Description>
Brigatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.

>  <EBC_ID>
EBC-13820

>  <IUPAC Name>
5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine

>  <Main Tar all refs>
PHARMA RESOURCES GMBH; PHARMARESOURCES CO.; NUVALENT - WO2021/226269, 2021, A1 | PHARMA RESOURCES GMBH; PHARMARESOURCES CO.; NUVALENT - WO2021/226269, 2021, A1 | JAPANESE FOUNDATION FOR CANCER RESEARCH - US2020/397786, 2020, A1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED - WO2012/51587, 2012, A1 | BETTA PHARMACEUTICALS CO LTD - US2022/402948, 2022, A1 | Bioorg. Med. Chem., 2022, vol. 70 | Bioorg. Med. Chem. Lett., 2022, vol. 66 | UNIVERSITY OF OSLO - WO2022/69684, 2022, A1 | Bioorg. Med. Chem. Lett., 2020, vol. 30, # 16 | Bioorg. Med. Chem. Lett., 2020, vol. 30, # 16 | ACS Med. Chem. Lett., 2019, vol. 10, # 6, p. 869 - 873 | UNIVERSITY OF TORONTO - US2019/91205, 2019, A1 | J. Med. Chem., 2016, vol. 59, # 10, p. 4948 - 4964 | DANA-FARBER CANCER INSTITUTE - WO2017/53657, 2017, A1 | SHANGHAITECH UNIVERSITY - EP3778590, 2021, A1 | SHANGHAITECH UNIVERSITY - EP3778590, 2021, A1 | J. Med. Chem., 2016, vol. 59, # 10, p. 4948 - 4964 | Bioorg. Med. Chem. Lett., 2020, vol. 30, # 16 | Eur. J. Med. Chem., 2020, vol. 193

>  <Main tar all>
H-2 class II histocompatibility antigen gamma chain pX=10.0 | Proto-oncogene?tyrosine-protein?kinase?ROS?(G2032R) pX=10.0 | ALK receptor tyrosine kinase pX=9.52 | epidermal growth factor receptor pX=9.3 | Epidermal growth factor receptor (T790M) pX=9.15 | epidermal growth factor receptor pX=9.09 | ALK tyrosine kinase receptor (L1152P) pX=9.0 | leukocyte receptor tyrosine kinase pX=9.0 | Epidermal growth factor receptor (Del19/T790M/C797S) pX=8.82 | Epidermal growth factor receptor (T790M/L858R) pX=8.82 | Epidermal growth factor receptor (C797S/T790M/L858R) pX=8.8 | Epidermal growth factor receptor (Del19/T790M/C797S) pX=8.72 | c-ros oncogene 1, receptor tyrosine kinase pX=8.72 | Echinoderm microtubule-associated protein-like 4 pX=8.7 | Cullin-4A pX=8.68 | Protein cereblon pX=8.68 | fms related receptor tyrosine kinase 3 pX=8.68 | Epidermal growth factor receptor (C797S/T790M/L858R) pX=8.6 | Nucleophosmin pX=8.57

$$$$
Amifampridine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 N 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C 0 1.54 0 0
M  V30 8 N -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z385438794

>  <MW>
109.064

>  <MW (desalted)>
109.129

>  <ClogP>
0.391

>  <logS>
0.186

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
64.93

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Antagonist | Antagonist

>  <Activity coefficients and valu>
pIC50 = 6.18  | IC50  2.5 ?M | IC50  10.3 ?M

>  <CAS>
54-96-6

>  <Description>
Amifampridine is a voltage gated potassium channel blocker. It is used to treat Lambert-Eaton myasthenic syndrome.

>  <EBC_ID>
EBC-03947

>  <IUPAC Name>
pyridine-3,4-diamine

>  <Main Tar all refs>
Curr. Pharm. Des., 2013, vol. 19, # 26, p. 4776 - 4786 | J. Biol. Chem., 2021, vol. 296 | J. Biol. Chem., 2021, vol. 296

>  <Main tar all>
Topoisomerase dna ii 180kda (Beta) pX=6.18 | Kv3.3 pX=5.6 | Kv3.4 pX=4.99

$$$$
Phenelzine Dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 N -2.1339 -3.08 0 0
M  V30 4 N -0.8002 -3.85 0 0
M  V30 5 C -0.8002 -5.39 0 0
M  V30 6 C 0.5335 -6.16 0 0
M  V30 7 C 0.5335 -7.7 0 0
M  V30 8 C 1.8672 -8.47 0 0
M  V30 9 C 1.8672 -10.01 0 0
M  V30 10 C 0.5335 -10.78 0 0
M  V30 11 C -0.8002 -10.01 0 0
M  V30 12 C -0.8002 -8.47 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 2 8 9
M  V30 7 1 9 10
M  V30 8 2 10 11
M  V30 9 1 11 12
M  V30 10 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z927192062

>  <MW>
208.053

>  <MW (desalted)>
136.194

>  <ClogP>
1.033

>  <logS>
-2.45

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
38.05

>  <RotBonds>
3

>  <CAS>
16904-30-6

>  <Description>
Phenelzine, with the formula ?-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.

>  <EBC_ID>
EBC-15021

>  <IUPAC Name>
(2-phenylethyl)hydrazine dihydrochloride

$$$$
Acipimox
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 N 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 N 0 1.54 0 0 CHG=1
M  V30 8 O -1.3337 2.31 0 0 CHG=-1
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 O 2.6674 -3.08 0 0
M  V30 11 O -0 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 1 5 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198155438

>  <MW>
154.038

>  <MW (desalted)>
154.123

>  <ClogP>
-0.165

>  <logS>
0.166

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
77.13

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  227 nM | Ki (inhibition constant) = 0.309 ?M | Ki (inhibition constant) = 0.309 ?M | Ki (inhibition constant) = 0.309 ?M | Ki (inhibition constant) = 0.309 ?M | EC50 = 0.34 ?M | Ki (inhibition constant)  2.8 ?M | Ki (inhibition constant)  3.3 ?M | Ki (inhibition constant)  5.4 ?M | Ki (inhibition constant)  5.9 ?M | Ki (inhibition constant)  6.3 ?M | Ki (inhibition constant)  7 ?M

>  <CAS>
51037-30-0

>  <Description>
Acipimox is a niacin derivative used as a hypolipidemic agent. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. It is used in Fredrickson type IIb and type IV hyperlipoproteinemia.

>  <EBC_ID>
EBC-11165

>  <IUPAC Name>
5-carboxy-2-methylpyrazin-1-ium-1-olate

>  <Main Tar all refs>
Biochem. Pharmacol., 2002, vol. 64, # 4, p. 645 - 648 | Med. Res. Rev., 2007, vol. 27, # 3, p. 417 - 433 | Med. Res. Rev., 2007, vol. 27, # 3, p. 417 - 433 | Med. Res. Rev., 2007, vol. 27, # 3, p. 417 - 433 | Med. Res. Rev., 2007, vol. 27, # 3, p. 417 - 433 | Med. Res. Rev., 2007, vol. 27, # 3, p. 417 - 433 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679 | J. Enzyme Inhib. Med. Chem., 2022, vol. 37, # 1, p. 672 - 679

>  <Main tar all>
Hydroxycarboxylic acid receptor 3 pX=6.64 | nicotinic acetylcholine receptor ?-like 1 pX=6.51 | nicotinic acetylcholine receptor ?-like 1 pX=6.51 | nicotinic acetylcholine receptor ?1 subunit pX=6.51 | nicotinic acetylcholine receptor ?1 subunit pX=6.51 | Hydroxycarboxylic acid receptor 2 pX=6.47 | Carbonic anhydrase 5B, mitochondrial pX=5.55 | carbonic anhydrase 1 pX=5.48 | carbonic anhydrase 3 pX=5.27 | carbonic anhydrase 14 pX=5.23 | carbonic anhydrase 9 pX=5.2 | carbonic anhydrase 6 pX=5.15

$$$$
Amifostine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.2863 3.4374 0 0
M  V30 2 C 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0
M  V30 4 C 7.2874 2.6674 0 0
M  V30 5 N 8.621 3.4374 0 0
M  V30 6 C 9.9547 2.6674 0 0
M  V30 7 C 11.2884 3.4374 0 0
M  V30 8 S 12.6221 2.6674 0 0
M  V30 9 P 13.9558 3.4374 0 0
M  V30 10 O 15.2894 4.2074 0 0
M  V30 11 O 14.7258 2.1037 0 0
M  V30 12 O 13.1858 4.771 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269145833

>  <MW>
214.054

>  <MW (desalted)>
214.223

>  <ClogP>
-1.846

>  <logS>
1.317

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
95.58

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  56.6 % | inhibition rate Active   | inhibition rate Active

>  <CAS>
20537-88-6

>  <Description>
Amifostine is a cytoprotective adjuvant used for reduction in the cumulative renal toxicity in patients with ovarian cancer and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.

>  <EBC_ID>
EBC-13436

>  <IUPAC Name>
({2-[(3-aminopropyl)amino]ethyl}sulfanyl)phosphonic acid

>  <Main Tar all refs>
PAIRNOMIX; PETROVSKI SLAVE; ANDRESEN J MICHAEL - WO2019/18119, 2019, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1

>  <Main tar all>
KNa1.1 pX=5.12 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3

$$$$
Thiabendazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6894 -0.5328 0 0
M  V30 2 N -1.2248 -0.0569 0 0
M  V30 3 C -0.3196 -1.3028 0 0
M  V30 4 C -1.2248 -2.5487 0 0
M  V30 5 S -2.6894 -2.0728 0 0
M  V30 6 C 1.2204 -1.3028 0 0
M  V30 7 N 2.1256 -0.0569 0 0
M  V30 8 C 3.5902 -0.5328 0 0
M  V30 9 C 4.9239 0.2372 0 0
M  V30 10 C 6.2576 -0.5328 0 0
M  V30 11 C 6.2576 -2.0728 0 0
M  V30 12 C 4.9239 -2.8428 0 0
M  V30 13 C 3.5902 -2.0728 0 0
M  V30 14 N 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 1 5
M  V30 6 1 3 6
M  V30 7 2 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 13 14
M  V30 16 1 6 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104480436

>  <MW>
201.036

>  <MW (desalted)>
201.248

>  <ClogP>
2.358

>  <logS>
-3.19

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
41.57

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  400 nM | Ki (inhibition constant) = 0.4 ?M | Ki (inhibition constant)  0.61 ?M | inhibition percentage Active   | EC50  0.55 mg/l | Ki (inhibition constant)  11.02 ?M

>  <CAS>
148-79-8

>  <Description>
Thiabendazole is a broad-spectrum anthelmintic that is active against a variety of helminths. It is used for the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.

>  <EBC_ID>
EBC-03505

>  <IUPAC Name>
2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole

>  <Main Tar all refs>
J. Med. Chem., 2006, vol. 49, # 2, p. 511 - 522 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 24, p. 6862 - 6864 | Drug Metab. Dispos., 2001, vol. 29, # 1, p. 30 - 35 | Xenobiotica, 2012, vol. 42, p. 989 | Sci. Total Environ., 2019, vol. 688, p. 1145 - 1154 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1966 - 1975

>  <Main tar all>
Methionyl aminopeptidase 1 pX=6.4 | Methionyl aminopeptidase 2 pX=6.4 | CYP1A2 pX=6.21 | NADPH-cytochrome P450 reductase pX=6.0 | Fumarate reductase pX=5.56 | CYP2C9*3 pX=4.96

$$$$
Tocainide hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 3.96 0 0
M  V30 3 C 5.7337 3.19 0 0
M  V30 4 N 7.0674 3.96 0 0
M  V30 5 C 5.7337 1.65 0 0
M  V30 6 O 4.4 0.88 0 0
M  V30 7 N 7.0674 0.88 0 0
M  V30 8 C 7.0674 -0.66 0 0
M  V30 9 C 8.401 -1.43 0 0
M  V30 10 C 9.7347 -0.66 0 0
M  V30 11 C 8.401 -2.97 0 0
M  V30 12 C 7.0674 -3.74 0 0
M  V30 13 C 5.7337 -2.97 0 0
M  V30 14 C 5.7337 -1.43 0 0
M  V30 15 C 4.4 -0.66 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 9 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 8 14
M  V30 14 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1449775098

>  <MW>
228.103

>  <MW (desalted)>
192.258

>  <ClogP>
0.257

>  <logS>
-3.017

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
55.12

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Blocker | Blocker

>  <Activity coefficients and valu>
IC50 = 270 ?M | IC50 = 270 ?M | IC50  581.3 ?M | IC50  756.7 ?M

>  <CAS>
71395-14-7

>  <Description>
Tocainide is an orally active class 1b antiarrhythmic agent that interferes with cardiac sodium channels. It is used for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

>  <EBC_ID>
EBC-03621

>  <IUPAC Name>
2-amino-N-(2,6-dimethylphenyl)propanamide hydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2000, vol. 43, # 20, p. 3792 - 3798 | J. Med. Chem., 2000, vol. 43, # 20, p. 3792 - 3798 | PAIRNOMIX - WO2018/64498, 2018, A1 | PAIRNOMIX - WO2018/64498, 2018, A1

>  <Main tar all>
Nav?1 pX=3.57 | Nav1.7 pX=3.57 | Nav1.6 pX=3.24 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=3.12

$$$$
Guanethidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -1.8196 -5.1563 0 0
M  V30 2 C -0.4859 -5.9263 0 0
M  V30 3 N -0.4859 -7.4663 0 0
M  V30 4 N 0.8478 -5.1563 0 0
M  V30 5 C 2.1815 -5.9263 0 0
M  V30 6 C 3.5151 -5.1563 0 0
M  V30 7 N 4.8488 -5.9263 0 0
M  V30 8 C 6.0706 -4.9888 0 0
M  V30 9 C 7.5974 -5.1898 0 0
M  V30 10 C 8.5349 -6.4115 0 0
M  V30 11 C 8.3339 -7.9384 0 0
M  V30 12 C 7.1121 -8.8759 0 0
M  V30 13 C 5.5853 -8.6748 0 0
M  V30 14 C 4.6478 -7.4531 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 7 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198152903

>  <MW>
198.184

>  <MW (desalted)>
198.308

>  <ClogP>
1.354

>  <logS>
-0.959

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
65.14

>  <RotBonds>
3

>  <CAS>
55-65-2

>  <Description>
Guanethidine is an antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is used in the management of moderate and severe hypertension.

>  <EBC_ID>
EBC-12252

>  <IUPAC Name>
N-[2-(azocan-1-yl)ethyl]guanidine

$$$$
Guanoxan hydrobromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0
M  V30 2 N 4.8537 -4.2607 0 0
M  V30 3 C 4.8537 -2.7207 0 0
M  V30 4 N 3.52 -1.9507 0 0
M  V30 5 N 6.1874 -1.9507 0 0
M  V30 6 C 6.1874 -0.4107 0 0
M  V30 7 C 7.521 0.3593 0 0
M  V30 8 C 7.521 1.8993 0 0
M  V30 9 O 8.8547 2.6693 0 0
M  V30 10 C 10.1884 1.8993 0 0
M  V30 11 C 11.5221 2.6693 0 0
M  V30 12 C 12.8558 1.8993 0 0
M  V30 13 C 12.8558 0.3593 0 0
M  V30 14 C 11.5221 -0.4107 0 0
M  V30 15 C 10.1884 0.3593 0 0
M  V30 16 O 8.8547 -0.4107 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 10 15
M  V30 15 1 15 16
M  V30 16 1 7 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z911465460

>  <MW>
288.141

>  <MW (desalted)>
207.229

>  <ClogP>
0.546

>  <logS>
-3.04

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
80.36

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  3.55 nM | Ki (inhibition constant)  85 nM

>  <CAS>
2093702-96-4

>  <Description>
Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine. It acts as a blocker of alpha-2 adrenoceptors.

>  <EBC_ID>
EBC-28046

>  <IUPAC Name>
N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]guanidine hydrobromide

>  <Main Tar all refs>
BR. J. PHARMACOL., 1992, vol. 106, # 1, p. 101 - 108 | BR. J. PHARMACOL., 1992, vol. 106, # 1, p. 101 - 108

>  <Main tar all>
Nischarin pX=8.45 | ?2A-adrenoceptor pX=7.07

$$$$
Carbidopa
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.4374 3.2863 0 0
M  V30 2 C 2.6674 4.62 0 0 CFG=1
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 O 1.3337 -2.31 0 0
M  V30 9 C 0 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 1.54 0 0
M  V30 12 N 1.8974 5.9537 0 0
M  V30 13 N 0.3574 5.9537 0 0
M  V30 14 C 4.001 5.39 0 0
M  V30 15 O 4.001 6.93 0 0
M  V30 16 O 5.3347 4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 4 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 1 2 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2301684895

>  <MW>
226.095

>  <MW (desalted)>
226.229

>  <ClogP>
-0.445

>  <logS>
-0.852

>  <HBD>
5

>  <HBA>
6

>  <TPSA>
115.81

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Agonist

>  <Activity coefficients and valu>
IC50  142 nM | IC50  190 nM | mRNA expression level increase Active

>  <CAS>
28860-95-9

>  <Description>
Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier.  Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy levodopa/carbidopa is not efficient reducing nausea.

>  <EBC_ID>
EBC-01053

>  <IUPAC Name>
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid

>  <Main Tar all refs>
BENEVOLENTAI LIMITED - WO2017/98237, 2017, A1 | BENEVOLENTAI LIMITED - WO2017/98237, 2017, A1 | TEXAS TECH UNIVERSITY SYSTEM - US2017/319527, 2017, A1

>  <Main tar all>
Membrane primary amine oxidase pX=6.85 | phenylalanine decarboxylase pX=6.72 | Aryl hydrocarbon receptor pX=6.5

$$$$
Procarbazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 6.7856 0 0
M  V30 3 N 5.7337 6.0156 0 0
M  V30 4 N 5.7337 4.4756 0 0
M  V30 5 C 7.0674 3.7056 0 0
M  V30 6 C 7.0674 2.1656 0 0
M  V30 7 C 8.401 1.3956 0 0
M  V30 8 C 8.401 -0.1444 0 0
M  V30 9 C 7.0674 -0.9144 0 0
M  V30 10 C 5.7337 -0.1444 0 0
M  V30 11 C 5.7337 1.3956 0 0
M  V30 12 C 7.0674 -2.4544 0 0
M  V30 13 O 5.7337 -3.2244 0 0
M  V30 14 N 8.401 -3.2244 0 0
M  V30 15 C 8.401 -4.7644 0 0
M  V30 16 C 9.7347 -5.5344 0 0
M  V30 17 C 7.0674 -5.5344 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 9 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759748

>  <MW>
257.129

>  <MW (desalted)>
221.299

>  <ClogP>
-0.083

>  <logS>
-2.61

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
53.16

>  <RotBonds>
5

>  <CAS>
366-70-1

>  <Description>
Procarbazine hydrochloride is an alkylating agent, with anticancer activity. It is indicated for use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.

>  <EBC_ID>
EBC-06702

>  <IUPAC Name>
4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide hydrochloride

$$$$
Tripelennamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 0.9726 0 0
M  V30 3 N 5.7337 1.7426 0 0
M  V30 4 C 5.7337 3.2826 0 0
M  V30 5 C 7.0674 0.9726 0 0
M  V30 6 C 8.401 1.7426 0 0
M  V30 7 N 9.7347 0.9726 0 0
M  V30 8 C 11.0684 1.7426 0 0
M  V30 9 C 12.4021 0.9726 0 0
M  V30 10 C 13.7358 1.7426 0 0
M  V30 11 C 15.0694 0.9726 0 0
M  V30 12 C 15.0694 -0.5674 0 0
M  V30 13 C 13.7358 -1.3374 0 0
M  V30 14 C 12.4021 -0.5674 0 0
M  V30 15 C 9.7347 -0.5674 0 0
M  V30 16 C 11.0684 -1.3374 0 0
M  V30 17 C 11.0684 -2.8774 0 0
M  V30 18 C 9.7347 -3.6474 0 0
M  V30 19 C 8.401 -2.8774 0 0
M  V30 20 N 8.401 -1.3374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 7 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546621741

>  <MW>
291.15

>  <MW (desalted)>
255.358

>  <ClogP>
3.306

>  <logS>
-3.14

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
19.37

>  <RotBonds>
6

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
pA2  8.49

>  <CAS>
154-69-8

>  <Description>
Tripelennamine is a histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is a psychoactive drug  that is used as an antipruritic and first-generation antihistamine.

>  <EBC_ID>
EBC-06703

>  <IUPAC Name>
N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1973, vol. 16, # 9, p. 963 - 968

>  <Main tar all>
H1 receptor pX=8.49

$$$$
Chloroprocaine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -2.31 0 0
M  V30 2 C -5.3347 -3.08 0 0
M  V30 3 N -4.001 -2.31 0 0
M  V30 4 C -4.001 -0.77 0 0
M  V30 5 C -2.6674 -0 0 0
M  V30 6 C -2.6674 -3.08 0 0
M  V30 7 C -1.3337 -2.31 0 0
M  V30 8 O 0 -3.08 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 O 2.6674 -3.08 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 -0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 N 1.3337 3.85 0 0
M  V30 16 C 2.6674 1.54 0 0
M  V30 17 C 2.6674 -0 0 0
M  V30 18 Cl 4.001 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z802864938

>  <MW>
270.114

>  <MW (desalted)>
270.755

>  <ClogP>
2.909

>  <logS>
-2.94

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
55.56

>  <RotBonds>
7

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
133-16-4

>  <Description>
Chloroprocaine is a local anesthetic given by injection during surgical procedures and labor and delivery. Chloroprocaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential.

>  <EBC_ID>
EBC-06712

>  <IUPAC Name>
2-(diethylamino)ethyl 4-amino-2-chlorobenzoate

$$$$
Promethazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.8537 1.694 0 0
M  V30 3 C 6.1874 2.464 0 0
M  V30 4 C 7.521 1.694 0 0
M  V30 5 N 7.521 0.154 0 0
M  V30 6 C 8.8547 -0.616 0 0
M  V30 7 C 10.1884 0.154 0 0
M  V30 8 C 11.5221 -0.616 0 0
M  V30 9 C 11.5221 -2.156 0 0
M  V30 10 C 10.1884 -2.926 0 0
M  V30 11 C 8.8547 -2.156 0 0
M  V30 12 S 7.521 -2.926 0 0
M  V30 13 C 6.1874 -2.156 0 0
M  V30 14 C 4.8537 -2.926 0 0
M  V30 15 C 3.52 -2.156 0 0
M  V30 16 C 3.52 -0.616 0 0
M  V30 17 C 4.8537 0.154 0 0
M  V30 18 C 6.1874 -0.616 0 0
M  V30 19 N 6.1874 4.004 0 0
M  V30 20 C 4.8537 4.774 0 0
M  V30 21 C 7.521 4.774 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 2 6 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 5 18
M  V30 19 2 13 18
M  V30 20 1 3 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1151174635

>  <MW>
320.111

>  <MW (desalted)>
284.419

>  <ClogP>
4.4

>  <logS>
-4.8

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
3

>  <Action on targets>
Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pA2  8.93  | IC50  2 nM | inhibition percentage  31 % | Ki (inhibition constant)  2.7E-09 M | Ki (inhibition constant)  31.9 nM

>  <CAS>
58-33-3

>  <Description>
Promethazine is a first generation histamine H1 receptor antagonist. It is also a moderate mACh receptor antagonist, has affinity to 5-HT2A, 5-HT2C, D2 and alpha-1-adrenergic receptors. Promethazine is used for the treatment of allergic conditions, nausea and vomiting, and motion sickness.

>  <EBC_ID>
EBC-06814

>  <IUPAC Name>
dimethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine hydrochloride

>  <Main Tar all refs>
Br. J. Pharmacol. Chemother., 1955, vol. 10, # 3, p. 270 - 278 | Br. J. Pharmacol., 1980, vol. 68, # 4, p. 687 - 696 | Eur. J. Clin. Pharmacol., 2002, vol. 57, # 12, p. 847 - 851 | EUR. J. PHARMACOL., 1986, vol. 123, # 1, p. 133 - 143 | EUR. J. PHARMACOL., 1990, vol. 191, # 2, p. 221 - 224

>  <Main tar all>
Histamine receptor pX=8.93 | H1 receptor pX=8.7 | Cytochrome P450 2C9 pX=8.65 | mAChR pX=8.57 | Octopamine receptor pX=7.5

$$$$
Cyclophosphamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.9142 5.9675 0 0
M  V30 2 N -2.9142 4.4275 0 0
M  V30 3 C -4.2479 3.6575 0 0
M  V30 4 C -1.5805 3.6575 0 0
M  V30 5 C -1.5805 2.1175 0 0
M  V30 6 O -0.2468 1.3475 0 0
M  V30 7 C -0.2468 -0.1925 0 0
M  V30 8 C -1.7868 -0.1925 0 0
M  V30 9 C -0.2468 -1.7325 0 0
M  V30 10 C 1.0868 -2.5025 0 0
M  V30 11 C 1.0868 -4.0425 0 0
M  V30 12 C -0.2468 -4.8125 0 0
M  V30 13 C -1.5805 -4.0425 0 0
M  V30 14 C -1.5805 -2.5025 0 0
M  V30 15 C 1.2932 -0.1925 0 0
M  V30 16 C 2.0632 1.1412 0 0
M  V30 17 C 3.6032 1.1412 0 0
M  V30 18 C 4.3732 -0.1925 0 0
M  V30 19 C 3.6032 -1.5262 0 0
M  V30 20 N 2.0632 -1.5262 0 0
M  V30 21 O 7.8932 -0.385 0 0
M  V30 22 C 9.2268 0.385 0 0
M  V30 23 O 9.2268 1.925 0 0
M  V30 24 C 10.5605 -0.385 0 0
M  V30 25 C 11.8942 0.385 0 0
M  V30 26 C 13.2279 -0.385 0 0
M  V30 27 O 14.5616 0.385 0 0
M  V30 28 O 13.2279 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 7 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546621745

>  <MW>
388.2

>  <MW (desalted)>
270.369

>  <ClogP>
2.354

>  <logS>
-1.468

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
25.36

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  21.2 ?M

>  <CAS>
562-10-7

>  <EBC_ID>
EBC-84045

>  <IUPAC Name>
2-[bis(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=4.67

$$$$
Nizatidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.836 -8.6987 0 0
M  V30 2 N -1.836 -7.1587 0 0
M  V30 3 C -0.5023 -6.3887 0 0
M  V30 4 C -0.5023 -4.8487 0 0
M  V30 5 N -1.836 -4.0787 0 0 CHG=1
M  V30 6 O -1.836 -2.5387 0 0
M  V30 7 O -3.1697 -4.8487 0 0 CHG=-1
M  V30 8 N 0.8314 -7.1587 0 0
M  V30 9 C 2.165 -6.3887 0 0
M  V30 10 C 3.4987 -7.1587 0 0
M  V30 11 S 4.8324 -6.3887 0 0
M  V30 12 C 6.1661 -7.1587 0 0
M  V30 13 C 7.4998 -6.3887 0 0
M  V30 14 C 7.6607 -4.8571 0 0
M  V30 15 S 9.1671 -4.5369 0 0
M  V30 16 C 9.9371 -5.8706 0 0
M  V30 17 C 11.4686 -6.0316 0 0
M  V30 18 N 12.095 -7.4384 0 0
M  V30 19 C 13.6266 -7.5994 0 0
M  V30 20 C 11.1898 -8.6843 0 0
M  V30 21 N 8.9066 -7.015 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5 CFG=2
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 3 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 2 16 21
M  V30 21 1 13 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553983

>  <MW>
331.114

>  <MW (desalted)>
331.457

>  <ClogP>
-0.162

>  <logS>
-2.06

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
83.33

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50  495 ?M

>  <CAS>
76963-41-2

>  <Description>
Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. It is used for the treatment of acid-reflux disorders, peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.

>  <EBC_ID>
EBC-11197

>  <IUPAC Name>
dimethyl[(4-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine

>  <Main Tar all refs>
COLLIDION INC - WO2023/278604, 2023, A1

>  <Main tar all>
Alpha-crystallin A chain pX=3.31

$$$$
Chloroquine phosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -8.4319 -2.6987 0 0
M  V30 2 C -6.9197 -2.9897 0 0
M  V30 3 N -5.9115 -1.8256 0 0
M  V30 4 C -6.4156 -0.3704 0 0
M  V30 5 C -5.4074 0.7937 0 0
M  V30 6 C -4.3993 -2.1166 0 0
M  V30 7 C -3.3911 -0.9525 0 0
M  V30 8 C -1.8789 -1.2435 0 0
M  V30 9 C -0.8707 -0.0794 0 0
M  V30 10 C -1.3748 1.3758 0 0
M  V30 11 N 0.6416 -0.3704 0 0
M  V30 12 C 1.6497 0.7937 0 0
M  V30 13 C 1.1456 2.2489 0 0
M  V30 14 C 2.1538 3.413 0 0
M  V30 15 N 3.6661 3.122 0 0
M  V30 16 C 4.1701 1.6668 0 0
M  V30 17 C 5.6824 1.3758 0 0
M  V30 18 C 6.1865 -0.0794 0 0
M  V30 19 Cl 7.6987 -0.3704 0 0
M  V30 20 C 5.1783 -1.2435 0 0
M  V30 21 C 3.6661 -0.9525 0 0
M  V30 22 C 3.162 0.5027 0 0
M  V30 23 O 12.7587 -1.54 0 0
M  V30 24 P 12.7587 0 0 0
M  V30 25 O 12.7587 1.54 0 0
M  V30 26 O 14.2987 -0 0 0
M  V30 27 O 11.2187 0 0 0
M  V30 28 O 0 -9.1497 0 0
M  V30 29 P 0 -7.6097 0 0
M  V30 30 O 0 -6.0697 0 0
M  V30 31 O 1.54 -7.6097 0 0
M  V30 32 O -1.54 -7.6097 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 12 22
M  V30 23 1 16 22
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 1 28 29
M  V30 29 2 29 30
M  V30 30 1 29 31
M  V30 31 1 29 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541662176

>  <MW>
515.863

>  <MW (desalted)>
319.872

>  <ClogP>
5.06

>  <logS>
1.19

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
28.16

>  <RotBonds>
8

>  <Action on targets>
Substrate | Inhibitor

>  <Activity coefficients and valu>
pKa (association)  8.4 - 10.6 | IC50  0.23 nM

>  <CAS>
50-63-5

>  <Description>
Chloroquine is an aminoquinoline that is an inhibitor of autophagy and has antimalarial and anticancer activities. Chloroquine phosphate is widely used to treat malaria and rheumatoid arthritis.

>  <EBC_ID>
EBC-07364

>  <IUPAC Name>
7-chloro-N-[5-(diethylamino)pentan-2-yl]quinolin-4-amine; bis(phosphoric acid)

>  <Main Tar all refs>
ACS Infect. Dis., 2017, vol. 3, # 2, p. 119 - 131 | ACS Infect. Dis., 2022, vol. 8, # 8, p. 1700 - 1710

>  <Main tar all>
Hematin pX=10.6 | Heme ligase pX=9.64

$$$$
Bevantolol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -13.86 0 0
M  V30 2 O 0 -12.32 0 0
M  V30 3 C 1.3337 -11.55 0 0
M  V30 4 C 1.3337 -10.01 0 0
M  V30 5 C 2.6674 -9.24 0 0
M  V30 6 C 4.001 -10.01 0 0
M  V30 7 C 5.3347 -9.24 0 0
M  V30 8 C 6.6684 -10.01 0 0
M  V30 9 N 8.0021 -9.24 0 0
M  V30 10 C 9.3358 -10.01 0 0
M  V30 11 C 10.6694 -9.24 0 0
M  V30 12 O 10.6694 -7.7 0 0
M  V30 13 C 12.0031 -10.01 0 0
M  V30 14 O 13.3368 -9.24 0 0
M  V30 15 C 14.6705 -10.01 0 0
M  V30 16 C 16.0041 -9.24 0 0
M  V30 17 C 17.3378 -10.01 0 0
M  V30 18 C 17.3378 -11.55 0 0
M  V30 19 C 16.0041 -12.32 0 0
M  V30 20 C 16.0041 -13.86 0 0
M  V30 21 C 14.6705 -11.55 0 0
M  V30 22 C 4.001 -11.55 0 0
M  V30 23 C 2.6674 -12.32 0 0
M  V30 24 O 2.6674 -13.86 0 0
M  V30 25 C 1.3337 -14.63 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 2 15 21
M  V30 22 2 6 22
M  V30 23 1 22 23
M  V30 24 2 3 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z31382955

>  <MW>
345.194

>  <MW (desalted)>
345.433

>  <ClogP>
2.995

>  <logS>
-3.48

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
59.95

>  <RotBonds>
10

>  <Action on targets>
- | Antagonist | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 15 nM | pA2  7.8  | IC50 = 42.8 nM

>  <CAS>
59170-23-9

>  <Description>
Bevantolol is a beta-1 adrenoceptor antagonist. It is effective as other beta blockers for the treatment of angina pectoris and hypertension.

>  <EBC_ID>
EBC-08523

>  <IUPAC Name>
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol

>  <Main Tar all refs>
Curr. Pharm. Des., 2004, vol. 10, # 13, p. 1519 - 1536 | J. PHARMACOL. EXP. THER., 1976, vol. 199, # 2, p. 329 - 335 | SOM INNOVATION BIOTECH SL - WO2014/202646, 2014, A1

>  <Main tar all>
?1-adrenoceptor pX=7.82 | ?-adrenoceptor pX=7.8 | Vesicular monoamine transporter 2 pX=7.37

$$$$
Bumetanide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 -0.77 0 0
M  V30 2 C -5.3347 -0 0 0
M  V30 3 C -4.001 -0.77 0 0
M  V30 4 C -2.6674 -0 0 0
M  V30 5 N -1.3337 -0.77 0 0
M  V30 6 C -1.3337 -2.31 0 0
M  V30 7 C -2.6674 -3.08 0 0
M  V30 8 C -2.6674 -4.62 0 0
M  V30 9 C -1.3337 -5.39 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 C 0 -3.08 0 0
M  V30 12 O 1.3337 -2.31 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 0 -0 0 0
M  V30 15 C 0 1.54 0 0
M  V30 16 C 1.3337 2.31 0 0
M  V30 17 C 2.6674 1.54 0 0
M  V30 18 C 2.6674 -0 0 0
M  V30 19 S 1.3337 -5.39 0 0
M  V30 20 O 0.5637 -6.7237 0 0
M  V30 21 O 2.1037 -4.0563 0 0
M  V30 22 N 2.6674 -6.16 0 0
M  V30 23 C -4.001 -5.39 0 0
M  V30 24 O -5.3347 -4.62 0 0
M  V30 25 O -4.001 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 10 19
M  V30 21 2 19 20
M  V30 22 2 19 21
M  V30 23 1 19 22
M  V30 24 1 8 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541758727

>  <MW>
364.109

>  <MW (desalted)>
364.416

>  <ClogP>
3.372

>  <logS>
-4.38

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
118.72

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate

>  <Activity coefficients and valu>
biofilm formation rate increase Active   | biofilm formation rate increase Active   | Kd (dissociation constant)  1.43E-08 M | Ki (inhibition constant) = 21.1 nM | Ki (inhibition constant) = 25.8 nM | IC50  0.039 ?M | Ki (inhibition constant) = 62 nM | Ki (inhibition constant) = 159 nM | Kd (dissociation constant)  1.75E-07 M | Ki (inhibition constant) = 250 nM | Ki (inhibition constant) = 303 nM | Km (Michaelis constant)  306 nM

>  <CAS>
28395-03-1

>  <Description>
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide also inhibits several isoforms of carbonic anhydrase.

>  <EBC_ID>
EBC-04409

>  <IUPAC Name>
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid

>  <Main Tar all refs>
Life Sci., 2021, vol. 273 | Life Sci., 2021, vol. 273 | Mol. Neurobiol., 2018, p. 1 - 11 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Eur. J. Pharm. Sci., 2019, vol. 133, p. 95 - 103 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | Org. Biomol. Chem., 2008, vol. 6, # 14, p. 2499 - 2506 | TOTTORI UNIVERSITY - US2018/338899, 2018, A1 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | Curr. Pharm. Des., 2008, vol. 14, # 7, p. 641 - 648 | J. Pharmacol. Exp. Ther., 2004, vol. 308, # 3, p. 1021 - 1029

>  <Main tar all>
Accessory gene regulator A pX=7.92 | Accessory gene regulator protein A pX=7.92 | Alternative prion protein pX=7.84 | carbonic anhydrase 12 pX=7.68 | carbonic anhydrase 9 pX=7.59 | Organic anion transporter 3 pX=7.41 | carbonic anhydrase 7 pX=7.21 | Carbonic anhydrase 5B, mitochondrial pX=6.8 | Histone acetyltransferase KAT8 pX=6.76 | carbonic anhydrase 14 pX=6.6 | carbonic anhydrase 4 pX=6.52 | Solute carrier family 22 member 11 pX=6.51

$$$$
fluorescein disodium salt
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na -1.3337 5.39 0 0 CHG=1
M  V30 2 Na 10.6694 -1.54 0 0 CHG=1
M  V30 3 O -0 4.62 0 0 CHG=-1
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 O 0.4285 2.6041 0 0
M  V30 6 C 2.6674 4.62 0 0
M  V30 7 C 2.6674 6.16 0 0
M  V30 8 C 4.001 6.93 0 0
M  V30 9 C 5.3347 6.16 0 0
M  V30 10 C 5.3347 4.62 0 0
M  V30 11 C 4.001 3.85 0 0
M  V30 12 C 4.001 2.31 0 0
M  V30 13 C 5.3347 1.54 0 0
M  V30 14 C 6.6684 2.31 0 0
M  V30 15 C 8.0021 1.54 0 0
M  V30 16 C 8.0021 -0 0 0
M  V30 17 O 9.3358 -0.77 0 0 CHG=-1
M  V30 18 C 6.6684 -0.77 0 0
M  V30 19 C 5.3347 0 0 0
M  V30 20 O 4.001 -0.77 0 0
M  V30 21 C 2.6674 0 0 0
M  V30 22 C 1.3337 -0.77 0 0
M  V30 23 C -0 0 0 0
M  V30 24 O -1.3337 -0.77 0 0
M  V30 25 C 0 1.54 0 0
M  V30 26 C 1.3337 2.31 0 0
M  V30 27 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 2 4 5
M  V30 3 1 4 6
M  V30 4 1 6 7
M  V30 5 2 7 8
M  V30 6 1 8 9
M  V30 7 2 9 10
M  V30 8 1 10 11
M  V30 9 2 6 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 2 16 18
M  V30 17 1 18 19
M  V30 18 2 13 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 12 27
M  V30 28 1 21 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1160865418

>  <MW>
376.27

>  <MW (desalted)>
332.306

>  <ClogP>
-3.39

>  <logS>
-7.16

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
89.49

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | - | -

>  <Activity coefficients and valu>
Kd (dissociation constant) = 36.4 nM | percentage increase Active   | percentage increase Active

>  <CAS>
518-47-8

>  <Description>
Fluorescein is a dye used in angiography or angioscopy of the iris and retina.

>  <EBC_ID>
EBC-13035

>  <IUPAC Name>
disodium 2-(6-oxido-3-oxo-3H-xanthen-9-yl)benzoate

>  <Main Tar all refs>
BRACCO SPA - US2014/161732, 2014, A1 | Mol. Pharm., 2016, vol. 13, # 2, p. 438 - 448 | Mol. Pharm., 2016, vol. 13, # 2, p. 438 - 448

>  <Main tar all>
kinase insert domain receptor pX=7.44 | OATP1B3 pX=6.0 | OATP2B1 pX=6.0

$$$$
Duvelisib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0 1.54 0 0
M  V30 2 C 0 -0 0 0 CFG=2
M  V30 3 N -1.3337 -0.77 0 0
M  V30 4 C -2.6674 -0 0 0
M  V30 5 N -4.001 -0.77 0 0
M  V30 6 C -5.3347 -0 0 0
M  V30 7 N -5.3347 1.54 0 0
M  V30 8 C -4.001 2.31 0 0
M  V30 9 N -3.6809 3.8163 0 0
M  V30 10 C -2.1493 3.9773 0 0
M  V30 11 N -1.5229 2.5705 0 0
M  V30 12 C -2.6674 1.54 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 4.001 -0.77 0 0
M  V30 16 C 5.3347 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 C 5.3347 -3.08 0 0
M  V30 20 Cl 5.3347 -4.62 0 0
M  V30 21 C 4.001 -2.31 0 0
M  V30 22 C 2.6674 -3.08 0 0
M  V30 23 O 2.6674 -4.62 0 0
M  V30 24 N 1.3337 -2.31 0 0
M  V30 25 C 0 -3.08 0 0
M  V30 26 C 0 -4.62 0 0
M  V30 27 C -1.3337 -5.39 0 0
M  V30 28 C -2.6674 -4.62 0 0
M  V30 29 C -2.6674 -3.08 0 0
M  V30 30 C -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 4 12
M  V30 13 1 8 12
M  V30 14 1 2 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 2 15 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 13 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 2 26 27
M  V30 31 1 27 28
M  V30 32 2 28 29
M  V30 33 1 29 30
M  V30 34 2 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280951

>  <MW>
416.863

>  <MW (desalted)>
416.863

>  <ClogP>
4.39

>  <logS>
-7.149

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
86.8

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) = 23 pM | Ki (inhibition constant)  100 - 1000 pM

>  <CAS>
1201438-56-3

>  <Description>
Duvelisib is an inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

>  <EBC_ID>
EBC-24031

>  <IUPAC Name>
8-chloro-2-phenyl-3-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one

>  <Main Tar all refs>
INFINITY PHARMACEUTICALS INC - US2014/120083, 2014, A1 | INFINITY PHARMACEUTICALS INC - US2014/120083, 2014, A1

>  <Main tar all>
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta pX=10.6 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma pX=10.0

$$$$
Probucol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -2.31 0 0
M  V30 2 C 4.001 -3.85 0 0
M  V30 3 C 2.461 -3.85 0 0
M  V30 4 C 5.541 -3.85 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -6.16 0 0
M  V30 7 C 5.3347 -7.7 0 0
M  V30 8 S 6.6684 -8.47 0 0
M  V30 9 C 8.0021 -7.7 0 0
M  V30 10 C 8.7721 -9.0337 0 0
M  V30 11 C 7.2321 -6.3663 0 0
M  V30 12 S 9.3358 -6.93 0 0
M  V30 13 C 10.6694 -7.7 0 0
M  V30 14 C 12.0031 -6.93 0 0
M  V30 15 C 13.3368 -7.7 0 0
M  V30 16 C 13.3368 -9.24 0 0
M  V30 17 O 14.6705 -10.01 0 0
M  V30 18 C 12.0031 -10.01 0 0
M  V30 19 C 10.6694 -9.24 0 0
M  V30 20 C 12.0031 -11.55 0 0
M  V30 21 C 12.0031 -13.09 0 0
M  V30 22 C 10.4631 -11.55 0 0
M  V30 23 C 13.5431 -11.55 0 0
M  V30 24 C 14.6705 -6.93 0 0
M  V30 25 C 16.0041 -6.16 0 0
M  V30 26 C 15.4405 -8.2637 0 0
M  V30 27 C 13.9005 -5.5963 0 0
M  V30 28 C 4.001 -8.47 0 0
M  V30 29 C 2.6674 -7.7 0 0
M  V30 30 C 2.6674 -6.16 0 0
M  V30 31 O 1.3337 -5.39 0 0
M  V30 32 C 1.3337 -8.47 0 0
M  V30 33 C 0 -9.24 0 0
M  V30 34 C 0.5637 -7.1363 0 0
M  V30 35 C 2.1037 -9.8037 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 13 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 20 23
M  V30 24 1 15 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 1 7 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 5 30
M  V30 32 1 30 31
M  V30 33 1 29 32
M  V30 34 1 32 33
M  V30 35 1 32 34
M  V30 36 1 32 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404498

>  <MW>
516.842

>  <MW (desalted)>
516.842

>  <ClogP>
10.967

>  <logS>
-10.6

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
8

>  <Action on targets>
Activator | Inhibitor | -

>  <Activity coefficients and valu>
enzyme activity rate increase Active   | inhibition rate Active   | enzyme activity decrease Active

>  <CAS>
23288-49-5

>  <Description>
Probucol is a potent antioxidant that inhibits the oxidation of cholesterol in low-density lipoprotein, which prevents the formation of macrophage-derived foam cells that lead to atherosclerotic vascular lesions. Probucol is an anti-hyperlipidemic drug, used to lower LDL and HDL cholesterol.

>  <EBC_ID>
EBC-07542

>  <IUPAC Name>
2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol

>  <Main Tar all refs>
Mol. Neurobiol., 2020 | Int. J. Mol. Sci., 2023, vol. 24, # 2 | GARCIA BENNETT; GIRI; ONG LAU - WO2020/154770, 2020, A1

>  <Main tar all>
Glutathione peroxidase 1 pX=8.0 | ABCA1 pX=7.0 | COX-1  pX=7.0

$$$$
Spironolactone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.5277 -9.2727 0 0
M  V30 2 C 4.0645 -9.3716 0 0
M  V30 3 O 4.7472 -10.752 0 0
M  V30 4 S 4.9186 -8.0902 0 0
M  V30 5 C 4.2359 -6.7098 0 0 CFG=2
M  V30 6 C 2.6991 -6.6108 0 0
M  V30 7 C 2.0164 -5.2304 0 0
M  V30 8 C 0.4796 -5.1314 0 0
M  V30 9 C -0.2031 -3.751 0 0
M  V30 10 O -1.74 -3.6521 0 0
M  V30 11 C 0.651 -2.4696 0 0
M  V30 12 C 2.1878 -2.5686 0 0
M  V30 13 C 2.8705 -3.949 0 0 CFG=1
M  V30 14 C 3.7246 -2.6675 0 0
M  V30 15 C 4.4073 -4.0479 0 0 CFG=1
M  V30 16 C 5.2614 -2.7665 0 0
M  V30 17 C 6.7982 -2.8655 0 0
M  V30 18 C 7.4809 -4.2459 0 0 CFG=1
M  V30 19 C 8.05 -2.8148 0 0
M  V30 20 C 6.6268 -5.5273 0 0 CFG=1
M  V30 21 C 7.5816 -6.7356 0 0
M  V30 22 C 9.0258 -6.2009 0 0
M  V30 23 C 8.9636 -4.6622 0 0 CFG=1
M  V30 24 C 8.9014 -3.1234 0 0
M  V30 25 C 10.3456 -2.5888 0 0
M  V30 26 C 11.3004 -3.7971 0 0
M  V30 27 O 12.8391 -3.7349 0 0
M  V30 28 O 10.4463 -5.0785 0 0
M  V30 29 C 5.09 -5.4283 0 0 CFG=2
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 7
M  V30 14 1 13 14 CFG=1
M  V30 15 1 15 13
M  V30 16 1 15 16 CFG=1
M  V30 17 1 16 17
M  V30 18 1 18 17
M  V30 19 1 18 19 CFG=1
M  V30 20 1 20 18
M  V30 21 1 20 21 CFG=1
M  V30 22 1 21 22
M  V30 23 1 23 22
M  V30 24 1 18 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 23 28 CFG=1
M  V30 31 1 29 20 CFG=3
M  V30 32 1 29 5
M  V30 33 1 29 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616196

>  <MW>
416.573

>  <MW (desalted)>
416.573

>  <ClogP>
2.839

>  <logS>
-5.01

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
60.44

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Blocker | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.013 nM | inhibition percentage  520 % | IC50 = 0.4 nM

>  <CAS>
52-01-7

>  <Description>
Spironolactone is a potassium sparing diuretic like eplerenone that competitively inhibits mineralocorticoid receptors in the distal convoluted tubule to promote sodium and water excretion and potassium retention. It is indicated to treat a number of conditions including heart failure, deem, hyperaldosteronism, adrenal hyperplasia, hypertension, and nephrotic syndrome.

>  <EBC_ID>
EBC-09098

>  <IUPAC Name>
(1R,3aS,3bR,4R,9aR,9bS,11aS)-4-(acetylsulfanyl)-9a,11a-dimethyl-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydrospiro[cyclopenta[a]phenanthrene-1,2'-oxolane]-5',7-dione

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2009, vol. 9, # 9, p. 1113 - 1126 | Circulation, 2003, vol. 107, # 6, p. 889 - 895 | GLAXOSMITHKLINE PLC - US2007/219348, 2007, A1

>  <Main tar all>
Androgen receptor pX=10.9 | Kv11.1 pX=10.3 | Mineralocorticoid receptor pX=9.4

$$$$
Florfenicol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -9.0337 1.1826 0 0
M  V30 2 S -7.4937 1.1826 0 0
M  V30 3 O -7.4937 -0.3574 0 0
M  V30 4 O -7.4937 2.7226 0 0
M  V30 5 C -5.9537 1.1826 0 0
M  V30 6 C -5.1837 2.5163 0 0
M  V30 7 C -3.6437 2.5163 0 0
M  V30 8 C -2.8737 1.1826 0 0
M  V30 9 C -3.6437 -0.151 0 0
M  V30 10 C -5.1837 -0.151 0 0
M  V30 11 C -1.3337 1.1826 0 0 CFG=1
M  V30 12 O -0.5637 -0.151 0 0
M  V30 13 C -0.5637 2.5163 0 0 CFG=1
M  V30 14 C -1.3337 3.85 0 0
M  V30 15 F -0.5637 5.1837 0 0
M  V30 16 N 0.9763 2.5163 0 0
M  V30 17 C 1.7463 3.85 0 0
M  V30 18 O 0.9763 5.1837 0 0
M  V30 19 C 3.2863 3.85 0 0
M  V30 20 Cl 4.0563 5.1837 0 0
M  V30 21 Cl 4.0563 2.5163 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 11 8
M  V30 12 1 11 12 CFG=3
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 13 16 CFG=1
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2065671685

>  <MW>
358.213

>  <MW (desalted)>
358.213

>  <ClogP>
0.032

>  <logS>
-2.955

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
83.47

>  <RotBonds>
6

>  <Action on targets>
Blocker | Substrate | Substrate

>  <Activity coefficients and valu>
inhibition percentage  77.5 % | metabolite formation Active   | metabolite formation Active

>  <CAS>
73231-34-2

>  <Description>
Florfenicol is a fluorinated derivative of thiamphenicol. Florfenicol inhibits bacterial protein synthesis, it is used as an antibacterial.

>  <EBC_ID>
EBC-47475

>  <IUPAC Name>
2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide

>  <Main Tar all refs>
Pharm. Res., 2019, vol. 36, # 9 | Food Chem. Toxicol., 2022, vol. 169 | Food Chem. Toxicol., 2022, vol. 169

>  <Main tar all>
Nav1.8 pX=5.54 | Cytochrome P450 2C9 pX=4.3 | Cytochrome P450 2D6 pX=4.3

$$$$
Lovastatin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 0 0 0
M  V30 2 C 6.6684 0.77 0 0
M  V30 3 C 8.0021 0 0 0 CFG=2
M  V30 4 C 8.0021 -1.54 0 0
M  V30 5 C 9.3358 0.77 0 0
M  V30 6 O 9.3358 2.31 0 0
M  V30 7 O 10.6694 0 0 0
M  V30 8 C 12.0031 0.77 0 0 CFG=1
M  V30 9 C 12.0031 2.31 0 0
M  V30 10 C 13.3368 3.08 0 0 CFG=1
M  V30 11 C 13.3368 4.62 0 0
M  V30 12 C 14.6705 2.31 0 0
M  V30 13 C 14.6705 0.77 0 0
M  V30 14 C 16.0041 0 0 0
M  V30 15 C 16.0041 -1.54 0 0
M  V30 16 C 14.6705 -2.31 0 0 CFG=2
M  V30 17 C 14.6705 -3.85 0 0
M  V30 18 C 13.3368 -1.54 0 0 CFG=2
M  V30 19 C 12.0031 -2.31 0 0
M  V30 20 C 12.0031 -3.85 0 0
M  V30 21 C 10.6694 -4.62 0 0 CFG=2
M  V30 22 C 9.3358 -3.85 0 0
M  V30 23 C 8.0021 -4.62 0 0 CFG=1
M  V30 24 O 6.6684 -3.85 0 0
M  V30 25 C 8.0021 -6.16 0 0
M  V30 26 C 9.3358 -6.93 0 0
M  V30 27 O 9.3358 -8.47 0 0
M  V30 28 O 10.6694 -6.16 0 0
M  V30 29 C 13.3368 0 0 0 CFG=1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=1
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 16 15
M  V30 16 1 16 17 CFG=3
M  V30 17 1 18 16
M  V30 18 1 18 19 CFG=3
M  V30 19 1 19 20
M  V30 20 1 21 20 CFG=1
M  V30 21 1 21 22
M  V30 22 1 23 22
M  V30 23 1 23 24 CFG=3
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 21 28
M  V30 29 1 18 29
M  V30 30 1 29 8
M  V30 31 1 29 13 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754931258

>  <MW>
404.54

>  <MW (desalted)>
404.54

>  <ClogP>
4.082

>  <logS>
-4.56

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
72.83

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.007 nM

>  <CAS>
75330-75-5

>  <Description>
Lovastatin is a cell-permeable HMG-CoA reductase inhibitor. It is a prodrug of its more potent metabolite, lovastatin hydroxy acid. Lovastatin is used in the treatment of hypercholesterolemia

>  <EBC_ID>
EBC-02080

>  <IUPAC Name>
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate

>  <Main Tar all refs>
J. MED. CHEM., 1994, vol. 37, # 20, p. 3240 - 3246

>  <Main tar all>
hydroxymethylglutaryl-CoA reductase pX=11.2

$$$$
Perphenazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -5.3347 9.24 0 0
M  V30 2 C -4.001 8.47 0 0
M  V30 3 C -2.6674 9.24 0 0
M  V30 4 N -1.3337 8.47 0 0
M  V30 5 C -0 9.24 0 0
M  V30 6 C 1.3337 8.47 0 0
M  V30 7 N 1.3337 6.93 0 0
M  V30 8 C 2.6674 6.16 0 0
M  V30 9 C 2.6674 4.62 0 0
M  V30 10 C 4.001 3.85 0 0
M  V30 11 N 4.001 2.31 0 0
M  V30 12 C 5.3347 1.54 0 0
M  V30 13 C 6.6684 2.31 0 0
M  V30 14 C 8.0021 1.54 0 0
M  V30 15 C 8.0021 -0 0 0
M  V30 16 C 6.6684 -0.77 0 0
M  V30 17 C 5.3347 0 0 0
M  V30 18 S 4.001 -0.77 0 0
M  V30 19 C 2.6674 0 0 0
M  V30 20 C 1.3337 -0.77 0 0
M  V30 21 C -0 0 0 0
M  V30 22 C 0 1.54 0 0
M  V30 23 Cl -1.3337 2.31 0 0
M  V30 24 C 1.3337 2.31 0 0
M  V30 25 C 2.6674 1.54 0 0
M  V30 26 C -0 6.16 0 0
M  V30 27 C -1.3337 6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 1 24 25
M  V30 26 1 11 25
M  V30 27 2 19 25
M  V30 28 1 7 26
M  V30 29 1 26 27
M  V30 30 1 4 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532754

>  <MW>
403.969

>  <MW (desalted)>
403.969

>  <ClogP>
3.807

>  <logS>
-3.96

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
29.95

>  <RotBonds>
6

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor | Inhibitor | Antagonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0244 nM | IC50  0.0244 nM | Ki (inhibition constant) = 0.182 nM | Ki (inhibition constant) = 0.182 nM | IC50  0.201 nM | IC50  0.201 nM | Ki (inhibition constant) = 0.458 nM | Ki (inhibition constant) = 0.688 nM | pIC50  9.15  | Kb (antagonist dissociation constant)  0.73 nM | Ki (inhibition constant)  0.79 nM | Ki (inhibition constant)  0.79 nM

>  <CAS>
58-39-9

>  <Description>
Perphenazine is a typical antipsychotic drug, inhibits 5-HT2A receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor. It is described as a typical antipsychotic and has been used extensively for schizophrenia and schizophrenia-like psychoses.

>  <EBC_ID>
EBC-00669

>  <IUPAC Name>
2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol

>  <Main Tar all refs>
Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Eur. Neuropsychopharmacol., 2009, vol. 19, # 1, p. 1 - 13 | Eur. Neuropsychopharmacol., 2009, vol. 19, # 1, p. 1 - 13 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Eur. J. Pharmacol., 2011, vol. 666, # 1-3, p. 43 - 52 | Eur. Neuropsychopharmacol., 2009, vol. 19, # 1, p. 1 - 13 | Eur. Neuropsychopharmacol., 2009, vol. 19, # 1, p. 1 - 13 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | SCIENCE, 1978, vol. 199, # 4327, p. 443 - 445 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154 | EUR. J. PHARMACOL., 1983, vol. 91, # 1, p. 153 - 154

>  <Main tar all>
D2 receptor (isoform 2) pX=10.6 | D2S receptor pX=10.6 | D2 receptor (isoform?1) pX=9.74 | D2L receptor pX=9.74 | D3 receptor pX=9.7 | D3 receptor pX=9.7 | H1 receptor pX=9.34 | ?2-adrenoceptor pX=9.16 | D2L receptor pX=9.15 | Dopamine receptor pX=9.14 | D2 receptor pX=9.1 | D2 receptor pX=9.1

$$$$
Sertaconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -6.3579 -7.0789 0 0
M  V30 2 C -4.8515 -6.7587 0 0
M  V30 3 C -3.8211 -7.9031 0 0
M  V30 4 C -2.3147 -7.583 0 0
M  V30 5 C -1.8389 -6.1183 0 0
M  V30 6 C -0.3325 -5.7982 0 0
M  V30 7 C 0.698 -6.9426 0 0
M  V30 8 N 0.2221 -8.4072 0 0
M  V30 9 C 1.1273 -9.6531 0 0
M  V30 10 C 0.2221 -10.899 0 0
M  V30 11 N -1.2426 -10.4231 0 0
M  V30 12 C -1.2426 -8.8831 0 0
M  V30 13 O 0.1434 -4.3335 0 0
M  V30 14 C 1.6497 -4.0133 0 0
M  V30 15 C 2.1256 -2.5487 0 0
M  V30 16 C 1.2204 -1.3028 0 0
M  V30 17 S 2.1256 -0.0569 0 0
M  V30 18 C 3.5902 -0.5328 0 0
M  V30 19 C 4.9239 0.2372 0 0
M  V30 20 Cl 4.9239 1.7772 0 0
M  V30 21 C 6.2576 -0.5328 0 0
M  V30 22 C 6.2576 -2.0728 0 0
M  V30 23 C 4.9239 -2.8428 0 0
M  V30 24 C 3.5902 -2.0728 0 0
M  V30 25 C -2.8693 -4.9739 0 0
M  V30 26 Cl -2.3934 -3.5093 0 0
M  V30 27 C -4.3757 -5.2941 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 8 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 15 24
M  V30 26 2 18 24
M  V30 27 2 5 25
M  V30 28 1 25 26
M  V30 29 1 25 27
M  V30 30 2 2 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2194031487

>  <MW>
437.77

>  <MW (desalted)>
437.77

>  <ClogP>
6.16

>  <logS>
-6.666

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
27.05

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Blocker | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.28 ?M | decrease rate Active   | decrease rate Active   | IC50 >= 2 ?M | inhibition percentage  58.6 % | inhibition percentage  58.6 % | mRNA expression level increase  84 % | IC50  8.4 ?M

>  <CAS>
99592-32-2

>  <Description>
Sertaconazole is a topical antifungal agent used in the treatment of interdigital tinea pedis in immunocompetent patients.

>  <EBC_ID>
EBC-01061

>  <IUPAC Name>
1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

>  <Main Tar all refs>
Biochem. Pharmacol., 2022, vol. 204 | Helmholtz Association - WO2018/115319, 2018, A2 | Helmholtz Association - WO2018/115319, 2018, A2 | UNIVERSITY OF CALIFORNIA - WO2022/93871, 2022, A1 | Pharm. Res., 2019, vol. 36, # 9 | Pharm. Res., 2019, vol. 36, # 9 | Naunyn-Schmiedeberg's Arch. Pharmacol., 2021, vol. 394, # 6, p. 1231 - 1249 | Eur. J. Med. Chem., 2014, vol. 84, p. 284 - 301

>  <Main tar all>
Long-chain-fatty-acid-CoA ligase 4 pX=6.55 | CYP7B1 pX=6.0 | CYP7B1 pX=6.0 | Replicase polyprotein 1ab pX=5.7 | Kv7.1 pX=5.15 | Kv7.1 pX=5.15 | tubulin alpha 1a pX=5.12 | indoleamine 2,3-dioxygenase 1 pX=5.08

$$$$
Vildagliptin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.5899 -4.6359 0 0
M  V30 2 C 1.5898 -3.0959 0 0 CFG=2
M  V30 3 C 0.2171 -3.7934 0 0
M  V30 4 C 1.056 -2.3182 0 0 CFG=2
M  V30 5 C 2.4289 -3.0158 0 0
M  V30 6 C 3.802 -2.3182 0 0 CFG=2
M  V30 7 C 2.963 -3.7934 0 0
M  V30 8 C 1.5898 -1.7007 0 0
M  V30 9 C 2.4289 -0.2255 0 0 CFG=2
M  V30 10 C 1.056 -0.9231 0 0
M  V30 11 C 3.802 -0.9231 0 0
M  V30 12 N 2.4289 1.3145 0 0
M  V30 13 C 1.0952 2.0845 0 0
M  V30 14 C 1.0951 3.6245 0 0
M  V30 15 O 2.4288 4.3945 0 0
M  V30 16 N -0.2386 4.3944 0 0
M  V30 17 C -1.6454 3.768 0 0
M  V30 18 C -2.6759 4.9124 0 0
M  V30 19 C -1.906 6.2461 0 0
M  V30 20 C -0.3996 5.926 0 0 CFG=1
M  V30 21 C 0.7448 6.9565 0 0
M  V30 22 N 1.8892 7.987 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 9 11
M  V30 9 1 9 8
M  V30 10 1 9 10
M  V30 11 1 4 10
M  V30 12 1 2 8
M  V30 13 1 6 11
M  V30 14 1 9 12 CFG=1
M  V30 15 1 12 13
M  V30 16 1 13 14
M  V30 17 2 14 15
M  V30 18 1 14 16
M  V30 19 1 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 20 19
M  V30 23 1 20 16
M  V30 24 1 20 21 CFG=1
M  V30 25 3 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741976872

>  <MW>
303.399

>  <MW (desalted)>
303.399

>  <ClogP>
0.692

>  <logS>
-2.417

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
76.36

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  0.552 nM

>  <CAS>
274901-16-5

>  <Description>
Vildagliptin is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4  enzyme. Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults.

>  <EBC_ID>
EBC-11319

>  <IUPAC Name>
(2S)-1-(2-{[(1r,3s,5R,7S)-3-hydroxyadamantan-1-yl]amino}acetyl)pyrrolidine-2-carbonitrile

>  <Main Tar all refs>
KING ABDULAZIZ UNIVERSITY - US10654800, 2020, B1

>  <Main tar all>
dipeptidyl peptidase 4 pX=9.26

$$$$
Adefovir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 C 2.8465 -1.9405 0 0
M  V30 9 C 1.3401 -2.2607 0 0
M  V30 10 O 0.8642 -3.7253 0 0
M  V30 11 C -0.6421 -4.0455 0 0
M  V30 12 P -1.118 -5.5101 0 0
M  V30 13 O -1.5939 -6.9748 0 0
M  V30 14 O -2.5826 -5.0342 0 0
M  V30 15 O 0.3466 -5.986 0 0
M  V30 16 C 2.4172 0.77 0 0
M  V30 17 N 3.3224 2.0159 0 0
M  V30 18 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 1 7 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 2 18
M  V30 19 1 6 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977297

>  <MW>
273.186

>  <MW (desalted)>
273.186

>  <ClogP>
-1.873

>  <logS>
0.271

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
136.38

>  <RotBonds>
5

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
EC50 = 0.01 ?M | EC50 = 0.21 ?M

>  <CAS>
106941-25-7

>  <Description>
Adefovir is an active metabolite of the antiviral nucleoside analog adefovir dipivoxil. It inhibits cytopathogenicity induced by herpes simplex virus 1 (HSV-1) and HSV-2.

>  <EBC_ID>
EBC-00673

>  <IUPAC Name>
{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid

>  <Main Tar all refs>
Curr. Med. Chem. Anti-infec. Agents., 2003, vol. 2, # 3, p. 227 - 240 | Antimicrob. Agents Chemother., 2006, vol. 50, # 7, p. 2471 - 2477

>  <Main tar all>
DNA pX=8.0 | DNA polymerase (Epsilon) pX=6.68

$$$$
Telmisatran
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.7343 -1.6146 0 0
M  V30 2 C -7.7343 -3.1546 0 0
M  V30 3 C -6.4006 -3.9246 0 0
M  V30 4 C -5.0669 -3.1546 0 0
M  V30 5 N -4.9059 -1.623 0 0
M  V30 6 C -3.3996 -1.3028 0 0
M  V30 7 C -2.6296 0.0309 0 0
M  V30 8 C -3.3996 1.3645 0 0
M  V30 9 C -1.0896 0.0309 0 0
M  V30 10 C -0.3196 -1.3028 0 0
M  V30 11 C -1.0896 -2.6365 0 0
M  V30 12 C -2.6296 -2.6365 0 0
M  V30 13 N -3.66 -3.7809 0 0
M  V30 14 C -3.3399 -5.2873 0 0
M  V30 15 C -4.4843 -6.3178 0 0
M  V30 16 C -4.1641 -7.8241 0 0
M  V30 17 C -5.3086 -8.8546 0 0
M  V30 18 C -6.7732 -8.3787 0 0
M  V30 19 C -7.0934 -6.8723 0 0
M  V30 20 C -5.9489 -5.8419 0 0
M  V30 21 C -7.9176 -9.4091 0 0
M  V30 22 C -7.5974 -10.9155 0 0
M  V30 23 C -8.7419 -11.9459 0 0
M  V30 24 C -10.2065 -11.4701 0 0
M  V30 25 C -10.5267 -9.9637 0 0
M  V30 26 C -9.3823 -8.9333 0 0
M  V30 27 C -9.7024 -7.4269 0 0
M  V30 28 O -8.558 -6.3964 0 0
M  V30 29 O -11.1671 -6.951 0 0
M  V30 30 C 1.2204 -1.3028 0 0
M  V30 31 N 2.1256 -0.0569 0 0
M  V30 32 C 3.5902 -0.5328 0 0
M  V30 33 C 4.9239 0.2372 0 0
M  V30 34 C 6.2576 -0.5328 0 0
M  V30 35 C 6.2576 -2.0728 0 0
M  V30 36 C 4.9239 -2.8428 0 0
M  V30 37 C 3.5902 -2.0728 0 0
M  V30 38 N 2.1256 -2.5487 0 0
M  V30 39 C 1.6497 -4.0133 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 6 12
M  V30 13 1 12 13
M  V30 14 1 4 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 18 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 21 26
M  V30 30 1 26 27
M  V30 31 2 27 28
M  V30 32 1 27 29
M  V30 33 1 10 30
M  V30 34 2 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 2 32 37
M  V30 42 1 37 38
M  V30 43 1 30 38
M  V30 44 1 38 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551967334

>  <MW>
514.617

>  <MW (desalted)>
514.617

>  <ClogP>
7.293

>  <logS>
-8.22

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
72.94

>  <RotBonds>
7

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
Kd (dissociation constant) = 0.0021 nM | Kd (dissociation constant) = 0.0021 nM

>  <CAS>
144701-48-4

>  <Description>
Telmisartan is a nonpeptide angiotensin II receptor antagonist which selectively and insurmountably inhibits the angiotensin II AT1 receptor subtype. Telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.

>  <EBC_ID>
EBC-02079

>  <IUPAC Name>
4'-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}-[1,1'-biphenyl]-2-carboxylic acid

>  <Main Tar all refs>
Br. J. Pharmacol., 2007, vol. 151, # 7, p. 952 - 962 | Br. J. Pharmacol., 2007, vol. 151, # 7, p. 952 - 962

>  <Main tar all>
AT1 receptor pX=11.7 | AT1 receptor pX=11.7

$$$$
Verapamil hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 2.5263 0 0
M  V30 3 O 5.7337 3.2963 0 0
M  V30 4 C 7.0674 2.5263 0 0
M  V30 5 C 8.401 3.2963 0 0
M  V30 6 C 9.7347 2.5263 0 0
M  V30 7 C 9.7347 0.9863 0 0
M  V30 8 C 11.0684 0.2163 0 0
M  V30 9 C 12.4021 0.9863 0 0
M  V30 10 N 13.7358 0.2163 0 0
M  V30 11 C 13.7358 -1.3237 0 0
M  V30 12 C 15.0694 0.9863 0 0
M  V30 13 C 16.4031 0.2163 0 0
M  V30 14 C 17.7368 0.9863 0 0
M  V30 15 C 19.0705 0.2163 0 0
M  V30 16 C 18.3005 -1.1174 0 0
M  V30 17 N 17.5305 -2.4511 0 0
M  V30 18 C 19.8405 1.5499 0 0
M  V30 19 C 21.3805 1.5499 0 0
M  V30 20 C 19.0705 2.8836 0 0
M  V30 21 C 20.4041 -0.5537 0 0
M  V30 22 C 21.7378 0.2163 0 0
M  V30 23 C 23.0715 -0.5537 0 0
M  V30 24 C 23.0715 -2.0937 0 0
M  V30 25 O 24.4052 -2.8637 0 0
M  V30 26 C 25.7389 -2.0937 0 0
M  V30 27 C 21.7378 -2.8637 0 0
M  V30 28 O 21.7378 -4.4037 0 0
M  V30 29 C 20.4041 -5.1737 0 0
M  V30 30 C 20.4041 -2.0937 0 0
M  V30 31 C 8.401 0.2163 0 0
M  V30 32 C 7.0674 0.9863 0 0
M  V30 33 O 5.7337 0.2163 0 0
M  V30 34 C 4.4 0.9863 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 10 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 3 16 17
M  V30 16 1 15 18
M  V30 17 1 18 19
M  V30 18 1 18 20
M  V30 19 1 15 21
M  V30 20 1 21 22
M  V30 21 2 22 23
M  V30 22 1 23 24
M  V30 23 1 24 25
M  V30 24 1 25 26
M  V30 25 2 24 27
M  V30 26 1 27 28
M  V30 27 1 28 29
M  V30 28 1 27 30
M  V30 29 2 21 30
M  V30 30 2 7 31
M  V30 31 1 31 32
M  V30 32 2 4 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557407143

>  <MW>
491.063

>  <MW (desalted)>
454.602

>  <ClogP>
4.466

>  <logS>
-4.84

>  <HBD>
0

>  <HBA>
6

>  <TPSA>
63.95

>  <RotBonds>
13

>  <Action on targets>
Inhibitor | Inhibitor | Blocker | Antagonist | Blocker

>  <Activity coefficients and valu>
Ki (inhibition constant) = 1.4 nM | IC50 = 1.4 nM | IC50  3.4 nM | IC50  2.45E-09 g/mL | IC50  30 nM

>  <CAS>
152-11-4

>  <Description>
Verapamil is a non-dihydropyridine calcium channel blocker used in the treatment of angina, arrhythmia, and hypertension.

>  <EBC_ID>
EBC-12798

>  <IUPAC Name>
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1996, vol. 39, # 15, p. 2922 - 2938 | J. MED. CHEM., 1996, vol. 39, # 15, p. 2922 - 2938 | Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258 | Arzneimittelforschung, 1999, vol. 49, # 8, p. 673 - 678 | Toxicol. Appl. Pharmacol., 2011, vol. 252, # 3, p. 250 - 258

>  <Main tar all>
Cav1.2 pX=8.85 | Peripheral-type benzodiazepine receptor-associated protein 1 pX=8.85 | Kv11.1 pX=8.47 | Cav1.1 pX=8.3 | Kv3.1 pX=7.52

$$$$
Mitoxantrone dihydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 O -8.0021 -13.09 0 0
M  V30 4 C -6.6684 -12.32 0 0
M  V30 5 C -6.6684 -10.78 0 0
M  V30 6 N -5.3347 -10.01 0 0
M  V30 7 C -5.3347 -8.47 0 0
M  V30 8 C -4.001 -7.7 0 0
M  V30 9 N -4.001 -6.16 0 0
M  V30 10 C -2.6674 -5.39 0 0
M  V30 11 C -2.6674 -3.85 0 0
M  V30 12 C -1.3337 -3.08 0 0
M  V30 13 C -0 -3.85 0 0
M  V30 14 N 1.3337 -3.08 0 0
M  V30 15 C 2.6674 -3.85 0 0
M  V30 16 C 4.001 -3.08 0 0
M  V30 17 N 5.3347 -3.85 0 0
M  V30 18 C 6.6684 -3.08 0 0
M  V30 19 C 8.0021 -3.85 0 0
M  V30 20 O 9.3358 -3.08 0 0
M  V30 21 C -0 -5.39 0 0
M  V30 22 C 1.3337 -6.16 0 0
M  V30 23 O 2.6674 -5.39 0 0
M  V30 24 C 1.3337 -7.7 0 0
M  V30 25 C 2.6674 -8.47 0 0
M  V30 26 O 4.001 -7.7 0 0
M  V30 27 C 2.6674 -10.01 0 0
M  V30 28 C 1.3337 -10.78 0 0
M  V30 29 C 0 -10.01 0 0
M  V30 30 O -1.3337 -10.78 0 0
M  V30 31 C 0 -8.47 0 0
M  V30 32 C -1.3337 -7.7 0 0
M  V30 33 O -2.6674 -8.47 0 0
M  V30 34 C -1.3337 -6.16 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 9 10
M  V30 8 1 10 11
M  V30 9 2 11 12
M  V30 10 1 12 13
M  V30 11 1 13 14
M  V30 12 1 14 15
M  V30 13 1 15 16
M  V30 14 1 16 17
M  V30 15 1 17 18
M  V30 16 1 18 19
M  V30 17 1 19 20
M  V30 18 2 13 21
M  V30 19 1 21 22
M  V30 20 2 22 23
M  V30 21 1 22 24
M  V30 22 1 24 25
M  V30 23 1 25 26
M  V30 24 2 25 27
M  V30 25 1 27 28
M  V30 26 2 28 29
M  V30 27 1 29 30
M  V30 28 1 29 31
M  V30 29 2 24 31
M  V30 30 1 31 32
M  V30 31 2 32 33
M  V30 32 1 32 34
M  V30 33 2 10 34
M  V30 34 1 21 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2569867923

>  <MW>
516.154

>  <MW (desalted)>
444.481

>  <ClogP>
2.299

>  <logS>
-3.618

>  <HBD>
8

>  <HBA>
10

>  <TPSA>
163.18

>  <RotBonds>
12

>  <Action on targets>
Substrate | Inhibitor | Substrate | Inhibitor | Allosteric Modulator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
percentage increase Active   | IC50 < 0.0001 ?M | IC50  0.081 ng/mL | IC50 (ab)  0.58 nM | IC50  1.33 nM | EC50 ~ 1.9 nM | IC50  0.003 ?M

>  <CAS>
70476-82-3

>  <Description>
Mitoxantrone is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.  Mitoxantrone is a DNA-reactive agent that intercalates into deoxyribonucleic acid through hydrogen bonding, causes crosslinks and strand breaks.

>  <EBC_ID>
EBC-00689

>  <IUPAC Name>
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione dihydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2017, vol. 363, # 2, p. 196 - 210 | Hum. Cell, 2022, vol. 35, # 5, p. 1621 - 1629 | Mol. Pharmacol., 2003, vol. 63, # 1, p. 65 - 72 | Mol. Pharmacol., 2003, vol. 64, # 3, p. 610 - 618 | Drug Metab. Dispos., 2018, vol. 46, # 12, p. 1856 - 1866 | FASEB J., 2020, vol. 34, # 4, p. 4890 - 4903 | Cancers, 2020, vol. 12, # 12, p. 1 - 22

>  <Main tar all>
ABCB1 pX=10.0 | DNA topoisomerase pX=10.0 | broad substrate specificity atp-binding cassette transporter abcg2 pX=9.74 | ABCG2 pX=9.24 | ABCG2 pX=8.88 | ABCG2 (F439A) pX=8.72 | DNA topoisomerase II pX=8.52

$$$$
Pentolinium tartrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.0958 -1.3954 0 0
M  V30 2 N -4.001 -0.1495 0 0 CHG=1
M  V30 3 C -2.6674 0.6205 0 0
M  V30 4 C -1.3337 -0.1495 0 0
M  V30 5 C 0 0.6205 0 0
M  V30 6 C 1.3337 -0.1495 0 0
M  V30 7 C 2.6674 0.6205 0 0
M  V30 8 N 4.001 -0.1495 0 0 CHG=1
M  V30 9 C 3.0958 -1.3954 0 0
M  V30 10 C 4.6274 1.2573 0 0
M  V30 11 C 6.159 1.0964 0 0
M  V30 12 C 6.4792 -0.41 0 0
M  V30 13 C 5.1455 -1.18 0 0
M  V30 14 C -5.1455 -1.18 0 0
M  V30 15 C -6.4792 -0.41 0 0
M  V30 16 C -6.159 1.0964 0 0
M  V30 17 C -4.6274 1.2573 0 0
M  V30 18 O 13.7802 1.925 0 0
M  V30 19 C 13.7802 0.385 0 0 CFG=2
M  V30 20 C 12.4465 -0.385 0 0 CFG=1
M  V30 21 O 12.4465 -1.925 0 0
M  V30 22 C 11.1128 0.385 0 0
M  V30 23 O 9.7792 -0.385 0 0
M  V30 24 O 11.1128 1.925 0 0 CHG=-1
M  V30 25 C 15.1139 -0.385 0 0
M  V30 26 O 16.4476 0.385 0 0
M  V30 27 O 15.1139 -1.925 0 0
M  V30 28 O 0.6668 -5.005 0 0
M  V30 29 C 0.6668 -6.545 0 0 CFG=2
M  V30 30 C -0.6668 -7.315 0 0 CFG=1
M  V30 31 O -0.6668 -8.855 0 0
M  V30 32 C -2.0005 -6.545 0 0
M  V30 33 O -3.3342 -7.315 0 0
M  V30 34 O -2.0005 -5.005 0 0 CHG=-1
M  V30 35 C 2.0005 -7.315 0 0
M  V30 36 O 3.3342 -6.545 0 0
M  V30 37 O 2.0005 -8.855 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 1 2 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 2 17
M  V30 19 1 19 18 CFG=1
M  V30 20 1 19 20
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 19 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 29 28 CFG=1
M  V30 29 1 29 30
M  V30 30 1 30 31 CFG=1
M  V30 31 1 30 32
M  V30 32 2 32 33
M  V30 33 1 32 34
M  V30 34 1 29 35
M  V30 35 2 35 36
M  V30 36 1 35 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2901807455

>  <MW>
538.274

>  <MW (desalted)>
240.428

>  <ClogP>
-6.111

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
12

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
inhibition percentage  85.6 %

>  <CAS>
52-62-0

>  <Description>
Pentolinium tartrate is a nicotinic antagonist. It has been used as a ganglionic blocking agent in hypertension.

>  <EBC_ID>
EBC-28054

>  <IUPAC Name>
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium bis((2R,3R)-3-carboxy-2,3-dihydroxypropanoate)

>  <Main Tar all refs>
Pharm. Res., 2019, vol. 36, # 9

>  <Main tar all>
Nav1.8 pX=5.77

$$$$
Gliclazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.2354 -8.478 0 0
M  V30 2 C -5.4654 -7.1443 0 0
M  V30 3 C -6.2354 -5.8106 0 0
M  V30 4 C -5.4654 -4.4769 0 0
M  V30 5 C -3.9254 -4.4769 0 0
M  V30 6 C -3.1554 -5.8106 0 0
M  V30 7 C -3.9254 -7.1443 0 0
M  V30 8 S -3.1554 -3.1432 0 0
M  V30 9 O -1.8217 -3.9132 0 0
M  V30 10 O -4.4891 -2.3732 0 0
M  V30 11 N -2.3854 -1.8096 0 0
M  V30 12 C -0.8454 -1.8096 0 0
M  V30 13 O -0.0754 -3.1432 0 0
M  V30 14 N -0.0754 -0.4759 0 0
M  V30 15 N 1.4646 -0.4759 0 0
M  V30 16 C 2.3698 0.77 0 0
M  V30 17 C 3.8344 0.2941 0 0
M  V30 18 C 5.2991 0.77 0 0
M  V30 19 C 6.2043 -0.4759 0 0
M  V30 20 C 5.2991 -1.7218 0 0
M  V30 21 C 3.8344 -1.2459 0 0
M  V30 22 C 2.3698 -1.7218 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 17 21
M  V30 23 1 21 22
M  V30 24 1 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801977

>  <MW>
323.13

>  <MW (desalted)>
323.411

>  <ClogP>
1.093

>  <logS>
-4.205

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
78.51

>  <RotBonds>
2

>  <Action on targets>
Blocker | Blocker | Blocker | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
protein expression level increase Active   | Ki (inhibition constant)  42.4 nM | Ki (inhibition constant)  42.4 nM | IC50 = 45.8 nM | Kd (dissociation constant) > 100 nM | IC50 < 100 nM

>  <CAS>
21187-98-4

>  <Description>
Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker. It is used to treat hyperglycemia in patients with type 2 diabetes mellitus.

>  <EBC_ID>
EBC-80093

>  <IUPAC Name>
1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea

>  <Main Tar all refs>
Vasc. Pharmacol., 2018, vol. 102, p. 21 - 28 | Br. J. Pharmacol., 2006, vol. 149, # 5, p. 542 - 550 | Br. J. Pharmacol., 2006, vol. 149, # 5, p. 542 - 550 | Biochem. Pharmacol., 2004, vol. 68, # 5, p. 901 - 910 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1

>  <Main tar all>
Kir6.1 pX=8.0 | KATP channel SUR2B pX=7.37 | KATP?channel?SUR1 pX=7.37 | Kir6.2 pX=7.34 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=7.0 | Kv9.1 pX=7.0

$$$$
Decitabine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 N 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=1
M  V30 7 C 2.5796 5.5648 0 0
M  V30 8 C 2.1037 4.1002 0 0 CFG=2
M  V30 9 O 3.0089 2.8543 0 0
M  V30 10 C 0.5637 4.1002 0 0 CFG=1
M  V30 11 C -0.3415 2.8543 0 0
M  V30 12 O 0.2849 1.4474 0 0
M  V30 13 O 0.0878 5.5648 0 0
M  V30 14 C 0 8.78 0 0
M  V30 15 O -1.3337 8.01 0 0
M  V30 16 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=1
M  V30 11 1 11 12
M  V30 12 1 10 13
M  V30 13 1 6 13
M  V30 14 1 5 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 2 2 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2467077030

>  <MW>
228.086

>  <MW (desalted)>
228.205

>  <ClogP>
-1.901

>  <logS>
-1.04

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
120.74

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | IC50  6.5 nM | EC50  12.6 nM | percentage increase Active   | percentage increase Active   | Percentage of GFP+ cells increase Active   | Proliferation decrease rate Active   | apoptosis rate increase Active   | decrease rate Active

>  <CAS>
2353-33-5

>  <Description>
Decitabine is an analog of cytidine which can be incorporated into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects. Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines. It is indicated for the treatment of patients with myelodysplastic syndromes.

>  <EBC_ID>
EBC-00686

>  <IUPAC Name>
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one

>  <Main Tar all refs>
ASCENTAGE PHARMACEUTICAL GROUP CO LTD - WO2021/18032, 2021, A1 | CLEAVE THERAPEUTICS INC; CLEAVE THERAPEUTICS - WO2021/231323, 2021, A1 | ORYZON GENOMICS S A; ORYZON GENOMICS S.A. - WO2017/157813, 2017, A1 | WASHINGTON UNIVERSITY IN ST. LOUIS - WO2017/218551, 2017, A1 | WASHINGTON UNIVERSITY IN ST. LOUIS - WO2017/218551, 2017, A1 | Cancers, 2022, vol. 14, # 14 | Biol. Pharm. Bull., 2019, vol. 42, # 3, p. 448 - 452 | NATIONAL TAIWAN UNIVERSITY - US2022/226378, 2022, A1 | Food Chem. Toxicol., 2019, vol. 130, p. 161 - 173

>  <Main tar all>
MDM2 proto-oncogene pX=8.43 | Transitional endoplasmic reticulum ATPase pX=8.19 | DNA methyltransferase pX=7.9 | DNA (cytosine-5-)-methyltransferase 3? pX=7.7 | DNA methyltransferase 1 pX=7.7 | cyclin dependent kinase 9 pX=7.3 | DNA (cytosine-5)-methyltransferase PliMCI pX=7.0 | DNA (cytosine-5-)-methyltransferase pX=7.0 | Histone?deacetylase pX=7.0

$$$$
Inosine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.8998 -8.466 0 0
M  V30 2 C -1.0608 -6.9344 0 0
M  V30 3 C 0.1851 -6.0292 0 0 CFG=1
M  V30 4 O 0.1851 -4.4892 0 0
M  V30 5 C 1.6497 -4.0133 0 0 CFG=2
M  V30 6 C 2.5549 -5.2592 0 0 CFG=2
M  V30 7 O 4.0949 -5.2592 0 0
M  V30 8 C 1.6497 -6.5051 0 0 CFG=2
M  V30 9 O 2.1256 -7.9697 0 0
M  V30 10 N 2.1256 -2.5487 0 0
M  V30 11 C 1.2204 -1.3028 0 0
M  V30 12 N 2.1256 -0.0569 0 0
M  V30 13 C 3.5902 -0.5328 0 0
M  V30 14 C 4.9239 0.2372 0 0
M  V30 15 O 4.9239 1.7772 0 0
M  V30 16 N 6.2576 -0.5328 0 0
M  V30 17 C 6.2576 -2.0728 0 0
M  V30 18 N 4.9239 -2.8428 0 0
M  V30 19 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 3
M  V30 9 1 8 9 CFG=3
M  V30 10 1 5 10 CFG=1
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 10 19
M  V30 21 2 13 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681890654

>  <MW>
268.081

>  <MW (desalted)>
268.226

>  <ClogP>
-3.106

>  <logS>
-1.277

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
129.2

>  <RotBonds>
2

>  <Action on targets>
Activator | Agonist

>  <Activity coefficients and valu>
inhibition rate Active   | percentage increase Active

>  <CAS>
58-63-9

>  <Description>
Inosine is a nutritional supplement touted to improve athletic performance. It has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 and A2A receptors.

>  <EBC_ID>
EBC-47437

>  <IUPAC Name>
9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

>  <Main Tar all refs>
Cells, 2020, vol. 9, # 3 | Cell. Signal., 2016, vol. 28, # 6, p. 552 - 560

>  <Main tar all>
A3 receptor pX=7.0 | A2A receptor pX=5.52

$$$$
Lorsartan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.8029 -4.735 0 0
M  V30 2 C 6.4692 -5.505 0 0
M  V30 3 C 5.1355 -4.735 0 0
M  V30 4 C 3.8019 -5.505 0 0
M  V30 5 C 3.8019 -7.045 0 0
M  V30 6 N 5.0477 -7.9502 0 0
M  V30 7 C 4.5719 -9.4148 0 0
M  V30 8 Cl 5.477 -10.6607 0 0
M  V30 9 C 3.0319 -9.4148 0 0
M  V30 10 C 2.1267 -10.6607 0 0
M  V30 11 O 0.5951 -10.4997 0 0
M  V30 12 N 2.556 -7.9502 0 0
M  V30 13 C 1.0913 -7.4743 0 0
M  V30 14 C 0.7712 -5.968 0 0
M  V30 15 C -0.6935 -5.4921 0 0
M  V30 16 C -1.0137 -3.9857 0 0
M  V30 17 C 0.1308 -2.9553 0 0
M  V30 18 C 1.5954 -3.4311 0 0
M  V30 19 C 1.9156 -4.9375 0 0
M  V30 20 C -0.1894 -1.4489 0 0
M  V30 21 C -1.654 -0.973 0 0
M  V30 22 C -1.9742 0.5333 0 0
M  V30 23 C -0.8298 1.5638 0 0
M  V30 24 C 0.6349 1.0879 0 0
M  V30 25 C 0.955 -0.4185 0 0
M  V30 26 C 2.4197 -0.8943 0 0
M  V30 27 N 3.6656 0.0109 0 0
M  V30 28 N 4.9114 -0.8943 0 0
M  V30 29 N 4.4356 -2.359 0 0
M  V30 30 N 2.8956 -2.359 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 12
M  V30 12 1 5 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 21 1 17 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 20 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 26 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2417557127

>  <MW>
422.162

>  <MW (desalted)>
422.911

>  <ClogP>
3.852

>  <logS>
-6.576

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
92.51

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Antagonist | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage Active   | pA2  9.93  | IC50  0.31 nM | Ki (inhibition constant)  0.9 nM | IC50  1.3 nM

>  <CAS>
114798-26-4

>  <Description>
Losartan is an angiotensin II receptor blocker used to treat hypertension.

>  <EBC_ID>
EBC-12874

>  <IUPAC Name>
(2-butyl-4-chloro-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2007, vol. 320, # 1, p. 211 - 217 | Farmaco, 2003, vol. 58, # 11, p. 1193 - 1199 | Regul. Pept., 2002, vol. 106, # 1-3, p. 33 - 38 | Nucl. Med. Biol., 2021, vol. 96-97, p. 41 - 49 | PROC. NATL. ACAD. SCI. U. S. A., 1995, vol. 92, # 20, p. 9240 - 9244

>  <Main tar all>
Urate anion exchanger 1 pX=10.0 | AT1 receptor pX=9.93 | AT1 receptor pX=9.51 | AT1 receptor pX=9.05 | AT1 receptor pX=8.89

$$$$
Mifepristone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.1796 -5.4603 0 0
M  V30 2 C 2.6955 -5.1892 0 0
M  V30 3 C 4.2115 -4.9181 0 0
M  V30 4 C 5.7274 -4.6471 0 0 CFG=2
M  V30 5 O 5.8386 -6.183 0 0
M  V30 6 C 5.2994 -3.1677 0 0
M  V30 7 C 6.574 -2.3035 0 0
M  V30 8 C 7.7898 -3.2487 0 0 CFG=1
M  V30 9 C 9.3058 -2.9776 0 0 CFG=2
M  V30 10 C 9.829 -1.5293 0 0
M  V30 11 C 11.345 -1.2582 0 0
M  V30 12 C 12.3377 -2.4355 0 0
M  V30 13 C 13.8537 -2.1644 0 0
M  V30 14 C 14.8464 -3.3418 0 0
M  V30 15 O 16.3624 -3.0707 0 0
M  V30 16 C 14.3232 -4.7901 0 0
M  V30 17 C 12.8072 -5.0612 0 0
M  V30 18 C 11.8145 -3.8839 0 0
M  V30 19 C 10.2985 -4.155 0 0
M  V30 20 C 9.7753 -5.6034 0 0 CFG=2
M  V30 21 C 8.2593 -5.8744 0 0
M  V30 22 C 7.2666 -4.6971 0 0 CFG=2
M  V30 23 C 6.5949 -6.0829 0 0
M  V30 24 C 10.768 -6.7807 0 0
M  V30 25 C 12.284 -6.5096 0 0
M  V30 26 C 13.2767 -7.6869 0 0
M  V30 27 C 12.7535 -9.1353 0 0
M  V30 28 C 11.2375 -9.4064 0 0
M  V30 29 C 10.2448 -8.2291 0 0
M  V30 30 N 13.7462 -10.3126 0 0
M  V30 31 C 13.223 -11.761 0 0
M  V30 32 C 15.2622 -10.0416 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 3 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 12 18
M  V30 19 2 18 19
M  V30 20 1 9 19
M  V30 21 1 20 19
M  V30 22 1 20 21
M  V30 23 1 22 21
M  V30 24 1 8 22
M  V30 25 1 22 4
M  V30 26 1 22 23 CFG=1
M  V30 27 1 20 24 CFG=1
M  V30 28 1 24 25
M  V30 29 2 25 26
M  V30 30 1 26 27
M  V30 31 2 27 28
M  V30 32 1 28 29
M  V30 33 2 24 29
M  V30 34 1 27 30
M  V30 35 1 30 31
M  V30 36 1 30 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480424

>  <MW>
429.267

>  <MW (desalted)>
429.594

>  <ClogP>
4.648

>  <logS>
-5.291

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
40.54

>  <RotBonds>
3

>  <Action on targets>
Antagonist | Antagonist | Inhibitor | Antagonist | Antagonist | Antagonist | Antagonist

>  <Activity coefficients and valu>
IC50  0.002 nM | IC50  0.008 nM | IC50 = 0.008 nM | IC50  0.011 - 0.018 nM | IC50  0.028 nM | EC50  0.04 nM | EC50  0.04 nM

>  <CAS>
84371-65-3

>  <Description>
Mifepristone is an antagonist of glucocorticoid, progesterone, and androgen receptors. Mifepristone have been used for the induction of medical abortions.

>  <EBC_ID>
EBC-06067

>  <IUPAC Name>
(1S,3aS,3bS,10R,11aS)-10-[4-(dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(prop-1-yn-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

>  <Main Tar all refs>
Mol. Endocrinol., 2007, vol. 21, # 5, p. 1066 - 1081 | J. Med. Chem., 2004, vol. 47, # 21, p. 4985 - 4988 | J. Med. Chem., 2004, vol. 47, # 21, p. 4985 - 4988 | PFIZER INC - US6436929, 2002, B1 | J. Med. Chem., 2000, vol. 43, # 26, p. 5010 - 5016 | Mol. Endocrinol., 2007, vol. 21, # 5, p. 1066 - 1081 | Mol. Endocrinol., 2007, vol. 21, # 5, p. 1066 - 1081

>  <Main tar all>
Progesterone receptor (isoform B) pX=11.7 | Glucocorticoid receptor pX=11.1 | nuclear glucocorticoid receptor pX=11.1 | Progesterone receptor pX=11.0 | Progesterone receptor (isoform A) pX=10.6 | NCoR pX=10.4 | Nuclear receptor corepressor 1 pX=10.4

$$$$
Calcium leucovorin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Ca 2.6674 7.7 0 0 CHG=2
M  V30 2 N -21.3389 1.54 0 0
M  V30 3 C -20.0052 2.31 0 0
M  V30 4 N -20.0052 3.85 0 0
M  V30 5 C -18.6715 4.62 0 0
M  V30 6 O -18.6715 6.16 0 0
M  V30 7 C -17.3378 3.85 0 0
M  V30 8 N -16.0041 4.62 0 0
M  V30 9 C -16.0041 6.16 0 0
M  V30 10 O -14.6705 6.93 0 0
M  V30 11 C -14.6705 3.85 0 0
M  V30 12 C -13.3368 4.62 0 0
M  V30 13 N -12.0031 3.85 0 0
M  V30 14 C -10.6694 4.62 0 0
M  V30 15 C -10.6694 6.16 0 0
M  V30 16 C -9.3358 6.93 0 0
M  V30 17 C -8.0021 6.16 0 0
M  V30 18 C -8.0021 4.62 0 0
M  V30 19 C -9.3358 3.85 0 0
M  V30 20 C -6.6684 6.93 0 0
M  V30 21 O -6.6684 8.47 0 0
M  V30 22 N -5.3347 6.16 0 0
M  V30 23 C -4.001 6.93 0 0 CFG=1
M  V30 24 C -2.6674 6.16 0 0
M  V30 25 C -1.3337 6.93 0 0
M  V30 26 C 0 6.16 0 0
M  V30 27 O 0 4.62 0 0
M  V30 28 O 1.3337 6.93 0 0 CHG=-1
M  V30 29 C -4.001 8.47 0 0
M  V30 30 O -2.6674 9.24 0 0
M  V30 31 O -5.3347 9.24 0 0 CHG=-1
M  V30 32 C -14.6705 2.31 0 0
M  V30 33 N -16.0041 1.54 0 0
M  V30 34 C -17.3378 2.31 0 0
M  V30 35 N -18.6715 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 5 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 8 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 2 17 18
M  V30 17 1 18 19
M  V30 18 2 14 19
M  V30 19 1 17 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 23 22 CFG=3
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 23 29
M  V30 29 2 29 30
M  V30 30 1 29 31
M  V30 31 1 11 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 2 7 34
M  V30 35 1 34 35
M  V30 36 1 3 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2683233771

>  <MW>
511.113

>  <MW (desalted)>
473.439

>  <ClogP>
-10.498

>  <HBD>
5

>  <HBA>
12

>  <TPSA>
221.21

>  <RotBonds>
9

>  <CAS>
1492-18-8

>  <Description>
Leucovorin is a folate analog used to treat the toxic effects of methotrexate and other folate antagonists, to treat megaloblastic anemia, and to provide palliative treatment of colorectal cancer.

>  <EBC_ID>
EBC-15053

>  <IUPAC Name>
calcium (2S)-2-[(4-{[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioate

$$$$
Dimethyl fumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.62 2.6674 0 0
M  V30 2 O 3.85 1.3337 0 0
M  V30 3 C 2.31 1.3337 0 0
M  V30 4 O 1.54 2.6674 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 C 0 0 0 0
M  V30 7 C -0.77 -1.3337 0 0
M  V30 8 O 0 -2.6674 0 0
M  V30 9 O -2.31 -1.3337 0 0
M  V30 10 C -3.08 -2.6674 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802810

>  <MW>
144.042

>  <MW (desalted)>
144.125

>  <ClogP>
0.784

>  <logS>
-0.684

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
52.6

>  <RotBonds>
4

>  <Action on targets>
Activator | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | fold decrease Active   | fold decrease Active

>  <CAS>
624-49-7

>  <Description>
Dimethyl fumarate is an anti-inflammatory drug. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis.  Dimethyl fumarate up-regulate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress.

>  <EBC_ID>
EBC-13767

>  <IUPAC Name>
1,4-dimethyl (2E)-but-2-enedioate

>  <Main Tar all refs>
Redox Biol., 2020, vol. 36 | CURACLE CO LTD - US2016/67206, 2016, A1 | CURACLE CO LTD - US2016/67206, 2016, A1

>  <Main tar all>
Nuclear factor erythroid 2-related factor 2 pX=8.0 | MLP pX=7.0 | Plasminogen activator inhibitor 1 pX=7.0

$$$$
Olopatadine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.57 5.9923 0 0
M  V30 3 N 8.57 4.4523 0 0
M  V30 4 C 7.2363 3.6823 0 0
M  V30 5 C 9.9037 3.6823 0 0
M  V30 6 C 9.9037 2.1423 0 0
M  V30 7 C 11.2374 1.3723 0 0
M  V30 8 C 11.2374 -0.1677 0 0
M  V30 9 C 12.6248 -0.8359 0 0
M  V30 10 C 13.7537 0.2116 0 0
M  V30 11 C 15.2253 -0.2424 0 0
M  V30 12 C 15.568 -1.7438 0 0
M  V30 13 C 14.4391 -2.7912 0 0
M  V30 14 C 12.9675 -2.3373 0 0
M  V30 15 C 12.0074 -3.5413 0 0
M  V30 16 O 10.4674 -3.5413 0 0
M  V30 17 C 9.5072 -2.3373 0 0
M  V30 18 C 8.0356 -2.7912 0 0
M  V30 19 C 6.9067 -1.7438 0 0
M  V30 20 C 7.2494 -0.2424 0 0
M  V30 21 C 6.1205 0.8051 0 0
M  V30 22 C 4.6489 0.3512 0 0
M  V30 23 O 4.3062 -1.1502 0 0
M  V30 24 O 3.52 1.3986 0 0
M  V30 25 C 8.721 0.2116 0 0
M  V30 26 C 9.8499 -0.8359 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 2 20 25
M  V30 25 1 25 26
M  V30 26 1 8 26
M  V30 27 2 17 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568665949

>  <MW>
373.144

>  <MW (desalted)>
337.412

>  <ClogP>
1.094

>  <logS>
-3.857

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
49.77

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.35 nM

>  <CAS>
140462-76-6

>  <Description>
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions. Olopatadine is used to treat allergic conjunctivitis and rhinitis.

>  <EBC_ID>
EBC-11262

>  <IUPAC Name>
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid hydrochloride

>  <Main Tar all refs>
JPN. J. PHARMACOL., 1993, vol. 61, # 2, p. 87 - 92

>  <Main tar all>
H1 receptor pX=9.46

$$$$
Acetylhydroxamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.85 -1.3337 0 0
M  V30 2 C 2.31 -1.3337 0 0
M  V30 3 O 1.54 -2.6674 0 0
M  V30 4 N 1.54 0 0 0
M  V30 5 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z59181917

>  <MW>
75.032

>  <MW (desalted)>
75.067

>  <ClogP>
-1.594

>  <logS>
0.62

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
49.33

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.52 nM | IC50 = 12 nM | IC50  12.61 nM

>  <CAS>
546-88-3

>  <Description>
Acetohydroxamic acid reversibly inhibits the bacterial enzyme urease. It is used to treat urea splitting bacterial infections of the urinary tract.

>  <EBC_ID>
EBC-13138

>  <IUPAC Name>
N-hydroxyacetamide

>  <Main Tar all refs>
Curr. Med. Chem., 2008, vol. 15, # 22, p. 2192 - 2222 | Bioorg. Med. Chem., 2005, vol. 13, # 21, p. 6070 - 6082 | Sci. Total Environ., 2022, vol. 808

>  <Main tar all>
MMP12 pX=9.28 | Histone?deacetylase pX=7.92 | Urease (gene URE) pX=7.9

$$$$
Recorcinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 0 0 0 0
M  V30 7 O -1.3337 -0.77 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474576

>  <MW>
110.037

>  <MW (desalted)>
110.111

>  <ClogP>
0.808

>  <logS>
-0.56

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
40.46

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50 < 0.4 nM | EC50 = 7 nM | Ki (inhibition constant) = 8.72 nM

>  <CAS>
108-46-3

>  <Description>
Resorcinol is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses, and warts. It can inhibit peroxidases in the thyroid and subsequently block the synthesis of thyroid hormones and cause goiter.

>  <EBC_ID>
EBC-00524

>  <IUPAC Name>
benzene-1,3-diol

>  <Main Tar all refs>
J. Med. Chem., 2012, vol. 55, # 17, p. 7786 - 7795 | J. Med. Chem., 2012, vol. 55, # 17, p. 7786 - 7795 | Eur. J. Med. Chem., 2009, vol. 44, # 1, p. 312 - 321

>  <Main tar all>
Heat shock protein HSP 90-alpha pX=9.4 | erb-b2 receptor tyrosine kinase 2 pX=8.15 | Phospholipase A2 (gene PLA2G1B) pX=8.06

$$$$
Phloroglucinol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 O 4.001 -0.77 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 0 0 0 0
M  V30 8 O -1.3337 -0.77 0 0
M  V30 9 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 2 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474594

>  <MW>
126.032

>  <MW (desalted)>
126.11

>  <ClogP>
0.141

>  <logS>
-0.141

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
60.69

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.00023 ?M

>  <CAS>
108-73-6

>  <Description>
Phloroglucinol is a naturally occurring phenol that exhibits diverse biological activities. It inhibits Tyrosinase (Ki=0.23 nM) and phospholipase A2, gene PLA2G1B (Ki=8.77 nM).

>  <EBC_ID>
EBC-48043

>  <IUPAC Name>
benzene-1,3,5-triol

>  <Main Tar all refs>
ChemMedChem, 2007, vol. 2, # 4, p. 449 - 478

>  <Main tar all>
tyrosinase pX=9.64

$$$$
Mercaptopurine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 C 2.4172 0.77 0 0
M  V30 9 N 3.3224 2.0159 0 0
M  V30 10 C 4.787 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 2 10
M  V30 11 1 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z314598824

>  <MW>
152.016

>  <MW (desalted)>
152.177

>  <ClogP>
0.823

>  <logS>
-2.47

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
54.46

>  <RotBonds>
0

>  <Action on targets>
- | -

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.02 ?M | concentration (parameter)  0.15 ?M

>  <CAS>
50-44-2

>  <Description>
Mercaptopurine is an antimetabolite antineoplastic agent with immunosuppressant properties. It is indicated for remission induction and maintenance therapy of acute lymphatic leukemia.

>  <EBC_ID>
EBC-11043

>  <IUPAC Name>
9H-purine-6-thiol

>  <Main Tar all refs>
J. Med. Chem., 2006, vol. 49, # 25, p. 7479 - 7486 | Br. J. Clin. Pharmacol., 1998, vol. 45

>  <Main tar all>
Hypoxanthine-guanine-xanthine phosphoribosyltransferase pX=7.7 | transaminase pX=6.82

$$$$
6-Acetamidohexanoic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.2626 4.001 0 0
M  V30 2 C 5.5963 4.771 0 0
M  V30 3 O 5.5963 6.311 0 0
M  V30 4 N 6.93 4.001 0 0
M  V30 5 C 8.2637 4.771 0 0
M  V30 6 C 9.5974 4.001 0 0
M  V30 7 C 10.931 4.771 0 0
M  V30 8 C 12.2647 4.001 0 0
M  V30 9 C 13.5984 4.771 0 0
M  V30 10 C 14.9321 4.001 0 0
M  V30 11 O 16.2658 4.771 0 0
M  V30 12 O 14.9321 2.461 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56914861

>  <MW>
173.105

>  <MW (desalted)>
173.21

>  <ClogP>
-0.379

>  <logS>
-0.24

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
6

>  <CAS>
57-08-9

>  <Description>
6-Acetamidohexanoic acid is a pharmaceutical intermediate. It is used as a cicatrization helper.

>  <EBC_ID>
EBC-12516

>  <IUPAC Name>
6-acetamidohexanoic acid

$$$$
Methoxamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.0674 4.7227 0 0
M  V30 3 O 8.401 3.9527 0 0
M  V30 4 C 8.401 2.4127 0 0
M  V30 5 C 9.7347 1.6427 0 0
M  V30 6 C 9.7347 0.1027 0 0
M  V30 7 C 8.401 -0.6673 0 0
M  V30 8 O 8.401 -2.2073 0 0
M  V30 9 C 9.7347 -2.9773 0 0
M  V30 10 C 7.0674 0.1027 0 0
M  V30 11 C 7.0674 1.6427 0 0
M  V30 12 C 5.7337 -0.6673 0 0
M  V30 13 O 4.4 0.1027 0 0
M  V30 14 C 5.7337 -2.2073 0 0
M  V30 15 C 7.0674 -2.9773 0 0
M  V30 16 N 4.4 -2.9773 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 7 10
M  V30 9 1 10 11
M  V30 10 2 4 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2753379879

>  <MW>
247.098

>  <MW (desalted)>
211.258

>  <ClogP>
0.592

>  <logS>
-1.946

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
64.71

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.00017 nM

>  <CAS>
61-16-5

>  <Description>
Methoxamine hydrochloride is an alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. It is indicated for the treatment and management of hypotension.

>  <EBC_ID>
EBC-04241

>  <IUPAC Name>
2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1984, vol. 27, # 4, p. 495 - 503

>  <Main tar all>
?1-adrenoceptor pX=12.8

$$$$
Bupropion hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 5.7337 0.385 0 0
M  V30 3 C 7.0674 1.155 0 0
M  V30 4 N 7.0674 2.695 0 0
M  V30 5 C 5.7337 3.465 0 0
M  V30 6 C 4.4 4.235 0 0
M  V30 7 C 4.9637 2.1313 0 0
M  V30 8 C 6.5037 4.7987 0 0
M  V30 9 C 8.401 0.385 0 0
M  V30 10 O 9.7347 1.155 0 0
M  V30 11 C 8.401 -1.155 0 0
M  V30 12 C 9.7347 -1.925 0 0
M  V30 13 C 9.7347 -3.465 0 0
M  V30 14 C 8.401 -4.235 0 0
M  V30 15 C 7.0674 -3.465 0 0
M  V30 16 Cl 5.7337 -4.235 0 0
M  V30 17 C 7.0674 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 5 7
M  V30 6 1 5 8
M  V30 7 1 3 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 14 15
M  V30 14 1 15 16
M  V30 15 1 15 17
M  V30 16 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741979718

>  <MW>
275.084

>  <MW (desalted)>
239.741

>  <ClogP>
3.211

>  <logS>
-4.095

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.1

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.004 ?M | IC50  0.058 ?M

>  <CAS>
31677-93-7

>  <Description>
Bupropion is a norepinephrine/dopamine-reuptake inhibitor, it is used most commonly for the management of Major Depressive Disorder, Seasonal Affective Disorder, and as an aid for smoking cessation.  Bupropion binds to the dopamine transporter.

>  <EBC_ID>
EBC-03692

>  <IUPAC Name>
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrochloride

>  <Main Tar all refs>
Drug Metab. Dispos., 2001, vol. 29, # 8, p. 1123 - 1129 | Drug Metab. Dispos., 2000, vol. 28, # 10, p. 1176 - 1183

>  <Main tar all>
Cytochrome P450 3A4 pX=8.4 | Cytochrome P450 2D6 pX=7.24

$$$$
Diclofenac
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3347 1.54 0 0
M  V30 2 C 5.3347 0 0 0
M  V30 3 O 6.6684 -0.77 0 0
M  V30 4 C 4.001 -0.77 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 C 5.3347 -4.62 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 N 6.6684 -2.31 0 0
M  V30 12 C 8.0021 -3.08 0 0
M  V30 13 C 9.3358 -2.31 0 0
M  V30 14 Cl 9.3358 -0.77 0 0
M  V30 15 C 10.6694 -3.08 0 0
M  V30 16 C 10.6694 -4.62 0 0
M  V30 17 C 9.3358 -5.39 0 0
M  V30 18 C 8.0021 -4.62 0 0
M  V30 19 Cl 6.6684 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 12 18
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57664869

>  <MW>
295.017

>  <MW (desalted)>
296.149

>  <ClogP>
4.726

>  <logS>
-4.32

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.33

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.5 pM

>  <CAS>
15307-86-5

>  <Description>
Diclofenac is a potent and nonselective anti-inflammatory agent (NSAID) , acts as a COX inhibitor. Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma.

>  <EBC_ID>
EBC-03832

>  <IUPAC Name>
2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1

>  <Main tar all>
COX-1  pX=11.8

$$$$
Etacrynic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C -1.3337 3.85 0 0
M  V30 5 C 1.3337 3.85 0 0
M  V30 6 O 2.6674 4.62 0 0
M  V30 7 C 1.3337 2.31 0 0
M  V30 8 C 2.6674 1.54 0 0
M  V30 9 C 2.6674 -0 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 O 1.3337 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 2.6674 -4.62 0 0
M  V30 14 O 4.001 -5.39 0 0
M  V30 15 O 1.3337 -5.39 0 0
M  V30 16 C 0 0 0 0
M  V30 17 Cl -1.3337 -0.77 0 0
M  V30 18 C 0 1.54 0 0
M  V30 19 Cl -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 2 10 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 7 18
M  V30 19 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1590781983

>  <MW>
302.011

>  <MW (desalted)>
303.138

>  <ClogP>
3.445

>  <logS>
-4.743

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
63.6

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.141 ?M | inhibition percentage = 81.88 % | IC50  0.374 ?M | IC50  0.4 ?M | IC50  0.4 ?mol/l | IC50  0.58 ?M | Km (Michaelis constant)  0.76 ?M | Kd (dissociation constant)  9.54E-07 M | IC50  1.11 ?M | inhibition percentage  65.1 % | IC50 = 3.1 ?M | IC50  3.3 ?M | IC50  3.3 ?M | IC50 = 4.0078 ?M | IC50  4.33 ?M

>  <CAS>
58-54-8

>  <Description>
Ethacrynic acid is a loop diuretic with anticancer activity. It is used for the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.

>  <EBC_ID>
EBC-03779

>  <IUPAC Name>
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid

>  <Main Tar all refs>
PLoS ONE, 2019, vol. 14, # 3 | Biochem. J., 2005, vol. 388, # 3, p. 763 - 771 | Med. Chem. Res., 2022, vol. 31, # 12, p. 2119 - 2131 | J. Am. Chem. Soc., 2006, vol. 128, # 26, p. 8459 - 8467 | Protein Cell, 2021, vol. 12, # 6, p. 493 - 501 | J. Pharmacol. Exp. Ther., 2004, vol. 308, # 3, p. 1021 - 1029 | ChemMedChem, 2018, vol. 13, # 12, p. 1210 - 1217 | Mol. Neurobiol., 2018, p. 1 - 11 | J. Enzyme Inhib. Med. Chem., 2021, vol. 36, # 1, p. 147 - 153 | Bioorg. Med. Chem., 2012, vol. 20, # 7, p. 2316 - 2322 | Bioorg. Med. Chem. Lett., 2006, vol. 16, # 22, p. 5744 - 5747 | Proc. Natl. Acad. Sci. U. S. A., 2022, vol. 119, # 40 | Biochem. Biophys. Rep., 2021, vol. 27 | NATIONAL CANCER CENTER KOREA - US2011/288176, 2011, A1 | Bioorg. Med. Chem. Lett., 2022, vol. 77

>  <Main tar all>
glutathione S-transferase alpha 3 pX=6.85 | glutathione transferase pX=6.66 | H-PGDS pX=6.43 | L-PGDS pX=6.4 | glutathione S-transferase mu 1 pX=6.4 | Organic anion transporter 3 pX=6.24 | H-PGDS pX=6.12 | Alternative prion protein pX=6.02 | CoV 3C-like (main) protease pX=5.95 | glutathione S-transferase pi pX=5.57 | UDP-glucose 4-epimerase (gene galE) pX=5.51 | Hemoglobin subunit beta (GAG>GTG) pX=5.48 | glutathione S-transferase alpha 3 pX=5.48 | Protein-glutamine gamma-glutamyltransferase 2 pX=5.4 | Glutathione S-transferase 1-1 pX=5.36

$$$$
Orphenadrine citrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.335 -1.2705 0 0
M  V30 2 N -5.0013 -0.5005 0 0
M  V30 3 C -5.0013 1.0395 0 0
M  V30 4 C -3.6676 -1.2705 0 0
M  V30 5 C -2.3339 -0.5005 0 0
M  V30 6 O -1.0003 -1.2705 0 0
M  V30 7 C 0.3334 -0.5005 0 0
M  V30 8 C 1.6671 -1.2705 0 0
M  V30 9 C 3.0008 -0.5005 0 0
M  V30 10 C 4.3345 -1.2705 0 0
M  V30 11 C 4.3345 -2.8105 0 0
M  V30 12 C 3.0008 -3.5805 0 0
M  V30 13 C 1.6671 -2.8105 0 0
M  V30 14 C 0.3334 1.0395 0 0
M  V30 15 C -1.0003 1.8095 0 0
M  V30 16 C -1.0003 3.3495 0 0
M  V30 17 C 0.3334 4.1195 0 0
M  V30 18 C 1.6671 3.3495 0 0
M  V30 19 C 1.6671 1.8095 0 0
M  V30 20 C 3.0008 1.0395 0 0
M  V30 21 O 7.8545 -2.677 0 0
M  V30 22 C 9.1881 -1.907 0 0
M  V30 23 O 10.5218 -2.677 0 0
M  V30 24 C 9.1881 -0.367 0 0
M  V30 25 C 10.5218 0.403 0 0
M  V30 26 O 11.2918 -0.9307 0 0
M  V30 27 C 11.8555 1.173 0 0
M  V30 28 C 13.1892 0.403 0 0
M  V30 29 O 14.5229 1.173 0 0
M  V30 30 O 13.1892 -1.137 0 0
M  V30 31 C 9.7518 1.7367 0 0
M  V30 32 O 10.5218 3.0704 0 0
M  V30 33 O 8.2118 1.7367 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 21 1 19 20
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 25 31
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z234896463

>  <MW>
461.205

>  <MW (desalted)>
269.381

>  <ClogP>
3.901

>  <logS>
-3.08

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
11

>  <CAS>
4682-36-4

>  <Description>
Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.

>  <EBC_ID>
EBC-11114

>  <IUPAC Name>
2-hydroxypropane-1,2,3-tricarboxylic acid; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine

$$$$
Sildenafil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.3325 -5.7982 0 0
M  V30 2 C 0.1434 -4.3335 0 0
M  V30 3 C 1.6497 -4.0133 0 0
M  V30 4 C 2.1256 -2.5487 0 0
M  V30 5 N 1.2204 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 1.6497 1.4077 0 0
M  V30 8 C 3.5902 -0.5328 0 0
M  V30 9 C 4.9239 0.2372 0 0
M  V30 10 O 4.9239 1.7772 0 0
M  V30 11 N 6.2576 -0.5328 0 0
M  V30 12 C 6.2576 -2.0728 0 0
M  V30 13 N 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 C 7.5913 -2.8428 0 0
M  V30 16 C 8.925 -2.0728 0 0
M  V30 17 C 10.2586 -2.8428 0 0
M  V30 18 C 10.2586 -4.3828 0 0
M  V30 19 C 8.925 -5.1528 0 0
M  V30 20 C 7.5913 -4.3828 0 0
M  V30 21 O 6.2576 -5.1528 0 0
M  V30 22 C 6.2576 -6.6928 0 0
M  V30 23 C 4.9239 -7.4628 0 0
M  V30 24 S 11.5923 -2.0728 0 0
M  V30 25 O 12.3623 -3.4065 0 0
M  V30 26 O 10.8223 -0.7391 0 0
M  V30 27 N 12.926 -1.3028 0 0
M  V30 28 C 12.926 0.2372 0 0
M  V30 29 C 14.2597 1.0072 0 0
M  V30 30 N 15.5934 0.2372 0 0
M  V30 31 C 16.927 1.0072 0 0
M  V30 32 C 15.5934 -1.3028 0 0
M  V30 33 C 14.2597 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 4 14
M  V30 15 2 8 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 17 24
M  V30 27 2 24 25
M  V30 28 2 24 26
M  V30 29 1 24 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 30 32
M  V30 35 1 32 33
M  V30 36 1 27 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480413

>  <MW>
474.205

>  <MW (desalted)>
474.576

>  <ClogP>
2.218

>  <logS>
-3.763

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
109.13

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
concentration increase Active

>  <CAS>
139755-83-2

>  <Description>
Sildenafil is a phosphodiesterase inhibitor used for the treatment of erectile dysfunction. In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5).

>  <EBC_ID>
EBC-13158

>  <IUPAC Name>
5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-7-one

>  <Main Tar all refs>
Biochemistry, 2019, vol. 58, # 6, p. 799 - 808

>  <Main tar all>
phosphodiesterase 5A2 pX=12.0

$$$$
Nonivamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -11.55 0 0
M  V30 2 C 5.3347 -12.32 0 0
M  V30 3 C 6.6684 -11.55 0 0
M  V30 4 C 8.0021 -12.32 0 0
M  V30 5 C 9.3358 -11.55 0 0
M  V30 6 C 10.6694 -12.32 0 0
M  V30 7 C 12.0031 -11.55 0 0
M  V30 8 C 13.3368 -12.32 0 0
M  V30 9 C 14.6705 -11.55 0 0
M  V30 10 O 14.6705 -10.01 0 0
M  V30 11 N 16.0041 -12.32 0 0
M  V30 12 C 17.3378 -11.55 0 0
M  V30 13 C 18.6715 -12.32 0 0
M  V30 14 C 20.0052 -11.55 0 0
M  V30 15 C 21.3389 -12.32 0 0
M  V30 16 C 21.3389 -13.86 0 0
M  V30 17 O 22.6725 -14.63 0 0
M  V30 18 C 20.0052 -14.63 0 0
M  V30 19 O 20.0052 -16.17 0 0
M  V30 20 C 18.6715 -16.94 0 0
M  V30 21 C 18.6715 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 18 21
M  V30 21 2 13 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z373586944

>  <MW>
293.401

>  <MW (desalted)>
293.401

>  <ClogP>
3.835

>  <logS>
-4.47

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
58.56

>  <RotBonds>
10

>  <Action on targets>
Agonist | Inhibitor | Inhibitor | Activator

>  <Activity coefficients and valu>
EC50  63.1 nM | IC50 > 1000 nM | Ki (inhibition constant)  1.2 ?M | IC50  1.7 ?M

>  <CAS>
2444-46-4

>  <Description>
Nonivamide is a naturally occurring analog of capsaicin, isolated from peppers, described to produce effects similar to capsaicin. It is an agonist of the transient receptor potential cation channel subfamily V member 1. It serves as a transient agonist of these receptors, which are potentiated by pro-inflammatory drugs, a phenomenon that leads to thermal hyperalgesia, or increased heat sensation.

>  <EBC_ID>
EBC-03864

>  <IUPAC Name>
N-[(4-hydroxy-3-methoxyphenyl)methyl]nonanamide

>  <Main Tar all refs>
Angew. Chem. Int. Ed., 2007, vol. 46, # 48, p. 9312 - 9315 | Eur. J. Pharm. Sci., 2012, vol. 47, # 5, p. 941 - 951 | FEBS Lett., 1998, vol. 436, # 3, p. 449 - 454 | Mol. Pharmacol., 2011, vol. 80, # 3, p. 509 - 517

>  <Main tar all>
TRPV1 pX=7.2 | ?2B-adrenoceptor pX=6.0 | CB1 receptor pX=5.92 | RyR1 pX=5.77

$$$$
Roxadustat
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.3347 -4.62 0 0
M  V30 2 C -4.001 -5.39 0 0
M  V30 3 N -2.6674 -4.62 0 0
M  V30 4 C -1.3337 -5.39 0 0
M  V30 5 C 0 -4.62 0 0
M  V30 6 O 0 -3.08 0 0
M  V30 7 N 1.3337 -5.39 0 0
M  V30 8 C 2.6674 -4.62 0 0
M  V30 9 C 4.001 -5.39 0 0
M  V30 10 O 5.3347 -4.62 0 0
M  V30 11 O 4.001 -6.93 0 0
M  V30 12 C -1.3337 -6.93 0 0
M  V30 13 O 0 -7.7 0 0
M  V30 14 C -2.6674 -7.7 0 0
M  V30 15 C -2.6674 -9.24 0 0
M  V30 16 C -4.001 -10.01 0 0
M  V30 17 C -5.3347 -9.24 0 0
M  V30 18 O -6.6684 -10.01 0 0
M  V30 19 C -8.0021 -9.24 0 0
M  V30 20 C -9.3358 -10.01 0 0
M  V30 21 C -10.6694 -9.24 0 0
M  V30 22 C -10.6694 -7.7 0 0
M  V30 23 C -9.3358 -6.93 0 0
M  V30 24 C -8.0021 -7.7 0 0
M  V30 25 C -5.3347 -7.7 0 0
M  V30 26 C -4.001 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 4 12
M  V30 12 1 12 13
M  V30 13 2 12 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 19 24
M  V30 25 2 17 25
M  V30 26 1 25 26
M  V30 27 2 2 26
M  V30 28 1 14 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037280642

>  <MW>
352.341

>  <MW (desalted)>
352.341

>  <ClogP>
4.96

>  <logS>
-4.449

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
108.75

>  <RotBonds>
5

>  <CAS>
808118-40-3

>  <Description>
Roxadustat (FG-4592) is a hypoxia-inducible factor prolyl hydroxylase enzyme (HIF-PH) inhibitor.

>  <EBC_ID>
EBC-11389

$$$$
Lubiprostone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.9577 14.9039 0 0
M  V30 2 C 1.4327 14.6895 0 0
M  V30 3 C 0.8558 13.2617 0 0
M  V30 4 C -0.6692 13.0473 0 0
M  V30 5 C -1.2461 11.6195 0 0
M  V30 6 F -2.674 12.1964 0 0
M  V30 7 F 0.1817 11.0426 0 0
M  V30 8 C -1.823 10.1916 0 0 CFG=1
M  V30 9 O -3.129 11.0077 0 0
M  V30 10 C -0.3167 9.8714 0 0
M  V30 11 C 0.1592 8.4068 0 0
M  V30 12 C -0.8713 7.2624 0 0 CFG=2
M  V30 13 C -0.7103 5.7308 0 0 CFG=1
M  V30 14 C 0.6234 4.9608 0 0
M  V30 15 C 1.9571 5.7308 0 0
M  V30 16 C 3.2908 4.9608 0 0
M  V30 17 C 4.6244 5.7308 0 0
M  V30 18 C 5.9581 4.9608 0 0
M  V30 19 C 7.2918 5.7308 0 0
M  V30 20 C 8.6255 4.9608 0 0
M  V30 21 O 9.9592 5.7308 0 0
M  V30 22 O 8.6255 3.4208 0 0
M  V30 23 C -2.1171 5.1044 0 0
M  V30 24 O -2.4373 3.5981 0 0
M  V30 25 C -3.1476 6.2489 0 0
M  V30 26 C -2.3776 7.5825 0 0 CFG=1
M  V30 27 O -2.8535 9.0472 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 8 5 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 13 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 26 25 CFG=1
M  V30 26 1 12 26
M  V30 27 1 26 27
M  V30 28 1 8 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037281137

>  <MW>
390.462

>  <MW (desalted)>
390.462

>  <ClogP>
3.832

>  <logS>
-5.322

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
83.83

>  <RotBonds>
11

>  <Action on targets>
Agonist | Activator

>  <Activity coefficients and valu>
pIC50  8.9  | EC50  17.27 nM

>  <CAS>
333963-40-9

>  <Description>
Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. It is used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation.

>  <EBC_ID>
EBC-07245

>  <IUPAC Name>
7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-octahydrocyclopenta[b]pyran-5-yl]heptanoic acid

>  <Main Tar all refs>
Br. J. Pharmacol., 2008, vol. 154, # 1, p. 126 - 135 | Am. J. Physiol. Cell Physiol., 2004, vol. 287, # 5 56-5, p. C1173-C1183

>  <Main tar all>
EP receptor pX=8.9 | ClC-2 pX=7.76

$$$$
Bifonazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.9045 -9.4148 0 0
M  V30 2 C -2.3804 -7.9502 0 0
M  V30 3 N -1.1345 -7.045 0 0
M  V30 4 C 0.1114 -7.9502 0 0
M  V30 5 N -0.3645 -9.4148 0 0
M  V30 6 C -1.1345 -5.505 0 0
M  V30 7 C 0.1992 -4.735 0 0
M  V30 8 C 0.1992 -3.195 0 0
M  V30 9 C 1.5329 -2.425 0 0
M  V30 10 C 2.8665 -3.195 0 0
M  V30 11 C 2.8665 -4.735 0 0
M  V30 12 C 1.5329 -5.505 0 0
M  V30 13 C -2.4682 -4.735 0 0
M  V30 14 C -3.8019 -5.505 0 0
M  V30 15 C -5.1355 -4.735 0 0
M  V30 16 C -5.1355 -3.195 0 0
M  V30 17 C -3.8019 -2.425 0 0
M  V30 18 C -2.4682 -3.195 0 0
M  V30 19 C -6.4692 -2.425 0 0
M  V30 20 C -7.8029 -3.195 0 0
M  V30 21 C -9.1366 -2.425 0 0
M  V30 22 C -9.1366 -0.885 0 0
M  V30 23 C -7.8029 -0.115 0 0
M  V30 24 C -6.4692 -0.885 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 1 5
M  V30 6 1 3 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 7 12
M  V30 14 1 6 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 13 18
M  V30 21 1 16 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z275375166

>  <MW>
310.392

>  <MW (desalted)>
310.392

>  <ClogP>
4.741

>  <logS>
-5.594

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.82

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 56.5 nM | Ki (inhibition constant) = 56.5 nM | IC50  0.08 ?M | inhibition percentage  91 % | Kd (dissociation constant) < 0.1 ?M | IC50  120 nM | IC50  0.18 ?M | IC50  0.24 ?M | Kd (dissociation constant)  0.43 ?M | IC50  790 nM | IC50 = 0.8 ?M | IC50  1.1 ?M | IC50  1110 nM | inhibition percentage  89 % | Kd (dissociation constant)  1.4 ?M

>  <CAS>
60628-96-8

>  <Description>
Bifonazole is an azole antifungal drug. Bifonazole works by inhibiting the production of ergosterol, which is an essential component of fungal cell membranes. It acts to destabilize the fungal cyctochrome p450 51 enzyme. It is used for the treatment of various topical fungal infections, including athlete's foot.

>  <EBC_ID>
EBC-01060

>  <IUPAC Name>
1-({[1,1'-biphenyl]-4-yl}(phenyl)methyl)-1H-imidazole

>  <Main Tar all refs>
Curr. Med. Chem., 2008, vol. 15, # 9, p. 868 - 899 | J. Med. Chem., 2003, vol. 46, # 12, p. 2345 - 2351 | Aquat. Toxicol., 2018, vol. 201, p. 11 - 20 | Drug Metab. Dispos., 2011, vol. 39, # 6, p. 1039 - 1046 | J. Mol. Biol., 2010, vol. 397, # 4, p. 1067 - 1078 | Aquat. Toxicol., 2018, vol. 198, p. 73 - 81 | Aquat. Toxicol., 2019, vol. 207, p. 187 - 196 | Toxicology, 2006, vol. 219, # 1-3, p. 33 - 40 | FEBS J., 2014, vol. 281, # 6, p. 1700 - 1713 | Bioorg. Med. Chem., 2008, vol. 16, # 16, p. 7715 - 7727 | PROCTER & GAMBLE CO - US2014/227208, 2014, A1 | Biochem. Pharmacol., 2022, vol. 204 | Aquat. Toxicol., 2018, vol. 198, p. 73 - 81 | UNILEVER (PLC & NV) - US2004/43044, 2004, A1 | ChemMedChem, 2021, vol. 16, # 18, p. 2786 - 2801

>  <Main tar all>
CYP17A1 pX=7.25 | Steroid 17-alpha-hydroxylase/17,20 lyase (gene CYP17A1) pX=7.25 | CYP27A1 pX=7.1 | CYP3A pX=7.0 | CYP51A1 pX=7.0 | CYP1A1 pX=6.92 | CYP1A1 pX=6.74 | Aromatase (gene CYP19A1) pX=6.62 | CYP7B1 pX=6.37 | CYP17A1 pX=6.1 | Cytochrome P450 3A4 pX=6.1 | Long-chain-fatty-acid-CoA ligase 4 pX=5.96 | Aromatase 1 pX=5.95 | Cytochrome b5 pX=5.91 | Mycocyclosin synthase pX=5.85

$$$$
Gefitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 1.54 0 0
M  V30 2 O 0 -0 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 4.001 -0.77 0 0
M  V30 6 N 5.3347 0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 N 6.6684 -2.31 0 0
M  V30 9 C 5.3347 -3.08 0 0
M  V30 10 N 5.3347 -4.62 0 0
M  V30 11 C 6.6684 -5.39 0 0
M  V30 12 C 8.0021 -4.62 0 0
M  V30 13 C 9.3358 -5.39 0 0
M  V30 14 C 9.3358 -6.93 0 0
M  V30 15 F 10.6694 -7.7 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 Cl 8.0021 -9.24 0 0
M  V30 18 C 6.6684 -6.93 0 0
M  V30 19 C 4.001 -2.31 0 0
M  V30 20 C 2.6674 -3.08 0 0
M  V30 21 C 1.3337 -2.31 0 0
M  V30 22 O 0 -3.08 0 0
M  V30 23 C -1.3337 -2.31 0 0
M  V30 24 C -1.3337 -0.77 0 0
M  V30 25 C -2.6674 -0 0 0
M  V30 26 N -2.6674 1.54 0 0
M  V30 27 C -4.001 2.31 0 0
M  V30 28 C -4.001 3.85 0 0
M  V30 29 O -2.6674 4.62 0 0
M  V30 30 C -1.3337 3.85 0 0
M  V30 31 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 11 18
M  V30 19 1 9 19
M  V30 20 1 5 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 3 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 26 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610485

>  <MW>
446.902

>  <MW (desalted)>
446.902

>  <ClogP>
5.602

>  <logS>
-5.23

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
68.74

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.028 nM | Ki (inhibition constant)  0.07 nM | Ki (inhibition constant) = 0.07 nM | Ki (inhibition constant)  0.12 nM | cell viability decrease Active   | Kd (dissociation constant)  0.5 nM | Kd (dissociation constant)  0.52 nM | IC50  0.562 nM | Kd (dissociation constant)  0.57 nM

>  <CAS>
184475-35-2

>  <Description>
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor. It appear to be most efficacious in treating certain EGFR gene mutations prevalent in Asian populations.

>  <EBC_ID>
EBC-07543

>  <IUPAC Name>
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

>  <Main Tar all refs>
Biochemistry, 2020, vol. 59, # 14, p. 1428 - 1441 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | Cancer Res., 2008, vol. 68, # 2, p. 571 - 579 | JAPANESE FOUNDATION FOR CANCER RESEARCH - US2020/397786, 2020, A1 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132 | UNIVERSITY OF COLORADO (SYSTEM) - WO2019/51155, 2019, A1 | Nat. Biotechnol., 2008, vol. 26, # 1, p. 127 - 132

>  <Main tar all>
Epidermal growth factor receptor (L858R) pX=10.6 | Epidermal growth factor receptor (delE746-A750) pX=10.2 | epidermal growth factor receptor pX=10.2 | Epidermal growth factor receptor (L861Q) pX=9.92 | Epidermal growth factor receptor (Del19) pX=9.52 | Epidermal growth factor receptor (L747-P753del, insS) pX=9.3 | Epidermal growth factor receptor (L747-T751del, Sins) pX=9.28 | erb-b2 receptor tyrosine kinase 2 pX=9.25 | Epidermal growth factor receptor (L747-A750del, insP) pX=9.24

$$$$
Tolterodine tartrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.5183 -2.0005 0 0
M  V30 2 C 3.9783 -2.0005 0 0
M  V30 3 C 3.2083 -3.3342 0 0
M  V30 4 N 3.2083 -0.6668 0 0
M  V30 5 C 1.6683 -0.6668 0 0
M  V30 6 C 0.8983 0.6668 0 0
M  V30 7 C -0.6417 0.6668 0 0 CFG=2
M  V30 8 C -1.4117 2.0005 0 0
M  V30 9 C -2.9517 2.0005 0 0
M  V30 10 C -3.7217 3.3342 0 0
M  V30 11 C -2.9517 4.6679 0 0
M  V30 12 C -1.4117 4.6679 0 0
M  V30 13 C -0.6417 3.3342 0 0
M  V30 14 C -1.4117 -0.6668 0 0
M  V30 15 C -0.6417 -2.0005 0 0
M  V30 16 C -1.4117 -3.3342 0 0
M  V30 17 C -0.6417 -4.6679 0 0
M  V30 18 C -2.9517 -3.3342 0 0
M  V30 19 C -3.7217 -2.0005 0 0
M  V30 20 C -2.9517 -0.6668 0 0
M  V30 21 O -3.7217 0.6668 0 0
M  V30 22 C 3.9783 0.6668 0 0
M  V30 23 C 3.2083 2.0005 0 0
M  V30 24 C 5.5183 0.6668 0 0
M  V30 25 O 12.8194 1.925 0 0
M  V30 26 C 12.8194 0.385 0 0 CFG=2
M  V30 27 C 11.4857 -0.385 0 0 CFG=1
M  V30 28 O 11.4857 -1.925 0 0
M  V30 29 C 10.152 0.385 0 0
M  V30 30 O 8.8183 -0.385 0 0
M  V30 31 O 10.152 1.925 0 0
M  V30 32 C 14.153 -0.385 0 0
M  V30 33 O 15.4867 0.385 0 0
M  V30 34 O 14.153 -1.925 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 14 20
M  V30 22 1 20 21
M  V30 23 1 4 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 26 25 CFG=1
M  V30 27 1 26 27
M  V30 28 1 27 28 CFG=1
M  V30 29 1 27 29
M  V30 30 2 29 30
M  V30 31 1 29 31
M  V30 32 1 26 32
M  V30 33 2 32 33
M  V30 34 1 32 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801945

>  <MW>
475.574

>  <MW (desalted)>
325.488

>  <ClogP>
5.24

>  <logS>
-3.268

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
23.47

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Antagonist | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  9.51  | pKi  9  | pKi  8.75  | pKi  8.75  | pKi  8.62  | pKi  8.58

>  <CAS>
124937-52-6

>  <Description>
Tolterodine is a muscarinic receptor antagonist used to treat overactive bladder with urinary incontinence, urgency, and frequency.

>  <EBC_ID>
EBC-13599

>  <IUPAC Name>
(2R,3R)-2,3-dihydroxybutanedioic acid; 2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899 | BJU Int., 2008, vol. 101, # 8, p. 1036 - 1042 | BJU Int., 2008, vol. 101, # 8, p. 1036 - 1042 | BJU Int., 2008, vol. 101, # 8, p. 1036 - 1042 | J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899 | J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899

>  <Main tar all>
mAChR pX=9.51 | M1 receptor pX=9.0 | M2 receptor pX=8.75 | M3 receptor pX=8.75 | M5 receptor pX=8.62 | M4 receptor pX=8.58

$$$$
Eptifibatide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 57 60 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -8.8373 -7.0358 0 0
M  V30 2 C -7.6618 -6.0409 0 0
M  V30 3 N -6.2125 -6.5614 0 0
M  V30 4 C -5.037 -5.5665 0 0
M  V30 5 C -3.5876 -6.087 0 0
M  V30 6 C -2.4122 -5.0921 0 0
M  V30 7 C -0.9628 -5.6126 0 0
M  V30 8 C 0.2127 -4.6177 0 0 CFG=2
M  V30 9 N -1.121 -3.8477 0 0
M  V30 10 C -0.8008 -2.3414 0 0
M  V30 11 O -1.8313 -1.1969 0 0
M  V30 12 C 0.7307 -2.1804 0 0
M  V30 13 C 1.9117 -0.9782 0 0
M  V30 14 S 3.418 -1.2984 0 0
M  V30 15 S 4.4485 -0.1539 0 0
M  V30 16 C 5.9548 -0.4741 0 0
M  V30 17 C 6.9853 0.6703 0 0 CFG=2
M  V30 18 N 8.4916 0.3501 0 0
M  V30 19 C 9.5221 1.4946 0 0
M  V30 20 O 9.0462 2.9592 0 0
M  V30 21 C 11.0284 1.1744 0 0 CFG=2
M  V30 22 C 12.2743 2.0796 0 0
M  V30 23 C 13.5202 1.1744 0 0
M  V30 24 C 13.0443 -0.2902 0 0
M  V30 25 N 11.5043 -0.2902 0 0
M  V30 26 C 10.4739 -1.4347 0 0
M  V30 27 O 8.9675 -1.1145 0 0
M  V30 28 C 10.9497 -2.8993 0 0 CFG=2
M  V30 29 C 12.4561 -3.2195 0 0
M  V30 30 C 12.932 -4.6841 0 0
M  V30 31 C 12.0268 -5.93 0 0
M  V30 32 N 12.932 -7.1759 0 0
M  V30 33 C 14.3966 -6.7 0 0
M  V30 34 C 15.7303 -7.47 0 0
M  V30 35 C 17.064 -6.7 0 0
M  V30 36 C 17.064 -5.16 0 0
M  V30 37 C 15.7303 -4.39 0 0
M  V30 38 C 14.3966 -5.16 0 0
M  V30 39 N 9.9193 -4.0437 0 0
M  V30 40 C 8.4129 -3.7236 0 0
M  V30 41 O 7.9371 -2.2589 0 0
M  V30 42 C 7.3825 -4.868 0 0 CFG=2
M  V30 43 C 7.8584 -6.3326 0 0
M  V30 44 C 9.3647 -6.6528 0 0
M  V30 45 O 10.3952 -5.5084 0 0
M  V30 46 O 9.8406 -8.1174 0 0
M  V30 47 N 5.8761 -4.5478 0 0
M  V30 48 C 4.8457 -5.6923 0 0
M  V30 49 O 5.3216 -7.1569 0 0
M  V30 50 C 3.3393 -5.3721 0 0
M  V30 51 N 2.3089 -6.5165 0 0
M  V30 52 C 0.8025 -6.1963 0 0
M  V30 53 O -0.2029 -7.3629 0 0
M  V30 54 C 6.5094 2.1349 0 0
M  V30 55 O 5.003 2.4551 0 0
M  V30 56 N 7.5399 3.2794 0 0
M  V30 57 N -7.9357 -4.5254 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 21 19
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 21 25 CFG=3
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 28 26
M  V30 29 1 28 29 CFG=3
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 2 34 35
M  V30 36 1 35 36
M  V30 37 2 36 37
M  V30 38 1 37 38
M  V30 39 1 30 38
M  V30 40 2 33 38
M  V30 41 1 28 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 42 40
M  V30 45 1 42 43 CFG=3
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 44 46
M  V30 49 1 42 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 48 50
M  V30 53 1 50 51
M  V30 54 1 51 52
M  V30 55 1 8 52
M  V30 56 2 52 53
M  V30 57 1 17 54 CFG=1
M  V30 58 2 54 55
M  V30 59 1 54 56
M  V30 60 1 2 57
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2241982440

>  <MW>
831.962

>  <MW (desalted)>
831.962

>  <ClogP>
-2.882

>  <logS>
-4.189

>  <HBD>
10

>  <HBA>
12

>  <TPSA>
326.39

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  27.7 nM

>  <CAS>
188627-80-7

>  <Description>
Eptifibatide is a peptide-based antagonist for glycoprotein IIb/IIIa (Integrin?alpha-IIb?beta?3) used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention.

>  <EBC_ID>
EBC-12386

>  <IUPAC Name>
2-[(3R,11S,17S,20S,25aS)-3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid

>  <Main Tar all refs>
Cell, 2022, vol. 185, # 19, p. 3533 - 27,3550

>  <Main tar all>
integrin ?IIb?3 pX=7.56

$$$$
Fabomotizole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.2586 4.3828 0 0
M  V30 2 C 8.925 3.6128 0 0
M  V30 3 O 7.5913 4.3828 0 0
M  V30 4 C 6.2576 3.6128 0 0
M  V30 5 C 6.2576 2.0728 0 0
M  V30 6 C 4.9239 1.3028 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 S -0.3196 2.8428 0 0
M  V30 11 C -1.0896 4.1765 0 0
M  V30 12 C -2.6296 4.1765 0 0
M  V30 13 N -3.3996 2.8428 0 0
M  V30 14 C -2.6296 1.5091 0 0
M  V30 15 C -3.3996 0.1755 0 0
M  V30 16 O -4.9396 0.1755 0 0
M  V30 17 C -5.7096 1.5091 0 0
M  V30 18 C -4.9396 2.8428 0 0
M  V30 19 N 2.1256 4.0887 0 0
M  V30 20 C 3.5902 3.6128 0 0
M  V30 21 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 9 19
M  V30 20 1 19 20
M  V30 21 2 7 20
M  V30 22 1 20 21
M  V30 23 2 4 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z351640822

>  <MW>
307.411

>  <MW (desalted)>
307.411

>  <ClogP>
3.51

>  <logS>
-3.587

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
50.38

>  <RotBonds>
6

>  <CAS>
173352-21-1

>  <Description>
An anxiolytic drug. Fabomotizole produces anxiolytic and neuroprotective effects without any muscle relaxant actions.

>  <EBC_ID>
EBC-50083

>  <IUPAC Name>
6-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-1,3-benzodiazole

$$$$
Bromhexine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 0.2994 0 0
M  V30 3 N 5.7337 1.0694 0 0
M  V30 4 C 7.0674 0.2994 0 0
M  V30 5 C 7.0674 -1.2406 0 0
M  V30 6 C 8.401 -2.0106 0 0
M  V30 7 C 8.401 -3.5506 0 0
M  V30 8 Br 9.7347 -4.3206 0 0
M  V30 9 C 7.0674 -4.3206 0 0
M  V30 10 C 5.7337 -3.5506 0 0
M  V30 11 Br 4.4 -4.3206 0 0
M  V30 12 C 5.7337 -2.0106 0 0
M  V30 13 N 4.4 -1.2406 0 0
M  V30 14 C 5.7337 2.6094 0 0
M  V30 15 C 4.4 3.3794 0 0
M  V30 16 C 4.4 4.9194 0 0
M  V30 17 C 5.7337 5.6894 0 0
M  V30 18 C 7.0674 4.9194 0 0
M  V30 19 C 7.0674 3.3794 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 10 12
M  V30 11 2 5 12
M  V30 12 1 12 13
M  V30 13 1 3 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2106590248

>  <MW>
412.591

>  <MW (desalted)>
376.13

>  <ClogP>
4.884

>  <logS>
-5.163

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.26

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50  1.8 ?M

>  <CAS>
611-75-6

>  <Description>
Bromhexine HCl is an expectorant/mucolytic agent which works by dissolving hard phlegm. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated.

>  <EBC_ID>
EBC-07637

>  <IUPAC Name>
2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline hydrochloride

>  <Main Tar all refs>
ANDRESEN J MICHAEL; PETROVSKI SLAVE; PAIRNOMIX - WO2019/18119, 2019, A1

>  <Main tar all>
KNa1.1 pX=5.74

$$$$
Chenodeoxycholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3626 -7.2893 0 0
M  V30 2 C 4.7822 -5.8629 0 0 CFG=2
M  V30 3 C 3.2567 -5.6522 0 0
M  V30 4 C 2.3115 -6.868 0 0
M  V30 5 C 0.786 -6.6574 0 0
M  V30 6 O -0.1592 -7.8732 0 0
M  V30 7 O 0.2057 -5.2309 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 C 5.2994 -3.1677 0 0
M  V30 10 C 6.574 -2.3035 0 0
M  V30 11 C 7.7898 -3.2487 0 0 CFG=1
M  V30 12 C 9.3058 -2.9776 0 0 CFG=2
M  V30 13 C 9.829 -1.5293 0 0 CFG=2
M  V30 14 O 8.8363 -0.3519 0 0
M  V30 15 C 11.345 -1.2582 0 0
M  V30 16 C 12.3377 -2.4355 0 0 CFG=2
M  V30 17 C 13.8537 -2.1644 0 0
M  V30 18 C 14.8464 -3.3418 0 0 CFG=2
M  V30 19 O 16.3624 -3.0707 0 0
M  V30 20 C 14.3232 -4.7901 0 0
M  V30 21 C 12.8072 -5.0612 0 0
M  V30 22 C 11.8145 -3.8839 0 0 CFG=1
M  V30 23 C 11.2913 -5.3323 0 0
M  V30 24 C 10.2985 -4.155 0 0 CFG=1
M  V30 25 C 9.7753 -5.6034 0 0
M  V30 26 C 8.2593 -5.8744 0 0
M  V30 27 C 7.2666 -4.6971 0 0 CFG=2
M  V30 28 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 2 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 16 17
M  V30 17 1 18 17
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 12 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 8
M  V30 30 1 11 27
M  V30 31 1 27 28 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1172235745

>  <MW>
392.572

>  <MW (desalted)>
392.572

>  <ClogP>
4.514

>  <logS>
-5.07

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
77.76

>  <RotBonds>
4

>  <Action on targets>
- | Antagonist | Substrate | Substrate

>  <Activity coefficients and valu>
EC50 = 8.3 nM | EC50  0.1 - 1 ?M | percentage increase Active   | percentage increase Active

>  <CAS>
474-25-9

>  <Description>
Chenodeoxycholic acid is an epimer of ursodeoxycholic acid. Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.  It is used for the treatment of primary biliary cirrhosis.

>  <EBC_ID>
EBC-11080

>  <IUPAC Name>
(4R)-4-[(1R,3aS,3bR,4R,5aS,7R,9aS,9bS,11aR)-4,7-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
Curr. Med. Chem., 2010, vol. 17, # 2, p. 139 - 159 | ORPHAGEN PHARMACEUTICALS - US8389739, 2013, B1 | PLoS ONE, 2017, vol. 12, # 1 | PLoS ONE, 2017, vol. 12, # 1

>  <Main tar all>
Farnesoid X receptor pX=8.08 | Lectin, Galactoside-Binding, Soluble, 4 - Farnesoid X Receptor pX=7.0 | OATP1B1 pX=7.0 | OATP1B3 pX=7.0

$$$$
Bosutinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -5.39 0 0
M  V30 2 O -2.6674 -4.62 0 0
M  V30 3 C -1.3337 -5.39 0 0
M  V30 4 C 0 -4.62 0 0
M  V30 5 C 1.3337 -5.39 0 0
M  V30 6 N 2.6674 -4.62 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C 0 -3.08 0 0
M  V30 10 N -1.3337 -3.85 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 N 2.6674 0 0 0
M  V30 13 C 4.001 -0.77 0 0
M  V30 14 C 5.3347 0 0 0
M  V30 15 C 6.6684 -0.77 0 0
M  V30 16 O 8.0021 -0 0 0
M  V30 17 C 8.0021 1.54 0 0
M  V30 18 C 9.3358 2.31 0 0
M  V30 19 C 9.3358 3.85 0 0
M  V30 20 N 10.6694 4.62 0 0
M  V30 21 C 10.6694 6.16 0 0
M  V30 22 C 12.0031 6.93 0 0
M  V30 23 N 13.3368 6.16 0 0
M  V30 24 C 14.6705 6.93 0 0
M  V30 25 C 13.3368 4.62 0 0
M  V30 26 C 12.0031 3.85 0 0
M  V30 27 C 6.6684 -2.31 0 0
M  V30 28 O 8.0021 -3.08 0 0
M  V30 29 C 8.0021 -4.62 0 0
M  V30 30 C 5.3347 -3.08 0 0
M  V30 31 C 4.001 -2.31 0 0
M  V30 32 C 1.3337 -6.93 0 0
M  V30 33 Cl 2.6674 -7.7 0 0
M  V30 34 C 0 -7.7 0 0
M  V30 35 C -1.3337 -6.93 0 0
M  V30 36 Cl -2.6674 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 3 9 10
M  V30 10 2 8 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 1 20 26
M  V30 27 1 15 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 27 30
M  V30 31 1 30 31
M  V30 32 2 7 31
M  V30 33 1 13 31
M  V30 34 1 5 32
M  V30 35 1 32 33
M  V30 36 2 32 34
M  V30 37 1 34 35
M  V30 38 2 3 35
M  V30 39 1 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216885221

>  <MW>
530.446

>  <MW (desalted)>
530.446

>  <ClogP>
5.087

>  <logS>
-4.527

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
82.88

>  <RotBonds>
9

>  <Action on targets>
Inhibitor | Inhibitor | - | - | - | - | Inhibitor | - | - | - | Inhibitor | Inhibitor | - | Inhibitor

>  <Activity coefficients and valu>
IC50  7.51E-09 mM | Kd (dissociation constant)  0.023 nM | Kd (dissociation constant)  0.029 nM | Kd (dissociation constant)  0.037 nM | Kd (dissociation constant)  0.039 nM | Kd (dissociation constant)  0.036 nM | IC50  3.85E-08 mM | Kd (dissociation constant)  0.047 nM | Kd (dissociation constant)  0.057 nM | Kd (dissociation constant)  0.062 nM | IC50  1.3E-07 mM | IC50  0.174 nM | Kd (dissociation constant)  0.18 nM | IC50  0.242 nM

>  <CAS>
380843-75-4

>  <Description>
Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile.

>  <EBC_ID>
EBC-11336

>  <IUPAC Name>
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

>  <Main Tar all refs>
FOX CHASE CANCER CENTER; BARTS HEALTH NHS TRUST - WO2013/187967, 2013, A1 | YALE UNIVERSITY - WO2017/79267, 2017, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | FOX CHASE CANCER CENTER; BARTS HEALTH NHS TRUST - WO2013/187967, 2013, A1 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | FOX CHASE CANCER CENTER; BARTS HEALTH NHS TRUST - WO2013/187967, 2013, A1 | Cancer Res., 2006, vol. 66, # 23, p. 11314 - 11322 | Nat. Biotechnol., 2011, vol. 29, # 11, p. 1046 - 1051 | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE - WO2015/179436, 2015, A1

>  <Main tar all>
SRC proto-oncogene, non-receptor tyrosine kinase pX=11.1 | Tyrosine-protein?kinase?ABL1?phosphorylated pX=10.6 | Tyrosine-protein?kinase?ABL1?(F317L) pX=10.5 | Tyrosine-protein?kinase?ABL1?(M351T) pX=10.4 | Tyrosine-protein?kinase?ABL1?(Q252H) phosphorylated pX=10.4 | Tyrosine-protein?kinase?ABL1?(Y253F) phosphorylated pX=10.4 | WEE1 G2 checkpoint kinase pX=10.4 | Tyrosine-protein?kinase?ABL1?(E255K) phosphorylated pX=10.3 | Tyrosine-protein kinase ABL pX=10.2 | Tyrosine-protein?kinase?ABL1?(H396P) phosphorylated pX=10.2 | checkpoint kinase 1 pX=9.89 | FGR proto-oncogene, Src family tyrosine kinase pX=9.76 | Tyrosine-protein?kinase?ABL1?(F317I) phosphorylated pX=9.74 | mitogen-activated protein kinase kinase kinase 3 pX=9.62

$$$$
Ibrutinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 N 2.4172 0.77 0 0
M  V30 9 C 3.3224 2.0159 0 0
M  V30 10 C 2.8465 3.4805 0 0
M  V30 11 C 1.3401 3.8007 0 0
M  V30 12 C 0.8642 5.2653 0 0
M  V30 13 C 1.8947 6.4098 0 0
M  V30 14 O 1.4188 7.8744 0 0
M  V30 15 C 2.4493 9.0188 0 0
M  V30 16 C 1.9734 10.4835 0 0
M  V30 17 C 3.0039 11.6279 0 0
M  V30 18 C 4.5102 11.3077 0 0
M  V30 19 C 4.9861 9.8431 0 0
M  V30 20 C 3.9556 8.6987 0 0
M  V30 21 C 3.401 6.0896 0 0
M  V30 22 C 3.8769 4.625 0 0
M  V30 23 C 4.787 1.54 0 0
M  V30 24 C 2.8465 -1.9405 0 0 CFG=2
M  V30 25 C 3.8769 -3.085 0 0
M  V30 26 C 3.401 -4.5496 0 0
M  V30 27 C 1.8947 -4.8698 0 0
M  V30 28 N 0.8642 -3.7253 0 0
M  V30 29 C 1.3401 -2.2607 0 0
M  V30 30 C -0.6421 -4.0455 0 0
M  V30 31 O -1.118 -5.5101 0 0
M  V30 32 C -1.6726 -2.9011 0 0
M  V30 33 C -3.1789 -3.2212 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 21 2 13 21
M  V30 22 1 21 22
M  V30 23 2 10 22
M  V30 24 1 9 23
M  V30 25 2 2 23
M  V30 26 1 6 23
M  V30 27 1 24 7 CFG=3
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 1 24 29
M  V30 34 1 28 30
M  V30 35 2 30 31
M  V30 36 1 30 32
M  V30 37 2 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1302446275

>  <MW>
440.497

>  <MW (desalted)>
440.497

>  <ClogP>
4.069

>  <logS>
-6.792

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
99.16

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3E-05 ?M | IC50  0.1 nM | IC50 > 0.1 - 10 nM | IC50 > 0.1 - 10 nM | IC50 > 0.1 - 10 nM | IC50 = 0.1 nM | IC50 > 0.1 - 10 nM | Ki (inhibition constant)  0.451 - 0.566 nM | IC50 < 0.5 nM | IC50  0.5 nM | IC50  0.5 nM | EC50  0.58 nM | IC50  0.7 nM | IC50  1 nM | IC50  0.001 ?mol/l | IC50  0.99 nM

>  <CAS>
936563-96-1

>  <Description>
Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.

>  <EBC_ID>
EBC-11432

>  <IUPAC Name>
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

>  <Main Tar all refs>
J. Am. Chem. Soc., 2020, vol. 142, # 43, p. 18522 - 18531 | UNIVERSITY SYSTEM OF OHIO - WO2019/14684, 2019, A1 | DUNAD THERAPEUTICS; DUNAD THERAPEUTICS LTD; 2692372 ONTARIO INC - WO2021/99842, 2021, A1 | DUNAD THERAPEUTICS; DUNAD THERAPEUTICS LTD; 2692372 ONTARIO INC - WO2021/99842, 2021, A1 | DUNAD THERAPEUTICS; DUNAD THERAPEUTICS LTD; 2692372 ONTARIO INC - WO2021/99842, 2021, A1 | ABBVIE INC - EP2543375, 2013, A1 | DUNAD THERAPEUTICS; DUNAD THERAPEUTICS LTD; 2692372 ONTARIO INC - WO2021/99842, 2021, A1 | Cancers, 2020, vol. 12, # 12, p. 1 - 17 | ACS Med. Chem. Lett., 2020, vol. 11, # 10, p. 1863 - 1868 | ABBVIE INC - WO2010/9342, 2010, A2 | J. Med. Chem., 2018, vol. 61, # 10, p. 4608 - 4627 | J. Pharmacol. Exp. Ther., 2017, vol. 363, # 2, p. 240 - 252 | J. Med. Chem., 2022, vol. 65, # 7, p. 5300 - 5316 | J. Med. Chem., 2021, vol. 64, # 19, p. 14129 - 14141 | Mol. Cancer Ther., 2018, vol. 17, # 10, p. 2156 - 2163 | J. Med. Chem., 2021, vol. 64, # 19, p. 14129 - 14141

>  <Main tar all>
Bruton tyrosine kinase pX=10.5 | BLK proto-oncogene, Src family tyrosine kinase pX=10.0 | BMX non-receptor tyrosine kinase pX=10.0 | SRC proto-oncogene, non-receptor tyrosine kinase pX=10.0 | epidermal growth factor receptor pX=10.0 | erb-b2 receptor tyrosine kinase 4 pX=10.0 | fibroblast growth factor receptor (activity) pX=10.0 | AKR1C3 pX=9.35 | Tyrosine-protein?kinase?etk pX=9.3 | epidermal growth factor receptor pX=9.3 | tec protein tyrosine kinase pX=9.3 | B-Cell Receptor pX=9.24 | TXK tyrosine kinase pX=9.15 | Bruton tyrosine kinase (isoform?BTK-A) pX=9.0 | Epidermal growth factor receptor (T790M/L858R) pX=9.0 | PLC?2 pX=9.0

$$$$
Sparfloxacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.001 -2.31 0 0
M  V30 2 C -2.6674 -3.08 0 0 CFG=1
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 N 0 -3.08 0 0
M  V30 5 C 0 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0 CFG=1
M  V30 7 C -1.3337 -6.93 0 0
M  V30 8 N -2.6674 -4.62 0 0
M  V30 9 C 1.3337 -2.31 0 0
M  V30 10 C 1.3337 -0.77 0 0
M  V30 11 F 0 0 0 0
M  V30 12 C 2.6674 0 0 0
M  V30 13 N 2.6674 1.54 0 0
M  V30 14 C 4.001 -0.77 0 0
M  V30 15 C 5.3347 0 0 0
M  V30 16 O 5.3347 1.54 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 C 6.6684 -2.31 0 0
M  V30 19 N 5.3347 -3.08 0 0
M  V30 20 C 5.3347 -4.62 0 0
M  V30 21 C 6.1047 -5.9537 0 0
M  V30 22 C 4.5647 -5.9537 0 0
M  V30 23 C 4.001 -2.31 0 0
M  V30 24 C 2.6674 -3.08 0 0
M  V30 25 F 2.6674 -4.62 0 0
M  V30 26 C 8.0021 -0 0 0
M  V30 27 O 8.0021 1.54 0 0
M  V30 28 O 9.3358 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 2 8
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 20 22
M  V30 24 1 19 23
M  V30 25 2 14 23
M  V30 26 1 23 24
M  V30 27 2 9 24
M  V30 28 1 24 25
M  V30 29 1 17 26
M  V30 30 2 26 27
M  V30 31 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1590783391

>  <MW>
392.4

>  <MW (desalted)>
392.4

>  <ClogP>
-0.605

>  <logS>
-3.01

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
98.9

>  <RotBonds>
3

>  <Action on targets>
- | Inhibitor | Blocker | Inhibitor

>  <Activity coefficients and valu>
MIC = 0.007 ?g/mL | IC50 = 0.13 ?g/mL | IC50  0.34 ?M | IC50 = 0.21 ?g/mL

>  <CAS>
110871-86-8

>  <Description>
Sparfloxacin is a fluoroquinolone antibiotic indicated  to treat bacterial respiratory infections and sinusitis. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.

>  <EBC_ID>
EBC-14156

>  <IUPAC Name>
5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2006, vol. 50, # 11, p. 3717 - 3723 | Antimicrob. Agents Chemother., 1998, vol. 42, # 10, p. 2678 - 2681 | J. Pharmacol. Exp. Ther., 2001, vol. 296, # 3, p. 806 - 810 | Mini-Rev. Med. Chem., 2011, vol. 11, # 9, p. 771 - 821

>  <Main tar all>
Norm, Na+-Driven Multidrug Efflux Pump pX=7.75 | DNA?gyrase pX=6.48 | Kv11.1 pX=6.47 | DNA negative supercoiling pX=6.27

$$$$
Cinnamaldehyde
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 C 0 4.62 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3219847383

>  <MW>
132.058

>  <MW (desalted)>
132.159

>  <ClogP>
2.049

>  <logS>
-1.882

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
17.07

>  <RotBonds>
2

>  <Action on targets>
- | - | Agonist | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant) < 0.15 ?M | Km (Michaelis constant) = 0.29 ?M | protein expression level decrease Active   | Km (Michaelis constant) = 0.55 ?M | Ki (inhibition constant)  0.7 ?M | Ki (inhibition constant)  0.7 ?M | Ki (inhibition constant)  0.7 ?M | IC50  1.6 ?M | activity percentage  84.1 % | decrease rate Active   | EC50  3 ?M | inhibition percentage  89.56 %

>  <CAS>
14371-10-9

>  <Description>
Cinnamaldehyde is a naturally occurring flavonoid. It is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.

>  <EBC_ID>
EBC-00536

>  <IUPAC Name>
(2E)-3-phenylprop-2-enal

>  <Main Tar all refs>
Chem.-Biol. Interact., 2009, vol. 178, # 1-3, p. 36 - 39 | Chem.-Biol. Interact., 2009, vol. 178, # 1-3, p. 36 - 39 | GOODCAP PHARMACEUTICALS - WO2022/79574, 2022, A1 | BIOCHIM. BIOPHYS. ACTA, 1979, vol. 569, # 2, p. 117 - 123 | Drug Metab. Pharmacokinet., 2009, vol. 24, # 6, p. 490 - 499 | Drug Metab. Pharmacokinet., 2009, vol. 24, # 3, p. 226 - 234 | Drug Metab. Pharmacokinet., 2009, vol. 24, # 3, p. 226 - 234 | Cell Calcium, 2009, vol. 45, # 3, p. 300 - 309 | Drug Metab. Dispos., 2016, vol. 44, # 4, p. 534 - 543 | Cancers, 2020, vol. 12, # 2 | Br. J. Pharmacol., 2008, vol. 153, # 8, p. 1739 - 1749 | NAT DEFENSE EDUCATION AND RES FOUND; NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION - US2014/38921, 2014, A1

>  <Main tar all>
aldehyde dehydrogenase 2 family member pX=6.82 | Aldehyde Dehydrogenase Family 1 pX=6.54 | TRP channel pX=6.3 | Aldehyde dehydrogenase pX=6.26 |  UDP glucuronosyltransferase family 2 member B7 pX=6.15 | UDP-glucuronosyltransferase 1-1 pX=6.15 | UDP-glucuronosyltransferase 1A1 pX=6.15 | TRPM7 pX=5.8 | Cytochrome P450 2A6 pX=5.72 | Alpha-enolase pX=5.6 | TRPA1 pX=5.52 | CYP2E1 pX=5.41

$$$$
Niclosamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -3.08 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 C 4.001 -6.93 0 0
M  V30 5 C 2.6674 -7.7 0 0
M  V30 6 Cl 2.6674 -9.24 0 0
M  V30 7 C 1.3337 -6.93 0 0
M  V30 8 C 1.3337 -5.39 0 0
M  V30 9 C 0 -4.62 0 0
M  V30 10 O 0 -3.08 0 0
M  V30 11 N -1.3337 -5.39 0 0
M  V30 12 C -2.6674 -4.62 0 0
M  V30 13 C -4.001 -5.39 0 0
M  V30 14 C -5.3347 -4.62 0 0
M  V30 15 C -5.3347 -3.08 0 0
M  V30 16 C -4.001 -2.31 0 0
M  V30 17 C -2.6674 -3.08 0 0
M  V30 18 Cl -1.3337 -2.31 0 0
M  V30 19 N -6.6684 -2.31 0 0 CHG=1
M  V30 20 O -8.0021 -3.08 0 0
M  V30 21 O -6.6684 -0.77 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 20 1 15 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57902203

>  <MW>
325.986

>  <MW (desalted)>
327.12

>  <ClogP>
4.345

>  <logS>
-5.31

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
92.47

>  <RotBonds>
3

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
qualitative Active

>  <CAS>
50-65-7

>  <Description>
Niclosamide is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models. It inhibits STAT3 and stimulates autophagy by reversibly inhibiting mammalian target of rapamycin complex 1 signaling.

>  <EBC_ID>
EBC-00595

>  <IUPAC Name>
5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide

>  <Main Tar all refs>
Toxicology, 2021, vol. 457

>  <Main tar all>
Estrogen-related receptor-? pX=10.0

$$$$
Doxorubicin hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 43 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -2.793 0 0
M  V30 3 O 5.7337 -2.023 0 0
M  V30 4 C 5.7337 -0.483 0 0
M  V30 5 C 4.4 0.287 0 0
M  V30 6 C 4.4 1.827 0 0
M  V30 7 C 5.7337 2.597 0 0
M  V30 8 C 7.0674 1.827 0 0
M  V30 9 C 8.401 2.597 0 0
M  V30 10 O 8.401 4.137 0 0
M  V30 11 C 9.7347 1.827 0 0
M  V30 12 C 11.0684 2.597 0 0
M  V30 13 O 11.0684 4.137 0 0
M  V30 14 C 12.4021 1.827 0 0
M  V30 15 C 13.7358 2.597 0 0
M  V30 16 C 15.0694 1.827 0 0 CFG=2
M  V30 17 O 16.586 1.5596 0 0
M  V30 18 C 15.0694 0.287 0 0
M  V30 19 C 13.7358 -0.483 0 0 CFG=2
M  V30 20 O 13.7358 -2.023 0 0
M  V30 21 C 15.0694 -2.793 0 0 CFG=1
M  V30 22 C 16.4031 -2.023 0 0
M  V30 23 C 17.7368 -2.793 0 0 CFG=2
M  V30 24 N 19.0705 -2.023 0 0
M  V30 25 C 17.7368 -4.333 0 0 CFG=2
M  V30 26 O 19.0705 -5.103 0 0
M  V30 27 C 16.4031 -5.103 0 0 CFG=2
M  V30 28 C 16.4031 -6.643 0 0
M  V30 29 O 15.0694 -4.333 0 0
M  V30 30 C 12.4021 0.287 0 0
M  V30 31 C 11.0684 -0.483 0 0
M  V30 32 O 11.0684 -2.023 0 0
M  V30 33 C 9.7347 0.287 0 0
M  V30 34 C 8.401 -0.483 0 0
M  V30 35 O 8.401 -2.023 0 0
M  V30 36 C 7.0674 0.287 0 0
M  V30 37 C 15.5961 3.2742 0 0
M  V30 38 O 17.1127 3.5416 0 0
M  V30 39 C 14.6063 4.4539 0 0
M  V30 40 O 15.133 5.901 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 2 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 12 14
M  V30 13 1 14 15
M  V30 14 1 16 15
M  V30 15 1 16 17 CFG=3
M  V30 16 1 16 18
M  V30 17 1 19 18
M  V30 18 1 19 20 CFG=3
M  V30 19 1 21 20 CFG=1
M  V30 20 1 21 22
M  V30 21 1 23 22
M  V30 22 1 23 24 CFG=3
M  V30 23 1 25 23
M  V30 24 1 25 26 CFG=3
M  V30 25 1 25 27
M  V30 26 1 27 28 CFG=3
M  V30 27 1 27 29
M  V30 28 1 21 29
M  V30 29 1 19 30
M  V30 30 1 14 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 1 31 33
M  V30 34 2 11 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 34 36
M  V30 38 2 4 36
M  V30 39 1 8 36
M  V30 40 1 16 37 CFG=1
M  V30 41 2 37 38
M  V30 42 1 37 39
M  V30 43 1 39 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557399790

>  <MW>
579.98

>  <MW (desalted)>
543.519

>  <ClogP>
0.317

>  <logS>
-4.55

>  <HBD>
6

>  <HBA>
12

>  <TPSA>
206.07

>  <RotBonds>
5

>  <Action on targets>
Substrate | Substrate | Inhibitor | Inhibitor | Allosteric Modulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Allosteric Modulator

>  <Activity coefficients and valu>
IC50  7 nM | IC50  0.013 ?M | GI50  0.03 ?M | IC50  40.9 nM | percentage of necrotic cells  70 % | CC50 (cytotoxic concentration)  106.6 nM | IC50  0.11 ?M | IC50  0.11 ?M | IC50  0.1311 ?M | IC50  0.15 ?M

>  <CAS>
25316-40-9

>  <Description>
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. It is used to treat various cancers and Kaposi's Sarcoma.

>  <EBC_ID>
EBC-11150

>  <IUPAC Name>
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2007, vol. 17, # 4, p. 1122 - 1126 | Eur. J. Med. Chem., 2007, vol. 42, # 2, p. 248 - 255 | Med. Chem., 2020, vol. 16, # 2, p. 192 - 201 | Biochemistry, 2011, vol. 50, # 37, p. 8057 - 8066 | SHALTECH - WO2021/127583, 2021, A1 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 10, p. 1246 - 1255 | Pharmaceutics, 2020, vol. 12, # 11, p. 1 - 20 | Eur. J. Med. Chem., 2018, vol. 158, p. 286 - 301 | Chem. Commun., 2019, vol. 55, # 71, p. 10627 - 10630 | SHALTECH - WO2021/127583, 2021, A1

>  <Main tar all>
ABCB1 pX=8.15 | ABCC1 pX=7.89 | Sigma intracellular receptor 2 pX=7.52 | ABCG2 pX=7.39 | human leukocyte antigen-DR pX=7.19 | Glutamate carboxypeptidase 2 (isoform PSMA') pX=6.97 | ABCC1 pX=6.96 | Inosine-5'-monophosphate dehydrogenase pX=6.96 | ferredoxin:thioredoxin reductase pX=6.88 | human leukocyte antigen-DR10 pX=6.82

$$$$
Sulfisoxazole acetyl
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.1345 -2.425 0 0
M  V30 2 C 2.4682 -1.655 0 0
M  V30 3 O 2.4682 -0.115 0 0
M  V30 4 N 3.8019 -2.425 0 0
M  V30 5 C 3.8019 -3.965 0 0
M  V30 6 O 5.0477 -4.8702 0 0
M  V30 7 N 4.5719 -6.3348 0 0
M  V30 8 C 3.0319 -6.3348 0 0
M  V30 9 C 2.1267 -7.5807 0 0
M  V30 10 C 2.556 -4.8702 0 0
M  V30 11 C 1.0913 -4.3943 0 0
M  V30 12 S 5.1355 -1.655 0 0
M  V30 13 O 5.9055 -2.9887 0 0
M  V30 14 O 4.3655 -0.3213 0 0
M  V30 15 C 6.4692 -0.885 0 0
M  V30 16 C 6.4692 0.655 0 0
M  V30 17 C 7.8029 1.425 0 0
M  V30 18 C 9.1366 0.655 0 0
M  V30 19 N 10.4702 1.425 0 0
M  V30 20 C 9.1366 -0.885 0 0
M  V30 21 C 7.8029 -1.655 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 4 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 20 21
M  V30 22 2 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681892022

>  <MW>
309.078

>  <MW (desalted)>
309.341

>  <ClogP>
1.026

>  <logS>
-2.107

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
106.5

>  <RotBonds>
2

>  <CAS>
80-74-0

>  <Description>
Sulfisoxazole acetyl is an ester of sulfisoxazole, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity.

>  <EBC_ID>
EBC-26722

>  <IUPAC Name>
N-(4-aminobenzenesulfonyl)-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamide

$$$$
Desloratadine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -0.6917 -2.9969 0 0
M  V30 2 C 0.7799 -2.543 0 0
M  V30 3 C 1.1226 -1.0416 0 0
M  V30 4 C 2.5942 -0.5877 0 0
M  V30 5 C 3.7231 -1.6352 0 0
M  V30 6 C 5.1106 -0.967 0 0
M  V30 7 C 5.1106 0.573 0 0
M  V30 8 C 3.7769 1.343 0 0
M  V30 9 C 3.7769 2.883 0 0
M  V30 10 N 5.1106 3.653 0 0
M  V30 11 C 6.4442 2.883 0 0
M  V30 12 C 6.4442 1.343 0 0
M  V30 13 C 6.4981 -1.6352 0 0
M  V30 14 N 7.627 -0.5877 0 0
M  V30 15 C 9.0985 -1.0416 0 0
M  V30 16 C 9.4412 -2.543 0 0
M  V30 17 C 8.3123 -3.5905 0 0
M  V30 18 C 6.8407 -3.1365 0 0
M  V30 19 C 5.8806 -4.3406 0 0
M  V30 20 C 4.3406 -4.3406 0 0
M  V30 21 C 3.3804 -3.1365 0 0
M  V30 22 C 1.9088 -3.5905 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 5 21
M  V30 24 1 21 22
M  V30 25 2 2 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801903

>  <MW>
310.124

>  <MW (desalted)>
310.821

>  <ClogP>
3.826

>  <logS>
-3.667

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.92

>  <RotBonds>
0

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50 < 0.1 nM

>  <CAS>
100643-71-8

>  <Description>
Desloratadine is a second generation tricyclic antihistamine, it is a potent antagonist for human histamine H1 receptor. It is used to treat seasonal and non seasonal allergic rhinitis, pruritus, and urticaria.

>  <EBC_ID>
EBC-06071

>  <IUPAC Name>
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaene

>  <Main Tar all refs>
J. Am. Chem. Soc., 2020, vol. 142, # 29, p. 12690 - 12698

>  <Main tar all>
H1 receptor pX=10.0

$$$$
Mirabegron
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -4.3425 -17.4757 0 0
M  V30 2 C -3.4374 -16.2298 0 0
M  V30 3 N -3.9132 -14.7652 0 0
M  V30 4 C -2.6674 -13.86 0 0
M  V30 5 C -2.6674 -12.32 0 0
M  V30 6 C -1.3337 -11.55 0 0
M  V30 7 O 0 -12.32 0 0
M  V30 8 N -1.3337 -10.01 0 0
M  V30 9 C 0 -9.24 0 0
M  V30 10 C 0 -7.7 0 0
M  V30 11 C 1.3337 -6.93 0 0
M  V30 12 C 2.6674 -7.7 0 0
M  V30 13 C 4.001 -6.93 0 0
M  V30 14 C 5.3347 -7.7 0 0
M  V30 15 N 6.6684 -6.93 0 0
M  V30 16 C 8.0021 -7.7 0 0
M  V30 17 C 9.3358 -6.93 0 0 CFG=2
M  V30 18 O 9.3358 -5.39 0 0
M  V30 19 C 10.6694 -7.7 0 0
M  V30 20 C 12.0031 -6.93 0 0
M  V30 21 C 13.3368 -7.7 0 0
M  V30 22 C 13.3368 -9.24 0 0
M  V30 23 C 12.0031 -10.01 0 0
M  V30 24 C 10.6694 -9.24 0 0
M  V30 25 C 2.6674 -9.24 0 0
M  V30 26 C 1.3337 -10.01 0 0
M  V30 27 C -1.4215 -14.7652 0 0
M  V30 28 S -1.8974 -16.2298 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=3
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 19 24
M  V30 25 2 12 25
M  V30 26 1 25 26
M  V30 27 2 9 26
M  V30 28 2 4 27
M  V30 29 1 27 28
M  V30 30 1 2 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1980444597

>  <MW>
396.506

>  <MW (desalted)>
396.506

>  <ClogP>
1.32

>  <logS>
-3.858

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
100.27

>  <RotBonds>
9

>  <Action on targets>
Agonist | Agonist | Inhibitor | Inhibitor | Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
pEC50  9.21 | pEC50  9.21 | Ki (inhibition constant)  2.5 nM | Ki (inhibition constant)  2.5 nM | EC50  7.9 nmol/l | EC50  7.9 nmol/l | EC50  10 nM

>  <CAS>
223673-61-8

>  <Description>
Mirabegron is a beta-3 adrenergic agonist. It is used to treat overactive bladder and neurogenic detrusor overactivity.

>  <EBC_ID>
EBC-26934

>  <IUPAC Name>
2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide

>  <Main Tar all refs>
Pharmacol. Res. Perspect., 2020, vol. 8, # 5 | Pharmacol. Res. Perspect., 2020, vol. 8, # 5 | Eur. J. Pharm. Sci., 2012, vol. 46, # 5, p. 381 - 387 | Eur. J. Pharm. Sci., 2012, vol. 46, # 5, p. 381 - 387 | J. Pharmacol. Toxicol. Methods, 2017, vol. 87, p. 74 - 81 | J. Pharmacol. Toxicol. Methods, 2017, vol. 87, p. 74 - 81 | Sumitomo Chemical (w/o Dongwoo Fine-Chem); Sumitomo Pharma (in: Sumitomo Chemical); SUMITOMO CHEMICAL COMPANY LIMITED - WO2022/175848, 2022, A1

>  <Main tar all>
?3-adrenoceptor pX=9.21 | ?3-adrenoceptor pX=9.21 | ?2-adrenoceptor pX=8.6 | ?2-adrenoceptor pX=8.6 | ?1-adrenoceptor pX=8.1 | ?1-adrenoceptor pX=8.1 | ?3-adrenoceptor pX=8.0

$$$$
Demeclocycline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 7.0674 3.8981 0 0
M  V30 3 N 8.401 3.1281 0 0
M  V30 4 C 9.7347 3.8981 0 0
M  V30 5 C 8.401 1.5881 0 0 CFG=1
M  V30 6 C 9.7347 0.8181 0 0 CFG=2
M  V30 7 C 11.0684 1.5881 0 0
M  V30 8 C 12.4021 0.8181 0 0 CFG=2
M  V30 9 C 13.7358 1.5881 0 0 CFG=2
M  V30 10 O 13.7358 3.1281 0 0
M  V30 11 C 15.0694 0.8181 0 0
M  V30 12 C 16.4031 1.5881 0 0
M  V30 13 Cl 16.4031 3.1281 0 0
M  V30 14 C 17.7368 0.8181 0 0
M  V30 15 C 17.7368 -0.7219 0 0
M  V30 16 C 16.4031 -1.4919 0 0
M  V30 17 O 16.4031 -3.0319 0 0
M  V30 18 C 15.0694 -0.7219 0 0
M  V30 19 C 13.7358 -1.4919 0 0
M  V30 20 O 13.7358 -3.0319 0 0
M  V30 21 C 12.4021 -0.7219 0 0
M  V30 22 C 11.0684 -1.4919 0 0
M  V30 23 O 11.0684 -3.0319 0 0
M  V30 24 C 9.7347 -0.7219 0 0 CFG=1
M  V30 25 O 9.7347 -2.2619 0 0
M  V30 26 C 8.401 -1.4919 0 0
M  V30 27 O 8.401 -3.0319 0 0
M  V30 28 C 7.0674 -0.7219 0 0
M  V30 29 C 7.0674 0.8181 0 0
M  V30 30 O 5.7337 1.5881 0 0
M  V30 31 C 5.7337 -1.4919 0 0
M  V30 32 O 5.7337 -3.0319 0 0
M  V30 33 N 4.4 -0.7219 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 5 3 CFG=1
M  V30 4 1 6 5
M  V30 5 1 6 7 CFG=3
M  V30 6 1 8 7 CFG=3
M  V30 7 1 8 9
M  V30 8 1 9 10 CFG=3
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 12 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 1 16 18
M  V30 17 2 11 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 8 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 24 22
M  V30 25 1 6 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 5 29
M  V30 32 1 29 30
M  V30 33 1 28 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802217

>  <MW>
500.075

>  <MW (desalted)>
464.853

>  <ClogP>
-0.576

>  <logS>
-3.267

>  <HBD>
6

>  <HBA>
9

>  <TPSA>
181.62

>  <RotBonds>
2

>  <Action on targets>
Substrate | Substrate | Substrate | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Active   |  Active   | MIC  16 ?g/ml | IC50  38.6 ?M | IC50  39 ?M | IC50  47 ?M | IC50  59.6 ?M

>  <CAS>
64-73-3

>  <Description>
Demeclocycline is a tetracycline antibiotic used to treat a wide variety of susceptible bacterial infections.

>  <EBC_ID>
EBC-28053

>  <IUPAC Name>
(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2019, vol. 63, # 9 | Antimicrob. Agents Chemother., 2019, vol. 63, # 9 | ACS Infect. Dis., 2019, vol. 5, # 4, p. 618 - 633 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 10 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 10 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 10 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 10

>  <Main tar all>
Alternate type 1 ferripyoverdine receptor fpvB pX=5.0 | Ferripyoverdine receptor pX=5.0 | Flavin-dependent monooxygenase pX=4.5 | EPH receptor B1 pX=4.41 | EPH receptor B4 pX=4.41 | EPH receptor B3 pX=4.33 | EPH receptor B2 pX=4.22

$$$$
Piperacillin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.974 -11.668 0 0
M  V30 2 C 0.974 -10.128 0 0
M  V30 3 N 2.3076 -9.358 0 0
M  V30 4 C 2.3076 -7.818 0 0
M  V30 5 C 3.6413 -7.048 0 0
M  V30 6 N 4.975 -7.818 0 0
M  V30 7 C 6.3087 -7.048 0 0
M  V30 8 O 6.3087 -5.508 0 0
M  V30 9 N 7.6423 -7.818 0 0
M  V30 10 C 8.976 -7.048 0 0 CFG=1
M  V30 11 C 10.3097 -7.818 0 0
M  V30 12 O 10.3097 -9.358 0 0
M  V30 13 N 11.6434 -7.048 0 0
M  V30 14 C 12.9771 -7.818 0 0 CFG=1
M  V30 15 C 14.4646 -7.4194 0 0 CFG=1
M  V30 16 S 15.7561 -6.5806 0 0
M  V30 17 C 16.9529 -7.5498 0 0
M  V30 18 C 17.7917 -6.2582 0 0
M  V30 19 C 18.3251 -8.2489 0 0
M  V30 20 C 16.4011 -8.9875 0 0 CFG=1
M  V30 21 N 14.8632 -8.9069 0 0
M  V30 22 C 13.3756 -9.3055 0 0
M  V30 23 O 12.6056 -10.6392 0 0
M  V30 24 C 17.2398 -10.2791 0 0
M  V30 25 O 18.7777 -10.1985 0 0
M  V30 26 O 16.5407 -11.6512 0 0
M  V30 27 C 8.976 -5.508 0 0
M  V30 28 C 7.6423 -4.738 0 0
M  V30 29 C 7.6423 -3.198 0 0
M  V30 30 C 8.976 -2.428 0 0
M  V30 31 C 10.3097 -3.198 0 0
M  V30 32 C 10.3097 -4.738 0 0
M  V30 33 C 4.975 -9.358 0 0
M  V30 34 O 6.3087 -10.128 0 0
M  V30 35 C 3.6413 -10.128 0 0
M  V30 36 O 3.6413 -11.668 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 20 17
M  V30 20 1 20 21
M  V30 21 1 15 21 CFG=1
M  V30 22 1 21 22
M  V30 23 1 14 22
M  V30 24 2 22 23
M  V30 25 1 20 24 CFG=3
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 1 10 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 27 32
M  V30 35 1 6 33
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 3 35
M  V30 39 2 35 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2587996977

>  <MW>
517.163

>  <MW (desalted)>
517.555

>  <ClogP>
1.697

>  <logS>
-6.109

>  <HBD>
3

>  <HBA>
7

>  <TPSA>
156.43

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Substrate | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.001 ?M | IC50 = 0.003 ?g/mL | MIC95  0.1 ?g/ml | IC50 = 0.006 ?g/mL | IC50 = 17 nM | IC50  0.01 ?g/ml

>  <CAS>
61477-96-1

>  <Description>
Piperacillin is a penicillin antibiotic combined with tazobactam to treat piperacillin-resistant, piperacillin/tazobactam? susceptible, ?-lactamase generating strains of several bacteria.

>  <EBC_ID>
EBC-12090

>  <IUPAC Name>
(2S,5R,6R)-6-[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

>  <Main Tar all refs>
ACS Infect. Dis., 2022, vol. 8, # 7, p. 1241 - 1252 | Antimicrob. Agents Chemother., 2000, vol. 44, # 6, p. 1518 - 1523 | Nat. Commun., 2022, vol. 13, # 1 | Antimicrob. Agents Chemother., 2000, vol. 44, # 6, p. 1518 - 1523 | Antimicrob. Agents Chemother., 1999, vol. 43, # 5, p. 1124 - 1128 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790

>  <Main tar all>
Penicillin-binding?protein?3 pX=9.0 | Penicillin Binding Protein 3B pX=8.24 | Multidrug?efflux?pump?subunit?AcrB pX=7.99 | Penicillin Binding Protein 3A pX=7.94 | Penicillin-binding?protein 2X pX=7.77 | Penicillin-binding?protein?3 pX=7.71

$$$$
Lomitapide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 50 55 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 4.2433 9.5024 0 0
M  V30 2 C 4.7192 8.0378 0 0
M  V30 3 F 3.2545 7.5619 0 0
M  V30 4 F 6.1838 8.5137 0 0
M  V30 5 C 5.1951 6.5731 0 0
M  V30 6 N 4.1646 5.4287 0 0
M  V30 7 C 4.6405 3.9641 0 0
M  V30 8 O 6.1468 3.6439 0 0
M  V30 9 C 3.61 2.8196 0 0
M  V30 10 C 2.5796 3.9641 0 0
M  V30 11 C 1.0732 3.6439 0 0
M  V30 12 C 0.0428 4.7883 0 0
M  V30 13 C -1.4636 4.4682 0 0
M  V30 14 N -2.4941 5.6126 0 0
M  V30 15 C -4.0004 5.2924 0 0
M  V30 16 C -5.0309 6.4369 0 0
M  V30 17 C -4.555 7.9015 0 0
M  V30 18 C -3.0486 8.2217 0 0
M  V30 19 C -2.0182 7.0772 0 0
M  V30 20 N -5.5854 9.0459 0 0
M  V30 21 C -7.0918 8.7257 0 0
M  V30 22 O -8.1222 9.8702 0 0
M  V30 23 C -7.5677 7.2611 0 0
M  V30 24 C -6.5372 6.1167 0 0
M  V30 25 C -7.0131 4.652 0 0
M  V30 26 C -8.5194 4.3319 0 0
M  V30 27 C -9.5499 5.4763 0 0
M  V30 28 C -9.074 6.9409 0 0
M  V30 29 C -10.1045 8.0854 0 0
M  V30 30 C -11.6108 7.7652 0 0
M  V30 31 C -12.6413 8.9096 0 0
M  V30 32 C -12.1654 10.3743 0 0
M  V30 33 C -10.6591 10.6944 0 0
M  V30 34 C -9.6286 9.55 0 0
M  V30 35 C -13.1959 11.5187 0 0
M  V30 36 F -14.2263 12.6631 0 0
M  V30 37 F -12.0514 12.5492 0 0
M  V30 38 F -14.3403 10.4882 0 0
M  V30 39 C 4.8559 1.9144 0 0
M  V30 40 C 6.3623 2.2346 0 0
M  V30 41 C 7.3927 1.0902 0 0
M  V30 42 C 6.9168 -0.3744 0 0
M  V30 43 C 5.4105 -0.6946 0 0
M  V30 44 C 4.38 0.4498 0 0
M  V30 45 C 2.84 0.4498 0 0
M  V30 46 C 1.8096 -0.6946 0 0
M  V30 47 C 0.3032 -0.3744 0 0
M  V30 48 C -0.1727 1.0902 0 0
M  V30 49 C 0.8578 2.2346 0 0
M  V30 50 C 2.3641 1.9144 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 19
M  V30 20 1 17 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 23 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 29 34
M  V30 37 1 32 35
M  V30 38 1 35 36
M  V30 39 1 35 37
M  V30 40 1 35 38
M  V30 41 1 9 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 43 44
M  V30 47 2 39 44
M  V30 48 1 44 45
M  V30 49 1 45 46
M  V30 50 2 46 47
M  V30 51 1 47 48
M  V30 52 2 48 49
M  V30 53 1 49 50
M  V30 54 2 45 50
M  V30 55 1 9 50
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1696860003

>  <MW>
693.279

>  <MW (desalted)>
693.72

>  <ClogP>
7.001

>  <logS>
-9.796

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
61.44

>  <RotBonds>
12

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.5 nM

>  <CAS>
182431-12-5

>  <Description>
Lomitapide is a microsomal triglyceride transfer protein inhibitor used to lower cholesterol associated with homozygous familial hypercholesterolemia, reducing risk of cardiovascular events such as myocardial infarction and stroke.

>  <EBC_ID>
EBC-27436

>  <IUPAC Name>
N-(2,2,2-trifluoroethyl)-9-(4-{4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-amido]piperidin-1-yl}butyl)-9H-fluorene-9-carboxamide

>  <Main Tar all refs>
Annu. Rep. Med. Chem., 2007, vol. 42, p. 161 - 175

>  <Main tar all>
Microsomal triglyceride transfer protein pX=9.3

$$$$
D-Serine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.85 1.3337 0 0
M  V30 2 C 2.31 1.3337 0 0 CFG=2
M  V30 3 C 1.54 2.6674 0 0
M  V30 4 O 2.31 4.001 0 0
M  V30 5 C 1.54 0 0 0
M  V30 6 O 2.31 -1.3337 0 0
M  V30 7 O 0 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1070067572

>  <MW>
105.043

>  <MW (desalted)>
105.093

>  <ClogP>
-2.811

>  <logS>
0.63

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
2

>  <Action on targets>
- | Agonist | Agonist | Agonist | Inhibitor | Agonist | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
EC50  0.082 ?M | EC50  0.147 ?M | EC50  0.147 ?M | EC50  0.18 ?M | IC50  0.4 ?M | EC50  0.51 ?M | EC50  0.6 ?M | EC50  0.6 ?M | Ki (inhibition constant)  0.95 ?M

>  <CAS>
312-84-5

>  <Description>
D-Serine  is a non-essential amino acid occurring in natural form as the L-isomer. D-Serine is subtype-specific agonists for NMDA receptor.

>  <EBC_ID>
EBC-03039

>  <IUPAC Name>
(2R)-2-amino-3-hydroxypropanoic acid

>  <Main Tar all refs>
Eur. J. Pharmacol., 1987, vol. 142, # 3, p. 487 - 488 | J. Med. Chem., 2022, vol. 65, # 1, p. 734 - 746 | J. Med. Chem., 2022, vol. 65, # 1, p. 734 - 746 | ACS Chem. Neurosci., 2017, vol. 8, # 8, p. 1681 - 1687 | EUR. J. PHARMACOL., 1986, vol. 126, # 3, p. 303 - 307 | ACS Chem. Neurosci., 2017, vol. 8, # 8, p. 1681 - 1687 | J. PHARMACOL. EXP. THER., 1996, vol. 278, # 2, p. 808 - 816 | J. PHARMACOL. EXP. THER., 1996, vol. 278, # 2, p. 808 - 816 | SUN PHARMACEUTICAL INDUSTRIES LIMITED - WO2019/104179, 2019, A1

>  <Main tar all>
NMDA receptor pX=7.09 | GluN2D pX=6.83 | Glutamate receptor ionotropic, NMDA 1 pX=6.83 | GluN2C pX=6.74 | glycine receptor ?1 subunit pX=6.4 | GluN2B pX=6.29 | GluN1a pX=6.22 | Glutamate receptor ionotropic, NMDA 2A pX=6.22 | GluN2C pX=6.02

$$$$
Parachlorophenol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 Cl 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104473434

>  <MW>
128.003

>  <MW (desalted)>
128.556

>  <ClogP>
2.485

>  <logS>
-1.73

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
20.23

>  <RotBonds>
0

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 666 pM

>  <CAS>
106-48-9

>  <Description>
Parachlorophenol is an antibacterial agent used to prevent infections in root canals. The major mode of action of chlorophenols appears to be the uncoupling of oxidative phosphorylation.

>  <EBC_ID>
EBC-03080

>  <IUPAC Name>
4-chlorophenol

>  <Main Tar all refs>
B. Braun Melsungen Aktiengesellschaft - WO2002/40005, 2002, A2

>  <Main tar all>
Nav1.1 pX=9.18

$$$$
L-Pyroglutamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 2.3935 4.39 0 0
M  V30 2 C 1.0598 3.62 0 0
M  V30 3 O -0.2739 4.39 0 0
M  V30 4 C 1.0598 2.08 0 0 CFG=2
M  V30 5 C 2.3057 1.1748 0 0
M  V30 6 C 1.8298 -0.2898 0 0
M  V30 7 C 0.2898 -0.2898 0 0
M  V30 8 O -0.6154 -1.5357 0 0
M  V30 9 N -0.1861 1.1748 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 4 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1154378309

>  <MW>
129.043

>  <MW (desalted)>
129.114

>  <ClogP>
-1.147

>  <logS>
0.15

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
66.4

>  <RotBonds>
1

>  <CAS>
98-79-3

>  <Description>
L-Pyroglutamic acid is an urease inhibitor.

>  <EBC_ID>
EBC-04029

>  <IUPAC Name>
(2S)-5-oxopyrrolidine-2-carboxylic acid

$$$$
Pralidoxime chloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0 CHG=-1
M  V30 2 C 7.521 1.925 0 0
M  V30 3 N 7.521 0.385 0 0 CHG=1
M  V30 4 C 8.8547 -0.385 0 0
M  V30 5 C 8.8547 -1.925 0 0
M  V30 6 C 7.521 -2.695 0 0
M  V30 7 C 6.1874 -1.925 0 0
M  V30 8 C 6.1874 -0.385 0 0
M  V30 9 C 4.8537 0.385 0 0
M  V30 10 N 4.8537 1.925 0 0
M  V30 11 O 3.52 2.695 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11 CFG=2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57931208

>  <MW>
172.612

>  <MW (desalted)>
137.159

>  <ClogP>
-3.666

>  <logS>
-1.11

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
36.47

>  <RotBonds>
1

>  <Action on targets>
- | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Activator | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  25.72 ?M | Kd (dissociation constant)  25.72 ?M | IC50  32.6 ?M | IC50  32.6 ?M | IC50  0.17 mM | Ki (inhibition constant)  180 ?M | enzyme reactivation rate Active   | Ki (inhibition constant)  390 ?M

>  <CAS>
51-15-0

>  <Description>
Pralidoxime HCl is an antidote to organophosphate pesticides and chemicals. It is an acetylcholinesterase (AChE) reactivator.

>  <EBC_ID>
EBC-09105

>  <IUPAC Name>
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride

>  <Main Tar all refs>
Bioorg. Med. Chem., 2014, vol. 22, # 9, p. 2684 - 2691 | Bioorg. Med. Chem., 2014, vol. 22, # 9, p. 2684 - 2691 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | J. MED. CHEM., 1989, vol. 32, # 2, p. 493 - 503 | Eur. J. Med. Chem., 2022, vol. 238 | Biomolecules, 2020, vol. 10, # 6 | Eur. J. Med. Chem., 2022, vol. 238

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=4.59 | acetylcholinesterase (Cartwright blood group) pX=4.59 | Organic cation/carnitine transporter 2 pX=4.49 | Organic cation/carnitine transporter 2 pX=4.49 | mAChR pX=3.77 | Acetylcholinesterase 1 pX=3.74 | acetylcholinesterase (acetyl.beta-methylcholinesterase) pX=3.7 | butyrylcholinesterase pX=3.41

$$$$
Dacarbazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7272 6.7 0 0
M  V30 2 N 2.3935 5.93 0 0
M  V30 3 C 1.0598 6.7 0 0
M  V30 4 N 2.3935 4.39 0 0
M  V30 5 N 1.0598 3.62 0 0
M  V30 6 C 1.0598 2.08 0 0
M  V30 7 N 2.3057 1.1748 0 0
M  V30 8 C 1.8298 -0.2898 0 0
M  V30 9 N 0.2898 -0.2898 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 C -1.6507 1.6507 0 0
M  V30 12 O -2.7951 0.6202 0 0
M  V30 13 N -1.9709 3.157 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=2
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289761610

>  <MW>
182.092

>  <MW (desalted)>
182.183

>  <ClogP>
0.477

>  <logS>
-1.496

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
99.73

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  34 %

>  <CAS>
4342-03-4

>  <Description>
Dacarbazine is an antineoplastic agent used to treat malignant melanoma and Hodgkin's disease.

>  <EBC_ID>
EBC-24021

>  <IUPAC Name>
5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide

>  <Main Tar all refs>
Mol. Pharmacol., 2015, vol. 88, # 3, p. 428 - 436

>  <Main tar all>
CYP27A1 pX=4.11

$$$$
Nitroxoline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6674 -4.62 0 0
M  V30 2 C 2.6674 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 C 2.6674 0 0 0
M  V30 6 N 2.6674 1.54 0 0 CHG=1
M  V30 7 O 1.3337 2.31 0 0
M  V30 8 O 4.001 2.31 0 0 CHG=-1
M  V30 9 C 4.001 -0.77 0 0
M  V30 10 C 5.3347 0 0 0
M  V30 11 C 6.6684 -0.77 0 0
M  V30 12 C 6.6684 -2.31 0 0
M  V30 13 N 5.3347 -3.08 0 0
M  V30 14 C 4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 5 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 2 14
M  V30 15 1 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56922155

>  <MW>
190.038

>  <MW (desalted)>
190.156

>  <ClogP>
2.084

>  <logS>
-2.36

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
76.26

>  <RotBonds>
1

>  <Action on targets>
Blocker

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
4008-48-4

>  <Description>
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections.

>  <EBC_ID>
EBC-03494

>  <IUPAC Name>
5-nitroquinolin-8-ol

>  <Main Tar all refs>
ACS Synth. Biol., 2022, vol. 11, # 8, p. 2820 - 2828

>  <Main tar all>
H2 receptor pX=9.0

$$$$
Ibuprofen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C -1.3337 3.85 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 C 1.3337 -2.31 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C -0 -3.08 0 0
M  V30 14 O -0 -4.62 0 0
M  V30 15 O -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1695709473

>  <MW>
206.131

>  <MW (desalted)>
206.281

>  <ClogP>
3.679

>  <logS>
-3.54

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 4.85 pM

>  <CAS>
15687-27-1

>  <Description>
Ibuprofen is an NSAID and non-selective COX inhibitor. Ibuprofen is the most commonly used and prescribed NSAID, used as an analgesic, anti-inflammatory and antipyretic.

>  <EBC_ID>
EBC-03688

>  <IUPAC Name>
2-[4-(2-methylpropyl)phenyl]propanoic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1

>  <Main tar all>
COX-1  pX=11.3

$$$$
Guaietolin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 2.31 0 0
M  V30 2 C 0 3.08 0 0
M  V30 3 O 1.3337 2.31 0 0
M  V30 4 C 2.6674 3.08 0 0
M  V30 5 C 2.6674 4.62 0 0
M  V30 6 C 4.001 5.39 0 0
M  V30 7 C 5.3347 4.62 0 0
M  V30 8 C 5.3347 3.08 0 0
M  V30 9 C 4.001 2.31 0 0
M  V30 10 O 4.001 0.77 0 0
M  V30 11 C 5.3347 0 0 0
M  V30 12 C 6.6684 0.77 0 0
M  V30 13 O 6.6684 2.31 0 0
M  V30 14 C 8.0021 0 0 0
M  V30 15 O 9.3358 0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509558249

>  <MW>
212.105

>  <MW (desalted)>
212.242

>  <ClogP>
0.631

>  <logS>
-1.596

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
58.92

>  <RotBonds>
6

>  <CAS>
63834-83-3

>  <EBC_ID>
EBC-129026

>  <IUPAC Name>
3-(2-ethoxyphenoxy)propane-1,2-diol

$$$$
Carboxine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -3.08 0 0
M  V30 2 C 2.6674 -4.62 0 0
M  V30 3 C 4.001 -5.39 0 0
M  V30 4 S 4.001 -6.93 0 0
M  V30 5 C 2.6674 -7.7 0 0
M  V30 6 C 1.3337 -6.93 0 0
M  V30 7 O 1.3337 -5.39 0 0
M  V30 8 C 5.3347 -4.62 0 0
M  V30 9 O 6.6684 -5.39 0 0
M  V30 10 N 5.3347 -3.08 0 0
M  V30 11 C 6.6684 -2.31 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 8.0021 -0 0 0
M  V30 14 C 9.3358 -0.77 0 0
M  V30 15 C 9.3358 -2.31 0 0
M  V30 16 C 8.0021 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 3 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741975591

>  <MW>
235.067

>  <MW (desalted)>
235.302

>  <ClogP>
2.139

>  <logS>
-3.161

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.33

>  <RotBonds>
2

>  <CAS>
5234-68-4

>  <Description>
Fungicide. Carboxin is a systemic agricultural fungicide and seed protectant.

>  <EBC_ID>
EBC-04341

>  <IUPAC Name>
2-methyl-N-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide

$$$$
Aminoglutethimide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.8604 0.6771 0 0
M  V30 2 C 1.3337 -0.77 0 0
M  V30 3 C 2.3236 -1.9497 0 0
M  V30 4 C 3.6573 -2.7197 0 0
M  V30 5 C 3.6573 -4.2597 0 0
M  V30 6 C 2.3236 -5.0297 0 0
M  V30 7 O 2.3236 -6.5697 0 0
M  V30 8 N 0.9899 -4.2597 0 0
M  V30 9 C 0.9899 -2.7197 0 0
M  V30 10 O -0.3438 -1.9497 0 0
M  V30 11 C 3.3135 -0.77 0 0
M  V30 12 C 2.7868 0.6771 0 0
M  V30 13 C 3.7766 1.8568 0 0
M  V30 14 C 5.2933 1.5894 0 0
M  V30 15 N 6.2831 2.7691 0 0
M  V30 16 C 5.82 0.1423 0 0
M  V30 17 C 4.8301 -1.0374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 2 9 10
M  V30 11 1 3 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z800191876

>  <MW>
232.121

>  <MW (desalted)>
232.278

>  <ClogP>
0.766

>  <logS>
-2.06

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
72.19

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 4.3 nM | Ki (inhibition constant) = 4.3 nM | IC50 = 5.2 nM | Km (Michaelis constant) = 38 nM

>  <CAS>
125-84-8

>  <Description>
Aminoglutethimide is an adrenocortical steroid synthesis inhibitor. It is used for the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.

>  <EBC_ID>
EBC-03739

>  <IUPAC Name>
3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione

>  <Main Tar all refs>
Curr. Med. Chem. Imun. Endoc. and Metab. Agents., 2003, vol. 3, # 3, p. 216 - 276 | Curr. Med. Chem. Imun. Endoc. and Metab. Agents., 2003, vol. 3, # 3, p. 216 - 276 | Bioorg. Med. Chem. Lett., 2010, vol. 20, # 10, p. 3050 - 3064 | STEROIDS, 1995, vol. 60, # 5, p. 423 - 427

>  <Main tar all>
Aromatase (gene CYP19A1) pX=8.37 | CYP19A1 pX=8.37 | CYP19A1 pX=8.28 | Aromatase (peptide) pX=7.42

$$$$
Sodium lauryl sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 26.5778 7.6447 0 0 CHG=1
M  V30 2 C 6.5726 5.3347 0 0
M  V30 3 C 7.9063 6.1047 0 0
M  V30 4 C 9.24 5.3347 0 0
M  V30 5 C 10.5737 6.1047 0 0
M  V30 6 C 11.9074 5.3347 0 0
M  V30 7 C 13.241 6.1047 0 0
M  V30 8 C 14.5747 5.3347 0 0
M  V30 9 C 15.9084 6.1047 0 0
M  V30 10 C 17.2421 5.3347 0 0
M  V30 11 C 18.5758 6.1047 0 0
M  V30 12 C 19.9094 5.3347 0 0
M  V30 13 C 21.2431 6.1047 0 0
M  V30 14 O 22.5768 5.3347 0 0
M  V30 15 S 23.9105 6.1047 0 0
M  V30 16 O 23.1405 7.4384 0 0
M  V30 17 O 24.6805 4.771 0 0
M  V30 18 O 25.2441 6.8747 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 2 15 17
M  V30 16 1 15 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1365432828

>  <MW>
288.137

>  <MW (desalted)>
266.397

>  <ClogP>
4.521

>  <logS>
-5.26

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
66.43

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.53 ?M | Ki (inhibition constant) = 2 ?M | IC50  2.3 ?M | IC50  2.8 ?M | IC50  2.9 ?M | IC50 = 5.2 ?M | MIC = 2 ?g/mL | IC50  15 ?M | Ki (inhibition constant)  15 ?M | Ki (inhibition constant)  15 ?M | Ki (inhibition constant)  15 ?M | Ki (inhibition constant)  18 ?M | IC50  23 ?M | IC50  27.1 ?M | IC50  29 ?M

>  <CAS>
151-21-3

>  <Description>
Sodium lauryl sulfate has an inhibitory effect on beta-lactamase, coagulation factor X. It also acts as a skin irritant. It  is an anionic surfactant used in cosmetics and pharmaceuticals as a fat emulsifier, wetting agent, and detergent.

>  <EBC_ID>
EBC-03742

>  <IUPAC Name>
sodium dodecyl sulfate

>  <Main Tar all refs>
Clin. Pharmacokinet., 2009, vol. 48, # 1, p. 1 - 22 | J. Med. Chem., 2009, vol. 52, # 14, p. 4338 - 4344 | J. Med. Chem., 2019, vol. 62, # 18, p. 8443 - 8460 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | UNIVERSITY OF CALIFORNIA - WO2007/22059, 2007, A2 | J. Antibiot., 2002, vol. 55, # 3, p. 279 - 287 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Science, 2020, vol. 369, # 6502, p. 403 - 413 | Mol. Pharm., 2020, vol. 17, # 3, p. 748 - 756 | Science, 2020, vol. 369, # 6502, p. 403 - 413

>  <Main tar all>
coagulation factor X pX=5.82 | Glycoprotein 41 pX=5.7 | epoxide hydrolase 2 pX=5.64 | OATP2B1 pX=5.55 | OATP1B1 pX=5.54 | epoxide hydrolase 2 pX=5.28 | Beta-Lactamase AmpC pX=5.16 | ?1A-adrenoceptor pX=4.82 | 5-HT1A receptor pX=4.82 | A3 receptor pX=4.82 | PTGR1 pX=4.82 | D3 receptor pX=4.74 | phosphodiesterase 4D pX=4.64 | ABCG2 pX=4.57 | M1 receptor pX=4.54

$$$$
Lenalidomide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 C 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 C 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 C 3.3224 -0.4759 0 0
M  V30 8 O 2.8465 -1.9405 0 0
M  V30 9 N 2.4172 0.77 0 0
M  V30 10 C 3.3224 2.0159 0 0
M  V30 11 C 4.787 1.54 0 0
M  V30 12 C 0.8772 0.77 0 0
M  V30 13 C 0.1072 -0.5637 0 0
M  V30 14 C -1.4328 -0.5637 0 0
M  V30 15 C -2.2028 0.77 0 0
M  V30 16 O -3.7428 0.77 0 0
M  V30 17 N -1.4328 2.1037 0 0
M  V30 18 C 0.1072 2.1037 0 0
M  V30 19 O 0.8772 3.4374 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 2 2 11
M  V30 13 1 9 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 12 18
M  V30 21 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515385074

>  <MW>
259.096

>  <MW (desalted)>
259.261

>  <ClogP>
-0.412

>  <logS>
-2.319

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
92.5

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
binding rate Active

>  <CAS>
191732-72-6

>  <Description>
Lenalidomide is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide. It is used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.

>  <EBC_ID>
EBC-11297

>  <IUPAC Name>
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

>  <Main Tar all refs>
DANA-FARBER CANCER INSTITUTE - WO2020/263832, 2020, A1

>  <Main tar all>
Protein cereblon pX=10.0

$$$$
Flufenamic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 -0 0 0
M  V30 2 C -1.3337 -0.77 0 0
M  V30 3 O -2.6674 0 0 0
M  V30 4 C -1.3337 -2.31 0 0
M  V30 5 C 0 -3.08 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 C -1.3337 -5.39 0 0
M  V30 8 C -2.6674 -4.62 0 0
M  V30 9 C -2.6674 -3.08 0 0
M  V30 10 N -4.001 -2.31 0 0
M  V30 11 C -5.3347 -3.08 0 0
M  V30 12 C -5.3347 -4.62 0 0
M  V30 13 C -6.6684 -5.39 0 0
M  V30 14 C -8.0021 -4.62 0 0
M  V30 15 C -8.0021 -3.08 0 0
M  V30 16 C -6.6684 -2.31 0 0
M  V30 17 C -9.3358 -2.31 0 0
M  V30 18 F -10.6694 -1.54 0 0
M  V30 19 F -8.5658 -0.9763 0 0
M  V30 20 F -10.1058 -3.6437 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 15 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56797275

>  <MW>
281.066

>  <MW (desalted)>
281.23

>  <ClogP>
5.526

>  <logS>
-4.35

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
49.33

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
decrease rate Active

>  <CAS>
530-78-9

>  <Description>
Flufenamic acid is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders. It inhibits Prostaglandin G/H synthase 2. It is also an inhibitor of various ion channels, including TRP channels.

>  <EBC_ID>
EBC-04210

>  <IUPAC Name>
2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid

>  <Main Tar all refs>
NATIONWIDE CHILDREN'S HOSPITAL INC - WO2020/61649, 2020, A1

>  <Main tar all>
integrin, alpha M subunit (complement component 3 receptor 3 subunit) pX=10.0

$$$$
Lonidamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.6802 -5.1578 0 0
M  V30 2 C 1.6497 -4.0133 0 0
M  V30 3 O 0.1434 -4.3335 0 0
M  V30 4 C 2.1256 -2.5487 0 0
M  V30 5 N 1.2204 -1.3028 0 0
M  V30 6 N 2.1256 -0.0569 0 0
M  V30 7 C 1.6497 1.4077 0 0
M  V30 8 C 2.6802 2.5521 0 0
M  V30 9 C 4.1865 2.2319 0 0
M  V30 10 C 5.217 3.3764 0 0
M  V30 11 C 4.7411 4.841 0 0
M  V30 12 Cl 5.7716 5.9855 0 0
M  V30 13 C 3.2348 5.1612 0 0
M  V30 14 C 2.2043 4.0168 0 0
M  V30 15 Cl 0.698 4.3369 0 0
M  V30 16 C 3.5902 -0.5328 0 0
M  V30 17 C 4.9239 0.2372 0 0
M  V30 18 C 6.2576 -0.5328 0 0
M  V30 19 C 6.2576 -2.0728 0 0
M  V30 20 C 4.9239 -2.8428 0 0
M  V30 21 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 14 15
M  V30 16 1 6 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 4 21
M  V30 23 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1137008901

>  <MW>
320.012

>  <MW (desalted)>
321.158

>  <ClogP>
5.029

>  <logS>
-4.932

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
55.12

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) ~ 2.51E-06 M | IC50 = 58 ?M

>  <CAS>
50264-69-2

>  <Description>
Lonidamine is an orally administered small molecule that inhibits glycolysis by the inactivation of hexokinase. It is investigated for treatment in benign prostatic hyperplasia, prostate disorders, and cancer/tumors.

>  <EBC_ID>
EBC-03786

>  <IUPAC Name>
1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid

>  <Main Tar all refs>
FASEB J., 2020, vol. 34, # 3, p. 3943 - 3955 | JOSEPH FOURIER UNIVERSITY; UNIVERSITY OF POITIERS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - WO2005/39589, 2005, A2

>  <Main tar all>
Hexokinase-2 pX=5.6 | CFTR pX=4.24

$$$$
Fluconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -3.2382 -2.9887 0 0
M  V30 2 C -2.4682 -1.655 0 0
M  V30 3 C -1.1345 -2.425 0 0
M  V30 4 N -1.1345 -3.965 0 0
M  V30 5 C 0.1114 -4.8702 0 0
M  V30 6 N -0.3645 -6.3348 0 0
M  V30 7 C -1.9045 -6.3348 0 0
M  V30 8 N -2.3804 -4.8702 0 0
M  V30 9 C -1.6982 -0.3213 0 0
M  V30 10 N -0.1582 -0.3213 0 0
M  V30 11 C 0.747 0.9246 0 0
M  V30 12 N 2.2116 0.4487 0 0
M  V30 13 C 2.2116 -1.0913 0 0
M  V30 14 N 0.747 -1.5672 0 0
M  V30 15 C -3.8019 -0.885 0 0
M  V30 16 C -5.1355 -1.655 0 0
M  V30 17 C -6.4692 -0.885 0 0
M  V30 18 C -6.4692 0.655 0 0
M  V30 19 F -7.8029 1.425 0 0
M  V30 20 C -5.1355 1.425 0 0
M  V30 21 C -3.8019 0.655 0 0
M  V30 22 F -2.4682 1.425 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 10 14
M  V30 16 1 2 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 20 21
M  V30 23 2 15 21
M  V30 24 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z235354561

>  <MW>
306.104

>  <MW (desalted)>
306.271

>  <ClogP>
-0.44

>  <logS>
-2.9

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
81.65

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.39 nM | IC50  0.00073 ?M

>  <CAS>
86386-73-4

>  <Description>
Fluconazole is a triazole antifungal agent that is effective against most Candida strains. Fluconazole is a selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-?-demethylase.

>  <EBC_ID>
EBC-03846

>  <IUPAC Name>
2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol

>  <Main Tar all refs>
ROCHE HOLDING AG - WO2014/205136, 2014, A1 | Drug Dev. Res., 2023

>  <Main tar all>
nuclear estrogen receptor pX=9.41 | CYP51A1 pX=9.14

$$$$
Indomethacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 5.9228 0 0
M  V30 2 O 7.5913 4.3828 0 0
M  V30 3 C 6.2576 3.6128 0 0
M  V30 4 C 6.2576 2.0728 0 0
M  V30 5 C 4.9239 1.3028 0 0
M  V30 6 C 3.5902 2.0728 0 0
M  V30 7 N 2.1256 1.5969 0 0
M  V30 8 C 1.6497 0.1323 0 0
M  V30 9 O 2.6802 -1.0121 0 0
M  V30 10 C 0.1434 -0.1879 0 0
M  V30 11 C -0.3325 -1.6525 0 0
M  V30 12 C -1.8389 -1.9727 0 0
M  V30 13 C -2.8693 -0.8282 0 0
M  V30 14 Cl -4.3757 -1.1484 0 0
M  V30 15 C -2.3934 0.6364 0 0
M  V30 16 C -0.8871 0.9566 0 0
M  V30 17 C 1.2204 2.8428 0 0
M  V30 18 C -0.3196 2.8428 0 0
M  V30 19 C 2.1256 4.0887 0 0
M  V30 20 C 1.6497 5.5533 0 0
M  V30 21 C 0.1434 5.8735 0 0
M  V30 22 O -0.8871 4.7291 0 0
M  V30 23 O -0.3325 7.3382 0 0
M  V30 24 C 3.5902 3.6128 0 0
M  V30 25 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 7 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 19 24
M  V30 25 2 6 24
M  V30 26 1 24 25
M  V30 27 2 3 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56784896

>  <MW>
357.077

>  <MW (desalted)>
357.788

>  <ClogP>
4.18

>  <logS>
-4.31

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
68.53

>  <RotBonds>
4

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.1 pM

>  <CAS>
53-86-1

>  <Description>
Indomethacin is an widely used  anti-inflammatory agent. It is a inhibitor of AKR1C3 and non-selective COX inhibitor.

>  <EBC_ID>
EBC-04405

>  <IUPAC Name>
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1

>  <Main tar all>
COX-1  pX=13.0

$$$$
Risperidone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.9206 -16.5827 0 0
M  V30 2 C 12.4143 -16.9029 0 0
M  V30 3 N 11.9384 -18.3675 0 0
M  V30 4 C 10.4321 -18.6877 0 0
M  V30 5 C 9.9562 -20.1523 0 0
M  V30 6 C 8.4498 -20.4725 0 0
M  V30 7 C 7.4194 -19.3281 0 0
M  V30 8 C 7.8952 -17.8635 0 0
M  V30 9 N 9.4016 -17.5433 0 0
M  V30 10 C 9.8775 -16.0786 0 0
M  V30 11 O 8.847 -14.9342 0 0
M  V30 12 C 11.3838 -15.7585 0 0
M  V30 13 C 11.8597 -14.2938 0 0
M  V30 14 C 10.8292 -13.1494 0 0
M  V30 15 N 11.3051 -11.6848 0 0
M  V30 16 C 10.2747 -10.5403 0 0
M  V30 17 C 10.7506 -9.0757 0 0
M  V30 18 C 12.2569 -8.7555 0 0
M  V30 19 C 13.2874 -9.9 0 0
M  V30 20 C 12.8115 -11.3646 0 0
M  V30 21 C 12.7328 -7.2909 0 0
M  V30 22 N 11.8276 -6.045 0 0
M  V30 23 O 12.7328 -4.7991 0 0
M  V30 24 C 14.1974 -5.275 0 0
M  V30 25 C 15.5311 -4.505 0 0
M  V30 26 C 16.8648 -5.275 0 0
M  V30 27 F 18.1985 -4.505 0 0
M  V30 28 C 16.8648 -6.815 0 0
M  V30 29 C 15.5311 -7.585 0 0
M  V30 30 C 14.1974 -6.815 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 2 2 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 15 20
M  V30 23 1 18 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 21 30
M  V30 34 2 24 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480428

>  <MW>
410.484

>  <MW (desalted)>
410.484

>  <ClogP>
2.711

>  <logS>
-2.51

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
61.94

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | Inhibitor | Antagonist | - | Inverse agonist | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Antagonist | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Inhibitor

>  <Activity coefficients and valu>
pKb  10.3  | Ki (inhibition constant)  0.15 nM | pKi  9.79 | pKb  9.72 | Kd (dissociation constant) = 0.3 nM | IC50  0.3 nM | pKb  9.5  | Ka (association constant)  0.35 nM | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.5 nM | Ki (inhibition constant)  0.56 nM | pKi  9.13  | pEC50 = 9.1  | IC50  0.89 nM | pKi > 9  | pKi > 9  | pKi  8 - 9  | pKi  9  | pKi  8 - 9  | pKi  9  | pKi  8 - 9  | pKi  8 - 9  | Ki (inhibition constant) = 1 nM | IC50  1 - 10 nM | pKi  8 - 9  | pKi  8 - 9  | pKi  9  | Ki (inhibition constant)  1.6 nM | stimulation rate  197 % | IC50  1.6 nM

>  <CAS>
106266-06-2

>  <Description>
Risperidone is a second-generation antipsychotic medication used to treat a number of mental health disorders including schizophrenia, bipolar mania, psychosis, or as an adjunct in severe depression.

>  <EBC_ID>
EBC-13572

>  <IUPAC Name>
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one

>  <Main Tar all refs>
SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | J. Med. Chem., 2014, vol. 57, # 22, p. 9578 - 9597 | Br. J. Pharmacol., 2016, vol. 173, # 1, p. 155 - 166 | J. Recept. Signal Transduction, 2019, vol. 39, # 1, p. 9 - 17 | ACADIA PHARMACEUTICALS INC - US2009/53329, 2009, A1 | J. Pharmacol. Exp. Ther., 2005, vol. 315, # 3, p. 1278 - 1287 | SUVEN LIFE SCIENCES LIMITED - WO2011/80750, 2011, A1 | J. Pharmacol. Exp. Ther., 2014, vol. 350, # 3, p. 589 - 604 | Eur. J. Pharmacol., 2007, vol. 573, # 1-3, p. 148 - 160 | Eur. J. Med. Chem., 2018, vol. 145, p. 790 - 804 | Bioorg. Med. Chem., 1999, vol. 7, # 7, p. 1263 - 1271 | J. Pharmacol. Exp. Ther., 2008, vol. 324, # 2, p. 587 - 599 | Curr. Top. Med. Chem., 2010, vol. 10, # 5, p. 554 - 578 | ACADIA PHARMACEUTICALS INC - WO2006/17614, 2006, A1 | J. PHARMACOL. EXP. THER., 1988, vol. 247, # 2, p. 661 - 670 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | PHARMANEUROBOOST - EP1541197, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - EP1541197, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - EP1541197, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | J. PHARMACOL. EXP. THER., 1995, vol. 275, # 1, p. 101 - 113 | angolul : Chemical Works of Gedeon Richter Plc. Gedeon Richter Plc. - WO2005/12266, 2005, A1 | ANIMA SRL - WO2010/112529, 2010, A1 | PHARMANEUROBOOST - US2005/203130, 2005, A1 | J. Pharmacol. Exp. Ther., 2000, vol. 292, # 1, p. 54 - 66 | Bioorg. Med. Chem., 1999, vol. 7, # 7, p. 1263 - 1271 | Br. J. Pharmacol., 2013, vol. 170, # 3, p. 532 - 545 | Eur. J. Pharmacol., 2015, vol. 748, p. 10 - 17

>  <Main tar all>
5-HT2A receptor pX=10.3 | 5-HT2A receptor pX=9.82 | D2 receptor pX=9.79 | G protein subunit alpha q pX=9.72 | D2 receptor pX=9.52 | D2S receptor pX=9.52 | ?1B-adrenoceptor pX=9.5 | 5-HT2 receptor pX=9.46 | ?1A-adrenoceptor pX=9.4 | 5-HT7 receptor pX=9.4 | ?1-adrenoceptor pX=9.3 | ?1D-adrenoceptor pX=9.25 | 5-HT7 receptor pX=9.13 | 5-HT7A?receptor pX=9.1 | D2L receptor pX=9.05 | ?1-adrenoceptor pX=9.0 | ?1A-adrenoceptor pX=9.0 | ?2B-adrenoceptor pX=9.0 | ?2B-adrenoceptor pX=9.0 | ?2C-adrenoceptor pX=9.0 | ?2C-adrenoceptor pX=9.0 | 5-HT1B receptor pX=9.0 | 5-HT1B receptor pX=9.0 | 5-HT2C receptor pX=9.0 | D3 receptor pX=9.0 | D4 receptor pX=9.0 | D4 receptor pX=9.0 | H1 receptor pX=9.0 | ?2-adrenoceptor pX=8.8 | Beta-arrestin-2 pX=8.8 | Kv11.1 pX=8.8

$$$$
Bosentan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 42 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 O -1.3337 -5.39 0 0
M  V30 3 C -1.3337 -6.93 0 0
M  V30 4 C 0 -7.7 0 0
M  V30 5 C 0 -9.24 0 0
M  V30 6 C -1.3337 -10.01 0 0
M  V30 7 C -2.6674 -9.24 0 0
M  V30 8 C -2.6674 -7.7 0 0
M  V30 9 O -4.001 -6.93 0 0
M  V30 10 C -5.3347 -7.7 0 0
M  V30 11 C -5.3347 -9.24 0 0
M  V30 12 N -4.001 -10.01 0 0
M  V30 13 S -4.001 -11.55 0 0
M  V30 14 O -5.541 -11.55 0 0
M  V30 15 O -2.461 -11.55 0 0
M  V30 16 C -4.001 -13.09 0 0
M  V30 17 C -2.6674 -13.86 0 0
M  V30 18 C -2.6674 -15.4 0 0
M  V30 19 C -4.001 -16.17 0 0
M  V30 20 C -5.3347 -15.4 0 0
M  V30 21 C -5.3347 -13.86 0 0
M  V30 22 C -4.001 -17.71 0 0
M  V30 23 C -4.001 -19.25 0 0
M  V30 24 C -5.541 -17.71 0 0
M  V30 25 C -2.461 -17.71 0 0
M  V30 26 N -6.6684 -10.01 0 0
M  V30 27 C -8.0021 -9.24 0 0
M  V30 28 N -8.0021 -7.7 0 0
M  V30 29 C -6.6684 -6.93 0 0
M  V30 30 O -6.6684 -5.39 0 0
M  V30 31 C -5.3347 -4.62 0 0
M  V30 32 C -4.001 -5.39 0 0
M  V30 33 O -2.6674 -4.62 0 0
M  V30 34 C -9.3358 -10.01 0 0
M  V30 35 N -9.3358 -11.55 0 0
M  V30 36 C -10.6694 -12.32 0 0
M  V30 37 C -12.0031 -11.55 0 0
M  V30 38 C -12.0031 -10.01 0 0
M  V30 39 N -10.6694 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 2 13 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 23 1 19 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 22 25
M  V30 27 2 11 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 10 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 27 34
M  V30 37 1 34 35
M  V30 38 2 35 36
M  V30 39 1 36 37
M  V30 40 2 37 38
M  V30 41 1 38 39
M  V30 42 2 34 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532762

>  <MW>
551.614

>  <MW (desalted)>
551.614

>  <ClogP>
4.167

>  <logS>
-6.89

>  <HBD>
2

>  <HBA>
9

>  <TPSA>
145.65

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.08 nM | Ki (inhibition constant)  1.73 nM | Ki (inhibition constant)  1.73 nM

>  <CAS>
147536-97-8

>  <Description>
Bosentan is a competitive and dual antagonist of endothelin-1. It is used in the treatment of pulmonary arterial hypertension, to improve exercise ability and to decrease the rate of clinical worsening.

>  <EBC_ID>
EBC-06096

>  <IUPAC Name>
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl]benzene-1-sulfonamide

>  <Main Tar all refs>
Curr. Med. Chem., 2002, vol. 9, # 3, p. 349 - 383 | J. Cardiovasc. Pharmacol., 2010, vol. 56, # 3, p. 246 - 254 | J. Cardiovasc. Pharmacol., 2010, vol. 56, # 3, p. 246 - 254

>  <Main tar all>
ETA receptor pX=10.1 | ETB receptor pX=8.76 | ETB receptor pX=8.76

$$$$
Digitoxin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 54 61 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.6627 13.6275 0 0
M  V30 2 C 7.6554 12.4502 0 0 CFG=1
M  V30 3 O 9.1714 12.7212 0 0
M  V30 4 C 10.1641 11.5439 0 0 CFG=2
M  V30 5 C 9.6409 10.0955 0 0
M  V30 6 C 8.1249 9.8245 0 0 CFG=2
M  V30 7 O 7.6017 8.3761 0 0
M  V30 8 C 7.1322 11.0018 0 0 CFG=2
M  V30 9 O 5.6162 10.7307 0 0
M  V30 10 O 11.68 11.815 0 0
M  V30 11 C 12.6728 10.6377 0 0 CFG=2
M  V30 12 C 14.1887 10.9087 0 0 CFG=1
M  V30 13 C 14.712 12.3571 0 0
M  V30 14 O 15.1815 9.7314 0 0
M  V30 15 C 14.6582 8.283 0 0 CFG=2
M  V30 16 C 13.1423 8.012 0 0
M  V30 17 C 12.1495 9.1893 0 0 CFG=2
M  V30 18 O 10.6336 8.9182 0 0
M  V30 19 O 15.651 7.1057 0 0
M  V30 20 C 15.1277 5.6573 0 0 CFG=2
M  V30 21 C 16.1205 4.48 0 0 CFG=1
M  V30 22 C 17.6364 4.7511 0 0
M  V30 23 O 15.5972 3.0316 0 0
M  V30 24 C 14.0813 2.7605 0 0 CFG=2
M  V30 25 C 13.0886 3.9378 0 0
M  V30 26 C 13.6118 5.3862 0 0 CFG=2
M  V30 27 O 12.6191 6.5636 0 0
M  V30 28 O 13.5581 1.3121 0 0
M  V30 29 C 12.0421 1.0411 0 0 CFG=1
M  V30 30 C 11.5189 -0.4073 0 0
M  V30 31 C 10.0029 -0.6784 0 0
M  V30 32 C 9.0102 0.4989 0 0 CFG=1
M  V30 33 C 8.487 -0.9495 0 0
M  V30 34 C 9.5334 1.9473 0 0 CFG=2
M  V30 35 C 8.5407 3.1246 0 0
M  V30 36 C 7.0247 2.8536 0 0
M  V30 37 C 6.5015 1.4052 0 0 CFG=2
M  V30 38 C 7.4942 0.2279 0 0 CFG=2
M  V30 39 C 6.971 -1.2205 0 0
M  V30 40 C 5.4551 -1.4916 0 0
M  V30 41 C 4.4623 -0.3143 0 0 CFG=2
M  V30 42 C 3.7906 -1.7 0 0
M  V30 43 C 2.9231 -0.2642 0 0 CFG=2
M  V30 44 C 2.4951 1.2151 0 0
M  V30 45 C 3.7697 2.0793 0 0
M  V30 46 C 4.9856 1.1341 0 0 CFG=2
M  V30 47 O 5.3545 2.6293 0 0
M  V30 48 C 1.9779 -1.4801 0 0
M  V30 49 C 2.406 -2.9594 0 0
M  V30 50 C 1.1314 -3.8236 0 0
M  V30 51 O 1.0813 -5.3628 0 0
M  V30 52 O -0.0845 -2.8784 0 0
M  V30 53 C 0.4388 -1.43 0 0
M  V30 54 C 11.0494 2.2184 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 8 6
M  V30 8 1 8 2
M  V30 9 1 8 9 CFG=3
M  V30 10 1 4 10 CFG=1
M  V30 11 1 11 10 CFG=3
M  V30 12 1 11 12
M  V30 13 1 12 13 CFG=1
M  V30 14 1 12 14
M  V30 15 1 15 14
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 11 17
M  V30 19 1 17 18 CFG=3
M  V30 20 1 15 19 CFG=1
M  V30 21 1 20 19 CFG=3
M  V30 22 1 20 21
M  V30 23 1 21 22 CFG=1
M  V30 24 1 21 23
M  V30 25 1 24 23
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 20 26
M  V30 29 1 26 27 CFG=3
M  V30 30 1 24 28 CFG=1
M  V30 31 1 29 28 CFG=1
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 32 31
M  V30 35 1 32 33 CFG=1
M  V30 36 1 32 34
M  V30 37 1 34 35 CFG=3
M  V30 38 1 35 36
M  V30 39 1 37 36 CFG=3
M  V30 40 1 38 37
M  V30 41 1 32 38
M  V30 42 1 38 39 CFG=1
M  V30 43 1 39 40
M  V30 44 1 41 40
M  V30 45 1 41 42 CFG=1
M  V30 46 1 41 43
M  V30 47 1 43 44
M  V30 48 1 44 45
M  V30 49 1 46 45
M  V30 50 1 37 46
M  V30 51 1 46 41
M  V30 52 1 46 47 CFG=1
M  V30 53 1 43 48 CFG=1
M  V30 54 2 48 49
M  V30 55 1 49 50
M  V30 56 2 50 51
M  V30 57 1 50 52
M  V30 58 1 52 53
M  V30 59 1 48 53
M  V30 60 1 34 54
M  V30 61 1 29 54
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552200029

>  <MW>
764.939

>  <MW (desalted)>
764.939

>  <ClogP>
2.854

>  <logS>
-4.69

>  <HBD>
5

>  <HBA>
12

>  <TPSA>
182.83

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
percentage increase  119 %

>  <CAS>
71-63-6

>  <Description>
Digitoxin is a cardiac glycoside used in the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure. It inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations.

>  <EBC_ID>
EBC-13579

>  <IUPAC Name>
4-[(1R,3aS,3bR,5aR,7S,9aS,9bS,11aR)-7-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-2,5-dihydrofuran-2-one

>  <Main Tar all refs>
Br. J. Pharmacol., 2017, vol. 174, # 18, p. 3094 - 3106

>  <Main tar all>
sodium:potassium-exchanging ATPase pX=9.28

$$$$
Fosfomycin disodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na -4.3265 -1.9846 0 0 CHG=1
M  V30 2 Na -0.1191 -3.1119 0 0 CHG=1
M  V30 3 C 0.4446 3.1991 0 0
M  V30 4 C 0.4446 1.6591 0 0 CFG=2
M  V30 5 O 1.2146 0.3254 0 0
M  V30 6 C -0.3254 0.3254 0 0 CFG=2
M  V30 7 P -1.6591 -0.4446 0 0
M  V30 8 O -2.4291 0.8891 0 0
M  V30 9 O -2.9928 -1.2146 0 0 CHG=-1
M  V30 10 O -0.8891 -1.7782 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 4 3 CFG=3
M  V30 2 1 4 5
M  V30 3 1 6 5
M  V30 4 1 4 6
M  V30 5 1 6 7 CFG=3
M  V30 6 2 7 8
M  V30 7 1 7 9
M  V30 8 1 7 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1583387379

>  <MW>
182.023

>  <MW (desalted)>
138.059

>  <ClogP>
-0.425

>  <logS>
0.78

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
75.72

>  <RotBonds>
1

>  <Action on targets>
Stimulator

>  <Activity coefficients and valu>
enzyme activity rate decrease Active

>  <CAS>
26016-99-9

>  <Description>
Fosfomycin is a blood-brain barrier penetrating, broad-spectrum antibiotic with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis. It is used to treat uncomplicated urinary tract infections.

>  <EBC_ID>
EBC-07731

>  <IUPAC Name>
disodium [(2R,3S)-3-methyloxiran-2-yl]phosphonate

>  <Main Tar all refs>
Antibiotics, 2020, vol. 9, # 4

>  <Main tar all>
tyrosinase pX=3.16

$$$$
Cholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3626 -7.2893 0 0
M  V30 2 C 4.7822 -5.8629 0 0 CFG=2
M  V30 3 C 3.2567 -5.6522 0 0
M  V30 4 C 2.3115 -6.868 0 0
M  V30 5 C 0.786 -6.6574 0 0
M  V30 6 O -0.1592 -7.8732 0 0
M  V30 7 O 0.2057 -5.2309 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 C 5.2994 -3.1677 0 0
M  V30 10 C 6.574 -2.3035 0 0
M  V30 11 C 7.7898 -3.2487 0 0 CFG=1
M  V30 12 C 9.3058 -2.9776 0 0 CFG=2
M  V30 13 C 9.829 -1.5293 0 0 CFG=2
M  V30 14 O 8.8363 -0.3519 0 0
M  V30 15 C 11.345 -1.2582 0 0
M  V30 16 C 12.3377 -2.4355 0 0 CFG=2
M  V30 17 C 13.8537 -2.1644 0 0
M  V30 18 C 14.8464 -3.3418 0 0 CFG=2
M  V30 19 O 16.3624 -3.0707 0 0
M  V30 20 C 14.3232 -4.7901 0 0
M  V30 21 C 12.8072 -5.0612 0 0
M  V30 22 C 11.8145 -3.8839 0 0 CFG=1
M  V30 23 C 11.2913 -5.3323 0 0
M  V30 24 C 10.2985 -4.155 0 0 CFG=1
M  V30 25 C 9.7753 -5.6034 0 0
M  V30 26 C 8.2593 -5.8744 0 0 CFG=2
M  V30 27 O 7.7361 -7.3228 0 0
M  V30 28 C 7.2666 -4.6971 0 0 CFG=2
M  V30 29 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 2 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 12 11 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 16 17
M  V30 17 1 18 17
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 12 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 26 25
M  V30 28 1 26 27 CFG=3
M  V30 29 1 28 26
M  V30 30 1 28 8
M  V30 31 1 11 28
M  V30 32 1 28 29 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1954806455

>  <MW>
408.571

>  <MW (desalted)>
408.571

>  <ClogP>
2.427

>  <logS>
-3.31

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
97.99

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  64 nM | IC50  0.51 ?M | Kd (dissociation constant)  1700 nM

>  <CAS>
81-25-4

>  <Description>
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. It is an agonist G-protein coupled bile acid receptor 1.

>  <EBC_ID>
EBC-08822

>  <IUPAC Name>
(4R)-4-[(1R,3aS,3bR,4R,5aS,7R,9aS,9bS,11S,11aR)-4,7,11-trihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
ACS Chem. Biol., 2016, vol. 11, # 1, p. 211 - 221 | Steroids, 2014, vol. 86, p. 39 - 44 | ACS Chem. Biol., 2016, vol. 11, # 1, p. 211 - 221

>  <Main tar all>
Avidin 2 pX=7.19 | Aldo-keto reductase family 1 member B10 pX=6.29 | Avidin 1 pX=5.77

$$$$
Loratadine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.4328 9.8597 0 0
M  V30 2 C 5.7665 9.0897 0 0
M  V30 3 O 5.7665 7.5497 0 0
M  V30 4 C 7.1002 6.7797 0 0
M  V30 5 O 8.4339 7.5497 0 0
M  V30 6 N 7.1002 5.2397 0 0
M  V30 7 C 8.4339 4.4697 0 0
M  V30 8 C 8.4339 2.9297 0 0
M  V30 9 C 7.1002 2.1597 0 0
M  V30 10 C 7.1002 0.6197 0 0
M  V30 11 C 8.4877 -0.0485 0 0
M  V30 12 C 9.6166 0.999 0 0
M  V30 13 C 11.0882 0.5451 0 0
M  V30 14 C 11.4308 -0.9563 0 0
M  V30 15 Cl 12.9024 -1.4103 0 0
M  V30 16 C 10.3019 -2.0038 0 0
M  V30 17 C 8.8304 -1.5499 0 0
M  V30 18 C 7.8702 -2.7539 0 0
M  V30 19 C 6.3302 -2.7539 0 0
M  V30 20 C 5.37 -1.5499 0 0
M  V30 21 C 3.8984 -2.0038 0 0
M  V30 22 C 2.7695 -0.9563 0 0
M  V30 23 C 3.1122 0.5451 0 0
M  V30 24 N 4.5838 0.999 0 0
M  V30 25 C 5.7127 -0.0485 0 0
M  V30 26 C 5.7665 2.9297 0 0
M  V30 27 C 5.7665 4.4697 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 16 17
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 1 10 25
M  V30 27 2 20 25
M  V30 28 1 9 26
M  V30 29 1 26 27
M  V30 30 1 6 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553845

>  <MW>
382.883

>  <MW (desalted)>
382.883

>  <ClogP>
5.051

>  <logS>
-4.57

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
42.43

>  <RotBonds>
2

>  <Action on targets>
- | Inhibitor | Antagonist | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter) = 0.0004 ?M | IC50  3 - 1 nM | IC50  5.4 nM | Ki (inhibition constant)  0.006 ?M

>  <CAS>
79794-75-5

>  <Description>
Loratadine is a second generation antihistamine used to manage the symptoms of allergic rhinitis. It is selective for peripheral H1 receptors.

>  <EBC_ID>
EBC-11203

>  <IUPAC Name>
ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate

>  <Main Tar all refs>
Curr. Top. Med. Chem., 2008, vol. 8, # 13, p. 1102 - 1112 | IDOGEN AB - WO2008/147283, 2008, A1 | J. Am. Chem. Soc., 2020, vol. 142, # 29, p. 12690 - 12698 | Drug Metab. Dispos., 2008, vol. 36, # 3, p. 523 - 528

>  <Main tar all>
Kv11.1 pX=9.4 | Aldehyde oxidase pX=8.52 | H1 receptor pX=8.27 | Cytochrome P450 2C19 pX=8.22

$$$$

  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.0896 0.0309 0 0
M  V30 2 S -0.3196 -1.3028 0 0
M  V30 3 C 1.2204 -1.3028 0 0
M  V30 4 N 2.1256 -0.0569 0 0
M  V30 5 C 3.5902 -0.5328 0 0
M  V30 6 C 4.9239 0.2372 0 0
M  V30 7 C 6.2576 -0.5328 0 0
M  V30 8 Cl 7.5913 0.2372 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 O 7.5913 -2.8428 0 0
M  V30 11 C 7.5913 -4.3828 0 0
M  V30 12 C 8.925 -5.1528 0 0
M  V30 13 C 8.925 -6.6928 0 0
M  V30 14 C 7.5913 -7.4628 0 0
M  V30 15 C 6.2576 -6.6928 0 0
M  V30 16 Cl 4.9239 -7.4628 0 0
M  V30 17 C 6.2576 -5.1528 0 0
M  V30 18 Cl 4.9239 -4.3828 0 0
M  V30 19 C 4.9239 -2.8428 0 0
M  V30 20 C 3.5902 -2.0728 0 0
M  V30 21 N 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 19 2 9 19
M  V30 20 1 19 20
M  V30 21 2 5 20
M  V30 22 1 20 21
M  V30 23 1 3 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3069281092

>  <MW>
357.95

>  <MW (desalted)>
359.658

>  <ClogP>
6.44

>  <logS>
-7.325

>  <HBD>
1

>  <HBA>
1

>  <TPSA>
37.91

>  <RotBonds>
3

>  <CAS>
68786-66-3

>  <EBC_ID>
EBC-84235

>  <IUPAC Name>
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzodiazole

$$$$
Axitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 11.5923 8.2328 0 0
M  V30 2 N 11.5923 6.6928 0 0
M  V30 3 C 10.2586 5.9228 0 0
M  V30 4 O 10.2586 4.3828 0 0
M  V30 5 C 8.925 6.6928 0 0
M  V30 6 C 8.925 8.2328 0 0
M  V30 7 C 7.5913 9.0028 0 0
M  V30 8 C 6.2576 8.2328 0 0
M  V30 9 C 6.2576 6.6928 0 0
M  V30 10 C 7.5913 5.9228 0 0
M  V30 11 S 7.5913 4.3828 0 0
M  V30 12 C 6.2576 3.6128 0 0
M  V30 13 C 6.2576 2.0728 0 0
M  V30 14 C 4.9239 1.3028 0 0
M  V30 15 C 3.5902 2.0728 0 0
M  V30 16 C 2.1256 1.5969 0 0
M  V30 17 C 1.6497 0.1323 0 0
M  V30 18 C 2.6802 -1.0121 0 0
M  V30 19 C 2.2043 -2.4768 0 0
M  V30 20 C 3.2348 -3.6212 0 0
M  V30 21 C 2.7589 -5.0858 0 0
M  V30 22 C 1.2525 -5.406 0 0
M  V30 23 C 0.2221 -4.2616 0 0
M  V30 24 N 0.698 -2.7969 0 0
M  V30 25 N 1.2204 2.8428 0 0
M  V30 26 N 2.1256 4.0887 0 0
M  V30 27 C 3.5902 3.6128 0 0
M  V30 28 C 4.9239 4.3828 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 17 16 CFG=2
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 26 2 16 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 2 15 27
M  V30 30 1 27 28
M  V30 31 2 12 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216885372

>  <MW>
386.47

>  <MW (desalted)>
386.47

>  <ClogP>
3.327

>  <logS>
-6.317

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
70.67

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0002 ?M | IC50 = 0.25 nM | IC50 = 0.29 nM | IC50 = 1.2 nM | IC50 = 1.7 nM | IC50 = 2.5 nM

>  <CAS>
319460-85-0

>  <Description>
Axitinib is a VEGFR and kinase inhibitor. It is used for the treatment of advanced renal cell carcinoma.

>  <EBC_ID>
EBC-17083

>  <IUPAC Name>
N-methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide

>  <Main Tar all refs>
Eur. J. Med. Chem., 2018, vol. 160, p. 61 - 81 | Pharmacol. Ther., 2009, vol. 123, # 1, p. 117 - 141 | Pharmacol. Ther., 2009, vol. 123, # 1, p. 117 - 141 | Pharmacol. Ther., 2009, vol. 123, # 1, p. 117 - 141 | Pharmacol. Ther., 2009, vol. 123, # 1, p. 117 - 141 | Pharmacol. Ther., 2009, vol. 123, # 1, p. 117 - 141

>  <Main tar all>
ABL proto-oncogene 1, non-receptor tyrosine kinase pX=9.7 | kinase insert domain receptor pX=9.6 | fms related receptor tyrosine kinase 4 pX=9.54 | fms related receptor tyrosine kinase 1 pX=8.92 | Mast/stem cell growth factor receptor Kit pX=8.77 | platelet derived growth factor receptor beta pX=8.6

$$$$
Benzatropine mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.4193 0.9945 0 0
M  V30 2 N -2.8839 1.4703 0 0
M  V30 3 C -3.3164 3.2005 0 0 CFG=1
M  V30 4 C -4.5205 2.2403 0 0
M  V30 5 C -4.5205 0.7003 0 0
M  V30 6 C -3.3164 -0.2598 0 0 CFG=2
M  V30 7 C -1.815 0.0828 0 0
M  V30 8 C -1.1469 1.4703 0 0 CFG=1
M  V30 9 C -1.815 2.8578 0 0
M  V30 10 O 0.3931 1.4703 0 0
M  V30 11 C 1.1631 0.1367 0 0
M  V30 12 C 0.3931 -1.197 0 0
M  V30 13 C 1.1631 -2.5307 0 0
M  V30 14 C 0.3931 -3.8644 0 0
M  V30 15 C -1.1469 -3.8644 0 0
M  V30 16 C -1.9169 -2.5307 0 0
M  V30 17 C -1.1469 -1.197 0 0
M  V30 18 C 2.7031 0.1367 0 0
M  V30 19 C 3.4731 1.4703 0 0
M  V30 20 C 5.0131 1.4703 0 0
M  V30 21 C 5.7831 0.1367 0 0
M  V30 22 C 5.0131 -1.197 0 0
M  V30 23 C 3.4731 -1.197 0 0
M  V30 24 C 10.8431 -1.54 0 0
M  V30 25 S 10.8431 0 0 0
M  V30 26 O 10.8431 1.54 0 0
M  V30 27 O 12.3831 -0 0 0
M  V30 28 O 9.3031 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 2 CFG=3
M  V30 7 1 6 7
M  V30 8 1 8 7
M  V30 9 1 8 9
M  V30 10 1 3 9
M  V30 11 1 8 10 CFG=1
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 12 17
M  V30 20 1 11 18
M  V30 21 1 18 19
M  V30 22 2 19 20
M  V30 23 1 20 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 2 18 23
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 2 25 27
M  V30 30 1 25 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802006

>  <MW>
403.182

>  <MW (desalted)>
307.429

>  <ClogP>
3.52

>  <logS>
-2.619

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.24 nM | Ki (inhibition constant)  0.55 nM | Ki (inhibition constant)  3.2 nM

>  <CAS>
132-17-2

>  <Description>
Benztropine is a centrally-acting antagonist of M1 muscarinic acetylcholine receptors. It is used as an adjunct in the treatment of Parkinson's disease.

>  <EBC_ID>
EBC-07857

>  <IUPAC Name>
(1R,3R,5S)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; methanesulfonic acid

>  <Main Tar all refs>
Life Sci., 1991, vol. 49, # 17, p. 1229 - 1235 | Biochem. Pharmacol., 1983, vol. 32, # 2, p. 377 - 380 | Life Sci., 1991, vol. 49, # 17, p. 1229 - 1235

>  <Main tar all>
M1 receptor pX=9.62 | mAChR pX=9.26 | M2 receptor pX=8.49

$$$$
Esculin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.3337 -5.39 0 0
M  V30 2 C -2.6674 -4.62 0 0
M  V30 3 C -2.6674 -3.08 0 0 CFG=1
M  V30 4 O -1.3337 -2.31 0 0
M  V30 5 C -1.3337 -0.77 0 0 CFG=1
M  V30 6 O 0 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 2.6674 0 0 0
M  V30 9 C 4.001 -0.77 0 0
M  V30 10 C 5.3347 0 0 0
M  V30 11 C 6.6684 -0.77 0 0
M  V30 12 C 6.6684 -2.31 0 0
M  V30 13 O 8.0021 -3.08 0 0
M  V30 14 O 5.3347 -3.08 0 0
M  V30 15 C 4.001 -2.31 0 0
M  V30 16 C 2.6674 -3.08 0 0
M  V30 17 C 1.3337 -2.31 0 0
M  V30 18 O 0 -3.08 0 0
M  V30 19 C -2.6674 -0 0 0 CFG=2
M  V30 20 O -2.6674 1.54 0 0
M  V30 21 C -4.001 -0.77 0 0 CFG=1
M  V30 22 O -5.3347 -0 0 0
M  V30 23 C -4.001 -2.31 0 0 CFG=2
M  V30 24 O -5.3347 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 9 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 7 17
M  V30 19 1 17 18
M  V30 20 1 19 5
M  V30 21 1 19 20 CFG=1
M  V30 22 1 19 21
M  V30 23 1 21 22 CFG=3
M  V30 24 1 21 23
M  V30 25 1 23 3
M  V30 26 1 23 24 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1494829512

>  <MW>
340.079

>  <MW (desalted)>
340.282

>  <ClogP>
-0.731

>  <logS>
-2.144

>  <HBD>
5

>  <HBA>
8

>  <TPSA>
145.91

>  <RotBonds>
3

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC50  831 nM

>  <CAS>
531-75-9

>  <Description>
The main activities of Esculine focus on capillary protection, as it improves capillary permeability and fragility. It is reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thus preserving the integrity of the perivascular connective tissue. Esculine also showed good antioxidant properties, protecting triglycerides against auto-oxidation at high temperatures. Esculin is sometimes used as a vasoprotective agent.

>  <EBC_ID>
EBC-12127

>  <IUPAC Name>
7-hydroxy-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-chromen-2-one

>  <Main Tar all refs>
UNIVERSITY OF CALIFORNIA - WO2008/128100, 2008, A1

>  <Main tar all>
Androgen receptor pX=6.08

$$$$
Ampicillin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.7786 1.4798 0 0
M  V30 2 C 3.6342 2.5103 0 0
M  V30 3 C 4.7786 3.5407 0 0
M  V30 4 S 2.729 1.2644 0 0
M  V30 5 C 1.2644 1.7403 0 0 CFG=2
M  V30 6 C -0.2756 1.7403 0 0 CFG=2
M  V30 7 N -1.3646 0.6513 0 0
M  V30 8 C -2.8521 1.0499 0 0
M  V30 9 O -3.2507 2.5374 0 0
M  V30 10 C -3.941 -0.0391 0 0 CFG=2
M  V30 11 N -3.5425 -1.5266 0 0
M  V30 12 C -5.4286 0.3595 0 0
M  V30 13 C -6.5175 -0.7294 0 0
M  V30 14 C -8.005 -0.3308 0 0
M  V30 15 C -8.4036 1.1567 0 0
M  V30 16 C -7.3147 2.2456 0 0
M  V30 17 C -5.8272 1.8471 0 0
M  V30 18 C -0.2756 3.2803 0 0
M  V30 19 O -1.3646 4.3692 0 0
M  V30 20 N 1.2644 3.2803 0 0
M  V30 21 C 2.729 3.7561 0 0 CFG=1
M  V30 22 C 3.2049 5.2208 0 0
M  V30 23 O 2.1744 6.3652 0 0
M  V30 24 O 4.7112 5.541 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 10 8
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 6 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 5 20 CFG=3
M  V30 22 1 21 20
M  V30 23 1 21 2
M  V30 24 1 21 22 CFG=1
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1603854590

>  <MW>
349.11

>  <MW (desalted)>
349.405

>  <ClogP>
-1.204

>  <logS>
-4.789

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
112.73

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | - | Substrate | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor | -

>  <Activity coefficients and valu>
IC50  0.01 ?g/ml | IC50  0.01 ?g/ml | IC50  0.01 ?g/ml | IC50  0.01 ?g/ml | Ki (inhibition constant) = 57 nM | IC50  0.022 ?g/ml | MIC  0.071 ?mol/l | MIC  0.071 ?mol/l | IC50 < 0.025 ?g/mL | MIC  0.03 ?g/ml | IC50  0.046 ?g/ml | MIC  0.05 ?g/ml | Kd (dissociation constant)  0.15 ?M | MIC  0.06 ?g/ml | MIC  0.0625 ?g/ml | MIC  0.18 ?M | Kd (dissociation constant)  0.19 ?M | IC50  0.077 ?g/ml | Kd (dissociation constant)  0.23 ?M | Kd (dissociation constant)  0.24 ?M | inhibition percentage <= 50 % | inhibition percentage <= 50 % | inhibition percentage <= 50 % | qualitative Active   | qualitative Active   | IC50  0.12 ?g/ml | IC50  0.12 ?g/ml | MIC  0.125 ?g/ml | MIC  0.13 - 32 ?g/ml | MIC  0.13 - 32 ?g/ml | MIC95  2.5 ?g/ml | IC50  0.14 ?g/ml | Kd (dissociation constant)  0.45 ?M | EC50 < 0.5 ?M | MIC  0.2 mg/l | MIC90  2 ?g/ml | MIC90  2 ?g/ml | Kd (dissociation constant)  0.64 ?M | MIC  0.25 ?g/ml | MIC <= 0.25 mg/l | Km (Michaelis constant)  0.877 ?M | Km (Michaelis constant) = 0.9 ?M | Kd (dissociation constant)  0.91 ?M

>  <CAS>
69-53-4

>  <Description>
Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. It is used for the treatment of a variety of infections caused by gram-positive and gram-negative bacteria as well as some anaerobes.

>  <EBC_ID>
EBC-13454

>  <IUPAC Name>
(2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2000, vol. 44, # 6, p. 1725 - 1727 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | J. Inorg. Biochem., 2023, vol. 243 | J. Inorg. Biochem., 2023, vol. 243 | Antimicrob. Agents Chemother., 1998, vol. 42, # 11, p. 2943 - 2949 | Med. Chem., 2019, vol. 15, # 2, p. 196 - 206 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | ChemBioChem, 2020, vol. 21, # 15, p. 2187 - 2195 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Bioorg. Med. Chem., 2020, vol. 28, # 9 | Antibiotics, 2022, vol. 11, # 8 | J. Nat. Prod., 2020, vol. 83, # 10, p. 3004 - 3011 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2015, vol. 59, # 5, p. 2785 - 2790 | Antimicrob. Agents Chemother., 2014, vol. 58, # 11, p. 6508 - 6517 | Antimicrob. Agents Chemother., 2014, vol. 58, # 11, p. 6508 - 6517 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Bioorg. Med. Chem., 2021, vol. 29 | Nat. Commun., 2022, vol. 13, # 1 | Nat. Commun., 2022, vol. 13, # 1 | Nat. Commun., 2022, vol. 13, # 1 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4 | VENATORX PHARMACEUTICALS INC - WO2019/226931, 2019, A1 | J. Heterocycl. Chem., 2022, vol. 59, # 9, p. 1573 - 1590 | PLoS ONE, 2020, vol. 15, # 2 | PLoS ONE, 2020, vol. 15, # 2 | Bioorg. Chem., 2021, vol. 110 | REDX PHARMA PLC - WO2017/93747, 2017, A1 | J. Med. Chem., 2021, vol. 64, # 9, p. 6310 - 6328 | Antimicrob. Agents Chemother., 2014, vol. 58, # 11, p. 6544 - 6549 | Antimicrob. Agents Chemother., 2000, vol. 44, # 5, p. 1387 - 1390 | Antimicrob. Agents Chemother., 2020, vol. 64, # 4

>  <Main tar all>
D-alanyl-D-alanine carboxypeptidase pX=7.54 | D-alanyl-D-alanine carboxypeptidase DacC pX=7.54 | Penicillin-binding?protein 7 pX=7.54 | Penicillin-binding?protein 8 pX=7.54 | Beta-lactamase SHV-24 pX=7.24 | Penicillin-binding?protein?3 pX=7.2 | Beta lactamase TEM-1B pX=7.15 | Beta-lactamase CTX-M-15 pX=7.15 | Penicillin-binding?protein?3 pX=7.15 | Beta-lactamase ESBL pX=7.07 | Penicillin-binding?protein 2X pX=6.88 | Beta-Lactamase AmpC pX=6.84 | Beta-lactamase NDM-4 pX=6.82 | Dihydropteroate synthase pX=6.76 | Methionyl aminopeptidase 2 pX=6.75 | Sortase A pX=6.74 | Beta-lactamase AIM-1 pX=6.72 | Penicillin-binding?protein 1A pX=6.66 | Beta-lactamase NDM-6 pX=6.64 | Beta-lactamase IMP-7 pX=6.62 | Penicillin-binding?protein 1B pX=6.54 | Penicillin-binding?protein 2 pX=6.54 | Penicillin-binding?protein 5 pX=6.54 | Penicillin-binding?protein 2 pX=6.51 | Penicillin-binding?protein B1 pX=6.51 | Penicillin-binding?protein 2B pX=6.46 | Penicillin-binding?protein 2B pX=6.46 | Leucine-tRNA ligase (gene lars-1) pX=6.45 | Phospho-N-acetylmuramoyl-pentapeptide-transferase pX=6.43 | phospho-n-acetylmuramoyl-pentapeptide-transferase pX=6.43 | Multidrug?efflux?pump?subunit?AcrB pX=6.42 | Penicillin-binding?protein 2A pX=6.4 | Beta-lactamase VIM-2 pX=6.35 | Penicillin-binding?protein 1A pX=6.3 | UDP-N-acetylmuramate dehydrogenase pX=6.24 | DNA supercoiling protein pX=6.2 | DNA topoisomerase II pX=6.2 | NAD-dependent protein deacetylase sirtuin-3, mitochondrial pX=6.19 | DNA topoisomerase II pX=6.15 | Pseudomonas-derived cephalosporinase-1 pX=6.15 | Beta-lactamase DHA-1 pX=6.06 | Beta-Lactamase AmpC pX=6.05 | Beta-lactamase NDM-1 pX=6.04

$$$$
Candesartan cilexetil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 50 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.3196 1.3645 0 0
M  V30 2 C -1.0896 0.0309 0 0
M  V30 3 O -0.3196 -1.3028 0 0
M  V30 4 C 1.2204 -1.3028 0 0
M  V30 5 N 2.1256 -0.0569 0 0
M  V30 6 C 3.5902 -0.5328 0 0
M  V30 7 C 4.9239 0.2372 0 0
M  V30 8 C 6.2576 -0.5328 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 4.9239 -4.3828 0 0
M  V30 12 O 3.5902 -5.1528 0 0
M  V30 13 O 6.2576 -5.1528 0 0
M  V30 14 C 6.2576 -6.6928 0 0
M  V30 15 C 4.9239 -7.4628 0 0
M  V30 16 O 7.5913 -7.4628 0 0
M  V30 17 C 7.5913 -9.0028 0 0
M  V30 18 O 6.2576 -9.7728 0 0
M  V30 19 O 8.925 -9.7728 0 0
M  V30 20 C 8.925 -11.3128 0 0
M  V30 21 C 10.2586 -12.0828 0 0
M  V30 22 C 10.2586 -13.6228 0 0
M  V30 23 C 8.925 -14.3928 0 0
M  V30 24 C 7.5913 -13.6228 0 0
M  V30 25 C 7.5913 -12.0828 0 0
M  V30 26 C 3.5902 -2.0728 0 0
M  V30 27 N 2.1256 -2.5487 0 0
M  V30 28 C 1.6497 -4.0133 0 0
M  V30 29 C 0.1434 -4.3335 0 0
M  V30 30 C -0.3325 -5.7982 0 0
M  V30 31 C -1.8389 -6.1183 0 0
M  V30 32 C -2.8693 -4.9739 0 0
M  V30 33 C -2.3934 -3.5093 0 0
M  V30 34 C -0.8871 -3.1891 0 0
M  V30 35 C -4.3757 -5.2941 0 0
M  V30 36 C -4.8515 -6.7587 0 0
M  V30 37 C -6.3579 -7.0789 0 0
M  V30 38 C -7.3884 -5.9344 0 0
M  V30 39 C -6.9125 -4.4698 0 0
M  V30 40 C -5.4061 -4.1496 0 0
M  V30 41 C -4.9302 -2.685 0 0
M  V30 42 N -5.8354 -1.4391 0 0
M  V30 43 N -4.9302 -0.1932 0 0
M  V30 44 N -3.4656 -0.6691 0 0
M  V30 45 N -3.4656 -2.2091 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 20 25
M  V30 26 1 10 26
M  V30 27 2 6 26
M  V30 28 1 26 27
M  V30 29 1 4 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 29 34
M  V30 38 1 32 35
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 2 38 39
M  V30 43 1 39 40
M  V30 44 2 35 40
M  V30 45 1 40 41
M  V30 46 2 41 42
M  V30 47 1 42 43
M  V30 48 2 43 44
M  V30 49 1 44 45
M  V30 50 1 41 45
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515383338

>  <MW>
610.254

>  <MW (desalted)>
610.66

>  <ClogP>
7.084

>  <logS>
-8.441

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
143.34

>  <RotBonds>
13

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.64 nM

>  <CAS>
145040-37-5

>  <Description>
Candesartan cilexetil is an angiotensin receptor blocker used to treat hypertension, systolic hypertension, left ventricular hypertrophy, and delay progression of diabetic nephropathy.

>  <EBC_ID>
EBC-11266

>  <IUPAC Name>
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylate

>  <Main Tar all refs>
J. MED. CHEM., 1996, vol. 39, # 3, p. 625 - 656

>  <Main tar all>
AT1 receptor pX=9.19

$$$$
Avanafil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.5329 3.735 0 0
M  V30 2 O 1.5329 2.195 0 0
M  V30 3 C 0.1992 1.425 0 0
M  V30 4 C 0.1992 -0.115 0 0
M  V30 5 C -1.1345 -0.885 0 0
M  V30 6 C -2.4682 -0.115 0 0
M  V30 7 C -3.8019 -0.885 0 0
M  V30 8 N -5.1355 -0.115 0 0
M  V30 9 C -6.4692 -0.885 0 0
M  V30 10 N -6.4692 -2.425 0 0
M  V30 11 C -7.8029 -3.195 0 0
M  V30 12 N -9.1366 -2.425 0 0
M  V30 13 C -9.1366 -0.885 0 0
M  V30 14 C -7.8029 -0.115 0 0
M  V30 15 C -7.8029 1.425 0 0
M  V30 16 O -9.1366 2.195 0 0
M  V30 17 N -6.4692 2.195 0 0
M  V30 18 C -6.4692 3.735 0 0
M  V30 19 C -7.8029 4.505 0 0
M  V30 20 N -9.1366 3.735 0 0
M  V30 21 C -10.4702 4.505 0 0
M  V30 22 C -10.4702 6.045 0 0
M  V30 23 C -9.1366 6.815 0 0
M  V30 24 N -7.8029 6.045 0 0
M  V30 25 N -7.8029 -4.735 0 0
M  V30 26 C -6.557 -5.6402 0 0
M  V30 27 C -7.0329 -7.1048 0 0
M  V30 28 C -8.5729 -7.1048 0 0
M  V30 29 C -9.0488 -5.6402 0 0 CFG=1
M  V30 30 C -10.5134 -5.1643 0 0
M  V30 31 O -10.8336 -3.658 0 0
M  V30 32 C -2.4682 1.425 0 0
M  V30 33 C -1.1345 2.195 0 0
M  V30 34 Cl -1.1345 3.735 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 26 1 11 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 29 28
M  V30 31 1 29 25
M  V30 32 1 29 30 CFG=1
M  V30 33 1 30 31
M  V30 34 2 6 32
M  V30 35 1 32 33
M  V30 36 2 3 33
M  V30 37 1 33 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802070

>  <MW>
483.179

>  <MW (desalted)>
483.951

>  <ClogP>
2.357

>  <logS>
-4.234

>  <HBD>
3

>  <HBA>
9

>  <TPSA>
125.39

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  3.1 nM

>  <CAS>
330784-47-9

>  <Description>
Avanafil is a potent and highly selective phosphodiesterase-5 (PDE-5) inhibitor. It is used to treat erectile dysfunction

>  <EBC_ID>
EBC-03919

>  <IUPAC Name>
4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-[(pyrimidin-2-yl)methyl]pyrimidine-5-carboxamide

>  <Main Tar all refs>
SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. - US2016/46654, 2016, A1

>  <Main tar all>
phosphodiesterase 5A pX=8.51

$$$$
Empagliflozin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -6.8676 1.965 0 0
M  V30 2 C -6.8676 3.505 0 0
M  V30 3 C -5.5339 4.275 0 0 CFG=1
M  V30 4 O -5.5339 5.815 0 0
M  V30 5 C -4.2002 6.585 0 0 CFG=2
M  V30 6 C -2.8665 5.815 0 0 CFG=2
M  V30 7 O -1.5329 6.585 0 0
M  V30 8 C -2.8665 4.275 0 0 CFG=1
M  V30 9 O -1.5329 3.505 0 0
M  V30 10 C -4.2002 3.505 0 0 CFG=2
M  V30 11 O -4.2002 1.965 0 0
M  V30 12 C -4.2002 8.125 0 0
M  V30 13 C -5.5339 8.895 0 0
M  V30 14 C -5.5339 10.435 0 0
M  V30 15 C -4.2002 11.205 0 0
M  V30 16 Cl -4.2002 12.745 0 0
M  V30 17 C -2.8665 10.435 0 0
M  V30 18 C -1.5329 11.205 0 0
M  V30 19 C -0.1992 10.435 0 0
M  V30 20 C 1.1345 11.205 0 0
M  V30 21 C 2.4682 10.435 0 0
M  V30 22 C 2.4682 8.895 0 0
M  V30 23 O 3.8019 8.125 0 0
M  V30 24 C 3.8019 6.585 0 0 CFG=1
M  V30 25 C 5.0477 5.6798 0 0
M  V30 26 C 4.5719 4.2152 0 0
M  V30 27 O 3.0319 4.2152 0 0
M  V30 28 C 2.556 5.6798 0 0
M  V30 29 C 1.1345 8.125 0 0
M  V30 30 C -0.1992 8.895 0 0
M  V30 31 C -2.8665 8.895 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 3
M  V30 11 1 10 11 CFG=3
M  V30 12 1 5 12 CFG=1
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 24 23 CFG=1
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 24 28
M  V30 30 2 22 29
M  V30 31 1 29 30
M  V30 32 2 19 30
M  V30 33 1 17 31
M  V30 34 2 12 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802079

>  <MW>
450.145

>  <MW (desalted)>
450.909

>  <ClogP>
2.585

>  <logS>
-4.154

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
108.61

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3.1 nM | IC50  3.1 nM

>  <CAS>
864070-44-0

>  <Description>
Empagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus.

>  <EBC_ID>
EBC-27125

>  <IUPAC Name>
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

>  <Main Tar all refs>
SHANGPHARMA VENTURE DEVELOPMENT JIANGSU - US2013/324464, 2013, A1 | Annual Reports in Medicinal Chemistry, 2011, vol. 46, p. 103 - 115

>  <Main tar all>
Sodium/glucose cotransporter 1 pX=8.51 | Sodium/glucose cotransporter 2 pX=8.51

$$$$
Fulvestrant
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 44 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.8283 1.5316 0 0
M  V30 2 C 2.6674 0 0 0 CFG=2
M  V30 3 C 1.3337 0.77 0 0
M  V30 4 C 0 0 0 0
M  V30 5 C 0 -1.54 0 0 CFG=1
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -1.54 0 0 CFG=2
M  V30 8 C 4.132 -2.0159 0 0
M  V30 9 C 5.0372 -0.77 0 0
M  V30 10 C 4.132 0.4759 0 0 CFG=2
M  V30 11 O 4.6079 1.9405 0 0
M  V30 12 C 1.3337 -3.85 0 0 CFG=2
M  V30 13 C 2.6674 -4.62 0 0
M  V30 14 C 4.001 -3.85 0 0
M  V30 15 C 5.3347 -4.62 0 0
M  V30 16 C 6.6684 -3.85 0 0
M  V30 17 C 8.0021 -4.62 0 0
M  V30 18 C 9.3358 -3.85 0 0
M  V30 19 C 10.6694 -4.62 0 0
M  V30 20 C 12.0031 -3.85 0 0
M  V30 21 C 13.3368 -4.62 0 0
M  V30 22 S 14.6705 -3.85 0 0
M  V30 23 O 14.6705 -2.31 0 0
M  V30 24 C 16.0041 -4.62 0 0
M  V30 25 C 17.3378 -3.85 0 0
M  V30 26 C 18.6715 -4.62 0 0
M  V30 27 C 20.0052 -3.85 0 0
M  V30 28 F 20.7752 -5.1837 0 0
M  V30 29 F 19.2352 -2.5163 0 0
M  V30 30 C 21.3389 -3.08 0 0
M  V30 31 F 22.6725 -2.31 0 0
M  V30 32 F 22.1089 -4.4137 0 0
M  V30 33 F 20.5689 -1.7463 0 0
M  V30 34 C 0 -4.62 0 0
M  V30 35 C -1.3337 -3.85 0 0
M  V30 36 C -2.6674 -4.62 0 0
M  V30 37 C -4.001 -3.85 0 0
M  V30 38 O -5.3347 -4.62 0 0
M  V30 39 C -4.001 -2.31 0 0
M  V30 40 C -2.6674 -1.54 0 0
M  V30 41 C -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 2 7
M  V30 8 1 7 8 CFG=1
M  V30 9 1 8 9
M  V30 10 1 10 9
M  V30 11 1 2 10
M  V30 12 1 10 11 CFG=1
M  V30 13 1 12 6
M  V30 14 1 12 13 CFG=3
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 1 27 30
M  V30 32 1 30 31
M  V30 33 1 30 32
M  V30 34 1 30 33
M  V30 35 1 12 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 1 37 39
M  V30 41 2 39 40
M  V30 42 1 40 41
M  V30 43 1 5 41
M  V30 44 2 35 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038967

>  <MW>
606.771

>  <MW (desalted)>
606.771

>  <ClogP>
7.35

>  <logS>
-9.268

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
57.53

>  <RotBonds>
15

>  <Action on targets>
Antagonist | Inhibitor

>  <Activity coefficients and valu>
GI50 increase Active   | IC50  0.003 nM

>  <CAS>
129453-61-8

>  <Description>
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

>  <EBC_ID>
EBC-46052

>  <IUPAC Name>
(1S,3aS,4R,9bS,11aS)-11a-methyl-4-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl]-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol

>  <Main Tar all refs>
Breast Cancer Res. Treat., 2020, vol. 180, # 3, p. 635 - 646 | ACS Chem. Biol., 2017, vol. 12, # 2, p. 494 - 503

>  <Main tar all>
nuclear estrogen receptor pX=12.0 | Estrogen receptor pX=11.5

$$$$
Cysteamine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 N 7.37 -0.6668 0 0
M  V30 3 C 5.83 -0.6668 0 0
M  V30 4 C 5.06 0.6668 0 0
M  V30 5 S 3.52 0.6668 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474494

>  <MW>
113.007

>  <MW (desalted)>
77.149

>  <ClogP>
-0.252

>  <logS>
-0.563

>  <HBD>
2

>  <HBA>
1

>  <TPSA>
26.02

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter) = 8 ?M | Ki (inhibition constant) = 15 ?M | Ki (inhibition constant) = 15 ?M | IC50  38 ?M | IC50  40 ?M | inhibition rate Active   | inhibition rate Active   | IC50  60 ?M | IC50  91 ?M | Ki (inhibition constant) = 0.15 mM | IC50  200 ?M | IC50  240 ?M

>  <CAS>
156-57-0

>  <Description>
Cysteamine is a cystine depleting agent used to treat the effects of cystinosis.

>  <EBC_ID>
EBC-02074

>  <IUPAC Name>
2-aminoethane-1-thiol hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1975, vol. 18, # 4, p. 323 - 331 | Bioorg. Med. Chem., 2006, vol. 14, # 19, p. 6737 - 6744 | Chem. Biol. Drug Des., 2012, vol. 80, # 6, p. 937 - 946 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | UNIVERSITY OF KENTUCKY - WO2021/41942, 2021, A1 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1 | Biochem. Pharmacol., 2005, vol. 69, # 6, p. 961 - 970 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1 | MESHABERASE; MESHABERASE LLC; GOVERNMENT OF THE UNITED STATES - US2014/314841, 2014, A1

>  <Main tar all>
DNA pX=5.1 | Urease (gene URE) pX=4.82 | glutaminyl-peptide cyclotransferase pX=4.82 | MMP2 pX=4.42 | MMP7 pX=4.4 | Prolyl 4-hydroxylase subunit alpha-1 pX=4.3 | Protein disulfide-isomerase pX=4.3 | MMP12 pX=4.22 | MMP14 pX=4.04 | Protein-glutamine gamma-glutamyltransferase 2 pX=3.82 | MMP9 pX=3.7 | MMP8 pX=3.62

$$$$
Mesalamine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 3.85 0 0
M  V30 2 C 1.3337 2.31 0 0
M  V30 3 C 2.6674 1.54 0 0
M  V30 4 C 2.6674 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 O 1.3337 -2.31 0 0
M  V30 7 C 0 0 0 0
M  V30 8 C 0 1.54 0 0
M  V30 9 C -1.3337 -0.77 0 0
M  V30 10 O -2.6674 0 0 0
M  V30 11 O -1.3337 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 2 2 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127471

>  <MW>
153.043

>  <MW (desalted)>
153.135

>  <ClogP>
1.056

>  <logS>
-0.95

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
83.55

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.28 ?M | IC50 = 370 nM | IC50  0.49 ?M | IC50  0.49 ?M | EC50  1.7 ?M | EC50  1.7 ?M | IC50  7.53 ?M | IC50  7.8 ?M | IC50  7.8 ?M

>  <CAS>
89-57-6

>  <Description>
Mesalazine is an anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel diseaseis.It is used to treat mild to moderate active ulcerative colitis and also to maintain remission once achieved.

>  <EBC_ID>
EBC-00537

>  <IUPAC Name>
5-amino-2-hydroxybenzoic acid

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | Nat. Chem. Biol., 2011, vol. 7, # 6, p. 375 - 383 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | Bioorg. Med. Chem. Lett., 2019, vol. 29, # 9, p. 1106 - 1112 | CORNING INC - US2013/316985, 2013, A1 | CORNING INC - US2013/316985, 2013, A1 | Eur. J. Med. Chem., 2019, vol. 180, p. 86 - 98 | J. Med. Chem., 2018, vol. 61, # 16, p. 7144 - 7167 | J. Med. Chem., 2018, vol. 61, # 16, p. 7144 - 7167

>  <Main tar all>
thiosulfate sulfurtransferase pX=6.55 | sepiapterin reductase pX=6.43 | 10 kDa chaperonin 1 pX=6.31 | 60 kDa chaperonin pX=6.31 | GPR35 pX=5.77 | Beta-arrestin-2 pX=5.77 | COX-1  pX=5.12 | 2-Hydroxyacid oxidase 1 pX=5.11 | glycolate oxidase pX=5.11

$$$$
Saccharin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.6497 -4.0133 0 0
M  V30 2 C 2.1256 -2.5487 0 0
M  V30 3 N 1.2204 -1.3028 0 0
M  V30 4 S 2.1256 -0.0569 0 0
M  V30 5 O 0.7919 0.7131 0 0
M  V30 6 O 2.752 1.3499 0 0
M  V30 7 C 3.5902 -0.5328 0 0
M  V30 8 C 4.9239 0.2372 0 0
M  V30 9 C 6.2576 -0.5328 0 0
M  V30 10 C 6.2576 -2.0728 0 0
M  V30 11 C 4.9239 -2.8428 0 0
M  V30 12 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 2 12
M  V30 13 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z256708526

>  <MW>
182.999

>  <MW (desalted)>
183.185

>  <ClogP>
0.718

>  <logS>
-1.77

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.24

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 3.599 nM | Ki (inhibition constant)  10 nM | Ki (inhibition constant)  0.091 ?M | Ki (inhibition constant)  100 nM | Ki (inhibition constant) = 104 nM

>  <CAS>
81-07-2

>  <Description>
Saccharin is a non-nutritive artificial sweetener for sweetening foods and drinks. Saccharin has bacteriostatic and microbiome-modulating properties. It has been investigated for the treatment of Hypertension and Hyperglycemia.

>  <EBC_ID>
EBC-03311

>  <IUPAC Name>
2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione

>  <Main Tar all refs>
Bioorg. Med. Chem., 2013, vol. 21, # 6, p. 1495 - 1502 | Angew. Chem. Int. Ed., 2007, vol. 46, # 40, p. 7697 - 7699 | J. Enzyme Inhib. Med. Chem., 2023, vol. 38, # 1 | Bioorg. Med. Chem., 2015, vol. 23, # 4, p. 849 - 854 | Bioorg. Med. Chem. Lett., 2011, vol. 21, # 2, p. 710 - 714

>  <Main tar all>
carbonic anhydrase pX=8.44 | carbonic anhydrase 7 pX=8.0 | ?-carbonic anhydrase pX=7.04 | carbonic anhydrase 9 pX=7.0 | carbonic anhydrase 2 pX=6.98

$$$$
Mexiletine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 4.0277 0 0
M  V30 3 C 5.7337 3.2577 0 0
M  V30 4 N 7.0674 4.0277 0 0
M  V30 5 C 5.7337 1.7177 0 0
M  V30 6 O 7.0674 0.9477 0 0
M  V30 7 C 7.0674 -0.5923 0 0
M  V30 8 C 8.401 -1.3623 0 0
M  V30 9 C 9.7347 -0.5923 0 0
M  V30 10 C 8.401 -2.9023 0 0
M  V30 11 C 7.0674 -3.6723 0 0
M  V30 12 C 5.7337 -2.9023 0 0
M  V30 13 C 5.7337 -1.3623 0 0
M  V30 14 C 4.4 -0.5923 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 8 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 7 13
M  V30 13 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2237335016

>  <MW>
215.108

>  <MW (desalted)>
179.259

>  <ClogP>
2.569

>  <logS>
-2.899

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
35.25

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.28 nM

>  <CAS>
5370-01-4

>  <Description>
Mexiletine is a class 1B antiarrhythmic agent used in the treatment of ventricular arrhythmias.

>  <EBC_ID>
EBC-28041

>  <IUPAC Name>
1-(2,6-dimethylphenoxy)propan-2-amine hydrochloride

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 1999, vol. 289, # 2, p. 853 - 858

>  <Main tar all>
7-Methoxycoumarin-O-Demethylase pX=9.55

$$$$
Riluzole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.3196 -1.3028 0 0
M  V30 2 C 1.2204 -1.3028 0 0
M  V30 3 N 2.1256 -0.0569 0 0
M  V30 4 C 3.5902 -0.5328 0 0
M  V30 5 C 4.9239 0.2372 0 0
M  V30 6 C 6.2576 -0.5328 0 0
M  V30 7 C 6.2576 -2.0728 0 0
M  V30 8 O 7.5913 -2.8428 0 0
M  V30 9 C 8.925 -2.0728 0 0
M  V30 10 F 10.2586 -1.3028 0 0
M  V30 11 F 9.695 -3.4065 0 0
M  V30 12 F 8.155 -0.7391 0 0
M  V30 13 C 4.9239 -2.8428 0 0
M  V30 14 C 3.5902 -2.0728 0 0
M  V30 15 S 2.1256 -2.5487 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 12 2 7 13
M  V30 13 1 13 14
M  V30 14 2 4 14
M  V30 15 1 14 15
M  V30 16 1 2 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z164707762

>  <MW>
234.007

>  <MW (desalted)>
234.198

>  <ClogP>
3.235

>  <logS>
-4.01

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
48.14

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Blocker | Activator | Inhibitor | - | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Activator | Blocker | Activator | Activator | Activator | -

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.2 ?M | Ki (inhibition constant) = 0.2 ?M | IC50 = 0.27 ?M | Kd (dissociation constant)  662 nM | Ki (inhibition constant)  1.2 ?M | IC50  1.2 ?M | inhibition percentage  100 % | EC50  1.9 ?M | inhibition rate Active   | EC50 = 2 ?M | inhibition rate Active   | IC50 = 2.2 ?M | IC50  2.8 ?M | IC50 = 4 ?M | Ki (inhibition constant) = 4 ?M | IC50  4.73 ?M | percentage of viable cells decrease Active   | stimulation rate  200 % | IC50  5.3 ?M | IC50 ~ 6 ?M | IC50 ~ 6 ?M | EC50  6.2 ?M | Km (Michaelis constant)  6.24 ?M

>  <CAS>
1744-22-5

>  <Description>
Riluzole is a glutamate antagonist. It is used as an anticonvulsant and to prolong the survival of patients with amyotrophic lateral sclerosis.

>  <EBC_ID>
EBC-11108

>  <IUPAC Name>
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine

>  <Main Tar all refs>
Biochem. Pharmacol., 2006, vol. 72, # 6, p. 770 - 782 | Biochem. Pharmacol., 2006, vol. 72, # 6, p. 770 - 782 | Biochem. Pharmacol., 2006, vol. 72, # 6, p. 770 - 782 | Int. J. Mol. Sci., 2020, vol. 21, # 1 | J. Pharmacol. Exp. Ther., 2006, vol. 319, # 1, p. 323 - 331 | Toxicol. Lett., 2023, vol. 373, p. 53 - 61 | Life Sci., 2008, vol. 82, # 1-2, p. 11 - 20 | Mol. Pharmacol., 2009, vol. 75, # 2, p. 281 - 295 | Int. J. Mol. Sci., 2020, vol. 21, # 1 | Curr. Med. Chem., 2007, vol. 14, # 13, p. 1437 - 1457 | Int. J. Mol. Sci., 2020, vol. 21, # 1 | Bioorg. Med. Chem. Lett., 1995, vol. 5, # 19, p. 2259 - 2262 | Bioorg. Chem., 2021, vol. 109 | J. Med. Chem., 2001, vol. 44, # 2, p. 115 - 137 | Annual Reports in Medicinal Chemistry, 2011, vol. 46, p. 385 - 401 | J. Med. Chem., 1998, vol. 41, # 17, p. 3298 - 3302 | Oncogenesis, 2018, vol. 7, # 11 | Mol. Pharmacol., 2009, vol. 75, # 2, p. 281 - 295 | Br. J. Pharmacol., 2022, vol. 179, # 3, p. 473 - 486 | Eur. J. Pharmacol., 2002, vol. 449, # 1-2, p. 47 - 54 | Eur. J. Pharmacol., 2002, vol. 449, # 1-2, p. 47 - 54 | Br. J. Pharmacol., 2014, vol. 171, # 1, p. 158 - 170 | J. PHARMACOL. EXP. THER., 1997, vol. 282, # 3, p. 1465 - 1472

>  <Main tar all>
Nav?1 pX=6.7 | Nav1.7 pX=6.7 | Cav2.2 pX=6.57 | Heterogeneous nuclear ribonucleoprotein A1 pX=6.18 | Kv4.3 pX=5.92 | Voltage-gated?sodium?channel pX=5.92 | Nav1.5 pX=5.8 | KCa3.1 pX=5.72 | G1/S-specific cyclin-D1-internal ribosomal entry site (IRES) pX=5.7 | KCa2.1 pX=5.7 | Transcriptional regulator Myc-1 internal ribosome entry site (IRES) pX=5.7 | Sodium Channel, Voltage-Gated, Type II pX=5.66 | mGlu1 receptor pX=5.55 | Nav1.7 pX=5.4 | Pteridine reductase 1 pX=5.4 | Voltage-gated sodium channel, TTX-Sensitive pX=5.33 | Cystine/glutamate transporter pX=5.3 | KCa1.1 pX=5.28 | Sodium channel protein type 5 subunit alpha (isoform 4) pX=5.28 | KCa2 pX=5.22 | KCa2 pX=5.22 | TRPC5 pX=5.21 | CYP1A1 pX=5.2

$$$$
Methyldopa
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.4374 3.2863 0 0
M  V30 2 C 2.6674 4.62 0 0 CFG=2
M  V30 3 N 1.8974 5.9537 0 0
M  V30 4 C 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0
M  V30 11 O -1.3337 -0.77 0 0
M  V30 12 C 0 1.54 0 0
M  V30 13 C 4.001 5.39 0 0
M  V30 14 O 4.001 6.93 0 0
M  V30 15 O 5.3347 4.62 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 5 12
M  V30 13 1 2 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1508915075

>  <MW>
211.084

>  <MW (desalted)>
211.215

>  <ClogP>
-2.264

>  <logS>
-0.81

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
103.78

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
decrease rate Active   | IC50 = 0.9 nM

>  <CAS>
555-30-6

>  <Description>
Methyldopa is a centrally-acting alpha-2 adrenergic agonist. It is used to manage hypertension alone or in combination with hydrochlorothiazide, and to treat hypertensive crises.

>  <EBC_ID>
EBC-03598

>  <IUPAC Name>
(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid

>  <Main Tar all refs>
NATIONWIDE CHILDREN'S HOSPITAL INC - WO2020/61649, 2020, A1 | J. Med. Chem., 1967, vol. 10, # 5, p. 852 - 855

>  <Main tar all>
integrin, alpha M subunit (complement component 3 receptor 3 subunit) pX=10.0 | L-Aromatic amino-acid decarboxylase  pX=9.05

$$$$
Minoxidil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 N 1.3337 -5.39 0 0
M  V30 6 C 0 -4.62 0 0
M  V30 7 N -1.3337 -5.39 0 0
M  V30 8 N 0 -3.08 0 0 CHG=1
M  V30 9 O -1.3337 -2.31 0 0 CHG=-1
M  V30 10 N 4.001 -5.39 0 0
M  V30 11 C 5.3347 -4.62 0 0
M  V30 12 C 6.6684 -5.39 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 14 C 5.3347 -7.7 0 0
M  V30 15 C 4.001 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541638524

>  <MW>
209.128

>  <MW (desalted)>
209.248

>  <ClogP>
0.021

>  <logS>
-2.61

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
95.11

>  <RotBonds>
1

>  <Action on targets>
Opener

>  <Activity coefficients and valu>
inhibition percentage  25 %

>  <CAS>
38304-91-5

>  <Description>
Minoxidil is an antihypertensive vasodilating agent used for resistant hypertension that is symptomatic or has caused end organ damage. Minoxidil is an ATP-sensitive potassium channel opener. It is also a potent inhibitor of soybean lipoxygenaseare.

>  <EBC_ID>
EBC-06508

>  <IUPAC Name>
2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate

>  <Main Tar all refs>
L'OREAL SA - US6057351, 2000, A

>  <Main tar all>
KNa1.1 pX=6.52

$$$$
Diatrizoic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 O -1.3337 3.85 0 0
M  V30 4 N 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 I 4.001 2.31 0 0
M  V30 8 C 2.6674 -0 0 0
M  V30 9 N 4.001 -0.77 0 0
M  V30 10 C 4.001 -2.31 0 0
M  V30 11 O 5.3347 -3.08 0 0
M  V30 12 C 2.6674 -3.08 0 0
M  V30 13 C 1.3337 -0.77 0 0
M  V30 14 I 1.3337 -2.31 0 0
M  V30 15 C 0 0 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 17 O -2.6674 0 0 0
M  V30 18 O -1.3337 -2.31 0 0
M  V30 19 C 0 1.54 0 0
M  V30 20 I -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 8 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 15 19
M  V30 19 2 5 19
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56886396

>  <MW>
613.77

>  <MW (desalted)>
613.914

>  <ClogP>
0.76

>  <logS>
-4.06

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
95.5

>  <RotBonds>
3

>  <CAS>
117-96-4

>  <Description>
Diatrizoate is an injected contrast agent used in radiology, it is used for gastrointestinal studies, angiography, and urography.

>  <EBC_ID>
EBC-12608

>  <IUPAC Name>
3,5-diacetamido-2,4,6-triiodobenzoic acid

$$$$
Promazine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 1.2705 0 0
M  V30 3 N 5.7337 0.5005 0 0
M  V30 4 C 5.7337 -1.0395 0 0
M  V30 5 C 7.0674 1.2705 0 0
M  V30 6 C 8.401 0.5005 0 0
M  V30 7 C 9.7347 1.2705 0 0
M  V30 8 N 11.0684 0.5005 0 0
M  V30 9 C 12.4021 1.2705 0 0
M  V30 10 C 12.4021 2.8105 0 0
M  V30 11 C 13.7358 3.5805 0 0
M  V30 12 C 15.0694 2.8105 0 0
M  V30 13 C 15.0694 1.2705 0 0
M  V30 14 C 13.7358 0.5005 0 0
M  V30 15 S 13.7358 -1.0395 0 0
M  V30 16 C 12.4021 -1.8095 0 0
M  V30 17 C 12.4021 -3.3495 0 0
M  V30 18 C 11.0684 -4.1195 0 0
M  V30 19 C 9.7347 -3.3495 0 0
M  V30 20 C 9.7347 -1.8095 0 0
M  V30 21 C 11.0684 -1.0395 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 8 21
M  V30 22 2 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1592690521

>  <MW>
320.111

>  <MW (desalted)>
284.419

>  <ClogP>
4.399

>  <logS>
-4.685

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
6.48

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Antagonist | Blocker

>  <Activity coefficients and valu>
Ki (inhibition constant)  71.6 nM | pIC50  6.6  | inhibition percentage  88 % | inhibition percentage  88.1 %

>  <CAS>
53-60-1

>  <Description>
Promazine is an antagonist at D2 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors with antipsychotic effects. It belongs to the phenothiazine class of antipsychotics, used to treat schizophrenia.

>  <EBC_ID>
EBC-08266

>  <IUPAC Name>
dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine hydrochloride

>  <Main Tar all refs>
Mol. Pharmacol., 1985, vol. 28, # 5, p. 391 - 399 | BIOCHEM. PHARMACOL., 1978, vol. 27, # 3, p. 307 - 316 | PURDUE UNIVERSITY SYSTEM - WO2013/67519, 2013, A3 | Pharm. Res., 2019, vol. 36, # 9

>  <Main tar all>
D2L receptor pX=7.15 | Dopamine receptor pX=6.6 | D2 receptor pX=5.87 | Nav1.8 pX=5.87

$$$$
Venetoclax
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 61 68 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 15.7763 -6.8998 0 0
M  V30 2 C 14.2597 -7.1672 0 0
M  V30 3 C 14.7864 -8.6143 0 0
M  V30 4 C 14.2597 -5.6272 0 0
M  V30 5 C 12.926 -4.8572 0 0
M  V30 6 C 11.5923 -5.6272 0 0
M  V30 7 C 11.5923 -7.1672 0 0
M  V30 8 C 12.926 -7.9372 0 0
M  V30 9 C 10.2586 -7.9372 0 0
M  V30 10 C 10.2586 -9.4772 0 0
M  V30 11 C 8.925 -10.2472 0 0
M  V30 12 C 7.5913 -9.4772 0 0
M  V30 13 Cl 6.2576 -10.2472 0 0
M  V30 14 C 7.5913 -7.9372 0 0
M  V30 15 C 8.925 -7.1672 0 0
M  V30 16 C 10.2586 -4.8572 0 0
M  V30 17 N 10.2586 -3.3172 0 0
M  V30 18 C 8.925 -2.5472 0 0
M  V30 19 C 8.925 -1.0072 0 0
M  V30 20 N 10.2586 -0.2372 0 0
M  V30 21 C 11.5923 -1.0072 0 0
M  V30 22 C 11.5923 -2.5472 0 0
M  V30 23 C 10.2586 1.3028 0 0
M  V30 24 C 11.5923 2.0728 0 0
M  V30 25 C 11.5923 3.6128 0 0
M  V30 26 C 10.2586 4.3828 0 0
M  V30 27 C 10.2586 5.9228 0 0
M  V30 28 O 8.925 6.6928 0 0
M  V30 29 N 11.5923 6.6928 0 0
M  V30 30 S 11.5923 8.2328 0 0
M  V30 31 O 13.1323 8.2328 0 0
M  V30 32 O 10.0523 8.2328 0 0
M  V30 33 C 11.5923 9.7728 0 0
M  V30 34 C 12.926 10.5428 0 0
M  V30 35 C 12.926 12.0828 0 0
M  V30 36 C 11.5923 12.8528 0 0
M  V30 37 N 11.5923 14.3928 0 0
M  V30 38 C 10.2586 15.1628 0 0
M  V30 39 C 10.2586 16.7028 0 0
M  V30 40 C 8.925 17.4728 0 0
M  V30 41 C 8.925 19.0128 0 0
M  V30 42 O 10.2586 19.7828 0 0
M  V30 43 C 11.5923 19.0128 0 0
M  V30 44 C 11.5923 17.4728 0 0
M  V30 45 C 10.2586 12.0828 0 0
M  V30 46 C 10.2586 10.5428 0 0
M  V30 47 N 8.925 12.8528 0 0 CHG=1
M  V30 48 O 8.925 14.3928 0 0
M  V30 49 O 7.5913 12.0828 0 0 CHG=-1
M  V30 50 C 8.925 3.6128 0 0
M  V30 51 O 7.5913 4.3828 0 0
M  V30 52 C 6.2576 3.6128 0 0
M  V30 53 C 6.2576 2.0728 0 0
M  V30 54 N 4.9239 1.3028 0 0
M  V30 55 C 3.5902 2.0728 0 0
M  V30 56 N 2.1256 1.5969 0 0
M  V30 57 C 1.2204 2.8428 0 0
M  V30 58 C 2.1256 4.0887 0 0
M  V30 59 C 3.5902 3.6128 0 0
M  V30 60 C 4.9239 4.3828 0 0
M  V30 61 C 8.925 2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 14 15
M  V30 16 2 9 15
M  V30 17 1 6 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 17 22
M  V30 25 1 20 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 2 30 32
M  V30 35 1 30 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 1 40 41
M  V30 44 1 41 42
M  V30 45 1 42 43
M  V30 46 1 43 44
M  V30 47 1 39 44
M  V30 48 2 36 45
M  V30 49 1 45 46
M  V30 50 2 33 46
M  V30 51 1 45 47
M  V30 52 2 47 48
M  V30 53 1 47 49
M  V30 54 2 26 50
M  V30 55 1 50 51
M  V30 56 1 51 52
M  V30 57 1 52 53
M  V30 58 2 53 54
M  V30 59 1 54 55
M  V30 60 1 55 56
M  V30 61 1 56 57
M  V30 62 2 57 58
M  V30 63 1 58 59
M  V30 64 2 55 59
M  V30 65 1 59 60
M  V30 66 2 52 60
M  V30 67 1 50 61
M  V30 68 2 23 61
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2037279542

>  <MW>
868.439

>  <MW (desalted)>
868.439

>  <ClogP>
10.312

>  <logS>
-9.607

>  <HBD>
3

>  <HBA>
10

>  <TPSA>
172.03

>  <RotBonds>
12

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
decrease rate of viability Active   | decrease rate of viability Active   | decrease rate of viability Active   | Ki (inhibition constant) < 1E-05 ?M | IC50  5.2E-11 M | binding rate Active

>  <CAS>
1257044-40-8

>  <Description>
Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia.

>  <EBC_ID>
EBC-17182

>  <IUPAC Name>
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide

>  <Main Tar all refs>
SYROS PHARMACEUTICALS INC - WO2018/231859, 2018, A1 | SYROS PHARMACEUTICALS INC - WO2018/231859, 2018, A1 | SYROS PHARMACEUTICALS INC - WO2018/231859, 2018, A1 | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH; ROCHE HOLDING AG; ABBVIE INC - US2010/305122, 2010, A1 | MERRIMACK PHARMACEUTICALS INC - WO2017/123616, 2017, A1 | Antiviral Res., 2022, vol. 207

>  <Main tar all>
Apoptosis regulator Bcl-2 pX=11.2 | apoptosis regulator bcl-2 pX=11.2 | cyclin dependent kinase 7 pX=11.2 | Apoptosis regulator, Bcl-2 pX=11.0 | Bcl-2 homologous antagonist/killer pX=10.3 | PreS2-LHBS pX=9.91

$$$$
Drotaverine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -5.7352 0 0
M  V30 3 C 5.7337 -4.9652 0 0
M  V30 4 O 5.7337 -3.4252 0 0
M  V30 5 C 7.0674 -2.6552 0 0
M  V30 6 C 7.0674 -1.1152 0 0
M  V30 7 C 8.401 -0.3452 0 0
M  V30 8 C 9.7347 -1.1152 0 0
M  V30 9 C 11.0684 -0.3452 0 0
M  V30 10 C 11.0684 1.1948 0 0
M  V30 11 N 9.7347 1.9648 0 0
M  V30 12 C 9.7347 3.5048 0 0
M  V30 13 C 11.0684 4.2748 0 0
M  V30 14 C 12.4021 3.5048 0 0
M  V30 15 C 13.7358 4.2748 0 0
M  V30 16 C 15.0694 3.5048 0 0
M  V30 17 O 16.4031 4.2748 0 0
M  V30 18 C 17.7368 3.5048 0 0
M  V30 19 C 19.0705 4.2748 0 0
M  V30 20 C 15.0694 1.9648 0 0
M  V30 21 O 16.4031 1.1948 0 0
M  V30 22 C 17.7368 1.9648 0 0
M  V30 23 C 19.0705 1.1948 0 0
M  V30 24 C 13.7358 1.1948 0 0
M  V30 25 C 12.4021 1.9648 0 0
M  V30 26 C 9.7347 -2.6552 0 0
M  V30 27 C 8.401 -3.4252 0 0
M  V30 28 O 8.401 -4.9652 0 0
M  V30 29 C 9.7347 -5.7352 0 0
M  V30 30 C 9.7347 -7.2752 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 16 20
M  V30 19 1 20 21
M  V30 20 1 21 22
M  V30 21 1 22 23
M  V30 22 2 20 24
M  V30 23 1 24 25
M  V30 24 1 10 25
M  V30 25 2 14 25
M  V30 26 2 8 26
M  V30 27 1 26 27
M  V30 28 2 5 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56896159

>  <MW>
433.968

>  <MW (desalted)>
397.507

>  <ClogP>
5.28

>  <logS>
-5.03

>  <HBD>
0

>  <HBA>
5

>  <TPSA>
49.28

>  <RotBonds>
10

>  <CAS>
985-12-6

>  <Description>
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4. It is used to alleviate gastrointestinal and genitourinary smooth muscle spasms.

>  <EBC_ID>
EBC-15030

>  <IUPAC Name>
1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxy-3,4-dihydroisoquinoline hydrochloride

$$$$
Oxyphenonium bromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0 CHG=-1
M  V30 2 C 4.6063 7.0449 0 0
M  V30 3 C 5.94 6.2749 0 0
M  V30 4 N 5.94 4.7349 0 0 CHG=1
M  V30 5 C 4.4 4.7349 0 0
M  V30 6 C 7.48 4.7349 0 0
M  V30 7 C 8.25 3.4013 0 0
M  V30 8 C 5.94 3.1949 0 0
M  V30 9 C 7.2737 2.4249 0 0
M  V30 10 O 7.2737 0.8849 0 0
M  V30 11 C 8.6074 0.1149 0 0
M  V30 12 O 9.941 0.8849 0 0
M  V30 13 C 8.6074 -1.4251 0 0
M  V30 14 O 7.0674 -1.4251 0 0
M  V30 15 C 8.6074 -2.9651 0 0
M  V30 16 C 9.941 -3.7351 0 0
M  V30 17 C 9.941 -5.2751 0 0
M  V30 18 C 8.6074 -6.0451 0 0
M  V30 19 C 7.2737 -5.2751 0 0
M  V30 20 C 7.2737 -3.7351 0 0
M  V30 21 C 10.1474 -1.4251 0 0
M  V30 22 C 10.9174 -0.0914 0 0
M  V30 23 C 12.4574 -0.0914 0 0
M  V30 24 C 13.2274 -1.4251 0 0
M  V30 25 C 12.4574 -2.7587 0 0
M  V30 26 C 10.9174 -2.7587 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 4 6
M  V30 5 1 6 7
M  V30 6 1 4 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 11 13
M  V30 12 1 13 14
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 1 19 20
M  V30 19 1 15 20
M  V30 20 1 13 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1544404024

>  <MW>
428.404

>  <MW (desalted)>
348.5

>  <ClogP>
0.876

>  <logS>
-4.82

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
46.53

>  <RotBonds>
9

>  <Action on targets>
-

>  <Activity coefficients and valu>
pKd  9.95

>  <CAS>
50-10-2

>  <Description>
Oxyphenonium is an anticholinergic drug, a medication that reduces the effect of acetylcholine. Oxyphenonium is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome.

>  <EBC_ID>
EBC-14176

>  <IUPAC Name>
{2-[(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxy]ethyl}diethylmethylazanium bromide

>  <Main Tar all refs>
BR. J. PHARMACOL., 1987, vol. 90, # 4, p. 701 - 707

>  <Main tar all>
mAChR pX=9.95

$$$$
Penicillin G potassium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 K 6.2176 5.8611 0 0 CHG=1
M  V30 2 C 4.7786 1.4798 0 0
M  V30 3 C 3.6342 2.5103 0 0
M  V30 4 C 4.7786 3.5407 0 0
M  V30 5 S 2.729 1.2644 0 0
M  V30 6 C 1.2644 1.7403 0 0 CFG=2
M  V30 7 C -0.2756 1.7403 0 0 CFG=2
M  V30 8 N -1.3646 0.6513 0 0
M  V30 9 C -2.8521 1.0499 0 0
M  V30 10 O -3.2507 2.5374 0 0
M  V30 11 C -3.941 -0.0391 0 0
M  V30 12 C -5.4286 0.3595 0 0
M  V30 13 C -6.5175 -0.7294 0 0
M  V30 14 C -8.005 -0.3308 0 0
M  V30 15 C -8.4036 1.1567 0 0
M  V30 16 C -7.3147 2.2456 0 0
M  V30 17 C -5.8272 1.8471 0 0
M  V30 18 C -0.2756 3.2803 0 0
M  V30 19 O -1.3646 4.3692 0 0
M  V30 20 N 1.2644 3.2803 0 0
M  V30 21 C 2.729 3.7561 0 0 CFG=1
M  V30 22 C 3.2049 5.2208 0 0
M  V30 23 O 2.1744 6.3652 0 0
M  V30 24 O 4.7112 5.541 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 6 5
M  V30 5 1 6 7
M  V30 6 1 7 8 CFG=3
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 9 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 15 16
M  V30 15 1 16 17
M  V30 16 2 12 17
M  V30 17 1 7 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 6 20 CFG=3
M  V30 21 1 21 20
M  V30 22 1 21 3
M  V30 23 1 21 22 CFG=1
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z756424446

>  <MW>
372.48

>  <MW (desalted)>
334.39

>  <ClogP>
-1.069

>  <logS>
-4.93

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
89.54

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  125 ?M | Ki (inhibition constant) = 0.748 mM

>  <CAS>
113-98-4

>  <Description>
Penicillin G is a ?-lactam antibiotic that is effective mainly for Gram-positive bacteria. Penicillin G is used for the treatment of bacterial infections and in livestock production.

>  <EBC_ID>
EBC-07478

>  <IUPAC Name>
potassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

>  <Main Tar all refs>
Mol. Pharmacol., 2018, vol. 94, # 3, p. 1057 - 1068 | J. Enzyme Inhib. Med. Chem., 2002, vol. 17, # 4, p. 271 - 277

>  <Main tar all>
Organic cation/carnitine transporter 2 pX=3.9 | Glucose-6-phosphate 1-dehydrogenase pX=3.13

$$$$
Sulbactum
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.7786 1.4798 0 0
M  V30 2 C 3.6342 2.5103 0 0
M  V30 3 C 4.7786 3.5407 0 0
M  V30 4 C 2.729 1.2644 0 0 CFG=1
M  V30 5 N 1.2644 1.7403 0 0
M  V30 6 C 1.2644 3.2803 0 0 CFG=1
M  V30 7 C -0.2756 3.2803 0 0
M  V30 8 C -0.2756 1.7403 0 0
M  V30 9 O -1.3646 0.6513 0 0
M  V30 10 S 2.729 3.7561 0 0
M  V30 11 O 2.4246 5.2658 0 0
M  V30 12 O 3.8626 4.7985 0 0
M  V30 13 C 3.2049 -0.2003 0 0
M  V30 14 O 2.1744 -1.3447 0 0
M  V30 15 O 4.7112 -0.5204 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 6 10
M  V30 11 1 2 10
M  V30 12 2 10 11
M  V30 13 2 10 12
M  V30 14 1 4 13 CFG=3
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1563146038

>  <MW>
233.242

>  <MW (desalted)>
233.242

>  <ClogP>
0.314

>  <logS>
-1.69

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
91.75

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.365 nM | Ki (inhibition constant)  6.23 nM | Ki (inhibition constant)  7.59 nM | Ki (inhibition constant) = 0.01 ?M | IC50  0.011 ?M | Ki (inhibition constant)  11.1 nM

>  <CAS>
68373-14-8

>  <Description>
Sulbactam is a beta-lactamase inhibitor. It has a wide range of antibacterial activity that includes Gram-positive and Gram-negative aerobic and anaerobic bacteria. It is an antibiotic combined with other antibiotics to treat a variety of susceptible bacterial infections.

>  <EBC_ID>
EBC-07481

>  <IUPAC Name>
(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2017, vol. 61, # 7 | Antimicrob. Agents Chemother., 2015, vol. 59, # 10, p. 5976 - 5983 | Antimicrob. Agents Chemother., 2015, vol. 59, # 10, p. 5976 - 5983 | Antimicrob. Agents Chemother., 1999, vol. 43, # 7, p. 1644 - 1650 | PFIZER INC - WO2004/108733, 2004, A1 | Antimicrob. Agents Chemother., 2015, vol. 59, # 10, p. 5976 - 5983

>  <Main tar all>
Beta-lactamase CTX-M-64 pX=9.44 | Beta-lactamase CTX-M-15 pX=8.21 | Beta-lactamase CTX-M-55 pX=8.12 | Beta-lactamase TEM pX=8.0 | Beta-lactamase pX=7.96 | Beta-lactamase CTX-M-123 pX=7.95

$$$$
Trilostane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.0693 3.24 0 0
M  V30 2 C 7.3975 1.8543 0 0 CFG=2
M  V30 3 C 6.4048 3.0316 0 0
M  V30 4 C 4.8888 2.7605 0 0
M  V30 5 C 4.3656 1.3121 0 0 CFG=1
M  V30 6 C 5.3583 0.1348 0 0 CFG=1
M  V30 7 C 4.8351 -1.3136 0 0
M  V30 8 C 3.3191 -1.5846 0 0
M  V30 9 C 2.3264 -0.4073 0 0 CFG=1
M  V30 10 O 1.8032 -1.8557 0 0
M  V30 11 C 0.8105 -0.6784 0 0 CFG=2
M  V30 12 C -0.1823 0.4989 0 0
M  V30 13 C 0.3409 1.9473 0 0
M  V30 14 C 1.8569 2.2184 0 0
M  V30 15 C 2.8496 1.0411 0 0 CFG=2
M  V30 16 C 3.3729 2.4895 0 0
M  V30 17 C -0.6518 3.1246 0 0
M  V30 18 N -1.6445 4.302 0 0
M  V30 19 O -1.6982 0.2279 0 0
M  V30 20 C 6.8743 0.4059 0 0 CFG=2
M  V30 21 C 8.0901 -0.5393 0 0
M  V30 22 C 9.3647 0.3249 0 0
M  V30 23 C 8.9367 1.8042 0 0 CFG=2
M  V30 24 O 9.8819 3.0201 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 10 CFG=3
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 15 14
M  V30 16 1 5 15
M  V30 17 1 15 9
M  V30 18 1 15 16 CFG=1
M  V30 19 1 13 17
M  V30 20 3 17 18
M  V30 21 1 12 19
M  V30 22 1 20 6
M  V30 23 1 2 20
M  V30 24 1 20 21 CFG=1
M  V30 25 1 21 22
M  V30 26 1 23 22
M  V30 27 1 2 23
M  V30 28 1 23 24 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759903

>  <MW>
329.433

>  <MW (desalted)>
329.433

>  <ClogP>
2.335

>  <logS>
-3.04

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
76.78

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.026 ?M | IC50  0.042 ?M

>  <CAS>
13647-35-3

>  <Description>
Trilostane is a synthetic steroid, which interferes with the formation of both cortisol and aldosterone. It is an inhibitor of 3 beta-hydroxysteroid dehydrogenase. It is used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.

>  <EBC_ID>
EBC-11126

>  <IUPAC Name>
(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile

>  <Main Tar all refs>
J. Ethnopharmacol., 2023, vol. 305 | J. Ethnopharmacol., 2023, vol. 305

>  <Main tar all>
3beta-hydroxysteroid dehydrogenase 4 pX=7.59 | 3-beta-Hydroxysteroid dehydrogenase 1 pX=7.38

$$$$
Deoxycholic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.3626 -7.2893 0 0
M  V30 2 C 4.7822 -5.8629 0 0 CFG=2
M  V30 3 C 3.2567 -5.6522 0 0
M  V30 4 C 2.3115 -6.868 0 0
M  V30 5 C 0.786 -6.6574 0 0
M  V30 6 O -0.1592 -7.8732 0 0
M  V30 7 O 0.2057 -5.2309 0 0
M  V30 8 C 5.7274 -4.6471 0 0 CFG=1
M  V30 9 C 5.2994 -3.1677 0 0
M  V30 10 C 6.574 -2.3035 0 0
M  V30 11 C 7.7898 -3.2487 0 0 CFG=1
M  V30 12 C 9.3058 -2.9776 0 0 CFG=2
M  V30 13 C 9.829 -1.5293 0 0
M  V30 14 C 11.345 -1.2582 0 0
M  V30 15 C 12.3377 -2.4355 0 0 CFG=2
M  V30 16 C 13.8537 -2.1644 0 0
M  V30 17 C 14.8464 -3.3418 0 0 CFG=2
M  V30 18 O 16.3624 -3.0707 0 0
M  V30 19 C 14.3232 -4.7901 0 0
M  V30 20 C 12.8072 -5.0612 0 0
M  V30 21 C 11.8145 -3.8839 0 0 CFG=1
M  V30 22 C 11.2913 -5.3323 0 0
M  V30 23 C 10.2985 -4.155 0 0 CFG=1
M  V30 24 C 9.7753 -5.6034 0 0
M  V30 25 C 8.2593 -5.8744 0 0 CFG=2
M  V30 26 O 7.7361 -7.3228 0 0
M  V30 27 C 7.2666 -4.6971 0 0 CFG=2
M  V30 28 C 6.5949 -6.0829 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 2 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13 CFG=3
M  V30 13 1 13 14
M  V30 14 1 15 14 CFG=3
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=3
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 21 20
M  V30 21 1 21 15
M  V30 22 1 21 22 CFG=1
M  V30 23 1 23 21
M  V30 24 1 12 23
M  V30 25 1 23 24 CFG=1
M  V30 26 1 25 24
M  V30 27 1 25 26 CFG=3
M  V30 28 1 27 25
M  V30 29 1 27 8
M  V30 30 1 27 11
M  V30 31 1 27 28 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1416203075

>  <MW>
392.572

>  <MW (desalted)>
392.572

>  <ClogP>
4.514

>  <logS>
-4.6

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
77.76

>  <RotBonds>
4

>  <Action on targets>
Activator | Substrate | Substrate

>  <Activity coefficients and valu>
EC50  0.05 ?M | percentage increase Active   | percentage increase Active

>  <CAS>
83-44-3

>  <Description>
Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. Deoxycholic acid is a cytolytic agent used for improvement in appearance of moderate to severe fullness associated with submental fat in adults.

>  <EBC_ID>
EBC-13851

>  <IUPAC Name>
(4R)-4-[(1R,3aS,3bR,5aR,7R,9aS,9bS,11S,11aR)-7,11-dihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid

>  <Main Tar all refs>
Pharmacol. Res., 2019, vol. 141, p. 319 - 330 | PLoS ONE, 2017, vol. 12, # 1 | PLoS ONE, 2017, vol. 12, # 1

>  <Main tar all>
GPBA receptor pX=7.3 | OATP1B1 pX=6.0 | OATP1B3 pX=6.0

$$$$
Lamivudine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 C 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=2
M  V30 7 C 2.5796 5.5648 0 0
M  V30 8 S 2.1037 4.1002 0 0
M  V30 9 C 0.5637 4.1002 0 0 CFG=2
M  V30 10 C -0.3415 2.8543 0 0
M  V30 11 O 0.2849 1.4474 0 0
M  V30 12 O 0.0878 5.5648 0 0
M  V30 13 C 0 8.78 0 0
M  V30 14 O -1.3337 8.01 0 0
M  V30 15 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 1 9 12
M  V30 12 1 6 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 2 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1509637175

>  <MW>
229.256

>  <MW (desalted)>
229.256

>  <ClogP>
-1.462

>  <logS>
-1.22

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
88.15

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  1.9 pM | Kd (dissociation constant)  2.4 pM

>  <CAS>
134678-17-4

>  <Description>
Lamivudine is a cytidine analog that inhibits the reverse transcriptases of HIV1, HIV2, and hepatitis B. It is used to treat HIV-1 and HBV.

>  <EBC_ID>
EBC-03887

>  <IUPAC Name>
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261

>  <Main tar all>
Organic cation transporter 1 pX=11.7 | Organic cation transporter 3 pX=11.6

$$$$
Adenosine 5'-?monophosphate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 6.1207 3.85 0 0
M  V30 2 C 6.1207 2.31 0 0
M  V30 3 N 7.4543 1.54 0 0
M  V30 4 C 7.4543 0 0 0
M  V30 5 N 6.1207 -0.77 0 0
M  V30 6 C 4.787 0 0 0
M  V30 7 N 3.3224 -0.4759 0 0
M  V30 8 C 2.4172 0.77 0 0
M  V30 9 N 3.3224 2.0159 0 0
M  V30 10 C 4.787 1.54 0 0
M  V30 11 C 2.8465 -1.9405 0 0 CFG=2
M  V30 12 O 3.7517 -3.1864 0 0
M  V30 13 C 2.8465 -4.4323 0 0 CFG=2
M  V30 14 C 3.3224 -5.8969 0 0
M  V30 15 O 2.2919 -7.0414 0 0
M  V30 16 P 2.7678 -8.506 0 0
M  V30 17 O 3.2437 -9.9706 0 0
M  V30 18 O 1.3032 -8.9819 0 0
M  V30 19 O 4.2324 -8.0301 0 0
M  V30 20 C 1.3818 -3.9564 0 0 CFG=1
M  V30 21 O 0.136 -4.8616 0 0
M  V30 22 C 1.3818 -2.4164 0 0 CFG=1
M  V30 23 O 0.136 -1.5112 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 2 10
M  V30 11 1 6 10
M  V30 12 1 11 7 CFG=3
M  V30 13 1 11 12
M  V30 14 1 13 12
M  V30 15 1 13 14 CFG=3
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 21 1 20 13
M  V30 22 1 20 21 CFG=1
M  V30 23 1 20 22
M  V30 24 1 22 11
M  V30 25 1 22 23 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216887941

>  <MW>
347.221

>  <MW (desalted)>
347.221

>  <ClogP>
-3.225

>  <logS>
-0.526

>  <HBD>
5

>  <HBA>
10

>  <TPSA>
186.07

>  <RotBonds>
4

>  <Action on targets>
- | Inhibitor | Inhibitor | Inhibitor | - | Agonist | Activator | Activator | Activator

>  <Activity coefficients and valu>
EC50  10 nM | Ki (inhibition constant)  47.5 nM | Ki (inhibition constant)  47.5 nM | Ki (inhibition constant)  89 nM | Km (Michaelis constant) = 100 nM | EC50  214 nM | EC50 = 0.3 ?M | EC50 = 0.3 ?M | EC50 = 0.3 ?M

>  <CAS>
61-19-8

>  <Description>
Adenosine monophosphate is a nucleotide that is found in RNA. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26679

>  <IUPAC Name>
{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

>  <Main Tar all refs>
TRAFFICK THERAPEUTICS - WO2008/138123, 2008, A1 | MOL. PHARMACOL., 1994, vol. 45, # 6, p. 1101 - 1111 | MOL. PHARMACOL., 1994, vol. 45, # 6, p. 1101 - 1111 | BIOCHEM. BIOPHYS. RES. COMMUN., 1996, vol. 219, # 2, p. 469 - 474 | Anti-Cancer Agents Med. Chem., 2008, vol. 8, # 7, p. 783 - 789 | J. Biol. Chem., 2004, vol. 279, # 19, p. 19790 - 19799 | CHINESE ACADEMY OF SCIENCES; Shanghai Institute of Materia Medica (in: CAS) - WO2016/8404, 2016, A1 | CHINESE ACADEMY OF SCIENCES; Shanghai Institute of Materia Medica (in: CAS) - WO2016/8404, 2016, A1 | CHINESE ACADEMY OF SCIENCES; Shanghai Institute of Materia Medica (in: CAS) - WO2016/8404, 2016, A1

>  <Main tar all>
CFTR pX=8.0 | A1 receptor pX=7.32 | A1 receptor pX=7.32 | P3 purinoceptor-like protein (P3LP) receptor pX=7.05 | adenylate?kinase pX=7.0 | oxoglutarate receptor pX=6.67 | protein kinase AMP-activated catalytic subunit alpha 2 pX=6.52 | protein kinase AMP-activated non-catalytic subunit beta 1 pX=6.52 | protein kinase AMP-activated non-catalytic subunit gamma 1 pX=6.52

$$$$
Sodium L-ascorbate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na -3.1153 2.1266 0 0 CHG=1
M  V30 2 O 2.3935 5.93 0 0
M  V30 3 C 2.3935 4.39 0 0
M  V30 4 C 1.0598 3.62 0 0 CFG=2
M  V30 5 O -0.2739 4.39 0 0
M  V30 6 C 1.0598 2.08 0 0 CFG=1
M  V30 7 O 2.3057 1.1748 0 0
M  V30 8 C 1.8298 -0.2898 0 0
M  V30 9 O 2.735 -1.5357 0 0
M  V30 10 C 0.2898 -0.2898 0 0
M  V30 11 C -0.1861 1.1748 0 0
M  V30 12 O -1.6507 1.6507 0 0 CHG=-1
M  V30 13 O -0.6154 -1.5357 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 4 3
M  V30 3 1 4 5 CFG=1
M  V30 4 1 4 6
M  V30 5 1 6 7 CFG=1
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 8 10
M  V30 9 2 10 11
M  V30 10 1 6 11
M  V30 11 1 11 12
M  V30 12 1 10 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255486556

>  <MW>
198.014

>  <MW (desalted)>
176.124

>  <ClogP>
-6.487

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
110.05

>  <RotBonds>
2

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
increase rate Active

>  <CAS>
134-03-2

>  <Description>
Sodium L-ascorbate  is a more bioavailable form of vitamin C. It is an electron donor, an endogenous antioxidant agent.

>  <EBC_ID>
EBC-26180

>  <IUPAC Name>
sodium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate

>  <Main Tar all refs>
Biomed. Pharmacother., 2018, vol. 103, p. 362 - 372

>  <Main tar all>
Extracellular sulfatase Sulf-2 pX=5.0

$$$$
Tioconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -0.3934 -2.9027 0 0
M  V30 2 C -0.0732 -1.3964 0 0
M  V30 3 S -1.1036 -0.2519 0 0
M  V30 4 C -0.3336 1.0817 0 0
M  V30 5 C 1.1727 0.7616 0 0
M  V30 6 C 1.3337 -0.77 0 0
M  V30 7 C 2.6674 -1.54 0 0
M  V30 8 O 2.6674 -3.08 0 0
M  V30 9 C 4.001 -3.85 0 0
M  V30 10 C 5.3347 -3.08 0 0
M  V30 11 N 6.6684 -3.85 0 0
M  V30 12 C 8.0753 -3.2236 0 0
M  V30 13 C 9.1057 -4.3681 0 0
M  V30 14 N 8.3357 -5.7017 0 0
M  V30 15 C 6.8294 -5.3816 0 0
M  V30 16 C 4.001 -5.39 0 0
M  V30 17 C 5.3347 -6.16 0 0
M  V30 18 C 5.3347 -7.7 0 0
M  V30 19 C 4.001 -8.47 0 0
M  V30 20 Cl 4.001 -10.01 0 0
M  V30 21 C 2.6674 -7.7 0 0
M  V30 22 C 2.6674 -6.16 0 0
M  V30 23 Cl 1.3337 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 11 15
M  V30 17 1 9 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 1 21 22
M  V30 24 2 16 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2520891696

>  <MW>
385.981

>  <MW (desalted)>
387.711

>  <ClogP>
4.787

>  <logS>
-5.846

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
27.05

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.02 ?M | Ki (inhibition constant)  0.04 ?M | pIC50  7.34 | IC50  70 nM | Ki (inhibition constant)  0.1 ?M | Kd (dissociation constant)  0.15 ?M | Kd (dissociation constant)  0.15 ?M | Kd (dissociation constant)  0.21 ?M | Ki (inhibition constant)  0.38 ?M | Ki (inhibition constant)  0.4 ?M

>  <CAS>
65899-73-2

>  <Description>
Tioconazole is an antifungal and antiprotozoal agent. It is an inhibitor of Cytochrome P450 CYP51A1 and 2B6.

>  <EBC_ID>
EBC-03904

>  <IUPAC Name>
1-{2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

>  <Main Tar all refs>
Drug Metab. Dispos., 2002, vol. 30, # 3, p. 314 - 318 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 314 - 318 | J. Med. Chem., 2017, vol. 60, # 17, p. 7284 - 7299 | J. Biol. Chem., 2018, vol. 293, # 50, p. 19201 - 19210 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 314 - 318 | FEBS J., 2014, vol. 281, # 6, p. 1700 - 1713 | FEBS J., 2014, vol. 281, # 6, p. 1700 - 1713 | J. Biol. Chem., 2022, vol. 298, # 9 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 314 - 318 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 314 - 318

>  <Main tar all>
Cytochrome P450 3A4 pX=7.7 | Cytochrome P450 2C19 pX=7.4 | CYP51A1 pX=7.34 | CYP1A1 pX=7.15 | Cytochrome P450 2B6 pX=7.0 | CYP7B1 pX=6.82 | CYP7B1 pX=6.82 | CYP8B1 pX=6.68 | CYP2E1 pX=6.42 | CYP1A2 pX=6.4

$$$$
D-alpha-Tocopherol acetate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.378 -11.1062 0 0
M  V30 2 C 6.918 -11.1062 0 0
M  V30 3 C 7.688 -9.7725 0 0
M  V30 4 C 7.688 -12.4399 0 0
M  V30 5 C 9.228 -12.4399 0 0
M  V30 6 C 9.998 -13.7736 0 0
M  V30 7 C 11.538 -13.7736 0 0 CFG=1
M  V30 8 C 12.308 -12.4399 0 0
M  V30 9 C 12.308 -15.1072 0 0
M  V30 10 C 13.848 -15.1072 0 0
M  V30 11 C 14.618 -16.4409 0 0
M  V30 12 C 16.158 -16.4409 0 0 CFG=1
M  V30 13 C 16.928 -17.7746 0 0
M  V30 14 C 16.928 -15.1072 0 0
M  V30 15 C 16.158 -13.7736 0 0
M  V30 16 C 16.928 -12.4399 0 0
M  V30 17 C 18.468 -12.4399 0 0 CFG=2
M  V30 18 C 18.2006 -13.9565 0 0
M  V30 19 C 18.2006 -10.9233 0 0
M  V30 20 C 19.3803 -9.9334 0 0
M  V30 21 C 20.8274 -10.4601 0 0
M  V30 22 C 22.0071 -9.4702 0 0
M  V30 23 C 21.7397 -7.9536 0 0
M  V30 24 C 23.4543 -9.9969 0 0
M  V30 25 O 24.634 -9.007 0 0
M  V30 26 C 26.0811 -9.5337 0 0
M  V30 27 O 27.2608 -8.5438 0 0
M  V30 28 C 26.3485 -11.0503 0 0
M  V30 29 C 23.7217 -11.5135 0 0
M  V30 30 C 25.1688 -12.0402 0 0
M  V30 31 C 22.542 -12.5034 0 0
M  V30 32 C 22.8094 -14.02 0 0
M  V30 33 C 21.0948 -11.9767 0 0
M  V30 34 O 19.9151 -12.9666 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16 CFG=3
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 24 29
M  V30 29 1 29 30
M  V30 30 2 29 31
M  V30 31 1 31 32
M  V30 32 1 31 33
M  V30 33 2 21 33
M  V30 34 1 33 34
M  V30 35 1 17 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2681891483

>  <MW>
472.392

>  <MW (desalted)>
472.743

>  <ClogP>
12.154

>  <logS>
-10.667

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
35.53

>  <RotBonds>
14

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
58-95-7

>  <Description>
D-alpha-Tocopherol acetate is a form of vitamin E used to treat and prevent vitamin deficiencies.

>  <EBC_ID>
EBC-27184

>  <IUPAC Name>
(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl acetate

$$$$
Bendroflumethiazide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -4.001 -3.85 0 0
M  V30 2 S -2.6674 -3.08 0 0
M  V30 3 O -1.8974 -4.4137 0 0
M  V30 4 O -3.4374 -1.7463 0 0
M  V30 5 C -1.3337 -2.31 0 0
M  V30 6 C 0 -3.08 0 0
M  V30 7 C 1.3337 -2.31 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 N 2.6674 -0 0 0
M  V30 10 C 4.001 -0.77 0 0
M  V30 11 C 5.3347 -0 0 0
M  V30 12 C 6.6684 -0.77 0 0
M  V30 13 C 8.0021 -0 0 0
M  V30 14 C 9.3358 -0.77 0 0
M  V30 15 C 9.3358 -2.31 0 0
M  V30 16 C 8.0021 -3.08 0 0
M  V30 17 C 6.6684 -2.31 0 0
M  V30 18 N 4.001 -2.31 0 0
M  V30 19 S 2.6674 -3.08 0 0
M  V30 20 O 1.9444 -4.4397 0 0
M  V30 21 O 3.3903 -4.4397 0 0
M  V30 22 C 0 -0 0 0
M  V30 23 C -1.3337 -0.77 0 0
M  V30 24 C -2.6674 -0 0 0
M  V30 25 F -4.001 0.77 0 0
M  V30 26 F -3.8118 -1.0305 0 0
M  V30 27 F -1.8974 1.3337 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 10 18
M  V30 19 1 18 19
M  V30 20 1 7 19
M  V30 21 2 19 20
M  V30 22 2 19 21
M  V30 23 2 8 22
M  V30 24 1 22 23
M  V30 25 2 5 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 24 26
M  V30 29 1 24 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575277625

>  <MW>
421.038

>  <MW (desalted)>
421.415

>  <ClogP>
1.727

>  <logS>
-3.826

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
118.36

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  130 nM | Kd (dissociation constant)  210 nM | Kd (dissociation constant)  360 nM | Kd (dissociation constant)  440 nM | Kd (dissociation constant)  480 nM | Kd (dissociation constant)  910 nM | Kd (dissociation constant)  1600 nM | Kd (dissociation constant)  1700 nM

>  <CAS>
73-48-3

>  <Description>
Bendroflumethiazide is a diuretic used to suppress lactation and to treat hypertension and edema.

>  <EBC_ID>
EBC-14162

>  <IUPAC Name>
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

>  <Main Tar all refs>
PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June | PLoS ONE, 2021, vol. 16, # 6 June

>  <Main tar all>
carbonic anhydrase 14 pX=6.89 | carbonic anhydrase 9 pX=6.68 | Carbonic anhydrase 5B, mitochondrial pX=6.44 | carbonic anhydrase 7 pX=6.36 | carbonic anhydrase 12 pX=6.32 | carbonic anhydrase 13 pX=6.04 | carbonic anhydrase 1 pX=5.8 | carbonic anhydrase 2 pX=5.77

$$$$
Canagliflozin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -6.93 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 0 -4.62 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 C 4.001 -6.93 0 0
M  V30 10 C 5.2469 -7.8352 0 0
M  V30 11 C 4.771 -9.2998 0 0
M  V30 12 C 3.231 -9.2998 0 0
M  V30 13 S 2.7552 -7.8352 0 0
M  V30 14 C 2.3258 -10.5457 0 0
M  V30 15 C 2.9522 -11.9526 0 0
M  V30 16 C 2.047 -13.1984 0 0
M  V30 17 C 0.5155 -13.0375 0 0
M  V30 18 F -0.3897 -14.2834 0 0
M  V30 19 C -0.1109 -11.6306 0 0
M  V30 20 C 0.7943 -10.3847 0 0
M  V30 21 C 1.3337 -0.77 0 0 CFG=2
M  V30 22 O 0 0 0 0
M  V30 23 C 0 1.54 0 0 CFG=2
M  V30 24 C -1.3337 2.31 0 0
M  V30 25 O -2.6674 1.54 0 0
M  V30 26 C 1.3337 2.31 0 0 CFG=1
M  V30 27 O 1.3337 3.85 0 0
M  V30 28 C 2.6674 1.54 0 0 CFG=2
M  V30 29 O 4.001 2.31 0 0
M  V30 30 C 2.6674 0 0 0 CFG=1
M  V30 31 O 4.001 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 9 13
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 17 19
M  V30 21 1 19 20
M  V30 22 2 14 20
M  V30 23 1 21 5 CFG=3
M  V30 24 1 21 22
M  V30 25 1 23 22
M  V30 26 1 23 24 CFG=3
M  V30 27 1 24 25
M  V30 28 1 26 23
M  V30 29 1 26 27 CFG=1
M  V30 30 1 26 28
M  V30 31 1 28 29 CFG=3
M  V30 32 1 28 30
M  V30 33 1 30 21
M  V30 34 1 30 31 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235801995

>  <MW>
444.141

>  <MW (desalted)>
444.516

>  <ClogP>
4.552

>  <logS>
-5.812

>  <HBD>
4

>  <HBA>
5

>  <TPSA>
90.15

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 2 nM

>  <CAS>
842133-18-0

>  <Description>
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM.

>  <EBC_ID>
EBC-11393

>  <IUPAC Name>
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2015, vol. 25, # 5, p. 993 - 997

>  <Main tar all>
Sodium/glucose cotransporter 2 pX=8.7

$$$$
Sirolimus
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 65 68 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.8094 -8.8295 0 0
M  V30 2 O 9.3782 -9.3979 0 0
M  V30 3 C 8.1703 -8.4427 0 0 CFG=2
M  V30 4 C 8.3936 -6.919 0 0
M  V30 5 C 7.1856 -5.9637 0 0 CFG=2
M  V30 6 C 7.4089 -4.44 0 0
M  V30 7 C 8.8401 -3.8715 0 0 CFG=1
M  V30 8 C 10.0481 -4.8268 0 0
M  V30 9 C 9.0634 -2.3478 0 0 CFG=2
M  V30 10 C 7.6322 -2.9163 0 0
M  V30 11 C 6.4243 -1.9611 0 0
M  V30 12 O 6.6475 -0.4373 0 0
M  V30 13 C 4.993 -2.5295 0 0 CFG=2
M  V30 14 C 4.7697 -4.0533 0 0
M  V30 15 C 3.7851 -1.5743 0 0
M  V30 16 C 2.3539 -2.1428 0 0
M  V30 17 C 2.1306 -3.6665 0 0
M  V30 18 C 1.1459 -1.1876 0 0 CFG=1
M  V30 19 O -0.2726 -1.787 0 0
M  V30 20 C 1.3176 0.4889 0 0 CFG=1
M  V30 21 O -0.1772 0.1187 0 0
M  V30 22 C -1.2452 1.2283 0 0
M  V30 23 C 0.464 1.7706 0 0
M  V30 24 O -1.0747 1.8334 0 0
M  V30 25 C 1.4192 2.9786 0 0 CFG=2
M  V30 26 C 1.0035 4.4614 0 0
M  V30 27 C 2.8632 2.4434 0 0
M  V30 28 C 4.4549 2.9969 0 0 CFG=2
M  V30 29 C 4.7113 4.5154 0 0
M  V30 30 C 5.6629 2.0416 0 0
M  V30 31 C 7.0941 2.6101 0 0
M  V30 32 C 8.3021 1.6549 0 0
M  V30 33 C 9.7333 2.2234 0 0
M  V30 34 C 10.9412 1.2681 0 0
M  V30 35 C 12.3725 1.8366 0 0
M  V30 36 C 12.5957 3.3604 0 0
M  V30 37 C 13.5804 0.8814 0 0 CFG=2
M  V30 38 C 15.0116 1.4499 0 0
M  V30 39 C 16.2196 0.4947 0 0 CFG=2
M  V30 40 C 17.6508 1.0631 0 0
M  V30 41 C 18.8587 0.1079 0 0
M  V30 42 C 18.6355 -1.4158 0 0 CFG=1
M  V30 43 C 19.8434 -2.3711 0 0
M  V30 44 C 17.2042 -1.9843 0 0 CFG=1
M  V30 45 O 18.4122 -2.9395 0 0
M  V30 46 O 15.9963 -1.0291 0 0
M  V30 47 C 16.9809 -3.508 0 0
M  V30 48 O 18.1889 -4.4633 0 0
M  V30 49 C 15.0256 -4.4667 0 0
M  V30 50 O 16.2647 -5.4405 0 0
M  V30 51 N 14.3418 -3.1213 0 0
M  V30 52 C 15.5497 -4.0765 0 0
M  V30 53 C 15.3264 -5.6003 0 0
M  V30 54 C 13.8952 -6.1687 0 0
M  V30 55 C 12.6872 -5.2135 0 0
M  V30 56 C 12.9105 -3.6898 0 0 CFG=1
M  V30 57 C 11.7026 -2.7345 0 0
M  V30 58 O 11.9259 -1.2108 0 0
M  V30 59 O 10.2714 -3.303 0 0
M  V30 60 O 13.8037 2.4051 0 0
M  V30 61 C 15.2349 2.9736 0 0
M  V30 62 C 5.7544 -6.5322 0 0
M  V30 63 C 5.5311 -8.056 0 0
M  V30 64 C 6.739 -9.0112 0 0 CFG=1
M  V30 65 O 6.5158 -10.5349 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 13 11
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 18 16
M  V30 18 1 18 19 CFG=1
M  V30 19 1 18 20
M  V30 20 1 20 21 CFG=3
M  V30 21 1 21 22
M  V30 22 1 20 23 CFG=1
M  V30 23 2 23 24
M  V30 24 1 25 23
M  V30 25 1 25 26 CFG=3
M  V30 26 1 25 27
M  V30 27 1 28 27
M  V30 28 1 28 29 CFG=3
M  V30 29 1 28 30
M  V30 30 2 30 31
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 1 33 34
M  V30 34 2 34 35
M  V30 35 1 35 36
M  V30 36 1 37 35 CFG=1
M  V30 37 1 37 38
M  V30 38 1 39 38
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 1 42 41
M  V30 42 1 42 43 CFG=1
M  V30 43 1 42 44
M  V30 44 1 44 45 CFG=1
M  V30 45 1 44 46
M  V30 46 1 39 46 CFG=3
M  V30 47 1 44 47
M  V30 48 2 47 48
M  V30 49 1 47 49
M  V30 50 2 49 50
M  V30 51 1 49 51
M  V30 52 1 51 52
M  V30 53 1 52 53
M  V30 54 1 53 54
M  V30 55 1 54 55
M  V30 56 1 56 55
M  V30 57 1 56 51 CFG=1
M  V30 58 1 56 57
M  V30 59 2 57 58
M  V30 60 1 57 59
M  V30 61 1 9 59 CFG=3
M  V30 62 1 37 60 CFG=3
M  V30 63 1 60 61
M  V30 64 1 5 62
M  V30 65 1 62 63
M  V30 66 1 64 63
M  V30 67 1 3 64
M  V30 68 1 64 65 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568665260

>  <MW>
913.555

>  <MW (desalted)>
914.172

>  <ClogP>
7.039

>  <logS>
-5.578

>  <HBD>
3

>  <HBA>
12

>  <TPSA>
195.43

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
cell viability increase Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage  10 - 64 %

>  <CAS>
53123-88-9

>  <Description>
Sirolimus is an immunosuppressant used to prevent organ transplant rejections and to treat lymphangioleiomyomatosis. It acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production.

>  <EBC_ID>
EBC-11166

>  <IUPAC Name>
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0,4,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

>  <Main Tar all refs>
Mol. Pharm., 2018, vol. 15, # 5, p. 1996 - 2006 | UNIVERSITY OF CHICAGO - US2017/65581, 2017, A1 | UNIVERSITY OF CHICAGO - US2017/65581, 2017, A1 | UNIVERSITY SYSTEM OF MARYLAND - WO2004/24683, 2004, A2

>  <Main tar all>
CysLT1 receptor pX=12.0 | ? receptor pX=11.0 | Serine/threonine-protein kinase mTOR pX=11.0 | CCR5 pX=10.8

$$$$
Paricalcitol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6802 -5.1578 0 0
M  V30 2 C 1.6497 -4.0133 0 0 CFG=2
M  V30 3 C 0.1434 -4.3335 0 0
M  V30 4 C -0.8871 -3.1891 0 0
M  V30 5 C -2.3934 -3.5093 0 0 CFG=2
M  V30 6 C -2.8693 -4.9739 0 0
M  V30 7 C -3.4239 -2.3648 0 0
M  V30 8 C -4.4544 -1.2204 0 0
M  V30 9 C -4.5683 -3.3953 0 0
M  V30 10 O -2.2794 -1.3344 0 0
M  V30 11 C 2.1256 -2.5487 0 0 CFG=1
M  V30 12 C 1.2204 -1.3028 0 0
M  V30 13 C 2.1256 -0.0569 0 0
M  V30 14 C 3.5902 -0.5328 0 0 CFG=1
M  V30 15 C 4.9239 0.2372 0 0
M  V30 16 C 4.9239 1.7772 0 0
M  V30 17 C 6.2576 2.5472 0 0
M  V30 18 C 7.5913 1.7772 0 0
M  V30 19 C 8.925 2.5472 0 0
M  V30 20 C 10.2586 1.7772 0 0 CFG=1
M  V30 21 O 11.5923 2.5472 0 0
M  V30 22 C 10.2586 0.2372 0 0
M  V30 23 C 8.925 -0.5328 0 0 CFG=2
M  V30 24 O 8.925 -2.0728 0 0
M  V30 25 C 7.5913 0.2372 0 0
M  V30 26 C 6.2576 -0.5328 0 0
M  V30 27 C 6.2576 -2.0728 0 0
M  V30 28 C 4.9239 -2.8428 0 0
M  V30 29 C 3.5902 -2.0728 0 0 CFG=2
M  V30 30 C 3.4293 -3.6044 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 11 2 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 20 19
M  V30 20 1 20 21 CFG=1
M  V30 21 1 20 22
M  V30 22 1 23 22
M  V30 23 1 23 24 CFG=3
M  V30 24 1 23 25
M  V30 25 1 18 25
M  V30 26 1 15 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 29 28
M  V30 30 1 11 29
M  V30 31 1 29 14
M  V30 32 1 29 30 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2583384655

>  <MW>
416.636

>  <MW (desalted)>
416.636

>  <ClogP>
5.688

>  <logS>
-6.179

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
60.69

>  <RotBonds>
5

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
EC50 = 0.044 nM

>  <CAS>
131918-61-1

>  <Description>
Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease.

>  <EBC_ID>
EBC-13071

>  <IUPAC Name>
(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol

>  <Main Tar all refs>
ABBOTT LABORATORIES INC - WO2006/60765, 2006, A2

>  <Main tar all>
Vitamin D receptor pX=10.4

$$$$
Upadacitinib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.1972 -4.7169 0 0
M  V30 2 C 5.8635 -3.9469 0 0
M  V30 3 C 4.5298 -4.7169 0 0 CFG=2
M  V30 4 C 4.3689 -6.2485 0 0
M  V30 5 N 2.8625 -6.5687 0 0
M  V30 6 C 2.0925 -5.235 0 0
M  V30 7 C 3.123 -4.0905 0 0 CFG=2
M  V30 8 C 2.8028 -2.5842 0 0
M  V30 9 C 1.3959 -1.9578 0 0
M  V30 10 N 1.5569 -0.4263 0 0
M  V30 11 C 3.0633 -0.1061 0 0
M  V30 12 C 3.8333 1.2276 0 0
M  V30 13 N 5.3733 1.2276 0 0
M  V30 14 C 6.1433 -0.1061 0 0
M  V30 15 N 7.6496 -0.4263 0 0
M  V30 16 C 7.8106 -1.9578 0 0
M  V30 17 C 6.4037 -2.5842 0 0
M  V30 18 C 5.3733 -1.4398 0 0
M  V30 19 N 3.8333 -1.4398 0 0
M  V30 20 C 2.2361 -7.9755 0 0
M  V30 21 O 0.7046 -8.1365 0 0
M  V30 22 N 3.1413 -9.2214 0 0
M  V30 23 C 2.515 -10.6283 0 0
M  V30 24 C 3.4201 -11.8742 0 0
M  V30 25 F 4.3253 -13.12 0 0
M  V30 26 F 2.1743 -12.7794 0 0
M  V30 27 F 4.666 -10.969 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8 CFG=3
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 14 18
M  V30 20 1 18 19
M  V30 21 1 8 19
M  V30 22 1 11 19
M  V30 23 1 5 20
M  V30 24 2 20 21
M  V30 25 1 20 22
M  V30 26 1 22 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 24 26
M  V30 30 1 24 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2831495606

>  <MW>
380.157

>  <MW (desalted)>
380.368

>  <ClogP>
2.262

>  <logS>
-4.679

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
78.32

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.76 nmol/l | IC50  3.1 nM | IC50  8 nM | IC50  8.2 nmol/l | IC50  12 nmol/l | IC50  19 nmol/l

>  <CAS>
1310726-60-3

>  <Description>
Upadacitinib is an oral selective inhibitor of tyrosine-protein kinase JAK1 and a disease-modifying antirheumatic drug. It is used in the treatment of rheumatoid arthritis to slow down disease progression.

>  <EBC_ID>
EBC-26865

>  <IUPAC Name>
(3S,4R)-3-ethyl-4-{1,5,7,10-tetraazatricyclo[7.3.0.0,2,6]dodeca-2(6),3,7,9,11-pentaen-12-yl}-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

>  <Main Tar all refs>
Pharmacol. Res. Perspect., 2019, vol. 7, # 6 | J. Med. Chem., 2023, vol. 66, # 3, p. 2161 - 2168 | Dermatol. Ther., 2021, vol. 11, # 5, p. 1763 - 1776 | Pharmacol. Res. Perspect., 2019, vol. 7, # 6 | Pharmacol. Res. Perspect., 2019, vol. 7, # 6 | Pharmacol. Res. Perspect., 2019, vol. 7, # 6

>  <Main tar all>
Janus kinase 1 pX=9.12 | Janus kinase 2 pX=8.51 | Janus kinase 3 pX=8.1 | Interleukin-4 receptor subunit ? pX=8.09 | Interleukin-6 receptor pX=7.92 | Interferon ? receptor pX=7.72

$$$$
Risdiplam hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 18.7447 6.5582 0 0
M  V30 3 C 17.411 5.7882 0 0
M  V30 4 C 17.25 4.2567 0 0
M  V30 5 N 15.7437 3.9365 0 0
M  V30 6 N 14.9737 2.6028 0 0
M  V30 7 C 13.4337 2.6028 0 0
M  V30 8 C 12.6637 3.9365 0 0
M  V30 9 C 13.4337 5.2701 0 0
M  V30 10 C 12.6637 6.6038 0 0
M  V30 11 C 14.9737 5.2701 0 0
M  V30 12 N 16.0041 6.4146 0 0
M  V30 13 C 12.6637 1.2691 0 0
M  V30 14 C 13.4337 -0.0646 0 0
M  V30 15 C 12.6637 -1.3982 0 0
M  V30 16 O 13.4337 -2.7319 0 0
M  V30 17 N 11.1237 -1.3982 0 0
M  V30 18 C 10.3537 -2.7319 0 0
M  V30 19 C 8.8137 -2.7319 0 0
M  V30 20 C 8.0437 -1.3982 0 0
M  V30 21 C 8.8137 -0.0646 0 0
M  V30 22 C 10.3537 -0.0646 0 0
M  V30 23 N 11.1237 1.2691 0 0
M  V30 24 N 8.0437 -4.0656 0 0
M  V30 25 C 8.8137 -5.3993 0 0
M  V30 26 C 8.0437 -6.733 0 0
M  V30 27 N 6.5037 -6.733 0 0
M  V30 28 C 5.7337 -5.3993 0 0
M  V30 29 C 4.4 -6.1693 0 0
M  V30 30 C 4.4 -4.6293 0 0
M  V30 31 C 6.5037 -4.0656 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 1 9 11
M  V30 10 1 5 11
M  V30 11 2 11 12
M  V30 12 1 3 12
M  V30 13 1 7 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 24 2 22 23
M  V30 25 1 13 23
M  V30 26 1 19 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 28 30
M  V30 34 1 28 31
M  V30 35 1 24 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z4168286686

>  <MW>
437.925

>  <MW (desalted)>
401.464

>  <ClogP>
1.927

>  <logS>
-4.199

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
78.13

>  <RotBonds>
2

>  <CAS>
2460757-76-8

>  <Description>
Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy. It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription.

>  <EBC_ID>
EBC-28064

>  <IUPAC Name>
7-{4,7-diazaspiro[2.5]octan-7-yl}-2-{2,8-dimethylimidazo[1,2-b]pyridazin-6-yl}-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride

$$$$
Histamine dichloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 Cl 3.74 0 0 0
M  V30 3 N -1.0003 -3.08 0 0
M  V30 4 C -1.0003 -4.62 0 0
M  V30 5 C 0.3334 -5.39 0 0
M  V30 6 C 0.3334 -6.93 0 0
M  V30 7 C 1.5793 -7.8352 0 0
M  V30 8 N 1.1034 -9.2998 0 0
M  V30 9 C -0.4366 -9.2998 0 0
M  V30 10 N -0.9125 -7.8352 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 2 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 2 9 10
M  V30 8 1 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1267773750

>  <MW>
183.033

>  <MW (desalted)>
111.145

>  <ClogP>
-0.968

>  <logS>
-1.08

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
54.7

>  <RotBonds>
2

>  <Action on targets>
Agonist | Inhibitor

>  <Activity coefficients and valu>
pEC50  8.48 | Kd (dissociation constant)  15.3 nM

>  <CAS>
56-92-8

>  <Description>
Histamine is a depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Histamine is an ingredient of topical drugs for the relief of joint pain or muscle aches and pains.

>  <EBC_ID>
EBC-12021

>  <IUPAC Name>
2-(1H-imidazol-4-yl)ethan-1-amine dihydrochloride

>  <Main Tar all refs>
J. Med. Chem., 2020, vol. 63, # 10, p. 5297 - 5311 | Mol. Pharmacol., 2002, vol. 62, # 1, p. 38 - 47

>  <Main tar all>
H3 receptor pX=8.48 | H4 receptor pX=7.82

$$$$
CGA-72662
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.77 3.5246 0 0
M  V30 2 C 2.1037 4.2946 0 0
M  V30 3 N 2.1037 5.8346 0 0
M  V30 4 C 3.4374 6.6046 0 0
M  V30 5 N 3.4374 8.1446 0 0
M  V30 6 N 4.771 5.8346 0 0
M  V30 7 C 4.771 4.2946 0 0
M  V30 8 N 6.1047 3.5246 0 0
M  V30 9 C 6.1047 1.9846 0 0
M  V30 10 C 6.8747 0.6509 0 0
M  V30 11 C 5.3347 0.6509 0 0
M  V30 12 N 3.4374 3.5246 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 11
M  V30 12 1 7 12
M  V30 13 2 2 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255383207

>  <MW>
166.097

>  <MW (desalted)>
166.184

>  <ClogP>
0.455

>  <logS>
-2.407

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
102.74

>  <RotBonds>
2

>  <CAS>
66215-27-8

>  <Description>
Insecticide

>  <EBC_ID>
EBC-04334

>  <IUPAC Name>
N2-cyclopropyl-1,3,5-triazine-2,4,6-triamine

$$$$
Chloramine-T
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na 0 0 0 0 CHG=1
M  V30 2 C 4.8537 4.4275 0 0
M  V30 3 C 4.8537 2.8875 0 0
M  V30 4 C 6.1874 2.1175 0 0
M  V30 5 C 6.1874 0.5775 0 0
M  V30 6 C 4.8537 -0.1925 0 0
M  V30 7 C 3.52 0.5775 0 0
M  V30 8 C 3.52 2.1175 0 0
M  V30 9 S 4.8537 -1.7325 0 0
M  V30 10 O 3.3137 -1.7325 0 0
M  V30 11 O 6.3937 -1.7325 0 0
M  V30 12 N 4.8537 -3.2725 0 0 CHG=-1
M  V30 13 Cl 6.1874 -4.0425 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 2 3 8
M  V30 8 1 6 9
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 1 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1172235461

>  <MW>
226.978

>  <MW (desalted)>
205.662

>  <ClogP>
1.669

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
43.37

>  <RotBonds>
1

>  <CAS>
127-65-1

>  <Description>
Chloramine-T is a N-chlorinated and N-deprotonated sulfonamide used as a biocide and a mild disinfectant.

>  <EBC_ID>
EBC-152228

>  <IUPAC Name>
sodium chloro(4-methylbenzenesulfonyl)azanide

$$$$
Undecenoic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.5726 5.3347 0 0
M  V30 2 C 7.9063 6.1047 0 0
M  V30 3 O 7.9063 7.6447 0 0
M  V30 4 C 9.24 5.3347 0 0
M  V30 5 C 10.5737 6.1047 0 0
M  V30 6 C 11.9074 5.3347 0 0
M  V30 7 C 13.241 6.1047 0 0
M  V30 8 C 14.5747 5.3347 0 0
M  V30 9 C 15.9084 6.1047 0 0
M  V30 10 C 17.2421 5.3347 0 0
M  V30 11 C 18.5758 6.1047 0 0
M  V30 12 C 19.9094 5.3347 0 0
M  V30 13 C 21.2431 6.1047 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104479700

>  <MW>
184.146

>  <MW (desalted)>
184.275

>  <ClogP>
4.083

>  <logS>
-3.757

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
37.3

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  1.1 ?M

>  <CAS>
112-38-9

>  <Description>
Undecylenic acid is an antifungal used to treat tinea species infections. It is effective against Candida albicans. It is proposed that undecylenic acid exerts antimicrobial actions via interacting with nonspecific components in the cell membrane.

>  <EBC_ID>
EBC-03555

>  <IUPAC Name>
undec-10-enoic acid

>  <Main Tar all refs>
BMC Pharmacol. Toxicol., 2019, vol. 20, # 1

>  <Main tar all>
Potassium voltage-gated channel subfamily H member 1 (isoform 1) pX=5.96

$$$$
Tegafuris
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.1992 8.895 0 0
M  V30 2 C -1.1345 8.125 0 0
M  V30 3 C -1.1345 6.585 0 0
M  V30 4 N -2.4682 5.815 0 0
M  V30 5 C -2.4682 4.275 0 0
M  V30 6 C -1.2223 3.3698 0 0
M  V30 7 C -1.6982 1.9052 0 0
M  V30 8 C -3.2382 1.9052 0 0
M  V30 9 O -3.7141 3.3698 0 0
M  V30 10 C -3.8019 6.585 0 0
M  V30 11 O -5.1355 5.815 0 0
M  V30 12 N -3.8019 8.125 0 0
M  V30 13 C -2.4682 8.895 0 0
M  V30 14 O -2.4682 10.435 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 4 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 2 13
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104508106

>  <MW>
200.06

>  <MW (desalted)>
200.167

>  <ClogP>
-0.065

>  <logS>
-1.21

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
58.64

>  <RotBonds>
1

>  <Action on targets>
- | - | - | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant)  0.3 ?M | Km (Michaelis constant)  0.3 ?M | Km (Michaelis constant)  0.3 ?M | inhibition percentage Active

>  <CAS>
17902-23-7

>  <Description>
Tegafuris a prodrug of Fluorouracil, an antineoplastic agent that belongs in the class of pyrimidine analogues. It is used as the treatment of various cancers such as advanced gastric and colorectal cancers. It interferes with the 2'-deoxythymidylate synthesis in the pyrimidine pathway, resulting in inhibition of DNA synthesis.

>  <EBC_ID>
EBC-03486

>  <IUPAC Name>
5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
Drug Metab. Dispos., 2005, vol. 33, # 8, p. 1202 - 1210 | Drug Metab. Dispos., 2005, vol. 33, # 8, p. 1202 - 1210 | Drug Metab. Dispos., 2005, vol. 33, # 8, p. 1202 - 1210 | Nat. Commun., 2019, vol. 10, # 1

>  <Main tar all>
CYP2A6*18 pX=6.52 | CYP2A6*19 pX=6.52 | CYP2A6*7 pX=6.52 | Nucleoprotein pX=6.0

$$$$
Bromotheophylline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.5913 4.3828 0 0
M  V30 2 N 6.2576 3.6128 0 0
M  V30 3 C 6.2576 2.0728 0 0
M  V30 4 O 7.5913 1.3028 0 0
M  V30 5 N 4.9239 1.3028 0 0
M  V30 6 C 4.9239 -0.2372 0 0
M  V30 7 C 3.5902 2.0728 0 0
M  V30 8 N 2.1256 1.5969 0 0
M  V30 9 C 1.2204 2.8428 0 0
M  V30 10 Br -0.3196 2.8428 0 0
M  V30 11 N 2.1256 4.0887 0 0
M  V30 12 C 3.5902 3.6128 0 0
M  V30 13 C 4.9239 4.3828 0 0
M  V30 14 O 4.9239 5.9228 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 12 13
M  V30 14 1 2 13
M  V30 15 2 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57161790

>  <MW>
257.975

>  <MW (desalted)>
259.06

>  <ClogP>
0.929

>  <logS>
-3.05

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
69.3

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 10.2 ?M | Ki (inhibition constant) = 10.2 ?M

>  <CAS>
10381-75-6

>  <Description>
Bromotheophylline is used as a diuretic.

>  <EBC_ID>
EBC-03510

>  <IUPAC Name>
8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

>  <Main Tar all refs>
J. MED. CHEM., 1993, vol. 36, # 18, p. 2639 - 2644 | J. MED. CHEM., 1993, vol. 36, # 18, p. 2639 - 2644

>  <Main tar all>
A1 receptor pX=4.99 | A1 receptor pX=4.99

$$$$
Tacrine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.001 3.85 0 0
M  V30 2 C 4.001 2.31 0 0
M  V30 3 C 5.3347 1.54 0 0
M  V30 4 C 6.6684 2.31 0 0
M  V30 5 C 8.0021 1.54 0 0
M  V30 6 C 8.0021 -0 0 0
M  V30 7 C 6.6684 -0.77 0 0
M  V30 8 C 5.3347 0 0 0
M  V30 9 N 4.001 -0.77 0 0
M  V30 10 C 2.6674 0 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C -0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 C 1.3337 2.31 0 0
M  V30 15 C 2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 2 15
M  V30 17 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56790573

>  <MW>
198.116

>  <MW (desalted)>
198.264

>  <ClogP>
3.274

>  <logS>
-3.12

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
38.91

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
concentration (parameter) = 0.009 nM | IC50 = 2.67E-05 ?M | concentration (parameter) = 0.033 nM | IC50  0.00015 ?M | Ki (inhibition constant) = 0.15 nM | Ki (inhibition constant) = 0.151 nM | Ki (inhibition constant) = 0.151 nM | IC50 = 0.25 nM

>  <CAS>
321-64-2

>  <Description>
Tacrine is a centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.

>  <EBC_ID>
EBC-06032

>  <IUPAC Name>
1,2,3,4-tetrahydroacridin-9-amine

>  <Main Tar all refs>
PFIZER INC - US5422350, 1995, A | Eur. J. Med. Chem., 2011, vol. 46, # 8, p. 3250 - 3257 | PFIZER INC - US5422350, 1995, A | Phytochem. Lett., 2020, vol. 36, p. 134 - 138 | Eur. J. Med. Chem., 2005, vol. 40, # 12, p. 1307 - 1315 | J. Med. Chem., 1998, vol. 41, # 22, p. 4186 - 4189 | J. Med. Chem., 1998, vol. 41, # 22, p. 4186 - 4189 | Mini-Rev. Med. Chem., 2002, vol. 2, # 1, p. 27 - 36

>  <Main tar all>
CYP1A1 pX=11.0 | butyrylcholinesterase pX=10.6 | Cytochrome P450 2D6 pX=10.5 | Acetylcholinesterase 1 pX=9.82 | acetylcholinesterase (Cartwright blood group) pX=9.82 | acetylcholinesterase (Cartwright blood group) pX=9.82 | acetylcholinesterase (Cartwright blood group) pX=9.82 | acetylcholinesterase (Cartwright blood group) pX=9.6

$$$$
Tetryzoline hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 6.5037 -3.9865 0 0
M  V30 3 C 4.9637 -3.9865 0 0
M  V30 4 N 4.4878 -2.5219 0 0
M  V30 5 C 5.7337 -1.6167 0 0
M  V30 6 N 6.9796 -2.5219 0 0
M  V30 7 C 5.7337 -0.0767 0 0
M  V30 8 C 4.4 0.6933 0 0
M  V30 9 C 4.4 2.2333 0 0
M  V30 10 C 5.7337 3.0033 0 0
M  V30 11 C 7.0674 2.2333 0 0
M  V30 12 C 8.401 3.0033 0 0
M  V30 13 C 9.7347 2.2333 0 0
M  V30 14 C 9.7347 0.6933 0 0
M  V30 15 C 8.401 -0.0767 0 0
M  V30 16 C 7.0674 0.6933 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 2 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 7 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1695906783

>  <MW>
236.108

>  <MW (desalted)>
200.28

>  <ClogP>
3.535

>  <logS>
-3.04

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
24.39

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 11 nM

>  <CAS>
522-48-5

>  <Description>
Tetryzoline is an alpha-adrenergic agonist. It is used in the temporary symptomatic relief of discomfort and redness of the eyes due to minor irritations, as well as alleviate nasal congestion.

>  <EBC_ID>
EBC-03612

>  <IUPAC Name>
2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1979, vol. 22, # 11, p. 1290 - 1295

>  <Main tar all>
?-adrenoceptor pX=7.96

$$$$
Milrinone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 N 2.6674 -3.08 0 0
M  V30 4 C 2.6674 -4.62 0 0
M  V30 5 O 4.001 -5.39 0 0
M  V30 6 C 1.3337 -5.39 0 0
M  V30 7 C 1.3337 -6.93 0 0
M  V30 8 N 1.3337 -8.47 0 0
M  V30 9 C 0 -4.62 0 0
M  V30 10 C 0 -3.08 0 0
M  V30 11 C -1.3337 -2.31 0 0
M  V30 12 C -2.6674 -3.08 0 0
M  V30 13 C -4.001 -2.31 0 0
M  V30 14 N -4.001 -0.77 0 0
M  V30 15 C -2.6674 0 0 0
M  V30 16 C -1.3337 -0.77 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 3 7 8
M  V30 8 2 6 9
M  V30 9 1 9 10
M  V30 10 2 2 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501480412

>  <MW>
211.075

>  <MW (desalted)>
211.219

>  <ClogP>
-0.028

>  <logS>
-2.6

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
65.78

>  <RotBonds>
1

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
cell viability increase rate Active

>  <CAS>
78415-72-2

>  <Description>
Milrinone is an inhibitor of type 3 phosphodiesterases with inotropic, lusitropic, and vasodilatory properties. It is used for the short-term treatment of acute decompensated heart failure.

>  <EBC_ID>
EBC-08195

>  <IUPAC Name>
6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile

>  <Main Tar all refs>
Clin. Cancer Res., 2019, vol. 25, # 5, p. 1676 - 1687

>  <Main tar all>
cGMP-specific 3',5'-cGMP phosphodiesterase 3 pX=10.0

$$$$
Sulfapyridine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.3347 -1.54 0 0
M  V30 2 C 5.3347 -3.08 0 0
M  V30 3 C 6.6684 -3.85 0 0
M  V30 4 C 6.6684 -5.39 0 0
M  V30 5 C 5.3347 -6.16 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -3.85 0 0
M  V30 8 S 5.3347 -7.7 0 0
M  V30 9 O 3.7947 -7.7 0 0
M  V30 10 O 6.8747 -7.7 0 0
M  V30 11 N 5.3347 -9.24 0 0
M  V30 12 C 4.001 -10.01 0 0
M  V30 13 C 4.001 -11.55 0 0
M  V30 14 C 2.6674 -12.32 0 0
M  V30 15 C 1.3337 -11.55 0 0
M  V30 16 C 1.3337 -10.01 0 0
M  V30 17 N 2.6674 -9.24 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 2 8 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104492884

>  <MW>
249.057

>  <MW (desalted)>
249.289

>  <ClogP>
0.836

>  <logS>
-2.52

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
85.08

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKa (association)  8.56 | IC50  19.41 nM

>  <CAS>
144-83-2

>  <Description>
Sulfapyridine is a sulfonamide antibiotic with antibacterial and anti-inflammatory activities. Sulfapyridine has previously been used in the treatment of dermatological conditions and ulcerative colitis.

>  <EBC_ID>
EBC-04140

>  <IUPAC Name>
4-amino-N-(pyridin-2-yl)benzene-1-sulfonamide

>  <Main Tar all refs>
J. Hazard. Mater., 2018, vol. 341, p. 438 - 447 | J. Pharmacol. Exp. Ther., 2015, vol. 352, # 3, p. 529 - 540

>  <Main tar all>
dihydrofolate synthase pX=8.56 | sepiapterin reductase pX=7.71

$$$$
Rufinamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.4682 -0.115 0 0
M  V30 2 C 3.8019 -0.885 0 0
M  V30 3 O 5.1355 -0.115 0 0
M  V30 4 C 3.8019 -2.425 0 0
M  V30 5 C 5.0477 -3.3302 0 0
M  V30 6 N 4.5719 -4.7948 0 0
M  V30 7 C 5.477 -6.0407 0 0
M  V30 8 C 4.8507 -7.4476 0 0
M  V30 9 C 5.7559 -8.6934 0 0
M  V30 10 F 7.2874 -8.5325 0 0
M  V30 11 C 5.1295 -10.1003 0 0
M  V30 12 C 3.5979 -10.2613 0 0
M  V30 13 C 2.6927 -9.0154 0 0
M  V30 14 C 3.3191 -7.6085 0 0
M  V30 15 F 2.4139 -6.3626 0 0
M  V30 16 N 3.0319 -4.7948 0 0
M  V30 17 N 2.556 -3.3302 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 15 1 14 15
M  V30 16 1 6 16
M  V30 17 2 16 17
M  V30 18 1 4 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1532717444

>  <MW>
238.067

>  <MW (desalted)>
238.194

>  <ClogP>
0.514

>  <logS>
-2.1

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
73.8

>  <RotBonds>
3

>  <Action on targets>
Inactivator | Modulator | Stimulator

>  <Activity coefficients and valu>
IC50  3.1 ?M | EC50 = 3.8 ?M | EC50  3.9 ?M

>  <CAS>
106308-44-5

>  <Description>
Rufinamide is an antiepileptic drug used as adjunctive therapy to treat seizures associated with Lennox-Gastaut Syndrome.

>  <EBC_ID>
EBC-12722

>  <IUPAC Name>
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide

>  <Main Tar all refs>
Int. J. Mol. Sci., 2022, vol. 23, # 22 | Curr. Med. Chem., 2013, vol. 20, # 10, p. 1241 - 1285 | Int. J. Mol. Sci., 2022, vol. 23, # 22

>  <Main tar all>
Voltage-gated?sodium?channel pX=5.51 | Nav1.7 pX=5.42 | KCa1.1 pX=5.41

$$$$
Ibandronate sodium hydrate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 0 0 0
M  V30 2 Na 16.9668 -2.961 0 0 CHG=1
M  V30 3 C 4.4 -0.0873 0 0
M  V30 4 C 5.7337 0.6827 0 0
M  V30 5 C 7.0674 -0.0873 0 0
M  V30 6 C 8.401 0.6827 0 0
M  V30 7 C 9.7347 -0.0873 0 0
M  V30 8 N 11.0684 0.6827 0 0
M  V30 9 C 11.0684 2.2227 0 0
M  V30 10 C 12.4021 -0.0873 0 0
M  V30 11 C 13.7358 0.6827 0 0
M  V30 12 C 15.0694 -0.0873 0 0
M  V30 13 O 16.4031 -0.8573 0 0
M  V30 14 P 15.8394 1.2464 0 0
M  V30 15 O 16.6094 2.58 0 0
M  V30 16 O 14.5058 2.0164 0 0
M  V30 17 O 17.1731 0.4764 0 0
M  V30 18 P 14.2994 -1.421 0 0
M  V30 19 O 12.9658 -0.651 0 0
M  V30 20 O 13.5294 -2.7547 0 0
M  V30 21 O 15.6331 -2.191 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 4
M  V30 2 1 4 5
M  V30 3 1 5 6
M  V30 4 1 6 7
M  V30 5 1 7 8
M  V30 6 1 8 9
M  V30 7 1 8 10
M  V30 8 1 10 11
M  V30 9 1 11 12
M  V30 10 1 12 13
M  V30 11 1 12 14
M  V30 12 2 14 15
M  V30 13 1 14 16
M  V30 14 1 14 17
M  V30 15 1 12 18
M  V30 16 2 18 19
M  V30 17 1 18 20
M  V30 18 1 18 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553718

>  <MW>
359.087

>  <MW (desalted)>
319.229

>  <ClogP>
-3.627

>  <logS>
1.84

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
141.36

>  <RotBonds>
9

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 20 nM

>  <CAS>
138926-19-9

>  <Description>
Ibandronate sodium hydrate is a bisphosphonate. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate sodium hydrate induces apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl pyrophosphate synthase.

>  <EBC_ID>
EBC-08509

>  <IUPAC Name>
sodium hydrate hydrogen {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate

>  <Main Tar all refs>
J. Med. Chem., 2002, vol. 45, # 11, p. 2185 - 2196

>  <Main tar all>
farnesyl diphosphate synthase pX=7.7

$$$$
Diphenhydramine hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 4.4 -1.2158 0 0
M  V30 3 N 5.7337 -0.4458 0 0
M  V30 4 C 5.7337 1.0942 0 0
M  V30 5 C 7.0674 -1.2158 0 0
M  V30 6 C 8.401 -0.4458 0 0
M  V30 7 O 9.7347 -1.2158 0 0
M  V30 8 C 11.0684 -0.4458 0 0
M  V30 9 C 12.4021 -1.2158 0 0
M  V30 10 C 13.7358 -0.4458 0 0
M  V30 11 C 15.0694 -1.2158 0 0
M  V30 12 C 15.0694 -2.7558 0 0
M  V30 13 C 13.7358 -3.5258 0 0
M  V30 14 C 12.4021 -2.7558 0 0
M  V30 15 C 11.0684 1.0942 0 0
M  V30 16 C 9.7347 1.8642 0 0
M  V30 17 C 9.7347 3.4042 0 0
M  V30 18 C 11.0684 4.1742 0 0
M  V30 19 C 12.4021 3.4042 0 0
M  V30 20 C 12.4021 1.8642 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 3 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 2 9 14
M  V30 14 1 8 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2239078678

>  <MW>
291.139

>  <MW (desalted)>
255.355

>  <ClogP>
3.452

>  <logS>
-3.397

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Antagonist | -

>  <Activity coefficients and valu>
IC50 = 1 nM | EC50  3.1 nM | pA2  8.14

>  <CAS>
147-24-0

>  <Description>
Diphenhydramine is a first-generation H1 receptor antihistamine.  It is used in various allergic conditions such as rhinitis, urticaria and conjunctivitis.

>  <EBC_ID>
EBC-03776

>  <IUPAC Name>
[2-(diphenylmethoxy)ethyl]dimethylamine hydrochloride

>  <Main Tar all refs>
J. MED. CHEM., 1990, vol. 33, # 11, p. 2970 - 2976 | UNIVERSITY OF HULL - WO2007/66068, 2007, A2 | J. Med. Chem., 1971, vol. 14, # 1, p. 24 - 30

>  <Main tar all>
H1 receptor pX=9.0 | TRPV1 pX=8.51 | Histamine receptor pX=8.14

$$$$
Oxcarbazepine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.7665 2.9297 0 0
M  V30 2 C 7.1002 2.1597 0 0
M  V30 3 O 8.4339 2.9297 0 0
M  V30 4 N 7.1002 0.6197 0 0
M  V30 5 C 8.4877 -0.0485 0 0
M  V30 6 C 9.6166 0.999 0 0
M  V30 7 C 11.0882 0.5451 0 0
M  V30 8 C 11.4308 -0.9563 0 0
M  V30 9 C 10.3019 -2.0038 0 0
M  V30 10 C 8.8304 -1.5499 0 0
M  V30 11 C 7.8702 -2.7539 0 0
M  V30 12 C 6.3302 -2.7539 0 0
M  V30 13 O 5.662 -4.1414 0 0
M  V30 14 C 5.37 -1.5499 0 0
M  V30 15 C 3.8984 -2.0038 0 0
M  V30 16 C 2.7695 -0.9563 0 0
M  V30 17 C 3.1122 0.5451 0 0
M  V30 18 C 4.5838 0.999 0 0
M  V30 19 C 5.7127 -0.0485 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 4 19
M  V30 21 2 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551967555

>  <MW>
252.09

>  <MW (desalted)>
252.268

>  <ClogP>
1.206

>  <logS>
-3.163

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
63.4

>  <RotBonds>
0

>  <Action on targets>
Agonist | Inhibitor | Blocker | Blocker | Blocker | Inhibitor | Inhibitor | Inhibitor | Blocker | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  18.1 ?M | inhibition percentage  35 % | inhibition percentage  31.2 % | IC50  95.1 ?M | IC50  95.1 ?M | inhibition percentage  43 % | inhibition percentage  43 % | IC50 = 161 ?M | IC50  211.5 ?M | Ki (inhibition constant)  228 ?M | Ki (inhibition constant)  270 ?M | inhibition percentage  27 % | inhibition percentage  27 % | Ki (inhibition constant)  270 ?M

>  <CAS>
28721-07-5

>  <Description>
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures. The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity.

>  <EBC_ID>
EBC-03777

>  <IUPAC Name>
9-oxo-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide

>  <Main Tar all refs>
Chem. Res. Toxicol., 2008, vol. 21, # 7, p. 1457 - 1467 | Drug Metab. Dispos., 2015, vol. 43, # 6, p. 812 - 818 | J. Med. Chem., 1999, vol. 42, # 14, p. 2582 - 2587 | PAIRNOMIX - WO2018/64498, 2018, A1 | PAIRNOMIX - WO2018/64498, 2018, A1 | Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109 | Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109 | Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, # 1, p. 81 - 104 | PAIRNOMIX - WO2018/64498, 2018, A1 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021014, Owner: NOVARTIS, Number: 000, Revision: 14.01.2000 00:00:00, 2000 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021014, Owner: NOVARTIS, Number: 000, Revision: 14.01.2000 00:00:00, 2000 | Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109 | Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109 | Report Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA021014, Owner: NOVARTIS, Number: 000, Revision: 14.01.2000 00:00:00, 2000

>  <Main tar all>
Pregnane X receptor pX=4.74 | UDP-glucuronosyltransferase 1A1 pX=4.43 | Voltage-gated?sodium?channel pX=4.18 | Nav1.6 pX=4.02 | Nav1.6 pX=4.02 | Liver carboxylesterase 1 pX=3.88 | carboxylesterase 1 pX=3.88 | Nav1.7 pX=3.79 | Sodium channel protein type 8 subunit alpha (R1872Q) pX=3.67 | Cytochrome P450 2C19 pX=3.64 | CYP3A pX=3.57 | Carboxylesterase 2 pX=3.57 | Cocaine esterase pX=3.57 | Cytochrome P450, E-class, CYP3A pX=3.57

$$$$
Voriconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.6313 1.1518 0 0
M  V30 2 C 1.6313 -0.3882 0 0 CFG=1
M  V30 3 C 0.2976 -1.1582 0 0
M  V30 4 N 0.2976 -2.6982 0 0
M  V30 5 C -1.036 -3.4682 0 0
M  V30 6 N -2.3697 -2.6982 0 0
M  V30 7 C -2.3697 -1.1582 0 0
M  V30 8 C -1.036 -0.3882 0 0
M  V30 9 F -1.036 1.1518 0 0
M  V30 10 C 2.965 -1.1582 0 0 CFG=2
M  V30 11 O 2.195 -2.4919 0 0
M  V30 12 C 4.2987 -1.9282 0 0
M  V30 13 N 4.2987 -3.4682 0 0
M  V30 14 C 5.5446 -4.3734 0 0
M  V30 15 N 5.0687 -5.838 0 0
M  V30 16 C 3.5287 -5.838 0 0
M  V30 17 N 3.0528 -4.3734 0 0
M  V30 18 C 3.735 0.1755 0 0
M  V30 19 C 2.965 1.5092 0 0
M  V30 20 C 3.735 2.8429 0 0
M  V30 21 C 5.275 2.8429 0 0
M  V30 22 F 6.045 4.1765 0 0
M  V30 23 C 6.045 1.5092 0 0
M  V30 24 C 5.275 0.1755 0 0
M  V30 25 F 6.045 -1.1582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 2 10
M  V30 11 1 10 11 CFG=3
M  V30 12 1 10 12 CFG=1
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 13 17
M  V30 19 1 10 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 1 23 24
M  V30 26 2 18 24
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521553720

>  <MW>
349.115

>  <MW (desalted)>
349.31

>  <ClogP>
0.523

>  <logS>
-3.749

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
76.72

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  4 nM | IC90  0.066 ?g/ml | MIC  0.008 - 0.015 mg/l | MIC  0.03 ?M | MIC  0.03 ?M | amount  37 nM | MIC80  0.0625 ?g/ml | Kd (dissociation constant)  56 nM | MIC  0.03 - 0.12 ?g/ml | MIC < 0.03 mg/L | MIC80 < 0.125 ?g/ml | MIC80 < 0.125 ?g/ml | MIC  0.0313 ?g/ml | MIC  0.0313 ?g/ml | IC50  0.12 ?M | inhibition percentage  62 % | MIC  0.044 ?g/ml | MIC  0.044 ?g/ml

>  <CAS>
137234-62-9

>  <Description>
Voriconazole is a triazole antifungal medication used to treat serious fungal infections,  including invasive candidiasis, invasive aspergillosis, and emerging fungal infections. Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase.

>  <EBC_ID>
EBC-06050

>  <IUPAC Name>
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2016, vol. 60, # 8, p. 4530 - 4538 | Antimicrob. Agents Chemother., 2018, vol. 62, # 5 | UNIVERSITY OF ILLINOIS (SYSTEM) - WO2021/30183, 2021, A1 | PLoS ONE, 2018, vol. 13, # 1 | PLoS ONE, 2018, vol. 13, # 1 | Bioorg. Med. Chem. Lett., 2017, vol. 27, # 19, p. 4564 - 4570 | J. Med. Chem., 2020, vol. 63, # 10, p. 5341 - 5359 | J. Med. Chem., 2018, vol. 61, # 13, p. 5679 - 5691 | Antimicrob. Agents Chemother., 2019, vol. 63, # 7 | Antimicrob. Agents Chemother., 2014, vol. 58, # 7, p. 3626 - 3635 | Eur. J. Med. Chem., 2021, vol. 221 | Eur. J. Med. Chem., 2021, vol. 221 | Eur. J. Med. Chem., 2023, vol. 257 | Eur. J. Med. Chem., 2023, vol. 257 | Drug Metab. Pharmacokinet., 2021, vol. 39 | Br. J. Clin. Pharmacol., 2010, vol. 69, # 6, p. 593 - 597 | Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, # 2 | THE UNIVERSITY OF TEXAS SYSTEM; HEALTH RESEARCH, INC - WO2021/252068, 2021, A1

>  <Main tar all>
CYP51A1 pX=8.4 | Sterol 14-demethylase (CYP51B) pX=7.68 | sterol 14-demethylase (lanosterol 14alpha-demethylase) pX=7.64 | Plasma Membrane ATPase 1 pX=7.52 | Plasma membrane ATPase 1 pX=7.52 | ATPase, type III secretion system, H+-transporting pX=7.43 | histone deacetylase 1 pX=7.35 | Lanosterol 14-alpha demethylase erg11 pX=7.25 | CYP51A pX=7.07 | Callose synthase pX=7.07 | CYP51A1 pX=7.05 | Histone?deacetylase pX=7.05 | Lanosterol 14-alpha demethylase (Y140F) pX=7.05 | Lanosterol 14-alpha demethylase (Y140H) pX=7.05 | Cytochrome P450 2B6 pX=6.92 | Cytochrome P450 3A4 pX=6.91 | Pre-mRNA-processing-splicing factor 8 pX=6.9 | Pre-mRNA-processing-splicing factor 8 intein pX=6.9

$$$$
Azacitidine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.3337 12.63 0 0
M  V30 2 C 1.3337 11.09 0 0
M  V30 3 N 2.6674 10.32 0 0
M  V30 4 C 2.6674 8.78 0 0
M  V30 5 N 1.3337 8.01 0 0
M  V30 6 C 1.3337 6.47 0 0 CFG=2
M  V30 7 O 2.5796 5.5648 0 0
M  V30 8 C 2.1037 4.1002 0 0 CFG=2
M  V30 9 C 3.0089 2.8543 0 0
M  V30 10 O 4.5404 3.0153 0 0
M  V30 11 C 0.5637 4.1002 0 0 CFG=1
M  V30 12 O -0.3415 2.8543 0 0
M  V30 13 C 0.0878 5.5648 0 0 CFG=1
M  V30 14 O -1.3768 6.0407 0 0
M  V30 15 C 0 8.78 0 0
M  V30 16 O -1.3337 8.01 0 0
M  V30 17 N 0 10.32 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 8
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 6
M  V30 14 1 13 14 CFG=1
M  V30 15 1 5 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 2 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515383340

>  <MW>
244.205

>  <MW (desalted)>
244.205

>  <ClogP>
-2.198

>  <logS>
-0.97

>  <HBD>
4

>  <HBA>
8

>  <TPSA>
140.97

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition rate Active   | Ki (inhibition constant)  0.012 ?M | protein expression level increase Active   | IC50  109.5 nM

>  <CAS>
320-67-2

>  <Description>
Azacitidine is a pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. It is used to treat certain subtypes of myelodysplastic syndrome.

>  <EBC_ID>
EBC-11024

>  <IUPAC Name>
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one

>  <Main Tar all refs>
ASCENTAGE PHARMACEUTICAL GROUP CO LTD - WO2021/18032, 2021, A1 | J. Enzyme Inhib. Med. Chem., 2023, vol. 38, # 1 | ALX ONCOLOGY INC - WO2021/247430, 2021, A1 | CLEAVE THERAPEUTICS INC; CLEAVE THERAPEUTICS - WO2021/231323, 2021, A1

>  <Main tar all>
MDM2 proto-oncogene pX=8.39 | carbonic anhydrase 2 pX=7.92 | DNA methyltransferase pX=7.11 | Transitional endoplasmic reticulum ATPase pX=6.96

$$$$
Sonidegib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.6694 -7.7 0 0
M  V30 2 C 10.6694 -9.24 0 0 CFG=1
M  V30 3 C 12.0031 -10.01 0 0
M  V30 4 N 12.0031 -11.55 0 0
M  V30 5 C 10.6694 -12.32 0 0
M  V30 6 C 9.3358 -11.55 0 0 CFG=1
M  V30 7 C 8.0021 -12.32 0 0
M  V30 8 O 9.3358 -10.01 0 0
M  V30 9 C 13.3368 -12.32 0 0
M  V30 10 C 14.6705 -11.55 0 0
M  V30 11 C 16.0041 -12.32 0 0
M  V30 12 C 16.0041 -13.86 0 0
M  V30 13 N 17.3378 -14.63 0 0
M  V30 14 C 17.3378 -16.17 0 0
M  V30 15 O 16.0041 -16.94 0 0
M  V30 16 C 18.6715 -16.94 0 0
M  V30 17 C 20.0052 -16.17 0 0
M  V30 18 C 21.3389 -16.94 0 0
M  V30 19 C 21.3389 -18.48 0 0
M  V30 20 C 20.0052 -19.25 0 0
M  V30 21 C 18.6715 -18.48 0 0
M  V30 22 C 17.3378 -19.25 0 0
M  V30 23 C 20.0052 -20.79 0 0
M  V30 24 C 21.3389 -21.56 0 0
M  V30 25 C 21.3389 -23.1 0 0
M  V30 26 C 20.0052 -23.87 0 0
M  V30 27 O 20.0052 -25.41 0 0
M  V30 28 C 21.3389 -26.18 0 0
M  V30 29 F 22.6725 -26.95 0 0
M  V30 30 F 20.5689 -27.5137 0 0
M  V30 31 F 22.1089 -24.8463 0 0
M  V30 32 C 18.6715 -23.1 0 0
M  V30 33 C 18.6715 -21.56 0 0
M  V30 34 C 14.6705 -14.63 0 0
M  V30 35 N 13.3368 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 2 8
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 16 21
M  V30 23 1 21 22
M  V30 24 1 20 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 28 31
M  V30 33 2 26 32
M  V30 34 1 32 33
M  V30 35 2 23 33
M  V30 36 2 12 34
M  V30 37 1 34 35
M  V30 38 2 9 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588040168

>  <MW>
485.498

>  <MW (desalted)>
485.498

>  <ClogP>
5.84

>  <logS>
-7.764

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
63.69

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.3 nM | IC50  0.002 - 0.004 ?M | IC50  5.5 nM

>  <CAS>
956697-53-3

>  <Description>
Sonidegib is an antineoplastic agent used for the treatment of locally advanced recurrent basal cell carcinoma following surgery and radiation therapy. Sonidegib effectively inhibits the regulator called smoothened, preventing the hedgehog pathway from functioning.

>  <EBC_ID>
EBC-11443

>  <IUPAC Name>
N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2010, vol. 1, # 3, p. 130 - 134 | Novartis (w/o Sandoz); NOVARTIS AG - EP3023097, 2016, A1 | Eur. J. Med. Chem., 2016, vol. 110, p. 115 - 125

>  <Main tar all>
SMO pX=8.89 | SMO pX=8.7 | Hedgehog protein, Hint domain pX=8.26

$$$$
Conivaptan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 43 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.7731 1.3602 0 0
M  V30 2 C 9.6075 0.3537 0 0
M  V30 3 N 8.1081 0.7052 0 0
M  V30 4 C 7.3105 -0.6122 0 0
M  V30 5 C 8.317 -1.7778 0 0
M  V30 6 C 8.0331 -3.2915 0 0
M  V30 7 C 6.6728 -4.0133 0 0
M  V30 8 N 5.2603 -3.3998 0 0
M  V30 9 C 4.0946 -4.4062 0 0
M  V30 10 O 4.3834 -5.9189 0 0
M  V30 11 C 2.6402 -3.9 0 0
M  V30 12 C 1.4746 -4.9064 0 0
M  V30 13 C 0.0202 -4.4002 0 0
M  V30 14 C -0.2686 -2.8875 0 0
M  V30 15 N -1.723 -2.3812 0 0
M  V30 16 C -2.0118 -0.8686 0 0
M  V30 17 O -0.8462 0.1379 0 0
M  V30 18 C -3.4662 -0.3623 0 0
M  V30 19 C -4.6318 -1.3687 0 0
M  V30 20 C -6.0862 -0.8625 0 0
M  V30 21 C -6.375 0.6502 0 0
M  V30 22 C -5.2094 1.6566 0 0
M  V30 23 C -3.755 1.1504 0 0
M  V30 24 C -2.5894 2.1568 0 0
M  V30 25 C -2.8781 3.6695 0 0
M  V30 26 C -1.7125 4.6759 0 0
M  V30 27 C -0.2581 4.1697 0 0
M  V30 28 C 0.0307 2.657 0 0
M  V30 29 C -1.135 1.6506 0 0
M  V30 30 C 0.897 -1.881 0 0
M  V30 31 C 2.3514 -2.3873 0 0
M  V30 32 C 4.8593 -1.9129 0 0
M  V30 33 C 3.3287 -1.743 0 0
M  V30 34 C 2.7105 -0.3325 0 0
M  V30 35 C 3.623 0.9081 0 0
M  V30 36 C 5.1536 0.7382 0 0
M  V30 37 C 5.7717 -0.6723 0 0
M  V30 38 N 9.7365 -1.1809 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 18 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 24 29
M  V30 31 2 14 30
M  V30 32 1 30 31
M  V30 33 2 11 31
M  V30 34 1 8 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 2 35 36
M  V30 39 1 36 37
M  V30 40 1 4 37
M  V30 41 2 32 37
M  V30 42 1 5 38
M  V30 43 1 2 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038959

>  <MW>
498.574

>  <MW (desalted)>
498.574

>  <ClogP>
5.002

>  <logS>
-8.855

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
78.09

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi = 9.32  | pKi = 9.32  | pKi = 8.95

>  <CAS>
210101-16-9

>  <Description>
Conivaptan is an antidiuretic hormone inhibitor used to raise serum sodium levels.

>  <EBC_ID>
EBC-27237

>  <IUPAC Name>
N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),2(6),3,11,13-pentaene-9-carbonyl}phenyl)-[1,1'-biphenyl]-2-carboxamide

>  <Main Tar all refs>
Chem. Biol. Drug Des., 2014, vol. 83, # 2, p. 207 - 223 | Chem. Biol. Drug Des., 2014, vol. 83, # 2, p. 207 - 223 | CUMBERLAND PHARMACEUTICALS INC; ASTELLAS PHARMA INC. - US2004/176354, 2004, A1

>  <Main tar all>
V1A receptor pX=9.32 | V1A receptor pX=9.32 | V2 receptor pX=8.95

$$$$
Clopidogrel hydrogen sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.7164 2.42 0 0
M  V30 2 O -0.3827 3.19 0 0
M  V30 3 C 0.9509 2.42 0 0
M  V30 4 O 2.2846 3.19 0 0
M  V30 5 C 0.9509 0.88 0 0 CFG=1
M  V30 6 N -0.3827 0.11 0 0
M  V30 7 C -0.3827 -1.43 0 0
M  V30 8 C -1.7164 -2.2 0 0
M  V30 9 C -3.0501 -1.43 0 0
M  V30 10 S -4.5147 -1.9059 0 0
M  V30 11 C -5.4199 -0.66 0 0
M  V30 12 C -4.5147 0.5859 0 0
M  V30 13 C -3.0501 0.11 0 0
M  V30 14 C -1.7164 0.88 0 0
M  V30 15 C 2.2846 0.11 0 0
M  V30 16 C 3.6183 0.88 0 0
M  V30 17 C 4.952 0.11 0 0
M  V30 18 C 4.952 -1.43 0 0
M  V30 19 C 3.6183 -2.2 0 0
M  V30 20 C 2.2846 -1.43 0 0
M  V30 21 Cl 0.9509 -2.2 0 0
M  V30 22 O 10.012 -1.54 0 0
M  V30 23 S 10.012 0 0 0
M  V30 24 O 10.012 1.54 0 0
M  V30 25 O 11.552 -0 0 0
M  V30 26 O 8.472 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 5 3 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 9 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 5 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 15 20
M  V30 23 1 20 21
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 2 23 25
M  V30 27 1 23 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759896

>  <MW>
419.9

>  <MW (desalted)>
321.822

>  <ClogP>
4.208

>  <logS>
-2.85

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
29.54

>  <RotBonds>
4

>  <Action on targets>
Substrate

>  <Activity coefficients and valu>
concentration (parameter)  0.53 - 0.62 ng/ml

>  <CAS>
113665-84-2

>  <Description>
Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.

>  <EBC_ID>
EBC-07538

>  <IUPAC Name>
methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; sulfuric acid

>  <Main Tar all refs>
TASLY PHARMACEUTICAL GROUP CO., LTD. - EP3315505, 2018, A1

>  <Main tar all>
Esterase pX=8.9

$$$$
Aliskiren fumarate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 86 85 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.0123 -3.8954 0 0
M  V30 2 O 9.5 -3.6043 0 0
M  V30 3 C 8.9959 -2.1492 0 0
M  V30 4 C 7.4837 -1.8581 0 0
M  V30 5 C 6.9796 -0.403 0 0
M  V30 6 O 5.4674 -0.1119 0 0
M  V30 7 C 4.9633 1.3432 0 0
M  V30 8 C 3.451 1.6343 0 0
M  V30 9 C 2.9469 3.0894 0 0
M  V30 10 C 1.4347 3.3805 0 0
M  V30 11 C 0.4265 2.2163 0 0 CFG=1
M  V30 12 C -1.0857 2.5074 0 0
M  V30 13 C -2.0939 1.3432 0 0 CFG=2
M  V30 14 N -1.5898 -0.1119 0 0
M  V30 15 C -3.6061 1.6343 0 0 CFG=1
M  V30 16 O -4.1102 3.0894 0 0
M  V30 17 C -4.6143 0.4701 0 0
M  V30 18 C -6.1266 0.7612 0 0 CFG=1
M  V30 19 C -6.6306 2.2163 0 0
M  V30 20 C -8.1429 2.5074 0 0
M  V30 21 C -5.6225 3.3805 0 0
M  V30 22 C -7.1347 -0.403 0 0
M  V30 23 O -8.647 -0.1119 0 0
M  V30 24 N -6.6306 -1.8581 0 0
M  V30 25 C -5.1184 -2.1492 0 0
M  V30 26 C -4.6143 -3.6043 0 0
M  V30 27 C -6.0695 -4.1084 0 0
M  V30 28 C -3.1591 -3.1002 0 0
M  V30 29 C -4.1102 -5.0595 0 0
M  V30 30 O -2.598 -5.3505 0 0
M  V30 31 N -5.1184 -6.2236 0 0
M  V30 32 C 0.9306 0.7612 0 0
M  V30 33 C 2.4429 0.4701 0 0
M  V30 34 C -0.0776 -0.403 0 0
M  V30 35 C 3.9551 4.2536 0 0
M  V30 36 C 5.4674 3.9625 0 0
M  V30 37 C 5.9714 2.5074 0 0
M  V30 38 O 7.4837 2.2163 0 0
M  V30 39 C 7.9878 0.7612 0 0
M  V30 40 C 34.5674 -3.8954 0 0
M  V30 41 O 33.0552 -3.6043 0 0
M  V30 42 C 32.5511 -2.1492 0 0
M  V30 43 C 31.0389 -1.8581 0 0
M  V30 44 C 30.5348 -0.403 0 0
M  V30 45 O 29.0225 -0.1119 0 0
M  V30 46 C 28.5184 1.3432 0 0
M  V30 47 C 27.0062 1.6343 0 0
M  V30 48 C 26.5021 3.0894 0 0
M  V30 49 C 24.9899 3.3805 0 0
M  V30 50 C 23.9817 2.2163 0 0 CFG=1
M  V30 51 C 22.4694 2.5074 0 0
M  V30 52 C 21.4613 1.3432 0 0 CFG=2
M  V30 53 N 21.9654 -0.1119 0 0
M  V30 54 C 19.949 1.6343 0 0 CFG=1
M  V30 55 O 19.4449 3.0894 0 0
M  V30 56 C 18.9409 0.4701 0 0
M  V30 57 C 17.4286 0.7612 0 0 CFG=1
M  V30 58 C 16.9245 2.2163 0 0
M  V30 59 C 15.4123 2.5074 0 0
M  V30 60 C 17.9327 3.3805 0 0
M  V30 61 C 16.4204 -0.403 0 0
M  V30 62 O 14.9082 -0.1119 0 0
M  V30 63 N 16.9245 -1.8581 0 0
M  V30 64 C 18.4368 -2.1492 0 0
M  V30 65 C 18.9409 -3.6043 0 0
M  V30 66 C 17.4857 -4.1084 0 0
M  V30 67 C 20.396 -3.1002 0 0
M  V30 68 C 19.4449 -5.0595 0 0
M  V30 69 O 20.9572 -5.3505 0 0
M  V30 70 N 18.4368 -6.2236 0 0
M  V30 71 C 24.4858 0.7612 0 0
M  V30 72 C 25.998 0.4701 0 0
M  V30 73 C 23.4776 -0.403 0 0
M  V30 74 C 27.5103 4.2536 0 0
M  V30 75 C 29.0225 3.9625 0 0
M  V30 76 C 29.5266 2.5074 0 0
M  V30 77 O 31.0389 2.2163 0 0
M  V30 78 C 31.5429 0.7612 0 0
M  V30 79 O 3.08 -10.6373 0 0
M  V30 80 C 1.54 -10.6373 0 0
M  V30 81 O 0.77 -9.3036 0 0
M  V30 82 C 0.77 -11.971 0 0
M  V30 83 C -0.77 -11.971 0 0
M  V30 84 C -1.54 -13.3047 0 0
M  V30 85 O -0.77 -14.6383 0 0
M  V30 86 O -3.08 -13.3047 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=3
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15
M  V30 15 1 15 16 CFG=3
M  V30 16 1 15 17
M  V30 17 1 18 17 CFG=3
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 1 18 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 26 28
M  V30 28 1 26 29
M  V30 29 2 29 30
M  V30 30 1 29 31
M  V30 31 1 11 32
M  V30 32 1 32 33
M  V30 33 1 32 34
M  V30 34 1 9 35
M  V30 35 2 35 36
M  V30 36 1 36 37
M  V30 37 2 7 37
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 40 41
M  V30 41 1 41 42
M  V30 42 1 42 43
M  V30 43 1 43 44
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 2 47 48
M  V30 48 1 48 49
M  V30 49 1 50 49 CFG=3
M  V30 50 1 50 51
M  V30 51 1 52 51
M  V30 52 1 52 53 CFG=3
M  V30 53 1 52 54
M  V30 54 1 54 55 CFG=3
M  V30 55 1 54 56
M  V30 56 1 57 56 CFG=3
M  V30 57 1 57 58
M  V30 58 1 58 59
M  V30 59 1 58 60
M  V30 60 1 57 61
M  V30 61 2 61 62
M  V30 62 1 61 63
M  V30 63 1 63 64
M  V30 64 1 64 65
M  V30 65 1 65 66
M  V30 66 1 65 67
M  V30 67 1 65 68
M  V30 68 2 68 69
M  V30 69 1 68 70
M  V30 70 1 50 71
M  V30 71 1 71 72
M  V30 72 1 71 73
M  V30 73 1 48 74
M  V30 74 2 74 75
M  V30 75 1 75 76
M  V30 76 2 46 76
M  V30 77 1 76 77
M  V30 78 1 77 78
M  V30 79 1 79 80
M  V30 80 2 80 81
M  V30 81 1 80 82
M  V30 82 2 82 83
M  V30 83 1 83 84
M  V30 84 2 84 85
M  V30 85 1 84 86
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2568726960

>  <MW>
1218.798

>  <MW (desalted)>
551.758

>  <ClogP>
3.514

>  <logS>
-7.401

>  <HBD>
4

>  <HBA>
7

>  <TPSA>
146.13

>  <RotBonds>
40

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 0.4 nM | IC50 = 0.6 nM

>  <CAS>
173334-58-2

>  <Description>
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.

>  <EBC_ID>
EBC-15050

>  <IUPAC Name>
(2E)-but-2-enedioic acid; bis((2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide)

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2011, vol. 2, # 10, p. 747 - 751 | Annu. Rep. Med. Chem., 2006, vol. 41, p. 155 - 157

>  <Main tar all>
renin pX=9.4 | Pepsin A pX=9.22

$$$$
Darifenacin hydrobromide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Br 0 0 0 0
M  V30 2 N 14.1194 5.1829 0 0
M  V30 3 C 15.0246 3.937 0 0
M  V30 4 O 16.5562 4.098 0 0
M  V30 5 C 14.3982 2.5302 0 0
M  V30 6 C 13.7719 1.1233 0 0 CFG=2
M  V30 7 C 14.5419 -0.2104 0 0
M  V30 8 C 13.5114 -1.3548 0 0
M  V30 9 N 12.1045 -0.7284 0 0
M  V30 10 C 10.7709 -1.4984 0 0
M  V30 11 C 10.7709 -3.0384 0 0
M  V30 12 C 9.4372 -3.8084 0 0
M  V30 13 C 9.4372 -5.3484 0 0
M  V30 14 C 8.1035 -6.1184 0 0
M  V30 15 C 6.7698 -5.3484 0 0
M  V30 16 O 5.3052 -5.8243 0 0
M  V30 17 C 4.4 -4.5784 0 0
M  V30 18 C 5.3052 -3.3326 0 0
M  V30 19 C 6.7698 -3.8084 0 0
M  V30 20 C 8.1035 -3.0384 0 0
M  V30 21 C 12.2655 0.8031 0 0
M  V30 22 C 12.9914 3.1565 0 0
M  V30 23 C 11.7455 2.2514 0 0
M  V30 24 C 10.3386 2.8777 0 0
M  V30 25 C 10.1776 4.4093 0 0
M  V30 26 C 11.4235 5.3145 0 0
M  V30 27 C 12.8304 4.6881 0 0
M  V30 28 C 15.8051 1.9038 0 0
M  V30 29 C 17.051 2.809 0 0
M  V30 30 C 18.4578 2.1826 0 0
M  V30 31 C 18.6188 0.651 0 0
M  V30 32 C 17.3729 -0.2541 0 0
M  V30 33 C 15.9661 0.3722 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 3 5
M  V30 4 1 6 5 CFG=3
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 1 18 19
M  V30 18 2 15 19
M  V30 19 1 19 20
M  V30 20 2 12 20
M  V30 21 1 9 21
M  V30 22 1 6 21
M  V30 23 1 5 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 22 27
M  V30 30 1 5 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 2 28 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616192

>  <MW>
507.462

>  <MW (desalted)>
426.55

>  <ClogP>
3.621

>  <logS>
-4.94

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
55.56

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  9.56  | pKb  9.31  | Ki (inhibition constant) = 2.3 nM | Ki (inhibition constant) = 5.5 nM | Ki (inhibition constant) = 8.6 nM

>  <CAS>
133099-07-7

>  <Description>
Darifenacin is an M3 muscarinic receptor blocker used to treat urinary incontinence.

>  <EBC_ID>
EBC-11257

>  <IUPAC Name>
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 328, # 3, p. 893 - 899 | Pharmacol. Res., 2009, vol. 59, # 5, p. 300 - 305 | J. Med. Chem., 2002, vol. 45, # 4, p. 984 - 987 | J. Med. Chem., 2002, vol. 45, # 4, p. 984 - 987 | J. Med. Chem., 2002, vol. 45, # 4, p. 984 - 987

>  <Main tar all>
mAChR pX=9.56 | M3 receptor pX=9.31 | M5 receptor pX=8.64 | M1 receptor pX=8.26 | M4 receptor pX=8.07

$$$$
(R/S)-Colchicine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7023 -4.3636 0 0
M  V30 2 O 2.2152 -2.9115 0 0
M  V30 3 C 3.7291 -2.6296 0 0
M  V30 4 C 4.242 -1.1775 0 0
M  V30 5 C 5.756 -0.8956 0 0
M  V30 6 C 6.0467 0.6167 0 0
M  V30 7 C 7.4103 1.3324 0 0
M  V30 8 C 8.82 0.7124 0 0
M  V30 9 N 9.9902 1.7136 0 0
M  V30 10 C 9.7083 3.2275 0 0
M  V30 11 O 8.2562 3.7404 0 0
M  V30 12 C 10.8785 4.2287 0 0
M  V30 13 C 9.2143 -0.7762 0 0
M  V30 14 C 10.7533 -0.7231 0 0
M  V30 15 C 11.7545 -1.8933 0 0
M  V30 16 O 13.2431 -1.4991 0 0
M  V30 17 C 11.4638 -3.4057 0 0
M  V30 18 O 12.7002 -4.3237 0 0
M  V30 19 C 14.1135 -3.712 0 0
M  V30 20 C 10.1001 -4.1213 0 0
M  V30 21 C 8.6904 -3.5013 0 0
M  V30 22 C 8.2962 -2.0127 0 0
M  V30 23 C 6.7571 -2.0658 0 0
M  V30 24 C 6.2442 -3.5179 0 0
M  V30 25 O 7.2454 -4.6881 0 0
M  V30 26 C 6.7325 -6.1401 0 0
M  V30 27 C 4.7303 -3.7998 0 0
M  V30 28 O 4.2174 -5.2519 0 0
M  V30 29 C 2.7034 -5.5338 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 8 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 17 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 13 22
M  V30 23 1 22 23
M  V30 24 1 5 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 24 27
M  V30 29 2 3 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1431321925

>  <MW>
399.437

>  <MW (desalted)>
399.437

>  <ClogP>
1.195

>  <logS>
-4.63

>  <HBD>
1

>  <HBA>
6

>  <TPSA>
83.09

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | - | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 13 nM | EC50 = 0.014 ?M | IC50  0.02 ?M | IC50  0.02 ?M | IC50 = 37 nM

>  <CAS>
54192-66-4

>  <Description>
(R/S)-Colchicine is a racemic colchicine mixture. Colchicine is an alkaloid used in the symptomatic relief of pain in attacks of gout and to treat the inflammatory symptoms of Familial Mediterranean Fever. Colchicine acts via the downstream inhibition of inflammation caused by tubulin disruption.

>  <EBC_ID>
EBC-15033

>  <IUPAC Name>
N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0,2,7]hexadeca-1(16),2,4,6,11,14-hexaen-10-yl}acetamide

>  <Main Tar all refs>
PFIZER INC - US2005/75357, 2005, A1 | Bioorg. Med. Chem. Lett., 2009, vol. 19, # 15, p. 4410 - 4415 | Bioorg. Med. Chem., 2011, vol. 19, # 14, p. 4183 - 4191 | Eur. J. Med. Chem., 2010, vol. 45, # 8, p. 3420 - 3438 | PFIZER INC - US2005/75357, 2005, A1

>  <Main tar all>
ABCB1 pX=7.89 | Caspase pX=7.85 | Microtubule Protein pX=7.7 | tubulin alpha 1a pX=7.7 | ABCG2 pX=7.43

$$$$
Zidovudine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1992 8.895 0 0
M  V30 2 C -1.1345 8.125 0 0
M  V30 3 C -1.1345 6.585 0 0
M  V30 4 N -2.4682 5.815 0 0
M  V30 5 C -2.4682 4.275 0 0 CFG=1
M  V30 6 C -1.2223 3.3698 0 0
M  V30 7 C -1.6982 1.9052 0 0 CFG=2
M  V30 8 N -0.793 0.6593 0 0
M  V30 9 N 0.7386 0.8203 0 0 CHG=1
M  V30 10 N 2.2701 0.9812 0 0 CHG=-1
M  V30 11 C -3.2382 1.9052 0 0 CFG=1
M  V30 12 C -4.1434 0.6593 0 0
M  V30 13 O -5.6749 0.8203 0 0
M  V30 14 O -3.7141 3.3698 0 0
M  V30 15 C -3.8019 6.585 0 0
M  V30 16 O -5.1355 5.815 0 0
M  V30 17 N -3.8019 8.125 0 0
M  V30 18 C -2.4682 8.895 0 0
M  V30 19 O -2.4682 10.435 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 2 8 9
M  V30 9 2 9 10
M  V30 10 1 7 11
M  V30 11 1 11 12 CFG=1
M  V30 12 1 12 13
M  V30 13 1 11 14
M  V30 14 1 5 14
M  V30 15 1 4 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 2 18
M  V30 20 2 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z754931264

>  <MW>
267.241

>  <MW (desalted)>
267.241

>  <ClogP>
0.044

>  <logS>
-0.68

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
108.3

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.021 nM | Ki (inhibition constant)  0.03 nM | inhibition percentage  32 % | inhibition percentage  32 % | inhibition percentage  32 % | inhibition percentage  32 % | IC50 = 0.18 nM | Ki (inhibition constant)  0.205 nM | IC50  0.23 nM | IC50  0.23 nM

>  <CAS>
30516-87-1

>  <Description>
Zidovudine is a dideoxynucleoside compound. It is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. It is used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.

>  <EBC_ID>
EBC-13244

>  <IUPAC Name>
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | SAMARITAN PHARMACEUTICALS; GEORGETOWN UNIVERSITY - WO2004/108076, 2004, A2 | GEORGETOWN UNIVERSITY; SAMARITAN PHARMACEUTICALS - WO2004/108076, 2004, A2 | SAMARITAN PHARMACEUTICALS; GEORGETOWN UNIVERSITY - WO2004/108076, 2004, A2 | SAMARITAN PHARMACEUTICALS; GEORGETOWN UNIVERSITY - WO2004/108076, 2004, A2 | JAPAN TOBACCO INC - WO2007/89030, 2007, A1 | J. Pharmacol. Exp. Ther., 2009, vol. 329, # 1, p. 252 - 261 | HOWARD UNIVERSITY - US2017/8839, 2017, A1 | HOWARD UNIVERSITY - US2017/8839, 2017, A1

>  <Main tar all>
Organic cation transporter 1 pX=10.7 | Organic cation transporter 3 pX=10.5 | CCR5 pX=10.2 | CCR5 pX=10.2 | CD4 pX=10.2 | CXCR4 pX=10.2 | RNA-directed DNA polymerase pX=9.74 | Organic cation transporter 2 pX=9.69 | Integrase pX=9.64 | Integrase pX=9.64

$$$$
Letrozole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 5.5339 2.965 0 0
M  V30 2 C 4.2002 2.195 0 0
M  V30 3 C 2.8665 1.425 0 0
M  V30 4 C 2.8665 -0.115 0 0
M  V30 5 C 1.5329 -0.885 0 0
M  V30 6 C 0.1992 -0.115 0 0
M  V30 7 C 0.1992 1.425 0 0
M  V30 8 C 1.5329 2.195 0 0
M  V30 9 C -1.1345 -0.885 0 0
M  V30 10 C -2.4682 -0.115 0 0
M  V30 11 C -3.8019 -0.885 0 0
M  V30 12 C -5.1355 -0.115 0 0
M  V30 13 C -5.1355 1.425 0 0
M  V30 14 C -6.4692 2.195 0 0
M  V30 15 N -7.8029 2.965 0 0
M  V30 16 C -3.8019 2.195 0 0
M  V30 17 C -2.4682 1.425 0 0
M  V30 18 N -1.1345 -2.425 0 0
M  V30 19 C 0.1114 -3.3302 0 0
M  V30 20 N -0.3645 -4.7948 0 0
M  V30 21 C -1.9045 -4.7948 0 0
M  V30 22 N -2.3804 -3.3302 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 3 14 15
M  V30 16 2 13 16
M  V30 17 1 16 17
M  V30 18 2 10 17
M  V30 19 1 9 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 18 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741968261

>  <MW>
285.303

>  <MW (desalted)>
285.303

>  <ClogP>
1.429

>  <logS>
-4.12

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
78.29

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.02 nM | Ki (inhibition constant) = 0.02 nM | IC50  0.46 - 0.66 nM

>  <CAS>
112809-51-5

>  <Description>
Letrozole is an orally active aromatase inhibitor. It is used in the treatment of hormonally-responsive breast cancer after surgery.

>  <EBC_ID>
EBC-04408

>  <IUPAC Name>
4-[(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]benzonitrile

>  <Main Tar all refs>
Bioorg. Med. Chem., 2012, vol. 20, # 7, p. 2427 - 2434 | Bioorg. Med. Chem., 2012, vol. 20, # 7, p. 2427 - 2434 | THERAMEX SA - EP1431292, 2004, A1

>  <Main tar all>
CYP19A1 pX=10.7 | CYP19A1 pX=10.7 | Aromatase (gene CYP19A1) pX=9.34

$$$$
Cephalexin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.0529 1.0518 0 0
M  V30 2 C 3.7192 1.8218 0 0
M  V30 3 C 2.3855 1.0518 0 0
M  V30 4 N 1.0518 1.8218 0 0
M  V30 5 C 1.0518 3.3618 0 0 CFG=2
M  V30 6 S 2.3855 4.1318 0 0
M  V30 7 C 3.7192 3.3618 0 0
M  V30 8 C -0.4882 3.3618 0 0 CFG=2
M  V30 9 N -1.5771 4.4508 0 0
M  V30 10 C -1.1785 5.9383 0 0
M  V30 11 O 0.309 6.3369 0 0
M  V30 12 C -2.2675 7.0273 0 0 CFG=2
M  V30 13 N -3.755 6.6287 0 0
M  V30 14 C -1.8689 8.5148 0 0
M  V30 15 C -2.9578 9.6037 0 0
M  V30 16 C -2.5592 11.0913 0 0
M  V30 17 C -1.0717 11.4898 0 0
M  V30 18 C 0.0172 10.4009 0 0
M  V30 19 C -0.3814 8.9134 0 0
M  V30 20 C -0.4882 1.8218 0 0
M  V30 21 O -1.5771 0.7329 0 0
M  V30 22 C 2.3855 -0.4882 0 0
M  V30 23 O 1.0518 -1.2582 0 0
M  V30 24 O 3.7192 -1.2582 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 21 1 8 20
M  V30 22 1 4 20
M  V30 23 2 20 21
M  V30 24 1 3 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1880962282

>  <MW>
347.389

>  <MW (desalted)>
347.389

>  <ClogP>
-1.84

>  <logS>
-3.959

>  <HBD>
3

>  <HBA>
5

>  <TPSA>
112.73

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.035 ?g/ml | IC50 = 1627 nM | IC50  0.67 ?g/ml

>  <CAS>
15686-71-2

>  <Description>
Cephalexin is used to treat certain susceptible bacterial infections.

>  <EBC_ID>
EBC-26680

>  <IUPAC Name>
(6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

>  <Main Tar all refs>
Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555 | Antimicrob. Agents Chemother., 1999, vol. 43, # 5, p. 1124 - 1128 | Antimicrob. Agents Chemother., 2015, vol. 59, # 6, p. 3548 - 3555

>  <Main tar all>
Penicillin-binding?protein?3 pX=7.0 | Penicillin-binding?protein 2X pX=5.79 | Penicillin-binding?protein 2X pX=5.71

$$$$
Sulfasalazine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 10.6694 -3.08 0 0
M  V30 2 C 12.0031 -3.85 0 0
M  V30 3 O 13.3368 -3.08 0 0
M  V30 4 C 12.0031 -5.39 0 0
M  V30 5 C 13.3368 -6.16 0 0
M  V30 6 C 13.3368 -7.7 0 0
M  V30 7 N 14.6705 -8.47 0 0
M  V30 8 N 16.0041 -7.7 0 0
M  V30 9 C 17.3378 -8.47 0 0
M  V30 10 C 18.6715 -7.7 0 0
M  V30 11 C 20.0052 -8.47 0 0
M  V30 12 C 20.0052 -10.01 0 0
M  V30 13 C 18.6715 -10.78 0 0
M  V30 14 C 17.3378 -10.01 0 0
M  V30 15 S 21.3389 -10.78 0 0
M  V30 16 O 20.5689 -12.1137 0 0
M  V30 17 O 22.1089 -9.4463 0 0
M  V30 18 N 22.6725 -11.55 0 0
M  V30 19 C 22.6725 -13.09 0 0
M  V30 20 C 24.0062 -13.86 0 0
M  V30 21 C 24.0062 -15.4 0 0
M  V30 22 C 22.6725 -16.17 0 0
M  V30 23 C 21.3389 -15.4 0 0
M  V30 24 N 21.3389 -13.86 0 0
M  V30 25 C 12.0031 -8.47 0 0
M  V30 26 C 10.6694 -7.7 0 0
M  V30 27 C 10.6694 -6.16 0 0
M  V30 28 O 9.3358 -5.39 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 6 CFG=2
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 12 15
M  V30 16 2 15 16
M  V30 17 2 15 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 19 24
M  V30 26 1 6 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 4 27
M  V30 30 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1521554012

>  <MW>
398.393

>  <MW (desalted)>
398.393

>  <ClogP>
3.88

>  <logS>
-3.95

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
141.31

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Stimulator

>  <Activity coefficients and valu>
IC50  39.5 nM | IC50  0.043 ?M | IC50  0.3 ?M | IC50  0.39 ?M | EC50  916 nM

>  <CAS>
599-79-1

>  <Description>
Sulfasalazine is a prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is covalently linked to the antibiotic sulfapyridine by an azo bond. Sulfasalazine inhibits cystine uptake through the system xc- cysteine-glutamate transporter, also inhibits sepiapterin reductase. Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis.

>  <EBC_ID>
EBC-04435

>  <IUPAC Name>
2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid

>  <Main Tar all refs>
Mol. Diversity, 2016, vol. 20, # 2, p. 439 - 451 | J. Biol. Chem., 2016, vol. 291, # 2, p. 652 - 657 | PLoS ONE, 2019, vol. 14, # 3 | Eur. J. Pharmacol., 2014, vol. 723, # 1, p. 346 - 352 | Eur. J. Med. Chem., 2020, vol. 191

>  <Main tar all>
Neuraminidase pX=7.4 | Sepiapterin reductase (SPR) pX=7.37 | glutathione S-transferase mu 2 pX=6.52 | V-type ATPase V1 motor A subunit pX=6.41 | ABCG2 pX=6.04

$$$$
Granisetron
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.6338 -9.6548 0 0
M  V30 2 N -1.1097 -8.1902 0 0
M  V30 3 C -2.8679 -7.09 0 0 CFG=1
M  V30 4 C -2.7471 -8.6253 0 0
M  V30 5 C -1.5761 -9.6254 0 0
M  V30 6 C -0.0408 -9.5046 0 0
M  V30 7 C 0.9593 -8.3336 0 0 CFG=2
M  V30 8 C 0.8385 -6.7983 0 0
M  V30 9 C -0.3325 -5.7982 0 0 CFG=1
M  V30 10 C -1.8678 -5.919 0 0
M  V30 11 N 0.1434 -4.3335 0 0
M  V30 12 C 1.6497 -4.0133 0 0
M  V30 13 O 2.6802 -5.1578 0 0
M  V30 14 C 2.1256 -2.5487 0 0
M  V30 15 N 1.2204 -1.3028 0 0
M  V30 16 N 2.1256 -0.0569 0 0
M  V30 17 C 1.6497 1.4077 0 0
M  V30 18 C 3.5902 -0.5328 0 0
M  V30 19 C 4.9239 0.2372 0 0
M  V30 20 C 6.2576 -0.5328 0 0
M  V30 21 C 6.2576 -2.0728 0 0
M  V30 22 C 4.9239 -2.8428 0 0
M  V30 23 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 2 CFG=3
M  V30 8 1 7 8
M  V30 9 1 9 8
M  V30 10 1 9 10
M  V30 11 1 3 10
M  V30 12 1 9 11 CFG=1
M  V30 13 1 11 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 14 23
M  V30 26 2 18 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2588038960

>  <MW>
312.195

>  <MW (desalted)>
312.409

>  <ClogP>
1.715

>  <logS>
-2.757

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
50.16

>  <RotBonds>
2

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pIC50  10.48 | pIC50  10.35 | Kd (dissociation constant)  0.083 nM | Kd (dissociation constant)  0.17 nM | Kd (dissociation constant)  0.2 nM

>  <CAS>
109889-09-0

>  <Description>
Granisetron is a serotonin 5-HT3 receptor antagonist. It is used as an antiemetic to treat nausea and vomiting following chemotherapy.

>  <EBC_ID>
EBC-03921

>  <IUPAC Name>
1-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-1H-indazole-3-carboxamide

>  <Main Tar all refs>
Neuropharmacology, 2014, vol. 86, p. 378 - 388 | Neuropharmacology, 2014, vol. 86, p. 378 - 388 | J. Biol. Chem., 2004, vol. 279, # 22, p. 23294 - 23301 | J. Biol. Chem., 2000, vol. 275, # 8, p. 5620 - 5625 | Bioorg. Med. Chem., 2013, vol. 21, # 23, p. 7523 - 7528

>  <Main tar all>
5-HT3A pX=10.5 | 5-HT3B pX=10.4 | 5-HT3AB pX=10.1 | 5-HT3A pX=9.77 | 5-HT3B pX=9.7

$$$$
Tolvaptan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.9237 11.4232 0 0
M  V30 2 C 11.3953 10.9693 0 0
M  V30 3 C 12.5242 12.0167 0 0
M  V30 4 C 13.9957 11.5628 0 0
M  V30 5 C 14.3384 10.0614 0 0
M  V30 6 C 13.2095 9.014 0 0
M  V30 7 C 11.7379 9.4679 0 0
M  V30 8 C 10.609 8.4204 0 0
M  V30 9 O 9.1375 8.8743 0 0
M  V30 10 N 10.9517 6.919 0 0
M  V30 11 C 9.8228 5.8716 0 0
M  V30 12 C 10.1655 4.3702 0 0
M  V30 13 C 9.0366 3.3227 0 0
M  V30 14 C 7.565 3.7766 0 0
M  V30 15 C 6.4361 2.7292 0 0
M  V30 16 O 4.9645 3.1831 0 0
M  V30 17 N 6.7788 1.2278 0 0
M  V30 18 C 8.2802 0.8851 0 0
M  V30 19 C 8.9484 -0.5024 0 0
M  V30 20 C 8.2802 -1.8899 0 0
M  V30 21 C 6.7788 -2.2326 0 0
M  V30 22 O 6.4361 -3.734 0 0
M  V30 23 C 5.5748 -1.2724 0 0
M  V30 24 C 4.2411 -2.0424 0 0
M  V30 25 C 2.9074 -1.2724 0 0
M  V30 26 Cl 1.5737 -2.0424 0 0
M  V30 27 C 2.9074 0.2676 0 0
M  V30 28 C 4.2411 1.0376 0 0
M  V30 29 C 5.5748 0.2676 0 0
M  V30 30 C 7.2223 5.278 0 0
M  V30 31 C 5.7508 5.7319 0 0
M  V30 32 C 8.3512 6.3255 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 1 17 29
M  V30 31 2 23 29
M  V30 32 2 14 30
M  V30 33 1 30 31
M  V30 34 1 30 32
M  V30 35 2 11 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610480

>  <MW>
448.155

>  <MW (desalted)>
448.941

>  <ClogP>
4.31

>  <logS>
-7.597

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
69.64

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.0008 nM

>  <CAS>
150683-30-0

>  <Description>
Tolvaptan is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist.

>  <EBC_ID>
EBC-07798

>  <IUPAC Name>
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2006, vol. 316, # 2, p. 564 - 571

>  <Main tar all>
V2 receptor pX=12.1

$$$$
Rebamipide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.3347 1.54 0 0
M  V30 2 C 6.6684 0.77 0 0
M  V30 3 O 8.0021 1.54 0 0
M  V30 4 C 6.6684 -0.77 0 0
M  V30 5 C 5.3347 -1.54 0 0
M  V30 6 C 5.3347 -3.08 0 0
M  V30 7 C 6.6684 -3.85 0 0
M  V30 8 C 6.6684 -5.39 0 0
M  V30 9 O 8.0021 -6.16 0 0
M  V30 10 N 5.3347 -6.16 0 0
M  V30 11 C 4.001 -5.39 0 0
M  V30 12 C 2.6674 -6.16 0 0
M  V30 13 C 1.3337 -5.39 0 0
M  V30 14 C 1.3337 -3.85 0 0
M  V30 15 C 2.6674 -3.08 0 0
M  V30 16 C 4.001 -3.85 0 0
M  V30 17 N 8.0021 -1.54 0 0
M  V30 18 C 9.3358 -0.77 0 0
M  V30 19 O 9.3358 0.77 0 0
M  V30 20 C 10.6694 -1.54 0 0
M  V30 21 C 12.0031 -0.77 0 0
M  V30 22 C 13.3368 -1.54 0 0
M  V30 23 C 13.3368 -3.08 0 0
M  V30 24 Cl 14.6705 -3.85 0 0
M  V30 25 C 12.0031 -3.85 0 0
M  V30 26 C 10.6694 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 6 16
M  V30 17 2 11 16
M  V30 18 1 4 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 25 26
M  V30 28 2 20 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2289798874

>  <MW>
370.072

>  <MW (desalted)>
370.786

>  <ClogP>
1.965

>  <logS>
-5.582

>  <HBD>
3

>  <HBA>
4

>  <TPSA>
95.5

>  <RotBonds>
5

>  <Action on targets>
- | Inhibitor

>  <Activity coefficients and valu>
Km (Michaelis constant)  1.01 ?M | Kd (dissociation constant)  1.86E-06 M

>  <CAS>
90098-04-7

>  <Description>
Rebamipide is a gastroprotective agent used in combination with other similar therapies to treat gastritis and protect the gastric mucosa.

>  <EBC_ID>
EBC-17077

>  <IUPAC Name>
2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid

>  <Main Tar all refs>
Xenobiotica, 2002, vol. 32, # 7, p. 573 - 586 | Mol. Neurobiol., 2018, p. 1 - 11

>  <Main tar all>
Cytochrome P450 3A4 pX=6.0 | Alternative prion protein pX=5.73

$$$$
Dihydroergotamine mesylate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 48 54 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.5411 -7.2184 0 0
M  V30 2 N -2.5411 -5.6784 0 0
M  V30 3 C -1.2074 -4.9084 0 0
M  V30 4 C -1.2074 -3.3684 0 0 CFG=1
M  V30 5 C -2.5411 -2.5984 0 0
M  V30 6 C -3.8748 -3.3684 0 0 CFG=1
M  V30 7 C -3.8748 -4.9084 0 0 CFG=1
M  V30 8 C -5.2084 -5.6784 0 0
M  V30 9 C -6.5421 -4.9084 0 0
M  V30 10 C -8.0067 -5.3843 0 0
M  V30 11 N -8.9119 -4.1384 0 0
M  V30 12 C -8.0067 -2.8925 0 0
M  V30 13 C -8.3269 -1.3862 0 0
M  V30 14 C -7.1825 -0.3557 0 0
M  V30 15 C -5.7179 -0.8316 0 0
M  V30 16 C -5.2084 -2.5984 0 0
M  V30 17 C -6.5421 -3.3684 0 0
M  V30 18 C 0.1263 -2.5984 0 0
M  V30 19 O 1.46 -3.3684 0 0
M  V30 20 N 0.1263 -1.0584 0 0
M  V30 21 C 1.46 -0.2884 0 0 CFG=2
M  V30 22 C 2.0863 -1.6953 0 0
M  V30 23 O 0.5548 0.9575 0 0
M  V30 24 C 1.46 2.2033 0 0 CFG=1
M  V30 25 O -0.0464 2.5235 0 0
M  V30 26 C 1.1398 3.7097 0 0 CFG=2
M  V30 27 C -0.1939 4.4797 0 0
M  V30 28 C 0.1263 5.986 0 0
M  V30 29 C 1.6578 6.147 0 0
M  V30 30 N 2.2842 4.7401 0 0
M  V30 31 C 3.7489 4.2643 0 0
M  V30 32 O 4.8933 5.2947 0 0
M  V30 33 C 4.069 2.7579 0 0 CFG=2
M  V30 34 C 5.5337 2.282 0 0
M  V30 35 C 6.6781 3.3125 0 0
M  V30 36 C 6.3579 4.8188 0 0
M  V30 37 C 7.5024 5.8493 0 0
M  V30 38 C 8.967 5.3734 0 0
M  V30 39 C 9.2872 3.8671 0 0
M  V30 40 C 8.1427 2.8366 0 0
M  V30 41 N 2.9246 1.7275 0 0
M  V30 42 C 2.9246 0.1875 0 0
M  V30 43 O 4.1705 -0.7177 0 0
M  V30 44 C 14.3472 -1.54 0 0
M  V30 45 S 14.3472 0 0 0
M  V30 46 O 14.3472 1.54 0 0
M  V30 47 O 15.8872 -0 0 0
M  V30 48 O 12.8072 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 2 CFG=3
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 6 16
M  V30 18 1 16 17
M  V30 19 1 9 17
M  V30 20 2 12 17
M  V30 21 1 4 18 CFG=1
M  V30 22 2 18 19
M  V30 23 1 18 20
M  V30 24 1 21 20 CFG=3
M  V30 25 1 21 22 CFG=1
M  V30 26 1 21 23
M  V30 27 1 24 23
M  V30 28 1 24 25 CFG=3
M  V30 29 1 24 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 26 30 CFG=3
M  V30 35 1 30 31
M  V30 36 2 31 32
M  V30 37 1 33 31
M  V30 38 1 33 34 CFG=3
M  V30 39 1 34 35
M  V30 40 1 35 36
M  V30 41 2 36 37
M  V30 42 1 37 38
M  V30 43 2 38 39
M  V30 44 1 39 40
M  V30 45 2 35 40
M  V30 46 1 33 41
M  V30 47 1 24 41
M  V30 48 1 41 42
M  V30 49 1 21 42
M  V30 50 2 42 43
M  V30 51 1 44 45
M  V30 52 2 45 46
M  V30 53 2 45 47
M  V30 54 1 45 48
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2939838603

>  <MW>
679.268

>  <MW (desalted)>
583.677

>  <ClogP>
4.765

>  <logS>
-5.084

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
118.21

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  0.27 nM | IC50  0.55 nM | IC50  0.65 nM | pKi  8.55  | pKi  8.33

>  <CAS>
6190-39-2

>  <Description>
Dihydroergotamine mesylate is a derivative of ergotamine and an agonist of the serotonin (5-HT) receptor. Dihydroergotamine mesylate have been used in the treatment of migraine headaches.

>  <EBC_ID>
EBC-08683

>  <IUPAC Name>
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carboxamide; methanesulfonic acid

>  <Main Tar all refs>
ABBVIE INC - US2014/179704, 2014, A1 | ABBVIE INC - US2014/179704, 2014, A1 | ABBVIE INC - US2014/179704, 2014, A1 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, vol. 346, # 3, p. 249 - 254 | Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, vol. 346, # 3, p. 249 - 254

>  <Main tar all>
5-HT1A receptor pX=9.57 | 5-HT1B receptor pX=9.26 | 5-HT1D receptor pX=9.19 | 5-HT1B receptor pX=8.55 | 5-HT receptor pX=8.33

$$$$
Dasatanib
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6674 -3.08 0 0
M  V30 2 C -1.3337 -2.31 0 0
M  V30 3 C -1.3337 -0.77 0 0
M  V30 4 C 0 -0 0 0
M  V30 5 C 1.3337 -0.77 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 Cl 2.6674 -3.08 0 0
M  V30 8 C 0 -3.08 0 0
M  V30 9 N 0 -4.62 0 0
M  V30 10 C -1.3337 -5.39 0 0
M  V30 11 O -2.6674 -4.62 0 0
M  V30 12 C -1.3337 -6.93 0 0
M  V30 13 C -0.0878 -7.8352 0 0
M  V30 14 N -0.5637 -9.2998 0 0
M  V30 15 C -2.1037 -9.2998 0 0
M  V30 16 N -3.0089 -10.5457 0 0
M  V30 17 C -4.5404 -10.3847 0 0
M  V30 18 C -5.4456 -11.6306 0 0
M  V30 19 C -6.9772 -11.4696 0 0
M  V30 20 N -7.6036 -10.0628 0 0
M  V30 21 C -6.6984 -8.8169 0 0
M  V30 22 C -7.3247 -7.41 0 0
M  V30 23 N -5.1668 -8.9779 0 0
M  V30 24 N -7.8824 -12.7155 0 0
M  V30 25 C -7.256 -14.1224 0 0
M  V30 26 C -8.1612 -15.3683 0 0
M  V30 27 N -9.6928 -15.2073 0 0
M  V30 28 C -10.5979 -16.4532 0 0
M  V30 29 C -12.1295 -16.2922 0 0
M  V30 30 O -13.0347 -17.5381 0 0
M  V30 31 C -10.3191 -13.8004 0 0
M  V30 32 C -9.4139 -12.5546 0 0
M  V30 33 S -2.5796 -7.8352 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 2 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 2 17 23
M  V30 25 1 19 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 27 31
M  V30 33 1 31 32
M  V30 34 1 24 32
M  V30 35 1 15 33
M  V30 36 1 12 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546610486

>  <MW>
487.156

>  <MW (desalted)>
488.006

>  <ClogP>
2.529

>  <logS>
-5.122

>  <HBD>
3

>  <HBA>
8

>  <TPSA>
106.51

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 1 pM | cell viability decrease Active   | pKi  10.8  | Kd (dissociation constant)  0.02 nM | IC50  0.025 nM | IC50 = 30 pM | IC50  0.03 nM | Kd (dissociation constant)  0.032 nM | Kd (dissociation constant)  0.029 nM

>  <CAS>
302962-49-8

>  <Description>
Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy.

>  <EBC_ID>
EBC-11324

>  <IUPAC Name>
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

>  <Main Tar all refs>
Mini-Rev. Med. Chem., 2007, vol. 7, # 2, p. 191 - 201 | Int. J. Hematol., 2022, vol. 116, # 4, p. 534 - 543 | J. Med. Chem., 2008, vol. 51, # 17, p. 5149 - 5171 | YALE UNIVERSITY - WO2017/79267, 2017, A1 | HUNAN WARRANT PHARMACEUTICAL; HUNAN WARRANT PHARMACEUTICAL TECHNOLOGY DEVELOPMENT; HUNAN MEDICAL SCIENCE AND TECHNOLOGY DEVELOPMENT - EP4019020, 2022, A1 | J. Med. Chem., 2006, vol. 49, # 23, p. 6819 - 6832 | Cancers, 2023, vol. 15, # 2 | J. Med. Chem., 2019, vol. 62, # 20, p. 9281 - 9298 | J. Med. Chem., 2019, vol. 62, # 20, p. 9281 - 9298

>  <Main tar all>
C-terminal Src kinase pX=12.0 | FER tyrosine kinase pX=11.0 | Tyrosine-protein kinase ABL pX=10.8 | Tyrosine-protein?kinase?ABL1?phosphorylated pX=10.7 | ABL proto-oncogene 1, non-receptor tyrosine kinase pX=10.6 | BCR-ABL tyrosine kinase pX=10.5 | Neuronal proto-oncogene tyrosine-protein kinase Src pX=10.5 | Tyrosine-protein?kinase?ABL1?nonphosphorylated pX=10.5 | Tyrosine-protein?kinase?ABL1?phosphorylated pX=10.5

$$$$
Adefovir dipivoxil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -7.231 -14.0818 0 0
M  V30 2 C -6.7551 -12.6172 0 0
M  V30 3 C -5.2905 -13.0931 0 0
M  V30 4 C -8.2197 -12.1413 0 0
M  V30 5 C -6.2792 -11.1526 0 0
M  V30 6 O -7.3097 -10.0081 0 0
M  V30 7 O -4.7729 -10.8324 0 0
M  V30 8 C -4.297 -9.3678 0 0
M  V30 9 O -2.7906 -9.0476 0 0
M  V30 10 P -2.3147 -7.583 0 0
M  V30 11 O -0.8501 -8.0588 0 0
M  V30 12 C -1.8389 -6.1183 0 0
M  V30 13 O -0.3325 -5.7982 0 0
M  V30 14 C 0.1434 -4.3335 0 0
M  V30 15 C 1.6497 -4.0133 0 0
M  V30 16 N 2.1256 -2.5487 0 0
M  V30 17 C 1.2204 -1.3028 0 0
M  V30 18 N 2.1256 -0.0569 0 0
M  V30 19 C 3.5902 -0.5328 0 0
M  V30 20 C 4.9239 0.2372 0 0
M  V30 21 N 4.9239 1.7772 0 0
M  V30 22 N 6.2576 -0.5328 0 0
M  V30 23 C 6.2576 -2.0728 0 0
M  V30 24 N 4.9239 -2.8428 0 0
M  V30 25 C 3.5902 -2.0728 0 0
M  V30 26 O -3.7794 -7.1071 0 0
M  V30 27 C -4.0996 -5.6007 0 0
M  V30 28 O -2.9551 -4.5703 0 0
M  V30 29 C -3.2753 -3.0639 0 0
M  V30 30 O -2.1308 -2.0335 0 0
M  V30 31 C -4.7399 -2.588 0 0
M  V30 32 C -4.264 -1.1234 0 0
M  V30 33 C -5.2158 -4.0527 0 0
M  V30 34 C -6.2045 -2.1121 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 1 16 25
M  V30 26 2 19 25
M  V30 27 1 10 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 31 32
M  V30 34 1 31 33
M  V30 35 1 31 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546616202

>  <MW>
501.199

>  <MW (desalted)>
501.471

>  <ClogP>
1.398

>  <logS>
-3.566

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
166.98

>  <RotBonds>
15

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  3.383 nM | IC50  0.006 ?M | IC50  0.006 ?M

>  <CAS>
142340-99-6

>  <Description>
Adefovir dipivoxil a diester prodrug of adefovir, an acyclic nucleotide analog. Adefovir dipivoxil is used for treatment of hepatitis B.

>  <EBC_ID>
EBC-11264

>  <IUPAC Name>
[({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoate

>  <Main Tar all refs>
EQUIGERMINAL, S.A. - US2019/216831, 2019, A1 | ChemMedChem, 2015, vol. 10, # 8, p. 1351 - 1364 | ChemMedChem, 2018, vol. 13, # 17, p. 1779 - 1796

>  <Main tar all>
RNA-directed DNA polymerase pX=8.47 | Adenylate cyclase Toxin (ACT) pX=8.22 | adenylate?cyclase pX=8.22

$$$$
Isavuconazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.965 -1.1582 0 0
M  V30 2 C -1.6313 -1.9282 0 0 CFG=1
M  V30 3 C -1.6313 -3.4682 0 0
M  V30 4 N -2.8772 -4.3734 0 0
M  V30 5 C -2.4013 -5.838 0 0
M  V30 6 C -0.8613 -5.838 0 0
M  V30 7 S -0.3854 -4.3734 0 0
M  V30 8 C -3.3065 -7.0839 0 0
M  V30 9 C -2.6801 -8.4907 0 0
M  V30 10 C -3.5853 -9.7366 0 0
M  V30 11 C -5.1169 -9.5756 0 0
M  V30 12 C -6.0221 -10.8215 0 0
M  V30 13 N -6.9273 -12.0674 0 0
M  V30 14 C -5.7433 -8.1688 0 0
M  V30 15 C -4.8381 -6.9229 0 0
M  V30 16 C -0.2976 -1.1582 0 0 CFG=2
M  V30 17 O 0.4724 -2.4919 0 0
M  V30 18 C 1.036 -0.3882 0 0
M  V30 19 N 2.3697 -1.1582 0 0
M  V30 20 C 3.7766 -0.5318 0 0
M  V30 21 N 4.807 -1.6762 0 0
M  V30 22 C 4.037 -3.0099 0 0
M  V30 23 N 2.5307 -2.6897 0 0
M  V30 24 C -1.0676 0.1755 0 0
M  V30 25 C -2.6076 0.1755 0 0
M  V30 26 C -3.3776 1.5092 0 0
M  V30 27 F -4.9176 1.5092 0 0
M  V30 28 C -2.6076 2.8429 0 0
M  V30 29 C -1.0676 2.8429 0 0
M  V30 30 C -0.2976 1.5092 0 0
M  V30 31 F 1.2424 1.5092 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 3 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 3 12 13
M  V30 14 2 11 14
M  V30 15 1 14 15
M  V30 16 2 8 15
M  V30 17 1 2 16
M  V30 18 1 16 17 CFG=3
M  V30 19 1 16 18 CFG=1
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 19 23
M  V30 26 1 16 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 24 30
M  V30 34 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3041534037

>  <MW>
437.465

>  <MW (desalted)>
437.465

>  <ClogP>
2.687

>  <logS>
-5.431

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
87.62

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  61 nM | EC50  0.17 ?M | Kd (dissociation constant)  228 nM | IC50  0.62 ?M | IC50  0.96 ?M | IC50  1016 nM

>  <CAS>
241479-67-4

>  <Description>
Isavuconazole is an triazole antifungal with broad spectrum of activity and good safety profile. Isavucoanzole exhibits antifungal activity against most strains of Aspergillus flavus, Aspergillus fumigatus, Aspergillus niger, and Mucorales such as Rhizopus oryzae and Mucormycetes species in vivo and in vitro.

>  <EBC_ID>
EBC-27097

>  <IUPAC Name>
4-{2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile

>  <Main Tar all refs>
Int. J. Antimicrob. Agents, 2019, vol. 54, # 4, p. 449 - 455 | Antiviral Res., 2020, vol. 174 | Int. J. Antimicrob. Agents, 2019, vol. 54, # 4, p. 449 - 455 | Front. Pharmacol., 2023, vol. 14 | J. Med. Chem., 2021, vol. 64, # 23, p. 17511 - 17522 | J. Steroid Biochem. Mol. Biol., 2020, vol. 199

>  <Main tar all>
CYP51A1 pX=7.21 | Glycoprotein pX=6.77 | Lanosterol 14-alpha demethylase (CYP51B) pX=6.64 | Cytochrome P450 3A4 pX=6.21 | CYP51A1 pX=6.02 | CYP11B2 pX=5.99

$$$$
Tamoxifen
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 -2.31 0 0
M  V30 2 C 0 -3.08 0 0
M  V30 3 C 1.3337 -2.31 0 0
M  V30 4 C 2.6674 -3.08 0 0
M  V30 5 C 2.6674 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 4.001 -6.93 0 0
M  V30 8 C 2.6674 -7.7 0 0
M  V30 9 C 1.3337 -6.93 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 C 4.001 -2.31 0 0
M  V30 12 C 4.001 -0.77 0 0
M  V30 13 C 5.3347 0 0 0
M  V30 14 C 6.6684 -0.77 0 0
M  V30 15 O 8.0021 0 0 0
M  V30 16 C 9.3358 -0.77 0 0
M  V30 17 C 10.6694 0 0 0
M  V30 18 N 12.0031 -0.77 0 0
M  V30 19 C 13.3368 0 0 0
M  V30 20 C 12.0031 -2.31 0 0
M  V30 21 C 6.6684 -2.31 0 0
M  V30 22 C 5.3347 -3.08 0 0
M  V30 23 C 1.3337 -0.77 0 0
M  V30 24 C -0 -0 0 0
M  V30 25 C -0 1.54 0 0
M  V30 26 C 1.3337 2.31 0 0
M  V30 27 C 2.6674 1.54 0 0
M  V30 28 C 2.6674 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 2 14 21
M  V30 22 1 21 22
M  V30 23 2 11 22
M  V30 24 1 3 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 23 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2527624834

>  <MW>
371.515

>  <MW (desalted)>
371.515

>  <ClogP>
6.818

>  <logS>
-6.543

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
12.47

>  <RotBonds>
8

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  3.109 pM | Ki (inhibition constant)  3.109 pM | IC50 = 5.6 pM

>  <CAS>
10540-29-1

>  <Description>
Tamoxifen is a selective estrogen receptor modulator that inhibits growth and promotes apoptosis in estrogen receptor positive tumors. It is used to treat estrogen receptor positive breast cancer, reduce the risk of invasive breast cancer following surgery, or reduce the risk of breast cancer in high risk women.

>  <EBC_ID>
EBC-12635

>  <IUPAC Name>
(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine

>  <Main Tar all refs>
Mol. Pharmacol., 2019, vol. 96, # 2, p. 272 - 296 | Mol. Pharmacol., 2019, vol. 96, # 2, p. 272 - 296 | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT - WO2011/46596, 2011, A2

>  <Main tar all>
Estrogen receptor pX=11.5 | Estrogen receptor pX=11.5 | nuclear estrogen receptor pX=11.3

$$$$
Elexacaftor
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 44 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0089 -5.9257 0 0
M  V30 2 C 2.1037 -4.6798 0 0 CFG=2
M  V30 3 C 0.5637 -4.6798 0 0
M  V30 4 N 0.0878 -3.2152 0 0
M  V30 5 C -1.3768 -2.7393 0 0
M  V30 6 N -2.5213 -3.7698 0 0
M  V30 7 C -3.9859 -3.2939 0 0
M  V30 8 C -4.3061 -1.7875 0 0
M  V30 9 C -3.1616 -0.7571 0 0
M  V30 10 C -1.697 -1.233 0 0
M  V30 11 C -0.5526 -0.2025 0 0
M  V30 12 O -0.8728 1.3039 0 0
M  V30 13 N 0.9121 -0.6784 0 0
M  V30 14 S 2.0565 0.3521 0 0
M  V30 15 O 1.026 1.4965 0 0
M  V30 16 O 3.087 -0.7924 0 0
M  V30 17 C 3.2009 1.3825 0 0
M  V30 18 C 3.04 2.9141 0 0
M  V30 19 N 4.4468 3.5405 0 0
M  V30 20 C 4.767 5.0468 0 0
M  V30 21 N 5.4773 2.396 0 0
M  V30 22 C 4.7073 1.0624 0 0
M  V30 23 C 5.3337 -0.3445 0 0
M  V30 24 N -5.1303 -4.3243 0 0
M  V30 25 C -4.9694 -5.8559 0 0
M  V30 26 C -6.3762 -6.4823 0 0
M  V30 27 C -7.4067 -5.3378 0 0
M  V30 28 O -8.9383 -5.4988 0 0
M  V30 29 C -9.8434 -4.2529 0 0
M  V30 30 C -11.375 -4.4139 0 0
M  V30 31 C -11.536 -2.8823 0 0
M  V30 32 C -11.214 -5.9455 0 0
M  V30 33 C -12.9066 -4.5749 0 0
M  V30 34 F -14.4381 -4.7358 0 0
M  V30 35 F -13.0675 -3.0433 0 0
M  V30 36 F -12.7456 -6.1064 0 0
M  V30 37 N -6.6367 -4.0042 0 0
M  V30 38 C 1.3337 -2.31 0 0
M  V30 39 C 0.3032 -1.1656 0 0
M  V30 40 C 2.3641 -1.1656 0 0
M  V30 41 C 2.5796 -3.2152 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 2 14 16
M  V30 17 1 14 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 2 21 22
M  V30 23 1 17 22
M  V30 24 1 22 23
M  V30 25 1 7 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 30 32
M  V30 34 1 30 33
M  V30 35 1 33 34
M  V30 36 1 33 35
M  V30 37 1 33 36
M  V30 38 2 27 37
M  V30 39 1 24 37
M  V30 40 1 4 38
M  V30 41 1 38 39
M  V30 42 1 38 40
M  V30 43 1 38 41
M  V30 44 1 2 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z3675381442

>  <MW>
597.653

>  <MW (desalted)>
597.653

>  <ClogP>
4.434

>  <logS>
-5.319

>  <HBD>
1

>  <HBA>
8

>  <TPSA>
124.24

>  <RotBonds>
8

>  <Action on targets>
Activator | Stimulator

>  <Activity coefficients and valu>
EC50  0.07 ?M | ciliary beat frequency increase Active

>  <CAS>
2216712-66-0

>  <Description>
Elexacaftor is a small molecule CFTR corrector used in combination with tezacaftor and ivacaftor for the treatment of cystic fibrosis patients with one F508del-CFTR mutation.

>  <EBC_ID>
EBC-27367

>  <IUPAC Name>
N-[(1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

>  <Main Tar all refs>
VERTEX PHARMACEUTICALS (OLD) - WO2018/107100, 2018, A1 | STANFORD UNIVERSITY - WO2022/40447, 2022, A2

>  <Main tar all>
CFTR (delF508) pX=7.15 | CFTR pX=7.0

$$$$
Succinic acid
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 7 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.3574 1.3337 0 0
M  V30 2 C 0.9763 2.1037 0 0
M  V30 3 O 0.9763 3.6437 0 0
M  V30 4 C 2.31 1.3337 0 0
M  V30 5 C 3.6437 2.1037 0 0
M  V30 6 C 4.9774 1.3337 0 0
M  V30 7 O 6.311 2.1037 0 0
M  V30 8 O 4.9774 -0.2063 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127453

>  <MW>
118.027

>  <MW (desalted)>
118.088

>  <ClogP>
-0.526

>  <logS>
0.74

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
74.6

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Agonist | Substrate | Inhibitor | Stimulator | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 9 ?M | pEC50  4.54 - 4.85 | Km (Michaelis constant)  18 ?M | IC50 = 5.74 ?g/mL | percentage increase Active   | IC50  261 ?M

>  <CAS>
110-15-6

>  <Description>
Succinic acid is an essential component of the Krebs or citric acid cycle and serves an electron donor in the production of fumaric acid and FADH2. It also has been shown to be a good ""natural"" antibiotic because of its relative acidic or caustic nature. It is used for nutritional supplementation, also for treating dietary shortage or imbalance.

>  <EBC_ID>
EBC-26049

>  <IUPAC Name>
butanedioic acid

>  <Main Tar all refs>
J. Biol. Chem., 2007, vol. 282, # 7, p. 4524 - 4532 | Br. J. Pharmacol., 2017, vol. 174, # 9, p. 796 - 808 | Am. J. Physiol. Renal Physiol., 2011, vol. 301 | Chem. Pharm. Bull., 2010, vol. 58, # 9, p. 1236 - 1239 | CSL LIMITED - WO2017/93482, 2017, A1 | ChemMedChem, 2022, vol. 17, # 1

>  <Main tar all>
Egl nine homolog 1 pX=5.05 | succinate receptor pX=4.85 | Na+/dicarboxylate cotransporter 3 pX=4.74 | acetylcholinesterase (Cartwright blood group) pX=4.31 | coagulation factor VII pX=4.22 | jumonji domain containing 6, arginine demethylase and lysine hydroxylase pX=3.58

$$$$
Racemethionine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.2863 3.4374 0 0
M  V30 2 S 4.62 2.6674 0 0
M  V30 3 C 5.9537 3.4374 0 0
M  V30 4 C 7.2874 2.6674 0 0
M  V30 5 C 8.621 3.4374 0 0
M  V30 6 N 8.621 4.9774 0 0
M  V30 7 C 9.9547 2.6674 0 0
M  V30 8 O 11.2884 3.4374 0 0
M  V30 9 O 9.9547 1.1274 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57127440

>  <MW>
149.051

>  <MW (desalted)>
149.211

>  <ClogP>
-1.731

>  <logS>
-0.59

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
63.32

>  <RotBonds>
4

>  <CAS>
59-51-8

>  <Description>
Racemethionine is a racemic form of the respective sulfur aminoacid. It participates in synthesis of tissue proteins, vitamins, enzymes and hormones taking part in nitrogen, carbohydrate and fat metabolisms, and it is the important source of methyl groups for synthesis of all nucleic acids, as well as the sulfur source for sulfonic compounds. Methionine is used to prevent liver damage in acetaminophen poisoning. It is also used for increasing the acidity of urine, treating liver disorders, and improving wound healing.

>  <EBC_ID>
EBC-26091

>  <IUPAC Name>
2-amino-4-(methylsulfanyl)butanoic acid

$$$$
Niacin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0 4.62 0 0
M  V30 2 C 1.3337 3.85 0 0
M  V30 3 O 2.6674 4.62 0 0
M  V30 4 C 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 N 0 0 0 0
M  V30 9 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56755709

>  <MW>
123.032

>  <MW (desalted)>
123.109

>  <ClogP>
0.799

>  <logS>
-0.36

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
50.19

>  <RotBonds>
1

>  <Action on targets>
Agonist

>  <Activity coefficients and valu>
EC50  33 pg/ml

>  <CAS>
59-67-6

>  <Description>
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions. Niacin inhibits hepatocyte diacylglycerol acyltransferase-2, and a high density lipoprotein (HDL) catabolism receptor.

>  <EBC_ID>
EBC-00528

>  <IUPAC Name>
pyridine-3-carboxylic acid

>  <Main Tar all refs>
Eur. J. Pharmacol., 2016, vol. 791, p. 124 - 136

>  <Main tar all>
Hydroxycarboxylic acid receptor 2 pX=9.57

$$$$
Tavaborole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.6497 -4.0133 0 0
M  V30 2 B 2.1256 -2.5487 0 0
M  V30 3 O 1.2204 -1.3028 0 0
M  V30 4 C 2.1256 -0.0569 0 0
M  V30 5 C 3.5902 -0.5328 0 0
M  V30 6 C 4.9239 0.2372 0 0
M  V30 7 C 6.2576 -0.5328 0 0
M  V30 8 F 7.5913 0.2372 0 0
M  V30 9 C 6.2576 -2.0728 0 0
M  V30 10 C 4.9239 -2.8428 0 0
M  V30 11 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 2 11
M  V30 12 2 5 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1198279578

>  <MW>
152.044

>  <MW (desalted)>
151.931

>  <ClogP>
1.241

>  <logS>
-1.5

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.46

>  <RotBonds>
0

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  157 nM | KI (concentration required for half-maximal inactivation)  0.46 ?M | Ki (inhibition constant)  841 nM | IC50 ~ 0.83 ?M | KI (concentration required for half-maximal inactivation)  2.01 ?M | KI (concentration required for half-maximal inactivation)  2.54 ?M

>  <CAS>
174671-46-6

>  <Description>
Tavaborole is an antifungal agent used to treat onychomycosis, a fungal infection of the nail. Tavaborole exerts its antifungal activity by blocking cellular protein synthesis through the formation of an adduct with cytoplasmic leucyl-aminoacyl transfer RNA (tRNA) synthetase.

>  <EBC_ID>
EBC-03407

>  <IUPAC Name>
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol

>  <Main Tar all refs>
ACS Med. Chem. Lett., 2020, vol. 11, # 11, p. 2277 - 2284 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 286 - 289 | ACS Med. Chem. Lett., 2020, vol. 11, # 11, p. 2277 - 2284 | Antimicrob. Agents Chemother., 2018, vol. 62, # 9 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 286 - 289 | J. Enzyme Inhib. Med. Chem., 2018, vol. 33, # 1, p. 286 - 289

>  <Main tar all>
?-carbonic anhydrases pX=6.8 | carbonic anhydrase 2 pX=6.34 | ?-carbonic anhydrase pX=6.08 | Leucine-tRNA ligase (L-leucine:tRNALeu ligase (AMP-forming)) pX=6.08 | carbonic anhydrase 1 pX=5.7 | carbonic anhydrase pX=5.6

$$$$
(R)-Oxiracetam
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.2739 5.93 0 0
M  V30 2 C -0.2739 4.39 0 0
M  V30 3 O -1.6075 3.62 0 0
M  V30 4 C 1.0598 3.62 0 0
M  V30 5 N 1.0598 2.08 0 0
M  V30 6 C 2.3057 1.1748 0 0
M  V30 7 C 1.8298 -0.2898 0 0 CFG=2
M  V30 8 O 2.735 -1.5357 0 0
M  V30 9 C 0.2898 -0.2898 0 0
M  V30 10 C -0.1861 1.1748 0 0
M  V30 11 O -1.6507 1.6507 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1255379534

>  <MW>
158.069

>  <MW (desalted)>
158.155

>  <ClogP>
-1.199

>  <logS>
-0.086

>  <HBD>
2

>  <HBA>
3

>  <TPSA>
83.63

>  <RotBonds>
2

>  <CAS>
68252-28-8

>  <Description>
(R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam. Oxiracetam is a nootropic drug of the racetam family and stimulant.

>  <EBC_ID>
EBC-12573

>  <IUPAC Name>
2-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]acetamide

$$$$
Aspirin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 6.16 0 0
M  V30 2 C 2.6674 4.62 0 0
M  V30 3 O 4.001 3.85 0 0
M  V30 4 O 1.3337 3.85 0 0
M  V30 5 C 1.3337 2.31 0 0
M  V30 6 C 2.6674 1.54 0 0
M  V30 7 C 2.6674 -0 0 0
M  V30 8 C 1.3337 -0.77 0 0
M  V30 9 C 0 0 0 0
M  V30 10 C 0 1.54 0 0
M  V30 11 C -1.3337 2.31 0 0
M  V30 12 O -1.3337 3.85 0 0
M  V30 13 O -2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104474430

>  <MW>
180.042

>  <MW (desalted)>
180.157

>  <ClogP>
1.023

>  <logS>
-1.81

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
63.6

>  <RotBonds>
3

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 1.67 pM

>  <CAS>
50-78-2

>  <Description>
Aspirin is a non-selective, irreversible COX inhibitor. It is a salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events.

>  <EBC_ID>
EBC-03525

>  <IUPAC Name>
2-(acetyloxy)benzoic acid

>  <Main Tar all refs>
EURO CELTIQUE S.A. - US2002/99049, 2002, A1

>  <Main tar all>
COX-1  pX=11.8

$$$$
Etilefrin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 N 2.6674 -4.62 0 0
M  V30 4 C 4.001 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 O 5.3347 -3.08 0 0
M  V30 7 C 6.6684 -5.39 0 0
M  V30 8 C 8.0021 -4.62 0 0
M  V30 9 C 9.3358 -5.39 0 0
M  V30 10 C 9.3358 -6.93 0 0
M  V30 11 C 8.0021 -7.7 0 0
M  V30 12 O 8.0021 -9.24 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 7 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z56836691

>  <MW>
181.11

>  <MW (desalted)>
181.232

>  <ClogP>
0.441

>  <logS>
-0.71

>  <HBD>
3

>  <HBA>
3

>  <TPSA>
52.49

>  <RotBonds>
4

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Substrate | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  22 ?M | Ki (inhibition constant)  25 ?M | IC50 = 51.4 ?M | Km (Michaelis constant)  214 - 232.9 ?M | IC50  447 ?M

>  <CAS>
709-55-7

>  <Description>
Etilefrin shows binding affinity to alpha-adrenergic receptor.

>  <EBC_ID>
EBC-03548

>  <IUPAC Name>
3-[2-(ethylamino)-1-hydroxyethyl]phenol

>  <Main Tar all refs>
Mol. Pharmacol., 1976, vol. 12, # 1, p. 16 - 31 | J. BIOL. CHEM., 1976, vol. 251, # 22, p. 6915 - 6923 | Chem. Pharm. Bull., 2011, vol. 59, # 2, p. 249 - 253 | Biochem. Pharmacol., 2020, vol. 171 | Biochem. Pharmacol., 2005, vol. 70, # 12, p. 1851 - 1860

>  <Main tar all>
?-adrenoceptor pX=4.66 | ?-adrenoceptor pX=4.6 | Cytochrome P450 2D6 pX=4.29 | Organic cation transporter 1 pX=3.67 | Organic cation transporter 1 pX=3.35

$$$$
Sulfacetamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 7.7 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 O -1.3337 5.39 0 0
M  V30 4 N 1.3337 5.39 0 0
M  V30 5 S 1.3337 3.85 0 0
M  V30 6 O -0.2063 3.85 0 0
M  V30 7 O 2.8737 3.85 0 0
M  V30 8 C 1.3337 2.31 0 0
M  V30 9 C 2.6674 1.54 0 0
M  V30 10 C 2.6674 -0 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 N 1.3337 -2.31 0 0
M  V30 13 C 0 0 0 0
M  V30 14 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 2 5 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z57202572

>  <MW>
214.041

>  <MW (desalted)>
214.242

>  <ClogP>
-0.976

>  <logS>
-1.49

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
89.26

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
neuropathology decrease Active   | neuropathology decrease Active   | Ki (inhibition constant) ~ 3.27 ?M | IC50 = 18 ?M | IC50 = 18 ?M

>  <CAS>
144-80-9

>  <Description>
Sulfacetamide is a corticosteroid used to treat inflammatory ocular conditions and acne vulgaris. It is used for the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.

>  <EBC_ID>
EBC-03499

>  <IUPAC Name>
N-(4-aminobenzenesulfonyl)acetamide

>  <Main Tar all refs>
Alzheimers. Res. Ther., 2022, vol. 14, # 1 | Alzheimers. Res. Ther., 2022, vol. 14, # 1 | Proc. Natl. Acad. Sci. U. S. A., 2020, vol. 117, # 44, p. 27381 - 27387 | Bioorg. Med. Chem., 2010, vol. 18, # 8, p. 2849 - 2863 | Bioorg. Med. Chem., 2010, vol. 18, # 8, p. 2849 - 2863

>  <Main tar all>
Amyloid-beta protein 1-42 pX=6.0 | Apolipoprotein E4 pX=6.0 | CoV 3C-like (main) protease pX=5.49 | dihydrofolate reductase pX=4.74 | dihydrofolate reductase pX=4.74

$$$$
Diethyltoluamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3337 6.93 0 0
M  V30 2 C 0 6.16 0 0
M  V30 3 N 0 4.62 0 0
M  V30 4 C -1.3337 3.85 0 0
M  V30 5 C -1.3337 2.31 0 0
M  V30 6 C 1.3337 3.85 0 0
M  V30 7 O 2.6674 4.62 0 0
M  V30 8 C 1.3337 2.31 0 0
M  V30 9 C 2.6674 1.54 0 0
M  V30 10 C 2.6674 -0 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C -1.3337 -0.77 0 0
M  V30 14 C 0 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z31723661

>  <MW>
191.131

>  <MW (desalted)>
191.269

>  <ClogP>
2.164

>  <logS>
-2.855

>  <HBD>
0

>  <HBA>
1

>  <TPSA>
20.31

>  <RotBonds>
3

>  <Action on targets>
- | - | Activator | Inhibitor | - | - | - | Antagonist | Antagonist | Antagonist | Antagonist | Antagonist | Antagonist

>  <Activity coefficients and valu>
Km (Michaelis constant)  40.2 ?M | Km (Michaelis constant)  41 ?M | mRNA expression level increase Active   | inhibition percentage < 50 % | Km (Michaelis constant)  842.5 ?M | Km (Michaelis constant)  842.5 ?M | Km (Michaelis constant)  842.5 ?M | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active   | inhibition percentage Active

>  <CAS>
134-62-3

>  <Description>
Diethyltoluamide is the most common active ingredient in insect repellents. It is intended to provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects.

>  <EBC_ID>
EBC-03516

>  <IUPAC Name>
N,N-diethyl-3-methylbenzamide

>  <Main Tar all refs>
Drug Metab. Dispos., 2002, vol. 30, # 3, p. 289 - 294 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 289 - 294 | Food Chem. Toxicol., 2022, vol. 170 | Aquat. Toxicol., 2019, vol. 208, p. 196 - 207 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 289 - 294 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 289 - 294 | Drug Metab. Dispos., 2002, vol. 30, # 3, p. 289 - 294 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841 | Science, 2008, vol. 319, # 5871, p. 1838 - 1841

>  <Main tar all>
Cytochrome P450 2B6 pX=4.4 | CYP1A2 pX=4.39 | Constitutive androstane receptor pX=4.0 | Teleost-specific glutathione S-transferase Gstr1 pX=4.0 | Cytochrome P450 2A6 pX=3.07 | Cytochrome P450 2C19 pX=3.07 | Cytochrome P450 3A4 pX=3.07 | Odorant receptor 1 pX=3.0 | Odorant receptor 2 pX=3.0 | Odorant receptor 47a pX=3.0 | Odorant receptor 7 pX=3.0 | Odorant receptor 8 pX=3.0 | Odorant receptor coreceptor pX=3.0

$$$$
Clorprenaline
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -4.62 0 0
M  V30 2 C 1.3337 -5.39 0 0
M  V30 3 C 1.3337 -6.93 0 0
M  V30 4 N 2.6674 -4.62 0 0
M  V30 5 C 4.001 -5.39 0 0
M  V30 6 C 5.3347 -4.62 0 0
M  V30 7 O 5.3347 -3.08 0 0
M  V30 8 C 6.6684 -5.39 0 0
M  V30 9 C 8.0021 -4.62 0 0
M  V30 10 C 9.3358 -5.39 0 0
M  V30 11 C 9.3358 -6.93 0 0
M  V30 12 C 8.0021 -7.7 0 0
M  V30 13 C 6.6684 -6.93 0 0
M  V30 14 Cl 5.3347 -7.7 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z666296432

>  <MW>
213.092

>  <MW (desalted)>
213.704

>  <ClogP>
2.13

>  <logS>
-2.18

>  <HBD>
2

>  <HBA>
2

>  <TPSA>
32.26

>  <RotBonds>
4

>  <CAS>
3811-25-4

>  <Description>
Clorprenaline is a ?2-adrenergic receptor agonist. As a bronchodilator it has been used for the treatment of bronchial asthma, bronchitis and other respiratory diseases.

>  <EBC_ID>
EBC-12023

>  <IUPAC Name>
1-(2-chlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol

$$$$
Nicoboxil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6674 -9.24 0 0
M  V30 2 C 4.001 -10.01 0 0
M  V30 3 C 5.3347 -9.24 0 0
M  V30 4 C 6.6684 -10.01 0 0
M  V30 5 O 8.0021 -9.24 0 0
M  V30 6 C 9.3358 -10.01 0 0
M  V30 7 C 10.6694 -9.24 0 0
M  V30 8 O 12.0031 -10.01 0 0
M  V30 9 C 13.3368 -9.24 0 0
M  V30 10 O 13.3368 -7.7 0 0
M  V30 11 C 14.6705 -10.01 0 0
M  V30 12 C 16.0041 -9.24 0 0
M  V30 13 C 17.3378 -10.01 0 0
M  V30 14 C 17.3378 -11.55 0 0
M  V30 15 N 16.0041 -12.32 0 0
M  V30 16 C 14.6705 -11.55 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z743362616

>  <MW>
223.121

>  <MW (desalted)>
223.268

>  <ClogP>
2.091

>  <logS>
-1.766

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
48.42

>  <RotBonds>
8

>  <Action on targets>
-

>  <Activity coefficients and valu>
Km (Michaelis constant)  1.52 mM

>  <CAS>
13912-80-6

>  <Description>
Nicoboxil is considered a rubefacient. The primary therapeutic use for which nicoboxil is currently indicated for is as an active ingredient in combination with the capsaicinoid nonivamide compound as a topical analgesic for the temporary relief of the pain of rheumatism, arthritis, lumbago, muscular aches, sprains and strains, sporting injuries, and other conditions where local warmth is beneficial.

>  <EBC_ID>
EBC-13552

>  <IUPAC Name>
2-butoxyethyl pyridine-3-carboxylate

>  <Main Tar all refs>
XENOBIOTICA, 1992, vol. 22, # 3, p. 273 - 282

>  <Main tar all>
Carboxylesterase pX=2.82

$$$$
Sulfisoxazole
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8019 -2.425 0 0
M  V30 2 C 3.8019 -3.965 0 0
M  V30 3 N 5.0477 -4.8702 0 0
M  V30 4 O 4.5719 -6.3348 0 0
M  V30 5 C 3.0319 -6.3348 0 0
M  V30 6 N 2.1267 -7.5807 0 0
M  V30 7 S 0.5951 -7.4197 0 0
M  V30 8 O 0.7561 -5.8882 0 0
M  V30 9 O 0.4341 -8.9513 0 0
M  V30 10 C -0.9365 -7.2588 0 0
M  V30 11 C -1.8417 -8.5046 0 0
M  V30 12 C -3.3732 -8.3437 0 0
M  V30 13 C -3.9996 -6.9368 0 0
M  V30 14 N -5.5312 -6.7758 0 0
M  V30 15 C -3.0944 -5.6909 0 0
M  V30 16 C -1.5628 -5.8519 0 0
M  V30 17 C 2.556 -4.8702 0 0
M  V30 18 C 1.0913 -4.3943 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7 CFG=2
M  V30 7 2 7 8
M  V30 8 2 7 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 10 16
M  V30 17 1 5 17
M  V30 18 2 2 17
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z335430322

>  <MW>
267.068

>  <MW (desalted)>
267.304

>  <ClogP>
0.371

>  <logS>
-3.061

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
93.78

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 7 nM | IC50 = 70 nM | IC50 < 100 nM

>  <CAS>
127-69-5

>  <Description>
Sulfisoxazole is a sulfonamide antibiotic, it's a short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. It is used for the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.

>  <EBC_ID>
EBC-12324

>  <IUPAC Name>
4-amino-N-(3,4-dimethyl-2,5-dihydro-1,2-oxazol-5-ylidene)benzene-1-sulfonamide

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 2003, vol. 13, # 23, p. 4217 - 4221 | Bioorg. Med. Chem. Lett., 2003, vol. 13, # 23, p. 4217 - 4221 | Curr. Med. Chem., 2003, vol. 10, # 11, p. 925 - 953

>  <Main tar all>
dihydrofolate reductase pX=8.15 | dihydrofolate reductase pX=7.15 | Integrase pX=7.0

$$$$
Mitotane
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 1.3337 -0.77 0 0
M  V30 2 C 2.6674 0 0 0
M  V30 3 Cl 2.6674 1.54 0 0
M  V30 4 C 4.001 -0.77 0 0
M  V30 5 C 4.001 -2.31 0 0
M  V30 6 C 5.3347 -3.08 0 0
M  V30 7 C 5.3347 -4.62 0 0
M  V30 8 C 4.001 -5.39 0 0
M  V30 9 Cl 4.001 -6.93 0 0
M  V30 10 C 2.6674 -4.62 0 0
M  V30 11 C 2.6674 -3.08 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 5.3347 1.54 0 0
M  V30 14 C 6.6684 2.31 0 0
M  V30 15 C 8.0021 1.54 0 0
M  V30 16 C 8.0021 0 0 0
M  V30 17 C 6.6684 -0.77 0 0
M  V30 18 Cl 6.6684 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 12 1 4 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z381079728

>  <MW>
317.954

>  <MW (desalted)>
320.041

>  <ClogP>
6.06

>  <logS>
-5.83

>  <HBD>
0

>  <HBA>
0

>  <TPSA>
0

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Agonist | Agonist | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) = 0.22 ?M | Ki (inhibition constant) = 0.22 ?M | induction percentage Active   | induction percentage Active   | EC50  3.2 ?M

>  <CAS>
53-19-0

>  <Description>
Mitotane is a derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types.

>  <EBC_ID>
EBC-03725

>  <IUPAC Name>
1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene

>  <Main Tar all refs>
Curr. Med. Chem., 2003, vol. 10, # 6, p. 453 - 477 | Curr. Med. Chem., 2003, vol. 10, # 6, p. 453 - 477 | J. Hazard. Mater., 2017, vol. 338, p. 57 - 65 | J. Hazard. Mater., 2017, vol. 338, p. 57 - 65 | ANDRESEN J MICHAEL; PETROVSKI SLAVE; PAIRNOMIX - WO2019/18119, 2019, A1

>  <Main tar all>
17-beta-hydroxysteroid dehydrogenase type 1 pX=6.66 | Estradiol 17-beta-dehydrogenase 1 pX=6.66 | Estrogen receptor pX=6.0 | Estrogen receptor pX=6.0 | KNa1.1 pX=5.49

$$$$
Meclofenamate sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Na -9.3358 -8.47 0 0 CHG=1
M  V30 2 C -1.3337 -0.77 0 0
M  V30 3 C -1.3337 -2.31 0 0
M  V30 4 C 0 -3.08 0 0
M  V30 5 C 0 -4.62 0 0
M  V30 6 C -1.3337 -5.39 0 0
M  V30 7 Cl -1.3337 -6.93 0 0
M  V30 8 C -2.6674 -4.62 0 0
M  V30 9 N -4.001 -5.39 0 0
M  V30 10 C -4.001 -6.93 0 0
M  V30 11 C -2.6674 -7.7 0 0
M  V30 12 C -2.6674 -9.24 0 0
M  V30 13 C -4.001 -10.01 0 0
M  V30 14 C -5.3347 -9.24 0 0
M  V30 15 C -5.3347 -7.7 0 0
M  V30 16 C -6.6684 -6.93 0 0
M  V30 17 O -6.6684 -5.39 0 0
M  V30 18 O -8.0021 -7.7 0 0 CHG=-1
M  V30 19 C -2.6674 -3.08 0 0
M  V30 20 Cl -4.001 -2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 2 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 2 6 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 2 11 12
M  V30 11 1 12 13
M  V30 12 2 13 14
M  V30 13 1 14 15
M  V30 14 2 10 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 8 19
M  V30 19 2 3 19
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z732242712

>  <MW>
316.999

>  <MW (desalted)>
296.149

>  <ClogP>
1.696

>  <logS>
-5.49

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
52.16

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50  5.64 nM | IC50 = 0.1 ?M

>  <CAS>
6385-02-0

>  <Description>
Meclofenamic acid is a nonsteroidal anti-inflammatory drug. It  is a dual COX-1/COX-2 inhibitor. It is used to treat mild to moderate pain, primary dysmenorrhea, heavy menstrual blood loss, rheumatoid arthritis, and osteoarthritis.

>  <EBC_ID>
EBC-04402

>  <IUPAC Name>
sodium 2-[(2,6-dichloro-3-methylphenyl)amino]benzoate

>  <Main Tar all refs>
Bioorg. Chem., 2019, vol. 85, p. 577 - 584 | Bioorg. Med. Chem. Lett., 1993, vol. 3, # 8, p. 1729 - 1734

>  <Main tar all>
Arachidonate 15-lipoxygenase (gene ALOX15) pX=8.25 | Cyclooxygenase pX=7.0

$$$$
?hlorphenamine maleate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.5453 -0.1216 0 0
M  V30 2 N -4.2116 -0.8916 0 0
M  V30 3 C -4.2116 -2.4316 0 0
M  V30 4 C -2.8779 -0.1216 0 0
M  V30 5 C -1.5443 -0.8916 0 0
M  V30 6 C -0.2106 -0.1216 0 0
M  V30 7 C 1.1231 -0.8916 0 0
M  V30 8 C 2.4568 -0.1216 0 0
M  V30 9 C 3.7905 -0.8916 0 0
M  V30 10 C 3.7905 -2.4316 0 0
M  V30 11 Cl 5.1241 -3.2016 0 0
M  V30 12 C 2.4568 -3.2016 0 0
M  V30 13 C 1.1231 -2.4316 0 0
M  V30 14 C -0.2106 1.4184 0 0
M  V30 15 C -1.5443 2.1884 0 0
M  V30 16 C -1.5443 3.7284 0 0
M  V30 17 C -0.2106 4.4984 0 0
M  V30 18 C 1.1231 3.7284 0 0
M  V30 19 N 1.1231 2.1884 0 0
M  V30 20 O 14.8041 -0 0 0
M  V30 21 C 13.2641 -0 0 0
M  V30 22 O 12.4941 -1.3337 0 0
M  V30 23 C 12.4941 1.3337 0 0
M  V30 24 C 10.9541 1.3337 0 0
M  V30 25 C 10.1841 -0 0 0
M  V30 26 O 10.9541 -1.3337 0 0
M  V30 27 O 8.6441 -0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 2 7 13
M  V30 14 1 6 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 14 19
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2311928354

>  <MW>
390.135

>  <MW (desalted)>
274.788

>  <ClogP>
3.148

>  <logS>
-2.958

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
16.13

>  <RotBonds>
7

>  <Action on targets>
Antagonist | Antagonist

>  <Activity coefficients and valu>
pKb  9.039  | IC50  0.012 ?M

>  <CAS>
113-92-8

>  <Description>
Chlorpheniramine is a histamine-H1 receptor antagonist.

>  <EBC_ID>
EBC-13382

>  <IUPAC Name>
(2Z)-but-2-enedioic acid; [3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine

>  <Main Tar all refs>
J. PHARM. PHARMACOL., 1973, vol. 25, # 11, p. 887 - 894 | J. MED. CHEM., 1986, vol. 29, # 7, p. 1178 - 1183

>  <Main tar all>
Histamine receptor pX=9.04 | H1 receptor pX=7.92

$$$$
Padimate O
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 -10.01 0 0
M  V30 2 C 5.3347 -9.24 0 0
M  V30 3 C 6.6684 -10.01 0 0
M  V30 4 C 8.0021 -9.24 0 0
M  V30 5 C 9.3358 -10.01 0 0
M  V30 6 C 9.3358 -11.55 0 0
M  V30 7 C 10.6694 -12.32 0 0
M  V30 8 C 10.6694 -9.24 0 0
M  V30 9 O 12.0031 -10.01 0 0
M  V30 10 C 13.3368 -9.24 0 0
M  V30 11 O 13.3368 -7.7 0 0
M  V30 12 C 14.6705 -10.01 0 0
M  V30 13 C 16.0041 -9.24 0 0
M  V30 14 C 17.3378 -10.01 0 0
M  V30 15 C 17.3378 -11.55 0 0
M  V30 16 C 16.0041 -12.32 0 0
M  V30 17 C 14.6705 -11.55 0 0
M  V30 18 N 18.6715 -12.32 0 0
M  V30 19 C 20.0052 -11.55 0 0
M  V30 20 C 18.6715 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1262254191

>  <MW>
277.204

>  <MW (desalted)>
277.402

>  <ClogP>
6.16

>  <logS>
-4.838

>  <HBD>
0

>  <HBA>
2

>  <TPSA>
29.54

>  <RotBonds>
9

>  <CAS>
21245-02-3

>  <Description>
Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products. It is indicated as an active UV-B filter to prevent photodamage.

>  <EBC_ID>
EBC-26412

>  <IUPAC Name>
2-ethylhexyl 4-(dimethylamino)benzoate

$$$$
Atropine (rac) sulfate
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 47 50 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.328 1.8567 0 0
M  V30 2 N -2.3585 3.0012 0 0
M  V30 3 C -1.868 4.7158 0 0
M  V30 4 C -3.3908 4.4863 0 0
M  V30 5 C -4.1608 3.1526 0 0
M  V30 6 C -3.5982 1.7191 0 0
M  V30 7 C -2.1266 1.2652 0 0
M  V30 8 C -0.8542 2.1327 0 0
M  V30 9 C -0.7391 3.6684 0 0
M  V30 10 O 0.4795 1.3627 0 0
M  V30 11 C 0.4795 -0.1773 0 0
M  V30 12 O -0.8542 -0.9473 0 0
M  V30 13 C 1.8132 -0.9473 0 0
M  V30 14 C 3.1468 -0.1773 0 0
M  V30 15 O 4.4805 -0.9473 0 0
M  V30 16 C 1.8132 -2.4873 0 0
M  V30 17 C 3.1468 -3.2573 0 0
M  V30 18 C 3.1468 -4.7973 0 0
M  V30 19 C 1.8132 -5.5673 0 0
M  V30 20 C 0.4795 -4.7973 0 0
M  V30 21 C 0.4795 -3.2573 0 0
M  V30 22 C 11.7133 1.8567 0 0
M  V30 23 N 10.6828 3.0012 0 0
M  V30 24 C 11.1733 4.7158 0 0
M  V30 25 C 9.6505 4.4863 0 0
M  V30 26 C 8.8805 3.1526 0 0
M  V30 27 C 9.4431 1.7191 0 0
M  V30 28 C 10.9147 1.2652 0 0
M  V30 29 C 12.1871 2.1327 0 0
M  V30 30 C 12.3022 3.6684 0 0
M  V30 31 O 13.5208 1.3627 0 0
M  V30 32 C 13.5208 -0.1773 0 0
M  V30 33 O 12.1871 -0.9473 0 0
M  V30 34 C 14.8545 -0.9473 0 0
M  V30 35 C 16.1882 -0.1773 0 0
M  V30 36 O 17.5219 -0.9473 0 0
M  V30 37 C 14.8545 -2.4873 0 0
M  V30 38 C 16.1882 -3.2573 0 0
M  V30 39 C 16.1882 -4.7973 0 0
M  V30 40 C 14.8545 -5.5673 0 0
M  V30 41 C 13.5208 -4.7973 0 0
M  V30 42 C 13.5208 -3.2573 0 0
M  V30 43 O 0 -11.7273 0 0
M  V30 44 S 0 -10.1873 0 0
M  V30 45 O 0 -8.6473 0 0
M  V30 46 O 1.54 -10.1873 0 0
M  V30 47 O -1.54 -10.1873 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 3 9
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 13 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 16 21
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 23 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 24 30
M  V30 34 1 29 31
M  V30 35 1 31 32
M  V30 36 2 32 33
M  V30 37 1 32 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 1 34 37
M  V30 41 1 37 38
M  V30 42 2 38 39
M  V30 43 1 39 40
M  V30 44 2 40 41
M  V30 45 1 41 42
M  V30 46 2 37 42
M  V30 47 1 43 44
M  V30 48 2 44 45
M  V30 49 2 44 46
M  V30 50 1 44 47
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z104475612

>  <MW>
676.817

>  <MW (desalted)>
289.369

>  <ClogP>
1.299

>  <logS>
-0.959

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
49.77

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  100 % | Ki (inhibition constant) = 0.06 nM | Ki (inhibition constant)  6.2E-11 M | Ki (inhibition constant)  0.12 nM | Ki (inhibition constant)  0.14 nM | Ki (inhibition constant) = 0.16 nM

>  <CAS>
1263045-48-2

>  <Description>
Atropine is a muscarinic antagonist used to treat poisoning by muscarinic agents, including organophosphates and other drugs.

>  <EBC_ID>
EBC-182249

>  <IUPAC Name>
bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate); sulfuric acid

>  <Main Tar all refs>
J. Pharmacol. Exp. Ther., 2010, vol. 334, # 1, p. 214 - 222 | UNIVERSITY OF NORTH CAROLINA SYSTEM - WO2004/13143, 2004, A2 | ACORDA THERAPEUTICS INC - WO2009/15236, 2009, A1 | EUR. J. PHARMACOL., 1993, vol. 231, # 3, p. 485 - 488 | Bioorg. Med. Chem. Lett., 2013, vol. 23, # 13, p. 3822 - 3825 | UNIVERSITY OF NORTH CAROLINA SYSTEM - WO2004/13143, 2004, A2

>  <Main tar all>
M1 receptor pX=11.3 | M2 receptor pX=10.2 | mAChR pX=10.2 | M3 receptor pX=9.92 | M5 receptor pX=9.85 | M4 receptor pX=9.8

$$$$
Acetoexamide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 -3.08 0 0
M  V30 2 C 6.6684 -3.85 0 0
M  V30 3 O 8.0021 -3.08 0 0
M  V30 4 C 6.6684 -5.39 0 0
M  V30 5 C 8.0021 -6.16 0 0
M  V30 6 C 8.0021 -7.7 0 0
M  V30 7 C 6.6684 -8.47 0 0
M  V30 8 C 5.3347 -7.7 0 0
M  V30 9 C 5.3347 -6.16 0 0
M  V30 10 S 6.6684 -10.01 0 0
M  V30 11 O 5.1284 -10.01 0 0
M  V30 12 O 8.2084 -10.01 0 0
M  V30 13 N 6.6684 -11.55 0 0
M  V30 14 C 5.3347 -12.32 0 0
M  V30 15 O 4.001 -11.55 0 0
M  V30 16 N 5.3347 -13.86 0 0
M  V30 17 C 4.001 -14.63 0 0
M  V30 18 C 4.001 -16.17 0 0
M  V30 19 C 2.6674 -16.94 0 0
M  V30 20 C 1.3337 -16.17 0 0
M  V30 21 C 1.3337 -14.63 0 0
M  V30 22 C 2.6674 -13.86 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1552195936

>  <MW>
324.114

>  <MW (desalted)>
324.395

>  <ClogP>
2.254

>  <logS>
-3.79

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
92.34

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant) > 100 nM | IC50 < 100 nM

>  <CAS>
968-81-0

>  <Description>
Acetohexamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 linked to the inwardly rectifying potassium channel. Acetohexamide is used to treat diabetes mellitus type 2; stimulate the pancreas to secrete insulin.

>  <EBC_ID>
EBC-07953

>  <IUPAC Name>
3-(4-acetylbenzenesulfonyl)-1-cyclohexylurea

>  <Main Tar all refs>
LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1 | LIGAND PHARMACEUTICALS INC - US2003/73728, 2003, A1

>  <Main tar all>
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 pX=7.0 | Kir6.2 pX=7.0

$$$$
Felodipine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.001 2.31 0 0
M  V30 2 C 2.6674 1.54 0 0
M  V30 3 O 2.6674 -0 0 0
M  V30 4 C 1.3337 -0.77 0 0
M  V30 5 O 0 0 0 0
M  V30 6 C 1.3337 -2.31 0 0
M  V30 7 C 2.6674 -3.08 0 0
M  V30 8 C 4.001 -2.31 0 0
M  V30 9 N 2.6674 -4.62 0 0
M  V30 10 C 1.3337 -5.39 0 0
M  V30 11 C 0 -4.62 0 0
M  V30 12 C 0 -3.08 0 0
M  V30 13 C -1.3337 -2.31 0 0
M  V30 14 C -2.6674 -3.08 0 0
M  V30 15 C -4.001 -2.31 0 0
M  V30 16 C -4.001 -0.77 0 0
M  V30 17 C -2.6674 0 0 0
M  V30 18 Cl -2.6674 1.54 0 0
M  V30 19 C -1.3337 -0.77 0 0
M  V30 20 Cl -0.7073 0.6369 0 0
M  V30 21 C -1.3337 -5.39 0 0
M  V30 22 O -2.6674 -4.62 0 0
M  V30 23 O -1.3337 -6.93 0 0
M  V30 24 C -2.6674 -7.7 0 0
M  V30 25 C 1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 6 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 13 19
M  V30 21 1 19 20
M  V30 22 1 11 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 10 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z239864852

>  <MW>
383.069

>  <MW (desalted)>
384.254

>  <ClogP>
5.297

>  <logS>
-3.46

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
64.63

>  <RotBonds>
6

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant) < 0.01 nM

>  <CAS>
72509-76-3

>  <Description>
Felodipine is an inhibitor of L-type calcium channels. Felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

>  <EBC_ID>
EBC-06048

>  <IUPAC Name>
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

>  <Main Tar all refs>
EUR. J. PHARMACOL., 1982, vol. 77, # 2-3, p. 201 - 202

>  <Main tar all>
Cav1.1 pX=11.0

$$$$
Pioglitazone hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 11.3452 9.2942 0 0
M  V30 3 C 12.6789 8.5242 0 0
M  V30 4 C 12.6789 6.9842 0 0
M  V30 5 C 14.0126 6.2142 0 0
M  V30 6 C 14.0126 4.6742 0 0
M  V30 7 C 12.6789 3.9042 0 0
M  V30 8 C 12.6789 2.3642 0 0
M  V30 9 C 11.3452 1.5942 0 0
M  V30 10 O 11.3452 0.0542 0 0
M  V30 11 C 10.0116 -0.7158 0 0
M  V30 12 C 10.0116 -2.2558 0 0
M  V30 13 C 8.6779 -3.0258 0 0
M  V30 14 C 7.3442 -2.2558 0 0
M  V30 15 C 6.0105 -3.0258 0 0
M  V30 16 C 6.0105 -4.5658 0 0
M  V30 17 S 7.2564 -5.471 0 0
M  V30 18 C 6.7805 -6.9356 0 0
M  V30 19 O 7.6857 -8.1815 0 0
M  V30 20 N 5.2405 -6.9356 0 0
M  V30 21 C 4.7646 -5.471 0 0
M  V30 22 O 3.3 -4.9951 0 0
M  V30 23 C 7.3442 -0.7158 0 0
M  V30 24 C 8.6779 0.0542 0 0
M  V30 25 N 11.3452 4.6742 0 0
M  V30 26 C 11.3452 6.2142 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 1 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 18 20
M  V30 19 1 20 21
M  V30 20 1 16 21
M  V30 21 2 21 22
M  V30 22 2 14 23
M  V30 23 1 23 24
M  V30 24 2 11 24
M  V30 25 2 7 25
M  V30 26 1 25 26
M  V30 27 2 4 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741968270

>  <MW>
392.9

>  <MW (desalted)>
356.439

>  <ClogP>
3.533

>  <logS>
-5.196

>  <HBD>
1

>  <HBA>
4

>  <TPSA>
68.29

>  <RotBonds>
7

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist | Inhibitor | - | Inhibitor | -

>  <Activity coefficients and valu>
EC50  0.27 ?M | EC50  490 nM | EC50  490 nM | EC50  490 nM | IC50  1 ?M | EC50  1.1 ?M | Ki (inhibition constant)  1.69 ?M | EC50 = 6680 nM

>  <CAS>
112529-15-4

>  <Description>
Pioglitazone is a selective agonist at peroxisome proliferator-activated receptor-gamma in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Pioglitazone is a thiazolidinedione used adjunctively with diet and exercise to normalize glycemic levels in adults with type 2 diabetes mellitus.

>  <EBC_ID>
EBC-11234

>  <IUPAC Name>
5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione hydrochloride

>  <Main Tar all refs>
Planta Med., 2006, vol. 72, # 10, p. 881 - 887 | Biochem. Biophys. Res. Commun., 2000, vol. 278, # 3, p. 704 - 711 | Chem. Pharm. Bull., 2002, vol. 50, # 1, p. 100 - 111 | Biochem. Biophys. Res. Commun., 2000, vol. 278, # 3, p. 704 - 711 | Chem. Biol., 2010, vol. 17, # 8, p. 892 - 902 | Drug Metab. Dispos., 2001, vol. 29, # 11, p. 1499 - 1504 | Drug Metab. Dispos., 2003, vol. 31, # 4, p. 439 - 446 | J. Med. Chem., 2003, vol. 46, # 23, p. 4883 - 4894

>  <Main tar all>
Peroxisome proliferator-activated receptor-? pX=6.57 | Peroxisome proliferator-activated receptor-?1 pX=6.31 | Peroxisome proliferator-activated receptor-? pX=6.31 | Retinoid X receptor-? pX=6.31 | Pantothenate kinase 3 pX=6.0 | Cytochrome P450 3A4 pX=5.96 | Cytochrome P450 2C8 pX=5.77 | Peroxisome proliferator-activated receptor-? pX=5.18

$$$$
Nifedipine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.3113 1.3989 0 0
M  V30 2 O 2.6674 -0 0 0
M  V30 3 C 1.1646 -0.1389 0 0
M  V30 4 O -0.1691 0.6311 0 0
M  V30 5 C 1.3337 -2.31 0 0
M  V30 6 C 2.6674 -3.08 0 0
M  V30 7 C 4.001 -2.31 0 0
M  V30 8 N 2.6674 -4.62 0 0
M  V30 9 C 1.3337 -5.39 0 0
M  V30 10 C 0 -4.62 0 0
M  V30 11 C 0 -3.08 0 0
M  V30 12 C -1.3337 -2.31 0 0
M  V30 13 C -2.6674 -3.08 0 0
M  V30 14 C -4.001 -2.31 0 0
M  V30 15 C -4.001 -0.77 0 0
M  V30 16 C -2.6674 0 0 0
M  V30 17 C -1.3337 -0.77 0 0
M  V30 18 N 0 0 0 0 CHG=1
M  V30 19 O 1.3337 -0.77 0 0
M  V30 20 O 0 1.54 0 0 CHG=-1
M  V30 21 C -1.3337 -5.39 0 0
M  V30 22 O -2.6674 -4.62 0 0
M  V30 23 O -1.3337 -6.93 0 0
M  V30 24 C -2.6674 -7.7 0 0
M  V30 25 C 1.3337 -6.93 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 5 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 10 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 9 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z90350374

>  <MW>
346.116

>  <MW (desalted)>
346.335

>  <ClogP>
3.125

>  <logS>
-2.389

>  <HBD>
1

>  <HBA>
5

>  <TPSA>
107.77

>  <RotBonds>
6

>  <Action on targets>
Antagonist | Antagonist | Antagonist | Antagonist | Antagonist | Antagonist | Blocker | Inhibitor | Antagonist

>  <Activity coefficients and valu>
IC50  10.7 pM | pA2  10.5  | pA2  10.5  | pA2  10.5  | pA2  10.5  | pA2  10  | IC50  0.13 nM | IC50  0.13 nM | pA2  9.75

>  <CAS>
21829-25-4

>  <Description>
Nifedipine blocks voltage gated L-type calcium channels in vascular smooth muscle and myocardial cells. Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.

>  <EBC_ID>
EBC-11141

>  <IUPAC Name>
3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

>  <Main Tar all refs>
Farmaco, 2002, vol. 57, # 2, p. 123 - 128 | EUR. J. PHARMACOL., 1995, vol. 283, # 1-3, p. 199 - 206 | EUR. J. PHARMACOL., 1995, vol. 283, # 1-3, p. 199 - 206 | EUR. J. PHARMACOL., 1995, vol. 283, # 1-3, p. 199 - 206 | EUR. J. PHARMACOL., 1995, vol. 283, # 1-3, p. 199 - 206 | J. PHARMACOL. EXP. THER., 1992, vol. 263, # 3, p. 1241 - 1247 | ChemMedChem, 2022, vol. 17, # 15 | Life Sci., 1982, vol. 30, # 25, p. 2191 - 2202 | Arzneimittelforschung, 1996, vol. 46, # 1, p. 15 - 24

>  <Main tar all>
Cav1.1 pX=11.0 | 5-HT1B receptor pX=10.5 | 5-HT1B receptor pX=10.5 | 5-HT1D receptor pX=10.5 | 5-HT1D receptor pX=10.5 | Voltage-gated potassium channel pX=10.0 | Cav1.2 pX=9.89 | voltage-gated calcium channel pX=9.89 | L-type calcium channel pX=9.75

$$$$
Levothyroxine sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na 12.0031 -3.85 0 0 CHG=1
M  V30 2 N 8.0021 -3.08 0 0
M  V30 3 C 8.0021 -4.62 0 0 CFG=1
M  V30 4 C 6.6684 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 4.001 -5.39 0 0
M  V30 7 C 2.6674 -4.62 0 0
M  V30 8 I 1.3337 -5.39 0 0
M  V30 9 C 2.6674 -3.08 0 0
M  V30 10 O 1.3337 -2.31 0 0
M  V30 11 C 1.3337 -0.77 0 0
M  V30 12 C 0 0 0 0
M  V30 13 C 0 1.54 0 0
M  V30 14 I -1.3337 2.31 0 0
M  V30 15 C 1.3337 2.31 0 0
M  V30 16 O 1.3337 3.85 0 0
M  V30 17 C 2.6674 1.54 0 0
M  V30 18 I 4.001 2.31 0 0
M  V30 19 C 2.6674 0 0 0
M  V30 20 C 4.001 -2.31 0 0
M  V30 21 I 4.001 -0.77 0 0
M  V30 22 C 5.3347 -3.08 0 0
M  V30 23 C 9.3358 -5.39 0 0
M  V30 24 O 9.3358 -6.93 0 0
M  V30 25 O 10.6694 -4.62 0 0 CHG=-1
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 3 2 CFG=3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 2 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 9 10
M  V30 9 1 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 1 13 15
M  V30 14 1 15 16
M  V30 15 2 15 17
M  V30 16 1 17 18
M  V30 17 1 17 19
M  V30 18 2 11 19
M  V30 19 2 9 20
M  V30 20 1 20 21
M  V30 21 1 20 22
M  V30 22 2 5 22
M  V30 23 1 3 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1551967075

>  <MW>
798.669

>  <MW (desalted)>
776.87

>  <ClogP>
2.825

>  <logS>
-5.766

>  <HBD>
2

>  <HBA>
4

>  <TPSA>
95.61

>  <RotBonds>
5

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
IC50 = 330 nM | inhibition percentage  87.6 %

>  <CAS>
55-03-8

>  <Description>
Levothyroxine is a synthetic T4 hormone used to treat hypothyroidism that can be used along with surgery and radioiodine therapy to manage thyrotropin-dependent well-differentiated thyroid cancer.

>  <EBC_ID>
EBC-14019

>  <IUPAC Name>
sodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate

>  <Main Tar all refs>
Bioorg. Med. Chem. Lett., 1996, vol. 6, # 10, p. 1145 - 1150 | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. - WO2016/24015, 2016, A1

>  <Main tar all>
GluN2D pX=6.48 | Cytochrome P450 2J2 pX=5.85

$$$$
Miglitol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0 6.16 0 0
M  V30 2 C 0 4.62 0 0
M  V30 3 C 1.3337 3.85 0 0
M  V30 4 N 1.3337 2.31 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 2.6674 -0 0 0 CFG=2
M  V30 7 O 4.001 -0.77 0 0
M  V30 8 C 1.3337 -0.77 0 0 CFG=1
M  V30 9 O 1.3337 -2.31 0 0
M  V30 10 C 0 0 0 0 CFG=2
M  V30 11 O -1.3337 -0.77 0 0
M  V30 12 C 0 1.54 0 0 CFG=1
M  V30 13 C -1.3337 2.31 0 0
M  V30 14 O -1.3337 3.85 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 8 6
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 4
M  V30 13 1 12 13 CFG=1
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1269163651

>  <MW>
207.224

>  <MW (desalted)>
207.224

>  <ClogP>
-1.256

>  <logS>
1.11

>  <HBD>
5

>  <HBA>
6

>  <TPSA>
104.39

>  <RotBonds>
3

>  <Action on targets>
-

>  <Activity coefficients and valu>
-

>  <CAS>
72432-03-2

>  <Description>
Miglitol is an oral alpha-glucosidase inhibitor used to improve glycemic control by delaying the digestion of carbohydrates. It is indicated  as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.

>  <EBC_ID>
EBC-07366

>  <IUPAC Name>
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol

$$$$
Olmesartan medoxomil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.4692 -5.505 0 0
M  V30 2 C 5.1355 -4.735 0 0
M  V30 3 C 3.8019 -5.505 0 0
M  V30 4 C 3.8019 -7.045 0 0
M  V30 5 N 5.0477 -7.9502 0 0
M  V30 6 C 4.5719 -9.4148 0 0
M  V30 7 C 3.0319 -9.4148 0 0
M  V30 8 C 2.1267 -10.6607 0 0
M  V30 9 O 0.5951 -10.4997 0 0
M  V30 10 O 2.753 -12.0676 0 0
M  V30 11 C 1.8478 -13.3134 0 0
M  V30 12 C 2.4742 -14.7203 0 0
M  V30 13 O 3.9806 -15.0405 0 0
M  V30 14 C 4.1415 -16.5721 0 0
M  V30 15 O 5.4752 -17.3421 0 0
M  V30 16 O 2.7347 -17.1984 0 0
M  V30 17 C 1.7042 -16.054 0 0
M  V30 18 C 0.1727 -16.215 0 0
M  V30 19 N 2.556 -7.9502 0 0
M  V30 20 C 1.0913 -7.4743 0 0
M  V30 21 C 0.7712 -5.968 0 0
M  V30 22 C -0.6935 -5.4921 0 0
M  V30 23 C -1.0137 -3.9857 0 0
M  V30 24 C 0.1308 -2.9553 0 0
M  V30 25 C 1.5954 -3.4311 0 0
M  V30 26 C 1.9156 -4.9375 0 0
M  V30 27 C -0.1894 -1.4489 0 0
M  V30 28 C -1.654 -0.973 0 0
M  V30 29 C -1.9742 0.5333 0 0
M  V30 30 C -0.8298 1.5638 0 0
M  V30 31 C 0.6349 1.0879 0 0
M  V30 32 C 0.955 -0.4185 0 0
M  V30 33 C 2.4197 -0.8943 0 0
M  V30 34 N 3.6656 0.0109 0 0
M  V30 35 N 4.9114 -0.8943 0 0
M  V30 36 N 4.4356 -2.359 0 0
M  V30 37 N 2.8956 -2.359 0 0
M  V30 38 C 5.477 -10.6607 0 0
M  V30 39 C 6.3822 -11.9066 0 0
M  V30 40 C 4.2312 -11.5659 0 0
M  V30 41 O 6.7229 -9.7555 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 17 18
M  V30 19 1 7 19
M  V30 20 1 4 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 21 26
M  V30 29 1 24 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 27 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 1 33 37
M  V30 42 1 6 38
M  V30 43 1 38 39
M  V30 44 1 38 40
M  V30 45 1 38 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1541759904

>  <MW>
558.585

>  <MW (desalted)>
558.585

>  <ClogP>
2.66

>  <logS>
-7.24

>  <HBD>
2

>  <HBA>
8

>  <TPSA>
154.34

>  <RotBonds>
11

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50  2.06 nM

>  <CAS>
144689-63-4

>  <Description>
Olmesartan is an angiotensin receptor blocker (ARB) used in the treatment of hypertension.

>  <EBC_ID>
EBC-12821

>  <IUPAC Name>
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate

>  <Main Tar all refs>
J. Pharmacol. Toxicol. Methods, 2020, vol. 102

>  <Main tar all>
AT1 receptor pX=8.69

$$$$
Cefazolin sodium
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Na -0.2818 -2.0282 0 0 CHG=1
M  V30 2 C 11.6891 0.6947 0 0
M  V30 3 C 10.1576 0.5338 0 0
M  V30 4 N 9.3876 -0.7999 0 0
M  V30 5 N 7.8812 -0.4797 0 0
M  V30 6 C 7.7202 1.0518 0 0
M  V30 7 S 6.3866 1.8218 0 0
M  V30 8 C 5.0529 1.0518 0 0
M  V30 9 C 3.7192 1.8218 0 0
M  V30 10 C 2.3855 1.0518 0 0
M  V30 11 N 1.0518 1.8218 0 0
M  V30 12 C 1.0518 3.3618 0 0 CFG=2
M  V30 13 S 2.3855 4.1318 0 0
M  V30 14 C 3.7192 3.3618 0 0
M  V30 15 C -0.4882 3.3618 0 0 CFG=2
M  V30 16 N -1.5771 4.4508 0 0
M  V30 17 C -1.1785 5.9383 0 0
M  V30 18 O 0.309 6.3369 0 0
M  V30 19 C -2.2675 7.0273 0 0
M  V30 20 N -1.8689 8.5148 0 0
M  V30 21 C -2.838 9.7116 0 0
M  V30 22 N -1.9993 11.0031 0 0
M  V30 23 N -0.5118 10.6046 0 0
M  V30 24 N -0.4312 9.0667 0 0
M  V30 25 C -0.4882 1.8218 0 0
M  V30 26 O -1.5771 0.7329 0 0
M  V30 27 C 2.3855 -0.4882 0 0
M  V30 28 O 3.7192 -1.2582 0 0
M  V30 29 O 1.0518 -1.2582 0 0 CHG=-1
M  V30 30 S 9.1271 1.6782 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 2 3 4
M  V30 3 1 4 5
M  V30 4 2 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 8 9
M  V30 8 2 9 10
M  V30 9 1 10 11
M  V30 10 1 12 11 CFG=1
M  V30 11 1 12 13
M  V30 12 1 13 14
M  V30 13 1 9 14
M  V30 14 1 12 15
M  V30 15 1 15 16 CFG=1
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 20 24
M  V30 25 1 15 25
M  V30 26 1 11 25
M  V30 27 2 25 26
M  V30 28 1 10 27
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 6 30
M  V30 32 1 3 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2756516844

>  <MW>
476.012

>  <MW (desalted)>
454.507

>  <ClogP>
-4.109

>  <HBD>
1

>  <HBA>
9

>  <TPSA>
158.92

>  <RotBonds>
7

>  <Action on targets>
Inhibitor | Inhibitor

>  <Activity coefficients and valu>
inhibition percentage  25 % | inhibition percentage  39 %

>  <CAS>
27164-46-1

>  <Description>
Cefazolin sodium is a  broad-spectrum first-generation cephalosporin antibiotic.

>  <EBC_ID>
EBC-08481

>  <IUPAC Name>
sodium (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[2-(1H-1,2,3,4-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

>  <Main Tar all refs>
Drug Metab. Dispos., 2014, vol. 42, # 7, p. 1103 - 1109 | Drug Metab. Dispos., 2015, vol. 43, # 6, p. 812 - 818

>  <Main tar all>
Carboxylesterase 2 pX=3.52 |  UDP glucuronosyltransferase family 1 member A8 pX=3.5

$$$$
Nomifensine
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 -3.08 0 0
M  V30 2 N 1.3337 -2.31 0 0
M  V30 3 C 1.3337 -0.77 0 0
M  V30 4 C 2.6674 0 0 0
M  V30 5 C 2.6674 1.54 0 0
M  V30 6 C 1.3337 2.31 0 0
M  V30 7 C 1.3337 3.85 0 0
M  V30 8 C 2.6674 4.62 0 0
M  V30 9 C 4.001 3.85 0 0
M  V30 10 C 4.001 2.31 0 0
M  V30 11 C 4.001 -0.77 0 0
M  V30 12 C 5.3347 0 0 0
M  V30 13 C 6.6684 -0.77 0 0
M  V30 14 C 6.6684 -2.31 0 0
M  V30 15 C 5.3347 -3.08 0 0
M  V30 16 N 5.3347 -4.62 0 0
M  V30 17 C 4.001 -2.31 0 0
M  V30 18 C 2.6674 -3.08 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 11 17
M  V30 19 1 17 18
M  V30 20 1 2 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2216900850

>  <MW>
238.328

>  <MW (desalted)>
238.328

>  <ClogP>
2.372

>  <logS>
-2.418

>  <HBD>
1

>  <HBA>
2

>  <TPSA>
29.26

>  <RotBonds>
1

>  <Action on targets>
Inhibitor | Modulator | - | - | - | Inhibitor | Antagonist

>  <Activity coefficients and valu>
Kd (dissociation constant) = 1.6 nM | EC50 = 3.1 nM | EC50 = 11 nM | EC50 = 11 nM | Kd (dissociation constant)  16 nM | IC50  35 nM | IC50  0.037 ?M

>  <CAS>
24526-64-5

>  <Description>
Nomifensine is an inhibitor of norepinephrine and dopamine reuptake. It is mainly used in scientific research, particularly in studies involving dopamine release in response to addiction.

>  <EBC_ID>
EBC-08728

>  <IUPAC Name>
2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine

>  <Main Tar all refs>
Eur. J. Med. Chem., 1993, vol. 28, p. 927 - 933 | ACS Med. Chem. Lett., 2013, vol. 4, # 1, p. 46 - 51 | SUMITOMO CHEMICAL COMPANY LIMITED; Sumitomo Pharma (in: Sumitomo Chemical); Sumitomo Chemical (w/o Dongwoo Fine-Chem) - WO2003/16274, 2003, A2 | Sumitomo Chemical (w/o Dongwoo Fine-Chem); Sumitomo Pharma (in: Sumitomo Chemical); SUMITOMO CHEMICAL COMPANY LIMITED - WO2003/16274, 2003, A2 | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY; MAYO FOUNDATION - US2008/200556, 2008, A1 | Eur. J. Pharmacol., 1989, vol. 166, # 3, p. 493 - 504 | EUR. J. PHARMACOL., 1981, vol. 70, # 3, p. 393 - 407

>  <Main tar all>
DAT pX=8.8 | NET pX=8.51 | Dopamine receptor pX=7.96 | Dopamine receptor pX=7.96 | EPH receptor B1 pX=7.8 | H1 receptor pX=7.46 | 5-HT receptor pX=7.43

$$$$
Azithromycin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 52 54 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.2687 10.6362 0 0
M  V30 2 C -3.6811 10.0224 0 0
M  V30 3 C -3.8557 8.4924 0 0 CFG=1
M  V30 4 O -2.3567 8.8452 0 0
M  V30 5 C -1.5579 7.5285 0 0
M  V30 6 O -0.0232 7.4009 0 0
M  V30 7 C -2.5633 6.362 0 0 CFG=2
M  V30 8 C -4.001 6.9139 0 0
M  V30 9 C -2.5999 4.6772 0 0 CFG=1
M  V30 10 O -1.2662 3.9072 0 0
M  V30 11 C 0.0675 4.6772 0 0 CFG=1
M  V30 12 C 0.0675 6.2172 0 0
M  V30 13 C 1.4012 6.9872 0 0 CFG=1
M  V30 14 C 0.4113 8.1669 0 0
M  V30 15 O 2.3911 8.1669 0 0
M  V30 16 C 1.8644 9.614 0 0
M  V30 17 C 2.7349 6.2172 0 0 CFG=1
M  V30 18 O 4.0685 6.9872 0 0
M  V30 19 C 2.7349 4.6772 0 0 CFG=2
M  V30 20 C 4.0685 3.9072 0 0
M  V30 21 O 1.4012 3.9072 0 0
M  V30 22 C -3.9165 3.8784 0 0 CFG=2
M  V30 23 C -5.2666 4.6193 0 0
M  V30 24 C -3.8831 2.3388 0 0 CFG=1
M  V30 25 O -2.533 1.5979 0 0
M  V30 26 C -2.4996 0.0583 0 0 CFG=2
M  V30 27 O -1.1495 -0.6826 0 0
M  V30 28 C -1.116 -2.2222 0 0 CFG=2
M  V30 29 C 0.2341 -2.9631 0 0
M  V30 30 C -2.4327 -3.021 0 0
M  V30 31 C -3.7828 -2.2801 0 0 CFG=1
M  V30 32 C -3.8162 -0.7405 0 0 CFG=1
M  V30 33 O -5.1663 0.0004 0 0
M  V30 34 N -5.0994 -3.0789 0 0
M  V30 35 C -5.066 -4.6185 0 0
M  V30 36 C -6.4495 -2.338 0 0
M  V30 37 C -5.1997 1.54 0 0 CFG=2
M  V30 38 C -4.1844 0.3821 0 0
M  V30 39 O -6.1638 0.3391 0 0
M  V30 40 C -6.5498 2.2809 0 0
M  V30 41 C -6.5832 3.8205 0 0 CFG=1
M  V30 42 C -5.9876 5.2406 0 0
M  V30 43 C -7.9333 4.5614 0 0
M  V30 44 N -7.9668 6.101 0 0
M  V30 45 C -9.3168 6.8419 0 0
M  V30 46 C -6.6501 6.8998 0 0 CFG=2
M  V30 47 C -5.3 6.1589 0 0
M  V30 48 C -6.6835 8.4394 0 0 CFG=1
M  V30 49 O -8.0336 9.1803 0 0
M  V30 50 C -5.3669 9.2382 0 0 CFG=1
M  V30 51 C -6.1415 10.5692 0 0
M  V30 52 O -4.7107 10.6314 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=1
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 17 13
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 19 21
M  V30 21 1 11 21
M  V30 22 1 9 22
M  V30 23 1 22 23 CFG=1
M  V30 24 1 22 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 32 31
M  V30 33 1 32 26
M  V30 34 1 32 33 CFG=1
M  V30 35 1 31 34 CFG=3
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 24 37
M  V30 39 1 37 38 CFG=1
M  V30 40 1 37 39 CFG=3
M  V30 41 1 37 40
M  V30 42 1 41 40
M  V30 43 1 41 42 CFG=3
M  V30 44 1 41 43
M  V30 45 1 43 44
M  V30 46 1 44 45
M  V30 47 1 46 44
M  V30 48 1 46 47 CFG=1
M  V30 49 1 48 46
M  V30 50 1 48 49 CFG=1
M  V30 51 1 48 50
M  V30 52 1 50 3
M  V30 53 1 50 51 CFG=1
M  V30 54 1 50 52 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1558483766

>  <MW>
748.984

>  <MW (desalted)>
748.984

>  <ClogP>
2.638

>  <logS>
-2.64

>  <HBD>
5

>  <HBA>
13

>  <TPSA>
180.08

>  <RotBonds>
7

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
Kd (dissociation constant)  4.67E-11 M

>  <CAS>
83905-01-5

>  <Description>
Azithromycin is a macrolide antibiotic used to treat a variety of bacterial infections.

>  <EBC_ID>
EBC-14146

>  <IUPAC Name>
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one

>  <Main Tar all refs>
Int. J. Mol. Sci., 2022, vol. 23, # 19

>  <Main tar all>
Protein X pX=10.3

$$$$
Sulfinpyrazone
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.3337 -0.77 0 0
M  V30 2 C 1.3337 -2.31 0 0
M  V30 3 C 2.5796 -3.2152 0 0
M  V30 4 C 4.0442 -2.7393 0 0
M  V30 5 C 5.1886 -3.7698 0 0
M  V30 6 S 6.6533 -3.2939 0 0
M  V30 7 O 6.9734 -1.7875 0 0
M  V30 8 C 7.7977 -4.3243 0 0
M  V30 9 C 9.2623 -3.8485 0 0
M  V30 10 C 10.4068 -4.8789 0 0
M  V30 11 C 10.0866 -6.3853 0 0
M  V30 12 C 8.622 -6.8611 0 0
M  V30 13 C 7.4775 -5.8307 0 0
M  V30 14 C 2.1037 -4.6798 0 0
M  V30 15 O 3.0089 -5.9257 0 0
M  V30 16 N 0.5637 -4.6798 0 0
M  V30 17 N 0.0878 -3.2152 0 0
M  V30 18 C -1.3768 -2.7393 0 0
M  V30 19 C -2.5213 -3.7698 0 0
M  V30 20 C -3.9859 -3.2939 0 0
M  V30 21 C -4.3061 -1.7875 0 0
M  V30 22 C -3.1616 -0.7571 0 0
M  V30 23 C -1.697 -1.233 0 0
M  V30 24 C -0.3415 -5.9257 0 0
M  V30 25 C 0.2849 -7.3326 0 0
M  V30 26 C -0.6203 -8.5784 0 0
M  V30 27 C -2.1519 -8.4175 0 0
M  V30 28 C -2.7783 -7.0106 0 0
M  V30 29 C -1.8731 -5.7647 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 3 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 2 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 18 23
M  V30 26 1 16 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 24 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1557407327

>  <MW>
404.482

>  <MW (desalted)>
404.482

>  <ClogP>
1.655

>  <logS>
-4.75

>  <HBD>
0

>  <HBA>
3

>  <TPSA>
57.69

>  <RotBonds>
6

>  <Action on targets>
Agonist | Agonist | Antagonist

>  <Activity coefficients and valu>
concentration (parameter)  2.6 nM | concentration (parameter)  2.6 nM | concentration (parameter)  11.3 nM

>  <CAS>
57-96-5

>  <Description>
Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. It also has an agonist effect on fmet-leu-phe receptor.

>  <EBC_ID>
EBC-08962

>  <IUPAC Name>
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione

>  <Main Tar all refs>
CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425 | CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425 | CAN. J. PHYSIOL. PHARMACOL., 1991, vol. 69, # 3, p. 419 - 425

>  <Main tar all>
FPR1 pX=8.59 | FPR1 pX=8.59 | C5a anaphylatoxin chemotactic receptor 1 pX=7.95

$$$$
Ramipril
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.2502 7.6128 0 0
M  V30 2 C 7.2502 6.0728 0 0
M  V30 3 O 8.5838 5.3028 0 0
M  V30 4 C 8.5838 3.7628 0 0
M  V30 5 O 7.2502 2.9928 0 0
M  V30 6 C 9.9175 2.9928 0 0 CFG=2
M  V30 7 C 9.9175 1.4528 0 0
M  V30 8 C 8.5838 0.6828 0 0
M  V30 9 C 8.5838 -0.8572 0 0
M  V30 10 C 9.9175 -1.6272 0 0
M  V30 11 C 9.9175 -3.1672 0 0
M  V30 12 C 8.5838 -3.9372 0 0
M  V30 13 C 7.2502 -3.1672 0 0
M  V30 14 C 7.2502 -1.6272 0 0
M  V30 15 N 11.2512 3.7628 0 0
M  V30 16 C 11.2512 5.3028 0 0 CFG=1
M  V30 17 C 9.9175 6.0728 0 0
M  V30 18 C 12.5849 6.0728 0 0
M  V30 19 O 12.5849 7.6128 0 0
M  V30 20 N 13.9185 5.3028 0 0
M  V30 21 C 15.3254 5.9292 0 0 CFG=1
M  V30 22 C 16.3559 4.7847 0 0
M  V30 23 C 15.5859 3.4511 0 0 CFG=2
M  V30 24 C 15.7468 1.9195 0 0
M  V30 25 C 14.34 1.2931 0 0
M  V30 26 C 13.3095 2.4376 0 0
M  V30 27 C 14.0795 3.7712 0 0 CFG=2
M  V30 28 C 15.6456 7.4355 0 0
M  V30 29 O 17.1102 7.9114 0 0
M  V30 30 O 14.5012 8.466 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 6 15 CFG=1
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=1
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 21 20
M  V30 22 1 21 22
M  V30 23 1 23 22 CFG=3
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 27 26
M  V30 28 1 23 27
M  V30 29 1 27 20 CFG=3
M  V30 30 1 21 28 CFG=3
M  V30 31 2 28 29
M  V30 32 1 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1515381509

>  <MW>
416.511

>  <MW (desalted)>
416.511

>  <ClogP>
1.54

>  <logS>
-4.34

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
95.94

>  <RotBonds>
10

>  <Action on targets>
Inhibitor

>  <Activity coefficients and valu>
IC50 = 4 nM

>  <CAS>
87333-19-5

>  <Description>
Ramipril is a prodrug form of the angiotensin-converting enzyme inhibitor ramiprilat. Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

>  <EBC_ID>
EBC-02055

>  <IUPAC Name>
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid

>  <Main Tar all refs>
Curr. Pharm. Des., 2012, vol. 18, # 2, p. 220 - 230

>  <Main tar all>
Angiotensin-converting enzyme pX=8.4

$$$$
Donepezil
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.5315 2.0728 0 0
M  V30 2 O 5.1978 1.3028 0 0
M  V30 3 C 3.8641 2.0728 0 0
M  V30 4 C 2.5304 1.3028 0 0
M  V30 5 C 1.1967 2.0728 0 0
M  V30 6 C -0.2679 1.5969 0 0
M  V30 7 C -1.1731 2.8428 0 0
M  V30 8 C -2.7131 2.8428 0 0
M  V30 9 C -3.4831 4.1765 0 0
M  V30 10 C -5.0231 4.1765 0 0
M  V30 11 C -5.7931 5.5102 0 0
M  V30 12 N -5.0231 6.8439 0 0
M  V30 13 C -5.7931 8.1775 0 0
M  V30 14 C -5.0231 9.5112 0 0
M  V30 15 C -5.7931 10.8449 0 0
M  V30 16 C -5.0231 12.1786 0 0
M  V30 17 C -3.4831 12.1786 0 0
M  V30 18 C -2.7131 10.8449 0 0
M  V30 19 C -3.4831 9.5112 0 0
M  V30 20 C -3.4831 6.8439 0 0
M  V30 21 C -2.7131 5.5102 0 0
M  V30 22 C -0.2679 4.0887 0 0
M  V30 23 O -0.7438 5.5533 0 0
M  V30 24 C 1.1967 3.6128 0 0
M  V30 25 C 2.5304 4.3828 0 0
M  V30 26 C 3.8641 3.6128 0 0
M  V30 27 O 5.1978 4.3828 0 0
M  V30 28 C 6.5315 3.6128 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 14 19
M  V30 20 1 12 20
M  V30 21 1 20 21
M  V30 22 1 9 21
M  V30 23 1 7 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 5 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 3 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1741977105

>  <MW>
379.492

>  <MW (desalted)>
379.492

>  <ClogP>
4.598

>  <logS>
-3.981

>  <HBD>
0

>  <HBA>
4

>  <TPSA>
38.77

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | - | - | Inhibitor

>  <Activity coefficients and valu>
IC50  0.0067 nM | IC50  0.0067 nM | IC50  0.027 nM | IC50  0.098 nM | amount  40.454 pg/ml | concentration (parameter)  47.11 pg/ml | IC50  0.164 nM

>  <CAS>
120014-06-4

>  <Description>
Donepezil is a piperidine based, potent, specific, non-competitive and reversible inhibitor of acetylcholinesterase (AChE).It is commonly used in the treatment of Alzheimer?s disease to improve cognition, memory, and behavior.

>  <EBC_ID>
EBC-02053

>  <IUPAC Name>
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one

>  <Main Tar all refs>
UNIVERSITY OF ALCALA; GOVERNMENT OF SPAIN; UNIVERSITAT AUTONOMA DE BARCELONA; OKAYAMA UNIVERSITY - EP2727916, 2014, A1 | UNIVERSITAT AUTONOMA DE BARCELONA; OKAYAMA UNIVERSITY; GOVERNMENT OF SPAIN; UNIVERSITY OF ALCALA - EP2727916, 2014, A1 | Chem. Biodivers., 2022, vol. 19, # 1 | Drug Dev. Res., 2022, vol. 83, # 6, p. 1394 - 1407 | Neurotoxic. Res., 2022, vol. 40, # 2, p. 432 - 448 | Eur. J. Pharmacol., 2018, vol. 832, p. 56 - 66 | Drug Dev. Res., 2022, vol. 83, # 6, p. 1394 - 1407

>  <Main tar all>
acetylcholinesterase (Cartwright blood group) pX=11.2 | acetylcholinesterase (Cartwright blood group) pX=11.2 | Acetylcholinesterase 1 pX=10.6 | acetylcholinesterase (Cartwright blood group) pX=10.0 | phosphodiesterase 4 pX=9.97 | 3'5'-cyclic nucleotide phosphodiesterase pX=9.91 | butyrylcholinesterase pX=9.79

$$$$
Betapar
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.851 -2.6445 0 0
M  V30 2 C 5.2994 -3.1677 0 0 CFG=1
M  V30 3 C 6.574 -2.3035 0 0
M  V30 4 C 7.7898 -3.2487 0 0 CFG=1
M  V30 5 C 9.3058 -2.9776 0 0 CFG=2
M  V30 6 C 9.829 -1.5293 0 0
M  V30 7 C 11.345 -1.2582 0 0
M  V30 8 C 12.3377 -2.4355 0 0
M  V30 9 C 13.8537 -2.1644 0 0
M  V30 10 C 14.8464 -3.3418 0 0
M  V30 11 O 16.3624 -3.0707 0 0
M  V30 12 C 14.3232 -4.7901 0 0
M  V30 13 C 12.8072 -5.0612 0 0
M  V30 14 C 11.8145 -3.8839 0 0 CFG=1
M  V30 15 C 11.2913 -5.3323 0 0
M  V30 16 C 10.2985 -4.155 0 0 CFG=1
M  V30 17 C 9.7753 -5.6034 0 0
M  V30 18 O 10.768 -6.7807 0 0
M  V30 19 C 8.2593 -5.8744 0 0
M  V30 20 C 7.2666 -4.6971 0 0 CFG=1
M  V30 21 C 6.5949 -6.0829 0 0
M  V30 22 C 5.7274 -4.6471 0 0 CFG=2
M  V30 23 O 5.5008 -6.1703 0 0
M  V30 24 C 4.3071 -5.2423 0 0
M  V30 25 O 4.1124 -6.7699 0 0
M  V30 26 C 3.0815 -4.3099 0 0
M  V30 27 O 1.6612 -4.9051 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 5 16
M  V30 18 1 16 17 CFG=1
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 20 19
M  V30 22 1 4 20
M  V30 23 1 20 21 CFG=1
M  V30 24 1 20 22
M  V30 25 1 22 2
M  V30 26 1 22 23 CFG=3
M  V30 27 1 22 24 CFG=1
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 30 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1530532760

>  <MW>
372.455

>  <MW (desalted)>
372.455

>  <ClogP>
2.18

>  <logS>
-3.8

>  <HBD>
2

>  <HBA>
5

>  <TPSA>
91.67

>  <RotBonds>
2

>  <Action on targets>
Antagonist

>  <Activity coefficients and valu>
IC25  0.3 - 1 ?M

>  <CAS>
1247-42-3

>  <Description>
Meprednisone is a glucocorticoid and a methylated derivative of prednisone. It is an antagonist of androgenic receptor.

>  <EBC_ID>
EBC-08662

>  <IUPAC Name>
(1R,2S,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione

>  <Main Tar all refs>
Chem. Res. Toxicol., 2008, vol. 21, # 4, p. 813 - 823

>  <Main tar all>
Androgen receptor pX=6.05

$$$$
Glipizide
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 -6.16 0 0
M  V30 2 C 6.6684 -6.93 0 0
M  V30 3 C 8.0021 -6.16 0 0
M  V30 4 N 9.3358 -6.93 0 0
M  V30 5 C 9.3358 -8.47 0 0
M  V30 6 C 8.0021 -9.24 0 0
M  V30 7 N 6.6684 -8.47 0 0
M  V30 8 C 10.6694 -9.24 0 0
M  V30 9 O 10.6694 -10.78 0 0
M  V30 10 N 12.0031 -8.47 0 0
M  V30 11 C 13.3368 -9.24 0 0
M  V30 12 C 14.6705 -8.47 0 0
M  V30 13 C 16.0041 -9.24 0 0
M  V30 14 C 17.3378 -8.47 0 0
M  V30 15 C 18.6715 -9.24 0 0
M  V30 16 C 18.6715 -10.78 0 0
M  V30 17 C 17.3378 -11.55 0 0
M  V30 18 C 16.0041 -10.78 0 0
M  V30 19 S 20.0052 -11.55 0 0
M  V30 20 O 19.2352 -12.8837 0 0
M  V30 21 O 20.7752 -10.2163 0 0
M  V30 22 N 21.3389 -12.32 0 0
M  V30 23 C 21.3389 -13.86 0 0
M  V30 24 O 20.0052 -14.63 0 0
M  V30 25 N 22.6725 -14.63 0 0
M  V30 26 C 22.6725 -16.17 0 0
M  V30 27 C 24.0062 -16.94 0 0
M  V30 28 C 24.0062 -18.48 0 0
M  V30 29 C 22.6725 -19.25 0 0
M  V30 30 C 21.3389 -18.48 0 0
M  V30 31 C 21.3389 -16.94 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 13 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 2 19 21
M  V30 23 1 19 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 26 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1575081877

>  <MW>
445.535

>  <MW (desalted)>
445.535

>  <ClogP>
2.571

>  <logS>
-3.417

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
130.15

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
pKi  8.86  | IC50  5.6 nM | IC50  5.6 nM

>  <CAS>
29094-61-9

>  <Description>
Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes. Glipizide regulates ATP-sensitive K(+) channels and insulin release.

>  <EBC_ID>
EBC-06101

>  <IUPAC Name>
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide

>  <Main Tar all refs>
J. PHARMACOL. EXP. THER., 1995, vol. 273, # 2, p. 778 - 786 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332 | Br. J. Pharmacol., 2000, vol. 129, # 7, p. 1323 - 1332

>  <Main tar all>
Potassium channel ATP dependent pX=8.86 | KATP?channel?SUR1 pX=8.25 | Kir6.2 pX=8.25

$$$$
Gentamicin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -6.6684 3.85 0 0
M  V30 2 N -5.3347 4.62 0 0
M  V30 3 C -4.001 3.85 0 0
M  V30 4 C -4.001 2.31 0 0 CFG=2
M  V30 5 C -5.3347 1.54 0 0
M  V30 6 C -5.3347 0 0 0
M  V30 7 C -4.001 -0.77 0 0 CFG=1
M  V30 8 N -4.001 -2.31 0 0
M  V30 9 C -2.6674 0 0 0
M  V30 10 O -1.3337 -0.77 0 0
M  V30 11 C 0 0 0 0
M  V30 12 C 1.3337 -0.77 0 0 CFG=1
M  V30 13 N 1.3337 -2.31 0 0
M  V30 14 C 2.6674 0 0 0
M  V30 15 C 2.6674 1.54 0 0 CFG=1
M  V30 16 N 4.001 2.31 0 0
M  V30 17 C 1.3337 2.31 0 0 CFG=2
M  V30 18 O 1.3337 3.85 0 0
M  V30 19 C 0 4.62 0 0 CFG=1
M  V30 20 O -1.3337 3.85 0 0
M  V30 21 C -2.6674 4.62 0 0
M  V30 22 C -2.6674 6.16 0 0 CFG=2
M  V30 23 C -4.184 5.8926 0 0
M  V30 24 O -3.1941 7.6071 0 0
M  V30 25 C -1.3337 6.93 0 0 CFG=2
M  V30 26 N -1.3337 8.47 0 0
M  V30 27 C -0 9.24 0 0
M  V30 28 C -0 6.16 0 0 CFG=1
M  V30 29 O 1.3337 6.93 0 0
M  V30 30 C 0 1.54 0 0 CFG=1
M  V30 31 O -1.3337 2.31 0 0
M  V30 32 O -2.6674 1.54 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 1 15 14
M  V30 15 1 15 16 CFG=3
M  V30 16 1 17 15
M  V30 17 1 17 18 CFG=1
M  V30 18 1 19 18 CFG=1
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 23 CFG=1
M  V30 23 1 22 24 CFG=3
M  V30 24 1 25 22
M  V30 25 1 25 26 CFG=3
M  V30 26 1 26 27
M  V30 27 1 25 28
M  V30 28 1 28 19
M  V30 29 1 28 29 CFG=1
M  V30 30 1 17 30
M  V30 31 1 30 11
M  V30 32 1 30 31 CFG=3
M  V30 33 1 9 32
M  V30 34 1 4 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1824014879

>  <MW>
463.301

>  <MW (desalted)>
463.569

>  <ClogP>
-2.108

>  <logS>
-0.12

>  <HBD>
8

>  <HBA>
12

>  <TPSA>
199.73

>  <RotBonds>
7

>  <CAS>
1403-66-3

>  <Description>
Gentamycin is an aminoglycoside antibiotic.

>  <EBC_ID>
EBC-146049

>  <IUPAC Name>
(2R,3R,4R,5R)-2-{[(1S,2S,4S,6R)-4,6-diamino-3-{[(3R,6S)-3-amino-6-[(methylamino)methyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol

$$$$
Selexipag
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3347 -7.7 0 0
M  V30 2 C 4.001 -6.93 0 0
M  V30 3 C 2.6674 -7.7 0 0
M  V30 4 N 4.001 -5.39 0 0
M  V30 5 C 5.3347 -4.62 0 0
M  V30 6 C 6.6684 -5.39 0 0
M  V30 7 C 8.0021 -4.62 0 0
M  V30 8 C 9.3358 -5.39 0 0
M  V30 9 O 10.6694 -4.62 0 0
M  V30 10 C 12.0031 -5.39 0 0
M  V30 11 C 13.3368 -4.62 0 0
M  V30 12 O 13.3368 -3.08 0 0
M  V30 13 N 14.6705 -5.39 0 0
M  V30 14 S 16.0041 -4.62 0 0
M  V30 15 O 17.3378 -3.85 0 0
M  V30 16 O 15.2341 -3.2863 0 0
M  V30 17 C 16.7741 -5.9537 0 0
M  V30 18 C 2.6674 -4.62 0 0
M  V30 19 C 1.3337 -5.39 0 0
M  V30 20 N 0 -4.62 0 0
M  V30 21 C 0 -3.08 0 0
M  V30 22 C -1.3337 -2.31 0 0
M  V30 23 C -2.6674 -3.08 0 0
M  V30 24 C -4.001 -2.31 0 0
M  V30 25 C -4.001 -0.77 0 0
M  V30 26 C -2.6674 0 0 0
M  V30 27 C -1.3337 -0.77 0 0
M  V30 28 C 1.3337 -2.31 0 0
M  V30 29 N 2.6674 -3.08 0 0
M  V30 30 C 1.3337 -0.77 0 0
M  V30 31 C 0 0 0 0
M  V30 32 C 0 1.54 0 0
M  V30 33 C 1.3337 2.31 0 0
M  V30 34 C 2.6674 1.54 0 0
M  V30 35 C 2.6674 0 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 2 14 16
M  V30 16 1 14 17
M  V30 17 1 4 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 22 27
M  V30 28 2 21 28
M  V30 29 1 28 29
M  V30 30 2 18 29
M  V30 31 1 28 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 2 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2242135673

>  <MW>
496.214

>  <MW (desalted)>
496.622

>  <ClogP>
4.176

>  <logS>
-4.536

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
101.49

>  <RotBonds>
11

>  <Action on targets>
Agonist | Agonist | Agonist

>  <Activity coefficients and valu>
EC50  6 nM | EC50  6 nM | EC50  100 nM

>  <CAS>
475086-01-2

>  <Description>
Selexipag is a non prostanoid IP prostacyclin receptor agonist used to treat pulmonary arterial hypertension.

>  <EBC_ID>
EBC-13811

>  <IUPAC Name>
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide

>  <Main Tar all refs>
J. Med. Chem., 2017, vol. 60, # 3, p. 913 - 927 | J. Med. Chem., 2017, vol. 60, # 3, p. 913 - 927 | J. Med. Chem., 2017, vol. 60, # 3, p. 913 - 927

>  <Main tar all>
IP receptor pX=8.22 | IP receptor pX=8.22 | DP1 receptor pX=7.0

$$$$
Droperiol
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -0.0964 -18.0192 0 0
M  V30 2 C 0.3794 -16.5546 0 0
M  V30 3 C -0.651 -15.4102 0 0
M  V30 4 C -0.1751 -13.9455 0 0
M  V30 5 C 1.3312 -13.6254 0 0
M  V30 6 C 2.3617 -14.7698 0 0
M  V30 7 C 1.8858 -16.2344 0 0
M  V30 8 C 1.8071 -12.1607 0 0
M  V30 9 O 3.3135 -11.8405 0 0
M  V30 10 C 0.7766 -11.0163 0 0
M  V30 11 C 1.2525 -9.5517 0 0
M  V30 12 C 0.2221 -8.4072 0 0
M  V30 13 N 0.698 -6.9426 0 0
M  V30 14 C -0.3325 -5.7982 0 0
M  V30 15 C 0.1434 -4.3335 0 0
M  V30 16 C 1.6497 -4.0133 0 0
M  V30 17 C 2.6802 -5.1578 0 0
M  V30 18 C 2.2043 -6.6224 0 0
M  V30 19 N 2.1256 -2.5487 0 0
M  V30 20 C 1.2204 -1.3028 0 0
M  V30 21 O -0.3196 -1.3028 0 0
M  V30 22 N 2.1256 -0.0569 0 0
M  V30 23 C 3.5902 -0.5328 0 0
M  V30 24 C 4.9239 0.2372 0 0
M  V30 25 C 6.2576 -0.5328 0 0
M  V30 26 C 6.2576 -2.0728 0 0
M  V30 27 C 4.9239 -2.8428 0 0
M  V30 28 C 3.5902 -2.0728 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 19 28
M  V30 31 2 23 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1592690523

>  <MW>
379.17

>  <MW (desalted)>
379.427

>  <ClogP>
3.056

>  <logS>
-4.524

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
52.65

>  <RotBonds>
6

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.4 nM | Ki (inhibition constant)  0.4 nM | pIC50  9.26  | pIC50  9.26  | Ki (inhibition constant)  0.7 nM | Ki (inhibition constant) = 0.7 nM | pIC50  8.57  | pIC50  8.57  | Ki (inhibition constant)  3.41 nM | Ki (inhibition constant)  3.41 nM

>  <CAS>
548-73-2

>  <Description>
Droperidol is a dopamine-2 receptor antagonist. Droperidol is a butyrophenone, with anti-emetic, sedative and anti-anxiety properties.

>  <EBC_ID>
EBC-08486

>  <IUPAC Name>
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

>  <Main Tar all refs>
J. Neurochem., 1981, vol. 36, # 1, p. 201 - 219 | J. Neurochem., 1981, vol. 36, # 1, p. 201 - 219 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | NEUROPHARMACOLOGY, 1977, vol. 16, # 9, p. 549 - 556 | Annu. Rep. Med. Chem., 1977, vol. 12, p. 249 - 259 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | PHARM. RES., 1989, vol. 6, # 7, p. 571 - 577 | J. Neurosci., 1990, vol. 10, # 8, p. 2587 - 2600 | J. Neurosci., 1990, vol. 10, # 8, p. 2587 - 2600

>  <Main tar all>
Dopamine receptor pX=9.4 | Dopamine receptor pX=9.4 | D2L receptor pX=9.26 | D2L receptor pX=9.26 | ?-adrenoceptor pX=9.15 | Noradrenaline Receptor, Alpha pX=9.15 | 5-HT2A receptor pX=8.57 | 5-HT2A receptor pX=8.57 | D2 receptor pX=8.47 | D2 receptor pX=8.47

$$$$
Topotecan
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1822 -4.5399 0 0
M  V30 2 C 3.2341 -5.7535 0 0
M  V30 3 C 3.811 -7.1813 0 0 CFG=1
M  V30 4 O 5.117 -6.3653 0 0
M  V30 5 C 2.3046 -7.5015 0 0
M  V30 6 O 1.2742 -6.3571 0 0
M  V30 7 O 1.8288 -8.9661 0 0
M  V30 8 C 2.8592 -10.1106 0 0
M  V30 9 C 4.3656 -9.7904 0 0
M  V30 10 C 4.8414 -8.3258 0 0
M  V30 11 C 6.3478 -8.0056 0 0
M  V30 12 C 7.3783 -9.15 0 0
M  V30 13 C 8.9183 -9.15 0 0
M  V30 14 N 9.9487 -8.0056 0 0
M  V30 15 C 11.4551 -8.3258 0 0
M  V30 16 C 12.4855 -7.1813 0 0
M  V30 17 C 13.9919 -7.5015 0 0
M  V30 18 C 14.4678 -8.9661 0 0
M  V30 19 O 15.9741 -9.2863 0 0
M  V30 20 C 13.4373 -10.1106 0 0
M  V30 21 C 13.9132 -11.5752 0 0
M  V30 22 N 12.8827 -12.7197 0 0
M  V30 23 C 13.3586 -14.1843 0 0
M  V30 24 C 11.3764 -12.3995 0 0
M  V30 25 C 11.931 -9.7904 0 0
M  V30 26 C 10.9005 -10.9348 0 0
M  V30 27 C 9.3941 -10.6147 0 0
M  V30 28 C 8.1483 -11.5198 0 0
M  V30 29 N 6.9024 -10.6147 0 0
M  V30 30 C 5.396 -10.9348 0 0
M  V30 31 O 4.9201 -12.3995 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 3 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 20 25
M  V30 26 1 15 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 13 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 12 29
M  V30 33 1 29 30
M  V30 34 1 9 30
M  V30 35 2 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1501485359

>  <MW>
421.164

>  <MW (desalted)>
421.446

>  <ClogP>
0.73

>  <logS>
-3.324

>  <HBD>
2

>  <HBA>
6

>  <TPSA>
103.2

>  <RotBonds>
3

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
increase rate Active   | IC50  0.4 nM | IC50  0.4 nM | IC50  0.0007 ?M | inhibition percentage Active   | inhibition percentage Active   | percentage of cells in G2/M phase  76.94 %

>  <CAS>
123948-87-8

>  <Description>
Topotecan is a Topoisomerase I inhibitor. Topotecan is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.

>  <EBC_ID>
EBC-07866

>  <IUPAC Name>
(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione

>  <Main Tar all refs>
Phytomedicine, 2019, vol. 57, p. 117 - 128 | Mol. Pharm., 2017, vol. 14, # 8, p. 2805 - 2814 | Mol. Pharm., 2017, vol. 14, # 8, p. 2805 - 2814 | Front. Pharmacol., 2022, vol. 13 | Cells, 2019, vol. 8, # 7 | Cells, 2019, vol. 8, # 7 | Eur. J. Pharmacol., 2016, vol. 789, p. 265 - 274

>  <Main tar all>
Alanine/serine/cysteine transporter 2 pX=10.0 | ABCG2 pX=9.4 | Broad substrate specificity ATP-binding cassette transporter ABCG2 pX=9.4 | topoisomerase (DNA) I mitochondrial pX=9.15 | ABCG2 pX=9.0 | ABCG2 (Q141K) pX=9.0 | tubulin alpha 1a pX=8.55

$$$$
Erlotinib hydrochloride
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0 0 0 0
M  V30 2 C 8.8547 -9.1603 0 0
M  V30 3 O 8.8547 -7.6203 0 0
M  V30 4 C 7.521 -6.8503 0 0
M  V30 5 C 7.521 -5.3103 0 0
M  V30 6 O 6.1874 -4.5403 0 0
M  V30 7 C 6.1874 -3.0003 0 0
M  V30 8 C 4.8537 -2.2303 0 0
M  V30 9 C 4.8537 -0.6903 0 0
M  V30 10 N 3.52 0.0797 0 0
M  V30 11 C 3.52 1.6197 0 0
M  V30 12 N 4.8537 2.3897 0 0
M  V30 13 C 6.1874 1.6197 0 0
M  V30 14 N 7.521 2.3897 0 0
M  V30 15 C 7.521 3.9297 0 0
M  V30 16 C 6.1874 4.6997 0 0
M  V30 17 C 6.1874 6.2397 0 0
M  V30 18 C 7.521 7.0097 0 0
M  V30 19 C 8.8547 6.2397 0 0
M  V30 20 C 10.1884 7.0097 0 0
M  V30 21 C 11.5221 7.7797 0 0
M  V30 22 C 8.8547 4.6997 0 0
M  V30 23 C 6.1874 0.0797 0 0
M  V30 24 C 7.521 -0.6903 0 0
M  V30 25 C 7.521 -2.2303 0 0
M  V30 26 O 8.8547 -3.0003 0 0
M  V30 27 C 10.1884 -2.2303 0 0
M  V30 28 C 11.5221 -3.0003 0 0
M  V30 29 O 12.8558 -2.2303 0 0
M  V30 30 C 14.1894 -3.0003 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 3
M  V30 2 1 3 4
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 2 8 9
M  V30 8 1 9 10
M  V30 9 2 10 11
M  V30 10 1 11 12
M  V30 11 2 12 13
M  V30 12 1 13 14
M  V30 13 1 14 15
M  V30 14 1 15 16
M  V30 15 2 16 17
M  V30 16 1 17 18
M  V30 17 2 18 19
M  V30 18 1 19 20
M  V30 19 3 20 21
M  V30 20 1 19 22
M  V30 21 2 15 22
M  V30 22 1 13 23
M  V30 23 1 9 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 7 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z1546621749

>  <MW>
429.897

>  <MW (desalted)>
393.436

>  <ClogP>
4.342

>  <logS>
-5.665

>  <HBD>
1

>  <HBA>
7

>  <TPSA>
74.73

>  <RotBonds>
10

>  <Action on targets>
Inhibitor | Inhibitor | Inhibitor | - | - | - | - | - | - | -

>  <Activity coefficients and valu>
Ki (inhibition constant)  0.025 nM | Ki (inhibition constant)  0.29 nM | IC50  0.3 nM | Kd (dissociation constant)  0.35 nM | Kd (dissociation constant)  0.48 nM | Kd (dissociation constant)  0.52 nM | Kd (dissociation constant)  0.52 nM | Kd (dissociation constant)  0.67 nM | Kd (dissociation constant)  0.67 nM | Kd (dissociation constant)  0.67 nM

>  <CAS>
183319-69-9

>  <Description>
Erlotinib Hydrochloride inhibits purified EGFR kinase. Erlotinib is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer.

>  <EBC_ID>
EBC-00693

>  <IUPAC Name>
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride

>  <Main Tar all refs>
Biochemistry, 2020, vol. 59, # 14, p. 1428 - 1441 | Biochemistry, 2020, vol. 59, # 14, p. 1428 - 1441 | DANA-FARBER CANCER INSTITUTE - WO2008/121467, 2008, A2 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336 | Nat. Biotechnol., 2005, vol. 23, # 3, p. 329 - 336

>  <Main tar all>
Epidermal growth factor receptor (L858R) pX=10.6 | epidermal growth factor receptor pX=9.54 | Epidermal growth factor receptor (L747-P753del, insS) pX=9.52 | Epidermal growth factor receptor (L747-T751del, Sins) pX=9.46 | Epidermal growth factor receptor (delE746-A750) pX=9.32 | Epidermal growth factor receptor (G719S) pX=9.28 | Epidermal growth factor receptor (L747-A750del, insP) pX=9.28 | Epidermal growth factor receptor (Del S752-I759) pX=9.17 | Epidermal growth factor receptor (G719C) pX=9.17 | Epidermal growth factor receptor (L861Q) pX=9.17

$$$$
Sofosbuvir
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.399 3.0059 0 0
M  V30 2 C 10.3042 1.76 0 0
M  V30 3 C 11.8358 1.921 0 0
M  V30 4 O 9.6779 0.3531 0 0
M  V30 5 C 10.583 -0.8928 0 0
M  V30 6 O 12.1146 -0.7318 0 0
M  V30 7 C 9.9567 -2.2996 0 0 CFG=2
M  V30 8 C 8.4251 -2.4606 0 0
M  V30 9 N 10.8619 -3.5455 0 0
M  V30 10 P 10.2355 -4.9524 0 0 CFG=2
M  V30 11 O 8.8286 -4.326 0 0
M  V30 12 O 9.6091 -6.3592 0 0
M  V30 13 C 8.0775 -6.5202 0 0
M  V30 14 C 7.1724 -5.2743 0 0 CFG=1
M  V30 15 O 5.6324 -5.2743 0 0
M  V30 16 C 5.1565 -3.8097 0 0 CFG=1
M  V30 17 N 3.6918 -3.3338 0 0
M  V30 18 C 2.5474 -4.3643 0 0
M  V30 19 C 1.0828 -3.8884 0 0
M  V30 20 C 0.7626 -2.382 0 0
M  V30 21 O -0.702 -1.9061 0 0
M  V30 22 N 1.907 -1.3516 0 0
M  V30 23 C 3.3717 -1.8274 0 0
M  V30 24 O 4.5161 -0.797 0 0
M  V30 25 C 6.4024 -2.9045 0 0 CFG=2
M  V30 26 C 5.3719 -1.76 0 0
M  V30 27 F 7.4328 -1.76 0 0
M  V30 28 C 7.6482 -3.8097 0 0 CFG=2
M  V30 29 O 9.1129 -3.3338 0 0
M  V30 30 O 11.6423 -5.5787 0 0
M  V30 31 C 11.8033 -7.1103 0 0
M  V30 32 C 13.2102 -7.7367 0 0
M  V30 33 C 13.3712 -9.2682 0 0
M  V30 34 C 12.1253 -10.1734 0 0
M  V30 35 C 10.7184 -9.5471 0 0
M  V30 36 C 10.5574 -8.0155 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=1
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 17 CFG=1
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 22 23
M  V30 23 1 17 23
M  V30 24 2 23 24
M  V30 25 1 25 16
M  V30 26 1 25 26 CFG=1
M  V30 27 1 25 27 CFG=3
M  V30 28 1 25 28
M  V30 29 1 28 14
M  V30 30 1 28 29 CFG=3
M  V30 31 1 10 30 CFG=3
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 2 31 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2235802138

>  <MW>
529.163

>  <MW (desalted)>
529.453

>  <ClogP>
0.843

>  <logS>
-4.561

>  <HBD>
3

>  <HBA>
6

>  <TPSA>
152.73

>  <RotBonds>
11

>  <Action on targets>
Inhibitor | -

>  <Activity coefficients and valu>
EC50  0.6 nM | EC50 = 13.3 nM

>  <CAS>
1190307-88-0

>  <Description>
Sofosbuvir is a direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents.

>  <EBC_ID>
EBC-58076

>  <IUPAC Name>
propan-2-yl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate

>  <Main Tar all refs>
GILEAD SCIENCES INC - US2013/109647, 2013, A1 | GILEAD SCIENCES INC - WO2013/40492, 2013, A2

>  <Main tar all>
Nonstructural protein 5B pX=9.22 | NS5B Polymerase pX=7.88

$$$$
Acitretin
  Mrv2205 11132318322D          

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0 4.62 0 0
M  V30 2 O 1.3337 3.85 0 0
M  V30 3 C 1.3337 2.31 0 0
M  V30 4 C 2.6674 1.54 0 0
M  V30 5 C 2.6674 -0 0 0
M  V30 6 C 4.001 -0.77 0 0
M  V30 7 C 1.3337 -0.77 0 0
M  V30 8 C 1.3337 -2.31 0 0
M  V30 9 C -0 -3.08 0 0
M  V30 10 C -0 -4.62 0 0
M  V30 11 C -1.3337 -5.39 0 0
M  V30 12 C -1.3337 -6.93 0 0
M  V30 13 C -2.6674 -7.7 0 0
M  V30 14 C -2.6674 -9.24 0 0
M  V30 15 C -4.001 -10.01 0 0
M  V30 16 C -4.001 -11.55 0 0
M  V30 17 O -2.6674 -12.32 0 0
M  V30 18 O -5.3347 -12.32 0 0
M  V30 19 C -1.3337 -10.01 0 0
M  V30 20 C 1.3337 -5.39 0 0
M  V30 21 C 0 0 0 0
M  V30 22 C -1.3337 -0.77 0 0
M  V30 23 C 0 1.54 0 0
M  V30 24 C -1.3337 2.31 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 14 19
M  V30 19 1 10 20
M  V30 20 2 7 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 2 3 23
M  V30 24 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Catalog ID>
Z2312273468

>  <MW>
326.188

>  <MW (desalted)>
326.429

>  <ClogP>
6.065

>  <logS>
-6.748

>  <HBD>
1

>  <HBA>
3

>  <TPSA>
46.53

>  <RotBonds>
6

>  <Action on targets>
Agonist | Agonist | Agonist | Agonist | Agonist | Inhibitor | Inhibitor | Inhibitor

>  <Activity coefficients and valu>
EC50  34 nM | EC50  50 nM | EC50  60 nM | decrease rate Active   | decrease rate Active   | Kd (dissociation constant)  0.1 ?M | inhibition percentage  87.04 % | inhibition percentage  87.04 %

>  <CAS>
55079-83-9

>  <Description>
Acitretin is an oral retinoid used in the treatment of severe psoriasis. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation seen in psoriasis.

>  <EBC_ID>
EBC-11169

>  <IUPAC Name>
(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid

>  <Main Tar all refs>
ROCHE HOLDING AG - US5807900, 1998, A | ROCHE HOLDING AG - US5807900, 1998, A | ROCHE HOLDING AG - US5807900, 1998, A | Antiviral Res., 2019, vol. 168, p. 146 - 155 | Antiviral Res., 2019, vol. 168, p. 146 - 155 | Biochemistry, 2021, vol. 60, # 9, p. 689 - 698 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1976 - 1984 | Drug Metab. Dispos., 2006, vol. 34, # 12, p. 1976 - 1984

>  <Main tar all>
Retinoic acid receptor-? pX=7.47 | Retinoic acid receptor-? pX=7.3 | Retinoic acid receptor-? pX=7.22 | Retinoic acid receptor RXR pX=7.1 | Retinoic acid receptor-? pX=7.1 | Haem oxygenase 1 pX=7.0 | ABCB1 pX=6.13 | ATP-dependent translocase ABCB1 pX=6.13

$$$$
